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LIST OF DEFINITIONS  
 
Complete test sequence: A test sequence (see definition below) is considered complete if it 
contains three qualified tests (see definition below). Otherwise, the test sequence is 
considered as incomplete. 
EpiOcularTM model: A Reconstructed human Cornea-like Epithelium (RhCE) tissue 
construct produced by MatTek Corporation, consisting of a non-keratinized multilayered 
epithelium prepared from non-transformed, human-derived epidermal keratinocytes. 
EpiOcularTM Eye Irritation Test (EIT): a test method that predicts the eye irritation potential 
of chemicals employing the EpiOcularTM RhCE construct as test system and a protocol with 
different exposure and post-exposure incubations for liquids and solids. 
Eye irritation Peptide Reactivity Assay (EPRA): a test method that predicts chemical 
reactivity, defined as the electrophilic potential of the chemical to react with cysteine or lysine 
containing peptides (same protocol as DPRA, but a slightly different prediction model). 
Negative control (NC): A reference test chemical that does not induce a cytotoxic effect in 
the treated tissues (i.e., does not reduce their viability). It is used to verify if the viability of the 
tissues used for testing, as quantified by the MTT assay, is within a defined acceptance 
range of optical density (OD). 
Positive control (PC): A reference test chemical known to induce a cytotoxic effect in the 
treated tissues as quantified by using the MTT assay. It is used to verify if the tissue batch 
used for testing is responding to the reference chemical within a defined acceptance range of 
% viability (relative to NC). It should be noted that the positive control does not need to be an 
in vivo irritant chemical (based on the Draize eye irritation test). 
Qualified run: A run (see definition below) is qualified when it meets the test acceptance 
criteria for the NC and PC, as defined in the corresponding SOP. Otherwise, the run is 
considered as non-qualified. 
Qualified test: A test (see definition below) is qualified when it meets the criteria for an 
acceptable test, as defined in the corresponding SOP, and is within a qualified run. 
Otherwise, the test is considered as non-qualified. 
Run: A run consists of multiple tests with different test chemicals (one test per test chemical) 
conducted concurrently with a test with NC and a test with PC, tested by one operator, as 
defined in the corresponding SOP. 
SkinEthicTM Human Corneal Epithelium (HCE) model: a RhCE construct produced by 
SkinEthicTM Laboratories, consisting of a multilayered epithelium prepared from immortalized 
human corneal epithelial cells. 
SkinEthicTM HCE Long-time Exposure (LE): a test method that predicts the eye irritation 
potential of chemicals employing the SkinEthicTM HCE RhCE construct as test system and a 
long-time exposure of test chemicals. 
SkinEthicTM HCE Short-time Exposure (SE): a test method that predicts the eye irritation 
potential of chemicals employing the SkinEthicTM HCE RhCE construct as test system and a 
short-time exposure of test chemicals. 
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SkinEthicTM HCE test strategy/method: A test strategy to predict the eye irritation potential 
of chemicals, consisting of three separate assays (i.e., EPRA, SkinEthicTM HCE SE, and 
SkinEthicTM HCE LE). In this test strategy, chemical reactivity, as determined by the EPRA, is 
used to decide if a chemical is tested with SkinEthicTM HCE SE (reactive chemicals) or 
SkinEthicTM HCE LE (non-reactive or inconclusive chemicals). 
Test: A single test chemical concurrently tested in a minimum of two/three tissue replicates 
as defined in the corresponding SOP. A “test” for a test chemical is defined when the 
cytotoxic effect by using MTT is quantitatively measured. A reported technical issue before 
the viability measurement is not considered as a “test” for the test chemical. 
Test chemical: Any chemical (substance or mixture) being tested as a single entity. 
Test sequence: The total number of tests performed for a single test chemical in a single 
laboratory, which includes any re-testing. A test sequence may include both qualified and 
non-qualified tests. The first two tests having technical issues for each test chemical, tests 
included in the first two runs presenting technical issues, and tests included in the first six 
non-qualified runs were not considered as part of a test sequence for the purposes of the 
present validation study. 
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Executive summary 
 
A prospective validation study of two in vitro test methods using Reconstructed human 
Cornea-like Epithelium (RhCE) models (MatTek EpiOcular™ and SkinEthic™ Human 
Corneal Epithelium (HCE)) for the identification of chemicals not requiring classification and 
labelling for serious eye damage/eye irritation, has been conducted by the European Union 
Reference Laboratory for Alternatives to Animal Testing (EURL ECVAM) and Cosmetics 
Europe - The Personal Care Association. Pre-validation studies with both test methods have 
served to optimise protocols and refine prediction models, and were able to show that both 
test methods are able to predict ocular toxicity properties of test substances with a high 
degree of accuracy, approximately 80% overall. The Eye Irritation Validation Study (EIVS), 
co-sponsored by EURL ECVAM and Cosmetics Europe, evaluated the validity (relevance 
and reliability) of these two RhCE test methods to discriminate chemicals not requiring 
classification and labelling for serious eye damage/eye irritancy (No Category) from 
chemicals requiring classification and labelling (Category 1 and Category 2) according to the 
United Nations Globally Harmonized System of Classification and Labelling of Chemicals 
(UN GHS) and as implemented by the EU Classification, Labelling and Packaging regulation 
(EU CLP) (UN, 2013; EC, 2008). These RhCE test methods are not intended to differentiate 
between UN GHS/EU CLP Category 1 (serious eye damage) and UN GHS/EU CLP 
Category 2 (eye irritation). This differentiation would be left to another tier of a test strategy 
as described e.g., by Scott et al. (2010). The EIVS has been undertaken in accordance with 
the principles and criteria documented in the OECD Guidance Document on the Validation 
and International Acceptance of New or Updated Test Methods for Hazard Assessment (No. 
34, OECD, 2005) and according to the Modular Approach to validation (Hartung et al., 2004). 
The protocols assessed were the original EpiOcular™ Eye Irritation Test (EIT) protocol for 
liquid chemicals, the original EpiOcular™ EIT protocol for solid chemicals, an EpiOcular™ 
EIT optimised protocol for solid chemicals, the SkinEthic™ HCE Short-time Exposure (SE) 
protocol, the SkinEthic™ HCE Long-time Exposure (LE) protocol, and the SkinEthic™ HCE 
test strategy (TS) combining the SE and LE protocols as well as the Eye irritation Peptide 
Reactivity Assay (EPRA). Two prediction models, using 50% or 60% mean tissue viability as 
the threshold differentiating classified (UN GHS Cat 1 and Cat 2) chemicals (mean tissue 
viability ≤ 50% or 60%) from non-classified (UN GHS No Cat) chemicals (mean tissue 
viability > 50% or 60%), were evaluated with each of the EpiOcular™ EIT protocols, while a 
single prediction model using a 50% mean tissue viability cut-off was evaluated with the 
SkinEthic™ HCE SE, LE and TS. The EpiOcular™ EIT was originally developed by MatTek 
Corporation with the single threshold of 60% mean tissue viability in the prediction model and 
the submission of the test method to EURL ECVAM for validation was based on this single 
prediction model. However, in the beginning of the EIVS and even before training and 
transferability took place, MatTek Corporation was faced with the necessity to replace the 
insert membrane used in the production of the EpiOcular™ tissues due to discontinued 
production of the insert membrane used until then (MTI-001a). A replacement insert 
membrane (MTI-003) was approved by the Validation Management Group (VMG) for use in 
EIVS after multiple testing of 94 chemicals at MatTek Corporation and comparative statistical 
analysis performed by the EURL ECVAM biostatistician on the use of the old MTI-001a insert 
membrane (discontinued) versus the new MTI-003 insert membrane. The results showed 
that with the MTI-003 membrane a sensitivity higher than 90% could potentially still be 
achieved using a 50% cut-off instead of 60%, with a significant gain in specificity. 
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Considering these new data, the VMG decided to evaluate two prediction models with 
EpiOcular™ EIT in EIVS, one based on the original cut-off at 60% mean tissue viability as in 
the submission to EURL ECVAM and a second one based on a cut-off at 50% mean tissue 
viability. 
EIVS included a statistically sufficient number of chemicals, supported by complete and 
quality assured in vivo Draize eye test data, for comparative evaluation of results. A total of 
104 selected test chemicals (52 liquids and 52 solids) were distributed as identity coded 
aliquots for blind ring trial testing as three runs in three laboratories for both test methods. 
One other chemical (chemical #27; 2-Ethylhexylthioglycolate) was sent to all participating 
laboratories for testing but was excluded and replaced by another chemical (one of the final 
104) at a very early stage of the study on request of one of the SkinEthic™ HCE participating 
laboratories because it was identified as a very strong MTT reducer. It has therefore been 
excluded from all the statistics described in the three statistics reports of this study. However, 
by the time chemical #27 was replaced by another chemical, it had already been tested in a 
complete test sequence by all three EpiOcular™ EIT participating laboratories. Since in 
EpiOcular™ EIT chemical #27 only produced minor interference with the MTT assay, it was 
decided to include it in all the statistics described in this report. Following the ring trial, the 52 
solid chemicals were re-tested, with an additional 8 others newly selected (all identity coded 
i.e., blind testing) in three runs in one laboratory, for validation of an optimised EpiOcular™ 
EIT solid chemicals protocol. Chemical #37 (PEG-40 hydrogenated castor oil) was originally 
selected by the EIVS VMG as being solid. However, all three laboratories participating in the 
main validation study of the EpiOcular™ EIT (Beiersdorf, Harlan and IIVS) independently 
considered the chemical as being liquid due to its low melting point and testing occurring in 
the spring/summer period. This chemical was therefore tested during the main part of EIVS 
using the liquid protocol of EpiOcular™ EIT. However, due to a VMG oversight, chemical #37 
was again shipped to Beiersdorf as a solid to be tested during the validation of the 
EpiOcular™ EIT optimised solid chemicals protocol. Since this time the testing occurred 
during the autumn/winter, Beiersdorf confirmed the physical state of the chemical as being 
solid upon receipt and tested it as such. Thus, chemical #37 was tested in both the liquid 
chemicals and solid chemicals protocols of EpiOcular™ EIT, somewhat in agreement with its 
borderline physical state. The VMG considered both sets of data (produced with the original 
liquid chemicals and the optimised solid chemicals protocols) as being valid and these were 
therefore included in all the statistics analyses. Nevertheless, the EpiOcular™ EIT predictive 
capacity was also calculated considering only the optimised solids protocol data (excluding 
the liquid chemicals protocol data) in accordance with the fact that this chemical had been 
tested in vivo as a solid and had been originally considered by the VMG as a solid during 
chemicals selection for the study. 
 
 
EpiOcular™ EIT main validation study 
The three laboratories participating in the validation of EpiOcular™ EIT, two European, 
Beiersdorf (the lead laboratory) and Harlan UK (naïve laboratory), and one in the US, IIVS, 
were trained by MatTek Corporation to assure optimal transfer of the test protocol into their 
facilities and to guarantee that the Standard Operating Procedure (SOP) did not allow for 
individual (different) interpretation of the experimental steps. All procedures and assay 
documentation were discussed and comments and suggestions for improvement and 
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clarification of the SOP were collected and implemented by MatTek Corporation in a final 
version of the SOP that was used in the ring trial of the validation study. The nine laboratory 
technicians assigned to the project (three per laboratory) performed the test method with 8 
coded test chemicals (2 liquid No Cat, 2 solid No Cat, 2 liquid Cat 2, 1 solid Cat 2, 1 liquid 
Cat 1 and 2 solid Cat 1) at their test facility to demonstrate transferability of the test method. 
The variability of the particular experiments performed by single operators was very low, as 
judged by the difference in viability between tissue replicates (only 1 out of 108 results 
showed a difference > 20%). All test chemicals were consistently predicted by the three 
laboratories and nine operators using 50% mean viability as the prediction model threshold 
differentiating classified (UN GHS Cat 1 and Cat 2) from non-classified (UN GHS No Cat) 
chemicals, while, using a 60% cut-off in the prediction model, 1 liquid chemical was predicted 
differently by one operator in one laboratory. Highly reproducible results were therefore 
obtained between operators and laboratories in the EpiOcular™ EIT transfer study. All the 
participating laboratories demonstrated their proficiency in performing the EpiOcular™ EIT 
and readiness to enter the formal validation study. 
Based on the results for the fraction of complete test sequences (99.7% in total), it can be 
concluded that the validation of the EpiOcular™ EIT was based on high-quality data. The 
acceptance criterion for this characteristic was unequivocally fulfilled (≥ 85%). One chemical 
(chemical #33; 2,2'-[[4-[(2-Methoxyethyl)amino]-3-nitrophenyl]imino]bis-ethanol; INCI name: 
HC BLUE NO. 11) was considered incompatible with the test method at Beiersdorf due to too 
high colour interference with the MTT assay and was therefore excluded from the statistical 
analysis for that laboratory. 
The EpiOcular™ EIT test method was found to be highly reproducible. The within-laboratory 
reproducibility (WLR) (93.6% and 95.2% concordance of classifications for the 50% and 60% 
cut-offs analysed in this study, respectively) and the between-laboratory reproducibility (BLR) 
(91.3% and 93.3% concordance of classifications for the 50% and 60% cut-offs analysed in 
this study, respectively) were significantly above the acceptance criteria set by the VMG 
(WLR ≥ 85% and BLR ≥ 80%). 
Taking 60% mean viability as the prediction model threshold differentiating classified (UN 
GHS Cat 1 and Cat 2) from non-classified (UN GHS No Cat) chemicals, the overall accuracy 
(79.0%) and specificity (70.5%) were ‘definitely acceptable’ according to the acceptance 
criteria as defined by the VMG (overall accuracy ≥ 75%; specificity ≥ 60%), whereas the 
sensitivity (87.6%) was between the limits of ‘definitely unacceptable’ (< 80%) and ‘definitely 
acceptable’ (≥ 90%). Considering only the liquid chemicals, the test method fulfilled all of the 
‘definitely acceptable’ criteria (overall accuracy of 81.9%; sensitivity of 98.3%; specificity of 
66.7%). For the solid chemicals both the overall accuracy (75.9%) and the specificity (74.8%) 
were ‘definitely acceptable’, whereas the sensitivity (76.9%) was ‘definitely unacceptable’. Of 
note, the solid chemicals protocol showed balanced predictive capacity values with the 60% 
cut-off. 
Taking 50% mean viability as the prediction model threshold differentiating classified (UN 
GHS Cat 1 and Cat 2) from non-classified (UN GHS No Cat) chemicals, the overall accuracy 
(77.9%) and specificity (74.5%) were ‘definitely acceptable’ according to the acceptance 
criteria defined by the VMG (overall accuracy ≥ 75%; specificity ≥ 60%), whereas the 
sensitivity (81.4%) was still between the limits of ‘definitely unacceptable’ (< 80%) and 
‘definitely acceptable’ (≥ 90%). Again, considering only the liquid chemicals, the test method 
fulfilled all of the ‘definitely acceptable’ criteria (overall accuracy of 82.5%; sensitivity of 
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96.2%; specificity of 69.8%), while for the solid chemicals only the specificity (79.7%) was 
‘definitely acceptable’. The overall accuracy (73.0%) fell short of ‘definitely acceptable’ (≥ 
75%) but surpassed ‘definitely unacceptable’ (< 65%), while the sensitivity (66.7%) was 
‘definitely unacceptable’. 
 
Based on these findings the VMG concluded that: 
- EpiOcular™ EIT can be easily transferred among properly equipped and staffed 
laboratories, including those having no prior experience in performance of similar test 
methods i.e., naïve laboratories. Experienced personnel can readily be trained in the test 
method, and the necessary equipment and supplies can be readily obtained. The 
EpiOcular™ EIT SOP is clearly written and the testing and analysis of results can be 
performed without difficulties. 
- The validation study was of high quality due to a near complete dataset with negligible re-
testing performed. 
- The WLR was well above the acceptance criterion set by the VMG (WLR ≥ 85%), and 
concordance of classifications within a single laboratory was above 90% for EpiOcular™ EIT 
in the participating laboratories. 
- The BLR was also well above the acceptance criterion set by the VMG (BLR ≥ 80%), and 
the concordance of final classifications obtained between the different participating 
laboratories was greater than 90% for EpiOcular™ EIT. 
- The EpiOcular™ EIT protocol for liquid chemicals met all of the VMG acceptance criteria for 
sensitivity, specificity and overall accuracy. The 60% cut-off was considered to be better than 
the 50% cut-off because it resulted in a better sensitivity and generated no false negatives 
based on the mode of all predictions (the 50% cut-off generated one false negative for a 
Category 2B chemical), with similar overall accuracy. 
- On the other hand, not all of the acceptance criteria were met by the EpiOcular™ EIT 
protocol for the solid chemicals. Sensitivity was < 90% even at the 60% cut-off and of the 6 
chemicals that were under-predicted with the 60% cut-off based on the mode of all 
predictions, one was classified in vivo as Category 1. 
- Analysis of the EIVS data for solid chemicals indicated scope for improvement through a 
balanced increase in sensitivity with decrease in specificity to attain a compromise of 
sensitivity ≥ 90% with specificity maintained ≥ 60%. Optimisation was therefore 
recommended for the EpiOcular™ EIT protocol for solid chemicals. 
Optimisation of the EpiOcular™ EIT solid chemicals protocol was performed at the method 
developer’s laboratory (MatTek Corporation) in order to increase the sensitivity of the assay 
to the level requested by the VMG. This optimisation led to an increase of the exposure time 
from 90 minutes to 6 hours. The optimisation work was performed independently of the EIVS 
but with guidance and scientific support from the VMG. The VMG provided 11 EIVS solid 
chemicals to MatTek Corporation for the optimisation of the EpiOcular™ EIT solid chemicals 
protocol, including the 6 solid chemicals that had been under-predicted (false negatives) by 
the original protocol plus 5 correctly predicted not classified (UN GHS No Cat) chemicals that 
had shown borderline results. MatTek Corporation was able to complete the optimisation of 
the solid chemicals protocol without delay, enabling follow-up validation within EIVS (post-
optimisation validation), including analysis of the results by the VMG. The validation of the 
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EpiOcular™ EIT optimised solids protocol was conducted with the original 52 EIVS solid 
chemicals plus an extra 8 selected to compensate for the 11 used during the optimisation of 
the protocol. The post-optimisation validation of the EpiOcular™ EIT optimised solid 
chemicals protocol took place in a single laboratory, at Beiersdorf (i.e., the lead laboratory for 
EpiOcular™ EIT in the original validation study), since the main purpose of this follow-up 
study was to evaluate the predictive capacity of the optimised protocol. Based on the very 
high reproducibility (WLR and BLR) achieved in the validation study of the original 
EpiOcular™ EIT protocols and of SkinEthic™ HCE, using multiple exposure times and post-
treatment incubation periods, the VMG considered that a simple change in exposure time in 
the EpiOcular™ EIT solid chemicals protocol would not affect the reproducibility of the test 
method. Nevertheless, the VMG decided to assess the WLR of the EpiOcular™ EIT 
optimised solid chemicals protocol at Beiersdorf and based on the results decide if any 




EpiOcular™ EIT post-optimisation validation study (solids protocol) 
Based on the results for the fraction of complete test sequences (98.3% in total), it can be 
concluded that the post-optimisation validation of the EpiOcular™ EIT optimised solid 
chemicals protocol at Beiersdorf was based on high-quality data. The acceptance criterion 
for this characteristic was unequivocally fulfilled (≥ 85%). One chemical (chemical #98; 4,4’-
(4,5,6,7-Tetrabromo-3H-2,1-benzoxathiol-3-ylidene)bis[2,6-dibromophenol] S,S-dioxide; INCI 
name: TETRABROMOPHENOL BLUE) was considered incompatible with the test method 
due to too high colour interference with the MTT assay and was therefore excluded from the 
statistical analysis. 
The EpiOcular™ EIT optimised solid chemicals protocol was found to be at least as 
reproducible as the original solid chemicals protocol, with 93.2% and 96.6% concordance of 
classifications (based on 59 chemicals) being obtained by Beiersdorf with the optimised 
protocol for the 50% and 60% cut-offs analysed in this study, respectively, as compared to 
92.0% and 94.0% obtained by the same laboratory with the original protocol (based on 50 
chemicals). Forty nine (49) chemicals are common to the two datasets. If only these are 
considered in the calculations, the concordance of classifications obtained by Beiersdorf 
were 91.8% (50% cut-off) and 95.9% (60% cut-off) for the optimised protocol and 91.8% 
(50% cut-off) and 93.9% (60% cut-off) for the original protocol. The WLR of the EpiOcular™ 
EIT optimised solid chemicals protocol was thus significantly above the acceptance criterion 
set by the VMG (WLR ≥ 85%). The WLR obtained by Beiersdorf with the optimised solid 
chemicals protocol (as described above) was also comparable to the WLR obtained by 
considering the data acquired by all three laboratories that participated in the validation of the 
original protocol, i.e., total concordance of classifications of 92.8% (based on 50 chemicals in 
Beiersdorf and 51 chemicals in Harlan and IIVS) or 92.5% (based on 49 chemicals in all 
three laboratories) for both the 50% and 60% cut-offs. 
Taking 60% mean viability as the prediction model threshold differentiating classified (UN 
GHS Cat 1 and Cat 2) from non-classified (UN GHS No Cat) chemicals, the overall accuracy 
(78.0%), the specificity (60.7%) and the sensitivity (93.5%) were all ‘definitely acceptable’ 
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according to the acceptance criteria as defined by the VMG (overall accuracy ≥ 75%; 
specificity ≥ 60%; sensitivity ≥ 90%). 
Taking 50% mean viability as the prediction model threshold differentiating classified (UN 
GHS Cat 1 and Cat 2) from non-classified (UN GHS No Cat) chemicals, the overall accuracy 
(76.8%) and the specificity (64.3%) were ‘definitely acceptable’ according to the acceptance 
criteria defined by the VMG (overall accuracy ≥ 75%; specificity ≥ 60%; sensitivity ≥ 90%), 
whereas the sensitivity (88.2%) was between the limits of ‘definitely unacceptable’ (< 80%) 
and ‘definitely acceptable’ (≥ 90%), but very close to being ‘definitely acceptable’. 
 
Based on these findings the VMG concluded that: 
- The validation of EpiOcular™ EIT optimised solids protocol was of high quality due to a 
near complete dataset with negligible re-testing performed. 
- The WLR was well above the acceptance criterion set by the VMG (WLR ≥ 85%), and 
concordance of classifications within a single laboratory was above 90% for EpiOcular™ EIT 
at Beiersdorf. 
- Further BLR evaluation was identified, by the core VMG, to be unnecessary given the 
previous good reproducibility of the EpiOcular™ EIT test method, and a similar (or even 
slightly better) WLR observed for the optimised solids protocol as compared to the original 
protocol. With the increased exposure time in the optimised solid chemicals protocol, a 
stronger separation between classified and not-classified chemicals in the viability scale was 
observed as compared to the original protocol, which is expected to improve the 
reproducibility of the test method. The fact that two SkinEthic™ HCE protocols with different 
exposure times were evaluated and showed equally high BLR provides additional evidence 
supporting the conclusion that further BLR assessment of the EpiOcular™ EIT optimised 
solid chemicals protocol is not necessary. 
- The optimised EpiOcular™ EIT protocol for solid chemicals met all of the VMG acceptance 
criteria for sensitivity, specificity and overall accuracy using the 60% cut-off, but not with the 
50% cut-off, with sensitivity being slightly lower than the ‘definitely acceptable’ criterion in the 
latter case. The overall accuracy was also higher with a 60% cut-off than with a 50% cut-off. 
The 60% cut-off was therefore considered to be better than the 50% cut-off with the 
optimised solids protocol, similarly to what had been concluded for the liquids protocol. 
- The overall predictive capacity of EpiOcular™ EIT considering a combination of the data 
obtained for the liquid chemicals protocol with the data obtained using the optimised solid 
chemicals protocol, and a cut-off of 60%, consists of a sensitivity of 95.7%, a specificity of 
63.0% (63.7% if chemical #37 is counted twice since it was tested both with the liquids 
protocol and with the optimised solids protocol) and an overall accuracy of 79.7% (79.8% if 
chemical #37 is counted twice). On this basis, all of the acceptance criteria defined by the 
VMG were met. Two out of 57 chemicals (2 solid Cat 2B chemicals) were under-predicted 
(false negatives) and 20 out of 54 chemicals (9 liquids and 11 solids) were over-predicted 
(false positives) based on the mode of all predictions. 
 
 
SkinEthic™ HCE main validation study 
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Two naïve laboratories participating in the validation of SkinEthic™ HCE, one European, 
CARDAM, and one in the US, CeeTox, were trained by the lead laboratory L'Oréal to assure 
optimal transfer of the SE and LE test protocols into their facilities and to guarantee that the 
SOP did not allow for individual (different) interpretation of the experimental steps. All 
procedures and assay documentation were discussed and comments and suggestions for 
improvement and clarification of the SOP were collected and implemented by L'Oréal in a 
final version of the SOP that was used in the ring trial of the validation study. The laboratory 
technicians from all three participating laboratories assigned to the project performed the test 
method with 14 coded test chemicals (3 No Cat, 2 Cat 2, 6 Cat 1 and 3 undefined) at their 
test facility to demonstrate transferability of the test method. The variability obtained with 
both the SE and LE protocols at the three laboratories was very low with SD below 18% 
being obtained for the majority of the tested chemicals in all laboratories. Concordance 
between results of the three laboratories that participated on the transfer study was very 
good, especially considering that highly challenging chemicals (including colorants and direct 
MTT reducers) had been selected for the study. The WLR ranged from 86.7% (CeeTox) to 
87.5% (L'Oréal and CARDAM) and the BLR between the three laboratories in particular was 
excellent (100% for the SE protocol and 92.3% for the LE protocol). All the participating 
laboratories demonstrated their proficiency in performing the SkinEthic™ HCE and readiness 
to enter the formal validation study. 
Based on the results for the fraction of complete test sequences (100% in total for the SE 
protocol, 99.7% in total for the LE protocol), it can be concluded that the validation of the 
SkinEthic™ HCE was based on high-quality data. The acceptance criterion for this 
characteristic was unequivocally fulfilled (≥ 85%). 
None of the 104 chemicals tested was considered incompatible with the test method by any 
of the three laboratories, with either the SE or the LE protocol. All chemicals were thus 
included in all of the statistical analyses. 
The SkinEthic™ HCE test method was found to be highly reproducible. The WLR (93.9% 
and 95.5% concordance of classifications for the SE and LE, respectively) and the BLR 
(92.3% concordance of classifications for both the SE and the LE protocols) were 
significantly above the acceptance criteria set by the VMG (WLR ≥ 85% and BLR ≥ 80%). 
The only prediction model that was evaluated used a mean viability of 50% as the threshold 
differentiating classified (UN GHS Cat 1 and Cat 2) from non-classified (UN GHS No Cat) 
chemicals. The specificity of this prediction model was found to be ‘definitely acceptable’ 
according to the acceptance criterion defined by the VMG (≥ 60%), regardless of the protocol 
or strategy (SE: 88.5%; LE: 65.5%; test strategy: 77.1%). The sensitivity was on the other 
hand ‘definitely unacceptable’ (< 80%) according to the same acceptance criteria (SE: 
42.7%; LE: 71.6%; test strategy: 54.5%). The overall accuracy was between the limits of 
‘definitely unacceptable’ (< 65%) and ‘definitely acceptable’ (≥ 75%) (SE: 65.6%; LE: 68.6%; 
test strategy: 65.8%). 
 
Based on these findings the VMG concluded that: 
- SkinEthic™ HCE SE and LE can be easily transferred among properly equipped and 
staffed laboratories, including those having no prior experience in performance of similar test 
methods i.e., (naïve laboratories). Experienced personnel can readily be trained in the test 
method, and the necessary equipment and supplies can be readily obtained. The 
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SkinEthic™ HCE SOP is clearly written and the testing and analysis of results can be 
performed without difficulties. 
- The validation study was of high quality due to a near complete dataset with negligible re-
testing performed. 
- The WLR was well above the acceptance criterion set by the VMG (WLR ≥ 85%), and 
concordance of classifications within a single laboratory was above 90% in the participating 
laboratories for both the SE and LE protocols of SkinEthic™ HCE. 
- The BLR was also well above the acceptance criterion set by the VMG (BLR ≥ 80%), and 
the concordance of final classifications obtained between the different participating 
laboratories was greater than 90% for both the SE and LE protocols of SkinEthic™ HCE. 
- Not all of the VMG acceptance criteria were met by either the SE or LE protocols of 
SkinEthic™ HCE alone. Sensitivity, in particular, was ‘definitely unacceptable’ being < 80% 
with both protocols (SE: 42.7%; LE: 71.6%). Moreover, of the 30 chemicals that were under-
predicted by SE and of the 15 that were under-predicted by LE based on the mode of all 
predictions, 14 and 5, respectively, were classified in vivo as Category 1, which is also 
‘definitely unacceptable’. 
- The use of EPRA to orient chemicals to the LE (non-reactive) or SE (reactive) protocol is 
also not valid due to a false negative rate of 45.5% and 10 Category 1 chemicals being 
under-predicted as non-irritants (based on the mode of all predictions). It was therefore 
decided not to conduct a reproducibility assessment of EPRA. 
- Analysis of the data for the SkinEthic™ HCE indicated scope for improvement. Further 
optimisation has therefore been recommended for the SkinEthic™ HCE test method 
considering different protocols for liquid chemicals and solid chemicals, as with EpiOcular™ 
EIT.  
  




1.1. Background and history 
 
The assessment of ocular toxicity, (i.e., eye irritation and serious eye damage) is important to 
ensure the safety of products and their components used in our daily life. In several EU 
legislations related to chemicals and products, the generation of information on eye irritation 
and serious eye damage represents a standard requirement (EC, 2006a). The traditional eye 
irritation test used to be the Draize eye test performed on albino rabbits (OECD TG 405; 
OECD, 2012a). However, ethical and scientific considerations as well as legal requirements 
in EU legislations have triggered the development and validation of alternative methods to 
the Draize eye test. In particular, the EU Cosmetics Regulation expressly forbids the use of 
animals in the safety evaluation of cosmetic products and ingredients (EC, 2009).  
Furthermore, the EU REACH (Registration, Evaluation, Authorisation and Restriction of 
Chemicals) legislation encourages the use of in vitro methods, in particular for serious eye 
damage/eye irritation testing (EC, 2006a). 
 
In order to reduce and/or replace the Draize rabbit eye test, the use of testing strategies is 
generally recommended, due to the fact that the range of criteria for injury and inflammation 
covered by the Draize rabbit eye test is unlikely to be covered by a single in vitro test (Eskes 
et al., 2005). A testing strategy has been suggested for regulatory purposes to replace or 
reduce animal testing (Scott et al., 2010). It proposes, based on the expected ocular toxicity 
profile of the test chemical, the use of one of the two following tiered testing approaches 
before progression of further in vitro testing:  
- the Bottom-Up approach, which starts with using in vitro test methods that can accurately 
identify chemicals not requiring classification for eye hazards according to the UN Globally 
Harmonized System of Classification and Labelling of Chemicals (UN GHS) and the EU 
Classification, Labelling and Packaging (EU CLP) system (UN, 2013; EC, 2008); and 
- the Top-Down approach, which starts with using in vitro test methods that can accurately 
identify chemicals inducing serious and/or irreversible eye damage (UN GHS / EU CLP 
Category 1). 
 
These two tiered testing approaches have served as the basis for the validation efforts 
undertaken for eye hazard testing during the last decade in Europe and in the United States 
(ICCVAM, 2006, 2010; ESAC 2007, 2009), and led to the regulatory adoption of three 
alternative test methods by the OECD since 2009 for both the top-down and bottom-up 
approaches (OECD, 2012b, 2013a,b).  
 
However, not all in vivo mechanisms of ocular toxicity may be covered by the test methods 
currently adopted. In particular, test methods using Reconstructed human Cornea-like 
Epithelia (RhCE), may be relevant for assessing conjunctiva epithelial responses (OECD, 
2010). Furthermore, considering the small prevalence of eye irritants and chemicals inducing 
serious eye damage (Adriaens et al., 2014), RhCE test methods could be very important to 
reduce animal testing by identifying chemicals not requiring classification in a non-animal 
testing strategy. 
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Two test methods based on commercially available RhCE models, the EpiOcularTM OCL-200 
and the SkinEthicTM Human Corneal Epithelium (HCE), were developed and underwent 
corporate (pre)validation studies in the early 2000’s (Blazka et al., 2003; Van Goethem et al., 
2006; Doucet et al., 2006). The EpiOcularTM OCL-200 uses non-transformed human 
epidermal keratinocytes cultured to form a stratified squamous, non-keratinized epithelium; 
whereas the SkinEthicTM HCE model uses immortalized human corneal cells which develop 
into a multi-layered tissue that resembles morphologically and physiologically the human 
corneal epithelium. In both cases, test materials can be applied neat directly on the surface 
of the reconstructed tissues. 
 
The corporate validation study on the EpiOcularTM OCL-200 assay and the corporate pre-
validation study on the SkinEthicTM HCE assay were submitted to the former European 
Centre for the Validation of Alternative Methods (ECVAM) for evaluation in December 2005. 
The ECVAM Eye Irritation Task Force positively reviewed the two submissions and 
recommended in 2006 protocol improvements prior to enter a formal validation study. The 
two assays have then undergone protocol optimisation and assessment in a multi-laboratory 
trial managed by Cosmetics Europe between 2007 and 2008 leading to the optimisation of 
the protocols and refinement of the prediction models of the two RhCE test methods (Harbell 
et al., 2009; Cotovio et al., 2010; Kaluzhny et al., 2011; Pfannenbecker et al., 2013; Alépée 
et al., 2013). In this optimisation and pre-validation study, the assays were shown to predict 
eye irritant properties of test substances with approximately 80% of accuracy, and the results 
of this optimisation study were submitted to ECVAM in 2008. 
 
Further to the request and review for additional data, the prospective Eye Irritation Validation 
Study (EIVS) on the two RhCE models was then initiated in December 2008. The study 
which ended in 2013 (see Table 1.1), was co-sponsored by EURL ECVAM and Cosmetics 
Europe. The primary goal of the EIVS was to evaluate the usefulness and limitations of the 
two RhCE in vitro test methods (each having two different protocols: Liquids and Solids for 
EpiOcularTM Eye Irritation Test (EIT); SE and LE for SkinEthicTM HCE) and of the 
EPRA+SkinEthicTM HCE SE/LE Test Strategy (TS) for discriminating non-classified test 
substances from classified ones (Freeman et al., 2010). For SkinEthicTM HCE, a total of 104 
coded chemicals were tested in both SE and LE in 3 runs and 3 replicate tissues per run, in 3 
laboratories, for each protocol. The same 104 chemicals were also tested in EPRA in 1 run 
with 3 replicate measurements in 1 laboratory. For EpiOcularTM EIT, a total of 52 liquids, 51 
solids and 1 chemical with borderline physical state (melting point near room temperature) 
were tested in the liquids and solids protocols, respectively, in 3 runs and 2 replicate tissues 
per run, in 3 laboratories, for each protocol. 
 
Optimisation of the EpiOcularTM EIT solids protocol was performed at the method developer’s 
laboratory (MatTek Corporation) in order to increase the sensitivity of the assay to the level 
requested by the VMG. This optimisation led to an increase of the exposure time from 90 min 
to 6 hours. 
 
Fifty two of these core EIVS test substances plus an additional 8 selected test substances 
were tested in blind in three runs in one laboratory in a follow-up validation of an optimised 
EpiOcular™ EIT solids protocol. 
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Table 1.1: Chronology and Management of the EURL ECVAM - Cosmetics Europe Eye 
Irritation Validation Study (EIVS) 
Year Month / Meeting / Teleconference Key Discussions / Decisions / Actions 
2005 December - First submissions to ECVAM of corporate pre-validation study on the 
SkinEthic
TM
 HCE test method (Van Goethem et al., 2006) and of a corporate 
validation study on the EpiOcular
TM
 ET50 test method for surfactants and 
surfactant-based formulations 
2006 ECVAM Eye Irritation Task Force 
meeting 
- Requirement for additional information on both SkinEthic
TM
 HCE and 
EpiOcular
TM
 ET50 test methods before initiation of a formal validation study 
2008 September - Updated submission to ECVAM including optimisation and pre-validation of 
the SkinEthic
TM
 HCE model (Cotovio et al., 2010; Alépée et al., 2013) and of the 
EpiOcular
TM 
Eye Irritation Test method (Kaluzhny et al., 2011; Pfannenbecker et 
al., 2013)   
 December: 1
st
  Validation 
Management Group (VMG) meeting 
of the Eye Irritation Validation Study 
(EIVS) 
- Planning of the study including project plan; discussions on study design 
initiated; request for additional information on the EPRA test; chemicals 
selection initiated 
2009 February - Submission of the Cyl/Lys EPRA and GSH/GSSG reactivity assays to 
ECVAM as an integral part of the SkinEthic
TM
 HCE submission 
 April: 2
nd
 EIVS VMG Meeting - Discussion on the use of two tissue replicates (instead of three) with the 
EpiOcular
TM
 EIT test method in EIVS (in accordance with what was used in pre-
validation studies); conduct and management of the study; discussion on 
project plan and study design; discussion on study acceptance criteria initiated; 
discussion on the EPRA submission; decision not to include the GSH/GSSG 
reactivity assay in the SkinEthic
TM
 HCE test strategy and to withdraw it 
from EIVS; discussion on chemicals selection 
  June: 3
rd
 EIVS VMG Meeting - Conduct and management of the study; discussion on project plan and study 
design; Approval of prediction model to be used with EPRA in EIVS; 
planning of training and transferability of EPRA at TNO; discussion on 
chemicals selection; discussion on EPRA reliability study design 
 June: EIVS VMG Teleconference - Discussion on study design 
 June - TNO training on EPRA completed 
 July: EIVS VMG Teleconference - Discussion on study design 
 July: EIVS VMG Teleconference - Decision on and approval of EIVS study design 
 August: EIVS VMG Meeting during 
WC8 
- Chemicals acquisition initiated; discussion on chemicals selection; 
discussion on TNO EPRA training and transferability studies 
 September: 4
th
 EIVS VMG Meeting - Conduct and management of the study; discussion on study acceptance 
criteria; planning of the quality assurance audits on the RhCE production sites; 
SOPs and contracts with the participating laboratories; discussion on chemicals 
selection 
 October: EIVS VMG 
Teleconference  
- Discussion on chemicals selection; planning of quality assurance audits on the 
RhCE production sites 
 October - TNO EPRA transferability study completed 
 November: EIVS VMG 
Teleconference  
- Approval of the EPRA training and transferability results and report from 
TNO; planning of quality assurance audits on the RhCE production sites 
  November: 5
th
 EIVS VMG Meeting  - Approval of EPRA reliability study design; conduct and management of the 
study; discussion on project plan; discussion on guidance on study conduct and 
study acceptance criteria; discussion on chemicals selection 
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 December: EIVS VMG 
Teleconference 
- Discussion on chemicals selection 
2010 January: EIVS VMG 
Teleconference 
- Discussion on chemicals selection: identification of first set of 77 chemicals for 
EPRA testing, of which only 73 were actually tested (eligible for final selection 
for EIVS) 
 January: EIVS VMG 
Teleconference 
- Discussion on chemicals selection; discussion on discontinued production of 
MTI-001a insert membrane, its replacement by the MTI-001b insert membrane 
for the EpiOcular
TM
 EIT tissue production at MatTek Corporation and the 
discovery of a problem with the new insert membrane, which was bursting with 
certain chemicals; discussion on the conduct of adapted controls for colorants 
and direct MTT reducers 
 January: EIVS VMG 
Teleconference  
- Follow-up on discussion on problem with insert used to produce EpiOcular
TM
 
EIT tissues at MatTek Corporation; follow-up on discussion on the conduct of 
adapted controls for colorants and direct MTT reducers 
 February: EIVS VMG 
Teleconference 
- Discussion on guidance on study conduct and study acceptance criteria; 
discussion on chemicals selection 
 March: EIVS VMG Teleconference - Discussion on guidance on study conduct and study acceptance criteria; 
discussion on chemicals selection 
 March - Quality Assurance audit on the SkinEthic
TM
 HCE tissues production site 
 March: 6
th
 EIVS VMG Meeting  - EPRA SOP finalised and approved; conduct and management of the study; 
discussion on guidance on study conduct and study acceptance criteria; update 
on problem encountered with insert used to produce EpiOcular
TM
 EIT tissues at 
MatTek Corporation: initiation of testing of two new insert membranes (MTI-002 
and MTI-003); discussion on chemicals selection 
 April - SkinEthic
TM
 HCE participating laboratories training and transferability 
studies completed 
 May: EIVS VMG Teleconference - Review of first set of EPRA results for 55 chemicals obtained by TNO 
 May - Quality Assurance audit on the EpiOcular
TM
 EIT tissues production site 
 May - Statistical analysis on the use of two tissue replicates with the 
EpiOcular
TM
 EIT test method conducted by NICEATM 
 June: EIVS VMG Teleconference - Approval of the SkinEthic
TM
 HCE training and transferability results and 
SOP; Selection of a first set of 34 chemicals for EIVS testing (based on first 
set of EPRA results) and decision to ship them to the laboratories for testing;  
Identification of second set of 55 chemicals for EPRA testing, of which only 49 
were actually tested (eligible for final selection for EIVS) 
 June - Communication from MatTek Corporation to VMG on their decision to 
withdraw the use of MTI-002 insert membrane for EpiOcular
TM
 EIT tissue 
production due to supply difficulties and to poorer performance as 
compared to the other inserts 
 June - Chemicals  coding and distribution initiated 
 June - SkinEthic
TM
 HCE experimental phase started 
 September: EIVS VMG 
Teleconference 
- Review of second set of EPRA results for 53 chemicals obtained by TNO; 
Selection of a second set of 46 chemicals for EIVS testing (based on 
second set of EPRA results) and decision to ship them to the laboratories for 
testing 
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 September: EIVS VMG 
Teleconference 
- Approval of comparative statistical analysis on use of old MTI-001a insert 
membrane (discontinued) versus bursting MTI-001b insert membrane versus 
new MTI-003 insert membranes with the EpiOcular
TM
 EIT test method and 
decision to use MTI-003 insert membrane in the multi-laboratory testing 
part of the validation study; Decision to evaluate two prediction models 
for EpiOcular
TM
 EIT in EIVS, one based on a cut-off at 60% viability as in the 
original submission and a second one based on a cut-off at 50% viability 




 EIVS VMG Meeting - Approval of quality assurance audits of the RhCE production sites; 
Approval to use of two tissue replicates (instead of three) with the 
EpiOcular
TM
 EIT test method in EIVS (supported by statistical analysis 
performed by NICEATM); discussion on project plan and on guidance on study 
conduct and study acceptance criteria: general consensus reached on both 
documents; preparation and discussion of a Statistical Analysis and Reporting 
Plan; discussion on chemicals selection 
 November: EIVS VMG 
Teleconference 
- Discussion of an issue with meeting acceptance criteria with positive control for 
LE during initial testing performed by one of the participating laboratories of the 
SkinEthic
TM
 HCE test method and planning of a strategy to solve the problem; 
discussion on chemicals selection 
 November - EpiOcular
TM
 EIT participating laboratories training and transferability 
studies completed 
 November: EIVS VMG 
Teleconference 
- Approval of the EpiOcular
TM
 training and transferability results; Approval 
of the final Project Plan and of the Guidance on EIVS Conduct & 
Performance Criteria document; discussion on chemicals selection 
 December: EIVS VMG 
Teleconference 
- Discussion on chemicals selection: OECD toolbox analysis of selected 
chemicals & decision to withdraw from the study a chemical that had been 
selected in the second set of 46 chemicals due to inconsistent physical state 
between what had been tested in vivo (red to brown liquid) and what was 
acquired for EIVS (white crystalline solid) 
 December: EIVS VMG 
Teleconference 
- Discussion on chemicals selection: identification of third and final set of 15 
chemicals for EPRA testing, of which only 14 were actually tested (eligible for 
final selection for EIVS) 
2011 January: EIVS VMG 
Teleconference 
- Review of new data from SkinEthic
TM
 HCE participating laboratory that had 
shown issues with the LE positive control and approval of continuation of testing 
at that laboratory  
 February - Approval of the EpiOcular
TM
 EIT SOP  
 March: EIVS VMG Teleconference - Discussion on chemicals selection: decision to replace a strong MTT reducer 
that had been selected in the first set of 34 chemicals, based on results 
obtained by one of the SkinEthic™ HCE participating laboratories; decision to 
include in the final chemicals selection 2 strong colorants that produced 
permanent coloration of the cornea in vivo as extra EIVS chemicals 
 March - EpiOcular
TM
 EIT experimental phase started 
 April: EIVS VMG Teleconference - Review of third set of EPRA results for 33 chemicals obtained by TNO (6 of 
which were re-tests); Completion of EIVS chemicals selection: Selection of 
a third and final set of 28 chemicals for EIVS testing (based on third set of 
EPRA results) and decision to ship them to the laboratories for testing 
 April - Chemicals  coding and distribution completed 
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 June: EIVS VMG Teleconference - Approval of the final Statistical Analysis and Reporting Plan; monitoring of 
testing progression in all participating laboratories; discussion on the inclusion 
of an addendum to the Guidance on EIVS Conduct & Performance Criteria 
document  providing further instructions for the testing of direct MTT reducers 
and/or coloured test chemicals 
 June: EIVS VMG Teleconference - Approval of the Addendum to the Guidance on EIVS Conduct & 
Performance Criteria document 
 November: 8
th
 EIVS VMG Meeting - Preliminary analysis of results from main validation study (completed for 
the three EpiOcular
TM
 EIT participating laboratories and for two of the three 
SkinEthic
TM
 HCE  participating laboratories): recommendations for 
EpiOcular
TM
 EIT to optimise its protocol for solid materials and for 
SkinEthic
TM
 HCE to optimise both its protocols; Decision not to conduct a 
multi-laboratory reliability assessment of EPRA due to the non-validity of 
the proposed SkinEthic
TM
 HCE testing strategy 
 November: EIVS VMG 
Teleconference 
- VMG communication to MatTek Corporation and Beiersdorf on the outcome 
obtained with the EpiOcular
TM
 EIT test method and the need to optimised the 
solids protocol based on the preliminary results; VMG communication to L’Oréal 
on the outcome obtained with the SkinEthic
TM
 HCE test method, the non-validity 
of the testing strategy, and the need to optimise the SE and LE protocols 
potentially for the testing of liquids and solids, respectively, based on the 
preliminary results 
2012 February - EpiOcular
TM
 EIT experimental phase officially completed in all three 
participating laboratories, including all the necessary re-testing identified 
by the VMG 
 February - First version of EpiOcular
TM
 EIT EIVS statistics report available 
 February: EIVS VMG 
Teleconference 
- Discussion on chemicals selection for optimisation and post- optimisation  
validation of EpiOcular
TM
 EIT and SkinEthic
TM
 HCE; revision of timelines for 
ESAC peer-review 
 May - First version of SkinEthic
TM
 HCE EIVS statistics report available 
 May: 9
th
 EIVS VMG Meeting - Review of the EpiOcular
TM
 EIT and SkinEthic
TM
 HCE statistics reports on the 
results from the main validation study; planning of the optimisation and possible 
post-optimisation validation of the EpiOcular
TM




 June - First version of EIVS Chemicals Selection Report available 
 June: EIVS VMG Teleconference - Discussions with L’Oréal about optimisation of a SkinEthic
TM
 HCE protocol for 
liquid chemicals; discussion on chemicals selection for post- optimisation  
validation of EpiOcular
TM
 EIT and SkinEthic
TM
 HCE 
 July - Official communication to ESAC and the public on the outcome of the 
main part of EIVS 
 August - Statistical analyses on the use of two tissue replicates with the 
SkinEthic
TM
 HCE SE and LE protocols conducted by NICEATM 
 October: EIVS VMG 
Teleconference 
- MatTek Corporation reporting to VMG on the successful optimisation of the 
EpiOcular
TM
 EIT solids protocol – request from the VMG for more information; 
discussion on chemicals selection for the post- optimisation validation of the 
EpiOcular
TM
 EIT optimised solids protocol; decision from L’Oréal to withdraw 
from optimising the SkinEthic
TM
 HCE test method within EIVS as more time will 
be required to get to a positive outcome 
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 December: EIVS VMG 
Teleconference 
- Review of further data on the optimisation of the EpiOcular
TM
 EIT solids protocol 
provided by MatTek Corportation; approval of chemicals selection for the 
post- optimisation validation of the EpiOcular
TM
 EIT optimised solids 
protocol; planning of the post-optimisation validation of the EpiOcular
TM
 EIT 
optimised solids protocol: decision to conduct the work at Beiersdorf  
 December: EIVS VMG 
Teleconference 
- Request to MatTek Corporation for further data on the optimisation of the 
EpiOcular
TM
 EIT solids protocol to support a VMG approval of the optimised 
protocol; planning of the post-optimisation validation of the EpiOcular
TM
 EIT 
optimised solids protocol; revised statistics report from the main validation study 
on the EpiOcular
TM
 EIT test method made available and presented to the VMG 
2013 January: EIVS VMG 
Teleconference 
- Approval of the EpiOcular
TM
 EIT optimised solids protocol; review of 
comments received on the revised statistics report from the main validation 
study on the EpiOcular
TM
 EIT test method 
 February - Chemicals  coding and distribution for the validation of the optimised 
EpiOcular
TM
 EIT solids protocol 
 March - Experimental work for the validation of the optimised EpiOcular
TM
 EIT 
solids protocol started at Beiersdorf 
 April - SkinEthic
TM
 HCE experimental phase officially completed in all three 
participating laboratories, including all the necessary re-testing identified 
by the VMG 
 April: EIVS VMG Teleconference - Review of EIVS Chemicals Selection Report; debriefing on Cosmetics Europe 
HPLC project; discussion on outstanding EIVS activities 
 June - Experimental work for the validation of the optimised EpiOcular
TM
 EIT 
solids protocol completed at Beiersdorf 
 June: EIVS VMG Teleconference - Planning of next steps: report on potential reasons for misclassifications, closing 
of chemicals repository at TNO, drafting of statistics report on the post-
optimisation validation study on the EpiOcular
TM
 EIT optimised solids, drafting of 
Validation Study Report, preparation of ESAC peer-review 
 July - First version of the statistics report on the post-optimisation validation 
study of the EpiOcular
TM
 EIT optimised solids protocol available 
 September: EIVS VMG 
Teleconference 
- Review of reasons for misclassifications in EIVS main study; review of the 
statistics report on the post-optimisation validation study on the EpiOcular
TM
 EIT 
optimised solids protocol; planning of next steps: drafting of the Validation Study 
Report and preparation of ESAC peer-review; Approval of the results from 
the post-optimisation validation study on the EpiOcular
TM
 EIT optimised 
solids protocol and of the overall results of the EIVS validation study 
 November: 10
th
 and final EIVS 
VMG Meeting 
- Discussion on final VMG recommendations on EpiOcular™ EIT and 
SkinEthic™ HCE; Discussion on the Chemicals Selection Report, the 
Statistics Reports and the Validation Study Report; Presentation and 
discussion of the Cosmetics Europe study on the use of HPLC with RhCE 
assays to increase applicability to coloured chemicals; Preparation of 
OECD SPSFs on EpiOcular™ EIT and on HPLC-photometry as an 
alternative formazan detection system for RhCE/MTT-based test methods; 
Preparation of ESAC peer-review of EIVS, the post-optimisation validation 
of the EpiOcular
TM
 EIT optimised solids protocol and of HPLC-photometry 
as an alternative formazan detection system for RhCE/MTT-based test 
methods 
2014 January - Final version of the Chemicals Selection Report available; Approval of 
final Chemicals Selection Report 
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 March - Seventh and final version of the EpiOcular
TM
 EIT EIVS statistics report 
available; Eighth and final version of the SkinEthic
TM
 HCE EIVS statistics 
report available; Fifth and final version of the statistics report on the post-
optimisation validation study of the EpiOcular
TM
 EIT optimised solids 
protocol available 
  - Approval of the final EpiOcular
TM
 EIT and SkinEthic
TM
 HCE statistics 
reports (EIVS and post-optimisation validation) 
  - Approval of the final VMG conclusions on EIVS and recommendations on 
EpiOcular™ EIT and SkinEthic™ HCE 
- Approval of the Validation Study Report 
VMG = Validation Management Group; EIVS = Eye Irritation Validation Study; CSG = Chemicals Selection Group  
 
1.2. Goals and objectives of the study 
 
The objective of the EURL ECVAM – Cosmetics Europe Eye Irritation Validation Study 
(EIVS) was to evaluate the validity of the RhCE-based EpiOcularTM EIT and the SkinEthicTM 
HCE Short-time Exposure (SE), Long-time Exposure (LE) and Test Strategy (TS) through a 
prospective study for the regulatory hazard assessment of chemicals for serious eye 
damage/eye irritation according to the United Nations Globally Harmonized System of 
Classification and Labelling of Chemicals (UN GHS) and as implemented by the European 
Commission Regulation (EC) No 1272/2008 on classification, labelling and packaging of 
substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, 
and amending Regulation (EC) No 1907/2006 (EU CLP) (UN, 2013; EC, 2008). In particular, 
these RhCE-based test methods shall be incorporated into the Bottom-Up and Top-Down 
tiered test strategy schemes as defined by Scott and co-workers (2010) to identify chemicals 
not requiring classification and labelling for serious eye damage/eye irritation. The ultimate 
purpose of the Bottom-Up/Top-Down tiered test strategy is to replace the traditional in vivo 
Draize eye irritation test [Method B.5 of EC Regulation 440/2008 (EC, 2008) or OECD TG 
405 (OECD, 2012a)]. 
 
For this purpose, EIVS assessed the relevance (predictive capacity) and reliability 
(reproducibility within and between laboratories) of the EpiOcularTM EIT and the SkinEthicTM 
HCE SE, LE and TS by testing a statistically significant number of coded test chemicals 
(substances and mixtures), supported by complete and quality assured in vivo Draize eye 
irritation data for comparative evaluation of results. Specifically, the EIVS assessed the 
validity of the EpiOcularTM EIT protocol for liquids, the EpiOcularTM EIT protocol for solids, an 
optimised EpiOcular™ EIT protocol for solids, the SkinEthicTM HCE Short-time Exposure 
(SE) protocol, the SkinEthicTM HCE Long-time Exposure (LE) protocol, and the SkinEthicTM 
HCE test strategy combining the SE and LE protocols with the Eye irritation Peptide 
Reactivity Assay (EPRA). 
 
The RhCE models and protocols described above were evaluated to be used as stand-alone 
(independent) test methods to reliably discriminate chemicals not classified as eye irritant 
(“non-irritants”) from classified ones (in the framework of a Bottom-Up/Top-Down test 
strategy, Scott et al., 2010), defined according to UN GHS ( No Category versus Category 
1/Category 2A/Category 2B; UN, 2013) and as implemented in the EU CLP (No Category 
versus Category 1/Category 2; EC, 2008). 
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The SkinEthic™ HCE TS and the EpiOcular™ EIT were developed for maximum sensitivity 
(ability to detect positives, with low rate of false negatives) rather than for optimal overall 
accuracy with balanced sensitivity and specificity (ability to detect negatives, with low rate of 
false positives). Sensitivity had therefore a bigger weight than specificity and overall 
accuracy in their development. However, it was also sought to achieve a sufficiently high 
specificity and overall accuracy, in order to allow identification of the highest number of 
chemicals not requiring classification for serious eye damage/eye irritation. By achieving 
satisfactory specificity, the SkinEthic™ HCE TS and the EpiOcular™ EIT would represent 
stand-alone (independent) test methods for the identification of “non-irritants”. Importantly, 
the test methods are not intended to differentiate between UN GHS/EU CLP Category 1 
(irreversible/serious eye damage) and UN GHS/EU CLP Category 2 (reversible eye irritation 
effects). As proposed by the ECVAM workshop of February 2005, this differentiation would 
be left to another tier of the Bottom-Up/Top-Down test strategy (Scott et al., 2010). 
 
The EIVS was undertaken in accordance with the principles and criteria documented in the 
OECD Guidance Document on the Validation and International Acceptance of New or 
Updated Test Methods for Hazard Assessment (No. 34, OECD, 2005) and according to the 
Modular Approach to validation (Hartung et al., 2004).  
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2. Materials and methods 
 
2.1. Management and conduct of the validation study 
 
 
2.1.1. Study management 
 
The management structure of the EIVS on RhCE-based test methods, which took place 
between 2008 and 2013, is shown in Figure 2.1. The study comprised:  
- a Validation Management Group (VMG) responsible for overseeing the conduct of all 
aspects of the study; 
- a study coordinator (EURL ECVAM); 
- a study logistics coordinator (TNO); 
- an independent Chemicals Selection Group (CSG); 
- independent biostatististical analyses; 
- the lead and participating laboratories of the test methods evaluated; 
- and liaisons from the USA, Japan and Canada in the framework of the International 
Cooperation on Alternative Test Methods (ICATM). 
 
The VMG comprised a chair, co-chair, sponsor representatives (EURL ECVAM and 
Cosmetics Europe), coordinating organisation’s representatives (TNO and ECVAM), 
independent biostatisticians (TNO and EURL ECVAM), external scientists, the chair of the 
Chemicals Selection Group (CSG), representatives of the lead laboratories for each test 
method (L’Oréal and Beiersdorf), and liaisons from the USA, Japan and Canada. Its 
composition is shown in Figure 2.2.  
 
Operational decisions, including discussions regarding chemical selection, were taken by the 
core VMG only, i.e., did not involve the lead laboratories’ representatives. The 
representatives of the lead laboratories were consulted on technical issues relating to the 
test methods and supported the core VMG in monitoring the progress of the experimental 
work. The ICATM liaisons were invited to advise the VMG on all aspects of the study. 
 
The overall study coordination was conducted by EURL ECVAM. This included the 
organisation of all necessary VMG meetings and teleconferences, and the maintenance of a 
website where the EIVS documents not related to chemical selection were made available to 
VMG members and ICATM liaisons. EURL ECVAM was also responsible for organising the 
Quality Control audits on data collection, on data handling and analysis, as well as on the 
biostatistical reports produced by the TNO biostatistician. 
 
TNO (Quality of Life) on the other hand coordinated the communication flow between all 
parties, prepared the draft minutes of the VMG meetings and telephone conferences, 
organized the meetings between laboratories, and organised the study conduct. TNO was 
also responsibility for logistics of test chemical acquisition, coding and distribution. Finally, 
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Regarding sponsorship, EURL ECVAM and Cosmetics Europe co-sponsored the EIVS, with 
the main financial support being provided by Cosmetics Europe. 
 
Cosmetics Europe financed the following activities:  
- conduct of the EPRA; 
- lead and participating laboratories for the two test methods;  
- statistical support provided by TNO; 
- financial support of the independent chair of the VMG; 
- independent CRO responsible for the test chemicals purchase, coding and distribution to 
the laboratories (TNO); 
- overall logistical coordination of the study (TNO); 
- part of the independent Quality Assurance audits on the RhCE models production sites;  
- purchase cost of existing chemicals; 
- purchase of a proportion of the RhCE tissues; 
- preparation of the validation study report. 
 
EURL ECVAM on the other hand financed: 
- management and coordination of the study, including the organisation of VMG meetings 
and teleconferences; 
- statistical support provided by ECVAM; 
- part of the independent Quality Assurance audits on the RhCE models production sites;  
- independent Quality Control audit on data collection, handling and analysis; 
- independent Quality Control audit of the biostatistical report(s); 
- purchase of a proportion of the RhCE tissues; 
- publication of the study. 
 
 
2.1.2. Participating laboratories 
 
The laboratories participating in the study were defined as shown in Figure 2.1. The specific 
obligations and responsibilities of the participating laboratories included, but were not limited 
to, the adherence to the project plan and guidance on study conduct and its addendum 
throughout the study, the adherence to the test method SOP, the adherence to the work 
program, assuring compliance with GLP-like principles, specifying and applying proper 
Quality Assurance procedures, and meeting the data submission deadlines. All participating 
laboratories had competence in performing the test method(s) and provided competent 
personnel, adequate facilities, equipment, supplies, and proper health and safety guidelines. 
The lead laboratories were further responsible for preparing detailed SOP for the EpiOcularTM 
EIT, SkinEthicTM HCE SE/LE and EPRA, and for providing training to the technical staff of the 
other testing facilities. Each participating laboratory appointed a Study Director and a Safety 
Officer. 
 
The Study Directors represented the single point of study control with ultimate responsibility 
for the overall technical conduct of the study, the documentation and reporting of the results, 
as well as GLP adherence or adherence to the minimum quality requirements. The Study 
Director was responsible for collecting the data of his/her laboratory and to send them to the 
Logistics Coordinator of the study (to be forwarded to the TNO biostatistician). The Study 
Directors were also responsible for sending timely Study Reports to the contact person of the 
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VMG, i.e. the Logistics Coordinator, to allow for a proper monitoring of the progress of the 
study. Such reports included all relevant experimental data as well as all deviations from the 
Project Plan and SOP. The study directors were the primary contact point for the 
communications between the VMG and the testing facilities. 
 
The Safety Officers were not involved in the actual conduct of the validation study. They 
were responsible for receiving the blinded (coded) test chemicals and for transferring them to 
the responsible person of the laboratory. A sealed Safety Package containing the Material 
Safety Data Sheets (MSDSs) for all test chemicals accompanied the test chemicals and was 
retained by the Safety Officer until the completion of EIVS. The package would be opened by 
the Safety Officer only in case of an accident with one of the coded test chemicals at the 
laboratory. At the end of the validation study, all Safety Officers returned the packages to the 
Logistics Coordinator of the study. None of the Safety Packages had to be opened during the 
validation study. 
 
The participating laboratories were allowed to freely communicate and meet during the 
training and transferability phases of EIVS. Such meetings were organized by the lead 
laboratories and occurred without a formal approval by the VMG. However, during the testing 
phase, the participating laboratories and the personnel responsible for providing training on 
the test methods, no longer had any form of contact with each other regarding EIVS without 
the previous knowledge and approval by the VMG. All VMG approved meetings or other 
forms of communication between the participating laboratories during the testing phase were 
organised by the Logistics Coordinator (TNO) in collaboration with the lead laboratories. 
 
 
2.1.3. Study design 
 
The study design of the EIVS was defined prior to initiation of testing in a project plan agreed 
by the VMG. In addition, the VMG prepared a Guidance document on the conduct of the 
RhCE assays establishing pre-defined: testing procedures, criteria for re-conducting tests 
and runs, test acceptance criteria, biostatistical analyses procedures, study quality criterion, 
and the performance criteria to assess the scientific validity of the test methods. 
 
Reconstructed human Cornea-like Epithelium models 
Training of the participating laboratories in conducting the EpiOcularTM EIT or the SkinEthicTM 
HCE SE/LE assays were provided by the respective test method developer (MatTek 
Corporation for EpiOcularTM EIT and L’Oréal for SkinEthicTM HCE SE/LE). The lead 
laboratories (Beiersdorf for EpiOcularTM EIT and L’Oréal for the SkinEthicTM HCE), in 
collaboration with the test method developers, were responsible for issuing final test method 
Standard Operating Procedures (SOP). Upon completion of the training phase, the 
participating laboratories tested 5-10 chemicals to demonstrate transferability of the assay 
and to confirm test method protocol adequacy. The test method developers in collaboration 
with the participating laboratories were responsible for issuing training and transferability 
reports upon completion of the transferability studies. 
 
In the testing phase of EIVS, the test chemicals in the final chemical selection set (104 test 
chemicals plus 2 extra strong colorants) were tested using the four protocols of the two 
RhCE test methods (liquids protocol of EpiOcularTM EIT, solids protocol of EpiOcularTM EIT, 
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SkinEthicTM HCE SE and SkinEthicTM HCE LE) in at least three independent tests (using 
different tissue batches and performed in separate runs) by each of three independent 
laboratories (all chemicals were tested in each of the SkinEthicTM HCE protocols, while only 
the liquids (52 plus 1 solid that was considered as a liquid by the participating laboratories) 
were tested in the liquids protocol of EpiOcularTM EIT and only the solids (51 + 2 strong 
colorants) were tested in the solids protocol of EpiOcularTM EIT). One other chemical (#27) 
was sent to all participating laboratories for testing but was excluded and replaced by 
another chemical (one of the final 104) at a very early stage of the study on request of one of 
the SkinEthic™ HCE participating laboratories because it was identified as a very strong 
MTT reducer. However, by the time this chemical was replaced, it had already been tested in 
a complete test sequence by all three EpiOcular™ EIT participating laboratories. Since in 
EpiOcular™ EIT this chemical only produced minor interference with the MTT assay, it was 
decided to consider it in the statistical evaluations presented in this report. Each of the EIVS 
chemicals was tested with the two different exposure/post-treatment periods of the 
SkinEthicTM HCE SE/LE protocol, and with one of the two EpiOcularTM EIT exposure 
procedures depending on the test chemical being solid or liquid. Importantly, the three 
laboratories participating in the validation of EpiOcularTM EIT were not instructed on the 
physical state of the test chemicals. Therefore, each laboratory participating in the validation 
of the EpiOcularTM EIT decided on its own on the physical state of each test chemical and the 
appropriate exposure procedure to use. Finally, each control and test chemical included in 
one run was tested in two (EpiOcularTM EIT) or three (SkinEthicTM HCE SE/LE) replicate 
tissues. The VMG decision to use two replicate tissues instead of three with the EpiOcularTM 
EIT test method in EIVS was mostly due to technical considerations, but was also based on 
the fact that the pre-validation studies had already been performed with only two tissue 
replicates and was supported by biostatistical analyses performed by the US liaisons 
NICEATM (see chapter 2.1.3.1 below). 
 
The EIVS testing phase was conducted in three consecutive phases to allow for periodic 
opportunities to evaluate the frequency of technical errors and any other problems that might 
occur during testing. At the end of each testing phase the Study Directors forwarded the data 
acquired by their laboratories to the Logistics Coordinator after internal quality check who 
provided it to the TNO biostatistician for immediate preliminary analyses of Within Laboratory 
Reproducibility and compliance with Study Quality criteria (number of complete/incomplete 
test sequences as described in the Performance Criteria). Once completed, these phased 
statistical analyses and their conclusions were provided to the core VMG who reviewed them 
and determined if modifications to the protocol and/or study plan were warranted/appropriate 
in order to avoid future occurrences of identified issues. 
 
Eye Irritation Peptide Reactivity assay 
During the chemicals selection phase, all eligible chemicals identified by the CSG had their 
chemical reactivity determined based on the Cysteine/Lysine Eye Irritation Peptide Reactivity 
Assay (EPRA), in a blind study at TNO, with a single test consisting of three replicate 
measurements. Before testing with EPRA started at TNO, the EPRA developer (Procter & 
Gamble) trained TNO in conducting the assay. Upon completion of the training phase, TNO 
tested 11 test chemicals to demonstrate transferability of the assay and to confirm test 
method protocol adequacy. TNO was responsible for issuing training and transfer reports 
upon completion of the transferability study. The results of the training and transferability 
were reviewed and approved by the VMG before TNO progressed with testing of chemicals 
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eligible for selection for EIVS. TNO and the test method developer (P&G) were responsible 
for issuing a final SOP that was used during testing. 
 
Since chemicals found eligible by the CSG did not all become available for EPRA testing at 
TNO at the same time (due to differences in the time required to gain access to in vivo 
Draize eye irritation study reports for different chemicals, and to differences in the time 
required to obtain commercially available and proprietary chemical samples), the selection of 
a final test chemical set was phased, with subsets of 28-46 test chemicals being selected by 
the CSG in different stages, as the data from the EPRA analysis became available, and until 
the final amount of 104 test chemicals was reached. These chemical subsets were as 
balanced as possible considering the criteria described in chapter 2.3 and, upon approval by 
the core VMG, they were distributed to the participating laboratories for viability assessment. 
The VMG had agreed that a multi-laboratory reproducibility assessment of the EPRA, using a 
subset of the full validation set (at least 20 chemicals), tested in three laboratories and in 
three independent tests (performed in separate runs) consisting of three replicate 
measurements each to determine the WLR and BLR of the assay, would be conducted only 
after finalisation of the testing of the 104 selected chemicals with SkinEthicTM HCE SE and 
LE, if these viability data together with EPRA data acquired by TNO during chemicals 
selection for all these 104 chemicals would demonstrate the validity of the SkinEthicTM HCE 
TS. This preliminary evaluation of the usefulness of the SkinEthicTM HCE TS upon 
completion of the viability assessment study demonstrated its non-validity and therefore, the 
VMG decide not to conduct the multi-laboratory reproducibility assessment of the EPRA. 
Should this have been conducted, the lead laboratory for this reproducibility study would 
have been L’Oréal and the other participating laboratories would have been TNO and 
CARDAM. 
 
2.1.3.1. Number of tissue replicates used in EpiOcularTM EIT 
The EpiOcularTM EIT was developed using two concurrently tested tissue replicates on the 
basis of practical considerations in the technical procedures for conduct of this test method, 
i.e., the washing procedure after chemical exposure is done on two replicate tissues together 
and therefore the use of an uneven number of tissue replicates is not technically possible. 
The variability between two concurrently treated tissue replicates was found to be low in the 
296 pairs of replicates produced by seven laboratories for a wide set of test chemicals during 
the pre-validation study of the EpiOcularTM EIT. Briefly, 99%, 95%, 90% and 74% of the 296 
pairs of concurrently treated tissue replicates showed a difference of viability below 20%, 
15%, 10% and 5%, respectively. Two independent biostatisticians from ECVAM and 
NICEATM evaluated the data and their conclusions led the VMG to consider the use of two 
tissue replicates for EpiOcularTM EIT in EIVS as sufficiently statistically and scientifically 
justified. 
 
2.1.3.2. Data submission 
The Logistics Coordinator collected the data from each participating laboratory via the Study 
Directors at the end of each RhCE testing phase and forwarded it to the TNO biostatistician. 
The TNO biostatistician organised the data in specific data collection software (MS EXCEL 
spreadsheets). The collected data was circulated to every participating laboratory for a 
quality check. At the end of each RhCE testing phase a preliminary analysis of WLR and 
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compliance with Study Quality criteria (number of complete / incomplete test sequences as 
defined by the Guidance on Study Conduct & Performance Criteria VMG document) was 
performed without decoding the test chemicals (to avoid breaking the code before completion 
of the study). Upon completion of the RhCE testing phases by all participating laboratories 
and preliminary “blind” determination of WLR and Study Quality criteria for each laboratory, 
test chemicals were decoded and the TNO biostatistician conducted a complete statistical 
analysis of the data and provided biostatistical reports to the VMG. The VMG did a quality 
control of the processes of data collection, handling and analysis, as well as of the final 
biostatistics reports.   
 
2.1.3.3. Data analysis and statistics 
The data management procedures and statistical tools that were used for data analysis 
included in the final biostatistics reports were described in the Guidance document on the 
conduct of the EIVS and in a Statistical Analysis and Reporting Plan. The biostatistics 
analyses procedures reported in the Statistical Analysis and Reporting Plan were developed 
by the ECVAM and TNO biostatisticians before completion of the experimental phase of the 
study and were approved by the VMG before the biostatistics analyses began. 
 
The reproducibility and predictive capacity of EpiOcular™ EIT were evaluated for the whole 
test method (liquids plus solids) because each test chemical was tested in a single protocol 
(as a solid or a liquid), but the two protocols were also evaluated separately in terms of their 
predictive capacity. For SkinEthicTM HCE, since all of the selected test chemicals were tested 
in both the SE and the LE protocols, these two protocols were fully independently assessed 
for their reproducibility and predictive capacity, considering them as independent test 
methods. The EPRA/SE/LE TS was evaluated for its predictive capacity only. 
Two prediction models were evaluated separately for EpiOcular™ EIT, the first using 60% 
mean tissue viability as the threshold differentiating classified (UN GHS Cat 1 and Cat 2) 
chemicals (mean tissue viability ≤ 60%) from non-classified (UN GHS No Cat) chemicals 
(mean tissue viability > 60%) and the second using a threshold of 50% mean tissue viability. 
The EpiOcular™ EIT was originally developed by MatTek Corporation with the single 
threshold of 60% mean tissue viability in the prediction model and the submission of the test 
method to ECVAM for validation only mentioned this single prediction model. However, in the 
beginning of the EIVS and even before training and transferability took place, MatTek 
Corporation was faced with the necessity to replace the insert membrane used in the 
production of the EpiOcular™ tissues due to discontinued production of the insert membrane 
used until then (MTI-001a). A replacement insert membrane (MTI-003) was approved by the 
VMG for use in EIVS after multiple testing of 94 chemicals at MatTek Corporation and 
comparative statistical analysis performed by the EURL ECVAM biostatistician on the use of 
the old MTI-001a insert membrane (discontinued) versus the new MTI-003 insert membrane. 
The results showed that with the MTI-003 membrane a sensitivity higher than 90% could 
potentially still be achieved using a 50% cut-off instead of 60%, with a significant gain in 
specificity. Considering these new data, the VMG decided to evaluate two prediction models 
with EpiOcular™ EIT in EIVS, one based on the original cut-off at 60% mean tissue viability 
as in the submission to ECVAM and a second one based on a cut-off at 50% mean tissue 
viability. A single prediction model using 50% mean tissue viability as the threshold 
differentiating classified (UN GHS Cat 1 and Cat 2) chemicals (mean tissue viability ≤ 50%) 
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from non-classified (UN GHS No Cat) chemicals (mean tissue viability > 50%) was evaluated 
with the SkinEthic™ HCE SE, LE and TS. 
 
2.1.3.3.1. Within-laboratory reproducibility 
For each laboratory, concordance of classifications and overall Standard Deviation (SD) 
were calculated based only on qualified tests from test chemicals for which at least two 
qualified tests (see definitions for details) were available. In addition, the Standard Deviation 
associated with each laboratory was calculated using all available test sequences, i.e., 
including both qualified and non-qualified tests (see definitions for details). 
 
2.1.3.3.2. Between-laboratory reproducibility 
For the calculation of BLR the final classification for each test chemical in each participating 
laboratory was established by using the arithmetic mean value of viability over the different 
qualified tests performed. Concordance of classifications between laboratories and overall 
Standard Deviation of the study were calculated based only on qualified tests (see definitions 
for details) from test chemicals for which at least one qualified test per laboratory was 
available. In addition, the overall Standard Deviation of the study was calculated using all 
available test sequences, i.e., including both qualified and non-qualified tests (see definitions 
for details). 
 
2.1.3.3.3. Predictive capacity 
All qualified tests for each test chemical (see definitions for details) were used to calculate 
the predictive capacity values. The calculations were based on the individual predictions of 
each qualified test in each laboratory and not on the arithmetic mean values of viability over 
the different qualified tests performed.  
 
2.1.3.4. Quality aspects 
Laboratories 
Participating laboratories that were compliant with Good Laboratory Practices (GLP) 
performed the studies in accordance with GLP standards (OECD, 1999). Non GLP-compliant 
laboratories used the OECD principles of GLP as guidelines for conducting the validation 
study. Any deviations from these principles were documented along with a discussion of their 
impact on the study results. 
The following requirements were considered essential for the mutual acceptance of 
information produced during the validation process (Balls et al., 1995): 
• Qualified personnel, and appropriate facilities, equipment and materials to be 
available for the timely and proper conduct of the study 
• Records of the qualifications, training and experience, and a job description for each 
professional and technical individual involved in the study, to be maintained. 
• For each study, an individual with appropriate qualifications, training and experience 
to be appointed as responsible for the study overall conduct and for any report 
issued (Study Director).  
• Instruments used for the generation of experimental data to be inspected regularly, 
cleaned, maintained and calibrated according to established SOPs, if available, or to 
manufacturers' instructions. Records of these processes to be kept, and made 
available for inspection on request. 
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• Reagents to be labelled, as appropriate, to indicate their source, identity, 
concentration and stability.  The labelling should include the preparation and expiry 
dates, and specific storage conditions. 
• All data generated during a study to be recorded directly, promptly and legibly by the 
individual(s) responsible.  These entries should be attributable and dated. 
• All changes to data should be identified with the date and the identity of the 
individual responsible, and a reason for the change should be documented at the 
time. 
 
Tissue model suppliers 
According to OECD GLP Consensus Document No.5 “Compliance of Laboratory Suppliers 
with GLP Principles”, the responsibility for the quality and fitness for use of equipment and 
materials rests entirely with the management of the test facility (OECD, 1999). 
The acceptability of equipment and materials in laboratories complying to GLP principles 
should therefore be guaranteed to any regulatory authority to whom studies are submitted. In 
some countries where GLP has been implemented, suppliers belong to national regulatory or 
voluntary accreditation schemes (for example, for laboratory animals) which can provide 
users with additional documentary evidence that they are using a test system of a defined 
quality. 
The audits on the RhCE tissue production sites (MatTek Corporation and EpiSkin 
Laboratories), were carried out by TNO and ECVAM, and focused on the procedures 
established to guarantee a defined quality of the tissue models, as defined in an audit 
protocol previously approved by the VMG. 
 
Records and archives 
At the end of EIVS, the original raw (not applicable for GLP-compliant laboratories) and 
processed data or copies thereof were submitted to ECVAM and Cosmetics Europe for 
storing and archiving. In addition, other records relevant to EIVS (instrument logs, calibration 
records, facility logs, etc.) were asked to be made available for inspection upon request by 
the VMG. 
Raw and processed data or copies thereof (depending if the laboratory is or not GLP 
compliant) were asked to be stored and archived at the participating laboratory for at least 
five years after completion of EIVS. The data which are stored electronically were asked to 
be periodically copied, and backup files produced and maintained. 
 
 
2.1.4. Pre-defined study quality criterion  
To limit the bias introduced in the calculations of reproducibility and predictive capacity due 
to the exclusion of the most variable tests (non-qualified tests) from some of the calculations 
(see chapter 2.1.3.3), and also to avoid further bias introduced by a reduction of the data 
used in some of the calculations (at least 104 test chemicals are needed to reach the 
statistical power defined for the study), the VMG decided to define a target value for the 
number of complete test sequences that should be available after re-testing as an objective 
to secure the quality of the study, i.e., to limit the amount of missing data due to the 
predefined test acceptance criteria (see chapters 2.2.1.4 and 2.2.2.1.4). The target value 
defined prior to the initiation of the validation study was as follows: 
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In each participating laboratory, at least 85% of the test sequences (see definitions for 




2.1.5. Pre-defined performance criteria to assess the scientific validity of the test 
methods 
Prior to the initiation of the validation study, the VMG defined test method performance 
criteria for reliability and predictive capacity, which it considered appropriate for judging the 
performance of the SkinEthicTM HCE SE, LE and TS and of the EpiOcularTM EIT with the test 
chemicals selected for EIVS.  
One recommendation of a previous ESAC Peer Review Panel on cell-based assays was to 
receive guidance from the VMG to evaluate the performance of these cell-based assays. 
Therefore, within the framework of EIVS, the VMG also suggests the use of these test 
method performance criteria as a basis for the evaluation of the performance of the 
SkinEthicTM HCE LE, SE and TS and of the EpiOcularTM EIT by the ESAC Peer Review 
Panel after the completion of EIVS. 
The test method performance criteria developed by the VMG for EIVS and described below 
took into account: (a) the background and specific objectives of the validation study (see 
chapter 1 above); (b) the requirements of regulatory authorities and industry when testing 
and classifying chemicals for eye irritation; (c) the within test variability in the in vivo Draize 
eye test and the manner in which Draize eye test data are currently used for classifying eye 
hazards according to UN GHS / EU CLP (UN, 2013; EC, 2008); (d) the standards of 
performance which are expected from the in vitro tests evaluated; (e) the way in which the in 
vitro tests are to be used (as a test within a tiered test strategy); and (f) the power of the 
design of the validation study. 
 
2.1.5.1. Acceptance criteria for reproducibility 
Analysis of reproducibility were not limited to the parameters described below. Other 
statistical tools, e.g., the overall Standard Deviation of the study calculated from all qualified 
tests as well as from all available tests (qualified and non-qualified), were also considered 
before making a final recommendation on the reproducibility of the test methods. 
Within-laboratory reproducibility  
The concordance of classifications (UN GHS  / EU CLP not classified versus classified) for 
the set of chemicals tested during validation obtained in different, independent runs within a 








 The within laboratory reproducibility values obtained in the pre-validation of the SkinEthic
TM
 HCE were of 90 to 100% 
concordance of classifications, and for EpiOcular
TM
 EIT of 95 to 100% concordance of classifications (considering the 
classification cut-off of 60% viability). 
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Between-laboratory reproducibility 
The concordance of final classifications (UN GHS / EU CLP not classified versus classified) 
for the set of chemicals tested during validation obtained by the different participating 
laboratories should ideally be equal or higher () than 80%2. 
 
2.1.5.2. Acceptance criteria for predictive capacity 
The SkinEthicTM HCE SE, LE and TS and the EpiOcularTM EIT (liquids and solids protocols) 
were assessed for their usefulness as stand-alone (independent) test methods to identify 
chemicals not requiring classification for serious eye damage/eye irritation (UN GHS / EU 
CLP No Category; “non-irritants”) and their reliable discrimination from all classes of 
classified chemicals as e.g., the initial step of a Bottom-Up approach (in the framework of a 
Bottom-Up/Top-Down test strategy, Scott et al., 2010). As already mentioned above, the 
SkinEthic™ HCE and the EpiOcular™ EIT were developed for maximum sensitivity (ability to 
detect positives, with low rate of false negatives) rather than for optimal accuracy with 
balanced sensitivity and specificity (ability to detect negatives, with low rate of false 
positives). However, it was also sought to achieve a sufficiently high specificity in order to 
allow the identification of the highest number of chemicals not classified as irritant to the eye. 
By achievement of satisfactory specificity, the SkinEthic™ HCE and the EpiOcular™ EIT 
would present stand-alone (independent) test methods for identification of “non-classified” 
chemicals. 
Based on these premises, the EIVS VMG defined “definitely acceptable” and “definitely 
unacceptable” rates of over-prediction and under-prediction to evaluate the scientific validity 
of the SkinEthicTM HCE SE, LE and TS and of the EpiOcularTM EIT, which are outlined in 
Table 2.1. In particular, the following points were felt to be important to recommend the test 
methods as being sufficiently predictive to be considered as scientifically valid: 
(a) Ten percent (10%) false negatives should be “definitely acceptable” (sensitivity ≥ 90%), 
while more than 20% would be “definitely unacceptable”3. In previous validation studies 
for eye irritation led by ECVAM (cytotoxicity and cell-based assays) or ICCVAM 
(organotypic assays) the peer-review panels responsible for evaluating the validated 
test methods considered 0% false negatives as a test method performance criterion for 
acceptance of test methods to be used as an initial step in a Bottom-Up test strategy 
(identification of chemicals not classified as eye irritant). However, the Draize rabbit 
eye test shows the potential for up to 12% over classification of chemicals as UN GHS 
Category 2 (instead of UN GHS No Category) due solely to its within test variability 
(Adriaens et al., 2014). The actual rate of over-prediction of the Draize test may be 
even higher when considering other factors like between laboratory variability and 
predictivity. Thus, the EIVS VMG agreed that a False Negative rate up to 10% should 
be “definitely acceptable” for the UN GHS and EU CLP classification and labelling 
systems (UN, 2013; EC, 2008) for a test method to be considered useful as a stand-




 The between laboratory reproducibility values obtained in the pre-validation of the SkinEthic
TM
 HCE were of 95 to 100% 
concordance of classifications, and for EpiOcular
TM
 EIT 100% concordance of classifications (considering the classification cut-
off of 60% viability). 
3
 During pre-validation, the EpiOcular
TM
 EIT showed a sensitivity of 100% (considering the classification cut-off of 60% viability), 
while the SkinEthic
TM
 HCE test strategy showed a sensitivity of 87%. 
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alone test for the identification of chemicals not requiring classification for serious eye 
damage/eye irritation (initial step in a Bottom-up approach). Nevertheless, the nature, 
severity, duration, and frequency of in vivo eye injuries (based on the Draize eye 
irritation test) for chemicals that produce false negative results from in vitro tests were 
fully discussed and considered by the VMG in assessing the usefulness and limitations 
of the in vitro test methods for regulatory hazard classification and labelling purposes. 
(b) Ideally, no ocular corrosives/severe eye irritants (Category 1) should be under-
predicted as No Category, but more than 10% Category 1 chemicals being under-
classified as No Category would be “definitely unacceptable”. By using all qualified 
tests to calculate the predictive capacity values, the probability of obtaining 0% under-
prediction of Category 1 chemicals (0 out of about 200 tests) is extremely low due to 
the accepted fact that reproducibility of SkinEthicTM HCE SE/LE and EpiOcularTM EIT 
both within and between laboratories is not 100%. Therefore, the rate of under-
prediction of Category 1 chemicals as No Category (Category 1 → No Category), was 
calculated using the mode of the in vitro predictions of all qualified tests obtained in the 
three participating laboratories for each test chemical classified as UN GHS/EU CLP 
Category 1 based on in vivo Draize eye irritation data. This approach more closely 
reflects the real testing situation (post-validation). Thus, in a post-validation testing 
situation, a single qualified test obtained in one laboratory is usually sufficient to 
classify a test chemical, but if a borderline result, such as non-concordant replicate 
measurements and/or mean percent viability equal to 50±5%, is obtained, a second 
test may be considered, as well as a third one, in case of discordant results between 
the first two tests, in which case the mode of the three classifications is taken as the 
final decision. 
(c) About 40% false positives should be “definitely acceptable” (specificity ≥ 60%), while 
more than 50% would be “definitely unacceptable”4. Since the purpose of the test 
methods will be the identification of chemicals not requiring classification for serious 
eye damage/eye irritation (UN GHS/EU CLP No Category) as an initial step of a 
Bottom-Up test strategy (Scott et al., 2010), the VMG considered that it is acceptable to 
have a lower specificity than sensitivity (higher false positives than false negatives). 
Nevertheless, specificity should not be too low in order to allow for the correct 
identification of the majority of the non-classified chemicals. 
(d) About 25% of overall misclassifications would be “definitely acceptable” (overall 
accuracy ≥ 75%), while more than 35% would be “definitely unacceptable”. Potential 
reasons for misclassification were analysed in detail, including individual tissue score 
lesions of misclassified chemicals, which may be considered in future regulatory 
acceptance of the evaluated assays. 
(e) Misclassification of borderline chemicals, identified from in vivo Draize eye irritation 
data and/or structure-activity relationship considerations, would be easier to justify 
compared to non-borderline chemicals. 
The VMG also decided that if the rates of over-prediction and under-prediction achieved in 
EIVS would fall between the “definitely acceptable” and the “definitely unacceptable” 




 During pre-validation, the EpiOcular
TM
 EIT showed a specificity of 68% (considering the classification cut-off of 60% viability), 
while the SkinEthic
TM
 HCE test strategy showed a specificity of 69%. 
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margins, a recommendation on the scientific validity of the test method would not be made 
before all of the validation data would have been evaluated and discussed, including a 
thorough discussion on the potential reasons for misclassification and limitations of the test 
method. 
 
Table 2.1. Acceptance performance criteria for over-prediction and under-prediction rates in 






















≤ 10 0 ≤ 40 ≤ 25 
Further evaluations 
necessary before any 
recommendation is made 
10 < FN ≤ 20 0 < Cat 1 FN ≤ 10 40 < FP ≤ 50 25 < OM ≤ 35 
“Definitely unacceptable” 
rates 
> 20 > 10 > 50 > 35 
a
 equal to (1-Sensitivity), 
b
 based on the mode of all qualified tests, 
c
 equal to (1-Specificity), 
d
 equal to (1-Overall accuracy) 
 
 
2.2. Test Methods 
 
The EIVS assessed the validity of the EpiOcularTM EIT protocol for liquids, the EpiOcularTM 
EIT protocol for solids, the SkinEthicTM HCE Short-time Exposure (SE) protocol, the 
SkinEthicTM HCE Long-time Exposure (LE) protocol, and the SkinEthicTM HCE test strategy 
(TS) combining the SE and LE protocols with the Eye irritation Peptide Reactivity Assay 
(EPRA). Both, the EpiOcularTM EIT and the SkinEthicTM HCE test methods use as test 
systems reconstructed human corne-like epethilium (RhCE), and protocols consist of a 
topical exposure of the neat test chemical to the epithelial surface of the tissue construct. 
 
 
2.2.1. EpiOcularTM EIT 
Use of the EpiOcular™ OCL-200 RhCE model for eye hazard characterization has been 
established for several years. The utility of the model for determining the degree of eye 
irritation potential of surfactants and surfactant-containing materials was initially 
demonstrated using a time-to-toxicity protocol which measures the time at which 50% of 
cultured cells (ET50) remain viable, relative to negative controls (Blazka et al., 2003). This 
ET50-based test method was submitted to the former European Centre for the Validation of 
Alternative Methods (ECVAM) for evaluation in December 2005. ECVAM positively reviewed 
the submission in 2006 and recommended to MatTek Corporation (the test method 
developer) the development of a protocol covering a wider applicability domain to include 
also non-surfactant chemicals, prior to entering a formal validation study. Following ECVAM 
recommendations, MatTek Corporation developed the EpiOcular™ Eye Irritation Test (EIT), 
a test method with a wide applicability domain, which was then assessed between 2007 and 
2009 in a multi-laboratory trial involving 7 laboratories and managed by Cosmetics Europe 
(Kaluzhny et al., 2011; Pfannenbecker et al., 2013). In this pre-validation study, the test 
method was shown to be transferable and to reproducibly discriminate chemicals not 
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requiring a classification for eye irritation or serious eye damage (No Category) from all 
classified chemicals (Category 2 and Category 1) under UN GHS with 98% concordance 
between laboratories (Pfannenbecker et al., 2013). Furthermore, the predictive capacity of 
the test method for liquids and solids combined (using cell viability > 60% for triggering 
identification of non-classified chemicals) was shown to give an overall accuracy of 85%, with 
a sensitivity of 98% and a specificity of 73% (Kaluzhny et al., 2011). The results of this study 
were submitted to ECVAM in 2008. The EpiOcular™ EIT protocol used in the pre-validation 
and the present validation study differs from the ET50 protocol in that it uses a single 
exposure time for each chemical tested.   
The assessment of chemicals ocular hazards using the EpiOcular™ EIT test method is 
based on the depth of injury model of Maurer and Jester (Jester, 2006; Jester et al., 2001; 
Maurer et al., 2002), where slight to moderate irritants act on the corneal epithelium leading 
to cell death. In this assay, the test article is applied to the surface of the cornea epithelial 
construct for a fixed period, removed, and the tissue allowed to express the resulting 
damage. Liquids and solids are treated with different exposure and post-exposure 
incubations. Concurrent negative and positive control are used with each assay. Two tissue 
replicates are used for each treatment and control group. Relative tissue viability is 
determined against the negative control-treated tissues by the reduction of the vital dye MTT 
(3-[4,5 - dimethylthiazol-2-yl] - 2,5 - diphenyltetrazolium bromide).  
 
2.2.1.1. Functional characteristics 
The EpiOcular™ OCL-200 RhCE model uses normal human epidermal keratinocytes 
cultured to form a stratified squamous epithelium (Sheasgreen et al., 1996). The EpiOcular™ 
tissue construct is a non-keratinized multilayered epithelium prepared from non-transformed, 
human-derived epidermal keratinocytes. It is intended to model the cornea epithelium with 
progressively stratified but not cornified cells. These cells are not transformed or transfected 
with genes to induce an extended life span in culture. The “tissue” is prepared in inserts with 
a porous membrane (MTI-003) through which the nutrients pass to the cells. A cell 
suspension is seeded into the MTI-003 membrane in specialized medium. After a period of 
initial cell proliferation, the medium is removed from the top of the tissue so that the epithelial 
surface is in direct contact with the air. This allows the test chemical to be directly applied to 
the epithelial surface in a fashion similar to how the corneal epithelium would be exposed in 
vivo. The ability to expose the tissue topically is essential to model the same kind of 
progressive injury expected in vivo. It also allows both solid and liquid test chemicals to be 
applied directly to the tissue.  
The key parameter involved in the EpiOcularTM functional quality control is the ET50, which is 
the exposure time required for 0.3% (v/v) Triton X-100 to reduce the tissue viability (as 
measured by the MTT assay) to 50% (Kaluzhny et al., 2011). The ET50 represents an indirect 
measure of the tissue barrier properties, due to the fact that Triton X-100 is applied topically 
to the EpiOcularTM tissue and allowed to interact with the tissue for various time durations. To 
affect the capacity of the tissue to reduce MTT, Triton X-100 must penetrate into the tissue 
and permeate to the supra-basal and basal tissue layers, since the MTT assay monitors the 
mitochondrial activity present, primarily in the supra-basal and basal cell layers of the 3-D 
tissue. Reproducible ET50 values thus indicate that the tissue thickness and barrier properties 
are constant. A reproducible barrier function is important for determining the toxicities of test 
materials applied to the apical tissue surface, as they must penetrate across the apical cell 
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layers to interact with and affect the viable cells within the tissue (i.e., the basal cell layer). In 
the ET50 EpiOcular
TM quality control assay, the tissues are exposed to 100μL 0.3% Triton X-
100 for 5, 20, and 60 minutes (n = 2 tissues per exposure time). In addition, negative control 
tissues are exposed to 100μL of ultrapure water for 60 minutes. The purpose of this quality 
control assay is to ensure reproducible tissue properties across independent lots of the 
tissue produced over time (Kaluzhny et al., 2011). 
Histological evaluation is another functional quality control of the tissues. Cultures are fixed 
with 10% (v/v) formalin, embedded in paraffin, and cut into 5μm cross-sections. The sections 
are then stained with haematoxylin and eosin (HE) by following standard procedures, and 
observed under a light microscope. An EpiOcularTM tissue should exhibit at least 3–4 layers 
of viable cells and should lack a cornified layer. 
 
2.2.1.2. Standard operating procedures  
The test protocol and prediction model of the EpiOcular™ EIT were developed by MatTek 
Corporation using a total of 60 chemicals (39 liquids and 21 solids) from across a range of 
chemical classes (Kaluzhny et al., 2011). Standard Operating Procedure on how to perform 
the EpiOcular™ EIT was available prior to initiation of the present validation study, and 
following training and transferability (see chapter 3.1.1.2.3), the SOP was revised to take into 
account any clarifications deemed necessary. The final SOP used during EIVS was 
approved by the VMG before initiating the practical testing phase of EIVS. 
The SOP comprises a detailed description on how to perform the assay and includes 
negative and positive controls as well as controls for possible interfering compounds such as 
MTT-reducers and colorants (Kaluzhny et al., 2011). In particular, separate protocols are 
employed for liquids and solids. In the original protocols submitted to EURL ECVAM for 
validation tissues are exposed to liquids for 30 minutes followed by a 120-minute post-
treatment incubation and to solids for 90 minutes followed by 18-hour post treatment 
incubation (Figure 2.3). However, during EIVS the EpiOcular™ EIT solid chemicals protocol 
was optimised and the exposure time was increased from 90 minutes to 6 hours, with the 
post-treatment incubation time being maintained at 18 hours. 
Briefly for liquids, all test articles that could be pipetted at 37°C were tested with the liquids 
protocol. The EpiOcularTM tissues were transferred from proprietary agarose where they 
were package into 6-well plates containing 1 mL of medium (provided with the OCL-200 kit) 
and pre-incubated for one hour under standard culture conditions, which are defined as an 
atmosphere with 95 ± 3% relative humidity, 5 ± 0.5% (v/v) CO2, and a temperature of 37 ± 
1°C. After 1 hour, the medium was changed and the EpiOcularTM cultures were further pre-
incubated overnight (16–18 hours) under standard culture conditions. On day 1 of the test, 
the tissues were pre-treated for 30 minutes with 20 μL of calcium and magnesium-free 
DPBS. If the DPBS did not spread across the tissue surface, the plate was tapped to ensure 
that the entire tissue surface was in contact with the liquid. Next, 50 μL of the NC (ultrapure 
H2O), the positive control (methyl acetate, CAS No. 79-20-9), or liquid test articles were 
applied topically onto each tissue and the tissues were incubated for 30 ± 2 minutes under 
standard culture conditions. Each test article and control were tested with duplicate tissues (n 
= 2). To prepare for rinsing the tissues, three 150 mL beakers were filled with 100 mL DPBS 
for each test article. After a 30-minute exposure to the test articles or controls, each pair of 
duplicate tissues was successively rinsed by dipping, swirling, and decanting through its set 
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of three beakers. After the final rinse and decanting, the tissues were immersed in 5 mL of 
EpiOcularTM assay medium in a 12-well plate for 12 ± 2 minutes (post-soak) at room 
temperature. After the post-soak period, the medium was decanted from the cell culture 
inserts and the inserts containing the tissues were transferred to a 6-well plate containing 
1mL of warm medium (37°C) and post-incubated for 120 ± 15 minutes under standard 
culture conditions. Finally, the tissue viability was assessed by using the MTT assay 

















Figure 2.3.  Testing strategy for MatTek EpiOcular™ Eye Irritation Test 
 
Regarding solids, any test sample that could not be pipetted at 37°C was tested using the 
solids protocol. Prior to exposure of the test sample, the tissues were prepared, pre-
incubated, and pre-wet with DPBS, as described previously for liquid test articles. Next, 50 
μL of the control substances (H2O and methyl acetate), or approximately 50 mg of solid test 
material, were applied topically to the EpiOcularTM tissues, the latter by using a calibrated 
tool (micro spatula, spoon, or syringe). Each test sample and control was tested in duplicate 
tissues, as described above. The tissues were exposed to the test chemicals for 90 ± 5 
minutes (6 hours ± 15 minutes in the optimised protocol) under SCC. The rinsing and post-
soak conditions were the same as those described for the liquid samples, except that the 
tissues exposed to solid test samples were post-incubated for 18 hours ± 15 minutes (the 
post soak was increased from 12 ± 2 minutes to 25 ± 2 minutes in the optimised protocol 
while the post-treatment incubation time was maintained at 18 hours ± 15 minutes). After the 
18-hour post-incubation period, tissue viability was determined by using the MTT assay 




30 min exposure 
90 min exposure (original) 
6 hour exposure (optimised) 
18 hour post incubation 
Viability assessment 
Solids 
120 min post incubation 
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2.2.1.3. Endpoints and prediction model 
Potential ocular hazard effects of chemicals are assessed by measuring the viability of the 
treated tissues following a fixed time treatment and post-incubation time as described above. 
The relative tissue viability (against the negative control-treated constructs) is assessed by 
the reduction of the vital dye MTT (3-[4,5 - dimethylthiazol-2-yl] - 2,5 - diphenyltetrazolium 
bromide). The chemical is predicted to be classified according to the UN GHS and EU CLP 
classification scheme (UN, 2013; EC, 2008), if the relative cell viability falls below a pre-
determined level. The initial cut-off proposed by the test developer was 60% cell viability as 
shown in table 2.2 (Kaluzhny et al., 2011). Briefly:  
- if the test article-treated tissue viability is > 60% relative to negative control-treated tissue 
viability, the test article is considered not to require classification according to the UN GHS / EU 
CLP classification schemes (UN, 2013; EC, 2008). 
- if the test article-treated tissue viability is  60% relative to negative control-treated tissue 
viability, the test article is identified as classified according to the UN GHS / EU CLP 
classification schemes (UN, 2013; EC, 2008). 
 
Table 2.2. Prediction model initially proposed for the EpiOcularTM EIT (Kaluzhny et al., 2011) 
In vitro result In vivo prediction (UN GHS / EU CLP) 
mean tissue viability  60%  classified (Cat 1 and Cat 2) 
mean tissue viability > 60% non-classified (no-category) 
 
In the beginning of the EIVS and even before training and transferability took place, MatTek 
Corporation was faced with the necessity to replace the insert membrane used in the 
production of the EpiOcular™ tissues due to discontinued production of the insert membrane 
used until then (MTI-001a). A replacement insert membrane (MTI-003) was approved by the 
Validation Management Group (VMG) for use in EIVS after multiple testing of 94 chemicals 
at MatTek Corporation and comparative statistical analysis performed by the EURL ECVAM 
biostatistician on the use of the old MTI-001a insert membrane (discontinued) versus the 
new MTI-003 insert membrane. The results showed that with the MTI-003 membrane a 
sensitivity higher than 90% could potentially still be achieved using a 50% cut-off instead of 
60%, with a significant gain in specificity. Considering these new data, the VMG decided to 
evaluate two prediction models with EpiOcular™ EIT in EIVS, one based on the original cut-
off at 60% mean tissue viability as in the submission to EURL ECVAM and a second one 
based on a cut-off at 50% mean tissue viability. 
 
2.2.1.4. Run and test acceptance criteria 
The run and test acceptance criteria are based on the results obtained for the negative 
control, positive control and test chemicals. Furthermore, if applicable, controls should be 
used to evaluate the non-specific colour and MTT reduction interference as described in the 
EpiOcularTM EIT SOP.  The following run and test acceptance criteria as described in the 
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EpiOcularTM EIT SOP have been approved by the VMG prior to the practical testing phase of 
the EIVS.  
 1) the negative control OD > 1.0 and < 2.3,  
 2) the mean relative viability of the positive control is 
 a) 30 minute exposure: below 50% of control viability 
 b) 90 minute exposure (or 6 hour in the optimised protocol): below 50% of control 
viability 
3) the difference of viability between the two tissues of a single chemical is < 20% in the 
same run (for positive and negative control tissues and tissues of single chemicals). This 
applies also to the killed controls (single chemicals and negative killed control) and the 
colorant controls which will be calculated as percent values related to the viability of the 
relating negative control. 
 
2.2.1.5. Applicability and limitations 
The EpiOcular™ EIT allows discriminating non-classified from classified materials according 
to the UN GHS/ EU CLP classification schemes. However, it has not been designed to 
differentiate between UN GHS / EU CLP Category 1 (serious eye damage) and Category 2 
(eye irritation) classifications. The test method allows the hazard identification of mono 
and multi-component test chemicals. Gasses and aerosols cannot be evaluated with the 
current protocol. Other than that no further limitations are currently known regarding the 
spectrum chemicals to which the assay is applicable to, so that it is assumed to be applicable 
to the full spectrum of chemical classes and physico-chemical properties.  
 
 
2.2.2. SkinEthicTM HCE SE, LE and test strategy 
The SkinEthic™ HCE test method for assessing the  potential ocular hazards of chemicals 
was originally developed by Van Goethem et al. (2006), which used a short exposure time 
(SE). Evaluation of this protocol using an enlarged set of test substances (about 100) led to 
the optimisation of the SkinEthicTM HCE test method to include two exposure times. The 
short exposure time (SE), consists of a 10-minute exposure of tissue to test substance with 
no post-treatment incubation, while the long exposure time (LE) exposes the tissue to test 
substance for 1 hour with a further post-treatment incubation of 16 hours.   
In a pre-validation study involving 3 different laboratories, the SkinEthic™ HCE test method 
showed 95% (19/20) concordant predictions between-laboratories for the LE protocol to 
identify non-classified versus classified test substances (Alépée et al., 2013). Van Goethem 
et al. (2006) showed for the SkinEthic™ HCE SE an accuracy of 80%, a sensitivity of 100% 
and a specificity of 56% based on 20 test chemicals. Further optimisation by testing 435 
substances showed the SkinEthic™ HCE LE protocol to have an overall accuracy of 82%, 
and a balanced sensitivity and specificity of 81% and 83% respectively (Cotovio et al., 2010). 
By combining the two exposure times in a paradigm that uses the Eye irritation Peptide 
Reactivity Assay (EPRA) to allocate test chemicals to one or other treatment time, the overall 
accuracy was shown to increase to nearly 80%, with a sensitivity of 86.7% and a specificity 
of 68.9% (under GHS, submission reviewed by EURL ECVAM). The criterion for allocation of 
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test substances to either short or long exposure times is based on their intrinsic chemical 
reactivity, as defined by their electrophilic potential to react with cysteine- or lysine-containing 
peptides and measured through EPRA. The EPRA corresponds to the direct peptide 
reactivity assay (DPRA) developed by Gerberick and co-workers (2007), with minor 
differences in the protocol and prediction model.   
 
2.2.2.1. SkinEthicTM human reconstructed corneal epithelium 
The SkinEthic™ HCE model uses immortalised human corneal cells which, when cultured in 
defined conditions, develop into a multi-layered tissue which resembles morphologically and 
physiologically the human corneal epithelium (Nguyen et al., 2003). The test method consists 
of a topical exposure of the neat test substance onto the SkinEthicTM
 
HCE, followed by cell 
viability assessment. Viability decrease in test substance treated tissues is expressed 
comparatively to negative controls (PBS treated tissues). Percent (%) viability is used to 
predict and classify eye irritation potential following a defined prediction model. 
 
2.2.2.1.1. Functional characteristics 
To construct SkinEthic™ HCE tissues, immortalized human corneal epithelial cells are 
cultured in a chemically defined medium, on a permeable synthetic membrane insert, and 
at the air-liquid interface. Under these culture conditions, the transformed human corneal 
epithelial cell line (LSU Eye Centre, New Orleans, USA) forms a corneal epithelial tissue 
(mucosa), resembling ultra-structurally (tissue morphology and thickness) the corneal 
mucosa of the human eye (Nguyen et al., 2003). As in vivo epithelium, the SkinEthic
TM
 
HCE model is characterized by the presence of intermediate filaments, mature hemi-
desmosomes and desmosomes, and specific cytokeratins. The 0.5 cm² multilayered 
epithelium contains about 5 to 7 cell layers, including columnar cells and Wing cells.  
Each lot of tissues is quality assured according to specific quality control standards 
including: histology (cell layers) and tissue viability (MTT mean optical density) and 
reproducibility (SD). 
 
2.2.2.1.2. Standard operating procedures 
The test protocol and prediction model of the SkinEthic™ HCE SE was developed by 
Goethem et al. (2006) using 20 chemicals, and the SkinEthic™ HCE LE by Cotovio et al. 
(2010) using 102 substances.  Standard Operating Procedure on how to perform the 
SkinEthic™ HCE was available prior to initiation of the present validation study, and was 
revised to take into account any clarifications deemed necessary by the VMG. The final SOP 
used during EIVS was approved by the VMG before initiating the practical testing phase of 
EIVS. 
The SOP comprises a detailed description on how to perform the assay and includes 
negative and positive controls as well as controls for possible interfering compounds such as 
MTT-reducers and colorants. Briefly, the SkinEthicTM HCE tissue cultures are placed in 1 mL 
maintenance medium (6-wells plate). The culture inserts are incubated (at least overnight) at 
37°C, 5% CO2 in a humidified incubator. Following this equilibration period, the cultures are 
transferred into a 24-wells plate containing 300 μL SkinEthicTM maintenance medium per 
well. Test substances are applied topically onto the SkinEthicTM HCE for 10 minutes (short 
exposure time treatment) or 1 hour (long exposure time treatment). Three tissue replicates 
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are used per test substance, positive control and negative control. Tissues are then rinsed to 
remove the test substance and transferred to fresh medium. After a 10 minutes treatment 
(short exposure time treatment) or after a 1 hourr treatment + 16 hours post incubation 
period (long exposure time treatment), the MTT assay is performed by transferring the 
tissues to wells containing 0.3 mL MTT medium (0.5 mg/mL). After 3 hours MTT incubation 
at 37°C, 5% CO2 in a humidified incubator, the blue formazan salt formed is extracted with 
1.5 mL isopropanol per tissue (new 24-well plates, extraction time: from 2 hours (minimum) 
to overnight). After shaking, the optical density of the extracted formazan (200 μL per well of 
a 96 well plate, 2 aliquots) is determined using a spectrophotometer at 570 nm (filter band 
pass ± 30 nm). The percentage viability of each of the treated tissues is then calculated from 
the percentage MTT conversion in the test substances treated tissues relative to the 
corresponding negative controls (100% viable).  
 
2.2.2.1.3. Endpoints and prediction model 
Cell viability determination was used as the endpoint of the SkiEthic
TM
 HCE test method 
and is based on cellular mitochondrial dehydrogenase activity, measured by tetrazolium 
salt MTT reduction [(3-4,5-dimethyl triazole 2-yl) 2,5-diphenyltetrazoliumbromide], and 
conversion into a blue formazan salt that is quantitatively measured after extraction from 
tissues (Mossman, 1983). The reduction of cell viability in treated tissues is compared to 
negative controls and expressed as a % value. Measurements rely on optical densities 
measurement at 570 nm (filter band pass ± 30 nm) by using a spectrophotometer multi-
well plate reader.  
Tissues treated with chemicals classified for eye hazards (UN GHS/EU CLP Category 2 and 
Category 1) are expected to show a decrease in viability below a certain threshold in respect to 
the negative control. The prediction model proposed by the test developer is shown in table 
2.3, i.e., according to UN GHS and EU CLP classification: 
- if the % viability is > 50%, the test substance is predicted as not requiring classification 
(No Category); 
- if the % viability is ≤ 50%, the test substance is predicted as requiring classified for 
ocular hazards (Category 1 / Category 2) . 
The prediction model does not discriminate UN GHS / EU CLP Cat 1 from Cat 2. 
 
Table 2.3. Prediction model proposed for the SkinEthicTM HCE  
In vitro result In vivo prediction (UN GHS / EU CLP) 
mean tissue viability  50%  classified (Cat 1 and Cat 2) 




2.2.2.1.4. Run and test acceptance criteria 
The run and test acceptance criteria are based on the results obtained for the negative 
control, positive control and test chemicals. Furthermore, if applicable, controls should be 
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used to evaluate the non-specific colour and MTT reduction interference as described in the 
SkinEthicTM HCE SOP.  The following run and test acceptance criteria as described in the 
SkinEthicTM HCE SOP have been approved by the VMG prior to the practical testing phase of 
the EIVS.  
 
 1) Negative control 
For both exposure times (SE and LE), a run meets the acceptance criteria if the mean 
Optical Density (ODNC) of the three replicate tissues treated with NC is ≥ 0.7 at 570 nm 
(± 30nm) with an upper acceptance limit of 1.5, and if the Standard Deviation calculated 
for the % viability of the three treated replicate tissues (2 values from each of three 
tissues) is ≤ 18% (mean % viability = 100%). The absolute OD of the negative control 
(NC) tissues (PBS treated) in the MTT-test is an indicator of tissue viability in the testing 
laboratory after shipping and storage procedures and under use conditions.  
 
2) Positive control 
The % viability measured is an indicator of tissue response capacity in the testing 
laboratory after shipping and storage procedures, and under use conditions. For both 
exposure times, a run meets the acceptance criteria if the mean viability of the three 
replicate tissues (2 values from each of three tissues) treated with the positive control, 
expressed as % of the negative control, is ≤ 50% and the Standard Deviation value is ≤ 
18%. 
The run is qualified (qualified run) if both the negative and the positive controls data fulfil 
the above criteria requirements. Otherwise, the run will be considered as non-qualified. 
Non-qualified runs have to be documented and reported. 
 
 3) Test chemicals 
For both exposure times, a test meets the acceptance criterion if the Standard Deviation 
calculated for the % viability of the three treated replicate tissues (2 values from each of 
three tissues) is ≤ 18%. For a given test chemical, if the Standard Deviation exceeds 
18%, the test substance should be retested.  
A qualified test for a single test substance is a “test” for which all pre-defined acceptance 
criteria are fulfilled (variability of replicates) within a qualified run. Otherwise, the test will 
be considered as not qualified. 
 
 
2.2.2.1.5. Applicability and limitations 
The SkinEthic™ HCE test method only discriminates test chemicals in 2 different classes: 
as “No Category” (No Cat) or as classified (GHS Category 1 / Category 2) according to 
UN GHS and EU CLP. However, it has not been designed to differentiate between UN GHS 
/ EU CLP Category 1 (serious eye damage) and Category 2 (eye irritation) classifications. 
The test method allows the hazard identification of mono and multi-component test 
chemicals. Gasses and aerosols cannot be evaluated with the current protocols. Other 
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than that no further limitations are currently known regarding the spectrum chemicals to 
which the assay is applicable to, so that it is assumed to be applicable to the full spectrum of 
chemical classes and physico-chemical properties.  
 
2.2.2.2. Test strategy with EPRA 
The SkinEthicTM HCE test strategy uses three separate assays, i.e., EPRA, SkinEthicTM HCE 
SE, and SkinEthicTM HCE LE. In this strategy, test chemicals are tested in the short-time 
exposure (SkinEthicTM HCE SE: 10 min exposure without post-treatment incubation) or in the 
long-time exposure (SkinEthicTM HCE LE: 1 hour exposure followed by 16 hour post-
treatment incubation) depending on their chemical reactivity (defined as the electrophilic 
potential to react with cysteine or lysine containing peptides), as measured by EPRA.  
The chemical reactivity of the test chemical is reported as percent depletion of the 
nucleophile, which is determined as the reduction of the peptide concentration in the samples 
relative to the average concentration of the controls. If the percent cysteine and lysine peptide 
depletion relative to the control is > 5.95%, the test chemical is categorised as reactive. If the 
percent cysteine and lysine peptide depletion is ≤ 5.95%, the test chemical is categorised as 
non-reactive. Thus chemicals demonstrating an ability to bind in significant amounts to a 
cysteine- or lysine-containing peptide are deemed to be reactive (Gerberick et al., 2007), and 
are allocated to the short exposure (10 minutes) time treatment, while those chemicals that 
do not show significant binding to cysteine and lysine peptides and are considered non-
reactive are allocated to the long exposure (1 hour exposure + 16 hours post-treatment 
incubation) time treatment (Figure 2.4).  The validity of the testing strategy was determined in 




































Figure 2.4.  Testing strategy for SkinEthic™ HCE 
 
 
2.3. Chemicals selection and distribution 
 
Chemical selection during the EIVS was carried out by the Chemicals Selection Group 
(CGS) as described by Cole and co-workers (see chemicals selection report; Cole et al., 
2014). The CSG was composed of the following members: 
Tom Cole (ECVAM; coordinator) 
João Barroso (ECVAM) 
Chantra Eskes (independent scientist) 
William Stokes (NICEATM) 
Amanda Cockshott (HSE; UK Competent Authority) 




Non reactive Reactive 
SkinEthic™ HCE exposure 
10 minutes 1 hour 
No post incubation 16 hour post incubation 
Viability assessment 
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The roles and responsibilities of the CSG are shown in Figure 2.1. The members of 
Competent Authorities (Amanda Cockshott and Betty Hakkert) gave support in reviewing in 
vivo Draize eye irritation reports on CosIng ingredients provided by DG SANCO. 
In the framework of the International Cooperation on Alternative Test Methods (ICATM), 
liaisons from NICEATM, ICCVAM, JaCVAM and Health Canada are invited to propose 
eligible test chemicals for selection, supported by quality assured in vivo Draize eye irritation 
data. 
Final approval of the test chemicals proposed by the CSG was the responsibility of the core 
VMG. Respecting non-disclosure of chemical identities to the test facilities, the VMG lead 
laboratory representatives did not participate in the selection process. 
A principal requirement for chemical selection was availability of complete and quality 
assured supporting in vivo data sets, for comparative evaluation of in vitro method predictive 
capacity. Systematic assignment of serious eye damage/eye irritation classifications from in 
vivo data was facilitated by computation of reported scores compiled into a customised Excel 
template. In cases of insufficient data for assignment of classification category, or other 
anomaly, the template assigns 'study criteria not met' (SCNM) effectively disqualifying the 
chemical from selection for EIVS, regardless of any precautionary regulatory classification. 
Considering the two in vitro test methods included four alternative time combinations for 
exposure and incubation (EpiOcular™ EIT separating liquids from solids, SkinEthic™ HCE 
differentiating EPRA reactive from non-reactive chemicals) effectively four protocols were 
under evaluation, requiring a balanced chemical selection of: (i) classified versus non-
classified chemicals; (ii) solids versus liquids; and (iii) EPRA reactivity versus non-reactivity. 
Statistical power analysis (sample size calculation) by the ECVAM biostatistician and the 
TNO biostatistician stipulated a minimum requirement of 26 classified chemicals and 26 non-
classified chemicals per protocol, therefore totalling 104 chemicals in complement (52 
classified and 52 non-classified chemicals). Acknowledging the difficulty of fulfilling all three 
chemicals selection conditions listed above, the VMG allowed margins for approximation. 
Thus, the symmetry of classified versus non-classified was set at 50±5%, with a 50/50 
weighting of category 1 and category 2, and including adequate representation of sub-
categories 2A and 2B. For physical state, liquids versus solids, 50±10% was admitted. 
Considering EPRA reactivity was only determined ad hoc to the chemical selection, the 
division of reactive versus non-reactive was set with a wider margin at 50±15%. 
Essentially five recognised databases introduced primary sources for shortlisting eligible 
chemicals or formed a basis for inquiring access to original proprietary studies: 
 1) ECETOC database of eye irritation reference chemicals (ECETOC, 1998). 
2) EC (DG-SANCO) Cosmetics Ingredients (CosIng) database (EC, 1996; 2006b; 
Pauwels, 2008). 
3) EC New Chemicals Database (NCD) of notified substances (EC, 1967; 1979; 
1992). 
 4) ICCVAM (NICEATM) database of eye irritation reference chemicals. 
 5) US EPA database of pesticide actives. 
The ECETOC database is a published compilation, providing a ready source of consolidated 
in vivo data sets on established reference chemicals. The ICCVAM database, which overlaps 
ECETOC, and originally published as a summary version, is maintained by NICEATM with 
comprehensive data and additional chemicals for internal regulatory and research use. The 
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US EPA database is an unpublished compendium, also maintained for regulatory use. 
Through liaison with NICEATM, the ICCVAM and EPA databases provided quality assured in 
vivo data. 
CosIng is a comprehensive inventory, but simply providing references to summary data only, 
available in official SCCS/P opinions which cover just a limited number of chemicals. When 
indicated (cited as source references in SCCS/P opinions) the original study reports 
containing raw in vivo data are generally proprietary documents, retained in confidential 
archive by DG-SANCO. Under bilateral arrangement, original study reports on shortlisted 
chemicals were provided for internal review of eligibility, where priority was given to retail 
rather than proprietary chemicals. Subsequently, permissions were confirmed from in vivo 
study owners allowing citation of eye irritation scores as supporting data, respective of 
chemicals actually selected.    
NCD is also comprehensive of chemicals, but again with only summary data registered, 
condensed from proprietary studies fulfilled under regulatory obligation. Access to complete 
proprietary in vivo data sets required cooperation of individual sponsors to provide original 
study reports for review of eligibility, including agreement to release of data on relevant 
chemicals ultimately selected. Bilateral collaboration with individual manufacturers also 
secured supply of proprietary sample material for in vitro assay. 
Logistically, the chemical selection was managed in two stages, first determining eligible and 
available substances for preliminary EPRA, followed by definitive selection for in vitro assay. 
In practice, a protracted period of investigation and confirmation was required to resolve 
selection of a balanced final set. To facilitate VMG overview and monitoring of progress, an 
operational master list was generated (ultimately comprising 160 potentially eligible and 
available chemicals). 
From the VMG master list of 160 chemicals, 135 were eventually shortlisted for EPRA. 
Chronologically, with EPRA results on a first batch of 55 chemicals presented to the VMG in 
May 2010, a first set of 34 chemicals was definitively selected for in vitro testing. A second 
set of 45 chemicals was subsequently added to the definitive selection, following EPRA 
results on a second batch of 53, reported to the VMG in August 2010. Further development 
of the master list continued until the end of 2010, when a third batch of chemicals was 
shortlisted for EPRA testing. Following acquisition and reactivity analysis, EPRA results on 
27 extra chemicals were presented to the VMG in April 2011 with addition of 28 chemicals to 
complete the definitive selection for EIVS ring trial in vitro testing, totalling 107. 
The published ECETOC database contains eye irritation in vivo data compiled from 149 
studies (132 pure chemicals). With priority given to chemicals not previously tested during 
pre-validation method development, 31 were selected for EIVS (11 solids, 20 liquids): 7 
category 1, 4 category 2A, 3 category 2B, 17 GHS unclassified. 
A documented overview of CosIng had identified 131 chemicals with supporting references 
(via SCCS/P opinions) to full in vivo study reports archived at DG-SANCO, including 72 pure 
chemicals (preparations, mainly aqueous dilutions, excluded). Reduced to 38, indicated as 
available through retail supply, 21 were determined eligible by fully compliant in vivo data 
sets. Ultimately, 14 were selected for EIVS, including 2 proprietary chemicals also found 
available from the original 72 shortlist (12 solids, 2 liquids): 4 category 1, 3 category 2A, 1 
category 2B, 6 GHS unclassified. 
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Adopting a pragmatic approach to short-listing eligible chemicals from NCD, about 300 eye 
irritants were found among about 20 companies affiliated to the EPAA, aiming to facilitate 
cooperation in obtaining proprietary data and/or sample material. Eliminating chemicals with 
incomplete data sets (relating to animal welfare) and/or insufficient purity, provided a shortlist 
of 70 irritants. Similarly, about 200 eligible non-irritants were sorted from NCD. From twelve 
companies actually solicited, six provided in vivo study reports for review of eligibility, 
comprising 35 chemicals (18 irritants, 17 non-irritants). In addition, two companies not 
formally affiliated to EPAA also contributed another 30 study reports (18 irritants, 12 non-
irritants) bringing the total to 65 candidates (36 irritants, 29 non-irritants). Eventually from 
NCD etc. (proprietary) 40 chemicals were selected for EIVS (19 solids, 21 liquids): 16 
category 1, 4 category 2A, 20 GHS unclassified. 
With collaborative assistance of NICEATM, about 50 chemicals from the ICCVAM database 
were initially proposed for consideration. Review of eligibility and selection requirement 
provided a shortlist of 26 (21 non-ECETOC) from which 15 were definitively selected for 
EIVS (8 solids, 7 liquids): 1 category 1, 2 category 2A, 8 category 2B, and 4 GHS 
unclassified. 
Through liaison with NICEATM, 26 chemicals from the US EPA pesticide actives database 
were proposed. Review of eligibility and availability determined a shortlist of 10, from which 7 
were selected according to requirement for EIVS (4 solids, 3 liquids): 1 category 2B, 6 GHS 
unclassified. 
The EIVS chemical selection had achieved the principal objective of a balanced set with 
respect to eye irritancy, physical state and EPRA reactivity. The 107 chemicals included 3 
extra to the original quota of 104. Two supplementary chemicals (chemicals # 106 and 107), 
of unique interest due to observed permanent coloration in vivo, were included for separate 
evaluation. The third additional chemical was introduced as a replacement for one which was 
reported to cause significant interference during in vitro assay (direct MTT reducer) (chemical 
# 27).  
Following the ring trial in vitro testing of the 107 chemicals, and with statistical evaluation of 
results, the EpiOcular™ EIT protocol for solids was subject to further optimisation. 
Subsequently, the EpiOcular™ EIT protocol for solids was then subject to post-optimisation 
validation, with repeat testing of all EIVS solids, including 8 additional, extending the EIVS 
definitive set to a complement of 115 test item chemicals (Table 2.4). The supplementary 
solids comprised two GHS category 1, three category 2A, one category 2B and two GHS 
unclassified.  
With reference to the GHS criteria for eye irritation classification, the scope and frequency 
represented in the in vivo data for the EIVS irritant chemicals was reviewed. For the category 
1 chemicals, symptom persistence was predominant, particularly cornea opacity (CO) and 
conjunctiva redness (CR) although with CO severity also significant. Logically, for the 
category 2 chemicals, CO and CR symptoms were again prevalent compared to conjunctiva 
chemosis (CC) and iritis (IR). 
For overview of the chemical domain represented in EIVS, the selected chemicals were each 
assigned a molecular class profile according to OECD QSAR Toolbox analysis. Organic 
molecules usually comprise combinations of chemical genre with multiple functional groups. 
From about 430 predefined categories, 95 were identified among the EIVS set. Three 
inorganic salts were additional. 
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Table 2.4. 115 EIVS chemicals: 55 no category, 14 category 2B, 16 category 2A, 30 category 1. Identity, Physical State, EPRA Reactivity, GHS 















































































































































































































































Physical State: L = Liquid, S = Solid; EPRA Reactivity: R = Reactive, NR = Non-Reactive 
GHS classification category (cat) criteria:  
CO = cornea opacity, CR = conjunctiva redness, CC = conjunctiva chemosis, IR = Iritis 
s = single score (any animal, any time), m = mean score (days 1-3, at least 2/3 or 4/6 animals), i = irreversible score (21 days, any animal) 













2370-63-0 L R no cat   ECETOC retail 
Alkoxy|Ether| 
Methacrylate 
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3446-89-7 L R no cat   ECETOC retail 
Aldehyde|Aryl| 
Sulfide 








6940-78-9 L R no cat   ECETOC retail Alkyl halide +   




retail Alkyl halide +   
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629-82-3 L NR no cat   
Proprietary 
NCD etc. 






1680-31-5 L NR no cat   
Proprietary 
NCD etc. 
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20 
ricinoleic acid  
tin salt 


















+   
22 
3-phenoxy 
benzyl alcohol  
13826-35-2  L NR no cat   ICCVAM retail 
Alcohol|Benzyl| 
Ether 
+   
23 
ethyl thioglycolate 
INCI name:  
ETHYL 
THIOGLYCOLATE 
623-51-8 L NR no cat   ECETOC retail 
Carboxylic acid 
ester|Thioalcohol +   
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reducer in vitro: 
Not tested in 
SkinEthic™ HCE) 
7659-86-1 L R no cat   ECETOC retail 
  
 





118-82-1 S NR no cat   ECETOC retail 
Benzyl|Phenol| 







3234-85-3 S NR no cat   ECETOC retail 
Carboxylic acid 
ester 
+  + 
SiOOOH3CCH3H3CNHNH2SiOCH3OH3COH3CFFFSiOCH3OH3COH3CFFF










































INCI name:  
HC BLUE NO. 11 















DISPERSE RED 17 
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+  + 
SiOOOH3CCH3H3CNHNH2SiOCH3OH3COH3CFFFSiOCH3OH3COH3CFFF













































INCI name:  
POLY 
QUATERNIUM-10 













120-14-9  S R no cat   ICCVAM retail 
Aldehyde|Aryl| 










retail Inorganic Salt +  + 
OOOOO






94-13-3 S NR no cat   ICCVAM retail 
Carboxylic acid 
ester|Phenol 


























33089-61-1 S R no cat   
US-EPA 
pesticide 
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INCI name:  
PPG-2 PROPYL 
ETHER 
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134-62-3 L NR cat 2B CO-m≥1 
US-EPA 
pesticide 






83-72-7 S R cat 2B CR-m≥2 
Proprietary 
DG-SANCO 










+ + + 
63 4-nitrobenzoic acid 62-23-7 S R cat 2B CR-m≥2 ICCVAM retail 
Carboxylic acid| 
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1569-01-3 L NR cat 2A CO-m≥1 ICCVAM retail 
Alcohol|Alkoxy| 
Ether 

























1119-62-6 S R cat 2A CO-m≥1 ECETOC retail 
Carboxylic acid| 




INCI name:  
2-AMINO-3-
HYDROXYPYRIDINE 

















Carboxylic acid +  + 









































































6484-52-2 S NR cat 2A CR-m≥2 ECETOC retail Inorganic Salt +  + 







2365-48-2 L R cat 1 CO-s=4 ECETOC retail 
Carboxylic acid 
ester|Thioalcohol 















(~ 30%, aqueous) 
INCI name:  
COCO-BETAINE 




























(~ 30%, aqueous) 

















(~ 40%, aqueous) 
INCI name:  
TEA-C12-14  
ALKYL SULFATE 
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87 
sodium alkyl  
ether sulphate 








































+   
89 
ethoxylated (5 EO) 
alkyl (C10-14) 
alcohol 






Ether +   
OOOOO




(~ 50%, aqueous) 
INCI name:  
LAURYL 
GLUCOSIDE 



























17831-71-9 L R cat 1 
CO-s=4,  
IR-m>1.5 








ECETOC retail Alcohol +  + 
94 
dodecanoic acid  
INCI name:  
LAURIC ACID 
143-07-7 S NR cat 1 
CO-i>21,  
CR-i>21 








INCI name:  
1-NAPHTHALENE 
ACETIC ACID 












+  + 





62-76-0 S NR cat 1 
CO-s=4,  
CO-i>21 
















































INCI name:  
ETHYL LAUROYL 
ARGINATE HCL 
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INCI name:  
BASIC ORANGE 31 
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82-66-6 S NR no cat   
US-EPA 
pesticide 
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The majority of the EIVS chemicals are pure single constituent substances, each 
represented by a discrete molecular structure. However, the selection included 8 polymers (3 
homopolymers, 5 copolymers) 4 occurring in aqueous medium. The EIVS set also included 
10 quasi polymers (8 occurring as aqueous liquids) characterised by limited molecular weight 
distributions corresponding to serial analogues differentiated by incremental chain lengths 
(e.g., alkyl C10-C16) but predominantly of specific molecular weight in overall composition 
(e.g., alkyl C12: lauryl / dodecyl). The range included alkyl, acyl and ethoxy analogue 
compositions. Another 2 chemicals (discrete compositions) produced as aqueous liquids 
brought the total number of aqueous chemicals to 14 selected. 
Overall distributions of GHS classification with physical state and EPRA reactivity have been 
compiled (Tables 2.5 and 2.6). In addition, proportions of published versus proprietary in vivo 
data sources, and retail versus proprietary substance supply, have been summed. While in 
vivo data sources were equal between published and proprietary, over 80% of the chemicals 
were indicated as available for laboratory supply through regular commercial retail. The EIVS 
set therefore provides ample option for sub-set selection of performance standard reference 
chemicals, relevant to future validation projects on eye irritation. 
Independent coding and distribution of test chemicals was conducted by TNO. TNO is 
certified according to ISO 9001 and GLP, and has proven experience of reliable services. 
TNO purchased, coded and supplied commercially available chemicals, including cosmetic 
ingredients from the CosIng inventory. Non-commercially available chemicals were sent 
directly to TNO for coding and distribution. All test chemicals were randomly coded. Each 
test chemical had a code that was unique for each laboratory. The same code was used for 
the SkinEthic™ HCE SE and for the SkinEthic™ HCE LE protocols. The codes were 
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Table 2.5. Distribution of UN GHS classification and physical state of the EIVS chemicals. 
Numbers in brackets are for the extra chemicals used in the validation of the optimised 
EpiOcular™ EIT solid chemicals protocol. 
  
GHS Classification (category) 
Liquid (Liq) / Solid (Sol) 
Cat 1 Cat 2A Cat 2B No Cat 
Liq Sol Liq Sol Liq Sol Liq Sol 
Totals: 






























Grand Total 104a,b (+8) 
a
 excluding the two extra chemicals that produced permanent coloration in vivo (chemicals 106 and 107 in Table 2.4)
 
b
 excluding the chemical that was replaced due to very strong direct MTT reduction (chemical 27 in Table 2.4)
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Table 2.6. Distribution of UN GHS classification and EPRA reactivity of the EIVS chemicals. 
Numbers in brackets are for the extra chemicals used in the validation of the optimised 
EpiOcular™ EIT solid chemicals protocol. 
  
GHS Classification (category) 
EPRA Reactive (R) / Non-Reactive (NR) 
Cat 1 Cat 2A Cat 2B No Cat 































Grand Total 104a,b (+8) 
a
 excluding the two extra chemicals that produced permanent coloration in vivo (chemicals 106 and 107 in Table 2.4)
 
b
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3. Results 
 
3.1. EpiOcularTM EIT 
 
3.1.1. Main validation study 
In the following, a summary of the results obtained in the main validation study of the 
EpiOcular™ EIT and the conclusions of the VMG based on those results are given. Please 
refer to Annex 1 containing the "EIVS Statistical Analysis and Reporting on the EpiOcular™ 
EIT" by Carina Rubingh (EIVS biostatistician from TNO) for more detailed statistical analysis 
of the study. 
The three laboratories participating in the validation of EpiOcular™ EIT, two European, 
Beiersdorf (the lead laboratory) and Harlan UK (naïve laboratory), and one in the US, IIVS, 
were trained by MatTek Corporation to assure optimal transfer of the test protocol into their 
facilities and to guarantee that the Standard Operating Procedure (SOP) did not allow for 
individual (different) interpretation of the experimental steps. All procedures and assay 
documentation were discussed and comments and suggestions for improvement and 
clarification of the SOP were collected and implemented by MatTek Corporation in a final 
version of the SOP that was used in the ring trial of the validation study. The nine laboratory 
technicians assigned to the project (three per laboratory) performed the test method with 8 
coded test chemicals (2 liquid No Cat, 2 solid No Cat, 2 liquid Cat 2, 1 solid Cat 2, 1 liquid 
Cat 1 and 2 solid Cat 1) at their test facility to demonstrate transferability of the test method. 
The variability of the particular experiments performed by single operators was very low, as 
judged by the difference in viability between tissue replicates (only 1 out of 108 results 
showed a difference > 20%). All test chemicals were consistently predicted by the three 
laboratories and nine operators using 50% mean viability as the prediction model threshold 
differentiating classified (UN GHS Cat 1 and Cat 2) from non-classified (UN GHS No Cat) 
chemicals, while, using a 60% cut-off in the prediction model, 1 liquid chemical was predicted 
differently by one operator in one laboratory. Highly reproducible results were therefore 
obtained between operators and laboratories in the EpiOcular™ EIT transfer study. All the 
participating laboratories demonstrated their proficiency in performing the EpiOcular™ EIT 
and readiness to enter the formal validation study. 
Tables 3.1 and 3.2 on pages 86 and 87 show the final corrected viabilities and corresponding 
predictions for the 60% viability cut-off obtained for the liquid chemicals tested in the main 
validation study. Tables 3.3 and 3.4 on pages 88 and 89 show the final corrected viabilities 
and corresponding predictions for the 60% viability cut-off obtained for the solid chemicals 
tested in the main validation study. Based on the results for the fraction of complete test 
sequences (99.7% in total), it can be concluded that the validation of the EpiOcular™ EIT 
was based on high-quality data. The acceptance criterion for this characteristic was 
unequivocally fulfilled (≥ 85%). One chemical (chemical #33; 2,2'-[[4-[(2-
Methoxyethyl)amino]-3-nitrophenyl]imino]bis-ethanol; INCI name: HC BLUE NO. 11) was 
considered incompatible with the test method at Beiersdorf due to too high colour 
interference with the MTT assay and was therefore excluded from the statistical analysis for 
that laboratory. 
The EpiOcular™ EIT test method was found to be highly reproducible. The WLR (93.6% and 
95.2% concordance of classifications for the 50% and 60% cut-offs analysed in this study, 
respectively) and the BLR (91.3% and 93.3% concordance of classifications for the 50% and 
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60% cut-offs analysed in this study, respectively) were significantly above the acceptance 
criteria set by the VMG (WLR ≥ 85% and BLR ≥ 80%). 
Taking 60% mean viability as the prediction model threshold differentiating classified (UN 
GHS Cat 1 and Cat 2) from non-classified (UN GHS No Cat) chemicals, the overall accuracy 
(79.0%) and specificity (70.5%) were ‘definitely acceptable’ according to the acceptance 
criteria as defined by the VMG (overall accuracy ≥ 75%; specificity ≥ 60%), whereas the 
sensitivity (87.6%) was between the limits of ‘definitely unacceptable’ (< 80%) and ‘definitely 
acceptable’ (≥ 90%). Considering only the liquid chemicals, the test method fulfilled all of the 
‘definitely acceptable’ criteria (overall accuracy of 81.9%; sensitivity of 98.3%; specificity of 
66.7%). For the solid chemicals both the overall accuracy (75.9%) and the specificity (74.8%) 
were ‘definitely acceptable’, whereas the sensitivity (76.9%) was ‘definitely unacceptable’. Of 
note, the solid chemicals protocol showed balanced predictive capacity values with the 60% 
cut-off. 
Taking 50% mean viability as the prediction model threshold differentiating classified (UN 
GHS Cat 1 and Cat 2) from non-classified (UN GHS No Cat) chemicals, the overall accuracy 
(77.9%) and specificity (74.5%) were ‘definitely acceptable’ according to the acceptance 
criteria defined by the VMG (overall accuracy ≥ 75%; specificity ≥ 60%), whereas the 
sensitivity (81.4%) was still between the limits of ‘definitely unacceptable’ (< 80%) and 
‘definitely acceptable’ (≥ 90%). Again, considering only the liquid chemicals, the test method 
fulfilled all of the ‘definitely acceptable’ criteria (overall accuracy of 82.5%; sensitivity of 
96.2%; specificity of 69.8%), while for the solid chemicals only the specificity (79.7%) was 
‘definitely acceptable’. The overall accuracy (73.0%) fell short of ‘definitely acceptable’ (≥ 
75%) but surpassed ‘definitely unacceptable’ (< 65%), while the sensitivity (66.7%) was 
‘definitely unacceptable’. 
 
Based on these findings the VMG concluded that: 
- EpiOcular™ EIT can be easily transferred among properly equipped and staffed 
laboratories, including those having no prior experience in performance of similar test 
methods i.e., naïve laboratories. Experienced personnel can readily be trained in the test 
method, and the necessary equipment and supplies can be readily obtained. The 
EpiOcular™ EIT SOP is clearly written and the testing and analysis of results can be 
performed without difficulties. 
- The validation study was of high quality due to a near complete dataset with negligible re-
testing performed. 
- The WLR was well above the acceptance criterion set by the VMG (WLR ≥ 85%), and 
concordance of classifications within a single laboratory was above 90% for EpiOcular™ EIT 
in the participating laboratories. 
- The BLR was also well above the acceptance criterion set by the VMG (BLR ≥ 80%), and 
the concordance of final classifications obtained between the different participating 
laboratories was greater than 90% for EpiOcular™ EIT. 
- The EpiOcular™ EIT protocol for liquid chemicals met all of the VMG acceptance criteria for 
sensitivity, specificity and overall accuracy. The 60% cut-off was considered to be better than 
the 50% cut-off because it resulted in a better sensitivity and generated no false negatives 
Page 84 of 613 
based on the mode of all predictions (the 50% cut-off generated one false negative for a 
Category 2B chemical), with similar overall accuracy. 
- On the other hand, not all of the acceptance criteria were met by the EpiOcular™ EIT 
protocol for the solid chemicals. Sensitivity was < 90% even at the 60% cut-off and of the 6 
chemicals that were under-predicted with the 60% cut-off based on the mode of all 
predictions, one was classified in vivo as Category 1. 
- Analysis of the EIVS data for solid chemicals indicated scope for improvement through a 
balanced increase in sensitivity with decrease in specificity to attain a compromise of 
sensitivity ≥ 90% with specificity maintained ≥ 60%. Optimisation was therefore 
recommended for the EpiOcular™ EIT protocol for solid chemicals. 
Optimisation of the EpiOcular™ EIT solid chemicals protocol was performed at the method 
developer’s laboratory (MatTek Corporation) in order to increase the sensitivity of the assay 
to the level requested by the VMG. This optimisation led to an increase of the exposure time 
from 90 minutes to 6 hours. The optimisation work was performed independently of the EIVS 
but with guidance and scientific support from the VMG. The VMG provided 11 EIVS solid 
chemicals to MatTek Corporation for the optimisation of the EpiOcular™ EIT solid chemicals 
protocol, including the 6 solid chemicals that had been under-predicted (false negatives) by 
the original protocol plus 5 correctly predicted not classified (UN GHS No Cat) chemicals that 
had shown borderline results. MatTek Corporation was able to complete the optimisation of 
the solid chemicals protocol without delay, enabling follow-up validation within EIVS (post-
optimisation validation), including analysis of the results by the VMG. The validation of the 
EpiOcular™ EIT optimised solids protocol was conducted with the original 52 EIVS solid 
chemicals plus an extra 8 selected to compensate for the 11 used during the optimisation of 
the protocol. The post-optimisation validation of the EpiOcular™ EIT optimised solid 
chemicals protocol took place in a single laboratory, at Beiersdorf (i.e., the lead laboratory for 
EpiOcular™ EIT in the original validation study), since the main purpose of this follow-up 
study was to evaluate the predictive capacity of the optimised protocol. Based on the very 
high reproducibility (WLR and BLR) achieved in the validation study of the original 
EpiOcular™ EIT protocols and of SkinEthic™ HCE, using multiple exposure times and post-
treatment incubation periods, the VMG considered that a simple change in exposure time in 
the EpiOcular™ EIT solid chemicals protocol would not affect the reproducibility of the test 
method. Nevertheless, the VMG decided to assess the WLR of the EpiOcular™ EIT 
optimised solid chemicals protocol at Beiersdorf and based on the results decide if any 
additional reproducibility data (e.g., BLR) generated with the new protocol would be 
necessary. 
 
3.1.2. Post-optimisation validation of the optimised EpiOcular™ EIT solid chemicals 
protocol 
In the following, a summary of the results obtained in the post-optimisation validation study of 
the optimised EpiOcular™ EIT solid chemicals protocol and the conclusions of the VMG 
based on those results are given. Please refer to Annex 2 containing the "EIVS Statistical 
Analysis of the Data Generated under SOP Ver 8.0 of EpiOcular™ EIT" by Roman Liška 
(EIVS biostatistician from EURL ECVAM) for more detailed statistical analysis of the study. 
Tables 3.3 and 3.4 on pages 88 and 89 show the final corrected viabilities and corresponding 
predictions for the 60% viability cut-off obtained for the solid chemicals tested in the post-
optimisation validation of the optimised EpiOcular™ EIT solid chemicals protocol. Based on 
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the results for the fraction of complete test sequences (98.3% in total), it can be concluded 
that the post-optimisation validation of the EpiOcular™ EIT optimised solid chemicals 
protocol at Beiersdorf was based on high-quality data. The acceptance criterion for this 
characteristic was unequivocally fulfilled (≥ 85%). One chemical (chemical #98; 4,4’-(4,5,6,7-
Tetrabromo-3H-2,1-benzoxathiol-3-ylidene)bis[2,6-dibromophenol] S,S-dioxide; INCI name: 
TETRABROMOPHENOL BLUE) was considered incompatible with the test method due to 
too high colour interference with the MTT assay and was therefore excluded from the 
statistical analysis. 
The EpiOcular™ EIT optimised solid chemicals protocol was found to be at least as 
reproducible as the original solid chemicals protocol, with 93.2% and 96.6% concordance of 
classifications (based on 59 chemicals) being obtained by Beiersdorf with the optimised 
protocol for the 50% and 60% cut-offs analysed in this study, respectively, as compared to 
92.0% and 94.0% obtained by the same laboratory with the original protocol (based on 50 
chemicals). Forty nine (49) chemicals are common to the two datasets. If only these are 
considered in the calculations, the concordance of classifications obtained by Beiersdorf 
were 91.8% (50% cut-off) and 95.9% (60% cut-off) for the optimised protocol and 91.8% 
(50% cut-off) and 93.9% (60% cut-off) for the original protocol. The WLR of the EpiOcular™ 
EIT optimised solid chemicals protocol was thus significantly above the acceptance criterion 
set by the VMG (WLR ≥ 85%). The WLR obtained by Beiersdorf with the optimised solid 
chemicals protocol (as described above) was also comparable to the WLR obtained by 
considering the data acquired by all three laboratories that participated in the validation of the 
original protocol, i.e., total concordance of classifications of 92.8% (based on 50 chemicals in 
Beiersdorf and 51 chemicals in Harlan and IIVS) or 92.5% (based on 49 chemicals in all 
three laboratories) for both the 50% and 60% cut-offs. 
Taking 60% mean viability as the prediction model threshold differentiating classified (UN 
GHS Cat 1 and Cat 2) from non-classified (UN GHS No Cat) chemicals, the overall accuracy 
(78.0%), the specificity (60.7%) and the sensitivity (93.5%) were all ‘definitely acceptable’ 
according to the acceptance criteria as defined by the VMG (overall accuracy ≥ 75%; 
specificity ≥ 60%; sensitivity ≥ 90%). 
Taking 50% mean viability as the prediction model threshold differentiating classified (UN 
GHS Cat 1 and Cat 2) from non-classified (UN GHS No Cat) chemicals, the overall accuracy 
(76.8%) and the specificity (64.3%) were ‘definitely acceptable’ according to the acceptance 
criteria defined by the VMG (overall accuracy ≥ 75%; specificity ≥ 60%; sensitivity ≥ 90%), 
whereas the sensitivity (88.2%) was between the limits of ‘definitely unacceptable’ (< 80%) 
and ‘definitely acceptable’ (≥ 90%), but very close to being ‘definitely acceptable’. 
 
Based on these findings the VMG concluded that: 
- The validation of EpiOcular™ EIT optimised solids protocol was of high quality due to a 
near complete dataset with negligible re-testing performed. 
- The WLR was well above the acceptance criterion set by the VMG (WLR ≥ 85%), and 
concordance of classifications within a single laboratory was above 90% for EpiOcular™ EIT 
at Beiersdorf. 
- Further BLR evaluation was identified, by the core VMG, to be unnecessary given the 
previous good reproducibility of the EpiOcular™ EIT test method, and a similar (or even 
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slightly better) WLR observed for the optimised solids protocol as compared to the original 
protocol. With the increased exposure time in the optimised solid chemicals protocol, a 
stronger separation between classified and not-classified chemicals in the viability scale was 
observed as compared to the original protocol, which is expected to improve the 
reproducibility of the test method. The fact that two SkinEthic™ HCE protocols with different 
exposure times were evaluated and showed equally high BLR provides additional evidence 
supporting the conclusion that further BLR assessment of the EpiOcular™ EIT optimised 
solid chemicals protocol is not necessary. 
- The optimised EpiOcular™ EIT protocol for solid chemicals met all of the VMG acceptance 
criteria for sensitivity, specificity and overall accuracy using the 60% cut-off, but not with the 
50% cut-off, with sensitivity being slightly lower than the ‘definitely acceptable’ criterion in the 
latter case. The overall accuracy was also higher with a 60% cut-off than with a 50% cut-off. 
The 60% cut-off was therefore considered to be better than the 50% cut-off with the 
optimised solids protocol, similarly to what had been concluded for the liquids protocol. 
- The overall predictive capacity of EpiOcular™ EIT considering a combination of the data 
obtained for the liquid chemicals protocol with the data obtained using the optimised solid 
chemicals protocol, and a cut-off of 60%, consists of a sensitivity of 95.7%, a specificity of 
63.0% (63.7% if chemical #37 is counted twice since it was tested both with the liquids 
protocol and with the optimised solids protocol) and an overall accuracy of 79.7% (79.8% if 
chemical #37 is counted twice). On this basis, all of the acceptance criteria defined by the 
VMG are met. Two out of 57 chemicals (2 solid Cat 2B chemicals) were under-predicted 
(false negatives) and 20 out of 54 chemicals (9 liquids and 11 solids) were over predicted 
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Test 1 Test 2 Test 3 Test 1 Test 2 Test 3 Test 1 Test 2 Test 3
1 111-25-1 No Cat 67.8 68.8 71.3 66.7 62.5 70.4 75.3 68.2 62.7
2 135-98-8 No Cat 83.0 80.1 77.3 74.6 79.8 78.9 84.2 79.3 80.4
3 2370-63-0 No Cat 55.4 63.0 64.2 37.2 38.1 38.6 51.4 49.0 47.5
4 25103-09-7 No Cat 106.9 104.6 115.5 60.8 57.9 64.3 100.9 93.0 94.8
5 3446-89-7 No Cat 83.5 72.2 86.4 56.7 41.4 40.3 71.8 65.4 50.3
6 629-19-6 No Cat 81.2 83.7 90.9 73.2 71.1 84.7 88.6 80.7 81.3
7 6940-78-9 No Cat 34.6 42.3 38.7 31.0 36.8 36.6 40.5 43.4 32.1
8 111-83-1 No Cat 101.4 97.3 102.8 89.6 94.7 94.8 101.2 99.6 95.2
9 1647-16-1 No Cat 95.4 101.9 98.0 91.9 82.6 96.5 106.0 100.5 98.3
10 3970-62-5 No Cat 33.0 31.1 35.3 14.4 9.8 13.2 16.6 23.8 16.8
11 111-90-0 No Cat 29.8 27.5 29.8 21.2 19.0 16.4 31.6 33.7 28.9
12 68123-18-2 No Cat 94.1 91.5 91.6 92.7 91.9 96.7 96.4 92.5 94.6
13 455946-46-0 No Cat 107.9 87.8 105.4 88.8 97.5 85.1 84.0 81.4 85.8
14 629-82-3 No Cat 98.3 98.7 104.9 90.6 97.9 103.0 94.6 95.7 96.9
15 1680-31-5 No Cat 97.2 101.7 109.5 104.9 93.0 106.3 102.4 93.9 95.3
16 868839-23-0 No Cat 100.4 110.9 103.3 103.8 102.1 94.0 95.7 105.5 102.9
17 63705-03-3 No Cat 102.5 98.1 91.9 86.9 100.6 103.9 96.6 98.1 95.3
18 109292-17-3 No Cat 112.3 69.6 109.5 101.5 91.0 96.8 94.1 95.3 95.0
19 471277-16-4 No Cat 106.4 106.4 111.8 108.8 105.3 113.1 95.6 98.4 98.9
20 71828-07-4 No Cat 31.1 57.2 49.8 9.1 0.0 19.1 48.1 33.2 41.5
21 342573-75-5 No Cat 82.8 82.9 83.2 71.8 67.4 77.6 86.2 81.5 85.4
22 13826-35-2 No Cat 51.6 39.3 45.1 24.0 23.3 13.0 37.7 35.5 39.0
23 623-51-8 No Cat 40.8 46.0 39.5 17.5 22.4 4.9 18.9 8.6 10.4
24 106-91-2 No Cat 48.4 45.6 43.5 28.0 19.4 21.3 53.0 33.9 32.6
25 51-03-6 No Cat 107.6 105.0 101.3 104.8 108.9 104.9 95.0 103.2 107.3
26 60207-90-1 No Cat 22.7 19.4 22.4 30.6 40.7 35.6 31.6 35.6 35.3
27 7659-86-1 No Cat 100.3 107.5 98.1 115.1 85.6 95.0 99.8 101.5 99.4
37 61788-85-0 No Cat 80.4 75.0 79.7 74.2 66.5 78.3 86.3 80.1 78.0
54 542-76-7 Cat 2B 48.8 47.8 45.2 17.1 25.2 19.9 51.8 43.1 30.1
55 78-84-2 Cat 2B 2.3 2.1 2.1 2.2 1.8 2.6 2.5 2.6 2.5
56 542-08-5 Cat 2B 46.4 54.5 60.3 20.8 26.5 27.3 47.5 34.8 29.6
57 105-30-6 Cat 2B 24.4 19.8 19.1 5.0 7.7 6.5 20.4 20.3 12.6
58 29911-27-1 Cat 2B 22.0 22.7 22.2 6.8 2.1 2.6 14.4 13.4 13.0
59 609-14-3 Cat 2B 62.6 67.5 78.3 46.6 36.3 47.0 56.6 52.8 43.6
60 134-62-3 Cat 2B 20.5 13.6 12.6 6.7 16.0 9.3 26.8 13.8 21.2
67 96-48-0 Cat 2A 15.0 10.8 10.7 4.1 4.3 4.9 13.6 15.3 14.6
68 96-41-3 Cat 2A 3.5 2.4 4.3 4.0 2.8 3.3 2.7 7.0 3.0
69 383178-66-3 Cat 2A 13.2 15.0 13.9 10.5 14.0 16.9 13.6 14.4 14.1
70 52793-97-2 Cat 2A 12.5 17.9 15.4 9.9 10.3 12.9 14.3 12.3 12.2
71 1569-01-3 Cat 2A 5.2 6.2 4.7 7.9 7.4 4.0 7.7 9.1 7.4
72 18472-51-0 Cat 2A 4.7 2.2 4.9 5.4 3.7 3.8 5.4 3.2 3.1
80 2365-48-2 Cat 1 18.1 16.6 17.7 6.3 0.0 15.3 9.3 5.0 9.7
81 5351-04-2 Cat 1 2.5 1.8 3.1 3.6 3.2 3.4 5.6 3.9 3.1
82 68424-94-2 Cat 1 4.5 1.6 5.4 1.5 2.1 1.7 5.3 6.9 2.6
83 61789-40-0 Cat 1 5.5 6.1 5.3 4.6 3.6 7.6 5.4 6.8 4.0
84 61791-32-0 Cat 1 12.6 5.6 22.1 6.7 7.0 4.2 17.8 18.7 9.3
85 90583-18-9 Cat 1 15.9 18.1 26.7 5.6 9.2 12.5 14.0 13.1 17.8
86 68815-56-5 Cat 1 25.3 20.7 27.2 41.8 23.4 24.8 31.8 32.7 20.5
87 68891-38-3 Cat 1 26.3 26.3 33.6 20.0 14.4 22.2 30.8 17.4 24.4
88 118569-52-1 Cat 1 4.5 5.3 7.4 5.2 7.8 5.4 3.9 7.0 3.5
89 66455-15-0 Cat 1 10.7 7.2 10.6 5.8 7.8 8.1 9.0 12.6 9.7
90 110615-47-9 Cat 1 40.4 28.5 25.6 25.4 32.6 14.4 35.5 34.7 30.8
91 1760-24-3 Cat 1 20.0 35.0 38.3 17.6 12.4 20.4 21.1 19.6 19.5
92 17831-71-9 Cat 1 47.5 41.0 49.8 18.2 14.8 13.1 39.6 39.3 51.2
% Viability (final corrected)
TABLE 3.1. EpiOcular
TM
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Test 1 Test 2 Test 3 Test 1 Test 2 Test 3 Test 1 Test 2 Test 3
1 111-25-1 No Cat NI NI NI NI NI NI NI NI NI
2 135-98-8 No Cat NI NI NI NI NI NI NI NI NI
3 2370-63-0 No Cat I NI NI I I I I I I
4 25103-09-7 No Cat NI NI NI NI I NI NI NI NI
5 3446-89-7 No Cat NI NI NI I I I NI NI I
6 629-19-6 No Cat NI NI NI NI NI NI NI NI NI
7 6940-78-9 No Cat I I I I I I I I I
8 111-83-1 No Cat NI NI NI NI NI NI NI NI NI
9 1647-16-1 No Cat NI NI NI NI NI NI NI NI NI
10 3970-62-5 No Cat I I I I I I I I I
11 111-90-0 No Cat I I I I I I I I I
12 68123-18-2 No Cat NI NI NI NI NI NI NI NI NI
13 455946-46-0 No Cat NI NI NI NI NI NI NI NI NI
14 629-82-3 No Cat NI NI NI NI NI NI NI NI NI
15 1680-31-5 No Cat NI NI NI NI NI NI NI NI NI
16 868839-23-0 No Cat NI NI NI NI NI NI NI NI NI
17 63705-03-3 No Cat NI NI NI NI NI NI NI NI NI
18 109292-17-3 No Cat NI NI NI NI NI NI NI NI NI
19 471277-16-4 No Cat NI NI NI NI NI NI NI NI NI
20 71828-07-4 No Cat I I I I I I I I I
21 342573-75-5 No Cat NI NI NI NI NI NI NI NI NI
22 13826-35-2 No Cat I I I I I I I I I
23 623-51-8 No Cat I I I I I I I I I
24 106-91-2 No Cat I I I I I I I I I
25 51-03-6 No Cat NI NI NI NI NI NI NI NI NI
26 60207-90-1 No Cat I I I I I I I I I
27 7659-86-1 No Cat NI NI NI NI NI NI NI NI NI
37 61788-85-0 No Cat NI NI NI NI NI NI NI NI NI
54 542-76-7 Cat 2B I I I I I I I I I
55 78-84-2 Cat 2B I I I I I I I I I
56 542-08-5 Cat 2B I I NI I I I I I I
57 105-30-6 Cat 2B I I I I I I I I I
58 29911-27-1 Cat 2B I I I I I I I I I
59 609-14-3 Cat 2B NI NI NI I I I I I I
60 134-62-3 Cat 2B I I I I I I I I I
67 96-48-0 Cat 2A I I I I I I I I I
68 96-41-3 Cat 2A I I I I I I I I I
69 383178-66-3 Cat 2A I I I I I I I I I
70 52793-97-2 Cat 2A I I I I I I I I I
71 1569-01-3 Cat 2A I I I I I I I I I
72 18472-51-0 Cat 2A I I I I I I I I I
80 2365-48-2 Cat 1 I I I I I I I I I
81 5351-04-2 Cat 1 I I I I I I I I I
82 68424-94-2 Cat 1 I I I I I I I I I
83 61789-40-0 Cat 1 I I I I I I I I I
84 61791-32-0 Cat 1 I I I I I I I I I
85 90583-18-9 Cat 1 I I I I I I I I I
86 68815-56-5 Cat 1 I I I I I I I I I
87 68891-38-3 Cat 1 I I I I I I I I I
88 118569-52-1 Cat 1 I I I I I I I I I
89 66455-15-0 Cat 1 I I I I I I I I I
90 110615-47-9 Cat 1 I I I I I I I I I
91 1760-24-3 Cat 1 I I I I I I I I I
92 17831-71-9 Cat 1 I I I I I I I I I
TABLE 3.2. EpiOcular
TM






Predictions (60% viability cut-off)
Beiersdorf Harlan IIVS
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Test 1 Test 2 Test 3 Test 1 Test 2 Test 3 Test 1 Test 2 Test 3 Test 1 Test 2 Test 3
28 118-82-1 No Cat 99.4 99.6 95.8 94.9 94.5 90.9 105.4 112.9 100.6 119.0 91.9 109.3
29 3234-85-3 No Cat 82.9 91.8 88.2 57.4 112.0 83.0 102.5 105.7 101.4 136.5 105.6 98.6
30 598-65-2 No Cat 55.6 39.0 46.8 35.0 25.2 14.2 55.4 51.8 69.2 3.1 3.1 2.3
31 14075-53-7 No Cat 82.1 90.3 62.3 96.6 77.4 96.3 98.2 97.8 103.9 91.8 88.6 85.3
32 84540-47-6 No Cat 0.0 0.9 0.2 1.1 0.9 0.9 2.5 2.8 2.1 2.6 2.3 2.2
33 23920-15-2 No Cat - - - 44.1 48.3 40.3 88.9 89.2 83.2 4.9 2.0 4.1
34 3179-89-3 No Cat 111.1 111.5 116.5 81.4 54.1 63.2 95.6 107.1 80.9 12.3 14.5 -1.9
35 1603-02-7 No Cat 73.7 72.0 77.0 62.3 69.3 77.4 99.9 95.2 99.4 32.5 40.6 55.9
36 101-20-2 No Cat 110.9 102.8 107.5 103.1 88.2 98.5 110.7 110.8 105.6 100.5 110.0 109.5
37 61788-85-0 No Cat 80.4 75.0 79.7 74.2 66.5 78.3 86.3 80.1 78.0 89.2 65.2 68.1
38 103597-45-1 No Cat 102.8 100.9 119.7 99.7 113.0 95.8 101.1 101.9 108.0 118.2 94.7 95.2
39 187393-00-6            No Cat 101.9 99.5 117.3 100.9 114.7 88.4 102.5 101.7 104.8 116.3 108.6 99.4
40 75150-29-7 No Cat 49.4 59.5 62.1 72.9 56.2 60.2 62.3 63.0 60.2 64.0 44.9 58.3
41 88122-99-0 No Cat 101.2 98.8 90.4 98.2 86.4 88.8 99.3 102.5 94.0 102.6 111.3 117.2
42 66170-10-3 No Cat 64.7 85.0 58.7 53.4 66.0 60.1 85.3 81.8 70.5 3.2 4.2 2.7
43 302776-68-7 No Cat 93.9 112.1 102.6 125.3 91.6 163.7 99.8 102.0 103.4 123.6 126.8 92.9
44 231278-20-9 No Cat 104.5 98.7 97.3 101.6 95.0 103.9 98.1 94.2 102.9 114.8 106.2 115.2
45 72956-09-3 No Cat 110.6 101.4 118.8 112.5 97.9 112.6 98.6 98.4 94.8 98.4 102.2 86.4
46 68610-92-4 No Cat 68.4 68.9 72.6 73.1 58.9 80.0 65.2 60.8 57.8 66.0 59.8 62.0
47 120-14-9 No Cat 4.4 5.0 4.6 3.4 2.0 3.2 3.2 2.9 2.6 1.9 2.0 2.5
48 7631-90-5 No Cat 2.7 3.6 3.0 2.8 3.1 2.5 2.7 2.5 2.4 2.4 2.4 2.4
49 94-13-3 No Cat 0.0 0.0 0.0 11.7 5.5 3.8 11.9 15.8 15.6 5.6 3.2 3.1
50 144550-36-7 No Cat 89.7 89.6 83.5 99.1 97.1 96.7 95.6 92.7 97.4 86.5 99.6 99.5
51 33089-61-1 No Cat 99.1 91.5 101.1 93.3 100.1 84.8 95.4 98.7 106.0 23.4 40.0 43.7
52 53112-28-0 No Cat 104.8 103.1 130.8 106.5 105.7 93.4 101.3 95.1 105.7 138.5 110.8 105.9
53 153719-23-4 No Cat 93.0 105.7 119.4 108.2 123.4 104.0 106.3 101.7 107.2 110.8 117.4 104.2
108  145701-23-1 No Cat - - - - - - - - - 102.0 111.0 89.8
109  82-66-6 No Cat - - - - - - - - - 83.1 89.5 100.0
61 83-72-7 Cat 2B 16.0 15.9 22.9 17.0 11.3 9.4 16.3 16.4 21.4 2.5 3.5 3.0
62 104-36-9 Cat 2B 115.2 110.1 101.7 101.7 104.7 105.9 109.8 105.2 97.1 106.5 116.5 98.0
63 62-23-7 Cat 2B 40.6 34.3 27.0 56.8 41.0 50.2 49.6 38.9 43.7 6.0 4.7 5.8
64 96568-04-6 Cat 2B 36.9 22.8 30.0 16.0 20.7 35.1 39.6 29.7 28.2 1.9 2.1 1.9
65 79-92-5 Cat 2B 50.5 52.1 51.7 20.3 16.2 51.8 63.8 41.6 53.9 6.2 4.8 3.2
66 3926-62-3 Cat 2B 6.0 8.0 6.4 4.8 2.7 3.0 2.7 6.6 2.0 2.3 2.7 2.1
110  82657-04-3 Cat 2B - - - - - - - - - 105.1 114.1 111.4
73 1119-62-6 Cat 2A 73.9 88.1 89.0 78.4 86.0 87.8 102.5 105.8 82.9 4.1 2.9 20.4
74 16867-03-1 Cat 2A 72.5 65.9 88.8 76.7 74.5 81.6 87.2 99.3 88.8 51.5 23.0 18.3
75 532-32-1 Cat 2A 74.8 81.1 83.9 17.4 2.0 2.7 5.0 5.8 4.4 1.9 2.0 6.5
76 362525-73-3 Cat 2A 54.8 53.5 53.4 59.0 32.3 52.8 26.9 26.3 28.7 2.5 3.1 2.4
77 189813-45-4 Cat 2A 103.6 94.1 92.8 94.7 61.8 65.2 98.2 107.3 103.6 55.0 59.8 56.5
78 76855-69-1 Cat 2A 79.9 80.9 88.9 65.8 62.0 63.4 87.8 86.9 85.9 52.8 46.4 48.4
79 6484-52-2 Cat 2A 2.4 3.3 2.2 2.7 2.8 2.2 2.9 2.3 3.2 2.2 2.1 2.1
111  619-66-9 Cat 2A - - - - - - - - - 3.9 3.9 3.4
112  83-56-7 Cat 2A - - - - - - - - - 29.1 19.3 14.7
113  74918-21-1 Cat 2A - - - - - - - - - 5.9 6.7 4.7
93 110-03-2 Cat 1 11.5 9.5 5.7 6.2 9.3 8.5 10.3 21.3 18.0 2.3 2.5 2.1
94 143-07-7 Cat 1 2.1 2.3 2.6 5.7 3.0 2.6 5.2 5.8 4.3 1.3 2.6 1.2
95 41253-21-8 Cat 1 2.4 2.5 2.2 2.5 2.7 2.7 1.6 2.3 2.1 2.4 2.4 2.0
96 86-87-3 Cat 1 28.9 41.1 36.1 35.5 35.3 30.9 33.2 38.9 54.1 12.3 9.5 6.0
97 62-76-0 Cat 1 56.2 47.2 55.5 55.3 51.7 51.0 59.0 55.1 51.1 27.6 29.8 29.6
98 4430-25-5 Cat 1 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 - - -
99 2634-33-5 Cat 1 2.6 2.8 3.1 3.3 2.3 2.4 1.9 2.0 1.7 2.1 2.2 2.7
100 60372-77-2 Cat 1 9.8 3.6 2.4 10.0 14.9 8.5 10.5 8.2 8.9 18.0 15.0 20.1
101 97404-02-9 Cat 1 34.1 33.2 34.3 26.2 50.6 42.0 19.9 21.6 13.8 2.3 2.5 2.2
102 27344-41-8 Cat 1 10.1 110.2 124.3 38.0 55.0 52.1 76.7 87.8 108.2 14.3 14.6 19.8
103 2820-37-3 Cat 1 2.0 3.5 2.0 1.9 1.9 1.6 1.7 2.1 2.1 1.3 1.4 1.4
104 171887-03-9 Cat 1 37.4 38.9 42.9 40.3 36.3 48.4 47.1 34.8 24.4 25.7 22.7 17.1
105 54424-29-2 Cat 1 2.5 2.8 2.4 3.9 2.6 1.9 2.1 2.4 2.4 2.4 2.4 2.1
114  105812-81-5 Cat 1 - - - - - - - - - 5.7 7.6 2.9
115  65-85-0 Cat 1 - - - - - - - - - 2.3 2.1 2.1
TABLE 3.3. EpiOcular
TM






% Viability (final corrected)
Beiersdorf (original) Harlan (original) IIVS (original) Beiersdorf (optimised)
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28 118-82-1 No Cat NI NI NI NI NI NI NI NI NI NI NI NI
29 3234-85-3 No Cat NI NI NI I NI NI NI NI NI NI NI NI
30 598-65-2 No Cat I I I I I I I I NI I I I
31 14075-53-7 No Cat NI NI NI NI NI NI NI NI NI NI NI NI
32 84540-47-6 No Cat I I I I I I I I I I I I
33 23920-15-2 No Cat - - - I I I NI NI NI I I I
34 3179-89-3 No Cat NI NI NI NI I NI NI NI NI I I I
35 1603-02-7 No Cat NI NI NI NI NI NI NI NI NI I I I
36 101-20-2 No Cat NI NI NI NI NI NI NI NI NI NI NI NI
37 61788-85-0 No Cat NI NI NI NI NI NI NI NI NI NI NI NI
38 103597-45-1 No Cat NI NI NI NI NI NI NI NI NI NI NI NI
39 187393-00-6            No Cat NI NI NI NI NI NI NI NI NI NI NI NI
40 75150-29-7 No Cat I I NI NI I NI NI NI NI NI I I
41 88122-99-0 No Cat NI NI NI NI NI NI NI NI NI NI NI NI
42 66170-10-3 No Cat NI NI I I NI NI NI NI NI I I I
43 302776-68-7 No Cat NI NI NI NI NI NI NI NI NI NI NI NI
44 231278-20-9 No Cat NI NI NI NI NI NI NI NI NI NI NI NI
45 72956-09-3 No Cat NI NI NI NI NI NI NI NI NI NI NI NI
46 68610-92-4 No Cat NI NI NI NI I NI NI NI I NI I NI
47 120-14-9 No Cat I I I I I I I I I I I I
48 7631-90-5 No Cat I I I I I I I I I I I I
49 94-13-3 No Cat I I I I I I I I I I I I
50 144550-36-7 No Cat NI NI NI NI NI NI NI NI NI NI NI NI
51 33089-61-1 No Cat NI NI NI NI NI NI NI NI NI I I I
52 53112-28-0 No Cat NI NI NI NI NI NI NI NI NI NI NI NI
53 153719-23-4 No Cat NI NI NI NI NI NI NI NI NI NI NI NI
108  145701-23-1 No Cat - - - - - - - - - NI NI NI
109  82-66-6 No Cat - - - - - - - - - NI NI NI
61 83-72-7 Cat 2B I I I I I I I I I I I I
62 104-36-9 Cat 2B NI NI NI NI NI NI NI NI NI NI NI NI
63 62-23-7 Cat 2B I I I I I I I I I I I I
64 96568-04-6 Cat 2B I I I I I I I I I I I I
65 79-92-5 Cat 2B I I I I I I NI I I I I I
66 3926-62-3 Cat 2B I I I I I I I I I I I I
110  82657-04-3 Cat 2B - - - - - - - - - NI NI NI
73 1119-62-6 Cat 2A NI NI NI NI NI NI NI NI NI I I I
74 16867-03-1 Cat 2A NI NI NI NI NI NI NI NI NI I I I
75 532-32-1 Cat 2A NI NI NI I I I I I I I I I
76 362525-73-3 Cat 2A I I I I I I I I I I I I
77 189813-45-4 Cat 2A NI NI NI NI NI NI NI NI NI I I I
78 76855-69-1 Cat 2A NI NI NI NI NI NI NI NI NI I I I
79 6484-52-2 Cat 2A I I I I I I I I I I I I
111  619-66-9 Cat 2A - - - - - - - - - I I I
112  83-56-7 Cat 2A - - - - - - - - - I I I
113  74918-21-1 Cat 2A - - - - - - - - - I I I
93 110-03-2 Cat 1 I I I I I I I I I I I I
94 143-07-7 Cat 1 I I I I I I I I I I I I
95 41253-21-8 Cat 1 I I I I I I I I I I I I
96 86-87-3 Cat 1 I I I I I I I I I I I I
97 62-76-0 Cat 1 I I I I I I I I I I I I
98 4430-25-5 Cat 1 I I I I I I I I I - - -
99 2634-33-5 Cat 1 I I I I I I I I I I I I
100 60372-77-2 Cat 1 I I I I I I I I I I I I
101 97404-02-9 Cat 1 I I I I I I I I I I I I
102 27344-41-8 Cat 1 I NI NI I I I NI NI NI I I I
103 2820-37-3 Cat 1 I I I I I I I I I I I I
104 171887-03-9 Cat 1 I I I I I I I I I I I I
105 54424-29-2 Cat 1 I I I I I I I I I I I I
114  105812-81-5 Cat 1 - - - - - - - - - I I I
115  65-85-0 Cat 1 - - - - - - - - - I I I
TABLE 3.4. EpiOcular
TM






Predictions (60% viability cut-off)
Beiersdorf (original) Harlan (original) IIVS (original) Beiersdorf (optimised)
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3.2. SkinEthicTM HCE SE, LE and test strategy (TS) 
 
3.2.1. Main validation study  
In the following, a summary of the results obtained in the main validation study of the 
SkinEthic™ HCE and the conclusions of the VMG based on those results are given. Please 
refer to Annex 3 containing the "EIVS Statistical Analysis and Reporting on the SkinEthic™ 
HCE" by Carina Rubingh (EIVS biostatistician from TNO) for more detailed statistical 
analysis of the study. 
Two naïve laboratories participating in the validation of SkinEthic™ HCE, one European, 
CARDAM, and one in the US, CeeTox, were trained by the lead laboratory L'Oréal to assure 
optimal transfer of the SE and LE test protocols into their facilities and to guarantee that the 
SOP did not allow for individual (different) interpretation of the experimental steps. All 
procedures and assay documentation were discussed and comments and suggestions for 
improvement and clarification of the SOP were collected and implemented by L'Oréal in a 
final version of the SOP that was used in the ring trial of the validation study. The laboratory 
technicians from all three participating laboratories assigned to the project performed the test 
method with 14 coded test chemicals (3 No Cat, 2 Cat 2, 6 Cat 1 and 3 undefined) at their 
test facility to demonstrate transferability of the test method. The variability obtained with 
both the SE and LE protocols at the three laboratories was very low with SD below 18% 
being obtained for the majority of the tested chemicals in all laboratories. Concordance 
between results of the three laboratories that participated on the transfer study was very 
good, especially considering that highly challenging chemicals (including colorants and direct 
MTT reducers) had been selected for the study. The WLR ranged from 86.7% (CeeTox) to 
87.5% (L'Oréal and CARDAM) and the BLR between the three laboratories in particular was 
excellent (100% for the SE protocol and 92.3% for the LE protocol). All the participating 
laboratories demonstrated their proficiency in performing the SkinEthic™ HCE and readiness 
to enter the formal validation study. 
Tables 3.5 and 3.6 on pages 92 and 93 show the final predictions obtained with SkinEthic™ 
HCE SE (50% viability cut-off) in the main validation study. Tables 3.7 and 3.8 on pages 94 
and 95 show the final predictions obtained with SkinEthic™ HCE LE (50% viability cut-off) in 
the main validation study. Tables 3.9 and 3.10 on pages 96 and 97 show the final predictions 
obtained with SkinEthic™ HCE TS (SE or LE predictions depending on EPRA results and 
based on a 50% viability cut-off) in the main validation study. Based on the results for the 
fraction of complete test sequences (100% in total for the SE protocol, 99.7% in total for the 
LE protocol), it can be concluded that the validation of the SkinEthic™ HCE was based on 
high-quality data. The acceptance criterion for this characteristic was unequivocally fulfilled 
(≥ 85%). 
None of the 104 chemicals tested was considered incompatible with the test method by any 
of the three laboratories, with either the SE or the LE protocol. All chemicals were thus 
included in all of the statistical analyses. 
The SkinEthic™ HCE test method was found to be highly reproducible. The WLR (93.9% 
and 95.5% concordance of classifications for the SE and LE, respectively) and the BLR 
(92.3% concordance of classifications for both the SE and LE protocols) were significantly 
above the acceptance criteria set by the VMG (WLR ≥ 85% and BLR ≥ 80%). 
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The only prediction model that was evaluated used a mean viability of 50% as the threshold 
differentiating classified (UN GHS Cat 1 and Cat 2) from non-classified (UN GHS No Cat) 
chemicals. The specificity of this prediction model was found to be ‘definitely acceptable’ 
according to the acceptance criterion defined by the VMG (≥ 60%), regardless of the protocol 
or strategy (SE: 88.5%; LE: 65.5%; test strategy: 77.1%). The sensitivity was on the other 
hand ‘definitely unacceptable’ (< 80%) according to the same acceptance criteria (SE: 
42.7%; LE: 71.6%; test strategy: 54.5%). The overall accuracy was between the limits of 
‘definitely unacceptable’ (< 65%) and ‘definitely acceptable’ (≥ 75%) (SE: 65.6%; LE: 68.6%; 
test strategy: 65.8%). 
 
Based on these findings the VMG concluded that: 
- SkinEthic™ HCE SE and LE can be easily transferred among properly equipped and 
staffed laboratories, including those having no prior experience in performance of similar test 
methods i.e., (naïve laboratories). Experienced personnel can readily be trained in the test 
method, and the necessary equipment and supplies can be readily obtained. The 
SkinEthic™ HCE SOP is clearly written and the testing and analysis of results can be 
performed without difficulties. 
- The validation study was of high quality due to a near complete dataset with negligible re-
testing performed. 
- The WLR was well above the acceptance criterion set by the VMG (WLR ≥ 85%), and 
concordance of classifications within a single laboratory was above 90% in the participating 
laboratories for both the SE and LE protocols of SkinEthic™ HCE. 
- The BLR was also well above the acceptance criterion set by the VMG (BLR ≥ 80%), and 
the concordance of final classifications obtained between the different participating 
laboratories was greater than 90% for both the SE and LE protocols of SkinEthic™ HCE. 
- Not all of the VMG acceptance criteria were met by either the SE or LE protocols of 
SkinEthic™ HCE alone. Sensitivity, in particular, was ‘definitely unacceptable’ being < 80% 
with both protocols (SE: 42.7%; LE: 71.6%). Moreover, of the 30 chemicals that were 
underpredicted by SE and of the 15 that were underpredicted by LE based on the mode of all 
predictions, 14 and 5, respectively,  were classified in vivo as Category 1, which is also 
‘definitely unacceptable’. 
- The use of EPRA to orient chemicals to the LE (non-reactive) or SE (reactive) protocol is 
also not valid due to a false negative rate of 45.5% and 10 Category 1 chemicals being 
underpredicted as non-irritants (based on the mode of all predictions). It was therefore 
decided not to conduct a reproducibility assessment of EPRA. 
- Analysis of the data for the SkinEthic™ HCE indicated scope for improvement. Further 
optimisation has therefore been recommended for the SkinEthic™ HCE test method 
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Test 1 Test 2 Test 3 Test 1 Test 2 Test 3 Test 1 Test 2 Test 3
1 111-25-1 L No Cat NI NI NI NI NI NI NI NI NI
2 135-98-8 L No Cat NI NI NI NI NI NI NI NI NI
3 2370-63-0 L No Cat NI NI NI NI NI NI NI NI NI
4 25103-09-7 L No Cat I I I I I I I I I
5 3446-89-7 L No Cat NI NI NI NI NI NI NI NI NI
6 629-19-6 L No Cat NI NI NI NI NI NI NI NI NI
7 6940-78-9 L No Cat NI NI NI NI NI NI NI NI NI
8 111-83-1 L No Cat NI NI NI NI NI NI NI NI NI
9 1647-16-1 L No Cat NI NI NI NI NI NI NI NI NI
10 3970-62-5 L No Cat I I I I I I I I I
11 111-90-0 L No Cat NI NI NI NI NI NI NI NI NI
12 68123-18-2 L No Cat NI NI NI NI NI NI NI NI NI
13 455946-46-0 L No Cat NI NI NI NI NI NI NI NI NI
14 629-82-3 L No Cat NI NI NI NI NI NI NI NI NI
15 1680-31-5 L No Cat NI NI NI NI NI NI NI NI NI
16 868839-23-0 L No Cat NI NI NI NI NI NI NI NI NI
17 63705-03-3 L No Cat NI NI NI NI NI NI NI NI NI
18 109292-17-3 L No Cat NI NI NI NI NI NI NI NI NI
19 471277-16-4 L No Cat NI NI NI NI NI NI NI NI NI
20 71828-07-4 L No Cat I I NI NI NI NI NI I I
21 342573-75-5 L No Cat NI NI NI NI NI NI NI NI NI
22 13826-35-2 L No Cat NI NI NI NI I I NI NI NI
23 623-51-8 L No Cat I I I I I I I I I
24 106-91-2 L No Cat NI NI NI NI NI NI NI NI NI
25 51-03-6 L No Cat NI NI NI NI NI NI NI NI NI
26 60207-90-1 L No Cat NI NI NI NI NI NI NI NI NI
28 118-82-1 S No Cat NI NI NI NI NI NI NI NI NI
29 3234-85-3 S No Cat NI NI NI NI NI NI NI NI NI
30 598-65-2 S No Cat NI NI NI NI NI NI NI NI NI
31 14075-53-7 S No Cat NI NI NI NI NI NI NI NI NI
32 84540-47-6 S No Cat NI NI NI I I I I I I
33 23920-15-2 S No Cat NI NI NI NI NI NI NI NI NI
34 3179-89-3 S No Cat NI NI NI NI NI NI NI NI NI
35 1603-02-7 S No Cat I NI I I NI I I I I
36 101-20-2 S No Cat NI NI NI NI NI NI NI NI NI
37 61788-85-0 S No Cat NI NI NI NI NI NI NI NI NI
38 103597-45-1 S No Cat NI NI NI NI NI NI NI NI NI
39 187393-00-6 S No Cat NI NI NI NI NI NI NI NI NI
40 75150-29-7 S No Cat NI NI NI NI NI NI NI NI NI
41 88122-99-0 S No Cat NI NI NI NI NI NI NI NI NI
42 66170-10-3 S No Cat NI NI NI NI NI NI NI NI NI
43 302776-68-7 S No Cat NI NI NI NI NI NI NI NI NI
44 231278-20-9 S No Cat NI NI NI NI NI NI NI NI NI
45 72956-09-3 S No Cat NI NI NI NI NI NI NI NI NI
46 68610-92-4 S No Cat NI NI NI NI NI NI NI NI NI
47 120-14-9 S No Cat NI NI NI NI NI NI NI NI NI
48 7631-90-5 S No Cat I I NI I I I I I I
49 94-13-3 S No Cat NI NI NI NI NI NI NI NI NI
50 144550-36-7 S No Cat NI NI NI NI NI NI NI NI NI
51 33089-61-1 S No Cat NI NI NI NI NI NI NI NI NI
52 53112-28-0 S No Cat NI NI NI NI NI NI NI NI NI
53 153719-23-4 S No Cat NI NI NI NI NI NI NI NI NI
TABLE 3.5. SkinEthic
TM
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54 542-76-7 L Cat 2B NI NI NI NI NI NI NI NI I
55 78-84-2 L Cat 2B I I I I I I I I I
56 542-08-5 L Cat 2B NI NI NI NI NI NI NI NI NI
57 105-30-6 L Cat 2B I I I I I I I I I
58 29911-27-1 L Cat 2B I I I I I I I I I
59 609-14-3 L Cat 2B NI NI NI NI NI NI NI NI NI
60 134-62-3 L Cat 2B I I I I I I I I I
61 83-72-7 S Cat 2B NI NI NI NI NI NI NI NI NI
62 104-36-9 S Cat 2B NI NI NI NI NI NI NI NI NI
63 62-23-7 S Cat 2B NI NI NI NI NI NI NI NI NI
64 96568-04-6 S Cat 2B NI NI NI NI NI NI NI NI NI
65 79-92-5 S Cat 2B NI NI NI NI NI NI NI NI NI
66 3926-62-3 S Cat 2B NI NI NI NI NI NI NI NI NI
67 96-48-0 L Cat 2A I I I I I I I I I
68 96-41-3 L Cat 2A I I I I I I I I I
69 383178-66-3 L Cat 2A NI I NI NI NI NI NI NI NI
70 52793-97-2 L Cat 2A I I I I I I I I I
71 1569-01-3 L Cat 2A I I I I I I I I I
72 18472-51-0 L Cat 2A I I I I I I I I I
73 1119-62-6 S Cat 2A NI NI NI NI I I NI NI NI
74 16867-03-1 S Cat 2A NI NI NI NI NI I NI NI NI
75 532-32-1 S Cat 2A NI I I NI NI NI I I I
76 362525-73-3 S Cat 2A NI NI NI I NI NI NI NI NI
77 189813-45-4 S Cat 2A NI NI NI I NI NI NI NI NI
78 76855-69-1 S Cat 2A NI NI NI NI NI NI NI NI NI
79 6484-52-2 S Cat 2A NI NI NI NI NI NI NI NI NI
80 2365-48-2 L Cat 1 I I I I I I I I I
81 5351-04-2 L Cat 1 I I I I I I I I I
82 68424-94-2 L Cat 1 I I I I I I I I I
83 61789-40-0 L Cat 1 I I I I I I I I I
84 61791-32-0 L Cat 1 I I I I I I I I I
85 90583-18-9 L Cat 1 NI NI NI NI NI NI NI NI NI
86 68815-56-5 L Cat 1 NI NI NI NI NI NI NI NI NI
87 68891-38-3 L Cat 1 NI NI NI NI NI I NI NI NI
88 118569-52-1 L Cat 1 I I I I I I I I I
89 66455-15-0 L Cat 1 NI NI NI NI NI I NI NI NI
90 110615-47-9 L Cat 1 NI NI NI NI NI NI NI I I
91 1760-24-3 L Cat 1 NI I NI I I I I I I
92 17831-71-9 L Cat 1 NI NI NI NI NI NI NI NI NI
93 110-03-2 S Cat 1 NI NI NI NI NI NI NI NI NI
94 143-07-7 S Cat 1 NI NI NI NI NI NI NI NI NI
95 41253-21-8 S Cat 1 I I I I I I I I I
96 86-87-3 S Cat 1 NI NI NI NI NI NI NI NI NI
97 62-76-0 S Cat 1 NI NI NI NI NI NI NI NI NI
98 4430-25-5 S Cat 1 NI NI NI NI NI NI NI NI NI
99 2634-33-5 S Cat 1 I I I I I I I I I
100 60372-77-2 S Cat 1 I NI I I I I I NI NI
101 97404-02-9 S Cat 1 NI NI NI NI NI NI NI NI NI
102 27344-41-8 S Cat 1 NI NI NI NI NI NI NI NI NI
103 2820-37-3 S Cat 1 I I I I I I I I I
104 171887-03-9 S Cat 1 NI NI NI NI NI NI NI NI NI
105 54424-29-2 S Cat 1 I I I I I I I I I
TABLE 3.6. SkinEthic
TM
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1 111-25-1 L No Cat I I I I I I I I I
2 135-98-8 L No Cat I I I I I I I I I
3 2370-63-0 L No Cat I I I I I I I I I
4 25103-09-7 L No Cat I I I I I I I I I
5 3446-89-7 L No Cat I I I I I I I I I
6 629-19-6 L No Cat I I I I I I I I I
7 6940-78-9 L No Cat I I I I I I I I I
8 111-83-1 L No Cat I I I I I I I I I
9 1647-16-1 L No Cat NI I NI I I I I I I
10 3970-62-5 L No Cat I I I I I I I I I
11 111-90-0 L No Cat I I I NI NI NI NI NI I
12 68123-18-2 L No Cat NI NI NI NI NI NI NI NI NI
13 455946-46-0 L No Cat NI NI NI NI NI NI NI NI NI
14 629-82-3 L No Cat NI NI NI NI NI NI NI NI NI
15 1680-31-5 L No Cat NI NI NI NI NI NI NI NI NI
16 868839-23-0 L No Cat NI NI NI NI NI NI NI NI NI
17 63705-03-3 L No Cat NI NI NI NI NI NI NI NI NI
18 109292-17-3 L No Cat NI NI NI NI NI NI NI NI NI
19 471277-16-4 L No Cat NI NI NI NI NI NI NI NI NI
20 71828-07-4 L No Cat I I I I I . I I I
21 342573-75-5 L No Cat NI NI NI NI NI NI NI NI NI
22 13826-35-2 L No Cat I I I I I I I I I
23 623-51-8 L No Cat I I I I I I I I I
24 106-91-2 L No Cat I I I I I I I I I
25 51-03-6 L No Cat NI NI NI NI NI NI NI NI NI
26 60207-90-1 L No Cat I I I I I I I I I
28 118-82-1 S No Cat NI NI NI NI NI NI NI NI NI
29 3234-85-3 S No Cat NI NI NI NI NI NI NI NI NI
30 598-65-2 S No Cat NI NI NI NI NI NI NI NI NI
31 14075-53-7 S No Cat NI NI NI NI NI NI NI NI NI
32 84540-47-6 S No Cat I I I I I I I I I
33 23920-15-2 S No Cat NI NI NI NI NI NI NI NI NI
34 3179-89-3 S No Cat I I NI NI NI NI NI NI NI
35 1603-02-7 S No Cat NI NI NI NI NI NI NI NI NI
36 101-20-2 S No Cat NI NI NI NI NI NI NI NI NI
37 61788-85-0 S No Cat NI NI NI NI NI NI NI NI NI
38 103597-45-1 S No Cat NI NI NI NI NI NI NI NI NI
39 187393-00-6            S No Cat NI NI NI NI NI NI NI NI NI
40 75150-29-7 S No Cat NI NI NI NI NI NI NI NI NI
41 88122-99-0 S No Cat NI NI NI NI NI NI NI NI NI
42 66170-10-3 S No Cat NI NI NI NI NI NI NI NI NI
43 302776-68-7 S No Cat NI NI NI NI NI NI NI NI NI
44 231278-20-9 S No Cat NI NI NI NI NI NI NI NI NI
45 72956-09-3 S No Cat NI NI NI NI NI NI NI NI NI
46 68610-92-4 S No Cat NI NI NI NI NI NI NI NI NI
47 120-14-9 S No Cat NI NI NI I I NI I I I
48 7631-90-5 S No Cat I I I I I I I I I
49 94-13-3 S No Cat NI NI NI NI NI NI NI NI NI
50 144550-36-7 S No Cat NI NI NI NI NI NI NI NI NI
51 33089-61-1 S No Cat NI NI NI NI NI NI NI NI NI
52 53112-28-0 S No Cat NI NI NI NI NI NI NI NI NI
53 153719-23-4 S No Cat NI NI NI NI NI NI NI NI NI
TABLE 3.7. SkinEthic
TM
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Test 1 Test 2 Test 3 Test 1 Test 2 Test 3 Test 1 Test 2 Test 3
54 542-76-7 L Cat 2B I I I I I I I I I
55 78-84-2 L Cat 2B I I I I I I I I I
56 542-08-5 L Cat 2B I I I I I I I I I
57 105-30-6 L Cat 2B I I I I I I I I I
58 29911-27-1 L Cat 2B I I I I I I I I I
59 609-14-3 L Cat 2B I I I I I I I I I
60 134-62-3 L Cat 2B I I I I I I I I I
61 83-72-7 S Cat 2B NI NI NI I I I NI NI NI
62 104-36-9 S Cat 2B NI NI NI NI NI NI NI NI NI
63 62-23-7 S Cat 2B NI NI NI NI NI NI NI NI NI
64 96568-04-6 S Cat 2B NI NI NI NI NI NI NI NI NI
65 79-92-5 S Cat 2B NI I I NI NI NI I NI NI
66 3926-62-3 S Cat 2B I I I I I I NI I I
67 96-48-0 L Cat 2A I I I I I I I I I
68 96-41-3 L Cat 2A I I I I I I I I I
69 383178-66-3 L Cat 2A I I I I I I I I I
70 52793-97-2 L Cat 2A I I I I I I I I I
71 1569-01-3 L Cat 2A I I I I I I I I I
72 18472-51-0 L Cat 2A I I I I I I I I I
73 1119-62-6 S Cat 2A NI NI NI NI NI NI NI NI NI
74 16867-03-1 S Cat 2A NI NI NI NI NI NI NI NI NI
75 532-32-1 S Cat 2A I I I I I I I I I
76 362525-73-3 S Cat 2A NI NI NI NI NI NI NI NI NI
77 189813-45-4 S Cat 2A NI NI NI NI NI NI NI NI NI
78 76855-69-1 S Cat 2A NI NI NI NI NI NI NI NI NI
79 6484-52-2 S Cat 2A NI NI NI I I I I NI I
80 2365-48-2 L Cat 1 I I I I I I I I I
81 5351-04-2 L Cat 1 I I I I I I I I I
82 68424-94-2 L Cat 1 I I I I I I I I I
83 61789-40-0 L Cat 1 I I I I I I I I I
84 61791-32-0 L Cat 1 I I I I I I I I I
85 90583-18-9 L Cat 1 I I I I I I I I I
86 68815-56-5 L Cat 1 I I I I I I I I I
87 68891-38-3 L Cat 1 I I I I I I I I I
88 118569-52-1 L Cat 1 I I I I I I I I I
89 66455-15-0 L Cat 1 I I I I I I I I I
90 110615-47-9 L Cat 1 I I I I I I I I I
91 1760-24-3 L Cat 1 I I I I I I I I I
92 17831-71-9 L Cat 1 I I I I I I I I I
93 110-03-2 S Cat 1 I I I I NI NI I I I
94 143-07-7 S Cat 1 I I I I I I I I I
95 41253-21-8 S Cat 1 I I I I I I I I I
96 86-87-3 S Cat 1 I NI NI I I NI I I I
97 62-76-0 S Cat 1 NI I NI NI NI NI NI NI NI
98 4430-25-5 S Cat 1 NI NI NI NI NI I I I I
99 2634-33-5 S Cat 1 I I I I I I I I I
100 60372-77-2 S Cat 1 I I I I I I I I I
101 97404-02-9 S Cat 1 NI NI NI NI NI NI NI NI I
102 27344-41-8 S Cat 1 NI NI NI NI NI NI NI NI NI
103 2820-37-3 S Cat 1 I I I I I I I I I
104 171887-03-9 S Cat 1 NI NI NI NI NI NI NI NI NI
105 54424-29-2 S Cat 1 I I I I I I I I I
TABLE 3.8. SkinEthic
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Test 1 Test 2 Test 3 Test 1 Test 2 Test 3 Test 1 Test 2 Test 3
1 111-25-1 L No Cat NI NI NI NI NI NI NI NI NI
2 135-98-8 L No Cat I I I I I I I I I
3 2370-63-0 L No Cat NI NI NI NI NI NI NI NI NI
4 25103-09-7 L No Cat I I I I I I I I I
5 3446-89-7 L No Cat NI NI NI NI NI NI NI NI NI
6 629-19-6 L No Cat NI NI NI NI NI NI NI NI NI
7 6940-78-9 L No Cat NI NI NI NI NI NI NI NI NI
8 111-83-1 L No Cat I I I I I I I I I
9 1647-16-1 L No Cat NI I NI I I I I I I
10 3970-62-5 L No Cat I I I I I I I I I
11 111-90-0 L No Cat I I I NI NI NI NI NI I
12 68123-18-2 L No Cat NI NI NI NI NI NI NI NI NI
13 455946-46-0 L No Cat NI NI NI NI NI NI NI NI NI
14 629-82-3 L No Cat NI NI NI NI NI NI NI NI NI
15 1680-31-5 L No Cat NI NI NI NI NI NI NI NI NI
16 868839-23-0 L No Cat NI NI NI NI NI NI NI NI NI
17 63705-03-3 L No Cat NI NI NI NI NI NI NI NI NI
18 109292-17-3 L No Cat NI NI NI NI NI NI NI NI NI
19 471277-16-4 L No Cat NI NI NI NI NI NI NI NI NI
20 71828-07-4 L No Cat I I I I I . I I I
21 342573-75-5 L No Cat NI NI NI NI NI NI NI NI NI
22 13826-35-2 L No Cat I I I I I I I I I
23 623-51-8 L No Cat I I I I I I I I I
24 106-91-2 L No Cat NI NI NI NI NI NI NI NI NI
25 51-03-6 L No Cat NI NI NI NI NI NI NI NI NI
26 60207-90-1 L No Cat I I I I I I I I I
28 118-82-1 S No Cat NI NI NI NI NI NI NI NI NI
29 3234-85-3 S No Cat NI NI NI NI NI NI NI NI NI
30 598-65-2 S No Cat NI NI NI NI NI NI NI NI NI
31 14075-53-7 S No Cat NI NI NI NI NI NI NI NI NI
32 84540-47-6 S No Cat NI NI NI I I I I I I
33 23920-15-2 S No Cat NI NI NI NI NI NI NI NI NI
34 3179-89-3 S No Cat NI NI NI NI NI NI NI NI NI
35 1603-02-7 S No Cat I NI I I NI I I I I
36 101-20-2 S No Cat NI NI NI NI NI NI NI NI NI
37 61788-85-0 S No Cat NI NI NI NI NI NI NI NI NI
38 103597-45-1 S No Cat NI NI NI NI NI NI NI NI NI
39 187393-00-6            S No Cat NI NI NI NI NI NI NI NI NI
40 75150-29-7 S No Cat NI NI NI NI NI NI NI NI NI
41 88122-99-0 S No Cat NI NI NI NI NI NI NI NI NI
42 66170-10-3 S No Cat NI NI NI NI NI NI NI NI NI
43 302776-68-7 S No Cat NI NI NI NI NI NI NI NI NI
44 231278-20-9 S No Cat NI NI NI NI NI NI NI NI NI
45 72956-09-3 S No Cat NI NI NI NI NI NI NI NI NI
46 68610-92-4 S No Cat NI NI NI NI NI NI NI NI NI
47 120-14-9 S No Cat NI NI NI NI NI NI NI NI NI
48 7631-90-5 S No Cat I I I I I I I I I
49 94-13-3 S No Cat NI NI NI NI NI NI NI NI NI
50 144550-36-7 S No Cat NI NI NI NI NI NI NI NI NI
51 33089-61-1 S No Cat NI NI NI NI NI NI NI NI NI
52 53112-28-0 S No Cat NI NI NI NI NI NI NI NI NI
53 153719-23-4 S No Cat NI NI NI NI NI NI NI NI NI
TABLE 3.9. SkinEthic
TM
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Test 1 Test 2 Test 3 Test 1 Test 2 Test 3 Test 1 Test 2 Test 3
54 542-76-7 L Cat 2B NI NI NI NI NI NI NI NI I
55 78-84-2 L Cat 2B I I I I I I I I I
56 542-08-5 L Cat 2B NI NI NI NI NI NI NI NI NI
57 105-30-6 L Cat 2B I I I I I I I I I
58 29911-27-1 L Cat 2B I I I I I I I I I
59 609-14-3 L Cat 2B I I I I I I I I I
60 134-62-3 L Cat 2B I I I I I I I I I
61 83-72-7 S Cat 2B NI NI NI NI NI NI NI NI NI
62 104-36-9 S Cat 2B NI NI NI NI NI NI NI NI NI
63 62-23-7 S Cat 2B NI NI NI NI NI NI NI NI NI
64 96568-04-6 S Cat 2B NI NI NI NI NI NI NI NI NI
65 79-92-5 S Cat 2B NI NI NI NI NI NI NI NI NI
66 3926-62-3 S Cat 2B NI NI NI NI NI NI NI NI NI
67 96-48-0 L Cat 2A I I I I I I I I I
68 96-41-3 L Cat 2A I I I I I I I I I
69 383178-66-3 L Cat 2A NI I NI NI NI NI NI NI NI
70 52793-97-2 L Cat 2A I I I I I I I I I
71 1569-01-3 L Cat 2A I I I I I I I I I
72 18472-51-0 L Cat 2A I I I I I I I I I
73 1119-62-6 S Cat 2A NI NI NI NI I I NI NI NI
74 16867-03-1 S Cat 2A NI NI NI NI NI I NI NI NI
75 532-32-1 S Cat 2A I I I I I I I I I
76 362525-73-3 S Cat 2A NI NI NI NI NI NI NI NI NI
77 189813-45-4 S Cat 2A NI NI NI I NI NI NI NI NI
78 76855-69-1 S Cat 2A NI NI NI NI NI NI NI NI NI
79 6484-52-2 S Cat 2A NI NI NI I I I I NI I
80 2365-48-2 L Cat 1 I I I I I I I I I
81 5351-04-2 L Cat 1 I I I I I I I I I
82 68424-94-2 L Cat 1 I I I I I I I I I
83 61789-40-0 L Cat 1 I I I I I I I I I
84 61791-32-0 L Cat 1 I I I I I I I I I
85 90583-18-9 L Cat 1 NI NI NI NI NI NI NI NI NI
86 68815-56-5 L Cat 1 NI NI NI NI NI NI NI NI NI
87 68891-38-3 L Cat 1 NI NI NI NI NI I NI NI NI
88 118569-52-1 L Cat 1 I I I I I I I I I
89 66455-15-0 L Cat 1 I I I I I I I I I
90 110615-47-9 L Cat 1 I I I I I I I I I
91 1760-24-3 L Cat 1 I I I I I I I I I
92 17831-71-9 L Cat 1 NI NI NI NI NI NI NI NI NI
93 110-03-2 S Cat 1 I I I I NI NI I I I
94 143-07-7 S Cat 1 I I I I I I I I I
95 41253-21-8 S Cat 1 I I I I I I I I I
96 86-87-3 S Cat 1 NI NI NI NI NI NI NI NI NI
97 62-76-0 S Cat 1 NI I NI NI NI NI NI NI NI
98 4430-25-5 S Cat 1 NI NI NI NI NI NI NI NI NI
99 2634-33-5 S Cat 1 I I I I I I I I I
100 60372-77-2 S Cat 1 I I I I I I I I I
101 97404-02-9 S Cat 1 NI NI NI NI NI NI NI NI I
102 27344-41-8 S Cat 1 NI NI NI NI NI NI NI NI NI
103 2820-37-3 S Cat 1 I I I I I I I I I
104 171887-03-9 S Cat 1 NI NI NI NI NI NI NI NI NI
105 54424-29-2 S Cat 1 I I I I I I I I I
TABLE 3.10. SkinEthic
TM














4.1. Overall study conclusions  
 
Considering the findings of the main validation of the EpiOcular™ EIT original liquids and 
solids protocols the VMG concluded that: 
- EpiOcular™ EIT can be easily transferred among properly equipped and staffed 
laboratories, including those having no prior experience in similar test methods i.e., naïve 
laboratories. Experienced personnel can readily be trained in the test method, and the 
necessary equipment and supplies can be readily obtained. The EpiOcular™ EIT SOP is 
clearly written and the testing and analysis of results can be performed without difficulties. 
- Based on the predefined study quality criterion, the main validation study was of high 
quality due to a near complete dataset with negligible re-testing performed (99.7% complete 
test sequences in total which is higher than the predefined acceptance cut-off of 85%). 
- The 60% cut-off was considered to be better than the 50% cut-off because it resulted in a 
better sensitivity with very similar overall accuracy. 
- The overall WLR based on concordance of classifications within each laboratory for the 
60% cut-off was 95.2%, which was well above the acceptance criterion set by the VMG (≥ 
85%). 
- The BLR based on the concordance of final classifications obtained between the different 
participating laboratories for the 60% cut-off was 93.3%, also well above the acceptance 
criterion set by the VMG (≥ 80%). 
- The EpiOcular™ EIT protocol for liquid chemicals using the 60% cut-off had sensitivity of 
98.3%, specificity of 66.7% and overall accuracy of 81.9%, thus meeting all of the 
acceptance criteria defined by the VMG (≥ 90%, ≥ 60% and ≥ 75%, respectively). 
- On the other hand, not all of the acceptance criteria were met by the EpiOcular™ EIT 
protocol for the solid chemicals. Sensitivity was < 90% even at the 60% cut-off and of the 6 
chemicals that were under-predicted with the 60% cut-off based on the mode of all 
predictions, one was classified in vivo as Category 1. 
- Analysis of the EIVS data for solid chemicals indicated scope for improvement through a 
balanced increase in sensitivity with decrease in specificity to attain a compromise of 
sensitivity ≥ 90% with specificity maintained ≥ 60%. Further optimisation was therefore 
recommended for the EpiOcular™ EIT protocol for solid chemicals. 
 
Optimisation of the EpiOcular™ EIT solids protocol was performed at the method developer’s 
laboratory (MatTek Corporation) in order to increase the sensitivity of the assay to the level 
requested by the VMG. This optimisation led to an increase of the exposure time from 90 min 
to 6 hours. MatTek Corporation was able to complete the optimisation of the solid chemicals 
protocol without delay, enabling follow-up validation within EIVS (post-optimisation 
validation), including analysis of the results by the VMG. The post-optimisation validation of 
the EpiOcular™ EIT optimised solid chemicals protocol took place in a single laboratory, at 
Beiersdorf (i.e., the lead laboratory for EpiOcular™ EIT in the original validation study). 
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- Based on the predefined study quality criterion, the post-optimisation validation study was 
of high quality due to a near complete dataset with negligible re-testing performed (98.3% 
complete test sequences in total, which is higher than the predefined acceptance cut-off of 
85%). 
-The WLR of the optimised EpiOcular™ EIT solids protocol was 96.6%, which was well 
above the acceptance criterion set by the VMG (≥ 85%). 
-Given the previous good reproducibility of the EpiOcular™ EIT test method, and a similar (or 
even slightly better) WLR observed for the optimised solids protocol as compared to the 
original protocol, the VMG considered that it is unnecessary to perform further BLR 
evaluation of EpiOcular™ EIT. With the increased exposure time in the optimised solid 
chemicals protocol, a stronger separation between irritants and non-irritants in the viability 
scale was observed as compared to the original protocol, which is expected to improve the 
reproducibility of the test method. The fact that two SkinEthic™ HCE protocols with different 
exposure times were evaluated and showed equally high BLR provides additional evidence 
supporting the conclusion that further BLR assessment of the EpiOcular™ EIT optimised 
solid chemicals protocol is not necessary. 
- The optimised EpiOcular™ EIT protocol for solid chemicals showed a sensitivity of 93.5%, 
specificity of 60.7% and overall accuracy of 78.0% using the 60% cut-off, thus meeting all of 
the acceptance criteria defined by the VMG (≥ 90%, ≥ 60% and ≥ 75%, respectively). 
- The overall predictive capacity of EpiOcular™ EIT considering a combination of the data 
obtained with the liquid chemicals protocol with the data obtained with the optimised solid 
chemicals protocol, and a cut-off of 60%, consists of a sensitivity of 95.7%, a specificity of 
63.0% (63.7% if chemical #37 is counted twice since it was tested both with the liquids 
protocol and with the optimised solids protocol) and an overall accuracy of 79.7% (79.8% if 
chemical #37 is counted twice), thus meeting all of the acceptance criteria defined by the 
VMG. Two out of 57 chemicals (2 solid Cat 2B chemicals) were under-predicted (false 
negatives) and 20 out of 54 chemicals (9 liquids and 11 solids) were over-predicted (false 
positives) based on the mode of all predictions. 
 
 
Considering the findings of the validation of the SkinEthic™ HCE the VMG concluded that: 
- SkinEthic™ HCE SE and LE can be easily transferred among properly equipped and 
staffed laboratories, including those having no prior experience in similar test methods i.e., 
(naïve laboratories). Experienced personnel can readily be trained in the test method, and 
the necessary equipment and supplies can be readily obtained. The SkinEthic™ HCE SOP is 
clearly written and the testing and analysis of results can be performed without difficulties. 
- Based on the predefined study quality criterion, the validation study was of high quality due 
to a near complete datasets with negligible re-testing performed (100% and 99.7% complete 
test sequences in total for the SE and LE, respectively, which is higher than the predefined 
acceptance cut-off of 85%). 
- The overall WLR based on concordance of classifications within each laboratory was 93.9% 
and 95.5% for the SE and LE, respectively, which was well above the acceptance criterion 
set by the VMG (≥ 85%). 
Page 101 of 613 
- The BLR based on the concordance of final classifications obtained between the different 
participating laboratories was 92.3% for both the SE and LE, also well above the acceptance 
criterion set by the VMG (≥ 80%). 
- The specificity of SkinEthic™ HCE was found to be ‘definitely acceptable’ according to the 
acceptance criterion defined by the VMG (≥ 60%), regardless of the protocol or strategy (SE: 
88.5%; LE: 65.5%; test strategy: 77.1%). The sensitivity was on the other hand ‘definitely 
unacceptable’ (< 80%) according to the same acceptance criteria (SE: 42.7%; LE: 71.6%; 
test strategy: 54.5%). The overall accuracy was between the limits of ‘definitely 
unacceptable’ (< 65%) and ‘definitely acceptable’ (≥ 75%) (SE: 65.6%; LE: 68.6%; test 
strategy: 65.8%). 
- Analysis of the data for the SkinEthic™ HCE indicated scope for improvement. Further 
optimisation has therefore been recommended for the SkinEthic™ HCE test method 





4.2. VMG recommendations 
 
The VMG acknowledges that due to the variability of individual animal responses within the 
same test in the in vivo Draize eye test (animal-to-animal within-test variability) there is an 
overall probability of about 12% that chemicals classified as UN GHS Cat 2 by the in vivo 
Draize eye test could be equally identified as UN GHS No Cat (Adriaens et al., 2014). This 
probability would most likely significantly increase if the variability of the in vivo responses 
between repeated tests and between laboratories would also be considered (Weil & Scala, 
1971; Marzulli and Ruggles, 1973; Cormier et al., 1996). These estimates should therefore 
be acknowledged when considering the validity of alternative methods and testing strategies 
for serious eye damage/eye irritation. 
Considering the above and based on the datasets acquired in this study the VMG considers 
the EpiOcular™ EIT original liquid chemicals protocol and the optimised solid chemicals 
protocol as scientifically valid (reproducible and accurate) to identify chemicals not requiring 
classification for serious eye damage/eye irritation according to the UN GHS classification 
system and thus recommends to proceed to peer-review. The VMG recommends that the 
60% cut-off is used rather than the 50% cut-off because (i) for the liquid chemicals protocol 
the 60% cut-off resulted in a better sensitivity, with very similar overall accuracy, and 
generated no false negatives based on the mode of all predictions as compared to the 50% 
cut-off, which generated one false negative for a Category 2B chemical, and (ii) for the 
optimised solids protocol the 60% cut-off met all of the acceptance criteria defined by the 
VMG and resulted in better sensitivity and overall accuracy than the 50% cut-off, which failed 
to meet the ‘definitely acceptable’ criterion for sensitivity. 
Considering the 60% cut-off, the EpiOcular™ EIT has an overall accuracy of 80% (82% 
based on 53 liquid chemicals and 78% based on 59 solid chemicals), sensitivity of 96% (98% 
based on 26 liquid chemicals and 94% based on 31 solid chemicals), false negative rate of 
4% (2% based on 26 liquid chemicals and 6% based on 31 solid chemicals), specificity of 
63% (65% based on 27 liquid chemicals and 61% based on 28 solid chemicals) and false 
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positive rate of 37% (35% based on 27 liquid chemicals and 39% based on 28 solid 
chemicals), when compared to in vivo rabbit eye test data classified according to the UN 
GHS classification system. The false positive rate obtained (i.e., in vivo UN GHS No 
Category chemicals producing a mean percent tissue viability ≤ 60%, which are therefore 
predicted by EpiOcular™ EIT as requiring classification and labelling) is not critical in the 
since all test chemicals that produce a tissue viability ≤ 60% will require further testing with 
other adequately valid in vitro test methods, or as a last option in rabbits, using a sequential 
testing strategy in a weight-of-evidence approach. 
The EpiOcular™ EIT should be used within a testing strategy such as the Bottom-Up/Top-
Down approach suggested by Scott et al. (2010) e.g., as an initial step in a Bottom-Up 
approach or as one of the last steps in a Top-Down approach to identify chemicals not 
requiring classification and labelling according to UN GHS. A chemical identified as not 
requiring classification and labelling for serious eye damage/eye irritation by EpiOcular™ EIT 
should not require any further testing in other test methods within the testing strategy. 
However, the EpiOcular™ EIT is not intended to differentiate between UN GHS Category 1 
(serious eye damage) and UN GHS Category 2 (eye irritation). This differentiation will need 
to be addressed by another tier of the testing strategy (Scott et al., 2010). A chemical that is 
identified as requiring classification for eye irritation/serious eye damage with EpiOcular™ 
EIT will thus require additional testing (in vitro and/or in vivo) to establish a definitive 
classification. The EpiOcular™ EIT is therefore not considered valid as a stand-alone 
replacement for the in vivo Draize rabbit eye test. 
The validation study demonstrated that EpiOcular™ EIT is able to detect all types of ocular 
effects observed in vivo (i.e., corneal, iridal and conjunctival injuries). In this respect, it should 
be noted that effects on the iris are of lesser importance for classification of chemicals 
according to UN GHS, since iritis on its own rarely drives the UN GHS classification of 
chemicals in vivo (both Category 1 and Category 2) (1.8-3.1% of the chemicals). In fact, test 
chemical that cause classifiable effects to the iris also almost always cause classifiable 
corneal opacity (Adriaens et al., 2014). 
A wide range of chemical types, including polymers, NLPs (no-longer polymers), liquids, 
solids, waxes, viscous materials, gel-like chemicals, coloured chemicals, non-coloured 
chemicals, oxidisers, reducers, inert chemicals, cosmetics ingredients (including dyes, 
preservatives and UV filters), industrial chemicals, pesticides, chemical intermediates, 
pharmaceuticals, a wide range of chemical classes (as identified by OECD Toolbox 
analysis), a wide range of molecular weights, a wide range of chemical structures, etc., have 
been included in the EIVS. Based on this comprehensive chemical set, no clear limitations of 
applicability could be identified. In particular, neither false positive nor false negative results 
could be associated to a particular chemical type. The VMG therefore recommends that 
EpiOcular™ EIT is considered applicable to the testing of all types of substances and 
mixtures, until proven contrary. However, more detailed analysis of the data have revealed 
that liquid test chemicals that are positive in EpiOcular™ EIT (i.e., that produce a tissue 
viability ≤ 60%) and have LogP > 2.5 may correspond to false positive predictions. For such 
test chemicals, additional testing should be considered using another in vitro test method 
able to identify chemicals that do not require classification for eye irritation or serious eye 
damage (UN GHS No Category) rather than using an in vitro test method able to identify 
chemicals inducing serious eye damage (UN GHS Category 1) as is normally suggested in a 
Bottom-Up approach (Scott et al., 2010). 
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Chemical #37 was tested as a liquid in the EpiOcular™ EIT during validation of the original 
liquid and solid chemicals protocols (main part of EIVS) and as a solid during the validation 
of the EpiOcular™ EIT optimised solid chemicals protocol, based on independent decisions 
of the participating laboratories, considering the instructions provided in the validated SOP. 
Given this, the VMG recommends that section B.5.6 of the EpiOcular™ EIT SOP is amended 
to further clarify the procedure for identifying the protocol to be used for test chemicals with 
unclear physical state. It is recommended that all viscous, waxy and gel-like chemicals are 
placed in a water bath for 15 minutes at 37°C before deciding if they should be tested with 
the liquids or the solids protocol. Moreover, the test chemical should not be brought to room 
temperature before testing and should be applied directly from the water bath. 
Based on the data acquired in EIVS, the VMG concluded that the test and run acceptance 
criteria for EpiOcular™ EIT (1.0 < ODNC < 2.3; PC mean viability < 50%; Viability range 
between tissue replicates < 20%) and SkinEthic™ HCE (0.7 ≤ ODNC ≤ 1.5; PC mean viability 
≤ 50%; SD between tissue replicates ≤ 18%) are adequate. It should however be noted that, 
as indicated in the last version of the EpiOcular™ EIT SOP, recent experience has shown 
that under certain circumstances like extended shipping time (e.g., > 4 days to Japan) the 
negative control OD can be < 1.0 in particular with the test protocol for solids. In such cases 
a lower acceptance limit for the negative control OD of > 0.8 may be more appropriate. 
Moreover, the VMG recognises that, based on the EIVS data, a stricter acceptance criterion 
for the positive control of the SkinEthic™ HCE SE protocol, like PC mean viability ≤ 30%, 
would probably have been more appropriate than the 50% cut-off used in EIVS. The VMG 
therefore recommends that any future similar or modified RhCE/MTT-based test method 
aiming at identifying chemicals not requiring classification for serious eye damage/eye 
irritation (using tissues modelling the corneal epithelium), including an optimised SkinEthic™ 
HCE test method, use positive control(s) and associated acceptance criteria that are strict 
enough to allow easy detection of inappropriate conduct of the assay. Such a strict 
combination of positive control and associated acceptance criterion were already used with 
the liquid and solid chemicals protocols of EpiOcular™ EIT and with the LE protocol of 
SkinEthic™ HCE in EIVS. This allowed for early detection and correction of an issue in the 
conduct of the SkinEthic™ HCE LE assay at the CeeTox laboratory, thus demonstrating the 
high value of having such strict criteria for the positive control in place. 
The core VMG does not recommend the use of EPRA to orient chemicals to the LE (non-
reactive) or SE (reactive) protocols as proposed in the SkinEthic™ HCE TS. The LE and the 
SE protocols alone are also not considered suitable to identify chemicals not requiring 
classification for serious eye damage/eye irritation. The VMG therefore recommends 
optimisation of the SkinEthic™ HCE test method considering different protocols for liquid 
chemicals and solid chemicals. Nevertheless, the VMG acknowledges the high 
reproducibility of the SkinEthic™ HCE regardless of the protocol used (SE or LE). 
Based on the highly reproducible data acquired with both EpiOcular™ EIT and SkinEthic™ 
HCE in EIVS using multiple exposure times and post-treatment incubation periods, it is 
reasonable to conclude that the reproducibility of this type of test methods is not affected by 
varying the exposure or the post-treatment incubation times. 
An independent statistical analysis of the data acquired in EIVS with SkinEthic™ HCE SE 
and LE protocols using three replicate tissues per test demonstrated that reducing the 
number of replicates from 3 to 2 will have almost no impact on the classification decision for 
a given test. The probability is less than 1% that such a reduction would change the 
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classification for a given test. Based on this and on similar findings obtained with EpiOcular™ 
EIT, the VMG concludes that the use of two tissue replicates in any similar or modified 
RhCE/MTT-based test method aiming at identifying chemicals not requiring classification for 
serious eye damage/eye irritation (using tissues modelling the corneal epithelium) is 
statistically and scientifically justified. 
The VMG considers that the current endpoint detection system using standard absorbance 
(OD) measurement with a spectrophotometer is appropriate to assess direct MTT-reducers 
and colour interfering test chemicals, when the observed interference with the measurement 
of MTT formazan is not too strong (i.e., the ODs of the tissue extracts obtained with the test 
chemical without any correction for direct MTT reduction and/or colour interference are within 
the linear range of the spectrophotometer) (e.g., below 140% of the negative control) or 
when the uncorrected percent viability obtained with the test chemical is ≤ 60%, thus already 
identifying the test chemical as requiring classification and labelling. Nevertheless, results for 
test chemicals producing non-specific MTT reduction and/or colour interference ≥ 60% of the 
negative control should be taken with caution. Standard absorbance (OD) can however not 
be measured when the interference with the measurement of MTT formazan is too strong 
(i.e., leading to uncorrected ODs falling outside of the linear range of the spectrophotometer) 
and the uncorrected percent viability obtained with the test chemical is > 60%. For coloured 
test chemicals or test chemicals that become coloured in contact with water or isopropanol 
that interfere too strongly with the MTT-reduction assay an alternative endpoint detection 
system like HPLC/UPLC-photometry may be required. This is because the HPLC/UPLC 
system allows for the separation of the MTT formazan from the chemical before its 
quantification. 
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Summary 
The goal of the Eye Irritation Validation Study (EIVS) was to assess the relevance 
(predictive capacity) and reliability (reproducibility within and between laboratories) 
of the SkinEthicTM HCE SE, LE and test strategy and of the EpiOcularTM EIT, by 
testing a statistically significant number of coded test chemicals (substances and 
mixtures), supported by complete and quality assured in vivo Draize eye irritation 
data for comparative evaluation of results. In this report a complete, objective and 
transparent analysis of within-laboratory and between-laboratory reproducibility as 
well as predictive capacity based on the submitted test data for EpiOcular™ EIT is 
presented. 
 
Based on the results for the fraction of complete test sequences (99.7% in total), 
the within-laboratory variability (93.6% and 95.2% concordance in total, using a 
50% cut-off and a 60% cut-off value, respectively) and the between laboratory 
variability (91.3% and 93.2% concordance in total, using a 50% cut-off and a 60% 
cut-off value, respectively), the validation of the EpiOcularTM EIT was based on 
high-quality data. The acceptance criteria for these three characteristics were easily 
fulfilled. 
 
One chemical (chemical 33; 2,2'-[[4-[(2-methoxyethyl)amino]-3-
nitrophenyl]imino]bis-ethanol INCI name: HC BLUE NO. 11) for Beiersdorf was 
excluded from the statistical analysis, since it was not compatible with the test 
method. 
 
The EpiOcular™ EIT test method is highly reproducible. The within-laboratory 
reproducibility (WLR) and between-laboratory reproducibility (BLR) was well above 
the acceptance criteria set by the VMG (i.e. WLR ≥ 85% and BLR ≥ 80%). 
 
Using a 50% cut-off value, meaning that a chemical for which the mean viabililty 
was below 50% is classified as irritant, the accuracy (0.777) and the specificity 
(0.740) are ‘definitely acceptable’ according to the acceptance criteria as defined by 
the VMG, whereas some further evaluation is recommended for the sensitivity 
(0.814). It is seen that the test method fulfils the acceptance criteria if only liquids 
are taken into account (accuracy=0.822; sensitivity=0.962; specificity=0.687). On 
the other hand, not all of the acceptance criteria were met by the protocol for the 
solid chemicals (accuracy=0.730; sensitivity=0.667; specificity=0.797). 
 
Using a 60% cut-off value, meaning that a chemical for which the mean viabililty 
was below 60% is classified as irritant, the accuracy (0.788) and the specificity 
(0.699) are ‘definitely acceptable’ according to the acceptance criteria as defined by 
the VMG, whereas some further evaluation is recommended for the sensitivity 
(0.876). It is seen that the test method fulfils the acceptance criteria if only liquids 
are taken into account (accuracy=0.816; sensitivity=0.983; specificity=0.654). On 
the other hand, not all of the acceptance criteria were met by the protocol for the 
solid chemicals (accuracy=0.759; sensitivity=0.769; specificity=0.748). 
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1 Introduction 
The goal of the Eye Irritation Validation Study (EIVS) was to assess the relevance 
(predictive capacity) and reliability (reproducibility within and between laboratories) 
of the SkinEthicTM HCE SE, LE and test strategy and of the EpiOcularTM EIT, by 
testing a statistically significant number of coded test chemicals (substances and 
mixtures), supported by complete and quality assured in vivo Draize eye irritation 
data for comparative evaluation of results. 
 
Specifically, EIVS assessed the validity of the SkinEthicTM HCE SE, LE and test 
strategy and of the EpiOcularTM EIT as stand-alone (independent) test methods to 
reliably discriminate chemicals not classified as eye irritant (“non-irritants”) from all 
classes of eye irritant chemicals (in the framework of a Bottom-Up/Top-Down test 
strategy, Scott L. et al., 2010), defined according to the United Nations Globally 
Harmonized System (GHS) of Classification and Labelling of Chemicals (UN GHS: 
No Category versus Category 1/Category 2A/Category 2B; UN, 2007) and as 
implemented in the European Commission Regulation (EC) No 1272/2008 on 
classification, labelling and packaging of substances and mixtures, amending and 
repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) 
No 1907/2006 (EU CLP: No Category versus Category 1/Category 2). 
 
The SkinEthic™ HCE test strategy and the EpiOcular™ EIT were developed for 
maximum sensitivity (ability to detect positives, with low rate of false negatives) 
rather than for optimal overall accuracy with balanced sensitivity and specificity 
(ability to detect negatives, with low rate of false positives). Sensitivity had therefore 
a bigger weight than specificity and overall accuracy in their development. However, 
it was also sought to achieve a sufficiently high specificity and overall accuracy, in 
order to allow identification of the highest number of chemicals not classified as 
irritant to the eye. By achieving satisfactory specificity, the SkinEthic™ HCE test 
strategy and the EpiOcular™ EIT would represent stand-alone (independent) test 
methods for the identification of “non-irritants”. Importantly, the test methods were 
not intended to differentiate between UN GHS/EU CLP Category 1 (irreversible 
effects) and UN GHS/EU CLP Category 2 (reversible effects). As proposed by the 
ECVAM workshop of February 2005, this differentiation would be left to another tier 
of the Bottom-Up/Top-Down test strategy (Scott L. et al., 2010). 
 
The EIVS was undertaken in accordance with the principles and criteria 
documented in the OECD Guidance Document on the Validation and International 
Acceptance of New or Updated Test Methods for Hazard Assessment (No. 34, 
OECD, 2005) and according to the Modular Approach to validation (Hartung T. et 
al., 2004). 
 
The objective of this report is to summarize and present a complete, objective and 
transparent analysis of within-laboratory and between-laboratory reproducibility as 
well as predictive capacity based on the submitted test data for EpiOcular™ EIT. 
The results for the SkinEthic™ HCE test strategy will be reported in a separate 
report. 
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2 Material and Methods 
2.1 Study Design 
The EpiOcularTM EIT was tested in three laboratories. 
 
Lead Laboratory Beiersdorf (Germany) 
Additional Laboratory 1 Harlan (UK) 
Additional Laboratory 2 IIVS (USA) 
  
Each laboratory tested the same 106 chemicals in three runs each, in two tissues. 
These chemicals were coded and distributed by TNO (The Netherlands). The 
chemicals were tested blinded. Contact between the laboratories during the testing 
was not allowed in order to safeguard the blinding. More details regarding the study 
design can be found in the project plan (appendix VIII). 
 
The chemicals that were used in the validation study are listed in Table 2.1.1.  
Table 2.1.1 List of tested chemicals in EIVS validation study 
Chemical Substance name State CAS # GHS Class 
1 1-bromohexane Liquid 111-25-1 no cat 
2 1-methylpropyl benzene Liquid 135-98-8 no cat 
3 2-ethoxyethyl methacrylate Liquid 2370-63-0 no cat 
4 iso-octylthioglycolate INCI name: ISOOCTYL THIOGLYCOLATE Liquid 25103-09-7 no cat 
5 4-(methylthio)-benzaldehyde Liquid 3446-89-7 no cat 
6 dipropyl disulphide Liquid 629-19-6 no cat 
7 1-bromo-4-chlorobutane Liquid 6940-78-9 no cat 
8 1-bromo-octane Liquid 111-83-1 no cat 
9 1,9-decadiene Liquid 1647-16-1 no cat 
10 2,2-dimethyl-3-pentanol  Liquid 3970-62-5 no cat 
11 2-(2-ethoxyethoxy) ethanol INCI name: ETHOXYDIGLYCOL Liquid 111-90-0 no cat 
12 bisphenol A, epichlorohydrin polymer, ethoxylated, propoxylated (53-
57% aqueous emulsion) 
Liquid 68123-18-2  no cat 
13 bisphenol A, diethylene triamine, epichlorohydrin polymer, ethoxylated, 
propoxylated (56% aqueous emulsion) 
Liquid 455946-46-0 no cat 
14 dioctyl ether INCI name: DICAPRYLYL ETHER Liquid 629-82-3 no cat 
15 dioctyl carbonate INCI name: DICAPRYLYL CARBONATE Liquid 1680-31-5 no cat 
16 2-propylheptyl octanoate INCI name: PROPYLHEPTYL CAPRYLATE Liquid 868839-23-0 no cat 
17 polyglyceryl-3 diisooctadecanoate INCI name: POLYGLYCERYL-3 
DIISOSTEARATE 
Liquid 63705-03-3 no cat 
18 steareth-10 allyl ether/acrylates copolymer (30% aqueous) INCI name: 
STEARETH-10 ALLYL ETHER/ACRYLATES COPOLYMER 
Liquid 109292-17-3 no cat 
19 dimethyl siloxane, mono dimethylvinylsiloxy- and  mono 
trimethoxysiloxy-terminated  (95%) 
Liquid 471277-16-4 no cat 
20 ricinoleic acid tin salt Liquid 71828-07-4 no cat 
21 1-ethyl-3-methylimidazolium ethylsulphate Liquid 342573-75-5 no cat 
22 3-phenoxybenzyl alcohol  Liquid 13826-35-2  no cat  
23 ethyl thioglycolate INCI name: ETHYL THIOGLYCOLATE Liquid 623-51-8  no cat  
24 glycidyl methacrylate  Liquid 106-91-2  no cat  
25 piperonyl butoxide INCI name: PIPERONYL BUTOXIDE Liquid 51-03-6 no cat 
26 propiconazole Liquid 60207-90-1 no cat 
27
1
 2-ethylhexylthioglycolate Liquid 7659-86-1 no cat 
28 4,4'-methylene bis-(2,6-di-tert-butylphenol) Solid 118-82-1 no cat 
29 tetradecyl tetradecanoate INCI name: MYRISTYL MYRISTATE Solid 3234-85-3 no cat 
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Chemical Substance name State CAS # GHS Class 
30 1,1-dimethylguanidine sulphate Solid 598-65-2 no cat 
31 potassium tetrafluoroborate Solid 14075-53-7 no cat 
32 2,6-dihydroxy-3,4-dimethylpyridine INCI name: 2,6-DIHYDROXY-3,4-
DIMETHYLPYRIDINE 
Solid 84540-47-6 no cat 
33 2,2'-[[4-[(2-methoxyethyl)amino]-3-nitrophenyl]imino]bis-ethanol INCI 
name: HC BLUE NO. 11 
Solid 23920-15-2 no cat 
34 2,2'-[[3-methyl-4-[(4-nitrophenyl)azo]phenyl]imino]bis-ethanol INCI 
name: DISPERSE RED 17 
Solid 3179-89-3 no cat 
35 2,5,6-triamino-4-pyrimidinol sulphate INCI name: 2,5,6-TRIAMINO-4-
PYRIMIDINOL SULFATE 
Solid 1603-02-7 no cat 
36 1-(4-chlorophenyl)-3-(3,4-dichlorophenyl) urea INCI name: 
TRICLOCARBAN 
Solid 101-20-2 no cat 
37
3
 polyethylene glycol (PEG-40) hydrogenated castor oil INCI name: PEG-40 
HYDROGENATED CASTOR OIL 
Solid 61788-85-0 no cat 
38 2,2'-methylene-bis-(6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-
tetramethylbutyl)phenol)  INCI name: METHYLENE BIS-BENZOTRIAZOLYL 
TETRAMETHYLBUTYLPHENOL 
Solid 103597-45-1 no cat 
39 2,2'-[6-(4-methoxyphenyl)-1,3,5-triazine-2,4-diyl]bis[5-[(2-
ethylhexyl)oxy]-phenol]  INCI name: BIS-ETHYLHEXYLOXYPHENOL 
METHOXYPHENYL TRIAZINE 
Solid 187393-00-6            no cat 
40 acrylamidopropyltrimonium chloride/acrylamide copolymer Solid 75150-29-7 no cat 
41 tris(2-ethylhexyl)-4,4',4''-(1,3,5-triazine-2,4,6-triyltriimino) tribenzoate 
INCI name: ETHYLHEXYL TRIAZONE 
Solid 88122-99-0 no cat 
42 trisodium mono-(5-(1,2-dihydroxyethyl)-4-oxido-2-oxo-2,5-dihydro-
furan-3-yl) phosphate INCI name: SODIUM ASCORBYL PHOSPHATE 
Solid 66170-10-3 no cat 
43 hexyl 2-(1-(diethylaminohydroxyphenyl)methanoyl) benzoate INCI 
name: DIETHYLAMINO HYDROXYBENZOYL HEXYL BENZOATE 
Solid 302776-68-7 no cat 
44 [3-chloro-4-[(3-fluorobenzyl)oxy]phenyl](6-iodoquinazolin-4-yl)amine Solid 231278-20-9 no cat 
45 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]propan-
2-ol 
Solid 72956-09-3 no cat 
46 cellulose, 2-(2-hydroxy-3-(trimethylammonium)propoxy)ethyl ether 
chloride (91%) INCI name: POLYQUATERNIUM-10 
Solid 68610-92-4 no cat 
47 3,4-dimethoxy benzaldehyde INCI name: VERATRALDEHYDE Solid 120-14-9  no cat 
48 sodium hydrogensulphite  INCI name: SODIUM BISULFITE Solid 7631-90-5  no cat 
49 propyl-4-hydroxybenzoate INCI name: PROPYLPARABEN Solid 94-13-3 no cat 
50 iodosulfuron-methyl-sodium  Solid 144550-36-7 no cat 
51 1,5-di(2,4-dimethylphenyl)-3-methyl-1,3,5-triazapenta-1,4-diene 
common name: Amitraz 
Solid 33089-61-1 no cat 
52 2-anilino-4,6-dimethylpyrimidine common name: Pyrimethanil Solid 53112-28-0 no cat 
53 3-(2-chloro-thiazol-5-ylmethyl)-5-methyl[1,3,5]oxadiazinan-4-ylidene-N-
nitroamine common name: Thiamethoxam 
Solid 153719-23-4 no cat 
54 3-chloropropionitrile Liquid 542-76-7 cat 2B 
55 2-methylpropanal INCI name: 2-METHYLPROPANAL Liquid 78-84-2 cat 2B 
56 isopropyl acetoacetate Liquid 542-08-5 cat 2B 
57 2-methyl-1-pentanol Liquid 105-30-6 cat 2B 
58 1-(1-methyl-2-propoxyethoxy)propan-2-ol INCI name: PPG-2 PROPYL 
ETHER 
Liquid 29911-27-1 cat 2B 
59 ethyl-2-methyl acetoacetate Liquid 609-14-3 cat 2B 
60 diethyl toluamide INCI name: DIETHYL TOLUAMIDE  common name: 
DEET 
Liquid 134-62-3 cat 2B 
61 2-hydroxy-1,4-naphthoquinone INCI name: LAWSONE Solid 83-72-7 cat 2B 
62 1,4-dibutoxy benzene Solid 104-36-9 cat 2B 
63 4-nitrobenzoic acid Solid 62-23-7 cat 2B 
64 ethyl 2,6-dichloro-5-fluoro-beta-oxo-3-pyridine propionate Solid 96568-04-6 cat 2B 
65 2,2-dimethyl-3-methylenebicyclo [2.2.1] heptane INCI name: 
CAMPHENE 
Solid 79-92-5 cat 2B 
66 sodium chloroacetate Solid 3926-62-3 cat 2B 
67 gamma-butyrolactone INCI name: BUTYROLACTONE Liquid 96-48-0 cat 2A 
68 
cyclopentanol 
Liquid 96-41-3 cat 2A (ICCVAM: cat 
2B) 
69 alkyl (C10-16) glucoside sodium carboxylate (~ 30% aqueous) INCI name: 
SODIUM CARBOXYMETHYL C10-16 ALKYL GLUCOSIDE 
Liquid 383178-66-3 cat 2A (ICCVAM: cat 
2B) 
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Chemical Substance name State CAS # GHS Class 
70 methyl N,N,N-trimethyl-4-[(4,7,7-trimethyl-3-oxobicyclo[2.2.1]hept-2-
ylidene)methyl]anilinium sulphate (30% aqueous) INCI name: CAMPHOR 
BENZALKONIUM METHOSULFATE 
Liquid 52793-97-2 cat 2A 
71 
1-propoxy-2-propanol INCI name: PROPYLENE GLYCOL PROPYL ETHER 
Liquid 1569-01-3 cat 2A (ICCVAM: cat 
2B) 
72 2,4,11,13-tetraazatetradecanediimidamide, N,N''-bis(4-chlorophenyl)-
3,12-diimino-, di-D-gluconate (20% aqueous) INCI name: 
CHLORHEXIDINE DIGLUCONATE 




Solid 1119-62-6 cat 2A (ICCVAM: cat 
2B) 
74 2-amino-3-hydroxy pyridine INCI name: 2-AMINO-3-HYDROXYPYRIDINE Solid 16867-03-1 cat 2A 
75 sodium benzoate INCI name: SODIUM BENZOATE Solid 532-32-1 cat 2A 
76 6,7-dihydro-2,3-dimethyl-imidazo[1,2-a]pyridin-8(5H)-one Solid 362525-73-3 cat 2A 
77 methyl (2E)-[2-(chloromethyl)phenyl](methoxyimino) acetate Solid 189813-45-4 cat 2A 
78 (2R,3R)-3-((R)-1-(tert-butyldimethylsiloxy)ethyl)-4-oxoazetidin-2-yl 
acetate 
Solid 76855-69-1 cat 2A 
79 
ammonium nitrate INCI name: AMMONIUM NITRATE 
Solid 6484-52-2 cat 2A (ICCVAM: cat 
2B) 
80 methylthioglycolate INCI name: METHYL THIOGLYCOLATE Liquid 2365-48-2 cat 1 
81 3-diethylaminopropionitrile Liquid 02/04/5351 cat 1 
82 coco alkyl dimethyl betaine (~ 30% aqueous) INCI name: COCO-BETAINE Liquid 68424-94-2 cat 1 
83 coco amidopropyl betaine (~ 30% aqueous) INCI name: 
COCAMIDOPROPYL BETAINE 
Liquid 61789-40-0 cat 1 
84 sodium coco amphoacetate (~ 30% aqueous) Liquid 61791-32-0 cat 1 
85 triethanol ammonium alkyl sulphate (~ 40% aqueous) INCI name: TEA-
C12-14 ALKYL SULFATE 
Liquid 90583-18-9 cat 1 
86 di-sodium alkyl ether sulfosuccinate (~ 30% aqueous) INCI name: 
DISODIUM LAURETH SULFOSUCCINATE 
Liquid 68815-56-5 cat 1 
87 sodium alkyl ether sulphate (~ 30% aqueous) INCI name: SODIUM 
LAURETH SULFATE 
Liquid 68891-38-3 cat 1 
88 bisphenol A, diethylene triamine, epichlorohydrin, polypropylene glycol 
diglycidyl ether, polymer (~ 60% aqueous) 
Liquid 118569-52-1 cat 1 
89 ethoxylated (5 EO) alkyl (C10-14) alcohol Liquid 66455-15-0 cat 1 
90 alkyl (C10-16) glucoside (~ 50% aqueous) INCI name: LAURYL 
GLUCOSIDE 
Liquid 110615-47-9 cat 1 
91 (ethylenediaminepropyl)trimethoxysilane Liquid 1760-24-3 cat 1 
92 tetraethylene glycol diacrylate Liquid 17831-71-9 cat 1 
93 2,5-dimethyl-2,5-hexanediol Solid 110-03-2 cat 1 
94 dodecanoic acid  INCI name: LAURIC ACID Solid 143-07-7 cat 1 
95 1,2,4-triazole sodium salt Solid 41253-21-8 cat 1 
96 1-naphthalene acetic acid Solid 86-87-3 cat 1 
97 sodium oxalate INCI name: SODIUM OXALATE Solid 62-76-0 cat 1 
98 4,4'-(4,5,6,7-tetrabromo-3H-2,1-benzoxathiol-3-ylidene)bis[2,6-
dibromophenol] S,S-dioxide INCI name: TETRABROMOPHENOL BLUE 
Solid 4430-25-5 cat 1 
99 1,2-benzisothiazol-3(2H)-one  INCI name: BENZISOTHIAZOLINONE Solid 2634-33-5 cat 1 
100 ethyl lauroyl arginate HCl INCI name: ETHYL LAUROYL ARGINATE HCL Solid 60372-77-2 cat 1 
101 2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride INCI 
name: BASIC ORANGE 31 
Solid 97404-02-9 cat 1 
102 disodium 2,2'-([1,1'-biphenyl]-4,4'-
diyldivinylene)bis(benzenesulphonate) INCI name: DISODIUM 
DISTYRYLBIPHENYL DISULFONATE 
Solid 27344-41-8 cat 1 
103 3,4-dimethyl-1H-pyrazole Solid 2820-37-3 cat 1 
104 N-(2-amino-4,6-dichloropyrimidin-5-yl) formamide Solid 171887-03-9 cat 1 




ylidene)methyl)-2-methylbenzenamine hydrochloride INCI name: BASIC 
VIOLET 2 





Solid 134429-57-5 cat 1 
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1 sent to all participating laboratories for testing but excluded at a very early stage of the study on 
request of one of the participating laboratories because it was identified as a very strong MTT 
reducer 
2 extra chemicals not for statistics but for a later purpose of evaluation using an HPLC based 
detection system. 
3 Chemical 37 (polyethylene glycol (PEG-40) hydrogenated castor oil, INCI name: PEG-40 
HYDROGENATED CASTOR OIL) was originally selected by the EIVS VMG as being a solid. 
However, all three laboratories participating in the validation of the EpiOcular™ EIT independently 
considered the chemical as being liquid due to its low melting point and tested it using the liquid 
protocol of EpiOcular™ EIT (see statistical report on EpiOcular™ EIT). Hence, chemical 37 was 
reclassified as liquid by the VMG and was statistically analysed as such. 
 
Chemical 106 (4-((4-amino-3-methylphenyl)(4-imino-3-methyl-2,5-cyclohexadien-1-
ylidene)methyl)-2-methylbenzenamine hydrochloride INCI name: BASIC VIOLET 2) 
and chemical 107 (xanthylium, 3,6-bis(diethylamino)-9-[2-
(methoxycarbonyl)phenyl]-tetrafluoroborate) were sent to all participating 
laboratories for testing but excluded at a very early stage of the study on request of 
one of the participating laboratories because it was identified as a very strong MTT 
reducer. These two chemicals are excluded from any statistical analysis. Hence, the 
statistical analysis is based on 104 chemicals. 
 
In Table 2.1.2, the decoding of the chemicals is given. 
 
Table 2.1.2 Decoding of chemicals 
Chemical Substance name BDF Harlan IIVS 
1 1-bromohexane B56 H47 V95 
2 1-methylpropyl benzene B63 H26 V92 
3 2-ethoxyethyl methacrylate B3 H9 V29 
4 iso-octylthioglycolate INCI name: ISOOCTYL THIOGLYCOLATE B16 H6 V20 
5 4-(methylthio)-benzaldehyde B11 H48 V96 
6 dipropyl disulphide B9 H67 V90 
7 1-bromo-4-chlorobutane B10 H21 V81 
8 1-bromo-octane B25 H35 V48 
9 1,9-decadiene B6 H68 V38 
10 2,2-dimethyl-3-pentanol  B24 H25 V40 
11 2-(2-ethoxyethoxy) ethanol INCI name: ETHOXYDIGLYCOL B39 H42 V49 
12 
bisphenol A, epichlorohydrin polymer, ethoxylated, propoxylated (53-57% aqueous 
emulsion) 
B57 H73 V94 
13 
bisphenol A, diethylene triamine, epichlorohydrin polymer, ethoxylated, propoxylated 
(56% aqueous emulsion) 
B48 H66 V61 
14 dioctyl ether INCI name: DICAPRYLYL ETHER B61 H52 V33 
15 dioctyl carbonate INCI name: DICAPRYLYL CARBONATE B85 H28 V55 
16 2-propylheptyl octanoate INCI name: PROPYLHEPTYL CAPRYLATE B18 H59 V10 
17 polyglyceryl-3 diisooctadecanoate INCI name: POLYGLYCERYL-3 DIISOSTEARATE B84 H87 V75 
18 
steareth-10 allyl ether/acrylates copolymer (30% aqueous) INCI name: STEARETH-10 
ALLYL ETHER/ACRYLATES COPOLYMER 
B35 H30 V41 
19 
dimethyl siloxane, mono dimethylvinylsiloxy- and  mono trimethoxysiloxy-terminated  
(95%) 
B106 H115 V114 
20 ricinoleic acid tin salt B20 H46 V8 
21 1-ethyl-3-methylimidazolium ethylsulphate B38 H24 V103 
22 3-phenoxybenzyl alcohol  B54 H98 V47 
23 ethyl thioglycolate INCI name: ETHYL THIOGLYCOLATE B129 H128 V127 
24 glycidyl methacrylate  B133 H117 V126 
25 piperonyl butoxide INCI name: PIPERONYL BUTOXIDE B191 H186 V150 
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Chemical Substance name BDF Harlan IIVS 
26 propiconazole B155 H159 V170 
27 2-ethylhexylthioglycolate B60 H71 V11 
28 4,4'-methylene bis-(2,6-di-tert-butylphenol) B43 H86 V30 
29 tetradecyl tetradecanoate INCI name: MYRISTYL MYRISTATE B128 H116 V136 
30 1,1-dimethylguanidine sulphate B124 H133 V130 
31 potassium tetrafluoroborate B135 H134 V140 
32 
2,6-dihydroxy-3,4-dimethylpyridine INCI name: 2,6-DIHYDROXY-3,4-
DIMETHYLPYRIDINE 
B101 H76 V80 
33 
2,2'-[[4-[(2-methoxyethyl)amino]-3-nitrophenyl]imino]bis-ethanol INCI name: HC BLUE 
NO. 11 
B87 H20 V58 
34 
2,2'-[[3-methyl-4-[(4-nitrophenyl)azo]phenyl]imino]bis-ethanol INCI name: DISPERSE 
RED 17 
B80 H54 V37 
35 
2,5,6-triamino-4-pyrimidinol sulphate INCI name: 2,5,6-TRIAMINO-4-PYRIMIDINOL 
SULFATE 
B71 H10 V66 
36 1-(4-chlorophenyl)-3-(3,4-dichlorophenyl) urea INCI name: TRICLOCARBAN B46 H14 V72 
37 
polyethylene glycol (PEG-40) hydrogenated castor oil INCI name: PEG-40 
HYDROGENATED CASTOR OIL 
B113 H107 V115 
38 
2,2'-methylene-bis-(6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol)  INCI 
name: METHYLENE BIS-BENZOTRIAZOLYL TETRAMETHYLBUTYLPHENOL 
B92 H88 V59 
39 
2,2'-[6-(4-methoxyphenyl)-1,3,5-triazine-2,4-diyl]bis[5-[(2-ethylhexyl)oxy]-phenol]  
INCI name: BIS-ETHYLHEXYLOXYPHENOL METHOXYPHENYL TRIAZINE 
B79 H53 V1 
40 acrylamidopropyltrimonium chloride/acrylamide copolymer B26 H58 V54 
41 
tris(2-ethylhexyl)-4,4',4''-(1,3,5-triazine-2,4,6-triyltriimino) tribenzoate INCI name: 
ETHYLHEXYL TRIAZONE 
B115 H111 V109 
42 
trisodium mono-(5-(1,2-dihydroxyethyl)-4-oxido-2-oxo-2,5-dihydro-furan-3-yl) 
phosphate INCI name: SODIUM ASCORBYL PHOSPHATE 
B109 H105 V111 
43 
hexyl 2-(1-(diethylaminohydroxyphenyl)methanoyl) benzoate INCI name: 
DIETHYLAMINO HYDROXYBENZOYL HEXYL BENZOATE 
B110 H106 V107 
44 [3-chloro-4-[(3-fluorobenzyl)oxy]phenyl](6-iodoquinazolin-4-yl)amine B107 H109 V105 
45 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]propan-2-ol B112 H112 V108 
46 
cellulose, 2-(2-hydroxy-3-(trimethylammonium)propoxy)ethyl ether chloride (91%) 
INCI name: POLYQUATERNIUM-10 
B108 H108 V113 
47 3,4-dimethoxy benzaldehyde INCI name: VERATRALDEHYDE B105 H110 V106 
48 sodium hydrogensulphite  INCI name: SODIUM BISULFITE B136 H131 V123 
49 propyl-4-hydroxybenzoate INCI name: PROPYLPARABEN B178 H155 V197 
50 iodosulfuron-methyl-sodium  B168 H167 V146 
51 
1,5-di(2,4-dimethylphenyl)-3-methyl-1,3,5-triazapenta-1,4-diene common name: 
Amitraz 
B169 H161 V156 
52 2-anilino-4,6-dimethylpyrimidine common name: Pyrimethanil B145 H188 V166 
53 
3-(2-chloro-thiazol-5-ylmethyl)-5-methyl[1,3,5]oxadiazinan-4-ylidene-N-nitroamine 
common name: Thiamethoxam 
B177 H176 V164 
54 3-chloropropionitrile B58 H79 V104 
55 2-methylpropanal INCI name: 2-METHYLPROPANAL B121 H130 V133 
56 isopropyl acetoacetate B118 H124 V134 
57 2-methyl-1-pentanol B30 H34 V50 
58 1-(1-methyl-2-propoxyethoxy)propan-2-ol INCI name: PPG-2 PROPYL ETHER B134 H136 V128 
59 ethyl-2-methyl acetoacetate B130 H138 V132 
60 diethyl toluamide INCI name: DIETHYL TOLUAMIDE  common name: DEET B125 H126 V131 
61 2-hydroxy-1,4-naphthoquinone INCI name: LAWSONE B59 H4 V69 
62 1,4-dibutoxy benzene B122 H135 V139 
63 4-nitrobenzoic acid B132 H123 V137 
64 ethyl 2,6-dichloro-5-fluoro-beta-oxo-3-pyridine propionate B34 H33 V101 
65 2,2-dimethyl-3-methylenebicyclo [2.2.1] heptane INCI name: CAMPHENE B117 H121 V117 
66 sodium chloroacetate B119 H139 V129 
67 gamma-butyrolactone INCI name: BUTYROLACTONE B22 H96 V15 
68 cyclopentanol B78 H22 V52 
69 
alkyl (C10-16) glucoside sodium carboxylate (~ 30% aqueous) INCI name: SODIUM 
CARBOXYMETHYL C10-16 ALKYL GLUCOSIDE 
B8 H56 V36 
70 
methyl N,N,N-trimethyl-4-[(4,7,7-trimethyl-3-oxobicyclo[2.2.1]hept-2-
ylidene)methyl]anilinium sulphate (30% aqueous) INCI name: CAMPHOR 
B138 H127 V118 
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Chemical Substance name BDF Harlan IIVS 
BENZALKONIUM METHOSULFATE 
71 1-propoxy-2-propanol INCI name: PROPYLENE GLYCOL PROPYL ETHER B28 H104 V3 
72 
2,4,11,13-tetraazatetradecanediimidamide, N,N''-bis(4-chlorophenyl)-3,12-diimino-, 
di-D-gluconate (20% aqueous) INCI name: CHLORHEXIDINE DIGLUCONATE 
B137 H122 V120 
73 3,3'-dithiopropionic acid B15 H3 V27 
74 2-amino-3-hydroxy pyridine INCI name: 2-AMINO-3-HYDROXYPYRIDINE B99 H39 V39 
75 sodium benzoate INCI name: SODIUM BENZOATE B23 H85 V28 
76 6,7-dihydro-2,3-dimethyl-imidazo[1,2-a]pyridin-8(5H)-one B81 H74 V87 
77 methyl (2E)-[2-(chloromethyl)phenyl](methoxyimino) acetate B2 H44 V34 
78 (2R,3R)-3-((R)-1-(tert-butyldimethylsiloxy)ethyl)-4-oxoazetidin-2-yl acetate B40 H19 V85 
79 ammonium nitrate INCI name: AMMONIUM NITRATE B131 H125 V119 
80 methylthioglycolate INCI name: METHYL THIOGLYCOLATE B45 H78 V93 
81 3-diethylaminopropionitrile B27 H15 V2 
82 coco alkyl dimethyl betaine (~ 30% aqueous) INCI name: COCO-BETAINE B67 H102 V71 
83 coco amidopropyl betaine (~ 30% aqueous) INCI name: COCAMIDOPROPYL BETAINE B53 H65 V88 
84 sodium coco amphoacetate (~ 30% aqueous) B100 H82 V26 
85 
triethanol ammonium alkyl sulphate (~ 40% aqueous) INCI name: TEA-C12-14 ALKYL 
SULFATE 
B7 H77 V42 
86 
di-sodium alkyl ether sulfosuccinate (~ 30% aqueous) INCI name: DISODIUM LAURETH 
SULFOSUCCINATE 
B31 H103 V6 
87 sodium alkyl ether sulphate (~ 30% aqueous) INCI name: SODIUM LAURETH SULFATE B64 H27 V19 
88 
bisphenol A, diethylene triamine, epichlorohydrin, polypropylene glycol diglycidyl 
ether, polymer (~ 60% aqueous) 
B17 H89 V25 
89 ethoxylated (5 EO) alkyl (C10-14) alcohol B73 H16 V98 
90 alkyl (C10-16) glucoside (~ 50% aqueous) INCI name: LAURYL GLUCOSIDE B14 H70 V83 
91 (ethylenediaminepropyl)trimethoxysilane B44 H72 V84 
92 tetraethylene glycol diacrylate B174 H175 V191 
93 2,5-dimethyl-2,5-hexanediol B21 H41 V16 
94 dodecanoic acid  INCI name: LAURIC ACID B104 H90 V32 
95 1,2,4-triazole sodium salt B13 H60 V5 
96 1-naphthalene acetic acid B52 H95 V53 
97 sodium oxalate INCI name: SODIUM OXALATE B70 H62 V22 
98 
4,4'-(4,5,6,7-tetrabromo-3H-2,1-benzoxathiol-3-ylidene)bis[2,6-dibromophenol] S,S-
dioxide INCI name: TETRABROMOPHENOL BLUE 
B102 H83 V9 
99 1,2-benzisothiazol-3(2H)-one  INCI name: BENZISOTHIAZOLINONE B29 H92 V18 
100 ethyl lauroyl arginate HCl INCI name: ETHYL LAUROYL ARGINATE HCL B199 H163 V154 
101 
2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride INCI name: BASIC 
ORANGE 31 
B37 H51 V65 
102 
disodium 2,2'-([1,1'-biphenyl]-4,4'-diyldivinylene)bis(benzenesulphonate) INCI name: 
DISODIUM DISTYRYLBIPHENYL DISULFONATE 
B47 H50 V68 
103 3,4-dimethyl-1H-pyrazole B76 H91 V56 
104 N-(2-amino-4,6-dichloropyrimidin-5-yl) formamide B88 H12 V45 
105 1,2-dihydro-1,3,4,6-tetramethyl-2-oxo-pyrimidinium hydrogensulphate B33 H61 V86 
106 
4-((4-amino-3-methylphenyl)(4-imino-3-methyl-2,5-cyclohexadien-1-ylidene)methyl)-
2-methylbenzenamine hydrochloride INCI name: BASIC VIOLET 2 
B74 H23 V13 
107 xanthylium, 3,6-bis(diethylamino)-9-[2-(methoxycarbonyl)phenyl]-tetrafluoroborate B55 H36 V14 
 
2.2 Archiving 
A data file in a flat file format will be provided which includes all quality checked 
test-results from all three laboratories for possible later use. A readme-file will be 
provided which explains each variable in the data set.  
 
The SAS code which was used for statistical analysis is provided in Appendix II. 
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2.3 Receipt of data 
The study results were received by the statistician from the Trial coordinator. The 
receipt of data was reported in an excel file. The report on the receipt of data can be 
found in Appendix III. 
2.4 Acceptance criteria 
2.4.1 Test acceptance criteria 
The test acceptance criteria are described in detail in the EpiOcularTM SOP.. 
 
In short, the following test acceptance criteria are applied. 
 
Subject Criteria Remark 
NC response 1.0 < OD < 2.3  
PC mean viability < 50%  
Tissue variability  Range < 20% Between replicates, for chemicals, PC and NC 
2.4.2 Study acceptance criteria 
The study acceptance criteria are described in detail in the Guidance on eye 
irritation validation study (EIVS) conduct for the reconstructed human tissue (RhT) 
assays and performance criteria to assess the scientific validity of SkinEthicTM HCE 
and EpiOcularTM EIT and its addendum (see appendix VII and VIII). 
 
In short, the following study acceptance criteria are applied. 
 
Subject Criteria Remark 
Complete test sequences >= 85% In each laboratory 
Within laboratory variability 
(concordance of classification) 
>= 85% Using test chemicals for which at least two 
qualified tests are available 
Between laboratory variability 
(concordance of classification) 
>= 80% Using test chemicals for which at least one 
qualified test per laboratory is available 
Sensitivity >=90% Based on all qualified tests 
Specificity >=60% Based on all qualified tests 
Accuracy >=75% Based on all qualified tests 
 
A test sequence is considered complete if it contains three qualified tests. 
Otherwise, the test sequence is considered as incomplete. 
 
If the test method fulfils the above stated acceptance criteria, the performance of 
the method is considered to be ‘definitely acceptable’. For sensitivity, specificity and 
accuracy, some additional criteria are defined to be able to distinguish between a 
definitely unacceptable performance and a performance which might need some 
further evaluation. These criteria are defined as follows: 
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 False Negativesa (%) False Positivesb (%) Overall 
misclassificationsc (%) 
“Definitely acceptable” rates  ≤ 10 ≤ 40 ≤ 25 
Further evaluations 
necessary before any 
recommendation is made 
10 < FN ≤ 20 40 < FP ≤ 50 25 < OM ≤ 35 
“Definitely unacceptable” 
rates > 20 > 50 > 35 
a
 equal to (1-Sensitivity), b equal to (1-Specificity), c equal to (1-Overall accuracy) 
2.5 Statistical methods 
The statistical analyses are performed according to the Statistical Analysis and 
Reporting Plan for the ECVAM/COLIPA Eye Irritation Validation Study on 
Reconstructed Human Tissue Models (final version May 3, 2011). The statistical 
analysis is based on the performance criteria document Guidance on eye irritation 
validation study (EIVS) conduct for the reconstructed human tissue (RhT) assays 
and performance criteria to assess the scientific validity of SkinEthicTM HCE and 
EpiOcularTM EIT and its addendum (see appendix VII and VIII). 
2.5.1 Quality checks 
Before starting the statistical analyses, the following quality checks were done: 
- Is the information complete? 
- Are the test acceptance criteria always met? 
- Are there any deviations from the study plan? 
- Are there any remarks and special observations as given in the reporting 
sheet by the study personal? 
 
Some chemicals might be incompatible with the test method. Evaluation of 
compatibility was evaluated for colouring or MTT-reducing chemicals by the 
following criteria: 
 
RULE 1 – IF the mean of %NSC or %NSMTT of all qualified tests obtained for a 
chemical in one laboratory is less than or equal to (≤) 50%, THEN this chemical is 
considered to be compatible with the test method. The chemical should be included in 
the overview tables, and included in all statistical calculations of reproducibility and 
predictive capacity. 
  
RULE 2 – IF the mean of %NSC or %NSMTT of all qualified tests obtained for a 
chemical in one laboratory is greater than (>) 50% AND their classification (I or NI) 
remains the same upon correction, THEN this chemical is considered to be compatible 
with the test method. The chemical should be included in the overview tables, and 
included in all statistical calculations of reproducibility and predictive capacity. 
  
RULE 3 – IF the mean of %NSC or %NSMTT of all qualified tests obtained for a 
chemical in one laboratory is greater than (>) 50% AND the classification of at least 
one of the qualified tests changes upon correction, THEN this chemical is considered 
to be incompatible with the test method. The chemical should be included in the 
overview tables, but excluded from all statistical calculations of reproducibility and 
predictive capacity. 
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2.5.2 Descriptive statistics 
The descriptive statistics contain summary tables on the chemical selection set (e.g. 
cross tables with solids/liquids), the number of qualified tests, the number of 
complete test sequences, etcetera. 
2.5.3 Within Laboratory Reproducibility (WLR) 
For each laboratory, concordance of classifications and overall Standard Deviation 
were calculated based on qualified tests from test chemicals for which at least two 
qualified tests are available. For each laboratory, concordance of classifications and 
overall Standard Deviation were also calculated based on all tests performed, 
including both qualified and non-qualified tests. The WLR is calculated using a 50% 
and a 60% cut-off. 
2.5.4 Between laboratory Reproducibility (BLR) 
For the calculation of BLR the final classification for each test chemical in each 
participating laboratory should be obtained by using the arithmetic mean value of 
viability over the different qualified tests performed. Concordance of classifications 
between laboratories and overall Standard Deviation of the study were calculated 
based only on qualified tests from test chemicals for which at least one qualified test 
per laboratory is available. The overall Standard Deviation of the study is also 
calculated based on all tests performed, including both qualified and non-qualified 
tests. The BLR is calculated using a 50% and a 60% cut-off. 
2.5.5 Predictive capacity (accuracy) 
All qualified tests for each test chemical were used to calculate the predictive 
capacity values. The calculations were based on the individual predictions of each 
qualified test in each laboratory and not on the arithmetic mean values of viability 
over the different qualified tests performed. The predictive capacity is calculated 
using a 50% and a 60% cut-off. 
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3 Results 
3.1 Quality checks 
Data were imported from the original spread sheets into a SAS data base. All test 
results in the data base are checked by the laboratories and their approval was 
given for completeness and correctness before the statistical analysis was started. 
 
The remarks and special observations as given by the study personal in the 
reporting sheets are listed in Appendix IV.  
 
In Table 3.1.1, the number of non-qualified and qualified runs are given, based on 
the acceptance criteria for NC and PC. 
Table 3.1.1 Number of non-qualified and qualified runs, based on the acceptance criteria for NC 
and PC, subdivided into laboratories 
laboratory  No. Qualified % No .Non-Qualified % 
Beiersdorf NC 42 100.0 0 0.0 
 PC 41 97.6 1 2.4 
Harlan NC 42 97.7 1 2.3 
 PC 43 100.0 0 0.0 
IIVS NC 44 100.0 0 0.0 
 PC 44 100.0 0 0.0 
 
There were no major deviations from the study plan (see appendix IV for detailed 
remarks). 
3.2 Descriptive statistics 
3.2.1 Distribution of test chemicals 
 
In Table 3.2.1 the distribution of test chemicals is given. The 104 chemicals were 
equally distributed among irritants (50%) and non-irritants (50%) and among liquids 
(50%) and solids (50%). 
Table 3.2.1 Distribution of test chemicals (upper: frequencies, lower: percentages) 



















1  Chemical 37 (polyethylene glycol (PEG-40) hydrogenated castor oil INCI name: PEG-40 
HYDROGENATED CASTOR OIL) was listed as solid. However, all three laboratories used the 
liquid protocol to test this chemical. Hence, chemical 37 is statistically analysed as a liquid.  
 
Corrections on total viability were made for MTT-reducing and/or colouring 
chemicals. Whether this correction had to be made was decided by the laboratory. 
For some chemicals, the judgement whether it regards an MTT-reducer or a 
colorant differed between laboratories as is shown in Table 3.2.2. In appendix I, a 
list is given of all MTT-reducing and/or colouring chemicals. If a chemical is treated 
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as an MTT-reducer or a colorant in at least one of the laboratories, it is listed in 
appendix I. 
Table 3.2.2 Colouring or MTT-reducing chemicals which are treated differently between 
laboratories are indicated by #. 
MTT Colouring 
Chemical name Beiersdorf Harlan IIVS  Beiersdorf Harlan IIVS  
1 1-bromohexane No No No  No No No  
2 1-methylpropyl benzene No No No  No No No  
3 2-ethoxyethyl methacrylate No No No  No No No  
4 iso-octylthioglycolate INCI name: ISOOCTYL THIOGLYCOLATE Yes Yes Yes  No No No  
5 4-(methylthio)-benzaldehyde Yes Yes Yes  No No No  
6 dipropyl disulphide No No No  No No No  
7 1-bromo-4-chlorobutane No No No  No No No  
8 1-bromo-octane No No No  No No No  
9 1,9-decadiene No No Yes # No No No  
10 2,2-dimethyl-3-pentanol  No No Yes # No No No  
11 2-(2-ethoxyethoxy) ethanol INCI name: ETHOXYDIGLYCOL No No No  No No No  
12 bisphenol A, epichlorohydrin polymer, ethoxylated, 
propoxylated (53-57% aqueous emulsion) 
No No No  No No Yes # 
13 bisphenol A, diethylene triamine, epichlorohydrin polymer, 
ethoxylated, propoxylated (56% aqueous emulsion) 
No No No  No No Yes # 
14 dioctyl ether INCI name: DICAPRYLYL ETHER No No No  No No No  
15 dioctyl carbonate INCI name: DICAPRYLYL CARBONATE No No No  No No No  
16 2-propylheptyl octanoate INCI name: PROPYLHEPTYL 
CAPRYLATE 
No No No  No No No  
17 polyglyceryl-3 diisooctadecanoate INCI name: 
POLYGLYCERYL-3 DIISOSTEARATE 
No No No  No No No  
18 steareth-10 allyl ether/acrylates copolymer (30% aqueous) 
INCI name: STEARETH-10 ALLYL ETHER/ACRYLATES 
COPOLYMER 
No No No  No No No  
19 dimethyl siloxane, mono dimethylvinylsiloxy- and  mono 
trimethoxysiloxy-terminated  (95%) 
No No No  No No No  
20 ricinoleic acid tin salt Yes Yes Yes  No No No  
21 1-ethyl-3-methylimidazolium ethylsulphate No No No  No No No  
22 3-phenoxybenzyl alcohol  Yes Yes Yes  No No No  
23 ethyl thioglycolate INCI name: ETHYL THIOGLYCOLATE Yes Yes Yes  No No No  
24 glycidyl methacrylate  No No Yes # No No No  
25 piperonyl butoxide INCI name: PIPERONYL BUTOXIDE Yes Yes Yes  No No No  
26 propiconazole Yes No No # No No No  
28 4,4'-methylene bis-(2,6-di-tert-butylphenol) No No No  No No No  
29 tetradecyl tetradecanoate INCI name: MYRISTYL MYRISTATE Yes No No # No No No  
30 1,1-dimethylguanidine sulphate Yes No No # No No No  
31 potassium tetrafluoroborate No No No  No No No  
32 2,6-dihydroxy-3,4-dimethylpyridine INCI name: 2,6-
DIHYDROXY-3,4-DIMETHYLPYRIDINE 
Yes Yes Yes  No Yes No # 
33 2,2'-[[4-[(2-methoxyethyl)amino]-3-nitrophenyl]imino]bis-
ethanol INCI name: HC BLUE NO. 11 
Yes Yes Yes  Yes Yes Yes  
34 2,2'-[[3-methyl-4-[(4-nitrophenyl)azo]phenyl]imino]bis-
ethanol INCI name: DISPERSE RED 17 
Yes Yes Yes  Yes Yes Yes  
35 2,5,6-triamino-4-pyrimidinol sulphate INCI name: 2,5,6-
TRIAMINO-4-PYRIMIDINOL SULFATE 
Yes Yes Yes  No No No  
36 1-(4-chlorophenyl)-3-(3,4-dichlorophenyl) urea INCI name: 
TRICLOCARBAN 
Yes No No # No No No  
37 polyethylene glycol (PEG-40) hydrogenated castor oil INCI 
name: PEG-40 HYDROGENATED CASTOR OIL 
No No No  No No No  
38 2,2'-methylene-bis-(6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-
tetramethylbutyl)phenol)  INCI name: METHYLENE BIS-
BENZOTRIAZOLYL TETRAMETHYLBUTYLPHENOL 
No No No  No No No  
39 2,2'-[6-(4-methoxyphenyl)-1,3,5-triazine-2,4-diyl]bis[5-[(2-
ethylhexyl)oxy]-phenol]  INCI name: BIS-
ETHYLHEXYLOXYPHENOL METHOXYPHENYL TRIAZINE 
No No No  No No No  
40 acrylamidopropyltrimonium chloride/acrylamide copolymer No No No  No No No  
41 tris(2-ethylhexyl)-4,4',4''-(1,3,5-triazine-2,4,6-triyltriimino) No No No  No No No  
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MTT Colouring 
Chemical name Beiersdorf Harlan IIVS  Beiersdorf Harlan IIVS  
tribenzoate INCI name: ETHYLHEXYL TRIAZONE 
42 trisodium mono-(5-(1,2-dihydroxyethyl)-4-oxido-2-oxo-2,5-
dihydro-furan-3-yl) phosphate INCI name: SODIUM 
ASCORBYL PHOSPHATE 
Yes Yes Yes  No No No  
43 hexyl 2-(1-(diethylaminohydroxyphenyl)methanoyl) benzoate 
INCI name: DIETHYLAMINO HYDROXYBENZOYL HEXYL 
BENZOATE 
No No No  No No No  
44 [3-chloro-4-[(3-fluorobenzyl)oxy]phenyl](6-iodoquinazolin-4-
yl)amine 
No No No  No No No  
45 1-(9H-carbazol-4-yloxy)-3-[[2-(2-
methoxyphenoxy)ethyl]amino]propan-2-ol 
No No No  No No No  
46 cellulose, 2-(2-hydroxy-3-
(trimethylammonium)propoxy)ethyl ether chloride (91%) 
INCI name: POLYQUATERNIUM-10 
No No No  No No No  
47 3,4-dimethoxy benzaldehyde INCI name: VERATRALDEHYDE No Yes No # No No No  
48 sodium hydrogensulphite  INCI name: SODIUM BISULFITE Yes No No # No No No  
49 propyl-4-hydroxybenzoate INCI name: PROPYLPARABEN Yes Yes Yes  No No No  
50 iodosulfuron-methyl-sodium  Yes No Yes # No No No  
51 1,5-di(2,4-dimethylphenyl)-3-methyl-1,3,5-triazapenta-1,4-
diene common name: Amitraz 
Yes No No # No No No  
52 2-anilino-4,6-dimethylpyrimidine common name: 
Pyrimethanil 
No No No  No No No  
53 3-(2-chloro-thiazol-5-ylmethyl)-5-methyl[1,3,5]oxadiazinan-4-
ylidene-N-nitroamine common name: Thiamethoxam 
Yes No No # No No No  
54 3-chloropropionitrile No No No  No No No  
55 2-methylpropanal INCI name: 2-METHYLPROPANAL No No No  No No No  
56 isopropyl acetoacetate Yes Yes Yes  No No No  
57 2-methyl-1-pentanol No No Yes # No No No  
58 1-(1-methyl-2-propoxyethoxy)propan-2-ol INCI name: PPG-2 
PROPYL ETHER 
No No Yes # No No No  
59 ethyl-2-methyl acetoacetate No No No  No No No  
60 diethyl toluamide INCI name: DIETHYL TOLUAMIDE  common 
name: DEET 
Yes No No # No No No  
61 2-hydroxy-1,4-naphthoquinone INCI name: LAWSONE No No No  No No No  
62 1,4-dibutoxy benzene Yes No No # No No No  
63 4-nitrobenzoic acid No No No  No No No  
64 ethyl 2,6-dichloro-5-fluoro-beta-oxo-3-pyridine propionate No No No  No No No  
65 2,2-dimethyl-3-methylenebicyclo [2.2.1] heptane INCI name: 
CAMPHENE 
No No No  No No No  
66 sodium chloroacetate No No Yes # No No No  
67 gamma-butyrolactone INCI name: BUTYROLACTONE No No Yes # No No No  
68 cyclopentanol No No No  No No No  
69 alkyl (C10-16) glucoside sodium carboxylate (~ 30% aqueous) 
INCI name: SODIUM CARBOXYMETHYL C10-16 ALKYL 
GLUCOSIDE 
No No No  No No No  
70 methyl N,N,N-trimethyl-4-[(4,7,7-trimethyl-3-
oxobicyclo[2.2.1]hept-2-ylidene)methyl]anilinium sulphate 
(30% aqueous) INCI name: CAMPHOR BENZALKONIUM 
METHOSULFATE 
No No No  No No No  
71 1-propoxy-2-propanol INCI name: PROPYLENE GLYCOL 
PROPYL ETHER 
No No No  No No No  
72 2,4,11,13-tetraazatetradecanediimidamide, N,N''-bis(4-
chlorophenyl)-3,12-diimino-, di-D-gluconate (20% aqueous) 
INCI name: CHLORHEXIDINE DIGLUCONATE 
No Yes Yes # Yes No No # 
73 3,3'-dithiopropionic acid No No No  No No No  
74 2-amino-3-hydroxy pyridine INCI name: 2-AMINO-3-
HYDROXYPYRIDINE 
Yes Yes Yes  No Yes Yes # 
75 sodium benzoate INCI name: SODIUM BENZOATE No No No  No No No  
76 6,7-dihydro-2,3-dimethyl-imidazo[1,2-a]pyridin-8(5H)-one No No No  No No No  
77 methyl (2E)-[2-(chloromethyl)phenyl](methoxyimino) acetate No No No  No No No  
78 (2R,3R)-3-((R)-1-(tert-butyldimethylsiloxy)ethyl)-4-
oxoazetidin-2-yl acetate 
No No No  No No No  
79 ammonium nitrate INCI name: AMMONIUM NITRATE No No No  No No No  
80 methylthioglycolate INCI name: METHYL THIOGLYCOLATE Yes Yes Yes  No No No  
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MTT Colouring 
Chemical name Beiersdorf Harlan IIVS  Beiersdorf Harlan IIVS  
81 3-diethylaminopropionitrile Yes Yes Yes  No No No  
82 coco alkyl dimethyl betaine (~ 30% aqueous) INCI name: 
COCO-BETAINE 
No No No  No No No  
83 coco amidopropyl betaine (~ 30% aqueous) INCI name: 
COCAMIDOPROPYL BETAINE 
No No No  No No No  
84 sodium coco amphoacetate (~ 30% aqueous) Yes No Yes # No No No  
85 triethanol ammonium alkyl sulphate (~ 40% aqueous) INCI 
name: TEA-C12-14 ALKYL SULFATE 
No No No  No No No  
86 di-sodium alkyl ether sulfosuccinate (~ 30% aqueous) INCI 
name: DISODIUM LAURETH SULFOSUCCINATE 
No No No  No No No  
87 sodium alkyl ether sulphate (~ 30% aqueous) INCI name: 
SODIUM LAURETH SULFATE 
No No No  No No No  
88 bisphenol A, diethylene triamine, epichlorohydrin, 
polypropylene glycol diglycidyl ether, polymer (~ 60% 
aqueous) 
Yes Yes Yes  No No Yes # 
89 ethoxylated (5 EO) alkyl (C10-14) alcohol No No No  No No No  
90 alkyl (C10-16) glucoside (~ 50% aqueous) INCI name: LAURYL 
GLUCOSIDE 
No Yes No # No No No  
91 (ethylenediaminepropyl)trimethoxysilane Yes Yes Yes  No No No  
92 tetraethylene glycol diacrylate Yes Yes Yes  No No No  
93 2,5-dimethyl-2,5-hexanediol No No No  No No No  
94 dodecanoic acid  INCI name: LAURIC ACID No No No  No No No  
95 1,2,4-triazole sodium salt Yes Yes Yes  No No No  
96 1-naphthalene acetic acid No No No  No No No  
97 sodium oxalate INCI name: SODIUM OXALATE No No No  No No No  
98 4,4'-(4,5,6,7-tetrabromo-3H-2,1-benzoxathiol-3-
ylidene)bis[2,6-dibromophenol] S,S-dioxide INCI name: 
TETRABROMOPHENOL BLUE 
Yes Yes Yes  Yes Yes Yes  
99 1,2-benzisothiazol-3(2H)-one  INCI name: 
BENZISOTHIAZOLINONE 
No No Yes # No No No  
100 ethyl lauroyl arginate HCl INCI name: ETHYL LAUROYL 
ARGINATE HCL 
Yes No No # No No No  
101 2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium 
chloride INCI name: BASIC ORANGE 31 
No No No  Yes No No # 
102 disodium 2,2'-([1,1'-biphenyl]-4,4'-
diyldivinylene)bis(benzenesulphonate) INCI name: DISODIUM 
DISTYRYLBIPHENYL DISULFONATE 
No No No  No No No  
103 3,4-dimethyl-1H-pyrazole Yes No No # No No No  
104 N-(2-amino-4,6-dichloropyrimidin-5-yl) formamide No No No  No No No  
105 1,2-dihydro-1,3,4,6-tetramethyl-2-oxo-pyrimidinium 
hydrogensulphate 
No No No  No No No  
 
3.2.2 Number and fraction of qualified and non-qualified tests 
If the difference in viability between the two tested tissues was above 20%, the test 
was considered to be non-qualified. This could concern the tests for the NC, the PC 
and the chemicals. The number and fraction of qualified and non-qualified tests are 
presented in Table 3.2.3, subdivided into laboratories and total. Some chemicals 
were not compatible with the test method, as is also shown in Table 3.2.3. These 
chemicals were excluded for statistical analysis (‘Excluded’ in Table 3.2.3). The 
reasons for the non-qualification of a test or the exclusion of a chemical is 
presented in Appendix V. 
Table 3.2.3 Number and fraction of qualified and non-qualified tests 
laboratory Call No. Fraction (%) 
Beiersdorf Qualified and included 309 93.9 
 Non-Qualified 15 4.6 
 Excluded 5 1.5 
Harlan Qualified and included 312 99.0 
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laboratory Call No. Fraction (%) 
 Non-Qualified 3 1.0 
IIVS Qualified and included 312 97.5 
 Non-Qualified 8 2.5 
Total Qualified and included 933 96.8 
 Non-Qualified 26 2.7 
 Excluded 5 0.5 
3.2.3 Chemicals within a run 
Table 3.2.4 shows the chemicals within each run subdivided into laboratories. The 
chemicals are tested in each run with a test with NC and a test with PC. 
Table 3.2.4 Chemicals within each run subdivided into laboratories (chemicals with test numbers 
between brackets) 
laboratory run  
Beiersdorf EIVS_BDF_liquids_14219F_08_01 3(1) 6(1) 7(1) 8(1) 9(1) 16(1) 69(1) 70(1) 83(1) 87(1) 
 
EIVS_BDF_liquids_14222B_09_04 3(2) 6(2) 7(2) 8(2) 9(2) 16(2) 69(2) 70(2) 83(2) 87(2) 
 
EIVS_BDF_liquids_14225D_10_07 3(3) 6(3) 7(3) 8(3) 9(3) 16(3) 69(3) 70(3) 83(3) 87(3) 
 
EIVS_BDF_liquids_14225E_10_06 1(1) 2(1) 5(1) 11(1) 54(1) 67(1) 68(1) 80(1) 85(1)  
 
EIVS_BDF_liquids_14234C_11_09 1(2) 2(2) 5(2) 11(2) 54(2) 67(2) 68(2) 80(2) 85(2)  
 
EIVS_BDF_liquids_14241C_12_13 1(3) 2(3) 5(3) 11(3) 54(3) 67(3) 68(3) 80(3) 85(3)  
 
EIVS_BDF_liquids_14248A_13_17 4(1) 14(1) 22(1) 23(1) 56(1) 57(1) 71(1) 81(1) 89(1) 91(1) 
 
EIVS_BDF_liquids_14256A_14_19 4(2) 14(2) 22(2) 23(2) 56(2) 57(2) 71(2) 81(2) 89(2) 91(2) 
 
EIVS_BDF_liquids_14256C_14_21 10(1) 17(1) 21(1) 24(1) 37(1) 55(1) 58(1) 59(1) 90(1)  
 
EIVS_BDF_liquids_14263A_15_22 4(3) 14(3) 22(3) 23(3) 56(3) 57(3) 71(3) 81(3) 89(3) 91(3) 
 
EIVS_BDF_liquids_14263B_15_24 10(2) 17(2) 21(2) 24(2) 55(2) 58(2) 59(2) 72(2) 90(2)  
 
EIVS_BDF_liquids_14277E_17_27 10(3) 17(3) 21(3) 24(3) 55(3) 58(3) 59(3) 72(3) 90(3)  
 
EIVS_BDF_liquids_14283A_18_29 12(1) 13(1) 15(1) 18(1) 19(1) 20(1) 82(1) 84(1) 86(1) 88(1) 
 
EIVS_BDF_liquids_14289D_19_32 12(2) 13(2) 15(2) 18(2) 19(2) 20(2) 82(2) 84(2) 86(2) 88(2) 
 
EIVS_BDF_liquids_14296A_20_34 12(3) 13(3) 15(3) 18(3) 19(3) 20(3) 82(3) 84(3) 86(3) 88(3) 
 
EIVS_BDF_liquids_15003B_21_38 25(1) 26(1) 37(2) 60(1) 92(1)      
 
EIVS_BDF_liquids_15007B_23_40 25(2) 26(2) 37(3) 60(2) 72(4) 92(2)     
 
EIVS_BDF_liquids_15013A_24_42 25(3) 26(3) 37(4) 60(3) 92(3)      
 
EIVS_BDF_solids_14219D_08_02 28(1) 35(1) 36(1) 73(1) 74(1) 93(1) 95(1) 96(1) 97(1)  
 
EIVS_BDF_solids_14222A_09_05 28(2) 35(2) 36(2) 73(2) 74(2) 93(2) 95(2) 96(2) 97(2)  
 
EIVS_BDF_solids_14225C_10_08 28(3) 35(3) 36(3) 73(3) 74(3) 93(3) 95(3) 96(3) 97(3)  
 
EIVS_BDF_solids_14234A_11_10 30(1) 41(1) 42(1) 48(1) 62(1) 76(1) 77(1) 94(1) 103(1) 105(1) 
 
EIVS_BDF_solids_14234B_11_11 32(1) 34(1) 47(1) 61(1) 64(1) 79(1)     
 
EIVS_BDF_solids_14241A_12_15 32(2) 34(2) 47(2) 61(2) 64(2) 74(4) 79(2)    
 
EIVS_BDF_solids_14241B_12_14 30(2) 41(2) 42(2) 48(2) 62(2) 76(2) 77(2) 94(2) 103(2) 105(2) 
 
EIVS_BDF_solids_14248B_13_16 30(3) 41(3) 42(3) 48(3) 62(3) 76(3) 77(3) 94(3) 103(3) 105(3) 
 
EIVS_BDF_solids_14248C_13_18 32(3) 34(3) 47(3) 61(3) 64(3) 79(3)     
 
EIVS_BDF_solids_14256B_14_20 31(1) 43(1) 44(1) 46(1) 63(1) 65(1) 66(1) 75(1) 78(1) 104(1) 
 
EIVS_BDF_solids_14263C_15_23 31(2) 43(2) 44(2) 46(2) 63(2) 65(2) 66(2) 75(2) 78(2) 104(2) 
 
EIVS_BDF_solids_14277D_17_26 31(3) 43(3) 44(3) 46(3) 63(3) 65(3) 66(3) 75(3) 78(3) 104(3) 
 
EIVS_BDF_solids_14283B_18_30 29(1) 50(1) 98(1) 101(1) 107(1)      
 
EIVS_BDF_solids_14283C_18_28 31(3) 43(3) 44(3) 46(3) 63(3) 65(3) 66(3) 75(3) 78(3) 104(3) 
 
EIVS_BDF_solids_14289C_19_31 38(1) 39(1) 40(1) 45(1) 49(1) 51(1) 52(1) 53(1) 99(1) 102(1) 
 
EIVS_BDF_solids_14289E_19_33 29(2) 50(2) 98(2) 101(2) 107(2)      
 
EIVS_BDF_solids_14296B_20_36 38(2) 39(2) 40(2) 45(2) 49(2) 51(2) 52(2) 53(2) 99(2) 102(2) 
 
EIVS_BDF_solids_14296C_20_35 29(3) 50(3) 98(3) 101(3) 107(3)      
 
EIVS_BDF_solids_15003A_21_37 38(3) 39(3) 40(3) 45(3) 49(3) 51(3) 52(3) 53(3) 99(3) 102(3) 
 
EIVS_BDF_solids_15003B_21_39 100(1) 107(4)         
 
EIVS_BDF_solids_15007B_23_41 100(2)          
 
EIVS_BDF_solids_15013A_24_43 75(5) 100(3)         
 
EIVS_BDF_solids_15019A_25_44 29(4) 50(4)         
 
EIVS_BDF_solids_15025A_26_50 33(5) 107(5)         
Harlan EIVS_HARLAN_LIQUIDS_14296D_20_10 5(1) 22(1) 80(1)        
 
EIVS_HARLAN_LIQUIDS_15003C_21_11 5(2) 22(2) 80(2)        
 
EIVS_HARLAN_LIQUIDS_15007C_23_12 5(3) 22(3) 80(3)        
 
EIVS_HARLAN_LIQUIDS_15029A_27_14 4(1) 23(1) 56(1) 72(1) 81(1) 90(1) 91(1)    
 
EIVS_HARLAN_LIQUIDS_15030A_28_15 4(2) 23(2) 56(2) 72(2) 81(2) 90(2) 91(2)    
 
EIVS_HARLAN_LIQUIDS_15033A_31_16 4(3) 23(3) 56(3) 72(3) 81(3) 90(3) 91(3)    
 
EIVS_HARLAN_LIQUIDS_15033B_31_16 12(1) 13(1) 15(1) 18(1) 19(1) 26(1) 60(1) 82(1) 84(1) 86(1) 
 
EIVS_HARLAN_LIQUIDS_15034A_32_17 12(2) 13(2) 15(2) 18(2) 19(2) 26(2) 60(2) 82(2) 84(2) 86(2) 
 
EIVS_HARLAN_LIQUIDS_15035A_33_18 12(3) 13(3) 15(3) 18(3) 19(3) 26(3) 60(3) 82(3) 84(3) 86(3) 
 
EIVS_HARLAN_LIQUIDS_15037A_34_19 20(1) 25(1) 88(1) 92(1)       
 
EIVS_HARLAN_LIQUIDS_15040B_38_20 20(2) 25(2) 88(2) 92(2)       
 
EIVS_HARLAN_LIQUIDS_15046B_41_21 20(3) 25(3) 88(3) 92(3)       
 
EIVS_HARLAN_SOLIDS_14296E_20_10 35(1) 42(1) 47(1) 95(1)       
 
EIVS_HARLAN_SOLIDS_15003C_21_11 35(2) 42(2) 47(2) 95(2)       
 
EIVS_HARLAN_SOLIDS_15007A_23_12 35(3) 42(3) 47(3) 95(3)       
 
EIVS_HARLAN_SOLIDS_15013B_24_13 32(1) 34(1) 74(1)        
 
EIVS_HARLAN_SOLIDS_15029B_27_14 32(2) 33(2) 34(2) 74(2)       
 
EIVS_HARLAN_SOLIDS_15030B_28_15 32(3) 33(3) 34(3) 74(3)       
 
EIVS_HARLAN_SOLIDS_15037B_34_19 33(4) 40(1) 49(1) 98(1) 106(1) 107(1)     
 
EIVS_HARLAN_SOLIDS_15040A_38_20 40(2) 49(2) 98(2) 106(2) 107(2)      
 
EIVS_HARLAN_Solids_15033C_31_16 29(1) 38(1) 39(1) 50(1) 51(1) 52(1) 53(1) 100(1) 101(1) 102(1) 
 
EIVS_HARLAN_Solids_15034B_32_17 29(2) 38(2) 39(2) 50(2) 51(2) 52(2) 53(2) 100(2) 101(2) 102(2) 
 
EIVS_HARLAN_Solids_15035B_33_18 29(3) 38(3) 39(3) 50(3) 51(3) 52(3) 53(3) 100(3) 101(3) 102(3) 
 
EIVS_Harlan_Solids_15046A_41_21 40(3) 49(3) 98(3) 106(3) 107(3)      
 
EIVS_Harlan_Solids_15048A_42_22 40(4) 49(4) 98(4) 106(4) 107(4)      
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laboratory run  
 
EIVS_Harlan_liquids_14225A_10_01 2(1) 3(1) 7(1) 8(1) 16(1) 68(1) 69(1) 70(1) 83(1) 87(1) 
 
EIVS_Harlan_liquids_14234D_11_02 2(2) 3(2) 7(2) 8(2) 16(2) 68(2) 69(2) 70(2) 83(2) 87(2) 
 
EIVS_Harlan_liquids_14241E_12_03 2(3) 3(3) 7(3) 8(3) 16(3) 68(3) 69(3) 70(3) 83(3) 87(3) 
 
EIVS_Harlan_liquids_14248E_13_04 1(1) 6(1) 9(1) 11(1) 14(1) 54(1) 57(1) 67(1) 85(1) 89(1) 
 
EIVS_Harlan_liquids_14263D_15_05 1(2) 6(2) 9(2) 11(2) 14(2) 54(2) 57(2) 67(2) 85(2) 89(2) 
 
EIVS_Harlan_liquids_14270A_16_06 1(3) 6(3) 9(3) 11(3) 14(3) 54(3) 57(3) 67(3) 85(3) 89(3) 
 
EIVS_Harlan_liquids_14277B_17_07 10(1) 17(1) 21(1) 24(1) 37(1) 55(1) 58(1) 59(1) 71(1)  
 
EIVS_Harlan_liquids_14283D_18_08 10(2) 17(2) 21(2) 24(2) 37(2) 55(2) 58(2) 59(2) 71(2)  
 
EIVS_Harlan_liquids_14289A_19_09 10(3) 17(3) 21(3) 24(3) 37(3) 55(3) 58(3) 59(3) 71(3)  
 
EIVS_Harlan_solids_14225B_10_01 28(1) 36(1) 41(1) 61(1) 73(1) 77(1) 93(1) 96(1) 97(1) 105(1) 
 
EIVS_Harlan_solids_14234E_11_02 28(2) 36(2) 41(2) 61(2) 73(2) 77(2) 93(2) 96(2) 97(2) 105(2) 
 
EIVS_Harlan_solids_14241D_12_03 28(3) 36(3) 41(3) 61(3) 73(3) 77(3) 93(3) 96(3) 97(3) 105(3) 
 
EIVS_Harlan_solids_14248F_13_04 48(1) 62(1) 63(1) 64(1) 76(1) 78(1) 79(1) 94(1) 103(1) 104(1) 
 
EIVS_Harlan_solids_14263E_15_05 48(2) 62(2) 63(2) 64(2) 76(2) 78(2) 79(2) 94(2) 103(2) 104(2) 
 
EIVS_Harlan_solids_14270B_16_06 48(3) 62(3) 63(3) 64(3) 76(3) 78(3) 79(3) 94(3) 103(3) 104(3) 
 
EIVS_Harlan_solids_14277C_17_07 30(1) 31(1) 43(1) 44(1) 45(1) 46(1) 65(1) 66(1) 75(1) 99(1) 
 
EIVS_Harlan_solids_14283E_18_08 30(2) 31(2) 43(2) 44(2) 45(2) 46(2) 65(2) 66(2) 75(2) 99(2) 
 
EIVS_Harlan_solids_14289B_19_09 30(3) 31(3) 43(3) 44(3) 45(3) 46(3) 65(3) 66(3) 75(3) 99(3) 
IIVS EIVS_IIVS_liquids_14219_week1_number1_AH 1(1) 2(1) 5(1) 6(1) 7(1) 8(1) 11(1) 54(1) 68(1) 80(1) 
 
EIVS_IIVS_liquids_14219_week1_number1_HI 3(1) 9(1) 16(1) 67(1) 69(1) 70(1) 83(1) 85(1) 87(1)  
 
EIVS_IIVS_liquids_14222_week2_number2_AH 1(2) 2(2) 5(2) 6(2) 7(2) 8(2) 11(2) 54(2) 68(2) 80(2) 
 
EIVS_IIVS_liquids_14222_week2_number2_HI 3(2) 9(2) 16(2) 67(2) 69(2) 70(2) 83(2) 85(2) 87(2)  
 
EIVS_IIVS_liquids_14225_week3_number3_AH 1(3) 2(3) 5(3) 6(3) 7(3) 8(3) 11(3) 54(3) 68(3) 80(3) 
 
EIVS_IIVS_liquids_14225_week3_number3_HI 3(3) 9(3) 16(3) 67(3) 69(3) 70(3) 83(3) 85(3) 87(3)  
 
EIVS_IIVS_liquids_14234_week4_number4_HI 4(1) 14(1) 17(1) 22(1) 57(1) 71(1) 81(1) 89(1) 90(1) 91(1) 
 
EIVS_IIVS_liquids_14241_week5_number6_HI 4(2) 14(2) 17(2) 22(2) 57(2) 71(2) 81(2) 89(2) 90(2) 91(2) 
 
EIVS_IIVS_liquids_14248_week6_number5_AH 10(1) 21(1) 23(1) 24(1) 37(1) 55(1) 56(1) 58(1) 59(1) 72(1) 
 
EIVS_IIVS_liquids_14248_week6_number7_HI 4(3) 14(3) 17(3) 22(3) 57(3) 71(3) 81(3) 89(3) 90(3) 91(3) 
 
EIVS_IIVS_liquids_14256_week7_number6_AH 10(2) 21(2) 24(2) 37(2) 55(2) 56(2) 58(2) 59(2) 72(2)  
 
EIVS_IIVS_liquids_14263_week8_number8_AH 10(3) 21(3) 23(2) 24(3) 37(3) 55(3) 56(3) 58(3) 59(3) 72(3) 
 
EIVS_IIVS_liquids_14270_week9_number10_AH 10(4) 15(1) 18(1) 19(1) 20(1) 23(3) 60(1) 82(1) 84(1) 86(1) 
 
EIVS_IIVS_liquids_14277_week10_number12_AH 15(2) 18(2) 19(2) 20(2) 25(1) 26(1) 60(2) 82(2) 84(2) 86(2) 
 
EIVS_IIVS_liquids_14283_week11_number13_AH 15(3) 18(3) 19(3) 20(3) 25(2) 26(2) 60(3) 82(3) 84(3) 86(3) 
 
EIVS_IIVS_liquids_14289_week12_number14_AH 12(1) 13(1) 88(1)        
 
EIVS_IIVS_liquids_14289_week12_number15_AH 20(4) 92(1)         
 
EIVS_IIVS_liquids_14296_week13_number17_AH 12(2) 13(2) 88(2)        
 
EIVS_IIVS_liquids_14296_week13_number18_AH 26(3) 92(2)         
 
EIVS_IIVS_liquids_15003_week14_number19_AH 12(3) 13(3) 88(3)        
 
EIVS_IIVS_liquids_15003_week14_number20_AH 26(4) 92(3)         
 
EIVS_IIVS_liquids_15007_week16_number22_AH 25(3) 90(4)         
 
EIVS_IIVS_solids_14219_week1_number1_MK 28(1) 61(1) 73(1) 74(1) 93(1) 95(1) 96(1) 97(1)   
 
EIVS_IIVS_solids_14222_week2_number2_MK 28(2) 61(2) 73(2) 74(2) 93(2) 95(2) 96(2) 97(2)   
 
EIVS_IIVS_solids_14225_week3_number3_MK 28(3) 61(3) 73(3) 74(3) 93(3) 95(3) 96(3) 97(3)   
 
EIVS_IIVS_solids_14234_week4_number4_MK 32(1) 34(1) 35(1) 36(1) 41(1) 42(1) 45(1) 75(1) 99(1)  
 
EIVS_IIVS_solids_14241_week5_number5_MK 32(2) 34(2) 35(2) 36(2) 41(2) 42(2) 45(2) 75(2) 99(2)  
 
EIVS_IIVS_solids_14248_week6_number6_MK 32(3) 34(3) 35(3) 36(3) 41(3) 42(3) 45(3) 75(3) 99(3)  
 
EIVS_IIVS_solids_14256_week7_number7_AH 43(1) 44(1) 46(1) 47(1) 65(1) 79(1)     
 
EIVS_IIVS_solids_14256_week7_number7_MK 33(1) 64(1) 76(1) 77(1) 78(1) 94(1) 103(1) 104(1) 105(1)  
 
EIVS_IIVS_solids_14263_week8_number8_MK 34(4) 64(2) 76(2) 77(2) 78(2) 94(2) 103(2) 104(2) 105(2)  
 
EIVS_IIVS_solids_14263_week8_number9_AH 43(2) 44(2) 46(2) 47(2) 65(2) 79(2)     
 
EIVS_IIVS_solids_14270_week9_number10_MK 33(2) 64(3) 76(3) 77(3) 78(3) 94(3) 103(3) 104(3) 105(3)  
 
EIVS_IIVS_solids_14270_week9_number11_AH 43(3) 44(3) 46(3) 47(3) 51(1) 52(1) 53(1) 65(3) 79(3) 100(1) 
 
EIVS_IIVS_solids_14277_week10_number11_MK 30(1) 31(1) 34(5) 63(1) 98(1) 106(1)     
 
EIVS_IIVS_solids_14283_week11_number12_MK 30(2) 31(2) 48(1) 62(1) 63(2) 66(1) 98(2) 106(2)   
 
EIVS_IIVS_solids_14289_week12_number13_MK 30(3) 31(3) 48(2) 62(2) 63(3) 66(2) 98(3) 106(3)   
 
EIVS_IIVS_solids_14296_week13_number14_MK 29(1) 38(1) 39(1) 40(1) 49(1) 50(1) 101(1) 102(1) 107(1)  
 
EIVS_IIVS_solids_15003_week14_number15_MK 29(2) 38(2) 39(2) 40(2) 49(2) 50(2) 101(2) 102(2) 107(2)  
 
EIVS_IIVS_solids_15007_week15_number16_MK 29(3) 38(3) 39(3) 40(3) 49(3) 50(3) 101(3) 102(3) 107(3)  
 
EIVS_IIVS_solids_15007_week16_number23_AH 51(2) 52(2) 53(2) 100(2)       
 
EIVS_IIVS_solids_15013_week16_number17_MK 33(3) 48(3) 62(3) 66(3) 104(4) 107(4)     
 
EIVS_IIVS_solids_15013_week17_number24_AH 51(3) 52(3) 53(3) 100(3)       
 
EIVS_IIVS_solids_15030_week18_number19_MK 33(4) 107(5)         
3.2.4 Number of tests within each test sequence 
 
In Table 3.2.5, the number of tests within each test sequence is given, subdivided 
into laboratories and chemicals. 
Table 3.2.5 Number of tests within each test sequence 
  laboratory   laboratory 
Chemical Beiersdorf Harlan IIVS Chemical Beiersdorf Harlan IIVS 
1 3 3 3 55 3 3 3 
2 3 3 3 56 3 3 3 
3 3 3 3 57 3 3 3 
4 3 3 3 58 3 3 3 
5 3 3 3 59 3 3 3 
6 3 3 3 60 3 3 3 
7 3 3 3 61 3 3 3 
8 3 3 3 62 3 3 3 
9 3 3 3 63 4 3 3 
10 3 3 4 64 3 3 3 
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11 3 3 3 65 4 3 3 
12 3 3 3 66 4 3 3 
13 3 3 3 67 3 3 3 
14 3 3 3 68 3 3 3 
15 3 3 3 69 3 3 3 
16 3 3 3 70 3 3 3 
17 3 3 3 71 3 3 3 
18 3 3 3 72 3 3 3 
19 3 3 3 73 3 3 3 
20 3 3 4 74 4 3 3 
21 3 3 3 75 5 3 3 
22 3 3 3 76 3 3 3 
23 3 3 3 77 3 3 3 
24 3 3 3 78 4 3 3 
25 3 3 3 79 3 3 3 
26 3 3 4 80 3 3 3 
28 3 3 3 81 3 3 3 
29 4 3 3 82 3 3 3 
30 3 3 3 83 3 3 3 
31 4 3 3 84 3 3 3 
32 3 3 3 85 3 3 3 
33 5 3 4 86 3 3 3 
34 3 3 5 87 3 3 3 
35 3 3 3 88 3 3 3 
36 3 3 3 89 3 3 3 
37 4 3 3 90 3 3 4 
38 3 3 3 91 3 3 3 
39 3 3 3 92 3 3 3 
40 3 4 3 93 3 3 3 
41 3 3 3 94 3 3 3 
42 3 3 3 95 3 3 3 
43 4 3 3 96 3 3 3 
44 4 3 3 97 3 3 3 
45 3 3 3 98 3 4 3 
46 4 3 3 99 3 3 3 
47 3 3 3 100 3 3 3 
48 3 3 3 101 3 3 3 
49 3 4 3 102 3 3 3 
50 4 3 3 103 3 3 3 
51 3 3 3 104 4 3 4 
52 3 3 3 105 3 3 3 
53 3 3 3 1061 5 4 3 
54 3 3 3 1071 5 4 5 
1 extra chemicals not for statistics but for a later purpose of evaluation using an HPLC based 
detection system. 
3.2.5 Non-qualified and excluded chemicals 
 
A listing of the number and fraction of non-qualified or excluded chemicals is given 
in Table 3.2.6. 
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Table 3.2.6 List, number and fraction of non-qualified or excluded chemicals, subdivided into 
laboratories and chemicals 
laboratory Chemical Reason No. Fraction (%) 
Beiersdorf 29 Non-Qualified 1 25 
 31 Non-Qualified 1 25 
 33 Excluded 5 100 
 37 Non-Qualified 1 25 
 43 Non-Qualified 1 25 
 44 Non-Qualified 1 25 
 46 Non-Qualified 1 25 
 50 Non-Qualified 1 25 
 63 Non-Qualified 1 25 
 65 Non-Qualified 1 25 
 66 Non-Qualified 1 25 
 74 Non-Qualified 1 25 
 75 Non-Qualified 2 40 
 78 Non-Qualified 1 25 
 104 Non-Qualified 1 25 
Harlan 40 Non-Qualified 1 25 
 49 Non-Qualified 1 25 
 98 Non-Qualified 1 25 
IIVS 10 Non-Qualified 1 25 
 20 Non-Qualified 1 25 
 26 Non-Qualified 1 25 
 33 Non-Qualified 1 25 
 34 Non-Qualified 2 40 
 90 Non-Qualified 1 25 
 104 Non-Qualified 1 25 
In Figure 3.2.1, a boxplot is given of the differences between uncorrected viabilities 
for every pair of tissue replicates used for each chemical, including both qualified 





TNO report | TNO2013 R10396 | Final  22 / 173
Figure 3.2.1 Differences between uncorrected viabilities for every pair of tissue replicates, per 
laboratory and total, including both qualified and unqualified tests. 
 
3.2.6 Chemicals with complete test sequences 
A total of three qualified tests is considered as a complete test sequence. A list of 
chemicals with a complete test sequence is given in Table 3.2.7. Each of the 
laboratory had a fraction of more than 96% complete test sequences, as is shown in 
Table 3.2.8. Overall, 96.5% of the 106 tested chemicals had a complete test 
sequence in three laboratories.  
Table 3.2.7 A list of chemicals with a complete test sequence 
Chemical Beiersdorf Harlan IIVS Chemical Beiersdorf Harlan IIVS 
1 3 3 3 55 3 3 3 
2 3 3 3 56 3 3 3 
3 3 3 3 57 3 3 3 
4 3 3 3 58 3 3 3 
5 3 3 3 59 3 3 3 
6 3 3 3 60 3 3 3 
7 3 3 3 61 3 3 3 
8 3 3 3 62 3 3 3 
9 3 3 3 63 3 3 3 
10 3 3 3 64 3 3 3 
11 3 3 3 65 3 3 3 
12 3 3 3 66 3 3 3 
13 3 3 3 67 3 3 3 
14 3 3 3 68 3 3 3 
15 3 3 3 69 3 3 3 
16 3 3 3 70 3 3 3 
17 3 3 3 71 3 3 3 
18 3 3 3 72 3 3 3 
19 3 3 3 73 3 3 3 
20 3 3 3 74 3 3 3 
21 3 3 3 75 3 3 3 
22 3 3 3 76 3 3 3 
23 3 3 31 77 3 3 3 
24 3 3 3 78 3 3 3 
25 3 3 3 79 3 3 3 
26 3 3 3 80 31 31 31 
28 3 3 3 81 3 3 3 
29 3 3 3 82 3 3 3 
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Chemical Beiersdorf Harlan IIVS Chemical Beiersdorf Harlan IIVS 
30 3 3 3 83 3 3 3 
31 3 3 3 84 3 3 3 
32 3 3 3 85 3 3 3 
33 excluded 3 3 86 3 3 3 
34 3 3 3 87 3 3 3 
35 3 3 3 88 3 3 3 
36 3 3 3 89 3 3 3 
37 3 3 3 90 3 3 3 
38 3 3 3 91 3 3 3 
39 3 3 3 92 3 3 3 
40 3 3 3 93 3 3 3 
41 3 3 3 94 3 3 3 
42 3 3 3 95 3 3 3 
43 3 3 3 96 3 3 3 
44 3 3 3 97 3 3 3 
45 3 3 3 98 3 3 3 
46 3 3 3 99 3 3 3 
47 3 3 3 100 3 3 3 
48 3 3 3 101 3 3 3 
49 3 3 3 102 3 3 3 
50 3 3 3 103 3 3 3 
51 3 3 3 104 3 3 3 
52 3 3 3 105 3 3 3 
53 3 3 3     
54 3 3 3     
1 On May 10th 2012, after an evaluation of the first draft of the statistics report, the core VMG 
overrode the rule identifying 50% NSMTT as a cut-off to consider a chemical compatible with the 
test system as described in Chapter 2.5.1. of this report. In all these cases, rule 3 in Chapter 2.5.1. 
is fulfilled since the mean %NSC of all qualified tests is greater than (>) 50% and the classification 
of these qualified tests changes upon correction (from non-irritant to irritant). However, the viability 
values obtained in the qualified tests are definitely within the linear range of the OD measurements 
(within the 100% scale) and therefore, even though there is a strong MTT reduction occurring this 
is not interfering with the analytical capacity to measure formazan production. Moreover, the 
variability obtained between the different tests and controls is low. As such, these chemicals were 
considered compatible with the test method and their data were therefore included in all of the 
statistical analyses. 
Table 3.2.8 Fraction of chemicals with a complete test sequence, subdivided into laboratories and 
total 






Logically, less than 1% of the chemicals had an incomplete test sequence. These 
chemicals are presented in Table 3.2.9. The fraction of incomplete test sequences 
per laboratory as well as in total is given in Table 3.2.10. Only for Beiersdorf, one 
chemical with an incomplete test sequence was found. This chemical (2,2'-[[4-[(2-
methoxyethyl)amino]-3-nitrophenyl]imino]bis-ethanol INCI name: HC BLUE NO. 11) 
was incompatible with the test method for Beiersdorf. 
Table 3.2.9 Chemicals with incomplete test sequences 
laboratory order Excluded Non-qualified 
Beiersdorf 33 5 0 










Given Table 3.2.8 and Table 3.2.10, the criteria of at least 85% complete test 
sequences in each laboratory was met, as is also summarized in Table 3.2.11. 
Table 3.2.11 Statement whether the test method has fulfilled the performance criteria (at least 85% 
complete test sequences) concerning the fraction of complete test sequences. 
laboratory Fraction Statement: criteria is 
Beiersdorf 99.0 fulfilled 
Harlan 100.0 fulfilled 
IIVS 100.0 fulfilled 
Total 99.7 fulfilled 
3.2.7 Negative and Positive controls 
 
The results for the negative and positive controls are presented in summarizing 




Figure 3.2.2 Mean OD-values for the Negative controls (Performance criteria: 1.0 < mean ODnc < 
2.3), per laboratory and total 
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Figure 3.2.3 Differences in viabilities for the Negative controls (Performance criteria: difference <= 
20%), per laboratory and total 
 
 
Figure 3.2.4 Mean viabilities for the Positive controls (Performance criteria: mean viability <= 50%) 
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Figure 3.2.5 Differences in viabilities for the Positive controls (Performance criteria: difference <= 
20%), per laboratory and total 
Table 3.2.12 Numerical statistical values for the Negative and Positive Control (lower: 25th 
percentile – 1.5*IQR, p25: 25th percentile, median: 50th percentile, p75: 75th percentile, 
upper: 75th percentile + 1.5*IQR, with IQR = 75th percentile – 25th percentile). 
    Liquids Solids 
 Variable1 laboratory lower p25 median p75 upper lower p25 median p75 upper 
ODnc Beiersdorf 1.40 1.64 1.75 1.90 2.14 1.47 1.63 1.71 1.79 1.98 
  Harlan 1.40 1.66 1.73 1.85 1.95 1.38 1.57 1.65 1.74 1.96 
  IIVS 1.74 1.85 1.90 2.00 2.08 1.55 1.68 1.70 1.78 1.88 
  Total 1.40 1.70 1.85 1.92 2.14 1.45 1.62 1.70 1.77 1.98 
NCdiff Beiersdorf 0.28 1.34 3.89 6.07 10.12 0.10 0.77 2.51 4.30 7.32 
  Harlan 0.61 1.93 3.52 6.08 11.28 0.03 2.15 3.01 5.07 6.88 
  IIVS 0.13 2.04 3.13 4.81 7.12 0.21 1.33 3.61 5.97 9.19 
  Total 0.13 1.90 3.54 5.72 11.28 0.03 1.29 2.86 5.13 10.38 
meanPC Beiersdorf 18.27 30.34 36.17 40.97 46.41 21.47 26.61 30.86 34.76 37.41 
  Harlan 6.76 17.90 27.06 28.97 31.81 12.31 19.21 23.93 32.81 45.10 
  IIVS 26.23 31.30 34.63 36.45 39.63 20.63 24.83 29.16 31.31 35.84 
  Total 16.38 28.09 31.30 36.07 46.41 12.31 24.09 28.90 32.87 45.10 
PCdiff Beiersdorf 1.17 2.83 3.86 6.35 10.30 0.57 1.88 3.45 5.25 8.28 
  Harlan 0.04 0.76 1.57 4.13 6.88 0.40 1.22 1.46 3.36 3.36 
  IIVS 0.00 2.12 3.76 6.19 9.66 0.18 1.62 2.16 4.95 9.67 
  Total 0.00 1.57 3.48 6.08 10.30 0.18 1.45 2.24 4.96 9.67 
1
 ODnc = optical density for negative control, NCdiff = difference between replicates 
of the negative control, meanPC = viability for positive control, PCdiff = difference 
between replicates of the positive control (all in % viability, except for ODnc). 
3.2.8 Summary of all tests results 
 
Finally, a summary of all tests results (including the non-qualified and excluded test 
results) are presented in Appendix VI. 
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3.3 Reproducibility and accuracy using a 50% cut-off 
In this section, a 50% cut-off was applied to determine the irritancy of the chemical. 
If the viability is above 50%, the chemical is considered to be non-irritant. If the 
viability is 50% or below, the chemical is considered to be irritant.  
3.3.1 Within-laboratory variability 
For each laboratory, concordance of classification was calculated based on 
qualified test from test chemicals for which at least two qualified tests were 
available. In Table 3.3.1 the concordance within each laboratory as well as in total 
is given. 
Table 3.3.1 Concordance within laboratories and total 
laboratory 
WLV 
concordant No. Fraction(%) 
Beiersdorf NO 7 6.8 
YES 96 93.2 
Harlan NO 6 5.8 
YES 98 94.2 
IIVS NO 7 6.7 
YES 97 93.3 
Total NO 20 6.4 
YES 291 93.6 
 
Additional descriptive statistics can identify possible reasons for non-concordant 
results. These are presented in Table 3.3.2. For each non-concordant result the 
state (liquid/solid), the GHS classification, whether it is colouring or MTTreducer 
and the test results are given. 
Table 3.3.2 Additional descriptive statistics on non-concordant results within laboratories 
       Test 
laboratory chemical name LS colouring MTT GHS class 1 2 3 
Beiersdorf 20 ricinoleic acid tin salt Liquid No Yes no cat 31.1 57.2 49.8 
 22 3-phenoxybenzyl alcohol  Liquid No Yes no cat 51.6 39.3 45.1 
 30 1,1-dimethylguanidine sulphate Solid No Yes no cat 55.6 39.0 46.8 
 40 acrylamidopropyltrimonium 
chloride/acrylamide copolymer 
Solid No No no cat 
49.4 59.5 62.1 
 56 isopropyl acetoacetate Liquid No Yes cat 2B 46.4 54.5 60.3 
 97 sodium oxalate INCI name: SODIUM 
OXALATE 
Solid No No cat 1 
56.2 47.2 55.5 
 102 disodium 2,2'-([1,1'-biphenyl]-4,4'-
diyldivinylene)bis(benzenesulphonat
e) INCI name: DISODIUM 
DISTYRYLBIPHENYL DISULFONATE 
Solid No No cat 1 
10.1 110.2 124.3 
Harlan 5 4-(methylthio)-benzaldehyde Liquid No Yes no cat 56.7 41.4 40.3 
 63 4-nitrobenzoic acid Solid No No cat 2B 56.8 41.0 50.2 
 65 2,2-dimethyl-3-methylenebicyclo 
[2.2.1] heptane INCI name: 
CAMPHENE 
Solid No No cat 2B 
20.3 16.2 51.8 
 76 6,7-dihydro-2,3-dimethyl-
imidazo[1,2-a]pyridin-8(5H)-one 
Solid No No cat 2A 
59.0 32.3 52.8 
 101 2-[(4-aminophenyl)azo]-1,3-
dimethyl-1H-imidazolium chloride 
Solid No No cat 1 
26.2 50.6 42.0 
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INCI name: BASIC ORANGE 31 
 102 disodium 2,2'-([1,1'-biphenyl]-4,4'-
diyldivinylene)bis(benzenesulphonat
e) INCI name: DISODIUM 
DISTYRYLBIPHENYL DISULFONATE 
Solid No No cat 1 
38.0 55.0 52.1 
IIVS 3 2-ethoxyethyl methacrylate Liquid No No no cat 51.4 49.0 47.5 
 24 glycidyl methacrylate  Liquid No Yes no cat 53.0 33.9 32.6 
 54 3-chloropropionitrile Liquid No No cat 2B 51.8 43.1 30.1 
 59 ethyl-2-methyl acetoacetate Liquid No No cat 2B 56.6 52.8 43.6 
 65 2,2-dimethyl-3-methylenebicyclo 
[2.2.1] heptane INCI name: 
CAMPHENE 
Solid No No cat 2B 
63.8 41.6 53.9 
 92 tetraethylene glycol diacrylate Liquid No Yes cat 1 39.6 39.3 51.2 
 96 1-naphthalene acetic acid Solid No No cat 1 33.2 38.9 54.1 
 
The concordance of classifications (irritant/non-irritant) for the set of chemicals 
tested during validation obtained in different, independent runs within a single 
laboratory should ideally be equal or higher than 85% for all participating 
laboratories. As summarized in Table 3.3.3, this criteria was met for each laboratory 
as well as in total. 
Table 3.3.3 Statement whether the test method has fulfilled the performance criteria concerning 
the concordance of classifications within one laboratory. 
laboratory Fraction(%) Statement: criteria is 
Beiersdorf 93.2 fulfilled 
Harlan 94.2 fulfilled 
IIVS 93.3 fulfilled 
Total 93.6 fulfilled 
 
The within-laboratory variability is described by the concordance of classifications. 
Correlation coefficients between viability measurements give also information on 
this variability. Since the Pearson correlation coefficient is sensitive for outlying test 
results and high leverages, both the Pearson and the Spearman correlation 
coefficients (using ranks instead of the original test results) were calculated. These 
coefficients are presented in Table 3.3.4. 
Table 3.3.4 Pearson and Spearman correlation coefficients between tests results within each 
laboratory as well as in total. 
Correlation 
Coefficient laboratory Qual1 - Qual2 Qual1 - Qual3 Qual2 - Qual3 
Pearson Beiersdorf 0.945 0.942 0.977 
 Harlan 0.958 0.970 0.955 
 IIVS 0.988 0.978 0.984 
 Mean 0.964 0.963 0.972 
Spearman Beiersdorf 0.933 0.942 0.974 
 Harlan 0.951 0.966 0.951 
 IIVS 0.973 0.959 0.960 
 Mean 0.952 0.955 0.962 
 
The arithmetic mean, standard deviation and coefficient of variation from the three 
valid tests are given per laboratory (see Table 3.3.5). The overall standard deviation 
and coefficient of variation is also using all available tests results, hence qualified 
and non-qualified. The results are presented in Table 3.3.6.Note that the coefficient 
of variation is not a useful measure if the mean is close to zero. 
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Table 3.3.5 Arithmetic mean, standard deviation (std) and coefficient of variation (cv) from the 
three valid tests are given per laboratory (n = number of qualified tests that was used 
for the calculation of the mean, std and cv) 
 laboratory 
 Beiersdorf Harlan IIVS 
Chemical mean std cv n mean std cv n mean std cv n 
1 69.3 1.8 2.6 3 66.6 4.0 6.0 3 68.7 6.3 9.2 3 
2 80.1 2.8 3.5 3 77.8 2.8 3.5 3 81.3 2.6 3.1 3 
3 60.9 4.8 7.8 3 38.0 0.7 1.9 3 49.3 1.9 3.9 3 
4 109.0 5.8 5.3 3 61.0 3.2 5.3 3 96.2 4.1 4.3 3 
5 80.7 7.5 9.3 3 46.1 9.2 19.9 3 62.5 11.0 17.6 3 
6 85.3 5.0 5.9 3 76.3 7.3 9.6 3 83.6 4.4 5.3 3 
7 38.5 3.8 9.9 3 34.8 3.3 9.5 3 38.6 5.9 15.2 3 
8 100.5 2.9 2.8 3 93.0 3.0 3.2 3 98.7 3.1 3.2 3 
9 98.4 3.3 3.3 3 90.4 7.1 7.9 3 101.6 4.0 3.9 3 
10 33.1 2.1 6.4 3 12.5 2.4 19.5 3 19.1 4.1 21.5 3 
11 29.1 1.3 4.6 3 18.9 2.4 12.9 3 31.4 2.4 7.7 3 
12 92.4 1.4 1.6 3 93.7 2.6 2.7 3 94.5 2.0 2.1 3 
13 100.4 11.0 10.9 3 90.5 6.4 7.0 3 83.8 2.2 2.6 3 
14 100.6 3.7 3.7 3 97.2 6.3 6.4 3 95.7 1.1 1.2 3 
15 102.8 6.2 6.1 3 101.4 7.3 7.2 3 97.2 4.6 4.7 3 
16 104.9 5.4 5.2 3 100.0 5.2 5.2 3 101.4 5.1 5.0 3 
17 97.5 5.3 5.5 3 97.1 9.0 9.3 3 96.7 1.4 1.4 3 
18 97.1 23.9 24.6 3 96.4 5.2 5.4 3 94.8 0.6 0.6 3 
19 108.2 3.1 2.8 3 109.1 3.9 3.6 3 97.6 1.8 1.8 3 
20 46.0 13.4 29.1 3 9.4 9.5 101.4 3 40.9 7.5 18.3 3 
21 83.0 0.2 0.2 3 72.3 5.1 7.1 3 84.4 2.5 3.0 3 
22 45.3 6.1 13.5 3 20.1 6.1 30.6 3 37.4 1.8 4.7 3 
23 42.1 3.4 8.1 3 14.9 9.0 60.5 3 12.6 5.5 43.9 3 
24 45.8 2.5 5.4 3 22.9 4.5 19.7 3 39.8 11.4 28.7 3 
25 104.6 3.2 3.1 3 106.2 2.3 2.2 3 101.9 6.3 6.2 3 
26 21.5 1.8 8.5 3 35.6 5.1 14.2 3 34.2 2.2 6.5 3 
28 98.3 2.2 2.2 3 93.5 2.2 2.4 3 106.3 6.2 5.8 3 
29 87.6 4.5 5.1 3 84.1 27.3 32.5 3 103.2 2.3 2.2 3 
30 47.1 8.3 17.6 3 24.8 10.4 42.0 3 58.8 9.2 15.7 3 
31 78.2 14.4 18.4 3 90.1 11.0 12.2 3 100.0 3.4 3.4 3 
32 0.4 0.5 132.4 3 1.0 0.2 15.6 3 2.5 0.3 12.8 3 
33 excluded 44.3 4.0 9.1 3 87.1 3.4 3.9 3 
34 113.0 3.0 2.7 3 66.2 13.9 21.0 3 94.6 13.1 13.9 3 
35 74.2 2.5 3.4 3 69.7 7.5 10.8 3 98.2 2.6 2.6 3 
36 107.1 4.1 3.8 3 96.6 7.6 7.9 3 109.0 3.0 2.7 3 
37 78.4 2.9 3.7 3 73.0 6.0 8.2 3 81.5 4.3 5.3 3 
38 107.8 10.3 9.6 3 102.8 9.0 8.8 3 103.7 3.8 3.6 3 
39 106.2 9.6 9.1 3 101.3 13.2 13.0 3 103.0 1.6 1.6 3 
40 57.0 6.7 11.8 3 63.1 8.7 13.8 3 61.8 1.5 2.4 3 
41 96.8 5.7 5.9 3 91.1 6.2 6.8 3 98.6 4.3 4.4 3 
42 69.5 13.8 19.9 3 59.8 6.3 10.5 3 79.2 7.8 9.8 3 
43 102.8 9.1 8.9 3 126.9 36.0 28.4 3 101.8 1.8 1.8 3 
44 100.2 3.8 3.8 3 100.1 4.6 4.6 3 98.4 4.4 4.5 3 
45 110.3 8.7 7.9 3 107.7 8.5 7.9 3 97.3 2.2 2.2 3 
46 70.0 2.3 3.2 3 70.7 10.7 15.2 3 61.3 3.7 6.1 3 
47 4.7 0.3 7.0 3 2.9 0.8 26.8 3 2.9 0.3 11.2 3 
48 3.1 0.5 15.2 3 2.8 0.3 10.4 3 2.5 0.2 6.6 3 
49 0.0 0.0 . 3 7.0 4.2 59.4 3 14.4 2.2 15.4 3 
50 87.6 3.5 4.0 3 97.6 1.3 1.3 3 95.3 2.4 2.5 3 
51 97.3 5.1 5.2 3 92.7 7.7 8.3 3 100.0 5.4 5.4 3 
52 112.9 15.5 13.7 3 101.9 7.3 7.2 3 100.7 5.3 5.3 3 
53 106.0 13.2 12.5 3 111.9 10.2 9.1 3 105.1 2.9 2.8 3 
54 47.3 1.9 3.9 3 20.7 4.1 19.9 3 41.7 10.9 26.3 3 
55 2.2 0.1 3.9 3 2.2 0.4 18.6 3 2.5 0.1 2.7 3 
56 53.7 7.0 13.0 3 24.9 3.5 14.1 3 37.3 9.2 24.7 3 
57 21.1 2.9 13.5 3 6.4 1.3 21.2 3 17.8 4.5 25.3 3 
58 22.3 0.4 1.6 3 3.8 2.6 67.6 3 13.6 0.7 5.3 3 
59 69.5 8.1 11.6 3 43.3 6.1 14.0 3 51.0 6.7 13.2 3 
60 15.6 4.3 27.7 3 10.6 4.8 44.9 3 20.6 6.5 31.7 3 
61 18.3 4.0 22.1 3 12.6 4.0 31.5 3 18.0 2.9 16.3 3 
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 laboratory 
 Beiersdorf Harlan IIVS 
Chemical mean std cv n mean std cv n mean std cv n 
62 109.0 6.8 6.2 3 104.1 2.1 2.1 3 104.0 6.4 6.2 3 
63 34.0 6.8 20.0 3 49.3 7.9 16.1 3 44.1 5.4 12.2 3 
64 29.9 7.1 23.6 3 23.9 10.0 41.6 3 32.5 6.2 19.1 3 
65 51.4 0.8 1.7 3 29.4 19.5 66.1 3 53.1 11.1 20.9 3 
66 6.8 1.1 15.9 3 3.5 1.2 33.0 3 3.8 2.4 65.0 3 
67 12.2 2.5 20.4 3 4.5 0.4 8.9 3 14.5 0.8 5.6 3 
68 3.4 1.0 28.6 3 3.4 0.6 17.8 3 4.2 2.4 57.9 3 
69 14.0 0.9 6.6 3 13.8 3.2 23.2 3 14.1 0.4 2.9 3 
70 15.2 2.7 17.6 3 11.0 1.6 14.7 3 12.9 1.2 8.9 3 
71 5.4 0.8 14.2 3 6.5 2.1 32.6 3 8.0 0.9 11.3 3 
72 3.9 1.5 38.8 3 4.3 1.0 22.4 3 3.9 1.3 33.7 3 
73 83.7 8.5 10.1 3 84.1 5.0 5.9 3 97.1 12.3 12.7 3 
74 75.7 11.8 15.6 3 77.6 3.6 4.7 3 91.8 6.5 7.1 3 
75 79.9 4.7 5.8 3 7.3 8.7 118.3 3 5.1 0.7 13.5 3 
76 53.9 0.8 1.4 3 48.1 14.0 29.2 3 27.3 1.3 4.6 3 
77 96.8 5.9 6.1 3 73.9 18.1 24.5 3 103.0 4.6 4.4 3 
78 83.2 4.9 5.9 3 63.7 1.9 3.0 3 86.9 1.0 1.1 3 
79 2.6 0.5 20.7 3 2.6 0.3 13.5 3 2.8 0.5 16.4 3 
80 17.5 0.8 4.6 3 7.2 7.7 107.0 3 8.0 2.6 32.3 3 
81 2.5 0.7 26.8 3 3.4 0.2 5.3 3 4.2 1.3 29.8 3 
82 3.8 2.0 52.4 3 1.8 0.3 17.7 3 4.9 2.2 43.8 3 
83 5.6 0.4 7.7 3 5.3 2.1 39.1 3 5.4 1.4 25.8 3 
84 13.5 8.3 61.5 3 6.0 1.6 26.1 3 15.3 5.2 34.0 3 
85 20.2 5.7 28.3 3 9.1 3.5 38.2 3 15.0 2.5 16.6 3 
86 24.4 3.3 13.6 3 30.0 10.2 34.0 3 28.3 6.8 24.0 3 
87 28.7 4.2 14.6 3 18.9 4.0 21.3 3 24.2 6.7 27.8 3 
88 5.8 1.5 26.5 3 6.1 1.5 24.0 3 4.8 1.9 39.3 3 
89 9.5 2.0 21.2 3 7.2 1.2 17.3 3 10.4 1.9 18.2 3 
90 31.5 7.8 24.8 3 24.2 9.2 37.9 3 33.7 2.5 7.4 3 
91 31.1 9.8 31.4 3 16.8 4.0 24.0 3 20.1 0.9 4.4 3 
92 46.1 4.5 9.9 3 15.4 2.6 16.8 3 43.4 6.8 15.6 3 
93 8.9 3.0 33.2 3 8.0 1.6 19.9 3 16.5 5.7 34.3 3 
94 2.3 0.3 11.6 3 3.8 1.7 44.9 3 5.1 0.7 14.5 3 
95 2.4 0.2 6.5 3 2.7 0.1 4.4 3 2.0 0.3 16.9 3 
96 35.4 6.2 17.4 3 33.9 2.6 7.7 3 42.1 10.8 25.7 3 
97 53.0 5.0 9.5 3 52.7 2.3 4.3 3 55.0 4.0 7.2 3 
98 0.0 0.0 . 3 0.0 0.0 . 3 0.0 0.0 . 3 
99 2.8 0.3 10.0 3 2.7 0.5 20.2 3 1.9 0.2 8.3 3 
100 5.3 4.0 75.5 3 11.1 3.3 29.8 3 9.2 1.2 12.9 3 
101 33.9 0.6 1.7 3 39.6 12.4 31.3 3 18.4 4.1 22.4 3 
102 81.6 62.3 76.4 3 48.4 9.1 18.8 3 90.9 16.0 17.5 3 
103 2.5 0.9 35.9 3 1.8 0.2 11.3 3 2.0 0.2 12.7 3 
104 39.7 2.8 7.1 3 41.6 6.2 14.8 3 35.5 11.3 32.0 3 
105 2.6 0.2 8.3 3 2.8 1.0 36.3 3 2.3 0.2 8.4 3 
Table 3.3.6 Standard deviation (std) and coefficient of variation (cv) from all available tests results 
(Q=qualified and NQ=non-qualified) per laboratory (n = number of tests that was used 
for the calculations) 
 laboratory 
 Beiersdorf Harlan IIVS 
 Q Q+NQ Q Q+NQ Q Q+NQ 
Chemical std cv n std cv n std cv n std cv n std cv n std cv n 
1 1.8 2.6 3 1.8 2.6 3 4.0 6.0 3 4.0 6.0 3 6.3 9.2 3 6.3 9.2 3 
2 2.8 3.5 3 2.8 3.5 3 2.8 3.5 3 2.8 3.5 3 2.6 3.1 3 2.6 3.1 3 
3 4.8 7.8 3 4.8 7.8 3 0.7 1.9 3 0.7 1.9 3 1.9 3.9 3 1.9 3.9 3 
4 5.8 5.3 3 5.8 5.3 3 3.2 5.3 3 3.2 5.3 3 4.1 4.3 3 4.1 4.3 3 
5 7.5 9.3 3 7.5 9.3 3 9.2 19.9 3 9.2 19.9 3 11.0 17.6 3 11.0 17.6 3 
6 5.0 5.9 3 5.0 5.9 3 7.3 9.6 3 7.3 9.6 3 4.4 5.3 3 4.4 5.3 3 
7 3.8 9.9 3 3.8 9.9 3 3.3 9.5 3 3.3 9.5 3 5.9 15.2 3 5.9 15.2 3 
8 2.9 2.8 3 2.9 2.8 3 3.0 3.2 3 3.0 3.2 3 3.1 3.2 3 3.1 3.2 3 
9 3.3 3.3 3 3.3 3.3 3 7.1 7.9 3 7.1 7.9 3 4.0 3.9 3 4.0 3.9 3 
10 2.1 6.4 3 2.1 6.4 3 2.4 19.5 3 2.4 19.5 3 4.1 21.5 3 15.3 57.5 4 
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 laboratory 
 Beiersdorf Harlan IIVS 
 Q Q+NQ Q Q+NQ Q Q+NQ 
Chemical std cv n std cv n std cv n std cv n std cv n std cv n 
11 1.3 4.6 3 1.3 4.6 3 2.4 12.9 3 2.4 12.9 3 2.4 7.7 3 2.4 7.7 3 
12 1.4 1.6 3 1.4 1.6 3 2.6 2.7 3 2.6 2.7 3 2.0 2.1 3 2.0 2.1 3 
13 11.0 10.9 3 11.0 10.9 3 6.4 7.0 3 6.4 7.0 3 2.2 2.6 3 2.2 2.6 3 
14 3.7 3.7 3 3.7 3.7 3 6.3 6.4 3 6.3 6.4 3 1.1 1.2 3 1.1 1.2 3 
15 6.2 6.1 3 6.2 6.1 3 7.3 7.2 3 7.3 7.2 3 4.6 4.7 3 4.6 4.7 3 
16 5.4 5.2 3 5.4 5.2 3 5.2 5.2 3 5.2 5.2 3 5.1 5.0 3 5.1 5.0 3 
17 5.3 5.5 3 5.3 5.5 3 9.0 9.3 3 9.0 9.3 3 1.4 1.4 3 1.4 1.4 3 
18 23.9 24.6 3 23.9 24.6 3 5.2 5.4 3 5.2 5.4 3 0.6 0.6 3 0.6 0.6 3 
19 3.1 2.8 3 3.1 2.8 3 3.9 3.6 3 3.9 3.6 3 1.8 1.8 3 1.8 1.8 3 
20 13.4 29.1 3 13.4 29.1 3 9.5 101.4 3 9.5 101.4 3 7.5 18.3 3 9.4 25.1 4 
21 0.2 0.2 3 0.2 0.2 3 5.1 7.1 3 5.1 7.1 3 2.5 3.0 3 2.5 3.0 3 
22 6.1 13.5 3 6.1 13.5 3 6.1 30.6 3 6.1 30.6 3 1.8 4.7 3 1.8 4.7 3 
23 3.4 8.1 3 3.4 8.1 3 9.0 60.5 3 9.0 60.5 3 5.5 43.9 3 5.5 43.9 3 
24 2.5 5.4 3 2.5 5.4 3 4.5 19.7 3 4.5 19.7 3 11.4 28.7 3 11.4 28.7 3 
25 3.2 3.1 3 3.2 3.1 3 2.3 2.2 3 2.3 2.2 3 6.3 6.2 3 6.3 6.2 3 
26 1.8 8.5 3 1.8 8.5 3 5.1 14.2 3 5.1 14.2 3 2.2 6.5 3 2.4 7.0 4 
28 2.2 2.2 3 2.2 2.2 3 2.2 2.4 3 2.2 2.4 3 6.2 5.8 3 6.2 5.8 3 
29 4.5 5.1 3 4.1 4.7 4 27.3 32.5 3 27.3 32.5 3 2.3 2.2 3 2.3 2.2 3 
30 8.3 17.6 3 8.3 17.6 3 10.4 42.0 3 10.4 42.0 3 9.2 15.7 3 9.2 15.7 3 
31 14.4 18.4 3 11.9 15.5 4 11.0 12.2 3 11.0 12.2 3 3.4 3.4 3 3.4 3.4 3 
32 0.5 132.4 3 0.5 132.4 3 0.2 15.6 3 0.2 15.6 3 0.3 12.8 3 0.3 12.8 3 
33 . . . . . . 4.0 9.1 3 4.0 9.1 3 3.4 3.9 3 43.6 66.8 4 
34 3.0 2.7 3 3.0 2.7 3 13.9 21.0 3 13.9 21.0 3 13.1 13.9 3 11.3 12.3 5 
35 2.5 3.4 3 2.5 3.4 3 7.5 10.8 3 7.5 10.8 3 2.6 2.6 3 2.6 2.6 3 
36 4.1 3.8 3 4.1 3.8 3 7.6 7.9 3 7.6 7.9 3 3.0 2.7 3 3.0 2.7 3 
37 2.9 3.7 3 8.1 10.9 4 6.0 8.2 3 6.0 8.2 3 4.3 5.3 3 4.3 5.3 3 
38 10.3 9.6 3 10.3 9.6 3 9.0 8.8 3 9.0 8.8 3 3.8 3.6 3 3.8 3.6 3 
39 9.6 9.1 3 9.6 9.1 3 13.2 13.0 3 13.2 13.0 3 1.6 1.6 3 1.6 1.6 3 
40 6.7 11.8 3 6.7 11.8 3 8.7 13.8 3 8.8 14.5 4 1.5 2.4 3 1.5 2.4 3 
41 5.7 5.9 3 5.7 5.9 3 6.2 6.8 3 6.2 6.8 3 4.3 4.4 3 4.3 4.4 3 
42 13.8 19.9 3 13.8 19.9 3 6.3 10.5 3 6.3 10.5 3 7.8 9.8 3 7.8 9.8 3 
43 9.1 8.9 3 7.6 7.4 4 36.0 28.4 3 36.0 28.4 3 1.8 1.8 3 1.8 1.8 3 
44 3.8 3.8 3 3.7 3.6 4 4.6 4.6 3 4.6 4.6 3 4.4 4.5 3 4.4 4.5 3 
45 8.7 7.9 3 8.7 7.9 3 8.5 7.9 3 8.5 7.9 3 2.2 2.2 3 2.2 2.2 3 
46 2.3 3.2 3 6.4 9.6 4 10.7 15.2 3 10.7 15.2 3 3.7 6.1 3 3.7 6.1 3 
47 0.3 7.0 3 0.3 7.0 3 0.8 26.8 3 0.8 26.8 3 0.3 11.2 3 0.3 11.2 3 
48 0.5 15.2 3 0.5 15.2 3 0.3 10.4 3 0.3 10.4 3 0.2 6.6 3 0.2 6.6 3 
49 0.0 . 3 0.0 . 3 4.2 59.4 3 3.4 50.0 4 2.2 15.4 3 2.2 15.4 3 
50 3.5 4.0 3 3.2 3.6 4 1.3 1.3 3 1.3 1.3 3 2.4 2.5 3 2.4 2.5 3 
51 5.1 5.2 3 5.1 5.2 3 7.7 8.3 3 7.7 8.3 3 5.4 5.4 3 5.4 5.4 3 
52 15.5 13.7 3 15.5 13.7 3 7.3 7.2 3 7.3 7.2 3 5.3 5.3 3 5.3 5.3 3 
53 13.2 12.5 3 13.2 12.5 3 10.2 9.1 3 10.2 9.1 3 2.9 2.8 3 2.9 2.8 3 
54 1.9 3.9 3 1.9 3.9 3 4.1 19.9 3 4.1 19.9 3 10.9 26.3 3 10.9 26.3 3 
55 0.1 3.9 3 0.1 3.9 3 0.4 18.6 3 0.4 18.6 3 0.1 2.7 3 0.1 2.7 3 
56 7.0 13.0 3 7.0 13.0 3 3.5 14.1 3 3.5 14.1 3 9.2 24.7 3 9.2 24.7 3 
57 2.9 13.5 3 2.9 13.5 3 1.3 21.2 3 1.3 21.2 3 4.5 25.3 3 4.5 25.3 3 
58 0.4 1.6 3 0.4 1.6 3 2.6 67.6 3 2.6 67.6 3 0.7 5.3 3 0.7 5.3 3 
59 8.1 11.6 3 8.1 11.6 3 6.1 14.0 3 6.1 14.0 3 6.7 13.2 3 6.7 13.2 3 
60 4.3 27.7 3 4.3 27.7 3 4.8 44.9 3 4.8 44.9 3 6.5 31.7 3 6.5 31.7 3 
61 4.0 22.1 3 4.0 22.1 3 4.0 31.5 3 4.0 31.5 3 2.9 16.3 3 2.9 16.3 3 
62 6.8 6.2 3 6.8 6.2 3 2.1 2.1 3 2.1 2.1 3 6.4 6.2 3 6.4 6.2 3 
63 6.8 20.0 3 5.6 16.4 4 7.9 16.1 3 7.9 16.1 3 5.4 12.2 3 5.4 12.2 3 
64 7.1 23.6 3 7.1 23.6 3 10.0 41.6 3 10.0 41.6 3 6.2 19.1 3 6.2 19.1 3 
65 0.8 1.7 3 4.1 7.7 4 19.5 66.1 3 19.5 66.1 3 11.1 20.9 3 11.1 20.9 3 
66 1.1 15.9 3 1.1 16.6 4 1.2 33.0 3 1.2 33.0 3 2.4 65.0 3 2.4 65.0 3 
67 2.5 20.4 3 2.5 20.4 3 0.4 8.9 3 0.4 8.9 3 0.8 5.6 3 0.8 5.6 3 
68 1.0 28.6 3 1.0 28.6 3 0.6 17.8 3 0.6 17.8 3 2.4 57.9 3 2.4 57.9 3 
69 0.9 6.6 3 0.9 6.6 3 3.2 23.2 3 3.2 23.2 3 0.4 2.9 3 0.4 2.9 3 
70 2.7 17.6 3 2.7 17.6 3 1.6 14.7 3 1.6 14.7 3 1.2 8.9 3 1.2 8.9 3 
71 0.8 14.2 3 0.8 14.2 3 2.1 32.6 3 2.1 32.6 3 0.9 11.3 3 0.9 11.3 3 
72 1.5 38.8 3 1.5 38.8 3 1.0 22.4 3 1.0 22.4 3 1.3 33.7 3 1.3 33.7 3 
73 8.5 10.1 3 8.5 10.1 3 5.0 5.9 3 5.0 5.9 3 12.3 12.7 3 12.3 12.7 3 
74 11.8 15.6 3 9.7 12.9 4 3.6 4.7 3 3.6 4.7 3 6.5 7.1 3 6.5 7.1 3 
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 laboratory 
 Beiersdorf Harlan IIVS 
 Q Q+NQ Q Q+NQ Q Q+NQ 
Chemical std cv n std cv n std cv n std cv n std cv n std cv n 
75 4.7 5.8 3 25.1 40.5 5 8.7 118.3 3 8.7 118.3 3 0.7 13.5 3 0.7 13.5 3 
76 0.8 1.4 3 0.8 1.4 3 14.0 29.2 3 14.0 29.2 3 1.3 4.6 3 1.3 4.6 3 
77 5.9 6.1 3 5.9 6.1 3 18.1 24.5 3 18.1 24.5 3 4.6 4.4 3 4.6 4.4 3 
78 4.9 5.9 3 4.1 4.9 4 1.9 3.0 3 1.9 3.0 3 1.0 1.1 3 1.0 1.1 3 
79 0.5 20.7 3 0.5 20.7 3 0.3 13.5 3 0.3 13.5 3 0.5 16.4 3 0.5 16.4 3 
80 0.8 4.6 3 0.8 4.6 3 7.7 107.0 3 7.7 107.0 3 2.6 32.3 3 2.6 32.3 3 
81 0.7 26.8 3 0.7 26.8 3 0.2 5.3 3 0.2 5.3 3 1.3 29.8 3 1.3 29.8 3 
82 2.0 52.4 3 2.0 52.4 3 0.3 17.7 3 0.3 17.7 3 2.2 43.8 3 2.2 43.8 3 
83 0.4 7.7 3 0.4 7.7 3 2.1 39.1 3 2.1 39.1 3 1.4 25.8 3 1.4 25.8 3 
84 8.3 61.5 3 8.3 61.5 3 1.6 26.1 3 1.6 26.1 3 5.2 34.0 3 5.2 34.0 3 
85 5.7 28.3 3 5.7 28.3 3 3.5 38.2 3 3.5 38.2 3 2.5 16.6 3 2.5 16.6 3 
86 3.3 13.6 3 3.3 13.6 3 10.2 34.0 3 10.2 34.0 3 6.8 24.0 3 6.8 24.0 3 
87 4.2 14.6 3 4.2 14.6 3 4.0 21.3 3 4.0 21.3 3 6.7 27.8 3 6.7 27.8 3 
88 1.5 26.5 3 1.5 26.5 3 1.5 24.0 3 1.5 24.0 3 1.9 39.3 3 1.9 39.3 3 
89 2.0 21.2 3 2.0 21.2 3 1.2 17.3 3 1.2 17.3 3 1.9 18.2 3 1.9 18.2 3 
90 7.8 24.8 3 7.8 24.8 3 9.2 37.9 3 9.2 37.9 3 2.5 7.4 3 2.1 6.1 4 
91 9.8 31.4 3 9.8 31.4 3 4.0 24.0 3 4.0 24.0 3 0.9 4.4 3 0.9 4.4 3 
92 4.5 9.9 3 4.5 9.9 3 2.6 16.8 3 2.6 16.8 3 6.8 15.6 3 6.8 15.6 3 
93 3.0 33.2 3 3.0 33.2 3 1.6 19.9 3 1.6 19.9 3 5.7 34.3 3 5.7 34.3 3 
94 0.3 11.6 3 0.3 11.6 3 1.7 44.9 3 1.7 44.9 3 0.7 14.5 3 0.7 14.5 3 
95 0.2 6.5 3 0.2 6.5 3 0.1 4.4 3 0.1 4.4 3 0.3 16.9 3 0.3 16.9 3 
96 6.2 17.4 3 6.2 17.4 3 2.6 7.7 3 2.6 7.7 3 10.8 25.7 3 10.8 25.7 3 
97 5.0 9.5 3 5.0 9.5 3 2.3 4.3 3 2.3 4.3 3 4.0 7.2 3 4.0 7.2 3 
98 0.0 . 3 0.0 . 3 0.0 . 3 0.0 . 4 0.0 . 3 0.0 . 3 
99 0.3 10.0 3 0.3 10.0 3 0.5 20.2 3 0.5 20.2 3 0.2 8.3 3 0.2 8.3 3 
100 4.0 75.5 3 4.0 75.5 3 3.3 29.8 3 3.3 29.8 3 1.2 12.9 3 1.2 12.9 3 
101 0.6 1.7 3 0.6 1.7 3 12.4 31.3 3 12.4 31.3 3 4.1 22.4 3 4.1 22.4 3 
102 62.3 76.4 3 62.3 76.4 3 9.1 18.8 3 9.1 18.8 3 16.0 17.5 3 16.0 17.5 3 
103 0.9 35.9 3 0.9 35.9 3 0.2 11.3 3 0.2 11.3 3 0.2 12.7 3 0.2 12.7 3 
104 2.8 7.1 3 4.0 10.6 4 6.2 14.8 3 6.2 14.8 3 11.3 32.0 3 19.0 43.4 4 
105 0.2 8.3 3 0.2 8.3 3 1.0 36.3 3 1.0 36.3 3 0.2 8.4 3 0.2 8.4 3 
                   
Overall                   
Mean 5.0     5.3     5.5     5.5     3.9     4.5   
SD 7.0     7.2     5.5     5.5     3.3     5.4   
3.3.2 Between-laboratory variability 
The arithmetic mean value of viability over the different qualified tests per laboratory 
was used to calculate the inter-laboratory variability. For calculation on the between-
laboratory variability, only those chemicals are included for which at least one 
qualified test per laboratory was available. Table 3.3.7 gives the mean standard 
deviation as well as the standard deviation of the standard deviations 
Table 3.3.7 Mean standard deviation and standard deviation per chemical considering the 
standard deviations as reported for each participating laboratory (Q=qualified and 
NQ=non-qualified). 
Q Q+NQ 
Chemical mean SD std SD mean SD std SD 
1 4.0 2.2 4.0 2.2 
2 2.7 0.1 2.7 0.1 
3 2.5 2.1 2.5 2.1 
4 4.4 1.3 4.4 1.3 
5 9.2 1.8 9.2 1.8 
6 5.6 1.5 5.6 1.5 
7 4.3 1.4 4.3 1.4 
8 3.0 0.1 3.0 0.1 
9 4.8 2 4.8 2.0 
10 2.9 1.1 6.6 7.5 
11 2.1 0.6 2.1 0.6 
12 2.0 0.6 2.0 0.6 
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Q Q+NQ 
Chemical mean SD std SD mean SD std SD 
13 6.5 4.4 6.5 4.4 
14 3.7 2.6 3.7 2.6 
15 6.0 1.4 6.0 1.4 
16 5.2 0.2 5.2 0.2 
17 5.2 3.8 5.2 3.8 
18 9.9 12.3 9.9 12.3 
19 2.9 1.1 2.9 1.1 
20 10.1 3 10.8 2.3 
21 2.6 2.5 2.6 2.5 
22 4.7 2.5 4.7 2.5 
23 6.0 2.8 6.0 2.8 
24 6.1 4.7 6.1 4.7 
25 3.9 2.1 3.9 2.1 
26 3.0 1.8 3.1 1.7 
28 3.5 2.3 3.5 2.3 
29 11.4 13.9 11.2 14.0 
30 9.3 1.1 9.3 1.1 
31 9.6 5.6 8.8 4.7 
32 0.3 0.2 0.3 0.2 
34 10.0 6.1 9.4 5.7 
35 4.2 2.9 4.2 2.9 
36 4.9 2.4 4.9 2.4 
37 4.4 1.5 6.2 1.9 
38 7.7 3.5 7.7 3.5 
39 8.1 5.9 8.1 5.9 
40 5.6 3.7 5.7 3.7 
41 5.4 1 5.4 1.0 
42 9.3 4 9.3 4.0 
43 15.7 18 15.1 18.3 
44 4.3 0.4 4.2 0.5 
45 6.4 3.7 6.4 3.7 
46 5.6 4.5 7.0 3.5 
47 0.5 0.3 0.5 0.3 
48 0.3 0.2 0.3 0.2 
49 2.1 2.1 1.9 1.7 
50 2.4 1.1 2.3 0.9 
51 6.1 1.4 6.1 1.4 
52 9.4 5.4 9.4 5.4 
53 8.8 5.3 8.8 5.3 
54 5.6 4.7 5.6 4.7 
55 0.2 0.2 0.2 0.2 
56 6.6 2.9 6.6 2.9 
57 2.9 1.6 2.9 1.6 
58 1.2 1.2 1.2 1.2 
59 6.9 1 6.9 1.0 
60 5.2 1.2 5.2 1.2 
61 3.6 0.6 3.6 0.6 
62 5.1 2.6 5.1 2.6 
63 6.7 1.3 6.3 1.4 
64 7.7 2 7.7 2.0 
65 10.5 9.3 11.6 7.7 
66 1.6 0.8 1.6 0.8 
67 1.2 1.1 1.2 1.1 
68 1.3 1 1.3 1.0 
69 1.5 1.5 1.5 1.5 
70 1.8 0.8 1.8 0.8 
71 1.3 0.7 1.3 0.7 
72 1.3 0.3 1.3 0.3 
73 8.6 3.7 8.6 3.7 
74 7.3 4.1 6.6 3.0 
75 4.7 4 11.5 12.5 
76 5.3 7.5 5.3 7.5 
77 9.5 7.4 9.5 7.4 
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Q Q+NQ 
Chemical mean SD std SD mean SD std SD 
78 2.6 2.1 2.3 1.6 
79 0.5 0.1 0.5 0.1 
80 3.7 3.6 3.7 3.6 
81 0.7 0.5 0.7 0.5 
82 1.5 1.0 1.5 1.0 
83 1.3 0.8 1.3 0.8 
84 5.0 3.4 5.0 3.4 
85 3.9 1.7 3.9 1.7 
86 6.8 3.4 6.8 3.4 
87 5.0 1.5 5.0 1.5 
88 1.6 0.2 1.6 0.2 
89 1.7 0.4 1.7 0.4 
90 6.5 3.5 6.3 3.8 
91 4.9 4.5 4.9 4.5 
92 4.6 2.1 4.6 2.1 
93 3.4 2.1 3.4 2.1 
94 0.9 0.7 0.9 0.7 
95 0.2 0.1 0.2 0.1 
96 6.5 4.1 6.5 4.1 
97 3.8 1.4 3.8 1.4 
98 0.0 0.0 0.0 0.0 
99 0.3 0.2 0.3 0.2 
100 2.8 1.5 2.8 1.5 
101 5.7 6.1 5.7 6.1 
102 29.1 28.9 29.1 28.9 
103 0.4 0.4 0.4 0.4 
104 6.8 4.3 9.7 8.1 
105 0.5 0.5 0.5 0.5 
     
Overall     
Mean 4.8  5.0  
SD 3.9  4.0  
 
Concordance of classification between laboratories was calculated based on 
qualified test from test chemicals for which at least one qualified test was available. 
In Table 3.3.8 the concordance between laboratories is given. 
Table 3.3.8 Concordance between laboratories 
BLV 
concordant No. Fraction(%) 
NO 9 8.7 
YES 94 91.3 
 
Additional descriptive statistics can identify possible reasons for non-concordant 
results. These are presented in Table 3.3.9. For each non-concordant result the 
state (liquid/solid), the GHS classification, whether it is colouring or MTTreducer 
and the test results are given. 
Table 3.3.9 Additional descriptive statistics on non-concordant results between laboratories 
Chemical name LS coloring MTT GHS 
classification 
Beiersdorf Harlan IIVS 
3 2-ethoxyethyl methacrylate Liquid No No no cat 60.9 38.0 49.3 
5 4-(methylthio)-benzaldehyde Liquid No Yes no cat 80.7 46.1 62.5 
30 1,1-dimethylguanidine sulphate Solid No No no cat . 24.8 58.8 
30 1,1-dimethylguanidine sulphate Solid No Yes no cat 47.1 . . 
56 isopropyl acetoacetate Liquid No Yes cat 2B 53.7 24.9 37.3 
59 ethyl-2-methyl acetoacetate Liquid No No cat 2B 69.5 43.3 51.0 
65 2,2-dimethyl-3-methylenebicyclo 
[2.2.1] heptane INCI name: CAMPHENE 
Solid No No cat 2B 51.4 29.4 53.1 
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75 sodium benzoate INCI name: SODIUM 
BENZOATE 
Solid No No cat 2A 79.9 7.3 5.1 
76 6,7-dihydro-2,3-dimethyl-imidazo[1,2-
a]pyridin-8(5H)-one 
Solid No No cat 2A 53.9 48.1 27.3 
102 disodium 2,2'-([1,1'-biphenyl]-4,4'-
diyldivinylene)bis(benzenesulphonate) 
INCI name: DISODIUM 
DISTYRYLBIPHENYL DISULFONATE 
Solid No No cat 1 81.6 48.4 90.9 
 
The concordance for the set of chemicals tested during validation obtained by the 
different participating laboratories should ideally be equal or higher than 80%. As 
summarized in Table 3.3.10, this criteria was met.   
Table 3.3.10 Statement whether the test method has fulfilled the performance criteria concerning 
the concordance of classifications between laboratories. 
Fraction (%) Statement: criteria is 
91.3 fulfilled 
 
A two-way ANOVA was applied to test for differences in mean viabilities between 
laboratories and chemicals. Due to higher variation for higher mean viabilities, data 
were analysed after log-transformation. Since it is not possible to take the LOG of 
zero, four observations were excluded for analysis (all three means for 4,4'-(4,5,6,7-
tetrabromo-3H-2,1-benzoxathiol-3-ylidene)bis[2,6-dibromophenol] S,S-dioxide INCI 
name: TETRABROMOPHENOL BLUE (chemical 98) and the mean for propyl-4-
hydroxybenzoate INCI name: PROPYLPARABEN (chemical 49) from Beiersdorf). 
After log-transformation, three outlying observations (2,6-dihydroxy-3,4-
dimethylpyridine INCI name: 2,6-DIHYDROXY-3,4-DIMETHYLPYRIDINE (chemical 
32) and sodium benzoate INCI name: SODIUM BENZOATE (chemical 75) from 
Beiersdorf; sodium benzoate INCI name: SODIUM BENZOATE (chemical 75) from 
IIVS) were removed before analysis in order to fulfil the ANOVA-requirements. An 
outlier was defined as an observation with a residual > 3* residual error. The results 
from the two-way ANOVA are presented in Table 3.3.11. The null hypothesis of no 
difference was rejected at the 0.01 level of probability (α=0.01). 
Table 3.3.11 Two-way ANOVA with factors laboratory and chemical, applied to the arithmetic 
mean value of the included test results (based on log-transformation) 
Effect NumDF DenDF FValue pvalue 
laboratory 2 198 24.66 <.0001 
chemical 101 198 69.33 <.0001 
  
Both factors were statistically significant. A Tukey post-hoc test was performed to 
test the differences between the three laboratories. The results of this post-hoc test 
are given in Table 3.3.12. Significant differences were found between Beiersdorf 
and Harlan (p<0.0001) and between Harlan and IIVS (p<0.0001). The mean viability 
over all chemicals was statistically significant lower for Harlan compared to 
Beiersdorf and IIVS.  
Table 3.3.12 Results of the Tukey post-hoc test on differences between laboratories (after log-
transformation) 
laboratory vs Estimate Standard Error DF Tukey-corrected p-value 
Beiersdorf Harlan 0.2369 0.03684 198 <.0001 
Beiersdorf IIVS 0.03057 0.03684 198 0.6850 
Harlan IIVS -0.2063 0.03656 198 <.0001 
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The between-laboratory variability is described by the concordance of 
classifications between laboratories. Correlations coefficients between viability 
measurements give also information on this variability. Since the Pearson 
correlation coefficient is sensitive for outlying test results and high leverages, both 
the Pearson and the Spearman correlation coefficients (using ranks instead of the 
original test results) were calculated. These coefficients are presented in Table 
3.3.13. 
Table 3.3.13 Pearson and Spearman correlation coefficients between test results of the three 
participating laboratories. 
laboratories Pearson Spearman 
Beiersdorf-Harlan 0.936 0.942 
Beiersdorf-IIVS 0.957 0.941 
Harlan-IIVS 0.957 0.955 
Mean correlation 0.950 0.946 
3.3.3 Predictive capacity (accuracy) 
All qualified tests for each test chemical was used to calculate the predictive 
capacity values. The calculations were based on the individual predictions of each 
qualified test in each laboratory.  
 
For each statistic of the prediction model, an acceptance rate was set by the VMG. 
These criteria are presented in Table 3.3.14. The sensitivity, specificity and overall 
accuracy, subdivided into laboratories and total, including the 95% confidence 
intervals as well as a statement whether the acceptance criteria are fulfilled are 
presented in Table 3.3.15 (for solids and liquids, separately) and Table 3.3.16 
(liquids and solids together). 
Table 3.3.14 Acceptance criteria for the prediction model 
 False Negativesa (%) False Positivesb (%) Overall 
misclassificationsc (%) 
“Definitely acceptable” rates  ≤ 10 ≤ 40 ≤ 25 
Further evaluations 
necessary before any 
recommendation is made 
10 < FN ≤ 20 40 < FP ≤ 50 25 < OM ≤ 35 
“Definitely unacceptable” 
rates > 20 > 50 > 35 
a
 equal to (1-Sensitivity), b equal to (1-Specificity), c equal to (1-Overall accuracy) 
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Table 3.3.15 The sensitivity, specificity and overall accuracy, subdivided into laboratories and total, 
including the 95% confidence intervals as well as a statement whether the acceptance 
criteria for the prediction model are fulfilled, calculated for the protocol for liquids (a) 
and solids (b), separately. 
(a) Liquids 







Beiersdorf Accuracy 132/159 0.830 0.763 0.885 definitely acceptable 
 Sensitivity 73/78 0.936 0.857 0.979 definitely acceptable 
 Specificity 59/81 0.728 0.618 0.821 definitely acceptable 
Harlan Accuracy 130/159 0.818 0.749 0.874 definitely acceptable 
 Sensitivity 78/78 1.000 0.954 1.000 definitely acceptable 
 Specificity 52/81 0.642 0.528 0.746 definitely acceptable 
IIVS Accuracy 130/159 0.818 0.749 0.874 definitely acceptable 
 Sensitivity 74/78 0.949 0.874 0.986 definitely acceptable 
 Specificity 56/81 0.691 0.579 0.789 definitely acceptable 
Total Accuracy 392/477 0.822 0.784 0.855 definitely acceptable 
 Sensitivity 225/234 0.962 0.928 0.982 definitely acceptable 
 Specificity 167/243 0.687 0.625 0.745 definitely acceptable 
 
(b) Solids 







Beiersdorf Accuracy 107/150 0.713 0.634 0.784 Further evaluation 
 Sensitivity 50/78 0.641 0.524 0.747 definitely unacceptable 
 Specificity 57/72 0.792 0.680 0.878 definitely acceptable 
Harlan Accuracy 109/153 0.712 0.634 0.783 Further evaluation 
 Sensitivity 52/78 0.667 0.551 0.769 definitely unacceptable 
 Specificity 57/75 0.760 0.647 0.851 definitely acceptable 
IIVS Accuracy 117/153 0.765 0.689 0.829 definitely acceptable 
 Sensitivity 54/78 0.692 0.578 0.792 definitely unacceptable 
 Specificity 63/75 0.840 0.737 0.914 definitely acceptable 
Total Accuracy 333/456 0.730 0.687 0.770 Further evaluation 
 Sensitivity 156/234 0.667 0.602 0.727 definitely unacceptable 
 Specificity 177/222 0.797 0.738 0.848 definitely acceptable 
Table 3.3.16 The sensitivity, specificity and overall accuracy, subdivided into laboratories and total, 
including the 95% confidence intervals as well as a statement whether the acceptance 
criteria for the prediction model are fulfilled 







Beiersdorf Accuracy 239/309 0.773 0.723 0.819 definitely acceptable 
 Sensitivity 123/156 0.788 0.716 0.850 definitely unacceptable 
 Specificity 116/153 0.758 0.682 0.824 definitely acceptable 
Harlan Accuracy 239/312 0.766 0.715 0.812 definitely acceptable 
 Sensitivity 130/156 0.833 0.765 0.888 further evaluation 
 Specificity 109/156 0.699 0.620 0.769 definitely acceptable 
IIVS Accuracy 247/312 0.792 0.742 0.835 definitely acceptable 
 Sensitivity 128/156 0.821 0.751 0.877 further evaluation 
 Specificity 119/156 0.763 0.688 0.827 definitely acceptable 
Total Accuracy 725/933 0.777 0.749 0.803 definitely acceptable 
 Sensitivity 381/468 0.814 0.776 0.848 further evaluation 
 Specificity 344/465 0.740 0.697 0.779 definitely acceptable 
 
In Table 3.3.17, the prediction for each qualified test result is given for liquids and 
solids separately, as well as the final classification based on the median of 
predictions.  
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Table 3.3.17 Final classification based on the median of all classifications for each chemicals, 
listed for (a) liquids and (b) solids 
(a) Liquids 





tests/Total Chemical GHS classification 1 2 3 1 2 3 1 2 3 
1 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
2 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
3 no cat NI NI NI I I I NI I I I 5/9 
4 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
5 no cat NI NI NI NI I I NI NI NI NI 2/9 
6 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
7 no cat I I I I I I I I I I 9/9 
8 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
9 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
10 no cat I I I I I I I I I I 9/9 
11 no cat I I I I I I I I I I 9/9 
12 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
13 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
14 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
15 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
16 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
17 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
18 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
19 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
20 no cat I NI I I I I I I I I 8/9 
21 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
22 no cat NI I I I I I I I I I 8/9 
23 no cat I I I I I I I I I I 9/9 
24 no cat I I I I I I NI I I I 8/9 
25 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
26 no cat I I I I I I I I I I 9/9 
37 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
54 cat 2B I I I I I I NI I I I 1/9 
55 cat 2B I I I I I I I I I I 0/9 
56 cat 2B I NI NI I I I I I I I 2/9 
57 cat 2B I I I I I I I I I I 0/9 
58 cat 2B I I I I I I I I I I 0/9 
59 cat 2B NI NI NI I I I NI NI I NI 5/9 
60 cat 2B I I I I I I I I I I 0/9 
67 cat 2A I I I I I I I I I I 0/9 
68 cat 2A (ICCVAM: cat 2B) I I I I I I I I I I 0/9 
69 cat 2A (ICCVAM: cat 2B) I I I I I I I I I I 0/9 
70 cat 2A I I I I I I I I I I 0/9 
71 cat 2A (ICCVAM: cat 2B) I I I I I I I I I I 0/9 
72 cat 2A (ICCVAM: cat 2B) I I I I I I I I I I 0/9 
80 cat 1 I I I I I I I I I I 0/9 
81 cat 1 I I I I I I I I I I 0/9 
82 cat 1 I I I I I I I I I I 0/9 
83 cat 1 I I I I I I I I I I 0/9 
84 cat 1 I I I I I I I I I I 0/9 
85 cat 1 I I I I I I I I I I 0/9 
86 cat 1 I I I I I I I I I I 0/9 
87 cat 1 I I I I I I I I I I 0/9 
88 cat 1 I I I I I I I I I I 0/9 
89 cat 1 I I I I I I I I I I 0/9 
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tests/Total Chemical GHS classification 1 2 3 1 2 3 1 2 3 
90 cat 1 I I I I I I I I I I 0/9 
91 cat 1 I I I I I I I I I I 0/9 
92 cat 1 I I I I I I I I NI I 1/9 
 
(b) Solids 





tests/Total Chemical GHS classification 1 2 3 1 2 3 1 2 3 
28 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
29 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
30 no cat NI I I I I I NI NI NI I 5/9 
31 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
32 no cat I I I I I I I I I I 9/9 
33 no cat . . . I I I NI NI NI undecided 3/6 
34 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
35 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
36 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
38 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
39 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
40 no cat I NI NI NI NI NI NI NI NI NI 1/9 
41 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
42 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
43 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
44 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
45 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
46 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
47 no cat I I I I I I I I I I 9/9 
48 no cat I I I I I I I I I I 9/9 
49 no cat I I I I I I I I I I 9/9 
50 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
51 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
52 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
53 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
61 cat 2B I I I I I I I I I I 0/9 
62 cat 2B NI NI NI NI NI NI NI NI NI NI 9/9 
63 cat 2B I I I NI I NI I I I I 2/9 
64 cat 2B I I I I I I I I I I 0/9 
65 cat 2B NI NI NI I I NI NI I NI NI 6/9 
66 cat 2B I I I I I I I I I I 0/9 
73 cat 2A (ICCVAM: cat 2B) NI NI NI NI NI NI NI NI NI NI 9/9 
74 cat 2A NI NI NI NI NI NI NI NI NI NI 9/9 
75 cat 2A NI NI NI I I I I I I I 3/9 
76 cat 2A NI NI NI NI I NI I I I NI 5/9 
77 cat 2A NI NI NI NI NI NI NI NI NI NI 9/9 
78 cat 2A NI NI NI NI NI NI NI NI NI NI 9/9 
79 cat 2A (ICCVAM: cat 2B) I I I I I I I I I I 0/9 
93 cat 1 I I I I I I I I I I 0/9 
94 cat 1 I I I I I I I I I I 0/9 
95 cat 1 I I I I I I I I I I 0/9 
96 cat 1 I I I I I I I I NI I 1/9 
97 cat 1 NI I NI NI NI NI NI NI NI NI 8/9 
98 cat 1 I I I I I I I I I I 0/9 
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tests/Total Chemical GHS classification 1 2 3 1 2 3 1 2 3 
99 cat 1 I I I I I I I I I I 0/9 
100 cat 1 I I I I I I I I I I 0/9 
101 cat 1 I I I I NI I I I I I 1/9 
102 cat 1 I NI NI I NI NI NI NI NI NI 7/9 
103 cat 1 I I I I I I I I I I 0/9 
104 cat 1 I I I I I I I I I I 0/9 
105 cat 1 I I I I I I I I I I 0/9 
3.4 Reproducibility and accuracy using a 60% cut-off 
In this section, a 60% cut-off was applied to determine the irritancy of the chemical. 
If the viability is above 60%, the chemical is considered to be non-irritant. If the 
viability is 60% or below, the chemical is considered to be irritant. Statistics which 
are independent of the cut-off value, like correlation coefficients and ANOVA 
results, are reported in section 3.3 for the 50% cut-off and are not repeated in this 
section. 
3.4.1 Within-laboratory variability 
For each laboratory, concordance of classification was calculated based on 
qualified test from test chemicals for which at least two qualified tests were 
available. In Table 3.4.1 the concordance within each laboratory as well as in total 
is given. 
Table 3.4.1 Concordance within laboratories and total 
laboratory 
WLV 
concordant No. Fraction(%) 
Beiersdorf NO 5 4.9 
 YES 98 95.1 
Harlan NO 6 5.8 
 YES 98 94.2 
IIVS NO 4 3.8 
 YES 100 96.2 
Total NO 15 4.8 
 YES 296 95.2 
 
Additional descriptive statistics can identify possible reasons for non-concordant 
results. These are presented in Table 3.4.2. For each non-concordant result the 
state (liquid/solid), the GHS classification, whether it is colouring or MTTreducer 
and the test results are given. 
Table 3.4.2 Additional descriptive statistics on non-concordant results within laboratories 
       Test 
laboratory chemical name LS colouring MTT GHS 
classification 
1 2 3 
Beiersdorf 3 2-ethoxyethyl methacrylate liquid No No no cat 55.4 63.0 64.2 
Beiersdorf 40 acrylamidopropyltrimonium 
chloride/acrylamide copolymer 
solid No No no cat 
49.4 59.5 62.1 
Beiersdorf 42 trisodium mono-(5-(1,2-
dihydroxyethyl)-4-oxido-2-oxo-2,5-
dihydro-furan-3-yl) phosphate INCI 
name: SODIUM ASCORBYL 
solid No Yes no cat 
64.7 85.0 58.7 
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PHOSPHATE 
Beiersdorf 56 isopropyl acetoacetate liquid No Yes cat 2B 46.4 54.5 60.3 
Beiersdorf 102 disodium 2,2'-([1,1'-biphenyl]-4,4'-
diyldivinylene)bis(benzenesulphonat
e) INCI name: DISODIUM 
DISTYRYLBIPHENYL DISULFONATE 
solid No No cat 1 
10.1 110.2 124.3 
Harlan 4 iso-octylthioglycolate INCI name: 
ISOOCTYL THIOGLYCOLATE 
liquid No Yes no cat 
60.8 57.9 64.3 
Harlan 29 tetradecyl tetradecanoate INCI 
name: MYRISTYL MYRISTATE 
solid No No no cat 
57.4 112.0 83.0 
Harlan 34 2,2'-[[3-methyl-4-[(4-
nitrophenyl)azo]phenyl]imino]bis-
ethanol INCI name: DISPERSE RED 
17 
solid Yes Yes no cat 
81.4 54.1 63.2 
Harlan 40 acrylamidopropyltrimonium 
chloride/acrylamide copolymer 
solid No No no cat 
72.9 56.2 60.2 
Harlan 42 trisodium mono-(5-(1,2-
dihydroxyethyl)-4-oxido-2-oxo-2,5-
dihydro-furan-3-yl) phosphate INCI 
name: SODIUM ASCORBYL 
PHOSPHATE 
solid No Yes no cat 
53.4 66.0 60.0 
Harlan 46 cellulose, 2-(2-hydroxy-3-
(trimethylammonium)propoxy)ethyl 
ether chloride (91%) INCI name: 
POLYQUATERNIUM-10 
solid No No no cat 
73.1 58.9 80.0 
IIVS 5 4-(methylthio)-benzaldehyde liquid No Yes no cat 71.8 65.4 50.3 
IIVS 30 1,1-dimethylguanidine sulphate solid No No no cat 55.4 51.8 69.2 
IIVS 46 cellulose, 2-(2-hydroxy-3-
(trimethylammonium)propoxy)ethyl 
ether chloride (91%) INCI name: 
POLYQUATERNIUM-10 
solid No No no cat 
65.2 60.8 57.8 
IIVS 65 2,2-dimethyl-3-methylenebicyclo 
[2.2.1] heptane INCI name: 
CAMPHENE 
solid No No cat 2B 
63.8 41.6 53.9 
 
The concordance of classifications (irritant/non-irritant) for the set of chemicals 
tested during validation obtained in different, independent runs within a single 
laboratory should ideally be equal or higher than 85% for all participating 
laboratories. As summarized in Table 3.4.3, this criteria was met for each laboratory 
as well as in total. 
Table 3.4.3 Statement whether the test method has fulfilled the performance criteria concerning 
the concordance of classifications within one laboratory. 
laboratory Fraction(%) Statement: criteria is 
Beiersdorf 95.1 fulfilled 
Harlan 94.2 fulfilled 
IIVS 96.2 fulfilled 
Total 95.2 fulfilled 
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3.4.2 Between-laboratory variability 
Concordance of classification between laboratories was calculated based on 
qualified test from test chemicals for which at least one qualified test was available 
for each laboratory. In Table 3.4.4 the concordance between laboratories is given. 
Table 3.4.4 Concordance between laboratories 
BLV 
concordant No. Fraction(%) 
NO 7 6.8 
YES 96 93.2 
 
Additional descriptive statistics can identify possible reasons for non-concordant 
results. These are presented in Table 3.4.5. For each non-concordant result the 
state (liquid/solid), the GHS classification, whether it is colouring or MTT-reducer 
and the test results are given. 
Table 3.4.5 Additional descriptive statistics on non-concordant results between laboratories 
Chemical name LS colouring MTT GHS 
classification 
Beiersdorf Harlan IIVS 
3 2-ethoxyethyl methacrylate liquid No No no cat 60.9 38.0 49.3 
5 4-(methylthio)-benzaldehyde liquid No Yes no cat 80.7 46.1 62.5 
40 acrylamidopropyltrimonium 
chloride/acrylamide copolymer 
solid No No no cat 57.0 63.1 61.8 
42 trisodium mono-(5-(1,2-
dihydroxyethyl)-4-oxido-2-oxo-2,5-
dihydro-furan-3-yl) phosphate INCI 
name: SODIUM ASCORBYL 
PHOSPHATE 
solid No Yes no cat 69.5 59.8 79.2 
59 ethyl-2-methyl acetoacetate liquid No No cat 2B 69.5 43.3 51.0 
75 sodium benzoate INCI name: SODIUM 
BENZOATE 
solid No No cat 2A 79.9 7.3 5.1 
102 disodium 2,2'-([1,1'-biphenyl]-4,4'-
diyldivinylene)bis(benzenesulphonate) 
INCI name: DISODIUM 
DISTYRYLBIPHENYL DISULFONATE 
solid No No cat 1 81.6 48.4 90.9 
 
The concordance for the set of chemicals tested during validation obtained by the 
different participating laboratories should ideally be equal or higher than 80%. As 
summarized in Table 3.4.6, this criteria was met.   
Table 3.4.6 Statement whether the test method has fulfilled the performance criteria concerning 
the concordance of classifications between laboratories. 
Fraction (%) Statement: criteria is 
93.2 fulfilled 
3.4.3 Predictive capacity (accuracy) 
All qualified tests for each test chemical was used to calculate the predictive 
capacity values. The calculations were based on the individual predictions of each 
qualified test in each laboratory.  
 
For each statistic of the prediction model, an acceptance rate was set by the VMG. 
These criteria are presented in Table 3.3.14. The sensitivity, specificity and overall 
accuracy, subdivided into laboratories and total, including the 95% confidence 
intervals as well as a statement whether the acceptance criteria are fulfilled are 
presented in Table 3.4.7 (for solids and liquids, separately) and Table 3.4.8 (liquids 
and solids together). 
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Table 3.4.7 The sensitivity, specificity and overall accuracy, subdivided into laboratories and total, 
including the 95% confidence intervals as well as a statement whether the acceptance 
criteria for the prediction model are fulfilled, calculated for the protocol for liquids (a) 
and solids (b), separately. 
(a) Liquids 







Beiersdorf Accuracy 130/159 0.818 0.749 0.874 definitely acceptable 
 Sensitivity 74/78 0.949 0.874 0.986 definitely acceptable 
 Specificity 56/81 0.691 0.579 0.789 definitely acceptable 
Harlan Accuracy 128/159 0.805 0.735 0.864 definitely acceptable 
 Sensitivity 78/78 1.000 0.954 1.000 definitely acceptable 
 Specificity 50/81 0.617 0.503 0.723 definitely acceptable 
IIVS Accuracy 131/159 0.824 0.756 0.880 definitely acceptable 
 Sensitivity 78/78 1.000 0.954 1.000 definitely acceptable 
 Specificity 53/81 0.654 0.540 0.757 definitely acceptable 
Total Accuracy 389/477 0.816 0.778 0.849 definitely acceptable 
 Sensitivity 230/234 0.983 0.957 0.995 definitely acceptable 
 Specificity 159/243 0.654 0.591 0.714 definitely acceptable 
 
(b) Solids 







Beiersdorf Accuracy 112/150 0.747 0.669 0.814 further evaluation 
 Sensitivity 58/78 0.744 0.632 0.836 definitely unacceptable 
 Specificity 54/72 0.750 0.634 0.845 definitely acceptable 
Harlan Accuracy 115/153 0.752 0.675 0.818 definitely acceptable 
 Sensitivity 63/78 0.808 0.703 0.888 further evaluation 
 Specificity 52/75 0.693 0.576 0.795 definitely acceptable 
IIVS Accuracy 119/153 0.778 0.704 0.841 definitely acceptable 
 Sensitivity 59/78 0.756 0.646 0.847 definitely unacceptable 
 Specificity 60/75 0.800 0.692 0.884 definitely acceptable 
Total Accuracy 346/456 0.759 0.717 0.797 definitely acceptable 
 Sensitivity 180/234 0.769 0.710 0.822 definitely unacceptable 
 Specificity 166/222 0.748 0.685 0.803 definitely acceptable 
 
Table 3.4.8 The sensitivity, specificity and overall accuracy, subdivided into laboratories and total, 
including the 95% confidence intervals as well as a statement whether the acceptance 
criteria for the prediction model are fulfilled 







Beiersdorf Accuracy 242/309 0.783 0.733 0.828 definitely acceptable 
 Sensitivity 132/156 0.846 0.780 0.899 further evaluation 
 Specificity 110/153 0.719 0.641 0.789 definitely acceptable 
Harlan Accuracy 243/312 0.779 0.729 0.824 definitely acceptable 
 Sensitivity 141/156 0.904 0.846 0.945 definitely acceptable 
 Specificity 102/156 0.654 0.574 0.728 definitely acceptable 
IIVS Accuracy 250/312 0.801 0.753 0.844 definitely acceptable 
 Sensitivity 137/156 0.878 0.816 0.925 further evaluation 
 Specificity 113/156 0.724 0.647 0.793 definitely acceptable 
Total Accuracy 735/933 0.788 0.760 0.814 definitely acceptable 
 Sensitivity 410/468 0.876 0.843 0.905 further evaluation 
 Specificity 325/465 0.699 0.655 0.740 definitely acceptable 
 
In Table 3.4.9, the prediction for each qualified test result is given for liquids and 
solids separately, as well as the final classification based on the median of 
predictions  
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Table 3.4.9. Final classification based on the median of all classifications for each chemicals, listed 
for (a) liquids and (b) solids 
(a) Liquids 





tests/Total Chemical GHS classification 1 2 3 1 2 3 1 2 3 
1 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
2 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
3 no cat I NI NI I I I I I I I 7/9 
4 no cat NI NI NI NI I NI NI NI NI NI 1/9 
5 no cat NI NI NI I I I NI NI I NI 4/9 
6 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
7 no cat I I I I I I I I I I 9/9 
8 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
9 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
10 no cat I I I I I I I I I I 9/9 
11 no cat I I I I I I I I I I 9/9 
12 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
13 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
14 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
15 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
16 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
17 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
18 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
19 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
20 no cat I I I I I I I I I I 9/9 
21 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
22 no cat I I I I I I I I I I 9/9 
23 no cat I I I I I I I I I I 9/9 
24 no cat I I I I I I I I I I 9/9 
25 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
26 no cat I I I I I I I I I I 9/9 
37 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
54 cat 2B I I I I I I I I I I 0/9 
55 cat 2B I I I I I I I I I I 0/9 
56 cat 2B I I NI I I I I I I I 1/9 
57 cat 2B I I I I I I I I I I 0/9 
58 cat 2B I I I I I I I I I I 0/9 
59 cat 2B NI NI NI I I I I I I I 3/9 
60 cat 2B I I I I I I I I I I 0/9 
67 cat 2A I I I I I I I I I I 0/9 
68 cat 2A (ICCVAM: cat 2B) I I I I I I I I I I 0/9 
69 cat 2A (ICCVAM: cat 2B) I I I I I I I I I I 0/9 
70 cat 2A I I I I I I I I I I 0/9 
71 cat 2A (ICCVAM: cat 2B) I I I I I I I I I I 0/9 
72 cat 2A (ICCVAM: cat 2B) I I I I I I I I I I 0/9 
80 cat 1 I I I I I I I I I I 0/9 
81 cat 1 I I I I I I I I I I 0/9 
82 cat 1 I I I I I I I I I I 0/9 
83 cat 1 I I I I I I I I I I 0/9 
84 cat 1 I I I I I I I I I I 0/9 
85 cat 1 I I I I I I I I I I 0/9 
86 cat 1 I I I I I I I I I I 0/9 
87 cat 1 I I I I I I I I I I 0/9 
88 cat 1 I I I I I I I I I I 0/9 
89 cat 1 I I I I I I I I I I 0/9 
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tests/Total Chemical GHS classification 1 2 3 1 2 3 1 2 3 
90 cat 1 I I I I I I I I I I 0/9 
91 cat 1 I I I I I I I I I I 0/9 
92 cat 1 I I I I I I I I I I 0/9 
 
(b) Solids 





tests/Total Chemical GHS classification 1 2 3 1 2 3 1 2 3 
28 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
29 no cat NI NI NI I NI NI NI NI NI NI 1/9 
30 no cat I I I I I I I I NI I 8/9 
31 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
32 no cat I I I I I I I I I I 9/9 
33 no cat . . . I I I NI NI NI 0.5 3/6 
34 no cat NI NI NI NI I NI NI NI NI NI 1/9 
35 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
36 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
38 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
39 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
40 no cat I I NI NI I NI NI NI NI NI 3/9 
41 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
42 no cat NI NI I I NI NI NI NI NI NI 2/9 
43 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
44 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
45 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
46 no cat NI NI NI NI I NI NI NI I NI 2/9 
47 no cat I I I I I I I I I I 9/9 
48 no cat I I I I I I I I I I 9/9 
49 no cat I I I I I I I I I I 9/9 
50 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
51 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
52 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
53 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
61 cat 2B I I I I I I I I I I 0/9 
62 cat 2B NI NI NI NI NI NI NI NI NI NI 9/9 
63 cat 2B I I I I I I I I I I 0/9 
64 cat 2B I I I I I I I I I I 0/9 
65 cat 2B I I I I I I NI I I I 1/9 
66 cat 2B I I I I I I I I I I 0/9 
73 cat 2A (ICCVAM: cat 2B) NI NI NI NI NI NI NI NI NI NI 9/9 
74 cat 2A NI NI NI NI NI NI NI NI NI NI 9/9 
75 cat 2A NI NI NI I I I I I I I 3/9 
76 cat 2A I I I I I I I I I I 0/9 
77 cat 2A NI NI NI NI NI NI NI NI NI NI 9/9 
78 cat 2A NI NI NI NI NI NI NI NI NI NI 9/9 
79 cat 2A (ICCVAM: cat 2B) I I I I I I I I I I 0/9 
93 cat 1 I I I I I I I I I I 0/9 
94 cat 1 I I I I I I I I I I 0/9 
95 cat 1 I I I I I I I I I I 0/9 
96 cat 1 I I I I I I I I I I 0/9 
97 cat 1 I I I I I I I I I I 0/9 
98 cat 1 I I I I I I I I I I 0/9 
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tests/Total Chemical GHS classification 1 2 3 1 2 3 1 2 3 
99 cat 1 I I I I I I I I I I 0/9 
100 cat 1 I I I I I I I I I I 0/9 
101 cat 1 I I I I I I I I I I 0/9 
102 cat 1 I NI NI I I I NI NI NI NI 5/9 
103 cat 1 I I I I I I I I I I 0/9 
104 cat 1 I I I I I I I I I I 0/9 
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4 Study Outcome 
 
 
The validation study is considered of high quality due to a very complete dataset 
with very little retesting needed. The test method is highly reproducible. The within-
laboratory reproducibility (WLR) and between-laboratory reproducibility (BLR) was 
well above the acceptance criteria set by the VMG (i.e. WLR ≥ 85% and BLR ≥ 
80%). 
 
The concordance of classifications within a single laboratory was above 90% for all 
participating laboratories. The concordance of final classifications obtained between 
the different participating laboratories was greater than 90%. 
 
The protocol for the liquid chemicals met all the acceptance criteria of the VMG for 
sensitivity, specificity and overall accuracy: the number of false negatives was 
below 10% (overall sensitivity was 0.962 and 0.983, using a cutoff of 50% and 60%, 
respectively), the number of false positives was below 40% (overall specificity was 
0.687 and 0.654, using a cutoff of 50% and 60%, respectively) and the overall 
misclassification was below 25% (overall accuracy was 0.822 and 0.816, using a 
cutoff of 50% and 60%, respectively). 
 
On the other hand, not all of the acceptance criteria were met by the protocol for the 
solid chemicals. An overall specificity of 0.797 (50% cutoff) and 0.748 (60% cutoff) 
met the criteria of less than 40% false positives, but the percentage of false 
negatives was above the acceptable rate of 10% (overall sensitivity 0.667 and 
0.769, using a cutoff of 50% and 60%, respectively). Having an overall accuracy of 
0.730 using a cutoff of 50%, the solid protocol needs further evaluation before a 
recommendation can be made. The overall accuracy based on a 60% cutoff met the 
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Appendix I MTT reducers and colourants 
Note that some chemicals are treated differently by the three laboratories, as is 
mentioned in section 3.2.1. If a chemical is treated as an MTT-reducer or a colorant 
in at least one of the laboratories, it is listed in appendix I. 
 
Chemical MTT colouring protocol name 
4 Yes No Liquids iso-octylthioglycolate INCI name: ISOOCTYL THIOGLYCOLATE 
5 Yes No Liquids 4-(methylthio)-benzaldehyde 
20 Yes No Liquids ricinoleic acid tin salt 
22 Yes No Liquids 3-phenoxybenzyl alcohol  
23 Yes No Liquids ethyl thioglycolate INCI name: ETHYL THIOGLYCOLATE 
25 Yes No Liquids piperonyl butoxide INCI name: PIPERONYL BUTOXIDE 
26 Yes No Liquids propiconazole 
29 Yes No Solids tetradecyl tetradecanoate INCI name: MYRISTYL MYRISTATE 
30 Yes No Solids 1,1-dimethylguanidine sulphate 
32 Yes No Solids 2,6-dihydroxy-3,4-dimethylpyridine INCI name: 2,6-DIHYDROXY-3,4-DIMETHYLPYRIDINE 
33 Yes Yes Solids 2,2'-[[4-[(2-methoxyethyl)amino]-3-nitrophenyl]imino]bis-ethanol INCI name: HC BLUE NO. 11 
34 Yes Yes Solids 2,2'-[[3-methyl-4-[(4-nitrophenyl)azo]phenyl]imino]bis-ethanol INCI name: DISPERSE RED 17 
35 Yes No Solids 2,5,6-triamino-4-pyrimidinol sulphate INCI name: 2,5,6-TRIAMINO-4-PYRIMIDINOL SULFATE 
36 Yes No Solids 1-(4-chlorophenyl)-3-(3,4-dichlorophenyl) urea INCI name: TRICLOCARBAN 
42 Yes No Solids trisodium mono-(5-(1,2-dihydroxyethyl)-4-oxido-2-oxo-2,5-dihydro-furan-3-yl) phosphate INCI 
name: SODIUM ASCORBYL PHOSPHATE 
48 Yes No Solids sodium hydrogensulphite INCI name: SODIUM BISULFITE 
49 Yes No Solids propyl-4-hydroxybenzoate INCI name: PROPYLPARABEN 
50 Yes No Solids iodosulfuron-methyl-sodium 
51 Yes No Solids 1,5-di(2,4-dimethylphenyl)-3-methyl-1,3,5-triazapenta-1,4-diene common name: Amitraz 
53 Yes No Solids 3-(2-chloro-thiazol-5-ylmethyl)-5-methyl[1,3,5]oxadiazinan-4-ylidene-N-nitroamine common 
name: Thiamethoxam 
56 Yes No Liquids isopropyl acetoacetate 
60 Yes No Liquids diethyl toluamide INCI name: DIETHYL TOLUAMIDE common name: DEET 
62 Yes No Solids 1,4-dibutoxy benzene 
72 No Yes Liquids 2,4,11,13-tetraazatetradecanediimidamide, N,N''-bis(4-chlorophenyl)-3,12-diimino-, di-D-
gluconate (20% aqueous) INCI name: CHLORHEXIDINE DIGLUCONATE 
74 Yes No Solids 2-amino-3-hydroxy pyridine INCI name: 2-AMINO-3-HYDROXYPYRIDINE 
80 Yes No Liquids methylthioglycolate INCI name: METHYL THIOGLYCOLATE 
81 Yes No Liquids 3-diethylaminopropionitrile 
84 Yes No Liquids sodium coco amphoacetate (~ 30% aqueous) 
88 Yes No Liquids bisphenol A, diethylene triamine, epichlorohydrin, polypropylene glycol diglycidyl ether, 
polymer (~ 60% aqueous) 
91 Yes No Liquids (ethylenediaminepropyl)trimethoxysilane 
92 Yes No Liquids tetraethylene glycol diacrylate 
95 Yes No Solids 1,2,4-triazole sodium salt 
98 Yes Yes Solids 4,4'-(4,5,6,7-tetrabromo-3H-2,1-benzoxathiol-3-ylidene)bis[2,6-dibromophenol] S,S-dioxide 
INCI name: TETRABROMOPHENOL BLUE 
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Chemical MTT colouring protocol name 
100 Yes No Solids ethyl lauroyl arginate HCl INCI name: ETHYL LAUROYL ARGINATE HCL 
101 No Yes Solids 2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride INCI name: BASIC ORANGE 31 
103 Yes No Solids 3,4-dimethyl-1H-pyrazole 
106
1
 Yes Yes Solids 4-((4-amino-3-methylphenyl)(4-imino-3-methyl-2,5-cyclohexadien-1-ylidene)methyl)-2-
methylbenzenamine hydrochloride INCI name: BASIC VIOLET 2 
107
1
 Yes Yes Solids xanthylium, 3,6-bis(diethylamino)-9-[2-(methoxycarbonyl)phenyl]-tetrafluoroborate 
1 extra chemicals not for statistics but for a later purpose of evaluation using an HPLC based detection system. 
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Appendix II SAS-code for statistical analysis 
/* ================================ */ 
/* STEP5_EpiOcular_SAP - Revision.sas   */ 
/*                        */ 
/* Data analysis according to SAP      */ 
/* 10-01-2012 Intial CdJ          */ 
/* 19-10-2012 final CdJ          */ 
/* ================================ */ 
 
LIBNAME RhT '\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data analysis'; 
OPTIONS fmtsearch=(RhT.formats work.formats) NOCENTER; 
 
PROC FORMAT; 
   VALUE fmtconcl 0 = 'Qualified and included' 
                  1 = 'Non-Qualified' 
      2 = 'Excluded'; 
   VALUE fmtc 0 = 'NQ' 
              1 = 'Ex' 
              . = ' '; 
   VALUE FMTINI 0 = 'NI' 
                1 = 'I'; 
RUN; 
 
/* Merge locked data with chemical information */ 
DATA chemorder; 
   INFILE '\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data analysis\chemorder_epiocular.txt'  
           DSD DELIMITER='09'x MISSOVER FIRSTOBS=2 lrecl=100000; 
   INFORMAT name $200. tnocode state predGHS CAS predEPA $30. EPRAfull LYS CYS  $100.; 
   FORMAT name $200. tnocode state predGHS  CAS predEPA EPRAfull $30. EPRAfull LYS CYS $100.; 
   INPUT order (tnocode name CAS state predGHS predEPA LYS CYS EPRAfull EPRA BDF harlan IIVS) ($); 
   IF order = . THEN DELETE; 
   LS = SCAN(state,1);      
   /* one chemical is treated by the laboratories as 'liquid' but stated as 'solid' */ 
   /* Hardened castor oil with approx. 40 mol EO (INCI name: PEG-40 Hydrogenated Castor Oil) (order 37) is listed as solid but analysed 
(statistically) as a liquid (based on VMG decision Nov10 2011) */ 
   IF order = 37 THEN LS = 'liquid'; 
   /* remove deselected chemical */ 
   IF order = 27 THEN DELETE; * other deselected chemicals are not in the list;    
   IF order < 54 THEN trueINI = "NI"; 
   ELSE trueINI = "I"; 
RUN; 
DATA chemorder2; 
   SET chemorder(keep = name order LS predGHS BDF rename=(BDF = chemical_code)) 
       chemorder(keep = name order LS predGHS harlan rename=(harlan = chemical_code)) 
       chemorder(keep = name order LS predGHS iivs rename=(iivs = chemical_code)); 
RUN; 
PROC SORT data= RhT.EpiOcular_locked; BY chemical_code; RUN; 
PROC SORT data= chemorder2; BY chemical_code; RUN; 
DATA pre_all; 
   MERGE RhT.EpiOcular_locked(in=ok2) chemorder2 (in=ok); 
   BY chemical_code; 
   IF ok and ok2; 
   *IF test >3 then delete; 
   IF order < 54 THEN trueINI = "NI"; 
   ELSE trueINI = "I"; 
   runN = INPUT(run,best12.); 
   IF MTT = '' THEN MTT = 'No'; 
   IF coloring = '' THEN coloring = 'No'; 
   IF UPCASE(MTT)='YES' THEN MTT = 'Yes'; 
   IF UPCASE(MTT)='NO' THEN MTT = 'No'; 
   IF UPCASE(coloring)='YES' THEN coloring = 'Yes'; 
   IF UPCASE(coloring)='NO' THEN coloring = 'No'; 
   RETAIN test 0; 
   test = test+1; 
   IF first.chemical_code THEN test=1; 
RUN; 




where order IN (27 106 107); 
run; 
/* 09082012 CdJ Revision */ 
/* 16082012 CdJ Revision: addapted rules */ 
PROC SORT data=pre_all; BY chemical_code; RUN; 
DATA rules/* (where=(order = 29))*/; 
   SET pre_all; 
   BY chemical_code; 
   if conclusion = 1 /* non-qual */ then delete; 
   IF viability >50 THEN pred50=0; 
   ELSE pred50 = 1; 
   IF viability >60 THEN pred60=0; 
   ELSE pred60 = 1; 
   IF meanTA >50 THEN pred50raw=0; 
   ELSE pred50raw = 1; 
   IF meanTA >60 THEN pred60raw=0; 
   ELSE pred60raw = 1; 
   FORMAT pred50 pred60 pred50raw pred60raw fmtpred.;   
RUN; 
DATA rules2; 
    SET rules; 
 BY chemical_code; 
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   RETAIN t 0; 
   t = t+1; 
   IF first.chemical_code THEN t=1; 
   IF t>3 then delete; 
RUN; 
PROC SORT data=rules2; BY order  laboratory protocol ; RUN; 
PROC TRANSPOSE data=rules2 out=allT1 prefix=p50_; 
   VAR pred50; 
   BY order  laboratory protocol ; 
   ID t; 
RUN;  
PROC TRANSPOSE data=rules2 out=allT2 prefix=p60_; 
   VAR pred60; 
   BY order  laboratory protocol ; 
   ID t; 
RUN;  
PROC TRANSPOSE data=rules2 out=allT1raw prefix=p50r_; 
   VAR pred50raw; 
   BY order  laboratory protocol ; 
   ID t; 
RUN;  
PROC TRANSPOSE data=rules2 out=allT2raw prefix=p60r_; 
   VAR pred60raw; 
   BY order  laboratory protocol ; 
   ID t; 
RUN;  
PROC TRANSPOSE data=rules2 out=allT3 prefix=v_; 
   VAR viability; 
   BY order  laboratory protocol ; 
   ID t; 
RUN;  
PROC TRANSPOSE data=rules2 out=allT4 prefix=TA_; 
   VAR meanTA; 
   BY order  laboratory protocol ; 
   ID t; 
RUN;  
PROC TRANSPOSE data=rules2 out=allT5 prefix=CC_; 
   VAR meanCC; 
   BY order  laboratory protocol ; 
   ID t; 
RUN;  
PROC TRANSPOSE data=rules2 out=allT6 prefix=KC_; 
   VAR meanKC; 
   BY order  laboratory protocol ; 
   ID t; 
RUN;  
DATA overall (drop=_name_); 
   MERGE allT1 allT2  allT1raw allT2raw allT3 allT4 allT5 allT6; 
   BY order  laboratory protocol ; 
RUN; 
PROC SORT data=overall; BY laboratory order; RUN; 
DATA rules3_no rules3_yes; 
   SET overall; 
   mean_nsc=mean(CC_1,CC_2,CC_3); 
   mean_mtt=mean(KC_1,KC_2,KC_3); 
   * rule 1 - IF mean (%NSC or %NSMTT) of all qualified tests obtained for a chemical in one laboratory is less than or equal to (=) 50%,  
   THEN this chemical is considered to be compatible with the test method. The chemical should be included in the overview tables, 
   and included in all statistical calculations of reproducibility and predictive capacity.; 
  IF mean_nsc <= 50 THEN DO; inclusion50_nsc = 'yes'; inclusion60_nsc = 'yes'; END; 
  IF mean_mtt<=50 THEN DO; inclusion50_mtt = 'yes'; inclusion60_mtt = 'yes'; END; 
  * rule 2 - IF mean (%NSC or %NSMTT) of all qualified tests obtained for a chemical in one laboratory is greater than (>) 50% AND  
  their classification (I or NI) remains the same upon correction, THEN this chemical is considered to be compatible with the test  
  method. The chemical should be included in the overview tables, and included in all statistical calculations of reproducibility and 
  predictive capacity.; 
  IF mean_nsc > 50 AND p50_1=p50r_1 AND  p50_2=p50r_2 AND p50_3=p50r_3 THEN inclusion50_nsc = 'yes'; 
  IF mean_nsc > 50 AND p60_1=p60r_1 AND  p60_2=p60r_2 AND p60_3=p60r_3 THEN inclusion60_nsc = 'yes'; 
  IF mean_mtt > 50 AND p50_1=p50r_1 AND  p50_2=p50r_2 AND p50_3=p50r_3 THEN inclusion50_mtt = 'yes'; 
  IF mean_mtt > 50 AND p60_1=p60r_1 AND  p60_2=p60r_2 AND p60_3=p60r_3 THEN inclusion60_mtt = 'yes'; 
* rule 3 - IF mean (%NSC or %NSMTT) of all qualified tests obtained for a chemical in one laboratory is greater than (>) 50% AND 
  the classification of at least one of the qualified tests changes upon correction, THEN this chemical is considered to be  
  incompatible with the test method. The chemical should be included in the overview tables, but excluded from all statistical  
  calculations of reproducibility and predictive capacity.; 
  IF mean_nsc > 50 AND (p50_1 NE p50r_1 OR  p50_2 NE p50r_2 OR p50_3 NE p50r_3) THEN inclusion50_nsc = 'no'; 
  IF mean_nsc > 50 AND (p60_1 NE p60r_1 OR  p60_2 NE p60r_2 OR p60_3 NE p60r_3) THEN inclusion60_nsc = 'no'; 
  IF mean_mtt > 50 AND (p50_1 NE p50r_1 OR  p50_2 NE p50r_2 OR p50_3 NE p50r_3) THEN inclusion50_mtt = 'no'; 
  IF mean_mtt > 50 AND (p60_1 NE p60r_1 OR  p60_2 NE p60r_2 OR p60_3 NE p60r_3) THEN inclusion60_mtt = 'no'; 
  * output; 
  IF inclusion50_nsc = 'no' OR inclusion50_mtt = 'no' OR inclusion60_nsc = 'no' OR inclusion60_mtt = 'no' THEN OUTPUT rules3_no; 
  ELSE OUTPUT rules3_yes;  
RUN; 
/* CONCLUSION */ 
/* new rules give same selection : chemical 33 (BDF only), 80 and 23 */ 
/* exclusion of 80 and 23 is overruled in VMG */ 
/* chemical 33 is excluded for BDF */ 
 
DATA pre_all; 
   SET pre_all; 
 
   /* remove chemical 106 and 107 for statistical analysis */ 
   IF chemical_code IN ('B74' 'H23' 'V13') THEN DELETE; * 106; 
   IF chemical_code IN ('B55' 'H36' 'V14') THEN DELETE; * 107; 
   /* for chemical 80 and 23 the VMG overrode the 50% rule regarding NSMTT */ 
   IF chemical_code IN ('B129' 'H128' 'V127') then conclusion = 0; * 23; 
   IF chemical_code IN ('B45' 'H78' 'V93') then conclusion = 0; * 80; 
   /* for chemical 33: non-compatible for Beiersdorf */ 
   IF chemical_code = 'B87' THEN conclusion = 2; 
RUN; 
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proc freq data=pre_all; 
   tables laboratory *conclusion; 
run; 
data tmp; 
   set pre_all; 
*   IF    chemical_code IN ('B87' 'H20' 'V58')  then output; * chemical 33; 





  /* ---------------------------------------- */ 
/* Section 4 of SAP: Quality check */ 
/* ---------------------------------------- */ 
 
/* 4.1.1 Quality check: is the information complete */ 
 
* quality check performed by laboratories; 
 
/* 4.1.2 acceptance criteria always met */ 
PROC SORT data=pre_all out=pre412 nodupkey; BY filename; RUN; 
PROC FREQ data=pre412 ; 
   TABLE laboratory*NCqual/out=table412_NC NOCOL NOPERCENT; 
   TABLE laboratory*PCqual/out=table412_PC NOCOL NOPERCENT; 
RUN; 
PROC TRANSPOSE data=table412_NC out=table412NCt; 
   VAR count; 
   ID NCqual; 
   BY laboratory; 
RUN; 
PROC TRANSPOSE data=table412_PC out=table412PCt; 
   VAR count; 
   ID PCqual; 
   BY laboratory; 
RUN; 
DATA table412; 
   SET table412NCt(in=nc) table412PCt(in=pc); 
   BY laboratory; 
   IF nc THEN var = 'NC'; 
   IF pc THEN var = 'PC'; 
   IF non_qualified = . THEN non_qualified = 0; 
   fraction_nq = 100* non_qualified/(non_qualified+qualified); 
   fraction_q = 100*qualified/(non_qualified+qualified); 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data analysis\Reports\Revision\EpiOcular_Table412.doc' 
notoc_data; 
PROC REPORT data = table412 NOWINDOWS HEADLINE HEADSKIP; 
   COLUMN laboratory var qualified fraction_q non_qualified fraction_nq; 
   DEFINE laboratory/GROUP; 
   DEFINE var/DISPLAY ' '; 
   DEFINE qualified/DISPLAY 'No.Qualified' width = 12 CENTER; 
   DEFINE fraction_q/DISPLAY '%' width = 5 format=8.1 CENTER; 
   DEFINE non_qualified/DISPLAY 'No.Non-Qualified' width = 16 CENTER; 
   DEFINE fraction_nq/DISPLAY '%' width = 5 format=8.1 CENTER; 
RUN; QUIT; 
ODS rtf close; 
 
/* 4.1.3 deviations from protocol */ 
 
* no major deviations; 
 
/* 4.1.4 remarks and special observations */ 
PROC SORT data=RhT.epiocular_remarks out=remarks; BY chemical_code; RUN; 
DATA table414; 
   MERGE chemorder2 remarks(in=ok); 
   BY chemical_code; 
   IF ok; 
RUN; 
PROC SORT data=table414; BY laboratory filename rr; RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data analysis\Reports\Revision\EpiOcular_Table414.doc' 
notoc_data; 
PROC REPORT data = table414 NOWINDOWS HEADLINE HEADSKIP; 
  COLUMN filename order remark; 
  DEFINE filename/ GROUP width = 50 FLOW; 
  DEFINE order/ DISPLAY 'Chemical'; 
  DEFINE remark/ DISPLAY FLOW WIDTH = 50; 
RUN; QUIT; 




/* ---------------------------------------- */ 
/* Section 5 of SAP: Descriptive statistics */ 
/* ---------------------------------------- */ 
 
/* 5.1 chemical selection set: distribution of test chemicals */ 
ods listing close; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data analysis\Reports\Revision\EpiOcular_Table5_1.doc' 
notoc_data; 
PROC FREQ data=chemorder; 
   TABLES trueINI * LS/norow nocol; 
   /* 10082012 CdJ Revision */ 
   WHERE order NOT IN (106 107); 
RUN; 
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/* 5.2 Table with number and fraction of qualified and non_qualified runs */ 
PROC FREQ data=pre_all noprint; 
   TABLES conclusion/out=table5_2LAB; 
   BY laboratory; 
RUN; 
PROC FREQ data=pre_all noprint; 
   TABLES conclusion/out=table5_2TOTAL; 
RUN; 
DATA table5_2; 
   SET table5_2LAB table5_2TOTAL (in=ok); 
   IF ok THEN laboratory = 'Total'; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data analysis\Reports\Revision\EpiOcular_Table5_2.doc' 
notoc_data; 
PROC REPORT data = table5_2 NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS laboratory conclusion count percent; 
   DEFINE laboratory/GROUP; 
   DEFINE conclusion /DISPLAY 'Call'; 
   DEFINE count/ DISPLAY 'No.'; 
   DEFINE percent/DISPLAY width = 15 format=8.1 'Fraction (%)'; 
RUN;QUIT; 
ODS RTF close; 
 
OPTIONS PS=42 LS=120; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data analysis\Reports\Revision\EpiOcular_Table5_2LIST.doc' 
notoc_data; 
PROC REPORT data=pre_all (where=(conclusion IN (1 2)) keep = run order conclusion laboratory name TAqual PCqual NCqual color_call 
MTT_call) 
            NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS conclusion laboratory order run NCqual PCqual TAqual color_call MTT_call; 
   DEFINE conclusion / GROUP width = 15; 
   DEFINE laboratory / GROUP width = 15; 
   DEFINE order/DISPLAY width = 4 'Chemical'; 
   DEFINE color_call/DISPLAY width = 12; 
   BREAK after laboratory/SKIP; 
RUN; QUIT; 
ODS RTF close; 
 
 
/* 5.3 Table of chemicals within each run */ 
DATA pre5_3; 
   SET pre_all; 
   newvar = trim(left(put(order,3.)))||'('||trim(left(run))||')'; 
RUN; 
PROC SORT data=pre5_3; BY filename; RUN; 
PROC TRANSPOSE data=pre5_3 out=pre5_3t; 
   VAR newvar; 
   BY filename; 
RUN; 
DATA table5_3(drop=_name_); 
   SET pre5_3t; 
   IF _N_ < 51 THEN laboratory = 'Beiersdorf'; 
   ELSE IF _N_ > 93 THEN laboratory = 'IIVS'; 
   ELSE laboratory = 'Harlan'; 
RUN; 
OPTIONS PS=42 LS=150; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data analysis\Reports\Revision\EpiOcular_Table5_3.doc' 
notoc_data; 
PROC REPORT data = table5_3 NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS laboratory filename col1 col2 col3 col4 col5 col6 col7 col8 col9 col10; 
   DEFINE laboratory/GROUP; 
   DEFINE filename/ GROUP width = 25 FLOW; 
   DEFINE col1 / DISPLAY " " width=8; 
   DEFINE col2 / DISPLAY " " width=8; 
   DEFINE col3 / DISPLAY " " width=8; 
   DEFINE col4 / DISPLAY " " width=8; 
   DEFINE col5 / DISPLAY " " width=8; 
   DEFINE col6 / DISPLAY " " width=8; 
   DEFINE col7 / DISPLAY " " width=8; 
   DEFINE col8 / DISPLAY " " width=8; 
   DEFINE col9 / DISPLAY " " width=8; 
   DEFINE col10 / DISPLAY " " width=8; 
RUN;QUIT; 
ODS RTF close; 
 
/* 5.4 Table with number of tests within each test sequence */ 
OPTIONS PS=55 LS=80; 
PROC SORT data=pre_all; BY laboratory tmp2 run; RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data analysis\Reports\Revision\EpiOcular_Table5_4.doc' 
notoc_data; 
PROC FREQ data=pre_all ; 
   TABLES order*laboratory/out=table5_4 NOROW NOCOL NOPERCENT; 
RUN; 
ODS RTF close; 
 
/* 5.5 Table with list, no and fraction of NQ tests */ 
PROC SORT data=pre_all; 
BY laboratory order;  
RUN; 
PROC FREQ data=pre_all NOPRINT; 
   TABLES conclusion/out=table5_5; 
   BY laboratory order; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data analysis\Reports\Revision\EpiOcular_Table5_5.doc' 
notoc_data; 
PROC PRINT data=table5_5(WHERE=(CONCLUSION IN (1 2)));  
RUN; 
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ODS RTF close; 
 
/* 5.6 Table with list and fraction of complete test sequences */ 
DATA pre5_6; 
   SET pre_all; 
   IF conclusion IN (1 2) THEN DELETE; 
RUN; 
PROC FREQ data=pre5_6 noprint; 
   TABLES laboratory * order/out=pre5_6b; 
RUN; 
DATA table5_6LIST; 
   SET pre5_6b; 
   IF count >=3 THEN OUTPUT; 
RUN; 
PROC SORT data=pre5_6b; BY order; RUN; 
PROC TRANSPOSE data=pre5_6b out=table5_6LIST; 
   VAR COUNT; 
   ID laboratory; 
   BY order; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\Revision\EpiOcular_Table5_6LIST_TESTRINKE.doc' notoc_data; 
PROC PRINT data=table5_6LIST; RUN; 
ODS RTF close; 
PROC FREQ data=pre5_6b (rename=(count=aantal)); 
   TABLES aantal* laboratory/out=table5_6B; 
RUN; 
/* Above proc Freq statement doesn't work! adaption below gives desired results, it seems. */ 
/*adaption by rinke to test*/ 
 
/*PROC FREQ data=pre5_6b noprint;*/ 
/*   TABLES laboratory/out=table5_6B;*/ 
/*RUN;*/ 
 /* end adaption by rinke to test*/ 
 
DATA table5_6LAB; 
   SET table5_6B; 
   fraction_complete = 100*count/104; 
   test_sequence_criteria = 'not fulfilled'; 
   IF fraction_complete > 85 THEN test_sequence_criteria = 'fulfilled'; 
RUN; 
PROC MEANS data=table5_6LAB NOPRINT; 
   VAR count; 
   OUTPUT out=table5_6D sum=sumcount; 
RUN; 
DATA table5_6OVERALL; 
   SET table5_6D; 
   fraction_complete = 100*sumcount/(3*104); 
   test_sequence_criteria = 'not fulfilled'; 
   IF fraction_complete >= 85 THEN test_sequence_criteria = 'fulfilled'; 
RUN; 
DATA table5_6; 
   SET table5_6LAB table5_6OVERALL(in=ok); 
   IF ok then laboratory = 'Total'; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\Revision\EpiOcular_Table5_6_TESTRINKE.doc' notoc_data; 
PROC REPORT data = table5_6 NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS laboratory fraction_complete; 
   DEFINE laboratory/DISPLAY; 
   DEFINE fraction_complete/DISPLAY format=8.1 'Fraction'; 
RUN; QUIT; 
ODS rtf close; 
PROC DATASETS library = work; 
   DELETE pre5_6 pre5_6b table5_6B table5_6D; 
RUN;QUIT; 
 
/* 5.7 Table with list and fraction of incomplete test sequences */ 
 
DATA pre5_7a pre5_7b; 
   SET pre_all; 
   IF conclusion IN (1 2) THEN output pre5_7a; 
   IF conclusion NOT IN (1 2) THEN output pre5_7b; 
RUN; 
PROC FREQ data=pre5_7a noprint; 
   TABLES laboratory * order/out=pre5_7a2; 
RUN; 
PROC FREQ data=pre5_7b noprint; 
   TABLES laboratory * order/out=pre5_7b2; 
RUN; 
DATA pre5_7; 
   MERGE pre5_7a2(rename=(count=OUT)) pre5_7b2(rename=(count=IN)); 
   BY laboratory order; 
   IF IN NOT IN (. 0 1 2) THEN complete = 'Yes'; 
   IF IN IN (. 0 1 2) THEN complete = 'No'; 
RUN; 
DATA table5_7LIST; 
   SET pre5_7; 
   IF IN = . THEN IN = 0; 
   IF complete = 'No' THEN OUTPUT; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data analysis\Reports\Revision\EpiOcular_Table5_7LIST.doc' 
notoc_data; 
PROC REPORT data = table5_7LIST NOWINDOWS HEADLINE HEADSKIP; 
   COLUMN laboratory order IN OUT; 
   DEFINE laboratory/GROUP; 
   DEFINE order /DISPLAY ; 
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   DEFINE IN/DISPLAY 'Qualified' width = 10 CENTER; 
   DEFINE OUT/DISPLAY 'Non-Qual or Excluded' width = 20 CENTER; 
RUN; QUIT; 
ODS RTF close; 
PROC FREQ data=table5_7LIST noprint; 
   TABLES laboratory/out=table5_7b; 
RUN; 
DATA table5_7LAB; 
   SET table5_7B; 
   fraction_incomplete = 100*count/104; 
   test_sequence_criteria = 'fulfilled'; 
   IF fraction_incomplete > 15 THEN test_sequence_criteria = 'not fulfilled'; 
RUN; 
PROC MEANS data=table5_7LAB NOPRINT; 
   VAR count; 
   OUTPUT out=table5_7D sum=sumcount; 
RUN; 
DATA table5_7OVERALL; 
   SET table5_7D; 
   fraction_incomplete = 100*sumcount/(3*104); 
   test_sequence_criteria = 'fulfilled'; 
   IF fraction_incomplete > 15 THEN test_sequence_criteria = 'not fulfilled'; 
RUN; 
DATA table5_7; 
   SET table5_7LAB table5_7OVERALL(in=ok); 
   IF ok then laboratory = 'Total'; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data analysis\Reports\Revision\EpiOcular_Table5_7.doc' 
notoc_data; 
PROC REPORT data = table5_7 NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS laboratory fraction_incomplete; 
   DEFINE laboratory/DISPLAY; 
   DEFINE fraction_incomplete/DISPLAY format=8.1 'Fraction'; 
RUN; QUIT; 
ODS rtf close; 
PROC DATASETS library = work; 
   DELETE pre5_7 pre5_7b table5_7B table5_7D; 
RUN;QUIT; 
 
/* 5.8 statement whether test method has fulfilled the performance criteria */ 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data analysis\Reports\Revision\EpiOcular_Table5_8.doc' 
notoc_data; 
PROC REPORT data = table5_6 NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS laboratory fraction_complete test_sequence_criteria; 
   DEFINE laboratory/DISPLAY; 
   DEFINE fraction_complete/DISPLAY format=8.1 'Fraction'; 
   DEFINE test_sequence_criteria/DISPLAY 'Statement: criteria is ' CENTER; 
RUN; QUIT; 
ODS rtf close; 
 
/* 5.9 Summarise results for  NC and PC */ 
 
PROC SORT data=pre_all out=pre5_9(keep = laboratory protocol ODnc NCdiff meanPC PCdiff)  nodupkey; 
   BY laboratory filename;  
RUN; 
DATA pre5_9b; 
   SET pre5_9 pre5_9(in=set2); 
   IF set2 THEN laboratory = 'Total'; 
RUN; 
DATA pre5_9c; 
   RETAIN labstate ODnc NCdiff meanPC PCdiff;  
   SET pre5_9b; 
   IF protocol = 'Liquids' THEN labstate = TRIM(LEFT(laboratory)) || TRIM(LEFT('(L)')); 
   IF protocol = 'Solids' THEN labstate = TRIM(LEFT(laboratory)) ||  TRIM(LEFT('(S)')); 
RUN; 
PROC SORT data=pre5_9c out=pre5_9d; BY protocol labstate; RUN; 
* Plots and statistics in R; 
 
* TAdiff for qualified and non-qualified tests in figure like above; 
PROC SORT data=pre_all out=pre5_9(keep = laboratory protocol TAdiff conclusion)  nodupkey; 
   BY laboratory filename order run;  
RUN; 
DATA pre5_9b; 
   SET pre5_9 pre5_9(in=set2); 
   IF set2 THEN laboratory = 'Total'; 
   IF conclusion NOT IN (0 1) THEN DELETE; 
RUN; 
DATA pre5_9c; 
   RETAIN labstate TAdiff;  
   SET pre5_9b; 
   IF protocol = 'Liquids' THEN labstate = TRIM(LEFT(laboratory)) || TRIM(LEFT('(L)')); 
   IF protocol = 'Solids' THEN labstate = TRIM(LEFT(laboratory)) ||  TRIM(LEFT('(S)')); 
RUN; 
PROC SORT data=pre5_9c out=pre5_9d; BY protocol labstate; RUN; 
 
/* 5.10 summarise results of all tests (including NQ and excl) */ 
PROC SORT data=pre_all; BY laboratory name; RUN; 
DATA pre5_10; 
   SET pre_all(drop=test); 
   BY laboratory name; 
   RETAIN test 0; 
   test = test+1; 
   IF first.name THEN test=1; 
   IF conclusion = 1 THEN c = 0; 
   IF conclusion = 2 THEN c = 1; 
RUN; 
OPTIONS PS=42 LS=120; 
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ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data analysis\Reports\Revision\EpiOcular_Table5_10.doc' 
notoc_data; 
PROC REPORT data=pre5_10 NOWINDOWS HEADLINE HEADSKIP ; 
   COLUMNS laboratory order trueINI test, (viability TAdiff c); 
   DEFINE laboratory / GROUP width = 10; 
   DEFINE order / GROUP width=5 'Chemical'; 
   DEFINE trueINI / "GHS" GROUP width=5; 
   DEFINE test / ACROSS "test"; 
   DEFINE viability / ANALYSIS format=8.1 'Mean'; 
   DEFINE TAdiff / ANALYSIS format=8.1 'Diff'; 
   DEFINE c / "  " ANALYSIS width = 2 format=fmtc.; 
   BREAK after laboratory/SKIP; 
RUN; 
ODS RTF close; 
  
/* --------------------------------------------- */ 
/* Section 6 of SAP: Intralaboratory variability */ 
/* --------------------------------------------- */ 
 
/* at least two qualified tests */ 
PROC SORT data=pre_all; BY laboratory name; RUN; 
PROC FREQ data=pre_all noprint; 
   TABLES conclusion/out=pre_WLV; 
   BY laboratory name; 
RUN; 
DATA pre_WLV2; 
   SET pre_WLV (where=(conclusion = 0 AND count >=2)); 
RUN; 
DATA pre_WLV3; 
   MERGE pre_all(drop=test where=(conclusion NOT IN (1 2))) pre_WLV2 (in=ok); 
   BY laboratory name; 
   IF ok; 
   IF viability > 50 THEN predINI = 'NI'; 
   ELSE predINI = 'I'; 
   IF viability > 60 THEN predINI60 = 'NI'; 
   ELSE predINI60 = 'I'; 
RUN; 
DATA WLV;  
   SET pre_WLV3; 
   BY laboratory name; 
   RETAIN test 0; 
   test = test+1; 
   IF first.name THEN test=1; 
   IF test > 3 THEN DELETE; 
RUN; 
 
/* 6.1 Table with concordance of classifications */ 
PROC SORT data=WLV; BY laboratory name; RUN; 
PROC TRANSPOSE data=WLV out=pre6_1; 
   BY laboratory name order; 
   ID test; 
   VAR predINI; 
RUN; 
PROC FREQ data=WLV noprint; 
   TABLES predINI/out=pre6_1; 
   BY laboratory name order; 
RUN;  
DATA pre6_1b; 
   SET pre6_1; 
   IF percent NE 100 THEN WLV_concordant = 'NO '; 
   ELSE WLV_concordant = 'YES'; 
RUN; 
PROC SORT data=pre6_1b out=pre6_1c nodupkey; 
   BY laboratory name order; 
RUN; 
PROC FREQ data=pre6_1c noprint; 
   TABLES WLV_concordant/out=table6_1LAB; 
   BY laboratory;  
RUN; 
PROC FREQ data=pre6_1c noprint; 
   TABLES WLV_concordant/out=table6_1TOTAL; 
RUN; 
DATA table6_1; 
   SET table6_1LAB table6_1TOTAL(in=ok); 
   IF ok THEN laboratory = 'Total'; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data analysis\Reports\Revision\EpiOcular_Table6_1.doc' 
notoc_data; 
PROC REPORT data=table6_1 NOWINDOWS HEADLINE HEADSKIP ; 
   COLUMNS laboratory WLV_concordant count percent; 
   DEFINE laboratory / GROUP width = 10; 
   DEFINE WLV_concordant / DISPLAY width=15 'WLV concordant'; 
   DEFINE count / DISPLAY FLOW 'No.'; 
   DEFINE percent / DISPLAY format=8.1 'Fraction(%)' width = 12; 
   BREAK after laboratory/SKIP; 
RUN; 
ODS RTF close;  
 
/* 6.2 Additional descriptives of non-concordant results */ 
DATA pre6_2; 
   MERGE WLV pre6_1c(keep = laboratory name order WLV_concordant); 
   BY laboratory name order; 
RUN; 
/* 16082012 CdJ revision */  
DATA pre6_2b; 
   SET pre6_2(where=(WLV_concordant = 'NO ')); 
   KEEP laboratory order name LS coloring MTT predGHS viability test; 
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RUN; 
PROC SORT data=pre6_2b; BY laboratory order name test; 
PROC TRANSPOSE data=pre6_2b out=pre6_2t(drop=_name_); 
   BY laboratory order name LS coloring mTT predGHS; 
   VAR viability; 
   ID test; 
RUN; 
DATA table6_2; 
   RETAIN laboratory order name LS coloring mtt predGHS _1 _2 _3; 
   SET pre6_2t; 
RUN; 
* view in excel to create table for report; 
 
/* 6.3 Statement per laboratory regarding WLV */ 
DATA table6_3 ; 
   SET table6_1LAB table6_1TOTAL(in=total); 
   IF total THEN laboratory = 'Total'; 
   WHERE WLV_concordant = 'YES'; 
   WLV_criteria = 'not fulfilled'; 
   IF percent >= 85 THEN WLV_criteria = 'fulfilled'; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data analysis\Reports\Revision\EpiOcular_Table6_3.doc' 
notoc_data; 
PROC REPORT data=table6_3 NOWINDOWS HEADLINE HEADSKIP ; 
   COLUMNS laboratory percent WLV_criteria; 
   DEFINE laboratory / GROUP width = 10; 
   DEFINE WLV_criteria / DISPLAY width=15 'Statement: criteria is '; 
   DEFINE percent / DISPLAY format=8.1 'Fraction(%)' width = 12; 
RUN; 
ODS RTF close;  
 
/* 6.4 Pearson Correlations */ 
PROC SORT data=WLV; BY laboratory name; RUN; 
PROC TRANSPOSE data=WLV out=WLVt; 
   BY laboratory name; 
   ID test; 
   VAR viability; 
RUN; 
PROC CORR data=WLVt noprint outp=pearson outs=spearman; 
   VAR _1 _2 _3; 
   BY laboratory; 
RUN; 
/*PROC GPLOT data=WLVt; */ 
/*   PLOT _1 * _2 _1 * _3 _2 * _3;*/ 
/*   BY laboratory;*/ 
/*RUN; QUIT;*/ 
DATA set1 (keep=laboratory _name_ _1 where=(_name_ NE '_1'))  
     set2 (keep=laboratory _name_ _2 where=(_name_ NE '_2'))  ; 
   SET pearson; 
   WHERE _TYPE_ = 'CORR'; 
RUN; 
PROC TRANSPOSE data=set1 out=set1T(drop=_name_) prefix = _1; 
   VAR _1; 
   BY laboratory; 
   ID _name_; 
RUN; 
PROC TRANSPOSE data=set2 out=set2T(drop=_name_) prefix = _2; 
   VAR _2; 
   BY laboratory; 
   ID _name_; 
RUN; 
DATA pre_pearson(drop=_2_1); 
   MERGE set1T set2T; 
   BY laboratory; 
   FORMAT _1_2 _1_3 _2_3 8.3; 
RUN; 
 
DATA set1 (keep=laboratory _name_ _1 where=(_name_ NE '_1'))  
     set2 (keep=laboratory _name_ _2 where=(_name_ NE '_2'))  ; 
   SET spearman; 
   WHERE _TYPE_ = 'CORR'; 
RUN; 
PROC TRANSPOSE data=set1 out=set1T(drop=_name_) prefix = _1; 
   VAR _1; 
   BY laboratory; 
   ID _name_; 
RUN; 
PROC TRANSPOSE data=set2 out=set2T(drop=_name_) prefix = _2; 
   VAR _2; 
   BY laboratory; 
   ID _name_; 
RUN; 
DATA pre_spearman(drop=_2_1); 
   MERGE set1T set2T; 
   BY laboratory; 




   SET pre_pearson (in=p) pre_spearman (in=s); 
   BY laboratory; 
   IF s THEN corr = 'spearman'; 
   IF p THEN corr = 'pearson'; 
RUN; 
PROC SORT data=pre6_4; BY corr; RUN; 
PROC MEANS data=pre6_4 noprint; 
   VAR _1_2 _1_3 _2_3; 
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   BY corr; 




   SET pre6_4 pre6_4b(in=m); 
   IF m THEN laboratory = 'Mean'; 
   IF laboratory = 'Beiersdorf' THEN tmp1 = 1; 
   IF laboratory = 'Harlan' THEN tmp1 = 2; 
   IF laboratory = 'IIVS' THEN tmp1 = 3; 
   IF laboratory = 'Mean' THEN tmp1 = 4; 
RUN;  
PROC SORT data=pretable6_4 out=table6_4(drop=tmp1 _type_ _freq_); BY corr tmp1; RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data analysis\Reports\Revision\EpiOcular_Table6_4.doc' 
notoc_data; 
PROC REPORT data=table6_4 NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS corr laboratory _1_2 _1_3 _2_3; 
   DEFINE corr / GROUP; 
   DEFINE laboratory/DISPLAY width = 15; 
   DEFINE _1_2/ DISPLAY 'Qual1 - Qual2' format=8.3 width = 15 CENTER; 
   DEFINE _1_3/ DISPLAY 'Qual1 - Qual3' format=8.3 width = 15 CENTER; 
   DEFINE _2_3/ DISPLAY 'Qual2 - Qual3' format=8.3 width = 15 CENTER; 
   BREAK after corr/SKIP; 
RUN; QUIT; 
ODS RTF close; 
 
/* 6.5 mean and mean diff */ 
PROC MEANS data=WLV noprint; 
   VAR viability; 
   CLASS laboratory name order;  
   OUTPUT out=table6_5(where=(_type_=7)) mean=means std=stds cv=cvs n=ns; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data analysis\Reports\Revision\EpiOcular_Table6_5.doc' 
notoc_data; 
PROC REPORT data=table6_5 NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS order laboratory,(means stds cvs ns); 
   DEFINE order / GROUP width = 5 'Chemical'; 
   DEFINE laboratory/ACROSS "_laboratory_"; 
   DEFINE means/ANALYSIS mean format=8.1 CENTER 'mean'; 
   DEFINE stds/ANALYSIS mean format=8.1 CENTER 'std'; 
   DEFINE cvs/ANALYSIS mean format=8.1 CENTER 'cv'; 
   DEFINE ns/ANALYSIS mean width=3 CENTER 'n'; 
RUN; QUIT; 
ODS RTF close; 
 
* also with non-qualified tests included; 
DATA inclnonqual; 
   SET pre_all(where=(conclusion NE 2)); 
RUN; 
PROC MEANS data=inclnonqual noprint; 
   VAR viability; 
   CLASS laboratory name order;  
   OUTPUT out=table6_5b(where=(_type_=7)) mean=meansnq std=stdsnq cv=cvsnq n=nsnq; 
RUN; 
DATA table6_5c; 
   MERGE table6_5 table6_5b; 
   BY laboratory name order; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data analysis\Reports\Revision\EpiOcular_Table6_5b.doc' 
notoc_data; 
PROC REPORT data=table6_5c NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS order laboratory,(("_Q_" stds cvs ns) ("_Q+NQ_" stdsnq cvsnq nsnq)); 
   DEFINE order / GROUP width = 5 'Chemical'; 
   DEFINE laboratory/ACROSS "_laboratory_"; 
   DEFINE stds/ANALYSIS mean format=8.1 CENTER 'std'; 
   DEFINE cvs/ANALYSIS mean format=8.1 CENTER 'cv'; 
   DEFINE ns/ANALYSIS mean width=3 CENTER 'n'; 
   DEFINE stdsnq/ANALYSIS mean format=8.1 CENTER 'std'; 
   DEFINE cvsnq/ANALYSIS mean format=8.1 CENTER 'cv'; 
   DEFINE nsnq/ANALYSIS mean width=3 CENTER 'n'; 
RUN; QUIT; 
ODS RTF close; 
 
 
/* --------------------------------------------- */ 
/* Section 7 of SAP: Interlaboratory variability */ 
/* --------------------------------------------- */ 
 
/* at least one qualified tests per laboratory*/ 
PROC SORT data=pre_all; BY laboratory name; RUN; 
PROC FREQ data=pre_all noprint; 
   TABLES conclusion/out=pre_BLV; 
   BY laboratory name; 
RUN; 
DATA pre_BLV2; 
   SET pre_BLV (where=(conclusion = 0 AND count >=1)); 
RUN; 
PROC SORT data=pre_BLV2; BY name; RUN: 
PROC TRANSPOSE data=pre_BLV2 out=pre_BLV2t; 
   VAR count;  
   ID laboratory; 
   BY name; 
RUN; 
DATA pre_BLV2t2; 
   SET pre_BLV2t; 
   IF Beiersdorf IN (0 .) OR Harlan IN (0 .) OR IIVS IN (0 .) THEN DELETE; 
RUN;  
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PROC SORT data=pre_all; BY name; RUN; 
DATA pre_BLV3; 
   MERGE pre_all(drop=test where=(conclusion NOT IN (1 2))) pre_BLV2t2 (in=ok); 
   BY name; 
   IF ok; 
   IF viability > 50 THEN predINI = 'NI'; 
   ELSE predINI = 'I'; 
RUN; 
PROC SORT data=pre_BLV3; BY laboratory name; RUN; 
DATA BLV;  
   SET pre_BLV3; 
   BY laboratory name; 
   RETAIN test 0; 
   test = test+1; 
   IF first.name THEN test=1; 
   IF test > 3 THEN DELETE; 
RUN; 
 
/* 7.1 Table with means, std, cv and pred */ 
PROC MEANS data=BLV noprint; 
   CLASS laboratory name order; 
   VAR viability; 
   OUTPUT out=pre7_1(where=(_type_ = 7)) mean = meanlab std = stdlab cv=cvlab n=nlab; 
RUN; 
PROC MEANS data=pre7_1 noprint; 
   CLASS name order; 
   VAR stdlab; 
   OUTPUT out=table7_1(where=(_type_ = 3)) mean = means std = stds cv=cvs n=ns; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data analysis\Reports\Revision\EpiOcular_Table7_1.doc' 
notoc_data; 
PROC REPORT data=table7_1 NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS order  means stds cvs; 
   DEFINE order / GROUP width = 5 'Chemical'; 
   DEFINE means/ANALYSIS mean format=8.1 CENTER 'mean SD'; 
   DEFINE stds/ANALYSIS mean format=8.1 CENTER 'std SD'; 
   DEFINE cvs/ANALYSIS mean format=8.1 CENTER 'cv SD'; 
RUN; QUIT; 
ODS RTF close; 
DATA table7_1b; 
   SET pre7_1; 
   IF meanlab > 50 THEN finalINI = 0; 
   ELSE finalINI = 1; 
   FORMAT finalINI fmtINI.; 
RUN; 
 
/* 7.1 Table with means, std, cv and pred - including NQ as well*/ 
PROC SORT data=pre_all; BY name; RUN; 
DATA pre_BLV3_NQ; 
   MERGE pre_all(drop=test where=(conclusion NOT IN ( 2))) pre_BLV2t2 (in=ok); 
   BY name; 
   IF ok; 
   IF viability > 50 THEN predINI = 'NI'; 
   ELSE predINI = 'I'; 
RUN; 
PROC SORT data=pre_BLV3_NQ; BY laboratory name; RUN; 
DATA BLV_NQ;  
   SET pre_BLV3_NQ; 
   BY laboratory name; 
   RETAIN test 0; 
   test = test+1; 
   IF first.name THEN test=1; 
   *IF test > 3 THEN DELETE; 
RUN; 
 
PROC MEANS data=BLV_NQ noprint; 
   CLASS laboratory name order; 
   VAR viability; 
   OUTPUT out=pre7_1_NQ(where=(_type_ = 7)) mean = meanlab std = stdlab cv=cvlab n=nlab; 
RUN; 
PROC MEANS data=pre7_1_NQ noprint; 
   CLASS name order; 
   VAR stdlab; 
   OUTPUT out=table7_1_NQ(where=(_type_ = 3)) mean = means std = stds cv=cvs n=ns; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data analysis\Reports\Revision\EpiOcular_Table7_1_NQ.doc' 
notoc_data; 
PROC REPORT data=table7_1_NQ NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS order  means stds cvs; 
   DEFINE order / GROUP width = 5 'Chemical'; 
   DEFINE means/ANALYSIS mean format=8.1 CENTER 'mean SD'; 
   DEFINE stds/ANALYSIS mean format=8.1 CENTER 'std SD'; 
   DEFINE cvs/ANALYSIS mean format=8.1 CENTER 'cv SD'; 
RUN; QUIT; 
ODS RTF close; 
 
/* 7.2 concordance final classifications */ 
PROC SORT data=table7_1b out=pre7_2; BY name order; RUN; 
PROC FREQ data=pre7_2 noprint;  
   TABLES finalINI/out=pre7_2b; 
   BY name order; 
RUN; 
DATA pre7_2c; 
   SET pre7_2b; 
   IF percent NE 100 THEN BLV_concordant = 'NO '; 
   ELSE BLV_concordant = 'YES'; 
RUN; 
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PROC SORT data=pre7_2c out=pre7_2d nodupkey; 
   BY name order;  
RUN; 
DATA pre7_2e; 
   MERGE pre7_2d pre7_2; 
   BY name order; 
RUN; 
PROC SORT data=BLV; BY laboratory name order; RUN; 
PROC SORT data=pre7_2e; BY laboratory name order; RUN; 
DATA pre7_2f; 
   MERGE BLV(where=(test=1)) pre7_2e(keep = laboratory name order BLV_concordant meanlab); 
   BY laboratory name order; 
RUN; 
DATA pre7_2g; 
   SET pre7_2f(where=(BLV_concordant = 'NO ')); 
   KEEP laboratory order name LS coloring MTT predGHS meanlab; 
RUN; 
PROC SORT data=pre7_2g; BY order name order name LS coloring mTT predGHS; RUN; 
PROC TRANSPOSE data=pre7_2g out=pre7_2t(drop=_name_); 
   BY order name LS coloring mTT predGHS; 
   VAR meanlab; 
   ID laboratory; 
RUN; 
DATA table7_2; 
   RETAIN order name LS coloring mtt predGHS Beiersdorf Harlan IIVS; 
   SET pre7_2t; 
RUN; 
* view in excel to create table for report; 
 
/* 7.3 descriptive statistics non-concordant results */ 
* see 7.2 ; 
 
/* 7.4 statement regarding BLV */ 
PROC FREQ data=pre7_2d; 
   TABLES BLV_concordant/out=tmp; 
RUN; 
DATA table7_4 ; 
   SET tmp; 
   WHERE BLV_concordant = 'YES'; 
   BLV_criteria = 'not fulfilled'; 
   IF percent >= 80 THEN BLV_criteria = 'fulfilled'; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data analysis\Reports\Revision\EpiOcular_Table7_4.doc' 
notoc_data; 
PROC REPORT data=table7_4 NOWINDOWS HEADLINE HEADSKIP ; 
   COLUMNS percent BLV_criteria; 
   DEFINE BLV_criteria / DISPLAY width=15 'Statement: criteria is '; 
   DEFINE percent / DISPLAY format=8.1 'Fraction(%)' width = 12; 
RUN; 
ODS RTF close;  
 
/* 7.5&7.6  Two-way ANOVA with laboratory and chemicals as factor */ 
DATA pre7_5; 
   SET pre7_1 (keep = laboratory name order meanlab); 
   IF meanlab NE 0 THEN meanlog = log(meanlab); 
RUN; 
ODS trace off; 
ODS listing close; 
PROC MIXED data=pre7_5; 
   CLASS laboratory name; 
   MODEL meanlog = laboratory name /outp=tmp1; 
   LSMEANS laboratory/pdiff cl adjust=tukey; 
   ODS OUTPUT tests3 = table7_5; 
   ODS OUTPUT lsmeans = table7_5partial; 
   ODS OUTPUT diffs = table7_6; 
   ODS OUTPUT covparms = covparms; 
RUN; 
ODS listing; 
PROC GPLOT data=tmp1; 
   PLOT resid * pred; 
RUN;QUIT; 
DATA pre7_5_nooutlier (drop=tmp0) table7_5_outliers(drop=tmp0); 
   MERGE tmp1 covparms; 
   RETAIN tmp0; 
   IF estimate NE . THEN tmp0 = estimate; ELSE estimate = tmp0; 
   IF abs(resid) <= 3*sqrt(estimate) THEN OUTPUT pre7_5_nooutlier;  
   ELSE OUTPUT table7_5_outliers; 
RUN; 
ODS listing close; 
PROC MIXED data=pre7_5_nooutlier; 
   CLASS laboratory name; 
   MODEL meanlog = laboratory name /outp=tmp1; 
   LSMEANS laboratory/pdiff cl adjust=tukey; 
   ODS OUTPUT tests3 = table7_5; 
   ODS OUTPUT lsmeans = table7_5partial; 
   ODS OUTPUT diffs = table7_6; 
   ODS OUTPUT covparms = covparms; 
RUN; 
ODS listing; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\Revision\EpiOcular_Table7_5residualplot.doc' notoc_data; 
PROC GPLOT data=tmp1; 
   PLOT resid * pred; 
RUN;QUIT; 
ODS RTF close; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data analysis\Reports\Revision\EpiOcular_Table7_5.doc' 
notoc_data; 
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PROC PRINT data=table7_5 NOOBS; RUN; 
ODS RTF close; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data analysis\Reports\Revision\EpiOcular_Table7_6.doc' 
notoc_data; 
PROC REPORT data=table7_6 NOWINDOWS HEADLINE HEADSKIP ; 
   COLUMNS laboratory _laboratory estimate stderr DF adjP; 
   DEFINE laboratory / DISPLAY; 
   DEFINE _laboratory /DISPLAY 'vs'; 
   DEFINE estimate/DISPLAY; 
   DEFINE stderr/DISPLAY; 
   DEFINE DF/DISPLAY; 
   DEFINE adjP/DISPLAY 'Tukey-corrected p-value' width=15; 
RUN; 
ODS RTF close; 
 
/* 7.7 Pearson correlations */ 
PROC SORT data=pre7_1; BY name; RUN; 
PROC TRANSPOSE data=pre7_1 out=pre7_7; 
   BY name; 
   ID laboratory; 
   VAR meanlab; 
RUN; 
PROC CORR data=pre7_7 noprint outp=pearson outs=spearman; 
   VAR Beiersdorf Harlan IIVS; 
RUN; 
/*PROC GPLOT data=pre7_7; */ 
/*   PLOT Beiersdorf * Harlan Beiersdorf * IIVS Harlan * IIVS;*/ 
/*RUN; QUIT;*/ 
DATA set1p (keep= _name_ Beiersdorf where=(_name_ NE 'Beiersdorf'))  
     set2p (keep= _name_ Harlan where=(_name_ NE 'Harlan'))  ; 
   SET pearson; 
   WHERE _TYPE_ = 'CORR'; 
RUN; 
DATA pre_pearson7_7(keep = laboratories pearson); 
   SET set1p(in=s1 rename=(Beiersdorf = pearson)) set2p(in=s2 rename=(Harlan = pearson)); 
   IF s1 THEN with = 'Beiersdorf'; 
   IF s2 THEN with = 'Harlan'; 
   IF _name_ = 'Beiersdorf' THEN DELETE; 
   Laboratories = TRIM(LEFT(with))||'-'||TRIM(LEFT(_name_)); 
RUN; 
DATA set1s (keep= _name_ Beiersdorf where=(_name_ NE 'Beiersdorf'))  
     set2s (keep= _name_ Harlan where=(_name_ NE 'Harlan'))  ; 
   SET spearman; 
   WHERE _TYPE_ = 'CORR'; 
RUN; 
DATA pre_spearman7_7(keep = laboratories spearman); 
   SET set1s(in=s1 rename=(Beiersdorf = spearman)) set2s(in=s2 rename=(Harlan = spearman)); 
   IF s1 THEN with = 'Beiersdorf'; 
   IF s2 THEN with = 'Harlan'; 
   IF _name_ = 'Beiersdorf' THEN DELETE; 
   Laboratories = TRIM(LEFT(with))||'-'||TRIM(LEFT(_name_)); 
RUN; 
DATA table7_7; 
   RETAIN laboratories pearson spearman; 
   MERGE pre_pearson7_7 pre_spearman7_7; 
   BY laboratories; 
   FORMAT pearson spearman 8.3; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data analysis\Reports\Revision\EpiOcular_Table7_7.doc' 
notoc_data; 
PROC REPORT data=table7_7 NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS laboratories pearson spearman; 
   DEFINE laboratories / DISPLAY; 
   DEFINE pearson/ DISPLAY  format=8.3 width = 15 CENTER; 
   DEFINE spearman/ DISPLAY format=8.3 width = 15 CENTER; 
RUN; QUIT; 
ODS RTF close; 
 
/* ------------------------------------- */ 
/* Section 8 of SAP: Predictive capacity */ 
/* ------------------------------------- */ 
 
PROC SORT data= pre_all; BY laboratory name; RUN; 
DATA PCA; 
   SET pre_all (drop=test); 
   BY laboratory name; 
   WHERE conclusion = 0; 
   RETAIN test 0; 
   test = test+1; 
   IF first.name THEN test=1; 
   IF test>3 THEN DELETE; 
   IF viability > 50 THEN predINI = 'NI'; 
   ELSE predINI = 'I'; 
RUN; 
/* 8.1 sens, spec, acc */ 
%MACRO predmodel(lab=, output=); 
DATA pre8_1; 
   SET PCA; 
   %IF &lab NE %THEN %DO; 
      WHERE laboratory = &lab; 
   %END; 
   IF trueINI = 'I' THEN DO; 
      IF predINI = 'I' THEN result = 'TP'; 
   ELSE IF predINI = 'NI' THEN result = 'FN'; 
   END; 
   ELSE IF trueINI = 'NI' THEN DO; 
      IF predINI = 'NI' THEN result = 'TN'; 
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   ELSE IF predINI = 'I' THEN result = 'FP'; 
   END; 
RUN; 
PROC SORT data=pre8_1; 
   BY trueINI predINI; 
RUN; 
DATA pre8_1b (drop=result); 
   SET pre8_1; 
   BY trueINI; 
   retain tp tn fp fn; 
   if (first.trueINI) then do; 
      tp=0; tn=0; fp=0; fn=0; 
   end; 
   if (result in ("TP")) then tp=tp+1; 
   if (result in ("TN")) then tn=tn+1; 
   if (result in ("FN")) then fn=fn+1; 
   if (result in ("FP")) then fp=fp+1; 
   else ; 
   if (last.trueINI) then output; 
run; 
DATA pre8_1C; 
   SET pre8_1B; 
   tntp=tn+tp; 
   fnfp=fn+fp; 
RUN; 
PROC SQL; 
   CREATE TABLE pre8_1D as 
   select sum(tp) as tp, sum(tn) as tn, sum(fp)as fp, sum(fn) as fn, sum(tntp) as 
          tntp, sum(fnfp) as fnfp 
   from pre8_1C; 
QUIT; 
PROC SQL; 
   CREATE TABLE pre8_1E as 
   select tp/(tp+fn) as sensitivity, tn/(tn+fp) as specificity, 
         (tn+tp)/(tn+tp+fn+fp) as accuracy 
    from pre8_1D; 
QUIT; 
PROC TRANSPOSE data=pre8_1D out=pre8_1F; 
   VAR tp tn fn fp tntp fnfp; 
RUN; 
DATA pre8_1G (drop=_name_ col1); 
   LENGTH group $20; 
   SET pre8_1F; 
   count=col1; 
   if _name_="tp" then do; 
      group="Sensitivity"; 
      response=0; 
      output; 
   end; 
   else if _name_="fn" then do; 
      group="Sensitivity"; 
      response=1; 
      output; 
   end; 
   else if _name_="tn" then do; 
      group="Specificity"; 
      response=0; 
      output; 
   end; 
   else if _name_="fp" then do; 
      group="Specificity"; 
      response=1; 
      output; 
   end; 
   else if _name_="tntp" then do; 
      group="Accuracy"; 
      response=0; 
      output; 
   end; 
   else if _name_="fnfp" then do; 
      group="Accuracy"; 
      response=1; 
      output; 
   end; 
RUN; 
PROC SORT data=pre8_1G; BY group; RUN; 
ODS trace off; 
ODS listing close; 
PROC FREQ data= pre8_1G; 
   WEIGHT count; 
   BY group; 
   TABLES response/alpha=0.05 binomial(p=0.5); 
   exact binomial; 




   SET pre8_1CI; 
   WHERE name1 IN ('_BIN_' 'XL_BIN' 'XU_BIN'); 
RUN; 
PROC TRANSPOSE data=pre8_1TOTAL out=pre8_1TOTALt; 
   VAR nvalue1; 
   ID name1; 
   BY group; 
RUN; 
PROC TRANSPOSE data=pre8_1G out=pre8_1H; 
   VAR count; 
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   ID response; 
   BY group; 
RUN; 
DATA &output; 
   MERGE pre8_1TOTALt pre8_1H; 








DATA table8_1 (keep = group laboratory _BIN_ XL_BIN XU_BIN abs); 
   SET table8_1BDF (in=set1) table8_1HARLAN (in=set2) 
       table8_1IIVS (in=set3) table8_1TOTAL (in=set4); 
   IF set1 THEN laboratory = 'Beiersdorf'; 
   IF set2 THEN laboratory = 'Harlan'; 
   IF set3 THEN laboratory = 'IIVS'; 
   IF set4 THEN laboratory = 'Total'; 
   x = PUT(_1,$3.); 
   y = PUT(_0+_1,$3.); 
   abs = x||'/'||y; 
RUN; 
* report @8.2; 
 
/* 8.2 statement regarding predictive capacity */ 
DATA table8_2; 
   SET table8_1; 
   LENGTH PC_criteria $25; 
   IF group = 'Sensitivity' THEN DO; 
      PC_criteria = 'further evaluation'; 
      IF _BIN_ >= 0.90 THEN PC_criteria = 'definitely acceptable'; 
      IF _BIN_ <= 0.80 THEN PC_criteria = 'definitely unacceptable'; 
   END; 
   IF group = 'Specificity' THEN DO; 
      PC_criteria = 'further evaluation'; 
      IF _BIN_ >= 0.60 THEN PC_criteria = 'definitely acceptable'; 
      IF _BIN_ <= 0.50 THEN PC_criteria = 'definitely unacceptable'; 
   END; 
   IF group = 'Accuracy' THEN DO; 
      PC_criteria = 'further evaluation'; 
      IF _BIN_ >= 0.75 THEN PC_criteria = 'definitely acceptable'; 
      IF _BIN_ <= 0.65 THEN PC_criteria = 'definitely unacceptable'; 
   END; 
RUN; 
 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data analysis\Reports\Revision\EpiOcular_Table8_1.doc' 
notoc_data; 
PROC REPORT data=table8_2 NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS laboratory group abs _BIN_ XL_BIN XU_BIN PC_criteria; 
   DEFINE laboratory/GROUP; 
   DEFINE group/DISPLAY 'Characteristic' width = 15;  
   DEFINE abs/DISPLAY 'No.'; 
   DEFINE _BIN_/DISPLAY 'Value' format=8.3 CENTER; 
   DEFINE XL_BIN/DISPLAY '95% lower limit'  format=8.3 width=15 CENTER; 
   DEFINE XU_BIN/DISPLAY '95% upper limit' format=8.3 width=15 CENTER; 
   DEFINE PC_criteria/DISPLAY 'Statement' width = 25; 
   BREAK after laboratory/SKIP; 
RUN; QUIT; 
ODS RTF close; 
 
/* 8.3 sens, spec, acc per subgroup */ 
%MACRO predmodel2(lab=, output=, state=); 
DATA pre8_1 %IF &state NE %THEN %DO; (WHERE=(LS =&state)) %END; ; 
   SET PCA; 
   %IF &lab NE %THEN %DO; 
      WHERE laboratory = &lab; 
   %END; 
   IF trueINI = 'I' THEN DO; 
      IF predINI = 'I' THEN result = 'TP'; 
   ELSE IF predINI = 'NI' THEN result = 'FN'; 
   END; 
   ELSE IF trueINI = 'NI' THEN DO; 
      IF predINI = 'NI' THEN result = 'TN'; 
   ELSE IF predINI = 'I' THEN result = 'FP'; 
   END; 
RUN; 
PROC SORT data=pre8_1; 
   BY trueINI predINI; 
RUN; 
DATA pre8_1b (drop=result); 
   SET pre8_1; 
   BY trueINI; 
   retain tp tn fp fn; 
   if (first.trueINI) then do; 
      tp=0; tn=0; fp=0; fn=0; 
   end; 
   if (result in ("TP")) then tp=tp+1; 
   if (result in ("TN")) then tn=tn+1; 
   if (result in ("FN")) then fn=fn+1; 
   if (result in ("FP")) then fp=fp+1; 
   else ; 
   if (last.trueINI) then output; 
run; 
DATA pre8_1C; 
   SET pre8_1B; 
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   tntp=tn+tp; 
   fnfp=fn+fp; 
RUN; 
PROC SQL; 
   CREATE TABLE pre8_1D as 
   select sum(tp) as tp, sum(tn) as tn, sum(fp)as fp, sum(fn) as fn, sum(tntp) as 
          tntp, sum(fnfp) as fnfp 
   from pre8_1C; 
QUIT; 
PROC SQL; 
   CREATE TABLE pre8_1E as 
   select tp/(tp+fn) as sensitivity, tn/(tn+fp) as specificity, 
         (tn+tp)/(tn+tp+fn+fp) as accuracy 
    from pre8_1D; 
QUIT; 
PROC TRANSPOSE data=pre8_1D out=pre8_1F; 
   VAR tp tn fn fp tntp fnfp; 
RUN; 
DATA pre8_1G (drop=_name_ col1); 
   LENGTH group $20; 
   SET pre8_1F; 
   count=col1; 
   if _name_="tp" then do; 
      group="Sensitivity"; 
      response=0; 
      output; 
   end; 
   else if _name_="fn" then do; 
      group="Sensitivity"; 
      response=1; 
      output; 
   end; 
   else if _name_="tn" then do; 
      group="Specificity"; 
      response=0; 
      output; 
   end; 
   else if _name_="fp" then do; 
      group="Specificity"; 
      response=1; 
      output; 
   end; 
   else if _name_="tntp" then do; 
      group="Accuracy"; 
      response=0; 
      output; 
   end; 
   else if _name_="fnfp" then do; 
      group="Accuracy"; 
      response=1; 
      output; 
   end; 
RUN; 
PROC SORT data=pre8_1G; BY group; RUN; 
ODS trace off; 
ODS listing close; 
PROC FREQ data= pre8_1G; 
   WEIGHT count; 
   BY group; 
   TABLES response/alpha=0.05 binomial(p=0.5); 
   exact binomial; 




   SET pre8_1CI; 
   WHERE name1 IN ('_BIN_' 'XL_BIN' 'XU_BIN'); 
RUN; 
PROC TRANSPOSE data=pre8_1TOTAL out=pre8_1TOTALt; 
   VAR nvalue1; 
   ID name1; 
   BY group; 
RUN; 
PROC TRANSPOSE data=pre8_1G out=pre8_1H; 
   VAR count; 
   ID response; 
   BY group; 
RUN; 
DATA &output; 
   MERGE pre8_1TOTALt pre8_1H; 












DATA table8_3 (keep = group laboratory state abs _BIN_ XL_BIN XU_BIN); 
   SET table8_1BDF_L (in=set1) table8_1HARLAN_L (in=set2) 
       table8_1IIVS_L (in=set3) table8_1TOTAL_L (in=set4)  
       table8_1BDF_S (in=set1b) table8_1HARLAN_S (in=set2b) 
       table8_1IIVS_S (in=set3b) table8_1TOTAL_S (in=set4b); 
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   IF set1 OR set1b THEN laboratory = 'Beiersdorf'; 
   IF set2 OR set2b THEN laboratory = 'Harlan'; 
   IF set3 OR set3b THEN laboratory = 'IIVS'; 
   IF set4 OR set4b THEN laboratory = 'Total'; 
   IF set1 OR set2 OR set3 OR set4 THEN state='Liquid'; 
   IF set1b OR set2b OR set3b OR set4b THEN state='Solid'; 
      x = PUT(_1,$3.); 
   y = PUT(_0+_1,$3.); 




   SET table8_3; 
   LENGTH PC_criteria $25; 
   IF group = 'Sensitivity' THEN DO; 
      PC_criteria = 'Further evaluation'; 
      IF _BIN_ >= 0.90 THEN PC_criteria = 'definitely acceptable'; 
      IF _BIN_ <= 0.80 THEN PC_criteria = 'definitely unacceptable'; 
   END; 
   IF group = 'Specificity' THEN DO; 
      PC_criteria = 'Further evaluation'; 
      IF _BIN_ >= 0.60 THEN PC_criteria = 'definitely acceptable'; 
      IF _BIN_ <= 0.50 THEN PC_criteria = 'definitely unacceptable'; 
   END; 
   IF group = 'Accuracy' THEN DO; 
      PC_criteria = 'Further evaluation'; 
      IF _BIN_ >= 0.75 THEN PC_criteria = 'definitely acceptable'; 
      IF _BIN_ <= 0.65 THEN PC_criteria = 'definitely unacceptable'; 
   END; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data analysis\Reports\Revision\EpiOcular_Table8_3.doc' 
notoc_data; 
PROC REPORT data=table8_3b(where=(state='Liquid')) NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS  laboratory group abs _BIN_ XL_BIN XU_BIN PC_criteria; 
   DEFINE laboratory/GROUP; 
   DEFINE abs / DISPLAY 'No.'; 
   DEFINE group/DISPLAY 'Characteristic' width = 15;  
   DEFINE _BIN_/DISPLAY 'Value' format=8.3 CENTER; 
   DEFINE XL_BIN/DISPLAY '95% lower limit'  format=8.3 width=15 CENTER; 
   DEFINE XU_BIN/DISPLAY '95% upper limit' format=8.3 width=15 CENTER; 
   DEFINE PC_criteria/DISPLAY 'Statement' width = 25; 
   BREAK after laboratory/SKIP; 
RUN; QUIT; 
PROC REPORT data=table8_3b(where=(state='Solid')) NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS  laboratory group abs _BIN_ XL_BIN XU_BIN PC_criteria; 
   DEFINE laboratory/GROUP; 
   DEFINE abs / DISPLAY 'No.'; 
   DEFINE group/DISPLAY 'Characteristic' width = 15;  
   DEFINE _BIN_/DISPLAY 'Value' format=8.3 CENTER; 
   DEFINE XL_BIN/DISPLAY '95% lower limit'  format=8.3 width=15 CENTER; 
   DEFINE XU_BIN/DISPLAY '95% upper limit' format=8.3 width=15 CENTER; 
   DEFINE PC_criteria/DISPLAY 'Statement' width = 25; 
   BREAK after laboratory/SKIP; 
RUN; QUIT; 
ODS RTF close; 
 
/* --------------------------------------------- */ 
/* Section 9 of SAP: Summary and recommendations */ 
/* --------------------------------------------- */ 
 
* in report; 
 
/* ---------------------- */ 
/* Additional tables */ 
/* --------------------- */ 
 
* some chemicals are treated differently by the labs concerning the coloring or mtt; 
PROC SORT data=pre_all out=extra0s (keep = order name laboratory mtt coloring) nodupkey; 
   BY order laboratory mtt coloring; 
RUN; 
PROC TRANSPOSE data=extra0s out=extra0a; 
   VAR mtt; 
   BY order name; 
   ID laboratory; 
RUN;  
DATA extra0_mtt(keep = order name beiersdorf harlan iivs mttcheck) ; 
   SET extra0a ; 
   BY order; 
   mttcheck = 'not ok'; 
   IF beiersdorf = harlan AND beiersdorf = IIVS and harlan = IIVS THEN mttcheck = ' '; 
   ELSE mttcheck = '#'; 
   *IF mttcheck = 'not ok' THEN OUTPUT; 
RUN; 
PROC TRANSPOSE data=extra0s out=extra0b; 
   VAR coloring; 
   BY order name; 
   ID laboratory; 
RUN;  
DATA extra0_color( keep = order name beiersdorf harlan iivs colorcheck); 
   SET  extra0b; 
   BY order; 
   colorcheck = 'not ok'; 
   IF beiersdorf = harlan AND beiersdorf = IIVS and harlan = IIVS THEN colorcheck = ' '; 
   ELSE colorcheck = '#'; 
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 * falsepos/falseneg; 
PROC SORT data=PCA; BY order predGHS; RUN; 
DATA PCA2; 
   SET PCA; 
   IF predINI = 'NI' THEN value = 0; 
   ELSE value = 1; 
   IF trueINI = 'NI' THEN true = 0; 
   ELSE true = 1; 
   mis=0; 
   IF value = 1 AND true = 0 THEN mis = 1; 
   IF value = 0 AND true = 1 THEN mis = 1; 
RUN; 
PROC TRANSPOSE data=PCA2(where=(laboratory = 'Beiersdorf')) out=extra1a prefix=B; 
   VAR value; 
   BY order name predGHS LS; 
   ID test; 
RUN; 
PROC TRANSPOSE data=PCA2(where=(laboratory = 'Harlan')) out=extra1b prefix=H; 
   VAR value; 
   BY order name predGHS LS; 
   ID test; 
RUN; 
PROC TRANSPOSE data=PCA2(where=(laboratory = 'IIVS')) out=extra1c prefix=V; 
   VAR value; 
   BY order name predGHS LS; 
   ID test; 
RUN; 
PROC TRANSPOSE data=PCA2(where=(laboratory = 'Beiersdorf')) out=extra1d prefix=misB; 
   VAR mis; 
   BY order name predGHS LS; 
   ID test; 
RUN; 
PROC TRANSPOSE data=PCA2(where=(laboratory = 'Harlan')) out=extra1e prefix=misH; 
   VAR mis; 
   BY order name predGHS LS; 
   ID test; 
RUN; 
PROC TRANSPOSE data=PCA2(where=(laboratory = 'IIVS')) out=extra1f prefix=misV; 
   VAR mis; 
   BY order name predGHS LS; 
   ID test; 
RUN; 
PROC SORT data=PCA2 out=PCA2b nodupkey; BY order; RUN; 
PROC TRANSPOSE data=PCA2b out=extra1g(rename=(count=true)); 
   VAR true; 
   BY order name; 
RUN; 
DATA extra1/*(keep = order name predGHS LS mis med) */; 
   MERGE extra1a extra1b extra1c extra1d extra1e extra1f extra1g; 
   BY order name; 
   med = MEDIAN(B1,B2,B3,H1,H2,H3,V1,V2,V3); 
   summis = SUM(misB1,misB2,misB3,misH1,misH2,misH3,misV1,misV2,misV3); 
   mis = '*'||TRIM(LEFT(PUT(summis,best12.)))||'/9'; 
   IF order = 33 THEN DO; 
         med = MEDIAN(H1,H2,H3,V1,V2,V3); 
         summis = SUM(misH1,misH2,misH3,misV1,misV2,misV3); 
         mis = '*'||TRIM(LEFT(PUT(summis,best12.)))||'/6'; 
   END; 
   FORMAT B1--V3 med fmtini.; 
   label mis = 'Mispredicted tests/Total' 
    med = 'Final classification based on median'; 
RUN; 
PROC SORT data=extra1; 
   BY LS order; 
RUN; 
* view in excel to create table for report; 
data tmp; 
   set pca; 
   where order = 33; 
run; 
 
/* -------------- */ 
/* Appendix I */ 
/* -------------- */ 
PROC sort data=pre_all out=appendix1 (keep = order name mtt coloring  protocol  
                                                                             where=(UPCASE(MTT) NE 'NO' OR UPCASE(coloring) NE 'NO')) nodupkey ;  
   BY order name;  
RUN; 
/* ---------------- */ 
/* Appendix IV */ 
/* ----------------*/ 
PROC SORT data=rht.Epiocular_remarks out=remarks; 
   BY chemical_code; 
RUN; 
PROC SORT data=chemorder2 out=chemorder3;  
   BY chemical_code; 
RUN; 
DATA appIV; 
   MERGE remarks(in=ok) chemorder3; 
   BY chemical_code; 
   IF ok; 
RUN; 
PROC SORT data=appIV; BY order; RUN; 
DATA appIVfinal(keep = order filename remark); 
   RETAIN order filename remark; 
   SET appIV; 
RUN; 
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/* ---------------- */ 




   SET pre_all; 
   IF viability > 50 THEN pred50 = 'NI'; 
   ELSE pred50 = 'I'; 
   IF viability > 60 THEN pred60 = 'NI'; 
   ELSE pred60 = 'I'; 
RUN;  
PROC SORT data=appVI; BY laboratory order test; RUN; 
 
/* ====================== */ 
/* ====================== */ 
/* USING THE 60% CUT-OFF */ 
/* ====================== */ 
/* ====================== */ 
 
/* --------------------------------------------- */ 
/* Section 6 of SAP: Intralaboratory variability */ 
/* --------------------------------------------- */ 
 
/* at least two qualified tests */ 
PROC SORT data=pre_all; BY laboratory name; RUN; 
PROC FREQ data=pre_all noprint; 
   TABLES conclusion/out=pre_WLV; 
   BY laboratory name; 
RUN; 
DATA pre_WLV2; 
   SET pre_WLV (where=(conclusion = 0 AND count >=2)); 
RUN; 
DATA pre_WLV3; 
   MERGE pre_all(drop=test where=(conclusion NOT IN (1 2))) pre_WLV2 (in=ok); 
   BY laboratory name; 
   IF ok; 
   IF viability > 60 THEN predINI = 'NI'; 
   ELSE predINI = 'I'; 
RUN; 
DATA WLV;  
   SET pre_WLV3; 
   BY laboratory name; 
   RETAIN test 0; 
   test = test+1; 
   IF first.name THEN test=1; 
   IF test > 3 THEN DELETE; 
RUN; 
 
/* 6.1 Table with concordance of classifications */ 
PROC SORT data=WLV; BY laboratory name; RUN; 
PROC TRANSPOSE data=WLV out=pre6_1; 
   BY laboratory name order; 
   ID test; 
   VAR predINI; 
RUN; 
PROC FREQ data=WLV noprint; 
   TABLES predINI/out=pre6_1; 
   BY laboratory name order; 
RUN;  
DATA pre6_1b; 
   SET pre6_1; 
   IF percent NE 100 THEN WLV_concordant = 'NO '; 
   ELSE WLV_concordant = 'YES'; 
RUN; 
PROC SORT data=pre6_1b out=pre6_1c nodupkey; 
   BY laboratory name order; 
RUN; 
PROC FREQ data=pre6_1c noprint; 
   TABLES WLV_concordant/out=table6_1LAB; 
   BY laboratory;  
RUN; 
PROC FREQ data=pre6_1c noprint; 
   TABLES WLV_concordant/out=table6_1TOTAL; 
RUN; 
DATA table6_1; 
   SET table6_1LAB table6_1TOTAL(in=ok); 
   IF ok THEN laboratory = 'Total'; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data analysis\Reports\Revision\EpiOcular_Table6_1_p60.doc' 
notoc_data; 
PROC REPORT data=table6_1 NOWINDOWS HEADLINE HEADSKIP ; 
   COLUMNS laboratory WLV_concordant count percent; 
   DEFINE laboratory / GROUP width = 10; 
   DEFINE WLV_concordant / DISPLAY width=15 'WLV concordant'; 
   DEFINE count / DISPLAY FLOW 'No.'; 
   DEFINE percent / DISPLAY format=8.1 'Fraction(%)' width = 12; 
   BREAK after laboratory/SKIP; 
RUN; 
ODS RTF close;  
 
/* 6.2 Additional descriptives of non-concordant results */ 
DATA pre6_2; 
   MERGE WLV pre6_1c(keep = laboratory name order WLV_concordant); 
   BY laboratory name order; 
RUN; 
/* 16082012 CdJ revision */  
DATA pre6_2b; 
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   SET pre6_2(where=(WLV_concordant = 'NO ')); 
   KEEP laboratory order name LS coloring MTT predGHS viability test; 
RUN; 
PROC SORT data=pre6_2b; BY laboratory order name test; 
PROC TRANSPOSE data=pre6_2b out=pre6_2t(drop=_name_); 
   BY laboratory order name LS coloring mTT predGHS; 
   VAR viability; 
   ID test; 
RUN; 
DATA table6_2; 
   RETAIN laboratory order name LS coloring mtt predGHS _1 _2 _3; 
   SET pre6_2t; 
RUN; 
* view in excel to create table for report; 
 
/* 6.3 Statement per laboratory regarding WLV */ 
DATA table6_3 ; 
   SET table6_1LAB table6_1TOTAL(in=total); 
   IF total THEN laboratory = 'Total'; 
   WHERE WLV_concordant = 'YES'; 
   WLV_criteria = 'not fulfilled'; 
   IF percent >= 85 THEN WLV_criteria = 'fulfilled'; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data analysis\Reports\Revision\EpiOcular_Table6_3_p60.doc' 
notoc_data; 
PROC REPORT data=table6_3 NOWINDOWS HEADLINE HEADSKIP ; 
   COLUMNS laboratory percent WLV_criteria; 
   DEFINE laboratory / GROUP width = 10; 
   DEFINE WLV_criteria / DISPLAY width=15 'Statement: criteria is '; 
   DEFINE percent / DISPLAY format=8.1 'Fraction(%)' width = 12; 
RUN; 
ODS RTF close;  
 
/* 6.4 Pearson Correlations */ 
/* is not depending on cut-off value */ 
 
/* 6.5 mean and mean diff */ 
/* is not depending on cut-off value */ 
 
/* --------------------------------------------- */ 
/* Section 7 of SAP: Interlaboratory variability */ 
/* --------------------------------------------- */ 
 
/* at least one qualified tests per laboratory*/ 
PROC SORT data=pre_all; BY laboratory name; RUN; 
PROC FREQ data=pre_all noprint; 
   TABLES conclusion/out=pre_BLV; 
   BY laboratory name; 
RUN; 
DATA pre_BLV2; 
   SET pre_BLV (where=(conclusion = 0 AND count >=1)); 
RUN; 
PROC SORT data=pre_BLV2; BY name; RUN: 
PROC TRANSPOSE data=pre_BLV2 out=pre_BLV2t; 
   VAR count;  
   ID laboratory; 
   BY name; 
RUN; 
DATA pre_BLV2t2; 
   SET pre_BLV2t; 
   IF Beiersdorf IN (0 .) OR Harlan IN (0 .) OR IIVS IN (0 .) THEN DELETE; 
RUN;  
PROC SORT data=pre_all; BY name; RUN; 
DATA pre_BLV3; 
   MERGE pre_all(drop=test) pre_BLV2t2 (in=ok); 
   BY name; 
   IF ok; 
   IF conclusion IN (1 2) THEN DELETE; 
   IF viability > 60 THEN predINI = 'NI'; 
   ELSE predINI = 'I'; 
RUN; 
PROC SORT data=pre_BLV3; BY laboratory name; RUN; 
DATA BLV;  
   SET pre_BLV3; 
   BY laboratory name; 
   RETAIN test 0; 
   test = test+1; 
   IF first.name THEN test=1; 
   IF test > 3 THEN DELETE; 
RUN; 
 
/* 7.1 Table with means, std, cv and pred */ 
/* is not depending on cut-off value */ 
PROC MEANS data=BLV noprint; 
   CLASS laboratory name order; 
   VAR viability; 
   OUTPUT out=pre7_1(where=(_type_ = 7)) mean = meanlab std = stdlab cv=cvlab n=nlab; 
RUN; 
PROC MEANS data=pre7_1 noprint; 
   CLASS name order; 
   VAR stdlab; 
   OUTPUT out=table7_1(where=(_type_ = 3)) mean = means std = stds cv=cvs n=ns; 
RUN; 
DATA table7_1b; 
   SET pre7_1; 
   IF meanlab > 60 THEN finalINI = 0; 
   ELSE finalINI = 1; 
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   FORMAT finalINI fmtINI.; 
RUN; 
 
/* 7.2 concordance final classifications */ 
PROC SORT data=table7_1b out=pre7_2; BY name order; RUN; 
PROC FREQ data=pre7_2 noprint;  
   TABLES finalINI/out=pre7_2b; 
   BY name order; 
RUN; 
DATA pre7_2c; 
   SET pre7_2b; 
   IF percent NE 100 THEN BLV_concordant = 'NO '; 
   ELSE BLV_concordant = 'YES'; 
RUN; 
PROC SORT data=pre7_2c out=pre7_2d nodupkey; 
   BY name order;  
RUN; 
PROC FREQ data=pre7_2d noprint; 
   TABLES BLV_concordant / out=table7_2; 
RUN; 
DATA pre7_2e; 
   MERGE pre7_2d pre7_2; 
   BY name order; 
RUN; 
PROC SORT data=BLV; BY laboratory name order; RUN; 
PROC SORT data=pre7_2e; BY laboratory name order; RUN; 
DATA pre7_2f; 
   MERGE BLV(where=(test=1)) pre7_2e(keep = laboratory name order BLV_concordant meanlab); 
   BY laboratory name order; 
RUN; 
DATA pre7_2g; 
   SET pre7_2f(where=(BLV_concordant = 'NO ')); 
   KEEP laboratory order name LS coloring MTT predGHS meanlab; 
RUN; 
PROC SORT data=pre7_2g; BY order name order name LS coloring mTT predGHS; RUN; 
PROC TRANSPOSE data=pre7_2g out=pre7_2t(drop=_name_); 
   BY order name LS coloring mTT predGHS; 
   VAR meanlab; 
   ID laboratory; 
RUN; 
DATA table7_2b; 
   RETAIN order name LS coloring mtt predGHS Beiersdorf Harlan IIVS; 
   SET pre7_2t; 
RUN; 
* view in excel to create table for report; 
 
/* 7.3 descriptive statistics non-concordant results */ 
* see 7.2 ; 
 
/* 7.4 statement regarding BLV */ 
PROC FREQ data=pre7_2d; 
   TABLES BLV_concordant/out=tmp; 
RUN; 
DATA table7_4 ; 
   SET tmp; 
   WHERE BLV_concordant = 'YES'; 
   BLV_criteria = 'not fulfilled'; 
   IF percent >= 80 THEN BLV_criteria = 'fulfilled'; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data analysis\Reports\Revision\EpiOcular_Table7_4_p60.doc' 
notoc_data; 
PROC REPORT data=table7_4 NOWINDOWS HEADLINE HEADSKIP ; 
   COLUMNS percent BLV_criteria; 
   DEFINE BLV_criteria / DISPLAY width=15 'Statement: criteria is '; 
   DEFINE percent / DISPLAY format=8.1 'Fraction(%)' width = 12; 
RUN; 
ODS RTF close;  
 
/* 7.5&7.6  Two-way ANOVA with laboratory and chemicals as factor */ 
/* is not depending on cut-off value */ 
 
/* 7.7 Pearson correlations */ 
/* is not depending on cut-off value */ 
 
 
/* ------------------------------------- */ 
/* Section 8 of SAP: Predictive capacity */ 
/* ------------------------------------- */ 
 
PROC SORT data= pre_all; BY laboratory name; RUN; 
DATA PCA; 
   SET pre_all (drop=test); 
   BY laboratory name; 
   WHERE conclusion = 0; 
   RETAIN test 0; 
   test = test+1; 
   IF first.name THEN test=1; 
   IF test>3 THEN DELETE; 
   IF viability > 60 THEN predINI = 'NI'; 
   ELSE predINI = 'I'; 
RUN; 
/* 8.1 sens, spec, acc */ 
%MACRO predmodel(lab=, output=); 
DATA pre8_1; 
   SET PCA; 
   %IF &lab NE %THEN %DO; 
      WHERE laboratory = &lab; 
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   %END; 
   IF trueINI = 'I' THEN DO; 
      IF predINI = 'I' THEN result = 'TP'; 
   ELSE IF predINI = 'NI' THEN result = 'FN'; 
   END; 
   ELSE IF trueINI = 'NI' THEN DO; 
      IF predINI = 'NI' THEN result = 'TN'; 
   ELSE IF predINI = 'I' THEN result = 'FP'; 
   END; 
RUN; 
PROC SORT data=pre8_1; 
   BY trueINI predINI; 
RUN; 
DATA pre8_1b (drop=result); 
   SET pre8_1; 
   BY trueINI; 
   retain tp tn fp fn; 
   if (first.trueINI) then do; 
      tp=0; tn=0; fp=0; fn=0; 
   end; 
   if (result in ("TP")) then tp=tp+1; 
   if (result in ("TN")) then tn=tn+1; 
   if (result in ("FN")) then fn=fn+1; 
   if (result in ("FP")) then fp=fp+1; 
   else ; 
   if (last.trueINI) then output; 
run; 
DATA pre8_1C; 
   SET pre8_1B; 
   tntp=tn+tp; 
   fnfp=fn+fp; 
RUN; 
PROC SQL; 
   CREATE TABLE pre8_1D as 
   select sum(tp) as tp, sum(tn) as tn, sum(fp)as fp, sum(fn) as fn, sum(tntp) as 
          tntp, sum(fnfp) as fnfp 
   from pre8_1C; 
QUIT; 
PROC SQL; 
   CREATE TABLE pre8_1E as 
   select tp/(tp+fn) as sensitivity, tn/(tn+fp) as specificity, 
         (tn+tp)/(tn+tp+fn+fp) as accuracy 
    from pre8_1D; 
QUIT; 
PROC TRANSPOSE data=pre8_1D out=pre8_1F; 
   VAR tp tn fn fp tntp fnfp; 
RUN; 
DATA pre8_1G (drop=_name_ col1); 
   LENGTH group $20; 
   SET pre8_1F; 
   count=col1; 
   if _name_="tp" then do; 
      group="Sensitivity"; 
      response=0; 
      output; 
   end; 
   else if _name_="fn" then do; 
      group="Sensitivity"; 
      response=1; 
      output; 
   end; 
   else if _name_="tn" then do; 
      group="Specificity"; 
      response=0; 
      output; 
   end; 
   else if _name_="fp" then do; 
      group="Specificity"; 
      response=1; 
      output; 
   end; 
   else if _name_="tntp" then do; 
      group="Accuracy"; 
      response=0; 
      output; 
   end; 
   else if _name_="fnfp" then do; 
      group="Accuracy"; 
      response=1; 
      output; 
   end; 
RUN; 
PROC SORT data=pre8_1G; BY group; RUN; 
ODS trace off; 
ODS listing close; 
PROC FREQ data= pre8_1G; 
   WEIGHT count; 
   BY group; 
   TABLES response/alpha=0.05 binomial(p=0.5); 
   exact binomial; 




   SET pre8_1CI; 
   WHERE name1 IN ('_BIN_' 'XL_BIN' 'XU_BIN'); 
RUN; 
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PROC TRANSPOSE data=pre8_1TOTAL out=pre8_1TOTALt; 
   VAR nvalue1; 
   ID name1; 
   BY group; 
RUN; 
PROC TRANSPOSE data=pre8_1G out=pre8_1H; 
   VAR count; 
   ID response; 
   BY group; 
RUN; 
DATA &output; 
   MERGE pre8_1TOTALt pre8_1H; 








DATA table8_1 (keep = group laboratory _BIN_ XL_BIN XU_BIN abs); 
   SET table8_1BDF (in=set1) table8_1HARLAN (in=set2) 
       table8_1IIVS (in=set3) table8_1TOTAL (in=set4); 
   IF set1 THEN laboratory = 'Beiersdorf'; 
   IF set2 THEN laboratory = 'Harlan'; 
   IF set3 THEN laboratory = 'IIVS'; 
   IF set4 THEN laboratory = 'Total'; 
   x = PUT(_1,$3.); 
   y = PUT(_0+_1,$3.); 
   abs = x||'/'||y; 
RUN; 
* report @8.2; 
 
/* 8.2 statement regarding predictive capacity */ 
DATA table8_2; 
   SET table8_1; 
   LENGTH PC_criteria $25; 
   IF group = 'Sensitivity' THEN DO; 
      PC_criteria = 'further evaluation'; 
      IF _BIN_ >= 0.90 THEN PC_criteria = 'definitely acceptable'; 
      IF _BIN_ <= 0.80 THEN PC_criteria = 'definitely unacceptable'; 
   END; 
   IF group = 'Specificity' THEN DO; 
      PC_criteria = 'further evaluation'; 
      IF _BIN_ >= 0.60 THEN PC_criteria = 'definitely acceptable'; 
      IF _BIN_ <= 0.50 THEN PC_criteria = 'definitely unacceptable'; 
   END; 
   IF group = 'Accuracy' THEN DO; 
      PC_criteria = 'further evaluation'; 
      IF _BIN_ >= 0.75 THEN PC_criteria = 'definitely acceptable'; 
      IF _BIN_ <= 0.65 THEN PC_criteria = 'definitely unacceptable'; 
   END; 
RUN; 
 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data analysis\Reports\Revision\EpiOcular_Table8_1_P60.doc' 
notoc_data; 
PROC REPORT data=table8_2 NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS laboratory group abs _BIN_ XL_BIN XU_BIN PC_criteria; 
   DEFINE laboratory/GROUP; 
   DEFINE group/DISPLAY 'Characteristic' width = 15;  
   DEFINE abs/DISPLAY 'No.'; 
   DEFINE _BIN_/DISPLAY 'Value' format=8.3 CENTER; 
   DEFINE XL_BIN/DISPLAY '95% lower limit'  format=8.3 width=15 CENTER; 
   DEFINE XU_BIN/DISPLAY '95% upper limit' format=8.3 width=15 CENTER; 
   DEFINE PC_criteria/DISPLAY 'Statement' width = 25; 
   BREAK after laboratory/SKIP; 
RUN; QUIT; 
ODS RTF close; 
 






%MACRO predmodel2(lab=, output=, state=); 
DATA pre8_1 %IF &state NE %THEN %DO; (WHERE=(UPCASE(LS) =&state)) %END; ; 
   SET PCA; 
   %IF &lab NE %THEN %DO; 
      WHERE laboratory = &lab; 
   %END; 
   IF trueINI = 'I' THEN DO; 
      IF predINI = 'I' THEN result = 'TP'; 
   ELSE IF predINI = 'NI' THEN result = 'FN'; 
   END; 
   ELSE IF trueINI = 'NI' THEN DO; 
      IF predINI = 'NI' THEN result = 'TN'; 
   ELSE IF predINI = 'I' THEN result = 'FP'; 
   END; 
RUN; 
 
PROC SORT data=pre8_1; 
   BY trueINI predINI; 
RUN; 
DATA pre8_1b (drop=result); 
   SET pre8_1; 
   BY trueINI; 
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   retain tp tn fp fn; 
   if (first.trueINI) then do; 
      tp=0; tn=0; fp=0; fn=0; 
   end; 
   if (result in ("TP")) then tp=tp+1; 
   if (result in ("TN")) then tn=tn+1; 
   if (result in ("FN")) then fn=fn+1; 
   if (result in ("FP")) then fp=fp+1; 
   else ; 
   if (last.trueINI) then output; 
run; 
DATA pre8_1C; 
   SET pre8_1B; 
   tntp=tn+tp; 
   fnfp=fn+fp; 
RUN; 
PROC SQL; 
   CREATE TABLE pre8_1D as 
   select sum(tp) as tp, sum(tn) as tn, sum(fp)as fp, sum(fn) as fn, sum(tntp) as 
          tntp, sum(fnfp) as fnfp 
   from pre8_1C; 
QUIT; 
PROC SQL; 
   CREATE TABLE pre8_1E as 
   select tp/(tp+fn) as sensitivity, tn/(tn+fp) as specificity, 
         (tn+tp)/(tn+tp+fn+fp) as accuracy 
    from pre8_1D; 
QUIT; 
PROC TRANSPOSE data=pre8_1D out=pre8_1F; 
   VAR tp tn fn fp tntp fnfp; 
RUN; 
DATA pre8_1G (drop=_name_ col1); 
   LENGTH group $20; 
   SET pre8_1F; 
   count=col1; 
   if _name_="tp" then do; 
      group="Sensitivity"; 
      response=0; 
      output; 
   end; 
   else if _name_="fn" then do; 
      group="Sensitivity"; 
      response=1; 
      output; 
   end; 
   else if _name_="tn" then do; 
      group="Specificity"; 
      response=0; 
      output; 
   end; 
   else if _name_="fp" then do; 
      group="Specificity"; 
      response=1; 
      output; 
   end; 
   else if _name_="tntp" then do; 
      group="Accuracy"; 
      response=0; 
      output; 
   end; 
   else if _name_="fnfp" then do; 
      group="Accuracy"; 
      response=1; 
      output; 
   end; 
RUN; 
PROC SORT data=pre8_1G; BY group; RUN; 
ODS trace off; 
ODS listing close; 
PROC FREQ data= pre8_1G; 
   WEIGHT count; 
   BY group; 
   TABLES response/alpha=0.05 binomial(p=0.5); 
   exact binomial; 




   SET pre8_1CI; 
   WHERE name1 IN ('_BIN_' 'XL_BIN' 'XU_BIN'); 
RUN; 
PROC TRANSPOSE data=pre8_1TOTAL out=pre8_1TOTALt; 
   VAR nvalue1; 
   ID name1; 
   BY group; 
RUN; 
PROC TRANSPOSE data=pre8_1G out=pre8_1H; 
   VAR count; 
   ID response; 
   BY group; 
RUN; 
DATA &output; 
   MERGE pre8_1TOTALt pre8_1H; 














DATA table8_3 (keep = group laboratory state abs _BIN_ XL_BIN XU_BIN); 
   SET table8_1BDF_L (in=set1) table8_1HARLAN_L (in=set2) 
       table8_1IIVS_L (in=set3) table8_1TOTAL_L (in=set4)  
       table8_1BDF_S (in=set1b) table8_1HARLAN_S (in=set2b) 
       table8_1IIVS_S (in=set3b) table8_1TOTAL_S (in=set4b); 
   IF set1 OR set1b THEN laboratory = 'Beiersdorf'; 
   IF set2 OR set2b THEN laboratory = 'Harlan'; 
   IF set3 OR set3b THEN laboratory = 'IIVS'; 
   IF set4 OR set4b THEN laboratory = 'Total'; 
   IF set1 OR set2 OR set3 OR set4 THEN state='Liquid'; 
   IF set1b OR set2b OR set3b OR set4b THEN state='Solid'; 
      x = PUT(_1,$3.); 
   y = PUT(_0+_1,$3.); 




   SET table8_3; 
   LENGTH PC_criteria $25; 
   IF group = 'Sensitivity' THEN DO; 
      PC_criteria = 'further evaluation'; 
      IF _BIN_ >= 0.90 THEN PC_criteria = 'definitely acceptable'; 
      IF _BIN_ <= 0.80 THEN PC_criteria = 'definitely unacceptable'; 
   END; 
   IF group = 'Specificity' THEN DO; 
      PC_criteria = 'further evaluation'; 
      IF _BIN_ >= 0.60 THEN PC_criteria = 'definitely acceptable'; 
      IF _BIN_ <= 0.50 THEN PC_criteria = 'definitely unacceptable'; 
   END; 
   IF group = 'Accuracy' THEN DO; 
      PC_criteria = 'further evaluation'; 
      IF _BIN_ >= 0.75 THEN PC_criteria = 'definitely acceptable'; 
      IF _BIN_ <= 0.65 THEN PC_criteria = 'definitely unacceptable'; 
   END; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data analysis\Reports\Revision\EpiOcular_Table8_3_p60.doc' 
notoc_data; 
PROC REPORT data=table8_3b(where=(state='Liquid')) NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS  laboratory group abs _BIN_ XL_BIN XU_BIN PC_criteria; 
   DEFINE laboratory/GROUP; 
   DEFINE abs / DISPLAY 'No.'; 
   DEFINE group/DISPLAY 'Characteristic' width = 15;  
   DEFINE _BIN_/DISPLAY 'Value' format=8.3 CENTER; 
   DEFINE XL_BIN/DISPLAY '95% lower limit'  format=8.3 width=15 CENTER; 
   DEFINE XU_BIN/DISPLAY '95% upper limit' format=8.3 width=15 CENTER; 
   DEFINE PC_criteria/DISPLAY 'Statement' width = 25; 
   BREAK after laboratory/SKIP; 
RUN; QUIT; 
PROC REPORT data=table8_3b(where=(state='Solid')) NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS  laboratory group abs _BIN_ XL_BIN XU_BIN PC_criteria; 
   DEFINE laboratory/GROUP; 
   DEFINE abs / DISPLAY 'No.'; 
   DEFINE group/DISPLAY 'Characteristic' width = 15;  
   DEFINE _BIN_/DISPLAY 'Value' format=8.3 CENTER; 
   DEFINE XL_BIN/DISPLAY '95% lower limit'  format=8.3 width=15 CENTER; 
   DEFINE XU_BIN/DISPLAY '95% upper limit' format=8.3 width=15 CENTER; 
   DEFINE PC_criteria/DISPLAY 'Statement' width = 25; 
   BREAK after laboratory/SKIP; 
RUN; QUIT; 
ODS RTF close; 
 
* additional table; 
PROC SORT data=PCA; BY order predGHS; RUN; 
DATA PCA2; 
   SET PCA; 
   IF predINI = 'NI' THEN value = 0; 
   ELSE value = 1; 
   IF trueINI = 'NI' THEN true = 0; 
   ELSE true = 1; 
   mis=0; 
   IF value = 1 AND true = 0 THEN mis = 1; 
   IF value = 0 AND true = 1 THEN mis = 1; 
RUN; 
PROC TRANSPOSE data=PCA2(where=(laboratory = 'Beiersdorf')) out=extra1a prefix=B; 
   VAR value; 
   BY order name predGHS LS; 
   ID test; 
RUN; 
PROC TRANSPOSE data=PCA2(where=(laboratory = 'Harlan')) out=extra1b prefix=H; 
   VAR value; 
   BY order name predGHS LS; 
   ID test; 
RUN; 
PROC TRANSPOSE data=PCA2(where=(laboratory = 'IIVS')) out=extra1c prefix=V; 
   VAR value; 
   BY order name predGHS LS; 
   ID test; 
RUN; 
PROC TRANSPOSE data=PCA2(where=(laboratory = 'Beiersdorf')) out=extra1d prefix=misB; 
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   VAR mis; 
   BY order name predGHS LS; 
   ID test; 
RUN; 
PROC TRANSPOSE data=PCA2(where=(laboratory = 'Harlan')) out=extra1e prefix=misH; 
   VAR mis; 
   BY order name predGHS LS; 
   ID test; 
RUN; 
PROC TRANSPOSE data=PCA2(where=(laboratory = 'IIVS')) out=extra1f prefix=misV; 
   VAR mis; 
   BY order name predGHS LS; 
   ID test; 
RUN; 
PROC SORT data=PCA2 out=PCA2b nodupkey; BY order; RUN; 
PROC TRANSPOSE data=PCA2b out=extra1g(rename=(count=true)); 
   VAR true; 
   BY order name; 
RUN; 
DATA extra1/*(keep = order name predGHS LS mis med)*/ ; 
   MERGE extra1a extra1b extra1c extra1d extra1e extra1f extra1g; 
   BY order name; 
   med = MEDIAN(B1,B2,B3,H1,H2,H3,V1,V2,V3); 
   summis = SUM(misB1,misB2,misB3,misH1,misH2,misH3,misV1,misV2,misV3); 
   mis = '*'||TRIM(LEFT(PUT(summis,best12.)))||'/9'; 
   IF order = 33 THEN DO; 
         med = MEDIAN(H1,H2,H3,V1,V2,V3); 
         summis = SUM(misH1,misH2,misH3,misV1,misV2,misV3); 
         mis = '*'||TRIM(LEFT(PUT(summis,best12.)))||'/6'; 
   END; 
   FORMAT B1--V3 med fmtini.; 
   label mis = 'Mispredicted tests/Total' 
    med = 'Final classification based on median'; 
RUN; 
PROC SORT data=extra1; 
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Appendix III Receipt of data 
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Liquids 
No Remark Used Filename Saved as version date  
 1 YES EIVS_Harlan_liquids_14225A_10_01.xls 1 11/03/2011 H9(1) H21(1) H22(1) H26(1) H27(1) H35(1) H56(1) H59(1) H65(1) H127(1) 
2 
wrong run 
numbers NO EIVS_Harlan_liquids_14234D_11_02.xls 1 22/03/2011 H9(1) H21(1) H22(1) H26(1) H27(1) H35(1) H56(1) H59(1) H65(1) H127(1) 
3 replacement of 3 YES EIVS_Harlan_liquids_14234D_11_02.xls 2 22/03/2011 H9(2) H21(2) H22(2) H26(2) H27(2) H35(2) H56(2) H59(2) H65(2) H127(2) 
4 YES EIVS_Harlan_liquids_14241E_12_03.xls 1 28/03/2011 H9(3) H21(3) H22(3) H26(3) H27(3) H35(3) H56(3) H59(3) H65(3) H127(3) 
5 YES EIVS_Harlan_liquids_14248E_13_04.xls 1 05/04/2011 H16(1) H34(1) H42(1) H47(1) H52(1) H67(1) H68(1) H77(1) H79(1) H96(1) 
6 YES EIVS_Harlan_liquids_14263D_15_05.xls 1 19/04/2011 H16(2) H34(2) H42(2) H47(2) H52(2) H67(2) H68(2) H77(2) H79(2) H96(2) 
7 YES EIVS_Harlan_liquids_14270A_16_06.xls 1 28/04/2011 H16(3) H34(3) H42(3) H47(3) H52(3) H67(3) H68(3) H77(3) H79(3) H96(3) 
8 YES EIVS_BDF_liquids_14219F_08_01.xls 1 29/04/2011 B8(1) B64(1) B138(1) B18(1) B53(1) B3(1) B6(1) B9(1) B10(1) B25(1) 
9 YES EIVS_BDF_liquids_14222B_09_04.xls 1 30/04/2011 B8(2) B64(2) B138(2) B18(2) B53(2) B3(2) B6(2) B9(2) B10(2) B25(2) 
10 YES EIVS_BDF_liquids_14225D_10_07.xls 1 01/05/2011 B8(3) B64(3) B138(3) B18(3) B53(3) B3(3) B6(3) B9(3) B10(3) B25(3) 
11 replaced by 80 NO EIVS_BDF_liquids_14225E_10_06.xls 1 02/05/2011 B39(1) B56(1) B58(1) B63(1) B78(1) B22(1) B7(1) B11(1) B45(1) B60(1) 
12 replaced by 81 NO EIVS_BDF_liquids_14234C_11_09.xls 1 03/05/2011 B39(2) B56(2) B58(2) B63(2) B78(2) B22(2) B7(2) B11(2) B45(2) B60(2) 
13 replaced by 82 NO EIVS_BDF_liquids_14241C_12_13.xls 1 04/05/2011 B39(3) B56(3) B58(3) B63(3) B78(3) B22(3) B7(3) B11(3) B45(3) B60(3) 
14 YES EIVS_Harlan_liquids_14283D_18_08.xls 1 09/05/2011 H24(2) H25(2) H87(2) H104(2) H107(2) H117(2) H130(2) H136(2) H138(2) 
15 YES EIVS_IIVS_liquids_14219_week1_number1_HI.xls 1 10/05/2011 V10(1) V11(1) V15(1) V19(1) V29(1) V36(1) V38(1) V42(1) V88(1) V118(1) 
16 YES EIVS_IIVS_liquids_14222_week2_number2_HI.xls 1 10/05/2011 V10(2) V11(2) V15(2) V19(2) V29(2) V36(2) V38(2) V42(2) V88(2) V118(2) 
17 YES EIVS_IIVS_liquids_14225_week3_number3_HI.xls 1 10/05/2011 V10(3) V11(3) V15(3) V19(3) V29(3) V36(3) V38(3) V42(3) V88(3) V118(3) 
18 YES EIVS_IIVS_liquids_14234_week4_number4_HI.xls 1 10/05/2011 V2(1) V3(1) V20(1) V33(1) V47(1) V50(1) V75(1) V83(1) V84(1) V98(1) 
19 YES EIVS_IIVS_liquids_14234_week5_number5KC_HI.xls 1 10/05/2011 V11(Kt) V15(Kt) V38(Kt) V2(Kt) V20(Kt) V47(Kt) V50(Kt) V84(Kt) 
20 YES EIVS_IIVS_liquids_14241_week5_number6_HI.xls 1 10/05/2011 V2(2) V3(2) V20(2) V33(2) V47(2) V50(2) V75(2) V83(2) V84(2) V98(2) 
21 YES EIVS_IIVS_liquids_14248_week6_number7_HI.xls 1 11/05/2011 V2(3) V3(3) V20(3) V33(3) V47(3) V50(3) V75(3) V83(3) V84(3) V98(3) 
22 YES EIVS_Harlan_liquids_14289A_19_09.xls 1 13/05/2011 H24(3) H25(3) H87(3) H104(3) H107(3) H117(3) H130(3) H136(3) H138(3) 
23 YES EIVS_Harlan_liquids_14277B_17_07.xls 1 13/05/2011 H24(1) H25(1) H87(1) H104(1) H107(1) H117(1) H130(1) H136(1) H138(1) 
24 PC code missing NO EIVS_HARLAN_LIQUIDS_14296D_20_10.xls 1 20/05/2011 H48(1) H71(1) H78(1) H98(1) 
25 YES EIVS_HARLAN_LIQUIDS_KC.xls 1 20/05/2011 H48(Kt) H71(Kt) H78(Kt) H98(Kt) 
26 replaced by 83 NO EIVS_BDF_liquids_14248A_13_17.xls 1 27/05/2011 B73(1) B61(1) B28(1) B30(1) B54(1) B129(1) B118(1) B44(1) B27(1) B16(1) 
27 YES EIVS_BDF_liquids_14248D_16_25.xls 1 27/05/2011 B54Kt B129Kt B118Kt B44Kt B27Kt B16Kt 
28 replaced by 84 NO EIVS_BDF_liquids_14256A_14_19.xls 1 27/05/2011 B73(2) B61(2) B28(2) B30(2) B54(2) B129(2) B118(2) B44(2) B27(2) B16(2) 
29 replaced by 85 NO EIVS_BDF_liquids_14263A_15_22.xls 1 27/05/2011 B73(3) B61(3) B28(3) B30(3) B54(3) B129(3) B118(3) B44(3) B27(3) B16(3) 
30 PC code missing NO EIVS_HARLAN_LIQUIDS_15003C_21_11.xls 1 01/06/2011 H48(2) H71(2) H78(2) H98(2) 
31 same as 25 NO EIVS_HARLAN_LIQUIDS_KC_11.xls 1 01/06/2011 H48(Kt) H71(Kt) H78(Kt) H98(Kt) 
32 YES EIVS_IIVS_liquids_14219_week1_number1_AH.xls 1 13/07/2011 V48(1) V49(1) V52(1) V81(1) V90(1) V92(1) V93(1) V95(1) V96(1) V104(1) 
33 YES EIVS_IIVS_liquids_14222_week2_number2_AH.xls 1 13/07/2011 V48(2) V49(2) V52(2) V81(2) V90(2) V92(2) V93(2) V95(2) V96(2) V104(2) 
34 YES EIVS_IIVS_liquids_14225_week3_number3_AH.xls 1 13/07/2011 V48(3) V49(3) V52(3) V81(3) V90(3) V92(3) V93(3) V95(3) V96(3) V104(3) 
35 YES EIVS_IIVS_liquids_14241_week6_number4KC_AH.xls 1 13/07/2011 V40Kt V93Kt V96Kt V120Kt V126Kt V127Kt V128Kt V134Kt 
36 YES EIVS_IIVS_liquids_14248_week6_number5_AH.xls 1 13/07/2011 V40(1) V103(1) V115(1) V120(1) V126(1) V127(1) V128(1) V132(1) V133(1) V134(1) 
37 YES EIVS_IIVS_liquids_14256_week7_number6_AH.xls 1 13/07/2011 V40(2) V103(2) V115(2) V120(2) V126(2) V127(2) V128(2) V132(2) V133(2) V134(2) 
38 YES EIVS_IIVS_liquids_14263_week8_number8_AH.xls 1 13/07/2011 V40(3) V103(3) V115(3) V120(3) V126(3) V127(2) V128(3) V132(3) V133(3) V134(3) 
39 PC code missing NO EIVS_HARLAN_LIQUIDS_15029A_27_14 1 13/07/2011 H6(1) H15(1) H70(1) H72(1) H122(1) H124(1) H128(1) 
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No Remark Used Filename Saved as version date  
 40 YES EIVS_HARLAN_LIQUIDS_KC_14.xls 1 13/07/2011 H6Kt H15Kt H70Kt H72Kt H122Kt H124Kt H128Kt 
41 
B137 is not 
correct reported NO EIVS_BDF_liquids_14256C_14_21.xls 1 14/07/2011 B121(1) B137(1) B38(1) B130(1) B133(1) B134(1) B14(1) B113(1) B84(1) B24(1) 
42 YES EIVS_BDF_liquids_14263B_15_24.xls 1 14/07/2011 B137(2) 
B137-
CC(1) B121(2) B38(2) B130(2) B133(2) B134(2) B14(2) B84(2) B24(2) 
43 YES EIVS_BDF_liquids_14277E_17_27.xls 1 14/07/2011 B137(3) 
B137-
CC(2) B121(3) B38(3) B130(3) B133(3) B134(3) B14(3) B84(3) B24(3) 
44 same as 32 NO EIVS_IIVS_liquids_14219_week1_number1_AH.xls 1 03/08/2011 V48(1) V49(1) V52(1) V81(1) V90(1) V92(1) V93(1) V95(1) V96(1) V104(1) 
45 same as 33 NO EIVS_IIVS_liquids_14222_week2_number2_AH.xls 1 03/08/2011 V48(2) V49(2) V52(2) V81(2) V90(2) V92(2) V93(2) V95(2) V96(2) V104(2) 
46 same as 34 NO EIVS_IIVS_liquids_14225_week3_number3_AH.xls 1 03/08/2011 V48(3) V49(3) V52(3) V81(3) V90(3) V92(3) V93(3) V95(3) V96(3) V104(3) 
47 same as 35 NO EIVS_IIVS_liquids_14241_week6_number4KC_AH.xls 1 03/08/2011 V40Kt V93Kt V96Kt V120Kt V126Kt V127Kt V128Kt V134Kt 
48 same as 36 NO EIVS_IIVS_liquids_14248_week6_number5_AH.xls 1 03/08/2011 V40(1) V103(1) V115(1) V120(1) V126(1) V127(1) V128(1) V132(1) V133(1) V134(1) 
49 same as 37 NO EIVS_IIVS_liquids_14256_week7_number6_AH.xls 1 03/08/2011 V40(2) V103(2) V115(2) V120(2) V126(2) V127(2) V128(2) V132(2) V133(2) V134(2) 
50 same as 38 NO EIVS_IIVS_liquids_14263_week8_number8_AH.xls 1 03/08/2011 V40(1) V103(1) V115(1) V120(1) V126(1) V127(2) V128(1) V132(1) V133(1) V134(1) 
51 YES EIVS_BDF_liquids_14277F_26_47.xls 1 28/07/2011 B17_KC B20_KC B100_KC 
52 
wrong filename 
(solid) NO EIVS_BDF_liquids_14277F_26_49.xls 1 28/07/2011 
B169_KC B177_KC 
53 YES EIVS_BDF_liquids_14283A_18_29.xls 1 28/07/2011 B17(1) B20(1) B31(1) B48(1) B57(1) B67(1) B85(1) B100(1) B106(1) B35(1) 
54 YES EIVS_BDF_liquids_14289D_19_32.xls 1 28/07/2011 B17(2) B20(2) B31(2) B48(2) B57(2) B67(2) B85(2) B100(2) B106(2) B35(2) 
55 YES EIVS_BDF_liquids_14296A_20_34.xls 1 28/07/2011 B17(3) B20(3) B31(3) B48(3) B57(3) B67(3) B85(3) B100(3) B106(3) B35(3) 
56 YES EIVS_BDF_liquids_15003B_21_38.xls 1 28/07/2011 B113(2) B125(1) B155(1) B174(1) B191(1) 
57 YES EIVS_BDF_liquids_15007B_23_40.xls 1 28/07/2011 B113(3) B125(2) B155(2) B174(2) B137(4) 
B137-
CC(4) B191(2) 
58 YES EIVS_BDF_liquids_15013A_24_42.xls 1 28/07/2011 B113(4) B125(3) B155(3) B174(3) B191(3) 
59 YES EIVS_BDF_liquids_15019A_26_45.xls 1 28/07/2011 B125_KC B155_KC B174_KC B191_KC 
60 YES EIVS_IIVS_liquids_14256_week12_number16KC_AH.xls 1 05/08/2011 V8_KC V26_KC V150_KC 
61 YES EIVS_IIVS_liquids_14270_week9_number10_AH.xls 1 05/08/2011 V40(4) V127(3) V6(1) V8(1) V26(1) V41(1) V55(1) V71(1) V114(1) V131(1) 
62 YES EIVS_IIVS_liquids_14277_week10_number12_AH.xls 1 05/08/2011 V6(2) V8(2) V26(2) V41(2) V55(2) V71(2) V114(2) V131(2) V150(1) V170(1) 
63 YES EIVS_IIVS_liquids_14283_week11_number13_AH.xls 1 05/08/2011 V6(3) V8 (ppt) V26(3) V41(3) V55(3) V71(3) V114(3) V131(3) V150(2) V170(2) 
64 YES EIVS_IIVS_liquids_14289_week12_number14_AH.xls 1 05/08/2011 V25(1) V25-CC(1) V61(1) V61-CC(1) V94(1) V94-CC(1) 
65 YES EIVS_IIVS_liquids_14289_week12_number15_AH.xls 1 05/08/2011 V8(4) V191(1) 
66 PC code missing NO EIVS_HARLAN_LIQUIDS_15030A_28_15.xls 1 17/08/2011 H6(2) H15(2) H70(2) H72(2) H122(2) H124(2) H128(2) 
67 PC code missing NO EIVS_HARLAN_LIQUIDS_15033A_31_16.xls 1 17/08/2011 H6(3) H15(3) H70(3) H72(3) H122(3) H124(3) H128(3) 
68 YES EIVS_HARLAN_LIQUIDS_15033B_31_16.xls 1 17/08/2011 H28(1) H30(1) H66(1) H73(1) H82(1) H102(1) H103(1) H115(1) H126(1) H159(1) 
69 YES EIVS_HARLAN_LIQUIDS_15034A_32_17.xls 1 17/08/2011 H28(2) H30(2) H66(2) H73(2) H82(2) H102(2) H103(2) H115(2) H126(2) H159(2) 
70 
replacement of 
41 YES EIVS_BDF_liquids_14256C_14_21.xls 2 26/08/2011 B121(1) B137(1) B38(1) B130(1) B133(1) B134(1) B14(1) B113(1) B84(1) B24(1) 
71 YES EIVS_IIVS_liquids_14234_week15_number21KC_AH.xls 1 30/08/2011 V25_KC V61_KC 
72 YES EIVS_IIVS_liquids_14296_week13_number17_AH.xls 1 30/08/2011 V25(2) V25_CC(2) V61(2) V61_CC(2) V94(2) V94_CC(2) 
73 YES EIVS_IIVS_liquids_14296_week13_number18_AH.xls 1 30/08/2011 V170(3) V191(2) 
74 YES EIVS_IIVS_liquids_15003_week14_number19_AH.xls 1 30/08/2011 V25(3) V25_CC(3) V61(3) V61_CC(3) V94(3) V94_CC(3) 
75 YES EIVS_IIVS_liquids_15003_week14_number20_AH.xls 1 30/08/2011 V170(4) V191(3) 
76 YES EIVS_IIVS_liquids_15007_week16_number22_AH.xls 1 30/08/2011 V83(4) V150(3) 
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 77 YES EIVS_IIVS_liquids_15007_week17_number25KC_AH.xls 1 30/08/2011 V191_KC 
78 YES EIVS_BDF_liquids_14277F_26_48.xls 1 05/09/2011 B11_KC B45_KC 
79 YES EIVS_BDF_liquids_15032A_31_52.xls 1 05/09/2011 B44_KC 
80 
replacement of 
11 YES EIVS_BDF_liquids_14225E_10_06_updated.xls EIVS_BDF_liquids_14225E_10_06.xls 1 07/09/2011 
B39(1) B56(1) B58(1) B63(1) B78(1) B22(1) B7(1) B11(1) B45(1) B60(1) 
81 
replacement of 
12 YES EIVS_BDF_liquids_14234C_11_09_updated.xls EIVS_BDF_liquids_14234C_11_09.xls 1 07/09/2011 
B39(2) B56(2) B58(2) B63(2) B78(2) B22(2) B7(2) B11(2) B45(2) B60(2) 
82 
replacement of 
13 YES EIVS_BDF_liquids_14241C_12_13_updated.xls EIVS_BDF_liquids_14241C_12_13.xls 1 07/09/2011 
B39(3) B56(3) B58(3) B63(3) B78(3) B22(3) B7(3) B11(3) B45(3) B60(3) 
83 
replacement of 
26 YES EIVS_BDF_liquids_14248A_13_17_updated.xls EIVS_BDF_liquids_14248A_13_17.xls 1 07/09/2011 B73(1) B61(1) B28(1) B30(1) B54(1) B129(1) B118(1) B44(1) B27(1) B16(1) 
84 
replacement of 
28 YES EIVS_BDF_liquids_14256A_14_19_updated.xls EIVS_BDF_liquids_14256A_14_19.xls 1 07/09/2011 B73(2) B61(2) B28(2) B30(2) B54(2) B129(2) B118(2) B44(2) B27(2) B16(2) 
85 
replacement of 
29 YES EIVS_BDF_liquids_14263A_15_22_updated.xls EIVS_BDF_liquids_14263A_15_22.xls 1 07/09/2011 B73(3) B61(3) B28(3) B30(3) B54(3) B129(3) B118(3) B44(3) B27(3) B16(3) 
86 YES EIVS_HARLAN_LIQUIDS_15035A_33_18.xls 1 19/09/2011 H28(3) H30(3) H66(3) H73(3) H82(3) H102(3) H103(3) H115(3) H126(3) H159(3) 
87 YES EIVS_HARLAN_LIQUIDS_15037A_34_19.xls 1 26/09/2011 H46(1) H89(1) H175(1) H186(1) 
88 YES EIVS_HARLAN_LIQUIDS_KC34.xls 1 26/09/2011 H46_KC H89_KC H175_KC H186_KC 
89 YES EIVS_HARLAN_LIQUIDS_15040B_38_20.xls 1 14/10/2011 H46(2) H89(2) H175(2) H186(2) 
90 same as 21 NO EIVS_IIVS_liquids_14248_week6_number7_HI.xls 1 20/10/2011 V2(3) V3(3) V20(3) V33(3) V47(3) V50(3) V75(3) V83(3) V84(3) V98(3) 
91 YES EIVS_HARLAN_LIQUIDS_15046B_41_21.xls 1 27/10/2011 H46(3) H89(3) H175(3) H186(3) 
92 PC code missing NO EIVS_HARLAN_LIQUIDS_15007C_23_12.xls 1 31/10/2011 H48(3) H71(3) H78(3) H98(3) 
93 
replacement of 
24 YES EIVS_HARLAN_LIQUIDS_14296D_20_10.xls 2 28/11/2011 H48(1) H71(1) H78(1) H98(1) 
94 
replacement of 
30 YES EIVS_HARLAN_LIQUIDS_15003C_21_11.xls 2 28/11/2011 H48(2) H71(2) H78(2) H98(2) 
95 
replacement of 
92 YES EIVS_HARLAN_LIQUIDS_15007C_23_12.xls 2 28/11/2011 H48(3) H71(3) H78(3) H98(3) 
96 
replacement of 
39 YES EIVS_HARLAN_LIQUIDS_15029A_27_14 2 28/11/2011 H6(1) H15(1) H70(1) H72(1) H122(1) H124(1) H128(1) 
97 
replacement of 
66 YES EIVS_HARLAN_LIQUIDS_15030A_28_15.xls 2 28/11/2011 H6(2) H15(2) H70(2) H72(2) H122(2) H124(2) H128(2) 
98 
replacement of 
67 YES EIVS_HARLAN_LIQUIDS_15033A_31_16.xls 2 28/11/2011 H6(3) H15(3) H70(3) H72(3) H122(3) H124(3) H128(3) 
 
Solids 
No Remark Used Filename Saved as version date content 
         1 YES EIVS_Harlan_solids_14225B_10_01.xls 1 11/03/2011 H3(1) H4(1) H14(1) H41(1) H44(1) H61(1) H62(1) H86(1) H95(1) H111(1) 
2 
wrong run 
numbers NO  EIVS_Harlan_solids_14234E_11_02.xls 1 22/03/2011 H3(1) H4(1) H14(1) H41(1) H44(1) H61(1) H62(1) H86(1) H95(1) H111(1) 
3 replacement of 3 YES EIVS_Harlan_solids_14234E_11_02.xls 2 22/03/2011 H3(2) H4(2) H14(2) H41(2) H44(2) H61(2) H62(2) H86(2) H95(2) H111(2) 
4 YES EIVS_Harlan_solids_14241D_12_03.xls 1 28/03/2011 H3(3) H4(3) H14(3) H41(3) H44(3) H61(3) H62(3) H86(3) H95(3) H111(3) 
5 YES EIVS_Harlan_solids_14248F_13_04.xls 1 05/04/2011 H12(1) H19(1) H33(1) H74(1) H90(1) H91(1) H123(1) H125(1) H131(1) H135(1) 
6 YES EIVS_Harlan_solids_14263E_15_05.xls 1 19/04/2011 H12(2) H19(2) H33(2) H74(2) H90(2) H91(2) H123(2) H125(2) H131(2) H135(2) 
7 YES EIVS_Harlan_solids_14270B_16_06.xls 1 28/04/2011 H12(3) H19(3) H33(3) H74(3) H90(3) H91(3) H123(3) H125(3) H131(3) H135(3) 
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         8 NO  EIVS_BDF_solids_14219D_08_02.xls 1 29/04/2011 B15(1) B21(1) B43(1) B52(1) B70(1) B13(1) B36(1) B46(1) B99(1) B71(1) 
9 YES EIVS_BDF_solids_14219E_09_03.xls 1 30/04/2011 B13_KC B36_KC B46_KC B99_KC B71_KC 
10 NO  EIVS_BDF_solids_14222A_09_05.xls 1 01/05/2011 B15(2) B21(2) B43(2) B52(2) B70(2) B13(2) B36(2) B46(2) B99(2) B71(2) 
11 replaced by 69 NO EIVS_BDF_solids_14225C_10_08.xls 1 02/05/2011 B15(3) B21(3) B43(3) B52(3) B70(3) B13(3) B36(3) B46(3) B99(3) B71(3) 
12 YES EIVS_Harlan_solids_14283E_18_08.xls 1 09/05/2011 
H85(2) H92(2) H106(2) H108(2) H109(2) H112(2) H121(2) H133(2) H134(2) H139(2) 
13 YES EIVS_Harlan_solids_14277C_17_07.xls 1 13/05/2011 
H85(1) H92(1) H106(1) H108(1) H109(1) H112(1) H121(1) H133(1) H134(1) H139(1) 
14 YES EIVS_Harlan_solids_14289B_19_09.xls 1 13/05/2011 
H85(3) H92(3) H106(3) H108(3) H109(3) H112(3) H121(3) H133(3) H134(3) H139(3) 
15 
replacement of 8; 
replaced by 67 NO EIVS_BDF_solids_14219D_08_02 revised.xls EIVS_BDF_solids_14219D_08_02.xls 1 29/04/2011 B15(1) B21(1) B43(1) B52(1) B70(1) B13(1) B36(1) B46(1) B99(1) B71(1) 
16 
replacement of 
10; replaced by 
68 NO EIVS_BDF_solids_14222A_09_05 revised.xls EIVS_BDF_solids_14222A_09_05.xls 1 01/05/2011 B15(2) B21(2) B43(2) B52(2) B70(2) B13(2) B36(2) B46(2) B99(2) B71(2) 
17 PC code missing NO EIVS_HARLAN_SOLIDS_14296E_20_10.xls 1 20/05/2011 H10(1) H60(1) H105(1) H110(1) 
18 YES EIVS_HARLAN_SOLIDS_KC.xls 1 20/05/2011 H10(Kt) H60(Kt) H105(Kt) H110(Kt) 
19 YES EIVS_BDF_solids_14219C_11_12.xls 1 27/05/2011 B109(Kt) B76(Kt) B136(Kt) B122(Kt) B124(Kt) 
20 YES EIVS_BDF_solids_14234A_11_10.xls 1 27/05/2011 B115(1) B33(1) B2(1) B81(1) B104(1) B109(1) B76(1) B136(1) B122(1) B124(1) 
21 YES EIVS_BDF_solids_14241B_12_14.xls 1 27/05/2011 B115(2) B33(2) B2(2) B81(2) B104(2) B109(2) B76(2) B136(2) B122(2) B124(2) 
22 YES EIVS_BDF_solids_14248B_13_16.xls 1 27/05/2011 B115(3) B33(3) B2(3) B81(3) B104(3) B109(3) B76(3) B136(3) B122(3) B124(3) 
23 
wrong run 
numbers NO  EIVS_HARLAN_SOLIDS_15003C_21_11.xls 1 01/06/2011 H10(1) H60(1) H105(1) H110(1) 
24 same as 18 NO  EIVS_HARLAN_SOLIDS_KC_11.xls 1 01/06/2011 H10(Kt) H60(Kt) H105(Kt) H110(Kt) 
25 
replacement of 
23; pc code 
missing NO EIVS_HARLAN_SOLIDS_15003C_21_11.xls 1 01/06/2011 H10(2) H60(2) H105(2) H110(2) 
26 replaced by 70 NO EIVS_BDF_solids_14234B_11_11.xls 1 01/06/2011 B59(1) B101(1) B80(1) 
B80CC(1
) B34(1) B105(1) B87(1) 
B87CC(1
) B131(1) 




) B59(2) B101(2) B34(2) B105(2) B131(2) B99(4) 




) B59(3) B101(3) B34(3) B105(3) B131(3) 
29 YES  EIVS_BDF_solids_14256B_14_20.xls 1 01/06/2011 B132(1) B40(1) B88(1) B107(1) B117(1) B119(1) B135(1) B110(1) B108(1) B23(1) 
30 YES  EIVS_BDF_solids_14263C_15_23.xls 1 01/06/2011 B132(2) B40(2) B88(2) B107(2) B117(2) B119(2) B135(2) B110(2) B108(2) B23(2) 
31 YES  EIVS_BDF_solids_14277D_17_26.xls 1 01/06/2011 B132(3) B40(3) B88(3) B107(3) B117(3) B119(3) B135(3) B110(3) B108(3) B23(3) 
32 YES  EIVS_BDF_solids_14283C_18_28.xls 1 01/06/2011 B132(3) B40(3) B88(3) B107(3) B117(3) B119(3) B135(3) B110(3) B108(3) B23(3) 
33 YES  EIVS_HARLAN_SOLIDS_15013B_24_13.xls 1 13/07/2011 H20(1) H39(1) H54(1) H76(1)      
34 YES  EIVS_HARLAN_SOLIDS_15029B_27_14.xls 1 13/07/2011 H20(2) H39(2) H54(2) H76(2)       
35 YES  EIVS_HARLAN_SOLIDS_KC_13.xls 1 13/07/2011 H20Kt H39Kt H54Kt H76Kt       
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42 YES EIVS_BDF_solids_14289C_19_31.xls 1 28/07/2011 B169(1) B177(1) B26(1) B29(1) B112(1) B178(1) B47(1) B79(1) B92(1) B145(1) 
43 YES EIVS_BDF_solids_14296B_20_36.xls 1 28/07/2011 B169(2) B177(2) B26(2) B29(2) B112(2) B178(2) B47(2) B79(2) B92(2) B145(2) 
44 YES EIVS_BDF_solids_15003A_21_37.xls 1 28/07/2011 B169(3) B177(3) B26(3) B29(3) B112(3) B178(3) B47(3) B79(3) B92(3) B145(3) 
45 YES EIVS_IIVS_solids_14256_week7_number7_AH.xls 1 05/08/2011 V105(1) V106(1) V107(1) V113(1) V117(1) V119(1)     
46 YES EIVS_IIVS_solids_14263_week8_number9_AH.xls 1 05/08/2011 V105(2) V106(2) V107(2) V113(2) V117(2) V119(2)     
47 YES EIVS_IIVS_solids_14270_week9_number11_AH.xls 1 05/08/2011 V105(3) V106(3) V107(3) V113(3) V117(3) V119(3) V154(1) V156(1) V164(1) V166(1) 
48 YES EIVS_HARLAN_Solids_15033C_31_16.xls 1 17/08/2011 H50(1) H51(1) H53(1) H88(1) H116(1) H161(1) H163(1) H167(1) H176(1) H188(1) 
49 YES EIVS_HARLAN_Solids_15034B_32_17.xls 1 17/08/2011 H50(2) H51(2) H53(2) H88(2) H116(2) H161(2) H163(2) H167(2) H176(2) H188(2) 
50 YES EIVS_IIVS_solids_15007_week16_number23_AH.xls 1 30/08/2011 V154(2) V156(2) V164(2) V166(2)       
51 YES EIVS_IIVS_solids_15013_week17_number24_AH.xls 1 30/08/2011 V154(3) V156(3) V164(3) V166(3)       
52 YES EIVS_IIVS_solids_14219_week1_number1_MK.xls 1 31/08/2011 
V5(1) V16(1) V21(1) V22(1) V27(1) V30(1) V39(1) V39_CC(
1) 
V53(1) V69(1) 
53 YES EIVS_IIVS_solids_14222_week2_number2_MK.xls 1 31/08/2011 
V5(2) V16(2) V21(2) V22(2) V27(2) V30(2) V39(2) V39_CC(
2) 
V53(2) V69(2) 
54 YES EIVS_IIVS_solids_14225_week3_number3_MK.xls 1 31/08/2011 
V5(3) V16(3)  V22(3) V27(3) V30(3) V39(3) V39_CC(
3) 
V53(3) V69(3) 
55 YES EIVS_IIVS_solids_14234_week4_number4_MK.xls 1 31/08/2011 V18(1) V28(1) V37(1) 
V37_CC(
1) V66(1) V72(1) V80(1) V108(1) V109(1) V111(1) 
56 YES EIVS_IIVS_solids_14241_week5_number5_MK.xls 1 31/08/2011 V18(2) V28(2) V37(2) 
V37_CC(
2) V66(2) V72(2) V80(2) V108(2) V109(2) V111(2) 
57 YES EIVS_IIVS_solids_14248_week6_number6_MK.xls 1 31/08/2011 V18(3) V28(3) V37(3) 
V37_CC(
3) V66(3) V72(3) V80(3) V108(3) V109(3) V111(3) 
58 YES EIVS_IIVS_solids_14256_week7_number7_MK.xls 1 31/08/2011 V32(1) V34(1) V45(1) V56(1) V58(1) 
V58_CC(
1) V85(1) V86(1) V87(1) V101(1) 
59 YES EIVS_IIVS_solids_14263_week8_number8_MK.xls 1 31/08/2011 V32(2) V34(2) V45(2) V56(2) V37(4) 
V37_CC(
4) V85(2) V86(2) V87(2) V101(2) 





61 YES EIVS_BDF_solids_15003B_21_39.xls 1 05/09/2011 B55(4) 
B55_CC(
4) B199(1) 
62 YES EIVS_BDF_solids_15007B_23_41.xls 1 05/09/2011 B199(2) 
63 
incorrect batch 
no NO EIVS_BDF_solids_15013A_24_43.xls 1 05/09/2011 B199(3) B47(4) B23(5) 




4) B128(4) B168(4) 












15 YES EIVS_BDF_solids_14219D_08_02 revised_updated.xls EIVS_BDF_solids_14219D_08_02.xls 1 07/09/2011 B15(1) B21(1) B43(1) B52(1) B70(1) B13(1) B36(1) B46(1) B99(1) B71(1) 
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68 
replacement of 
16 YES EIVS_BDF_solids_14222A_09_05 revised_updated.xls EIVS_BDF_solids_14222A_09_05.xls 1 07/09/2011 B15(2) B21(2) B43(2) B52(2) B70(2) B13(2) B36(2) B46(2) B99(2) B71(2) 
69 
replacement of 
11 YES EIVS_BDF_solids_14225C_10_08_updated.xls EIVS_BDF_solids_14225C_10_08.xls 1 07/09/2011 B15(3) B21(3) B43(3) B52(3) B70(3) B13(3) B36(3) B46(3) B99(3) B71(3) 
70 
replacement of 
26 YES EIVS_BDF_solids_14234B_11_11_updated.xls EIVS_BDF_solids_14234B_11_11.xls 1 07/09/2011 B59(1) B101(1) B80(1) 
B80CC(1









) B59(2) B101(2) B34(2) B105(2) B131(2) B99(4) 
72 
replacement of 




) B59(3) B101(3) B34(3) B105(3) B131(3) 
73 YES 
B74_colorant_dilution_EIVS_BDF_solids_14283B_18_30.

























76 run? YES 
B74_colorant_dilution_EIVS_BDF_solids_15025A_26_50.







































81 YES EIVS_HARLAN_Solids_15035B_33_18.xls 1 19/09/2011 H50(3) H51(3) H53(3) H88(3) H116(3) H161(3) H163(3) H167(3) H176(3) H188(3) 








) H155(1) H58(1) 
83 YES EIVS_HARLAN_SOLIDS_KC34.xls 1 26/09/2011 H23_KC H36_KC H83_KC 
H155_K
C 
84 YES EIVS_IIVS_solids_14270_week9_number10_MK.xls 1 19/10/2011 V32(3) V34(3) V45(3) V56(3) V58(2) 
V58CC(2
) V85(3) V86(3) V87(3) V101(3) 
85 YES EIVS_IIVS_solids_14277_week10_number11_MK.xls 1 19/10/2011 V37(5) 
V37CC(5
) V130(1) V137(1) V140(1) V9(1) V9CC(1) V13(1) 
V13CC(1
) 
86 YES EIVS_IIVS_solids_14283_week11_number12_MK.xls 1 19/10/2011 V123(1) V129(1) V130(2) V137(2) V139(1) V140(2) V9(2) V9CC(2) V13(2) 
V13CC(2
) 
87 YES EIVS_IIVS_solids_14289_week12_number13_MK.xls 1 19/10/2011 V123(2) V129(2) V130(3) V137(3) V139(2) V140(3) V9(3) V9CC(3) V13(3) 
V13CC(3
) 
88 YES EIVS_IIVS_solids_14296_week13_number14_MK.xls 1 19/10/2011 V1(1) V14(1) 
V14CC(1
) V54(1) V59(1) V65(1) V68(1) V136(1) V146(1) V197(1) 
89 YES EIVS_IIVS_solids_15003_week14_number15_MK.xls 1 19/10/2011 V1(2) V14(2) 
V14CC(2
) V54(2) V59(2) V65(2) V68(2) V136(2) V146(2) V197(2) 
90 YES EIVS_IIVS_solids_15007_week15_number16_MK.xls 1 19/10/2011 V1(3) V14(3) 
V14CC(3
) V54(3) V59(3) V65(3) V68(3) V136(3) V146(3) V197(3) 



















) V45(4) V123(3) V129(3) V139(3) 
93 YES EIVS_IIVS_solids_15030_week18_number19_MK.xls 1 19/10/2011 V14(5) V14CC(5 V58(4) V58CC(4
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No Remark Used Filename Saved as version date content 
         ) ) 






) H155(2) H58(2) 
95 run? NO EIVS_Harlan_Solids_15046A_41_21.xls 1 27/10/2011 H23 H23CC H36 H36CC H83 H83CC H155 H58 
96 run? NO EIVS_Harlan_Solids_15048A_42_22.xls 1 28/10/2011 H23 H23CC H36 H36CC H83 H83CC H155 H58 
97 
replacement of 






) H155(3) H58(3) 
98 
replacement of 






) H155(4) H58(4) 
99 PC code missing NO EIVS_HARLAN_SOLIDS_15007A_23_12.xls 1 31/10/2011 H10(3) H60(3) H105(3) H110(3) 
100 YES EIVS_HARLAN_SOLIDS_15007A_23_12.xls 1 31/10/2011 










63 YES EIVS_BDF_solids_15013A_24_43-revised.xls EIVS_BDF_solids_15013A_24_43.xls 1 09/12/2011 B199(3) B47(4) B23(5) 
102 
replacement of 
17 YES EIVS_HARLAN_SOLIDS_14296E_20_10.xls 2 28/11/2011 H10(1) H60(1) H105(1) H110(1) 
103 
replacemebt of 
25 YES EIVS_HARLAN_SOLIDS_15003C_21_11.xls 2 28/11/2011 H10(2) H60(2) H105(2) H110(2) 
104 
replacemebt of 
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Appendix IV Remarks and special observations by 
the study personal 
Chemical filename remark 
5 EIVS_BDF_liquids_14241C_12_13.xls After treatment precipitation of the substance in the original container was 
recognized. By warming at 37øC the precipitate dissolved partly. 
7 EIVS_IIVS_liquids_14222_week2_number2_AH.xls Tissue 1: Small amount of moisture observed during pulling of tissues- moisture 
removed by blotting insert on sterile, absorbant towels. 
10 EIVS_IIVS_liquids_14248_week6_number5_AH.xls Variability observed between tissues during the MTT incubation 
11 EIVS_Harlan_liquids_14248E_13_04.xls Both tissues stained pink after TI exposure and rinsing 
11 EIVS_Harlan_liquids_14263D_15_05.xls Both tissues stained pink after TI exposure and rinsing 
11 EIVS_Harlan_liquids_14270A_16_06.xls Both tissues stained pink after TI exposure and rinsing 
11 EIVS_IIVS_liquids_14219_week1_number1_AH.xls Tissue 2: Blister covering entire tissue noticed after 12 minute soak (blister appeared 
filled with media) 
11 EIVS_IIVS_liquids_14225_week3_number3_AH.xls Tissue 1 & 2: Blisters covering entire surface of tissue noticed during rinsing. Tissue 
2: Blister covering entire tissue remained after soak- blister appeared to be filled with 
media. Tissue 2: Blister popped during blotting on paper towels prio 
12 EIVS_BDF_liquids_14283A_18_29.xls "cream-like residues after treatment and post-soak, causes turbid suspension after 
extraction, mean OD 1,915 
12 EIVS_BDF_liquids_14283A_18_29.xls centrifugation as described in SOP, " 
12 EIVS_BDF_liquids_14289D_19_32.xls "cream-like residues after treatment and post-soak, causes turbid suspension after 
extraction, mean OD 1,51 
12 EIVS_BDF_liquids_14289D_19_32.xls centrifugation as described in SOP, " 
12 EIVS_BDF_liquids_14296A_20_34.xls "cream-like residues after treatment and post-soak, causes turbid suspension after 
extraction, mean OD 1,458 
12 EIVS_BDF_liquids_14296A_20_34.xls centrifugation as described in SOP, " 
12 EIVS_HARLAN_LIQUIDS_15033B_31_16.xls Residual test item on tissues following rinsing 
12 EIVS_HARLAN_LIQUIDS_15034A_32_17.xls Residual test item on tissues after rinsing and post soak 
12 EIVS_HARLAN_LIQUIDS_15035A_33_18.xls Residual test item on tissues after rinsing and post soak 
12 EIVS_IIVS_liquids_14289_week12_number14_AH.xls Tissues 1&2: residual test article after rinse/soak- after soak, soak media cloudy 
12 EIVS_IIVS_liquids_14296_week13_number17_AH.xls Tissues 1&2: Residual test article after rinse/soak. Soak wells cloudy after soak. 
Possible small blisters noticed on tissues during rinsing. 
12 EIVS_IIVS_liquids_15003_week14_number19_AH.xls Tissue 1&2: residual test article after rinse/soak. Soak wells cloudy after soak. 
Possible small blisters noticed on tissues after rinse/soak. 
13 EIVS_BDF_liquids_14283A_18_29.xls "cream-like residues after treatment and post-soak, causes turbid suspension after 
extraction, mean OD 3,369 
13 EIVS_BDF_liquids_14283A_18_29.xls centrifugation as described in SOP, " 
13 EIVS_BDF_liquids_14289D_19_32.xls "cream-like residues after treatment and post-soak, causes turbid suspension after 
extraction, mean OD 2.00 
13 EIVS_BDF_liquids_14289D_19_32.xls centrifugation as described in SOP, " 
13 EIVS_BDF_liquids_14296A_20_34.xls "cream-like residues after treatment and post-soak, causes turbid suspension after 
extraction, mean OD 1.914 
13 EIVS_BDF_liquids_14296A_20_34.xls centrifugation as described in SOP, " 
13 EIVS_HARLAN_LIQUIDS_15033B_31_16.xls Residual test item on tissues following rinsing 
13 EIVS_HARLAN_LIQUIDS_15034A_32_17.xls Residual test item on tissues after rinsing and post soak 
13 EIVS_HARLAN_LIQUIDS_15035A_33_18.xls Residual test item on tissues after rinsing and post soak 
13 EIVS_IIVS_liquids_14289_week12_number14_AH.xls Tissues 1&2: residual test article after rinse/soak- after soak, soak media cloudy. 
After overnight extraction, both tissues were noticed to have a dark purple ring 
around the perimeter of the tissue. 
13 EIVS_IIVS_liquids_14296_week13_number17_AH.xls Tissues 1&2: Residual test article after rinse/soak. Soak wells cloudy after soak. 
After isopropanol extraction, purple ring noted around the perimeter of the tissues. 
13 EIVS_IIVS_liquids_15003_week14_number19_AH.xls Tissues 1&2: residual test article after rinse/soak. Soak wells cloudy after soak. Dark 
purple ring around perimeter of the tissues observed after isopropanol extraction. 
17 EIVS_IIVS_liquids_14234_week4_number4_HI.xls possible residual test article (clear/shiny) 
17 EIVS_IIVS_liquids_14241_week5_number6_HI.xls possible residual test article (clear/shiny) 
17 EIVS_IIVS_liquids_14248_week6_number7_HI.xls possible residual test article 
20 EIVS_IIVS_liquids_14277_week10_number12_AH.xls Tissues 1&2: residual test article after rinse/soak 
20 EIVS_IIVS_liquids_14283_week11_number13_AH.xls Tissues 1 & 2: residual test article after rinse/soak. V8 samples loaded into wells 
designated for TA11 after centrifugation. 
20 EIVS_IIVS_liquids_14289_week12_number15_AH.xls "Tissues 1&2: residual test article noticed after addition to MTT. After the 2 hour 
plate shake, precipitate noticed in the in 24-wells containing isopropanol; 1mL of the 
extractant was transferred to a centrifuge tube and centrifuged at ~13,000 g f 
21 EIVS_IIVS_liquids_14256_week7_number6_AH.xls Tissue 1: small amount of excess media noticed prior to adding 20 æL DPBS. Media 
was blotted on sterile towels before DPBS addition. 
22 EIVS_BDF_liquids_14248A_13_17.xls After postincubation there are bubbles below the tissues and crustifications on the 
rim of the insert. 
22 EIVS_BDF_liquids_14256A_14_19.xls After postincubation there are bubbles below the tissues and crustifications on the 
rim of the insert. 
22 EIVS_BDF_liquids_14263A_15_22.xls After postincubation there are bubbles below the tissues and crustifications on the 
rim of the insert. 
22 EIVS_IIVS_liquids_14234_week4_number4_HI.xls MTT pattern of reduction is consistent with immiscibility of test article after dosing. 
(the part of the tissue actually making contact with the test article was completely 
dead) 
22 EIVS_IIVS_liquids_14241_week5_number6_HI.xls Tissue 1: MTT pattern of reduction is consistent with immiscibility of test article after 
dosing. (the part of the tissue actually making contact with the test article was 
completely dead) 
23 EIVS_BDF_liquids_14248A_13_17.xls "After incubation the medium is light yellow (pH8,5). 
23 EIVS_BDF_liquids_14248A_13_17.xls Crustification on the rim of the insert after postincubation. 
23 EIVS_BDF_liquids_14248A_13_17.xls After MTT-staining the color of the rest of the MTT-medium has turned to blue." 
23 EIVS_BDF_liquids_14256A_14_19.xls "After incubation the medium is light yellow (pH8,5). 
23 EIVS_BDF_liquids_14256A_14_19.xls Crustification on the rim of the insert after postincubation. 
23 EIVS_BDF_liquids_14256A_14_19.xls After MTT-staining the color of the rest of the MTT-medium has turned to blue." 
23 EIVS_BDF_liquids_14263A_15_22.xls "After incubation the medium is light yellow (pH8,5). 
23 EIVS_BDF_liquids_14263A_15_22.xls Crustification on the rim of the insert after postincubation. 
23 EIVS_BDF_liquids_14263A_15_22.xls After MTT-staining the color of the rest of the MTT-medium has turned to blue." 
23 EIVS_HARLAN_LIQUIDS_15029A_27_14.xls Media turned paler pink after exposure. 
23 EIVS_HARLAN_LIQUIDS_15030A_28_15.xls Media turned paler pink after exposure. 
  
TNO report | TNO2013 R10396 | Final  85 / 173
Chemical filename remark 
23 EIVS_HARLAN_LIQUIDS_15033A_31_16.xls Media turned lighter pink after exposure. 
23 EIVS_IIVS_liquids_14248_week6_number5_AH.xls Tissues 1&2: Media in wells slightly orange 
23 EIVS_IIVS_liquids_14256_week7_number6_AH.xls "Immediately after dosing, the test article was attempted to be spread; the millicell 
was dropped onto its side- some test article may have spilled into the media (media 
turned slightly orange)- after the 30 minute dosing period, both wells of tis 
23 EIVS_IIVS_liquids_14263_week8_number8_AH.xls Tissues 1&2: Media in wells turned slightly orange during 30 minute dosing period 
23 EIVS_IIVS_liquids_14270_week9_number10_AH.xls Tissues 1 & 2: media in wells turned slightly orange during dosing period 
26 EIVS_BDF_liquids_15003B_21_38.xls light yellow residues (like jelly) after washing, postsoak, postinkubation, MTT and 
extraction. 
26 EIVS_BDF_liquids_15007B_23_40.xls light yellow residues (like jelly) after washing, postsoak, postinkubation, MTT and 
extraction 
26 EIVS_BDF_liquids_15013A_24_42.xls light yellow residues (like jelly) after washing, postsoak, postinkubation, MTT and 
extraction 
26 EIVS_HARLAN_LIQUIDS_15033B_31_16.xls Residual test item on tissues following rinsing 
26 EIVS_HARLAN_LIQUIDS_15034A_32_17.xls Residual test item on tissues after rinsing and post soak 
26 EIVS_HARLAN_LIQUIDS_15035A_33_18.xls Residual test item on tissues after rinsing and post soak 
26 EIVS_IIVS_liquids_14277_week10_number12_AH.xls "Tissue 2: large residual test article after rinse/soak. Tissues 1 & 2: After 2 hour post-
incubation soak, droplets of test article noticed floating in the media of both wells. 
This floating test article may have been stuck to the outside of the 
26 EIVS_IIVS_liquids_14283_week11_number13_AH.xls Tissues 1 & 2; residual test article after rinse/soak. Extra care taken to wipe the 
outside of the millicells with sterile towels after soak 
26 EIVS_IIVS_liquids_14296_week13_number18_AH.xls Tissues 1&2: Residual test article remained on tissues after rinse/soak 
26 EIVS_IIVS_liquids_15003_week14_number20_AH.xls Tissue 1&2: residual test article after rinse/soak. 
29 EIVS_BDF_solids_14283B_18_30.xls residues after washing, post-soak, postincubation, MTT test and extraction 
29 EIVS_BDF_solids_14289E_19_33.xls no residues 
29 EIVS_BDF_solids_14296C_20_35.xls residues after washing and post-soak 
29 EIVS_BDF_solids_15019A_25_44.xls Residues after washing and post-soak. 
29 EIVS_HARLAN_Solids_15033C_31_16.xls Residual test item on tissues after rinsing and post soak. 
29 EIVS_IIVS_solids_14296_week13_number14_MK.xls Small amount of residual test article following rinsing and soaking. 
29 EIVS_IIVS_solids_15003_week14_number15_MK.xls Small amount of residual test article following rinsing and soaking. Tissue # 2 had 
twice as much residual test article in comparison to tissue # 1. 
29 EIVS_IIVS_solids_15007_week15_number16_MK.xls Small amount of residual test article following rinsing and soaking. 
30 EIVS_BDF_solids_14234A_11_10.xls solubilize in prewetting water -> liquid 
30 EIVS_BDF_solids_14241B_12_14.xls solubilize in prewetting water -> liquid 
30 EIVS_BDF_solids_14248B_13_16.xls solubilize in prewetting water -> liquid 
30 EIVS_Harlan_solids_14277C_17_07.xls For both tissues the test item was dissolved during the exposure period. 
30 EIVS_Harlan_solids_14283E_18_08.xls For both tissues the test item was dissolved during the exposure period. 
30 EIVS_Harlan_solids_14289B_19_09.xls For both tissues the test item was dissolved during the exposure period. 
30 EIVS_IIVS_solids_14277_week10_number11_MK.xls Media pooled within the millicells, observed following test article exposure. 
30 EIVS_IIVS_solids_14283_week11_number12_MK.xls Media pooled within the millicells following test aricle exposure time. 
30 EIVS_IIVS_solids_14289_week12_number13_MK.xls Media was observed to have pooled within the millicells following test article 
exposure time. 
31 EIVS_Harlan_solids_14277C_17_07.xls For both tissues the test item was dissolved during the exposure period. 
32 EIVS_BDF_solids_14234B_11_11.xls Medium yellow after exposure and washing . 
32 EIVS_BDF_solids_14241A_12_15.xls Small residues after rinsing and post-soak. 
32 EIVS_BDF_solids_14248C_13_18.xls Residues after rinsing an post soak. Medium yellow after exposure and post 
incubation. 
32 EIVS_HARLAN_SOLIDS_15013B_24_13.xls Media stained yellow after exposure. Tissues stained yellow/brown after rinsing and 
soaking. 
32 EIVS_HARLAN_SOLIDS_15013B_24_13.xls Media stained yellow after exposure. Tissues stained yellow/brown after rinsing and 
soaking. 
32 EIVS_HARLAN_SOLIDS_15029B_27_14.xls Media stained yellow after exposure. Tissues stained yellow/brown after rinsing and 
soaking. 
32 EIVS_HARLAN_SOLIDS_15029B_27_14.xls Media stained yellow after exposure. Tissues stained yellow/brown after rinsing and 
soaking. 
32 EIVS_HARLAN_SOLIDS_15030B_28_15.xls Media stained orange after exposure. Tissues stained brown/yellow after rinsing and 
soaking. 
32 EIVS_HARLAN_SOLIDS_15030B_28_15.xls Media stained orange after exposure. Tissues stained brown/yellow after rinsing and 
soaking. 
32 EIVS_IIVS_solids_14234_week4_number4_MK.xls "Media beneath millicells had turned a pale orange after test article exposure time. 
For both tissue replicates, there was possible residual test article and/or tissue 
staining observed after rinsing and soaking. Tissues appeared to be stained a br 
32 EIVS_IIVS_solids_14241_week5_number5_MK.xls "Media beneath millicells had turned a pale orange after test article exposure time. 
For both tissue replicates, there was possible residual test article and/or tissue 
staining observed after rinsing and soaking. Tissues appeared to be stained a br 
32 EIVS_IIVS_solids_14248_week6_number6_MK.xls "Media beneath millicells had turned a pale orange after test article exposure time. 
For both tissue replicates, there was possible residual test article and/or tissue 
staining observed after rinsing and soaking. Tissues appeared to be stained a br 
33 EIVS_BDF_solids_14234B_11_11.xls "Different amount of residues after washing and post-soak. 
33 EIVS_BDF_solids_14234B_11_11.xls In contrast to CC of B87 qualified! " 
33 EIVS_BDF_solids_14234B_11_11.xls "B87CC: Much more residues than B87 after washing and post-soak. The formazan-
extracts were diluted 5% in isopropanol (additional spreadsheets: B87_colorant-
1dilution_solids_14234B_11_11 and B87_colorant-dilution_solids_14234B_11_11 
33 EIVS_BDF_solids_14234B_11_11.xls NOT QUALIFIED!! OD >> 3,000" 
33 EIVS_BDF_solids_14241A_12_15.xls "Medium dark blue after exposure and post incubation, tissue 2 much more residues 
after rinsing and postsoak than tissue The formazan-extracts were diluted 5% in 
isopropanol (additional spreadsheets: B87_colorant-1dilution_solids_14241A_12_15 
and 
33 EIVS_BDF_solids_14241A_12_15.xls NOT QUALIFIED!! OD >> 3,000" 
33 EIVS_BDF_solids_14241A_12_15.xls "B87CC: Medium dark blue after exposure and post incubation, both tissues more 
residues after rinsing and postsoak than B87 tissues.The formazan-extracts were 
diluted 5% in isopropanol (additional spreadsheets: B87_colorant-
1dilution_solids_14241A_12 
33 EIVS_BDF_solids_14241A_12_15.xls NOT QUALIFIED!! OD >> 3,000" 
33 EIVS_BDF_solids_14248C_13_18.xls "Medium dark blue after exposure and post incubation, tissue 1 much more residues 
after rinsing and postsoak than tissue 2. The formazan-extracts were diluted 5% in 
isopropanol (additional spreadsheets: B87_colorant-1dilution_solids_14248C_13_18 
a 
33 EIVS_BDF_solids_14248C_13_18.xls NOT QUALIFIED!! OD of tissue 1 >> 3,000" 
33 EIVS_BDF_solids_14248C_13_18.xls "B87CC: Medium dark blue after exposure and post incubation, both tissues more 
residues after rinsing and postsoak than B87 tissues.The formazan-extracts were 
diluted 5% in isopropanol (additional spreadsheets: B87_colorant-
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1dilution_solids_14248C_13 
33 EIVS_BDF_solids_14248C_13_18.xls NOT QUALIFIED!! OD >> 3,000" 
33 EIVS_BDF_solids_15019A_25_44.xls "Different amount of residues after washing and post-soak. Tissue 1 = OD >> 3,000 
33 EIVS_BDF_solids_15019A_25_44.xls NOT QUALIFIED!! " 
33 EIVS_BDF_solids_15019A_25_44.xls "B87CC: Residues after washing and post-soak. The formazan-extracts were diluted 
2,5% in isopropanol (additional spreadsheets: B87_colorant-dilution_solids_15019A-
25_44) 
33 EIVS_BDF_solids_15019A_25_44.xls NOT QUALIFIED!! OD >> 3,000" 
33 EIVS_BDF_solids_15025A_26_50.xls Little Residues after washing and post-soak. 
33 EIVS_BDF_solids_15025A_26_50.xls B87CC:Little Residues after washing and post-soak. 
33 EIVS_HARLAN_SOLIDS_15013B_24_13.xls Media stained purple after exposure. Residual test item on tissues after rinsing and 
soaking. Media stained purple after 18 hour post exposure incubation. 
33 EIVS_HARLAN_SOLIDS_15013B_24_13.xls Media stained purple after exposure. Residual test item on tissues after rinsing and 
soaking. Media stained purple after 18 hour post exposure incubation. 
33 EIVS_HARLAN_SOLIDS_15029B_27_14.xls Media stained purple after exposure. Small amount of residual test item on tissues 
after rinsing and soaking. 
33 EIVS_HARLAN_SOLIDS_15029B_27_14.xls Media stained purple after exposure. Small amount of residual test item on tissues 
after rinsing and soaking. 
33 EIVS_HARLAN_SOLIDS_15030B_28_15.xls Media stained purple after exposure. Small amount of residual test item on tissues 
after rinsing and soaking. 
33 EIVS_HARLAN_SOLIDS_15030B_28_15.xls Media stained purple after exposure. Small amount of residual test item on tissues 
after rinsing and soaking. 
33 EIVS_HARLAN_SOLIDS_15037B_34_19.xls Media turned purple during exposure. Residual test item on tissues after rinsing and 
post soak. Tissues stained purple. 
33 EIVS_HARLAN_SOLIDS_15037B_34_19.xls Media turned purple during exposure. Residual test item on tissues after rinsing and 
post soak. Tissues stained purple. 
33 EIVS_IIVS_solids_14256_week7_number7_MK.xls Media beneath millicells had turned purple following test article exposure time. 
Tissues had slight staining following rinsing and soaking. 
33 EIVS_IIVS_solids_14256_week7_number7_MK.xls Media beneath millicells had turned purple following test article exposure time. 
Tissues had slight staining following rinsing and soaking. 
33 EIVS_IIVS_solids_14270_week9_number10_MK.xls Media beneath millicells turned purple after test article exposure time. Tissue 
staining observed around the outside perimeter after rinsing and soaking. 
33 EIVS_IIVS_solids_14270_week9_number10_MK.xls Media beneath millicells turned purple after test article exposure time. Tissue 
staining observed around the outside perimeter after rinsing and soaking. Residual 
test article on Tissue # 2 after rinsing and soaking. The media beneath the millicell 
33 EIVS_IIVS_solids_15013_week16_number17_MK.xls "Media beneath millicells observed to have turned purple following test article 
exposure time. Tissues were stained purple and large amount of residual test article 
following rinsing and soaking. Media beneath millicells turned purple, observed fol 
33 EIVS_IIVS_solids_15013_week16_number17_MK.xls "Media beneath millicells observed to have turned purple following test article 
exposure time. Tissues were stained purple and large amount of residual test article 
following rinsing and soaking. Media beneath millicells turned purple, observed fol 
33 EIVS_IIVS_solids_15030_week18_number19_MK.xls "Media beneath millicells observed to have turned purple following test article 
exposure time. Tissues stained purple in patchy areas and residual test article 
following rinsing and soaking. Tissue #2 had much less staining and residual test 
articl 
33 EIVS_IIVS_solids_15030_week18_number19_MK.xls "Media beneath millicells observed to have turned purple following test article 
exposure time. Tissues stained purple in patchy areas and residual test article 
following rinsing and soaking. Media beneath millicells turned dark purple, observed 
fol 
34 EIVS_BDF_solids_14234B_11_11.xls Red residues after washing , small residues after post-soak. 
34 EIVS_BDF_solids_14234B_11_11.xls B80CC: Red residues after washing , small residues after post-soak. 
34 EIVS_BDF_solids_14241A_12_15.xls Small residues after rinsing and post-soak. 
34 EIVS_BDF_solids_14241A_12_15.xls B80CC: Small residues after rinsing and post-soak. 
34 EIVS_BDF_solids_14248C_13_18.xls Small residues after rinsing an post soak. 
34 EIVS_BDF_solids_14248C_13_18.xls B80CC: Small residues after rinsing an post soak. 
34 EIVS_HARLAN_SOLIDS_15013B_24_13.xls Test item liquified in inserts during exposure. Tissues stained brown/purple after 
rinsing and soaking. 
34 EIVS_HARLAN_SOLIDS_15013B_24_13.xls Test item liquified in inserts during exposure. Tissues stained brown/purple after 
rinsing and soaking. 
34 EIVS_HARLAN_SOLIDS_15029B_27_14.xls Test item liquified in inserts during exposure. Tissues stained brown/purple after 
rinsing and soaking. 
34 EIVS_HARLAN_SOLIDS_15029B_27_14.xls Test item liquified in inserts during exposure. Tissues stained brown/purple after 
rinsing and soaking. 
34 EIVS_HARLAN_SOLIDS_15030B_28_15.xls Test item liquified during exposure. Tissues stained brown/purple after rinsing and 
soaking. 
34 EIVS_HARLAN_SOLIDS_15030B_28_15.xls Test item liquified during exposure. Tissues stained brown/purple after rinsing and 
soaking. 
34 EIVS_IIVS_solids_14234_week4_number4_MK.xls "For both tissue replicates, there was possible residual test article and/or tissue 
staining observed after rinsing and soaking. A small amount of extractant pooled into 
the millicell of tissue #1 during extraction period. Both tissues appeared to 
34 EIVS_IIVS_solids_14234_week4_number4_MK.xls For both tissue replicates, there was possible residual test article and/or tissue 
staining observed after rinsing and soaking. Both tissues appeared to be stained 
orange after the extraction period 
34 EIVS_IIVS_solids_14241_week5_number5_MK.xls For both tissue replicates, there was possible residual test article and/or tissue 
staining observed after rinsing and soaking. Both tissues appeared to be stained a 
brownish-orange after the extraction period 
34 EIVS_IIVS_solids_14241_week5_number5_MK.xls For both tissue replicates, there was possible residual test article and/or tissue 
staining observed after rinsing and soaking. Both tissues appeared to be stained 
orange after the extraction period 
34 EIVS_IIVS_solids_14248_week6_number6_MK.xls For both tissue replicates, there was possible residual test article and/or tissue 
staining observed after rinsing and soaking. Both tissues appeared to be stained a 
brownish-orange after the extraction period 
34 EIVS_IIVS_solids_14248_week6_number6_MK.xls For both tissue replicates, there was possible residual test article and/or tissue 
staining observed after rinsing and soaking. Both tissues appeared to be stained 
orange after the extraction period 
34 EIVS_IIVS_solids_14263_week8_number8_MK.xls Tissue staining observed following rinsing and soaking. Tissues appeared to be 
stained a brownish orange after extraction period. 
34 EIVS_IIVS_solids_14263_week8_number8_MK.xls Tissue staining observed following rinsing and soaking. Tissues appeared to be 
stained orange after extraction period. 
34 EIVS_IIVS_solids_14277_week10_number11_MK.xls Possible residual test article or tissue staining, observed following rinsing and 
soaking. Tissues stained a brownish orange after extraction. 
34 EIVS_IIVS_solids_14277_week10_number11_MK.xls Possible residual test article or tissue staining, observed following rinsing and 
soaking. Tissues stained orange after extraction. 
  
TNO report | TNO2013 R10396 | Final  87 / 173
Chemical filename remark 
35 EIVS_BDF_solids_14219D_08_02.xls After rinsing little residues left. 
35 EIVS_BDF_solids_14222A_09_05.xls More substance needed on both tissues (2x syringe), small residues after rinsing and 
postsoak on both tissues. 
35 EIVS_BDF_solids_14225C_10_08.xls Residues after rinsing and postsoak. 
35 EIVS_BDF_solids_14225C_10_08.xls No data because of cancelling B36. Two tissues were saved for using as killed 
contols. 
35 EIVS_HARLAN_SOLIDS_14296E_20_10.xls Residual test items on both tissues post rinsing 
35 EIVS_HARLAN_SOLIDS_15003C_21_11.xls Residual test item on both tissues post rinsing 
35 EIVS_HARLAN_SOLIDS_15007A_23_12.xls Residual test item on tissues post rinsing 
36 EIVS_BDF_solids_14219D_08_02.xls After rinsing small residues left. 
36 EIVS_BDF_solids_14222A_09_05.xls More substance needed on both tissues (2x syringe), very small residues after 
rinsing and postsoak on both tissues. 
36 EIVS_IIVS_solids_14234_week4_number4_MK.xls Small residual test article remained on tissues after rinsing and soaking 
36 EIVS_IIVS_solids_14248_week6_number6_MK.xls Small residual test article remained on tissues after rinsing and soaking. 
37 EIVS_BDF_liquids_14256C_14_21.xls viscous substance, not washed off, see photo " 113_after post soak", D>20 possibly 
because of pipetting mistake 
37 EIVS_BDF_liquids_15003B_21_38.xls foams during washing, residues (like jelly) after washing and postsoak 
37 EIVS_BDF_liquids_15007B_23_40.xls foams during washing, residues (like jelly) after washing and postsoak 
37 EIVS_BDF_liquids_15013A_24_42.xls foams during washing, residues (like jelly) after washing and postsoak 
37 EIVS_Harlan_liquids_14277B_17_07.xls Residual test item noted on both tissues following rinsing 
37 EIVS_Harlan_liquids_14283D_18_08.xls Residual test item noted on both tissues following rinsing 
37 EIVS_Harlan_liquids_14289A_19_09.xls Residual test item noted on both tissues following rinsing 
37 EIVS_IIVS_liquids_14248_week6_number5_AH.xls Tissue 1&2: Residual test article remained after dosing/rinsing 
37 EIVS_IIVS_liquids_14256_week7_number6_AH.xls Tissues 1 & 2: Residual test article remained after dosing/ rinsing 
37 EIVS_IIVS_liquids_14263_week8_number8_AH.xls Tissues 1&2: residual test article remained after rinsing/soaking 
38 EIVS_BDF_solids_14289C_19_31.xls Few residues after post soak on the inner wall of the inserts. 
38 EIVS_BDF_solids_14296B_20_36.xls Few residues after post soak on the inner wall of the inserts. 
38 EIVS_IIVS_solids_14296_week13_number14_MK.xls Small amount of residual test article following rinsing and soaking. 
38 EIVS_IIVS_solids_15003_week14_number15_MK.xls Very small amount of residual test article following rinsing and soaking. 
38 EIVS_IIVS_solids_15007_week15_number16_MK.xls Very small amount of residual test article following rinsing and soaking. 
39 EIVS_BDF_solids_14289C_19_31.xls Few residues after post soak. 
39 EIVS_BDF_solids_14296B_20_36.xls Few residues after post soak on the tissues and on the inner wall of the inserts. 
39 EIVS_BDF_solids_15003A_21_37.xls Few residues after post soak on the tissues and on the inner wall of the inserts. 
39 EIVS_IIVS_solids_14296_week13_number14_MK.xls "Immediately after dosing, it was noticed that some test article had spilled into the 6-
well plate of tissue # 1. The millicell was placed into a new 6-well plate containing 
fresh media. Small amount of residual test article on both tissues followin 
39 EIVS_IIVS_solids_15003_week14_number15_MK.xls Small amount of residual test article on both tissues following rinsing and soaking. 
39 EIVS_IIVS_solids_15007_week15_number16_MK.xls Small amount of residual test article on both tissues following rinsing and soaking. 
40 EIVS_BDF_solids_14289C_19_31.xls Substance remains completely on the tissue after washing. After post soak 
substance still on the tissue. Some liquid (yellow-brown) is above the substance. 
40 EIVS_BDF_solids_14296B_20_36.xls Substance remains completely on the tissue after washing. After post soak 
substance still on the tissue. Some liquid (yellow-brown) is above the substance. 
40 EIVS_BDF_solids_15003A_21_37.xls Substance remains completely on the tissue after washing. After post soak 
substance still on the tissue. Some liquid (yellow-brown) is above the substance. 
40 EIVS_HARLAN_SOLIDS_15037B_34_19.xls Test item turned to gel in insert during exposure. Residual test item on tissues after 
rinsing and post soak 
40 EIVS_Harlan_Solids_15046A_41_21.xls Test item turned to gel on tissues during exposure. Residual test item on tissues 
after rinsing and post soak. 
40 EIVS_Harlan_Solids_15048A_42_22.xls Test item turned to gel during exposure. Residual test item on tissues after rinsing 
and post soak. 
40 EIVS_IIVS_solids_14296_week13_number14_MK.xls Large amount of residual test article, the test article seemed to turn into a gel 
following rinsing and soaking. 
40 EIVS_IIVS_solids_15003_week14_number15_MK.xls Large amount of residual test article, the test article seemed to turn into a gel 
following rinsing and soaking. 
40 EIVS_IIVS_solids_15007_week15_number16_MK.xls Large amount of residual test article, the test article seemed to turn into a gel 
following rinsing and soaking. 
41 EIVS_IIVS_solids_14234_week4_number4_MK.xls Small residual test article remained on tissues after rinsing and soaking 
41 EIVS_IIVS_solids_14248_week6_number6_MK.xls Small residual test article remained on tissues after rinsing and soaking. 
42 EIVS_BDF_solids_14234A_11_10.xls solubilize in prewetting water -> liquid 
42 EIVS_BDF_solids_14241B_12_14.xls solubilize in prewetting water -> liquid 
42 EIVS_BDF_solids_14248B_13_16.xls solubilize in prewetting water -> liquid 
42 EIVS_HARLAN_SOLIDS_14296E_20_10.xls Test item liquified in tissue inserts 
42 EIVS_HARLAN_SOLIDS_15003C_21_11.xls Test item liquified in tissue inserts 
42 EIVS_HARLAN_SOLIDS_15007A_23_12.xls Test item liquified in tissue inserts 
42 EIVS_IIVS_solids_14234_week4_number4_MK.xls Media pooled into millicell of both tissues, noticed prior to treatment termination 
42 EIVS_IIVS_solids_14241_week5_number5_MK.xls Media pooled into millicell of both tissues, noticed prior to treatment termination 
42 EIVS_IIVS_solids_14248_week6_number6_MK.xls Media pooled into millicell of both tissues, noticed prior to treatment termination 
44 EIVS_IIVS_solids_14256_week7_number7_AH.xls Tissue 2: Small amount of residual test article 
44 EIVS_IIVS_solids_14263_week8_number9_AH.xls Tissues 1&2: Small residual test article after rinsing/soaking. 
44 EIVS_IIVS_solids_14270_week9_number11_AH.xls Tissue 2: small amount of residual test article after rinse/soak 
46 EIVS_BDF_solids_14256B_14_20.xls solubilized/wax after treatment, sticks even after postsoak 
46 EIVS_BDF_solids_14263C_15_23.xls solubilized/wax after treatment, sticks even after postsoak 
46 EIVS_BDF_solids_14277D_17_26.xls solubilized/wax after treatment, sticks even after postsoak 
46 EIVS_BDF_solids_14283C_18_28.xls solubilized/wax after treatment, sticks even after postsoak 
46 EIVS_Harlan_solids_14277C_17_07.xls Test item became a gel following exposure and as such it was not possible to 
remove it from the tissues during the rinsing process. 
46 EIVS_Harlan_solids_14283E_18_08.xls Test item became a gel following exposure and as such it was not possible to 
remove it from the tissues during the rinsing process. 
46 EIVS_Harlan_solids_14289B_19_09.xls Test item became a gel following exposure and as such it was not possible to 
remove it from the tissues during the rinsing process. 
46 EIVS_IIVS_solids_14256_week7_number7_AH.xls "Large amount of residual test article- test article appeared to ""gel"" atop tissue after 
rinsing. After 18 hr post-exposure incubation, the ""gel"" (possible residual test 
article) atop the tissue surfaces appears to possibly contain media- the 
46 EIVS_IIVS_solids_14263_week8_number9_AH.xls "Tissues 1& 2: residual test article after rinsing/soaking- test article appeared to 
""gel"" atop tissue. ""Gel"" appeared to increase in size during overnight (18 hr) 
incubation and ""gel"" contained pink coloration (possible media). Tissues were 
46 EIVS_IIVS_solids_14270_week9_number11_AH.xls "Tissues 1&2: Test article ""gelled"" atop tissue- residual test article after rinse/soak. 
After 18 hr post exposure incubation, the ""gel"" appeared to increase in size 
(possible media within ""gel""). After isopropanol extraction, spots of black 
47 EIVS_BDF_solids_14234B_11_11.xls "Substance dissolved or melted on the surface of the tissue after exposure. 
47 EIVS_HARLAN_SOLIDS_14296E_20_10.xls Test item liquified in tissue inserts 
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47 EIVS_HARLAN_SOLIDS_15003C_21_11.xls Test item liquified in tissue inserts 
47 EIVS_HARLAN_SOLIDS_15007A_23_12.xls Test item liquified in tissue inserts 
47 EIVS_IIVS_solids_14270_week9_number11_AH.xls Tissues 1&2: Small amount of residual test article remained after rinse/soak 
48 EIVS_BDF_solids_14234A_11_10.xls solubilize in prewetting water -> liquid, medium yellow after treatment pH 5,5 
48 EIVS_BDF_solids_14241B_12_14.xls solubilize in prewetting water -> liquid, medium yellow after treatment pH 5,5 
48 EIVS_BDF_solids_14248B_13_16.xls solubilize in prewetting water -> liquid, medium yellow after treatment pH 5,5 
48 EIVS_Harlan_solids_14248F_13_04.xls Test item dissolved by medium (both tissues) and assay medium turned yellow 
48 EIVS_Harlan_solids_14263E_15_05.xls Test item dissolved by medium (both tissues) and assay medium turned yellow 
48 EIVS_Harlan_solids_14270B_16_06.xls Test item dissolved by medium (both tissues) and assay medium turned yellow 
48 EIVS_IIVS_solids_14283_week11_number12_MK.xls Media beneath millicells had turned yellow, observed after exposure time. Media had 
also pooled within each millicell. 
48 EIVS_IIVS_solids_14289_week12_number13_MK.xls Media beneath millicells had turned yellow, observed after test article exposure time. 
Media had also pooled within each millicell. 
48 EIVS_IIVS_solids_15013_week16_number17_MK.xls Media beneath millicells observed to have turned yellow following test article 
exposure time; media was also noticed to have pooled within millicells. 
49 EIVS_HARLAN_SOLIDS_15040A_38_20.xls Tissues partially detatched from inserts after rinsing. 
50 EIVS_BDF_solids_14283B_18_30.xls small residues after washing, post-soak, postincubation, MTT test and extraction 
50 EIVS_BDF_solids_14289E_19_33.xls no residues 
50 EIVS_BDF_solids_14296C_20_35.xls residues after washing and post-soak 
50 EIVS_BDF_solids_15019A_25_44.xls Little residues after washing and post-soak. 
51 EIVS_BDF_solids_14296B_20_36.xls Few residues after washing and post soak. 
51 EIVS_IIVS_solids_15007_week16_number23_AH.xls Tissue 2: During blotting after the rinse/soak, the millicell fell outside of the hood- the 
tissue was rinsed in the assay media soak well, blotted, and then transferred to the 
6-well plate for the post-exposure 18 hr incubation. 
52 EIVS_BDF_solids_14289C_19_31.xls Few residues after post soak on the tissues and on the inner wall of the inserts. 
52 EIVS_BDF_solids_14296B_20_36.xls Few residues after post soak on the tissues and on the inner wall of the inserts. 
52 EIVS_BDF_solids_15003A_21_37.xls Few residues after post soak on the tissues. 
52 EIVS_IIVS_solids_15007_week16_number23_AH.xls Tissues 1&2: residual test article noticed after rinse/soak- residual test article 
appears to adhere to the inside of the millicell only. 
53 EIVS_BDF_solids_14289C_19_31.xls Few residues after washing and post soak. 
53 EIVS_BDF_solids_14296B_20_36.xls Few residues after washing and post soak. 
53 EIVS_BDF_solids_15003A_21_37.xls Few residues after washing and post soak. 
53 EIVS_IIVS_solids_14270_week9_number11_AH.xls Tissue 2: During dosing it was noticed that the media may have some test article (3 
small particles). This test article may have stuck to the outside and may have fallen 
into the media from the outside of the millicell. The tissue (millicell) was 
53 EIVS_IIVS_solids_15007_week16_number23_AH.xls Tissues 1&2: residual test article noticed after rinse/soak. 
53 EIVS_IIVS_solids_15013_week17_number24_AH.xls Tissues 1&2: possible residual test article remained after rinse soak. 
54 EIVS_Harlan_liquids_14248E_13_04.xls Both tissues stained pink after TI exposure and rinsing 
54 EIVS_Harlan_liquids_14263D_15_05.xls Both tissues stained pink after TI exposure and rinsing 
54 EIVS_Harlan_liquids_14270A_16_06.xls Both tissues stained pink after TI exposure and rinsing 
55 EIVS_BDF_liquids_14256C_14_21.xls Substance stinks(!) and flows out of the closed container! See photos "B121-
container-a" and "B121-container-b". Medium yellow after exposure, after rinsing and 
postincubation medium o.k. 
55 EIVS_BDF_liquids_14263B_15_24.xls Substance stinks(!) and flows out of the closed container! Medium yellow after 
exposure, after rinsing and postincubation medium o.k. 
55 EIVS_BDF_liquids_14277E_17_27.xls Substance stinks(!) and spreads out of the closed container! Medium yellow after 
exposure, after rinsing and postincubation medium o.k. 
55 EIVS_Harlan_liquids_14277B_17_07.xls The media was stained yellow following exposure. Both tissues stained yellow 
following rinsing. 
55 EIVS_Harlan_liquids_14283D_18_08.xls The media was stained yellow following exposure. Both tissues stained yellow 
following rinsing. 
55 EIVS_Harlan_liquids_14289A_19_09.xls The media was stained yellow following exposure. Both tissues stained yellow 
following rinsing. 
55 EIVS_IIVS_liquids_14248_week6_number5_AH.xls Tissues 1&2: Media in wells turned orange/yellow during 30 minute test article dose 
55 EIVS_IIVS_liquids_14256_week7_number6_AH.xls Media in both wells yellow (noticed during rinsing). 
55 EIVS_IIVS_liquids_14263_week8_number8_AH.xls Tissues 1&2: Media in wells turned yellow during 30 minute dosing period. 
56 EIVS_BDF_liquids_14248A_13_17.xls The sealing is seperated into two layers. 
56 EIVS_BDF_liquids_14256A_14_19.xls The sealing is seperated into two layers. 
56 EIVS_BDF_liquids_14263A_15_22.xls The sealing is seperated into two layers. 
57 EIVS_Harlan_liquids_14248E_13_04.xls Both tissues partially detached from insert. 
57 EIVS_Harlan_liquids_14270A_16_06.xls Partially detached tissue (1 tissue only) 
61 EIVS_BDF_solids_14234B_11_11.xls Medium yellow after exposure, yellow resudues after washing and soak step. 
61 EIVS_BDF_solids_14241A_12_15.xls Small residues after rinsing and post-soak. 
61 EIVS_BDF_solids_14248C_13_18.xls Small residues after rinsing an post soak. Medium yellow after exposure and post 
incubation. 
61 EIVS_Harlan_solids_14225B_10_01.xls The assay medium in the wells of treatment plate and the tissue surface were 
stained orange (both tissues) 
61 EIVS_Harlan_solids_14234E_11_02.xls The assay medium in the wells of treatment plate and the tissue surface were 
stained orange (both tissues) 
61 EIVS_Harlan_solids_14241D_12_03.xls The assay medium in the wells of treatment plate and the tissue surface were 
stained orange (both tissues) 
61 EIVS_IIVS_solids_14219_week1_number1_MK.xls Media beneath millicells of both tissues appeared to have turned orange following 
the test article exposure time. Both tissues also had possible residual test article 
and/or tissue staining observed after rinsing and soaking. 
61 EIVS_IIVS_solids_14222_week2_number2_MK.xls Media beneath millicells of both tissues appeared to have turned orange following 
the test article exposure time. Both tissues also had possible residual test article 
and/or tissue staining observed after rinsing and soaking. 
61 EIVS_IIVS_solids_14225_week3_number3_MK.xls Media beneath millicells of both tissues appeared to have turned orange following 
the test article exposure time. Both tissues also had possible residual test article 
and/or tissue staining observed after rinsing and soaking. 
65 EIVS_BDF_solids_14256B_14_20.xls wax, no direct contact between chemical and surface possible at whole area. 
Spotted blue areas after MTT -> no contact = no cytotox? 
65 EIVS_BDF_solids_14263C_15_23.xls "wax, pressed to a bar (~2 mm high), used a biopsy punch (diameter 8mm) to 
prepare a round plate, applicated on surface of tissues with a spatula 
65 EIVS_BDF_solids_14263C_15_23.xls found during preparation pretesting that chemical evaporates" 
65 EIVS_BDF_solids_14277D_17_26.xls "wax, pressed to a bar (~2 mm high), used a biopsy punch (diameter 8mm) to 
prepare a round plate, applicated on surface of tissues with a spatula 
65 EIVS_BDF_solids_14277D_17_26.xls found during preparation pretesting that chemical evaporates" 
65 EIVS_BDF_solids_14283C_18_28.xls "wax, pressed to a bar (~2 mm high), used a biopsy punch (diameter 8mm) to 
prepare a round plate, applicated on surface of tissues with a spatula 
65 EIVS_BDF_solids_14283C_18_28.xls found during preparation pretesting that chemical evaporates" 
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65 EIVS_Harlan_solids_14277C_17_07.xls Due to the physical naute of the test item the test item was moulded into a disc of a 
size to totally cover the tissue surface during exposure and was removed as a disc 
following exposure. 
65 EIVS_Harlan_solids_14283E_18_08.xls Due to the physical naute of the test item the test item was moulded into a disc of a 
size to totally cover the tissue surface during exposure and was removed as a disc 
following exposure. 
65 EIVS_Harlan_solids_14289B_19_09.xls Due to the physical naute of the test item the test item was moulded into a disc of a 
size to totally cover the tissue surface during exposure and was removed as a disc 
following exposure. 
66 EIVS_BDF_solids_14256B_14_20.xls solubilized after treatment 
66 EIVS_BDF_solids_14263C_15_23.xls solubilized after treatment 
66 EIVS_BDF_solids_14277D_17_26.xls solubilized after treatment 
66 EIVS_BDF_solids_14283C_18_28.xls solubilized after treatment 
66 EIVS_Harlan_solids_14277C_17_07.xls For both tissues the test item was dissolved during the exposure period. 
66 EIVS_Harlan_solids_14283E_18_08.xls For both tissues the test item was dissolved during the exposure period. 
66 EIVS_Harlan_solids_14289B_19_09.xls For both tissues the test item was dissolved during the exposure period. 
66 EIVS_IIVS_solids_14283_week11_number12_MK.xls Media pooled within the millicells following test aricle exposure time. 
66 EIVS_IIVS_solids_14289_week12_number13_MK.xls Media was observed to have pooled within the millicells following test article 
exposure time. 
66 EIVS_IIVS_solids_15013_week16_number17_MK.xls Media pooled within millicells, observed following test article exposure time. 
67 EIVS_Harlan_liquids_14248E_13_04.xls Both tissues stained pink after TI exposure and rinsing 
67 EIVS_Harlan_liquids_14263D_15_05.xls Both tissues stained pink after TI exposure and rinsing 
67 EIVS_Harlan_liquids_14270A_16_06.xls Both tissues stained pink after TI exposure and rinsing 
68 EIVS_BDF_liquids_14225E_10_06.xls "Parts of the sealing stick on the lid. 
68 EIVS_BDF_liquids_14225E_10_06.xls After post-soak a part of the tissue detaches from the membrane." 
68 EIVS_BDF_liquids_14234C_11_09.xls "Parts of the sealing stick on the lid. 
68 EIVS_BDF_liquids_14234C_11_09.xls After post-soak a part of the tissue detaches from the membrane." 
68 EIVS_BDF_liquids_14241C_12_13.xls "Parts of the sealing stick on the lid. 
71 EIVS_BDF_liquids_14248A_13_17.xls Parts of the sealing stick on the rim. 
71 EIVS_BDF_liquids_14256A_14_19.xls Parts of the sealing stick on the rim. 
71 EIVS_BDF_liquids_14263A_15_22.xls Parts of the sealing stick on the rim. 
71 EIVS_Harlan_liquids_14289A_19_09.xls One tissue partially detached post rinsing 
72 EIVS_BDF_liquids_14256C_14_21.xls "TECHNICAL ISSUE according to VMG decision! Both tissues pink after exposure, 
see photos, after extraction both tissues remain pink, however, a small amount of 
color maybe dissolved in isopropanol. Conclusion: Because this chemical is originally 
n 
72 EIVS_BDF_liquids_14256C_14_21.xls Medium turbid after exposure and postincubation, precipitate at the bottom of the 
wells, can be scracht off, see photos." 
72 EIVS_BDF_liquids_14263B_15_24.xls "Both tissues pink after exposure, see photos, after extraction both tissues remain 
pink. 
72 EIVS_BDF_liquids_14263B_15_24.xls Medium turbid after exposure and postincubation, precipitate at the bottom of the 
wells, can be scracht off." 
72 EIVS_BDF_liquids_14263B_15_24.xls "B137CC:Both tissues pink after exposure, see photos, after extraction both tissues 
remain pink. 
72 EIVS_BDF_liquids_14263B_15_24.xls Medium turbid after exposure and postincubation, precipitate at the bottom of the 
wells, can be scracht off." 
72 EIVS_BDF_liquids_14277E_17_27.xls "Both tissues pink after exposure, after extraction both tissues remain pink. 
72 EIVS_BDF_liquids_14277E_17_27.xls Medium turbid after exposure and postincubation, precipitate at the bottom of the 
wells, can be scracht off, although the testchemical is a liquid!" 
72 EIVS_BDF_liquids_14277E_17_27.xls "137CC:Both tissues pink after exposure, after extraction both tissues remain pink. 
72 EIVS_BDF_liquids_14277E_17_27.xls Medium turbid after exposure and postincubation, precipitate at the bottom of the 
wells, can be scracht off,although the testchemical is a liquid! " 
72 EIVS_BDF_liquids_15007B_23_40.xls B137CC 
72 EIVS_HARLAN_LIQUIDS_15029A_27_14.xls Media turned turbid after exposure. Tissues stained pink after rinsing and post-soak. 
72 EIVS_HARLAN_LIQUIDS_15030A_28_15.xls Media turned turbid after exposure. Tissues stained pink after rinsing and post-soak. 
72 EIVS_HARLAN_LIQUIDS_15033A_31_16.xls Media turned turbid during exposure. Tissues stained pink after rinsing and post-
soak. 
72 EIVS_IIVS_liquids_14248_week6_number5_AH.xls Tissues 1&2: Tissues stained pink ; 1st tissue well contained possible precipitate in 
media after dosing 
72 EIVS_IIVS_liquids_14256_week7_number6_AH.xls Tissues 1 & 2: Tissues stained pink after rinse/soak. Possible precipitate noticed in 
wells (media) under tissues. 
72 EIVS_IIVS_liquids_14263_week8_number8_AH.xls Tissues 1&2: tissues stained pink after rinse/soak; media in wells appears to have 
precipitate after 30 minute dosing period. Small amount of possible precipitate 
noticed in isopropanol 24-well plate. 
73 EIVS_BDF_solids_14222A_09_05.xls On one tissue small residues after rinsing and postsoak. 
73 EIVS_BDF_solids_14225C_10_08.xls Small residues after rinsing and postsoak. 
73 EIVS_Harlan_solids_14225B_10_01.xls Scattered residual test item adhered to tissue surface post risning and post soak 
(both tissues) 
73 EIVS_Harlan_solids_14234E_11_02.xls Scattered residual test item adhered to tissue surface post risning and post soak 
(both tissues) 
73 EIVS_Harlan_solids_14241D_12_03.xls Small amounts of test item still present on tissue surface post rinsing and post soak 
(both tissues) 
74 EIVS_BDF_solids_14219D_08_02.xls "After rinsing small residues left. 
74 EIVS_BDF_solids_14219D_08_02.xls After MTT-Term.: Tissue 2: small white area on the surface (residues?)." 
74 EIVS_BDF_solids_14222A_09_05.xls Residues after rinsing and postsoak on both tissues. 
74 EIVS_BDF_solids_14225C_10_08.xls Residues after rinsing and postsoak. 
74 EIVS_BDF_solids_14241A_12_15.xls Small brown residues after rinsing and post-soak. 
74 EIVS_HARLAN_SOLIDS_15013B_24_13.xls Residual test item on tissues after rinsing. 
74 EIVS_HARLAN_SOLIDS_15013B_24_13.xls Residual test item on tissues after rinsing. 
74 EIVS_HARLAN_SOLIDS_15029B_27_14.xls Residual test item on tissues after rinsing. 
74 EIVS_HARLAN_SOLIDS_15029B_27_14.xls Residual test item on tissues after rinsing. 
74 EIVS_HARLAN_SOLIDS_15030B_28_15.xls Residual test item on tissues after rinsing. 
74 EIVS_HARLAN_SOLIDS_15030B_28_15.xls Residual test item on tissues after rinsing. 
74 EIVS_IIVS_solids_14219_week1_number1_MK.xls For both tissue replicates, there was possible residual test article and/or tissue 
staining observed after rinsing and soaking. 
74 EIVS_IIVS_solids_14219_week1_number1_MK.xls For both tissue replicates, there was possible residual test article and/or tissue 
staining observed after rinsing and soaking. 
74 EIVS_IIVS_solids_14222_week2_number2_MK.xls For both tissue replicates, there was possible residual test article and/or tissue 
staining observed after rinsing and soaking. 
74 EIVS_IIVS_solids_14222_week2_number2_MK.xls For both tissue replicates, there was possible residual test article and/or tissue 
staining observed after rinsing and soaking. 
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74 EIVS_IIVS_solids_14225_week3_number3_MK.xls For both tissue replicates, there was possible residual test article and/or tissue 
staining observed after rinsing and soaking. 
74 EIVS_IIVS_solids_14225_week3_number3_MK.xls For both tissue replicates, there was possible residual test article and/or tissue 
staining observed after rinsing and soaking. 
75 EIVS_BDF_solids_14277D_17_26.xls "tissue1: medium in insert after treatment, chemical solubilised -> dead/damaged 
tissue 
75 EIVS_BDF_solids_14277D_17_26.xls tissue2: no medium in insert, chemical dry, not solubilised (like run1 and run2)" 
75 EIVS_BDF_solids_14283C_18_28.xls "tissue1: medium in insert after treatment, chemical solubilised -> dead/damaged 
tissue 
75 EIVS_BDF_solids_14283C_18_28.xls tissue2: no medium in insert, chemical dry, not solubilised (like run1 and run2)" 
75 EIVS_BDF_solids_15013A_24_43.xls Little residues after washing and post-soak. 
75 EIVS_Harlan_solids_14283E_18_08.xls Test item turned to liquid during exposure period 
75 EIVS_Harlan_solids_14289B_19_09.xls Test item turned to liquid during exposure period 
75 EIVS_IIVS_solids_14234_week4_number4_MK.xls Media pooled into millicell of both tissue, noticed prior to treatment termination 
75 EIVS_IIVS_solids_14241_week5_number5_MK.xls Media pooled into millicell of both tissue, noticed prior to treatment termination 
75 EIVS_IIVS_solids_14248_week6_number6_MK.xls Media pooled into millicell of both tissue, noticed prior to treatment termination 
76 EIVS_BDF_solids_14234A_11_10.xls "powder red-brown with crystal structure after treatment, removes from insert like a 
crust (whole piece) at rinsing 
76 EIVS_BDF_solids_14234A_11_10.xls small rests remain on surface of tissues after rinsing" 
76 EIVS_BDF_solids_14241B_12_14.xls "powder red-brown with crystal structure after treatment, removes from insert like a 
crust (whole piece) at rinsing 
76 EIVS_BDF_solids_14241B_12_14.xls small rests remain on surface of tissues after rinsing" 
76 EIVS_BDF_solids_14248B_13_16.xls "powder red-brown with crystal structure after treatment, removes from insert like a 
crust (whole piece) at rinsing 
76 EIVS_BDF_solids_14248B_13_16.xls small rests remain on surface of tissues after rinsing" 
76 EIVS_IIVS_solids_14270_week9_number10_MK.xls Small amount of residual test article on tissues after rinsing and soaking. 
79 EIVS_BDF_solids_14234B_11_11.xls Two tissues were rejected because there were only two (instead of three) feet below 
the inserts. 
79 EIVS_BDF_solids_14248C_13_18.xls Both tissues from Kit D, because of change of the surface, four tissues from kit C 
were rejected. 
79 EIVS_Harlan_solids_14248F_13_04.xls Test item dissolved by medium (both tissues) 
79 EIVS_Harlan_solids_14263E_15_05.xls Test item dissolved by medium (both tissues) 
79 EIVS_Harlan_solids_14270B_16_06.xls Test item dissolved by medium (both tissues) 
80 EIVS_BDF_liquids_14225E_10_06.xls "After treatment the medium has changed its color to yellow (pH7). The tissue is light 
yellow too. 
80 EIVS_BDF_liquids_14225E_10_06.xls After MTT-staining the color of the rest of the MTT-medium has turned to blue. An 
absorption spectrum is measured. 
80 EIVS_BDF_liquids_14225E_10_06.xls The substance stinks strongly therefore it is treated in seperate well-plates." 
80 EIVS_BDF_liquids_14234C_11_09.xls "Tissue2: Pre-incubation: PBS doesn't spread all over the tissue. After treatment the 
medium has changed its color to yellow (pH7). The tissue is light yellow too. 
80 EIVS_BDF_liquids_14234C_11_09.xls After MTT-staining the color of the rest of the MTT-medium has turned to blue. 
80 EIVS_BDF_liquids_14234C_11_09.xls The substance stinks strongly therefore it is incubated/treated in seperate well-
plates. " 
80 EIVS_BDF_liquids_14241C_12_13.xls "The sealing is strongly corooded and sticky and greasy. The substance stinks 
strongly therefore it is incubated/treated in seperate well-plates. 
80 EIVS_BDF_liquids_14241C_12_13.xls After treatment the medium has changed its color to yellow (pH7). The tissue is light 
yellow too. 
80 EIVS_BDF_liquids_14241C_12_13.xls After MTT-staining the color of the rest of the MTT-medium has turned to blue. 
80 EIVS_HARLAN_LIQUIDS_14296D_20_10.xls Media turned yellow after exposure. After 3 hours MTT exposure the MTT in the well 
had turned blue. 
80 EIVS_HARLAN_LIQUIDS_15003C_21_11.xls Media turned yellow after exposure. After 3 hours MTT exposure the MTT in the well 
had turned blue. 
80 EIVS_HARLAN_LIQUIDS_15007C_23_12.xls Media turned yellow after exposure. After 3 hours MTT exposure the MTT in the well 
had turned blue. 
81 EIVS_BDF_liquids_14248A_13_17.xls After postincubation the tissues were light yellow. 
81 EIVS_BDF_liquids_14256A_14_19.xls After postincubation the tissues were light yellow. 
81 EIVS_BDF_liquids_14263A_15_22.xls After postincubation the tissues were light yellow. 
82 EIVS_HARLAN_LIQUIDS_15033B_31_16.xls Medium turned yellow following exposure 
82 EIVS_HARLAN_LIQUIDS_15034A_32_17.xls Medium stained yellow after exposure 
82 EIVS_HARLAN_LIQUIDS_15035A_33_18.xls Medium stained yellow after exposure 
85 EIVS_BDF_liquids_14225E_10_06.xls Parts of the sealing are in the sample. 
85 EIVS_BDF_liquids_14234C_11_09.xls Parts of the sealing are in the sample. 
85 EIVS_BDF_liquids_14241C_12_13.xls Parts of the sealing are in the sample. 
86 EIVS_HARLAN_LIQUIDS_15033B_31_16.xls Medium turned yellow following exposure 
86 EIVS_HARLAN_LIQUIDS_15034A_32_17.xls Medium stained yellow after exposure 
86 EIVS_HARLAN_LIQUIDS_15035A_33_18.xls Medium stained yellow after exposure 
86 EIVS_IIVS_liquids_14283_week11_number13_AH.xls Tissues 1&2: during 30 minute test article dosing period, test article appeared as 
cloudy yellow prior to rinsing 
88 EIVS_BDF_liquids_14283A_18_29.xls medium purple after treatment, ph ~9, tissue slightly red 
88 EIVS_BDF_liquids_14289D_19_32.xls medium purple after treatment, ph ~9, tissue slightly red 
88 EIVS_BDF_liquids_14296A_20_34.xls medium purple after treatment, ph ~9, tissue slightly red 
88 EIVS_HARLAN_LIQUIDS_15037A_34_19.xls Media stained bright pink after exposure. Tissues stained bright pink after rinsing and 
post soak. 
88 EIVS_HARLAN_LIQUIDS_15040B_38_20.xls Media turnned bright pink during exposure. Tissues stained pink after rinsing and 
post soak. 
88 EIVS_HARLAN_LIQUIDS_15046B_41_21.xls Media stained bright pink after exposure. Tissues stained pink after rinsing and post 
soak. 
88 EIVS_IIVS_liquids_14289_week12_number14_AH.xls Tissues 1&2: Tissues stained pink-observed after rinse/soak 
88 EIVS_IIVS_liquids_14296_week13_number17_AH.xls Tissues 1&2: Tissues observed stained pink after rinse/soak 
88 EIVS_IIVS_liquids_15003_week14_number19_AH.xls Tissues 1&2: tissues observed to be stained pink after rinse/soak 
89 EIVS_BDF_liquids_14248A_13_17.xls During the washing the substance began to foam. 
89 EIVS_BDF_liquids_14256A_14_19.xls During the washing the substance began to foam. 
89 EIVS_BDF_liquids_14263A_15_22.xls During the washing the substance began to foam. 
90 EIVS_BDF_liquids_14256C_14_21.xls foams during washing 
90 EIVS_BDF_liquids_14263B_15_24.xls foams during washing 
90 EIVS_BDF_liquids_14277E_17_27.xls foams during washing 
90 EIVS_HARLAN_LIQUIDS_15029A_27_14.xls Residual test item left on tissues after rinsing. 
90 EIVS_HARLAN_LIQUIDS_15030A_28_15.xls Residual test item left on tissues after rinsing. 
90 EIVS_HARLAN_LIQUIDS_15033A_31_16.xls Residual test item left on tissues after rinsing. 
90 EIVS_IIVS_liquids_14234_week4_number4_HI.xls possible residual test article (clear/shiny) 
90 EIVS_IIVS_liquids_14241_week5_number6_HI.xls possible residual test article (clear/shiny) 
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90 EIVS_IIVS_liquids_14248_week6_number7_HI.xls possible residual test article (more on tissue 1 than tissue 2) 
90 EIVS_IIVS_liquids_15007_week16_number22_AH.xls Tissues 1&2: Possible residual test article observed after rinse/soak. Tissues 
appeared slightly orange in color after 2 hour post incubation period. 
91 EIVS_BDF_liquids_14248A_13_17.xls "The sealing is broken and parts of it are colored orange. It looks like that the 
substance crystillized on the rim. 
91 EIVS_BDF_liquids_14248A_13_17.xls After post-soak the color of the medium has changed to pink (pH9). After 
postincubation there is one big bubble below the tissues. Liquid is on the tissues 
after postincubation. The tissues are pink after extraction and there is a pink rubber-
like layer on 
91 EIVS_BDF_liquids_14256A_14_19.xls "The sealing is broken and parts of it are colored orange. It looks like that the 
substance crystillized on the rim. 
91 EIVS_BDF_liquids_14256A_14_19.xls After post-soak the color of the medium has changed to pink and there is big bubble 
below the tissue. After postincubation the bubbles are gone. Liquid is on the tissues 
after postincubation. The tissues are pink after extraction and there is a pink rubber 
91 EIVS_BDF_liquids_14263A_15_22.xls "The sealing is broken and parts of it are colored orange. It looks like that the 
substance crystillized on the rim. 
91 EIVS_BDF_liquids_14263A_15_22.xls After post-soak the color of the medium has changed to pink and there is big bubble 
below the tissue. Liquid is on the tissues after postincubation. The tissues are pink 
after extraction and there is a pink rubber-like layer on the tissue." 
91 EIVS_IIVS_liquids_14234_week4_number4_HI.xls possible residual test article (clear/shiny) 
91 EIVS_IIVS_liquids_14241_week5_number6_HI.xls possible residual test article (clear/shiny) 
91 EIVS_IIVS_liquids_14248_week6_number7_HI.xls possible residual test article 
93 EIVS_BDF_solids_14219D_08_02.xls More substance needed to cover the surface of the tissues (2x syringe). 
93 EIVS_BDF_solids_14222A_09_05.xls More substance needed on both tissues (2x syringe), small residues after rinsing and 
postsoak on both tissues. 
93 EIVS_Harlan_solids_14225B_10_01.xls Assay medium drawn into tissue insert during exposure and had completely 
dissolved the test item (both tissues) 
93 EIVS_Harlan_solids_14234E_11_02.xls Assay medium drawn into tissue insert during exposure and had completely 
dissolved the test item (both tissues) 
93 EIVS_Harlan_solids_14241D_12_03.xls Assay medium drawn into tissue insert during exposure and had dissolved the test 
item (both tissues) 
93 EIVS_IIVS_solids_14219_week1_number1_MK.xls Tissue # 1 appeared very wrinkly after rinse step. Tissue # 2 detached from the 
millicell and was found in rinse cup 2, the tissue was gently placed back into the 
millicell using forceps. 
93 EIVS_IIVS_solids_14222_week2_number2_MK.xls ~90% of tissue detached from each millicell 
94 EIVS_BDF_solids_14234A_11_10.xls remains on surface of tissues after rinsing, medium slightly yellow after post inc. 
94 EIVS_BDF_solids_14241B_12_14.xls remains on surface of tissues after rinsing, medium slightly yellow after post inc. 
94 EIVS_BDF_solids_14248B_13_16.xls remains on surface of tissues after rinsing, medium slightly yellow after post inc. 
94 EIVS_Harlan_solids_14263E_15_05.xls residual test item on tissues 
94 EIVS_Harlan_solids_14270B_16_06.xls Residual test item on both tissues 
94 EIVS_IIVS_solids_14256_week7_number7_MK.xls Small amount of residual test article on tissues following rinsing and soaking. 
94 EIVS_IIVS_solids_14263_week8_number8_MK.xls Residual test article on tissues following rinsing and soaking. 
94 EIVS_IIVS_solids_14270_week9_number10_MK.xls Residual test article on tissues following rinsing and soaking. 
95 EIVS_BDF_solids_14219D_08_02.xls exposure: substance dissolved or melted on the surface of the tissue. 
95 EIVS_HARLAN_SOLIDS_14296E_20_10.xls Test item liquified in tissue inserts/medium turned pink 
95 EIVS_HARLAN_SOLIDS_15003C_21_11.xls Test item liquified in tissue inserts/medium turned pink 
95 EIVS_HARLAN_SOLIDS_15007A_23_12.xls Test item liquified in tissue inserts/medium turned bright pink 
96 EIVS_BDF_solids_14219D_08_02.xls More substance needed to cover the surface of the tissues (2x syringe). After rinsing 
small residues left. 
96 EIVS_BDF_solids_14222A_09_05.xls Small residues after rinsing and postsoak on both tissues. 
96 EIVS_BDF_solids_14225C_10_08.xls Small residues after rinsing and postsoak. 
98 EIVS_BDF_solids_14283B_18_30.xls "Orange powder, after application blue border around the substance on the tissues. 
After washing and post-soak, the tissues are blue and have blue residues. The PBS 
is blue after washing . 
98 EIVS_BDF_solids_14283B_18_30.xls "B102CC: Orange powder, after application blue border around the substance on the 
tissues. After washing and post-soak, the tissues are blue and have blue residues. 
The PBS is blue after washing . 
98 EIVS_BDF_solids_14283B_18_30.xls MTT test: The medium of the CCs is blue, although the MTT-solution of the viabilty-
test is not blue. " 
98 EIVS_BDF_solids_14289E_19_33.xls "Orange powder, after application blue border around the substance on the tissues. 
After washing and post-soak, the tissues are blue and have blue residues. The PBS 
is blue after washing . 
98 EIVS_BDF_solids_14289E_19_33.xls B102CC: Orange powder, after application blue border around the substance on the 
tissues. After washing and post-soak, the tissues are blue and have blue residues. 
The PBS is blue after washing . 
98 EIVS_BDF_solids_14296C_20_35.xls Orange powder, after application blue border around the substance on the tissues. 
After washing and post-soak, the tissues are blue and have blue residues. The PBS 
is blue after washing . 
98 EIVS_BDF_solids_14296C_20_35.xls B102CC: Orange powder, after application blue border around the substance on the 
tissues. After washing and post-soak, the tissues are blue and have blue residues. 
The PBS is blue after washing . 
98 EIVS_HARLAN_SOLIDS_15037B_34_19.xls Residual test itemon tissues after rinsing and post soak. Tissues stained blue. 
98 EIVS_HARLAN_SOLIDS_15037B_34_19.xls Residual test itemon tissues after rinsing and post soak. Tissues stained blue. 
98 EIVS_HARLAN_SOLIDS_15040A_38_20.xls Residual test item on tissues after rinsing and post soak. Tissues stained blue. 
98 EIVS_HARLAN_SOLIDS_15040A_38_20.xls Residual test item on tissues after rinsing and post soak. Tissues stained blue. 
98 EIVS_Harlan_Solids_15046A_41_21.xls Residual test item on tissues after rinsing and post soak. Tissues sained blue. 
98 EIVS_Harlan_Solids_15046A_41_21.xls Residual test item on tissues after rinsing and post soak. Tissues sained blue. 
98 EIVS_Harlan_Solids_15048A_42_22.xls Tissues stained blue after rinsing and post soak. 
98 EIVS_Harlan_Solids_15048A_42_22.xls Tissues stained blue after rinsing and post soak. 
98 EIVS_IIVS_solids_14277_week10_number11_MK.xls Possible residual test article or tissue staining, observed following rinsing and 
soaking. Media beneath millicells turned blue following post-incubation. Tissues 
stained a dark blue after extraction. Isopropanol was a pale blue color. 
98 EIVS_IIVS_solids_14277_week10_number11_MK.xls Possible residual test article or tissue staining, observed following rinsing and 
soaking. Media beneath millicells turned blue following post-incubation. Tissues 
stained a dark blue after extraction. Isopropanol was a pale blue color. 
98 EIVS_IIVS_solids_14283_week11_number12_MK.xls Possible residual test article or tissue staining observed following rinsing and 
soaking. Media beneath millicells turned blue following post incubation. Tissues were 
stained dark blue after extraction. Isopropanol was a light blue color. 
98 EIVS_IIVS_solids_14283_week11_number12_MK.xls Possible residual test article or tissue staining observed following rinsing and 
soaking. Media beneath millicells turned blue following post incubation. Tissues were 
stained dark blue after extraction. Isopropanol was a light blue color. 
98 EIVS_IIVS_solids_14289_week12_number13_MK.xls Possible residual test article or tissue staining observed following rinsing and 
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soaking. Media beneath millicells turned blue following post incubation. Tissues were 
stained dark blue after extraction. Isopropanol was a light blue color. 
98 EIVS_IIVS_solids_14289_week12_number13_MK.xls Possible residual test article or tissue staining observed following rinsing and 
soaking. Media beneath millicells turned blue following post incubation. Tissues were 
stained dark blue after extraction. Isopropanol was a light blue color. 
99 EIVS_Harlan_solids_14277C_17_07.xls Scattered residual test item noted on both tissues following rinsing. 
100 EIVS_BDF_solids_15003B_21_39.xls "White powder / after exposure: powder dissolved on the surface of the tissues, 
tissues pink / after washing: PBS is turbid / after postincubation: below the inserts, 
precipitate at the bottom of the wells, can be scracht off / after extraction: t 
100 EIVS_BDF_solids_15007B_23_41.xls "White powder / after exposure: powder dissolved on the surface of the tissues, 
tissues pink / after washing: PBS is turbid / after postincubation: below the inserts, 
precipitate at the bottom of the wells, can be scracht off / after extraction: t 
100 EIVS_BDF_solids_15013A_24_43.xls "White powder / after exposure: powder dissolved on the surface of the tissues, 
tissues pink / after washing: PBS is turbid / after postincubation: below the inserts, 
precipitate at the bottom of the wells, can be scracht off / after extraction: t 
100 EIVS_HARLAN_Solids_15033C_31_16.xls Test item liquified in inserts during exposure. Tissues stained pink after rinsing and 
post soak. 
100 EIVS_HARLAN_Solids_15034B_32_17.xls Test item liquified in inserts during exposure. Tissues stained pink/brown after rinsing 
and post soak. 
100 EIVS_HARLAN_Solids_15035B_33_18.xls Test item liquified in inserts during exposure. Tissues stained pink after rinsing and 
post soak. 
100 EIVS_IIVS_solids_14270_week9_number11_AH.xls Tissues 1&2: Possible precipitate under tissues in well after test article incubation. 
Tissues stained dark pink after rinse/soak. Dark pink spots noticed in 6-well plates 
under tissues after 18 hr incubation. MTT media was yellow after 3 hr incub 
100 EIVS_IIVS_solids_15007_week16_number23_AH.xls Tissues 1&2: Tissues stained pink-observed after rinse/soak. 6-well plate that was 
used to incubate/dose test article contained pink spots- observed during rinse. Pink 
spots noticed on 6-well plate under tissues after 18 hr post incubation period. 
100 EIVS_IIVS_solids_15013_week17_number24_AH.xls Tissues 1&2: 6-well plate pink under tissues-observed during rinse/soak. Tissues 
stained pink after rinse/soak. 6-well plates pink under tissues observed after 18 hour 
incubation. MTT media wells were yellow/orange after 3 hr MTT incubation. Liqui 
101 EIVS_BDF_solids_14283B_18_30.xls after exposure: chemical dissolved on the surface of the tissues, tissues yellow 
101 EIVS_BDF_solids_14283B_18_30.xls B37CC: after exposure: chemical dissolved on the surface of the tissues, tissues 
yellow 
101 EIVS_BDF_solids_14289E_19_33.xls after exposure: chemical dissolved on the surface of the tissues, tissues yellow 
101 EIVS_BDF_solids_14289E_19_33.xls B37CC: after exposure: chemical dissolved on the surface of the tissues, tissues 
yellow 
101 EIVS_BDF_solids_14296C_20_35.xls after exposure: chemical dissolved on the surface of the tissues, tissues yellow 
101 EIVS_BDF_solids_14296C_20_35.xls B37CC: after exposure: chemical dissolved on the surface of the tissues, tissues 
yellow 
101 EIVS_HARLAN_Solids_15033C_31_16.xls Test item liquified in inserts during exposure. Media stained orange after exposure. 
Tissues stained orange after rinsing and post soak. 
101 EIVS_HARLAN_Solids_15034B_32_17.xls Test item liquified in inserts during exposure. Media stained orange after exposure. 
Tissues stained yellow after rinsing and post soak. 
101 EIVS_HARLAN_Solids_15035B_33_18.xls Test item liquified in inserts during exposure. Media stained orange after exposure. 
Tissues stained orange after rinsing and post soak. 
101 EIVS_IIVS_solids_14296_week13_number14_MK.xls "Media beneath millicells turned orange, observed following test article exposure 
time. Media was also noticed to have pooled within the millicells. Tissues stained 
yellow following rinsing and soaking. Media beneath millicells turned yellow, obser 
101 EIVS_IIVS_solids_15003_week14_number15_MK.xls "Media beneath millicells turned orange, observed following test article exposure 
time. Media was also noticed to have pooled within the millicells. Tissues stained 
yellow following rinsing and soaking. Media beneath millicells turned yellow, obser 
101 EIVS_IIVS_solids_15007_week15_number16_MK.xls "Media beneath millicells turned orange, observed following test article exposure 
time. Media was also noticed to have pooled within the millicells. Tissues stained 
yellow following rinsing and soaking. Media beneath millicells turned yellow, obser 
102 EIVS_BDF_solids_14289C_19_31.xls A lot of residues on the tissues after washing. Few residues after post soak. 
Immediately after transfering the inserts into the MTT-Medium the color of the tissues 
turns to apricot. 
102 EIVS_BDF_solids_14296B_20_36.xls Few residues on the tissues after washing. Few residues after post soak. 
102 EIVS_BDF_solids_15003A_21_37.xls Some residues on the tissues after washing and post soak. 
102 EIVS_BDF_solids_15013A_24_43.xls "Little residues after washing and post-soak. 
102 EIVS_BDF_solids_15013A_24_43.xls MISTAKE!: Because of missunderstanding an internal list this chemical was tested 
unnecessary !!" 
102 EIVS_HARLAN_Solids_15033C_31_16.xls Residual test item on tissues after rinsing and post soak. 
102 EIVS_HARLAN_Solids_15034B_32_17.xls Residual test item on tissues after rinsing and post soak. 
102 EIVS_HARLAN_Solids_15035B_33_18.xls Residual test item on tissues after rinsing and post soak. 
102 EIVS_IIVS_solids_14296_week13_number14_MK.xls Residual test article following rinsing and soaking. Tissue # 2 was noticed to have 
about half the viability in comparison to tissue # 1 following MTT incubation. 
102 EIVS_IIVS_solids_15003_week14_number15_MK.xls Small amount of residual test article following rinsing and soaking. 
102 EIVS_IIVS_solids_15007_week15_number16_MK.xls Small amount of residual test article following rinsing and soaking. 
103 EIVS_BDF_solids_14234A_11_10.xls solubilize in prewetting water -> liquid 
103 EIVS_BDF_solids_14241B_12_14.xls solubilize in prewetting water -> liquid 
103 EIVS_BDF_solids_14248B_13_16.xls solubilize in prewetting water -> liquid 
103 EIVS_Harlan_solids_14248F_13_04.xls Test item dissolved by medium (both tissues) 
103 EIVS_Harlan_solids_14263E_15_05.xls Test item dissolved by medium (both tissues) 
103 EIVS_Harlan_solids_14270B_16_06.xls Test item dissolved by medium (both tissues) 
104 EIVS_BDF_solids_14256B_14_20.xls sticks on surface like dots after postsoak and at MTT (photo), total dots area >1/2 of 
tissue area 
104 EIVS_BDF_solids_14263C_15_23.xls sticks on surface like dots after postsoak and at MTT (photo), total dots area >1/2 of 
tissue area 
104 EIVS_BDF_solids_14277D_17_26.xls sticks on surface like dots after postsoak and at MTT (photo), total dots area >1/2 of 
tissue area 
104 EIVS_BDF_solids_14283C_18_28.xls sticks on surface like dots after postsoak and at MTT (photo), total dots area >1/2 of 
tissue area 
104 EIVS_Harlan_solids_14248F_13_04.xls Areas of scattered residual test item post rinsing (both tissues) 
104 EIVS_Harlan_solids_14263E_15_05.xls Areas of scattered residual test item post rinsing (both tissues) 
104 EIVS_Harlan_solids_14270B_16_06.xls Residual test item ontissues post rinsing (both tissues) 
104 EIVS_IIVS_solids_14256_week7_number7_MK.xls Small amount of residual test article on tissues following rinsing and soaking. 
104 EIVS_IIVS_solids_14263_week8_number8_MK.xls Residual test article on tissues following rinsing and soaking. 
104 EIVS_IIVS_solids_14270_week9_number10_MK.xls Residual test article on tissues following rinsing and soaking. Tissue # 2 had about 
half as much residual test article in comparison to Tissue # 1 
104 EIVS_IIVS_solids_15013_week16_number17_MK.xls Small residual test article following rinsing and soaking. 
105 EIVS_BDF_solids_14234A_11_10.xls solubilize in prewetting water -> liquid, medium yellow after treatment pH1,5 
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105 EIVS_BDF_solids_14241B_12_14.xls solubilize in prewetting water -> liquid, medium yellow after treatment pH1,5 
105 EIVS_BDF_solids_14248B_13_16.xls solubilize in prewetting water -> liquid, medium yellow after treatment pH1,5 
105 EIVS_Harlan_solids_14225B_10_01.xls Assay medium in wells of treatment plate turned yellow and the medium was drawn 
into the tissue inserts during exposure completely dissolveing the test item (both 
tissues) 
105 EIVS_Harlan_solids_14234E_11_02.xls Assay medium in wells of treatment plate turned yellow and the medium was drawn 
into the tissue inserts during exposure completely dissolveing the test item (both 
tissues) 
105 EIVS_Harlan_solids_14241D_12_03.xls Assay medium in wells of treatment plate turned yellow and the medium was drawn 
into the tissue inserts during exposure dissolving the test item (both tissues) 
105 EIVS_IIVS_solids_14256_week7_number7_MK.xls Media beneath millicells had turned yellow following test article exposure time. Media 
had also pooled within each millicell during that time. 
105 EIVS_IIVS_solids_14263_week8_number8_MK.xls Media beneath millicells had turned yellow following test article exposure time, media 
also pooled within each millicell. 
105 EIVS_IIVS_solids_14270_week9_number10_MK.xls Media beneath millicells turned yellow after test article exposure time, media was 
also observed to have pooled within each millicell. 
106 EIVS_BDF_solids_14283B_18_30.xls "dark blue powder, residues after washing and post-soak 
106 EIVS_BDF_solids_14283B_18_30.xls NOT QUALIFIED!! OD >> 3,000" 
106 EIVS_BDF_solids_14283B_18_30.xls "B74CC: dark blue powder, residues after washing and post-soak 
106 EIVS_BDF_solids_14283B_18_30.xls NOT QUALIFIED!! OD >> 3,000" 
106 EIVS_BDF_solids_14289E_19_33.xls "dark blue powder, residues after washing and post-soak 
106 EIVS_BDF_solids_14289E_19_33.xls NOT QUALIFIED!! OD >> 3,000" 
106 EIVS_BDF_solids_14289E_19_33.xls "B74CC: dark blue powder, residues after washing and post-soak 
106 EIVS_BDF_solids_14289E_19_33.xls NOT QUALIFIED!! OD >> 3,000" 
106 EIVS_BDF_solids_14296C_20_35.xls "dark blue powder, residues after washing and post-soak 
106 EIVS_BDF_solids_14296C_20_35.xls NOT QUALIFIED!! OD >> 3,000" 
106 EIVS_BDF_solids_14296C_20_35.xls "B74CC: dark blue powder, residues after washing and post-soak 
106 EIVS_BDF_solids_14296C_20_35.xls NOT QUALIFIED!! OD >> 3,000" 
106 EIVS_BDF_solids_15019A_25_44.xls "Dark blue powder, residues after washing and post-soak 
106 EIVS_BDF_solids_15019A_25_44.xls NOT QUALIFIED!! OD >> 3,000" 
106 EIVS_BDF_solids_15019A_25_44.xls "B74CC: dark blue powder, residues after washing and post-soak 
106 EIVS_BDF_solids_15019A_25_44.xls NOT QUALIFIED!! OD >> 3,000" 
106 EIVS_BDF_solids_15025A_26_50.xls "A lot of residues after washing and post-soak. 
106 EIVS_BDF_solids_15025A_26_50.xls NOT QUALIFIED!! OD >> 3,000" 
106 EIVS_BDF_solids_15025A_26_50.xls "B74CC: A lot of residues after washing and post-soak. 
106 EIVS_BDF_solids_15025A_26_50.xls NOT QUALIFIED!! OD >> 3,000" 
106 EIVS_HARLAN_SOLIDS_15037B_34_19.xls Test item solidified on tissues during exposureResidual test item on tissues after 
rinsing and post soak. 
106 EIVS_HARLAN_SOLIDS_15037B_34_19.xls Test item solidified on tissues during exposureResidual test item on tissues after 
rinsing and post soak. 
106 EIVS_HARLAN_SOLIDS_15040A_38_20.xls Residual test item on tissues after rinsing and post soak. 
106 EIVS_HARLAN_SOLIDS_15040A_38_20.xls Residual test item on tissues after rinsing and post soak. 
106 EIVS_Harlan_Solids_15046A_41_21.xls Test item solidified on tissues during exposure. Residual test item on tissues after 
rinsing and post soak. 
106 EIVS_Harlan_Solids_15046A_41_21.xls Test item solidified on tissues during exposure. Residual test item on tissues after 
rinsing and post soak. 
106 EIVS_Harlan_Solids_15048A_42_22.xls Test item solidified on tissues during exposure. Residual test item on tissues after 
rinsing and post soak. 
106 EIVS_Harlan_Solids_15048A_42_22.xls Test item solidified on tissues during exposure. Residual test item on tissues after 
rinsing and post soak. 
106 EIVS_IIVS_solids_14277_week10_number11_MK.xls Residual test article and possible tissue staining, observed following rinsing and 
soaking. Media beneath millicells turned bright pink following post-incubation. 
Tissues stained a purplish pink after extraction. Isopropanol was bright pink. 
106 EIVS_IIVS_solids_14277_week10_number11_MK.xls Residual test article and possible tissue staining, observed following rinsing and 
soaking. Media beneath millicells turned bright pink following post-incubation. 
Tissues stained a purplish pink after extraction. Isopropanol was bright pink. 
106 EIVS_IIVS_solids_14283_week11_number12_MK.xls Possible tissue staining and residual test article following rinsing and soaking. Media 
beneath millicells turned bright pink following post incubation. Tissues were stained a 
purplish pink after extraction. Isopropanol was bright pink. 
106 EIVS_IIVS_solids_14283_week11_number12_MK.xls "Possible tissue staining and residual test article following rinsing and soaking. 
Media beneath millicells turned bright pink following post incubation. Tissues were 
stained a purplish pink after extraction. Isopropanol was bright pink. Following 
106 EIVS_IIVS_solids_14289_week12_number13_MK.xls Possible tissue staining and residual test article following rinsing and soaking. Media 
beneath millicells turned bright pink following post incubation. Tissues were stained a 
purplish pink after extraction. Isopropanol was bright pink. 
106 EIVS_IIVS_solids_14289_week12_number13_MK.xls Possible tissue staining and residual test article following rinsing and soaking. Tissue 
# 2 had about half as much residual test article in comparison to tissue # 1. Media 
beneath millicells turned bright pink following post incubation. Tissues w 
107 EIVS_BDF_solids_14283B_18_30.xls small residues after washing and post-soak, tissues pink 
107 EIVS_BDF_solids_14283B_18_30.xls B55CC: small residues after washing and post-soak, tissues pink 
107 EIVS_BDF_solids_14289E_19_33.xls small residues after washing and post-soak, tissues pink 
107 EIVS_BDF_solids_14289E_19_33.xls B55CC: small residues after washing and post-soak, tissues pink 
107 EIVS_BDF_solids_14296C_20_35.xls small residues after washing and post-soak, tissues pink 
107 EIVS_BDF_solids_14296C_20_35.xls B55CC: small residues after washing and post-soak, tissues pink 
107 EIVS_BDF_solids_15003B_21_39.xls tissues pink after exposure, little pink residues after washing and postsoak 
107 EIVS_BDF_solids_15025A_26_50.xls Residues after washig and post-soak. 
107 EIVS_BDF_solids_15025A_26_50.xls B55CC: Residues after washig and post-soak. 
107 EIVS_HARLAN_SOLIDS_15037B_34_19.xls Tissues stained pink after exposure, rinsing and post soak. 
107 EIVS_HARLAN_SOLIDS_15040A_38_20.xls Tissues stained pink after exposure, rinsing and post soak. Tissues partially 
detatched from inserts. 
107 EIVS_HARLAN_SOLIDS_15040A_38_20.xls Tissues stained pink after exposure, rinsing and post soak. Tissues partially 
detatched from inserts. 
107 EIVS_Harlan_Solids_15046A_41_21.xls Tissues stained bright pink after exposure, rinsing and post soak. 
107 EIVS_Harlan_Solids_15046A_41_21.xls Tissues stained bright pink after exposure, rinsing and post soak. 
107 EIVS_Harlan_Solids_15048A_42_22.xls Tissues stained bright pink after exposure, rinsing and post soak. Residual test item 
on tissues. 
107 EIVS_Harlan_Solids_15048A_42_22.xls Tissues stained bright pink after exposure, rinsing and post soak. Residual test item 
on tissues. 
107 EIVS_IIVS_solids_14296_week13_number14_MK.xls "Small amount of residual test article, tissues also stained bright pink following 
rinsing and soaking. Media beneath millicells turned bright pink, observed following 
post incubation period. Isopropanol extractant was a purplish-pink color. Tissue 
107 EIVS_IIVS_solids_14296_week13_number14_MK.xls Small amount of residual test article, tissues also stained bright pink following rinsing 
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and soaking. Media beneath millicells turned bright pink, observed following post 
incubation period. Isopropanol extractant was pink. 
107 EIVS_IIVS_solids_15003_week14_number15_MK.xls "Small amount of residual test article, tissues also stained bright pink following 
rinsing and soaking. Media beneath millicells turned bright pink, observed following 
post incubation period. Isopropanol extractant was a purplish-pink color. Tissue 
107 EIVS_IIVS_solids_15003_week14_number15_MK.xls Small amount of residual test article, tissues also stained bright pink following rinsing 
and soaking. Media beneath millicells turned bright pink, observed following post 
incubation period. Isopropanol extractant was pink. 
107 EIVS_IIVS_solids_15007_week15_number16_MK.xls "Small amount of residual test article, tissues also stained bright pink following 
rinsing and soaking. Media beneath millicells turned bright pink, observed following 
post incubation period. Isopropanol extractant was a purplish-pink color, with t 
107 EIVS_IIVS_solids_15007_week15_number16_MK.xls Small amount of residual test article, tissues also stained bright pink following rinsing 
and soaking. Media beneath millicells turned bright pink, observed following post 
incubation period. Isopropanol extractant was pink. 
107 EIVS_IIVS_solids_15013_week16_number17_MK.xls "Tissues were stained pink, small amount of residual test article following rinsing and 
soaking. Media beneath millicells turned bright pink, observed following post 
incubation period. Isopropanol extractant was a purplish-pink color. Tissues stain 
107 EIVS_IIVS_solids_15013_week16_number17_MK.xls Tissues were stained pink, small amount of residual test article following rinsing and 
soaking. Media beneath millicells turned bright pink, observed following post 
incubation period. Isopropanol extractant was pink. 
107 EIVS_IIVS_solids_15030_week18_number19_MK.xls "Tissues stained pink, small amount of residual test aricle following rinsing and 
soaking. Media beneath millicells turned bright pink, observed following post 
incubation period. Isopropanol extractant was a purplish-pink color. Tissues stained 
a p 
107 EIVS_IIVS_solids_15030_week18_number19_MK.xls Tissues stained pink, small amount of residual test aricle followind rinsing and 
soaking. Media beneath millicells turned bright pink, observed following post 
incubation period. Isopropanol extractant was a pink. 
   
. EIVS_BDF_liquids_14277E_17_27.xls "The tissues were delivered one day later, on Wednesday instead of Tuesday, 
because the delivery were delayed at the airport. So the tests started on Thursday. 
. EIVS_BDF_liquids_14277E_17_27.xls (According to SOP)" 
. EIVS_BDF_solids_14277D_17_26.xls tissues delivered on wednesday (1 day later than normal), testing performed on 
thursday/friday 
. EIVS_BDF_solids_14296B_20_36.xls "The tissues were delivered one day later, on Wednesday instead of Tuesday, 
because the delivery were delayed at the airport. So the tests started on Thursday 
. EIVS_BDF_solids_14296B_20_36.xls (According to SOP). 
. EIVS_BDF_solids_14296B_20_36.xls Because of this delay the maesurements were performed by Ute Demitz." 
. EIVS_BDF_solids_14296C_20_35.xls "The tissues were delivered one day later, on Wednesday instead of Tuesday, 
because the delivery were delayed at the airport. So the tests started on Thursday. 
. EIVS_BDF_solids_14296C_20_35.xls (According to SOP)" 
. EIVS_IIVS_liquids_14222_week2_number2_AH.xls Insert appeared to be interacting with MTT. Outside of insert blue/black color. 
(Noticed within minutes of transferring to MTT). Prior to adding to isopropanol, 
outside of inserts wiped with Kim wipe. 
. EIVS_BDF_solids_14277D_17_26.xls used an empty aliquot and did not remark that... 
. EIVS_IIVS_liquids_14289_week12_number14_AH.xls Tissues 1&2: Tissues stained pink-observed after rinse/soak 
. EIVS_IIVS_liquids_15003_week14_number19_AH.xls Tissues 1&2: tissues observed to be stained pink after rinse/soak 
. EIVS_IIVS_liquids_14296_week13_number17_AH.xls Tissues 1&2: Tissues observed stained pink after rinse/soak 
. EIVS_IIVS_liquids_14289_week12_number14_AH.xls Tissues 1&2: residual test article after rinse/soak- after soak, soak media cloudy. 
After overnight extraction, both tissues were noticed to have a darker red ring around 
the perimeter of the tissue. 
. EIVS_IIVS_liquids_15003_week14_number19_AH.xls "Tissue1: Upon pulling of tissues for 1 hour incubation, a small black spot noticed on 
tissue. Tissues 1&2: residual test article after rinse/soak. Soak wells cloudy after 
soak. Darker pink ring around perimeter of the tissues noticed after iso 
. EIVS_IIVS_liquids_14296_week13_number17_AH.xls Tissues 1&2: Residual test article after rinse/soak. Soak wells cloudy after soak. 
After isopropanol extraction, pink ring noted around the perimeter of the tissues. 
. EIVS_IIVS_liquids_14283_week11_number13_AH.xls "V8 was initially loaded onto the 96-well plate, when precipitate was noticed in the 
wells; therefore, 1 mL of the isopropanol extract for each tissue was centrifuged 
(~13,000 rpm for 2 minutes at room temperature) and then placed into the wel 
. EIVS_IIVS_liquids_14289_week12_number14_AH.xls Tissues 1&2: residual test article after rinse/soak- after soak, soak media cloudy 
. EIVS_IIVS_liquids_15003_week14_number19_AH.xls Tissue 1&2: residual test article after rinse/soak. Soak wells cloudy after soak. 
Possible small blisters noticed on tissues after rinse/soak. 
. EIVS_IIVS_liquids_14296_week13_number17_AH.xls Tissues 1&2: Residual test article after rinse/soak. Soak wells cloudy after soak. 
Possible small blisters noticed on tissues during rinsing. 
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Appendix V Reasoning for non-qualified and 
excluded test results 
conclusion laboratory Chemical run NCqual PCqual TAqual color_call MTT_call 
Excluded Beiersdorf 801 1 Qualified Qualified Qualified  meanKC>50 
  801 2 Qualified Qualified Qualified  meanKC>50 
  801 3 Qualified Qualified Qualified   
  33 1 Qualified Qualified Qualified meanCC>50   
  33 2 Qualified Qualified Non-qualified meanCC>50   
  33 3 Qualified Qualified Non-qualified meanCC>50   
  33 4 Qualified Qualified Non-qualified meanCC>50   
  33 5 Qualified Qualified Qualified    
 Harlan 801 1 Qualified Qualified Qualified  meanKC>50 
  801 2 Qualified Qualified Qualified  meanKC>50 
  801 3 Qualified Qualified Qualified  meanKC>50 
 IIVS 801 1 Qualified Qualified Qualified  meanKC>50 
  801 2 Qualified Qualified Qualified  meanKC>50 
  801 3 Qualified Qualified Qualified  meanKC>50 
  231 1 Qualified Qualified Qualified  meanKC>50 
  231 2 Qualified Qualified Qualified  meanKC>50 
  231 3 Qualified Qualified Qualified  meanKC>50 
Non-Qualified Beiersdorf 75 3 Qualified Non-qualified Non-qualified   
  75 3 Qualified Qualified Non-qualified   
  78 3 Qualified Non-qualified Qualified   
  104 3 Qualified Non-qualified Qualified   
  74 1 Qualified Qualified Non-qualified   
  44 3 Qualified Non-qualified Qualified   
  46 3 Qualified Non-qualified Qualified   
  43 3 Qualified Non-qualified Qualified   
  37 1 Qualified Qualified Non-qualified   
  65 3 Qualified Non-qualified Qualified   
  66 3 Qualified Non-qualified Qualified   
  29 3 Qualified Qualified Non-qualified   
  63 3 Qualified Non-qualified Qualified   
  31 3 Qualified Non-qualified Qualified   
  50 3 Qualified Qualified Non-qualified   
 Harlan 40 2 Non-qualified Qualified Qualified   
  98 2 Non-qualified Qualified Qualified   
  49 2 Non-qualified Qualified Qualified   
 IIVS 20 2 Qualified Qualified Non-qualified   
  34 2 Qualified Qualified Non-qualified   
  34 4 Qualified Qualified Non-qualified   
  10 1 Qualified Qualified Non-qualified   
  104 1 Qualified Qualified Non-qualified   
  33 3 Qualified Qualified Non-qualified meanCC>50  
  90 3 Qualified Qualified Non-qualified   
  26 1 Qualified Qualified Non-qualified   
1
 The core VMG overrode the rule identifying 50% NSMTT as a cut-off to consider a 
chemical compatible with the test method for chemicals 23 and 80 after an 
evaluation of the first draft of the statistics report during the VMG meeting at May 
10th 2012. So, chemical 23 and 80 are included for statistical analysis.  
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Appendix VI Summary of all test results for 
EpiOcularTM EIT 
NQ  = Non-qualified 
EX  = Excluded 
Diff = Difference or range 
Qual = Qualification (NQ = non-qualified) 
 
Note to chemical 23 (IIVS only) and to chemical 80 (Beiersdorf, Harlan and IIVS): 
 
On May 10th 2012, after an evaluation of the first draft of the statistics report, the 
core VMG overrode the rule identifying 50% NSMTT as a cut-off to consider a 
chemical compatible with the test system as described in Chapter 2.5.1. of this 
report. In all these cases, rule 3 in Chapter 2.5.1. is fulfilled since the mean %NSC 
of all qualified tests is greater than (>) 50% and the classification of these qualified 
tests changes upon correction (from non-irritant to irritant). However, the viability 
values obtained in the qualified tests are definitely within the linear range of the OD 
measurements (within the 100% scale) and therefore, even though there is a strong 
MTT reduction occurring this is not interfering with the analytical capacity to 
measure formazan production. Moreover, the variability obtained between the 
different tests and controls is low. As such, these chemicals were considered 
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      GHS       NC PC Uncorrected viability NSC NSMTT Final Final Classification 
laboratory chemical LS classification MTT Coloring test OD diff Qual Mean% Diff% Qual Mean% Diff% Qual Mean% Diff% Qual Mean% Diff% Qual viability Call 50% cut-off 60% cut-off 
Beiersdorf 1 liquid no cat No No 1 1.7 3.4   39.2 3.5   67.8 2.4               67.8   NI NI 
Beiersdorf 1 liquid no cat No No 2 1.7 6.1   40.6 1.6   68.8 16.5               68.8   NI NI 
Beiersdorf 1 liquid no cat No No 3 1.9 3.6   29.2 3   71.3 3.1               71.3   NI NI 
Beiersdorf 2 liquid no cat No No 1 1.7 3.4   39.2 3.5   83 6.3               83   NI NI 
Beiersdorf 2 liquid no cat No No 2 1.7 6.1   40.6 1.6   80.1 1.7               80.1   NI NI 
Beiersdorf 2 liquid no cat No No 3 1.9 3.6   29.2 3   77.3 8               77.3   NI NI 
Beiersdorf 3 liquid no cat No No 1 1.8 10.1   37.4 6.3   55.4 4.2               55.4   NI I 
Beiersdorf 3 liquid no cat No No 2 1.6 5.6   43.5 4.4   63 0.3               63   NI NI 
Beiersdorf 3 liquid no cat No No 3 1.6 0.3   46.4 1.2   64.2 6.8               64.2   NI NI 
Beiersdorf 4 liquid no cat Yes No 1 1.6 1.2   42.4 7   108.4 2.4         1.5 0.3   106.9   NI NI 
Beiersdorf 4 liquid no cat Yes No 2 2 7.9   33 4.3   105.9 1.3         1.3 0.2   104.6   NI NI 
Beiersdorf 4 liquid no cat Yes No 3 1.7 7.7   41 2.1   117 1.8         1.5 0.3   115.5   NI NI 
Beiersdorf 5 liquid no cat Yes No 1 1.7 3.4   39.2 3.5   83.6 0.6         0 0   83.5   NI NI 
Beiersdorf 5 liquid no cat Yes No 2 1.7 6.1   40.6 1.6   72.2 5.7         0 0   72.2   NI NI 
Beiersdorf 5 liquid no cat Yes No 3 1.9 3.6   29.2 3   86.4 3.2         0 0   86.4   NI NI 
Beiersdorf 6 liquid no cat No No 1 1.8 10.1   37.4 6.3   81.2 1.2               81.2   NI NI 
Beiersdorf 6 liquid no cat No No 2 1.6 5.6   43.5 4.4   83.7 1.4               83.7   NI NI 
Beiersdorf 6 liquid no cat No No 3 1.6 0.3   46.4 1.2   90.9 6.6               90.9   NI NI 
Beiersdorf 7 liquid no cat No No 1 1.8 10.1   37.4 6.3   34.6 3.1               34.6   I I 
Beiersdorf 7 liquid no cat No No 2 1.6 5.6   43.5 4.4   42.3 6.8               42.3   I I 
Beiersdorf 7 liquid no cat No No 3 1.6 0.3   46.4 1.2   38.7 4.6               38.7   I I 
Beiersdorf 8 liquid no cat No No 1 1.8 10.1   37.4 6.3   101.4 3.1               101.4   NI NI 
Beiersdorf 8 liquid no cat No No 2 1.6 5.6   43.5 4.4   97.3 1.5               97.3   NI NI 
Beiersdorf 8 liquid no cat No No 3 1.6 0.3   46.4 1.2   102.8 8.3               102.8   NI NI 
Beiersdorf 9 liquid no cat No No 1 1.8 10.1   37.4 6.3   95.4 11.5               95.4   NI NI 
Beiersdorf 9 liquid no cat No No 2 1.6 5.6   43.5 4.4   101.9 4.1               101.9   NI NI 
Beiersdorf 9 liquid no cat No No 3 1.6 0.3   46.4 1.2   98 11.2               98   NI NI 
Beiersdorf 10 liquid no cat No No 1 1.9 1.3   29 7.7   33 0.8               33   I I 
Beiersdorf 10 liquid no cat No No 2 2 4.3   33.3 7.8   31.1 8.2               31.1   I I 
Beiersdorf 10 liquid no cat No No 3 2 6.2   34.9 3   35.4 1.2               35.3   I I 
Beiersdorf 11 liquid no cat No No 1 1.7 3.4   39.2 3.5   29.8 2.9               29.8   I I 
Beiersdorf 11 liquid no cat No No 2 1.7 6.1   40.6 1.6   27.5 2.3               27.5   I I 
Beiersdorf 11 liquid no cat No No 3 1.9 3.6   29.2 3   29.9 1.4               29.8   I I 
Beiersdorf 12 liquid no cat No No 1 1.7 6   37.5 4.2   94.1 15.6               94.1   NI NI 
Beiersdorf 12 liquid no cat No No 2 1.4 0.5   18.3 4.9   91.5 9.6               91.5   NI NI 
Beiersdorf 12 liquid no cat No No 3 1.4 1.8   42.2 10.3   91.6 15.1               91.6   NI NI 
Beiersdorf 13 liquid no cat No No 1 1.7 6   37.5 4.2   107.9 9.8               107.9   NI NI 
Beiersdorf 13 liquid no cat No No 2 1.4 0.5   18.3 4.9   87.8 4               87.8   NI NI 
Beiersdorf 13 liquid no cat No No 3 1.4 1.8   42.2 10.3   105.4 9.8               105.4   NI NI 
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Beiersdorf 14 liquid no cat No No 1 1.6 1.2   42.4 7   98.3 1.5               98.3   NI NI 
Beiersdorf 14 liquid no cat No No 2 2 7.9   33 4.3   98.7 2.9               98.7   NI NI 
Beiersdorf 14 liquid no cat No No 3 1.7 7.7   41 2.1   104.9 0.4               104.9   NI NI 
Beiersdorf 15 liquid no cat No No 1 1.7 6   37.5 4.2   97.2 5.4               97.2   NI NI 
Beiersdorf 15 liquid no cat No No 2 1.4 0.5   18.3 4.9   101.7 8.1               101.7   NI NI 
Beiersdorf 15 liquid no cat No No 3 1.4 1.8   42.2 10.3   109.5 14.4               109.5   NI NI 
Beiersdorf 16 liquid no cat No No 1 1.8 10.1   37.4 6.3   100.4 1.8               100.4   NI NI 
Beiersdorf 16 liquid no cat No No 2 1.6 5.6   43.5 4.4   110.9 10.1               110.9   NI NI 
Beiersdorf 16 liquid no cat No No 3 1.6 0.3   46.4 1.2   103.3 12.2               103.3   NI NI 
Beiersdorf 17 liquid no cat No No 1 1.9 1.3   29 7.7   102.5 0.9               102.5   NI NI 
Beiersdorf 17 liquid no cat No No 2 2 4.3   33.3 7.8   98.1 5.1               98.1   NI NI 
Beiersdorf 17 liquid no cat No No 3 2 6.2   34.9 3   91.9 2.4               91.9   NI NI 
Beiersdorf 18 liquid no cat No No 1 1.7 6   37.5 4.2   112.3 5.3               112.3   NI NI 
Beiersdorf 18 liquid no cat No No 2 1.4 0.5   18.3 4.9   69.6 8.1               69.6   NI NI 
Beiersdorf 18 liquid no cat No No 3 1.4 1.8   42.2 10.3   109.5 7.1               109.5   NI NI 
Beiersdorf 19 liquid no cat No No 1 1.7 6   37.5 4.2   106.4 8.8               106.4   NI NI 
Beiersdorf 19 liquid no cat No No 2 1.4 0.5   18.3 4.9   106.4 12.7               106.4   NI NI 
Beiersdorf 19 liquid no cat No No 3 1.4 1.8   42.2 10.3   111.8 4.3               111.8   NI NI 
Beiersdorf 20 liquid no cat Yes No 1 1.7 6   37.5 4.2   58.7 0.9         27.5 11.4   31.1   I I 
Beiersdorf 20 liquid no cat Yes No 2 1.4 0.5   18.3 4.9   90.4 1.9         33.2 13.7   57.2   NI I 
Beiersdorf 20 liquid no cat Yes No 3 1.4 1.8   42.2 10.3   82 6.8         32.2 13.3   49.8   I I 
Beiersdorf 21 liquid no cat No No 1 1.9 1.3   29 7.7   82.9 10               82.8   NI NI 
Beiersdorf 21 liquid no cat No No 2 2 4.3   33.3 7.8   82.9 2.1               82.9   NI NI 
Beiersdorf 21 liquid no cat No No 3 2 6.2   34.9 3   83.2 1.6               83.2   NI NI 
Beiersdorf 22 liquid no cat Yes No 1 1.6 1.2   42.4 7   55.4 9.7         3.8 0.1   51.6   NI I 
Beiersdorf 22 liquid no cat Yes No 2 2 7.9   33 4.3   42.5 10.1         3.1 0.1   39.3   I I 
Beiersdorf 22 liquid no cat Yes No 3 1.7 7.7   41 2.1   48.8 3.1         3.7 0.1   45.1   I I 
Beiersdorf 23 liquid no cat Yes No 1 1.6 1.2   42.4 7   73.5 1.6         32.6 0.8   40.8   I I 
Beiersdorf 23 liquid no cat Yes No 2 2 7.9   33 4.3   72.9 1.5         26.9 0.6   46   I I 
Beiersdorf 23 liquid no cat Yes No 3 1.7 7.7   41 2.1   71.9 7.1         32.4 0.8   39.5   I I 
Beiersdorf 24 liquid no cat No No 1 1.9 1.3   29 7.7   48.4 9               48.4   I I 
Beiersdorf 24 liquid no cat No No 2 2 4.3   33.3 7.8   45.6 4.5               45.6   I I 
Beiersdorf 24 liquid no cat No No 3 2 6.2   34.9 3   43.5 2.3               43.5   I I 
Beiersdorf 25 liquid no cat Yes No 1 1.9 1.3   29.7 3.1   107.7 1.5         0 1   107.6   NI NI 
Beiersdorf 25 liquid no cat Yes No 2 1.8 3.6   30.7 2.4   105 4.7         0 1.1   105   NI NI 
Beiersdorf 25 liquid no cat Yes No 3 2.1 4.1   30.3 2.8   101.3 0.6         0 0.9   101.3   NI NI 
Beiersdorf 26 liquid no cat Yes No 1 1.9 1.3   29.7 3.1   31.7 1.1         9 3.1   22.7   I I 
Beiersdorf 26 liquid no cat Yes No 2 1.8 3.6   30.7 2.4   28.7 5.2         9.3 3.2   19.4   I I 
Beiersdorf 26 liquid no cat Yes No 3 2.1 4.1   30.3 2.8   30.5 0.6         8 2.7   22.4   I I 
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Beiersdorf 28 solid no cat No No 1 1.7 5.1   37.4 6.5   99.4 9.9               99.4   NI NI 
Beiersdorf 28 solid no cat No No 2 1.7 2.5   34.4 2.8   99.6 2.2               99.6   NI NI 
Beiersdorf 28 solid no cat No No 3 2 7.3   30.5 2.1   95.8 4.3               95.8   NI NI 
Beiersdorf 29 solid no cat Yes No 1 2 0.1   33.3 4.7   83.3 15.2         0.4 0.1   82.9   NI NI 
Beiersdorf 29 solid no cat Yes No 2 1.7 0.6   37.4 0.6   92.2 4.6         0.5 0.1   91.8   NI NI 
Beiersdorf 29 solid no cat Yes No 3 1.7 5.1   35.9 1.9   84.5 21.3 NQ       0.5 0.1   84 NQ NI NI 
Beiersdorf 29 solid no cat Yes No 4 1.8 2.5   24.3 1.6   88.6 16         0.4 0.1   88.2   NI NI 
Beiersdorf 30 solid no cat Yes No 1 1.6 0.1   29 2.6   55.6 4.5         0 0.2   55.6   NI I 
Beiersdorf 30 solid no cat Yes No 2 1.6 1.6   32.9 3.3   39 5         0 0.2   39   I I 
Beiersdorf 30 solid no cat Yes No 3 1.8 10.4   27.4 1.2   46.8 1.5         0 0.1   46.8   I I 
Beiersdorf 31 solid no cat No No 1 1.7 2.6   32 8.3   82.1 3.8               82.1   NI NI 
Beiersdorf 31 solid no cat No No 2 1.5 0.2   29.3 1.5   90.3 8.6               90.3   NI NI 
Beiersdorf 31 solid no cat No No 3 1.6 2   96.1 1.9 NQ 74 5.8               74 NQ NI NI 
Beiersdorf 31 solid no cat No No 4 1.6 0.7   35.1 19.5   62.3 10.4               62.3   NI NI 
Beiersdorf 32 solid no cat Yes No 1 1.7 5.3   31.6 3.9   3 0         3.2 0.1   0   I I 
Beiersdorf 32 solid no cat Yes No 2 1.9 1.2   31.2 2.7   3.8 0.6         2.9 0.1   0.9   I I 
Beiersdorf 32 solid no cat Yes No 3 1.7 0.8   26.4 10.8   3.5 0.3         3.3 0.1   0.2   I I 
Beiersdorf 33 solid no cat Yes Yes 1 1.7 5.3   31.6 3.9   89 17   4605.5 0   5.2 4.4   0 EX I I 
Beiersdorf 33 solid no cat Yes Yes 2 1.9 1.2   31.2 2.7   2949.4 114.5 NQ 4094 0   4.6 3.9   0 EX I I 
Beiersdorf 33 solid no cat Yes Yes 3 1.7 0.8   26.4 10.8   6452.6 152.7 NQ 9506.4 0   5.4 4.5   0 EX I I 
Beiersdorf 33 solid no cat Yes Yes 4 1.8 2.5   24.3 1.6   5396.7 166.8 NQ 8732.6 0   4.9 4.2   0 EX I I 
Beiersdorf 33 solid no cat Yes Yes 5 1.7 0.4   27.5 5.7   85.4 4.5   0.5 0   5.2 4.4   79.7 EX NI NI 
Beiersdorf 34 solid no cat Yes Yes 1 1.7 5.3   31.6 3.9   118 0.8   5.1 0.7   1.8 0   111.1   NI NI 
Beiersdorf 34 solid no cat Yes Yes 2 1.9 1.2   31.2 2.7   122.4 3.3   9.3 3.8   1.6 0   111.5   NI NI 
Beiersdorf 34 solid no cat Yes Yes 3 1.7 0.8   26.4 10.8   125.8 7.1   7.4 0.5   1.9 0   116.5   NI NI 
Beiersdorf 35 solid no cat Yes No 1 1.7 5.1   37.4 6.5   74.2 15.8         0.5 0   73.7   NI NI 
Beiersdorf 35 solid no cat Yes No 2 1.7 2.5   34.4 2.8   72.4 4.1         0.5 0   72   NI NI 
Beiersdorf 35 solid no cat Yes No 3 2 7.3   30.5 2.1   77.4 1.4         0.4 0   77   NI NI 
Beiersdorf 36 solid no cat Yes No 1 1.7 5.1   37.4 6.5   110.9 5.4         0 0.3   110.9   NI NI 
Beiersdorf 36 solid no cat Yes No 2 1.7 2.5   34.4 2.8   102.8 2.8         0 0.3   102.8   NI NI 
Beiersdorf 36 solid no cat Yes No 3 2 7.3   30.5 2.1   107.5 11.8         0 0.3   107.5   NI NI 
Beiersdorf 37 liquid no cat No No 1 1.9 1.3   29 7.7   62.9 46.5 NQ             62.9 NQ NI NI 
Beiersdorf 37 liquid no cat No No 2 1.9 1.3   29.7 3.1   80.4 6.1               80.4   NI NI 
Beiersdorf 37 liquid no cat No No 3 1.8 3.6   30.7 2.4   75 3               75   NI NI 
Beiersdorf 37 liquid no cat No No 4 2.1 4.1   30.3 2.8   79.7 10.8               79.7   NI NI 
Beiersdorf 38 solid no cat No No 1 1.6 3.2   26.8 5.5   102.8 0               102.8   NI NI 
Beiersdorf 38 solid no cat No No 2 1.7 2.9   35.5 4.7   100.9 5.2               100.9   NI NI 
Beiersdorf 38 solid no cat No No 3 1.5 3.5   25.3 1.8   119.7 3.7               119.7   NI NI 
Beiersdorf 39 solid no cat No No 1 1.6 3.2   26.8 5.5   101.9 0.8               101.9   NI NI 
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Beiersdorf 39 solid no cat No No 2 1.7 2.9   35.5 4.7   99.5 8.8               99.5   NI NI 
Beiersdorf 39 solid no cat No No 3 1.5 3.5   25.3 1.8   117.3 4               117.3   NI NI 
Beiersdorf 40 solid no cat No No 1 1.6 3.2   26.8 5.5   49.4 15.1               49.4   I I 
Beiersdorf 40 solid no cat No No 2 1.7 2.9   35.5 4.7   59.5 7.7               59.5   NI I 
Beiersdorf 40 solid no cat No No 3 1.5 3.5   25.3 1.8   62.1 5.4               62.1   NI NI 
Beiersdorf 41 solid no cat No No 1 1.6 0.1   29 2.6   101.2 5.3               101.2   NI NI 
Beiersdorf 41 solid no cat No No 2 1.6 1.6   32.9 3.3   98.8 0.4               98.8   NI NI 
Beiersdorf 41 solid no cat No No 3 1.8 10.4   27.4 1.2   90.4 4.9               90.4   NI NI 
Beiersdorf 42 solid no cat Yes No 1 1.6 0.1   29 2.6   64.8 6.4         0.1 0   64.7   NI NI 
Beiersdorf 42 solid no cat Yes No 2 1.6 1.6   32.9 3.3   85.2 1.4         0.1 0   85   NI NI 
Beiersdorf 42 solid no cat Yes No 3 1.8 10.4   27.4 1.2   58.8 4.3         0.1 0   58.7   NI I 
Beiersdorf 43 solid no cat No No 1 1.7 2.6   32 8.3   93.9 5.7               93.9   NI NI 
Beiersdorf 43 solid no cat No No 2 1.5 0.2   29.3 1.5   112.1 3.2               112.1   NI NI 
Beiersdorf 43 solid no cat No No 3 1.6 2   96.1 1.9 NQ 100.3 9.2               100.3 NQ NI NI 
Beiersdorf 43 solid no cat No No 4 1.6 0.7   35.1 19.5   102.6 14.4               102.6   NI NI 
Beiersdorf 44 solid no cat No No 1 1.7 2.6   32 8.3   104.5 3.7               104.5   NI NI 
Beiersdorf 44 solid no cat No No 2 1.5 0.2   29.3 1.5   98.8 4.5               98.7   NI NI 
Beiersdorf 44 solid no cat No No 3 1.6 2   96.1 1.9 NQ 104.1 3               104.1 NQ NI NI 
Beiersdorf 44 solid no cat No No 4 1.6 0.7   35.1 19.5   97.3 12.4               97.3   NI NI 
Beiersdorf 45 solid no cat No No 1 1.6 3.2   26.8 5.5   110.6 0.6               110.6   NI NI 
Beiersdorf 45 solid no cat No No 2 1.7 2.9   35.5 4.7   101.4 7               101.4   NI NI 
Beiersdorf 45 solid no cat No No 3 1.5 3.5   25.3 1.8   118.8 1.2               118.8   NI NI 
Beiersdorf 46 solid no cat No No 1 1.7 2.6   32 8.3   68.4 6.1               68.4   NI NI 
Beiersdorf 46 solid no cat No No 2 1.5 0.2   29.3 1.5   68.9 15.9               68.9   NI NI 
Beiersdorf 46 solid no cat No No 3 1.6 2   96.1 1.9 NQ 57.6 8.4               57.6 NQ NI I 
Beiersdorf 46 solid no cat No No 4 1.6 0.7   35.1 19.5   72.6 3.5               72.6   NI NI 
Beiersdorf 47 solid no cat No No 1 1.7 5.3   31.6 3.9   4.4 0.8               4.4   I I 
Beiersdorf 47 solid no cat No No 2 1.9 1.2   31.2 2.7   5 4.5               5   I I 
Beiersdorf 47 solid no cat No No 3 1.7 0.8   26.4 10.8   4.6 3.1               4.6   I I 
Beiersdorf 48 solid no cat Yes No 1 1.6 0.1   29 2.6   3.3 0.3         0.5 0.3   2.7   I I 
Beiersdorf 48 solid no cat Yes No 2 1.6 1.6   32.9 3.3   4.2 0.5         0.5 0.3   3.6   I I 
Beiersdorf 48 solid no cat Yes No 3 1.8 10.4   27.4 1.2   3.5 2         0.5 0.2   3   I I 
Beiersdorf 49 solid no cat Yes No 1 1.6 3.2   26.8 5.5   8.6 5.1         12.2 17.2   0   I I 
Beiersdorf 49 solid no cat Yes No 2 1.7 2.9   35.5 4.7   9.5 2.3         11.6 16.3   0   I I 
Beiersdorf 49 solid no cat Yes No 3 1.5 3.5   25.3 1.8   8.8 2.9         13.1 18.4   0   I I 
Beiersdorf 50 solid no cat Yes No 1 2 0.1   33.3 4.7   89.8 4         0.2 0.1   89.7   NI NI 
Beiersdorf 50 solid no cat Yes No 2 1.7 0.6   37.4 0.6   89.8 2.2         0.2 0.1   89.6   NI NI 
Beiersdorf 50 solid no cat Yes No 3 1.7 5.1   35.9 1.9   85.2 20.4 NQ       0.2 0.1   85 NQ NI NI 
Beiersdorf 50 solid no cat Yes No 4 1.8 2.5   24.3 1.6   83.7 8.7         0.2 0.1   83.5   NI NI 
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Beiersdorf 51 solid no cat Yes No 1 1.6 3.2   26.8 5.5   99.1 6.8         0 0.2   99.1   NI NI 
Beiersdorf 51 solid no cat Yes No 2 1.7 2.9   35.5 4.7   91.5 16.3         0 0.2   91.5   NI NI 
Beiersdorf 51 solid no cat Yes No 3 1.5 3.5   25.3 1.8   101.1 5.1         0 0.2   101.1   NI NI 
Beiersdorf 52 solid no cat No No 1 1.6 3.2   26.8 5.5   104.8 0.1               104.8   NI NI 
Beiersdorf 52 solid no cat No No 2 1.7 2.9   35.5 4.7   103.1 3.4               103.1   NI NI 
Beiersdorf 52 solid no cat No No 3 1.5 3.5   25.3 1.8   130.8 5.5               130.8   NI NI 
Beiersdorf 53 solid no cat Yes No 1 1.6 3.2   26.8 5.5   93.1 17.3         0.2 0.3   93   NI NI 
Beiersdorf 53 solid no cat Yes No 2 1.7 2.9   35.5 4.7   105.9 10.8         0.2 0.3   105.7   NI NI 
Beiersdorf 53 solid no cat Yes No 3 1.5 3.5   25.3 1.8   119.5 10.6         0.2 0.3   119.4   NI NI 
Beiersdorf 54 liquid cat 2B No No 1 1.7 3.4   39.2 3.5   48.8 0.5               48.8   I I 
Beiersdorf 54 liquid cat 2B No No 2 1.7 6.1   40.6 1.6   47.8 6.1               47.8   I I 
Beiersdorf 54 liquid cat 2B No No 3 1.9 3.6   29.2 3   45.2 6.9               45.2   I I 
Beiersdorf 55 liquid cat 2B No No 1 1.9 1.3   29 7.7   2.3 0.1               2.3   I I 
Beiersdorf 55 liquid cat 2B No No 2 2 4.3   33.3 7.8   2.1 0.4               2.1   I I 
Beiersdorf 55 liquid cat 2B No No 3 2 6.2   34.9 3   2.1 0.3               2.1   I I 
Beiersdorf 56 liquid cat 2B Yes No 1 1.6 1.2   42.4 7   48.5 2.8         2.1 0.6   46.4   I I 
Beiersdorf 56 liquid cat 2B Yes No 2 2 7.9   33 4.3   56.2 9.7         1.7 0.5   54.5   NI I 
Beiersdorf 56 liquid cat 2B Yes No 3 1.7 7.7   41 2.1   62.4 1.5         2 0.6   60.3   NI NI 
Beiersdorf 57 liquid cat 2B No No 1 1.6 1.2   42.4 7   24.4 4.7               24.4   I I 
Beiersdorf 57 liquid cat 2B No No 2 2 7.9   33 4.3   19.9 5.8               19.8   I I 
Beiersdorf 57 liquid cat 2B No No 3 1.7 7.7   41 2.1   19.1 3.7               19.1   I I 
Beiersdorf 58 liquid cat 2B No No 1 1.9 1.3   29 7.7   22 0.3               22   I I 
Beiersdorf 58 liquid cat 2B No No 2 2 4.3   33.3 7.8   22.7 6.9               22.7   I I 
Beiersdorf 58 liquid cat 2B No No 3 2 6.2   34.9 3   22.2 3.4               22.2   I I 
Beiersdorf 59 liquid cat 2B No No 1 1.9 1.3   29 7.7   62.6 11.1               62.6   NI NI 
Beiersdorf 59 liquid cat 2B No No 2 2 4.3   33.3 7.8   67.5 3.7               67.5   NI NI 
Beiersdorf 59 liquid cat 2B No No 3 2 6.2   34.9 3   78.3 7.1               78.3   NI NI 
Beiersdorf 60 liquid cat 2B Yes No 1 1.9 1.3   29.7 3.1   20.5 1.5         0 0.3   20.5   I I 
Beiersdorf 60 liquid cat 2B Yes No 2 1.8 3.6   30.7 2.4   13.6 2.7         0 0.3   13.6   I I 
Beiersdorf 60 liquid cat 2B Yes No 3 2.1 4.1   30.3 2.8   12.6 2.4         0 0.3   12.6   I I 
Beiersdorf 61 solid cat 2B No No 1 1.7 5.3   31.6 3.9   16 5.6               16   I I 
Beiersdorf 61 solid cat 2B No No 2 1.9 1.2   31.2 2.7   15.9 5.8               15.9   I I 
Beiersdorf 61 solid cat 2B No No 3 1.7 0.8   26.4 10.8   22.9 3.9               22.9   I I 
Beiersdorf 62 solid cat 2B Yes No 1 1.6 0.1   29 2.6   115.2 9.9         0 0.5   115.2   NI NI 
Beiersdorf 62 solid cat 2B Yes No 2 1.6 1.6   32.9 3.3   110.1 10.8         0 0.4   110.1   NI NI 
Beiersdorf 62 solid cat 2B Yes No 3 1.8 10.4   27.4 1.2   101.7 14.9         0 0.4   101.7   NI NI 
Beiersdorf 63 solid cat 2B No No 1 1.7 2.6   32 8.3   40.6 0.8               40.6   I I 
Beiersdorf 63 solid cat 2B No No 2 1.5 0.2   29.3 1.5   34.3 0.2               34.3   I I 
Beiersdorf 63 solid cat 2B No No 3 1.6 2   96.1 1.9 NQ 35.8 2.3               35.8 NQ I I 
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Beiersdorf 63 solid cat 2B No No 4 1.6 0.7   35.1 19.5   27 3.2               27   I I 
Beiersdorf 64 solid cat 2B No No 1 1.7 5.3   31.6 3.9   36.9 9.4               36.9   I I 
Beiersdorf 64 solid cat 2B No No 2 1.9 1.2   31.2 2.7   22.8 7.2               22.8   I I 
Beiersdorf 64 solid cat 2B No No 3 1.7 0.8   26.4 10.8   30 2.1               30   I I 
Beiersdorf 65 solid cat 2B No No 1 1.7 2.6   32 8.3   50.5 15.6               50.5   NI I 
Beiersdorf 65 solid cat 2B No No 2 1.5 0.2   29.3 1.5   52.1 1               52.1   NI I 
Beiersdorf 65 solid cat 2B No No 3 1.6 2   96.1 1.9 NQ 59.5 10.6               59.5 NQ NI I 
Beiersdorf 65 solid cat 2B No No 4 1.6 0.7   35.1 19.5   51.7 5.5               51.7   NI I 
Beiersdorf 66 solid cat 2B No No 1 1.7 2.6   32 8.3   6 3.1               6   I I 
Beiersdorf 66 solid cat 2B No No 2 1.5 0.2   29.3 1.5   8 1.4               8   I I 
Beiersdorf 66 solid cat 2B No No 3 1.6 2   96.1 1.9 NQ 5.6 0               5.6 NQ I I 
Beiersdorf 66 solid cat 2B No No 4 1.6 0.7   35.1 19.5   6.4 1.3               6.4   I I 
Beiersdorf 67 liquid cat 2A No No 1 1.7 3.4   39.2 3.5   15 2.9               15   I I 
Beiersdorf 67 liquid cat 2A No No 2 1.7 6.1   40.6 1.6   10.8 0               10.8   I I 
Beiersdorf 67 liquid cat 2A No No 3 1.9 3.6   29.2 3   10.7 0.9               10.7   I I 




No No 1 1.7 3.4   39.2 3.5   3.5 0.2               3.5   I I 




No No 2 1.7 6.1   40.6 1.6   2.4 0.2               2.4   I I 




No No 3 1.9 3.6   29.2 3   4.3 0.9               4.3   I I 




No No 1 1.8 10.1   37.4 6.3   13.2 1.5               13.2   I I 




No No 2 1.6 5.6   43.5 4.4   15 3.6               15   I I 




No No 3 1.6 0.3   46.4 1.2   13.9 2.2               13.9   I I 
Beiersdorf 70 liquid cat 2A No No 1 1.8 10.1   37.4 6.3   12.5 1.3               12.5   I I 
Beiersdorf 70 liquid cat 2A No No 2 1.6 5.6   43.5 4.4   17.9 1.8               17.9   I I 
Beiersdorf 70 liquid cat 2A No No 3 1.6 0.3   46.4 1.2   15.4 3               15.4   I I 




No No 1 1.6 1.2   42.4 7   5.2 0.7               5.2   I I 




No No 2 2 7.9   33 4.3   6.2 1.3               6.2   I I 




No No 3 1.7 7.7   41 2.1   4.7 2               4.7   I I 
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No Yes 1 2 4.3   33.3 7.8   8 2.6   3.3 1.4         4.7   I I 




No Yes 2 2 6.2   34.9 3   4.6 2.8   2.4 0.8         2.2   I I 




No Yes 3 1.8 3.6   30.7 2.4   7.5 0.4   2.6 0.9         4.9   I I 




No No 1 1.7 5.1   37.4 6.5   73.9 5.2               73.9   NI NI 




No No 2 1.7 2.5   34.4 2.8   88.1 0.3               88.1   NI NI 




No No 3 2 7.3   30.5 2.1   89 1.4               89   NI NI 
Beiersdorf 74 solid cat 2A Yes No 1 1.7 5.1   37.4 6.5   76.4 31.7 NQ       3.3 0.9   73.1 NQ NI NI 
Beiersdorf 74 solid cat 2A Yes No 2 1.7 2.5   34.4 2.8   75.8 11         3.3 0.9   72.5   NI NI 
Beiersdorf 74 solid cat 2A Yes No 3 2 7.3   30.5 2.1   68.8 2.7         2.9 0.8   65.9   NI NI 
Beiersdorf 74 solid cat 2A Yes No 4 1.9 1.2   31.2 2.7   91.8 7.2         3 0.8   88.8   NI NI 
Beiersdorf 75 solid cat 2A No No 1 1.7 2.6   32 8.3   74.8 10.2               74.8   NI NI 
Beiersdorf 75 solid cat 2A No No 2 1.5 0.2   29.3 1.5   81.1 1.1               81.1   NI NI 
Beiersdorf 75 solid cat 2A No No 3 1.6 2   96.1 1.9 NQ 41.3 76.9 NQ             41.3 NQ I I 
Beiersdorf 75 solid cat 2A No No 4 1.6 0.7   35.1 19.5   28.9 52 NQ             28.9 NQ I I 
Beiersdorf 75 solid cat 2A No No 5 1.8 2.1   24.4 4.9   83.9 6.9               83.9   NI NI 
Beiersdorf 76 solid cat 2A No No 1 1.6 0.1   29 2.6   54.8 8.1               54.8   NI I 
Beiersdorf 76 solid cat 2A No No 2 1.6 1.6   32.9 3.3   53.5 4.3               53.5   NI I 
Beiersdorf 76 solid cat 2A No No 3 1.8 10.4   27.4 1.2   53.4 0.5               53.4   NI I 
Beiersdorf 77 solid cat 2A No No 1 1.6 0.1   29 2.6   103.6 4.8               103.6   NI NI 
Beiersdorf 77 solid cat 2A No No 2 1.6 1.6   32.9 3.3   94.1 17.6               94.1   NI NI 
Beiersdorf 77 solid cat 2A No No 3 1.8 10.4   27.4 1.2   92.8 3.4               92.8   NI NI 
Beiersdorf 78 solid cat 2A No No 1 1.7 2.6   32 8.3   79.9 3.3               79.9   NI NI 
Beiersdorf 78 solid cat 2A No No 2 1.5 0.2   29.3 1.5   80.9 0.3               80.9   NI NI 
Beiersdorf 78 solid cat 2A No No 3 1.6 2   96.1 1.9 NQ 84.6 11.7               84.6 NQ NI NI 
Beiersdorf 78 solid cat 2A No No 4 1.6 0.7   35.1 19.5   88.9 2.7               88.9   NI NI 




No No 1 1.7 5.3   31.6 3.9   2.4 0.1               2.4   I I 




No No 2 1.9 1.2   31.2 2.7   3.3 1.4               3.3   I I 
Beiersdorf 79 solid cat 2A No No 3 1.7 0.8   26.4 10.8   2.2 0.1               2.2   I I 
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(ICCVAM: cat 
2B) 
Beiersdorf 801 liquid cat 1 Yes No 1 1.7 3.4   39.2 3.5   70.9 1.9         52.7 1.6   18.1   I I 
Beiersdorf 801 liquid cat 1 Yes No 2 1.7 6.1   40.6 1.6   68.6 8.6         52 1.6   16.6   I I 
Beiersdorf 801 liquid cat 1 Yes No 3 1.9 3.6   29.2 3   66.5 0.2         48.8 1.5   17.7   I I 
Beiersdorf 81 liquid cat 1 Yes No 1 1.6 1.2   42.4 7   2.6 0.2         0.1 0.3   2.5   I I 
Beiersdorf 81 liquid cat 1 Yes No 2 2 7.9   33 4.3   1.8 0.1         0.1 0.2   1.8   I I 
Beiersdorf 81 liquid cat 1 Yes No 3 1.7 7.7   41 2.1   3.2 0.4         0.1 0.3   3.1   I I 
Beiersdorf 82 liquid cat 1 No No 1 1.7 6   37.5 4.2   4.5 3.6               4.5   I I 
Beiersdorf 82 liquid cat 1 No No 2 1.4 0.5   18.3 4.9   1.6 0.3               1.6   I I 
Beiersdorf 82 liquid cat 1 No No 3 1.4 1.8   42.2 10.3   5.4 1               5.4   I I 
Beiersdorf 83 liquid cat 1 No No 1 1.8 10.1   37.4 6.3   5.5 2.9               5.5   I I 
Beiersdorf 83 liquid cat 1 No No 2 1.6 5.6   43.5 4.4   6.1 1.8               6.1   I I 
Beiersdorf 83 liquid cat 1 No No 3 1.6 0.3   46.4 1.2   5.3 3.1               5.3   I I 
Beiersdorf 84 liquid cat 1 Yes No 1 1.7 6   37.5 4.2   12.7 4.6         0 0.3   12.6   I I 
Beiersdorf 84 liquid cat 1 Yes No 2 1.4 0.5   18.3 4.9   5.7 1.1         0.1 0.4   5.6   I I 
Beiersdorf 84 liquid cat 1 Yes No 3 1.4 1.8   42.2 10.3   22.2 13         0.1 0.4   22.1   I I 
Beiersdorf 85 liquid cat 1 No No 1 1.7 3.4   39.2 3.5   15.9 3.7               15.9   I I 
Beiersdorf 85 liquid cat 1 No No 2 1.7 6.1   40.6 1.6   18.1 0.3               18.1   I I 
Beiersdorf 85 liquid cat 1 No No 3 1.9 3.6   29.2 3   26.7 1.1               26.7   I I 
Beiersdorf 86 liquid cat 1 No No 1 1.7 6   37.5 4.2   25.3 3.3               25.3   I I 
Beiersdorf 86 liquid cat 1 No No 2 1.4 0.5   18.3 4.9   20.7 4.5               20.7   I I 
Beiersdorf 86 liquid cat 1 No No 3 1.4 1.8   42.2 10.3   27.2 3.1               27.2   I I 
Beiersdorf 87 liquid cat 1 No No 1 1.8 10.1   37.4 6.3   26.3 0.3               26.3   I I 
Beiersdorf 87 liquid cat 1 No No 2 1.6 5.6   43.5 4.4   26.3 2.9               26.3   I I 
Beiersdorf 87 liquid cat 1 No No 3 1.6 0.3   46.4 1.2   33.6 8.3               33.6   I I 
Beiersdorf 88 liquid cat 1 Yes No 1 1.7 6   37.5 4.2   4.5 0.4         0 0.4   4.5   I I 
Beiersdorf 88 liquid cat 1 Yes No 2 1.4 0.5   18.3 4.9   5.3 0.1         0 0.5   5.3   I I 
Beiersdorf 88 liquid cat 1 Yes No 3 1.4 1.8   42.2 10.3   7.5 2.5         0 0.5   7.4   I I 
Beiersdorf 89 liquid cat 1 No No 1 1.6 1.2   42.4 7   10.7 3.5               10.7   I I 
Beiersdorf 89 liquid cat 1 No No 2 2 7.9   33 4.3   7.2 0               7.2   I I 
Beiersdorf 89 liquid cat 1 No No 3 1.7 7.7   41 2.1   10.7 2               10.6   I I 
Beiersdorf 90 liquid cat 1 No No 1 1.9 1.3   29 7.7   40.4 1.2               40.4   I I 
Beiersdorf 90 liquid cat 1 No No 2 2 4.3   33.3 7.8   28.5 3.4               28.5   I I 
Beiersdorf 90 liquid cat 1 No No 3 2 6.2   34.9 3   25.6 10.2               25.6   I I 
Beiersdorf 91 liquid cat 1 Yes No 1 1.6 1.2   42.4 7   20.6 0         0.6 0.1   20   I I 
Beiersdorf 91 liquid cat 1 Yes No 2 2 7.9   33 4.3   35.4 6.3         0.5 0.1   35   I I 
Beiersdorf 91 liquid cat 1 Yes No 3 1.7 7.7   41 2.1   38.9 7.9         0.6 0.1   38.3   I I 
Beiersdorf 92 liquid cat 1 Yes No 1 1.9 1.3   29.7 3.1   47.7 9.3         0.2 0.4   47.5   I I 
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Beiersdorf 92 liquid cat 1 Yes No 2 1.8 3.6   30.7 2.4   41.3 9.4         0.3 0.4   41   I I 
Beiersdorf 92 liquid cat 1 Yes No 3 2.1 4.1   30.3 2.8   50 2.8         0.2 0.3   49.8   I I 
Beiersdorf 93 solid cat 1 No No 1 1.7 5.1   37.4 6.5   11.5 0.9               11.5   I I 
Beiersdorf 93 solid cat 1 No No 2 1.7 2.5   34.4 2.8   9.5 4.2               9.5   I I 
Beiersdorf 93 solid cat 1 No No 3 2 7.3   30.5 2.1   5.7 1.2               5.7   I I 
Beiersdorf 94 solid cat 1 No No 1 1.6 0.1   29 2.6   2.1 0.4               2.1   I I 
Beiersdorf 94 solid cat 1 No No 2 1.6 1.6   32.9 3.3   2.3 0.3               2.3   I I 
Beiersdorf 94 solid cat 1 No No 3 1.8 10.4   27.4 1.2   2.6 0.3               2.6   I I 
Beiersdorf 95 solid cat 1 Yes No 1 1.7 5.1   37.4 6.5   2.4 0.1         0 0.3   2.4   I I 
Beiersdorf 95 solid cat 1 Yes No 2 1.7 2.5   34.4 2.8   2.5 0.1         0 0.3   2.5   I I 
Beiersdorf 95 solid cat 1 Yes No 3 2 7.3   30.5 2.1   2.2 0.2         0 0.3   2.2   I I 
Beiersdorf 96 solid cat 1 No No 1 1.7 5.1   37.4 6.5   28.9 10.3               28.9   I I 
Beiersdorf 96 solid cat 1 No No 2 1.7 2.5   34.4 2.8   41.1 10               41.1   I I 
Beiersdorf 96 solid cat 1 No No 3 2 7.3   30.5 2.1   36.1 1.7               36.1   I I 
Beiersdorf 97 solid cat 1 No No 1 1.7 5.1   37.4 6.5   56.2 4.5               56.2   NI I 
Beiersdorf 97 solid cat 1 No No 2 1.7 2.5   34.4 2.8   47.2 1.2               47.2   I I 
Beiersdorf 97 solid cat 1 No No 3 2 7.3   30.5 2.1   55.5 8               55.5   NI I 
Beiersdorf 98 solid cat 1 Yes Yes 1 2 0.1   33.3 4.7   28.4 8.4   12 10.6   27.9 1.1   0   I I 
Beiersdorf 98 solid cat 1 Yes Yes 2 1.7 0.6   37.4 0.6   21.1 2.4   8.9 6.5   31.7 1.3   0   I I 
Beiersdorf 98 solid cat 1 Yes Yes 3 1.7 5.1   35.9 1.9   23.4 1.9   5.6 0.4   32.1 1.3   0   I I 
Beiersdorf 99 solid cat 1 No No 1 1.6 3.2   26.8 5.5   2.6 0.1               2.6   I I 
Beiersdorf 99 solid cat 1 No No 2 1.7 2.9   35.5 4.7   2.8 0.1               2.8   I I 
Beiersdorf 99 solid cat 1 No No 3 1.5 3.5   25.3 1.8   3.1 0.5               3.1   I I 
Beiersdorf 100 solid cat 1 Yes No 1 1.9 13   23.6 5   9.8 1.1         0 0.1   9.8   I I 
Beiersdorf 100 solid cat 1 Yes No 2 1.7 3.1   21.5 3.6   3.6 0.3         0 0.1   3.6   I I 
Beiersdorf 100 solid cat 1 Yes No 3 1.8 2.1   24.4 4.9   2.4 0.2         0 0.1   2.4   I I 
Beiersdorf 101 solid cat 1 No Yes 1 2 0.1   33.3 4.7   34.6 10.6   0.4 0.1         34.1   I I 
Beiersdorf 101 solid cat 1 No Yes 2 1.7 0.6   37.4 0.6   33.5 5.8   0.3 0.1         33.2   I I 
Beiersdorf 101 solid cat 1 No Yes 3 1.7 5.1   35.9 1.9   34.6 2.8   0.3 0         34.3   I I 
Beiersdorf 102 solid cat 1 No No 1 1.6 3.2   26.8 5.5   10.1 3.7               10.1   I I 
Beiersdorf 102 solid cat 1 No No 2 1.7 2.9   35.5 4.7   110.3 9.6               110.2   NI NI 
Beiersdorf 102 solid cat 1 No No 3 1.5 3.5   25.3 1.8   124.3 3.5               124.3   NI NI 
Beiersdorf 103 solid cat 1 Yes No 1 1.6 0.1   29 2.6   2 0.1         0 0.2   2   I I 
Beiersdorf 103 solid cat 1 Yes No 2 1.6 1.6   32.9 3.3   3.5 0.7         0 0.2   3.5   I I 
Beiersdorf 103 solid cat 1 Yes No 3 1.8 10.4   27.4 1.2   2 0.4         0 0.2   2   I I 
Beiersdorf 104 solid cat 1 No No 1 1.7 2.6   32 8.3   37.4 5.8               37.4   I I 
Beiersdorf 104 solid cat 1 No No 2 1.5 0.2   29.3 1.5   38.9 2.5               38.9   I I 
Beiersdorf 104 solid cat 1 No No 3 1.6 2   96.1 1.9 NQ 33.1 14.2               33.1 NQ I I 
Beiersdorf 104 solid cat 1 No No 4 1.6 0.7   35.1 19.5   42.9 12               42.9   I I 
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Beiersdorf 105 solid cat 1 No No 1 1.6 0.1   29 2.6   2.5 0.1               2.5   I I 
Beiersdorf 105 solid cat 1 No No 2 1.6 1.6   32.9 3.3   2.8 0.1               2.8   I I 
Beiersdorf 105 solid cat 1 No No 3 1.8 10.4   27.4 1.2   2.4 0.2               2.4   I I 
Harlan 1 liquid no cat No No 1 1.8 3.4   25.8 6.9   66.7 3.5               66.7   NI NI 
Harlan 1 liquid no cat No No 2 1.7 13.7   29 1   62.5 7.6               62.5   NI NI 
Harlan 1 liquid no cat No No 3 1.7 3.5   31.5 9.5   70.5 5.4               70.4   NI NI 
Harlan 2 liquid no cat No No 1 1.7 7.2   25.4 5.6   74.6 7.9               74.6   NI NI 
Harlan 2 liquid no cat No No 2 1.7 1.4   28.8 3.8   79.8 0.8               79.8   NI NI 
Harlan 2 liquid no cat No No 3 1.9 6.2   31.8 1.1   78.9 4.3               78.9   NI NI 
Harlan 3 liquid no cat No No 1 1.7 7.2   25.4 5.6   37.2 5.2               37.2   I I 
Harlan 3 liquid no cat No No 2 1.7 1.4   28.8 3.8   38.1 4.3               38.1   I I 
Harlan 3 liquid no cat No No 3 1.9 6.2   31.8 1.1   38.6 2.7               38.6   I I 
Harlan 4 liquid no cat Yes No 1 1.8 5.7   15.2 0.8   98.9 5.2         38 0.2   60.8   NI NI 
Harlan 4 liquid no cat Yes No 2 1.9 0.8   28.1 0.3   94.7 3         36.8 0.2   57.9   NI I 
Harlan 4 liquid no cat Yes No 3 1.9 4.2   17.9 6.3   102.2 12.1         37.9 0.2   64.3   NI NI 
Harlan 5 liquid no cat Yes No 1 1.3 11.3   6.8 0.7   56.7 15.5         0 1.1   56.7   NI I 
Harlan 5 liquid no cat Yes No 2 1.8 0.6   16.4 0.9   41.4 5.4         0 0.8   41.4   I I 
Harlan 5 liquid no cat Yes No 3 2.3 3.5   12.7 0   40.3 0.4         0 0.6   40.3   I I 
Harlan 6 liquid no cat No No 1 1.8 3.4   25.8 6.9   73.2 14               73.2   NI NI 
Harlan 6 liquid no cat No No 2 1.7 13.7   29 1   71.1 6.9               71.1   NI NI 
Harlan 6 liquid no cat No No 3 1.7 3.5   31.5 9.5   84.7 7.4               84.7   NI NI 
Harlan 7 liquid no cat No No 1 1.7 7.2   25.4 5.6   31 3.6               31   I I 
Harlan 7 liquid no cat No No 2 1.7 1.4   28.8 3.8   36.8 10.6               36.8   I I 
Harlan 7 liquid no cat No No 3 1.9 6.2   31.8 1.1   36.6 5.8               36.6   I I 
Harlan 8 liquid no cat No No 1 1.7 7.2   25.4 5.6   89.6 6.5               89.6   NI NI 
Harlan 8 liquid no cat No No 2 1.7 1.4   28.8 3.8   94.8 3.4               94.7   NI NI 
Harlan 8 liquid no cat No No 3 1.9 6.2   31.8 1.1   94.8 5.3               94.8   NI NI 
Harlan 9 liquid no cat No No 1 1.8 3.4   25.8 6.9   91.9 7.3               91.9   NI NI 
Harlan 9 liquid no cat No No 2 1.7 13.7   29 1   82.6 13.3               82.6   NI NI 
Harlan 9 liquid no cat No No 3 1.7 3.5   31.5 9.5   96.5 7.3               96.5   NI NI 
Harlan 10 liquid no cat No No 1 1.9 6.1   27.3 0.5   14.4 0.3               14.4   I I 
Harlan 10 liquid no cat No No 2 1.8 1.1   18.1 4.1   9.8 1.3               9.8   I I 
Harlan 10 liquid no cat No No 3 1.5 2.8   22.9 2.2   13.2 1.7               13.2   I I 
Harlan 11 liquid no cat No No 1 1.8 3.4   25.8 6.9   21.3 3.6               21.2   I I 
Harlan 11 liquid no cat No No 2 1.7 13.7   29 1   19 0.4               19   I I 
Harlan 11 liquid no cat No No 3 1.7 3.5   31.5 9.5   16.4 0.9               16.4   I I 
Harlan 12 liquid no cat No No 1 1.7 1.8   15.6 2.3   92.7 3.7               92.7   NI NI 
Harlan 12 liquid no cat No No 2 1.6 4.3   29.8 1.6   91.9 6.1               91.9   NI NI 
Harlan 12 liquid no cat No No 3 1.6 4.2   29.4 1.1   96.7 2.7               96.7   NI NI 
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Harlan 13 liquid no cat No No 1 1.7 1.8   15.6 2.3   88.8 4.8               88.8   NI NI 
Harlan 13 liquid no cat No No 2 1.6 4.3   29.8 1.6   97.5 2.1               97.5   NI NI 
Harlan 13 liquid no cat No No 3 1.6 4.2   29.4 1.1   85.1 16.3               85.1   NI NI 
Harlan 14 liquid no cat No No 1 1.8 3.4   25.8 6.9   90.6 10.8               90.6   NI NI 
Harlan 14 liquid no cat No No 2 1.7 13.7   29 1   97.9 4.9               97.9   NI NI 
Harlan 14 liquid no cat No No 3 1.7 3.5   31.5 9.5   103.1 10               103   NI NI 
Harlan 15 liquid no cat No No 1 1.7 1.8   15.6 2.3   104.9 0.7               104.9   NI NI 
Harlan 15 liquid no cat No No 2 1.6 4.3   29.8 1.6   93 5.3               93   NI NI 
Harlan 15 liquid no cat No No 3 1.6 4.2   29.4 1.1   106.3 1.3               106.3   NI NI 
Harlan 16 liquid no cat No No 1 1.7 7.2   25.4 5.6   103.8 1.8               103.8   NI NI 
Harlan 16 liquid no cat No No 2 1.7 1.4   28.8 3.8   102.1 1.2               102.1   NI NI 
Harlan 16 liquid no cat No No 3 1.9 6.2   31.8 1.1   94 0.2               94   NI NI 
Harlan 17 liquid no cat No No 1 1.9 6.1   27.3 0.5   86.9 3.1               86.9   NI NI 
Harlan 17 liquid no cat No No 2 1.8 1.1   18.1 4.1   100.6 0.8               100.6   NI NI 
Harlan 17 liquid no cat No No 3 1.5 2.8   22.9 2.2   103.9 0.6               103.9   NI NI 
Harlan 18 liquid no cat No No 1 1.7 1.8   15.6 2.3   101.5 4.2               101.5   NI NI 
Harlan 18 liquid no cat No No 2 1.6 4.3   29.8 1.6   91 2.4               91   NI NI 
Harlan 18 liquid no cat No No 3 1.6 4.2   29.4 1.1   96.8 1.8               96.8   NI NI 
Harlan 19 liquid no cat No No 1 1.7 1.8   15.6 2.3   108.8 5.2               108.8   NI NI 
Harlan 19 liquid no cat No No 2 1.6 4.3   29.8 1.6   105.3 5               105.3   NI NI 
Harlan 19 liquid no cat No No 3 1.6 4.2   29.4 1.1   113.1 14.5               113.1   NI NI 
Harlan 20 liquid no cat Yes No 1 1.7 8.5   28 3.5   26.7 10.2         17.5 4   9.1   I I 
Harlan 20 liquid no cat Yes No 2 1.4 2.9   29 0.6   20.8 5.8         21.5 4.9   0   I I 
Harlan 20 liquid no cat Yes No 3 1.9 1.9   27.1 14.1   34.8 3.1         15.8 3.6   19.1   I I 
Harlan 21 liquid no cat No No 1 1.9 6.1   27.3 0.5   71.8 0.4               71.8   NI NI 
Harlan 21 liquid no cat No No 2 1.8 1.1   18.1 4.1   67.4 4.6               67.4   NI NI 
Harlan 21 liquid no cat No No 3 1.5 2.8   22.9 2.2   77.6 6.4               77.6   NI NI 
Harlan 22 liquid no cat Yes No 1 1.3 11.3   6.8 0.7   28.3 7.5         4.3 1   24   I I 
Harlan 22 liquid no cat Yes No 2 1.8 0.6   16.4 0.9   26.4 4.4         3.1 0.7   23.3   I I 
Harlan 22 liquid no cat Yes No 3 2.3 3.5   12.7 0   15.4 0.8         2.4 0.6   13   I I 
Harlan 23 liquid no cat Yes No 1 1.8 5.7   15.2 0.8   62.8 10.5         45.3 2.2   17.5   I I 
Harlan 23 liquid no cat Yes No 2 1.9 0.8   28.1 0.3   66.3 1.1         43.9 2.1   22.4   I I 
Harlan 23 liquid no cat Yes No 3 1.9 4.2   17.9 6.3   50 1.9         45.1 2.2   4.9   I I 
Harlan 24 liquid no cat No No 1 1.9 6.1   27.3 0.5   28 0.9               28   I I 
Harlan 24 liquid no cat No No 2 1.8 1.1   18.1 4.1   19.4 7.7               19.4   I I 
Harlan 24 liquid no cat No No 3 1.5 2.8   22.9 2.2   21.3 6.8               21.3   I I 
Harlan 25 liquid no cat Yes No 1 1.7 8.5   28 3.5   104.8 9.1         0 0.1   104.8   NI NI 
Harlan 25 liquid no cat Yes No 2 1.4 2.9   29 0.6   108.9 11.9         0 0.1   108.9   NI NI 
Harlan 25 liquid no cat Yes No 3 1.9 1.9   27.1 14.1   104.9 2.8         0 0.1   104.9   NI NI 
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Harlan 26 liquid no cat No No 1 1.7 1.8   15.6 2.3   30.6 3.1               30.6   I I 
Harlan 26 liquid no cat No No 2 1.6 4.3   29.8 1.6   40.7 8.1               40.7   I I 
Harlan 26 liquid no cat No No 3 1.6 4.2   29.4 1.1   35.6 4.3               35.6   I I 
Harlan 28 solid no cat No No 1 1.8 3.1   22.5 0.5   95 3.5               94.9   NI NI 
Harlan 28 solid no cat No No 2 2 2.4   25.1 1.4   94.5 4.3               94.5   NI NI 
Harlan 28 solid no cat No No 3 2 0.2   22.9 2.6   90.9 1.3               90.9   NI NI 
Harlan 29 solid no cat No No 1 1.6 16.2   35.4 2.2   57.4 12.3               57.4   NI I 
Harlan 29 solid no cat No No 2 1.4 2.9   32.8 0.6   112 11.3               112   NI NI 
Harlan 29 solid no cat No No 3 1.6 2.7   29.2 1.2   83 7.2               83   NI NI 
Harlan 30 solid no cat No No 1 1.6 2.1   19.2 1.2   35 6.7               35   I I 
Harlan 30 solid no cat No No 2 1.7 0   16.3 1.8   25.2 1.9               25.2   I I 
Harlan 30 solid no cat No No 3 1.6 3.7   29 15.6   14.2 6.6               14.2   I I 
Harlan 31 solid no cat No No 1 1.6 2.1   19.2 1.2   96.6 1.1               96.6   NI NI 
Harlan 31 solid no cat No No 2 1.7 0   16.3 1.8   77.4 8.3               77.4   NI NI 
Harlan 31 solid no cat No No 3 1.6 3.7   29 15.6   96.3 7.2               96.3   NI NI 
Harlan 32 solid no cat Yes Yes 1 1.7 5.1   12.3 1.5   4.3 1   0.3 0.1   2.8 0.5   1.1   I I 
Harlan 32 solid no cat Yes Yes 2 1.7 2.4   19.5 3.4   4.3 0.9   0.5 0.1   2.9 0.5   0.9   I I 
Harlan 32 solid no cat Yes Yes 3 1.7 0.7   17 1.4   4.1 0.3   0.4 0.2   2.8 0.5   0.9   I I 
Harlan 33 solid no cat Yes Yes 1 1.7 2.4   19.5 3.4   69.2 12.9   0.5 0.3   24.6 10.2   44.1   I I 
Harlan 33 solid no cat Yes Yes 2 1.7 0.7   17 1.4   77.1 15.7   4.6 5.1   24.2 10.1   48.3   I I 
Harlan 33 solid no cat Yes Yes 3 1.4 11.3   43.1 6.8   84.4 14.4   13.8 3   30.3 12.6   40.3   I I 
Harlan 34 solid no cat Yes Yes 1 1.7 5.1   12.3 1.5   106.6 16.7   11.4 4.2   13.8 3.8   81.4   NI NI 
Harlan 34 solid no cat Yes Yes 2 1.7 2.4   19.5 3.4   80.9 13.3   12.6 2.3   14.2 3.9   54.1   NI I 
Harlan 34 solid no cat Yes Yes 3 1.7 0.7   17 1.4   89.6 1.1   12.5 1.9   14 3.9   63.2   NI NI 
Harlan 35 solid no cat Yes No 1 1.6 5.3   27.3 7.7   65.1 0.7         2.8 0.1   62.3   NI NI 
Harlan 35 solid no cat Yes No 2 1.6 4.7   21.3 6.6   72.1 8.1         2.8 0.1   69.3   NI NI 
Harlan 35 solid no cat Yes No 3 1.6 2.2   16.2 0.7   80.3 13.3         2.9 0.1   77.4   NI NI 
Harlan 36 solid no cat No No 1 1.8 3.1   22.5 0.5   103.1 3.6               103.1   NI NI 
Harlan 36 solid no cat No No 2 2 2.4   25.1 1.4   88.2 14               88.2   NI NI 
Harlan 36 solid no cat No No 3 2 0.2   22.9 2.6   98.5 1               98.5   NI NI 
Harlan 37 liquid no cat No No 1 1.9 6.1   27.3 0.5   74.2 6.1               74.2   NI NI 
Harlan 37 liquid no cat No No 2 1.8 1.1   18.1 4.1   66.5 6.8               66.5   NI NI 
Harlan 37 liquid no cat No No 3 1.5 2.8   22.9 2.2   78.3 8.6               78.3   NI NI 
Harlan 38 solid no cat No No 1 1.6 16.2   35.4 2.2   99.7 6.2               99.7   NI NI 
Harlan 38 solid no cat No No 2 1.4 2.9   32.8 0.6   113 1.7               113   NI NI 
Harlan 38 solid no cat No No 3 1.6 2.7   29.2 1.2   95.8 7.9               95.8   NI NI 
Harlan 39 solid no cat No No 1 1.6 16.2   35.4 2.2   100.9 5.1               100.9   NI NI 
Harlan 39 solid no cat No No 2 1.4 2.9   32.8 0.6   114.7 1.1               114.7   NI NI 
Harlan 39 solid no cat No No 3 1.6 2.7   29.2 1.2   88.4 2.4               88.4   NI NI 
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Harlan 40 solid no cat No No 1 1.4 11.3   43.1 6.8   72.9 2               72.9   NI NI 
Harlan 40 solid no cat No No 2 0.7 5.5 NQ 45.1 0.4   52.9 8.8               52.9 NQ NI I 
Harlan 40 solid no cat No No 3 1.8 3.3   36.8 3.1   56.2 5.1               56.2   NI I 
Harlan 40 solid no cat No No 4 1.6 1   35.9 1.2   60.2 1.5               60.2   NI NI 
Harlan 41 solid no cat No No 1 1.8 3.1   22.5 0.5   98.2 4               98.2   NI NI 
Harlan 41 solid no cat No No 2 2 2.4   25.1 1.4   86.4 8.4               86.4   NI NI 
Harlan 41 solid no cat No No 3 2 0.2   22.9 2.6   88.8 4.1               88.8   NI NI 
Harlan 42 solid no cat Yes No 1 1.6 5.3   27.3 7.7   53.5 9.8         0.1 0.2   53.4   NI I 
Harlan 42 solid no cat Yes No 2 1.6 4.7   21.3 6.6   66.1 3.5         0.1 0.2   66   NI NI 
Harlan 42 solid no cat Yes No 3 1.6 2.2   16.2 0.7   60.2 3.1         0.1 0.3   60   NI NI 
Harlan 43 solid no cat No No 1 1.6 2.1   19.2 1.2   125.3 4.7               125.3   NI NI 
Harlan 43 solid no cat No No 2 1.7 0   16.3 1.8   91.6 2.1               91.6   NI NI 
Harlan 43 solid no cat No No 3 1.6 3.7   29 15.6   163.7 3.6               163.7   NI NI 
Harlan 44 solid no cat No No 1 1.6 2.1   19.2 1.2   101.6 6.3               101.6   NI NI 
Harlan 44 solid no cat No No 2 1.7 0   16.3 1.8   95 2.8               95   NI NI 
Harlan 44 solid no cat No No 3 1.6 3.7   29 15.6   103.9 4.8               103.9   NI NI 
Harlan 45 solid no cat No No 1 1.6 2.1   19.2 1.2   112.5 7.7               112.5   NI NI 
Harlan 45 solid no cat No No 2 1.7 0   16.3 1.8   97.9 6.9               97.9   NI NI 
Harlan 45 solid no cat No No 3 1.6 3.7   29 15.6   112.6 9.4               112.6   NI NI 
Harlan 46 solid no cat No No 1 1.6 2.1   19.2 1.2   73.1 0.4               73.1   NI NI 
Harlan 46 solid no cat No No 2 1.7 0   16.3 1.8   58.9 4.2               58.9   NI I 
Harlan 46 solid no cat No No 3 1.6 3.7   29 15.6   80 19.7               80   NI NI 
Harlan 47 solid no cat Yes No 1 1.6 5.3   27.3 7.7   3.5 2.3         0.1 0.5   3.4   I I 
Harlan 47 solid no cat Yes No 2 1.6 4.7   21.3 6.6   2 0.1         0.1 0.5   2   I I 
Harlan 47 solid no cat Yes No 3 1.6 2.2   16.2 0.7   3.3 1.2         0.1 0.5   3.2   I I 
Harlan 48 solid no cat No No 1 1.7 3.3   24.9 1.4   2.8 0.2               2.8   I I 
Harlan 48 solid no cat No No 2 1.7 2.8   20.7 1.4   3.1 0.3               3.1   I I 
Harlan 48 solid no cat No No 3 1.8 6.9   16.9 9.2   2.5 0.3               2.5   I I 
Harlan 49 solid no cat Yes No 1 1.4 11.3   43.1 6.8   11.7 0.9         0 0.2   11.7   I I 
Harlan 49 solid no cat Yes No 2 0.7 5.5 NQ 45.1 0.4   6.3 0.6         0 0.4   6.3 NQ I I 
Harlan 49 solid no cat Yes No 3 1.8 3.3   36.8 3.1   5.5 1.1         0 0.2   5.5   I I 
Harlan 49 solid no cat Yes No 4 1.6 1   35.9 1.2   3.8 3         0 0.2   3.8   I I 
Harlan 50 solid no cat No No 1 1.6 16.2   35.4 2.2   99.1 13.4               99.1   NI NI 
Harlan 50 solid no cat No No 2 1.4 2.9   32.8 0.6   97.2 8.6               97.1   NI NI 
Harlan 50 solid no cat No No 3 1.6 2.7   29.2 1.2   96.7 0.9               96.7   NI NI 
Harlan 51 solid no cat No No 1 1.6 16.2   35.4 2.2   93.3 0.3               93.3   NI NI 
Harlan 51 solid no cat No No 2 1.4 2.9   32.8 0.6   100.1 3               100.1   NI NI 
Harlan 51 solid no cat No No 3 1.6 2.7   29.2 1.2   84.8 2.7               84.8   NI NI 
Harlan 52 solid no cat No No 1 1.6 16.2   35.4 2.2   106.5 0.1               106.5   NI NI 
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Harlan 52 solid no cat No No 2 1.4 2.9   32.8 0.6   105.7 3.4               105.7   NI NI 
Harlan 52 solid no cat No No 3 1.6 2.7   29.2 1.2   93.4 3.7               93.4   NI NI 
Harlan 53 solid no cat No No 1 1.6 16.2   35.4 2.2   108.2 2.1               108.2   NI NI 
Harlan 53 solid no cat No No 2 1.4 2.9   32.8 0.6   123.4 4.4               123.4   NI NI 
Harlan 53 solid no cat No No 3 1.6 2.7   29.2 1.2   104 11.9               104   NI NI 
Harlan 54 liquid cat 2B No No 1 1.8 3.4   25.8 6.9   17.1 3.7               17.1   I I 
Harlan 54 liquid cat 2B No No 2 1.7 13.7   29 1   25.2 1.1               25.2   I I 
Harlan 54 liquid cat 2B No No 3 1.7 3.5   31.5 9.5   19.9 5.9               19.9   I I 
Harlan 55 liquid cat 2B No No 1 1.9 6.1   27.3 0.5   2.2 0.5               2.2   I I 
Harlan 55 liquid cat 2B No No 2 1.8 1.1   18.1 4.1   1.8 0.3               1.8   I I 
Harlan 55 liquid cat 2B No No 3 1.5 2.8   22.9 2.2   2.6 0.5               2.6   I I 
Harlan 56 liquid cat 2B Yes No 1 1.8 5.7   15.2 0.8   22.5 0.2         1.7 3.1   20.8   I I 
Harlan 56 liquid cat 2B Yes No 2 1.9 0.8   28.1 0.3   28.1 3.8         1.6 3   26.5   I I 
Harlan 56 liquid cat 2B Yes No 3 1.9 4.2   17.9 6.3   28.9 11.3         1.6 3.1   27.3   I I 
Harlan 57 liquid cat 2B No No 1 1.8 3.4   25.8 6.9   5 0.3               5   I I 
Harlan 57 liquid cat 2B No No 2 1.7 13.7   29 1   7.7 3.5               7.7   I I 
Harlan 57 liquid cat 2B No No 3 1.7 3.5   31.5 9.5   6.5 5.5               6.5   I I 
Harlan 58 liquid cat 2B No No 1 1.9 6.1   27.3 0.5   6.8 0.5               6.8   I I 
Harlan 58 liquid cat 2B No No 2 1.8 1.1   18.1 4.1   2.1 0.6               2.1   I I 
Harlan 58 liquid cat 2B No No 3 1.5 2.8   22.9 2.2   2.6 0.3               2.6   I I 
Harlan 59 liquid cat 2B No No 1 1.9 6.1   27.3 0.5   46.6 2.4               46.6   I I 
Harlan 59 liquid cat 2B No No 2 1.8 1.1   18.1 4.1   36.3 1.5               36.3   I I 
Harlan 59 liquid cat 2B No No 3 1.5 2.8   22.9 2.2   47 0.3               47   I I 
Harlan 60 liquid cat 2B No No 1 1.7 1.8   15.6 2.3   6.7 1.4               6.7   I I 
Harlan 60 liquid cat 2B No No 2 1.6 4.3   29.8 1.6   16 6.3               16   I I 
Harlan 60 liquid cat 2B No No 3 1.6 4.2   29.4 1.1   9.3 0.9               9.3   I I 
Harlan 61 solid cat 2B No No 1 1.8 3.1   22.5 0.5   17 3.1               17   I I 
Harlan 61 solid cat 2B No No 2 2 2.4   25.1 1.4   11.4 1.6               11.3   I I 
Harlan 61 solid cat 2B No No 3 2 0.2   22.9 2.6   9.4 0.9               9.4   I I 
Harlan 62 solid cat 2B No No 1 1.7 3.3   24.9 1.4   101.7 9.1               101.7   NI NI 
Harlan 62 solid cat 2B No No 2 1.7 2.8   20.7 1.4   104.7 6.2               104.7   NI NI 
Harlan 62 solid cat 2B No No 3 1.8 6.9   16.9 9.2   105.9 13.4               105.9   NI NI 
Harlan 63 solid cat 2B No No 1 1.7 3.3   24.9 1.4   56.8 3.5               56.8   NI I 
Harlan 63 solid cat 2B No No 2 1.7 2.8   20.7 1.4   41 1.2               41   I I 
Harlan 63 solid cat 2B No No 3 1.8 6.9   16.9 9.2   50.2 12.5               50.2   NI I 
Harlan 64 solid cat 2B No No 1 1.7 3.3   24.9 1.4   16 1.8               16   I I 
Harlan 64 solid cat 2B No No 2 1.7 2.8   20.7 1.4   20.7 5               20.7   I I 
Harlan 64 solid cat 2B No No 3 1.8 6.9   16.9 9.2   35.1 2.4               35.1   I I 
Harlan 65 solid cat 2B No No 1 1.6 2.1   19.2 1.2   20.4 0.4               20.3   I I 
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Harlan 65 solid cat 2B No No 2 1.7 0   16.3 1.8   16.2 1               16.2   I I 
Harlan 65 solid cat 2B No No 3 1.6 3.7   29 15.6   51.8 12.1               51.8   NI I 
Harlan 66 solid cat 2B No No 1 1.6 2.1   19.2 1.2   4.8 0.7               4.8   I I 
Harlan 66 solid cat 2B No No 2 1.7 0   16.3 1.8   2.7 0.8               2.7   I I 
Harlan 66 solid cat 2B No No 3 1.6 3.7   29 15.6   3 0.6               3   I I 
Harlan 67 liquid cat 2A No No 1 1.8 3.4   25.8 6.9   4.1 0.3               4.1   I I 
Harlan 67 liquid cat 2A No No 2 1.7 13.7   29 1   4.4 0.6               4.3   I I 
Harlan 67 liquid cat 2A No No 3 1.7 3.5   31.5 9.5   4.9 0.4               4.9   I I 




No No 1 1.7 7.2   25.4 5.6   4 0.6               4   I I 




No No 2 1.7 1.4   28.8 3.8   2.8 2               2.8   I I 




No No 3 1.9 6.2   31.8 1.1   3.3 1.8               3.3   I I 




No No 1 1.7 7.2   25.4 5.6   10.5 0.2               10.5   I I 




No No 2 1.7 1.4   28.8 3.8   14 2               14   I I 




No No 3 1.9 6.2   31.8 1.1   16.9 2               16.9   I I 
Harlan 70 liquid cat 2A No No 1 1.7 7.2   25.4 5.6   10 0.5               9.9   I I 
Harlan 70 liquid cat 2A No No 2 1.7 1.4   28.8 3.8   10.3 1.4               10.3   I I 
Harlan 70 liquid cat 2A No No 3 1.9 6.2   31.8 1.1   12.9 0.3               12.9   I I 




No No 1 1.9 6.1   27.3 0.5   7.9 3.6               7.9   I I 




No No 2 1.8 1.1   18.1 4.1   7.4 1.4               7.4   I I 




No No 3 1.5 2.8   22.9 2.2   4 1.6               4   I I 




Yes No 1 1.8 5.7   15.2 0.8   5.7 0.3         0.2 0.3   5.4   I I 




Yes No 2 1.9 0.8   28.1 0.3   4 1.1         0.2 0.3   3.7   I I 
Harlan 72 liquid cat 2A (ICCVAM: cat Yes No 3 1.9 4.2   17.9 6.3   4 1         0.2 0.3   3.8   I I 
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2B) 




No No 1 1.8 3.1   22.5 0.5   78.4 1.2               78.4   NI NI 




No No 2 2 2.4   25.1 1.4   86 6.3               86   NI NI 




No No 3 2 0.2   22.9 2.6   87.8 5.3               87.8   NI NI 
Harlan 74 solid cat 2A Yes Yes 1 1.7 5.1   12.3 1.5   81.3 7.4   0.2 0.1   4.4 0.9   76.7   NI NI 
Harlan 74 solid cat 2A Yes Yes 2 1.7 2.4   19.5 3.4   79.2 4.1   0.2 0.1   4.5 0.9   74.5   NI NI 
Harlan 74 solid cat 2A Yes Yes 3 1.7 0.7   17 1.4   86.3 1.8   0.3 0   4.4 0.9   81.6   NI NI 
Harlan 75 solid cat 2A No No 1 1.6 2.1   19.2 1.2   17.4 3.2               17.4   I I 
Harlan 75 solid cat 2A No No 2 1.7 0   16.3 1.8   2 0.4               2   I I 
Harlan 75 solid cat 2A No No 3 1.6 3.7   29 15.6   2.7 0.2               2.7   I I 
Harlan 76 solid cat 2A No No 1 1.7 3.3   24.9 1.4   59.1 0.8               59   NI I 
Harlan 76 solid cat 2A No No 2 1.7 2.8   20.7 1.4   32.3 4.7               32.3   I I 
Harlan 76 solid cat 2A No No 3 1.8 6.9   16.9 9.2   52.8 3.2               52.8   NI I 
Harlan 77 solid cat 2A No No 1 1.8 3.1   22.5 0.5   94.7 4.2               94.7   NI NI 
Harlan 77 solid cat 2A No No 2 2 2.4   25.1 1.4   61.8 9.3               61.8   NI NI 
Harlan 77 solid cat 2A No No 3 2 0.2   22.9 2.6   65.2 10.1               65.2   NI NI 
Harlan 78 solid cat 2A No No 1 1.7 3.3   24.9 1.4   65.8 0.1               65.8   NI NI 
Harlan 78 solid cat 2A No No 2 1.7 2.8   20.7 1.4   62 6.3               62   NI NI 
Harlan 78 solid cat 2A No No 3 1.8 6.9   16.9 9.2   63.4 6.1               63.4   NI NI 




No No 1 1.7 3.3   24.9 1.4   2.7 0.5               2.7   I I 




No No 2 1.7 2.8   20.7 1.4   2.9 0.2               2.8   I I 




No No 3 1.8 6.9   16.9 9.2   2.2 0.3               2.2   I I 
Harlan 801 liquid cat 1 Yes No 1 1.3 11.3   6.8 0.7   98.4 8.5         92.2 2.4   6.3   I I 
Harlan 801 liquid cat 1 Yes No 2 1.8 0.6   16.4 0.9   63.2 8.6         66.4 1.7   0   I I 
Harlan 801 liquid cat 1 Yes No 3 2.3 3.5   12.7 0   67.4 12         52.1 1.4   15.3   I I 
Harlan 81 liquid cat 1 Yes No 1 1.8 5.7   15.2 0.8   3.7 0.2         0.1 0.2   3.6   I I 
Harlan 81 liquid cat 1 Yes No 2 1.9 0.8   28.1 0.3   3.3 0.9         0.1 0.2   3.2   I I 
Harlan 81 liquid cat 1 Yes No 3 1.9 4.2   17.9 6.3   3.6 0.3         0.1 0.2   3.4   I I 
Harlan 82 liquid cat 1 No No 1 1.7 1.8   15.6 2.3   1.5 1.5               1.5   I I 
Harlan 82 liquid cat 1 No No 2 1.6 4.3   29.8 1.6   2.1 1.9               2.1   I I 
Harlan 82 liquid cat 1 No No 3 1.6 4.2   29.4 1.1   1.7 1               1.7   I I 
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Harlan 83 liquid cat 1 No No 1 1.7 7.2   25.4 5.6   4.6 1.3               4.6   I I 
Harlan 83 liquid cat 1 No No 2 1.7 1.4   28.8 3.8   3.6 0.9               3.6   I I 
Harlan 83 liquid cat 1 No No 3 1.9 6.2   31.8 1.1   7.6 1.1               7.6   I I 
Harlan 84 liquid cat 1 No No 1 1.7 1.8   15.6 2.3   6.7 3.1               6.7   I I 
Harlan 84 liquid cat 1 No No 2 1.6 4.3   29.8 1.6   7.1 4.1               7   I I 
Harlan 84 liquid cat 1 No No 3 1.6 4.2   29.4 1.1   4.2 2.3               4.2   I I 
Harlan 85 liquid cat 1 No No 1 1.8 3.4   25.8 6.9   5.6 0.5               5.6   I I 
Harlan 85 liquid cat 1 No No 2 1.7 13.7   29 1   9.2 1.7               9.2   I I 
Harlan 85 liquid cat 1 No No 3 1.7 3.5   31.5 9.5   12.5 1.3               12.5   I I 
Harlan 86 liquid cat 1 No No 1 1.7 1.8   15.6 2.3   41.8 4.9               41.8   I I 
Harlan 86 liquid cat 1 No No 2 1.6 4.3   29.8 1.6   23.4 5.4               23.4   I I 
Harlan 86 liquid cat 1 No No 3 1.6 4.2   29.4 1.1   24.8 5.6               24.8   I I 
Harlan 87 liquid cat 1 No No 1 1.7 7.2   25.4 5.6   20 2.7               20   I I 
Harlan 87 liquid cat 1 No No 2 1.7 1.4   28.8 3.8   14.4 3.5               14.4   I I 
Harlan 87 liquid cat 1 No No 3 1.9 6.2   31.8 1.1   22.2 2.9               22.2   I I 
Harlan 88 liquid cat 1 Yes No 1 1.7 8.5   28 3.5   5.2 1.7         0 0.3   5.2   I I 
Harlan 88 liquid cat 1 Yes No 2 1.4 2.9   29 0.6   7.8 3.3         0 0.4   7.8   I I 
Harlan 88 liquid cat 1 Yes No 3 1.9 1.9   27.1 14.1   5.4 1.7         0 0.3   5.4   I I 
Harlan 89 liquid cat 1 No No 1 1.8 3.4   25.8 6.9   5.8 3.9               5.8   I I 
Harlan 89 liquid cat 1 No No 2 1.7 13.7   29 1   7.8 2.3               7.8   I I 
Harlan 89 liquid cat 1 No No 3 1.7 3.5   31.5 9.5   8.1 2               8.1   I I 
Harlan 90 liquid cat 1 Yes No 1 1.8 5.7   15.2 0.8   29.7 4.3         4.3 0.6   25.4   I I 
Harlan 90 liquid cat 1 Yes No 2 1.9 0.8   28.1 0.3   36.8 1.5         4.2 0.6   32.6   I I 
Harlan 90 liquid cat 1 Yes No 3 1.9 4.2   17.9 6.3   18.7 1.7         4.3 0.6   14.4   I I 
Harlan 91 liquid cat 1 Yes No 1 1.8 5.7   15.2 0.8   18.9 2.3         1.4 0   17.6   I I 
Harlan 91 liquid cat 1 Yes No 2 1.9 0.8   28.1 0.3   13.8 3.6         1.3 0   12.4   I I 
Harlan 91 liquid cat 1 Yes No 3 1.9 4.2   17.9 6.3   21.8 1.9         1.3 0   20.4   I I 
Harlan 92 liquid cat 1 Yes No 1 1.7 8.5   28 3.5   18.2 0.3         0 2.8   18.2   I I 
Harlan 92 liquid cat 1 Yes No 2 1.4 2.9   29 0.6   14.8 5.8         0 3.4   14.8   I I 
Harlan 92 liquid cat 1 Yes No 3 1.9 1.9   27.1 14.1   13.1 8.9         0 2.5   13.1   I I 
Harlan 93 solid cat 1 No No 1 1.8 3.1   22.5 0.5   6.2 0.9               6.2   I I 
Harlan 93 solid cat 1 No No 2 2 2.4   25.1 1.4   9.3 0.1               9.3   I I 
Harlan 93 solid cat 1 No No 3 2 0.2   22.9 2.6   8.5 0.5               8.5   I I 
Harlan 94 solid cat 1 No No 1 1.7 3.3   24.9 1.4   5.7 0.3               5.7   I I 
Harlan 94 solid cat 1 No No 2 1.7 2.8   20.7 1.4   3 0.2               3   I I 
Harlan 94 solid cat 1 No No 3 1.8 6.9   16.9 9.2   2.6 0.7               2.6   I I 
Harlan 95 solid cat 1 Yes No 1 1.6 5.3   27.3 7.7   2.5 0.7         0 0.2   2.5   I I 
Harlan 95 solid cat 1 Yes No 2 1.6 4.7   21.3 6.6   2.7 0.7         0 0.2   2.7   I I 
Harlan 95 solid cat 1 Yes No 3 1.6 2.2   16.2 0.7   2.7 0.1         0 0.3   2.7   I I 
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Harlan 96 solid cat 1 No No 1 1.8 3.1   22.5 0.5   35.5 6.1               35.5   I I 
Harlan 96 solid cat 1 No No 2 2 2.4   25.1 1.4   35.3 2.7               35.3   I I 
Harlan 96 solid cat 1 No No 3 2 0.2   22.9 2.6   30.9 2.8               30.9   I I 
Harlan 97 solid cat 1 No No 1 1.8 3.1   22.5 0.5   55.3 4.8               55.3   NI I 
Harlan 97 solid cat 1 No No 2 2 2.4   25.1 1.4   51.7 1.7               51.7   NI I 
Harlan 97 solid cat 1 No No 3 2 0.2   22.9 2.6   51 4.1               51   NI I 
Harlan 98 solid cat 1 Yes Yes 1 1.4 11.3   43.1 6.8   21.7 2.4   8.5 3.3   16.1 5.7   0   I I 
Harlan 98 solid cat 1 Yes Yes 2 0.7 5.5 NQ 45.1 0.4   28.1 0.4   17.4 2.3   29.9 10.5   0 NQ I I 
Harlan 98 solid cat 1 Yes Yes 3 1.8 3.3   36.8 3.1   17.4 3.4   8.3 0.7   12.2 4.3   0   I I 
Harlan 98 solid cat 1 Yes Yes 4 1.6 1   35.9 1.2   17.5 10.3   4.2 1.4   14 4.9   0   I I 
Harlan 99 solid cat 1 No No 1 1.6 2.1   19.2 1.2   3.3 0.2               3.3   I I 
Harlan 99 solid cat 1 No No 2 1.7 0   16.3 1.8   2.3 1               2.3   I I 
Harlan 99 solid cat 1 No No 3 1.6 3.7   29 15.6   2.4 0.3               2.4   I I 
Harlan 100 solid cat 1 No No 1 1.6 16.2   35.4 2.2   10 3.9               10   I I 
Harlan 100 solid cat 1 No No 2 1.4 2.9   32.8 0.6   14.9 3.9               14.9   I I 
Harlan 100 solid cat 1 No No 3 1.6 2.7   29.2 1.2   8.5 2.4               8.5   I I 
Harlan 101 solid cat 1 No No 1 1.6 16.2   35.4 2.2   26.2 1.3               26.2   I I 
Harlan 101 solid cat 1 No No 2 1.4 2.9   32.8 0.6   50.6 8.2               50.6   NI I 
Harlan 101 solid cat 1 No No 3 1.6 2.7   29.2 1.2   42 15.9               42   I I 
Harlan 102 solid cat 1 No No 1 1.6 16.2   35.4 2.2   38 11.7               38   I I 
Harlan 102 solid cat 1 No No 2 1.4 2.9   32.8 0.6   55 15.9               55   NI I 
Harlan 102 solid cat 1 No No 3 1.6 2.7   29.2 1.2   52.1 7               52.1   NI I 
Harlan 103 solid cat 1 No No 1 1.7 3.3   24.9 1.4   1.9 0.2               1.9   I I 
Harlan 103 solid cat 1 No No 2 1.7 2.8   20.7 1.4   1.9 0.1               1.9   I I 
Harlan 103 solid cat 1 No No 3 1.8 6.9   16.9 9.2   1.6 0.2               1.6   I I 
Harlan 104 solid cat 1 No No 1 1.7 3.3   24.9 1.4   40.3 2.1               40.3   I I 
Harlan 104 solid cat 1 No No 2 1.7 2.8   20.7 1.4   36.3 0.4               36.3   I I 
Harlan 104 solid cat 1 No No 3 1.8 6.9   16.9 9.2   48.4 5.1               48.4   I I 
Harlan 105 solid cat 1 No No 1 1.8 3.1   22.5 0.5   3.9 0.3               3.9   I I 
Harlan 105 solid cat 1 No No 2 2 2.4   25.1 1.4   2.6 0.2               2.6   I I 
Harlan 105 solid cat 1 No No 3 2 0.2   22.9 2.6   1.9 0.1               1.9   I I 
IIVS 1 liquid no cat No No 1 1.8 4.9   37.8 0.5   75.3 3.5               75.3   NI NI 
IIVS 1 liquid no cat No No 2 1.7 1.2   31 2.6   68.2 3.1               68.2   NI NI 
IIVS 1 liquid no cat No No 3 2 2.2   32.5 7.7   62.7 0.1               62.7   NI NI 
IIVS 2 liquid no cat No No 1 1.8 4.9   37.8 0.5   84.2 2.9               84.2   NI NI 
IIVS 2 liquid no cat No No 2 1.7 1.2   31 2.6   79.3 2.8               79.3   NI NI 
IIVS 2 liquid no cat No No 3 2 2.2   32.5 7.7   80.5 0.1               80.4   NI NI 
IIVS 3 liquid no cat No No 1 1.8 1.9   34.7 3.7   51.4 0.6               51.4   NI I 
IIVS 3 liquid no cat No No 2 1.9 4.1   33.7 4.2   49 3.3               49   I I 
  
TNO report | TNO2013 R10396 | Final  115 / 173
      GHS       NC PC Uncorrected viability NSC NSMTT Final Final Classification 
laboratory chemical LS classification MTT Coloring test OD diff Qual Mean% Diff% Qual Mean% Diff% Qual Mean% Diff% Qual Mean% Diff% Qual viability Call 50% cut-off 60% cut-off 
IIVS 3 liquid no cat No No 3 1.9 2   26.2 6.2   47.5 1.4               47.5   I I 
IIVS 4 liquid no cat Yes No 1 1.8 10.1   37.6 2.3   105.7 0         4.8 4.8   100.9   NI NI 
IIVS 4 liquid no cat Yes No 2 1.9 0.5   39.6 5.8   97.5 1.8         4.5 4.5   93   NI NI 
IIVS 4 liquid no cat Yes No 3 1.9 0.1   39.2 7.7   99.5 2.4         4.6 4.6   94.8   NI NI 
IIVS 5 liquid no cat Yes No 1 1.8 4.9   37.8 0.5   72.4 2.8         0.6 0.6   71.8   NI NI 
IIVS 5 liquid no cat Yes No 2 1.7 1.2   31 2.6   66.1 4.4         0.7 0.6   65.4   NI NI 
IIVS 5 liquid no cat Yes No 3 2 2.2   32.5 7.7   50.9 17.8         0.6 0.6   50.3   NI I 
IIVS 6 liquid no cat No No 1 1.8 4.9   37.8 0.5   88.6 1.6               88.6   NI NI 
IIVS 6 liquid no cat No No 2 1.7 1.2   31 2.6   80.7 2.3               80.7   NI NI 
IIVS 6 liquid no cat No No 3 2 2.2   32.5 7.7   81.4 14.5               81.3   NI NI 
IIVS 7 liquid no cat No No 1 1.8 4.9   37.8 0.5   40.5 9.2               40.5   I I 
IIVS 7 liquid no cat No No 2 1.7 1.2   31 2.6   43.4 7.8               43.4   I I 
IIVS 7 liquid no cat No No 3 2 2.2   32.5 7.7   32.1 12.1               32.1   I I 
IIVS 8 liquid no cat No No 1 1.8 4.9   37.8 0.5   101.2 8               101.2   NI NI 
IIVS 8 liquid no cat No No 2 1.7 1.2   31 2.6   99.6 5.3               99.6   NI NI 
IIVS 8 liquid no cat No No 3 2 2.2   32.5 7.7   95.2 1.1               95.2   NI NI 
IIVS 9 liquid no cat Yes No 1 1.8 1.9   34.7 3.7   106 0.4         0 0   106   NI NI 
IIVS 9 liquid no cat Yes No 2 1.9 4.1   33.7 4.2   100.5 4.9         0 0   100.5   NI NI 
IIVS 9 liquid no cat Yes No 3 1.9 2   26.2 6.2   98.3 9         0 0   98.3   NI NI 
IIVS 10 liquid no cat Yes No 1 1.8 1.2   34.5 6.6   49.6 38.1 NQ       0.7 0.4   48.9 NQ I I 
IIVS 10 liquid no cat Yes No 2 1.9 3.5   36.5 2   17.3 1.9         0.7 0.4   16.6   I I 
IIVS 10 liquid no cat Yes No 3 1.9 3   34.7 9.7   24.5 1.2         0.7 0.4   23.8   I I 
IIVS 10 liquid no cat Yes No 4 2.1 4.8   34.8 3.9   17.4 0.8         0.6 0.4   16.8   I I 
IIVS 11 liquid no cat No No 1 1.8 4.9   37.8 0.5   31.6 1.2               31.6   I I 
IIVS 11 liquid no cat No No 2 1.7 1.2   31 2.6   33.7 0.9               33.7   I I 
IIVS 11 liquid no cat No No 3 2 2.2   32.5 7.7   28.9 0.1               28.9   I I 
IIVS 12 liquid no cat No Yes 1 1.9 3.3   30.2 1.4   96.7 2.2   0.2 0.2         96.4   NI NI 
IIVS 12 liquid no cat No Yes 2 1.9 3   35 6.7   92.6 5.2   0.1 0.2         92.5   NI NI 
IIVS 12 liquid no cat No Yes 3 2.1 7.1   31.2 2.1   94.8 0.2   0.2 0.2         94.6   NI NI 
IIVS 13 liquid no cat No Yes 1 1.9 3.3   30.2 1.4   84.4 0.8   0.4 0.2         84   NI NI 
IIVS 13 liquid no cat No Yes 2 1.9 3   35 6.7   81.7 0.4   0.2 0         81.4   NI NI 
IIVS 13 liquid no cat No Yes 3 2.1 7.1   31.2 2.1   86 1.3   0.2 0         85.8   NI NI 
IIVS 14 liquid no cat No No 1 1.8 10.1   37.6 2.3   94.6 1.3               94.6   NI NI 
IIVS 14 liquid no cat No No 2 1.9 0.5   39.6 5.8   95.7 2.2               95.7   NI NI 
IIVS 14 liquid no cat No No 3 1.9 0.1   39.2 7.7   96.9 6               96.9   NI NI 
IIVS 15 liquid no cat No No 1 2.1 4.8   34.8 3.9   102.4 5               102.4   NI NI 
IIVS 15 liquid no cat No No 2 2 6   33.7 2.3   93.9 2.3               93.9   NI NI 
IIVS 15 liquid no cat No No 3 2 2.9   29.3 0   95.3 11               95.3   NI NI 
IIVS 16 liquid no cat No No 1 1.8 1.9   34.7 3.7   95.7 3.1               95.7   NI NI 
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IIVS 16 liquid no cat No No 2 1.9 4.1   33.7 4.2   105.5 0.8               105.5   NI NI 
IIVS 16 liquid no cat No No 3 1.9 2   26.2 6.2   103 2.1               102.9   NI NI 
IIVS 17 liquid no cat No No 1 1.8 10.1   37.6 2.3   96.6 2.3               96.6   NI NI 
IIVS 17 liquid no cat No No 2 1.9 0.5   39.6 5.8   98.1 0.1               98.1   NI NI 
IIVS 17 liquid no cat No No 3 1.9 0.1   39.2 7.7   95.3 3.5               95.3   NI NI 
IIVS 18 liquid no cat No No 1 2.1 4.8   34.8 3.9   94.1 2.5               94.1   NI NI 
IIVS 18 liquid no cat No No 2 2 6   33.7 2.3   95.3 0.5               95.3   NI NI 
IIVS 18 liquid no cat No No 3 2 2.9   29.3 0   95 4               95   NI NI 
IIVS 19 liquid no cat No No 1 2.1 4.8   34.8 3.9   95.6 2.2               95.6   NI NI 
IIVS 19 liquid no cat No No 2 2 6   33.7 2.3   98.4 1               98.4   NI NI 
IIVS 19 liquid no cat No No 3 2 2.9   29.3 0   98.9 0.3               98.9   NI NI 
IIVS 20 liquid no cat Yes No 1 2.1 4.8   34.8 3.9   66.9 9.8         18.9 6.4   48.1   I I 
IIVS 20 liquid no cat Yes No 2 2 6   33.7 2.3   46.1 32.1 NQ       19.4 6.6   26.7 NQ I I 
IIVS 20 liquid no cat Yes No 3 2 2.9   29.3 0   52.5 0.6         19.3 6.6   33.2   I I 
IIVS 20 liquid no cat Yes No 4 1.9 2.2   31.3 1.6   62.4 2         20.9 7.1   41.5   I I 
IIVS 21 liquid no cat No No 1 1.8 1.2   34.5 6.6   86.2 3.8               86.2   NI NI 
IIVS 21 liquid no cat No No 2 1.9 3.5   36.5 2   81.5 10.8               81.5   NI NI 
IIVS 21 liquid no cat No No 3 1.9 3   34.7 9.7   85.4 1.7               85.4   NI NI 
IIVS 22 liquid no cat Yes No 1 1.8 10.1   37.6 2.3   39.7 9         1.9 0.2   37.7   I I 
IIVS 22 liquid no cat Yes No 2 1.9 0.5   39.6 5.8   37.4 13.8         1.8 0.2   35.5   I I 
IIVS 22 liquid no cat Yes No 3 1.9 0.1   39.2 7.7   40.9 17.4         1.9 0.2   39   I I 
IIVS 231 liquid no cat Yes No 1 1.8 1.2   34.5 6.6   75.5 5         56.5 17.8   18.9   I I 
IIVS 231 liquid no cat Yes No 2 1.9 3   34.7 9.7   64.2 6.1         55.6 17.5   8.6   I I 
IIVS 231 liquid no cat Yes No 3 2.1 4.8   34.8 3.9   60.5 9.7         50.1 15.7   10.4   I I 
IIVS 24 liquid no cat Yes No 1 1.8 1.2   34.5 6.6   54.9 2         1.9 0.8   53   NI I 
IIVS 24 liquid no cat Yes No 2 1.9 3.5   36.5 2   35.7 6.5         1.8 0.7   33.9   I I 
IIVS 24 liquid no cat Yes No 3 1.9 3   34.7 9.7   34.4 7.5         1.9 0.7   32.6   I I 
IIVS 25 liquid no cat Yes No 1 2 6   33.7 2.3   95 10.2         0 0   95   NI NI 
IIVS 25 liquid no cat Yes No 2 2 2.9   29.3 0   103.2 0.6         0 0   103.2   NI NI 
IIVS 25 liquid no cat Yes No 3 2 5   34.6 3.8   107.3 0.5         0 0.1   107.3   NI NI 
IIVS 26 liquid no cat No No 1 2 6   33.7 2.3   37.5 32.8 NQ             37.5 NQ I I 
IIVS 26 liquid no cat No No 2 2 2.9   29.3 0   31.6 5.6               31.6   I I 
IIVS 26 liquid no cat No No 3 1.9 3.7   36.1 6.1   35.6 3.5               35.6   I I 
IIVS 26 liquid no cat No No 4 2 4.6   38.3 3.6   35.3 2.1               35.3   I I 
IIVS 28 solid no cat No No 1 1.6 5   20.6 1.9   105.4 1.3               105.4   NI NI 
IIVS 28 solid no cat No No 2 1.5 2.6   35.8 9.7   112.9 4.1               112.9   NI NI 
IIVS 28 solid no cat No No 3 2.1 4.6   22 1.7   100.6 2.4               100.6   NI NI 
IIVS 29 solid no cat No No 1 1.7 4.1   31.9 0.3   102.5 6.7               102.5   NI NI 
IIVS 29 solid no cat No No 2 1.7 1.7   27.9 1.2   105.7 14.9               105.7   NI NI 
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IIVS 29 solid no cat No No 3 1.7 6   24.8 2.2   101.4 8.3               101.4   NI NI 
IIVS 30 solid no cat No No 1 1.7 6.6   33.3 8.2   55.4 9               55.4   NI I 
IIVS 30 solid no cat No No 2 1.7 2.5   21.8 0.2   51.8 2.1               51.8   NI I 
IIVS 30 solid no cat No No 3 1.6 4.8   30.1 4   69.2 5.2               69.2   NI NI 
IIVS 31 solid no cat No No 1 1.7 6.6   33.3 8.2   98.2 6.9               98.2   NI NI 
IIVS 31 solid no cat No No 2 1.7 2.5   21.8 0.2   97.8 3.8               97.8   NI NI 
IIVS 31 solid no cat No No 3 1.6 4.8   30.1 4   104 0.8               103.9   NI NI 
IIVS 32 solid no cat Yes No 1 1.7 1.5   31.2 1.6   3.3 0         0.8 0.4   2.5   I I 
IIVS 32 solid no cat Yes No 2 1.7 6.1   27.8 4.9   3.6 0.3         0.8 0.4   2.8   I I 
IIVS 32 solid no cat Yes No 3 1.7 0.3   34.3 2.2   2.9 0         0.8 0.4   2.1   I I 
IIVS 33 solid no cat Yes Yes 1 1.7 3.1   24.2 8.6   89.2 7.4   0.2 0.1   0.1 0   88.9   NI NI 
IIVS 33 solid no cat Yes Yes 2 1.6 1.3   29.5 5   89.7 3.5   0.4 0   0.1 0   89.2   NI NI 
IIVS 33 solid no cat Yes Yes 3 1.8 0.9   24.9 0.6   133.8 74.3 NQ 170.2 2.2   0.1 0   0 NQ I I 
IIVS 33 solid no cat Yes Yes 4 1.7 5.4   24 2.1   84.1 16.1   0.8 0.3   0.1 0.1   83.2   NI NI 
IIVS 34 solid no cat Yes Yes 1 1.7 1.5   31.2 1.6   108.8 0.7   7.4 1.5   5.8 3.7   95.6   NI NI 
IIVS 34 solid no cat Yes Yes 2 1.7 6.1   27.8 4.9   103.5 20.2 NQ 4.7 0.4   5.8 3.6   93 NQ NI NI 
IIVS 34 solid no cat Yes Yes 3 1.7 0.3   34.3 2.2   119.3 5.8   6.4 1   5.8 3.6   107.1   NI NI 
IIVS 34 solid no cat Yes Yes 4 1.7 6.5   27.9 1.8   90.8 20.5 NQ 4.7 0.2   6 3.8   80.1 NQ NI NI 
IIVS 34 solid no cat Yes Yes 5 1.7 6.6   33.3 8.2   91.6 1.9   4.8 0.9   5.8 3.7   80.9   NI NI 
IIVS 35 solid no cat Yes No 1 1.7 1.5   31.2 1.6   100.6 3.4         0.7 0.4   99.9   NI NI 
IIVS 35 solid no cat Yes No 2 1.7 6.1   27.8 4.9   95.9 14.7         0.7 0.3   95.2   NI NI 
IIVS 35 solid no cat Yes No 3 1.7 0.3   34.3 2.2   100.2 5.1         0.7 0.4   99.4   NI NI 
IIVS 36 solid no cat No No 1 1.7 1.5   31.2 1.6   110.7 0.3               110.7   NI NI 
IIVS 36 solid no cat No No 2 1.7 6.1   27.8 4.9   110.8 0.5               110.8   NI NI 
IIVS 36 solid no cat No No 3 1.7 0.3   34.3 2.2   105.6 3.6               105.6   NI NI 
IIVS 37 liquid no cat No No 1 1.8 1.2   34.5 6.6   86.3 7.2               86.3   NI NI 
IIVS 37 liquid no cat No No 2 1.9 3.5   36.5 2   80.1 4.7               80.1   NI NI 
IIVS 37 liquid no cat No No 3 1.9 3   34.7 9.7   78 0.6               78   NI NI 
IIVS 38 solid no cat No No 1 1.7 4.1   31.9 0.3   101.1 3.1               101.1   NI NI 
IIVS 38 solid no cat No No 2 1.7 1.7   27.9 1.2   101.9 1.3               101.9   NI NI 
IIVS 38 solid no cat No No 3 1.7 6   24.8 2.2   108 1.5               108   NI NI 
IIVS 39 solid no cat No No 1 1.7 4.1   31.9 0.3   102.5 6.4               102.5   NI NI 
IIVS 39 solid no cat No No 2 1.7 1.7   27.9 1.2   101.7 1.3               101.7   NI NI 
IIVS 39 solid no cat No No 3 1.7 6   24.8 2.2   104.8 2.7               104.8   NI NI 
IIVS 40 solid no cat No No 1 1.7 4.1   31.9 0.3   62.3 1.8               62.3   NI NI 
IIVS 40 solid no cat No No 2 1.7 1.7   27.9 1.2   63 4.4               63   NI NI 
IIVS 40 solid no cat No No 3 1.7 6   24.8 2.2   60.2 4.4               60.2   NI NI 
IIVS 41 solid no cat No No 1 1.7 1.5   31.2 1.6   99.3 9.1               99.3   NI NI 
IIVS 41 solid no cat No No 2 1.7 6.1   27.8 4.9   102.6 5.9               102.5   NI NI 
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IIVS 41 solid no cat No No 3 1.7 0.3   34.3 2.2   94 6.5               94   NI NI 
IIVS 42 solid no cat Yes No 1 1.7 1.5   31.2 1.6   85.7 7.2         0.4 0   85.3   NI NI 
IIVS 42 solid no cat Yes No 2 1.7 6.1   27.8 4.9   82.3 19.2         0.4 0   81.8   NI NI 
IIVS 42 solid no cat Yes No 3 1.7 0.3   34.3 2.2   70.9 10.1         0.4 0   70.5   NI NI 
IIVS 43 solid no cat No No 1 1.8 1.1   30.3 3.2   99.8 0.1               99.8   NI NI 
IIVS 43 solid no cat No No 2 1.8 9.2   31.7 3.6   102 0.7               102   NI NI 
IIVS 43 solid no cat No No 3 1.7 0.2   31.3 5.1   103.4 4.2               103.4   NI NI 
IIVS 44 solid no cat No No 1 1.8 1.1   30.3 3.2   98.1 0.6               98.1   NI NI 
IIVS 44 solid no cat No No 2 1.8 9.2   31.7 3.6   94.2 0.1               94.2   NI NI 
IIVS 44 solid no cat No No 3 1.7 0.2   31.3 5.1   102.9 5.1               102.9   NI NI 
IIVS 45 solid no cat No No 1 1.7 1.5   31.2 1.6   98.6 5.2               98.6   NI NI 
IIVS 45 solid no cat No No 2 1.7 6.1   27.8 4.9   98.4 5.4               98.4   NI NI 
IIVS 45 solid no cat No No 3 1.7 0.3   34.3 2.2   94.8 4.6               94.8   NI NI 
IIVS 46 solid no cat No No 1 1.8 1.1   30.3 3.2   65.2 7.8               65.2   NI NI 
IIVS 46 solid no cat No No 2 1.8 9.2   31.7 3.6   60.8 3.1               60.8   NI NI 
IIVS 46 solid no cat No No 3 1.7 0.2   31.3 5.1   57.8 3.9               57.8   NI I 
IIVS 47 solid no cat No No 1 1.8 1.1   30.3 3.2   3.2 0.2               3.2   I I 
IIVS 47 solid no cat No No 2 1.8 9.2   31.7 3.6   2.9 1               2.9   I I 
IIVS 47 solid no cat No No 3 1.7 0.2   31.3 5.1   2.6 0.3               2.6   I I 
IIVS 48 solid no cat No No 1 1.7 2.5   21.8 0.2   2.7 0.4               2.7   I I 
IIVS 48 solid no cat No No 2 1.6 4.8   30.1 4   2.5 0               2.5   I I 
IIVS 48 solid no cat No No 3 1.8 0.9   24.9 0.6   2.4 0               2.4   I I 
IIVS 49 solid no cat Yes No 1 1.7 4.1   31.9 0.3   11.9 4.4         0 0.1   11.9   I I 
IIVS 49 solid no cat Yes No 2 1.7 1.7   27.9 1.2   15.8 3         0 0.1   15.8   I I 
IIVS 49 solid no cat Yes No 3 1.7 6   24.8 2.2   15.6 2.5         0 0.1   15.6   I I 
IIVS 50 solid no cat Yes No 1 1.7 4.1   31.9 0.3   95.7 0.4         0.1 0.2   95.6   NI NI 
IIVS 50 solid no cat Yes No 2 1.7 1.7   27.9 1.2   92.8 12.6         0.1 0.2   92.7   NI NI 
IIVS 50 solid no cat Yes No 3 1.7 6   24.8 2.2   97.5 0.5         0.1 0.2   97.4   NI NI 
IIVS 51 solid no cat No No 1 1.7 0.2   31.3 5.1   95.4 2.7               95.4   NI NI 
IIVS 51 solid no cat No No 2 1.9 6.6   29.8 2.1   98.7 1.3               98.7   NI NI 
IIVS 51 solid no cat No No 3 1.8 1.3   28.8 1.5   106 4.3               106   NI NI 
IIVS 52 solid no cat No No 1 1.7 0.2   31.3 5.1   101.3 0               101.3   NI NI 
IIVS 52 solid no cat No No 2 1.9 6.6   29.8 2.1   95.1 2               95.1   NI NI 
IIVS 52 solid no cat No No 3 1.8 1.3   28.8 1.5   105.7 0.6               105.7   NI NI 
IIVS 53 solid no cat No No 1 1.7 0.2   31.3 5.1   106.3 3               106.3   NI NI 
IIVS 53 solid no cat No No 2 1.9 6.6   29.8 2.1   101.7 3.1               101.7   NI NI 
IIVS 53 solid no cat No No 3 1.8 1.3   28.8 1.5   107.2 10.1               107.2   NI NI 
IIVS 54 liquid cat 2B No No 1 1.8 4.9   37.8 0.5   51.8 3.5               51.8   NI I 
IIVS 54 liquid cat 2B No No 2 1.7 1.2   31 2.6   43.1 2.1               43.1   I I 
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IIVS 54 liquid cat 2B No No 3 2 2.2   32.5 7.7   30.1 4.5               30.1   I I 
IIVS 55 liquid cat 2B No No 1 1.8 1.2   34.5 6.6   2.5 0.2               2.5   I I 
IIVS 55 liquid cat 2B No No 2 1.9 3.5   36.5 2   2.6 0.3               2.6   I I 
IIVS 55 liquid cat 2B No No 3 1.9 3   34.7 9.7   2.5 0.4               2.5   I I 
IIVS 56 liquid cat 2B Yes No 1 1.8 1.2   34.5 6.6   47.9 3.2         0.4 0.4   47.5   I I 
IIVS 56 liquid cat 2B Yes No 2 1.9 3.5   36.5 2   35.2 1.8         0.4 0.4   34.8   I I 
IIVS 56 liquid cat 2B Yes No 3 1.9 3   34.7 9.7   30 5.2         0.4 0.4   29.6   I I 
IIVS 57 liquid cat 2B Yes No 1 1.8 10.1   37.6 2.3   20.4 3.7         0 0.4   20.4   I I 
IIVS 57 liquid cat 2B Yes No 2 1.9 0.5   39.6 5.8   20.3 2.1         0 0.4   20.3   I I 
IIVS 57 liquid cat 2B Yes No 3 1.9 0.1   39.2 7.7   12.6 5.3         0 0.4   12.6   I I 
IIVS 58 liquid cat 2B Yes No 1 1.8 1.2   34.5 6.6   16.1 2.7         1.6 1   14.4   I I 
IIVS 58 liquid cat 2B Yes No 2 1.9 3.5   36.5 2   15 0.7         1.6 0.9   13.4   I I 
IIVS 58 liquid cat 2B Yes No 3 1.9 3   34.7 9.7   14.6 2.9         1.6 1   13   I I 
IIVS 59 liquid cat 2B No No 1 1.8 1.2   34.5 6.6   56.6 5.1               56.6   NI I 
IIVS 59 liquid cat 2B No No 2 1.9 3.5   36.5 2   52.8 5.5               52.8   NI I 
IIVS 59 liquid cat 2B No No 3 1.9 3   34.7 9.7   43.6 0.7               43.6   I I 
IIVS 60 liquid cat 2B No No 1 2.1 4.8   34.8 3.9   26.8 7.8               26.8   I I 
IIVS 60 liquid cat 2B No No 2 2 6   33.7 2.3   13.8 5.4               13.8   I I 
IIVS 60 liquid cat 2B No No 3 2 2.9   29.3 0   21.2 2.6               21.2   I I 
IIVS 61 solid cat 2B No No 1 1.6 5   20.6 1.9   16.3 0.9               16.3   I I 
IIVS 61 solid cat 2B No No 2 1.5 2.6   35.8 9.7   16.4 10.1               16.4   I I 
IIVS 61 solid cat 2B No No 3 2.1 4.6   22 1.7   21.4 4               21.4   I I 
IIVS 62 solid cat 2B No No 1 1.7 2.5   21.8 0.2   109.8 4.8               109.8   NI NI 
IIVS 62 solid cat 2B No No 2 1.6 4.8   30.1 4   105.2 1.6               105.2   NI NI 
IIVS 62 solid cat 2B No No 3 1.8 0.9   24.9 0.6   97.1 0.3               97.1   NI NI 
IIVS 63 solid cat 2B No No 1 1.7 6.6   33.3 8.2   49.6 15.3               49.6   I I 
IIVS 63 solid cat 2B No No 2 1.7 2.5   21.8 0.2   38.9 6.1               38.9   I I 
IIVS 63 solid cat 2B No No 3 1.6 4.8   30.1 4   43.7 9.6               43.7   I I 
IIVS 64 solid cat 2B No No 1 1.7 3.1   24.2 8.6   39.6 15.7               39.6   I I 
IIVS 64 solid cat 2B No No 2 1.7 6.5   27.9 1.8   29.7 10               29.7   I I 
IIVS 64 solid cat 2B No No 3 1.6 1.3   29.5 5   28.2 1.4               28.2   I I 
IIVS 65 solid cat 2B No No 1 1.8 1.1   30.3 3.2   63.8 15.2               63.8   NI NI 
IIVS 65 solid cat 2B No No 2 1.8 9.2   31.7 3.6   41.6 0.3               41.6   I I 
IIVS 65 solid cat 2B No No 3 1.7 0.2   31.3 5.1   53.9 12.6               53.9   NI I 
IIVS 66 solid cat 2B Yes No 1 1.7 2.5   21.8 0.2   3.4 0.9         0.7 0.1   2.7   I I 
IIVS 66 solid cat 2B Yes No 2 1.6 4.8   30.1 4   7.3 0.3         0.8 0.1   6.6   I I 
IIVS 66 solid cat 2B Yes No 3 1.8 0.9   24.9 0.6   2.7 0.6         0.6 0.1   2   I I 
IIVS 67 liquid cat 2A Yes No 1 1.8 1.9   34.7 3.7   13.6 2.1         0 0   13.6   I I 
IIVS 67 liquid cat 2A Yes No 2 1.9 4.1   33.7 4.2   15.3 0.5         0 0   15.3   I I 
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IIVS 67 liquid cat 2A Yes No 3 1.9 2   26.2 6.2   14.6 0.8         0 0   14.6   I I 




No No 1 1.8 4.9   37.8 0.5   2.7 0.4               2.7   I I 




No No 2 1.7 1.2   31 2.6   7 4.4               7   I I 




No No 3 2 2.2   32.5 7.7   3 0.3               3   I I 




No No 1 1.8 1.9   34.7 3.7   13.6 5.7               13.6   I I 




No No 2 1.9 4.1   33.7 4.2   14.5 0.7               14.4   I I 




No No 3 1.9 2   26.2 6.2   14.1 4.3               14.1   I I 
IIVS 70 liquid cat 2A No No 1 1.8 1.9   34.7 3.7   14.3 0.6               14.3   I I 
IIVS 70 liquid cat 2A No No 2 1.9 4.1   33.7 4.2   12.3 3.5               12.3   I I 
IIVS 70 liquid cat 2A No No 3 1.9 2   26.2 6.2   12.2 1.8               12.2   I I 




No No 1 1.8 10.1   37.6 2.3   7.7 0.7               7.7   I I 




No No 2 1.9 0.5   39.6 5.8   9.1 3               9.1   I I 




No No 3 1.9 0.1   39.2 7.7   7.4 0.6               7.4   I I 




Yes No 1 1.8 1.2   34.5 6.6   6.7 5.6         1.3 0.5   5.4   I I 




Yes No 2 1.9 3.5   36.5 2   4.5 1.6         1.2 0.5   3.2   I I 




Yes No 3 1.9 3   34.7 9.7   4.3 1.5         1.3 0.5   3.1   I I 




No No 1 1.6 5   20.6 1.9   102.5 1.4               102.5   NI NI 




No No 2 1.5 2.6   35.8 9.7   105.8 2.3               105.8   NI NI 
IIVS 73 solid cat 2A (ICCVAM: cat No No 3 2.1 4.6   22 1.7   82.9 1.3               82.9   NI NI 
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2B) 
IIVS 74 solid cat 2A Yes Yes 1 1.6 5   20.6 1.9   89.2 6.5   0.3 0.1   1.7 0.1   87.2   NI NI 
IIVS 74 solid cat 2A Yes Yes 2 1.5 2.6   35.8 9.7   101.4 6   0.3 0.1   1.8 0.1   99.3   NI NI 
IIVS 74 solid cat 2A Yes Yes 3 2.1 4.6   22 1.7   90.4 4.9   0.2 0.1   1.3 0.1   88.8   NI NI 
IIVS 75 solid cat 2A No No 1 1.7 1.5   31.2 1.6   5 2.9               5   I I 
IIVS 75 solid cat 2A No No 2 1.7 6.1   27.8 4.9   5.8 1.5               5.8   I I 
IIVS 75 solid cat 2A No No 3 1.7 0.3   34.3 2.2   4.5 3.3               4.4   I I 
IIVS 76 solid cat 2A No No 1 1.7 3.1   24.2 8.6   26.9 7.2               26.9   I I 
IIVS 76 solid cat 2A No No 2 1.7 6.5   27.9 1.8   26.3 8               26.3   I I 
IIVS 76 solid cat 2A No No 3 1.6 1.3   29.5 5   28.7 1               28.7   I I 
IIVS 77 solid cat 2A No No 1 1.7 3.1   24.2 8.6   98.2 3.7               98.2   NI NI 
IIVS 77 solid cat 2A No No 2 1.7 6.5   27.9 1.8   107.3 4.9               107.3   NI NI 
IIVS 77 solid cat 2A No No 3 1.6 1.3   29.5 5   103.6 9               103.6   NI NI 
IIVS 78 solid cat 2A No No 1 1.7 3.1   24.2 8.6   87.8 1.7               87.8   NI NI 
IIVS 78 solid cat 2A No No 2 1.7 6.5   27.9 1.8   86.9 1.5               86.9   NI NI 
IIVS 78 solid cat 2A No No 3 1.6 1.3   29.5 5   85.9 1.8               85.9   NI NI 




No No 1 1.8 1.1   30.3 3.2   2.9 0.6               2.9   I I 




No No 2 1.8 9.2   31.7 3.6   2.3 0.8               2.3   I I 




No No 3 1.7 0.2   31.3 5.1   3.2 0.4               3.2   I I 
IIVS 801 liquid cat 1 Yes No 1 1.8 4.9   37.8 0.5   78.3 3.1         69 5.4   9.3   I I 
IIVS 801 liquid cat 1 Yes No 2 1.7 1.2   31 2.6   77.7 3.2         72.6 5.7   5   I I 
IIVS 801 liquid cat 1 Yes No 3 2 2.2   32.5 7.7   74.1 0.8         64.4 5   9.7   I I 
IIVS 81 liquid cat 1 Yes No 1 1.8 10.1   37.6 2.3   5.6 0.1         0 0.3   5.6   I I 
IIVS 81 liquid cat 1 Yes No 2 1.9 0.5   39.6 5.8   3.9 0.5         0 0.3   3.9   I I 
IIVS 81 liquid cat 1 Yes No 3 1.9 0.1   39.2 7.7   3.1 1.1         0 0.3   3.1   I I 
IIVS 82 liquid cat 1 No No 1 2.1 4.8   34.8 3.9   5.3 1.5               5.3   I I 
IIVS 82 liquid cat 1 No No 2 2 6   33.7 2.3   6.9 2.8               6.9   I I 
IIVS 82 liquid cat 1 No No 3 2 2.9   29.3 0   2.6 0.3               2.6   I I 
IIVS 83 liquid cat 1 No No 1 1.8 1.9   34.7 3.7   5.4 1.9               5.4   I I 
IIVS 83 liquid cat 1 No No 2 1.9 4.1   33.7 4.2   6.8 0.2               6.8   I I 
IIVS 83 liquid cat 1 No No 3 1.9 2   26.2 6.2   4 0.8               4   I I 
IIVS 84 liquid cat 1 Yes No 1 2.1 4.8   34.8 3.9   17.9 1.2         0.1 1   17.8   I I 
IIVS 84 liquid cat 1 Yes No 2 2 6   33.7 2.3   18.8 2.9         0.1 1   18.7   I I 
IIVS 84 liquid cat 1 Yes No 3 2 2.9   29.3 0   9.4 3.8         0.1 1   9.3   I I 
IIVS 85 liquid cat 1 No No 1 1.8 1.9   34.7 3.7   14 4.4               14   I I 
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IIVS 85 liquid cat 1 No No 2 1.9 4.1   33.7 4.2   13.1 1.9               13.1   I I 
IIVS 85 liquid cat 1 No No 3 1.9 2   26.2 6.2   17.8 4.9               17.8   I I 
IIVS 86 liquid cat 1 No No 1 2.1 4.8   34.8 3.9   31.8 2.4               31.8   I I 
IIVS 86 liquid cat 1 No No 2 2 6   33.7 2.3   32.7 7.6               32.7   I I 
IIVS 86 liquid cat 1 No No 3 2 2.9   29.3 0   20.5 13.4               20.5   I I 
IIVS 87 liquid cat 1 No No 1 1.8 1.9   34.7 3.7   30.8 3.7               30.8   I I 
IIVS 87 liquid cat 1 No No 2 1.9 4.1   33.7 4.2   17.4 1.9               17.4   I I 
IIVS 87 liquid cat 1 No No 3 1.9 2   26.2 6.2   24.4 0.4               24.4   I I 
IIVS 88 liquid cat 1 Yes Yes 1 1.9 3.3   30.2 1.4   5 0.1   0.2 0.1   0.9 0.1   3.9   I I 
IIVS 88 liquid cat 1 Yes Yes 2 1.9 3   35 6.7   8.1 1.5   0.2 0   0.9 0.1   7   I I 
IIVS 88 liquid cat 1 Yes Yes 3 2.1 7.1   31.2 2.1   4.5 0.5   0.2 0   0.8 0.1   3.5   I I 
IIVS 89 liquid cat 1 No No 1 1.8 10.1   37.6 2.3   9 1.6               9   I I 
IIVS 89 liquid cat 1 No No 2 1.9 0.5   39.6 5.8   12.6 1.9               12.6   I I 
IIVS 89 liquid cat 1 No No 3 1.9 0.1   39.2 7.7   9.7 0.7               9.7   I I 
IIVS 90 liquid cat 1 No No 1 1.8 10.1   37.6 2.3   35.5 3.5               35.5   I I 
IIVS 90 liquid cat 1 No No 2 1.9 0.5   39.6 5.8   34.8 6.9               34.7   I I 
IIVS 90 liquid cat 1 No No 3 1.9 0.1   39.2 7.7   33.2 24.5 NQ             33.2 NQ I I 
IIVS 90 liquid cat 1 No No 4 2 5   34.6 3.8   30.8 7.9               30.8   I I 
IIVS 91 liquid cat 1 Yes No 1 1.8 10.1   37.6 2.3   21.5 0.8         0.4 0.9   21.1   I I 
IIVS 91 liquid cat 1 Yes No 2 1.9 0.5   39.6 5.8   20 0.3         0.4 0.8   19.6   I I 
IIVS 91 liquid cat 1 Yes No 3 1.9 0.1   39.2 7.7   19.9 1.7         0.4 0.8   19.5   I I 
IIVS 92 liquid cat 1 Yes No 1 1.9 2.2   31.3 1.6   39.9 5.2         0.3 0.4   39.6   I I 
IIVS 92 liquid cat 1 Yes No 2 1.9 3.7   36.1 6.1   39.6 2.9         0.3 0.4   39.3   I I 
IIVS 92 liquid cat 1 Yes No 3 2 4.6   38.3 3.6   51.4 9.4         0.3 0.3   51.2   NI I 
IIVS 93 solid cat 1 No No 1 1.6 5   20.6 1.9   10.3 3.7               10.3   I I 
IIVS 93 solid cat 1 No No 2 1.5 2.6   35.8 9.7   21.3 1.7               21.3   I I 
IIVS 93 solid cat 1 No No 3 2.1 4.6   22 1.7   18 4.4               18   I I 
IIVS 94 solid cat 1 No No 1 1.7 3.1   24.2 8.6   5.2 4.4               5.2   I I 
IIVS 94 solid cat 1 No No 2 1.7 6.5   27.9 1.8   5.8 6.3               5.8   I I 
IIVS 94 solid cat 1 No No 3 1.6 1.3   29.5 5   4.3 2.3               4.3   I I 
IIVS 95 solid cat 1 Yes No 1 1.6 5   20.6 1.9   1.8 0.1         0.2 0.2   1.6   I I 
IIVS 95 solid cat 1 Yes No 2 1.5 2.6   35.8 9.7   2.5 0.4         0.2 0.3   2.3   I I 
IIVS 95 solid cat 1 Yes No 3 2.1 4.6   22 1.7   2.3 0         0.1 0.2   2.1   I I 
IIVS 96 solid cat 1 No No 1 1.6 5   20.6 1.9   33.2 4.6               33.2   I I 
IIVS 96 solid cat 1 No No 2 1.5 2.6   35.8 9.7   38.9 19.4               38.9   I I 
IIVS 96 solid cat 1 No No 3 2.1 4.6   22 1.7   54.1 5.1               54.1   NI I 
IIVS 97 solid cat 1 No No 1 1.6 5   20.6 1.9   59 4.8               59   NI I 
IIVS 97 solid cat 1 No No 2 1.5 2.6   35.8 9.7   55.1 2.8               55.1   NI I 
IIVS 97 solid cat 1 No No 3 2.1 4.6   22 1.7   51.1 11.8               51.1   NI I 
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IIVS 98 solid cat 1 Yes Yes 1 1.7 6.6   33.3 8.2   19.1 3   5.3 5.3   17.1 1.5   0   I I 
IIVS 98 solid cat 1 Yes Yes 2 1.7 2.5   21.8 0.2   28.8 0.2   18.8 8.1   17.1 1.5   0   I I 
IIVS 98 solid cat 1 Yes Yes 3 1.6 4.8   30.1 4   20.9 5.8   4.6 0.9   18.2 1.6   0   I I 
IIVS 99 solid cat 1 Yes No 1 1.7 1.5   31.2 1.6   2.2 0.1         0.4 0.2   1.9   I I 
IIVS 99 solid cat 1 Yes No 2 1.7 6.1   27.8 4.9   2.4 0.4         0.3 0.2   2   I I 
IIVS 99 solid cat 1 Yes No 3 1.7 0.3   34.3 2.2   2.1 0.2         0.4 0.2   1.7   I I 
IIVS 100 solid cat 1 No No 1 1.7 0.2   31.3 5.1   10.5 0.7               10.5   I I 
IIVS 100 solid cat 1 No No 2 1.9 6.6   29.8 2.1   8.2 0.2               8.2   I I 
IIVS 100 solid cat 1 No No 3 1.8 1.3   28.8 1.5   8.9 1.2               8.9   I I 
IIVS 101 solid cat 1 No No 1 1.7 4.1   31.9 0.3   19.9 4.4               19.9   I I 
IIVS 101 solid cat 1 No No 2 1.7 1.7   27.9 1.2   21.6 2.3               21.6   I I 
IIVS 101 solid cat 1 No No 3 1.7 6   24.8 2.2   13.8 8               13.8   I I 
IIVS 102 solid cat 1 No No 1 1.7 4.1   31.9 0.3   76.7 10.5               76.7   NI NI 
IIVS 102 solid cat 1 No No 2 1.7 1.7   27.9 1.2   87.8 3.7               87.8   NI NI 
IIVS 102 solid cat 1 No No 3 1.7 6   24.8 2.2   108.2 8.7               108.2   NI NI 
IIVS 103 solid cat 1 No No 1 1.7 3.1   24.2 8.6   1.7 0.2               1.7   I I 
IIVS 103 solid cat 1 No No 2 1.7 6.5   27.9 1.8   2.1 0.3               2.1   I I 
IIVS 103 solid cat 1 No No 3 1.6 1.3   29.5 5   2.1 0.2               2.1   I I 
IIVS 104 solid cat 1 No No 1 1.7 3.1   24.2 8.6   68.6 32.3 NQ             68.6 NQ NI NI 
IIVS 104 solid cat 1 No No 2 1.7 6.5   27.9 1.8   47.1 1.1               47.1   I I 
IIVS 104 solid cat 1 No No 3 1.6 1.3   29.5 5   34.9 1               34.8   I I 
IIVS 104 solid cat 1 No No 4 1.8 0.9   24.9 0.6   24.5 4               24.4   I I 
IIVS 105 solid cat 1 No No 1 1.7 3.1   24.2 8.6   2.1 0.1               2.1   I I 
IIVS 105 solid cat 1 No No 2 1.7 6.5   27.9 1.8   2.4 0.2               2.4   I I 
IIVS 105 solid cat 1 No No 3 1.6 1.3   29.5 5   2.4 0               2.4   I I 
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Chemical 106 and 107 are considered incompatible with the test method because of strong colour interference and so EpiOcularTM EIT shows a limitation for colours that strongly 
interfere with MTT using the current system of photometry. These two chemicals are excluded for the statistical analysis. 
      GHS       NC PC Uncorrected viability NSC NSMTT Final 
laboratory chemical LS classification MTT Coloring test OD diff Qual Mean% Diff% Qual Mean% Diff% Qual Mean% Diff% Qual Mean% Diff% Qual viability 
Beiersdorf 106 Solid cat 1 No Yes 1 1.96549 0.1119   33.285 4.73928   8056.7 0   8056.7 0         0 
Beiersdorf 106 Solid cat 1 No Yes 2 1.72938 0.5811   37.3921 0.56668   4578.53 0   4578.53 0         0 
Beiersdorf 106 Solid cat 1 No Yes 3 1.70828 5.1075   35.9354 1.87031   4633.97 0   4633.97 0         0 
Beiersdorf 106 Solid cat 1 No Yes 4 1.81303 2.5234   24.2523 1.59402   8732.59 0   4366.29 0         4366.29 
Beiersdorf 106 Solid cat 1 No Yes 5 1.7126 0.3825   27.4597 5.73397   9245.18 0   9245.18 0         0 
Beiersdorf 107 Solid cat 1 No Yes 1 1.96549 0.1119   33.285 4.73928   78.43 68.469 NQ 86.65 28.0516 NQ       0 
Beiersdorf 107 Solid cat 1 No Yes 2 1.72938 0.5811   37.3921 0.56668   98.27 9.833   64.16 27.1514 NQ       34.11 
Beiersdorf 107 Solid cat 1 No Yes 3 1.70828 5.1075   35.9354 1.87031   49.04 32.4948 NQ 56.53 22.4144 NQ       0 
Beiersdorf 107 Solid cat 1 No Yes 4 1.85775 12.9538   23.6361 4.97107   86.28 12.0737   96.69 33.4222 NQ       0 
Beiersdorf 107 Solid cat 1 No Yes 5 1.7126 0.3825   27.4597 5.73397   134.45 6.5485   115.32 43.2062 NQ       19.13 
Harlan 106 Solid cat 1 Yes Yes 1 1.379 11.2763   43.1291 6.81653   722.75 0   722.75 0   719.22 0   0 
Harlan 106 Solid cat 1 Yes Yes 2 0.74275 5.4527 NQ 45.1027 0.4039   1341.57 0   1341.57 0   1335.31 0   0 
Harlan 106 Solid cat 1 Yes Yes 3 1.81263 3.3377   36.7768 3.11703   549.78 0   549.78 0   547.16 0   0 
Harlan 106 Solid cat 1 Yes Yes 4 1.59113 1.0056   35.8787 1.1627   626.33 0   626.33 0   623.33 0   0 
Harlan 107 Solid cat 1 Yes Yes 1 1.379 11.2763   43.1291 6.81653   119.92 8.9195   90.05 2.248   70.56 14.0682   0 
Harlan 107 Solid cat 1 Yes Yes 2 0.74275 5.4527 NQ 45.1027 0.4039   78.56 30.2928 NQ 171.32 74.3184 NQ 131 26.1192 NQ 0 
Harlan 107 Solid cat 1 Yes Yes 3 1.81263 3.3377   36.7768 3.11703   84.19 3.1722   90.28 8.3856   53.68 10.7027   0 
Harlan 107 Solid cat 1 Yes Yes 4 1.59113 1.0056   35.8787 1.1627   162.2 18.886   93.4 12.9468   61.15 12.1926   7.65 
IIVS 106 Solid cat 1 Yes Yes 1 1.695 6.5782   33.2891 8.20059   186.76 1.3274   188.72 0.23599   176.36 0.26549   0 
IIVS 106 Solid cat 1 Yes Yes 2 1.69363 2.4799   21.795 0.17713   182.34 2.8342   183.21 2.33228   176.5 0.2657   0 
IIVS 106 Solid cat 1 Yes Yes 3 1.59688 4.7906   30.0665 4.00783   192.09 3.2877   194.12 1.34638   187.19 0.2818   0 
IIVS 107 Solid cat 1 Yes Yes 1 1.68213 4.102   31.9313 0.29724   71.76 13.0192   30.18 0.535   140.4 1.2781   0 
IIVS 107 Solid cat 1 Yes Yes 2 1.72388 1.6533   27.9095 1.16018   71.92 10.0645   74.4 28.3663 NQ 137 1.2472   0 
IIVS 107 Solid cat 1 Yes Yes 3 1.68425 5.967   24.833 2.22651   72.67 35.6242 NQ 57.19 28.3509 NQ 140.23 1.2765   0 
IIVS 107 Solid cat 1 Yes Yes 4 1.812 0.9382   24.862 0.55188   85.68 21.9095 NQ 64.16 25 NQ 130.34 1.1865   0 
IIVS 107 Solid cat 1 Yes Yes 5 1.6995 5.3545   23.9776 2.05943   79.16 30.2148 NQ 52.21 14.2101   138.98 1.2945   0 
 
Chemical 27 was sent to all participating laboratories for testing but was excluded at a very early stage of the study on request of one of the participating 
laboratories because it was identified as a very strong MTT reducer.  
corrected 
viability chemical laboratory protocol MTT coloring run ODnc NCdiff NCqual meanTA TAdiff TAqual CCdiff CCqual KCdiff KCqual PCqual meanPC PCdiff meanCC meanKC 
27 Beiersdorf Liquids Yes No 1 1.7173 3.4211 Qualified 100.344 0.9521 Qualified . . . . Qualified 39.2118 3.4852 . . 100.344 
27 Beiersdorf Liquids Yes No 2 1.7408 6.0721 Qualified 107.495 1.8009 Qualified . . . . Qualified 40.6448 1.5597 . . 107.495 
27 Beiersdorf Liquids Yes No 3 1.8545 3.6478 Qualified 98.055 3.1113 Qualified . . . . Qualified 29.1791 3.0385 . . 98.055 
27 Harlan Liquids Yes  1 1.2896 11.282 Qualified 132.005 5.4279 Qualified . . 2.5589 Qualified Qualified 6.7558 0.6591 . 16.9429 115.063 
27 Harlan Liquids Yes  2 1.7896 0.6147 Qualified 97.793 1.7881 Qualified . . 1.844 Qualified Qualified 16.3791 0.9499 . 12.2093 85.584 
27 Harlan Liquids Yes  3 2.2828 3.5045 Qualified 104.556 3.855 Qualified . . 1.4456 Qualified Qualified 12.7368 0.0438 . 9.5718 94.984 
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27 IIVS Liquids Yes No 1 1.7879 1.9017 Qualified 103.384 3.0203 Qualified . . 1.9017 Qualified Qualified 34.699 3.6915 . 3.5937 99.79 
27 IIVS Liquids Yes No 2 1.85 4.1081 Qualified 104.946 1.2973 Qualified . . 1.8378 Qualified Qualified 33.6757 4.2162 . 3.473 101.473 
27 IIVS Liquids Yes No 3 1.8655 2.037 Qualified 102.854 0.8845 Qualified . . 1.8226 Qualified Qualified 26.2262 6.1914 . 3.4441 99.41 
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GUIDANCE ON EYE IRRITATION VALIDATION STUDY (EIVS) 1 
CONDUCT FOR THE RECONSTRUCTED HUMAN TISSUE (RhT) 2 
ASSAYS AND PERFORMANCE CRITERIA TO ASSESS THE 3 
SCIENTIFIC VALIDITY OF SkinEthic
TM
 HCE AND EpiOcular
TM
 EIT 4 
Disclaimer: The Validation Management Group (VMG) of the Eye Irritation Validation Study 5 
(EIVS) proposes in this document a guidance on the conduct of certain aspects of EIVS, as well as 6 
“test method performance criteria” that describe the performance deemed by the VMG as 7 
necessary for a test method to be scientifically valid and considered for regulatory acceptance. 8 
Nevertheless, the EIVS VMG recognises that regulatory authorities ultimately make the 9 
determination of what is considered adequate performance for their relevant regulatory decisions. 10 
 11 
1. DEFINITIONS 12 
EpiOcular
TM
 model/construct: A reconstructed human tissue (RhT) construct produced by 13 
MatTek Corporation, consisting of a non-keratinized multilayered epithelium prepared from non-14 
transformed, human-derived epidermal keratinocytes. 15 
SkinEthic
TM
 Human Corneal Epithelium (HCE) model/construct: A RhT construct produced 16 
by SkinEthic
TM
 Laboratories, consisting of a a multilayered epithelium prepared from 17 
immortalized human corneal epithelial cells. 18 
EpiOcular
TM
 Eye Irritation Test (EIT): A test method to predict eye irritation, employing the 19 
EpiOcular
TM
 RhT construct as test system and a protocol defining different exposure and post-20 
exposure incubations for liquids and solids (i.e., liquids: 30 min exposure followed by 120 min 21 




 HCE Short-time Exposure (SE): A test method to predict eye irritation, employing 24 
the SkinEthic
TM
 HCE RhT construct as test system and a short-time exposure of test chemicals 25 
(i.e., 10 min exposure without post-treatment incubation). 26 
SkinEthic
TM
 HCE Long-time Exposure (LE): A test method to predict eye irritation, employing 27 
the SkinEthic
TM
 HCE RhT construct as test system and a long-time exposure of test chemicals 28 
(i.e., 1 h exposure followed by 16 h post-treatment incubation). 29 
Eye irritation Peptide Reactivity Assay (EPRA): A test method to predict chemical reactivity, 30 




 HCE test strategy/method: A test strategy to predict eye irritation, consisting of 33 
three separate assays (i.e., EPRA, SkinEthic
TM
 HCE SE, and SkinEthic
TM
 HCE LE). In the 34 
SkinEthic
TM
 HCE test strategy, chemical reactivity, as determined by the EPRA, is used to decide 35 
if a chemical is tested with SkinEthic
TM
 HCE SE (reactive chemicals) or SkinEthic
TM
 HCE LE 36 
(non-reactive or inclusive chemicals). 37 
Negative control (NC): A reference test chemical that does not induce a cytotoxic effect in the 38 
treated tissues (i.e., does not reduce their viability). It is used to verify if the viability of the tissues 39 
used for testing, as quantified by the MTT assay, is within a defined acceptance range of optical 40 
density (OD) (i.e., SkinEthic
TM
 HCE SE/LE: 0.7 ≤ ODNC < 1.5; EpiOcular
TM
 EIT: ODNC > 1.0). 41 
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Positive control (PC): A reference test chemical known to induce a cytotoxic effect in the treated 42 
tissues (i.e., SkinEthic
TM
 HCE SE/LE: < 50% viability; EpiOcular
TM
 EIT: < 50% viability), as 43 
quantified by using the MTT assay. It is used to verify if the tissue batch used for testing is 44 
responding to the reference chemical within a defined acceptance range of % viability (relative to 45 
NC). It should be noted that the positive control does not need to be an in vivo irritant chemical 46 
(based on the Draize eye irritation test). 47 
Test chemical: Any chemical (substance or mixture) being tested as a single entity. 48 
Test: A single test chemical concurrently tested in a minimum of two/three tissue replicates as 49 
defined in the corresponding SOP. A “test” for a test chemical is defined when the cytotoxic effect 50 
by using MTT is quantitatively measured. A reported technical issue before the viability 51 
measurement is not considered as a “test” for the test chemical (see section 2.2.3). 52 
Run: A run consists of multiple tests with different test chemicals (one test per test chemical) 53 
conducted concurrently with a test with NC and a test with PC, tested by one operator, as defined 54 
in the corresponding SOP. 55 
Qualified run: A run is qualified if it meets the test acceptance criteria for the NC and PC, as 56 
defined in the corresponding SOP. Otherwise, the run will be considered as non-qualified. 57 
Qualified test: A test is qualified if it meets the criteria for an acceptable test, as defined in the 58 
corresponding SOP, and is within a qualified run. Otherwise, the test will be considered as non-59 
qualified. 60 
Test sequence: The total number of tests performed for a single test chemical in a single 61 
laboratory, which includes any re-testing. A test sequence may include both qualified and non-62 
qualified tests. The first two tests having technical issues for each test chemical, tests included in 63 
the first two runs presenting technical issues, and tests included in the first six non-qualified runs 64 
are not considered as part of a test sequence. 65 
Complete test sequence: A test sequence is considered complete if it contains three qualified 66 
tests. Otherwise, the test sequence will be considered as incomplete. 67 
 68 
2. TESTING PROCEDURES 69 
2.1 Testing Chemicals for the Eye Irritation Validation Study (EIVS) 70 
In order to establish the reliability and relevance of the SkinEthic
TM
 HCE SE, LE and test strategy 71 
and of the EpiOcular
TM
 EIT during EIVS, all test chemicals selected for the validation study (at 72 
least 104) should be tested with SkinEthic
TM
 HCE SE, SkinEthic
TM
 HCE LE and 73 
EpiOcular
TM
 EIT in three laboratories. SkinEthic
TM
 HCE SE and SkinEthic
TM
 HCE LE will be 74 
run in parallel in the same three laboratories, while three other laboratories will be responsible for 75 
running the EpiOcular
TM
 EIT. In each laboratory, all test chemicals should be tested in three 76 
independent qualified runs per test method performed with different production tissue 77 
batches and at sufficiently spaced time points (at least one week apart), with the final objective 78 
of obtaining three qualified tests per test chemical. In each run, each test chemical, as well as the 79 
negative control (NC) and the positive control (PC) should be concurrently tested in a minimum of 80 
three tissue replicates for SkinEthic
TM
 HCE SE/LE and two tissue replicates for 81 
EpiOcular
TM
 EIT (see note below), respectively. Even if more than one test chemical is tested in 82 
the same run, one replicate set for each NC and PC is sufficient. 83 
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Any tissues pre-selection (before the testing, untreated tissues), procedural change or technical 84 
issue (during the testing, tissue treated) that may impact on test method reproducibility assessment, 85 
will be documented (see data reporting templates in the annexes to the SOPs) and reported to the 86 
core VMG. 87 
Note on the number of replicates for the EpiOcular
TM
 EIT: 88 
The EpiOcular
TM
 EIT has been developed using two concurrently tested tissue replicates on the 89 
basis of practical considerations in the technical procedures for conduct of this assay. The 90 
variability between two concurrently treated tissue replicates was found to be low in the 296 pairs 91 
of replicates produced by seven laboratories for a wide set of test chemicals during the pre-92 
validation study of the EpiOcular
TM
 EIT. Briefly, 99%, 95%, 90% and 74% of the 296 pairs of 93 
concurrently treated tissue replicates showed a difference of viability below 20%, 15%, 10% and 94 
5%, repectively. Two independent biostatisticians evaluated the data and their conclusions led the 95 
VMG to consider the use of two tissue replicates for EpiOcular
TM
 EIT in EIVS as sufficiently 96 
statistically and scientifically justified. 97 
 98 
2.2 Re-conducting Tests/Runs ("Re-testing"/"Re-running") 99 
It is possible that one or several tests pertaining to one or more test chemicals does/do not meet the 100 
test acceptance criteria as given in the corresponding SOP or is/are not acceptable for other 101 
reasons. It is also possible that acceptance criteria for the NC and/or PC, as defined in the 102 
corresponding SOP, are not met for one or more runs. In these cases, re-testing/re-running is 103 
allowed to complete missing data as described below. Importantly, each laboratory should not 104 
produce more than three qualified tests per test chemical, per test method, and re-testing/re-105 
running is allowed only to try to accomplish the objective of producing three qualified tests per 106 
test chemical, per test method. Excess production of data and subsequent data selection are 107 
regarded as not appropriate. All tested tissues must be reported. The extent of unacceptable 108 
tests/runs will be documented and the basis for the likely cause of each will be provided.  109 
2.2.1 Re-testing of test chemicals: If one or more test chemicals within a qualified run 110 
does/do not meet the test acceptance criteria (non-qualified test(s)), a maximum number of 111 
two additional tests per test chemical, per test method
1
, per laboratory is/are admissible ("re-112 
testing") to complement missing data. More precisely, since in case of re-testing also PC and 113 
NC have to be concurrently tested, a maximum number of two additional qualified runs may 114 
be conducted for each test chemical. Non-qualified tests have to be documented and reported. 115 
2.2.2 Re-running runs: If a run does not meet the acceptance criteria for the NC and/or PC, 116 
as defined in the corresponding SOP (non-qualified run), the full run must be repeated for 117 
all test chemicals included in the non-qualified run. A maximum number of six
2
 additional 118 
runs are admissible per laboratory, per test method
1
 ("re-running") to complement missing 119 
data due to failure of NC or PC acceptance criteria. Non-qualified runs have to be documented 120 
and reported. None of the tests within the first six non-qualified runs obtained by a laboratory 121 
for each test method
1
 should be considered for applying section 2.2.1, or for any calculations. 122 




 HCE SE and SkinEthic
TM
 HCE LE are considered as two separate and independent test 
methods when considering re-testing and re-running. 
2
 This limit was defined by calculating the critical (smallest) number of repetitions that will result in a 
probability less then 5% assuming a binomial distribution with a failing rate of 10% and 30 runs in total. 
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After producing six non-qualified runs with one test method
1
, a laboratory should stop testing 123 
and immediately inform the core VMG through the Coordinator Jan Lammers 124 
(jan.lammers@tno.nl), with the VMG Chair Stuart Freeman (stuart.j.freeman@talktalk.net) in 125 
copy (to take action in the absence of the Coordinator). The core VMG will then analyse in 126 
detail all the non-qualified runs obtained by the laboratory with that test method
1
 to that point, 127 
looking at e.g., the consistency/inconsistency of the reason(s) leading to non-qualification and 128 
the time span between the non-qualified runs, in order to decide if the tests within further non-129 
qualified runs should be considered as non-qualified tests. In such a case, further repetition of 130 
runs will be considered as re-testing for all test chemicals included in those runs. 131 
Moreover, after producing three consecutive non-qualified runs with one test method
1
, a 132 
laboratory should stop testing and immediately inform the core VMG through the Coordinator 133 
Jan Lammers (jan.lammers@tno.nl), with the VMG Chair Stuart Freeman 134 
(stuart.j.freeman@talktalk.net) in copy (to take action in the absence of the Coordinator). The 135 
core VMG will then investigate if the laboratory is having systematic technical problems, by 136 
looking at e.g., the consistency/inconsistency of the reason(s) leading to non-qualification. 137 
If the core VMG identifies a systematic technical problem as the cause for non-qualified runs, 138 
the lead laboratory may be informed and involved in troubleshooting. 139 
2.2.3 Re-testing/re-running for technical reasons: If a test/run fails because of technical 140 
reasons (technical issue) and the test/run was not finished (no viability measurement) re-141 
testing is allowed twice for each test chemical in each laboratory, for each test method
1
, and 142 
re-running is also allowed twice in each laboratory, for each test method
1
, independently of 143 
the provisions described in sections 2.2.1 and 2.2.2. The reasons will be documented and 144 
reported to the core VMG. 145 
Examples of technical issues include e.g. tissues that are mechanically damaged during the test 146 
or tissues for which some amount of test chemical is accidentally applied to the culture 147 
medium. If a technical issue occurs, all replicates of the corresponding test chemical should be 148 
withdrawn from any further step of the test procedure. It should be avoided that OD 149 
measurements of tissues with known unacceptable technical quality will be performed 150 
(including the remaining replicates of the test chemical). 151 
Moreover, if systematic technical issues occur in one laboratory, leading to loss of data for 152 
more than one test chemical, testing should be stopped and the core VMG informed 153 
immediately through the Coordinator Jan Lammers (jan.lammers@tno.nl), with the VMG 154 
Chair Stuart Freeman (stuart.j.freeman@talktalk.net) in copy (to take action in the absence of 155 
the Coordinator), so that appropriate measures can be taken (e.g. the lead laboratory informed 156 
and involved in trying to solve a potential technical problem). 157 
Tissues which feature obvious, visible damage (e.g. contamination or cuts in the epithelium) 158 
should be discarded and not used at all in order to avoid a posterior technical issue. 159 
 160 
3. TEST ACCEPTANCE CRITERIA 161 
The test acceptance criteria for test chemicals, NC, PC, Non Specific Color controls and Non 162 
Specific MTT reduction controls are described in the corresponding SOPs and have been approved 163 
by the VMG. For example regarding variability, these acceptance criteria were defined as follows: 164 
SkinEthic
TM
 HCE SE/LE: SD > 18%; EpiOcular
TM
 EIT: Range > 20%. Importantly, if during or 165 
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after completion of EIVS the predefined test acceptance criteria are found not to be appropriate 166 
due to failure of a high number of tests (non-qualified tests) and/or runs (non-qualified runs), the 167 
VMG may revise these criteria on the basis of the evaluation of the acquired data. All 168 
modifications have to be scientifically/statistically justified. 169 
 170 
4. CALCULATION OF RELIABILITY (REPRODUCIBILITY) AND 171 
PREDICTIVE CAPACITY (ACCURACY) 172 
The independent biostatistician assigned to the validation study will be responsible for calculating 173 
the reliability and predictive capacity values in EIVS, in accordance with the rules described 174 
below. The ECVAM biostatistician will perform an independent review and quality assurance 175 
on the calculations performed by the independent biostatistician. 176 
While the reproducibility and predictive capacity of EpiOcular
TM
 EIT will be evaluated in a single 177 
assessment (as described in sections 4.1-4.3) because each chemical will be tested in a single 178 
protocol (as a solid or a liquid), for SkinEthic
TM
 HCE three independent assessments will be 179 
performed. Since all the selected test chemicals will be tested in both SkinEthic
TM
 HCE SE and 180 
SkinEthic
TM
 HCE LE, these two assays can be evaluated not only as part of a testing strategy with 181 
EPRA but also as independent test methods. Thus, the SkinEthic
TM
 HCE testing strategy, the 182 
SkinEthic
TM
 HCE SE and the SkinEthic
TM
 HCE LE will all be independently evaluated for their 183 
reproducibility and predictive capacity as described in sections 4.1-4.3. Finally, the EPRA will be 184 
evaluated for its reproducibility according to sections 4.1 and 4.2 (see also Project Plan). 185 
 186 
4.1 Within Laboratory Reproducibility (WLR) 187 
For each laboratory, concordance of classifications and overall Standard Deviation will be 188 
calculated based only on qualified tests from test chemicals for which at least two qualified tests 189 
are available. The final report should state how many and which test chemicals per laboratory have 190 
none or only one qualified test (omitted from WLR calculations), as well as how many and which 191 
test chemicals per laboratory have two or three qualified tests (used for WLR calculations). In 192 
addition, the overall Standard Deviation associated with each laboratory will be calculated using 193 
all available test sequences, i.e. including both qualified and non-qualified tests. 194 
 195 
4.2 Between Laboratory Reproducibility (BLR) 196 
For the calculation of BLR the final classification for each test chemical in each participating 197 
laboratory should be obtained by using the arithmetic mean value of viability over the different 198 
qualified tests performed. Concordance of classifications between laboratories and overall 199 
Standard Deviation of the study will be calculated based only on qualified tests from test 200 
chemicals for which at least one qualified test per laboratory is available. The final report 201 
should state how many and which test chemicals do not have at least one qualified test per 202 
laboratory (omitted from BLR calculation), as well as how many and which test chemicals have 3, 203 
4, 5, 6, 7, 8 or 9 qualified tests that can be used to calculate BLR (with at least one qualified test 204 
per laboratory). In addition, the overall Standard Deviation of the study will be calculated using all 205 
available test sequences, i.e. including both qualified and non-qualified tests. 206 
 207 
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4.3 Predictive Capacity (Accuracy) 208 
All qualified tests for each test chemical will be used to calculate the predictive capacity values. 209 
The calculations will be based on the individual predictions of each qualified test in each 210 
laboratory and not on the arithmetic mean values of viability over the different qualified tests 211 
performed. 212 
By using all qualified tests to calculate the predictive capacity values, the probability of obtaining 213 
0% underprediction of Category 1 chemicals (0 out of about 200 tests), as requested in section 6.4 214 
(see below), is extremely low due to the accepted fact that reproducibility of SkinEthic
TM
 HCE 215 
SE/LE and EpiOcular
TM
 EIT both within and between laboratories is not 100% (see section 6.3). 216 
Therefore, the rate of underprediction of Category 1 chemicals as No Category (Cat 1 → No Cat), 217 
will be calculated using the mode of the in vitro predictions of all qualified tests obtained in the 218 
three participating laboratories for each test chemical classified as UN GHS/EU CLP Category 1 219 
based on in vivo Draize eye irritation data. This approach more closely reflects the real testing 220 
situation (post-validation). Thus, in a post-validation testing situation, a single qualified test 221 
obtained in one laboratory is usually sufficient to classify a test chemical, but if a borderline result, 222 
such as non-concordant replicate measurements and/or mean percent viability equal to 50±5%, is 223 
obtained, a second test may be considered, as well as a third one, in case of discordant results 224 
between the first two tests, in which case the mode of the three classifications is taken as the final 225 
decision. 226 
 227 
5. STUDY QUALITY CRITERION 228 
To limit the bias introduced in the calculations of reliability and predictive capacity due to the 229 
exclusion of the most variable tests (non-qualified tests) from some of the calculations (see section 230 
4), and also to avoid further bias introduced by a reduction of the data used in some of the 231 
calculations (at least 104 test chemicals are needed to reach the statistical power defined for the 232 
study), the VMG decided to define a target value for the number of complete test sequences that 233 
should be available after re-testing as an objective to secure the quality of the study, i.e. to limit the 234 
amount of missing data due to the predefined test acceptance criteria (see section 3). 235 
 236 
5.1 Target Number of Complete Test Sequences After Re-testing  237 
In each participating laboratory, at least 85% of the test sequences (see definition in section 1) 238 
should contain three qualified tests (89 out of 104 test sequences, for 104 test chemicals). 239 
If this criterion is not met, and before deciding that the required statistical power and study quality 240 
are not reached, the VMG may (i) investigate for potential reasons of misclassification, (ii) if 241 
deemed appropriate, revise the test acceptance criteria on the basis of the evaluation of the 242 
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6. PERFORMANCE CRITERIA TO ASSESS THE SCIENTIFIC 248 
VALIDITY OF THE TEST METHODS 249 
Prior to the initiation of the validation study, the VMG defined test method performance criteria, 250 
which it considered appropriate for judging the performance of the SkinEthic
TM
 HCE SE, LE and 251 
test strategy and of the EpiOcular
TM
 EIT with the test chemicals selected for EIVS. The test 252 
method performance criteria described below provide some guidance on the target values which 253 
the VMG would ideally like to attain in EIVS in terms of test method performance (reliability and 254 
predictive capacity) for the SkinEthic
TM
 HCE SE, LE and/or test strategy and for the EpiOcular
TM
 255 
EIT. One recommendation of a previous ESAC Peer Review Panel on cell-based assays was to 256 
receive guidance from the VMG to evaluate the performance of these cell-based assays. Therefore, 257 
within the framework of EIVS, the VMG also suggests the use of these test method performance 258 
criteria as a basis for the evaluation of the performance of the SkinEthic
TM
 HCE LE, SE and test 259 
strategy and of the EpiOcular
TM
 EIT by the ESAC Peer Review Panel after the completion of 260 
EIVS. 261 
The test method performance criteria developed by the VMG for EIVS and described below took 262 
into account: (a) the background and specific objectives of the validation study (see EIVS Project 263 
Plan); (b) the requirements of regulatory authorities and industry when testing and classifying 264 
chemicals for eye irritation; (c) the within test variability in the in vivo Draize eye irritation data 265 
and the manner in which those data are currently used for classifying eye irritants according to UN 266 
GHS / EU CLP (UN, 2007; EC, 2008); (d) the standards of performance which are expected from 267 
the in vitro tests evaluated; (e) the way in which the in vitro tests are to be used (as a test within a 268 
tiered test strategy); and (f) the power of the design of the validation study. 269 
It should be noted that the performance criteria on predictive capacity listed in section 6.4 should 270 
only be used to evaluate the validity of the SkinEthic
TM
 HCE SE, LE and test test strategy and of 271 
the EpiOcular
TM
 EIT as stand-alone test methods for the identification of chemicals not classified 272 
as eye irritants, in the framework of the Bottom-up/Top-down test strategy (please see the 273 
objective and goals of EIVS set out in the Project Plan). Therefore, even if the accuracy values 274 
obtained in EIVS for any of these RhT test methods are considered “definitely unacceptable” by 275 
the VMG as described in section 6.4, the test method(s) may still be useful for other purposes, e.g. 276 
the identification of chemicals not classified as eye irritants in combination with other 277 
appropriately validated test methods (i.e., use of more than one test method to identify the majority 278 
of non-classified chemicals). The EIVS VMG will consider these situations when evaluating the 279 
results of the validation study. 280 
 281 
6.1 Flexibility Clause 282 
Although the EIVS VMG is of the opinion that the definition of target values for test method 283 
performance prior to initiation of the experimental phase of a validation study is beneficial, 284 
bearing in mind the post-validation acceptance process, it also acknowledges that in a prospective 285 
validation study not all circumstances and possible outcomes can be considered beforehand. Thus, 286 
the following predefined and agreed target values are to be considered in the context of the 287 
practical study outcome. In case amendments are considered necessary, these will have to be 288 
scientifically justified. 289 
 290 
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6.2 Limitations of the Test Methods 291 
The VMG also considers that it will be important to define the limitations of the test methods, and 292 
try to rationalize any apparent reasons for misclassifications before making a final 293 
recommendation about the scientific validity of the RhT test methods under evaluation. If potential 294 
reasons for misclassification strictly related to the test methods are identified, these should be 295 
considered for defining the limitations of the test method. If the estimated reliability and/or 296 
accuracy values of a test method can be improved by excluding identified limitations, these values 297 
should also be compared to the predefined test method performance criteria (sections 6.3-6.4). 298 
 299 
6.3 Target Values for Reproducibility 300 
Analysis of reproducibility will not be limited to the parameters described below. Other statistical 301 
tools, e.g. the overall Standard Deviation and Coefficient of Variation of the study calculated from 302 
all qualified tests as from all available tests (qualified and non-qualified), will also be considered 303 
before making a final decision on the reproducibility of the test methods. 304 
6.3.1 Within one laboratory (and over time): The concordance of classifications (not 305 
classified / classified) for the set of chemicals tested during validation obtained in different, 306 
independent runs within a single laboratory should ideally be equal or higher () than 85% 307 
for all participating laboratories
3
. 308 
6.3.2 Between laboratories: The concordance of final classifications (not classified / 309 
classified) for the set of chemicals tested during validation obtained by the different 310 
participating laboratories should ideally be equal or higher () than 80%4. 311 
 312 
6.4 Target Values for Predictive Capacity (Accuracy) 313 
The SkinEthic
TM
 HCE SE, LE and test strategy and the EpiOcular
TM
 EIT are being validated for 314 
their usefulness as stand-alone (independent) test methods to identify chemicals not classified as 315 
eye irritant (UN GHS/EU CLP No Category; “non-irritants”) and their reliable discrimination from 316 
all classes of eye irritant chemicals as e.g. the initial step in a Bottom-Up approach (in the 317 
framework of a Bottom-Up/Top-Down test strategy, Scott L. et al., 2010). The SkinEthic™ HCE 318 
test strategy and the EpiOcular™ EIT were developed for maximum sensitivity (ability to detect 319 
positives, with low rate of false negatives) rather than for optimal accuracy with balanced 320 
sensitivity and specificity (ability to detect negatives, with low rate of false positives). However, it 321 
was also sought to achieve a sufficiently high specificity in order to allow the identification of the 322 
highest number of chemicals not classified as irritant to the eye. By achievement of satisfactory 323 
                                                 
3
 The within laboratory reproducibility values obtained in the pre-validation of the SkinEthic
TM
 
HCE were of 90 to 100% concordance of classifications, and for EpiOcular
TM
 EIT of 95 to 100% 
concordance of classifications (considering the classification cut-off of 60% viability) or of 90 to 
100% concordance of classifications (considering the classification cut-off of 50% viability). 
4
 The between laboratory reproducibility values obtained in the pre-validation of the SkinEthic
TM
 
HCE were of 95 to 100% concordance of classifications, and for EpiOcular
TM
 EIT 100% 
concordance of classifications (considering the classification cut-off of 60% viability) or 96% 
concordance of classifications (considering the classification cut-off of 50% viability). 
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specificity, the SkinEthic™ HCE test strategy and the EpiOcular™ EIT would present stand-alone 324 
(independent) test methods for identification of “non-irritants”. 325 
Based on these premises, the EIVS VMG defined “definitely acceptable” and “definitely 326 
unacceptable” rates of overprediction and underprediction for determining the predictive 327 
performance of the SkinEthic
TM
 HCE SE, LE and test strategy and of the EpiOcular
TM
 EIT, which 328 
are outlined in Table 1. In particular, the following points were felt to be important to recommend 329 
the test methods as being sufficiently predictive to be considered as scientifically valid: 330 
(a) About 10% false negatives should be “definitely acceptable” (sensitivity ≥ 90%), while 331 
more than 20% would be “definitely unacceptable”5. In previous validation studies for eye 332 
irritation led by ECVAM (Cytotoxicity and Cell-based assays) or ICCVAM (Organotypic 333 
assays) the Peer-Review Panels responsible for evaluating the validated test methods 334 
considered 0% false negatives as a test method performance criterion for acceptance of test 335 
methods to be used as an initial step in a Bottom-Up test strategy (identification of 336 
chemicals not classified as eye irritant). However, the Draize rabbit eye test shows the 337 
potential for up to 10% over classification of chemicals as UN GHS Cat. 2 (instead of UN 338 
GHS No Cat.) due solely to its within test variability (Zuang V. et al., 2010). The actual rate 339 
of overprediction of the Draize test may be even higher when considering other factors like 340 
between laboratory variability and predictivity. Thus, the EIVS VMG is of the opinion that a 341 
False Negative rate up to 10% should be “definitely acceptable” for the UN GHS and EU 342 
CLP classification and labelling systems (UN, 2007; EC, 2008) for a test method to be 343 
considered useful for the identification of chemicals not classified as eye irritants as a stand-344 
alone test (inititial step in a Bottom-up approach). Nevertheless, the nature, severity, 345 
duration, and frequency of in vivo eye injuries (based on the Draize eye irritation test) for 346 
chemicals that produce false negative results from in vitro tests will be fully discussed and 347 
considered by the VMG in assessing the usefulness and limitations of the in vitro test 348 
methods for regulatory hazard classification and labelling purposes. 349 
(b) Ideally, no ocular corrosives/severe eye irritants (Category 1) should be underpredicted as 350 
No Category, but more than 10% Cat 1 chemicals being underclassified as No Category 351 
would be “definitely unacceptable”. 352 
(c) About 40% false positives should be “definitely acceptable” (specificity ≥ 60%), while more 353 
than 50% would be “definitely unacceptable”6. Since the purpose of the test methods will be 354 
the identification of chemicals not classified as eye irritant (UN GHS/EU CLP No Category) 355 
as an initial step of a Bottom-Up test strategy (Scott L. et al. 2010), the VMG considered 356 
that it is acceptable to have a lower specificity than sensitivity (higher false positives than 357 
false negatives). Nevertheless, specificity should not be too low in order to allow for the 358 
correct identification of the majority of the chemicals not classified as irritant to the eye. 359 
 360 
                                                 
5
 During pre-validation, the EpiOcular
TM
 EIT showed a sensitivity of 99% (considering the 
classification cut-off of 60% viability) or of 96% (considering the classification cut-off of 50% 
viability), while the SkinEthic
TM
 HCE test strategy showed a sensitivity of 87%. 
6
 During pre-validation, the EpiOcular
TM
 EIT showed a specificity of 65% (considering the 
classification cut-off of 60% viability) or of 72% (considering the classification cut-off of 50% 
viability), while the SkinEthic
TM
 HCE test strategy showed a specificity of 69%. 
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(d) About 25% of overall misclassifications would be “definitely acceptable” (overall accuracy 361 
≥ 75%), while more than 35% would be “definitely unacceptable”. Potential reasons for 362 
misclassification will be analysed in detail, including individual tissue score lesions of 363 
misclassified chemicals, which may be considered in future regulatory acceptance of the 364 
evaluated assays. 365 
(e) Misclassification of borderline chemicals, identified from in vivo Draize eye irritation data 366 
and/or structure-activity relationship considerations, would be easier to justify compared to 367 
non-borderline chemicals. 368 
If the “definitely acceptable” rates of overprediction and underprediction defined in Table 1 are 369 
not attained in the validation study, but the rates obtained are not considered “definitely 370 
unacceptable” (Table 1), the VMG will not decide on the recommendation about the scientific 371 
validity of the test method before all the validation data have been evaluated and discussed as 372 





 HCE SE, SkinEthic
TM
 HCE LE and SkinEthic
TM
 HCE test 374 
strategy) as obtained in EIVS are considered “definitely unacceptable” by the VMG for a stand-375 
alone test method, even taking into account any possible limitations of the test methods, these may 376 
still be useful for other purposes, e.g. the identification of chemicals not classified as eye irritants 377 
in combination with other methods. The EIVS VMG will consider these situations when 378 
evaluating the results of the validation study.  379 
 380 
Table 1. VMG accepted rates of overprediction and underprediction for the SkinEthic
TM
 HCE SE, LE and 381 


















rates  ≤ 10 0 ≤ 40 ≤ 25 
Further evaluations 
necessary before any 
recommendation is made 
10 < FN ≤ 20 0 < Cat 1 FN ≤ 10 40 < FP ≤ 50 25 < OM ≤ 35 
“Definitely unacceptable” 
rates > 20 > 10 > 50 > 35 
a
 equal to (1-Sensitivity) 383 
b
 based on the mode of all qualified tests (see section 4.3) 384 
c
 equal to (1-Specificity) 385 
d
 equal to (1-Overall accuracy) 386 
387 
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ADDENDUM TO THE 
GUIDANCE ON EYE IRRITATION VALIDATION STUDY (EIVS) 
CONDUCT FOR THE RECONSTRUCTED HUMAN TISSUE (RhT) 
ASSAYS AND PERFORMANCE CRITERIA TO ASSESS THE 
SCIENTIFIC VALIDITY OF SkinEthicTM HCE AND EpiOcularTM EIT 
 
 
Instructions for the Testing of 




1. Controls for direct MTT-reducers and coloured test chemicals 
Controls for direct MTT-reducers (freeze killed tissues with MTT) and/or coloured test 
chemicals (living tissues without MTT) must always be performed irrespectively of the results 
of the viability tests. Therefore, even though Non-Specific MTT-reduction (NSMTT) and/or 
Non-Specific Colour (NSC) corrections will have no effect for MTT reducers and/or coloured 
test chemicals that are already identified as irritant in the viability tests, NSMTT and NSC 
controls must still be acquired for these chemicals. 
 
2. Test chemicals showing %NSMTT or %NSC > 50% in any of the control tests performed 
A test cannot be considered as non-qualified based only on the %NSMTT or %NSC values. 
According to the current EpiOcularTM EIT and SkinEthicTM HCE protocols, a %NSMTT or 
%NSC > 50% may suggest that the chemical is incompatible with the test method, but does 
not per se disqualify the test where it was obtained. A test can only be considered as non-
qualified based on the variability of the two (EpiOcularTM EIT) or three (SkinEthicTM HCE) 
tissue replicates used in the %viability measurements or controls, or if it is included in a non-
qualified run, where either the positive control or the negative control did not meet the test 
acceptance criteria. Moreover, the %NSMTT and %NSC cut-offs for deciding whether a 
direct-MTT reducer or coloured test chemical is compatible with the test method (currently 
defined as 50%) may be revised post-hoc by the Validation Management Group (VMG) once 
the testing phase of the ECVAM/COLIPA Eye Irritation Validation Study (EIVS) is 
completed and relevant statistical analysis have been performed.  
Therefore, the laboratories participating in EIVS should always try to obtain three qualified 
viability tests and controls for direct MTT-reducers and/or coloured test chemicals even if 
%NSC or %NSMTT are > 50%. It will be up to the VMG to decide whether the test chemical 
should be considered incompatible with the test method when analysing the data acquired by 
all participating laboratories. 
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3. Re-testing due to failure to meet test acceptance criteria 
Re-testing due to failure to meet test acceptance criteria should always be performed up to the 
maximum number of re-tests allowed and as long as three qualified tests (a complete test 
sequence) have not been obtained. Importantly, re-testing should continue up to the 
maximum number of re-tests allowed even when it becomes clear that a complete test 
sequence (three qualified tests) can no longer be obtained (see below: cases 5, 9, 13 and 18). 
This rule applies to all test chemicals (including coloured, non-coloured, MTT-reducer and 
non-MTT-reducer chemicals) and is important because according to sections 4.1, 4.2 and 4.3 
of the Guidance on EIVS Conduct and Performance Criteria, the Within Laboratory 
Reproducibility will be calculated for "test chemicals for which at least two qualified tests are 
available", the Between Laboratory Reproducibility will be calculated for "test chemicals for 
which at least one qualified test per laboratory is available", and the Predictive Capacity will 
be calculated using all qualified tests obtained for each test chemical. Therefore, the order of 
qualified/non-qualified results should not dictate whether to proceed with testing since this 
would artificially bias the evaluation of the robustness of the protocol. 
Finally, no further testing of a chemical by a laboratory should be performed once three 
qualified tests have been obtained for a test method (see below: cases 1, 2, 3, 6, 7, 10, 11, 15 
and 16). Excess production of data and subsequent data selection are regarded as not 
appropriate. All tested tissues must be reported. 
 
3.1. Extra re-testing of NSMTT control tissues due to failure to meet the test acceptance 
criterion 
NSMTT controls are tested independently from viability tests (and NSC controls) since they 
use freeze killed tissues, which can only be used after all tissues from the same batch have 
already been used in a previous week. Moreover, NSMTT controls for one test method1 only 
need to be performed once in each laboratory, for each direct MTT-reducer test chemical. If a 
NSMTT control within a qualified run does not meet the test acceptance criterion 
(SkinEthicTM HCE SE/LE: SD%NSMTT > 18%; EpiOcularTM EIT: Range%NSMTT > 20%) (non-
qualified NSMTT control test), a maximum number of two additional NSMTT control tests 
per direct MTT-reducer chemical, per test method1, per laboratory are admissible ("re-
testing") to try obtaining one qualified NSMTT control for that chemical. Each additional 
NSMTT control test must be acquired concurrently with the negative control. All non-
qualified NSMTT control tests have to be documented and reported. 
It is important to note that although only one qualified NSMTT control test needs to be 
performed in each laboratory for each test method1 for each direct MTT-reducer test 
chemical, a different %NSMTT value must be calculated from the single NSMTT control OD 
to correct each qualified viability test obtained. The %NSMTT value used to correct a 
qualified viability test must be calculated relative to the negative control that was run 
concurrently to that specific viability test. Depending on the negative control OD value that is 
used to calculate %NSMTT, it is possible that the same NSMTT control may meet the test 
acceptance criterion for one (or two) viability test(s), but not for the other. Thus, a NSMTT 
control only qualifies if it meets the test acceptance criterion for all the qualified 
viability tests it needs to correct. 
If more than one qualified NSMTT control test is obtained in one laboratory for the same test 
chemical with the same test method1, the mean of the different corrected OD values obtained 
                                                 
1 SkinEthicTM HCE SE and SkinEthicTM HCE LE are considered as two separate and independent test methods 
when considering re-testing and re-running. 
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for those NSMTT control tests (EpiOcularTM EIT: ODKC; SkinEthicTM HCE SE/LE: ODKT-
ODKU) should be used to calculate one single %NSMTT value per qualified viability test. 
 
3.2. Extra re-testing of coloured test chemicals due to failure to meet the test acceptance 
criterion in NSC control tissues 
For coloured chemicals, NSC controls must be run concurrently with every viability test since 
the same tissue batch must be used for a viability test and its NSC control. Therefore, a 
viability test that meets the test acceptance criterion (SkinEthicTM HCE SE/LE: SD%Viability ≤ 
18%; EpiOcularTM EIT: Range%Viability ≤ 20%) may still not qualify if the concurrent NSC 
control does not meet its test acceptance criterion (SkinEthicTM HCE SE/LE: SD%NSC > 18%; 
EpiOcularTM EIT: Range%NSC > 20%) (see below: for example, cases 6, 7, 8 and 9). In order 
to compensate for the higher probability of obtaining a non-qualified test with a coloured 
chemical (where two separate test acceptance criteria must be met) as compared to a non-
coloured chemical (where only one test acceptance criterion must be met), a maximum 
number of four additional tests per coloured chemical, per test method1, per laboratory are 
admissible to try obtaining a complete test sequence. Thus, a total of seven tests may be 
performed with coloured test chemicals in order to try obtaining three qualified tests (where 
both the viability test and the NSC control qualify). This corresponds to two extra re-tests in 
addition to the two already permitted in the Guidance on EIVS Conduct and Performance 
Criteria. However, the sixth and seventh tests for coloured test chemicals can only be 
performed if in the first five tests there are no more than two tests with SD%Viability > 18% 
(SkinEthicTM HCE SE/LE) or with Range%Viability > 20% (EpiOcularTM EIT), and no more 
than two tests with SD%NSC > 18% (SkinEthicTM HCE SE/LE) or with Range%NSC > 20% 
(EpiOcularTM EIT) (see below: cases 4, 5, 8, 9, 12, 13 and 14 where a 6th and 7th test cannot 
be performed; and cases 15, 16, 17 and 18 where up to 7 tests must be performed to generate a 
complete test sequence). Each additional viability test and NSC control test must be acquired 
concurrently with the positive control and the negative control. All non-qualified tests 
(including viability tests and concurrent NSC controls) have to be documented and reported. 
 
4. Re-running due to failure to meet test acceptance criteria for the positive or the negative 
control 
 
4.1. Extra re-running in each laboratory due to failure to meet test acceptance criteria for the 
positive or the negative control 
If a run does not meet the acceptance criteria for the negative control and/or positive control, 
as defined in the SkinEthicTM HCE and EpiOcularTM EIT protocols (non-qualified run), the 
full run must be repeated for all test chemicals included in the non-qualified run. A maximum 
number of eight2 additional runs are admissible per laboratory, per test method1 ("re-running") 
to complement missing data due to failure to meet the negative control or positive control 
acceptance criteria. Thus, in addition to the six re-runs already foreseen in the Guidance on 
EIVS Conduct and Performance Criteria, two extra re-runs are now permitted. This 
amendment is proposed because the total number of runs required to generate three tests per 
test chemical in one laboratory is higher than the 30 initially predicted, which did not consider 
the need to run NSMTT and NSC controls. Assuming that 1/3 of the chemicals (about 35) will 
                                                 
2 This limit was defined by calculating the critical (smallest) number of repetitions that will result in a 
probability less then 5% assuming a binomial distribution with a failing rate of 10% and 40 runs in total. 
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require controls in three runs, an extra 10 runs will be required to generate three tests per test 
chemical plus controls in one laboratory. These extra 10 runs justify the two extra re-runs now 
permitted. Non-qualified runs have to be documented and reported. None of the tests within 
the first eight non-qualified runs obtained by a laboratory for each test method1 should be 
considered non-qualified, nor should they be used for any calculations. 
 
5. Re-testing due to technical issues 
 
5.1. Extra re-testing of NSMTT control tissues due to technical issues 
A NSMTT control test for a direct MTT-reducer test chemical may be repeated twice (re-
tested) to replace NSMTT control tests that failed due to technical reasons (technical issue) 
and that were not finished (OD measurement not performed). These two re-tests are allowed 
in each laboratory and for each test method1, independently of the re-testing allowed due to 
failure to meet the test acceptance criterion (see section 3.1 above). A NSMTT control that 
fails due to technical reasons does not disqualify viability tests or NSC controls since, as 
explained above, NSMTT controls are independent from viability tests and NSC controls (see 
section 3.1). All technical issues must be documented and reported to the core VMG. 
 
 
5.2. Extra re-testing of coloured test chemicals due to technical issues in NSC control tissues 
A coloured test chemical may be re-tested twice (including viability test and NSC control) to 
replace tests that failed due to a technical issue in NSC controls and that were not finished 
(OD measurement not performed for either the viability tissues or the NSC control tissues). 
Thus, four re-tests (including viability test and NSC control) due to 2 technical issues in 
viability tissues and 2 technical issues in NSC control tissues are allowed per coloured test 
chemical in each laboratory, for each test method1, independently of the re-testing allowed 
due to failure to meet test acceptance criteria (see section 3.2 above). Each time a coloured 
test chemical is re-tested due to technical reasons, both the viability test and the NSC control 
must be re-tested concurrently since, as explained above, the same tissue batch must be used 
for the viability test and its NSC control (see section 3.1). All technical issues must be 
documented and reported to the core VMG. 
 5
 
  Test 1 Test 2 Test 3 Test 4 Test 5 Test 6 Test 7 
SD/range 
%Viab. < cut-off < cut-off < cut-off     
SD/range 





Test YES YES YES     
A 4th and 5th test is not required since all 3 first tests qualified. 
 
SD/range 
%Viab. < cut-off > cut-off < cut-off < cut-off    
SD/range 





Test YES No YES YES    
A 5th, 6th and 7th test is not required since 3 qualified tests were obtained in 4 tests. 
 
SD/range 
%Viab. > cut-off < cut-off > cut-off < cut-off < cut-off   
SD/range 





Test No YES No YES YES   
A 6th and 7th test is not required since 3 qualified tests were obtained in 5 tests. 
 
SD/range 
%Viab. > cut-off < cut-off > cut-off < cut-off > cut-off   
SD/range 





Test No YES No YES No   
A 6th and 7th test cannot be performed under the revised rules for re-testing since within the 
first 5 tests there are 3 tests with SD or range of %Viability above the cut-off. 
 
SD/range 
%Viab. > cut-off > cut-off < cut-off > cut-off *   
SD/range 





Test No No YES No *   
A 6th and 7th tests cannot be performed under the revised rules for re-testing since within the 
first 5 tests there are 3 tests with SD or range of %Viability above the cut-off. 
* A 5th test must be performed even though a complete test sequence (one containing 3 
qualified tests) can no longer be obtained in 5 tests. 
 6
 
  Test 1 Test 2 Test 3 Test 4 Test 5 Test 6 Test 7 
SD/range 
%Viab. < cut-off < cut-off < cut-off < cut-off    
SD/range 





Test YES YES No YES    
A 5th, 6th and 7th test is not required since 3 qualified tests were obtained in 4 tests. 
 
SD/range 
%Viab. < cut-off < cut-off < cut-off < cut-off < cut-off   
SD/range 





Test YES No YES No YES   
A 6th and 7th test is not required since 3 qualified tests were obtained in 5 tests. 
 
SD/range 
%Viab. < cut-off < cut-off < cut-off < cut-off < cut-off   
SD/range 





Test No No YES YES No   
A 6th and 7th test cannot be performed under the revised rules for re-testing since within the 
first 5 tests there are 3 tests with SD or range of %NSC above the cut-off. 
 
SD/range 
%Viab. < cut-off < cut-off < cut-off * *   
SD/range 





Test No No No * *   
A 6th and 7th test cannot be performed under the revised rules for re-testing since there are 
already 3 tests with SD or range of %NSC above the cut-off in the first 3 tests. 
* A 4th and 5th test must be performed even though a complete test sequence (one containing 3 
qualified tests) can no longer be obtained in 5 tests. 
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  Test 1 Test 2 Test 3 Test 4 Test 5 Test 6 Test 7 
SD/range 
%Viab. > cut-off < cut-off < cut-off < cut-off < cut-off   
SD/range 





Test No No YES YES YES   
A 6th and 7th test is not required since 3 qualified tests were obtained in 5 tests. 
 
SD/range 
%Viab. > cut-off > cut-off < cut-off < cut-off < cut-off   
SD/range 





Test No No YES YES YES   
A 6th and 7th test is not required since 3 qualified tests were obtained in 5 tests. 
 
SD/range 
%Viab. > cut-off > cut-off < cut-off < cut-off > cut-off   
SD/range 





Test No No YES YES No   
A 6th and 7th test cannot be performed under the revised rules for re-testing since within the 
first 5 tests there are 3 tests with SD or range of %Viability above the cut-off. 
 
SD/range 
%Viab. > cut-off > cut-off > cut-off * *   
SD/range 





Test No No No * *   
A 6th and 7th test cannot be performed under the revised rules for re-testing since there are 
already 3 tests with SD or range of %Viability above the cut-off in the first 3 tests. 
* A 4th and 5th test must be performed even though a complete test sequence (one containing 3 
qualified tests) can no longer be obtained in 5 tests. 
 
SD/range 
%Viab. > cut-off < cut-off > cut-off < cut-off > cut-off   
SD/range 





Test No YES No YES No   
A 6th and 7th test cannot be performed under the revised rules for re-testing since within the 




  Test 1 Test 2 Test 3 Test 4 Test 5 Test 6 Test 7 
SD/range 
%Viab. > cut-off < cut-off > cut-off < cut-off < cut-off < cut-off  
SD/range 





Test No YES No YES No YES  
A 6th test must be acquired under the revised rules for re-testing to try obtaining 3 qualified 
tests, since within the first 5 tests there are only 2 tests with SD or range of %Viability above 
the cut-off and only 2 tests with SD or range of %NSC above the cut-off. 
A 7th test is not required since 3 qualified tests were obtained in 6 tests. 
 
SD/range 
%Viab. > cut-off > cut-off < cut-off < cut-off < cut-off < cut-off < cut-off 
SD/range 





Test No No No No YES YES YES 
A 6th and 7th test must be acquired under the revised rules for re-testing to try obtaining 3 
qualified tests, since within the first 5 tests there are only 2 tests with SD or range of 
%Viability above the cut-off and only 2 tests with SD or range of %NSC above the cut-off. 
 
SD/range 
%Viab. > cut-off < cut-off < cut-off < cut-off < cut-off > cut-off < cut-off 
SD/range 





Test No YES No No YES No No 
A 6th and 7th test must be acquired under the revised rules for re-testing to try obtaining 3 
qualified tests, since within the first 5 tests there is only 1 test with SD or range of %Viability 
above the cut-off and only 2 tests with SD or range of %NSC above the cut-off. 
 
SD/range 
%Viab. > cut-off < cut-off < cut-off < cut-off > cut-off > cut-off * 
SD/range 





Test No YES No No No No * 
A 6th and 7th test must be acquired under the revised rules for re-testing to try obtaining 3 
qualified tests, since within the first 5 tests there are only 2 tests with SD or range of 
%Viability above the cut-off and only 2 tests with SD or range of %NSC above the cut-off. 
* A 7th test must be performed even though a complete test sequence (one containing 3 
qualified tests) can no longer be obtained in 7 tests. 
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 1 
EYE IRRITATION VALIDATION STUDY (EIVS) 2 
PROJECT PLAN 3 
Validation of the SkinEthic™ HCE SE, LE and Test Strategy and of the 4 
EpiOcular™ EIT for the Prediction of Acute Eye Irritation  5 
 6 
 7 
1. Definitions 8 
EpiOcular
TM
 model/construct: A reconstructed human tissue (RhT) construct produced by 9 
MatTek Corporation, consisting of a non-keratinized multilayered epithelium prepared from non-10 
transformed, human-derived epidermal keratinocytes. 11 
SkinEthic
TM
 Human Corneal Epithelium (HCE) model/construct: A RhT construct produced 12 
by SkinEthic
TM
 Laboratories, consisting of a a multilayered epithelium prepared from 13 
immortalized human corneal epithelial cells. 14 
EpiOcular
TM
 Eye Irritation Test (EIT): A test method to predict eye irritation, employing the 15 
EpiOcular
TM
 RhT construct as test system and a protocol defining different exposure and post-16 
exposure incubations for liquids and solids (i.e., liquids: 30 min exposure followed by 120 min 17 




 HCE Short-time Exposure (SE): A test method to predict eye irritation, employing 20 
the SkinEthic
TM
 HCE RhT construct as test system and a short-time exposure of test chemicals 21 
(i.e., 10 min exposure without post-treatment incubation). 22 
SkinEthic
TM
 HCE Long-time Exposure (LE): A test method to predict eye irritation, employing 23 
the SkinEthic
TM
 HCE RhT construct as test system and a long-time exposure of test chemicals 24 
(i.e., 1 h exposure followed by 16 h post-treatment incubation). 25 
Eye irritation Peptide Reactivity Assay (EPRA): A test method to predict chemical reactivity, 26 




 HCE test strategy/method: A test strategy to predict eye irritation, consisting of 29 
three separate assays (i.e., EPRA, SkinEthic
TM
 HCE SE, and SkinEthic
TM
 HCE LE). In the 30 
SkinEthic
TM
 HCE test strategy, chemical reactivity, as determined by the EPRA, is used to decide 31 
if a chemical is tested with SkinEthic
TM
 HCE SE (reactive chemicals) or SkinEthic
TM
 HCE LE 32 
(non-reactive or inconclusive chemicals). 33 
34 
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2. Study Objective 35 
The objective of this study is to formally validate the SkinEthic
TM
 HCE SE, LE and test strategy 36 
and the EpiOcular
TM
 EIT by inter-laboratory ring trial study, to facilitate international acceptance 37 
in regulatory schemes for hazard assessment of chemicals. In particular, these test 38 
methods/strategy shall be incorporated into a tiered test strategy (so-called Bottom-Up/Top-Down 39 
test strategy, as defined in an ECVAM workshop held in 2005, Scott L. et al., 2010) as e.g. the 40 
initial step in a Bottom-Up approach or the second step in a Top-Down Approach. The ultimate 41 
purpose of a tiered test strategy will be to replace the traditional in vivo Draize eye irritation test 42 
[Method B.5 of EC Regulation 440/2008 (EC, 2008a) or OECD TG 405 (OECD, 2002)]. 43 
3. Study Goals 44 
The goal of the Eye Irritation Validation Study (EIVS) is to assess the relevance (predictive 45 
capacity) and reliability (reproducibility within and between laboratories) of the SkinEthic
TM
 HCE 46 
SE, LE and test strategy and of the EpiOcular
TM
 EIT, by testing a statistically significant number 47 
of coded test chemicals (substances and mixtures), supported by complete and quality assured in 48 
vivo Draize eye irritation data for comparative evaluation of results. 49 
Specifically, EIVS will assess the validity of the SkinEthic
TM
 HCE SE, LE and test strategy and of 50 
the EpiOcular
TM
 EIT as stand-alone (independent) test methods to reliably discriminate chemicals 51 
not classified as eye irritant (“non-irritants”) from all classes of eye irritant chemicals (in the 52 
framework of a Bottom-Up/Top-Down test strategy, Scott L. et al., 2010), defined according to the 53 
United Nations Globally Harmonized System (GHS) of Classification and Labelling of Chemicals 54 
(UN GHS: No Category versus Category 1/Category 2A/Category 2B; UN, 2007) and as 55 
implemented in the European Commission Regulation (EC) No 1272/2008 on classification, 56 
labelling and packaging of substances and mixtures, amending and repealing Directives 57 
67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 (EU CLP: No 58 
Category versus Category 1/Category 2). 59 
The SkinEthic™ HCE test strategy and the EpiOcular™ EIT were developed for maximum 60 
sensitivity (ability to detect positives, with low rate of false negatives) rather than for optimal 61 
overall accuracy with balanced sensitivity and specificity (ability to detect negatives, with low rate 62 
of false positives). Sensitivity had therefore a bigger weight than specificity and overall accuracy 63 
in their development. However, it was also sought to achieve a sufficiently high specificity and 64 
overall accuracy, in order to allow identification of the highest number of chemicals not classified 65 
as irritant to the eye. By achieving satisfactory specificity, the SkinEthic™ HCE test strategy and 66 
the EpiOcular™ EIT would represent stand-alone (independent) test methods for the identification 67 
of “non-irritants”. Importantly, the test methods are not intended to differentiate between UN 68 
GHS/EU CLP Category 1 (irreversible effects) and UN GHS/EU CLP Category 2 (reversible 69 
effects). As proposed by the ECVAM workshop of February 2005, this differentiation would be 70 
left to another tier of the Bottom-Up/Top-Down test strategy (Scott L. et al., 2010). 71 
The EIVS will be undertaken in accordance with the principles and criteria documented in the 72 
OECD Guidance Document on the Validation and International Acceptance of New or Updated 73 
Test Methods for Hazard Assessment (No. 34, OECD, 2005) and according to the Modular 74 
Approach to validation (Hartung T. et al., 2004). 75 
4. Test Methods 76 
The SkinEthic
TM
 HCE SE, LE and test strategy and the EpiOcular
TM
 EIT have progressed through 77 
protocol optimisation and multi-laboratory assessment and will be evaluated in EIVS. The 78 
 EUROPEAN COMMISSION 
JOINT RESEARCH CENTRE 
 
 
Institute for Health and Consumer Protection 
European Centre for the Validation of Alternative Methods (ECVAM) 
 
ECVAM PROJECT PLAN FOR EIVS  Page 3 of 24 
SkinEthic
TM
 HCE SE/LE and the EpiOcular
TM
 EIT use as test systems reconstructed human tissue 79 
(RhT) constructs, and consist of a topical exposure of the neat test chemical to the epithelial surface 80 
of the tissue construct. 81 
The EpiOcular™ tissue construct is a non-keratinized multilayered epithelium prepared from non-82 
transformed, human-derived epidermal keratinocytes. It is intended to model the cornea epithelium 83 
with progressively stratified but not cornified cells. These cells are not transformed or transfected 84 
with genes to induce an extended life span in culture. The “tissue” is prepared in inserts with a 85 
porous membrane (MTI-003) through which the nutrients pass to the cells. A cell suspension is 86 
seeded into the MTI-003 membrane in specialized medium. After a period of initial cell 87 
proliferation, the medium is removed from the top of the tissue so that the epithelial surface is in 88 
direct contact with the air. This allows the test chemical to be directly applied to the epithelial 89 
surface in a fashion similar to how the corneal epithelium would be exposed in vivo. The ability to 90 
expose the tissue topically is essential to model the same kind of progressive injury expected in 91 
vivo. It also allows both solid and liquid test chemicals to be applied directly to the tissue. In the 92 
EpiOcular
TM
 EIT, liquids and solids are treated with different exposure and post-exposure incubations 93 
(i.e., liquids: 30 min exposure followed by 120 min post-treatment incubation, and solids: 90 min 94 
exposure followed by 18 hours post-treatment incubation). 95 
To construct SkinEthic™ HCE tissues, immortalized human corneal epithelial cells are cultured in 96 
a chemically defined medium and seeded on a polycarbonate membrane at the air–liquid interface. 97 
The tissue construct obtained is a multilayered epithelium resembling the in vivo corneal 98 
epithelium. As in vivo, columnar basal cells are present, including Wing cells. The model is 99 
characterized by the presence of specific ultra structural figures like intermediate filaments, mature 100 
hemi-desmosomes and desmosomes. Specific cytokeratins 64kD (K.3) have also been described 101 
(Nguyen D.H. et al., 2003). 102 
The SkinEthic
TM
 HCE test strategy uses three separate assays, i.e. EPRA, SkinEthic
TM
 HCE SE, 103 
and SkinEthic
TM
 HCE LE. In this strategy, test chemicals are tested in a short-time exposure 104 
(SkinEthic
TM
 HCE SE: 10 min exposure without post-treatment incubation) or a long-time 105 
exposure (SkinEthic
TM
 HCE LE: 1 h exposure followed by 16 h post-treatment incubation) 106 
depending on their chemical reactivity (defined as the electrophilic potential to react with cysteine 107 
or lysine containing peptides), as measured by the Eye irritation Peptide Reactivity Assay (EPRA). 108 





HCE SE or SkinEthic
TM
 HCE LE), the relative tissue viability is determined against the negative 110 
control-treated constructs by the reduction of the vital dye MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-111 
diphenyltetrazolium bromide). Tissues treated with eye irritants (UN GHS/EU CLP Category 2 and 112 
Category 1) are expected to show a decrease in viability below a certain threshold in respect to the 113 
negative control. 114 
115 
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5. Validation Management Group 116 
The management structure of EIVS and the responsibilities of the different members are shown in 117 
Figure 1. The Validation Management Group (VMG), with supervisory role, comprises: 118 
 119 
Core VMG 120 
- Chair (Stuart Freeman) 121 
- Co-chair (Valérie Zuang) 122 
- COLIPA sponsor representative (Pauline McNamee; alternate: Penny Jones) 123 
- ECVAM sponsor representative (João Barroso) 124 
- TNO coordinator representative (Jan Lammers; alternate: Ruud Woutersen) 125 
- TNO biostatistician (Carina de Jong-Rubingh) 126 
- ECVAM biostatistician (André Kleensang until 30.09.2010)
1
 127 
- Independent scientist (Chantra Eskes) 128 
- Chemicals Selection Group (CSG) coordinator (Thomas Cole) 129 
 130 
 131 
Representatives of the lead laboratories 132 
- SkinEthic
TM
 HCE test strategy lead laboratory: L’Oréal (Nathalie Alépée) 133 
- EpiOcular
TM
 EIT lead laboratory: Beiersdorf (Uwe Pfannenbecker) 134 
 135 
In addition, in the framework of the International Cooperation on Alternative Test Methods 136 
(ICATM), Liaisons from the USA, Japan and Canada are represented on the VMG namely: 137 
- NICEATM (William Stokes; alternates: Warren Casey, David Allen, Elizabeth Lipscomb) 138 
- ICCVAM (Jill Merrill) 139 
- JaCVAM (Hajime Kojima) 140 
- Health Canada (Alison McLaughlin) 141 
 142 
Operational decisions will be taken by the core VMG only. Representation of the lead laboratories 143 
allows consultation on technical issues relating to the test systems and monitoring progress of 144 
experimental work, but will not be involved in discussions regarding the chemicals selection. The 145 
ICATM liaisons are invited to advise the VMG. 146 
 147 
148 
                                               
1
 From 30 September 2010, there will be no official representation from an ECVAM biostatistician 
in the VMG. Nevertheless, ECVAM will continue providing the planned biostatistical support to 
EIVS after this date. 
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6. Study Coordination and Sponsorship  169 
6.1. Overall study coordination  170 
The overall study coordination will be conducted by ECVAM. This will include the organisation 171 
of all necessary VMG meetings and teleconferences, and the maintenance of a website where all 172 
EIVS documents not related to chemical selection are made available to VMG members and 173 
ICATM liaisons. ECVAM will also be responsible for organising the Quality Control audits on 174 
data collection, handling and analysis, as well as on the biostatistical reports produced by the TNO 175 
biostatistician. 176 
6.2. Logistical coordination and communication 177 
The TNO (Quality of Life) representative will coordinate the communication flow between all 178 
parties, draft minutes of VMG meetings and telephone conferences, organize meetings between 179 
laboratories, and organise the study conduct. TNO has also responsibility for logistics of test 180 
chemical acquisition, coding and distribution. Finally, the TNO representative will arrange quality 181 
control audits on the RhT production sites. 182 
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6.3. Study sponsorship  183 
ECVAM and COLIPA will co-sponsor EIVS, with the main financial support being provided by 184 
COLIPA. 185 
 186 
COLIPA will finance:  187 
- conduct of the chemical reactivity assays 188 
- lead and participating laboratories for the two test methods  189 
- statistical support provided by TNO 190 
- financial support of the independent chair of the VMG 191 
- independent CRO responsible for the test chemicals purchase, coding and distribution to the 192 
laboratories 193 
- overall logistical coordination of the study 194 
- part of the independent QC audit on the RhT models production sites  195 
- purchase cost of existing chemicals 196 
- purchase of a proportion of the RhT tissues 197 
 198 
ECVAM will finance: 199 
- management and coordination of the study, including the organisation of all VMG meetings 200 
- statistical support provided by ECVAM 201 
- part of the independent QC audit on the RhT models production sites  202 
- independent QC audit on data collection, handling and analysis 203 
- independent QC audit of the biostatistical report(s) 204 
- purchase of a proportion of the RhT tissues 205 
- publication of the study 206 
7. Chemicals Selection  207 
7.1. Chemicals Selection Group (CSG)  208 
The CSG is composed of the following members: 209 
Tom Cole (ECVAM; coordinator) 210 
João Barroso (ECVAM) 211 
Chantra Eskes (independent scientist) 212 
William Stokes (NICEATM) 213 
Amanda Cockshott (HSE; UK Competent Authority) 214 
Betty Hakkert (RIVM; NL Competent Authority) 215 
 216 
The roles and responsibilities of the CSG are shown in Figure 1. 217 
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The members of Competent Authorities (Amanda Cockshott and Betty Hakkert) will give support 218 
in reviewing in vivo Draize eye irritation reports on CosIng ingredients provided by DG SANCO. 219 
In the framework of the International Cooperation on Alternative Test Methods (ICATM), liaisons 220 
from NICEATM, ICCVAM, JaCVAM and Health Canada are invited to propose eligible test 221 
chemicals for selection, supported by quality assured in vivo Draize eye irritation data. 222 
7.2. Chemicals selection 223 
A principal criterion for selection of test chemicals is availability of supporting complete and 224 
quality assured in vivo Draize eye irritation data, for comparative evaluation of in vitro method 225 
predictive capacity. Complete in vivo Draize eye irritation data sets comprise severity and duration 226 
of ocular toxicity effects, registered over a 21 day observation period as irritation scores for 227 
corneal opacity, iritis and conjunctival chemosis/redness. Eligibility of test chemicals will be 228 
confirmed by compilation of in vivo Draize eye irritation data into a customised Excel template 229 
where algorithms generate systematic assignment of eye irritation EU DSD, UN GHS / EU CLP 230 
and US EPA classifications. 231 
Intending to challenge performance of the in vitro tissue models, diverse chemicals will be sought 232 
that have not been previously tested during protocol R&D, optimisation and pre-validation. 233 
Therefore, in shortlisting chemicals from recognised sources (e.g., ECETOC, TSCA, ZEBET, 234 
NIHS Japan, EPA, etc.) those chemicals reported in the original test submissions will be avoided. 235 
One potential source for screening eligible chemicals which will be considered by the CSG is the 236 
official European Commission inventory of cosmetic ingredients (CosIng). CosIng is supported by 237 
consolidated documentation (opinions) issued by the Scientific Committee on Consumer Safety 238 
(SCCS) with references to confidential in vivo Draize eye irritation studies archived by DG-239 
SANCO. In collaboration with SCCS and DG-SANCO, in vivo Draize eye irritation data on 240 
CosIng chemicals will be reviewed, and sample material availability determined. For eligible 241 
chemicals, in vivo Draize eye irritation study sponsors will be requested to authorise use and 242 
eventual publication of eye irritation data and, in cases of proprietary production, to supply sample 243 
material for in vitro assay. 244 
Proprietary new substances notified under Directive 67/548/EEC present another unique potential 245 
source, qualified by in vivo Draize eye irritation studies compliant with official guidelines and 246 
reviewed by Competent Authorities. Notification files (with summary in vivo Draize eye irritation 247 
data) archived in a confidential new chemicals database (NCD) accessible to authorised European 248 
Commission and Competent Authority personnel in the CSG, allow shortlisting of eligible 249 
candidates according to the notifier/producer. Under the auspices of the European Partnership for 250 
Alterative Approaches to Animal Testing (EPAA) affiliated companies will be invited to 251 
collaborate in determining availability of sample material, with release of supporting in vivo 252 
Draize eye irritation study reports. Initiative within cooperative companies to propose additional 253 
and/or alternative chemicals would also be welcomed. 254 
A sample size calculation by the ECVAM biostatistician and the TNO biostatistician has shown 255 
that 104 test chemicals will be required for this validation study. 256 
Ideally, chemical selection should achieve a balanced set of (i) irritancy (UN GHS/EU CLP 257 
categories 1 and 2 versus no category); (ii) physical state (liquids versus solids); and (iii) EPRA 258 
reactivity (reactive versus non-reactive). Acknowledging practicality of achieving a perfectly 259 
balanced set covering all three conditions, the VMG agreed the following limits: (i) an overall 260 
50±5% split of UN GHS/EU CLP categories 1 and 2 versus no category, with a 50/50 split 261 
between category 1 and category 2, including adequate representation of UN GHS sub-categories 262 
2A and 2B; (ii) an overall 50±10% split of solids versus liquids; and (iii) an overall 50±15% split 263 
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of reactive versus non-reactive chemicals (based on EPRA analyses). Similarly, the selection 264 
would aim for an even distribution of physical state (50±10% split of liquids versus solids) and 265 
EPRA reactivity (50±15% split of reactive versus non-reactive) among each irritancy sub-group 266 
(no category, category 2B, category 2A and category 1).  267 
Significantly, since EPRA reactivity is not known in advance, the parameter cannot be applied as 268 
an eligibility criterion a priori. Thus, the VMG agreed to a wider limit of acceptance (50±15%) for 269 
the proportion of reactive versus non-reactive chemicals. In event of EPRA results demonstrating 270 
significant bias in reactivity distribution, this limit would have to be reconsidered. 271 
The chemical selection would also aim for representation of a range of ocular toxicity effects, 272 
evident from distributions and persistence of irritation scores. 273 
Final approval of the test chemicals proposed by the CSG is the responsibility of the core VMG. 274 
Respecting non-disclosure of chemical identities to the test facilities, the VMG lead laboratory 275 
representatives will not participate in the selection process. 276 
The VMG recognises that commercial availability of selected test chemicals would facilitate future 277 
identification of performance standard reference chemicals, relevant to similar method catch-up 278 
studies (Performance Standards-based validation). Therefore, the CSG will limit the selection of 279 
proprietary chemicals and will aim at having at least ⅔ of commercially available chemicals (~70 280 
chemicals) in their final chemical selection (at least 104 test chemicals), which present a balanced 281 
distribution of irritancy, physical state and reactivity similar to the overall set of selected test 282 
chemicals (see above). As such, ample scope for establishing a robust set of reference chemicals 283 
upon completion of EIVS shall be ensured. 284 
8. Chemical Acquisition, Coding and Distribution 285 
Independent coding and distribution of test chemicals will be contracted out by the sponsor 286 
COLIPA to TNO. TNO is certified according to ISO 9001 and GLP, and has proven experience of 287 
reliable services. TNO will purchase, code and supply existing chemicals, including cosmetic 288 
ingredients from the CosIng inventory. The CSG coordinator will ask companies producing new 289 
chemicals to send samples directly to TNO for coding and distribution. All test chemicals will be 290 
randomly coded. Each test chemical will have a code that is unique for each laboratory. The same 291 
code will be used for the SkinEthic
TM
 HCE SE and for the SkinEthic
TM
 HCE LE assays but 292 
otherwise distinct codes will also be used for each test method/assay (i.e., EpiOcular
TM
 EIT, 293 
SkinEthic
TM
 HCE SE/LE and EPRA) that is run in the same laboratory. The codes will be 294 
generated and provided by the TNO biostatistician. Expiry dates will be provided for all test 295 
chemicals. Furthermore, when available, a single Molecular Weight and a single purity for each 296 
coded test chemical will be provided to the laboratories performing the EPRA to allow preparation 297 
of Molar solutions, as required by the EPRA Protocol. This includes pure substances and mixtures. 298 
For mixtures, the single purity will be determined by the sum of the proportion of its components 299 
(excluding water), while the single Molecular Weight will be determined by considering the 300 
individual Molecular Weights of each component in the mixture (excluding water) and their 301 
individual proportions. In exceptional cases (e.g., complex mixtures or polymers) Molecular 302 
Weights and exact proportions of components may not be available. 303 
Personnel responsible for chemical acquisition, coding and distribution shall be independent from 304 
those conducting the EPRA for EIVS. 305 
306 
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9. Receipt and Handling of Chemicals 307 
Coded test chemicals as well as a health and safety information package will be dispatched to the 308 
Safety Officer of each participating laboratory (see sections 10.1-10.3 and 11.4) in appropriate 309 
packaging, compliant with relevant regulatory requirements. The participating laboratories shall be 310 
notified by TNO when the test chemicals are shipped, shall make proper provision for their 311 
receipt, and promptly acknowledge that they have been received. Upon receipt at the laboratory, 312 
the test chemicals shall be stored in appropriate storage conditions as indicated in the unsealed 313 
accompanying documentation and must be stored for at least six months following submission of 314 
the final biostatistical report to the VMG. 315 
The health and safety information package will include a sealed envelope for each test chemical 316 
identified by chemical code. Each envelope will contain a MSDS and a certificate of analysis for 317 
the respective test chemical. A sealed envelope shall be opened at the laboratory only in an 318 
emergency/need-to-know situation. At the end of EIVS, the Safety Officer shall return the health 319 
and safety information package with all unopened envelopes to the VMG (Logistics Coordinator). 320 
If a sealed envelope from the health and safety information package is opened by the laboratory, 321 
the Safety Officer shall immediately notify the VMG designated contact, i.e. the Logistics 322 
Coordinator (Jan Lammers, TNO). 323 
The Study Director of each laboratory (see sections 10.1-10.3 and 11.1) shall receive essential 324 
information about the test chemicals (e.g. storage instructions). Upon receipt, each laboratory must 325 
complete and return the Test Chemical Receipt Report (Annex I). 326 
Appropriate routine safety procedures shall be followed in handling the test chemicals unless 327 
otherwise specified in the unsealed documentation supplied at the time of chemical distribution. 328 
Laboratory personnel shall be instructed to treat all coded test chemicals as very hazardous and to 329 
dispose of laboratory waste as toxic waste. 330 
10. Participating Laboratories 331 
The laboratories participating in the study are defined as shown in Figure 1. The specific 332 
obligations and responsibilities of the participating laboratories will be specified in contracts 333 
between the sponsor COLIPA and the laboratories. These include, but are not limited to, the 334 
adherence to this project plan throughout the study, the adherence to the test method protocol, the 335 
adherence to the work program, assuring compliance with GLP-like principles, specifying and 336 
applying proper Quality Assurance procedures, and meeting the data submission deadlines. The 337 
participating laboratories shall have competence in performing the test method(s) and shall provide 338 
competent personnel, adequate facilities, equipment, supplies, and proper health and safety 339 





 HCE SE/LE and EPRA, and for providing training to the technical 341 
staff of the other testing facilities. The contracts between COLIPA and the laboratories should also 342 
clarify the ownership of results and the publication procedures. 343 
The participating laboratories are allowed to freely communicate and meet during the training and 344 
transfer phases of EIVS. Such meetings will be organized by the lead laboratories and can occur 345 
without a formal approval by the VMG. However, during the testing phase, the participating 346 
laboratories and the personnel responsible for providing training on the test methods, will no 347 
longer contact each other regarding this validation study without the previous knowledge and 348 
approval by the VMG. All VMG approved meetings or other forms of communication between the 349 
participating laboratories during the testing phase will be organized by the Logistics Coordinator 350 
in collaboration with the lead laboratories. 351 
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10.1. Cys/Lys EPRA 352 
Three laboratories will participate in EIVS for testing with the EPRA. These are: 353 
 Lead laboratory – L’Oréal 354 
o Study Director: Nathalie Alépée 355 
o Safety Officer: Joan Eilstein 356 
 Laboratory 1 – TNO 357 
o Study Director: Brigitte Buscher 358 
o Safety Officer: Hans Ram 359 
 Laboratory 2 – CARDAM 360 
o Study Director: Griet Jacobs 361 
o Safety Officer: Frank Vander Plaetse / Katrien Smits 362 
10.2. EpiOcular
TM
 EIT 363 
Three laboratories will participate in EIVS for testing with the EpiOcular
TM
 EIT. These are: 364 
 Lead laboratory – Beiersdorf 365 
o Study Director: Uwe Pfannenbecker 366 
o Safety Officer: Peter Klaws 367 
 Laboratory 2 – Harlan Laboratories Ltd. (UK) 368 
o Study Director: Andrew Whittingham 369 
o Safety Officer: Christine Cauldwell 370 
 Laboratory 3 – IIVS 371 
o Study Director: Hans Raabe 372 
o Safety Officer: Nathan Wilt 373 
A reserve laboratory is also identified as Pierre-Fabre (Contact Person: Sandrine Bessou-Touya) 374 
10.3. SkinEthic
TM
 HCE SE/LE 375 
Three laboratories will participate in EIVS for for testing with the SkinEthic
TM
 HCE SE/LE. These 376 
are: 377 
 Lead laboratory – L’Oréal 378 
o Study Director: Nathalie Alépée 379 
o Safety Officer: Samuel Blond 380 
 Laboratory 2 – CARDAM 381 
o Study Director: An van Rompay 382 
o Safety Officer: Frank Vander Plaetse / An Jacobs 383 
 Laboratory 3 – CeeTox Inc. 384 
o Study Director: Colleen Toole 385 
o Safety Officer: Karen Rutherford 386 
A reserve laboratory is to be identified. 387 
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11. Laboratory Personnel 388 
11.1. Study Directors 389 
Each participating laboratory shall appoint a Study Director (see sections 10.1-10.3), a scientist of 390 
appropriate education, training, and experience in the field. The Study Director represents the 391 
single point of study control with ultimate responsibility for the overall technical conduct of the 392 
study, the documentation and reporting of the results, as well as GLP adherence or adherence to 393 
the minimum quality requirements (see section 14). 394 
The Study Director is responsible for collecting the data of his/her laboratory and to send them to 395 
the Logistics Coordinator of the study (to be forwarded to the TNO biostatistician) according to 396 
the timelines established in the Project Plan (see section 17). 397 
The Study Directors are also responsible for sending timely Study Reports to the contact person of 398 
the VMG, i.e. the Logistics Coordinator, who will monitor the progress of the study. Such reports 399 
should include all relevant experimental data as well as all deviations from the Project Plan and 400 
Test Method protocols. 401 
The study directors will be the primary contact point for the communications between the VMG 402 
and the testing facilities unless otherwise requested. 403 
11.2. Quality Assurance (QA) Officers 404 
For participating laboratories that are GLP compliant the Quality Assurance Officer shall assure 405 
conformity with GLP requirements for all aspects of the study (facilities, equipment, personnel, 406 
methods, practices, records, controls, SOPs, Test Method protocol, final reports (for data 407 
integrity), and archives). The Quality Assurance Officer is entirely separate from and independent 408 
of the personnel engaged in the direction and conduct of the study. 409 
Participating laboratories that are not GLP compliant, shall appoint an individual to assure that all 410 
records, documents, raw data and reports are available to the VMG if an inspection is requested, 411 
and ensure that the quality assurance provisions detailed in the section 14 (see below) have been 412 
implemented. 413 
11.3. Experimental team 414 




 HCE SE/LE and EPRA requires personnel 415 
trained and competent in the specific techniques and general laboratory procedures. Each 416 
individual engaged in the conduct of, or responsible for, the supervision of a validation study shall 417 
have education, training, and experience, or combination thereof, to enable that individual to 418 
perform the assigned duties. 419 
11.4. Safety Officers 420 
A designated Safety Officer (not otherwise involved in the actual conduct of the validation study) 421 
at each participating laboratory (see sections 10.1-10.3) will receive the blinded (coded) test 422 
chemicals and shall transfer the test chemicals to the responsible person of the laboratory. Sealed 423 
Material Safety Data Sheets (MSDSs) will accompany the test chemicals and the Safety Officer 424 
shall retain the package until the completion of EIVS. Additional sealed MSDSs can be sent to the 425 
testing facilities upon request of the Safety Officer if this information needs to be kept in more 426 
than one location. At the end of the validation study, the Safety Officer shall return the unopened 427 
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packages to the Logistics Coordinator of the study. If any laboratory personnel should open the 428 
packages at any time during the validation study, the Safety Officer shall promptly notify the 429 
VMG through the Logistics Coordinator (Jan Lammers, TNO). 430 
12. Study Design 431 
12.1. Eye irritation Peptide Reactivity Assay (“chemical reactivity”) 432 
Chemical reactivity is defined in this validation study as the electrophilic potential to react with 433 
cysteine or lysine containing peptides. 434 
The lead laboratory for the Cysteine/Lysine Eye Irritation Peptide Reactivity Assay (EPRA) is 435 
L’Oréal. Training of the other participating laboratories (TNO and CARDAM) in conducting the 436 
EPRA shall be provided by the test method developer (Procter & Gamble). The lead laboratory in 437 
collaboration with the test method developer will be responsible for issuing a final test method 438 
protocol. Upon completion of the training phase, participating laboratories shall test 5-10 test 439 
chemicals to demonstrate transferability of the assay and to confirm test method protocol 440 
adequacy. Importantly, training of TNO and CARDAM in conducting the EPRA and their 441 
respective transferability studies will not occur at the same time during EIVS because TNO will be 442 
involved in testing for chemical selection and for reliability assessment while CARDAM will only 443 
do testing for reliability assessment (see below). The trained participating laboratories will be 444 
responsible for issuing training and transfer reports upon completion of the transferability study. 445 
The results of the training phase and of the transferability study of a laboratory will be reviewed 446 
and approved by the VMG before that laboratory progresses with testing for EIVS (testing phase). 447 
If the transferability data do not meet test acceptance criteria, the VMG will work with the 448 
participating laboratory and the lead laboratory to identify the problems and make corrections 449 
where needed.  450 
In a first stage of the EIVS testing phase, all eligible chemicals identified by the CSG will have 451 
their chemical reactivity determined based on the EPRA, in a blind study in a single laboratory 452 
(TNO), with a single test consisting of three replicate measurements. Since chemicals found 453 
eligible by the CSG will not all become available for EPRA testing at TNO at the same time (due 454 
to differences in the time required to gain access to in vivo Draize eye irritation study reports for 455 
different chemicals, and to differences in the time required to obtain commercially available and 456 
proprietary chemical samples), the selection of a final test chemical set will be phased, with 457 
subsets of 30-50 test chemicals being selected by the CSG in different stages, as the data from the 458 
EPRA analysis becomes available, and until the final amount of at least 104 test chemicals is 459 
reached. These chemical subsets shall be as balanced as possible considering the criteria described 460 
in section 7.2 (with some flexibility allowed) and, upon approval by the core VMG, they will be 461 
distributed to the participating laboratories for viability assessment. Importantly, the total chemical 462 
set of at least 104 test chemicals (considering all selected subsets) shall be well balanced and meet 463 
all the criteria defined in section 7.2. 464 
Upon completion of the viability assessment study, a preliminary evaluation of the usefulness of 465 
the SkinEthic
TM
 HCE test strategy composed of the EPRA, the SkinEthic
TM
 HCE SE and the 466 
SkinEthic
TM
 HCE LE assays will be performed using the reactivity data obtained by TNO for all 467 
the selected test chemicals (at least 104) and the viability data obtained with SkinEthic
TM
 HCE SE 468 
and SkinEthic
TM
 HCE LE for the same test chemicals. If by combining the three assays in a test 469 
strategy a better predictive capacity is obtained as compared to the SkinEthic
TM
 HCE SE or the 470 
SkinEthic
TM
 HCE LE assays alone, chemical reactivity data will be obtained for a subset of the full 471 
validation set, in three laboratories (L’Oréal, TNO and CARDAM), in a second step to assess the 472 
reliability of the EPRA. Each of these three laboratories will test each test chemical in this subset 473 
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in three independent tests (performed in separate runs) consisting of three replicate measurements 474 
each, in order to strictly determine reproducibility (WLR and BLR) of the EPRA. TNO, as one of 475 
the three laboratories, will be testing these chemicals in three new independent tests (performed in 476 
separate runs). 477 
The definitive number and characteristics of the chemicals to be tested for reliability assessment of 478 
the EPRA will be decided on later by the VMG with the help of statistical power analysis 479 
performed by the biostatisticians, but at least 20 chemicals and up to the maximum number of 480 
chemicals that can be tested in two separate runs for one peptide will be tested. When selecting the 481 
subset of test chemicals to assess the reliability of the EPRA, preference will be given to test 482 
chemicals that classify differently in SkinEthic™ HCE SE and SkinEthic™ HCE LE, since this 483 
would allow the use of these data for calculating the predictive capacity of the SkinEthic
TM
 HCE 484 
test strategy. However, if all of these cannot be included in the selection, the data of a single test 485 
acquired by TNO for the selected test chemicals (at least 104) will be used to determine the 486 
predictive capacity of the proposed SkinEthic
TM
 HCE test strategy, and other chemicals may be 487 
chosen for reliability assessment. 488 
12.2. Biological assays 489 
The lead laboratories for the EpiOcular
TM
 EIT and the SkinEthic
TM
 HCE SE/LE are Beiersdorf and 490 
L’Oréal, respectively. Training of the participating laboratories in conducting the EpiOcularTM EIT 491 
or the SkinEthic
TM
 HCE SE/LE assays shall be provided by the respective test method developer 492 
(MatTek Corporation for EpiOcular
TM
 EIT and L’Oréal for SkinEthicTM HCE SE/LE). The lead 493 
laboratories in collaboration with the test method developers will be responsible for issuing final 494 
test method protocols. Upon completion of the training phase, participating laboratories shall test 495 
5-10 chemicals to demonstrate transferability of the assay and to confirm test method protocol 496 
adequacy. The test method developers in collaboration with the participating laboratories will be 497 
responsible for issuing training and transfer reports upon completion of the transferability studies. 498 
The results of the training phase and of the transferability studies for a particular test method will 499 
be reviewed and approved by the VMG before progression of the study for that test method. If the 500 
transferability data do not meet test acceptance criteria, the VMG will work with the participating 501 
laboratory and the lead laboratory to identify the problems and make corrections where needed. 502 
In the testing phase of EIVS, each of the test chemicals in the final chemical selection set (at least 503 




 HCE SE and 504 
SkinEthic
TM
 HCE LE) in at least three independent tests (using different tissue batches and 505 
performed in separate runs) by each of three independent laboratories (see Document “Guidance 506 
on Study Conduct and Test Method Performance Criteria for EIVS”). Thus, each chemical will be 507 
tested with the two different exposure/post-treatment periods of the SkinEthic
TM
 HCE SE/LE 508 
protocol (10 min and 1 h + 16 h post-treatment), and with one of the two EpiOcular
TM
 EIT 509 
exposure procedures depending on the test chemical being solid or liquid (30 min + 120 min post-510 
treatment, or 90 min + 18 h post-treatment). Importantly, the three laboratories participating in the 511 
validation of EpiOcular
TM
 EIT will not be instructed on the physical state of the test chemicals. 512 
Therefore, each laboratory participating in the validation of the EpiOcular
TM
 EIT shall decide on 513 
the physical state of each test chemical and the appropriate exposure procedure to use. Finally, 514 
each control and test chemical included in one run will be tested in two (EpiOcular
TM
 EIT) or three 515 
(SkinEthic
TM
 HCE SE/LE) replicate tissues. 516 
The EIVS RhT testing phase will be conducted in two or more consecutive phases to allow for 517 
periodic opportunities to evaluate the frequency of technical errors and any other problems that 518 
might occur during testing. At least at the end of each RhT testing phase the Study Directors will 519 
forward the data acquired by their laboratories to the Logistics Coordinator after internal quality 520 
check (see Table 2 in section 17) who will provide it to the TNO biostatistician for immediate 521 
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preliminary analyses of Within Laboratory Reproducibility (WLR) and compliance with Study 522 
Quality criteria (number of complete/incomplete test sequences as described in the Performance 523 
Criteria). Once completed, these phased statistical analyses and their conclusions will be provided 524 
to the core VMG who will review them and determine if modifications to the protocol and/or study 525 
plan are warranted/appropriate in order to avoid future occurrences of identified issues. All 526 
participating laboratories should adhere to these testing phases and ideally complete testing of all 527 
chemicals in one phase (by obtaining three qualified tests per chemical) before testing chemicals 528 
of following phases. However, for practical reasons and in order to minimise the cost of the study, 529 
the participating laboratories may delay the testing of MTT reducers and/or colorants in order to 530 
test them all together in a later testing phase, provided delayed chemicals will not expire. 531 
Moreover, chemicals with short expiry dates included in later testing phases of the study may be 532 
moved to an earlier phase to avoid testing after the expiration date. 533 
13. Data Collection, Handling, and Analysis 534 
The Logistics Coordinator will collect the data from each participating laboratory via the Study 535 
Directors (see section 11.1) at least at the end of each RhT testing phase (see section 12.2 and 536 
Table 2 in section 17) and will forward it to the TNO biostatistician. The TNO biostatistician will 537 
organise the data in specific data collection software (MS EXCEL spreadsheets). The collected 538 
data shall be circulated to every participating laboratory for a quality check. At the end of each 539 
RhT testing phase a preliminary analysis of WLR and compliance with Study Quality criteria (see 540 
above) will be performed without decoding the test chemicals (to avoid breaking the code before 541 
completion of the study). Upon completion of the RhT testing phases by all participating 542 
laboratories and preliminary “blind” determination of WLR and Study Quality criteria for each 543 
laboratory, test chemicals will be decoded and the TNO biostatistician will do a complete 544 
statistical analysis of the data and provide a final biostatistical report to the VMG. The ECVAM 545 
biostatistician will do a quality control of the processes of data collection, handling and analysis, 546 
as well as of the final biostatistical report. The data management procedures and statistical tools 547 
that will be used for data analysis and included in the final biostatistical report will be described in 548 
a Statistical Analyses and Reporting Plan. This Plan shall be developed by the ECVAM and TNO 549 
biostatisticians before the end of the experimental phase of the study and shall be approved by the 550 
VMG before the biostatistical analyses begin. 551 
Based on final data analysis, the VMG reserves the possibility to identify the most suitable test 552 
strategies for the identification of non classified chemicals from classified ones. 553 
The VMG has the responsibility of producing the final report and publication of the study. These 554 
will include the results of the EIVS and the VMG conclusions/recommendations on the outcome 555 
of the study. VMG conclusions/recommendations will be supported by the Performance Criteria 556 
defined by the VMG prior to initiation of the testing phase of EIVS. The draft statistical report and 557 
the draft validation study report shall be circulated to every participating laboratory for review and 558 
comments prior to finalisation. The VMG should review all comments received and make 559 
revisions if deemed appropriate. 560 
14. Quality Assurance, Good Laboratory Practice 561 
14.1. Laboratories 562 
Participating laboratories that are compliant with Good Laboratory Practices (GLP) will perform 563 
the studies in accordance with GLP standards (OECD, 1999). Non GLP-compliant laboratories 564 
shall use the OECD principles of GLP as guidelines for conducting the validation study. Any 565 
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deviations from these principles should be documented along with a discussion of their 566 
impact on the study results. 567 
It is considered that the following requirements (Balls M. et al., 1995) are essential for the mutual 568 
acceptance of information produced in the validation process: 569 
 Qualified personnel, and appropriate facilities, equipment and materials shall be available 570 
for the timely and proper conduct of the study 571 
 Records of the qualifications, training and experience, and a job description for each 572 
professional and technical individual involved in the study, shall be maintained. 573 
 For each study, an individual with appropriate qualifications, training and experience shall 574 
be appointed to be responsible for its overall conduct and for any report issued (Study 575 
Director, see section 11.1).  576 
 Instruments used for the generation of experimental data shall be inspected regularly, 577 
cleaned, maintained and calibrated according to established SOPs, if available, or to 578 
manufacturers' instructions. Records of these processes shall be kept, and made available 579 
for inspection on request. 580 
 Reagents shall be labelled, as appropriate, to indicate their source, identity, concentration 581 
and stability.  The labelling shall include the preparation and expiry dates, and specific 582 
storage conditions. 583 
 All data generated during a study shall be recorded directly, promptly and legibly by the 584 
individual(s) responsible.  These entries shall be attributable and dated. 585 
 All changes to data shall be identified with the date and the identity of the individual 586 
responsible, and a reason for the change shall be documented at the time. 587 
14.2. Tissue model suppliers 588 
According to OECD GLP Consensus Document No.5 “Compliance of Laboratory Suppliers with 589 
GLP Principles” the responsibility for the quality and fitness for use of equipment and materials 590 
rests entirely with the management of the test facility (OECD, 1999). 591 
The acceptability of equipment and materials in laboratories complying to GLP principles should 592 
therefore be guaranteed to any regulatory authority to whom studies are submitted. In some 593 
countries where GLP has been implemented, suppliers belong to national regulatory or voluntary 594 
accreditation schemes (for example, for laboratory animals) which can provide users with 595 
additional documentary evidence that they are using a test system of a defined quality. 596 
The audits on the RhT tissue production sites (MatTek Corporation and EpiSkin Laboratories) will 597 
be carried out by TNO and ECVAM, and will focus on the procedures established to guarantee a 598 
defined quality of the tissue models, as defined in the audit protocol previously approved by the 599 
VMG. 600 
15. Health and Safety 601 
Each laboratory shall conform to all applicable statutes in effect at the time of this validation 602 
study. The designated Safety Officer (see sections 10.1-10.3 and 11.4) shall be the point of contact 603 
for health and safety issues. 604 
16. Records and Archives 605 
At the end of EIVS, the original raw (if applicable; not possible for GLP compliant laboratories) 606 
and processed data or copies thereof shall be submitted to ECVAM and COLIPA for storing and 607 
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archiving. In addition, other records relevant to EIVS (instrument logs, calibration records, facility 608 
logs, etc.) should be made available for inspection upon request by the VMG. 609 
Raw and processed data or copies thereof (depending if the laboratory is or not GLP compliant) 610 
shall be stored and archived at the participating laboratory for at least five years after completion 611 
of EIVS. The data which are stored electronically shall be periodically copied, and backup files 612 
shall be produced and maintained. 613 
17. Timelines 614 
The following tables summarise the critical activities of the study and the estimated completion 615 
timelines. Timelines might need to be reviewed during the study. 616 
 617 
Table 1. Study timelines 618 
Critical activities Timing (*finalisation) 
Chemical eligibility / availability from suppliers 





o 29 October 2010 
o VMG III 3-4 June 2009* 
o 29 October 2010 
o 29 October 2010 
Project Plan 
o Finalisation 
o Approval by VMG  
 
o VMG VII 28-29 September 2010 
o 1 December 2010 
Guidance on Study Conduct and Test Method 
Performance Criteria for EIVS 
o Finalisation 
o Approval by VMG 
 
 
o VMG VII 28-29 September 2010 
o 1 December 2010 
Study design approval by VMG o 30 July 2009* 
EPRA 
o Cut-off for EPRA  
o EPRA updated/final Protocol approval 
 
 
o EPRA study plan 
o # and identity of chemicals tested for 
reproducibility assessment of EPRA 
EPRA testing at TNO for chemicals selection 
o Training  
o Transferability study  
o Beginning of testing 
EPRA reliability assessment 
o Training  
o Transferability study 
o Beginning of testing 
 
o VMG III 3-4 June 2009* 
o 18 December 2009* (slightly 
revised and approved on VMG VII 
28-29 September 2010) 
o VMG V 24-25 November 2009* 
o T.b.d. by July 2011 
 
 
o 3-4 June 2009* 
o 13 July-16 October 2009* 
o March 2010 
 
o T.b.d. by March 2011 
o T.b.d. by March 2011 
o T.b.d. by July 2011 
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SkinEthic
TM
 HCE SE/LE 
o Performance under UN GHS classification  
(TST data) 
o QA audit on RhT production site 
o Training 
o Transferability study 
o SkinEthicTM HCE SE/LE final Protocol 
approval 
o Beginning of testing (see Table 2) 
 
o VMG III 3-4 June 2009* 
 
o 19 March 2010* 
o 19-29 January 2010* 
o 8 February-9 April 2010* 
o 17 June 2010* 
 




o QA audit on RhT production site 
o Insert to be used 
o Cut-off to be used 
o Training 
o Transferability study 
o Final Protocol approval 
o Beginning of testing (see Table 2) 
 
o 26 May 2010* 
o 9 September 2010* 
o 9 September 2010* 
o October-November 2010 
o November 2010  
o December 2010 
o January 2011 
CSG final chemical selection and Core VMG 
approval 
o 1st set (34 test chemicals) 
o 2nd set (46 test chemicals) 
o 3rd and final set (24-27 test chemicals) 
 
 
o 10 June 2010* 
o 8 September 2010* 
o 10 December 2010 
Chemical coding and distribution June 2010-January 2011 
Participating laboratory contracts December 2009-January 2011 
Contract with SkinEthic Laboratories for the supply 
of SkinEthic
TM
 HCE tissues 
February 2010 





Delivery of final statistical report (biostatistician) 
Within 2 months after completion of testing 
phase 
Delivery of final study report (VMG) 
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34 test chemicals 
(selected on 10/06/2010) 
Starting date: 21 June 2010 
Finishing date: February 2011 
Data collection by Study Directors and 
dispatch to Logistics Coordinator: 
by February 2011 
~40 test chemicals 
(½ liquids, ½ solids) 
Starting date: December 2010 
Finishing date: March 2011 
Data collection by Study Directors and 
dispatch to Logistics Coordinator: 




46 test chemicals 
(selected on 08/09/2010) 
Starting date: October 2010 
Finishing date: May 2011 
Data collection by Study Directors and 
dispatch to Logistics Coordinator: 
by May 2011 
~40 test chemicals 
Starting date: March 2011 
Finishing date: May 2011 
Data collection by Study Directors and 
dispatch to Logistics Coordinator: 




24-27 test chemicals 
Starting date: March 2011 
Finishing date: July 2011 
Data collection by Study Directors and 
dispatch to Logistics Coordinator: 
by July 2011 
24-27 test chemicals 
Starting date: May 2011 
Finishing date: July 2011 
Data collection by Study Directors and 
dispatch to Logistics Coordinator: 
by July 2011 
 622 
18. Documents and Data 623 
1. ECVAM and/or the Logistics Coordinator, after consultation with the VMG, supplies EIVS 624 
documentation 'in confidence' to participating laboratories. Unless and until ECVAM places these 625 
documents in the public domain, they may not be published or communicated/distributed to other 626 
third parties without the knowledge and consent of ECVAM after consultation with the VMG. 627 
2. All study data generated by the contracted laboratories are the property of the European 628 
Commission/ECVAM and COLIPA. These data may not be published, communicated or 629 
circulated/distributed to third parties without the knowledge and consent of the European 630 
Commission/ECVAM and COLIPA, and the knowledge of the VMG. 631 
4. ECVAM and COLIPA reserve the right to be the first to promptly publish and communicate the 632 
outcomes of the validation process. 633 
634 
 EUROPEAN COMMISSION 
JOINT RESEARCH CENTRE 
 
 
Institute for Health and Consumer Protection 
European Centre for the Validation of Alternative Methods (ECVAM) 
 
ECVAM PROJECT PLAN FOR EIVS  Page 19 of 24 
19. References 635 
Balls, M., Blaauboer, B.J., Fentem, J.H., Bruner, L., Combes, R.D., Ekwall, B., Fielder, R.J., Guillouzo, A., 636 
Lewis, R.W., Lovell, D.P., Reinhardt, C.A., Repetto, G., Sladowski, D., Spielmann, H. and Zucco, F. (1995) 637 
Practical aspects of the validation of toxicity test procedures. ECVAM Workshop Report 5. ATLA 23, 129-638 
147. 639 
European Commission (EC) (2008a) REGULATION (EC) No 440/2008 OF THE EUROPEAN 640 
PARLIAMENT AND OF THE COUNCIL of 30 May 2008 laying down test methods pursuant to 641 
Regulation (EC) No 1907/2006 of the European Parliament and of the Council on the Registration, 642 
Evaluation, Authorisation and Restriction of Chemicals (REACH). Official Journal of the European Union 643 
L142, 1-739.  644 
European Commission (EC) (2008b) REGULATION (EC) No 1272/2008 OF THE EUROPEAN 645 
PARLIAMENT AND OF THE COUNCIL of 16 December 2008 on classification, labelling and packaging 646 
of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending 647 
Regulation (EC) No 1907/2006. Official Journal of the European Union L353, 1-1355.  648 
European Commission (EC) (2004) Directive 2004/73/EC of 29 April 2004 adapting to technical progress 649 
for the 29th time Council Directive 67/548/EEC on the approximation of laws, regulations and 650 
administrative provisions relating to the classification, packaging and labelling of dangerous substances. 651 
Official Journal of the European Union L152, 1-316. 652 
Hartung, T., Bremer, S., Casati, S., Coecke, S., Corvi, R., Fortaner, S., Gribaldo, L., Halder, M., Hoffmann, 653 
S., Roi A.J., Prieto, P., Sabbioni, E., Scott, L., Worth, A. and  Zuang. V. (2004) A modular approach to the 654 
ECVAM principles on test validity.  ATLA 32, 467-472. 655 
Nguyen, D.H., Beuerman, R.W., De Wever, B. and Rosdy, M. (2003) Three-dimensional construct of the 656 
human corneal epithelium for in vitro toxicology. In Alternatives Toxicological Methods, edited by Salem, 657 
H.and Katz S.A., CRC press, 47-159. 658 
OECD (1999) OECD Series on Principles of Good Laboratory Practice and Compliance Monitoring No. 5. 659 
Compliance of Laboratory  Suppliers with GLP Principles. Paris, France: Organisation for Economic 660 
Cooperation and Development. Available at: [http://www.oecd.org/env/testguidelines]. 661 
OECD (2002) Test Guideline 405. OECD Guideline for the Testing of Chemicals: Acute Eye 662 
Irritation/Corrosion. Paris, France: Organisation for Economic Cooperation and Development. Available at: 663 
[http://www.oecd.org/env/testguidelines]. 664 
OECD (2005). OECD Series on Testing and Assessment No. 34. Guidance Document on the Validation and 665 
International Acceptance of New or Updated Test Methods for Hazard Assessment. Paris, France: 666 
Organisation for Economic Cooperation and Development. Available at: 667 
[http://www.oecd.org/env/testguidelines]. 668 
Scott, L., Eskes, C., Hoffmann, S., Adriaens, E., Alepée, N., Bufo, M., Clothier, R., Facchini, D., Faller, C., 669 
Guest, R., Harbell, J., Hartung, T., Kamp, H., Varlet, B.L., Meloni, M., McNamee, P., Osborne, R., Pape, 670 
W., Pfannenbecker, U., Prinsen, M., Seaman, C., Spielmann, H., Stokes, W., Trouba, K., Berghe, C.V., 671 
Goethem, F.V., Vassallo, M., Vinardell, P., Zuang, V. (2010) A proposed eye irritation testing strategy to 672 
reduce and replace in vivo studies using Bottom-Up and Top-Down approaches. Toxicol In Vitro 24, 1-9. 673 
United Nations (UN) (2007) Globally Harmonized System of Classification and Labelling of Chemicals 674 
(GHS), Second revised edition, UN New York, USA and Geneva, Switzerland. Available at: 675 
[http://www.unece.org/trans/danger/publi/ghs/ghs_rev02/02files_e.html]. 676 
 EUROPEAN COMMISSION 
JOINT RESEARCH CENTRE 
 
 
Institute for Health and Consumer Protection 
European Centre for the Validation of Alternative Methods (ECVAM) 
 
ECVAM PROJECT PLAN FOR EIVS  Page 20 of 24 
Annex I - Test Chemicals Receipt Report Template 677 
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Testing Facility: 679 
 680 
Test Chemicals Received by: 681 
 682 
Test Chemicals Receipt Date: 683 
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1 Introduction
The main objective of this report is to provide statistical analysis of the data generated in the
second phase of the EpiOcularTM EIT validation trial, i.e. the evaluation of reproducibility
and predictive capacity of an optimised solids protocol. This second phase was performed in
the laboratory Beiersdorf with a set of 60 coded solid chemicals (see Table 1). The optimized
EpiOcularTM EIT Solids protocol is based on an amended Standard Operating Procedure
(SOP) Version 8.0, which includes an extended exposure time for solid test substances. Results
can be found in Sections 3 to 4.
EIVS# Code1 GHS CAS Name
28 B249 NC 118-82-1 4,4’-Methylene bis-(2,6-di-tert-butylphenol)
29 B267 NC 3234-85-3 Tetradecyl tetradecanoate
30 B204 NC 598-65-2 1,1-Dimethylguanidine sulphate
31 B298 NC 14075-53-7 Potassium tetrafluoroborate
32 B285 NC 84540-47-6 2,6-Dihydroxy-3,4-dimethylpyridine
33 B232 NC 23920-15-2 2,2’-[[4-[(2-Methoxyethyl)amino]-3-nitrophenyl]imino]bis-ethanol
34 B218 NC 3179-89-3 2,2’-[[3-Methyl-4-[(4-nitrophenyl)azo]phenyl]imino]bis-ethanol
35 B275 NC 1603-02-7 2,5,6-Triamino-4-pyrimidinol sulphate
36 B290 NC 101-20-2 1-(4-Chlorophenyl)-3-(3,4-dichlorophenyl) urea
37 B242 NC 61788-85-0 Polyethylene glycol (PEG-40) hydrogenated castor oil
38 B237 NC 103597-45-1 2,2’-Methylene-bis-(6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-tetramethylbutyl)phenol)
39 B274 NC 187393-00-6 2,2’-[6-(4-Methoxyphenyl)-1,3,5-triazine-2,4-diyl]bis[5-[(2-ethylhexyl)oxy]-phenol]
40 B287 NC 75150-29-7 Acrylamidopropyltrimonium chloride/acrylamide copolymer
41 B224 NC 88122-99-0 Tris(2-ethylhexyl)-4,4’,4”-(1,3,5-triazine-2,4,6-triyltriimino) tribenzoate
42 B246 NC 66170-10-3 Trisodium mono-(5-(1,2-dihydroxyethyl)-4-oxido-2-oxo-2,5-dihydro-furan-3-yl) phosphate
43 B245 NC 302776-68-7 Hexyl 2-(1-(diethylaminohydroxyphenyl)methanoyl) benzoate
44 B262 NC 231278-20-9 [3-Chloro-4-[(3-fluorobenzyl)oxy]phenyl](6-iodoquinazolin-4-yl)amine
45 B284 NC 72956-09-3 1-(9H-Carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]propan-2-ol
46 B283 NC 68610-92-4 Cellulose, 2-(2-hydroxy-3-(trimethylammonium)propoxy)ethyl ether chloride (91%)
47 B260 NC 120-14-9 3,4-Dimethoxy benzaldehyde
48 B243 NC 7631-90-5 Sodium hydrogensulphite
49 B266 NC 94-13-3 Propyl-4-hydroxybenzoate
50 B278 NC 144550-36-7 Iodosulfuron-methyl-sodium
51 B222 NC 33089-61-1 1,5-Di(2,4-dimethylphenyl)-3-methyl-1,3,5-triazapenta-1,4-diene
52 B205 NC 53112-28-0 2-Anilino-4,6-dimethylpyrimidine
53 B299 NC 153719-23-4 3-(2-Chloro-thiazol-5-ylmethyl)-5-methyl[1,3,5]oxadiazinan-4-ylidene-N-nitroamine
108 B634 NC 145701-23-1 Florasulam
109 B332 NC 82-66-6 Diphacinone
61 B221 2B 83-72-7 2-Hydroxy-1,4-naphthoquinone
62 B225 2B 104-36-9 1,4-Dibutoxy benzene
63 B231 2B 62-23-7 4-Nitrobenzoic acid
64 B228 2B 96568-04-6 Ethyl 2,6-dichloro-5-fluoro-beta-oxo-3-pyridine propionate
65 B253 2B 79-92-5 2,2-Dimethyl-3-methylenebicyclo [2.2.1] heptane
66 B226 2B 3926-62-3 Sodium chloroacetate
110 B451 2B 82657-04-3 Bifenthrin
73 B268 2A 1119-62-6 3,3’-Dithiopropionic acid
74 B282 2A 16867-03-1 2-Amino-3-hydroxy pyridine
75 B254 2A 532-32-1 Sodium benzoate
76 B201 2A 362525-73-3 6,7-Dihydro-2,3-dimethyl-imidazo[1,2-a]pyridin-8(5H)-one
77 B296 2A 189813-45-4 Methyl (2E)-[2-(chloromethyl)phenyl](methoxyimino) acetate
78 B271 2A 76855-69-1 (2R,3R)-3-((R)-1-(Tert-butyldimethylsiloxy)ethyl)-4-oxoazetidin-2-yl acetate
79 B235 2A 6484-52-2 Ammonium nitrate
111 B447 2A 619-66-9 4-Carboxybenzaldehyde
112 B608 2A 83-56-7 1,5-Naphthalenediol
113 B202 2A 74918-21-1 1,3-Bis-(2,4-diamnophenoxy)-propane tetrachloride
93 B250 1 110-03-2 2,5-Dimethyl-2,5-hexanediol
94 B213 1 143-07-7 Dodecanoic acid
95 B294 1 41253-21-8 1,2,4-Triazole sodium salt
96 B255 1 86-87-3 1-Naphthalene acetic acid
97 B291 1 62-76-0 Sodium oxalate
98* B252* 1 4430-25-5 4,4’-(4,5,6,7-Tetrabromo-3H-2,1-benzoxathiol-3-ylidene)bis[2,6-dibromophenol] S,S-dioxide
99 B214 1 2634-33-5 1,2-Benzisothiazol-3(2H)-one
100 B233 1 60372-77-2 Ethyl lauroyl arginate HCl
101 B281 1 97404-02-9 2-[(4-Aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride
102 B279 1 27344-41-8 Disodium 2,2’-([1,1’-biphenyl]-4,4’-diyldivinylene)bis(benzenesulphonate)
103 B244 1 2820-37-3 3,4-Dimethyl-1H-pyrazole
104 B207 1 171887-03-9 N-(2-Amino-4,6-dichloropyrimidin-5-yl) formamide
105 B261 1 54424-29-2 1,2-Dihydro-1,3,4,6-tetramethyl-2-oxo-pyrimidinium hydrogensulphate
114 B293 1 105812-81-5 3-piperidinemethanol, 4-(4-fluorophenyl)-1-methyl-, (3S,4R)
115 B276 1 65-85-0 Benzoic acid
EIVS#: chemicals selection number, Code1: code Beiersdorf under optimized protocol.
Table 1: Chemical Selection for Post-Optimisation Validation Activity for EpiOcularTM EIT solids prtocol.
To provide a more complete information about performance of the assay, the data obtained
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with the optimized EpiOcularTM EIT Solids protocol at Beiersdorf are integrated with data
obtained with the EpiOcularTM EIT Liquids protocol at three test facilities. Two classification
cut-off values 50% and 60% are considered for both solids and liquids protocols. Results can
be found in Section 5.
2 Note about chemicals
Out of 60 test chemicals, one chemical was excluded from final evaluation, i.e. chemical 98(de-
noted by asterix in Table 1), due to a too strong colour interference on the MTT assay.(strong
colorant)
Chemical 37 was originally selected by the EIVS VMG as being a solid. However, all
three laboratories participating in the core validation of theEpiOcularTM EIT independently
considered the chemical as being liquid due to its low melting point and testing during the
spring/summer period. This chemical was therefore tested during the core EIVS using the liq-
uid protocol of EpiOcularTM EIT. However, due to an oversight of the VMG, chemical 37 was
again shipped to Beiersdorf as a solid to be tested during the validation of the EpiOcularTM EIT
optimised solids protocol and because this time the testing occurred during the autumn/winter,
Beiersdorf confirmed the physical state of the chemical as being solid upon receipt and tested
it as such. Thus, chemical 37 ended up being tested in both the liquids and solids protocols
of EpiOcularTM EIT, somehow in agreement with its borderline physical state. The VMG
considered both sets of data as being valid and therefore the statistics analyses in this report
include both sets of data for this chemical (produced with the original liquids and the optimised
solids protocols). Nevertheless, the EpiOcularTM EIT predictive capacity was also calculated
considering only the optimised solids protocol data (excluding the liquids protocol data) in
accordance with the fact that this chemical had been tested in vivo as a solid and had been
originally considered by th VMG as a solid during chemicals selection for the study. The cor-
responding accuracy values are described in chapter 4.
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3 Reproducibility
The objective of this section is to compare final viabilities generated at Beiersdorf and MatTek
under optimized EpiOcularTM EIT Solids protocol. To guarantee comparability of the results,
the comparison is made on the common set of chemicals tested. Two sets of chemicals are used
for the comparison:
• Dataset 1. Set of 11 compounds provided by Cosmetics Europe to MatTek for opti-
mization of the EpiOcularTM EIT Solids protocol,
• Dataset 2. largest common set of compounds (20) used at Beiersdorf and MatTek under
optimized EpiOcularTM EIT Solids protocol.
The Dataset 2 contains Dataset 1 and additional chemicals that belong both to a) the set
of 60 chemicals tested at Beiersdorf and b) the set of 39 chemicals from an article by Kaluzhny
et al. (2011) tested at MatTek under optimized EpiOcularTM EIT Solids protocol.
3.1 Within laboratory reproducibility
The acceptance criterion for within laboratory reproducibility (WLR) is a minimum concor-
dance of classifications of 85%. The Table 2 reports the WLR statistics based on the data
generated under optimized EpiOcularTM EIT Solids protocol at Beiersdorf as well as the WLR
obtained in the validation of the original solids protocol by the three participating laboratories.
It can be seen that the optimised protocol provides similar (or even slightly better) WLR than
the original protocol.
50% cut-off 60% cut-off
optimized solids protocol BDF 93.2% (55/59) 96.6% (57/59)
original solids protocol
BDF 92.0% (46/50) 94.0% (47/50)
Harlan 90.2% (46/51) 90.2% (46/51)
IIVS 96.1% (49/51) 94.1% (48/51)
Total 92.8% (141/152) 92.8% (141/152)
Table 2: Within Laboratory Reproducibility (WLR) statistics for cut-off 50% and 60%.
3.2 Between Laboratory Reproducibility(BLR): Beiersdorf and MatTek labora-
tories
To calculate BLR, the final classification for each test chemical in each participating laboratory
is obtained by using the arithmetic mean value of viability over different qualified tests per-
formed. Using a 60% cut-off, the BLR (optimised solids protocol) for Dataset1 is 73% (8/11)
whereas 85% (17/20) for Dataset2. Identical BLR was obtained with the same set of chemicals
with the original protocol, although in this case the reproducibility is calculated for 3 labs while
only 2 for the optimised protocol. Nevertheless the acceptance criterion of BLR > 80% is met
in this dataset. See Tables 3-6 for detailed calculations.
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optimized protocol original protocol
EIVS # Code1 Code2 GHS MatTek Beiersdorf Beiersdorf Harlan IIVS
single mean single mean
35 B275 C011 NC NI NI NI NI I I NI I NI NI NI NI NI NI NI NI NI
37 B242 C002 NC NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
40 B287 C008 NC NI NI NI NI NI I NI NI I NI NI NI NI NI NI NI NI
42 B246 C004 NC I I I I I I I I NI NI NI NI NI NI NI NI NI
46 B283 C007 NC NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
62 B225 C001 2B NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
73 B268 C005 2A I NI I I I I I I NI NI NI NI NI NI NI NI NI
74 B282 C006 2A I I I I NI I I I NI NI NI NI NI NI NI NI NI
77 B296 C003 2A NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
78 B271 C010 2A NI I NI NI I I I NI NI NI NI NI NI NI NI NI
102 B279 C009 1 I I I I I I I I I NI NI I NI NI NI NI NI
WLR 82% (9/11) 64% (7/11) 82% (9/11) 91% (10/11) 100% (11/11)
BLR 82% (9/11) 91% (10/11)
EIVS #: chemicals selection number, Code1: code Beiersdorf under optimized protocol, Code2: Cosmetics Europe codes of 11
chemicals provided to MatTek for optimization
Table 3: Dataset1. Classification with a 50% cut-off.
optimized protocol original protocol
EIVS # Code1 Code2 GHS MatTek Beiersdorf Beiersdorf Harlan IIVS
single mean single mean
35 B275 C011 NC NI I NI NI I I I I NI NI NI NI NI NI NI NI NI
37 B242 C002 NC NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
40 B287 C008 NC NI NI NI NI NI I I I I I NI NI I NI NI NI NI
42 B246 C004 NC I I I I I I I I NI NI I I NI NI NI NI NI
46 B283 C007 NC NI NI NI NI NI I NI NI NI NI NI NI I NI NI NI I
62 B225 C001 2B NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
73 B268 C005 2A I I I I I I I I NI NI NI NI NI NI NI NI NI
74 B282 C006 2A I I I I I I I I NI NI NI NI NI NI NI NI NI
77 B296 C003 2A NI NI NI NI I I I I NI NI NI NI NI NI NI NI NI
78 B271 C010 2A I I I I I I I NI NI NI NI NI NI NI NI NI
102 B279 C009 1 I I I I I I I I I NI NI I I I NI NI NI
WLR 91% (10/11) 82% (9/11) 73% (8/11) 73% (8/11) 91% (10/11)
BLR 73% (8/11) 73% (8/11)
EIVS #: chemicals selection number, Code1: code Beiersdorf under optimized protocol, Code2: Cosmetics Europe codes of 11
chemicals provided to MatTek for optimization
Table 4: Dataset1. Classification with a 60% cut-off.
Looking at Table 4, there are 3 out of 8 chemicals(77, 40 and 35) in no cat GHS group
classified at Beiersdorf as I wheras at MatTek as NI. The underlying averaged viabilities are
quite different, 77: 57.1 vs 88.0, 40: 55.7 vs 72.7 and 35: 43.0 vs 80.8. (see Table 7)
7
optimized protocol original protocol
EIVS # Code1 Code2 GHS MatTek Beiersdorf Beiersdorf Harlan IIVS
single mean single mean
30 B204 NC I I I I I I I I NI I I I I I NI NI NI
31 B298 NC NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
35 B275 C011 NC NI NI NI NI I I NI I NI NI NI NI NI NI NI NI NI
37 B242 C002 NC NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
40 B287 C008 NC NI NI NI NI NI I NI NI I NI NI NI NI NI NI NI NI
42 B246 C004 NC I I I I I I I I NI NI NI NI NI NI NI NI NI
46 B283 C007 NC NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
49 B266 NC I I I I I I I I I I I I I I I I I I
62 B225 C001 2B NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
63 B231 2B I I I I I I I I I I NI I NI I I I
64 B228 2B I I I I I I I I I I I I I I I I
65 B253 2B I I I I I I I I NI NI NI I I NI NI I NI
66 B226 2B I I I I I I I I I I I I I I I I
73 B268 C005 2A I NI I I I I I I NI NI NI NI NI NI NI NI NI
74 B282 C006 2A I I I I NI I I I NI NI NI NI NI NI NI NI NI
77 B296 C003 2A NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
78 B271 C010 2A NI I NI NI I I I NI NI NI NI NI NI NI NI NI
79 B235 2A I I I I I I I I I I I I I I I I I
97 B291 1 I I I I I I I I I NI I NI NI NI NI NI NI NI
102 B279 C009 1 I I I I I I I I I NI NI I NI NI NI NI NI
WLR 90% (18/20) 80% (16/20) 80% (16/20) 85% (17/20) 95% (19/20)
BLR 90% (18/20) 85% (17/20)
EIVS #: chemicals selection number, Code1: code Beiersdorf under optimized protocol, Code2: Cosmetics Europe codes of 11
chemicals provided to MatTek for optimization
Table 5: Dataset2. Classification with a 50% cut-off.
optimized protocol original protocol
EIVS # Code1 Code2 GHS MatTek Beiersdorf Beiersdorf Harlan IIVS
single mean single mean
30 B204 NC I I I I I I I I I I I I I I I I NI
31 B298 NC NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
35 B275 C011 NC NI I NI NI I I I I NI NI NI NI NI NI NI NI NI
37 B242 C002 NC NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
40 B287 C008 NC NI NI NI NI NI I I I I I NI NI I NI NI NI NI
42 B246 C004 NC I I I I I I I I NI NI I I NI NI NI NI NI
46 B283 C007 NC NI NI NI NI NI I NI NI NI NI NI NI I NI NI NI I
49 B266 NC I I I I I I I I I I I I I I I I I I
62 B225 C001 2B NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI NI
63 B231 2B I I I I I I I I I I I I I I I I
64 B228 2B I I I I I I I I I I I I I I I I
65 B253 2B I I I I I I I I I I I I I I NI I I
66 B226 2B I I I I I I I I I I I I I I I I
73 B268 C005 2A I I I I I I I I NI NI NI NI NI NI NI NI NI
74 B282 C006 2A I I I I I I I I NI NI NI NI NI NI NI NI NI
77 B296 C003 2A NI NI NI NI I I I I NI NI NI NI NI NI NI NI NI
78 B271 C010 2A I I I I I I I NI NI NI NI NI NI NI NI NI
79 B235 2A I I I I I I I I I I I I I I I I I
97 B291 1 I I I I I I I I I I I I I I I I I I
102 B279 C009 1 I I I I I I I I I NI NI I I I NI NI NI
WLR 95% (19/20) 90% (18/20) 85% (17/20) 85% (17/20) 85% (17/20)
BLR 85% (17/20) 85% (17/20)
EIVS #: chemicals selection number, Code1: code Beiersdorf under optimized protocol, Code2: Cosmetics Europe codes of 11
chemicals provided to MatTek for optimization
Table 6: Dataset2. Classification with a 60% cut-off.
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optimized protocol original protocol
EIVS # Code1 Code2 GHS MatTek Beiersdorf Beiersdorf Harlan IIVS
30 B204 NC 7.6 3.5 5.5 3.1 3.1 2.3 55.6 39 46.8 35 25.2 14.2 55.4 51.8 69.2
31 B298 NC 124.6 101.0 117.2 91.8 88.6 85.3 82.1 90.3 62.3 96.6 77.4 96.3 98.2 97.8 103.9
35 B275 C011 NC 99.1 58.2 85.1 32.5 40.6 55.9 73.7 72 77 62.3 69.3 77.4 99.9 95.2 99.4
37 B242 C002 NC 118.9 80.1 88.2 89.2 65.2 68.1 80.4 75 79.7 74.2 66.5 78.3 86.3 80.1 78
40 B287 C008 NC 82.0 65.5 70.6 64 44.9 58.3 49.4 59.5 62.1 72.9 56.2 60.2 62.3 63 60.2
42 B246 C004 NC 18.2 11.1 21.2 3.2 4.2 2.7 64.7 85 58.7 53.4 66 60.1 85.3 81.8 70.5
46 B283 C007 NC 83.4 67.3 79.5 66 59.8 62 68.4 68.9 72.6 73.1 58.9 80 65.2 60.8 57.8
49 B266 NC 4.5 28.1 15.9 10.7 5.6 3.2 3.1 0 0 0 11.7 5.5 3.8 11.9 15.8 15.6
62 B225 C001 2B 103.8 110.8 98.4 106.5 116.5 98 115.2 110.1 101.7 101.7 104.7 105.9 109.8 105.2 97.1
63 B231 2B 15.9 3.4 6 4.7 5.8 40.6 34.3 27 56.8 41 50.2 49.6 38.9 43.7
64 B228 2B 2.8 7.8 1.9 2.1 1.9 36.9 22.8 30 16 20.7 35.1 39.6 29.7 28.2
65 B253 2B 2.2 4.5 31.4 6.2 4.8 3.2 50.5 52.1 51.7 20.3 16.2 51.8 63.8 41.6 53.9
66 B226 2B 3.4 4.8 2.3 2.7 2.1 6 8 6.4 4.8 2.7 3 2.7 6.6 2
73 B268 C005 2A 29.4 51.4 6.2 4.1 2.9 20.4 73.9 88.1 89 78.4 86 87.8 102.5 105.8 82.9
74 B282 C006 2A 17.0 16.9 11.4 51.5 23 18.3 72.5 65.9 88.8 76.7 74.5 81.6 87.2 99.3 88.8
77 B296 C003 2A 96.1 70.2 97.7 55 59.8 56.5 103.6 94.1 92.8 94.7 61.8 65.2 98.2 107.3 103.6
78 B271 C010 2A 56.6 43.9 52.8 46.4 48.4 79.9 80.9 88.9 65.8 62 63.4 87.8 86.9 85.9
79 B235 2A 3.0 2.8 5.1 2.2 2.1 2.1 2.4 3.3 2.2 2.7 2.8 2.2 2.9 2.3 3.2
97 B291 1 32.2 27.2 46.3 47.1 27.6 29.8 29.6 56.2 47.2 55.5 55.3 51.7 51 59 55.1 51.1
102 B279 C009 1 21.2 21.4 3.0 14.3 14.6 19.8 10.1 110.2 124.3 38 55 52.1 76.7 87.8 108.2
EIVS #: chemicals selection number, Code1: code Beiersdorf under optimized protocol, Code2: Cosmetics Europe codes of 11
chemicals provided to MatTek for optimization
Table 7: Average viability over qualified tests for Dataset 2.
4 Predictive Capacity (Accuracy)
Predictive Capacity was calculated on the basis of all individual predictions obtained for each
chemical in each individual qualified test. Moreover, the predictive capacity was calculated
considering the solids data obtained by Beiersdorf with the optimised solids protocol alone or
in combination with the data obtained by Beiersdorf, Harlan and IIVS with the liquid chemicals
in the main study (validation of the original liquids and solids protocols). In the latter case,
the data obtained by Beiersdorf on the 59 chemicals (excluding chemical 98) listed in Table 1 (3
qualified tests for each chemical) were combined with the data obtained by Beiersdorf, Harlan
and IIVS for the 52 liquid chemicals that were tested in the main study (9 qualified tests for each
chemical) (see Appendices B-D). Thus, different chemicals ended up with a different number of
independent classifications used for calculating predictive capacity i.e., 9 classifications (liquids)
or 3 classifications (solids). To avoid that different chemicals weight differently in the calculation
of predictive capacity from the combined data, a weighted calculation was used in this case
(Tables 8 - 11). In summary, the result of each individual qualified test obtained for each
chemical (from one or three laboratories) was captured as an independent classification in the
calculations and correction factors were applied so that all chemicals ended up with an equal
weight in the calculations. The positive and negative predictions for each chemical were divided
by the total number of predictions for that chemical so that each chemical contributes with a
final weight of 1 in the calculations. In this way, the accuracy values obtained better reflect
the real predictive capacity of the test method.
4.1 Analysis of the data generated at Beiersdorf with the optimised solids protocol
The predictive capacity statistics are based on the individual predictions obtained with each
qualified test. The estimates are given in Tables 8 and 9. A significant increase in sensitivity
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and accuracy is observed for the optimised solids protocol as compared to the original one, but,
as expected, a decrease in specificity was also observed.
All the definitely acceptable acceptance criteria defined by the VMG are met with the opti-
mised solids protocol using the 60% cut-off (when chemical 37 is included in the calculations),
while for the 50% cut-off the sensitivity is slightly lower than the definitely acceptance threshold
of 90%. The accuracy of the optimised solids protocol is also higher with a 60% cut-off than
with a 50% cut-off.
optimized Solids protocol original Solids protocol
Solids Specificity (37 incl) 64.3% (18/28)
Solids False Positives (37 incl) 35.7%
Solids Specificity (37 excl) 63.0% (17/27) 79.2% (57/72)
Solids False Positives (37 excl) 37.0% 20.8%
Solids Sensitivity 88.2% (27.3/31) 64.1% (50/78)
Solids False Negatives 11.8% 35.9%
Solids Accuracy (37 incl) 76.8% (45.3/59)
Solids Accuracy (37 excl) 76.4% (44.3/58) 71.3% (107/150)
Table 8: Beiersdorf. Predictive capacity statistics for cut-off 50%. Calculations are made with/without chemical
37 due to borderline melting temperature. Statistics reported for original Solids protocol are taken from TNO
report.
optimized Solids protocol original Solids protocol
Solids Specificity (37 incl) 60.7% (17/28)
Solids False Positives (37 incl) 39.3%
Solids Specificity (37 excl) 59.3% (16/27) 75.0% (54/72)
Solids False Positives (37 excl) 40.7% 25.0%
Solids Sensitivity 93.5% (29/31) 74.4% (58/78)
Solids False Negatives 6.5% 25.6%
Solids Accuracy (37 incl) 78.0% (46/59)
Solids Accuracy (37 excl) 77.6% (45/58) 74.7% (112/150)
Table 9: Beiersdorf. Predictive capacity statistics for cut-off 60%. Calculations are made with/without chemical
37 due to borderline melting temperature. Statistics reported for original Solids protocol are taken from TNO
report.
See Tables 14 to 17 for details.
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4.2 Are final viabilities lower under optimized EpiOcularTM EIT Solids protocol?
As the main difference between optimized and original EpiOcularTM EIT Solids protocol is
an extended exposure time, a natural question to ask is: ”Are final viabilities lower under
optimized EpiOcularTM EIT Solids protocol?”
To answer this question, the data from Beiersdorf were first split into two groups i.e. a)
group of the data for chemicals with in-vivo GHS classification as category 1, 2A or 2B (denote
by Group 1) and b) group of the data for chemicals not requiring classification based on vivo
data (GHS no category) (denote by Group 2), see Appendix A.
A Wilcoxson matched paired test was used on both groups of data. The null hypothesis
about equal viabilities generated under the two protocols is rejected for Group 1 whereas in
the case of Group 2 it cannot be rejected at level α = 5%. In fact, on average, the underlying
viability under the optimized protocol is statistically lower than under the original protocol in
Group 2.
This statistical finding should be interpreted as follows. No statistical significant differences
were observed between viabilities of original and optimised solids protocols for Group 1, but
significant differences were observed in Group 2, with viabilities obtained with the optimised
protocol being significantly lower than those obtained with the original protocol. This can also
be confirmed by observing the graphs included in Appendix A.
4.3 Analysis of data generated at all test facilities. Liquids and Solids Protocols.
Sensitivity, specificity and accuracy detailed statistics for data generated under optimized
Solids & original Liquids and original Solids & original Liquids EpiOcularTM EIT
protocols are shown in Table 10 (50% cut-off) and Table 11 (60% cut-off). The values of statis-
tics below the acceptance threshold are highlighted.(in orange if ”further evaluation necessary”
or in red if ”definitely unacceptable” rates are obtained)
All the definitely acceptable acceptance criteria decided by VMG are met with 60% cut-off. For
the 50% cut-off the sensitivity of the optimised solids protocol is below the definitely accep-
tance criterion of 90% but the combined sensitivity of the optimised solids and original liquids
protocol is still higher than 90% (definitely acceptable). The total accuracy is slightly higher
with 60% cut-off than with 50% cut-off. None of the cat 1 chemicals were underclassified with
either cut-off.
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Optimised Solids protocol Original Solids protocol
& &
Original Liquids protocol Original Liquids protocol
Liquids Specificity (37 incl) 68.7% (18.6/27) 68.7% (167/243)
Liquids False Positives (37 incl) 31.3% 31.3%
Solids Specificity (37 incl) 64.3% (18/28)
Solids False Positives (37 incl) 35.7%
Total Specificity (37 incl twice) 66.5% (36.6/55)
Total False Positives(37 incl twice) 33.5%
Liquids Specificity (37 excl) 67.5% (17.6/26)
Liquids False Positives (37 excl) 32.5%
Solids Specificity (37 excl) 63.0% (17/27) 79.7% (177/222)
Solids False Positives (37 excl) 37.0% 20.3%
Total Specificity (37 incl once) 65.8% (35.6/54) 74.0% (344/465)
Total False Positives (37 incl once) 34.2% 26.0%
Liquids Sensitivity 96.2% (25/26) 96.2% (225/234)
Liquids False Negatives 3.8% 3.8%
Solids Sensitivity 88.2% (27.3/31) 66.7% (156/234)
Solids False Negatives 11.8% 33.3%
Total Sensitivity 91.8% (52.3/57) 81.4% (381/468)
Total False Negatives 8.2% 18.6%
Liquids Accuracy (37 incl) 82.2% (43.6/53) 82.2% (392/477)
Solids Accuracy (37 incl) 76.8% (45.3/59)
Total Accuracy (37 incl twice) 79.4% (88.9/112)
Liquids Accuracy (37 excl) 81.8% (42.6/52)
Solids Accuracy (37 excl) 76.4% (44.3/58) 73.0% (333/456)
Total Accuracy (37 incl once) 79.2% (87.9/111) 77.7% (725/933)
Table 10: Predictive capacity statistics for Cut-off 50%.
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Optimised Solids protocol Original Solids protocol
& &
Original Liquids protocol Original Liquids protocol
Liquids Specificity (37 incl) 65.4% (17.7/27) 65.4% (159/243)
Liquids False Positives (37 incl) 34.6% 34.6%
Solids Specificity (37 incl) 60.7% (17/28)
Solids False Positives (37 incl) 39.3%
Total Specificity (37 incl twice) 63.0% (34.7/55)
Total False Positives(37 incl twice) 37.0%
Liquids Specificity (37 excl) 64.1% (16.7/26)
Liquids False Positives (37 excl) 35.9%
Solids Specificity (37 excl) 59.3% (16/27) 74.8% (166/222)
Solids False Positives (37 excl) 40.7% 25.2%
Total Specificity (37 incl once) 62.4% (33.7/54) 69.9% (325/465)
Total False Positives (37 incl once) 37.6% 30.1%
Liquids Sensitivity 98.3% (25.6/26) 98.3% (230/234)
Liquids False Negatives 1.7% 1.7%
Solids Sensitivity 93.5% (29/31) 76.9% (180/234)
Solids False Negatives 6.5% 23.1%
Total Sensitivity 95.7% (54.6/57) 87.6% (410/468)
Total False Negatives 4.3% 12.4%
Liquids Accuracy (37 incl) 81.6% (43.2/53) 81.6% (389/477)
Solids Accuracy (37 incl) 78.0% (46/59)
Total Accuracy (37 incl twice) 79.7% (89.2/112)
Liquids Accuracy (37 excl) 81.2% (42.2/52)
Solids Accuracy (37 excl) 77.6% (45/58) 75.9% (346/456)
Total Accuracy (37 incl once) 79.5% (88.2/111) 78.8% (735/933)




























































































































































































































































































































































































































































































































































































































EIVS # Code1 GHS Beiersdorf Beiersdorf Harlan IIVS
Liquids
1 no cat 67.8 68.8 71.3 66.7 62.5 70.4 75.3 68.2 62.7
2 no cat 83 80.1 77.3 74.6 79.8 78.9 84.2 79.3 80.4
3 no cat 55.4 63 64.2 37.2 38.1 38.6 51.4 49 47.5
4 no cat 106.9 104.6 115.5 60.8 57.9 64.3 100.9 93 94.8
5 no cat 83.5 72.2 86.4 56.7 41.4 40.3 71.8 65.4 50.3
6 no cat 81.2 83.7 90.9 73.2 71.1 84.7 88.6 80.7 81.3
7 no cat 34.6 42.3 38.7 31 36.8 36.6 40.5 43.4 32.1
8 no cat 101.4 97.3 102.8 89.6 94.7 94.8 101.2 99.6 95.2
9 no cat 95.4 101.9 98 91.9 82.6 96.5 106 100.5 98.3
10 no cat 33 31.1 35.3 14.4 9.8 13.2 16.6 23.8 16.8
11 no cat 29.8 27.5 29.8 21.2 19 16.4 31.6 33.7 28.9
12 no cat 94.1 91.5 91.6 92.7 91.9 96.7 96.4 92.5 94.6
13 no cat 107.9 87.8 105.4 88.8 97.5 85.1 84 81.4 85.8
14 no cat 98.3 98.7 104.9 90.6 97.9 103 94.6 95.7 96.9
15 no cat 97.2 101.7 109.5 104.9 93 106.3 102.4 93.9 95.3
16 no cat 100.4 110.9 103.3 103.8 102.1 94 95.7 105.5 102.9
17 no cat 102.5 98.1 91.9 86.9 100.6 103.9 96.6 98.1 95.3
18 no cat 112.3 69.6 109.5 101.5 91 96.8 94.1 95.3 95
19 no cat 106.4 106.4 111.8 108.8 105.3 113.1 95.6 98.4 98.9
20 no cat 31.1 57.2 49.8 9.1 0 19.1 48.1 33.2 41.5
21 no cat 82.8 82.9 83.2 71.8 67.4 77.6 86.2 81.5 85.4
22 no cat 51.6 39.3 45.1 24 23.3 13 37.7 35.5 39
23 no cat 40.8 46 39.5 17.5 22.4 4.9 18.9 8.6 10.4
24 no cat 48.4 45.6 43.5 28 19.4 21.3 53 33.9 32.6
25 no cat 107.6 105 101.3 104.8 108.9 104.9 95 103.2 107.3
26 no cat 22.7 19.4 22.4 30.6 40.7 35.6 31.6 35.6 35.3
37 no cat 80.4 75 79.7 74.2 66.5 78.3 86.3 80.1 78
Solids
28 B249 no cat 119 91.9 109.3 99.4 99.6 95.8 94.9 94.5 90.9 105.4 112.9 100.6
29 B267 no cat 136.5 105.6 98.6 82.9 91.8 88.2 57.4 112 83 102.5 105.7 101.4
30 B204 no cat 3.1 3.1 2.3 55.6 39 46.8 35 25.2 14.2 55.4 51.8 69.2
31 B298 no cat 91.8 88.6 85.3 82.1 90.3 62.3 96.6 77.4 96.3 98.2 97.8 103.9
32 B285 no cat 2.6 2.3 2.2 0 0.9 0.2 1.1 0.9 0.9 2.5 2.8 2.1
33 B232 no cat 4.9 2 4.1 44.1 48.3 40.3 88.9 89.2 83.2
34 B218 no cat 12.3 14.5 -1.9 111.1 111.5 116.5 81.4 54.1 63.2 95.6 107.1 80.9
35 B275 no cat 32.5 40.6 55.9 73.7 72 77 62.3 69.3 77.4 99.9 95.2 99.4
36 B290 no cat 100.5 110 109.5 110.9 102.8 107.5 103.1 88.2 98.5 110.7 110.8 105.6
37 B242 no cat 89.2 65.2 68.1
38 B237 no cat 118.2 94.7 95.2 102.8 100.9 119.7 99.7 113 95.8 101.1 101.9 108
39 B274 no cat 116.3 108.6 99.4 101.9 99.5 117.3 100.9 114.7 88.4 102.5 101.7 104.8
40 B287 no cat 64 44.9 58.3 49.4 59.5 62.1 72.9 56.2 60.2 62.3 63 60.2
41 B224 no cat 102.6 111.3 117.2 101.2 98.8 90.4 98.2 86.4 88.8 99.3 102.5 94
42 B246 no cat 3.2 4.2 2.7 64.7 85 58.7 53.4 66 60.1 85.3 81.8 70.5
43 B245 no cat 123.6 126.8 92.9 93.9 112.1 102.6 125.3 91.6 163.7 99.8 102 103.4
44 B262 no cat 114.8 106.2 115.2 104.5 98.7 97.3 101.6 95 103.9 98.1 94.2 102.9
45 B284 no cat 98.4 102.2 86.4 110.6 101.4 118.8 112.5 97.9 112.6 98.6 98.4 94.8
46 B283 no cat 66 59.8 62 68.4 68.9 72.6 73.1 58.9 80 65.2 60.8 57.8
47 B260 no cat 1.9 2 2.5 4.4 5 4.6 3.4 2 3.2 3.2 2.9 2.6
48 B243 no cat 2.4 2.4 2.4 2.7 3.6 3 2.8 3.1 2.5 2.7 2.5 2.4
49 B266 no cat 5.6 3.2 3.1 0 0 0 11.7 5.5 3.8 11.9 15.8 15.6
50 B278 no cat 86.5 99.6 99.5 89.7 89.6 83.5 99.1 97.1 96.7 95.6 92.7 97.4
51 B222 no cat 23.4 40 43.7 99.1 91.5 101.1 93.3 100.1 84.8 95.4 98.7 106
52 B205 no cat 138.5 110.8 105.9 104.8 103.1 130.8 106.5 105.7 93.4 101.3 95.1 105.7
53 B299 no cat 110.8 117.4 104.2 93 105.7 119.4 108.2 123.4 104 106.3 101.7 107.2
108 B332 no cat 83.1 89.5 100
109 B634 no cat 102 111 89.8
Table 12: No Category. Final viability for qualified tests.
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optimized original protocol
EIVS # Code1 GHS Beiersdorf Beiersdorf Harlan IIVS
Liquids
54 cat 2B 48.8 47.8 45.2 17.1 25.2 19.9 51.8 43.1 30.1
55 cat 2B 2.3 2.1 2.1 2.2 1.8 2.6 2.5 2.6 2.5
56 cat 2B 46.4 54.5 60.3 20.8 26.5 27.3 47.5 34.8 29.6
57 cat 2B 24.4 19.8 19.1 5 7.7 6.5 20.4 20.3 12.6
58 cat 2B 22 22.7 22.2 6.8 2.1 2.6 14.4 13.4 13
59 cat 2B 62.6 67.5 78.3 46.6 36.3 47 56.6 52.8 43.6
60 cat 2B 20.5 13.6 12.6 6.7 16 9.3 26.8 13.8 21.2
67 cat 2A 15 10.8 10.7 4.1 4.3 4.9 13.6 15.3 14.6
68 cat 2A 3.5 2.4 4.3 4 2.8 3.3 2.7 7 3
69 cat 2A 13.2 15 13.9 10.5 14 16.9 13.6 14.4 14.1
70 cat 2A 12.5 17.9 15.4 9.9 10.3 12.9 14.3 12.3 12.2
71 cat 2A 5.2 6.2 4.7 7.9 7.4 4 7.7 9.1 7.4
72 cat 2A 4.7 2.2 4.9 5.4 3.7 3.8 5.4 3.2 3.1
80 cat 1 18.1 16.6 17.7 6.3 0 15.3 9.3 5 9.7
81 cat 1 2.5 1.8 3.1 3.6 3.2 3.4 5.6 3.9 3.1
82 cat 1 4.5 1.6 5.4 1.5 2.1 1.7 5.3 6.9 2.6
83 cat 1 5.5 6.1 5.3 4.6 3.6 7.6 5.4 6.8 4
84 cat 1 12.6 5.6 22.1 6.7 7 4.2 17.8 18.7 9.3
85 cat 1 15.9 18.1 26.7 5.6 9.2 12.5 14 13.1 17.8
86 cat 1 25.3 20.7 27.2 41.8 23.4 24.8 31.8 32.7 20.5
87 cat 1 26.3 26.3 33.6 20 14.4 22.2 30.8 17.4 24.4
88 cat 1 4.5 5.3 7.4 5.2 7.8 5.4 3.9 7 3.5
89 cat 1 10.7 7.2 10.6 5.8 7.8 8.1 9 12.6 9.7
90 cat 1 40.4 28.5 25.6 25.4 32.6 14.4 35.5 34.7 30.8
91 cat 1 20 35 38.3 17.6 12.4 20.4 21.1 19.6 19.5
92 cat 1 47.5 41 49.8 18.2 14.8 13.1 39.6 39.3 51.2
Solids
61 B221 cat 2B 2.5 3.5 3 16 15.9 22.9 17 11.3 9.4 16.3 16.4 21.4
62 B225 cat 2B 106.5 116.5 98 115.2 110.1 101.7 101.7 104.7 105.9 109.8 105.2 97.1
63 B231 cat 2B 6 4.7 5.8 40.6 34.3 27 56.8 41 50.2 49.6 38.9 43.7
64 B228 cat 2B 1.9 2.1 1.9 36.9 22.8 30 16 20.7 35.1 39.6 29.7 28.2
65 B253 cat 2B 6.2 4.8 3.2 50.5 52.1 51.7 20.3 16.2 51.8 63.8 41.6 53.9
66 B226 cat 2B 2.3 2.7 2.1 6 8 6.4 4.8 2.7 3 2.7 6.6 2
110 B451 cat 2B 105.1 114.1 111.4
73 B268 cat 2A 4.1 2.9 20.4 73.9 88.1 89 78.4 86 87.8 102.5 105.8 82.9
74 B282 cat 2A 51.5 23 18.3 72.5 65.9 88.8 76.7 74.5 81.6 87.2 99.3 88.8
75 B254 cat 2A 1.9 2 6.5 74.8 81.1 83.9 17.4 2 2.7 5 5.8 4.4
76 B201 cat 2A 2.5 3.1 2.4 54.8 53.5 53.4 59 32.3 52.8 26.9 26.3 28.7
77 B296 cat 2A 55 59.8 56.5 103.6 94.1 92.8 94.7 61.8 65.2 98.2 107.3 103.6
78 B271 cat 2A 52.8 46.4 48.4 79.9 80.9 88.9 65.8 62 63.4 87.8 86.9 85.9
79 B235 cat 2A 2.2 2.1 2.1 2.4 3.3 2.2 2.7 2.8 2.2 2.9 2.3 3.2
111 B447 cat 2A 3.9 3.9 3.4
112 B608 cat 2A 29.1 19.3 14.7
113 B202 cat 2A 5.9 6.7 4.7
93 B250 cat 1 2.3 2.5 2.1 11.5 9.5 5.7 6.2 9.3 8.5 10.3 21.3 18
94 B213 cat 1 1.3 2.6 1.2 2.1 2.3 2.6 5.7 3 2.6 5.2 5.8 4.3
95 B294 cat 1 2.4 2.4 2 2.4 2.5 2.2 2.5 2.7 2.7 1.6 2.3 2.1
96 B255 cat 1 12.3 9.5 6 28.9 41.1 36.1 35.5 35.3 30.9 33.2 38.9 54.1
97 B291 cat 1 27.6 29.8 29.6 56.2 47.2 55.5 55.3 51.7 51 59 55.1 51.1
98 B252 cat 1 0 0 0 0 0 0 0 0 0
99 B214 cat 1 2.1 2.2 2.7 2.6 2.8 3.1 3.3 2.3 2.4 1.9 2 1.7
100 B233 cat 1 18 15 20.1 9.8 3.6 2.4 10 14.9 8.5 10.5 8.2 8.9
101 B281 cat 1 2.3 2.5 2.2 34.1 33.2 34.3 26.2 50.6 42 19.9 21.6 13.8
102 B279 cat 1 14.3 14.6 19.8 10.1 110.2 124.3 38 55 52.1 76.7 87.8 108.2
103 B244 cat 1 1.3 1.4 1.4 2 3.5 2 1.9 1.9 1.6 1.7 2.1 2.1
104 B207 cat 1 25.7 22.7 17.1 37.4 38.9 42.9 40.3 36.3 48.4 47.1 34.8 24.4
105 B261 cat 1 2.4 2.4 2.1 2.5 2.8 2.4 3.9 2.6 1.9 2.1 2.4 2.4
114 B293 cat 1 5.7 7.6 2.9
115 B276 cat 1 2.3 2.1 2.1
Table 13: GHS cat 1,2A, 2B. Final viability for qualified tests.
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C Final classifications cut-off 50%
optimized original protocol
EIVS # Code1 GHS Beiersdorf Beiersdorf Harlan IIVS
Liquids
1 no cat NI NI NI NI NI NI NI NI NI
2 no cat NI NI NI NI NI NI NI NI NI
3 no cat NI NI NI I I I NI I I
4 no cat NI NI NI NI NI NI NI NI NI
5 no cat NI NI NI NI I I NI NI NI
6 no cat NI NI NI NI NI NI NI NI NI
7 no cat I I I I I I I I I
8 no cat NI NI NI NI NI NI NI NI NI
9 no cat NI NI NI NI NI NI NI NI NI
10 no cat I I I I I I I I I
11 no cat I I I I I I I I I
12 no cat NI NI NI NI NI NI NI NI NI
13 no cat NI NI NI NI NI NI NI NI NI
14 no cat NI NI NI NI NI NI NI NI NI
15 no cat NI NI NI NI NI NI NI NI NI
16 no cat NI NI NI NI NI NI NI NI NI
17 no cat NI NI NI NI NI NI NI NI NI
18 no cat NI NI NI NI NI NI NI NI NI
19 no cat NI NI NI NI NI NI NI NI NI
20 no cat I NI I I I I I I I
21 no cat NI NI NI NI NI NI NI NI NI
22 no cat NI I I I I I I I I
23 no cat I I I I I I I I I
24 no cat I I I I I I NI I I
25 no cat NI NI NI NI NI NI NI NI NI
26 no cat I I I I I I I I I
37 no cat NI NI NI NI NI NI NI NI NI
Solids
28 B249 no cat NI NI NI NI NI NI NI NI NI NI NI NI
29 B267 no cat NI NI NI NI NI NI NI NI NI NI NI NI
30 B204 no cat I I I NI I I I I I NI NI NI
31 B298 no cat NI NI NI NI NI NI NI NI NI NI NI NI
32 B285 no cat I I I I I I I I I I I I
33 B232 no cat I I I I I I NI NI NI
34 B218 no cat I I I NI NI NI NI NI NI NI NI NI
35 B275 no cat I I NI NI NI NI NI NI NI NI NI NI
36 B290 no cat NI NI NI NI NI NI NI NI NI NI NI NI
37 B242 no cat NI NI NI
38 B237 no cat NI NI NI NI NI NI NI NI NI NI NI NI
39 B274 no cat NI NI NI NI NI NI NI NI NI NI NI NI
40 B287 no cat NI I NI I NI NI NI NI NI NI NI NI
41 B224 no cat NI NI NI NI NI NI NI NI NI NI NI NI
42 B246 no cat I I I NI NI NI NI NI NI NI NI NI
43 B245 no cat NI NI NI NI NI NI NI NI NI NI NI NI
44 B262 no cat NI NI NI NI NI NI NI NI NI NI NI NI
45 B284 no cat NI NI NI NI NI NI NI NI NI NI NI NI
46 B283 no cat NI NI NI NI NI NI NI NI NI NI NI NI
47 B260 no cat I I I I I I I I I I I I
48 B243 no cat I I I I I I I I I I I I
49 B266 no cat I I I I I I I I I I I I
50 B278 no cat NI NI NI NI NI NI NI NI NI NI NI NI
51 B222 no cat I I I NI NI NI NI NI NI NI NI NI
52 B205 no cat NI NI NI NI NI NI NI NI NI NI NI NI
53 B299 no cat NI NI NI NI NI NI NI NI NI NI NI NI
108 B634 no cat NI NI NI
109 B332 no cat NI NI NI
Table 14: No Category. Final classification cut-off 50%.
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optimized original protocol
EIVS # Code1 GHS Beiersdorf Beiersdorf Harlan IIVS
Liquids
54 cat 2B I I I I I I NI I I
55 cat 2B I I I I I I I I I
56 cat 2B I NI NI I I I I I I
57 cat 2B I I I I I I I I I
58 cat 2B I I I I I I I I I
59 cat 2B NI NI NI I I I NI NI I
60 cat 2B I I I I I I I I I
67 cat 2A I I I I I I I I I
68 cat 2A I I I I I I I I I
69 cat 2A I I I I I I I I I
70 cat 2A I I I I I I I I I
71 cat 2A I I I I I I I I I
72 cat 2A I I I I I I I I I
80 cat 1 I I I I I I I I I
81 cat 1 I I I I I I I I I
82 cat 1 I I I I I I I I I
83 cat 1 I I I I I I I I I
84 cat 1 I I I I I I I I I
85 cat 1 I I I I I I I I I
86 cat 1 I I I I I I I I I
87 cat 1 I I I I I I I I I
88 cat 1 I I I I I I I I I
89 cat 1 I I I I I I I I I
90 cat 1 I I I I I I I I I
91 cat 1 I I I I I I I I I
92 cat 1 I I I I I I I I NI
Solids
61 B221 cat 2B I I I I I I I I I I I I
62 B225 cat 2B NI NI NI NI NI NI NI NI NI NI NI NI
63 B231 cat 2B I I I I I I NI I NI I I I
64 B228 cat 2B I I I I I I I I I I I I
65 B253 cat 2B I I I NI NI NI I I NI NI I NI
66 B226 cat 2B I I I I I I I I I I I I
110 B451 cat 2B NI NI NI
73 B268 cat 2A I I I NI NI NI NI NI NI NI NI NI
74 B282 cat 2A NI I I NI NI NI NI NI NI NI NI NI
75 B254 cat 2A I I I NI NI NI I I I I I I
76 B201 cat 2A I I I NI NI NI NI I NI I I I
77 B296 cat 2A NI NI NI NI NI NI NI NI NI NI NI NI
78 B271 cat 2A NI I I NI NI NI NI NI NI NI NI NI
79 B235 cat 2A I I I I I I I I I I I I
111 B447 cat 2A I I I
112 B608 cat 2A I I I
113 B202 cat 2A I I I
93 B250 cat 1 I I I I I I I I I I I I
94 B213 cat 1 I I I I I I I I I I I I
95 B294 cat 1 I I I I I I I I I I I I
96 B255 cat 1 I I I I I I I I I I I NI
97 B291 cat 1 I I I NI I NI NI NI NI NI NI NI
98 B252 cat 1 I I I I I I I I I
99 B214 cat 1 I I I I I I I I I I I I
100 B233 cat 1 I I I I I I I I I I I I
101 B281 cat 1 I I I I I I I NI I I I I
102 B279 cat 1 I I I I NI NI I NI NI NI NI NI
103 B244 cat 1 I I I I I I I I I I I I
104 B207 cat 1 I I I I I I I I I I I I
105 B261 cat 1 I I I I I I I I I I I I
114 B293 cat 1 I I I
115 B276 cat 1 I I I
Table 15: GHS cat 1, 2A, 2B. cut-off 50%
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D Final classifications cut-off 60%
optimized original protocol
EIVS # Code1 GHS Beiersdorf Beiersdorf Harlan IIVS
Liquids
1 no cat NI NI NI NI NI NI NI NI NI
2 no cat NI NI NI NI NI NI NI NI NI
3 no cat I NI NI I I I I I I
4 no cat NI NI NI NI I NI NI NI NI
5 no cat NI NI NI I I I NI NI I
6 no cat NI NI NI NI NI NI NI NI NI
7 no cat I I I I I I I I I
8 no cat NI NI NI NI NI NI NI NI NI
9 no cat NI NI NI NI NI NI NI NI NI
10 no cat I I I I I I I I I
11 no cat I I I I I I I I I
12 no cat NI NI NI NI NI NI NI NI NI
13 no cat NI NI NI NI NI NI NI NI NI
14 no cat NI NI NI NI NI NI NI NI NI
15 no cat NI NI NI NI NI NI NI NI NI
16 no cat NI NI NI NI NI NI NI NI NI
17 no cat NI NI NI NI NI NI NI NI NI
18 no cat NI NI NI NI NI NI NI NI NI
19 no cat NI NI NI NI NI NI NI NI NI
20 no cat I I I I I I I I I
21 no cat NI NI NI NI NI NI NI NI NI
22 no cat I I I I I I I I I
23 no cat I I I I I I I I I
24 no cat I I I I I I I I I
25 no cat NI NI NI NI NI NI NI NI NI
26 no cat I I I I I I I I I
37 no cat NI NI NI NI NI NI NI NI NI
Solids
28 B249 no cat NI NI NI NI NI NI NI NI NI NI NI NI
29 B267 no cat NI NI NI NI NI NI I NI NI NI NI NI
30 B204 no cat I I I I I I I I I I I NI
31 B298 no cat NI NI NI NI NI NI NI NI NI NI NI NI
32 B285 no cat I I I I I I I I I I I I
33 B232 no cat I I I I I I NI NI NI
34 B218 no cat I I I NI NI NI NI I NI NI NI NI
35 B275 no cat I I I NI NI NI NI NI NI NI NI NI
36 B290 no cat NI NI NI NI NI NI NI NI NI NI NI NI
37 B242 no cat NI NI NI
38 B237 no cat NI NI NI NI NI NI NI NI NI NI NI NI
39 B274 no cat NI NI NI NI NI NI NI NI NI NI NI NI
40 B287 no cat NI I I I I NI NI I NI NI NI NI
41 B224 no cat NI NI NI NI NI NI NI NI NI NI NI NI
42 B246 no cat I I I NI NI I I NI NI NI NI NI
43 B245 no cat NI NI NI NI NI NI NI NI NI NI NI NI
44 B262 no cat NI NI NI NI NI NI NI NI NI NI NI NI
45 B284 no cat NI NI NI NI NI NI NI NI NI NI NI NI
46 B283 no cat NI I NI NI NI NI NI I NI NI NI I
47 B260 no cat I I I I I I I I I I I I
48 B243 no cat I I I I I I I I I I I I
49 B266 no cat I I I I I I I I I I I I
50 B278 no cat NI NI NI NI NI NI NI NI NI NI NI NI
51 B222 no cat I I I NI NI NI NI NI NI NI NI NI
52 B205 no cat NI NI NI NI NI NI NI NI NI NI NI NI
53 B299 no cat NI NI NI NI NI NI NI NI NI NI NI NI
108 B634 no cat NI NI NI
109 B332 no cat NI NI NI
Table 16: No Category. Final classification cut-off 60%.
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optimized original protocol
EIVS # Code1 GHS Beiersdorf Beiersdorf Harlan IIVS
Liquids
54 cat 2B I I I I I I I I I
55 cat 2B I I I I I I I I I
56 cat 2B I I NI I I I I I I
57 cat 2B I I I I I I I I I
58 cat 2B I I I I I I I I I
59 cat 2B NI NI NI I I I I I I
60 cat 2B I I I I I I I I I
67 cat 2A I I I I I I I I I
68 cat 2A I I I I I I I I I
69 cat 2A I I I I I I I I I
70 cat 2A I I I I I I I I I
71 cat 2A I I I I I I I I I
72 cat 2A I I I I I I I I I
80 cat 1 I I I I I I I I I
81 cat 1 I I I I I I I I I
82 cat 1 I I I I I I I I I
83 cat 1 I I I I I I I I I
84 cat 1 I I I I I I I I I
85 cat 1 I I I I I I I I I
86 cat 1 I I I I I I I I I
87 cat 1 I I I I I I I I I
88 cat 1 I I I I I I I I I
89 cat 1 I I I I I I I I I
90 cat 1 I I I I I I I I I
91 cat 1 I I I I I I I I I
92 cat 1 I I I I I I I I I
Solids
61 B221 cat 2B I I I I I I I I I I I I
62 B225 cat 2B NI NI NI NI NI NI NI NI NI NI NI NI
63 B231 cat 2B I I I I I I I I I I I I
64 B228 cat 2B I I I I I I I I I I I I
65 B253 cat 2B I I I I I I I I I NI I I
66 B226 cat 2B I I I I I I I I I I I I
110 B451 cat 2B NI NI NI
73 B268 cat 2A I I I NI NI NI NI NI NI NI NI NI
74 B282 cat 2A I I I NI NI NI NI NI NI NI NI NI
75 B254 cat 2A I I I NI NI NI I I I I I I
76 B201 cat 2A I I I I I I I I I I I I
77 B296 cat 2A I I I NI NI NI NI NI NI NI NI NI
78 B271 cat 2A I I I NI NI NI NI NI NI NI NI NI
79 B235 cat 2A I I I I I I I I I I I I
111 B447 cat 2A I I I
112 B608 cat 2A I I I
113 B202 cat 2A I I I
93 B250 cat 1 I I I I I I I I I I I I
94 B213 cat 1 I I I I I I I I I I I I
95 B294 cat 1 I I I I I I I I I I I I
96 B255 cat 1 I I I I I I I I I I I I
97 B291 cat 1 I I I I I I I I I I I I
98 B252 cat 1 I I I I I I I I I
99 B214 cat 1 I I I I I I I I I I I I
100 B233 cat 1 I I I I I I I I I I I I
101 B281 cat 1 I I I I I I I I I I I I
102 B279 cat 1 I I I I NI NI I I I NI NI NI
103 B244 cat 1 I I I I I I I I I I I I
104 B207 cat 1 I I I I I I I I I I I I
105 B261 cat 1 I I I I I I I I I I I I
114 B293 cat 1 I I I
115 B276 cat 1 I I I
Table 17: GHS cat 1, 2A, 2B. cut-off 60%
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Summary 
The goal of the Eye Irritation Validation Study (EIVS) was to assess the relevance 
(predictive capacity) and reliability (reproducibility within and between laboratories) 
of the SkinEthicTM HCE and of the EpiOcularTM EIT, by testing a statistically 
significant number of coded test chemicals (substances and mixtures), supported 
by complete and quality assured in vivo Draize eye irritation data for comparative 
evaluation of results. In this report a complete, objective and transparent analysis of 
within-laboratory and between-laboratory reproducibility as well as predictive 
capacity based on the submitted test data for SkinEthicTM HCE is presented. The 
results for the EpiOcularTM EIT are reported elsewhere (TNO2013 R10396). 
 
The statistical analyses are performed for the data generated using the short 
exposure protocol (SE), the long exposure protocol (LE) as well as based on the 
test strategy (selection of SE or LE based on reactivity analysis). Based on the 
results for the fraction of complete test sequences (100% in total for SE and 99.7% 
for LE), the within-laboratory variability (93.9% concordance in total for SE and 
95.5% concordance in total for LE) and the between-laboratory variability (92.3% 
concordance in total using the SE protocol and 92.3% concordance in total using 
the LE protocol), the validation of the SkinEthicTM HCE was based on high-quality 
data. The acceptance criteria for these three characteristics were easily fulfilled. 
 
The SkinEthic™ HCE test method is highly reproducible. The within-laboratory 
reproducibility (WLR) and between-laboratory reproducibility (BLR) was well above 
the acceptance criteria set by the VMG (i.e. WLR ≥ 85% and BLR ≥ 80%). 
 
A cut-off value of 50% was applied, meaning that a chemical for which the mean 
viabililty was below 50% is classified as irritant and non-irrant otherwise. The 
specificity of the prediction model was ‘definitely acceptable’ according to the 
acceptance criteria as defined by the VMG, regardless the protocol that was used 
(SE: 0.885; LE: 0.655; test strategy: 0.777). Further evaluation is needed regarding 
the accuracy (SE: 0.656; LE: 0.686; test strategy: 0.661). The results for the 
sensitivity are ‘definitely unacceptable’ according to the acceptance criteria as 
defined by the VMG (SE: 0.427; LE: 0.716; test strategy: 0.545).
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1 Introduction 
The goal of the Eye Irritation Validation Study (EIVS) was to assess the relevance 
(predictive capacity) and reliability (reproducibility within and between laboratories) 
of the SkinEthicTM HCE SE, LE and test strategy and of the EpiOcularTM EIT, by 
testing a statistically significant number of coded test chemicals (substances and 
mixtures), supported by complete and quality assured in vivo Draize eye irritation 
data for comparative evaluation of results. 
 
Specifically, EIVS assessed the validity of the SkinEthicTM HCE SE, LE and test 
strategy and of the EpiOcularTM EIT as stand-alone (independent) test methods to 
reliably discriminate chemicals not classified as eye irritant (“non-irritants”) from all 
classes of eye irritant chemicals (in the framework of a Bottom-Up/Top-Down test 
strategy, Scott L. et al., 2010), defined according to the United Nations Globally 
Harmonized System (GHS) of Classification and Labelling of Chemicals (UN GHS: 
No Category versus Category 1/Category 2A/Category 2B; UN, 2007) and as 
implemented in the European Commission Regulation (EC) No 1272/2008 on 
classification, labelling and packaging of substances and mixtures, amending and 
repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) 
No 1907/2006 (EU CLP: No Category versus Category 1/Category 2). 
 
The EpiOcular™ EIT was developed for maximum sensitivity (ability to detect 
positives, with low rate of false negatives) rather than for optimal overall accuracy 
with balanced sensitivity and specificity (ability to detect negatives, with low rate of 
false positives). Sensitivity had therefore a bigger weight than specificity and overall 
accuracy in their development. However, it was also sought to achieve a sufficiently 
high specificity and overall accuracy, in order to allow identification of the highest 
number of chemicals not classified as irritant to the eye. The SkinEthic™ HCE test 
strategy was developed to optimize the overall accuracy with balanced sensitivity 
and specificity. It was developed to oriented to the short or long exposure treatment 
based on the reactivity of the chemical, given balanced accuracy.  
By achieving satisfactory specificity, the SkinEthic™ HCE test strategy and the 
EpiOcular™ EIT would represent stand-alone (independent) test methods for the 
identification of “non-irritants”. Importantly, the test methods were not intended to 
differentiate between UN GHS/EU CLP Category 1 (irreversible effects) and UN 
GHS/EU CLP Category 2 (reversible effects). As proposed by the ECVAM 
workshop of February 2005, this differentiation would be left to another tier of the 
Bottom-Up/Top-Down test strategy (Scott L. et al., 2010). 
 
The EIVS was undertaken in accordance with the principles and criteria 
documented in the OECD Guidance Document on the Validation and International 
Acceptance of New or Updated Test Methods for Hazard Assessment (No. 34, 
OECD, 2005) and according to the Modular Approach to validation (Hartung T. et 
al., 2004). 
 
The objective of this report is to summarise and present a complete, objective and 
transparent analysis of within-laboratory and between-laboratory reproducibility as 
well as predictive capacity based on the submitted test data for SkinEthic™ HCE. 
The analysis is performed for the data generated using the short exposure protocol 
(SE), the long exposure protocol (LE) as well as based on the test strategy 
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(selection of SE or LE based on EPRA analysis). The results for the EpiOcular™ 
EIT protocol have been reported in a separate report. 
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2 Material and Methods 
2.1 Study Design 
The SkinEthic™ HCE was tested in three laboratories. 
 
Lead Laboratory L’OREAL (FR) 
Additional Laboratory 1 CARDAM (BE) 
Additional Laboratory 2 CEETOX (USA) 
  
Each laboratory tested the same 106 chemicals in three runs each, in three tissues 
(post-validation statistical analyses to investigate whether it would be sufficient to 
use two tissues instead of three tissues were conducted elsewhere; for 
completeness, the results of these separate analyses are given in appendix IX). 
These chemicals were coded and distributed by TNO (The Netherlands). The 
chemicals were tested blinded. Contact between the laboratories during the testing 
was not allowed in order to safeguard the blinding. More details regarding the study 
design can be found in the project plan (appendix VIII). 
 
The chemicals that were used in the validation study are listed in Table 2.1.1.  
Table 2.1.1 List of tested chemicals in EIVS validation study 
Chemical Substance name State CAS # GHS Class 
1 1-bromohexane Liquid 111-25-1 no cat 
2 1-methylpropyl benzene Liquid 135-98-8 no cat 
3 2-ethoxyethyl methacrylate Liquid 2370-63-0 no cat 
4 iso-octylthioglycolate INCI name: ISOOCTYL THIOGLYCOLATE Liquid 25103-09-7 no cat 
5 4-(methylthio)-benzaldehyde Liquid 3446-89-7 no cat 
6 dipropyl disulphide Liquid 629-19-6 no cat 
7 1-bromo-4-chlorobutane Liquid 6940-78-9 no cat 
8 1-bromo-octane Liquid 111-83-1 no cat 
9 1,9-decadiene Liquid 1647-16-1 no cat 
10 2,2-dimethyl-3-pentanol  Liquid 3970-62-5 no cat 
11 2-(2-ethoxyethoxy) ethanol INCI name: ETHOXYDIGLYCOL Liquid 111-90-0 no cat 
12 bisphenol A, epichlorohydrin polymer, ethoxylated, propoxylated (53-
57% aqueousemulsion) 
Liquid 68123-18-2  no cat 
13 bisphenol A, diethylene triamine, epichlorohydrin polymer, ethoxylated, 
propoxylated (56% aqueous emulsion) 
Liquid 455946-46-0 no cat 
14 dioctyl ether INCI name: DICAPRYLYL ETHER Liquid 629-82-3 no cat 
15 dioctyl carbonate INCI name: DICAPRYLYL CARBONATE Liquid 1680-31-5 no cat 
16 2-propylheptyl octanoate INCI name: PROPYLHEPTYL CAPRYLATE Liquid 868839-23-0 no cat 
17 polyglyceryl-3 diisooctadecanoate INCI name: POLYGLYCERYL-3 
DIISOSTEARATE 
Liquid 63705-03-3 no cat 
18 steareth-10 allyl ether/acrylates copolymer (30% aqueous) INCI name: 
STEARETH-10 ALLYL ETHER/ACRYLATES COPOLYMER 
Liquid 109292-17-3 no cat 
19 dimethyl siloxane, mono dimethylvinylsiloxy- and  mono 
trimethoxysiloxy-terminated  (95%) 
Liquid 471277-16-4 no cat 
20 ricinoleic acid tin salt Liquid 71828-07-4 no cat 
21 1-ethyl-3-methylimidazolium ethylsulphate Liquid 342573-75-5 no cat 
22 3-phenoxybenzyl alcohol  Liquid 13826-35-2  no cat  
23 ethyl thioglycolate INCI name: ETHYL THIOGLYCOLATE Liquid 623-51-8  no cat  
24 glycidyl methacrylate  Liquid 106-91-2  no cat  
25 piperonyl butoxide INCI name: PIPERONYL BUTOXIDE Liquid 51-03-6 no cat 
26 propiconazole Liquid 60207-90-1 no cat 
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Chemical Substance name State CAS # GHS Class 
27
1
 2-ethylhexylthioglycolate Liquid 7659-86-1 no cat 
28 4,4'-methylene bis-(2,6-di-tert-butylphenol) Solid 118-82-1 no cat 
29 tetradecyl tetradecanoate INCI name: MYRISTYL MYRISTATE Solid 3234-85-3 no cat 
30 1,1-dimethylguanidine sulphate Solid 598-65-2 no cat 
31 potassium tetrafluoroborate Solid 14075-53-7 no cat 
32 2,6-dihydroxy-3,4-dimethylpyridine INCI name: 2,6-DIHYDROXY-3,4-
DIMETHYLPYRIDINE 
Solid 84540-47-6 no cat 
33 2,2'-[[4-[(2-methoxyethyl)amino]-3-nitrophenyl]imino]bis-ethanol INCI 
name: HC BLUE NO. 11 
Solid 23920-15-2 no cat 
34 2,2'-[[3-methyl-4-[(4-nitrophenyl)azo]phenyl]imino]bis-ethanol INCI 
name: DISPERSE RED 17 
Solid 3179-89-3 no cat 
35 2,5,6-triamino-4-pyrimidinol sulphate INCI name: 2,5,6-TRIAMINO-4-
PYRIMIDINOL SULFATE 
Solid 1603-02-7 no cat 
36 1-(4-chlorophenyl)-3-(3,4-dichlorophenyl) urea INCI name: 
TRICLOCARBAN 
Solid 101-20-2 no cat 
37
3
 polyethylene glycol (PEG-40) hydrogenated castor oil INCI name: PEG-40 
HYDROGENATED CASTOR OIL 
Solid 61788-85-0 no cat 
38 2,2'-methylene-bis-(6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-
tetramethylbutyl)phenol)  INCI name: METHYLENE BIS-BENZOTRIAZOLYL 
TETRAMETHYLBUTYLPHENOL 
Solid 103597-45-1 no cat 
39 2,2'-[6-(4-methoxyphenyl)-1,3,5-triazine-2,4-diyl]bis[5-[(2-
ethylhexyl)oxy]-phenol]  INCI name: BIS-ETHYLHEXYLOXYPHENOL 
METHOXYPHENYL TRIAZINE 
Solid 187393-00-6            no cat 
40 acrylamidopropyltrimonium chloride/acrylamide copolymer Solid 75150-29-7 no cat 
41 tris(2-ethylhexyl)-4,4',4''-(1,3,5-triazine-2,4,6-triyltriimino) tribenzoate 
INCI name: ETHYLHEXYL TRIAZONE 
Solid 88122-99-0 no cat 
42 trisodium mono-(5-(1,2-dihydroxyethyl)-4-oxido-2-oxo-2,5-dihydro-
furan-3-yl) phosphate INCI name: SODIUM ASCORBYL PHOSPHATE 
Solid 66170-10-3 no cat 
43 hexyl 2-(1-(diethylaminohydroxyphenyl)methanoyl) benzoate INCI 
name: DIETHYLAMINO HYDROXYBENZOYL HEXYL BENZOATE 
Solid 302776-68-7 no cat 
44 [3-chloro-4-[(3-fluorobenzyl)oxy]phenyl](6-iodoquinazolin-4-yl)amine Solid 231278-20-9 no cat 
45 1-(9H-carbazol-4-yloxy)-3-[[2-(2-methoxyphenoxy)ethyl]amino]propan-
2-ol 
Solid 72956-09-3 no cat 
46 cellulose, 2-(2-hydroxy-3-(trimethylammonium)propoxy)ethyl ether 
chloride (91%) INCI name: POLYQUATERNIUM-10 
Solid 68610-92-4 no cat 
47 3,4-dimethoxy benzaldehyde INCI name: VERATRALDEHYDE Solid 120-14-9  no cat 
48 sodium hydrogensulphite  INCI name: SODIUM BISULFITE Solid 7631-90-5  no cat 
49 propyl-4-hydroxybenzoate INCI name: PROPYLPARABEN Solid 94-13-3 no cat 
50 iodosulfuron-methyl-sodium  Solid 144550-36-7 no cat 
51 1,5-di(2,4-dimethylphenyl)-3-methyl-1,3,5-triazapenta-1,4-diene 
common name: Amitraz 
Solid 33089-61-1 no cat 
52 2-anilino-4,6-dimethylpyrimidine common name: Pyrimethanil Solid 53112-28-0 no cat 
53 3-(2-chloro-thiazol-5-ylmethyl)-5-methyl[1,3,5]oxadiazinan-4-ylidene-N-
nitroamine common name: Thiamethoxam 
Solid 153719-23-4 no cat 
54 3-chloropropionitrile Liquid 542-76-7 cat 2B 
55 2-methylpropanal INCI name: 2-METHYLPROPANAL Liquid 78-84-2 cat 2B 
56 isopropyl acetoacetate Liquid 542-08-5 cat 2B 
57 2-methyl-1-pentanol Liquid 105-30-6 cat 2B 
58 1-(1-methyl-2-propoxyethoxy)propan-2-ol INCI name: PPG-2 PROPYL 
ETHER 
Liquid 29911-27-1 cat 2B 
59 ethyl-2-methyl acetoacetate Liquid 609-14-3 cat 2B 
60 diethyl toluamide INCI name: DIETHYL TOLUAMIDE  common name: 
DEET 
Liquid 134-62-3 cat 2B 
61 2-hydroxy-1,4-naphthoquinone INCI name: LAWSONE Solid 83-72-7 cat 2B 
62 1,4-dibutoxy benzene Solid 104-36-9 cat 2B 
63 4-nitrobenzoic acid Solid 62-23-7 cat 2B 
64 ethyl 2,6-dichloro-5-fluoro-beta-oxo-3-pyridine propionate Solid 96568-04-6 cat 2B 
65 2,2-dimethyl-3-methylenebicyclo [2.2.1] heptane INCI name: 
CAMPHENE 
Solid 79-92-5 cat 2B 
66 sodium chloroacetate Solid 3926-62-3 cat 2B 
67 gamma-butyrolactone INCI name: BUTYROLACTONE Liquid 96-48-0 cat 2A 
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Chemical Substance name State CAS # GHS Class 
68 
cyclopentanol 
Liquid 96-41-3 cat 2A (ICCVAM: cat 
2B) 
69 alkyl (C10-16) glucoside sodium carboxylate (~ 30% aqueous) INCI name: 
SODIUM CARBOXYMETHYL C10-16 ALKYL GLUCOSIDE 
Liquid 383178-66-3 cat 2A (ICCVAM: cat 
2B) 
70 methyl N,N,N-trimethyl-4-[(4,7,7-trimethyl-3-oxobicyclo[2.2.1]hept-2-
ylidene)methyl]anilinium sulphate (30% aqueous) INCI name: CAMPHOR 
BENZALKONIUM METHOSULFATE 
Liquid 52793-97-2 cat 2A 
71 
1-propoxy-2-propanol INCI name: PROPYLENE GLYCOL PROPYL ETHER 
Liquid 1569-01-3 cat 2A (ICCVAM: cat 
2B) 
72 2,4,11,13-tetraazatetradecanediimidamide, N,N''-bis(4-chlorophenyl)-
3,12-diimino-, di-D-gluconate (20% aqueous) INCI name: 
CHLORHEXIDINE DIGLUCONATE 




Solid 1119-62-6 cat 2A (ICCVAM: cat 
2B) 
74 2-amino-3-hydroxy pyridine INCI name: 2-AMINO-3-HYDROXYPYRIDINE Solid 16867-03-1 cat 2A 
75 sodium benzoate INCI name: SODIUM BENZOATE Solid 532-32-1 cat 2A 
76 6,7-dihydro-2,3-dimethyl-imidazo[1,2-a]pyridin-8(5H)-one Solid 362525-73-3 cat 2A 
77 methyl (2E)-[2-(chloromethyl)phenyl](methoxyimino) acetate Solid 189813-45-4 cat 2A 
78 (2R,3R)-3-((R)-1-(tert-butyldimethylsiloxy)ethyl)-4-oxoazetidin-2-yl 
acetate 
Solid 76855-69-1 cat 2A 
79 
ammonium nitrate INCI name: AMMONIUM NITRATE 
Solid 6484-52-2 cat 2A (ICCVAM: cat 
2B) 
80 methylthioglycolate INCI name: METHYL THIOGLYCOLATE Liquid 2365-48-2 cat 1 
81 3-diethylaminopropionitrile Liquid 02/04/5351 cat 1 
82 coco alkyl dimethyl betaine (~ 30% aqueous) INCI name: COCO-BETAINE Liquid 68424-94-2 cat 1 
83 coco amidopropyl betaine (~ 30% aqueous) INCI name: 
COCAMIDOPROPYL BETAINE 
Liquid 61789-40-0 cat 1 
84 sodium coco amphoacetate (~ 30% aqueous) Liquid 61791-32-0 cat 1 
85 triethanol ammonium alkyl sulphate (~ 40% aqueous) INCI name: TEA-
C12-14 ALKYL SULFATE 
Liquid 90583-18-9 cat 1 
86 di-sodium alkyl ether sulfosuccinate (~ 30% aqueous) INCI name: 
DISODIUM LAURETH SULFOSUCCINATE 
Liquid 68815-56-5 cat 1 
87 sodium alkyl ether sulphate (~ 30% aqueous) INCI name: SODIUM 
LAURETH SULFATE 
Liquid 68891-38-3 cat 1 
88 bisphenol A, diethylene triamine, epichlorohydrin, polypropylene glycol 
diglycidyl ether, polymer (~ 60% aqueous) 
Liquid 118569-52-1 cat 1 
89 ethoxylated (5 EO) alkyl (C10-14) alcohol Liquid 66455-15-0 cat 1 
90 alkyl (C10-16) glucoside (~ 50% aqueous) INCI name: LAURYL 
GLUCOSIDE 
Liquid 110615-47-9 cat 1 
91 (ethylenediaminepropyl)trimethoxysilane Liquid 1760-24-3 cat 1 
92 tetraethylene glycol diacrylate Liquid 17831-71-9 cat 1 
93 2,5-dimethyl-2,5-hexanediol Solid 110-03-2 cat 1 
94 dodecanoic acid  INCI name: LAURIC ACID Solid 143-07-7 cat 1 
95 1,2,4-triazole sodium salt Solid 41253-21-8 cat 1 
96 1-naphthalene acetic acid Solid 86-87-3 cat 1 
97 sodium oxalate INCI name: SODIUM OXALATE Solid 62-76-0 cat 1 
98 4,4'-(4,5,6,7-tetrabromo-3H-2,1-benzoxathiol-3-ylidene)bis[2,6-
dibromophenol] S,S-dioxide INCI name: TETRABROMOPHENOL BLUE 
Solid 4430-25-5 cat 1 
99 1,2-benzisothiazol-3(2H)-one  INCI name: BENZISOTHIAZOLINONE Solid 2634-33-5 cat 1 
100 ethyl lauroyl arginate HCl INCI name: ETHYL LAUROYL ARGINATE HCL Solid 60372-77-2 cat 1 
101 2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride INCI 
name: BASIC ORANGE 31 
Solid 97404-02-9 cat 1 
102 disodium 2,2'-([1,1'-biphenyl]-4,4'-
diyldivinylene)bis(benzenesulphonate) INCI name: DISODIUM 
DISTYRYLBIPHENYL DISULFONATE 
Solid 27344-41-8 cat 1 
103 3,4-dimethyl-1H-pyrazole Solid 2820-37-3 cat 1 
104 N-(2-amino-4,6-dichloropyrimidin-5-yl) formamide Solid 171887-03-9 cat 1 




ylidene)methyl)-2-methylbenzenamine hydrochloride INCI name: BASIC 
VIOLET 2 
Solid 3248-91-7 cat 1 
107
2
 xanthylium, 3,6-bis(diethylamino)-9-[2-(methoxycarbonyl)phenyl]- Solid 134429-57-5 cat 1 
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Chemical Substance name State CAS # GHS Class 
tetrafluoroborate 
1 sent to all participating laboratories for testing but excluded at a very early stage of the study on 
request of one of the participating laboratories because it was identified as a very strong MTT 
reducer 
2 extra chemicals not for statistics but for a later purpose of evaluation using an HPLC based 
detection system. 
3  Chemical 37 (polyethylene glycol (PEG-40) hydrogenated castor oil, INCI name: PEG-40 
HYDROGENATED CASTOR OIL) was originally selected by the EIVS VMG as being a solid. 
However, all three laboratories participating in the validation of the EpiOcular™ EIT independently 
considered the chemical as being liquid due to its low melting point and tested it using the liquid 
protocol of EpiOcular™ EIT (see statistical report on EpiOcular™ EIT). Hence, chemical 37 was 
reclassified as liquid by the VMG. 
 
Chemical 106 (4-((4-amino-3-methylphenyl)(4-imino-3-methyl-2,5-cyclohexadien-1-
ylidene)methyl)-2-methylbenzenamine hydrochloride INCI name: BASIC VIOLET 2) 
and chemical 107 (xanthylium, 3,6-bis(diethylamino)-9-[2-
(methoxycarbonyl)phenyl]-tetrafluoroborate) were sent to all participating 
laboratories for testing but excluded at a very early stage of the study on request of 
one of the participating laboratories because it was identified as a very strong MTT 
reducer. These two chemicals are excluded from any statistical analysis. Hence, the 
statistical analysis is based on 104 chemicals. 
 
In Table 2.1.2, the decoding of the chemicals is given. 
Table 2.1.2 Decoding of chemicals 
Chemical Substance name L’OREAL Cardam Ceetox 
1 1-bromohexane L94 C51 X5 
2 1-methylpropyl benzene L43 C99 X22 
3 2-ethoxyethyl methacrylate L51 C76 X93 
4 
iso-octylthioglycolate INCI name: ISOOCTYL 
THIOGLYCOLATE L7 C53 X62 
5 4-(methylthio)-benzaldehyde L12 C104 X68 
6 dipropyl disulphide L55 C78 X7 
7 1-bromo-4-chlorobutane L66 C82 X89 
8 1-bromo-octane L98 C60 X63 
9 1,9-decadiene L20 C54 X2 
10 2,2-dimethyl-3-pentanol  L87 C12 X30 
11 
2-(2-ethoxyethoxy) ethanol INCI name: 
ETHOXYDIGLYCOL L17 C65 X38 
12 
bisphenol A, epichlorohydrin polymer, 
ethoxylated, propoxylated (53-57% 
aqueousemulsion) L76 C4 X61 
13 
bisphenol A, diethylene triamine, epichlorohydrin 
polymer, ethoxylated, propoxylated (56% 
aqueous emulsion) L36 C20 X77 
14 dioctyl ether INCI name: DICAPRYLYL ETHER L75 C79 X59 
15 
dioctyl carbonate INCI name: DICAPRYLYL 
CARBONATE L53 C67 X94 
16 
2-propylheptyl octanoate INCI name: 
PROPYLHEPTYL CAPRYLATE L27 C37 X103 
17 
polyglyceryl-3 diisooctadecanoate INCI name: 
POLYGLYCERYL-3 DIISOSTEARATE L64 C83 X53 
18 
steareth-10 allyl ether/acrylates copolymer (30% 
aqueous) INCI name: STEARETH-10 ALLYL 
ETHER/ACRYLATES COPOLYMER L50 C71 X19 
19 
dimethyl siloxane, mono dimethylvinylsiloxy- and  
mono trimethoxysiloxy-terminated  (95%) L111 C114 X113 
20 ricinoleic acid tin salt L58 C58 X37 
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Chemical Substance name L’OREAL Cardam Ceetox 
21 1-ethyl-3-methylimidazolium ethylsulphate L72 C46 X82 
22 3-phenoxybenzyl alcohol  L101 C47 X3 
23 
ethyl thioglycolate INCI name: ETHYL 
THIOGLYCOLATE L140 C128 X139 
24 glycidyl methacrylate  L119 C139 X128 
25 
piperonyl butoxide INCI name: PIPERONYL 
BUTOXIDE L161 C141 X143 
26 propiconazole L185 C163 X190 
27 2-ethylhexylthioglycolate L74 C87 X17 
28 4,4'-methylene bis-(2,6-di-tert-butylphenol) L60 C85 X1 
29 
tetradecyl tetradecanoate INCI name: MYRISTYL 
MYRISTATE L127 C140 X120 
30 1,1-dimethylguanidine sulphate L134 C131 X131 
31 potassium tetrafluoroborate L122 C129 X116 
32 
2,6-dihydroxy-3,4-dimethylpyridine INCI name: 
2,6-DIHYDROXY-3,4-DIMETHYLPYRIDINE L57 C38 X91 
33 
2,2'-[[4-[(2-methoxyethyl)amino]-3-
nitrophenyl]imino]bis-ethanol INCI name: HC 




name: DISPERSE RED 17 L99 C45 X27 
35 
2,5,6-triamino-4-pyrimidinol sulphate INCI name: 
2,5,6-TRIAMINO-4-PYRIMIDINOL SULFATE L85 C30 X13 
36 
1-(4-chlorophenyl)-3-(3,4-dichlorophenyl) urea 
INCI name: TRICLOCARBAN L18 C2 X72 
37 
polyethylene glycol (PEG-40) hydrogenated castor 
oil INCI name: PEG-40 HYDROGENATED CASTOR 
OIL L109 C109 X110 
38 
2,2'-methylene-bis-(6-(2H-benzotriazol-2-yl)-4-
(1,1,3,3-tetramethylbutyl)phenol)  INCI name: 
METHYLENE BIS-BENZOTRIAZOLYL 
TETRAMETHYLBUTYLPHENOL L62 C39 X11 
39 
2,2'-[6-(4-methoxyphenyl)-1,3,5-triazine-2,4-
diyl]bis[5-[(2-ethylhexyl)oxy]-phenol]  INCI name: 
BIS-ETHYLHEXYLOXYPHENOL METHOXYPHENYL 
TRIAZINE L65 C14 X55 
40 
acrylamidopropyltrimonium chloride/acrylamide 
copolymer L15 C55 X40 
41 
tris(2-ethylhexyl)-4,4',4''-(1,3,5-triazine-2,4,6-
triyltriimino) tribenzoate INCI name: ETHYLHEXYL 
TRIAZONE L106 C105 X115 
42 
trisodium mono-(5-(1,2-dihydroxyethyl)-4-oxido-
2-oxo-2,5-dihydro-furan-3-yl) phosphate INCI 




benzoate INCI name: DIETHYLAMINO 
HYDROXYBENZOYL HEXYL BENZOATE L115 C108 X107 
44 
[3-chloro-4-[(3-fluorobenzyl)oxy]phenyl](6-
iodoquinazolin-4-yl)amine L112 C107 X112 
45 
1-(9H-carbazol-4-yloxy)-3-[[2-(2-




chloride (91%) INCI name: POLYQUATERNIUM-10 L114 C106 X109 
47 
3,4-dimethoxy benzaldehyde INCI name: 
VERATRALDEHYDE L113 C112 X111 
48 
sodium hydrogensulphite  INCI name: SODIUM 
BISULFITE L129 C135 X119 
49 
propyl-4-hydroxybenzoate INCI name: 
PROPYLPARABEN L169 C195 X173 
50 iodosulfuron-methyl-sodium  L148 C185 X158 
51 
1,5-di(2,4-dimethylphenyl)-3-methyl-1,3,5-
triazapenta-1,4-diene common name: Amitraz L156 C164 X169 
52 2-anilino-4,6-dimethylpyrimidine common name: L144 C166 X160 
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common name: Thiamethoxam L200 C196 X157 
54 3-chloropropionitrile L81 C19 X6 
55 
2-methylpropanal INCI name: 2-
METHYLPROPANAL L132 C134 X117 
56 isopropyl acetoacetate L131 C127 X138 
57 2-methyl-1-pentanol L92 C50 X33 
58 
1-(1-methyl-2-propoxyethoxy)propan-2-ol INCI 
name: PPG-2 PROPYL ETHER L120 C119 X133 
59 ethyl-2-methyl acetoacetate L133 C132 X118 
60 
diethyl toluamide INCI name: DIETHYL 
TOLUAMIDE  common name: DEET L125 C137 X127 
61 
2-hydroxy-1,4-naphthoquinone INCI name: 
LAWSONE L5 C96 X86 
62 1,4-dibutoxy benzene L118 C116 X125 
63 4-nitrobenzoic acid L126 C120 X123 
64 
ethyl 2,6-dichloro-5-fluoro-beta-oxo-3-pyridine 
propionate L79 C70 X50 
65 
2,2-dimethyl-3-methylenebicyclo [2.2.1] heptane 
INCI name: CAMPHENE L137 C124 X134 
66 sodium chloroacetate L123 C125 X129 
67 
gamma-butyrolactone INCI name: 
BUTYROLACTONE L45 C91 X45 
68 cyclopentanol L48 C26 X52 
69 
alkyl (C10-16) glucoside sodium carboxylate (~ 
30% aqueous) INCI name: SODIUM 




sulphate (30% aqueous) INCI name: CAMPHOR 
BENZALKONIUM METHOSULFATE L130 C123 X121 
71 
1-propoxy-2-propanol INCI name: PROPYLENE 




(20% aqueous) INCI name: CHLORHEXIDINE 
DIGLUCONATE L139 C138 X136 
73 3,3'-dithiopropionic acid L73 C49 X47 
74 
2-amino-3-hydroxy pyridine INCI name: 2-AMINO-
3-HYDROXYPYRIDINE L102 C34 X39 
75 sodium benzoate INCI name: SODIUM BENZOATE L11 C35 X36 
76 
6,7-dihydro-2,3-dimethyl-imidazo[1,2-a]pyridin-
8(5H)-one L4 C84 X70 
77 
methyl (2E)-[2-
(chloromethyl)phenyl](methoxyimino) acetate L67 C16 X84 
78 
(2R,3R)-3-((R)-1-(tert-butyldimethylsiloxy)ethyl)-
4-oxoazetidin-2-yl acetate L61 C15 X102 
79 
ammonium nitrate INCI name: AMMONIUM 
NITRATE L136 C136 X126 
80 
methylthioglycolate INCI name: METHYL 
THIOGLYCOLATE L9 C6 X31 
81 3-diethylaminopropionitrile L78 C90 X51 
82 
coco alkyl dimethyl betaine (~ 30% aqueous) INCI 
name: COCO-BETAINE L80 C64 X56 
83 
coco amidopropyl betaine (~ 30% aqueous) INCI 
name: COCAMIDOPROPYL BETAINE L82 C33 X83 
84 sodium coco amphoacetate (~ 30% aqueous) L37 C97 X29 
85 
triethanol ammonium alkyl sulphate (~ 40% 
aqueous) INCI name: TEA-C12-14 ALKYL SULFATE L23 C66 X28 
86 
di-sodium alkyl ether sulfosuccinate (~ 30% 
aqueous) INCI name: DISODIUM LAURETH 
SULFOSUCCINATE L16 C29 X66 
87 
sodium alkyl ether sulphate (~ 30% aqueous) INCI 
name: SODIUM LAURETH SULFATE L59 C77 X41 
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Chemical Substance name L’OREAL Cardam Ceetox 
88 
bisphenol A, diethylene triamine, epichlorohydrin, 
polypropylene glycol diglycidyl ether, polymer (~ 
60% aqueous) L33 C48 X42 
89 ethoxylated (5 EO) alkyl (C10-14) alcohol L42 C25 X25 
90 
alkyl (C10-16) glucoside (~ 50% aqueous) INCI 
name: LAURYL GLUCOSIDE L104 C13 X64 
91 (ethylenediaminepropyl)trimethoxysilane L29 C3 X81 
92 tetraethylene glycol diacrylate L174 C170 X165 
93 2,5-dimethyl-2,5-hexanediol L91 C63 X16 
94 dodecanoic acid  INCI name: LAURIC ACID L97 C94 X43 
95 1,2,4-triazole sodium salt L68 C75 X73 
96 1-naphthalene acetic acid L28 C88 X99 
97 sodium oxalate INCI name: SODIUM OXALATE L39 C36 X49 
98 
4,4'-(4,5,6,7-tetrabromo-3H-2,1-benzoxathiol-3-
ylidene)bis[2,6-dibromophenol] S,S-dioxide INCI 
name: TETRABROMOPHENOL BLUE L1 C28 X24 
99 
1,2-benzisothiazol-3(2H)-one  INCI name: 
BENZISOTHIAZOLINONE L83 C21 X21 
100 
ethyl lauroyl arginate HCl INCI name: ETHYL 
LAUROYL ARGINATE HCL L164 C193 X196 
101 
2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-
imidazolium chloride INCI name: BASIC ORANGE 
31 L13 C9 X80 
102 
disodium 2,2'-([1,1'-biphenyl]-4,4'-
diyldivinylene)bis(benzenesulphonate) INCI name: 
DISODIUM DISTYRYLBIPHENYL DISULFONATE L32 C103 X75 
103 3,4-dimethyl-1H-pyrazole L56 C62 X87 
104 
N-(2-amino-4,6-dichloropyrimidin-5-yl) 
formamide L96 C27 X46 
105 
1,2-dihydro-1,3,4,6-tetramethyl-2-oxo-




methylbenzenamine hydrochloride INCI name: 
BASIC VIOLET 2 L6 C52 X95 
107 
xanthylium, 3,6-bis(diethylamino)-9-[2-
(methoxycarbonyl)phenyl]-tetrafluoroborate L100 C56 X32 
 
2.2 Archiving 
One data file in a flat file format will be provided which includes all quality checked 
test-results from all three laboratories for possible later use. A readme-file will be 
provided which explains each variable in the data set.  
 
The SAS code which was used for statistical analysis is provided in Appendix II. 
2.3 Receipt of data 
The study results were received by the statistician from the Trial coordinator. The 
receipt of data was reported in an excel file. The report on the receipt of data can be 
found in Appendix III. 
2.4 Test acceptance criteria 
2.4.1 Test acceptance criteria 
The test acceptance criteria are described in detail in the SkinEthicTM HCE SOP.. 
 
In short, the following test acceptance criteria are applied. 
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Subject Criteria Remark 
NC response 0.7 < OD < 1.5  
PC mean viability ≤ 50%  
Tissue variability  Standard deviation ≤ 18% Over replicates, for chemicals, PC and NC 
 
2.4.2 Study acceptance criteria 
The study acceptance criteria are described in detail in the Guidance on eye 
irritation validation study (EIVS) conduct for the reconstructed human tissue (RhT) 
assays and performance criteria to assess the scientific validity of SkinEthicTM HCE 
and EpiOcularTM EIT and its addendum (see appendix VII and VIII). 
 
In short, the following study acceptance criteria are applied. 
 
Subject Criteria Remark 
Complete test sequences ≥ 85% In each laboratory 
Within laboratory variability 
(concordance of classification) 
≥ 85% Using test chemicals for which at least two 
qualified tests are available 
Between laboratory variability 
(concordance of classification) 
≥ 80% Using test chemicals for which at least one 
qualified test per laboratory is available 
Sensitivity ≥90% Based on all qualified tests 
Specificity ≥60% Based on all qualified tests 
Accuracy ≥75% Based on all qualified tests 
 
A test sequence is considered complete if it contains three qualified tests. 
Otherwise, the test sequence is considered as incomplete. 
 
If the test method fulfils the above stated acceptance criteria, the performance of 
the method is considered to be ‘definitely acceptable’. For sensitivity, specificity and 
accuracy, some additional criteria are defined to be able to distinguish between a 
definitely unacceptable performance and a performance which might need some 
further evaluation. These criteria are defined as follows: 
 
 False Negativesa (%) False Positivesb (%) Overall 
misclassificationsc (%) 
“Definitely acceptable” rates  ≤ 10 ≤ 40 ≤ 25 
Further evaluations 
necessary before any 
recommendation is made 
10 < FN ≤ 20 40 < FP ≤ 50 25 < OM ≤ 35 
“Definitely unacceptable” 
rates > 20 > 50 > 35 
a
 equal to (1-Sensitivity), b equal to (1-Specificity), c equal to (1-Overall accuracy) 
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2.5 Statistical methods 
The statistical analyses are performed according to the Statistical Analysis and 
Reporting Plan for the ECVAM/COLIPA Eye Irritation Validation Study on 
Reconstructed Human Tissue Models (final version May 5, 2011). The statistical 
analysis is based on the performance criteria document Guidance on eye irritation 
validation study (EIVS) conduct for the reconstructed human tissue (RhT) assays 
and performance criteria to assess the scientific validity of SkinEthicTM HCE and 
EpiOcularTM EIT and its addendum (see appendix VII and VIII). 
2.5.1 Quality checks 
Before starting the statistical analyses, the following quality checks were done: 
- Is the information complete? 
- Are the test acceptance criteria always met? 
- Are there any deviations from the study plan? 
- Are there any remarks and special observations as given in the reporting 
sheet by the study personal? 
 
Some chemicals might be incompatible with the test method. Evaluation of 
compatibility was evaluated for colouring or MTT-reducing chemicals by the 
following criteria: 
 
RULE 1 – IF the mean of %NSC or %NSMTT of all qualified tests obtained for a 
chemical in one laboratory is less than or equal to (≤) 50%, THEN this chemical is 
considered to be compatible with the test method. The chemical should be included in 
the overview tables, and included in all statistical calculations of reproducibility and 
predictive capacity. 
  
RULE 2 – IF the mean of %NSC or %NSMTT of all qualified tests obtained for a 
chemical in one laboratory is greater than (>) 50% AND their classification (I or NI) 
remains the same upon correction, THEN this chemical is considered to be compatible 
with the test method. The chemical should be included in the overview tables, and 
included in all statistical calculations of reproducibility and predictive capacity. 
  
RULE 3 – IF the mean of %NSC or %NSMTT of all qualified tests obtained for a 
chemical in one laboratory is greater than (>) 50% AND the classification of at least 
one of the qualified tests changes upon correction, THEN this chemical is considered 
to be incompatible with the test method. The chemical should be included in the 
overview tables, but excluded from all statistical calculations of reproducibility and 
predictive capacity. 
2.5.2 Descriptive statistics 
The descriptive statistics contain summary tables on the chemical selection set (e.g. 
cross tables with long exposure (LE) and short exposure (SE)), the number of 
qualified tests, the number of complete test sequences, etcetera. 
2.5.3 Within Laboratory Reproducibility (WLR) 
For each laboratory, concordance of classifications and overall Standard Deviation 
were calculated based on qualified tests from test chemicals for which at least two 
qualified tests are available. For each laboratory, concordance of classifications and 
overall Standard Deviation were also calculated based on all tests performed, 
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including both qualified and non-qualified tests. The WLR is calculated using the SE 
protocol, the LE protocol as well as using the test strategy. 
2.5.4 Between Laboratory Reproducibility (BLR) 
For the calculation of BLR the final classification for each test chemical in each 
participating laboratory should be obtained by using the arithmetic mean value of 
viability over the different qualified tests performed. Concordance of classifications 
between laboratories and overall Standard Deviation of the study were calculated 
based only on qualified tests from test chemicals for which at least one qualified test 
per laboratory is available. The overall Standard Deviation of the study is also 
calculated based on all tests performed, including both qualified and non-qualified 
tests. The BLR is calculated using the SE protocol, the LE protocol as well as using 
the test strategy. 
2.5.5 Predictive capacity (accuracy) 
All qualified tests for each test chemical were used to calculate the predictive 
capacity values. The calculations were based on the individual predictions of each 
qualified test in each laboratory and not on the arithmetic mean values of viability 
over the different qualified tests performed. The predictive capacity is calculated 
using the SE protocol, the LE protocol as well as using the test strategy. 
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3 Results 
3.1 Quality checks 
Data were imported from the original spread sheets into a SAS data base. All test 
results in the data base are checked by the laboratories and their approval was 
given for completeness and correctness before the statistical analysis was started. 
 
The remarks and special observations as given by the study personal in the 
reporting sheets are listed in Appendix IV.  
 
In Table 3.1.1, the number of non-qualified and qualified runs are given, based on 
the acceptance criteria for NC and PC. 
Table 3.1.1 Number of non-qualified and qualified runs, based on the acceptance criteria for NC and PC, 
subdivided into laboratories 
Protocol laboratory  No. Qualified % No .Non-Qualified % 
SE CARDAM NC 35 100.0 0 0.0 
  PC 35 100.0 0 0.0 
 CEETOX NC 40 100.0 0 0.0 
  PC 40 100.0 0 0.0 
 L’OREAL NC 34 100.0 0 0.0 
  PC 34 100.0 0 0.0 
LE CARDAM NC 33 100.0 0 0.0 
  PC 33 100.0 0 0.0 
 CEETOX NC 44 100.0 0 0.0 
  PC 36 81.8 8 18.2 
 L’OREAL NC 34 100.0 0 0.0 
  PC 33 97.1 1 2.9 
 
There were no major deviations from the study plan (see appendix IV for detailed 
remarks). 
3.2 Descriptive statistics 
3.2.1 Distribution of test chemicals 
 
In Table 3.2.1 the distribution of test chemicals is given. The 104 chemicals were 
equally distributed among irritants (50%) and non-irritants (50%) and among liquids 
(50%) and solids (50%). The distribution regarding the reactivity is given as well. 
Table 3.2.1 Distribution of test chemicals (upper: frequencies, lower: percentages; NR = non-
reactive, R = reactive) 





































1  Chemical 37 (polyethylene glycol (PEG-40) hydrogenated castor oil INCI name: PEG-40 
HYDROGENATED CASTOR OIL) was listed as solid, but is statistically analysed as a liquid.  
 
  
TNO report | TNO 2013 R11617 | Final report  17 / 305
Corrections on total viability were made for MTT-reducing and/or colouring 
chemicals. Whether this correction had to be made was decided by the laboratory. 
For some chemicals, the judgement whether it regards an MTT-reducer or a 
colorant differed between laboratories as is shown in Table 3.2.2. In appendix I, a 
list is given of all MTT-reducing and/or colouring chemicals. If a chemical is treated 
as an MTT-reducer or a colorant in at least one of the laboratories, it is listed in 
appendix I. 
Table 3.2.2 Colouring or MTT-reducing chemicals which are treated differently between 
laboratories are indicated by #. 
   MTT  Colouring  
Chemical Name Cardam Ceetox L’OREAL  Cardam Ceetox L’OREAL  
1 1-bromohexane No No Yes # No No No  
2 1-methylpropyl benzene No No Yes # No No No  
3 2-ethoxyethyl methacrylate No No No  No No No  
4 iso-octylthioglycolate INCI name: ISOOCTYL 
THIOGLYCOLATE 
Yes Yes Yes  No No No  
5 4-(methylthio)-benzaldehyde Yes Yes Yes  No No No  
6 dipropyl disulphide No No No  No No No  
7 1-bromo-4-chlorobutane No No Yes # No No No  
8 1-bromo-octane No No No  No No No  
9 1,9-decadiene Yes No Yes # No No No  
10 2,2-dimethyl-3-pentanol  No No No  No No No  
11 2-(2-ethoxyethoxy) ethanol INCI name: 
ETHOXYDIGLYCOL 
No No Yes # No No No  
12 bisphenol A, epichlorohydrin polymer, 
ethoxylated, propoxylated (53-57% 
aqueousemulsion) 
No No No  No No No  
13 bisphenol A, diethylene triamine, epichlorohydrin 
polymer, ethoxylated, propoxylated (56% aqueous 
emulsion) 
No No No  No No No  
14 dioctyl ether INCI name: DICAPRYLYL ETHER No Yes No # No No No  
15 dioctyl carbonate INCI name: DICAPRYLYL 
CARBONATE 
No No No  No No No  
16 2-propylheptyl octanoate INCI name: 
PROPYLHEPTYL CAPRYLATE 
No No Yes # No No No  
17 polyglyceryl-3 diisooctadecanoate INCI name: 
POLYGLYCERYL-3 DIISOSTEARATE 
No No No  No No No  
18 steareth-10 allyl ether/acrylates copolymer (30% 
aqueous) INCI name: STEARETH-10 ALLYL 
ETHER/ACRYLATES COPOLYMER 
No No No  No No No  
19 dimethyl siloxane, mono dimethylvinylsiloxy- and  
mono trimethoxysiloxy-terminated  (95%) 
No No No  No No No  
20 ricinoleic acid tin salt Yes No Yes # No No No  
21 1-ethyl-3-methylimidazolium ethylsulphate No No Yes # No No No  
22 3-phenoxybenzyl alcohol  No No No  No No No  
23 ethyl thioglycolate INCI name: ETHYL 
THIOGLYCOLATE 
Yes Yes Yes  No No No  
24 glycidyl methacrylate  No No Yes # No No No  
25 piperonyl butoxide INCI name: PIPERONYL 
BUTOXIDE 
Yes Yes Yes  No No No  
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   MTT  Colouring  
Chemical Name Cardam Ceetox L’OREAL  Cardam Ceetox L’OREAL  
26 propiconazole No No No  No No No  
28 4,4'-methylene bis-(2,6-di-tert-butylphenol) No No No  No No No  
29 tetradecyl tetradecanoate INCI name: MYRISTYL 
MYRISTATE 
No No No  No No No  
30 1,1-dimethylguanidine sulphate No No No  No No No  
31 potassium tetrafluoroborate No No No  No No No  
32 2,6-dihydroxy-3,4-dimethylpyridine INCI name: 
2,6-DIHYDROXY-3,4-DIMETHYLPYRIDINE 
No No Yes # Yes No Yes # 
33 2,2'-[[4-[(2-methoxyethyl)amino]-3-
nitrophenyl]imino]bis-ethanol INCI name: HC BLUE 
NO. 11 
Yes Yes Yes  Yes Yes Yes  
34 2,2'-[[3-methyl-4-[(4-
nitrophenyl)azo]phenyl]imino]bis-ethanol INCI 
name: DISPERSE RED 17 
Yes Yes Yes  Yes Yes Yes  
35 2,5,6-triamino-4-pyrimidinol sulphate INCI name: 
2,5,6-TRIAMINO-4-PYRIMIDINOL SULFATE 
Yes Yes Yes  No No No  
36 1-(4-chlorophenyl)-3-(3,4-dichlorophenyl) urea 
INCI name: TRICLOCARBAN 
No No No  No No No  
37 polyethylene glycol (PEG-40) hydrogenated castor 
oil INCI name: PEG-40 HYDROGENATED CASTOR 
OIL 
No Yes No # No No No  
38 2,2'-methylene-bis-(6-(2H-benzotriazol-2-yl)-4-
(1,1,3,3-tetramethylbutyl)phenol)  INCI name: 
METHYLENE BIS-BENZOTRIAZOLYL 
TETRAMETHYLBUTYLPHENOL 
No No No  No No No  
39 2,2'-[6-(4-methoxyphenyl)-1,3,5-triazine-2,4-
diyl]bis[5-[(2-ethylhexyl)oxy]-phenol]  INCI name: 
BIS-ETHYLHEXYLOXYPHENOL METHOXYPHENYL 
TRIAZINE 
No No No  No No No  
40 acrylamidopropyltrimonium chloride/acrylamide 
copolymer 
No No No  No No No  
41 tris(2-ethylhexyl)-4,4',4''-(1,3,5-triazine-2,4,6-
triyltriimino) tribenzoate INCI name: ETHYLHEXYL 
TRIAZONE 
No No No  No No No  
42 trisodium mono-(5-(1,2-dihydroxyethyl)-4-oxido-2-
oxo-2,5-dihydro-furan-3-yl) phosphate INCI name: 
SODIUM ASCORBYL PHOSPHATE 
Yes Yes Yes  No No No  
43 hexyl 2-(1-
(diethylaminohydroxyphenyl)methanoyl) benzoate 
INCI name: DIETHYLAMINO HYDROXYBENZOYL 
HEXYL BENZOATE 
No No No  No No No  
44 [3-chloro-4-[(3-fluorobenzyl)oxy]phenyl](6-
iodoquinazolin-4-yl)amine 
No No No  No No No  
45 1-(9H-carbazol-4-yloxy)-3-[[2-(2-
methoxyphenoxy)ethyl]amino]propan-2-ol 
No No No  No No No  
46 cellulose, 2-(2-hydroxy-3-
(trimethylammonium)propoxy)ethyl ether chloride 
(91%) INCI name: POLYQUATERNIUM-10 
No Yes No # No No No  
47 3,4-dimethoxy benzaldehyde INCI name: No No No  No No No  
  
TNO report | TNO 2013 R11617 | Final report  19 / 305
   MTT  Colouring  
Chemical Name Cardam Ceetox L’OREAL  Cardam Ceetox L’OREAL  
VERATRALDEHYDE 
48 sodium hydrogensulphite  INCI name: SODIUM 
BISULFITE 
Yes Yes No # No No No  
49 propyl-4-hydroxybenzoate INCI name: 
PROPYLPARABEN 
Yes Yes Yes  No No No  
50 iodosulfuron-methyl-sodium  No No No  No No No  
51 1,5-di(2,4-dimethylphenyl)-3-methyl-1,3,5-
triazapenta-1,4-diene common name: Amitraz 
No No No  No No No  
52 2-anilino-4,6-dimethylpyrimidine common name: 
Pyrimethanil 
No No No  No No No  
53 3-(2-chloro-thiazol-5-ylmethyl)-5-
methyl[1,3,5]oxadiazinan-4-ylidene-N-nitroamine 
common name: Thiamethoxam 
No No No  No No No  
54 3-chloropropionitrile No No No  No No No  
55 2-methylpropanal INCI name: 2-
METHYLPROPANAL 
No Yes Yes # No No No  
56 isopropyl acetoacetate No Yes No # No No No  
57 2-methyl-1-pentanol No No No  No No No  
58 1-(1-methyl-2-propoxyethoxy)propan-2-ol INCI 
name: PPG-2 PROPYL ETHER 
No Yes Yes # No No No  
59 ethyl-2-methyl acetoacetate No Yes Yes # No No No  
60 diethyl toluamide INCI name: DIETHYL TOLUAMIDE  
common name: DEET 
No No No  No No No  
61 2-hydroxy-1,4-naphthoquinone INCI name: 
LAWSONE 
No No No  Yes No Yes # 
62 1,4-dibutoxy benzene No No No  No No No  
63 4-nitrobenzoic acid No No No  No No No  
64 ethyl 2,6-dichloro-5-fluoro-beta-oxo-3-pyridine 
propionate 
No No No  No No No  
65 2,2-dimethyl-3-methylenebicyclo [2.2.1] heptane 
INCI name: CAMPHENE 
No No No  No No No  
66 sodium chloroacetate No No No  No No No  
67 gamma-butyrolactone INCI name: 
BUTYROLACTONE 
No No Yes # No No No  
68 cyclopentanol No No No  No No No  
69 alkyl (C10-16) glucoside sodium carboxylate (~ 30% 
aqueous) INCI name: SODIUM CARBOXYMETHYL 
C10-16 ALKYL GLUCOSIDE 
No No No  No No No  
70 methyl N,N,N-trimethyl-4-[(4,7,7-trimethyl-3-
oxobicyclo[2.2.1]hept-2-ylidene)methyl]anilinium 
sulphate (30% aqueous) INCI name: CAMPHOR 
BENZALKONIUM METHOSULFATE 
No No No  No No No  
71 1-propoxy-2-propanol INCI name: PROPYLENE 
GLYCOL PROPYL ETHER 
No Yes Yes # No No No  
72 2,4,11,13-tetraazatetradecanediimidamide, N,N''-
bis(4-chlorophenyl)-3,12-diimino-, di-D-gluconate 
(20% aqueous) INCI name: CHLORHEXIDINE 
DIGLUCONATE 
No Yes Yes # No No No  
73 3,3'-dithiopropionic acid No No No  No No No  
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   MTT  Colouring  
Chemical Name Cardam Ceetox L’OREAL  Cardam Ceetox L’OREAL  
74 2-amino-3-hydroxy pyridine INCI name: 2-AMINO-
3-HYDROXYPYRIDINE 
Yes Yes Yes  Yes No Yes # 
75 sodium benzoate INCI name: SODIUM BENZOATE No No No  No No No  
76 6,7-dihydro-2,3-dimethyl-imidazo[1,2-a]pyridin-
8(5H)-one 
No No No  No No No  
77 methyl (2E)-[2-
(chloromethyl)phenyl](methoxyimino) acetate 
No No No  No No No  
78 (2R,3R)-3-((R)-1-(tert-butyldimethylsiloxy)ethyl)-4-
oxoazetidin-2-yl acetate 
No No No  No No No  
79 ammonium nitrate INCI name: AMMONIUM 
NITRATE 
No No No  No No No  
80 methylthioglycolate INCI name: METHYL 
THIOGLYCOLATE 
Yes Yes Yes  No No No  
81 3-diethylaminopropionitrile Yes Yes No # No No No  
82 coco alkyl dimethyl betaine (~ 30% aqueous) INCI 
name: COCO-BETAINE 
No No No  No No No  
83 coco amidopropyl betaine (~ 30% aqueous) INCI 
name: COCAMIDOPROPYL BETAINE 
No No Yes # No No No  
84 sodium coco amphoacetate (~ 30% aqueous) No No No  No No No  
85 triethanol ammonium alkyl sulphate (~ 40% 
aqueous) INCI name: TEA-C12-14 ALKYL SULFATE 
No No No  No No No  
86 di-sodium alkyl ether sulfosuccinate (~ 30% 
aqueous) INCI name: DISODIUM LAURETH 
SULFOSUCCINATE 
No No No  No No No  
87 sodium alkyl ether sulphate (~ 30% aqueous) INCI 
name: SODIUM LAURETH SULFATE 
No No Yes # No No No  
88 bisphenol A, diethylene triamine, epichlorohydrin, 
polypropylene glycol diglycidyl ether, polymer (~ 
60% aqueous) 
Yes Yes Yes  No No No  
89 ethoxylated (5 EO) alkyl (C10-14) alcohol No No No  No No No  
90 alkyl (C10-16) glucoside (~ 50% aqueous) INCI 
name: LAURYL GLUCOSIDE 
No No Yes # No No No  
91 (ethylenediaminepropyl)trimethoxysilane Yes Yes Yes  No No No  
92 tetraethylene glycol diacrylate Yes Yes Yes  No No No  
93 2,5-dimethyl-2,5-hexanediol No No No  No No No  
94 dodecanoic acid  INCI name: LAURIC ACID No No No  No No No  
95 1,2,4-triazole sodium salt Yes No No # No No No  
96 1-naphthalene acetic acid No No No  No No No  
97 sodium oxalate INCI name: SODIUM OXALATE No No No  No No No  
98 4,4'-(4,5,6,7-tetrabromo-3H-2,1-benzoxathiol-3-
ylidene)bis[2,6-dibromophenol] S,S-dioxide INCI 
name: TETRABROMOPHENOL BLUE 
No Yes No # Yes Yes Yes  
99 1,2-benzisothiazol-3(2H)-one  INCI name: 
BENZISOTHIAZOLINONE 
No No No  No No No  
100 ethyl lauroyl arginate HCl INCI name: ETHYL 
LAUROYL ARGINATE HCL 
No No No  No No No  
101 2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-
imidazolium chloride INCI name: BASIC ORANGE 
31 
No No No  Yes No Yes # 
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   MTT  Colouring  
Chemical Name Cardam Ceetox L’OREAL  Cardam Ceetox L’OREAL  
102 disodium 2,2'-([1,1'-biphenyl]-4,4'-
diyldivinylene)bis(benzenesulphonate) INCI name: 
DISODIUM DISTYRYLBIPHENYL DISULFONATE 
No No No  No No No  
103 3,4-dimethyl-1H-pyrazole No Yes No # No No No  
104 N-(2-amino-4,6-dichloropyrimidin-5-yl) formamide No Yes No # No No No  
105 1,2-dihydro-1,3,4,6-tetramethyl-2-oxo-
pyrimidinium hydrogensulphate 
No No No  No Yes No # 
3.2.2 Number and fraction of qualified and non-qualified tests 
If the standard deviation of the viability between the three tested tissues was above 
18%, the test was considered to be non-qualified. This could concern the tests for 
the NC, the PC and the chemicals. The number and fraction of qualified and non-
qualified tests are presented in Table 3.2.3, subdivided into laboratories and total. 
The reasons for the non-qualification of a test is presented in Appendix V. 
Table 3.2.3 Number and fraction of qualified and non-qualified tests 
Procotol Laboratory Call No. Fraction (%) 
SE CARDAM Qualified and included 312 98.7 
 
 Non-Qualified 4 1.3 
 
CEETOX Qualified and included 312 99.7 
 
 Non-Qualified 1 0.3 
 
L’OREAL Qualified and included 312 98.7 
 
 Non-Qualified 4 1.3 
 
Total Qualified and included 936 99.0 
 
 Non-Qualified 9 1 
     
LE CARDAM Qualified and included 314 99.4 
 
 Non-Qualified 2 0.6 
 
CEETOX Qualified and included 311 81.8 
 
 Non-Qualified 69 18.2 
 
L’OREAL Qualified and included 312 96.3 
 
 Non-Qualified 12 3.7 
 
Total Qualified and included 937 91.9 
 
 Non-Qualified 83 8.1 
3.2.3 Chemicals within a run 
Table 3.2.4 shows the chemicals within each run subdivided into laboratories. The 
chemicals are tested in each run with a test with NC and a test with PC. 
Table 3.2.4 Chemicals within each run subdivided into laboratories (chemicals with test numbers 
between brackets) 
Protocol Laboratory Run 
SE Cardam EIVS_CARDAM_SE_10HCE029_35.xls C1(1) C2(1) C17(1) C19(1) C26(1) C30(1) C33(1) C34(1) C35(1) 
EIVS_CARDAM_SE_10HCE031_37.xls C1(2) C2(2) C17(2) C19(2) C26(2) C30(2) C33(2) C34(2) C35(2) 
EIVS_CARDAM_SE_10HCE032_38.xls C1(3) C2(3) C17(3) C19(3) C26(3) C30(3) C77(1) C34(3) C35(3) 
EIVS_CARDAM_SE_10HCE033_39(C77).xls C77(2) 
EIVS_CARDAM_SE_10HCE033_39.xls C33(3) C35(4) C36(1) C37(1) C49(1) C51(1) C54(1) C60(1) C63(1) C65(1) C66(1) C75(1) C76(1) 
EIVS_CARDAM_SE_10HCE034_40(C79).xls C79(1) 
EIVS_CARDAM_SE_10HCE034_40.xls C36(2) C37(2) C49(2) C51(2) C54(2) C60(2) C63(2) C65(2) C66(2) C75(2) C76(2) C77(3) C78(1) 
EIVS_CARDAM_SE1_10HCE035_41.xls C36(3) C37(3) C49(3) C51(3) C54(3) C60(3) C63(3) C65(3) C66(3) C75(3) C76(3) C78(2) C79(2) 
EIVS_CARDAM_SE2_10HCE035_41.xls C82(1) C85(1) C87(1) C88(1) C90(1) C91(1) C94(1) C96(1) 
EIVS_CARDAM_SE1_10HCE036_42.xls C78(3) C79(3) C82(2) C85(2) C87(2) C88(2) C90(2) C91(2) C94(2) C96(2) C99(1) C104(1) C3(1) 
EIVS_CARDAM_SE1_10HCE037_43.xls C82(3) C85(3) C87(3) C88(3) C90(3) C91(3) C94(3) C96(3) C99(2) C104(2) C3(2) C11(2) C12(2) 
EIVS_CARDAM_SE1_10HCE040_46.xls C99(3) C104(3) C3(3) C11(3) C12(3) C13(3) C15(3) C16(3) C21(3) C25(3) C27(3) C38(2) C45(1) 
EIVS_CARDAM_SE1_10HCE041_47.xls C38(3) C45(2) C46(2) C47(2) C50(2) C53(2) C62(2) C70(2) C83(2) C84(2) C98(1) C101(1) C119(1) 
EIVS_CARDAM_SE1_10HCE042_48.xls C45(3) C46(3) C47(3) C50(3) C53(3) C62(3) C70(3) C83(3) C84(3) C98(2) C101(2) C119(2) C123(2) 
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Protocol Laboratory Run 
EIVS_CARDAM_SE2_10HCE036_42.xls C11(1) C12(1) C13(1) C15(1) C16(1) C21(1) C25(1) C27(1) 
EIVS_CARDAM_SE2_10HCE037_43.xls C13(2) C15(2) C16(2) C21(2) C25(2) C27(2) C38(1) 
EIVS_CARDAM_SE2_10HCE040_46.xls C46(1) C47(1) C50(1) C53(1) C62(1) C70(1) C83(1) C84(1) 
EIVS_CARDAM_SE2_10HCE041_47.xls C123(1) C127(1) C132(1) C134(1) C6(1) 
EIVS_CARDAM_SE2_10HCE042_48.xls C127(2) C132(2) C134(2) C135(1) C136(1) C138(1) C6(2) 
EIVS_CARDAM_SE_10HCE044_50.xls C45(4) C53(4) C98(3) C101(3) C119(3) C123(3) C127(3) C132(3) C83(4) C6(3) 
EIVS_CARDAM_SE_11HCE001_Kt_2.xls C45(Kt) C53(Kt) C101(Kt) C113(Kt) C135(Kt) C128(Kt) 
EIVS_CARDAM_SE_11HCE003_3.xls C105(1) C106(1) C107(1) C108(1) C139(1) C110(1) C112(1) C134(3) C135(2) C136(2) C138(2) C128(1) 
EIVS_CARDAM_SE_11HCE005_5.xls C105(2) C106(2) C107(2) C108(2) C139(2) C110(2) C112(2) C113(1) C135(3) C136(3) C138(3) C128(2) 
EIVS_CARDAM_SE_11HCE006_6.xls C105(3) C106(3) C107(3) C108(3) C139(3) C110(3) C112(3) C113(2) C116(1) C120(1) C124(1) C128(3) 
EIVS_CARDAM_SE_11HCE007_7.xls C113(3) C109(1) C116(2) C120(2) C125(1) C129(1) C131(1) 
EIVS_CARDAM_SE_11HCE008_8.xls C124(2) C109(2) C125(2) C129(2) C131(2) 
EIVS_CARDAM_SE_11HCE009_9.xls C124(3) C109(3) C125(3) C129(3) C131(3) C116(3) C120(3) 
EIVS_CARDAM_SE_11HCE020_18.xls C4(1) C9(1) C20(1) C39(1) C28(1) C48(1) C52(1) C55(1) C58(1) 
EIVS_CARDAM_SE_11HCE022_19.xls C4(2) C9(2) C14(1) C20(2) C28(2) C29(1) C39(2) C48(2) C52(2) 
EIVS_CARDAM_SE_11HCE024_20.xls C4(3) C9(3) C14(2) C28(3) C29(2) C52(3) C56(1) C58(2) 
EIVS_CARDAM_SE_11HCE026_21.xls C14(3) C20(3) C29(3) C52(4) C56(2) C64(1) C67(1) C71(1) C97(1) C114(1) 
EIVS_CARDAM_SE_11HCE029_23.xls C39(3) C48(3) C55(2) C52(5) C56(3) C58(3) C103(1) C137(1) C140(1) C141(1) 
EIVS_CARDAM_SE_11HCE032_25.xls C55(3) C64(2) C67(2) C163(1) C164(1) C166(1) C170(1) C185(1) C193(1) C195(1) C196(1) C71(2) 
EIVS_CARDAM_SE_11HCE034_26.xls C97(2) C103(2) C114(2) C137(2) C140(2) C141(2) C163(2) C164(2) C166(2) C170(2) C185(2) C193(2) 
EIVS_CARDAM_SE_11HCE036_27.xls C64(3) C67(3) C71(3) C97(3) C103(3) C114(3) C137(3) C140(3) C141(3) C163(3) C195(2) C196(2) 
EIVS_CARDAM_SE_11HCE038_28.xls C164(3) C166(3) C170(3) C185(3) C193(3) C195(3) C196(3) 
Ceetox EIVS_CEETOX_SE_11HCE010 FK_16_v1.0 Set 2.xls x138(1) x139(1) 
EIVS_CEETOX_SE_10HCE023_25_v1.0.xls x1(1) x2(1) x5(1) x6(1) x7(1) x16(1) x22(1) x28(1) x36(1) x38(1) 
EIVS_CEETOX_SE_10HCE024_26_v1.0.xls x1(2) x2(2) x5(2) x6(2) x7(2) x16(2) x22(2) x28(2) x36(2) x38(2) 
EIVS_CEETOX_SE_10HCE025_27_v1.0.XLS x1(3) x2(3) x5(3) x6(3) x7(3) x16(3) x22(3) x28(3) x36(3) x38(3) 
EIVS_CEETOX_SE_10HCE027_29_v1.0.xls x63(1) x72(1) x73(1) x83(1) x86(1) x89(1) x93(1) x98(1) x99(1) x103(1) 
EIVS_CEETOX_SE_10HCE028_30_v1.0.xls x63(2) x72(2) x73(2) x83(2) x86(2) x89(2) x93(2) x98(2) x99(2) x103(2) 
EIVS_CEETOX_SE_10HCE042_48_v1.0.xls x63(3) x72(3) x73(3) x83(3) x86(3) x89(3) x93(3) x98(3) x99(3) x103(3) 
EIVS_CEETOX_SE_10HCE043_49_v1.0.xls x45(1) x47(1) x49(1) x51(1) x52(1) x59(1) x68(1) 
EIVS_CEETOX_SE_10HCE044_50_v1.0.xls x45(2) x47(2) x49(2) x51(2) x52(2) x59(2) x68(2) 
EIVS_CEETOX_SE_11HCE004_4_v1.0 JOEY.XLS x45(3) x47(3) x49(3) x51(3) x52(3) x59(3) x68(3) 
EIVS_CEETOX_SE_11HCE004_4_v1.0.xls x41(1) x17(1) x31(1) x91(1) x121(1) x3(1) x25(1) x30(1) x33(1) 
EIVS_CEETOX_SE_11HCE006_6_v1.0.xls x41(2) x17(2) x31(2) x91(2) x121(2) x3(2) x25(2) x30(2) x33(2) 
EIVS_CEETOX_SE_11HCE007_7_v1.0.xls x41(3) x17(3) x31(3) x91(3) x121(3) x3(3) x25(3) x30(3) x33(3) 
EIVS_CEETOX_SE_11HCE008_8_v1.0 JOEY.xls x13(1) x39(1) x8(1) x128(1) 
EIVS_CEETOX_SE_11HCE008_8_v1.0 LISA.xls x62(1) x64(1) x65(1) x81(1) x82(1) x117(1) x43(1) x44(1) 
EIVS_CEETOX_SE_11HCE013_13_v1.0 Set 1.xls x13(3) x39(3) x8(3) x128(3) x43(3) x62(3) x64(3) 
EIVS_CEETOX_SE_11HCE013_13_v1.0 Set 2.xls x65(3) x81(3) x82(3) x117(3) x112(1) x126(1) x21(1) 
EIVS_CEETOX_SE_11HCE022_19_v1.0.xls X21(3) X112(3) X126(3) X14(1) X46(1) X27(1) 
EIVS_CEETOX_SE_11HCE009_9_v1.0 LISA.xls x62(2) x65(2) x81(2) x82(2) x117(2) 
EIVS_CEETOX_SE_11HCE009_9_v1.0.xls x13(1) x39(2) x8(2) x128(2) x64(2) x43(2) x44(2) 




FK(1) X118 FK(1) 
EIVS_CEETOX_SE_11HCE047_37_v1.0 UPDATED.xls X14(2) X27(2) X46(2) X50(1) X53(1) X70(1) X84(1) X87(1) X102(1) X107(1) X108(1) X109(1) 
EIVS_CEETOX_SE_11HCE049_38_v1.0.xls X14(3) X27(3) X46(3) X50(2) X53(2) X70(2) X84(2) X87(2) X102(2) X107(2) X108(2) X109(2) 
EIVS_CEETOX_SE_11HCE051_39_v1.0 SET 1.xls X50(3) X53(3) X70(3) X84(3) X87(3) X102(3) X107(3) 
EIVS_CEETOX_SE_11HCE051_39_v1.0 SET 2.xls X108(3) X109(3) X110(1) X111(1) X114(1) X115(1) X116(1) 
EIVS_CEETOX_SE_11HCE053_40_v1.0 SET 1.xls X110(2) X111(2) X114(2) X115(2) X116(2) X118(1) X119(1) 
EIVS_CEETOX_SE_11HCE053_40_v1.0 SET 2.xls X123(1) X125(1) X129(1) X131(1) X133(1) X134(1) X136(1) 
EIVS_CEETOX_SE_11HCE055_41_v1.0 SET 1.xls X37(1) X143(1) X190(1) X131(2) X119(2) X173(1) X169(1) 
EIVS_CEETOX_SE_11HCE055_41_v1.0 SET 2.xls X133(2) X127(1) X139(1) X40(1) X111(3) X138(1) 
EIVS_CEETOX_SE_11HCE057_42_v1.0 SET 1.xls X37(2) X143(2) X190(2) X131(3) X119(3) X173(2) X169(2) 
EIVS_CEETOX_SE_11HCE057_42_v1.0 SET 2.xls X133(3) X127(2) X139(2) X40(2) X138(2) 
EIVS_CEETOX_SE_11HCE059_43_v1.0 SET 1.xls X37(3) X143(3) X190(3) X173(3) X169(3) X127(3) X139(3) 
EIVS_CEETOX_SE_11HCE059_43_v1.0 SET 2.xls X40(3) X138(3) X118(2) X125(2) X123(2) X134(2) X129(2) 
EIVS_CEETOX_SE_11HCE061_44_v1.0 SET 1.xls X118(3) X125(3) X123(3) X134(3) X129(3) X196(1) X110(3) 
EIVS_CEETOX_SE_11HCE061_44_v1.0 SET 2.xls X114(3) X115(3) X116(3) X136(2) X11(1) X19(1) X29(1) 
EIVS_CEETOX_SE_11HCE063_45_v1.0.xls X11(2) X19(2) X29(2) X196(2) X136(3) X24(1) X32(1) X42(1) X55(1) X56(1) 
EIVS_CEETOX_SE_11HCE065_46_v1.0.xls X19(3) X196(3) X24(2) X32(2) X42(2) X55(2) X56(2) X61(1) X66(1) X75(1) X77(1) X80(1) 
EIVS_CEETOX_SE_11HCE068_48_v1.0.xls X61(2) X66(2) X75(2) X77(2) X80(2) X94(1) X95(1) X113(1) X120(1) X157(1) X158(1) X160(1) X165(1) 
EIVS_CEETOX_SE_11HCE070_49_v1.0.xls X11(3) X19(4) X24(3) X29(3) X94(2) X95(2) X113(2) X120(2) X157(2) X158(2) X160(2) X165(2) 
EIVS_CEETOX_SE_12HCE002_2_v1.0.xls X32(3) X42(3) X55(3) X56(3) 
EIVS_CEETOX_SE_12HCE004_3_v1.0.xls X61(3) X66(3) X75(3) X77(3) X80(3) X94(3) X95(3) X113(3) X120(3) X157(3) X158(3) X160(3) X165(3) 
L’OREAL EIVS_LOREAL_SE_10HCE023_25.xls L5(1) L9(1) L11(1) L12(1) L17(1) L18(1) L20(1) L23(1) L24(1) L27(1) L28(1) 
EIVS_LOREAL_SE_10HCE024_26.xls L5(2) L9(2) L11(2) L12(2) L17(2) L18(2) L20(2) L23(2) L24(2) L27(2) L28(2) 
EIVS_LOREAL_SE_10HCE025_27.xls L30(1) L39(1) L43(1) L45(1) L48(1) L51(1) L55(1) L59(1) L60(1) L66(1) L68(1) L11(3) 
EIVS_LOREAL_SE_10HCE026_28.xls L9(3) L12(3) L17(3) L20(3) L27(3) L43(2) 
EIVS_LOREAL_SE_10HCE027_29.xls L30(2) L39(2) L43(3) L45(2) L48(2) L51(2) L55(2) L59(2) L60(2) L66(2) L68(2) L73(1) 
EIVS_LOREAL_SE_10HCE028_30.xls L5(3) L11(4) L23(3) L24(3) L30(3) L39(3) L48(3) L51(3) L55(3) L60(3) L68(3) 
EIVS_LOREAL_SE_10HCE029_35.xls L74(1) L75(1) L78(1) L81(1) L82(1) L85(1) L91(1) L94(1) L97(1) L98(1) L102(1) 
EIVS_LOREAL_SE_10HCE031_37.xls L45(3) L59(3) L66(3) L74(2) L82(2) L94(2) 
EIVS_LOREAL_SE_10HCE032_38.xls L74(3) L75(2) L78(2) L81(2) L82(3) L85(2) L91(2) L94(3) L97(2) L98(2) L102(2) 
EIVS_LOREAL_SE_10HCE033_39.xls L11(5) L18(3) L28(3) L73(2) L75(3) L78(3) L81(3) L85(3) L91(3) L97(3) 
EIVS_LOREAL_SE_10HCE034_40.xls L73(3) L98(3) L4(1) L7(1) L8(1) 
EIVS_LOREAL_SE_10HCE035_41.xls L4(2) L7(2) L8(2) L29(1) L42(1) L56(1) L57(1) L61(1) L63(1) L64(1) 
EIVS_LOREAL_SE_10HCE036_42.xls L102(3) L7(3) L29(2) L57(2) 
EIVS_LOREAL_SE_10HCE037_43.xls L4(3) L8(3) L29(3) L42(2) L56(2) L61(2) L57(3) L63(2) L64(2) L67(1) L70(1) 
EIVS_LOREAL_SE_10HCE040_46.xls L30(4) L42(3) L56(3) L61(3) L63(3) L64(3) L67(2) L70(2) L72(1) L79(1) L83(1) L87(1) 
EIVS_LOREAL_SE_10HCE041_47.xls L67(3) L72(2) L79(2) L83(2) L87(2) L90(1) L92(1) L96(1) L101(1) L99(1) 
EIVS_LOREAL_SE_10HCE042_48.xls L87(3) L90(2) L92(2) L99(2) L104(1) L119(1) L120(1) L130(1) L131(1) L132(1) 
EIVS_LOREAL_SE_10HCE043_49.xls L83(3) L96(2) L101(2) L104(1) L106(1) L107(1) L108(1) L109(1) L112(1) L113(1) 
EIVS_LOREAL_SE_10HCE044_50.xls L79(3) L96(3) L101(3) L106(2) L107(2) L108(2) L109(2) L112(2) L113(2) L114(1) L115(1) L118(1) 
EIVS_LOREAL_SE_11HCE020_18.xls L1(1) L6(1) L13(1) L15(1) L16(1) L32(1) L33(1) L36(1) L37(1) 
EIVS_LOREAL_SE_11HCE024_20.xls L144(1) L148(1) L156(1) L161(1) L164(1) L169(1) L174(1) L185(1) L200(1) L15(2) L6(2) 
EIVS_LOREAL_SE_11HCE026_21.xls L1(2) L13(2) L16(2) L32(2) L33(2) L36(2) L37(2) L50(2) L53(2) 
EIVS_LOREAL_SE_11HCE032_25(2).xls L100(3) 
EIVS_LOREAL_SE_11HCE034_26(2).xls L111(3) L125(3) L127(3) L144(3) L148(3) L156(3) L161(3) 
EIVS_LOREAL_SE_11HCE002_2.xls L122(1) L123(1) L126(1) L129(1) L133(1) L134(1) L136(1) L137(1) L139(1) L140(1) L114(2) L115(2) 
EIVS_LOREAL_SE_11HCE006_6.xls L70(3) L72(3) L90(3) L99(3) L104(2) L106(3) L107(3) L108(3) 
EIVS_LOREAL_SE_11HCE007_7.xls L109(3) L112(3) L113(3) L114(3) L115(3) L118(2) L119(2) L120(2) L122(2) L123(2) 
EIVS_LOREAL_SE_11HCE008_8.xls L118(3) L119(3) L120(3) L122(3) L123(3) L126(2) L129(2) L130(2) L131(2) L132(2) L133(2) L134(2) 
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EIVS_LOREAL_SE_11HCE009_9.xls L126(3) L129(3) L130(3) L131(3) L132(3) L133(3) L134(3) L136(2) L137(2) L139(2) L140(2) L92(3) L104(3) 
EIVS_LOREAL_SE_11HCE014_14.xls L136(3) L137(3) L139(3) L140(3) 
EIVS_LOREAL_SE_11HCE022_19 L50(1) L53(1) L58(1) L62(1) L65(1) L76(1) L80(1) L100(1) L111(1) L125(1) L127(1) 
EIVS_LOREAL_SE_11HCE029_23 L33(3) L58(2) L62(2) L65(2) L76(2) L80(2) L100(2) L111(2) L161(2) L169(2) L174(2) L6 
EIVS_LOREAL_SE_11HCE032_25(1) L125(2) L127(2) L144(2) L148(2) L156(2) L164(2) L185(2) L200(2) L1(3) L6(3) L13(3) L16(3) L58(3) 
EIVS_LOREAL_SE_11HCE034_26(1) L6(4) L15(3) L32(3) L36(3) L37(3) L50(3) L53(3) L58(4) L62(3) L65(3) L76(3) L80(3) L100(4) 
EIVS_LOREAL_SE_11HCE036_27 L6(5) L58(5) L164(3) L100(5) L169(3) L174(3) L185(3) L200(3) 
LE Cardam EIVS_CARDAM_LE_10HCE029_35.xls C1(1) C2(1) C17(1) C19(1) C26(1) C30(1) C33(1) C34(1) C35(1) 
EIVS_CARDAM_LE_10HCE031_37.xls C1(2) C2(2) C17(2) C19(2) C26(2) C30(2) C33(2) C34(2) C35(2) 
EIVS_CARDAM_LE_10HCE032_38.xls C1(3) C2(3) C17(3) C19(3) C26(3) C30(3) C77(1) C34(3) C35(3) 
EIVS_CARDAM_LE_10HCE033_W39.xls C33(3) C35(4) C36(1) C37(1) C49(1) C51(1) C54(1) C60(1) C63(1) C65(1) C66(1) C75(1) C76(1) 
EIVS_CARDAM_LE_10HCE033_W39_(C77).xls C77(2) 
EIVS_CARDAM_LE_10HCE034_40(C79).xls C79(1) 
EIVS_CARDAM_LE_10HCE034_40.xls C36(1) C37(1) C49(1) C51(1) C54(1) C60(1) C63(1) C65(1) C66(1) C75(1) C76(1) C77(1) C78(1) 
EIVS_CARDAM_LE_10HCE044_50.xls C45(4) C84(2) C98(2) C101(2) C119(3) C123(2) C127(2) C132(2) C135(2) C6(3) 
EIVS_CARDAM_LE_11HCE003_3.xls C84(3) C98(3) C101(3) C123(3) C127(3) C132(3) C134(2) C135(3) C106(1) C107(1) C128(1) 
EIVS_CARDAM_LE_11HCE005_5.xls C105(1) C106(2) C107(2) C108(1) C110(1) C112(1) C134(3) C135(4) C136(1) C138(1) C139(1) C128(2) 
EIVS_CARDAM_LE_11HCE006_6.xls C105(2) C106(3) C107(3) C108(2) C110(2) C112(2) C113(1) C116(1) C136(2) C138(2) C139(2) C128(3) 
EIVS_CARDAM_LE_11HCE007_7.xls C105(3) C109(1) C120(1) C108(3) C125(1) C129(1) C113(2) C116(2) C131(1) 
EIVS_CARDAM_LE_11HCE008_8.xls C110(3) C109(2) C120(2) C124(1) C125(2) C129(2) C131(2) 
EIVS_CARDAM_LE_11HCE009_9.xls C136(3) C109(3) C120(3) C124(2) C138(3) C112(3) C113(3) C116(3) C139(3) 
EIVS_CARDAM_LE_11HCE020_18.xls C124(3) C125(3) C129(3) C131(3) C4(1) C9(1) C20(1) C28(1) C48(1) C58(1) 
EIVS_CARDAM_LE_11HCE022_19.xls C4(2) C9(2) C14(1) C20(2) C28(2) C29(1) C39(1) C48(2) C52(1) 
EIVS_CARDAM_LE_11HCE024_20.xls C4(3) C9(3) C14(2) C28(3) C29(2) C52(2) C56(1) C58(2) 
EIVS_CARDAM_LE_11HCE026_21.xls C14(3) C20(3) C29(3) C52(3) C56(2) C64(1) C67(1) C71(1) C97(1) C114(1) 
EIVS_CARDAM_LE_11HCE029_23.xls C39(2) C48(3) C55(1) C52(4) C56(3) C58(3) C103(1) C137(1) C140(1) C141(1) 
EIVS_CARDAM_LE_11HCE032_25.xls C39(3) C55(2) C64(2) C67(2) C163(1) C164(1) C166(1) C185(1) C170(1) C193(1) C195(1) C196(1) 
EIVS_CARDAM_LE_11HCE034_26.xls C55(3) C71(2) C97(2) C103(2) C114(2) C137(2) C140(2) C141(2) C163(2) C164(2) C166(2) C170(2) 
EIVS_CARDAM_LE_11HCE036_27.xls C64(3) C67(3) C71(3) C97(3) C103(3) C114(3) C137(3) C166(3) C185(2) C193(2) C195(2) C196(2) 
EIVS_CARDAM_LE_11HCE038_28.xls C140(3) C141(3) C163(3) C164(3) C166(4) C170(3) C185(3) C193(3) C195(3) C196(3) 
EIVS_CARDAM_LE1_10HCE035_41.xls C36(2) C37(2) C49(2) C51(2) C54(2) C60(2) C63(2) C65(2) C66(2) C75(2) C76(2) C77(3) C78(1) 
EIVS_CARDAM_LE1_10HCE036_42.xls C36(3) C37(3) C49(3) C51(3) C54(3) C60(3) C63(3) C65(3) C66(3) C75(3) C76(3) C78(2) C79(2) 
EIVS_CARDAM_LE1_10HCE037_43.xlsx C78(3) C79(3) C82(3) C85(3) C87(3) C88(3) C90(3) C91(3) C94(2) C96(3) C99(1) C104(1) C3(1) 
EIVS_CARDAM_LE1_10HCE040_46.xls C94(3) C99(2) C104(2) C3(2) C11(2) C12(2) C13(2) C15(2) C16(2) C21(2) C25(2) C27(2) C38(1) 
EIVS_CARDAM_LE1_10HCE041_47.xls C99(3) C104(3) C3(3) C11(3) C12(3) C13(3) C15(3) C16(3) C21(3) C25(3) C27(3) C38(2) C45(2) 
EIVS_CARDAM_LE1_10HCE042_48.xls C38(3) C45(3) C46(3) C47(3) C50(3) C53(3) C62(3) C70(3) C83(3) C84(1) C98(1) C101(1) C119(2) 
EIVS_CARDAM_LE2_10HCE035_41.xls C79(1) C82(1) C85(1) C87(1) C88(1) C90(1) C91(1) C96(1) 
EIVS_CARDAM_LE2_10HCE036_42.xls C82(2) C85(2) C87(2) C88(2) C90(2) C91(2) C94(1) C96(2) 
EIVS_CARDAM_LE2_10HCE037_43.xlsx C11(1) C12(1) C13(1) C15(1) C16(1) C21(1) C25(1) C27(1) 
EIVS_CARDAM_LE2_10HCE040_46.xls C45(1) C46(1) C47(1) C50(1) C53(1) C62(1) C70(1) C83(1) 
EIVS_CARDAM_LE2_10HCE041_47.xls C46(2) C47(2) C50(2) C53(2) C62(2) C70(2) C83(2) C119(1) C6(1) 
EIVS_CARDAM_LE2_10HCE042_48.xls C123(1) C127(1) C132(1) C134(1) C135(1) C6(2) 
Ceetox EIVS_CEETOX_LE_10HCE023_25_v1.0 UPDATED.xls x1(1) x2(1) x5(1) x6(1) x7(1) x16(1) x22(1) x28(1) x36(1) x38(1) 
EIVS_CEETOX_LE_10HCE024_26_v1.0.xls x1(2) x2(2) x5(2) x6(2) x7(2) x16(2) x22(2) x28(2) x36(2) x38(2) 
EIVS_CEETOX_LE_10HCE042_48_v1.0 UPDATED.xls x1(3) x2(3) x5(3) x6(3) x7(3) x16(3) x22(3) x28(3) x36(3) x38(3) 
EIVS_CEETOX_LE_10HCE043_49_v1.0 UPDATED.xls x1(4) x2(4) x5(4) x6(4) x7(4) x16(4) x22(4) x28(4) x36(4) x38(4) 
EIVS_CEETOX_LE_10HCE044_50_v1.0 UPDATED.xls x1(5) x2(5) x5(5) x6(5) x7(5) x16(5) x22(5) x28(5) x36(5) x38(5) 
EIVS_CEETOX_LE_11HCE003_3_v1.0 .xls x63(1) x72(1) x73(1) x83(1) x86(1) x89(1) x93(1) x98(1) x99(1) x103(1) 
EIVS_CEETOX_LE_11HCE004_4_v1.0 JOEY Updated.xls x45(1) x47(1) x49(1) x51(1) x52(1) x59(1) x68(1) 
EIVS_CEETOX_LE_11HCE006_6_v1.0 SET 1 JOEY.XLS x72(2) x73(2) x83(2) x86(2) x89(2) x93(2) x98(2) x99(2) 
EIVS_CEETOX_LE_11HCE006_6_v1.0 SET 2 JOEY.XLS x45(2) x47(2) x49(2) x51(2) x52(2) x59(2) x68(2) 
EIVS_CEETOX_LE_11HCE007_7_v1.0 SET 1.xls x63(2) x72(3) x73(3) x83(3) x86(3) x89(3) x93(3) x98(3) x99(3) 
EIVS_CEETOX_LE_11HCE007_7_v1.0 SET 2 Joey.xls x45(3) x47(3) x49(3) x51(3) x52(3) 
EIVS_CEETOX_LE_11HCE008_8_v1.0 JOEY.xls x13(1) x39(1) x8(1) x128(1) x103(2) x49(4) 
EIVS_CEETOX_LE_11HCE008_8_v1.0 LISA.XLS x62(1) x64(1) x65(1) x81(1) x82(1) x117(1) x43(1) x44(1) 
EIVS_CEETOX_LE_11HCE009_9_v1.0 Joey FAILED RUN UPDATED.XLS x13(2) x39(2) x8(2) x128(2) x64(2) x43(2) x44(2) x103(3) x63(3) 
EIVS_CEETOX_LE_11HCE009_9_v1.0 LISA FAILED RUN UPDATED.XLS x62(2) x65(2) x81(2) x82(2) x117(2) 
EIVS_CEETOX_LE_11HCE013_13_v1.0 Set 1.xls x13(2) x39(1) x8(2) x128(2) x43(2) x62(2) x64(2) 
EIVS_CEETOX_LE_11HCE022_19_v1.0 SET 1.xls X21(2) X112(2) X126(2) X14(1) X46(1) X27(1) X50(1) X53(1) X70(1) X84(1) X87(1) X102(1) 
EIVS_CEETOX_LE_11HCE022_19_v1.0 SET 2.xls X108(1) X109(1) X110(1) X118(1) X136(1) X138(1) X139(1) X13(3) X43(3) X47(5) X59(3) X68(3) 
EIVS_CEETOX_LE_11HCE022_19_v1.0 SET 3.xls X62(3) X64(3) X65(3) X81(3) X82(3) X117(3) X128(3) X39(3) PC2(1) PC3(1) X107(1) 
EIVS_CEETOX_LE_11HCE034_26_v1.0 Set 1.xls X14(2) X46(2) X27(2) X50(2) X53(2) X70(2) X84(2) X87(2) X102(2) X107(2) X8(3) 
EIVS_CEETOX_LE_11HCE034_26_v1.0 Set 2.xls X108(2) X109(2) X110(2) X118(2) X136(2) X138(2) X139(2) X39(4) X21(3) X112(3) X126(3) 
EIVS_CEETOX_LE_11HCE034_26_v1.0 Set 3.xls X111(1) X114(1) X115(1) X116(1) X119(1) X123(1) X125(1) X129(1) X131(1) X133(1) X134(1) 
EIVS_CEETOX_LE_11HCE040_29_v1.0 SET 1.xls X14(3) X46(3) X27(3) X50(3) X53(3) X70(3) X84(3) X87(3) X102(3) X107(3) 
EIVS_CEETOX_LE_11HCE040_29_v1.0 SET 2.xls X108(3) X109(3) X110(3) X118(3) X136(3) X138(3) X139(3) X111(2) X114(2) X115(2) X116(2) 
L’OREAL EIVS_LOREAL_LE_10HCE023_25.xls L5(1) L9(1) L11(1) L12(1) L17(1) L18(1) L20(1) L23(1) L24(1) L27(1) L28(1)  
EIVS_LOREAL_LE_10HCE024_26.xls L5(2) L9(2) L11(2) L12(2) L17(2) L18(2) L20(2) L23(2) L24(2) L27(2) L28(2)  
EIVS_LOREAL_LE_10HCE025_27.xls L30(1) L39(1) L43(1) L45(1) L48(1) L51(1) L55(1) L59(1) L60(1) L66(1) L68(1) L11(3) 
EIVS_LOREAL_LE_10HCE026_28.xls L9(3) L12(3) L17(3) L20(3) L27(3) L43(2)       
EIVS_LOREAL_LE_10HCE027_29.xls L30(2) L39(1) L43(3) L45(2) L48(2) L51(2) L55(2) L59(2) L60(2) L66(2) L68(2) L73(1) 
EIVS_LOREAL_LE_10HCE028_30.xls L5(3) L11(4) L23(3)  L24(3) L30(3) L39(2) L48(3) L51(3) L55(3) L60(3) L68(3) 
EIVS_LOREAL_LE_10HCE031_37.xls L45(3) L59(3) L66(3) L74(1) L82(1) L94(1)       
EIVS_LOREAL_LE_10HCE032_38.xls L74(2) L75(1) L78(1) L81(1) L82(2) L85(1) L91(1) L94(2) L97(1) L98(1) L102(1)  
EIVS_LOREAL_LE_10HCE033_39.xls L18(3) L28(3) L39(3) L73(2) L75(2) L78(2) L81(2) L85(2) L91(2) L97(2)   
EIVS_LOREAL_LE_10HCE034_40(1).xls L73(3) L74(3) L75(3) L78(3) L81(3) L82(3) L91(3) L94(3) L97(3) L98(2) L102(2)  
EIVS_LOREAL_LE_10HCE034_40(2).xls L4(1) L7(1) L8(1)          
EIVS_LOREAL_LE_10HCE035_41.xls L85(3) L98(3) L4(2) L7(2) L8(2) L29(1) L42(1) L56(1) L57(1) L61(1) L63(1) L64(1) 
EIVS_LOREAL_LE_10HCE036_42.xls L102(3) L7(3) L29(2) L57(2)         
EIVS_LOREAL_LE_10HCE037_43.xls L4(3) L8(3) L29(3) L42(2) L56(2) L61(2) L57(3) L63(2) L64(2) L67(1) L70(1) 
EIVS_LOREAL_LE_10HCE040_46.xls L42(3) L56(3) L61(3) L63(3) L64(3) L67(2) L70(2) L72(1) L79(1) L83(1) L87(1) L92(1) 
EIVS_LOREAL_LE_10HCE041_47.xls L67(3) L72(2) L79(2) L83(2) L87(2) L90(1) L92(2) L96(1) L99(1) L101(1)  
EIVS_LOREAL_LE_10HCE042_48.xls L87(3) L90(2) L92(3) L99(2) L104(1) L119(1) L120(1) L130(1) L131(1) L132(1)   
EIVS_LOREAL_LE_10HCE043_49.xls L83(3) L96(2) L101(2) L104(2) L106(1) L107(1) L108(1) L109(1) L112(1) L113(1)   
EIVS_LOREAL_LE_10HCE044_50.xls L79(3) L96(3) L101(3) L106(2) L107(2) L108(2) L109(2) L112(2) L113(2) L114(1) L115(1) L118(1) 
EIVS_LOREAL_LE_11HCE002_2.xls L122(1) L123(1) L126(1) L129(1) L133(1) L134(1) L136(1) L137(1) L139(1) L140(1) L114(2) L115(2) 
EIVS_LOREAL_LE_11HCE006_6.xls L70(3) L72(3) L90(3) L99(3) L104(3) L106(3) L107(3) L108(3) 
EIVS_LOREAL_LE_11HCE007_7.xls L109(3) L112(3) L113(3) L114(3) L115(3) L118(2) L119(2) L120(2) L122(2) L123(2) 
EIVS_LOREAL_LE_11HCE008_8.xls L118(3) L119(3) L120(3) L122(3) L123(3) L126(2) L129(2) L130(2) L131(2) L132(2) L133(2) L134(2) 
EIVS_LOREAL_LE_11HCE009_9.xls L126(3) L129(3) L130(3) L131(3) L132(3) L133(3) L134(3) L136(2) L137(2) L139(2) L140(2) 
EIVS_LOREAL_LE_11HCE014_14.xls L136(3) L137(3) L139(3) L140(3) 
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Protocol Laboratory Run 
EIVS_LOREAL_LE_11HCE020_18.xls L1(1) L6(1) L13(1) L15(1) L16(1) L32(1) L33(1) L36(1) L37(1) 
EIVS_LOREAL_LE_11HCE022_19.xls L50(1) L53(1) L58(1) L62(1) L65(1) L76(1) L80(1) L100(1) L111(1) L125(1) L127(1) 
EIVS_LOREAL_LE_11HCE024_20.xls L144(1) L148(1) L156(1) L161(1) L164(1) L169(1) L174(1) L185(1) L200(1) L137(4) L6(2) 
EIVS_LOREAL_LE_11HCE026_21.xls L1(2) L13(2) L15(2) L16(2) L32(2) L33(2) L36(2) L37(2) L50(2) L53(2) L148(1) 
EIVS_LOREAL_LE_11HCE029_23.xls L33(3) L58(2) L62(2) L65(2) L76(2) L80(2) L100(2) L161(2) L169(2) L174(2) L111(2) L6 
EIVS_LOREAL_LE_11HCE032_25(1).xls L125(2) L127(2) L144(2) L148(2) L156(2) L164(2) L185(2) L200(2) L1(3) L6(3) L13(3) L16(3) L58(3) 
EIVS_LOREAL_LE_11HCE032_25(2).xls L100(3) 
EIVS_LOREAL_LE_11HCE034_26.xls L6(4) L15(3) L32(3) L36(3) L37(3) L50(3) L53(3) L62(3) L65(3) L76(3) L80(3) L111(3) L125(3) 
EIVS_LOREAL_LE_11HCE036_27.xls L6(5) L127(3) L144(3) L148(3) L156(3) L161(3) L164(3) L169(3) L174(3) L185(3) L200(3) 
 
3.2.4 Number of tests within each test sequence 
 
In Table 3.2.5, the number of tests within each test sequence is given, subdivided 
into laboratories and chemicals. 
Table 3.2.5a Number of tests within each test sequence (SE protocol) 
 laboratory  laboratory 
Chemical Cardam Ceetox L’OREAL Chemical Cardam Ceetox L’OREAL 
1 3 3 3 55 3 3 3 
2 3 3 3 56 3 3 3 
3 3 3 3 57 3 3 3 
4 4 3 3 58 3 3 3 
5 3 3 3 59 3 3 3 
6 3 3 3 60 3 3 3 
7 3 3 3 61 3 3 3 
8 3 3 3 62 3 3 3 
9 3 3 3 63 3 3 3 
10 3 3 3 64 3 3 3 
11 3 3 3 65 3 3 3 
12 3 3 3 66 3 3 3 
13 3 3 3 67 3 3 3 
14 3 3 3 68 3 3 3 
15 3 3 3 69 3 3 3 
16 3 3 3 70 3 3 3 
17 4 3 3 71 3 3 3 
18 3 4 3 72 3 3 3 
19 3 3 3 73 3 3 3 
20 3 3 5 74 3 3 3 
21 3 3 3 75 4 3 5 
22 3 3 3 76 3 3 3 
23 3 3 3 77 3 3 3 
24 3 3 3 78 3 3 3 
25 3 3 3 79 3 3 3 
26 3 3 3 80 3 3 3 
28 3 3 3 81 3 3 3 
29 3 3 3 82 3 3 3 
30 3 3 3 83 3 3 3 
31 3 3 3 84 3 3 3 
32 3 3 3 85 3 3 3 
33 3 3 3 86 3 3 3 
34 4 3 3 87 3 3 3 
35 3 3 3 88 3 3 3 
36 3 3 3 89 3 3 3 
37 3 3 3 90 3 3 3 
38 3 3 3 91 3 3 3 
39 3 3 3 92 3 3 3 
40 3 3 3 93 3 3 3 
41 3 3 3 94 3 3 3 
42 3 3 3 95 3 3 3 
43 3 3 3 96 3 3 3 
44 3 3 3 97 3 3 3 
45 3 3 3 98 3 3 3 
46 3 3 3 99 3 3 3 
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 laboratory  laboratory 
Chemical Cardam Ceetox L’OREAL Chemical Cardam Ceetox L’OREAL 
47 3 3 3 100 3 3 3 
48 3 3 3 101 3 3 3 
49 3 3 3 102 3 3 3 
50 3 3 3 103 3 3 3 
51 3 3 3 104 3 3 3 
52 3 3 3 105 3 3 3 
53 3 3 3 1061 5 3 5 
54 3 3 3 1071 3 3 5 
1 extra chemicals not for statistics but for a later purpose of evaluation using an HPLC based 
detection system. 
Table 3.2.5b Number of tests within each test sequence (LE protocol) 
 laboratory  laboratory 
Chemical Cardam Ceetox L’OREAL Chemical Cardam Ceetox L’OREAL 
1 3 5 4 55 3 5 3 
2 3 5 3 56 3 3 3 
3 3 3 3 57 3 3 3 
4 3 5 3 58 3 4 3 
5 3 4 3 59 3 3 3 
6 3 5 3 60 3 3 3 
7 3 3 3 61 3 3 3 
8 3 4 4 62 3 3 3 
9 3 5 3 63 3 3 3 
10 3 3 3 64 3 4 3 
11 3 5 3 65 3 4 4 
12 3 3 3 66 3 3 3 
13 3 3 3 67 3 3 3 
14 3 4 4 68 3 3 3 
15 3 3 3 69 3 3 3 
16 3 4 3 70 3 3 3 
17 3 3 3 71 3 5 3 
18 3 4 3 72 3 3 3 
19 3 4 3 73 3 6 3 
20 3 3 3 74 3 5 4 
21 3 5 3 75 4 4 4 
22 3 3 3 76 3 3 3 
23 3 3 3 77 3 3 3 
24 3 5 3 78 3 3 3 
25 3 3 3 79 3 4 3 
26 3 3 3 80 3 3 3 
28 3 5 3 81 3 3 4 
29 3 4 3 82 3 3 3 
30 3 3 3 83 3 3 4 
31 3 3 3 84 3 4 3 
32 3 3 3 85 3 5 3 
33 3 5 3 86 3 3 3 
34 4 3 3 87 3 3 3 
35 3 5 4 88 3 4 3 
36 3 3 3 89 3 3 3 
37 3 3 3 90 3 5 3 
38 3 4 3 91 3 5 3 
39 3 4 3 92 3 4 3 
40 3 3 3 93 3 5 4 
41 3 3 3 94 3 5 4 
42 3 3 3 95 3 3 3 
43 3 3 3 96 3 3 3 
44 3 4 3 97 3 3 3 
45 3 3 3 98 3 5 3 
46 3 3 3 99 3 4 3 
47 3 3 3 100 3 3 3 
48 4 3 3 101 3 3 3 
49 3 4 3 102 3 3 3 
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 laboratory  laboratory 
Chemical Cardam Ceetox L’OREAL Chemical Cardam Ceetox L’OREAL 
50 3 4 3 103 3 3 3 
51 3 3 3 104 3 3 3 
52 4 4 3 105 3 3 3 
53 3 4 3 1061 4 3 5 
54 3 5 4 1071 3 3 3 
1 extra chemicals not for statistics but for a later purpose of evaluation using an HPLC based 
detection system. 
3.2.5 Non-qualified and excluded chemicals 
 
A listing of the number and fraction of non-qualified chemicals is given in Table 
3.2.6. 
Table 3.2.6 List, number and fraction of non-qualified chemicals, subdivided into laboratories and 
chemicals 
Protocol Laboratory Chemical Reason No. Fraction (%) 
SE CARDAM 4 Non-Qualified 1 25 
  17 Non-Qualified 1 25 
  34 Non-Qualified 1 25 
  75 Non-Qualified 1 25 
 CEETOX 18 Non-Qualified 1 25 
 L'OREAL 75 Non-Qualified 2 40 
  20 Non-Qualified 2 40 
      
LE CARDAM 34 Non-Qualified 1 25 
  52 Non-Qualified 1 25 
 CEETOX 1 Non-Qualified 2 40 
  2 Non-Qualified 2 40 
  4 Non-Qualified 2 40 
  5 Non-Qualified 1 25 
  6 Non-Qualified 2 40 
  8 Non-Qualified 1 25 
  9 Non-Qualified 2 40 
  11 Non-Qualified 2 40 
  14 Non-Qualified 1 25 
  16 Non-Qualified 1 25 
  18 Non-Qualified 1 25 
  19 Non-Qualified 1 25 
  20 Non-Qualified 1 33.3 
  21 Non-Qualified 2 40 
  24 Non-Qualified 2 40 
  28 Non-Qualified 2 40 
  29 Non-Qualified 1 25 
  33 Non-Qualified 2 40 
  35 Non-Qualified 2 40 
  38 Non-Qualified 1 25 
  39 Non-Qualified 1 25 
  44 Non-Qualified 1 25 
  49 Non-Qualified 1 25 
  50 Non-Qualified 1 25 
  52 Non-Qualified 1 25 
  53 Non-Qualified 1 25 
  54 Non-Qualified 2 40 
  55 Non-Qualified 2 40 
  58 Non-Qualified 1 25 
  64 Non-Qualified 1 25 
  65 Non-Qualified 1 25 
  71 Non-Qualified 2 40 
  73 Non-Qualified 3 50 
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Protocol Laboratory Chemical Reason No. Fraction (%) 
  74 Non-Qualified 2 40 
  75 Non-Qualified 1 25 
  79 Non-Qualified 1 25 
  84 Non-Qualified 1 25 
  85 Non-Qualified 2 40 
  88 Non-Qualified 1 25 
  90 Non-Qualified 2 40 
  91 Non-Qualified 2 40 
  92 Non-Qualified 1 25 
  93 Non-Qualified 2 40 
  94 Non-Qualified 2 40 
  98 Non-Qualified 2 40 
  99 Non-Qualified 1 25 
 L'OREAL 1 Non-Qualified 1 25 
  8 Non-Qualified 1 25 
  14 Non-Qualified 1 25 
  35 Non-Qualified 1 25 
  54 Non-Qualified 1 25 
  65 Non-Qualified 1 25 
  74 Non-Qualified 1 25 
  75 Non-Qualified 1 25 
  81 Non-Qualified 1 25 
  83 Non-Qualified 1 25 
  93 Non-Qualified 1 25 
  94 Non-Qualified 1 25 
In Figure 3.2.1, a boxplot is given of the standard deviations between uncorrected 
viabilities for every set of 3 tissue replicates used for each chemical, including both 
qualified and unqualified tests, for each independent laboratory and for all 
laboratories together, as well as for both protocols.  
 
Figure 3.2.1 Standard deviations of uncorrected viabilities for every set of 3 tissue replicates, per 
laboratory and total, including both qualified and unqualified tests.  
 
3.2.6 Chemicals with complete test sequences 
A total of three qualified tests is considered as a complete test sequence. A list of 
chemicals with a complete test sequence is given in Table 3.2.7. Each of the 
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laboratory had a fraction of more than 98% complete test sequences, as is shown in 
Table 3.2.8.  
Table 3.2.7a A list of chemicals with a complete test sequence (SE protocol) 
Chemical Cardam Ceetox L’OREAL Chemical Cardam Ceetox L’OREAL 
1 3 3 3 55 3 3 3 
2 3 3 3 56 3 3 3 
3 3 3 3 57 3 3 3 
4 31 31 31 58 3 3 3 
5 3 3 3 59 3 3 3 
6 3 3 3 60 3 3 3 
7 3 3 3 61 3 3 3 
8 3 3 3 62 3 3 3 
9 3 3 3 63 3 3 3 
10 3 3 3 64 3 3 3 
11 3 3 3 65 3 3 3 
12 3 3 3 66 3 3 3 
13 3 3 3 67 3 3 3 
14 3 3 3 68 3 3 3 
15 3 3 3 69 3 3 3 
16 3 3 3 70 3 3 3 
17 3 3 3 71 3 3 3 
18 3 3 3 72 3 3 3 
19 3 3 3 73 3 3 3 
20 31 3 3 74 3 3 3 
21 3 3 3 75 3 3 3 
22 3 3 3 76 3 3 3 
23 3 31 3 77 3 3 3 
24 3 3 3 78 3 3 3 
25 3 3 3 79 3 3 3 
26 3 3 3 80 3 3 3 
28 3 3 3 81 3 3 3 
29 3 3 3 82 3 3 3 
30 3 3 3 83 3 3 3 
31 3 3 3 84 3 3 3 
32 3 3 3 85 3 3 3 
33 3 3 3 86 3 3 3 
34 3 3 3 87 3 3 3 
35 3 3 3 88 3 3 3 
36 3 3 3 89 3 3 3 
37 3 3 3 90 3 3 3 
38 3 3 3 91 3 31 3 
39 3 3 3 92 3 3 3 
40 3 3 3 93 3 3 3 
41 3 3 3 94 3 3 3 
42 3 3 3 95 3 3 3 
43 3 3 3 96 3 3 3 
44 3 3 3 97 3 3 3 
45 3 3 3 98 3 3 3 
46 3 3 3 99 3 3 3 
47 3 3 3 100 3 3 3 
48 3 3 3 101 3 3 3 
49 3 3 3 102 3 3 3 
50 3 3 3 103 3 3 3 
51 3 3 3 104 3 3 3 
52 3 3 3 105 3 3 3 
53 3 3 3     
54 3 3 3 
1On May 10th 2012, after an evaluation of the first draft of the statistics report, the core VMG 
overrode the rule identifying 50% NSMTT as a cut-off to consider a chemical compatible with the 
test system as described in Chapter 2.5.1. of this report. In all these cases, rule 3 in Chapter 2.5.1. 
is fulfilled since the mean %NSC of all qualified tests is greater than (>) 50% and the classification 
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of these qualified tests changes upon correction (from non-irritant to irritant). However, the viability 
values obtained in the qualified tests are definitely within the linear range of the OD measurements 
(within the 100% scale) and therefore, even though there is a strong MTT reduction occurring this 
is not interfering with the analytical capacity to measure formazan production. Moreover, the 
variability obtained between the different tests and controls is low. As such, these chemicals were 
considered compatible with the test method and their data were therefore included in all of the 
statistical analyses.  
Table 3.2.7b A list of chemicals with a complete test sequence (LE protocol) 
Chemical Cardam Ceetox L’OREAL Chemical Cardam Ceetox L’OREAL 
1 3 3 3 55 3 3 3 
2 3 3 3 56 3 3 3 
3 3 3 3 57 3 3 3 
4 31 31 3 58 3 3 3 
5 3 3 3 59 3 3 3 
6 3 3 3 60 3 3 3 
7 3 3 3 61 3 3 3 
8 3 3 3 62 3 3 3 
9 3 3 3 63 3 3 3 
10 3 3 3 64 3 3 3 
11 3 3 3 65 3 3 3 
12 3 3 3 66 3 3 3 
13 3 3 3 67 3 3 3 
14 3 3 3 68 3 3 3 
15 3 3 3 69 3 3 3 
16 3 3 3 70 3 3 3 
17 3 3 3 71 3 3 3 
18 3 3 3 72 3 3 3 
19 3 3 3 73 3 3 3 
20 3 2 3 74 3 3 3 
21 3 3 3 75 4 3 3 
22 3 3 3 76 3 3 3 
23 3 3 3 77 3 3 3 
24 3 3 3 78 3 3 3 
25 3 3 3 79 3 3 3 
26 3 3 3 80 3 31 3 
28 3 3 3 81 3 3 3 
29 3 3 3 82 3 3 3 
30 3 3 3 83 3 3 3 
31 3 3 3 84 3 3 3 
32 3 3 3 85 3 3 3 
33 3 3 3 86 3 3 3 
34 3 3 3 87 3 3 3 
35 3 3 3 88 3 3 3 
36 3 3 3 89 3 3 3 
37 3 3 3 90 3 3 3 
38 3 3 3 91 3 3 3 
39 3 3 3 92 3 3 3 
40 3 3 3 93 3 3 3 
41 3 3 3 94 3 3 3 
42 3 3 3 95 3 3 3 
43 3 3 3 96 3 3 3 
44 3 3 3 97 3 3 3 
45 3 3 3 98 3 3 3 
46 3 3 3 99 3 3 3 
47 3 3 3 100 3 3 3 
48 4 3 3 101 3 3 3 
49 3 3 3 102 3 3 3 
50 3 3 3 103 3 3 3 
51 3 3 3 104 3 3 3 
52 3 3 3 105 3 3 3 
53 3 3 3     
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54 3 3 3 
1On May 10th 2012, after an evaluation of the first draft of the statistics report, the core VMG 
overrode the rule identifying 50% NSMTT as a cut-off to consider a chemical compatible with the 
test system as described in Chapter 2.5.1. of this report. In all these cases, rule 3 in Chapter 2.5.1. 
is fulfilled since the mean %NSC of all qualified tests is greater than (>) 50% and the classification 
of these qualified tests changes upon correction (from non-irritant to irritant). However, the viability 
values obtained in the qualified tests are definitely within the linear range of the OD measurements 
(within the 100% scale) and therefore, even though there is a strong MTT reduction occurring this 
is not interfering with the analytical capacity to measure formazan production. Moreover, the 
variability obtained between the different tests and controls is low. As such, these chemicals were 
considered compatible with the test method and their data were therefore included in all of the 
statistical analyses. 
Table 3.2.8 Fraction of chemicals with a complete test sequence, subdivided into laboratories and 
total 
 Fraction (%) 
laboratory SE LE 
CARDAM 100.0 100.0 
CEETOX 100.0 99.0 
L’OREAL 100.0 100.0 
Total 100.0 99.7 
 
Given Table 3.2.8, the criteria of at least 85% complete test sequences in each 
laboratory was met, as is also summarized in Table 3.2.9. 
Table 3.2.9 Statement whether the test method has fulfilled the performance criteria (at least 85% 
complete test sequences) concerning the fraction of complete test sequences. 
 SE LE 
laboratory Fraction Statement: criteria is Fraction Statement: criteria is 
CARDAM 100.0 fulfilled 100.0 fulfilled 
CEETOX 100.0 fulfilled 99.0 fulfilled 
L’OREAL 100.0 fulfilled 100.0 fulfilled 
Total 100.0 fulfilled 99.7 fulfilled 
3.2.7 Negative and Positive controls 
 
The results for the negative and positive controls are presented in summarizing 
figures (see Figure 3.2.2, Figure 3.2.3 Figure 3.2.4, and Figure 3.2.5) as well as in 
Table 3.2.12. 
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Figure 3.2.2 Mean OD-values for the Negative controls (Performance criteria: 0.7 < mean ODnc < 
1.5), per laboratory and total  
 
Figure 3.2.3 Standard deviations in viabilities for the Negative controls (Performance criteria: 
standard deviation ≤ 18%), per laboratory and total 
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Figure 3.2.4 Mean viabilities for the Positive controls (Performance criteria: mean viability ≤ 50%) 
 
Figure 3.2.5 Standard deviations in viabilities for the Positive controls (Performance criteria: 
Standard deviations ≤ 18%), per laboratory and total 
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Table 3.2.12 Numerical statistical values for the Negative and Positive Control (lower: 25th 
percentile – 1.5*IQR, p25: 25th percentile, median: 50th percentile, p75: 75th percentile, 
upper: 75th percentile + 1.5*IQR, with IQR = 75th percentile – 25th percentile). 
    SE LE 
 Variable1 laboratory lower p25 median p75 upper lower p25 median p75 upper 
ODnc CARDAM 0.78 0.95 1.02 1.07 1.17 0.72 0.91 1.00 1.17 1.25 
  CEETOX 0.89 0.96 0.99 1.04 1.11 0.81 0.99 1.05 1.11 1.28 
  L’OREAL 0.94 1.04 1.07 1.12 1.2 1.04 1.12 1.15 1.18 1.22 
  Total 0.8 0.97 1.03 1.08 1.2 0.81 0.99 1.1 1.16 1.4 
NCstd CARDAM 0.57 3.44 5.47 6.64 9.67 1.34 3.81 7.2 9.19 13.12 
  CEETOX 1.29 3.9 4.78 6.2 7.28 1.56 3.35 5.84 8.00 12.55 
  L’OREAL 1.31 3.78 5.25 6.95 10.58 0.24 2.18 3.21 5.64 8.31 
  Total 0.57 3.59 5.00 6.6 10.58 0.24 3.05 5.4 7.76 13.12 
meanPC CARDAM 5.45 8.97 11.31 14.97 21.68 3.25 16.15 25.13 37.68 49.52 
  CEETOX 3.29 5.79 9.96 15.34 29.1 2.39 23.94 36.13 48.11 83.28 
  L’OREAL 3.58 10.26 12.8 18.23 29.16 0.84 18.85 28.07 37.47 46.43 
  Total 3.29 8.67 11.85 15.76 23.31 0.84 17.83 30.79 40.39 70.82 
PCstd CARDAM 0.15 0.99 1.67 2.17 3.95 0.79 3.43 4.4 6.31 10.00 
  CEETOX 0.43 0.91 1.82 3.25 6.27 0.18 2.87 4.41 6.82 12.67 
  L’OREAL 0.35 1.73 2.24 3.48 5.9 0.17 0.89 4.04 6.08 13.63 
  Total 0.15 1.21 1.82 3.08 5.78 0.17 2.64 4.31 6.37 10.00 
1
 ODnc = optical density for negative control, NCstd = standard deviation between 
replicates of the negative control, meanPC = viability for positive control, PCstd = 
standard devation between replicates of the positive control 
3.2.8 Summary of all tests results 
 
Finally, a summary of all tests results (including the non-qualified and excluded test 
results) are presented in Appendix VI. 
3.3 Reproducibility and accuracy using the SE protocol 
In this section, a 50% cut-off was applied to determine the irritancy of the chemical 
based on the SE protocol. If the viability is above 50%, the chemical is considered 
to be non-irritant. If the viability is 50% or below, the chemical is considered to be 
irritant.  
3.3.1 Within-laboratory variability 
For each laboratory, concordance of classification was calculated based on 
qualified test from test chemicals for which at least two qualified tests were 
available. In Table 3.3.1 the concordance within each laboratory as well as in total 
is given. 
Table 3.3.1 Concordance within laboratories and total 
  SE 
laboratory 
WLV 
concordant No. Fraction(%) 
CARDAM NO 7 6.7 
 YES 97 93.3 
CEETOX NO 8 7.7 
 YES 96 92.3 
L’OREAL NO 4 3.8 
 YES 100 96.2 
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  SE 
laboratory 
WLV 
concordant No. Fraction(%) 
Total NO 19 6.1 
 YES 293 93.9 
 
Additional descriptive statistics can identify possible reasons for non-concordant 
results. These are presented in Table 3.3.2. For each non-concordant result the 
reactivity, GHS classification, whether it is colouring or MTTreducer and the test 
results are given. 
Table 3.3.2 Additional descriptive statistics on non-concordant results within laboratories 
 Chemical     Test 
laboratory & reactivity1 name colouring MTT GHS class 1 2 3 
CARDAM 20 NR Ricinoleic acid tin salt No Yes no cat 46.2985 44.938 65.542 
 35 R 2,5,6-triamino-4-pyrimidinol sulphate INCI name: 
2,5,6-TRIAMINO-4-PYRIMIDINOL SULFATE 
No Yes no cat 21.820 68.206 13.977 
 48 NR sodium hydrogensulphite  INCI name: SODIUM 
BISULFITE 
No Yes no cat 39.332 43.625 53.660 
 69 R alkyl (C10-16) glucoside sodium carboxylate (~ 30% 
aqueous) INCI name: SODIUM CARBOXYMETHYL 
C10-16 ALKYL GLUCOSIDE 
No No cat 2A 
(ICCVAM:cat2B) 
81.825 34.715 68.611 
 75 NR sodium benzoate INCI name: SODIUM BENZOATE No No cat 2A 61.585 19.942 10.124 
 91 NR  (ethylenediaminepropyl)trimethoxysilane No Yes cat 1 58.078 41.530 55.730 
 100 NR ethyl lauroyl arginate HCl INCI name: ETHYL 
LAUROYL ARGINATE HCL 
No No cat 1 28.052 55.149 27.078 
CEETOX 22 NR 3-phenoxybenzyl alcohol  No No no cat 82.712 48.284 40.507 
 35 R 2,5,6-triamino-4-pyrimidinol sulphate INCI name: 
2,5,6-TRIAMINO-4-PYRIMIDINOL SULFATE 
No Yes no cat 9.883 66.492 4.429 
 73 R 3,3'-dithiopropionic acid No No cat 2A 
(ICCVAM:cat2B) 
65.464 47.596 35.656 
 74 R 2-amino-3-hydroxy pyridine INCI name: 2-AMINO-3-
HYDROXYPYRIDINE 
No Yes cat 2A 88.001 86.080 21.660 
 76 NR 6,7-dihydro-2,3-dimethyl-imidazo[1,2-a]pyridin-8(5H)-
one 
No No cat 2A 44.397 58.806 75.627 
 77 R methyl (2E)-[2-(chloromethyl)phenyl](methoxyimino) 
acetate 
No No cat 2A 49.749 102.332 101.634 
 87 R sodium alkyl ether sulphate (~ 30% aqueous) INCI 
name: SODIUM LAURETH SULFATE 
No No cat 1 81.973 87.036 31.902 
 89 NR ethoxylated (5 EO) alkyl (C10-14) alcohol No No cat 1 66.308 56.433 16.697 
L’OREAL 20 NR ricinoleic acid tin salt No Yes no cat 56.208 45.605 41.291 
 54 R 3-chloropropionitrile No No cat 2B 76.698 71.114 43.178 
 90 NR alkyl (C10-16) glucoside (~ 50% aqueous) INCI name: 
LAURYL GLUCOSIDE 
No Yes cat 1 51.517 23.173 32.711 
 100 NR ethyl lauroyl arginate HCl INCI name: ETHYL 
LAUROYL ARGINATE HCL 
No No cat 1 27.798 69.408 56.670 
1
 Reactivity: R = reactive, NR = non-reactive 
 
The concordance of classifications (irritant/non-irritant) for the set of chemicals 
tested during validation obtained in different, independent runs within a single 
laboratory should ideally be equal or higher than 85% for all participating 
laboratories. As summarized in Table 3.3.3, this criteria was met for each laboratory 
as well as in total. 
Table 3.3.3 Statement whether the test method has fulfilled the performance criteria concerning the 
concordance of classifications within one laboratory. 
 SE 
laboratory Fraction(%) Statement: criteria is 
CARDAM 93.3 fulfilled 
CEETOX 92.3 fulfilled 
L’OREAL 96.2 fulfilled 
Total 93.9 fulfilled 
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The intra-laboratory variability is described by the concordance of classifications. 
Correlation coefficients between viability measurements give also information on 
this variability. Since the Pearson correlation coefficient is sensitive to outlying test 
results and high leverages, both the Pearson and the Spearman correlation 
coefficients (using ranks instead of the original test results) were calculated. These 
coefficients are presented in Table 3.3.4. 
Table 3.3.4 Pearson and Spearman correlation coefficients between tests results within each laboratory 
as well as in total. 
Correlation laboratory Qual1 - Qual2 Qual1 - Qual3 Qual2 - Qual3 
Pearson L’OREAL 0.958 0.962 0.968 
 CARDAM 0.889 0.941 0.916 
 CEETOX 0.940 0.922 0.933 
 Mean 0.929 0.942 0.939 
Spearman L’OREAL 0.856 0.850 0.868 
 CARDAM 0.727 0.818 0.770 
 CEETOX 0.838 0.853 0.881 
 Mean 0.807 0.841 0.840 
 
Finally, the arithmetic mean, standard deviation and coefficient of variation from the 
three valid tests are given per laboratory as well as in total (see Table 3.3.5). Note 
that the coefficient of variation is not a useful measure if the mean is close to zero. 
Table 3.3.5 Arithmetic mean, standard deviation (std) and coefficient of variation (cv) from the three valid 
tests are given per laboratory as well as in total (n = number of qualified tests that was used 
for the calculation of the mean, std and cv) 
 laboratory 
 CARDAM CEETOX L’OREAL 
Chemical mean std cv n mean std cv n mean std cv n 
1 86.7 4.9 5.6 3 85.4 3.1 3.7 3 81.8 2.7 3.3 3 
2 85.6 15.7 18.4 3 92.0 10.7 11.6 3 93.3 3.6 3.9 3 
3 93.4 37.2 39.8 3 79.8 8.5 10.7 3 82.9 3.7 4.4 3 
4 31.0 8.0 25.7 3 0.0 0.0 . 3 8.8 4.2 48.1 3 
5 87.8 12.8 14.6 3 101.8 6.0 5.9 3 88.2 1.5 1.7 3 
6 110.6 6.4 5.8 3 110.6 11.0 9.9 3 112.8 5.8 5.1 3 
7 78.7 12.0 15.2 3 86.8 2.5 2.9 3 91.7 4.1 4.4 3 
8 109.2 13.1 12.0 3 106.2 8.5 8.0 3 104.1 1.5 1.4 3 
9 102.6 8.4 8.2 3 94.8 4.6 4.9 3 94.2 5.6 6.0 3 
10 37.3 9.9 26.7 3 40.8 4.4 10.9 3 30.7 3.7 11.9 3 
11 73.3 7.0 9.6 3 81.7 2.5 3.1 3 80.0 5.8 7.3 3 
12 104.8 2.4 2.3 3 96.1 5.1 5.3 3 89.8 5.1 5.7 3 
13 99.8 3.7 3.7 3 98.4 2.2 2.2 3 95.3 2.3 2.4 3 
14 101.7 7.6 7.5 3 99.3 5.5 5.6 3 87.6 2.6 2.9 3 
15 96.1 4.8 5.0 3 98.9 5.2 5.3 3 93.6 8.5 9.1 3 
16 98.3 5.7 5.8 3 93.9 4.9 5.2 3 105.4 5.6 5.3 3 
17 97.2 14.4 14.8 3 100.1 4.8 4.8 3 97.7 5.2 5.3 3 
18 92.5 7.4 8.0 3 92.3 12.7 13.8 3 100.3 4.8 4.8 3 
19 100.6 5.0 4.9 3 100.5 7.4 7.4 3 99.4 3.9 3.9 3 
20 52.3 11.5 22.0 3 111.2 10.3 9.2 3 47.7 7.7 16.1 3 
21 80.4 17.6 21.9 3 86.3 0.4 0.4 3 85.8 1.9 2.2 3 
22 82.8 19.3 23.3 3 57.2 22.5 39.3 3 68.7 16.7 24.3 3 
23 0.0 0.0 . 3 0.0 0.0 . 3 1.2 0.5 42.5 3 
24 70.4 8.2 11.7 3 68.1 6.3 9.2 3 68.3 3.1 4.5 3 
25 106.2 15.7 14.8 3 96.0 2.5 2.6 3 93.6 6.4 6.8 3 
26 103.1 3.8 3.7 3 97.9 1.7 1.7 3 94.3 7.0 7.5 3 
28 90.8 15.3 16.9 3 91.7 4.2 4.6 3 98.1 2.7 2.8 3 
29 104.9 4.4 4.2 3 99.2 4.1 4.1 3 90.8 0.3 0.3 3 
30 93.3 10.8 11.6 3 80.2 3.2 4.0 3 89.1 6.2 7.0 3 
31 100.9 10.0 9.9 3 98.9 0.4 0.4 3 93.7 4.4 4.7 3 
32 61.2 8.0 13.1 3 44.7 5.1 11.5 3 23.8 6.9 28.9 3 
33 88.8 10.5 11.8 3 91.5 5.7 6.2 3 91.3 7.1 7.8 3 
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 laboratory 
 CARDAM CEETOX L’OREAL 
Chemical mean std cv n mean std cv n mean std cv n 
34 106.9 13.4 12.5 3 108.1 18.7 17.3 3 108.7 10.0 9.2 3 
35 34.7 29.3 84.5 3 26.9 34.4 127.6 3 25.9 8.7 33.5 3 
36 105.2 7.0 6.6 3 96.5 5.4 5.6 3 93.9 2.3 2.5 3 
37 93.4 13.8 14.7 3 86.6 4.1 4.7 3 85.8 0.7 0.8 3 
38 99.9 10.8 10.8 3 94.3 9.3 9.8 3 94.3 5.3 5.6 3 
39 99.7 4.9 4.9 3 98.1 4.7 4.8 3 97.4 6.2 6.3 3 
40 96.6 3.3 3.4 3 84.9 1.2 1.4 3 85.4 12.7 14.9 3 
41 100.3 6.2 6.2 3 99.1 5.7 5.7 3 96.1 5.0 5.2 3 
42 90.2 2.1 2.3 3 84.2 8.8 10.4 3 91.7 11.5 12.6 3 
43 95.7 3.4 3.6 3 101.1 3.1 3.1 3 98.4 4.2 4.3 3 
44 98.2 5.7 5.8 3 100.4 1.9 1.9 3 97.0 3.4 3.5 3 
45 98.2 6.4 6.5 3 95.1 4.4 4.6 3 90.9 7.0 7.7 3 
46 89.5 3.4 3.8 3 92.2 9.9 10.8 3 86.5 5.9 6.8 3 
47 95.6 6.1 6.3 3 96.7 6.9 7.1 3 91.4 5.4 5.9 3 
48 45.5 7.4 16.1 3 28.4 10.7 37.8 3 39.4 5.5 13.9 3 
49 105.3 4.1 3.9 3 105.7 7.5 7.1 3 100.1 4.7 4.7 3 
50 92.7 8.4 9.0 3 90.1 4.6 5.1 3 91.1 5.4 6.0 3 
51 94.2 3.6 3.9 3 99.1 4.8 4.9 3 94.5 8.8 9.3 3 
52 99.0 3.2 3.3 3 107.2 5.4 5.1 3 96.6 8.2 8.5 3 
53 90.9 7.9 8.7 3 98.4 4.0 4.0 3 95.4 2.9 3.1 3 
54 72.1 8.5 11.8 3 80.9 7.2 8.9 3 63.7 18.0 28.2 3 
55 2.8 0.9 31.2 3 4.1 0.8 19.2 3 1.6 0.5 32.4 3 
56 81.5 12.9 15.9 3 90.0 3.9 4.4 3 71.1 2.9 4.0 3 
57 33.9 7.7 22.8 3 34.0 5.3 15.5 3 26.8 14.0 52.2 3 
58 34.4 8.4 24.5 3 32.5 1.9 6.0 3 16.0 5.3 33.2 3 
59 81.0 9.4 11.6 3 89.0 2.5 2.8 3 70.4 6.4 9.1 3 
60 33.4 3.4 10.2 3 33.8 7.8 23.0 3 21.2 4.0 18.8 3 
61 87.5 11.9 13.6 3 90.3 5.9 6.6 3 86.7 3.6 4.2 3 
62 95.3 2.9 3.1 3 97.0 4.7 4.9 3 91.8 6.1 6.7 3 
63 94.1 2.6 2.7 3 91.4 8.3 9.1 3 96.5 10.9 11.2 3 
64 93.5 8.2 8.8 3 90.8 5.6 6.2 3 95.2 7.8 8.2 3 
65 102.3 14.3 14.0 3 103.0 3.6 3.5 3 94.6 1.2 1.3 3 
66 86.3 20.0 23.2 3 82.8 2.0 2.4 3 81.6 2.5 3.1 3 
67 4.5 2.0 44.6 3 23.7 9.0 37.8 3 8.8 6.6 75.5 3 
68 2.6 2.1 82.0 3 4.9 0.5 10.2 3 4.0 2.9 72.5 3 
69 61.7 24.3 39.4 3 65.0 7.4 11.4 3 66.3 9.1 13.6 3 
70 10.1 2.2 21.8 3 8.9 3.4 37.7 3 14.5 4.1 28.3 3 
71 6.6 5.2 78.8 3 4.8 0.6 12.0 3 5.8 1.3 22.7 3 
72 3.9 0.7 17.3 3 2.6 2.3 86.6 3 3.3 1.6 50.1 3 
73 93.8 5.9 6.3 3 49.6 15.0 30.3 3 91.1 13.5 14.8 3 
74 93.9 9.1 9.7 3 65.2 37.8 57.9 3 88.2 1.8 2.1 3 
75 30.6 27.3 89.4 3 61.4 2.7 4.4 3 13.3 0.9 6.8 3 
76 80.8 8.7 10.8 3 59.6 15.6 26.2 3 60.0 6.0 9.9 3 
77 96.3 15.2 15.8 3 84.6 30.2 35.7 3 97.5 1.6 1.6 3 
78 91.1 10.8 11.8 3 99.0 6.6 6.7 3 91.3 2.0 2.2 3 
79 73.5 1.5 2.0 3 81.7 6.5 8.0 3 83.7 7.0 8.4 3 
80 3.0 3.2 105.5 3 0.2 0.4 155.7 3 0.0 0.0 . 3 
81 0.4 0.1 15.0 3 1.9 1.2 60.3 3 0.7 0.2 27.5 3 
82 3.4 1.1 33.6 3 1.3 0.4 29.1 3 4.8 1.3 27.9 3 
83 3.6 2.5 68.1 3 5.3 4.3 81.0 3 2.6 0.7 26.6 3 
84 23.0 10.5 45.9 3 8.6 6.0 69.4 3 20.3 4.9 24.3 3 
85 71.6 4.3 6.0 3 82.5 6.7 8.1 3 70.3 9.0 12.8 3 
86 95.5 14.3 15.0 3 80.2 5.4 6.7 3 87.4 2.3 2.6 3 
87 93.4 7.6 8.1 3 67.0 30.5 45.5 3 89.9 7.5 8.3 3 
88 6.8 3.5 50.8 3 4.8 2.6 55.3 3 3.9 0.5 13.4 3 
89 76.0 6.9 9.1 3 46.5 26.3 56.5 3 68.1 8.8 12.9 3 
90 77.5 23.2 29.9 3 75.5 9.6 12.7 3 35.8 14.4 40.3 3 
91 51.8 9.0 17.3 3 0.0 0.0 . 3 33.4 14.9 44.7 3 
92 82.3 3.3 4.1 3 81.7 4.8 5.8 3 79.8 2.5 3.1 3 
93 80.5 8.5 10.5 3 91.9 6.5 7.1 3 73.8 10.9 14.8 3 
94 78.5 3.2 4.0 3 60.6 12.2 20.1 3 76.9 1.6 2.1 3 
95 1.8 0.7 36.5 3 10.3 6.3 61.0 3 1.4 0.1 3.7 3 
96 90.7 8.4 9.2 3 99.0 1.9 1.9 3 91.7 17.4 18.9 3 
97 95.8 2.5 2.6 3 86.6 13.7 15.8 3 90.8 3.6 4.0 3 
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 laboratory 
 CARDAM CEETOX L’OREAL 
Chemical mean std cv n mean std cv n mean std cv n 
98 92.8 13.6 14.7 3 75.2 6.4 8.5 3 82.8 4.9 5.9 3 
99 22.0 4.6 21.0 3 8.1 5.5 68.6 3 23.3 5.1 21.8 3 
100 36.8 15.9 43.3 3 30.6 12.0 39.2 3 51.3 21.3 41.6 3 
101 91.7 8.3 9.1 3 91.0 6.3 6.9 3 79.2 1.6 2.0 3 
102 111.6 3.8 3.4 3 99.5 2.8 2.8 3 92.0 5.1 5.5 3 
103 7.6 2.2 29.6 3 4.2 2.1 50.8 3 5.1 0.4 7.7 3 
104 96.4 13.3 13.8 3 89.0 6.5 7.3 3 90.8 6.5 7.2 3 
105 9.2 1.6 17.1 3 5.9 0.5 7.7 3 7.9 0.8 10.2 3 
Table 3.3.6 Standard deviation (std) and coefficient of variation (cv) from all available tests results 
(Q=qualified and NQ=non-qualified) per laboratory (n = number of tests that was used 
for the calculations) 
 laboratory 
 CARDAM CEETOX L’OREAL 
 Q Q+NQ Q Q+NQ Q Q+NQ 
Chemical std cv n std cv n std cv n std cv n std cv n std cv n 
1 4.9 5.6 3 4.9 5.6 3 3.1 3.7 3 3.1 3.7 3 2.7 3.3 3 2.7 3.3 3 
2 15.7 18.4 3 15.7 18.4 3 10.7 11.6 3 10.7 11.6 3 3.6 3.9 3 3.6 3.9 3 
3 37.2 39.8 3 37.2 39.8 3 8.5 10.7 3 8.5 10.7 3 3.7 4.4 3 3.7 4.4 3 
4 8.0 25.7 3 16.5 70.5 3 0.0 . 3 0.0 . 3 4.2 48.1 3 4.2 48.1 3 
5 12.8 14.6 3 12.8 14.6 3 6.0 5.9 3 6.0 5.9 3 1.5 1.7 3 1.5 1.7 3 
6 6.4 5.8 3 6.4 5.8 3 11.0 9.9 3 11.0 9.9 3 5.8 5.1 3 5.8 5.1 3 
7 12.0 15.2 3 12.0 15.2 3 2.5 2.9 3 2.5 2.9 3 4.1 4.4 3 4.1 4.4 3 
8 13.1 12.0 3 13.1 12.0 3 8.5 8.0 3 8.5 8.0 3 1.5 1.4 3 1.5 1.4 3 
9 8.4 8.2 3 8.4 8.2 3 4.6 4.9 3 4.6 4.9 3 5.6 6.0 3 5.6 6.0 3 
10 9.9 26.7 3 9.9 26.7 3 4.4 10.9 3 4.4 10.9 3 3.7 11.9 3 3.7 11.9 3 
11 7.0 9.6 3 7.0 9.6 3 2.5 3.1 3 2.5 3.1 3 5.8 7.3 3 5.8 7.3 3 
12 2.4 2.3 3 2.4 2.3 3 5.1 5.3 3 5.1 5.3 3 5.1 5.7 3 5.1 5.7 3 
13 3.7 3.7 3 3.7 3.7 3 2.2 2.2 3 2.2 2.2 3 2.3 2.4 3 2.3 2.4 3 
14 7.6 7.5 3 7.6 7.5 3 5.5 5.6 3 5.5 5.6 3 2.6 2.9 3 2.6 2.9 3 
15 4.8 5.0 3 4.8 5.0 3 5.2 5.3 3 5.2 5.3 3 8.5 9.1 3 8.5 9.1 3 
16 5.7 5.8 3 5.7 5.8 3 4.9 5.2 3 4.9 5.2 3 5.6 5.3 3 5.6 5.3 3 
17 14.4 14.8 3 13.9 14.9 4 4.8 4.8 3 4.8 4.8 3 5.2 5.3 3 5.2 5.3 3 
18 7.4 8.0 3 7.4 8.0 3 12.7 13.8 3 47.3 68.3 4 4.8 4.8 3 4.8 4.8 3 
19 5.0 4.9 3 5.0 4.9 3 7.4 7.4 3 7.4 7.4 3 3.9 3.9 3 3.9 3.9 3 
20 11.5 22.0 3 11.5 22.0 3 10.3 9.2 3 10.3 9.2 3 7.7 16.1 3 10.3 22.5 5 
21 17.6 21.9 3 17.6 21.9 3 0.4 0.4 3 0.4 0.4 3 1.9 2.2 3 1.9 2.2 3 
22 19.3 23.3 3 19.3 23.3 3 22.5 39.3 3 22.5 39.3 3 16.7 24.3 3 16.7 24.3 3 
23 0.0 . 3 0.0 . 3 0.0 . 3 0.0 . 3 0.5 42.5 3 0.5 42.5 3 
24 8.2 11.7 3 8.2 11.7 3 6.3 9.2 3 6.3 9.2 3 3.1 4.5 3 3.1 4.5 3 
25 15.7 14.8 3 15.7 14.8 3 2.5 2.6 3 2.5 2.6 3 6.4 6.8 3 6.4 6.8 3 
26 3.8 3.7 3 3.8 3.7 3 1.7 1.7 3 1.7 1.7 3 7.0 7.5 3 7.0 7.5 3 
28 15.3 16.9 3 15.3 16.9 3 4.2 4.6 3 4.2 4.6 3 2.7 2.8 3 2.7 2.8 3 
29 4.4 4.2 3 4.4 4.2 3 4.1 4.1 3 4.1 4.1 3 0.3 0.3 3 0.3 0.3 3 
30 10.8 11.6 3 10.8 11.6 3 3.2 4.0 3 3.2 4.0 3 6.2 7.0 3 6.2 7.0 3 
31 10.0 9.9 3 10.0 9.9 3 0.4 0.4 3 0.4 0.4 3 4.4 4.7 3 4.4 4.7 3 
32 8.0 13.1 3 8.0 13.1 3 5.1 11.5 3 5.1 11.5 3 6.9 28.9 3 6.9 28.9 3 
33 10.5 11.8 3 10.5 11.8 3 5.7 6.2 3 5.7 6.2 3 7.1 7.8 3 7.1 7.8 3 
34 13.4 12.5 3 13.5 12.2 4 18.7 17.3 3 18.7 17.3 3 10.0 9.2 3 10.0 9.2 3 
35 29.3 84.5 3 29.3 84.5 3 34.4 127.6 3 34.4 127.6 3 8.7 33.5 3 8.7 33.5 3 
36 7.0 6.6 3 7.0 6.6 3 5.4 5.6 3 5.4 5.6 3 2.3 2.5 3 2.3 2.5 3 
37 13.8 14.7 3 13.8 14.7 3 4.1 4.7 3 4.1 4.7 3 0.7 0.8 3 0.7 0.8 3 
38 10.8 10.8 3 10.8 10.8 3 9.3 9.8 3 9.3 9.8 3 5.3 5.6 3 5.3 5.6 3 
39 4.9 4.9 3 4.9 4.9 3 4.7 4.8 3 4.7 4.8 3 6.2 6.3 3 6.2 6.3 3 
40 3.3 3.4 3 3.3 3.4 3 1.2 1.4 3 1.2 1.4 3 12.7 14.9 3 12.7 14.9 3 
41 6.2 6.2 3 6.2 6.2 3 5.7 5.7 3 5.7 5.7 3 5.0 5.2 3 5.0 5.2 3 
42 2.1 2.3 3 2.1 2.3 3 8.8 10.4 3 8.8 10.4 3 11.5 12.6 3 11.5 12.6 3 
43 3.4 3.6 3 3.4 3.6 3 3.1 3.1 3 3.1 3.1 3 4.2 4.3 3 4.2 4.3 3 
44 5.7 5.8 3 5.7 5.8 3 1.9 1.9 3 1.9 1.9 3 3.4 3.5 3 3.4 3.5 3 
45 6.4 6.5 3 6.4 6.5 3 4.4 4.6 3 4.4 4.6 3 7.0 7.7 3 7.0 7.7 3 
46 3.4 3.8 3 3.4 3.8 3 9.9 10.8 3 9.9 10.8 3 5.9 6.8 3 5.9 6.8 3 
47 6.1 6.3 3 6.1 6.3 3 6.9 7.1 3 6.9 7.1 3 5.4 5.9 3 5.4 5.9 3 
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 laboratory 
 CARDAM CEETOX L’OREAL 
 Q Q+NQ Q Q+NQ Q Q+NQ 
Chemical std cv n std cv n std cv n std cv n std cv n std cv n 
48 7.4 16.1 3 7.4 16.1 3 10.7 37.8 3 10.7 37.8 3 5.5 13.9 3 5.5 13.9 3 
49 4.1 3.9 3 4.1 3.9 3 7.5 7.1 3 7.5 7.1 3 4.7 4.7 3 4.7 4.7 3 
50 8.4 9.0 3 8.4 9.0 3 4.6 5.1 3 4.6 5.1 3 5.4 6.0 3 5.4 6.0 3 
51 3.6 3.9 3 3.6 3.9 3 4.8 4.9 3 4.8 4.9 3 8.8 9.3 3 8.8 9.3 3 
52 3.2 3.3 3 3.2 3.3 3 5.4 5.1 3 5.4 5.1 3 8.2 8.5 3 8.2 8.5 3 
53 7.9 8.7 3 7.9 8.7 3 4.0 4.0 3 4.0 4.0 3 2.9 3.1 3 2.9 3.1 3 
54 8.5 11.8 3 8.5 11.8 3 7.2 8.9 3 7.2 8.9 3 18.0 28.2 3 18.0 28.2 3 
55 0.9 31.2 3 0.9 31.2 3 0.8 19.2 3 0.8 19.2 3 0.5 32.4 3 0.5 32.4 3 
56 12.9 15.9 3 12.9 15.9 3 3.9 4.4 3 3.9 4.4 3 2.9 4.0 3 2.9 4.0 3 
57 7.7 22.8 3 7.7 22.8 3 5.3 15.5 3 5.3 15.5 3 14.0 52.2 3 14.0 52.2 3 
58 8.4 24.5 3 8.4 24.5 3 1.9 6.0 3 1.9 6.0 3 5.3 33.2 3 5.3 33.2 3 
59 9.4 11.6 3 9.4 11.6 3 2.5 2.8 3 2.5 2.8 3 6.4 9.1 3 6.4 9.1 3 
60 3.4 10.2 3 3.4 10.2 3 7.8 23.0 3 7.8 23.0 3 4.0 18.8 3 4.0 18.8 3 
61 11.9 13.6 3 11.9 13.6 3 5.9 6.6 3 5.9 6.6 3 3.6 4.2 3 3.6 4.2 3 
62 2.9 3.1 3 2.9 3.1 3 4.7 4.9 3 4.7 4.9 3 6.1 6.7 3 6.1 6.7 3 
63 2.6 2.7 3 2.6 2.7 3 8.3 9.1 3 8.3 9.1 3 10.9 11.2 3 10.9 11.2 3 
64 8.2 8.8 3 8.2 8.8 3 5.6 6.2 3 5.6 6.2 3 7.8 8.2 3 7.8 8.2 3 
65 14.3 14.0 3 14.3 14.0 3 3.6 3.5 3 3.6 3.5 3 1.2 1.3 3 1.2 1.3 3 
66 20.0 23.2 3 20.0 23.2 3 2.0 2.4 3 2.0 2.4 3 2.5 3.1 3 2.5 3.1 3 
67 2.0 44.6 3 2.0 44.6 3 9.0 37.8 3 9.0 37.8 3 6.6 75.5 3 6.6 75.5 3 
68 2.1 82.0 3 2.1 82.0 3 0.5 10.2 3 0.5 10.2 3 2.9 72.5 3 2.9 72.5 3 
69 24.3 39.4 3 24.3 39.4 3 7.4 11.4 3 7.4 11.4 3 9.1 13.6 3 9.1 13.6 3 
70 2.2 21.8 3 2.2 21.8 3 3.4 37.7 3 3.4 37.7 3 4.1 28.3 3 4.1 28.3 3 
71 5.2 78.8 3 5.2 78.8 3 0.6 12.0 3 0.6 12.0 3 1.3 22.7 3 1.3 22.7 3 
72 0.7 17.3 3 0.7 17.3 3 2.3 86.6 3 2.3 86.6 3 1.6 50.1 3 1.6 50.1 3 
73 5.9 6.3 3 5.9 6.3 3 15.0 30.3 3 15.0 30.3 3 13.5 14.8 3 13.5 14.8 3 
74 9.1 9.7 3 9.1 9.7 3 37.8 57.9 3 37.8 57.9 3 1.8 2.1 3 1.8 2.1 3 
75 27.3 89.4 3 22.3 73.0 4 2.7 4.4 3 2.7 4.4 3 0.9 6.8 3 8.9 45.7 5 
76 8.7 10.8 3 8.7 10.8 3 15.6 26.2 3 15.6 26.2 3 6.0 9.9 3 6.0 9.9 3 
77 15.2 15.8 3 15.2 15.8 3 30.2 35.7 3 30.2 35.7 3 1.6 1.6 3 1.6 1.6 3 
78 10.8 11.8 3 10.8 11.8 3 6.6 6.7 3 6.6 6.7 3 2.0 2.2 3 2.0 2.2 3 
79 1.5 2.0 3 1.5 2.0 3 6.5 8.0 3 6.5 8.0 3 7.0 8.4 3 7.0 8.4 3 
80 3.2 105.5 3 3.2 105.5 3 0.4 155.7 3 0.4 155.7 3 0.0 . 3 0.0 . 3 
81 0.1 15.0 3 0.1 15.0 3 1.2 60.3 3 1.2 60.3 3 0.2 27.5 3 0.2 27.5 3 
82 1.1 33.6 3 1.1 33.6 3 0.4 29.1 3 0.4 29.1 3 1.3 27.9 3 1.3 27.9 3 
83 2.5 68.1 3 2.5 68.1 3 4.3 81.0 3 4.3 81.0 3 0.7 26.6 3 0.7 26.6 3 
84 10.5 45.9 3 10.5 45.9 3 6.0 69.4 3 6.0 69.4 3 4.9 24.3 3 4.9 24.3 3 
85 4.3 6.0 3 4.3 6.0 3 6.7 8.1 3 6.7 8.1 3 9.0 12.8 3 9.0 12.8 3 
86 14.3 15.0 3 14.3 15.0 3 5.4 6.7 3 5.4 6.7 3 2.3 2.6 3 2.3 2.6 3 
87 7.6 8.1 3 7.6 8.1 3 30.5 45.5 3 30.5 45.5 3 7.5 8.3 3 7.5 8.3 3 
88 3.5 50.8 3 3.5 50.8 3 2.6 55.3 3 2.6 55.3 3 0.5 13.4 3 0.5 13.4 3 
89 6.9 9.1 3 6.9 9.1 3 26.3 56.5 3 26.3 56.5 3 8.8 12.9 3 8.8 12.9 3 
90 23.2 29.9 3 23.2 29.9 3 9.6 12.7 3 9.6 12.7 3 14.4 40.3 3 14.4 40.3 3 
91 9.0 17.3 3 9.0 17.3 3 0 . 3 0 . 3 14.9 44.7 3 14.9 44.7 3 
92 3.3 4.1 3 3.3 4.1 3 4.8 5.8 3 4.8 5.8 3 2.5 3.1 3 2.5 3.1 3 
93 8.5 10.5 3 8.5 10.5 3 6.5 7.1 3 6.5 7.1 3 10.9 14.8 3 10.9 14.8 3 
94 3.2 4.0 3 3.2 4.0 3 12.2 20.1 3 12.2 20.1 3 1.6 2.1 3 1.6 2.1 3 
95 0.7 36.5 3 0.7 36.5 3 6.3 61.0 3 6.3 61.0 3 0.1 3.7 3 0.1 3.7 3 
96 8.4 9.2 3 8.4 9.2 3 1.9 1.9 3 1.9 1.9 3 17.4 18.9 3 17.4 18.9 3 
97 2.5 2.6 3 2.5 2.6 3 13.7 15.8 3 13.7 15.8 3 3.6 4.0 3 3.6 4.0 3 
98 13.6 14.7 3 13.6 14.7 3 6.4 8.5 3 6.4 8.5 3 4.9 5.9 3 4.9 5.9 3 
99 4.6 21.0 3 4.6 21.0 3 5.5 68.6 3 5.5 68.6 3 5.1 21.8 3 5.1 21.8 3 
100 15.9 43.3 3 15.9 43.3 3 12.0 39.2 3 12.0 39.2 3 21.3 41.6 3 21.3 41.6 3 
101 8.3 9.1 3 8.3 9.1 3 6.3 6.9 3 6.3 6.9 3 1.6 2.0 3 1.6 2.0 3 
102 3.8 3.4 3 3.8 3.4 3 2.8 2.8 3 2.8 2.8 3 5.1 5.5 3 5.1 5.5 3 
103 2.2 29.6 3 2.2 29.6 3 2.1 50.8 3 2.1 50.8 3 0.4 7.7 3 0.4 7.7 3 
104 13.3 13.8 3 13.3 13.8 3 6.5 7.3 3 6.5 7.3 3 6.5 7.2 3 6.5 7.2 3 
105 1.6 17.1 3 1.6 17.1 3 0.5 7.7 3 0.5 7.7 3 0.8 10.2 3 0.8 10.2 3 
                   
Overall                   
Mean 8.4   8.4   6.8   7.2   5.4   5.5   
SD 6.5   6.4   7.0   8.0   4.3   4.3   
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3.3.2 Between-laboratory variability 
The arithmetic mean value of viability over the different qualified tests per laboratory 
was used to calculate the inter-laboratory variability. For calculation on the between-
laboratory variability, only those chemicals are included for which at least one 
qualified test per laboratory was available. Table 3.3.7 gives the mean standard 
deviation as well as the standard deviation of the standard deviations 
Table 3.3.7 Mean standard deviation and standard deviation per chemical considering the 




Chemical mean SD std SD mean SD std SD 
1 3.6 1.1 3.6 1.1 
2 10.0 6.1 10 6.1 
3 16.5 18.1 16.5 18.1 
4 4.1 4.0 6.9 8.6 
5 6.8 5.7 6.8 5.7 
6 7.7 2.8 7.7 2.8 
7 6.2 5.1 6.2 5.1 
8 7.7 5.8 7.7 5.8 
9 6.2 2.0 6.2 2 
10 6.0 3.4 6 3.4 
11 5.1 2.3 5.1 2.3 
12 4.2 1.6 4.2 1.6 
13 2.7 0.8 2.7 0.8 
14 5.2 2.5 5.2 2.5 
15 6.2 2.0 6.2 2 
16 5.4 0.4 5.4 0.4 
17 8.1 5.4 8 5.2 
18 8.3 4.0 19.8 23.8 
19 5.4 1.8 5.4 1.8 
20 9.8 2.0 10.7 0.7 
21 6.6 9.5 6.6 9.5 
22 19.5 2.9 19.5 2.9 
23 0.2 0.3 0.2 0.3 
24 5.9 2.6 5.9 2.6 
25 8.2 6.8 8.2 6.8 
26 4.2 2.7 4.2 2.7 
28 7.4 6.9 7.4 6.9 
29 2.9 2.3 2.9 2.3 
30 6.8 3.8 6.8 3.8 
31 4.9 4.8 4.9 4.8 
32 6.7 1.5 6.7 1.5 
33 7.8 2.5 7.8 2.5 
34 14.0 4.4 14.1 4.4 
35 24.1 13.6 24.1 13.6 
36 4.9 2.4 4.9 2.4 
37 6.2 6.8 6.2 6.8 
38 8.5 2.8 8.5 2.8 
39 5.3 0.8 5.3 0.8 
40 5.7 6.1 5.7 6.1 
41 5.6 0.6 5.6 0.6 
42 7.5 4.8 7.5 4.8 
43 3.6 0.5 3.6 0.5 
44 3.7 1.9 3.7 1.9 
45 5.9 1.4 5.9 1.4 
46 6.4 3.3 6.4 3.3 
47 6.1 0.7 6.1 0.7 
48 7.8 2.7 7.8 2.7 
49 5.4 1.8 5.4 1.8 
50 6.1 2.0 6.1 2 
51 5.8 2.7 5.8 2.7 
52 5.6 2.5 5.6 2.5 
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Q Q+NQ 
Chemical mean SD std SD mean SD std SD 
53 4.9 2.6 4.9 2.6 
54 11.2 5.9 11.2 5.9 
55 0.7 0.2 0.7 0.2 
56 6.6 5.5 6.6 5.5 
57 9.0 4.5 9 4.5 
58 5.2 3.2 5.2 3.2 
59 6.1 3.5 6.1 3.5 
60 5.1 2.4 5.1 2.4 
61 7.2 4.3 7.2 4.3 
62 4.6 1.6 4.6 1.6 
63 7.3 4.3 7.3 4.3 
64 7.2 1.4 7.2 1.4 
65 6.4 7.0 6.4 7 
66 8.2 10.3 8.2 10.3 
67 5.9 3.5 5.9 3.5 
68 1.8 1.2 1.8 1.2 
69 13.6 9.3 13.6 9.3 
70 3.2 1.0 3.2 1 
71 2.4 2.5 2.4 2.5 
72 1.5 0.8 1.5 0.8 
73 11.5 4.9 11.5 4.9 
74 16.2 19.0 16.2 19 
75 10.3 14.8 11.3 10 
76 10.1 5.0 10.1 5 
77 15.7 14.3 15.7 14.3 
78 6.5 4.4 6.5 4.4 
79 5.0 3.1 5 3.1 
80 1.2 1.7 1.2 1.7 
81 0.5 0.6 0.5 0.6 
82 1.0 0.5 1 0.5 
83 2.5 1.8 2.5 1.8 
84 7.2 3.0 7.2 3 
85 6.7 2.4 6.7 2.4 
86 7.3 6.2 7.3 6.2 
87 15.2 13.2 15.2 13.2 
88 2.2 1.5 2.2 1.5 
89 14.0 10.7 14 10.7 
90 15.7 6.9 15.7 6.9 
91 8.0 7.5 8 7.5 
92 3.5 1.2 3.5 1.2 
93 8.6 2.2 8.6 2.2 
94 5.6 5.7 5.6 5.7 
95 2.3 3.4 2.3 3.4 
96 9.2 7.8 9.2 7.8 
97 6.6 6.2 6.6 6.2 
98 8.3 4.7 8.3 4.7 
99 5.1 0.5 5.1 0.5 
100 16.4 4.7 16.4 4.7 
101 5.4 3.5 5.4 3.5 
102 3.9 1.2 3.9 1.2 
103 1.6 1.0 1.6 1 
104 8.8 3.9 8.8 3.9 
105 0.9 0.6 0.9 0.6 
     
     
Overall     
Mean 6.9  7.0  
SD 4.2  4.4  
 
Concordance of classification between laboratories was calculated based on 
qualified test from test chemicals for which at least one qualified test was available. 
In Table 3.3.8 the concordance between laboratories is given. 
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Table 3.3.8 Concordance between laboratories 
BLV 
concordant No. Fraction(%) 
NO 8 7.7 
YES 96 92.3 
 
Additional descriptive statistics can identify possible reasons for non-concordant 
results. These are presented in Table 3.3.9. For each non-concordant result the 
state (liquid/solid), the GHS classification, whether it is colouring or MTTreducer 
and the test results are given. 
 
Table 3.3.9 Additional descriptive statistics on non-concordant results between laboratories 
chemical name LS coloring MTT GHS class CEETOX CARDAM L’OREAL 
20 Ricinoleic acid tin salt Liquid No No no cat 111.155 52.25962 47.70122 
32 2,6-dihydroxy-3,4-
dimethylpyridine INCI name: 2,6-
DIHYDROXY-3,4-
DIMETHYLPYRIDINE 
Solid No No no cat 44.683 61.2251 23.7622 
73 3,3'-dithiopropionic acid Solid No No cat 2A 
(ICCVAM:c
at2B) 
49.572 93.804 91.091 
75 sodium benzoate INCI name: 
SODIUM BENZOATE 
Solid No No cat 2A 61.383 30.551 13.331 
89 ethoxylated (5 EO) alkyl (C10-
14) alcohol 
Liquid No No cat 1 46.479 75.962 68.120 
90 alkyl (C10-16) glucoside (~ 50% 
aqueous) INCI name: LAURYL 
GLUCOSIDE 
Liquid No No cat 1 75.471 77.506 35.8003 
91 (ethylenediaminepropyl)trimetho
xysilane 
Liquid No Yes Cat1 0 51.780 33.385 
100 ethyl lauroyl arginate HCl INCI 
name: ETHYL LAUROYL 
ARGINATE HCL 
Solid No No cat 1 30.575 36.760 51.292 
1
 identified as colourant, 2 identified as colourant and MTT-reducer, 3 identified as MTT-reducer 
 
The concordance for the set of chemicals tested during validation obtained by the 
different participating laboratories should ideally be equal or higher than 80%. As 
summarized in Table 3.3.10, this criteria was met.   
Table 3.3.10 Statement whether the test method has fulfilled the performance criteria concerning 
the concordance of classifications between laboratories. 
Fraction (%) Statement: criteria is 
92.3 fulfilled 
 
A two-way ANOVA was applied to test for differences in mean viabilities between 
laboratories and chemicals. Five outlying observations ((Ethylenediaminepropyl) 
trimethoxysilane, 3,3'-Dithiopropionic acid, Ricinoleic acid tin salt, and 
Sodium benzoate from CEETOX and alkyl (C10-16) glucoside (~ 50% aqueous) 
INCI name: LAURYL GLUCOSIDE from L’OREAL) were removed before analysis in 
order to fulfil the ANOVA-requirements. An outlier was defined as an observation 
with a residual > 3* residual error. The results from the two-way ANOVA are 
presented in Table 3.3.11. The null hypothesis of no difference was rejected at the 
0.01 level of probability (α=0.01). 
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Table 3.3.11 Two-way ANOVA with factors laboratory and chemical, applied to the arithmetic 
mean value of the included test results  
Effect NumDF DenDF FValue pvalue 
laboratory 2 201 11.96 <.0001 
chemical 103 201 83.98 <.0001 
Table 3.3.12 Results of the Tukey post-hoc test on differences between laboratories  
laboratory vs Estimate Standard Error DF Tukey-corrected p-value 
CARDAM CEETOX 2.9826 0.9200 202 0.0040 
CARDAM L’OREAL 4.3373 0.9065 202 <.0001 
CEETOX L’OREAL 1.3547 0.9200 202 0.3063 
  
The between-laboratory variability is described by the concordance of 
classifications between laboratories. Correlations coefficients between viability 
measurements give also information on this variability. Since the Pearson 
correlation coefficient is sensitive for outlying test results and high leverages, both 
the Pearson and the Spearman correlation coefficients (using ranks instead of the 
original test results) were calculated. These coefficients are presented in Table 
3.3.13. 
Table 3.3.13 Pearson and Spearman correlation coefficients between test results of the three 
participating laboratories. 
laboratories Pearson Spearman 
CARDAM-CEETOX 0.931 0.844 
CARDAM-L’OREAL 0.970 0.894 
CEETOX-L’OREAL 0.930 0.863 
3.3.3 Predictive capacity (accuracy) 
All qualified tests for each test chemical was used to calculate the predictive 
capacity values. The calculations were based on the individual predictions of each 
qualified test in each laboratory.  
 
For each statistic of the prediction model, an acceptance rate was set by the VMG. 
These criteria are presented in Table 3.3.14. The sensitivity, specificity and overall 
accuracy, subdivided into laboratories and total, including the 95% confidence 
intervals as well as a statement whether the acceptance criteria are fulfilled are 
presented in Table 3.3.15. 
Table 3.3.14 Acceptance criteria for the prediction model 
 False Negativesa (%) False Positivesb (%) Overall 
misclassificationsc (%) 
“Definitely acceptable” rates  ≤ 10 ≤ 40 ≤ 25 
Further evaluations 
necessary before any 
recommendation is made 
10 < FN ≤ 20 40 < FP ≤ 50 25 < OM ≤ 35 
“Definitely unacceptable” 
rates > 20 > 50 > 35 
a
 equal to (1-Sensitivity), b equal to (1-Specificity), c equal to (1-Overall accuracy) 
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Table 3.3.15 The sensitivity, specificity and overall accuracy, subdivided into laboratories and total, 
including the 95% confidence intervals as well as a statement whether the acceptance 











CARDAM Accuracy 204/312 0.654 0.598 0.707 further evaluation 
 Sensitivity 63/156 0.404 0.326 0.485 definitely unacceptable 
 Specificity 141/156 0.904 0.846 0.945 definitely acceptable 
CEETOX Accuracy 207/312 0.663 0.608 0.716 further evaluation 
 Sensitivity 70/156 0.449 0.369 0.530 definitely unacceptable 
 Specificity 137/156 0.878 0.816 0.925 definitely acceptable 
L’OREAL Accuracy 203/312 0.651 0.595 0.703 further evaluation 
 Sensitivity 67/156 0.429 0.351 0.511 definitely unacceptable 
 Specificity 136/156 0.872 0.809 0.920 definitely acceptable 
Total Accuracy 614/936 0.656 0.625 0.686 further evaluation 
 Sensitivity 200/468 0.427 0.382 0.474 definitely unacceptable 
 Specificity 414/468 0.885 0.852 0.912 definitely acceptable 
 
In Table 3.3.16, the prediction for each qualified test result is given as well as the 
final classification based on the median of predictions.  
Table 3.3.16 Final classification based on the median of all classifications for each chemical 





tests/Total chemical GHS 
classification 1 2 3 1 2 3 1 2 3 
1 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
2 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
3 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
4 no cat I I I I I I I I I I 9/9 
5 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
6 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
7 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
8 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
9 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
10 no cat I I I I I I I I I I 9/9 
11 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
12 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
13 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
14 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
15 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
16 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
17 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
18 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
19 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
20 no cat I I NI NI NI NI NI I I NI 4/9 
21 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
22 no cat NI NI NI NI I I NI NI NI NI 2/9 
23 no cat I I I I I I I I I I 9/9 
24 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
25 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
26 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
28 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
29 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
30 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
31 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
32 no cat NI NI NI I I I I I I I 6/9 
33 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
34 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
35 no cat I NI I I NI I I I I I 7/9 
36 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
37 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
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tests/Total chemical GHS 
classification 1 2 3 1 2 3 1 2 3 
38 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
39 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
40 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
41 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
42 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
43 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
44 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
45 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
46 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
47 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
48 no cat I I NI I I I I I I I 8/9 
49 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
50 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
51 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
52 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
53 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
54 cat 2B NI NI NI NI NI NI NI NI I NI 8/9 
55 cat 2B I I I I I I I I I I 0/9 
56 cat 2B NI NI NI NI NI NI NI NI NI NI 9/9 
57 cat 2B I I I I I I I I I I 0/9 
58 cat 2B I I I I I I I I I I 0/9 
59 cat 2B NI NI NI NI NI NI NI NI NI NI 9/9 
60 cat 2B I I I I I I I I I I 0/9 
61 cat 2B NI NI NI NI NI NI NI NI NI NI 9/9 
62 cat 2B NI NI NI NI NI NI NI NI NI NI 9/9 
63 cat 2B NI NI NI NI NI NI NI NI NI NI 9/9 
64 cat 2B NI NI NI NI NI NI NI NI NI NI 9/9 
65 cat 2B NI NI NI NI NI NI NI NI NI NI 9/9 
66 cat 2B NI NI NI NI NI NI NI NI NI NI 9/9 
67 cat 2A I I I I I I I I I I 0/9 
68 cat 2A 
(ICCVAM:cat2B) 
I I I I I I I I I I 0/9 
69 cat 2A 
(ICCVAM:cat2B) 
NI I NI NI NI NI NI NI NI NI 8/9 
70 cat 2A I I I I I I I I I I 0/9 
71 cat 2A 
(ICCVAM:cat2B) 
I I I I I I I I I I 0/9 
72 cat 2A 
(ICCVAM:cat2B) 
I I I I I I I I I I 0/9 
73 cat 2A 
(ICCVAM:cat2B) 
NI NI NI NI I I NI NI NI NI 7/9 
74 cat 2A NI NI NI NI NI I NI NI NI NI 8/9 
75 cat 2A NI I I NI NI NI I I I I 4/9 
76 cat 2A NI NI NI I NI NI NI NI NI NI 8/9 
77 cat 2A NI NI NI I NI NI NI NI NI NI 8/9 
78 cat 2A NI NI NI NI NI NI NI NI NI NI 9/9 
79 cat 2A 
(ICCVAM:cat2B) 
NI NI NI NI NI NI NI NI NI NI 9/9 
80 cat 1 I I I I I I I I I I 0/9 
81 cat 1 I I I I I I I I I I 0/9 
82 cat 1 I I I I I I I I I I 0/9 
83 cat 1 I I I I I I I I I I 0/9 
84 cat 1 I I I I I I I I I I 0/9 
85 cat 1 NI NI NI NI NI NI NI NI NI NI 9/9 
86 cat 1 NI NI NI NI NI NI NI NI NI NI 9/9 
87 cat 1 NI NI NI NI NI I NI NI NI NI 8/9 
88 cat 1 I I I I I I I I I I 0/9 
89 cat 1 NI NI NI NI NI I NI NI NI NI 8/9 
90 cat 1 NI NI NI NI NI NI NI I I NI 7/9 
91 cat 1 NI I NI I I I I I I I 2/9 
92 cat 1 NI NI NI NI NI NI NI NI NI NI 9/9 
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tests/Total chemical GHS 
classification 1 2 3 1 2 3 1 2 3 
93 cat 1 NI NI NI NI NI NI NI NI NI NI 9/9 
94 cat 1 NI NI NI NI NI NI NI NI NI NI 9/9 
95 cat 1 I I I I I I I I I I 0/9 
96 cat 1 NI NI NI NI NI NI NI NI NI NI 9/9 
97 cat 1 NI NI NI NI NI NI NI NI NI NI 9/9 
98 cat 1 NI NI NI NI NI NI NI NI NI NI 9/9 
99 cat 1 I I I I I I I I I I 0/9 
100 cat 1 I NI I I I I I NI NI I 3/9 
101 cat 1 NI NI NI NI NI NI NI NI NI NI 9/9 
102 cat 1 NI NI NI NI NI NI NI NI NI NI 9/9 
103 cat 1 I I I I I I I I I I 0/9 
104 cat 1 NI NI NI NI NI NI NI NI NI NI 9/9 
105 cat 1 I I I I I I I I I I 0/9 
3.4 Reproducibility and accuracy using the LE protocol 
In this section, a 50% cut-off was applied to determine the irritancy of the chemical 
based on the LE protocol. If the viability is above 50%, the chemical is considered 
to be non-irritant. If the viability is 50% or below, the chemical is considered to be 
irritant.  
3.4.1 Within-laboratory variability 
For each laboratory, concordance of classification was calculated based on 
qualified test from test chemicals for which at least two qualified tests were 
available. In Table 3.4.1 the concordance within each laboratory as well as in total 
is given. 
Table 3.4.1 Concordance within laboratories and total 
  LE 
laboratory 
WLV 
concordant No. Fraction(%) 
CARDAM NO 5 4.8 
 YES 99 95.2 
CEETOX NO 4 3.8 
 YES 100 96.2 
L’OREAL NO 5 4.8 
 YES 99 95.2 
Total NO 14 4.5 
 YES 298 95.5 
 
Additional descriptive statistics can identify possible reasons for non-concordant 
results. These are presented in Table 3.4.2. For each non-concordant result the 
reactivity, the GHS classification, whether it is colouring or MTTreducer and the test 
results are given. 
Table 3.4.2 Additional descriptive statistics on non-concordant results within laboratories 
 chemical     Test 
laboratory & reactivity
1
 name coloring mtt pGHS 1 2 3 
CARDAM 9 NR 1,9-decadiene No Yes no cat 56.085 31.179 58.519 
CARDAM 34 R  2,2'-[[3-methyl-4-[(4-
nitrophenyl)azo]phenyl]imino]bis-ethanol INCI 
name: DISPERSE RED 17 
Yes Yes no cat 49.866 43.554 56.498 
CARDAM 65 R 2,2-dimethyl-3-methylenebicyclo [2.2.1] 
heptane INCI name: CAMPHENE 
No No cat 2B 74.621 40.455 41.957 
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CARDAM 96 R 1-naphthalene acetic acid No No cat 1 42.678 68.453 77.196 
CARDAM 97 NR  sodium oxalate INCI name: SODIUM OXALATE No No cat 1 65.493 49.507 73.543 
CEETOX 47 R  3,4-dimethoxy benzaldehyde INCI name: 
VERATRALDEHYDE 
No No no cat 40.706 48.741 57.170 
CEETOX 93 NR 2,5-dimethyl-2,5-hexanediol No No cat 1 38.11 65.473 55.221 
CEETOX 96 R 1-naphthalene acetic acid No No cat 1 41.708 45.584 50.491 
CEETOX 98 R 4,4'-(4,5,6,7-tetrabromo-3H-2,1-benzoxathiol-3-
ylidene)bis[2,6-dibromophenol] S,S-dioxide INCI 
name: TETRABROMOPHENOL BLUE 
Yes Yes cat 1 75.025 74.437 40.963 
L’OREAL 11 NR 2-(2-ethoxyethoxy) ethanol INCI name: 
ETHOXYDIGLYCOL 
No Yes no cat 74.860 69.280 49.103 
L’OREAL 65 R 2,2-dimethyl-3-methylenebicyclo [2.2.1] 
heptane INCI name: CAMPHENE 
No No cat 2B 13.391 68.057 92.491 
L’OREAL 66 R sodium chloroacetate No No cat 2B 62.220 18.556 3.315 
L’OREAL 79 NR ammonium nitrate INCI name: AMMONIUM 
NITRATE 
No No cat 2A 
(ICCVAM:cat2B) 
17.636 52.806 47.748 
L’OREAL 101 NR 2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-
imidazolium chloride INCI name: BASIC ORANGE 
31 
Yes No cat 1 70.820 74.980 44.871 
1
 Reactivity: R = reactive, NR = non-reactive 
 
The concordance of classifications (irritant/non-irritant) for the set of chemicals 
tested during validation obtained in different, independent runs within a single 
laboratory should ideally be equal or higher than 85% for all participating 
laboratories. As summarized in Table 3.4.3, this criteria was met for each laboratory 
as well as in total. 
Table 3.4.3 Statement whether the test method has fulfilled the performance criteria concerning the 
concordance of classifications within one laboratory. 
 LE 
laboratory Fraction(%) Statement: criteria is 
CARDAM 95.2 fulfilled 
CEETOX 96.2 fulfilled 
L’OREAL 95.2 fulfilled 
Total 95.5 fulfilled 
 
The intra-laboratory variability is described by the concordance of classifications. 
Correlation coefficients between viability measurements give also information on 
this variability. Since the Pearson correlation coefficient is sensitive to outlying test 
results and high leverages, both the Pearson and the Spearman correlation 
coefficients (using ranks instead of the original test results) were calculated. These 
coefficients are presented in Table 3.4.4. 
Table 3.4.4 Pearson and Spearman correlation coefficients between tests results within each laboratory 
as well as in total. 
Correlation laboratory Qual1 - Qual2 Qual1 - Qual3 Qual2 - Qual3 
Pearson L’OREAL 0.963 0.947 0.972 
 CARDAM 0.930 0.970 0.947 
 CEETOX 0.970 0.962 0.967 
 Mean 0.954 0.960 0.962 
Spearman L’OREAL 0.926 0.912 0.901 
 CARDAM 0.924 0.924 0.935 
 CEETOX 0.927 0.929 0.938 
 Mean 0.926 0.922 0.925 
 
Finally, the arithmetic mean, standard deviation and coefficient of variation from the 
three valid tests are given per laboratory as well as in total (see Table 3.4.5). Note 
that the coefficient of variation is not a useful measure if the mean is close to zero. 
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Table 3.4.5 Arithmetic mean, standard deviation (std) and coefficient of variation (cv) from the three valid 
tests are given per laboratory as well as in total (n = number of qualified tests that was used 
for the calculation of the mean, std and cv) 
 laboratory 
 CARDAM CEETOX L’OREAL 
Chemical mean std cv n mean std cv n mean std cv n 
1 12.3 8.9 71.8 3 6.0 3.1 51.8 3 9.7 9.3 95.6 3 
2 4.8 4.2 88.1 3 2.4 0.4 17.3 3 2.5 0.8 34.3 3 
3 2.4 1.1 46.7 3 2.0 0.8 39.4 3 0.9 0.2 21.2 3 
4 2.4 3.6 148.7 3 0.0 0.0 . 3 36.7 1.4 3.7 3 
5 6.9 5.2 74.2 3 2.6 2.3 87.6 3 3.0 2.6 86.9 3 
6 17.4 4.3 24.9 3 6.0 3.2 52.6 3 9.7 5.7 58.5 3 
7 5.8 0.6 11.1 3 6.7 2.8 42.3 3 4.3 3.6 84.3 3 
8 34.3 11.6 33.8 3 28.7 7.1 24.8 3 22.7 6.9 30.1 3 
9 48.6 15.1 31.1 3 41.9 7.1 17.0 3 26.6 6.1 23.1 3 
10 1.1 0.8 67.6 3 2.6 1.0 38.6 3 1.1 0.2 20.8 3 
11 27.8 3.9 14.0 3 66.7 13.5 20.2 3 64.4 13.6 21.0 3 
12 96.7 3.9 4.0 3 101.4 11.0 10.9 3 91.1 6.7 7.3 3 
13 106.1 7.5 7.1 3 107.3 12.0 11.2 3 93.2 6.2 6.7 3 
14 95.3 21.8 22.9 3 99.5 10.3 10.4 3 92.2 6.5 7.0 3 
15 98.2 4.2 4.3 3 96.1 7.2 7.5 3 93.4 3.4 3.6 3 
16 94.4 18.7 19.8 3 98.4 2.2 2.2 3 98.9 4.2 4.2 3 
17 86.3 10.3 12.0 3 97.5 3.1 3.2 3 85.5 5.4 6.3 3 
18 101.4 5.9 5.8 3 100.5 6.1 6.1 3 96.5 6.1 6.4 3 
19 101.1 6.4 6.3 3 101.3 13.0 12.8 3 100.1 6.6 6.6 3 
20 15.6 7.8 50.4 3 30.7 9.1 29.7 2 0.0 0.0 . 3 
21 60.1 4.0 6.7 3 73.2 14.7 20.1 3 66.4 2.7 4.0 3 
22 1.1 0.2 14.6 3 3.0 1.0 33.3 3 1.1 0.0 3.2 3 
23 17.2 1.6 9.5 3 10.8 8.6 80.0 3 19.7 16.6 84.6 3 
24 1.3 0.2 17.7 3 1.7 0.3 15.3 3 0.6 0.2 39.4 3 
25 98.3 2.5 2.6 3 89.0 11.7 13.1 3 87.6 16.5 18.9 3 
26 3.6 0.4 10.7 3 3.1 0.6 18.4 3 2.6 0.4 14.8 3 
28 97.5 18.4 18.9 3 98.3 1.2 1.2 3 91.3 3.3 3.6 3 
29 100.7 6.6 6.6 3 99.5 8.7 8.7 3 91.0 3.8 4.1 3 
30 81.4 10.5 12.9 3 78.6 3.1 3.9 3 75.2 7.2 9.6 3 
31 104.7 8.4 8.0 3 100.4 2.7 2.7 3 91.6 6.3 6.9 3 
32 8.2 1.8 21.4 3 21.6 9.7 45.0 3 2.5 0.5 19.6 3 
33 106.8 1.4 1.3 3 101.0 13.0 12.8 3 95.0 8.3 8.8 3 
34 50.0 6.5 13.0 3 71.8 17.5 24.4 3 59.1 5.7 9.6 3 
35 92.0 12.7 13.8 3 90.3 14.3 15.8 3 90.0 5.9 6.5 3 
36 104.6 5.6 5.4 3 103.0 4.8 4.7 3 104.7 5.1 4.8 3 
37 99.0 8.4 8.5 3 96.4 6.5 6.7 3 86.3 3.6 4.2 3 
38 105.1 12.2 11.6 3 100.8 10.0 10.0 3 98.1 2.5 2.5 3 
39 101.3 12.0 11.8 3 99.4 12.4 12.5 3 95.6 1.9 2.0 3 
40 87.8 10.5 12.0 3 82.5 2.5 3.0 3 87.8 11.6 13.2 3 
41 98.2 1.4 1.5 3 97.7 7.7 7.9 3 95.2 2.1 2.2 3 
42 84.6 9.7 11.5 3 78.0 4.1 5.3 3 76.5 2.5 3.3 3 
43 106.3 1.9 1.8 3 99.0 7.7 7.7 3 94.6 0.9 1.0 3 
44 96.9 3.4 3.5 3 99.1 4.5 4.6 3 90.1 3.7 4.1 3 
45 105.3 8.1 7.7 3 93.3 9.3 9.9 3 93.2 4.4 4.7 3 
46 87.7 11.1 12.7 3 75.8 9.6 12.7 3 77.3 20.5 26.5 3 
47 81.1 5.8 7.1 3 48.9 8.2 16.8 3 41.0 9.2 22.5 3 
48 1.7 0.2 9.9 3 1.9 0.8 40.6 3 4.3 1.2 29.0 3 
49 66.1 13.4 20.2 3 87.5 6.6 7.5 3 85.2 5.3 6.3 3 
50 101.6 4.4 4.3 3 93.4 11.7 12.6 3 93.5 6.3 6.7 3 
51 104.5 4.2 4.0 3 99.5 12.3 12.4 3 88.6 19.0 21.5 3 
52 96.1 10.2 10.6 3 100.7 9.3 9.2 3 99.7 2.0 2.0 3 
53 114.0 10.3 9.0 3 92.7 11.5 12.4 3 100.1 10.9 10.9 3 
54 1.7 0.9 54.8 3 3.0 1.5 51.8 3 0.5 0.1 15.0 3 
55 0.8 0.1 16.7 3 1.8 0.9 47.4 3 1.0 0.0 3.3 3 
56 8.2 2.9 35.5 3 8.2 0.5 6.7 3 0.7 0.0 6.3 3 
57 0.8 0.3 36.9 3 1.6 0.8 50.6 3 0.7 0.4 58.8 3 
58 0.8 0.4 52.6 3 1.8 1.0 54.7 3 0.3 0.1 26.9 3 
59 31.4 9.4 29.8 3 25.1 2.5 10.1 3 13.9 11.6 83.1 3 
60 0.8 0.2 21.7 3 2.0 0.2 9.4 3 0.6 0.2 29.6 3 
61 79.5 17.1 21.5 3 8.9 1.2 13.7 3 75.6 8.8 11.7 3 
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 laboratory 
 CARDAM CEETOX L’OREAL 
Chemical mean std cv n mean std cv n mean std cv n 
62 92.8 12.6 13.5 3 96.7 2.5 2.6 3 89.2 3.6 4.0 3 
63 84.4 11.2 13.3 3 83.5 9.5 11.4 3 87.8 1.3 1.5 3 
64 70.7 7.6 10.8 3 77.6 8.5 11.0 3 73.4 4.9 6.7 3 
65 52.3 19.3 36.9 3 76.1 12.6 16.5 3 58.0 40.5 69.9 3 
66 3.7 4.1 112.0 3 18.0 24.8 137.8 3 28.0 30.6 109.1 3 
67 0.9 0.2 16.8 3 12.4 8.5 68.6 3 1.5 0.6 41.6 3 
68 0.9 0.3 36.8 3 1.3 0.3 20.3 3 0.6 0.3 55.6 3 
69 0.4 0.4 91.7 3 0.9 0.3 33.8 3 1.0 0.8 82.8 3 
70 1.1 0.4 33.4 3 1.8 0.4 21.5 3 0.9 0.1 12.3 3 
71 0.7 0.2 27.4 3 1.2 0.2 16.8 3 0.8 0.3 37.0 3 
72 0.8 0.1 14.8 3 0.9 0.1 7.8 3 1.9 1.3 67.7 3 
73 87.4 17.9 20.5 3 91.8 7.7 8.4 3 93.7 4.7 5.0 3 
74 134.0 65.3 48.7 3 84.0 7.9 9.4 3 91.1 13.3 14.6 3 
75 0.9 0.1 13.1 3 1.3 0.1 4.2 3 1.1 0.2 23.0 3 
76 86.0 12.1 14.0 3 65.8 12.2 18.6 3 71.1 9.7 13.6 3 
77 94.1 11.5 12.2 3 86.9 8.3 9.6 3 89.9 2.3 2.6 3 
78 87.8 12.7 14.5 3 82.5 5.8 7.0 3 86.0 1.6 1.8 3 
79 63.9 4.0 6.2 3 39.1 8.4 21.5 3 39.4 19.0 48.3 3 
80 1.4 1.6 115.7 3 0.0 0.0 . 3 0.4 0.7 173.2 3 
81 0.4 0.1 14.0 3 0.5 0.1 20.5 3 0.7 0.3 36.3 3 
82 0.7 0.3 48.1 3 0.9 0.4 40.6 3 0.3 0.1 25.9 3 
83 0.3 0.1 47.9 3 0.9 0.2 22.7 3 0.6 0.3 54.2 3 
84 0.5 0.2 30.2 3 1.5 0.5 34.7 3 0.5 0.1 26.4 3 
85 0.6 0.3 50.8 3 0.7 0.1 20.1 3 0.4 0.1 32.5 3 
86 8.2 6.1 73.8 3 2.7 1.3 46.4 3 7.7 3.5 45.6 3 
87 0.4 0.1 25.1 3 1.5 0.5 34.9 3 1.6 0.5 34.3 3 
88 0.7 0.3 37.3 3 1.2 1.0 88.3 3 0.8 0.2 21.3 3 
89 1.3 0.1 9.5 3 2.1 0.3 16.4 3 1.4 0.2 15.3 3 
90 9.6 3.9 40.3 3 2.8 1.0 34.6 3 10.9 12.4 113.3 3 
91 4.1 4.4 109.2 3 11.6 6.1 52.3 3 8.3 3.9 46.7 3 
92 6.2 1.1 17.1 3 7.6 3.1 40.4 3 3.9 3.2 83.6 3 
93 28.4 5.4 18.9 3 52.9 13.8 26.1 3 24.5 10.5 42.9 3 
94 18.5 4.8 26.0 3 12.7 12.7 100.0 3 14.8 2.8 19.2 3 
95 0.4 0.3 66.1 3 1.2 0.2 16.0 3 0.7 0.3 47.7 3 
96 62.8 17.9 28.6 3 45.9 4.4 9.6 3 41.0 7.6 18.6 3 
97 62.8 12.2 19.5 3 62.2 2.8 4.6 3 63.6 3.7 5.9 3 
98 74.1 9.0 12.1 3 63.5 19.5 30.7 3 32.3 12.4 38.3 3 
99 1.9 0.4 18.5 3 1.4 0.3 19.3 3 1.3 0.1 4.4 3 
100 1.6 0.2 13.1 3 2.1 0.3 16.1 3 1.1 0.3 27.8 3 
101 67.0 9.4 14.0 3 72.8 9.8 13.4 3 63.6 16.3 25.7 3 
102 95.0 5.0 5.3 3 85.0 20.0 23.5 3 83.0 4.9 6.0 3 
103 1.3 0.2 15.5 3 0.6 0.6 108.4 3 0.9 0.2 19.4 3 
104 84.0 12.9 15.3 3 76.9 11.0 14.3 3 87.4 8.9 10.2 3 
105 1.7 0.7 39.7 3 0.4 0.4 87.5 3 1.6 0.5 28.6 3 
Table 3.4.6 Standard deviation (std) and coefficient of variation (cv) from all available tests results 
(Q=qualified and NQ=non-qualified; non-qualified test results due to non-qualified PC 
results not included) per laboratory (n = number of tests that was used for the 
calculations) 
 laboratory 
 CARDAM CEETOX L’OREAL 
 Q Q+NQ Q Q+NQ Q Q+NQ 
Chemical std cv n std cv n std cv n std cv n std cv n std cv n 
1 8.9 71.8 3 8.9 71.8 3 3.1 51.8 3 3.1 51.8 3 9.3 95.6 3 9.3 95.6 3 
2 4.2 88.1 3 4.2 88.1 3 0.4 17.3 3 0.4 17.3 3 0.8 34.3 3 0.8 34.3 3 
3 1.1 46.7 3 1.1 46.7 3 0.8 39.4 3 0.8 39.4 3 0.2 21.2 3 0.2 21.2 3 
4 3.6 148.7 3 3.6 148.7 3 0.0 . 3 0.0 . 3 1.4 3.7 3 1.4 3.7 3 
5 5.2 74.2 3 5.2 74.2 3 2.3 87.6 3 2.3 87.6 3 2.6 86.9 3 2.6 86.9 3 
6 4.3 24.9 3 4.3 24.9 3 3.2 52.6 3 3.2 52.6 3 5.7 58.5 3 5.7 58.5 3 
7 0.6 11.1 3 0.6 11.1 3 2.8 42.3 3 2.8 42.3 3 3.6 84.3 3 3.6 84.3 3 
8 11.6 33.8 3 11.6 33.8 3 7.1 24.8 3 7.1 24.8 3 6.9 30.1 3 6.9 30.1 3 
9 15.1 31.1 3 15.1 31.1 3 7.1 17.0 3 7.1 17.0 3 6.1 23.1 3 6.1 23.1 3 
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 laboratory 
 CARDAM CEETOX L’OREAL 
 Q Q+NQ Q Q+NQ Q Q+NQ 
Chemical std cv n std cv n std cv n std cv n std cv n std cv n 
10 0.8 67.6 3 0.8 67.6 3 1.0 38.6 3 1.0 38.6 3 0.2 20.8 3 0.2 20.8 3 
11 3.9 14.0 3 3.9 14.0 3 13.5 20.2 3 13.5 20.2 3 13.6 21.0 3 13.6 21.0 3 
12 3.9 4.0 3 3.9 4.0 3 11.0 10.9 3 11.0 10.9 3 6.7 7.3 3 6.7 7.3 3 
13 7.5 7.1 3 7.5 7.1 3 12.0 11.2 3 12.0 11.2 3 6.2 6.7 3 6.2 6.7 3 
14 21.8 22.9 3 21.8 22.9 3 10.3 10.4 3 10.3 10.4 3 6.5 7.0 3 6.5 7.0 3 
15 4.2 4.3 3 4.2 4.3 3 7.2 7.5 3 7.2 7.5 3 3.4 3.6 3 3.4 3.6 3 
16 18.7 19.8 3 18.7 19.8 3 2.2 2.2 3 2.2 2.2 3 4.2 4.2 3 4.2 4.2 3 
17 10.3 12.0 3 10.3 12.0 3 3.1 3.2 3 3.1 3.2 3 5.4 6.3 3 5.4 6.3 3 
18 5.9 5.8 3 5.9 5.8 3 6.1 6.1 3 6.1 6.1 3 6.1 6.4 3 6.1 6.4 3 
19 6.4 6.3 3 6.4 6.3 3 13.0 12.8 3 13.0 12.8 3 6.6 6.6 3 6.6 6.6 3 
20 7.8 50.4 3 7.8 50.4 3 9.1 29.7 2 9.1 29.7 2 0.0 . 3 0.0 . 3 
21 4.0 6.7 3 4.0 6.7 3 14.7 20.1 3 14.7 20.1 3 2.7 4.0 3 2.7 4.0 3 
22 0.2 14.6 3 0.2 14.6 3 1.0 33.3 3 1.0 33.3 3 0.0 3.2 3 0.0 3.2 3 
23 1.6 9.5 3 1.6 9.5 3 8.6 80.0 3 8.6 80.0 3 16.6 84.6 3 16.6 84.6 3 
24 0.2 17.7 3 0.2 17.7 3 0.3 15.3 3 0.3 15.3 3 0.2 39.4 3 0.2 39.4 3 
25 2.5 2.6 3 2.5 2.6 3 11.7 13.1 3 11.7 13.1 3 16.5 18.9 3 16.5 18.9 3 
26 0.4 10.7 3 0.4 10.7 3 0.6 18.4 3 0.6 18.4 3 0.4 14.8 3 0.4 14.8 3 
28 18.4 18.9 3 18.4 18.9 3 1.2 1.2 3 1.2 1.2 3 3.3 3.6 3 3.3 3.6 3 
29 6.6 6.6 3 6.6 6.6 3 8.7 8.7 3 8.7 8.7 3 3.8 4.1 3 3.8 4.1 3 
30 10.5 12.9 3 10.5 12.9 3 3.1 3.9 3 3.1 3.9 3 7.2 9.6 3 7.2 9.6 3 
31 8.4 8.0 3 8.4 8.0 3 2.7 2.7 3 2.7 2.7 3 6.3 6.9 3 6.3 6.9 3 
32 1.8 21.4 3 1.8 21.4 3 9.7 45.0 3 9.7 45.0 3 0.5 19.6 3 0.5 19.6 3 
33 1.4 1.3 3 1.4 1.3 3 13.0 12.8 3 13.0 12.8 3 8.3 8.8 3 8.3 8.8 3 
34 6.5 13.0 3 5.8 11.9 4 17.5 24.4 3 17.5 24.4 3 5.7 9.6 3 5.7 9.6 3 
35 12.7 13.8 3 12.7 13.8 3 14.3 15.8 3 14.3 15.8 3 5.9 6.5 3 5.9 6.5 3 
36 5.6 5.4 3 5.6 5.4 3 4.8 4.7 3 4.8 4.7 3 5.1 4.8 3 5.1 4.8 3 
37 8.4 8.5 3 8.4 8.5 3 6.5 6.7 3 6.5 6.7 3 3.6 4.2 3 3.6 4.2 3 
38 12.2 11.6 3 12.2 11.6 3 10.0 10.0 3 10.0 10.0 3 2.5 2.5 3 2.5 2.5 3 
39 12.0 11.8 3 12.0 11.8 3 12.4 12.5 3 12.4 12.5 3 1.9 2.0 3 1.9 2.0 3 
40 10.5 12.0 3 10.5 12.0 3 2.5 3.0 3 2.5 3.0 3 11.6 13.2 3 11.6 13.2 3 
41 1.4 1.5 3 1.4 1.5 3 7.7 7.9 3 7.7 7.9 3 2.1 2.2 3 2.1 2.2 3 
42 9.7 11.5 3 9.7 11.5 3 4.1 5.3 3 4.1 5.3 3 2.5 3.3 3 2.5 3.3 3 
43 1.9 1.8 3 1.9 1.8 3 7.7 7.7 3 7.7 7.7 3 0.9 1.0 3 0.9 1.0 3 
44 3.4 3.5 3 3.4 3.5 3 4.5 4.6 3 4.5 4.6 3 3.7 4.1 3 3.7 4.1 3 
45 8.1 7.7 3 8.1 7.7 3 9.3 9.9 3 9.3 9.9 3 4.4 4.7 3 4.4 4.7 3 
46 11.1 12.7 3 11.1 12.7 3 9.6 12.7 3 9.6 12.7 3 20.5 26.5 3 20.5 26.5 3 
47 5.8 7.1 3 5.8 7.1 3 8.2 16.8 3 8.2 16.8 3 9.2 22.5 3 9.2 22.5 3 
48 0.2 9.9 3 0.6 43.3 4 0.8 40.6 3 0.8 40.6 3 1.2 29.0 3 1.2 29.0 3 
49 13.4 20.2 3 13.4 20.2 3 6.6 7.5 3 7.8 9.2 4 5.3 6.3 3 5.3 6.3 3 
50 4.4 4.3 3 4.4 4.3 3 11.7 12.6 3 11.7 12.6 3 6.3 6.7 3 6.3 6.7 3 
51 4.2 4.0 3 4.2 4.0 3 12.3 12.4 3 12.3 12.4 3 19.0 21.5 3 19.0 21.5 3 
52 10.2 10.6 3 13.6 15.0 4 9.3 9.2 3 9.3 9.2 3 2.0 2.0 3 2.0 2.0 3 
53 10.3 9.0 3 10.3 9.0 3 11.5 12.4 3 11.5 12.4 3 10.9 10.9 3 10.9 10.9 3 
54 0.9 54.8 3 0.9 54.8 3 1.5 51.8 3 1.5 51.8 3 0.1 15.0 3 0.1 15.0 3 
55 0.1 16.7 3 0.1 16.7 3 0.9 47.4 3 0.9 47.4 3 0.0 3.3 3 0.0 3.3 3 
56 2.9 35.5 3 2.9 35.5 3 0.5 6.7 3 0.5 6.7 3 0.0 6.3 3 0.0 6.3 3 
57 0.3 36.9 3 0.3 36.9 3 0.8 50.6 3 0.8 50.6 3 0.4 58.8 3 0.4 58.8 3 
58 0.4 52.6 3 0.4 52.6 3 1.0 54.7 3 1.0 54.7 3 0.1 26.9 3 0.1 26.9 3 
59 9.4 29.8 3 9.4 29.8 3 2.5 10.1 3 2.5 10.1 3 11.6 83.1 3 11.6 83.1 3 
60 0.2 21.7 3 0.2 21.7 3 0.2 9.4 3 0.2 9.4 3 0.2 29.6 3 0.2 29.6 3 
61 17.1 21.5 3 17.1 21.5 3 1.2 13.7 3 1.2 13.7 3 8.8 11.7 3 8.8 11.7 3 
62 12.6 13.5 3 12.6 13.5 3 2.5 2.6 3 2.5 2.6 3 3.6 4.0 3 3.6 4.0 3 
63 11.2 13.3 3 11.2 13.3 3 9.5 11.4 3 9.5 11.4 3 1.3 1.5 3 1.3 1.5 3 
64 7.6 10.8 3 7.6 10.8 3 8.5 11.0 3 8.5 11.0 3 4.9 6.7 3 4.9 6.7 3 
65 19.3 36.9 3 19.3 36.9 3 12.6 16.5 3 12.6 16.5 3 40.5 69.9 3 33.7 61.6 4 
66 4.1 112.0 3 4.1 112.0 3 24.8 137.8 3 24.8 137.8 3 30.6 109.1 3 30.6 109.1 3 
67 0.2 16.8 3 0.2 16.8 3 8.5 68.6 3 8.5 68.6 3 0.6 41.6 3 0.6 41.6 3 
68 0.3 36.8 3 0.3 36.8 3 0.3 20.3 3 0.3 20.3 3 0.3 55.6 3 0.3 55.6 3 
69 0.4 91.7 3 0.4 91.7 3 0.3 33.8 3 0.3 33.8 3 0.8 82.8 3 0.8 82.8 3 
70 0.4 33.4 3 0.4 33.4 3 0.4 21.5 3 0.4 21.5 3 0.1 12.3 3 0.1 12.3 3 
71 0.2 27.4 3 0.2 27.4 3 0.2 16.8 3 0.2 16.8 3 0.3 37.0 3 0.3 37.0 3 
72 0.1 14.8 3 0.1 14.8 3 0.1 7.8 3 0.1 7.8 3 1.3 67.7 3 1.3 67.7 3 
73 17.9 20.5 3 17.9 20.5 3 7.7 8.4 3 7.7 8.4 3 4.7 5.0 3 4.7 5.0 3 
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 laboratory 
 CARDAM CEETOX L’OREAL 
 Q Q+NQ Q Q+NQ Q Q+NQ 
Chemical std cv n std cv n std cv n std cv n std cv n std cv n 
74 65.3 48.7 3 65.3 48.7 3 7.9 9.4 3 7.9 9.4 3 13.3 14.6 3 13.3 14.6 3 
75 0.1 13.1 3 0.1 15.9 4 0.1 4.2 3 0.1 4.2 3 0.2 23.0 3 14.7 174.6 4 
76 12.1 14.0 3 12.1 14.0 3 12.2 18.6 3 12.2 18.6 3 9.7 13.6 3 9.7 13.6 3 
77 11.5 12.2 3 11.5 12.2 3 8.3 9.6 3 8.3 9.6 3 2.3 2.6 3 2.3 2.6 3 
78 12.7 14.5 3 12.7 14.5 3 5.8 7.0 3 5.8 7.0 3 1.6 1.8 3 1.6 1.8 3 
79 4.0 6.2 3 4.0 6.2 3 8.4 21.5 3 8.4 21.5 3 19.0 48.3 3 19.0 48.3 3 
80 1.6 115.7 3 1.6 115.7 3 0.0 . 3 0.0 . 3 0.7 173.2 3 0.7 173.2 3 
81 0.1 14.0 3 0.1 14.0 3 0.1 20.5 3 0.1 20.5 3 0.3 36.3 3 0.3 36.3 3 
82 0.3 48.1 3 0.3 48.1 3 0.4 40.6 3 0.4 40.6 3 0.1 25.9 3 0.1 25.9 3 
83 0.1 47.9 3 0.1 47.9 3 0.2 22.7 3 0.2 22.7 3 0.3 54.2 3 0.3 54.2 3 
84 0.2 30.2 3 0.2 30.2 3 0.5 34.7 3 0.5 34.7 3 0.1 26.4 3 0.1 26.4 3 
85 0.3 50.8 3 0.3 50.8 3 0.1 20.1 3 0.1 20.1 3 0.1 32.5 3 0.1 32.5 3 
86 6.1 73.8 3 6.1 73.8 3 1.3 46.4 3 1.3 46.4 3 3.5 45.6 3 3.5 45.6 3 
87 0.1 25.1 3 0.1 25.1 3 0.5 34.9 3 0.5 34.9 3 0.5 34.3 3 0.5 34.3 3 
88 0.3 37.3 3 0.3 37.3 3 1.0 88.3 3 1.0 88.3 3 0.2 21.3 3 0.2 21.3 3 
89 0.1 9.5 3 0.1 9.5 3 0.3 16.4 3 0.3 16.4 3 0.2 15.3 3 0.2 15.3 3 
90 3.9 40.3 3 3.9 40.3 3 1.0 34.6 3 1.0 34.6 3 12.4 113.3 3 12.4 113.3 3 
91 4.4 109.2 3 4.4 109.2 3 6.1 52.3 3 6.1 52.3 3 3.9 46.7 3 3.9 46.7 3 
92 1.1 17.1 3 1.1 17.1 3 3.1 40.4 3 3.1 40.4 3 3.2 83.6 3 3.2 83.6 3 
93 5.4 18.9 3 5.4 18.9 3 13.8 26.1 3 13.8 26.1 3 10.5 42.9 3 10.5 42.9 3 
94 4.8 26.0 3 4.8 26.0 3 12.7 100.0 3 12.7 100.0 3 2.8 19.2 3 2.8 19.2 3 
95 0.3 66.1 3 0.3 66.1 3 0.2 16.0 3 0.2 16.0 3 0.3 47.7 3 0.3 47.7 3 
96 17.9 28.6 3 17.9 28.6 3 4.4 9.6 3 4.4 9.6 3 7.6 18.6 3 7.6 18.6 3 
97 12.2 19.5 3 12.2 19.5 3 2.8 4.6 3 2.8 4.6 3 3.7 5.9 3 3.7 5.9 3 
98 9.0 12.1 3 9.0 12.1 3 19.5 30.7 3 19.5 30.7 3 12.4 38.3 3 12.4 38.3 3 
99 0.4 18.5 3 0.4 18.5 3 0.3 19.3 3 0.3 19.3 3 0.1 4.4 3 0.1 4.4 3 
100 0.2 13.1 3 0.2 13.1 3 0.3 16.1 3 0.3 16.1 3 0.3 27.8 3 0.3 27.8 3 
101 9.4 14.0 3 9.4 14.0 3 9.8 13.4 3 9.8 13.4 3 16.3 25.7 3 16.3 25.7 3 
102 5.0 5.3 3 5.0 5.3 3 20.0 23.5 3 20.0 23.5 3 4.9 6.0 3 4.9 6.0 3 
103 0.2 15.5 3 0.2 15.5 3 0.6 108.4 3 0.6 108.4 3 0.2 19.4 3 0.2 19.4 3 
104 12.9 15.3 3 12.9 15.3 3 11.0 14.3 3 11.0 14.3 3 8.9 10.2 3 8.9 10.2 3 
105 0.7 39.7 3 0.7 39.7 3 0.4 87.5 3 0.4 87.5 3 0.5 28.6 3 0.5 28.6 3 
                   
Overall                   
Mean 6.4   6.4   5.8   5.8   5.2   5.2   
SD 8.0   8.1   5.5   5.5   6.5   6.3   
3.4.2 Between-laboratory variability 
The arithmetic mean value of viability over the different qualified tests per laboratory 
was used to calculate the inter-laboratory variability. For calculation on the between-
laboratory variability, only those chemicals are included for which at least one 
qualified test per laboratory was available. Table 3.4.7 gives the mean standard 
deviation as well as the standard deviation of the standard deviations 
Table 3.4.7 Mean standard deviation and standard deviation per chemical considering the 
standard deviations as reported for each participating laboratory (Q=qualified and 
NQ=non-qualified; non-qualified test results due to non-qualified PC results not 
included).1. 
  Q Q+NQ 
Chemical mean SD std SD mean SD std SD 
1 7.1 3.4 7.1 3.4 
2 1.8 2.1 1.8 2.1 
3 0.7 0.5 0.7 0.5 
4 1.7 1.8 1.7 1.8 
5 3.3 1.6 3.3 1.6 
6 4.4 1.2 4.4 1.2 
7 2.4 1.5 2.4 1.5 
8 8.5 2.7 8.5 2.7 
9 9.5 4.9 9.5 4.9 
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  Q Q+NQ 
Chemical mean SD std SD mean SD std SD 
10 0.7 0.4 0.7 0.4 
11 10.3 5.6 10.3 5.6 
12 7.2 3.6 7.2 3.6 
13 8.6 3 8.6 3 
14 12.9 8 12.9 8 
15 4.9 2 4.9 2 
16 8.3 9 8.3 9 
17 6.3 3.7 6.3 3.7 
18 6 0.1 6 0.1 
19 8.7 3.7 8.7 3.7 
20 5.7 4.9 5.7 4.9 
21 7.1 6.6 7.1 6.6 
22 0.4 0.5 0.4 0.5 
23 9 7.5 9 7.5 
24 0.2 0 0.2 0 
25 10.2 7.1 10.2 7.1 
26 0.4 0.1 0.4 0.1 
28 7.6 9.4 7.6 9.4 
29 6.3 2.5 6.3 2.5 
30 6.9 3.7 6.9 3.7 
31 5.8 2.9 5.8 2.9 
32 4 5 4 5 
33 7.6 5.8 7.6 5.8 
34 9.9 6.6 9.6 6.8 
35 11 4.5 11 4.5 
36 5.2 0.4 5.2 0.4 
37 6.2 2.4 6.2 2.4 
38 8.2 5.1 8.2 5.1 
39 8.8 6 8.8 6 
40 8.2 5 8.2 5 
41 3.8 3.4 3.8 3.4 
42 5.5 3.8 5.5 3.8 
43 3.5 3.6 3.5 3.6 
44 3.9 0.6 3.9 0.6 
45 7.3 2.6 7.3 2.6 
46 13.8 5.9 13.8 5.9 
47 7.7 1.8 7.7 1.8 
48 0.7 0.5 0.9 0.3 
49 8.4 4.3 8.8 4.1 
50 7.5 3.8 7.5 3.8 
51 11.8 7.4 11.8 7.4 
52 7.2 4.5 8.3 5.9 
53 10.9 0.6 10.9 0.6 
54 0.8 0.7 0.8 0.7 
55 0.3 0.5 0.3 0.5 
56 1.2 1.5 1.2 1.5 
57 0.5 0.3 0.5 0.3 
58 0.5 0.5 0.5 0.5 
59 7.8 4.7 7.8 4.7 
60 0.2 0 0.2 0 
61 9 7.9 9 7.9 
62 6.2 5.5 6.2 5.5 
63 7.4 5.3 7.4 5.3 
64 7 1.9 7 1.9 
65 24.1 14.6 21.9 10.8 
66 19.8 13.9 19.8 13.9 
67 3.1 4.7 3.1 4.7 
68 0.3 0 0.3 0 
69 0.5 0.3 0.5 0.3 
70 0.3 0.1 0.3 0.1 
71 0.2 0.1 0.2 0.1 
72 0.5 0.7 0.5 0.7 
73 10.1 6.9 10.1 6.9 
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  Q Q+NQ 
Chemical mean SD std SD mean SD std SD 
74 28.8 31.7 28.8 31.7 
75 0.1 0.1 5 8.4 
76 11.3 1.4 11.3 1.4 
77 7.4 4.6 7.4 4.6 
78 6.7 5.6 6.7 5.6 
79 10.5 7.7 10.5 7.7 
80 0.8 0.8 0.8 0.8 
81 0.1 0.1 0.1 0.1 
82 0.3 0.2 0.3 0.2 
83 0.2 0.1 0.2 0.1 
84 0.3 0.2 0.3 0.2 
85 0.2 0.1 0.2 0.1 
86 3.6 2.4 3.6 2.4 
87 0.4 0.2 0.4 0.2 
88 0.5 0.5 0.5 0.5 
89 0.2 0.1 0.2 0.1 
90 5.7 5.9 5.7 5.9 
91 4.8 1.1 4.8 1.1 
92 2.5 1.2 2.5 1.2 
93 9.9 4.3 9.9 4.3 
94 6.8 5.2 6.8 5.2 
95 0.3 0.1 0.3 0.1 
96 10 7.1 10 7.1 
97 6.3 5.2 6.3 5.2 
98 13.6 5.4 13.6 5.4 
99 0.2 0.2 0.2 0.2 
100 0.3 0.1 0.3 0.1 
101 11.8 3.9 11.8 3.9 
102 10 8.7 10 8.7 
103 0.3 0.3 0.3 0.3 
104 10.9 2 10.9 2 
105 0.5 0.1 0.5 0.1 
          
Overall         
mean  5.8   5.8   
SD 5.1   5.0   
 
Concordance of classification between laboratories was calculated based on 
qualified test from test chemicals for which at least one qualified test was available. 
In Table 3.4.8 the concordance between laboratories is given. 
Table 3.4.8 Concordance between laboratories 
BLV 
concordant No. Fraction(%) 
NO 8 7.7 
YES 96 92.3 
 
Additional descriptive statistics can identify possible reasons for non-concordant 
results. These are presented in Table 3.4.9. For each non-concordant result the 
state (liquid/solid), the GHS classification, whether it is colouring or MTTreducer 
and the test results are given. 
 
Table 3.4.9 Additional descriptive statistics on non-concordant results between laboratories 
Chemical name LS coloring mtt GHS CEETOX CARDAM L_OREAL 
11 2-(2-ethoxyethoxy) ethanol INCI name: 
ETHOXYDIGLYCOL 
Liquid No No no cat 66.728 27.848 64.4153 
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Chemical name LS coloring mtt GHS CEETOX CARDAM L_OREAL 
34 2,2'-[[3-methyl-4-[(4-
nitrophenyl)azo]phenyl]imino]bis-ethanol 
INCI name: DISPERSE RED 17 
Solid Yes Yes no cat 71.761 49.973 59.120 
47 3,4-dimethoxy benzaldehyde INCI 
name: VERATRALDEHYDE 
Solid No No no cat 48.872 81.105 41.011 
61 2-hydroxy-1,4-naphthoquinone INCI 
name: LAWSONE 
Solid No No cat 2B 8.854 79.4611 75.6051 
79 ammonium nitrate INCI name: 
AMMONIUM NITRATE 
Solid No No cat 2A 
(ICCVAM:cat2B) 
39.138 63.890 39.396 
93 2,5-dimethyl-2,5-hexanediol Solid No No cat 1 52.935 28.438 24.543 
96 1-naphthalene acetic acid Solid No No cat 1 45.928 62.776 41.016 
98 4,4'-(4,5,6,7-tetrabromo-3H-2,1-
benzoxathiol-3-ylidene)bis[2,6-
dibromophenol] S,S-dioxide INCI name: 
TETRABROMOPHENOL BLUE 
Solid Yes No cat 1 63.4752 74.064 32.346 
1
 identified as colourant, 2 identified as colourant and MTT-reducer, 3 identified as MTT-reducer 
 
The concordance for the set of chemicals tested during validation obtained by the 
different participating laboratories should ideally be equal or higher than 80%. As 
summarized in Table 3.4.10, this criteria was met.   
Table 3.4.10 Statement whether the test method has fulfilled the performance criteria concerning 
the concordance of classifications between laboratories. 
Fraction (%) Statement: criteria is 
92.3 fulfilled 
 
A two-way ANOVA was applied to test for differences in mean viabilities between 
laboratories and chemicals. Data were log-transformed before analysis. Five 
outlying observations (2-hydroxy-1,4-naphthoquinone INCI name: LAWSONE and 
gamma-butyrolactone INCI name: BUTYROLACTONE for CEETOX and isopropyl 
acetoacetate and iso-octylthioglycolate for L’OREAL and iso-octylthioglycolate for 
CARDAM) were removed before analysis in order to fulfil the ANOVA-requirements. 
An outlier was defined as an observation with a residual > 3* residual error. The 
results from the two-way ANOVA are presented in Table 3.4.11. The null hypothesis 
of no difference was rejected at the 0.01 level of probability (α=0.01). 
Table 3.4.11 Two-way ANOVA with factors laboratory and chemical, applied to the arithmetic 
mean value of the included test results (based on log-transformation) 
Effect NumDF DenDF FValue pvalue 
laboratory 2 201 8.62 0.0003 
chemical 103 201 112.85 <.0001 
Table 3.4.12 Results of the Tukey post-hoc test on differences between laboratories (after log-
transformation)  
laboratory vs Estimate Standard Error DF Tukey-corrected p-value 
CARDAM CEETOX 1.0371 0.9571 201 0.5253 
CARDAM L’OREAL 3.8322 0.9535 201 0.0002 
CEETOX L’OREAL 2.7951 0.9606 201 0.0112 
  
There was no statistically significant difference between CARDAM and CEETOX (p-
value = 0.5253) nor between CEETOX and L’OREAL (p-value = 0.0112). 
The between-laboratory variability is described by the concordance of 
classifications between laboratories. Correlations coefficients between viability 
measurements give also information on this variability. Since the Pearson 
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correlation coefficient is sensitive for outlying test results and high leverages, both 
the Pearson and the Spearman correlation coefficients (using ranks instead of the 
original test results) were calculated. These coefficients are presented in Table 
3.4.13. 
Table 3.4.13 Pearson and Spearman correlation coefficients between test results of the three 
participating laboratories. 
laboratories Pearson Spearman 
CARDAM-CEETOX 0.958 0.942 
CARDAM-L’OREAL 0.968 0.937 
CEETOX-L’OREAL 0.968 0.920 
3.4.3 Predictive capacity (accuracy) 
All qualified tests for each test chemical was used to calculate the predictive 
capacity values. The calculations were based on the individual predictions of each 
qualified test in each laboratory.  
 
For each statistic of the prediction model, an acceptance rate was set by the VMG. 
These criteria are presented in Table 3.4.14. The sensitivity, specificity and overall 
accuracy, subdivided into laboratories and total, including the 95% confidence 
intervals as well as a statement whether the acceptance criteria are fulfilled are 
presented in Table 3.4.15. 
Table 3.4.14 Acceptance criteria for the prediction model 
 False Negativesa (%) False Positivesb (%) Overall 
misclassificationsc (%) 
“Definitely acceptable” rates  ≤ 10 ≤ 40 ≤ 25 
Further evaluations 
necessary before any 
recommendation is made 
10 < FN ≤ 20 40 < FP ≤ 50 25 < OM ≤ 35 
“Definitely unacceptable” 
rates > 20 > 50 > 35 
a
 equal to (1-Sensitivity), b equal to (1-Specificity), c equal to (1-Overall accuracy) 
Table 3.4.15 The sensitivity, specificity and overall accuracy, subdivided into laboratories and total, 
including the 95% confidence intervals as well as a statement whether the acceptance 











CARDAM Accuracy 211/312 0.676 0.621 0.728 further evaluation 
 Sensitivity 109/156 0.699 0.620 0.769 definitely unacceptable 
 Specificity 102/156 0.654 0.574 0.728 definitely acceptable 
CEETOX Accuracy 215/311 0.691 0.637 0.742 further evaluation 
 Sensitivity 112/156 0.718 0.640 0.787 definitely unacceptable 
 Specificity 103/155 0.665 0.584 0.738 definitely acceptable 
L'OREAL Accuracy 215/312 0.689 0.635 0.740 further evaluation 
 Sensitivity 114/156 0.731 0.654 0.799 definitely unacceptable 
 Specificity 101/156 0.647 0.567 0.722 definitely acceptable 
Total Accuracy 641/935 0.686 0.655 0.715 further evaluation 
 Sensitivity 335/468 0.716 0.673 0.756 definitely unacceptable 
 Specificity 306/467 0.655 0.610 0.698 definitely acceptable 
 
In Table 3.4.16, the prediction for each qualified test result is given as well as the 
final classification based on the median of predictions.  
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    CARDAM CEETOX L’OREAL based on tests/Total 
Chemical GHS 1 2 3 1 2 3 1 2 3 median  
1 no cat I I I I I I I I I I 9/9 
2 no cat I I I I I I I I I I 9/9 
3 no cat I I I I I I I I I I 9/9 
4 no cat I I I I I I I I I I 9/9 
5 no cat I I I I I I I I I I 9/9 
6 no cat I I I I I I I I I I 9/9 
7 no cat I I I I I I I I I I 9/9 
8 no cat I I I I I I I I I I 9/9 
9 no cat NI I NI I I I I I I I 7/9 
10 no cat I I I I I I I I I I 9/9 
11 no cat I I I NI NI NI NI NI I NI 4/9 
12 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
13 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
14 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
15 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
16 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
17 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
18 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
19 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
20 no cat I I I I I . I I I I 8/8 
21 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
22 no cat I I I I I I I I I I 9/9 
23 no cat I I I I I I I I I I 9/9 
24 no cat I I I I I I I I I I 9/9 
25 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
26 no cat I I I I I I I I I I 9/9 
28 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
29 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
30 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
31 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
32 no cat I I I I I I I I I I 9/9 
33 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
34 no cat I I NI NI NI NI NI NI NI NI 2/9 
35 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
36 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
37 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
38 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
39 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
40 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
41 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
42 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
43 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
44 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
45 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
46 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
47 no cat NI NI NI I I NI I I I I 5/9 
48 no cat I I I I I I I I I I 9/9 
49 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
50 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
51 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
52 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
53 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
54 cat 2B I I I I I I I I I I 0/9 
55 cat 2B I I I I I I I I I I 0/9 
56 cat 2B I I I I I I I I I I 0/9 
57 cat 2B I I I I I I I I I I 0/9 
58 cat 2B I I I I I I I I I I 0/9 
59 cat 2B I I I I I I I I I I 0/9 
60 cat 2B I I I I I I I I I I 0/9 
  






    CARDAM CEETOX L’OREAL based on tests/Total 
Chemical GHS 1 2 3 1 2 3 1 2 3 median  
61 cat 2B NI NI NI I I I NI NI NI NI 6/9 
62 cat 2B NI NI NI NI NI NI NI NI NI NI 9/9 
63 cat 2B NI NI NI NI NI NI NI NI NI NI 9/9 
64 cat 2B NI NI NI NI NI NI NI NI NI NI 9/9 
65 cat 2B NI I I NI NI NI I NI NI NI 6/9 
66 cat 2B I I I I I I NI I I I 1/9 
67 cat 2A I I I I I I I I I I 0/9 
68 cat 2A 
(ICCVAM:cat2B) 
I I I I I I I I I I 0/9 
69 cat 2A 
(ICCVAM:cat2B) 
I I I I I I I I I I 0/9 
70 cat 2A I I I I I I I I I I 0/9 
71 cat 2A 
(ICCVAM:cat2B) 
I I I I I I I I I I 0/9 
72 cat 2A 
(ICCVAM:cat2B) 
I I I I I I I I I I 0/9 
73 cat 2A 
(ICCVAM:cat2B) 
NI NI NI NI NI NI NI NI NI NI 9/9 
74 cat 2A NI NI NI NI NI NI NI NI NI NI 9/9 
75 cat 2A I I I I I I I I I I 0/9 
76 cat 2A NI NI NI NI NI NI NI NI NI NI 9/9 
77 cat 2A NI NI NI NI NI NI NI NI NI NI 9/9 
78 cat 2A NI NI NI NI NI NI NI NI NI NI 9/9 
79 cat 2A 
(ICCVAM:cat2B) 
NI NI NI I I I I NI I I 4/9 
80 cat 1 I I I I I I I I I I 0/9 
81 cat 1 I I I I I I I I I I 0/9 
82 cat 1 I I I I I I I I I I 0/9 
83 cat 1 I I I I I I I I I I 0/9 
84 cat 1 I I I I I I I I I I 0/9 
85 cat 1 I I I I I I I I I I 0/9 
86 cat 1 I I I I I I I I I I 0/9 
87 cat 1 I I I I I I I I I I 0/9 
88 cat 1 I I I I I I I I I I 0/9 
89 cat 1 I I I I I I I I I I 0/9 
90 cat 1 I I I I I I I I I I 0/9 
91 cat 1 I I I I I I I I I I 0/9 
92 cat 1 I I I I I I I I I I 0/9 
93 cat 1 I I I I NI NI I I I I 2/9 
94 cat 1 I I I I I I I I I I 0/9 
95 cat 1 I I I I I I I I I I 0/9 
96 cat 1 I NI NI I I NI I I I I 3/9 
97 cat 1 NI I NI NI NI NI NI NI NI NI 8/9 
98 cat 1 NI NI NI NI NI I I I I NI 5/9 
99 cat 1 I I I I I I I I I I 0/9 
100 cat 1 I I I I I I I I I I 0/9 
101 cat 1 NI NI NI NI NI NI NI NI I NI 8/9 
102 cat 1 NI NI NI NI NI NI NI NI NI NI 9/9 
103 cat 1 I I I I I I I I I I 0/9 
104 cat 1 NI NI NI NI NI NI NI NI NI NI 9/9 
105 cat 1 I I I I I I I I I I 0/9 
 
3.5 Reproducibility and accuracy using the test strategy 
In this section, a 50% cut-off was applied to determine the irritancy of the chemical 
based on the test strategy: results for reactive chemicals are based on the SE 
protocol and results for non-reactive chemicals are based on the LE protocol. If the 
  
TNO report | TNO 2013 R11617 | Final report  57 / 305
viability is above 50%, the chemical is considered to be non-irritant. If the viability is 
50% or below, the chemical is considered to be irritant.  
 
The selection of the protocol for each chemical is given in Table 3.5.1.The EPRA 
results that are used to determine the protocol are presented in Appendix X.  
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Table 3.5.1. Selection of protocol for each chemical 
Chemical name Protocol 
1 1-bromohexane SE 
2 1-methylpropyl benzene LE 
3 2-ethoxyethyl methacrylate SE 
4 iso-octylthioglycolate INCI name: ISOOCTYL THIOGLYCOLATE SE 
5 4-(methylthio)-benzaldehyde SE 
6 dipropyl disulphide SE 
7 1-bromo-4-chlorobutane SE 
8 1-bromo-octane LE 
9 1,9-decadiene LE 
10 2,2-dimethyl-3-pentanol  LE 
11 2-(2-ethoxyethoxy) ethanol INCI name: ETHOXYDIGLYCOL LE 
12 bisphenol A, epichlorohydrin polymer, ethoxylated, propoxylated 
(53-57% aqueousemulsion) 
SE 
13 bisphenol A, diethylene triamine, epichlorohydrin polymer, 
ethoxylated, propoxylated (56% aqueous emulsion) 
SE 
14 dioctyl ether INCI name: DICAPRYLYL ETHER LE 
15 dioctyl carbonate INCI name: DICAPRYLYL CARBONATE LE 
16 2-propylheptyl octanoate INCI name: PROPYLHEPTYL CAPRYLATE LE 
17 polyglyceryl-3 diisooctadecanoate INCI name: POLYGLYCERYL-3 
DIISOSTEARATE 
LE 
18 steareth-10 allyl ether/acrylates copolymer (30% aqueous) INCI 
name: STEARETH-10 ALLYL ETHER/ACRYLATES COPOLYMER 
SE 
19 dimethyl siloxane, mono dimethylvinylsiloxy- and  mono 
trimethoxysiloxy-terminated  (95%) 
LE 
20 ricinoleic acid tin salt LE 
21 1-ethyl-3-methylimidazolium ethylsulphate LE 
22 3-phenoxybenzyl alcohol  LE 
23 ethyl thioglycolate INCI name: ETHYL THIOGLYCOLATE LE 
24 glycidyl methacrylate  SE 
25 piperonyl butoxide INCI name: PIPERONYL BUTOXIDE LE 
26 propiconazole LE 
28 4,4'-methylene bis-(2,6-di-tert-butylphenol) LE 
29 tetradecyl tetradecanoate INCI name: MYRISTYL MYRISTATE LE 
30 1,1-dimethylguanidine sulphate LE 
31 potassium tetrafluoroborate SE 




INCI name: HC BLUE NO. 11 
SE 
34 2,2'-[[3-methyl-4-[(4-nitrophenyl)azo]phenyl]imino]bis-ethanol 
INCI name: DISPERSE RED 17 
SE 
35 2,5,6-triamino-4-pyrimidinol sulphate INCI name: 2,5,6-
TRIAMINO-4-PYRIMIDINOL SULFATE 
SE 
36 1-(4-chlorophenyl)-3-(3,4-dichlorophenyl) urea INCI name: 
TRICLOCARBAN 
LE 
37 polyethylene glycol (PEG-40) hydrogenated castor oil INCI name: 
PEG-40 HYDROGENATED CASTOR OIL 
SE 
38 2,2'-methylene-bis-(6-(2H-benzotriazol-2-yl)-4-(1,1,3,3- LE 
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Chemical name Protocol 
tetramethylbutyl)phenol)  INCI name: METHYLENE BIS-
BENZOTRIAZOLYL TETRAMETHYLBUTYLPHENOL 
39 2,2'-[6-(4-methoxyphenyl)-1,3,5-triazine-2,4-diyl]bis[5-[(2-
ethylhexyl)oxy]-phenol]  INCI name: BIS-ETHYLHEXYLOXYPHENOL 
METHOXYPHENYL TRIAZINE 
LE 
40 acrylamidopropyltrimonium chloride/acrylamide copolymer LE 
41 tris(2-ethylhexyl)-4,4',4''-(1,3,5-triazine-2,4,6-triyltriimino) 
tribenzoate INCI name: ETHYLHEXYL TRIAZONE 
LE 
42 trisodium mono-(5-(1,2-dihydroxyethyl)-4-oxido-2-oxo-2,5-
dihydro-furan-3-yl) phosphate INCI name: SODIUM ASCORBYL 
PHOSPHATE 
SE 
43 hexyl 2-(1-(diethylaminohydroxyphenyl)methanoyl) benzoate 








46 cellulose, 2-(2-hydroxy-3-(trimethylammonium)propoxy)ethyl 
ether chloride (91%) INCI name: POLYQUATERNIUM-10 
LE 
47 3,4-dimethoxy benzaldehyde INCI name: VERATRALDEHYDE SE 
48 sodium hydrogensulphite  INCI name: SODIUM BISULFITE LE 
49 propyl-4-hydroxybenzoate INCI name: PROPYLPARABEN LE 
50 iodosulfuron-methyl-sodium  SE 
51 1,5-di(2,4-dimethylphenyl)-3-methyl-1,3,5-triazapenta-1,4-diene 
common name: Amitraz 
SE 
52 2-anilino-4,6-dimethylpyrimidine common name: Pyrimethanil LE 
53 3-(2-chloro-thiazol-5-ylmethyl)-5-methyl[1,3,5]oxadiazinan-4-
ylidene-N-nitroamine common name: Thiamethoxam 
SE 
54 3-chloropropionitrile SE 
55 2-methylpropanal INCI name: 2-METHYLPROPANAL SE 
56 isopropyl acetoacetate SE 
57 2-methyl-1-pentanol LE 
58 1-(1-methyl-2-propoxyethoxy)propan-2-ol INCI name: PPG-2 
PROPYL ETHER 
SE 
59 ethyl-2-methyl acetoacetate LE 
60 diethyl toluamide INCI name: DIETHYL TOLUAMIDE  common 
name: DEET 
LE 
61 2-hydroxy-1,4-naphthoquinone INCI name: LAWSONE SE 
62 1,4-dibutoxy benzene SE 
63 4-nitrobenzoic acid SE 
64 ethyl 2,6-dichloro-5-fluoro-beta-oxo-3-pyridine propionate SE 
65 2,2-dimethyl-3-methylenebicyclo [2.2.1] heptane INCI name: 
CAMPHENE 
SE 
66 sodium chloroacetate SE 
67 gamma-butyrolactone INCI name: BUTYROLACTONE LE 
68 cyclopentanol LE 
69 alkyl (C10-16) glucoside sodium carboxylate (~ 30% aqueous) INCI 
name: SODIUM CARBOXYMETHYL C10-16 ALKYL GLUCOSIDE 
SE 
70 methyl N,N,N-trimethyl-4-[(4,7,7-trimethyl-3- SE 
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Chemical name Protocol 
oxobicyclo[2.2.1]hept-2-ylidene)methyl]anilinium sulphate (30% 
aqueous) INCI name: CAMPHOR BENZALKONIUM 
METHOSULFATE 




chlorophenyl)-3,12-diimino-, di-D-gluconate (20% aqueous) INCI 
name: CHLORHEXIDINE DIGLUCONATE 
SE 
73 3,3'-dithiopropionic acid SE 
74 2-amino-3-hydroxy pyridine INCI name: 2-AMINO-3-
HYDROXYPYRIDINE 
SE 
75 sodium benzoate INCI name: SODIUM BENZOATE LE 
76 6,7-dihydro-2,3-dimethyl-imidazo[1,2-a]pyridin-8(5H)-one LE 




79 ammonium nitrate INCI name: AMMONIUM NITRATE LE 
80 methylthioglycolate INCI name: METHYL THIOGLYCOLATE SE 
81 3-diethylaminopropionitrile SE 
82 coco alkyl dimethyl betaine (~ 30% aqueous) INCI name: COCO-
BETAINE 
LE 
83 coco amidopropyl betaine (~ 30% aqueous) INCI name: 
COCAMIDOPROPYL BETAINE 
LE 
84 sodium coco amphoacetate (~ 30% aqueous) LE 
85 triethanol ammonium alkyl sulphate (~ 40% aqueous) INCI name: 
TEA-C12-14 ALKYL SULFATE 
SE 
86 di-sodium alkyl ether sulfosuccinate (~ 30% aqueous) INCI name: 
DISODIUM LAURETH SULFOSUCCINATE 
SE 
87 sodium alkyl ether sulphate (~ 30% aqueous) INCI name: SODIUM 
LAURETH SULFATE 
SE 
88 bisphenol A, diethylene triamine, epichlorohydrin, polypropylene 
glycol diglycidyl ether, polymer (~ 60% aqueous) 
LE 
89 ethoxylated (5 EO) alkyl (C10-14) alcohol LE 
90 alkyl (C10-16) glucoside (~ 50% aqueous) INCI name: LAURYL 
GLUCOSIDE 
LE 
91 (ethylenediaminepropyl)trimethoxysilane LE 
92 tetraethylene glycol diacrylate SE 
93 2,5-dimethyl-2,5-hexanediol LE 
94 dodecanoic acid  INCI name: LAURIC ACID LE 
95 1,2,4-triazole sodium salt LE 
96 1-naphthalene acetic acid SE 
97 sodium oxalate INCI name: SODIUM OXALATE LE 
98 4,4'-(4,5,6,7-tetrabromo-3H-2,1-benzoxathiol-3-ylidene)bis[2,6-
dibromophenol] S,S-dioxide INCI name: TETRABROMOPHENOL 
BLUE 
SE 
99 1,2-benzisothiazol-3(2H)-one  INCI name: BENZISOTHIAZOLINONE SE 
100 ethyl lauroyl arginate HCl INCI name: ETHYL LAUROYL ARGINATE 
HCL 
LE 
101 2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride LE 
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Chemical name Protocol 
INCI name: BASIC ORANGE 31 
102 disodium 2,2'-([1,1'-biphenyl]-4,4'-
diyldivinylene)bis(benzenesulphonate) INCI name: DISODIUM 
DISTYRYLBIPHENYL DISULFONATE 
LE 
103 3,4-dimethyl-1H-pyrazole LE 




3.5.1 Predictive capacity (accuracy) 
All qualified tests for each test chemical was used to calculate the predictive 
capacity values. The calculations were based on the individual predictions of each 
qualified test in each laboratory.  
 
For each statistic of the prediction model, an acceptance rate was set by the VMG. 
These criteria are presented in Table 3.5.2. The sensitivity, specificity and overall 
accuracy, subdivided into laboratories and total, including the 95% confidence 
intervals as well as a statement whether the acceptance criteria are fulfilled are 
presented in Table 3.5.3. 
Table 3.5.2 Acceptance criteria for the prediction model 
 False Negativesa (%) False Positivesb (%) Overall 
misclassificationsc (%) 
“Definitely acceptable” rates  ≤ 10 ≤ 40 ≤ 25 
Further evaluations 
necessary before any 
recommendation is made 
10 < FN ≤ 20 40 < FP ≤ 50 25 < OM ≤ 35 
“Definitely unacceptable” 
rates > 20 > 50 > 35 
a
 equal to (1-Sensitivity), b equal to (1-Specificity), c equal to (1-Overall accuracy) 
Table 3.5.3 The sensitivity, specificity and overall accuracy, subdivided into laboratories and total, 
including the 95% confidence intervals as well as a statement whether the acceptance 











CARDAM Accuracy 206/312 0.660 0.605 0.713 further evaluation 
 Sensitivity 83/156 0.532 0.451 0.612 definitely unacceptable 
 Specificity 123/156 0.788 0.716 0.850 definitely acceptable 
CEETOX Accuracy 208/311 0.669 0.613 0.721 further evaluation 
 Sensitivity 87/156 0.558 0.476 0.637 definitely unacceptable 
 Specificity 121/155 0.781 0.707 0.843 definitely acceptable 
L'Oreal Accuracy 204/312 0.654 0.598 0.707 further evaluation 
 Sensitivity 85/156 0.545 0.463 0.625 definitely unacceptable 
 Specificity 119/156 0.763 0.688 0.827 definitely acceptable 
Total Accuracy 618/935 0.661 0.630 0.691 further evaluation 
 Sensitivity 255/468 0.545 0.499 0.591 definitely unacceptable 
 Specificity 363/467 0.777 0.737 0.814 definitely acceptable 
 
In Table 3.5.4, the prediction for each qualified test result is given as well as the 
final classification based on the median of predictions.  
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Table 3.5.4 Final classification based on the median of all classifications for each chemical 
  
                    
Final 
classification Mispredicted 
    CARDAM CEETOX L’OREAL based on tests/Total 
Chemical GHS 1 2 3 1 2 3 1 2 3 median  
1 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
2 no cat I I I I I I I I I I 9/9 
3 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
4 no cat I I I I I I I I I I 9/9 
5 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
6 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
7 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
8 no cat I I I I I I I I I I 9/9 
9 no cat NI I NI I I I I I I I 7/9 
10 no cat I I I I I I I I I I 9/9 
11 no cat I I I NI NI NI NI NI I NI 4/9 
12 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
13 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
14 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
15 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
16 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
17 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
18 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
19 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
20 no cat I I I I I . I I I I 8/8 
21 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
22 no cat I I I I I I I I I I 9/9 
23 no cat I I I I I I I I I I 9/9 
24 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
25 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
26 no cat I I I I I I I I I I 9/9 
28 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
29 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
30 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
31 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
32 no cat NI NI NI I I I I I I I 6/9 
33 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
34 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
35 no cat I NI I I NI I I I I I 7/9 
36 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
37 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
38 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
39 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
40 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
41 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
42 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
43 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
44 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
45 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
46 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
47 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
48 no cat I I I I I I I I I I 9/9 
49 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
50 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
51 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
52 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
53 no cat NI NI NI NI NI NI NI NI NI NI 0/9 
54 cat 2B NI NI NI NI NI NI NI NI I NI 8/9 
55 cat 2B I I I I I I I I I I 0/9 
56 cat 2B NI NI NI NI NI NI NI NI NI NI 9/9 
57 cat 2B I I I I I I I I I I 0/9 
58 cat 2B I I I I I I I I I I 0/9 
59 cat 2B I I I I I I I I I I 0/9 
60 cat 2B I I I I I I I I I I 0/9 
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Final 
classification Mispredicted 
    CARDAM CEETOX L’OREAL based on tests/Total 
Chemical GHS 1 2 3 1 2 3 1 2 3 median  
61 cat 2B NI NI NI NI NI NI NI NI NI NI 9/9 
62 cat 2B NI NI NI NI NI NI NI NI NI NI 9/9 
63 cat 2B NI NI NI NI NI NI NI NI NI NI 9/9 
64 cat 2B NI NI NI NI NI NI NI NI NI NI 9/9 
65 cat 2B NI NI NI NI NI NI NI NI NI NI 9/9 
66 cat 2B NI NI NI NI NI NI NI NI NI NI 9/9 
67 cat 2A I I I I I I I I I I 0/9 
68 cat 2A 
(ICCVAM:cat2B) 
I I I I I I I I I I 0/9 
69 cat 2A 
(ICCVAM:cat2B) 
NI I NI NI NI NI NI NI NI NI 8/9 
70 cat 2A I I I I I I I I I I 0/9 
71 cat 2A 
(ICCVAM:cat2B) 
I I I I I I I I I I 0/9 
72 cat 2A 
(ICCVAM:cat2B) 
I I I I I I I I I I 0/9 
73 cat 2A 
(ICCVAM:cat2B) 
NI NI NI NI I I NI NI NI NI 7/9 
74 cat 2A NI NI NI NI NI I NI NI NI NI 8/9 
75 cat 2A I I I I I I I I I I 0/9 
76 cat 2A NI NI NI NI NI NI NI NI NI NI 9/9 
77 cat 2A NI NI NI I NI NI NI NI NI NI 8/9 
78 cat 2A NI NI NI NI NI NI NI NI NI NI 9/9 
79 cat 2A 
(ICCVAM:cat2B) 
NI NI NI I I I I NI I I 4/9 
80 cat 1 I I I I I I I I I I 0/9 
81 cat 1 I I I I I I I I I I 0/9 
82 cat 1 I I I I I I I I I I 0/9 
83 cat 1 I I I I I I I I I I 0/9 
84 cat 1 I I I I I I I I I I 0/9 
85 cat 1 NI NI NI NI NI NI NI NI NI NI 9/9 
86 cat 1 NI NI NI NI NI NI NI NI NI NI 9/9 
87 cat 1 NI NI NI NI NI I NI NI NI NI 8/9 
88 cat 1 I I I I I I I I I I 0/9 
89 cat 1 I I I I I I I I I I 0/9 
90 cat 1 I I I I I I I I I I 0/9 
91 cat 1 I I I I I I I I I I 0/9 
92 cat 1 NI NI NI NI NI NI NI NI NI NI 9/9 
93 cat 1 I I I I NI NI I I I I 2/9 
94 cat 1 I I I I I I I I I I 0/9 
95 cat 1 I I I I I I I I I I 0/9 
96 cat 1 NI NI NI NI NI NI NI NI NI NI 9/9 
97 cat 1 NI I NI NI NI NI NI NI NI NI 8/9 
98 cat 1 NI NI NI NI NI NI NI NI NI NI 9/9 
99 cat 1 I I I I I I I I I I 0/9 
100 cat 1 I I I I I I I I I I 0/9 
101 cat 1 NI NI NI NI NI NI NI NI I NI 8/9 
102 cat 1 NI NI NI NI NI NI NI NI NI NI 9/9 
103 cat 1 I I I I I I I I I I 0/9 
104 cat 1 NI NI NI NI NI NI NI NI NI NI 9/9 
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4 Overall summary and recommendations 
The validation study is considered of high quality due to a very complete dataset. 
The test method is highly reproducible. The within-laboratory reproducibility (WLR) 
and between-laboratory reproducibility (BLR) was well above the acceptance 
criteria set by the VMG (i.e. WLR ≥ 85% and BLR ≥ 80%). 
 
The concordance of classifications within a single laboratory was above 90% for all 
participating laboratories. The concordance of final classifications obtained between 
the different participating laboratories was greater than 90%. 
 
A cut-off value of 50% was applied, meaning that a chemical for which the mean 
viabililty was below 50% is classified as irritant and non-irritant otherwise. The 
specificity of the prediction model was ‘definitely acceptable’ according to the 
acceptance criteria as defined by the VMG, regardless the protocol that was used 
(SE: 0.885; LE: 0.655; test strategy: 0.777). Further evaluation is needed regarding 
the accuracy (SE: 0.656; LE: 0.686; test strategy: 0.661). The results for the 
sensitivity are ‘definitely unaccaptable’ according to the acceptance criteria as 
defined by the VMG (SE: 0.427; LE: 0.716; test strategy: 0.545). 
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5 Signature 






Han van de Sandt, PhD Carina Rubingh, PhD 
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Appendix I MTT reducers and colourants 
Note that some chemicals are treated differently by the three laboratories, as is 
mentioned in section 3.2.1. If a chemical is treated as an MTT-reducer or a colorant 
in at least one of the laboratories, it is listed in appendix I. 
 
Chemical name coloring MTT 
4 iso-octylthioglycolate INCI name: ISOOCTYL THIOGLYCOLATE No Yes 
5 4-(methylthio)-benzaldehyde No Yes 
9 1,9-decadiene No Yes 
20 ricinoleic acid tin salt No Yes 
23 ethyl thioglycolate INCI name: ETHYL THIOGLYCOLATE No Yes 
25 piperonyl butoxide INCI name: PIPERONYL BUTOXIDE No Yes 
32 2,6-dihydroxy-3,4-dimethylpyridine INCI name: 2,6-DIHYDROXY-3,4-
DIMETHYLPYRIDINE 
Yes No 
33 2,2'-[[4-[(2-methoxyethyl)amino]-3-nitrophenyl]imino]bis-ethanol INCI name: 
HC BLUE NO. 11 
Yes Yes 
34 2,2'-[[3-methyl-4-[(4-nitrophenyl)azo]phenyl]imino]bis-ethanol INCI name: 
DISPERSE RED 17 
Yes Yes 
35 2,5,6-triamino-4-pyrimidinol sulphate INCI name: 2,5,6-TRIAMINO-4-
PYRIMIDINOL SULFATE 
No Yes 
42 trisodium mono-(5-(1,2-dihydroxyethyl)-4-oxido-2-oxo-2,5-dihydro-furan-3-yl) 
phosphate INCI name: SODIUM ASCORBYL PHOSPHATE 
No Yes 
48 sodium hydrogensulphite  INCI name: SODIUM BISULFITE No Yes 
49 propyl-4-hydroxybenzoate INCI name: PROPYLPARABEN No Yes 
61 2-hydroxy-1,4-naphthoquinone INCI name: LAWSONE Yes No 
74 2-amino-3-hydroxy pyridine INCI name: 2-AMINO-3-HYDROXYPYRIDINE Yes Yes 
80 methylthioglycolate INCI name: METHYL THIOGLYCOLATE No Yes 
81 3-diethylaminopropionitrile No Yes 
88 bisphenol A, diethylene triamine, epichlorohydrin, polypropylene glycol 
diglycidyl ether, polymer (~ 60% aqueous) 
No Yes 
91 (ethylenediaminepropyl)trimethoxysilane No Yes 
92 tetraethylene glycol diacrylate No Yes 
95 1,2,4-triazole sodium salt No Yes 
98 4,4'-(4,5,6,7-tetrabromo-3H-2,1-benzoxathiol-3-ylidene)bis[2,6-
dibromophenol] S,S-dioxide INCI name: TETRABROMOPHENOL BLUE 
Yes No 
101 2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium chloride INCI name: 
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Appendix II SAS-code for statistical analysis 
/* ================================ */ 
/* STEP5_SkinEthic_SAP.sas    */ 
/*           */ 
/* Data analysis according to SAP  */ 
/* 10-01-2012 Intial CdJ   */ 
/*           */ 
/* ================================ */ 
 
LIBNAME RhT '\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data analysis'; 
OPTIONS fmtsearch=(RhT.formats work.formats) NOCENTER; 
 
PROC FORMAT; 
   VALUE fmtconcl 0 = 'Qualified and included' 
                  1 = 'Non-Qualified' 
      2 = 'Excluded'; 
   VALUE fmtc 0 = 'NQ' 
              1 = 'Ex' 
              . = ' '; 
   VALUE FMTINI 0 = 'NI' 
                1 = 'I'; 
RUN; 
 
/* Merge locked data with chemical information */ 
 
DATA chemorder; 
   INFILE '\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\chemorder_skinethic.txt'  
           DSD DELIMITER='09'x MISSOVER FIRSTOBS=2; 
   INFORMAT name $200. tnocode $20. DPRA $40.; 
   FORMAT name $200. tnocode $20. DPRA $40.; 
   INPUT order (tnocode state name predGHS predEPA Loreal Cardam Ceetox DPRA) ($);   IF order = . 
THEN DELETE; 
   IF tnocode IN ('chemical102' 'chemical68' 'chemical49') THEN DELETE; * deselected chemicals; 
     LS = SCAN(state,1); 
   /* Hardened castor oil with approx. 40 mol EO (INCI name: PEG-40 Hydrogenated Castor Oil) */ 
   /* is listed as solid, but treated as liquid */ 
   /* decision by the VMG NOV10 2011 */ 
   IF order = 37 THEN LS = 'Solid';   
   IF order < 54 THEN trueINI = "NI"; 




   SET chemorder(keep = name order LS predGHS loreal DPRA rename=(loreal = chemical_code)) 
       chemorder(keep = name order LS predGHS cardam DPRA rename=(cardam = chemical_code)) 
       chemorder(keep = name order LS predGHS ceetox DPRA rename=(ceetox = chemical_code)); 
RUN; 
PROC SORT data= RhT.SE_meanviabilities_locked; BY chemical_code; RUN; 
PROC SORT data= RhT.LE_meanviabilities_locked; BY chemical_code; RUN; 
PROC SORT data= chemorder2; BY chemical_code; RUN; 
DATA pre_all_SE; 
   MERGE RhT.SE_meanviabilities_locked(in=ok2) chemorder2 (in=ok); 
   BY chemical_code; 
   IF ok and ok2; 
   tmp=chemical_code; 
   SUBSTR(tmp,1,1)=''; 
   tmp2=PUT(INPUT(tmp,best12.),z3.);  
   *IF test >3 then delete; 
   IF order < 54 THEN trueINI = "NI"; 
   ELSE trueINI = "I"; 
   runN = INPUT(run,best12.); 
   IF mean_NSC NE . THEN coloring = 'Yes'; 
   ELSE coloring = 'No'; 
   mean_NSMTT = mean_MTT; 
   IF mean_NSMTT NE . THEN MTT = 'Yes'; 
   ELSE MTT = 'No'; 
   RETAIN test 0; 
   test = test+1; 
   IF first.chemical_code THEN test=1; 
   IF (UPCASE(SUBSTR(DPRA,1,8)) IN ('REACTIVE' '"REACTIV') AND UPCASE(SUBSTR(DPRA,1,15)) NE 'NON-
REACTIVE AT') THEN keuze = 'SE'; 
   IF chemical_code = 'X13' and laboratory = '' then delete; * technical; 
   /* exclude runs with technical issues */ 
   IF run = -1 THEN DELETE; 
RUN; 
DATA pre_all_LE; 
   MERGE RhT.LE_meanviabilities_locked(in=ok2) chemorder2 (in=ok); 
   BY chemical_code; 
   IF ok and ok2;    
   tmp=chemical_code; 
   SUBSTR(tmp,1,1)=''; 
   tmp2=PUT(INPUT(tmp,best12.),z3.);  
   *IF test >3 then delete; 
   IF order < 54 THEN trueINI = "NI"; 
   ELSE trueINI = "I"; 
   runN = INPUT(run,best12.); 
   IF mean_NSC NE . THEN coloring = 'Yes'; 
   ELSE coloring = 'No'; 
   mean_NSMTT = mean_MTT; 
   IF mean_NSMTT NE . THEN MTT = 'Yes'; 
   ELSE MTT = 'No'; 
   RETAIN test 0; 
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   test = test+1; 
   IF first.chemical_code THEN test=1; 
   IF (UPCASE(SUBSTR(DPRA,1,8)) NOT IN ('REACTIVE' '"REACTIV') OR UPCASE(SUBSTR(DPRA,1,15)) EQ 'NON-
REACTIVE AT') THEN keuze = 'LE'; 
   IF PCqual = 1 OR NCqual = 1 OR qual_sd = 1 THEN conclusion = 1;    
   /* exclude runs with technical issues */ 
   IF run = -1 THEN DELETE; 
RUN; 
DATA pre_all; 
   SET pre_all_SE (in=se) pre_all_LE (in=LE); 
   IF SE THEN select = 'SE'; 
   IF LE THEN select = 'LE'; 
   /* exclude runs with technical issues */ 
   IF run = -1 THEN DELETE; 
   *IF run = . THEN DELETE; 
RUN; 
PROC SORT data=pre_all; BY laboratory tmp2; RUN; 
 
/* check wheter selection was made for SE or LE, not for both */ 
PROC SORT data=pre_all_SE out=tmp1 nodupkey; BY laboratory chemical_code; RUN; 
PROC SORT data=pre_all_LE out=tmp2 nodupkey; BY laboratory chemical_code; RUN; 
DATA niegoe; 
   SET tmp1(in=se) tmp2(in=le); 
   IF se AND le THEN OUTPUT niegoe; * empty; 
RUN; 
 
/* 09082012 CdJ Revision */ 
 
DATA pre_106107; 
   SET pre_all; 
   /* remove chemical 106 and 107 for statistical analysis */ 
   IF chemical_code IN ('L6' 'C52' 'X95' 'L100' 'C56' 'X32') THEN OUTPUT;  
RUN; 
DATA pre_all; 
   SET pre_all; 
   /* remove chemical 106 and 107 for statistical analysis */ 
   IF chemical_code IN ('L6' 'C52' 'X95') THEN DELETE; * 106; 
   IF chemical_code IN ('L100'  'C56' 'X32') THEN DELETE; * 107; 
   /* for some chemicals the VMG overrode the 50% rule regarding NSMTT */ 
   IF select = 'LE' THEN DO; 
      IF chemical_code IN ('C6' 'X31') and NCqual NE 1 AND PCqual NE 1 AND qual_sd NE 1 then conclusion 
= 0; * 80; 
   IF chemical_code IN ('C6' 'X31') and (NCqual EQ 1 OR PCqual EQ 1 OR qual_sd EQ 1) then conclusion 
= 1; * 80; 
      IF chemical_code IN ('X62' 'C53') and NCqual NE 1 AND PCqual NE 1 AND qual_sd NE 1 then 
conclusion = 0; * 4; 
      IF chemical_code IN ('X62' 'C53') and  (NCqual EQ 1 OR PCqual EQ 1 OR qual_sd EQ 1) then 
conclusion = 1; * 4; 
      IF chemical_code IN ('L58' 'C58') and NCqual NE 1 AND PCqual NE 1 AND qual_sd NE 1 then 
conclusion = 0; * 20; 
      IF chemical_code IN ('L58' 'C58') and (NCqual EQ 1 OR PCqual EQ 1 OR qual_sd EQ 1) then 
conclusion = 1; * 20; 
   END;   
   IF select = 'SE' THEN DO;    
      IF chemical_code = 'C53' AND run = 1 THEN qual_sd = 1; 
   /* for some chemicals the VMG overrode the 50% rule regarding NSMTT */ 
      IF chemical_code IN ('X139') and NCqual NE 1 AND PCqual NE 1 AND qual_sd NE 1 then conclusion = 
0; * 23; 
      IF chemical_code IN ('X139') and (NCqual EQ 1 OR PCqual EQ 1 OR qual_sd EQ 1) then conclusion = 
1; * 23; 
      IF chemical_code IN ('X62' 'C53' 'L7') and NCqual NE 1 AND PCqual NE 1 AND qual_sd NE 1 then 
conclusion = 0; * 4; 
      IF chemical_code IN ('X62' 'C53' 'L7') and (NCqual EQ 1 OR PCqual EQ 1 OR qual_sd EQ 1) then 
conclusion = 1; * 4; 
      IF chemical_code IN ('L58' 'C58') and NCqual NE 1 AND PCqual NE 1 AND qual_sd NE 1 then 
conclusion = 0; * 20; 
      IF chemical_code IN ('L58' 'C58') and (NCqual EQ 1 OR PCqual EQ 1 OR qual_sd EQ 1) then 
conclusion = 1; * 20; 
      IF chemical_code IN ('X81') and NCqual NE 1 AND PCqual NE 1 AND qual_sd NE 1 then conclusion = 0; 
* 91; 
      IF chemical_code IN ('X81') and (NCqual EQ 1 OR PCqual EQ 1 OR qual_sd EQ 1) then conclusion = 1; 
* 91; 
   /* conclusion for chemical 20 L'oreal is not correct */ 




   SET pre_all_LE; 
   /* remove chemical 106 and 107 for statistical analysis */ 
   IF chemical_code IN ('L6' 'C52' 'X95') THEN DELETE; * 106; 
   IF chemical_code IN ('L100'  'C56' 'X32') THEN DELETE; * 107; 
   /* for some chemicals the VMG overrode the 50% rule regarding NSMTT */ 
      IF chemical_code IN ('C6' 'X31') and NCqual NE 1 AND PCqual NE 1 AND qual_sd NE 1 then conclusion 
= 0; * 80; 
   IF chemical_code IN ('C6' 'X31') and (NCqual EQ 1 OR PCqual EQ 1 OR qual_sd EQ 1) then conclusion 
= 1; * 80; 
      IF chemical_code IN ('X62' 'C53') and NCqual NE 1 AND PCqual NE 1 AND qual_sd NE 1 then 
conclusion = 0; * 4; 
      IF chemical_code IN ('X62' 'C53') and  (NCqual EQ 1 OR PCqual EQ 1 OR qual_sd EQ 1) then 
conclusion = 1; * 4; 
      IF chemical_code IN ('L58' 'C58') and NCqual NE 1 AND PCqual NE 1 AND qual_sd NE 1 then 
conclusion = 0; * 20; 
      IF chemical_code IN ('L58' 'C58') and (NCqual EQ 1 OR PCqual EQ 1 OR qual_sd EQ 1) then 





/* === */ 
  
TNO report | TNO 2013 R11617 | Final report  69 / 305
/* SE   */ 
/* === */ 
 
PROC SORT data=pre_all_SE; BY chemical_code; RUN; 
DATA rules; 
   SET pre_all_SE; 
   BY chemical_code; 
   if conclusion = 1 /* non-qual */ then delete; 
   IF mean_viability >50 THEN pred50=0; 
   ELSE pred50 = 1; 
   IF mean_TA >50 THEN pred50raw=0; 
   ELSE pred50raw = 1; 
   FORMAT pred50  pred50raw  fmtpred.;   
RUN; 
DATA rules2; 
    SET rules; 
 BY chemical_code; 
   RETAIN t 0; 
   t = t+1; 
   IF first.chemical_code THEN t=1; 
   IF t>3 then delete; 
RUN; 
PROC SORT data=rules2; BY order  laboratory  ; RUN; 
PROC TRANSPOSE data=rules2 out=allT1 prefix=p50_; 
   VAR pred50; 
   BY order  laboratory  ; 
   ID t; 
RUN;  
PROC TRANSPOSE data=rules2 out=allT1raw prefix=p50r_; 
   VAR pred50raw; 
   BY order  laboratory  ; 
   ID t; 
RUN;  
PROC TRANSPOSE data=rules2 out=allT3 prefix=v_; 
   VAR mean_viability; 
   BY order  laboratory  ; 
   ID t; 
RUN;  
PROC TRANSPOSE data=rules2 out=allT4 prefix=TA_; 
   VAR mean_TA; 
   BY order  laboratory  ; 
   ID t; 
RUN;  
PROC TRANSPOSE data=rules2 out=allT5 prefix=CC_; 
   VAR mean_NSC; 
   BY order  laboratory  ; 
   ID t; 
RUN;  
PROC TRANSPOSE data=rules2 out=allT6 prefix=KC_; 
   VAR mean_NSMTT; 
   BY order  laboratory  ; 
   ID t; 
RUN;  
DATA overall (drop=_name_); 
   MERGE allT1  allT1raw allT3 allT4 allT5 allT6; 
   BY order  laboratory  ; 
RUN; 
PROC SORT data=overall; BY laboratory order; RUN; 
DATA rules3_no rules3_yes; 
   SET overall; 
   mean_nsc=mean(CC_1,CC_2,CC_3); 
   mean_mtt=mean(KC_1,KC_2,KC_3); 
   * rule 1 - IF mean (%NSC or %NSMTT) of all qualified tests obtained for a chemical in one laboratory 
is less than or equal to (=) 50%,  
   THEN this chemical is considered to be compatible with the test method. The chemical should be 
included in the overview tables, 
   and included in all statistical calculations of reproducibility and predictive capacity.; 
  IF mean_nsc <= 50 THEN DO; inclusion50_nsc = 'yes'; inclusion60_nsc = 'yes'; END; 
  IF mean_mtt<=50 THEN DO; inclusion50_mtt = 'yes'; inclusion60_mtt = 'yes'; END; 
  * rule 2 - IF mean (%NSC or %NSMTT) of all qualified tests obtained for a chemical in one laboratory 
is greater than (>) 50% AND  
  their classification (I or NI) remains the same upon correction, THEN this chemical is considered to 
be compatible with the test  
  method. The chemical should be included in the overview tables, and included in all statistical 
calculations of reproducibility and 
  predictive capacity.; 
  IF mean_nsc > 50 AND p50_1=p50r_1 AND  p50_2=p50r_2 AND p50_3=p50r_3 THEN inclusion50_nsc = 'yes'; 
  IF mean_mtt > 50 AND p50_1=p50r_1 AND  p50_2=p50r_2 AND p50_3=p50r_3 THEN inclusion50_mtt = 'yes'; 
* rule 3 - IF mean (%NSC or %NSMTT) of all qualified tests obtained for a chemical in one laboratory is 
greater than (>) 50% AND 
  the classification of at least one of the qualified tests changes upon correction, THEN this chemical 
is considered to be  
  incompatible with the test method. The chemical should be included in the overview tables, but 
excluded from all statistical  
  calculations of reproducibility and predictive capacity.; 
  IF mean_nsc > 50 AND (p50_1 NE p50r_1 OR  p50_2 NE p50r_2 OR p50_3 NE p50r_3) THEN inclusion50_nsc = 
'no'; 
  IF mean_mtt > 50 AND (p50_1 NE p50r_1 OR  p50_2 NE p50r_2 OR p50_3 NE p50r_3) THEN inclusion50_mtt = 
'no'; 
  * output; 
  IF inclusion50_nsc = 'no' OR inclusion50_mtt = 'no' OR inclusion60_nsc = 'no' OR inclusion60_mtt = 
'no' THEN OUTPUT rules3_no; 
  ELSE OUTPUT rules3_yes;  
RUN; 
/* CONCLUSION */ 
/* new rules give selection : chemical 4, 20 (Cardam only), 91 (Ceetox only) */ 
 
DATA select /*(keep = order laboratory run conclusion NCqual PCqual qual_sd)*/; 
   SET pre_all_SE; 
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   SET pre_all_SE; 
   /* remove chemical 106 and 107 for statistical analysis */ 
   IF chemical_code IN ('L6' 'C52' 'X95') THEN DELETE; * 106; 
   IF chemical_code IN ('L100'  'C56' 'X32') THEN DELETE; * 107; 
   /* for some chemicals the VMG overrode the 50% rule regarding NSMTT */ 
      IF chemical_code = 'C53' AND run = 1 THEN qual_sd = 1; 
   /* for some chemicals the VMG overrode the 50% rule regarding NSMTT */ 
      IF chemical_code IN ('X139') and NCqual NE 1 AND PCqual NE 1 AND qual_sd NE 1 then conclusion = 
0; * 23; 
      IF chemical_code IN ('X139') and (NCqual EQ 1 OR PCqual EQ 1 OR qual_sd EQ 1) then conclusion = 
1; * 23; 
      IF chemical_code IN ('X62' 'C53' 'L7') and NCqual NE 1 AND PCqual NE 1 AND qual_sd NE 1 then 
conclusion = 0; * 4; 
      IF chemical_code IN ('X62' 'C53' 'L7') and (NCqual EQ 1 OR PCqual EQ 1 OR qual_sd EQ 1) then 
conclusion = 1; * 4; 
      IF chemical_code IN ('L58' 'C58') and NCqual NE 1 AND PCqual NE 1 AND qual_sd NE 1 then 
conclusion = 0; * 20; 
      IF chemical_code IN ('L58' 'C58') and (NCqual EQ 1 OR PCqual EQ 1 OR qual_sd EQ 1) then 
conclusion = 1; * 20; 
      IF chemical_code IN ('X81') and NCqual NE 1 AND PCqual NE 1 AND qual_sd NE 1 then conclusion = 0; 
* 91; 
      IF chemical_code IN ('X81') and (NCqual EQ 1 OR PCqual EQ 1 OR qual_sd EQ 1) then conclusion = 1; 
* 91; 
RUN; 
PROC SORT data=RhT.SE2 out=ODnc(keep = laboratory run chemical_code meanODnc) nodupkey; 
   BY laboratory run chemical_code; 
   where chemical_code NE 'PC'; 
RUN; 
PROC SORT data=pre_all_SE; BY laboratory run chemical_code; RUN; 
DATA pre_all_SE; 
   MERGE pre_all_SE (in=ok) ODnc; 
   BY laboratory run chemical_code; 
   IF ok; 
RUN; 
 
* Table 3.2.2 - MTT and colouring differences  
* some chemicals are treated differently by the labs concerning the coloring or mtt; 
PROC SORT data=pre_all_SE out=extra0s (keep = order name laboratory mtt coloring where=(laboratory NE 
'')) nodupkey; 
   BY order laboratory mtt coloring; 
RUN; 
PROC TRANSPOSE data=extra0s out=extra0a; 
   VAR mtt; 
   BY order name; 
   ID laboratory; 
RUN;  
DATA extra0_mtt(keep = order name L_oreal ceetox cardam mttcheck) ; 
   SET extra0a ; 
   BY order; 
   mttcheck = 'not ok'; 
   IF l_oreal = ceetox AND L_oreal = cardam and cardam = ceetox THEN mttcheck = ' '; 
   ELSE mttcheck = '#'; 
   *IF mttcheck = 'not ok' THEN OUTPUT; 
RUN; 
PROC TRANSPOSE data=extra0s out=extra0b; 
   VAR coloring; 
   BY order name; 
   ID laboratory; 
RUN;  
DATA extra0_color( keep = order name L_oreal ceetox cardam colorcheck); 
   SET  extra0b; 
   BY order; 
   colorcheck = 'not ok'; 
   IF l_oreal = ceetox AND L_oreal = cardam and cardam = ceetox THEN colorcheck = ' '; 
   ELSE colorcheck = '#'; 
   *IF colorcheck = 'not ok' THEN OUTPUT; 
RUN; 
 
/* non-qual NC and PC */ 
PROC SORT data=pre_all_SE out=pre412 nodupkey; BY filename; RUN; 
PROC FREQ data=pre412 ; 
   TABLE laboratory*NCqual/out=table412_NC NOCOL NOPERCENT; 
   TABLE laboratory*PCqual/out=table412_PC NOCOL NOPERCENT; 
RUN; 
PROC TRANSPOSE data=table412_NC out=table412NCt; 
   VAR count; 
   ID NCqual; 
   BY laboratory; 
RUN; 
PROC TRANSPOSE data=table412_PC out=table412PCt; 
   VAR count; 
   ID PCqual; 
   BY laboratory; 
RUN; 
DATA table412; 
   SET table412NCt(in=nc) table412PCt(in=pc); 
   BY laboratory; 
   IF nc THEN var = 'NC'; 
   IF pc THEN var = 'PC'; 
   IF non_qualified = . THEN non_qualified = 0; 
   fraction_nq = 100* non_qualified/(non_qualified+qualified); 
   fraction_q = 100*qualified/(non_qualified+qualified); 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\Revision\SkinEthic_Table412.doc' notoc_data; 
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PROC REPORT data = table412 NOWINDOWS HEADLINE HEADSKIP; 
   COLUMN laboratory var qualified fraction_q non_qualified fraction_nq; 
   DEFINE laboratory/GROUP; 
   DEFINE var/DISPLAY ' '; 
   DEFINE qualified/DISPLAY 'No.Qualified' width = 12 CENTER; 
   DEFINE fraction_q/DISPLAY '%' width = 5 format=8.1 CENTER; 
   DEFINE non_qualified/DISPLAY 'No.Non-Qualified' width = 16 CENTER; 
   DEFINE fraction_nq/DISPLAY '%' width = 5 format=8.1 CENTER; 
RUN; QUIT; 
ODS rtf close; 
 
 
/* 5.2 Table with number and fraction of qualified and non_qualified runs */ 
PROC SORT data=pre_all_SE; BY laboratory; RUN; 
PROC FREQ data=pre_all_SE noprint; 
   TABLES conclusion/out=table5_2LAB; 
   BY laboratory; 
RUN; 
PROC FREQ data=pre_all_SE noprint; 
   TABLES conclusion/out=table5_2TOTAL; 
RUN; 
DATA table5_2; 
   SET table5_2LAB table5_2TOTAL (in=ok); 
   IF ok THEN laboratory = 'Total'; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\REVISION\SkinEthic_Table5_2.doc' notoc_data; 
PROC REPORT data = table5_2 NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS laboratory conclusion count percent; 
   DEFINE laboratory/GROUP; 
   DEFINE conclusion /DISPLAY 'Call'; 
   DEFINE count/ DISPLAY 'No.'; 
   DEFINE percent/DISPLAY width = 15 format=8.1 'Fraction (%)'; 
RUN;QUIT; 
ODS RTF close; 
 
OPTIONS PS=42 LS=120; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\REVISION\SkinEthic_Table5_2LIST.doc' notoc_data; 
PROC REPORT data=pre_all_SE (where=(conclusion IN (1 2)) keep = run order conclusion laboratory name 
qual_sd PCqual NCqual NSCcall NSMTTcall) 
            NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS conclusion laboratory order run NCqual PCqual qual_sd  NSCcall NSMTTcall; 
   DEFINE conclusion / GROUP width = 15; 
   DEFINE laboratory / GROUP width = 15; 
   DEFINE order/DISPLAY width = 4 'Chemical'; 
   DEFINE NSCcall/DISPLAY width = 12; 
   BREAK after laboratory/SKIP; 
RUN; QUIT; 
ODS RTF close; 
 
/* 5.4 Table with number of tests within each test sequence */ 
OPTIONS PS=55 LS=80; 
PROC SORT data=pre_all_SE; BY laboratory tmp2 run; RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\REVISION\SkinEthic_Table5_4.doc' notoc_data; 
PROC FREQ data=pre_all_SE ; 
   TABLES order*laboratory/out=table5_4 NOROW NOCOL NOPERCENT; 
RUN; 
ODS RTF close; 
 
/* 5.5 Table with list, no and fraction of NQ tests */ 
PROC SORT data=pre_all_SE; BY laboratory order; RUN; 
PROC FREQ data=pre_all_SE NOPRINT; 
   TABLES conclusion/out=table5_5; 
   BY laboratory order; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\REVISION\SkinEthic_Table5_5.doc' notoc_data; 
PROC PRINT data=table5_5(WHERE=(CONCLUSION IN (1 2))); RUN; 
ODS RTF close; 
 
/* 5.6 Table with list and fraction of complete test sequences */ 
DATA pre5_6; 
   SET pre_all_SE; 
   IF conclusion IN (1 2) THEN DELETE; 
RUN; 
PROC FREQ data=pre5_6 noprint; 
   TABLES laboratory * order/out=pre5_6b; 
RUN; 
DATA table5_6LIST; 
   SET pre5_6b; 
   IF count >=3 THEN OUTPUT; 
RUN; 
PROC SORT data=pre5_6b; BY order; RUN; 
PROC TRANSPOSE data=pre5_6b out=table5_6LIST; 
   VAR COUNT; 
   ID laboratory; 
   BY order; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\REVISION\SkinEthic_Table5_6LIST.doc' notoc_data; 
PROC PRINT data=table5_6LIST; RUN; 
ODS RTF close; 
/*switched off by Rinke*/ 
/*PROC FREQ data=table5_6LIST noprint;*/ 
/*   TABLES laboratory/out=table5_6B;*/ 
/*RUN;*/ 
/* Above proc Freq statement doesn't work! adaption below gives desired results, it seems. */ 
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/*adaption by rinke to test*/ 
 
PROC FREQ data=pre5_6b noprint; 
   TABLES laboratory/out=table5_6B; 
RUN; 
/*  end adaption by rinke to test*/ 
 
DATA table5_6LAB; 
   SET table5_6B; 
   fraction_complete = 100*count/104; 
   test_sequence_criteria = 'not fulfilled'; 
   IF fraction_complete > 85 THEN test_sequence_criteria = 'fulfilled'; 
RUN; 
PROC MEANS data=table5_6LAB NOPRINT; 
   VAR count; 
   OUTPUT out=table5_6D sum=sumcount; 
RUN; 
DATA table5_6OVERALL; 
   SET table5_6D; 
   fraction_complete = 100*sumcount/(3*104); 
   test_sequence_criteria = 'not fulfilled'; 
   IF fraction_complete >= 85 THEN test_sequence_criteria = 'fulfilled'; 
RUN; 
DATA table5_6; 
   SET table5_6LAB table5_6OVERALL(in=ok); 
   IF ok then laboratory = 'Total'; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\Revision\SkinEthic_Table5_6.doc' notoc_data; 
PROC REPORT data = table5_6 NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS laboratory fraction_complete; 
   DEFINE laboratory/DISPLAY; 
   DEFINE fraction_complete/DISPLAY format=8.1 'Fraction'; 
RUN; QUIT; 
ODS rtf close; 
PROC DATASETS library = work; 
   DELETE pre5_6 pre5_6b table5_6B table5_6D; 
RUN;QUIT; 
  
/* 5.7 Table with list and fraction of incomplete test sequences */ 
 
DATA pre5_7a pre5_7b; 
   SET pre_all_SE; 
   IF conclusion IN (1 2) THEN output pre5_7a; 
   IF conclusion NOT IN (1 2) THEN output pre5_7b; 
RUN; 
PROC FREQ data=pre5_7a noprint; 
   TABLES laboratory * order/out=pre5_7a2; 
RUN; 
PROC FREQ data=pre5_7b noprint; 
   TABLES laboratory * order/out=pre5_7b2; 
RUN; 
DATA pre5_7; 
   MERGE pre5_7a2(rename=(count=OUT)) pre5_7b2(rename=(count=IN)); 
   BY laboratory order; 
   IF IN NOT IN (. 0 1 2) THEN complete = 'Yes'; 
   IF IN IN (. 0 1 2) THEN complete = 'No'; 
RUN; 
DATA table5_7LIST; 
   SET pre5_7; 
   IF IN = . THEN IN = 0; 
   IF complete = 'No' THEN OUTPUT; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\Revision\SkinEthic_Table5_7LIST.doc' notoc_data; 
PROC REPORT data = table5_7LIST NOWINDOWS HEADLINE HEADSKIP; 
   COLUMN laboratory order IN OUT; 
   DEFINE laboratory/GROUP; 
   DEFINE order /DISPLAY ; 
   DEFINE IN/DISPLAY 'Qualified' width = 10 CENTER; 
   DEFINE OUT/DISPLAY 'Non-Qual or Excluded' width = 20 CENTER; 
RUN; QUIT; 
ODS RTF close; 
PROC FREQ data=table5_7LIST noprint; 
   TABLES laboratory/out=table5_7b; 
RUN; 
DATA table5_7LAB; 
   SET table5_7B; 
   fraction_incomplete = 100*count/104; 
   test_sequence_criteria = 'fulfilled'; 
   IF fraction_incomplete > 15 THEN test_sequence_criteria = 'not fulfilled'; 
RUN; 
PROC MEANS data=table5_7LAB NOPRINT; 
   VAR count; 
   OUTPUT out=table5_7D sum=sumcount; 
RUN; 
DATA table5_7OVERALL; 
   SET table5_7D; 
   fraction_incomplete = 100*sumcount/(3*104); 
   test_sequence_criteria = 'fulfilled'; 
   IF fraction_incomplete > 15 THEN test_sequence_criteria = 'not fulfilled'; 
RUN; 
DATA table5_7; 
   SET table5_7LAB table5_7OVERALL(in=ok); 
   IF ok then laboratory = 'Total'; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\Revision\SkinEthic_Table5_7.doc' notoc_data; 
PROC REPORT data = table5_7 NOWINDOWS HEADLINE HEADSKIP; 
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   COLUMNS laboratory fraction_incomplete; 
   DEFINE laboratory/DISPLAY; 
   DEFINE fraction_incomplete/DISPLAY format=8.1 'Fraction'; 
RUN; QUIT; 
ODS rtf close; 
PROC DATASETS library = work; 
   DELETE pre5_7 pre5_7b table5_7B table5_7D; 
RUN;QUIT; 
 
/* 5.8 statement whether test method has fulfilled the performance criteria */ 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\SkinEthic_Table5_8.doc' notoc_data; 
PROC REPORT data = table5_6 NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS laboratory fraction_complete test_sequence_criteria; 
   DEFINE laboratory/DISPLAY; 
   DEFINE fraction_complete/DISPLAY format=8.1 'Fraction'; 
   DEFINE test_sequence_criteria/DISPLAY 'Statement: criteria is ' CENTER; 
RUN; QUIT; 




/* 5.10 summarise results of all tests (including NQ and excl) */ 
DATA appVI (keep=laboratory order predGHS MTT coloring test meanODnc stdNC NCqual meanPC sdPC PCqual 
          mean_TA std_TA qual_sd mean_NSC mean_NSMTT mean_viability conclusion pred50); 
   RETAIN laboratory order predGHS MTT coloring test meanODnc stdNC NCqual meanPC sdPC PCqual 
          mean_TA std_TA qual_sd mean_NSC mean_NSMTT mean_viability conclusion pred50; 
   SET pre_all_SE; 
   IF mean_viability > 50 THEN pred50 = 'NI'; 
   ELSE pred50 = 'I'; 
RUN;  
PROC SORT data=appVI; BY laboratory order test; RUN; 
 
  
/* --------------------------------------------- */ 
/* Section 6 of SAP: Intralaboratory variability */ 
/* --------------------------------------------- */ 
 
/* at least two qualified tests */ 
PROC SORT data=pre_all_SE; BY laboratory name; RUN; 
PROC FREQ data=pre_all_SE noprint; 
   TABLES conclusion/out=pre_WLV; 
   BY laboratory name; 
RUN; 
DATA pre_WLV2; 
   SET pre_WLV (where=(conclusion = 0 AND count >=2)); 
RUN; 
DATA pre_WLV3; 
   MERGE pre_all_SE(drop=test where=(conclusion NOT IN (1 2))) pre_WLV2 (in=ok); 
   BY laboratory name; 
   IF ok; 
   IF mean_viability > 50 THEN predINI = 'NI'; 
   ELSE predINI = 'I'; 
RUN; 
DATA WLV;  
   SET pre_WLV3; 
   BY laboratory name; 
   RETAIN test 0; 
   test = test+1; 
   IF first.name THEN test=1; 
   IF test > 3 THEN DELETE; 
/* check mean viability dataset op excluded chemicals, pas daarop nummers hieronder aan */ 
   /* exclude chemicals */ 
/*   IF order IN (6 7 17 52 53 58 62 81 95 100) THEN DELETE;*/ 
   IF order IN ( 106 107) THEN DELETE; 
RUN; 
 
/* 6.1 Table with concordance of classifications */ 
PROC SORT data=WLV; BY laboratory name; RUN; 
PROC TRANSPOSE data=WLV out=pre6_1; 
   BY laboratory name order; 
   ID test; 
   VAR predINI; 
RUN; 
PROC FREQ data=WLV noprint; 
   TABLES predINI/out=pre6_1; 
   BY laboratory name order; 
RUN;  
DATA pre6_1b; 
   SET pre6_1; 
   IF percent NE 100 THEN WLV_concordant = 'NO '; 
   ELSE WLV_concordant = 'YES'; 
RUN; 
PROC SORT data=pre6_1b out=pre6_1c nodupkey; 
   BY laboratory name order; 
RUN; 
PROC FREQ data=pre6_1c noprint; 
   TABLES WLV_concordant/out=table6_1LAB; 
   BY laboratory;  
RUN; 
PROC FREQ data=pre6_1c noprint; 
   TABLES WLV_concordant/out=table6_1TOTAL; 
RUN; 
DATA table6_1; 
   SET table6_1LAB table6_1TOTAL(in=ok); 
   IF ok THEN laboratory = 'Total'; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\Revision\SkinEthic_Table6_1.doc' notoc_data; 
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PROC REPORT data=table6_1 NOWINDOWS HEADLINE HEADSKIP ; 
   COLUMNS laboratory WLV_concordant count percent; 
   DEFINE laboratory / GROUP width = 10; 
   DEFINE WLV_concordant / DISPLAY width=15 'WLV concordant'; 
   DEFINE count / DISPLAY FLOW 'No.'; 
   DEFINE percent / DISPLAY format=8.1 'Fraction(%)' width = 12; 
   BREAK after laboratory/SKIP; 
RUN; 
ODS RTF close;  
 
/* 6.2 Additional descriptives of non-concordant results */ 
DATA pre6_2; 
   MERGE WLV pre6_1c(keep = laboratory name order WLV_concordant); 
   BY laboratory name order; 
RUN; 
/* 16082012 CdJ revision */  
DATA pre6_2b; 
   SET pre6_2(where=(WLV_concordant = 'NO ')); 
   KEEP laboratory order name LS coloring MTT predGHS mean_viability test; 
RUN; 
PROC SORT data=pre6_2b; BY laboratory order name test; 
PROC TRANSPOSE data=pre6_2b out=pre6_2t(drop=_name_); 
   BY laboratory order name LS coloring mTT predGHS; 
   VAR mean_viability; 
   ID test; 
RUN; 
DATA table6_2; 
   RETAIN laboratory order name LS coloring mtt predGHS _1 _2 _3; 
   SET pre6_2t; 
RUN; 
* view in excel to create table for report; 
 
/* 6.3 Statement per laboratory regarding WLV */ 
DATA table6_3 ; 
   SET table6_1LAB table6_1TOTAL(in=total); 
   IF total THEN laboratory = 'Total'; 
   WHERE WLV_concordant = 'YES'; 
   WLV_criteria = 'not fulfilled'; 
   IF percent >= 85 THEN WLV_criteria = 'fulfilled'; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\REVISION\SkinEthic_Table6_3.doc' notoc_data; 
PROC REPORT data=table6_3 NOWINDOWS HEADLINE HEADSKIP ; 
   COLUMNS laboratory percent WLV_criteria; 
   DEFINE laboratory / GROUP width = 10; 
   DEFINE WLV_criteria / DISPLAY width=15 'Statement: criteria is '; 
   DEFINE percent / DISPLAY format=8.1 'Fraction(%)' width = 12; 
RUN; 
ODS RTF close;  
 
/* 6.4 Pearson Correlations */ 
PROC SORT data=WLV; BY laboratory name; RUN; 
PROC TRANSPOSE data=WLV out=WLVt; 
   BY laboratory name; 
   ID test; 
   VAR mean_viability; 
RUN; 
PROC CORR data=WLVt noprint outp=pearson outs=spearman; 
   VAR _1 _2 _3; 
   BY laboratory; 
RUN; 
/*PROC GPLOT data=WLVt; */ 
/*   PLOT _1 * _2 _1 * _3 _2 * _3;*/ 
/*   BY laboratory;*/ 
/*RUN; QUIT;*/ 
DATA set1 (keep=laboratory _name_ _1 where=(_name_ NE '_1'))  
     set2 (keep=laboratory _name_ _2 where=(_name_ NE '_2'))  ; 
   SET pearson; 
   WHERE _TYPE_ = 'CORR'; 
RUN; 
PROC TRANSPOSE data=set1 out=set1T(drop=_name_) prefix = _1; 
   VAR _1; 
   BY laboratory; 
   ID _name_; 
RUN; 
PROC TRANSPOSE data=set2 out=set2T(drop=_name_) prefix = _2; 
   VAR _2; 
   BY laboratory; 
   ID _name_; 
RUN; 
DATA pre_pearson(drop=_2_1); 
   MERGE set1T set2T; 
   BY laboratory; 
   FORMAT _1_2 _1_3 _2_3 8.3; 
RUN; 
 
DATA set1 (keep=laboratory _name_ _1 where=(_name_ NE '_1'))  
     set2 (keep=laboratory _name_ _2 where=(_name_ NE '_2'))  ; 
   SET spearman; 
   WHERE _TYPE_ = 'CORR'; 
RUN; 
PROC TRANSPOSE data=set1 out=set1T(drop=_name_) prefix = _1; 
   VAR _1; 
   BY laboratory; 
   ID _name_; 
RUN; 
PROC TRANSPOSE data=set2 out=set2T(drop=_name_) prefix = _2; 
   VAR _2; 
   BY laboratory; 
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   ID _name_; 
RUN; 
DATA pre_spearman(drop=_2_1); 
   MERGE set1T set2T; 
   BY laboratory; 




   SET pre_pearson (in=p) pre_spearman (in=s); 
   BY laboratory; 
   IF s THEN corr = 'spearman'; 
   IF p THEN corr = 'pearson'; 
RUN; 
PROC SORT data=pre6_4; BY corr; RUN; 
PROC MEANS data=pre6_4 noprint; 
   VAR _1_2 _1_3 _2_3; 
   BY corr; 





SET pre6_4 pre6_4b(in=m); 
   IF m THEN laboratory = 'Mean'; 
   IF laboratory = 'CARDAM' THEN tmp1 = 1; 
   IF laboratory = 'CEETOX' THEN tmp1 = 2; 
   IF laboratory = 'LOREAL' THEN tmp1 = 3; 
   IF laboratory = 'Mean' THEN tmp1 = 4; 
RUN;  
PROC SORT data=pretable6_4 out=table6_4(drop=tmp1 _type_ _freq_); BY corr tmp1; RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\REVISION\SkinEthic_Table6_4.doc' notoc_data; 
PROC REPORT data=table6_4 NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS corr laboratory _1_2 _1_3 _2_3; 
   DEFINE corr / GROUP; 
   DEFINE laboratory/DISPLAY width = 15; 
   DEFINE _1_2/ DISPLAY 'Qual1 - Qual2' format=8.3 width = 15 CENTER; 
   DEFINE _1_3/ DISPLAY 'Qual1 - Qual3' format=8.3 width = 15 CENTER; 
   DEFINE _2_3/ DISPLAY 'Qual2 - Qual3' format=8.3 width = 15 CENTER; 
   BREAK after corr/SKIP; 
RUN; QUIT; 
ODS RTF close; 
 
/* 6.5 mean and mean diff */ 
PROC MEANS data=WLV noprint; 
   VAR mean_viability; 
   CLASS laboratory name order;  
   OUTPUT out=table6_5(where=(_type_=7)) mean=means std=stds cv=cvs n=ns; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\Revision\SkinEthic_Table6_5.doc' notoc_data; 
PROC REPORT data=table6_5 NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS order laboratory,(means stds cvs ns); 
   DEFINE order / GROUP width = 5 'Chemical'; 
   DEFINE laboratory/ACROSS "_laboratory_"; 
   DEFINE means/ANALYSIS mean format=8.1 CENTER 'mean'; 
   DEFINE stds/ANALYSIS mean format=8.1 CENTER 'std'; 
   DEFINE cvs/ANALYSIS mean format=8.1 CENTER 'cv'; 
   DEFINE ns/ANALYSIS mean width=3 CENTER 'n'; 
RUN; QUIT; 
ODS RTF close; 
 
* also with non-qualified tests included; 
DATA inclnonqual; 
   SET pre_all_SE(where=(conclusion NE 2)); 
RUN; 
PROC MEANS data=inclnonqual noprint; 
   VAR mean_viability; 
   CLASS laboratory name order;  
   OUTPUT out=table6_5b(where=(_type_=7)) mean=meansnq std=stdsnq cv=cvsnq n=nsnq; 
RUN; 
DATA table6_5c; 
   MERGE table6_5 table6_5b; 
   BY laboratory name order; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\Revision\SkinEthic_Table6_5b.doc' notoc_data; 
PROC REPORT data=table6_5c NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS order laboratory,(("_Q_" stds cvs ns) ("_Q+NQ_" stdsnq cvsnq nsnq)); 
   DEFINE order / GROUP width = 5 'Chemical'; 
   DEFINE laboratory/ACROSS "_laboratory_"; 
   DEFINE stds/ANALYSIS mean format=8.1 CENTER 'std'; 
   DEFINE cvs/ANALYSIS mean format=8.1 CENTER 'cv'; 
   DEFINE ns/ANALYSIS mean width=3 CENTER 'n'; 
   DEFINE stdsnq/ANALYSIS mean format=8.1 CENTER 'std'; 
   DEFINE cvsnq/ANALYSIS mean format=8.1 CENTER 'cv'; 
   DEFINE nsnq/ANALYSIS mean width=3 CENTER 'n'; 
RUN; QUIT; 
ODS RTF close; 
/* --------------------------------------------- */ 
/* Section 7 of SAP: Interlaboratory variability */ 
/* --------------------------------------------- */ 
 
/* at least one qualified tests per laboratory*/ 
PROC SORT data=pre_all_SE; BY laboratory name; RUN; 
PROC FREQ data=pre_all_SE noprint; 
   TABLES conclusion/out=pre_BLV; 
   BY laboratory name; 
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RUN; 
DATA pre_BLV2; 
   SET pre_BLV (where=(conclusion IN (0 /*1*/) AND count >=1)); 
RUN; 
PROC SORT data=pre_BLV2 nodupkey; BY name laboratory; RUN: 
PROC TRANSPOSE data=pre_BLV2 out=pre_BLV2t; 
   VAR count;  
   ID laboratory; 
   BY name; 
RUN; 
DATA pre_BLV2t2; 
   SET pre_BLV2t; 
/*LABNAMES AANPASSEN*/ 
IF CARDAM IN (0 .) OR CEETOX IN (0 .) OR L_OREAL IN (0 .) THEN DELETE; 
RUN;  
PROC SORT data=pre_all_SE; BY name; RUN; 
DATA pre_BLV3; 
   MERGE pre_all_SE(drop=test where=(conclusion NOT IN (1 2) /*(2)*/)) pre_BLV2t2 (in=ok); 
   BY name; 
   IF ok; 
   IF mean_viability > 50 THEN predINI = 'NI'; 
   ELSE predINI = 'I'; 
RUN; 
PROC SORT data=pre_BLV3; BY laboratory name; RUN; 
DATA BLV;  
   SET pre_BLV3; 
   BY laboratory name; 
   RETAIN test 0; 
   test = test+1; 
   IF first.name THEN test=1; 
   IF test > 3 THEN DELETE; 
/*CHECK EXCLUDED CHEMS MET BOVEN*/ 
    IF order IN (106 107) THEN DELETE; 
RUN; 
 
/* 7.1 Table with means, std, cv and pred */ 
PROC MEANS data=BLV noprint; 
   CLASS laboratory name order; 
   VAR mean_viability; 
   OUTPUT out=pre7_1(where=(_type_ = 7)) mean = meanlab std = stdlab cv=cvlab n=nlab; 
RUN; 
PROC MEANS data=pre7_1 noprint; 
   CLASS name order; 
   VAR stdlab; 
   OUTPUT out=table7_1(where=(_type_ = 3)) mean = means std = stds cv=cvs n=ns; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\Revision\SkinEthic_Table7_1.doc' notoc_data; 
PROC REPORT data=table7_1 NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS order  means stds cvs; 
   DEFINE order / GROUP width = 5 'Chemical'; 
   DEFINE means/ANALYSIS mean format=8.1 CENTER 'mean SD'; 
   DEFINE stds/ANALYSIS mean format=8.1 CENTER 'std SD'; 
   DEFINE cvs/ANALYSIS mean format=8.1 CENTER 'cv SD'; 
RUN; QUIT; 
ODS RTF close; 
DATA table7_1b; 
   SET pre7_1; 
   IF meanlab > 50 THEN finalINI = 0; 
   ELSE finalINI = 1; 
   FORMAT finalINI fmtINI.; 
RUN; 
 
/* with NQ */ 
DATA pre_BLV3; 
   MERGE pre_all_SE(drop=test where=(conclusion NOT IN (2))) pre_BLV2t2 (in=ok); 
   BY name; 
   IF ok; 
   IF mean_viability > 50 THEN predINI = 'NI'; 
   ELSE predINI = 'I'; 
RUN; 
PROC SORT data=pre_BLV3; BY laboratory name; RUN; 
DATA BLVnq;  
   SET pre_BLV3; 
   BY laboratory name; 
   RETAIN test 0; 
   test = test+1; 
   IF first.name THEN test=1; 
/*CHECK EXCLUDED CHEMS MET BOVEN*/ 
    IF order IN (106 107) THEN DELETE; 
RUN; 
 
/* 7.1 Table with means, std, cv and pred with NQ*/ 
PROC MEANS data=BLVnq noprint; 
   CLASS laboratory name order; 
   VAR mean_viability; 
   OUTPUT out=pre7_1(where=(_type_ = 7)) mean = meanlab std = stdlab cv=cvlab n=nlab; 
RUN; 
PROC MEANS data=pre7_1 noprint; 
   CLASS name order; 
   VAR stdlab; 
   OUTPUT out=table7_1(where=(_type_ = 3)) mean = means std = stds cv=cvs n=ns; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\Revision\SkinEthic_Table7_1b.doc' notoc_data; 
PROC REPORT data=table7_1 NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS order  means stds cvs; 
   DEFINE order / GROUP width = 5 'Chemical'; 
   DEFINE means/ANALYSIS mean format=8.1 CENTER 'mean SD'; 
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   DEFINE stds/ANALYSIS mean format=8.1 CENTER 'std SD'; 
   DEFINE cvs/ANALYSIS mean format=8.1 CENTER 'cv SD'; 
RUN; QUIT; 
ODS RTF close; 
 
/* 7.2 concordance final classifications */ 
PROC SORT data=table7_1b out=pre7_2; BY name order; RUN; 
PROC FREQ data=pre7_2 noprint;  
   TABLES finalINI/out=pre7_2b; 
   BY name order; 
RUN; 
DATA pre7_2c; 
   SET pre7_2b; 
   IF percent NE 100 THEN BLV_concordant = 'NO '; 
   ELSE BLV_concordant = 'YES'; 
RUN; 
PROC SORT data=pre7_2c out=pre7_2d nodupkey; 
   BY name order;  
RUN; 
DATA pre7_2e; 
   MERGE pre7_2d pre7_2; 
   BY name order; 
RUN; 
PROC SORT data=BLV; BY laboratory name order; RUN; 
PROC SORT data=pre7_2e; BY laboratory name order; RUN; 
DATA pre7_2f; 
   MERGE BLV(where=(test=1)) pre7_2e(keep = laboratory name order BLV_concordant meanlab); 
   BY laboratory name order; 
RUN; 
DATA pre7_2g; 
   SET pre7_2f(where=(BLV_concordant = 'NO ')); 
   KEEP laboratory order name LS coloring MTT predGHS meanlab; 
RUN; 
PROC SORT data=pre7_2g; BY order name order name LS coloring mTT predGHS; RUN; 
PROC TRANSPOSE data=pre7_2g out=pre7_2t(drop=_name_); 
   BY order name LS coloring mTT predGHS; 
   VAR meanlab; 
   ID laboratory; 
RUN; 
DATA table7_2; 
   RETAIN order name LS coloring mtt predGHS CEETOX CARDAM L_OREAL; 
   SET pre7_2t; 
RUN; 
 
/* 7.3 descriptive statistics non-concordant results */ 
* see 7.2 ; 
 
 
/* 7.4 statement regarding BLV */ 
PROC FREQ data=pre7_2d; 
   TABLES BLV_concordant/out=tmp; 
RUN; 
DATA table7_4 ; 
   SET tmp; 
   WHERE BLV_concordant = 'YES'; 
   BLV_criteria = 'not fulfilled'; 
   IF percent >= 80 THEN BLV_criteria = 'fulfilled'; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\Revision\SkinEthic_Table7_4.doc' notoc_data; 
PROC REPORT data=table7_4 NOWINDOWS HEADLINE HEADSKIP ; 
   COLUMNS percent BLV_criteria; 
   DEFINE BLV_criteria / DISPLAY width=15 'Statement: criteria is '; 
   DEFINE percent / DISPLAY format=8.1 'Fraction(%)' width = 12; 
RUN; 
ODS RTF close;  
 
/* 7.5&7.6  Two-way ANOVA with laboratory and chemicals as factor */ 
DATA pre7_5; 
   SET pre7_1 (keep = laboratory name order meanlab); 
   IF meanlab NE 0 THEN meanlog = log(meanlab); * but analysed on original scale; 
RUN; 
ODS trace off; 
ODS listing close; 
PROC MIXED data=pre7_5; 
   CLASS laboratory name; 
   MODEL meanlab = laboratory name /outp=tmp1; 
   LSMEANS laboratory/pdiff cl adjust=tukey; 
   ODS OUTPUT tests3 = table7_5; 
   ODS OUTPUT lsmeans = table7_5partial; 
   ODS OUTPUT diffs = table7_6; 
   ODS OUTPUT covparms = covparms; 
RUN; 
ODS listing; 
PROC GPLOT data=tmp1; 
   PLOT resid * pred; 
RUN;QUIT; 
DATA pre7_5_nooutlier (drop=tmp0) table7_5_outliers(drop=tmp0); 
   MERGE tmp1 covparms; 
   RETAIN tmp0; 
   IF estimate NE . THEN tmp0 = estimate; ELSE estimate = tmp0; 
   IF abs(resid) <= 3*sqrt(estimate) THEN OUTPUT pre7_5_nooutlier;  
   ELSE OUTPUT table7_5_outliers; 
RUN; 
proc print data=table7_5_outliers; run; 
ODS listing close; 
PROC MIXED data=pre7_5_nooutlier; 
   CLASS laboratory name; 
   MODEL meanlab = laboratory name /outp=tmp1 ; 
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   LSMEANS laboratory/pdiff cl adjust=tukey alpha = 0.01; 
   ODS OUTPUT tests3 = table7_5; 
   ODS OUTPUT lsmeans = table7_5partial; 
   ODS OUTPUT diffs = table7_6; 
   ODS OUTPUT covparms = covparms; 
RUN; 
ODS listing; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\Revision\SkinEthic_Table7_5residualplot.doc' notoc_data; 
PROC GPLOT data=tmp1; 
   PLOT resid * pred; 
RUN;QUIT; 
ODS RTF close; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\Revision\SkinEthic_Table7_5.doc' notoc_data; 
PROC PRINT data=table7_5 NOOBS; RUN; 
ODS RTF close; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\Revision\SkinEthic_Table7_6.doc' notoc_data; 
PROC REPORT data=table7_6 NOWINDOWS HEADLINE HEADSKIP ; 
   COLUMNS laboratory _laboratory estimate stderr DF adjP; 
   DEFINE laboratory / DISPLAY; 
   DEFINE _laboratory /DISPLAY 'vs'; 
   DEFINE estimate/DISPLAY; 
   DEFINE stderr/DISPLAY; 
   DEFINE DF/DISPLAY; 
   DEFINE adjP/DISPLAY 'Tukey-corrected p-value' width=15; 
RUN; 
ODS RTF close; 
 
/* 7.7 Pearson correlations */ 
/* check labnames enzo hier beneden;*/ 
PROC SORT data=pre7_1; BY name; RUN; 
PROC TRANSPOSE data=pre7_1 out=pre7_7; 
   BY name; 
   ID laboratory; 
   VAR meanlab; 
RUN; 
PROC CORR data=pre7_7 noprint outp=pearson outs=spearman; 
VAR CEETOX CARDAM L_OREAL; 
RUN; 
/*PROC GPLOT data=pre7_7; */ 
/*   PLOT Beiersdorf * Harlan Beiersdorf * IIVS Harlan * IIVS;*/ 
/*RUN; QUIT;*/ 
DATA set1p (keep= _name_ CARDAM where=(_name_ NE 'CARDAM'))  
     set2p (keep= _name_ CEETOX where=(_name_ NE 'CEETOX'))  ; 
   SET pearson; 
   WHERE _TYPE_ = 'CORR'; 
RUN; 
DATA pre_pearson7_7(keep = laboratories pearson); 
   SET set1p(in=s1 rename=(CARDAM = pearson)) set2p(in=s2 rename=(CEETOX = pearson)); 
   IF s1 THEN with = 'CARDAM'; 
   IF s2 THEN with = 'CEETOX'; 
   IF _name_ = 'CARDAM' THEN DELETE; 
   Laboratories = TRIM(LEFT(with))||'-'||TRIM(LEFT(_name_)); 
RUN; 
DATA set1s (keep= _name_ CARDAM where=(_name_ NE 'CARDAM'))  
     set2s (keep= _name_ CEETOX where=(_name_ NE 'CEETOX'))  ; 
   SET spearman; 
   WHERE _TYPE_ = 'CORR'; 
RUN; 
DATA pre_spearman7_7(keep = laboratories spearman); 
   SET set1s(in=s1 rename=(CARDAM = spearman)) set2s(in=s2 rename=(CEETOX = spearman)); 
   IF s1 THEN with = 'CARDAM'; 
   IF s2 THEN with = 'CEETOX'; 
   IF _name_ = 'CARDAM' THEN DELETE; 
   Laboratories = TRIM(LEFT(with))||'-'||TRIM(LEFT(_name_)); 
RUN; 
DATA table7_7; 
   RETAIN laboratories pearson spearman; 
   MERGE pre_pearson7_7 pre_spearman7_7; 
   BY laboratories; 
   FORMAT pearson spearman 8.3; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\Revision\SkinEthic_Table7_7.doc' notoc_data; 
PROC REPORT data=table7_7 NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS laboratories pearson spearman; 
   DEFINE laboratories / DISPLAY; 
   DEFINE pearson/ DISPLAY  format=8.3 width = 15 CENTER; 
   DEFINE spearman/ DISPLAY format=8.3 width = 15 CENTER; 
RUN; QUIT; 
ODS RTF close; 
 
/* ------------------------------------- */ 
/* Section 8 of SAP: Predictive capacity */ 
/* ------------------------------------- */ 
 
PROC SORT data= pre_all_SE; BY laboratory name; RUN; 
DATA PCA; 
   SET pre_all_SE (drop=test); 
   BY laboratory name; 
   WHERE conclusion = 0; 
   RETAIN test 0; 
   test = test+1; 
   IF first.name THEN test=1; 
   IF test>3 THEN DELETE; 
   IF mean_viability > 50 THEN predINI = 'NI'; 
   ELSE predINI = 'I'; 
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RUN; 
/* 8.1 sens, spec, acc */ 
%MACRO predmodel(lab=, output=); 
DATA pre8_1; 
   SET PCA; 
   %IF &lab NE %THEN %DO; 
      WHERE laboratory = &lab; 
   %END; 
   IF trueINI = 'I' THEN DO; 
      IF predINI = 'I' THEN result = 'TP'; 
   ELSE IF predINI = 'NI' THEN result = 'FN'; 
   END; 
   ELSE IF trueINI = 'NI' THEN DO; 
      IF predINI = 'NI' THEN result = 'TN'; 
   ELSE IF predINI = 'I' THEN result = 'FP'; 
   END; 
RUN; 
PROC SORT data=pre8_1; 
   BY trueINI predINI; 
RUN; 
DATA pre8_1b (drop=result); 
   SET pre8_1; 
   BY trueINI; 
   retain tp tn fp fn; 
   if (first.trueINI) then do; 
      tp=0; tn=0; fp=0; fn=0; 
   end; 
   if (result in ("TP")) then tp=tp+1; 
   if (result in ("TN")) then tn=tn+1; 
   if (result in ("FN")) then fn=fn+1; 
   if (result in ("FP")) then fp=fp+1; 
   else ; 
   if (last.trueINI) then output; 
run; 
DATA pre8_1C; 
   SET pre8_1B; 
   tntp=tn+tp; 
   fnfp=fn+fp; 
RUN; 
PROC SQL; 
   CREATE TABLE pre8_1D as 
   select sum(tp) as tp, sum(tn) as tn, sum(fp)as fp, sum(fn) as fn, sum(tntp) as 
          tntp, sum(fnfp) as fnfp 
   from pre8_1C; 
QUIT; 
PROC SQL; 
   CREATE TABLE pre8_1E as 
   select tp/(tp+fn) as sensitivity, tn/(tn+fp) as specificity, 
         (tn+tp)/(tn+tp+fn+fp) as accuracy 
    from pre8_1D; 
QUIT; 
PROC TRANSPOSE data=pre8_1D out=pre8_1F; 
   VAR tp tn fn fp tntp fnfp; 
RUN; 
DATA pre8_1G (drop=_name_ col1); 
   LENGTH group $20; 
   SET pre8_1F; 
   count=col1; 
   if _name_="tp" then do; 
      group="Sensitivity"; 
      response=0; 
      output; 
   end; 
   else if _name_="fn" then do; 
      group="Sensitivity"; 
      response=1; 
      output; 
   end; 
   else if _name_="tn" then do; 
      group="Specificity"; 
      response=0; 
      output; 
   end; 
   else if _name_="fp" then do; 
      group="Specificity"; 
      response=1; 
      output; 
   end; 
   else if _name_="tntp" then do; 
      group="Accuracy"; 
      response=0; 
      output; 
   end; 
   else if _name_="fnfp" then do; 
      group="Accuracy"; 
      response=1; 
      output; 
   end; 
RUN; 
PROC SORT data=pre8_1G; BY group; RUN; 
ODS trace off; 
ODS listing close; 
PROC FREQ data= pre8_1G; 
   WEIGHT count; 
   BY group; 
   TABLES response/alpha=0.05 binomial(p=0.5); 
   exact binomial; 
   ODS OUTPUT BinomialProp = pre8_1CI; 
RUN; 
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ODS listing; 
DATA pre8_1TOTAL; 
   SET pre8_1CI; 
   WHERE name1 IN ('_BIN_' 'XL_BIN' 'XU_BIN'); 
RUN; 
PROC TRANSPOSE data=pre8_1TOTAL out=pre8_1TOTALt; 
   VAR nvalue1; 
   ID name1; 
   BY group; 
RUN; 
PROC TRANSPOSE data=pre8_1G out=pre8_1H; 
   VAR count; 
   ID response; 
   BY group; 
RUN; 
DATA &output; 
   MERGE pre8_1TOTALt pre8_1H; 








DATA table8_1 (keep = group laboratory _BIN_ XL_BIN XU_BIN abs abs2); 
   SET table8_1ceetox (in=set1) table8_1cardam (in=set2) 
       table8_1loreal (in=set3) table8_1TOTAL (in=set4); 
   IF set1 THEN laboratory = 'CEETOX'; 
   IF set2 THEN laboratory = 'CARDAM'; 
   IF set3 THEN laboratory = "L'Oreal"; 
   IF set4 THEN laboratory = 'Total'; 
   x = PUT(_1,$3.); 
   y = PUT(_0+_1,$3.); 
   z = PUT(_0,$3.); 
   abs = x||'/'||y; 
   abs2 = z||'/'||y; 
RUN; 
* report @8.2; 
 
/* 8.2 statement regarding predictive capacity */ 
DATA table8_2; 
   SET table8_1; 
   LENGTH PC_criteria $25; 
   IF group = 'Sensitivity' THEN DO; 
      PC_criteria = 'further evaluation'; 
      IF _BIN_ >= 0.90 THEN PC_criteria = 'definitely acceptable'; 
      IF _BIN_ <= 0.80 THEN PC_criteria = 'definitely unacceptable'; 
   END; 
   IF group = 'Specificity' THEN DO; 
      PC_criteria = 'further evaluation'; 
      IF _BIN_ >= 0.60 THEN PC_criteria = 'definitely acceptable'; 
      IF _BIN_ <= 0.50 THEN PC_criteria = 'definitely unacceptable'; 
   END; 
   IF group = 'Accuracy' THEN DO; 
      PC_criteria = 'further evaluation'; 
      IF _BIN_ >= 0.75 THEN PC_criteria = 'definitely acceptable'; 
      IF _BIN_ <= 0.65 THEN PC_criteria = 'definitely unacceptable'; 
   END; 
RUN; 
 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\Revision\SkinEthic_Table8_1.doc' notoc_data; 
PROC REPORT data=table8_2 NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS laboratory group abs2 _BIN_ XL_BIN XU_BIN PC_criteria; 
   DEFINE laboratory/GROUP; 
   DEFINE group/DISPLAY 'Characteristic' width = 15;  
   DEFINE abs2/DISPLAY 'No.'; 
   DEFINE _BIN_/DISPLAY 'Value' format=8.3 CENTER; 
   DEFINE XL_BIN/DISPLAY '95% lower limit'  format=8.3 width=15 CENTER; 
   DEFINE XU_BIN/DISPLAY '95% upper limit' format=8.3 width=15 CENTER; 
   DEFINE PC_criteria/DISPLAY 'Statement' width = 25; 
   BREAK after laboratory/SKIP; 
RUN; QUIT; 
ODS RTF close; 
 
 * falsepos/falseneg; 
PROC SORT data=PCA; BY order predGHS; RUN; 
DATA PCA2; 
   SET PCA; 
   IF predINI = 'NI' THEN value = 0; 
   ELSE value = 1; 
   IF trueINI = 'NI' THEN true = 0; 
   ELSE true = 1; 
   mis=0; 
   IF value = 1 AND true = 0 THEN mis = 1; 
   IF value = 0 AND true = 1 THEN mis = 1; 
RUN; 
PROC TRANSPOSE data=PCA2(where=(laboratory = 'CARDAM')) out=extra1a prefix=B; 
   VAR value; 
   BY order name predGHS LS; 
   ID test; 
RUN; 
PROC TRANSPOSE data=PCA2(where=(laboratory = 'CEETOX')) out=extra1b prefix=H; 
   VAR value; 
   BY order name predGHS LS; 
   ID test; 
RUN; 
PROC TRANSPOSE data=PCA2(where=(laboratory = "L'OREAL")) out=extra1c prefix=V; 
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   VAR value; 
   BY order name predGHS LS; 
   ID test; 
RUN; 
PROC TRANSPOSE data=PCA2(where=(laboratory = 'CARDAM')) out=extra1d prefix=misB; 
   VAR mis; 
   BY order name predGHS LS; 
   ID test; 
RUN; 
PROC TRANSPOSE data=PCA2(where=(laboratory = 'CEETOX')) out=extra1e prefix=misH; 
   VAR mis; 
   BY order name predGHS LS; 
   ID test; 
RUN; 
PROC TRANSPOSE data=PCA2(where=(laboratory = "L'OREAL")) out=extra1f prefix=misV; 
   VAR mis; 
   BY order name predGHS LS; 
   ID test; 
RUN; 
PROC SORT data=PCA2 out=PCA2b nodupkey; BY order; RUN; 
PROC TRANSPOSE data=PCA2b out=extra1g; 
   VAR true; 
   BY order name; 
RUN; 
DATA extra1; 
   MERGE extra1a extra1b extra1c extra1d extra1e extra1f extra1g; 
   BY order name; 
   med = MEDIAN(B1,B2,B3,H1,H2,H3,V1,V2,V3); 
   summis = SUM(misB1,misB2,misB3,misH1,misH2,misH3,misV1,misV2,misV3); 
   mis = '*'||TRIM(LEFT(PUT(summis,best12.)))||'/9'; 
   IF order = 20 THEN DO; 
         med = MEDIAN(H1,H2,H3,V1,V2,V3); 
         summis = SUM(misH1,misH2,misH3,misV1,misV2,misV3); 
         mis = '*'||TRIM(LEFT(PUT(summis,best12.)))||'/6'; 
   END; 
   IF order = 91 THEN DO; 
         med = MEDIAN(B1,B2,B3,V1,V2,V3); 
         summis = SUM(misB1,misB2,misB3,misV1,misV2,misV3); 
         mis = '*'||TRIM(LEFT(PUT(summis,best12.)))||'/6'; 
   END; 
   FORMAT B1--V3 med fmtini.; 
   label mis = 'Mispredicted tests/Total' 
    med = 'Final classification based on median'; 
RUN; 
PROC SORT data=extra1; 
   BY order; 
RUN; 
 
/* === */ 
/* LE  */ 
/* === */ 
 
PROC SORT data=pre_all_LE; BY chemical_code; RUN; 
DATA rules; 
   SET pre_all_LE; 
   BY chemical_code; 
   if conclusion = 1 /* non-qual */ then delete; 
   IF mean_viability >50 THEN pred50=0; 
   ELSE pred50 = 1; 
   IF mean_TA >50 THEN pred50raw=0; 
   ELSE pred50raw = 1; 
   FORMAT pred50  pred50raw  fmtpred.;   
   IF filename = '' then delete; 
RUN; 
DATA rules2; 
    SET rules; 
 BY chemical_code; 
   RETAIN t 0; 
   t = t+1; 
   IF first.chemical_code THEN t=1; 
   IF t>3 then delete; 
RUN; 
PROC SORT data=rules2; BY order  laboratory  ; RUN; 
PROC TRANSPOSE data=rules2 out=allT1 prefix=p50_; 
   VAR pred50; 
   BY order  laboratory  ; 
   ID t; 
RUN;  
PROC TRANSPOSE data=rules2 out=allT1raw prefix=p50r_; 
   VAR pred50raw; 
   BY order  laboratory  ; 
   ID t; 
RUN;  
PROC TRANSPOSE data=rules2 out=allT3 prefix=v_; 
   VAR mean_viability; 
   BY order  laboratory  ; 
   ID t; 
RUN;  
PROC TRANSPOSE data=rules2 out=allT4 prefix=TA_; 
   VAR mean_TA; 
   BY order  laboratory  ; 
   ID t; 
RUN;  
PROC TRANSPOSE data=rules2 out=allT5 prefix=CC_; 
   VAR mean_NSC; 
   BY order  laboratory  ; 
   ID t; 
RUN;  
PROC TRANSPOSE data=rules2 out=allT6 prefix=KC_; 
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   VAR mean_NSMTT; 
   BY order  laboratory  ; 
   ID t; 
RUN;  
DATA overall (drop=_name_); 
   MERGE allT1  allT1raw allT3 allT4 allT5 allT6; 
   BY order  laboratory  ; 
RUN; 
PROC SORT data=overall; BY laboratory order; RUN; 
DATA rules3_no rules3_yes; 
   SET overall; 
   mean_nsc=mean(CC_1,CC_2,CC_3); 
   mean_mtt=mean(KC_1,KC_2,KC_3); 
   * rule 1 - IF mean (%NSC or %NSMTT) of all qualified tests obtained for a chemical in one laboratory 
is less than or equal to (=) 50%,  
   THEN this chemical is considered to be compatible with the test method. The chemical should be 
included in the overview tables, 
   and included in all statistical calculations of reproducibility and predictive capacity.; 
   if mean_nsc NE . then do; 
  IF mean_nsc <= 50 THEN DO; inclusion50_nsc = 'yes'; inclusion60_nsc = 'yes'; END; 
   end; 
   if mean_mtt NE . then do; 
  IF mean_mtt<=50 THEN DO; inclusion50_mtt = 'yes'; inclusion60_mtt = 'yes'; END; 
   end; 
  * rule 2 - IF mean (%NSC or %NSMTT) of all qualified tests obtained for a chemical in one laboratory 
is greater than (>) 50% AND  
  their classification (I or NI) remains the same upon correction, THEN this chemical is considered to 
be compatible with the test  
  method. The chemical should be included in the overview tables, and included in all statistical 
calculations of reproducibility and 
  predictive capacity.; 
   if mean_nsc NE . then do; 
  IF mean_nsc > 50 AND p50_1=p50r_1 AND  p50_2=p50r_2 AND p50_3=p50r_3 THEN inclusion50_nsc = 'yes'; 
   end; 
   if mean_mtt NE . then do; 
  IF mean_mtt > 50 AND p50_1=p50r_1 AND  p50_2=p50r_2 AND p50_3=p50r_3 THEN inclusion50_mtt = 'yes'; 
   end; 
  * rule 3 - IF mean (%NSC or %NSMTT) of all qualified tests obtained for a chemical in one laboratory 
is greater than (>) 50% AND 
  the classification of at least one of the qualified tests changes upon correction, THEN this chemical 
is considered to be  
  incompatible with the test method. The chemical should be included in the overview tables, but 
excluded from all statistical  
  calculations of reproducibility and predictive capacity.; 
   if mean_nsc NE . then do; 
  IF mean_nsc > 50 AND (p50_1 NE p50r_1 OR  p50_2 NE p50r_2 OR p50_3 NE p50r_3) THEN inclusion50_nsc = 
'no'; 
   end; 
   if mean_mtt NE . then do; 
  IF mean_mtt > 50 AND (p50_1 NE p50r_1 OR  p50_2 NE p50r_2 OR p50_3 NE p50r_3) THEN inclusion50_mtt = 
'no'; 
   end; 
  * output; 
  IF inclusion50_nsc = 'no' OR inclusion50_mtt = 'no' OR inclusion60_nsc = 'no' OR inclusion60_mtt = 
'no' THEN OUTPUT rules3_no; 
  ELSE OUTPUT rules3_yes;  
RUN; 
/* CONCLUSION */ 
/* new rules give selection : chemical 4 (cardam and ceetox) and 80 (ceetox) */ 
 
DATA select (keep = order laboratory run conclusion); 
   SET pre_all_LE; 
   IF order IN (4 80) OR conclusion IN (1 2) THEN OUTPUT; 
RUN; 
DATA pre_all_LE; 
   SET pre_all_LE; 
   /* remove chemical 106 and 107 for statistical analysis */ 
   IF chemical_code IN ('L6' 'C52' 'X95') THEN DELETE; * 106; 
   IF chemical_code IN ('L100'  'C56' 'X32') THEN DELETE; * 107; 
   IF laboratory = '' THEN DELETE; 
   IF pcqual = 1 THEN conclusion = 1; 
   IF ncqual = 1 then conclusion = 1; 
   if qual_sd = 1 then conclusion = 1; 
   /* for some chemicals the VMG overrode the 50% rule regarding NSMTT */ 
   *IF chemical_code IN ('L140' 'C128' 'X139') then conclusion = 0; * 23; 
      IF chemical_code IN ('C6' 'X31') and NCqual NE 1 AND PCqual NE 1 AND qual_sd NE 1 then conclusion 
= 0; * 80; 
   IF chemical_code IN ('C6' 'X31') and (NCqual EQ 1 OR PCqual EQ 1 OR qual_sd EQ 1) then conclusion 
= 1; * 80; 
      IF chemical_code IN ('X62' 'C53') and NCqual NE 1 AND PCqual NE 1 AND qual_sd NE 1 then 
conclusion = 0; * 4; 
      IF chemical_code IN ('X62' 'C53') and  (NCqual EQ 1 OR PCqual EQ 1 OR qual_sd EQ 1) then 
conclusion = 1; * 4; 
      IF chemical_code IN ('L58' 'C58') and NCqual NE 1 AND PCqual NE 1 AND qual_sd NE 1 then 
conclusion = 0; * 20; 
      IF chemical_code IN ('L58' 'C58') and (NCqual EQ 1 OR PCqual EQ 1 OR qual_sd EQ 1) then 
conclusion = 1; * 20; 
RUN; 
data select; 
   set pre_all_le; 
*   where chemical_code = 'X31'; 
    where conclusion = 2; 
run; 
PROC SORT data=RhT.LE2 out=ODnc(keep = laboratory run chemical_code meanODnc) nodupkey; 
   BY laboratory run chemical_code; 
   where chemical_code NE 'PC'; 
RUN; 
PROC SORT data=pre_all_LE; BY laboratory run chemical_code; RUN; 
DATA pre_all_LE; 
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   MERGE pre_all_LE (in=ok) ODnc; 
   BY laboratory run chemical_code; 
   IF ok; 
RUN; 
PROC SORT data=pre_all_LE; BY chemical_code; RUN;  
 
* Table 3.2.2 - MTT and colouring differences  
* some chemicals are treated differently by the labs concerning the coloring or mtt; 
PROC SORT data=pre_all_LE out=extra0s (keep = order name laboratory mtt coloring where=(laboratory NE 
'')) nodupkey; 
   BY order laboratory mtt coloring; 
RUN; 
PROC TRANSPOSE data=extra0s out=extra0a; 
   VAR mtt; 
   BY order name; 
   ID laboratory; 
RUN;  
DATA extra0_mtt(keep = order name L_oreal ceetox cardam mttcheck) ; 
   SET extra0a ; 
   BY order; 
   mttcheck = 'not ok'; 
   IF l_oreal = ceetox AND L_oreal = cardam and cardam = ceetox THEN mttcheck = ' '; 
   ELSE mttcheck = '#'; 
   *IF mttcheck = 'not ok' THEN OUTPUT; 
RUN; 
PROC TRANSPOSE data=extra0s out=extra0b; 
   VAR coloring; 
   BY order name; 
   ID laboratory; 
RUN;  
DATA extra0_color( keep = order name L_oreal ceetox cardam colorcheck); 
   SET  extra0b; 
   BY order; 
   colorcheck = 'not ok'; 
   IF l_oreal = ceetox AND L_oreal = cardam and cardam = ceetox THEN colorcheck = ' '; 
   ELSE colorcheck = '#'; 
   *IF colorcheck = 'not ok' THEN OUTPUT; 
RUN; 
 
/* non-qual NC and PC */ 
PROC SORT data=pre_all_LE out=pre412 nodupkey; BY filename; RUN; 
PROC FREQ data=pre412 ; 
   TABLE laboratory*NCqual/out=table412_NC NOCOL NOPERCENT; 
   TABLE laboratory*PCqual/out=table412_PC NOCOL NOPERCENT; 
RUN; 
PROC TRANSPOSE data=table412_NC out=table412NCt; 
   VAR count; 
   ID NCqual; 
   BY laboratory; 
RUN; 
PROC TRANSPOSE data=table412_PC out=table412PCt; 
   VAR count; 
   ID PCqual; 
   BY laboratory; 
RUN; 
DATA table412; 
   SET table412NCt(in=nc) table412PCt(in=pc); 
   BY laboratory; 
   IF nc THEN var = 'NC'; 
   IF pc THEN var = 'PC'; 
   IF non_qualified = . THEN non_qualified = 0; 
   fraction_nq = 100* non_qualified/(non_qualified+qualified); 
   fraction_q = 100*qualified/(non_qualified+qualified); 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\Revision\SkinEthicLE_Table412.doc' notoc_data; 
PROC REPORT data = table412 NOWINDOWS HEADLINE HEADSKIP; 
   COLUMN laboratory var qualified fraction_q non_qualified fraction_nq; 
   DEFINE laboratory/GROUP; 
   DEFINE var/DISPLAY ' '; 
   DEFINE qualified/DISPLAY 'No.Qualified' width = 12 CENTER; 
   DEFINE fraction_q/DISPLAY '%' width = 5 format=8.1 CENTER; 
   DEFINE non_qualified/DISPLAY 'No.Non-Qualified' width = 16 CENTER; 
   DEFINE fraction_nq/DISPLAY '%' width = 5 format=8.1 CENTER; 
RUN; QUIT; 
ODS rtf close; 
 
/* 5.2 Table with number and fraction of qualified and non_qualified runs */ 
PROC SORT data=pre_all_LE; BY laboratory; RUN; 
PROC FREQ data=pre_all_LE noprint; 
   TABLES conclusion/out=table5_2LAB; 
   BY laboratory; 
RUN; 
PROC FREQ data=pre_all_LE noprint; 
   TABLES conclusion/out=table5_2TOTAL; 
RUN; 
DATA table5_2; 
   SET table5_2LAB table5_2TOTAL (in=ok); 
   IF ok THEN laboratory = 'Total'; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\REVISION\SkinEthicLE_Table5_2.doc' notoc_data; 
PROC REPORT data = table5_2 NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS laboratory conclusion count percent; 
   DEFINE laboratory/GROUP; 
   DEFINE conclusion /DISPLAY 'Call'; 
   DEFINE count/ DISPLAY 'No.'; 
   DEFINE percent/DISPLAY width = 15 format=8.1 'Fraction (%)'; 
RUN;QUIT; 
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ODS RTF close; 
 
OPTIONS PS=42 LS=120; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\REVISION\SkinEthicLE_Table5_2LIST.doc' notoc_data; 
PROC REPORT data=pre_all_LE (where=(conclusion IN (1 2)) keep = run order conclusion laboratory name 
qual_sd PCqual NCqual NSCcall NSMTTcall) 
            NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS conclusion laboratory order run NCqual PCqual qual_sd  NSCcall NSMTTcall; 
   DEFINE conclusion / GROUP width = 15; 
   DEFINE laboratory / GROUP width = 15; 
   DEFINE order/DISPLAY width = 4 'Chemical'; 
   DEFINE NSCcall/DISPLAY width = 12; 
   BREAK after laboratory/SKIP; 
RUN; QUIT; 
ODS RTF close;  
 
/* 5.4 Table with number of tests within each test sequence */ 
OPTIONS PS=55 LS=80; 
PROC SORT data=pre_all_LE; BY laboratory tmp2 run; RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\REVISION\SkinEthicLE_Table5_4.doc' notoc_data; 
PROC FREQ data=pre_all_LE ; 
   TABLES order*laboratory/out=table5_4 NOROW NOCOL NOPERCENT; 
RUN; 
ODS RTF close; 
* 106 en 107; 
data chem106_107; 
   set rht.LE_meanviabilities_locked; 
   IF chemical_code IN ('L6' 'C52' 'X95' 'L100' 'C56' 'X32') THEN output;  
run; 
data chem106_107; 
   set rht.SE_meanviabilities_locked; 
   IF chemical_code IN ('L6' 'C52' 'X95' 'L100' 'C56' 'X32') THEN output;  
run; 
/* 5.5 Table with list, no and fraction of NQ tests */ 
PROC SORT data=pre_all_LE; BY laboratory order; RUN; 
PROC FREQ data=pre_all_LE NOPRINT; 
   TABLES conclusion/out=table5_5; 
   BY laboratory order; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\REVISION\SkinEthicLE_Table5_5.doc' notoc_data; 
PROC PRINT data=table5_5(WHERE=(CONCLUSION IN (1 2))); RUN; 
ODS RTF close; 
 
/* 5.6 Table with list and fraction of complete test sequences */ 
DATA pre5_6; 
   SET pre_all_LE; 
   IF conclusion IN (1 2) THEN DELETE; 
RUN; 
PROC FREQ data=pre5_6 noprint; 
   TABLES laboratory * order/out=pre5_6b; 
RUN; 
DATA table5_6LIST; 
   SET pre5_6b; 
   IF count >=3 THEN OUTPUT; 
RUN; 
PROC SORT data=pre5_6b; BY order; RUN; 
PROC TRANSPOSE data=pre5_6b out=table5_6LIST; 
   VAR COUNT; 
   ID laboratory; 
   BY order; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\REVISION\SkinEthicLE_Table5_6LIST.doc' notoc_data; 
PROC PRINT data=table5_6LIST; RUN; 
ODS RTF close; 
 
PROC FREQ data=table5_6LIST noprint;   TABLES CARDAM /out=table5_6B1; RUN; 
PROC FREQ data=table5_6LIST noprint;   TABLES CEETOX /out=table5_6B2; RUN; 
PROC FREQ data=table5_6LIST noprint;   TABLES L_OREAL /out=table5_6B3; RUN; 
DATA table5_6C; 
   SET table5_6B1 (in=s1 rename=(cardam = aantal))  
       table5_6B2  (in=s2 rename=(ceetox = aantal)) 
       table5_6B3  (in=s3 rename=(l_oreal = aantal)); 
   if s1 then lab = 'CARDAM'; 
   if s2 then lab = 'CEETOX'; 
   if s3 then lab = 'LOREAL'; 
   IF aantal >2 THEN OUTPUT; 
RUN; 
PROC MEANS data=table5_6C noprint; 
   VAR count; 
   BY lab; 
   OUTPUT out=table5_6D sum=sums; 
RUN; 
DATA table5_6LAB; 
   SET table5_6D; 
   fraction_complete = 100*sums/104; 
   test_sequence_criteria = 'not fulfilled'; 
   IF fraction_complete > 85 THEN test_sequence_criteria = 'fulfilled'; 
RUN; 
PROC MEANS data=table5_6LAB NOPRINT; 
   VAR sums; 
   OUTPUT out=table5_6D sum=sumcount; 
RUN; 
DATA table5_6OVERALL; 
   SET table5_6D; 
   fraction_complete = 100*sumcount/(3*104); 
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   test_sequence_criteria = 'not fulfilled'; 
   IF fraction_complete >= 85 THEN test_sequence_criteria = 'fulfilled'; 
RUN; 
DATA table5_6; 
   SET table5_6LAB table5_6OVERALL(in=ok); 
   IF ok then laboratory = 'Total'; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\Revision\SkinEthicLE_Table5_6.doc' notoc_data; 
PROC REPORT data = table5_6 NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS laboratory fraction_complete; 
   DEFINE laboratory/DISPLAY; 
   DEFINE fraction_complete/DISPLAY format=8.1 'Fraction'; 
RUN; QUIT; 
ODS rtf close; 
PROC DATASETS library = work; 
   DELETE pre5_6 pre5_6b table5_6B table5_6D; 
RUN;QUIT; 
 
/* 5.7 Table with list and fraction of incomplete test sequences */ 
 
DATA pre5_7a pre5_7b; 
   SET pre_all_LE; 
   IF conclusion IN (1 2) THEN output pre5_7a; 
   IF conclusion NOT IN (1 2) THEN output pre5_7b; 
RUN; 
PROC FREQ data=pre5_7a noprint; 
   TABLES laboratory * order/out=pre5_7a2; 
RUN; 
PROC FREQ data=pre5_7b noprint; 
   TABLES laboratory * order/out=pre5_7b2; 
RUN; 
DATA pre5_7; 
   MERGE pre5_7a2(rename=(count=OUT)) pre5_7b2(rename=(count=IN)); 
   BY laboratory order; 
   IF IN NOT IN (. 0 1 2) THEN complete = 'Yes'; 
   IF IN IN (. 0 1 2) THEN complete = 'No'; 
RUN; 
DATA table5_7LIST; 
   SET pre5_7; 
   IF IN = . THEN IN = 0; 
   IF complete = 'No' THEN OUTPUT; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\Revision\SkinEthicLE_Table5_7LIST.doc' notoc_data; 
PROC REPORT data = table5_7LIST NOWINDOWS HEADLINE HEADSKIP; 
   COLUMN laboratory order IN OUT; 
   DEFINE laboratory/GROUP; 
   DEFINE order /DISPLAY ; 
   DEFINE IN/DISPLAY 'Qualified' width = 10 CENTER; 
   DEFINE OUT/DISPLAY 'Non-Qual or Excluded' width = 20 CENTER; 
RUN; QUIT; 
ODS RTF close; 
PROC FREQ data=table5_7LIST noprint; 
   TABLES laboratory/out=table5_7b; 
RUN; 
DATA table5_7LAB; 
   SET table5_7B; 
   fraction_incomplete = 100*count/104; 
   test_sequence_criteria = 'fulfilled'; 
   IF fraction_incomplete > 15 THEN test_sequence_criteria = 'not fulfilled'; 
RUN; 
PROC MEANS data=table5_7LAB NOPRINT; 
   VAR count; 
   OUTPUT out=table5_7D sum=sumcount; 
RUN; 
DATA table5_7OVERALL; 
   SET table5_7D; 
   fraction_incomplete = 100*sumcount/(3*104); 
   test_sequence_criteria = 'fulfilled'; 
   IF fraction_incomplete > 15 THEN test_sequence_criteria = 'not fulfilled'; 
RUN; 
DATA table5_7; 
   SET table5_7LAB table5_7OVERALL(in=ok); 
   IF ok then laboratory = 'Total'; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\Revision\SkinEthicLE_Table5_7.doc' notoc_data; 
PROC REPORT data = table5_7 NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS laboratory fraction_incomplete; 
   DEFINE laboratory/DISPLAY; 
   DEFINE fraction_incomplete/DISPLAY format=8.1 'Fraction'; 
RUN; QUIT; 
ODS rtf close;  
PROC DATASETS library = work; 
   DELETE pre5_7 pre5_7b table5_7B table5_7D; 
RUN;QUIT;  
 
/* 5.8 statement whether test method has fulfilled the performance criteria */ 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\SkinEthicLE_Table5_8.doc' notoc_data; 
PROC REPORT data = table5_6 NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS laboratory fraction_complete test_sequence_criteria; 
   DEFINE laboratory/DISPLAY; 
   DEFINE fraction_complete/DISPLAY format=8.1 'Fraction'; 
   DEFINE test_sequence_criteria/DISPLAY 'Statement: criteria is ' CENTER; 
RUN; QUIT; 
ODS rtf close; 
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/* 5.10 summarise results of all tests (including NQ and excl) */ 
DATA appVI (keep=laboratory order predGHS MTT coloring test meanODnc stdNC NCqual meanPC sdPC PCqual 
          mean_TA std_TA qual_sd mean_NSC mean_NSMTT mean_viability conclusion pred50); 
   RETAIN laboratory order predGHS MTT coloring test meanODnc stdNC NCqual meanPC sdPC PCqual 
          mean_TA std_TA qual_sd mean_NSC mean_NSMTT mean_viability conclusion pred50; 
   SET pre_all_LE; 
   IF mean_viability > 50 THEN pred50 = 'NI'; 
   ELSE pred50 = 'I'; 
RUN;  
PROC SORT data=appVI; BY laboratory order test; RUN; 
 
  
/* --------------------------------------------- */ 
/* Section 6 of SAP: Intralaboratory variability */ 
/* --------------------------------------------- */ 
 
/* at least two qualified tests */ 
PROC SORT data=pre_all_LE; BY laboratory name; RUN; 
PROC FREQ data=pre_all_LE noprint; 
   TABLES conclusion/out=pre_WLV; 
   BY laboratory name; 
RUN; 
DATA pre_WLV2; 
   SET pre_WLV (where=(conclusion = 0 AND count >=2)); 
RUN; 
DATA pre_WLV3; 
   MERGE pre_all_LE(drop=test where=(conclusion NOT IN (1 2))) pre_WLV2 (in=ok); 
   BY laboratory name; 
   IF ok; 
   IF mean_viability > 50 THEN predINI = 'NI'; 
   ELSE predINI = 'I'; 
RUN; 
DATA WLV;  
   SET pre_WLV3; 
   BY laboratory name; 
   RETAIN test 0; 
   test = test+1; 
   IF first.name THEN test=1; 
   IF test > 3 THEN DELETE; 
/* check mean viability dataset op excluded chemicals, pas daarop nummers hieronder aan */ 
   /* exclude chemicals */ 
/*   IF order IN (6 7 17 52 53 58 62 81 95 100) THEN DELETE;*/ 
   IF order IN (106 107) THEN DELETE; 
RUN; 
/* 6.1 Table with concordance of classifications */ 
PROC SORT data=WLV; BY laboratory name; RUN; 
PROC TRANSPOSE data=WLV out=pre6_1; 
   BY laboratory name order; 
   ID test; 
   VAR predINI; 
RUN; 
PROC FREQ data=WLV noprint; 
   TABLES predINI/out=pre6_1; 
   BY laboratory name order; 
RUN;  
DATA pre6_1b; 
   SET pre6_1; 
   IF percent NE 100 THEN WLV_concordant = 'NO '; 
   ELSE WLV_concordant = 'YES'; 
RUN; 
PROC SORT data=pre6_1b out=pre6_1c nodupkey; 
   BY laboratory name order; 
RUN; 
PROC FREQ data=pre6_1c noprint; 
   TABLES WLV_concordant/out=table6_1LAB; 
   BY laboratory;  
RUN; 
PROC FREQ data=pre6_1c noprint; 
   TABLES WLV_concordant/out=table6_1TOTAL; 
RUN; 
DATA table6_1; 
   SET table6_1LAB table6_1TOTAL(in=ok); 
   IF ok THEN laboratory = 'Total'; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\Revision\SkinEthicLE_Table6_1.doc' notoc_data; 
PROC REPORT data=table6_1 NOWINDOWS HEADLINE HEADSKIP ; 
   COLUMNS laboratory WLV_concordant count percent; 
   DEFINE laboratory / GROUP width = 10; 
   DEFINE WLV_concordant / DISPLAY width=15 'WLV concordant'; 
   DEFINE count / DISPLAY FLOW 'No.'; 
   DEFINE percent / DISPLAY format=8.1 'Fraction(%)' width = 12; 
   BREAK after laboratory/SKIP; 
RUN; 
ODS RTF close;  
 
/* 6.2 Additional descriptives of non-concordant results */ 
DATA pre6_2; 
   MERGE WLV pre6_1c(keep = laboratory name order WLV_concordant); 
   BY laboratory name order; 
RUN; 
/* 16082012 CdJ revision */  
DATA pre6_2b; 
   SET pre6_2(where=(WLV_concordant = 'NO ')); 
   KEEP laboratory order name LS coloring MTT predGHS mean_viability test; 
RUN; 
PROC SORT data=pre6_2b; BY laboratory order name test; 
PROC TRANSPOSE data=pre6_2b out=pre6_2t(drop=_name_); 
   BY laboratory order name LS coloring mTT predGHS; 
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   VAR mean_viability; 
   ID test; 
RUN; 
DATA table6_2; 
   RETAIN laboratory order name LS coloring mtt predGHS _1 _2 _3; 
   SET pre6_2t; 
RUN; 
* view in excel to create table for report; 
 
/* 6.3 Statement per laboratory regarding WLV */ 
DATA table6_3 ; 
   SET table6_1LAB table6_1TOTAL(in=total); 
   IF total THEN laboratory = 'Total'; 
   WHERE WLV_concordant = 'YES'; 
   WLV_criteria = 'not fulfilled'; 
   IF percent >= 85 THEN WLV_criteria = 'fulfilled'; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\REVISION\SkinEthicLE_Table6_3.doc' notoc_data; 
PROC REPORT data=table6_3 NOWINDOWS HEADLINE HEADSKIP ; 
   COLUMNS laboratory percent WLV_criteria; 
   DEFINE laboratory / GROUP width = 10; 
   DEFINE WLV_criteria / DISPLAY width=15 'Statement: criteria is '; 
   DEFINE percent / DISPLAY format=8.1 'Fraction(%)' width = 12; 
RUN; 
ODS RTF close;  
 
/* 6.4 Pearson Correlations */ 
PROC SORT data=WLV; BY laboratory name; RUN; 
PROC TRANSPOSE data=WLV out=WLVt; 
   BY laboratory name; 
   ID test; 
   VAR mean_viability; 
RUN; 
PROC CORR data=WLVt noprint outp=pearson outs=spearman; 
   VAR _1 _2 _3; 
   BY laboratory; 
RUN; 
/*PROC GPLOT data=WLVt; */ 
/*   PLOT _1 * _2 _1 * _3 _2 * _3;*/ 
/*   BY laboratory;*/ 
/*RUN; QUIT;*/ 
DATA set1 (keep=laboratory _name_ _1 where=(_name_ NE '_1'))  
     set2 (keep=laboratory _name_ _2 where=(_name_ NE '_2'))  ; 
   SET pearson; 
   WHERE _TYPE_ = 'CORR'; 
RUN; 
PROC TRANSPOSE data=set1 out=set1T(drop=_name_) prefix = _1; 
   VAR _1; 
   BY laboratory; 
   ID _name_; 
RUN; 
PROC TRANSPOSE data=set2 out=set2T(drop=_name_) prefix = _2; 
   VAR _2; 
   BY laboratory; 
   ID _name_; 
RUN; 
DATA pre_pearson(drop=_2_1); 
   MERGE set1T set2T; 
   BY laboratory; 
   FORMAT _1_2 _1_3 _2_3 8.3; 
RUN; 
 
DATA set1 (keep=laboratory _name_ _1 where=(_name_ NE '_1'))  
     set2 (keep=laboratory _name_ _2 where=(_name_ NE '_2'))  ; 
   SET spearman; 
   WHERE _TYPE_ = 'CORR'; 
RUN; 
PROC TRANSPOSE data=set1 out=set1T(drop=_name_) prefix = _1; 
   VAR _1; 
   BY laboratory; 
   ID _name_; 
RUN; 
PROC TRANSPOSE data=set2 out=set2T(drop=_name_) prefix = _2; 
   VAR _2; 
   BY laboratory; 
   ID _name_; 
RUN; 
DATA pre_spearman(drop=_2_1); 
   MERGE set1T set2T; 
   BY laboratory; 




   SET pre_pearson (in=p) pre_spearman (in=s); 
   BY laboratory; 
   IF s THEN corr = 'spearman'; 
   IF p THEN corr = 'pearson'; 
RUN; 
PROC SORT data=pre6_4; BY corr; RUN; 
PROC MEANS data=pre6_4 noprint; 
   VAR _1_2 _1_3 _2_3; 
   BY corr; 
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SET pre6_4 pre6_4b(in=m); 
   IF m THEN laboratory = 'Mean'; 
   IF laboratory = 'CARDAM' THEN tmp1 = 1; 
   IF laboratory = 'CEETOX' THEN tmp1 = 2; 
   IF laboratory = 'LOREAL' THEN tmp1 = 3; 
   IF laboratory = 'Mean' THEN tmp1 = 4; 
RUN;  
PROC SORT data=pretable6_4 out=table6_4(drop=tmp1 _type_ _freq_); BY corr tmp1; RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\REVISION\SkinEthicLE_Table6_4.doc' notoc_data; 
PROC REPORT data=table6_4 NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS corr laboratory _1_2 _1_3 _2_3; 
   DEFINE corr / GROUP; 
   DEFINE laboratory/DISPLAY width = 15; 
   DEFINE _1_2/ DISPLAY 'Qual1 - Qual2' format=8.3 width = 15 CENTER; 
   DEFINE _1_3/ DISPLAY 'Qual1 - Qual3' format=8.3 width = 15 CENTER; 
   DEFINE _2_3/ DISPLAY 'Qual2 - Qual3' format=8.3 width = 15 CENTER; 
   BREAK after corr/SKIP; 
RUN; QUIT; 
ODS RTF close; 
 
/* 6.5 mean and mean diff */ 
PROC MEANS data=WLV noprint; 
   VAR mean_viability; 
   CLASS laboratory name order;  
   OUTPUT out=table6_5(where=(_type_=7)) mean=means std=stds cv=cvs n=ns; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\Revision\SkinEthicLE_Table6_5.doc' notoc_data; 
PROC REPORT data=table6_5 NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS order laboratory,(means stds cvs ns); 
   DEFINE order / GROUP width = 5 'Chemical'; 
   DEFINE laboratory/ACROSS "_laboratory_"; 
   DEFINE means/ANALYSIS mean format=8.1 CENTER 'mean'; 
   DEFINE stds/ANALYSIS mean format=8.1 CENTER 'std'; 
   DEFINE cvs/ANALYSIS mean format=8.1 CENTER 'cv'; 
   DEFINE ns/ANALYSIS mean width=3 CENTER 'n'; 
RUN; QUIT; 
ODS RTF close; 
 
* also with non-qualified tests included; 
DATA inclnonqual; 
   SET pre_all_LE(where=(conclusion NE 2)); 
   IF conclusion = 1 and mean_viability = 0 and std_viability = 0 THEN DO; 
      IF mean_TA NE 0 THEN mean_viability = mean_TA; 
   IF std_TA NE 0 THEN std_viability = std_TA; 
   IF mean_MTT ne 0 THEN mean_viability = mean_TA - mean_MTT; 
   IF mean_TA = . THEN mean_viability = . ; 
   IF std_TA = . THEN std_viability = .; 
   END; 
   IF mean_viability = 0 AND std_viability = . THEN DELETE; 
   IF mean_viability = . THEN DELETE; 
RUN; 
PROC MEANS data=inclnonqual noprint; 
   VAR mean_viability; 
   CLASS laboratory name order;  
   OUTPUT out=table6_5b(where=(_type_=7)) mean=meansnq std=stdsnq cv=cvsnq n=nsnq; 
RUN; 
DATA table6_5c; 
   MERGE table6_5 table6_5b; 
   BY laboratory name order; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\Revision\SkinEthicLE_Table6_5b.doc' notoc_data; 
PROC REPORT data=table6_5c NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS order laboratory,(("_Q_" stds cvs ns) ("_Q+NQ_" stdsnq cvsnq nsnq)); 
   DEFINE order / GROUP width = 5 'Chemical'; 
   DEFINE laboratory/ACROSS "_laboratory_"; 
   DEFINE stds/ANALYSIS mean format=8.1 CENTER 'std'; 
   DEFINE cvs/ANALYSIS mean format=8.1 CENTER 'cv'; 
   DEFINE ns/ANALYSIS mean width=3 CENTER 'n'; 
   DEFINE stdsnq/ANALYSIS mean format=8.1 CENTER 'std'; 
   DEFINE cvsnq/ANALYSIS mean format=8.1 CENTER 'cv'; 
   DEFINE nsnq/ANALYSIS mean width=3 CENTER 'n'; 
RUN; QUIT; 
ODS RTF close; 
/* --------------------------------------------- */ 
/* Section 7 of SAP: Interlaboratory variability */ 
/* --------------------------------------------- */ 
 
/* at least one qualified tests per laboratory*/ 
PROC SORT data=pre_all_LE; BY laboratory name; RUN; 
PROC FREQ data=pre_all_LE noprint; 
   TABLES conclusion/out=pre_BLV; 
   BY laboratory name; 
RUN; 
DATA pre_BLV2; 
   SET pre_BLV (where=(conclusion = 0 AND count >=1)); 
RUN; 
PROC SORT data=pre_BLV2; BY name; RUN: 
PROC TRANSPOSE data=pre_BLV2 out=pre_BLV2t; 
   VAR count;  
   ID laboratory; 
   BY name; 
RUN; 
DATA pre_BLV2t2; 
   SET pre_BLV2t; 
/*LABNAMES AANPASSEN*/ 
IF CARDAM IN (0 .) OR CEETOX IN (0 .) OR L_OREAL IN (0 .) THEN DELETE; 
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RUN;  
PROC SORT data=pre_all_LE; BY name; RUN; 
DATA pre_BLV3; 
   MERGE pre_all_LE(drop=test where=(conclusion NOT IN (1 2))) pre_BLV2t2 (in=ok); 
   BY name; 
   IF ok; 
   IF mean_viability > 50 THEN predINI = 'NI'; 
   ELSE predINI = 'I'; 
RUN; 
PROC SORT data=pre_BLV3; BY laboratory name; RUN; 
DATA BLV;  
   SET pre_BLV3; 
   BY laboratory name; 
   RETAIN test 0; 
   test = test+1; 
   IF first.name THEN test=1; 
   IF test > 3 THEN DELETE; 
/*CHECK EXCLUDED CHEMS MET BOVEN*/ 
    IF order IN (106 107) THEN DELETE; 
RUN; 
 
/* 7.1 Table with means, std, cv and pred */ 
PROC MEANS data=BLV noprint; 
   CLASS laboratory name order; 
   VAR mean_viability; 
   OUTPUT out=pre7_1(where=(_type_ = 7)) mean = meanlab std = stdlab cv=cvlab n=nlab; 
RUN; 
PROC MEANS data=pre7_1 noprint; 
   CLASS name order; 
   VAR stdlab; 
   OUTPUT out=table7_1(where=(_type_ = 3)) mean = means std = stds cv=cvs n=ns; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\Revision\SkinEthicLE_Table7_1.doc' notoc_data; 
PROC REPORT data=table7_1 NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS order  means stds cvs; 
   DEFINE order / GROUP width = 5 'Chemical'; 
   DEFINE means/ANALYSIS mean format=8.1 CENTER 'mean SD'; 
   DEFINE stds/ANALYSIS mean format=8.1 CENTER 'std SD'; 
   DEFINE cvs/ANALYSIS mean format=8.1 CENTER 'cv SD'; 
RUN; QUIT; 
ODS RTF close; 
DATA table7_1b; 
   SET pre7_1; 
   IF meanlab > 50 THEN finalINI = 0; 
   ELSE finalINI = 1; 




/* with NQ */ 
PROC SORT data=pre_all_LE; BY laboratory name; RUN; 
PROC FREQ data=pre_all_LE noprint; 
   TABLES conclusion/out=pre_BLV; 
   BY laboratory name; 
RUN; 
DATA pre_BLV2; 
   SET pre_BLV (where=(conclusion = 0 AND count >=1)); 
RUN; 
PROC SORT data=pre_BLV2; BY name; RUN: 
PROC TRANSPOSE data=pre_BLV2 out=pre_BLV2t; 
   VAR count;  
   ID laboratory; 
   BY name; 
RUN; 
DATA pre_BLV2t2; 
   SET pre_BLV2t; 
/*LABNAMES AANPASSEN*/ 
IF CARDAM IN (0 .) OR CEETOX IN (0 .) OR L_OREAL IN (0 .) THEN DELETE; 
RUN;  
PROC SORT data=pre_all_LE; BY name; RUN; 
DATA pre_BLV3; 
   MERGE pre_all_LE(drop=test where=(conclusion NOT IN ( 2))) pre_BLV2t2 (in=ok); 
   BY name; 
   IF ok; 
   IF mean_viability > 50 THEN predINI = 'NI'; 
   ELSE predINI = 'I'; 
RUN; 
PROC SORT data=pre_BLV3; BY laboratory name; RUN; 
DATA BLVnq;  
   SET pre_BLV3; 
   BY laboratory name; 
   RETAIN test 0; 
   test = test+1; 
   IF first.name THEN test=1; 
 *  IF test > 3 THEN DELETE; 
/*CHECK EXCLUDED CHEMS MET BOVEN*/ 
    IF order IN (106 107) THEN DELETE; 
   IF conclusion = 1 and mean_viability = 0 and std_viability = 0 THEN DO; 
      IF mean_TA NE 0 THEN mean_viability = mean_TA; 
   IF std_TA NE 0 THEN std_viability = std_TA; 
   IF mean_MTT ne 0 THEN mean_viability = mean_TA - mean_MTT; 
   IF mean_TA = . THEN mean_viability = . ; 
   IF std_TA = . THEN std_viability = .; 
   END; 
   IF mean_viability = 0 AND std_viability = . THEN DELETE; 
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/* 7.1 Table with means, std, cv and pred */ 
PROC MEANS data=BLVnq noprint; 
   CLASS laboratory name order; 
   VAR mean_viability; 
   OUTPUT out=pre7_1(where=(_type_ = 7)) mean = meanlab std = stdlab cv=cvlab n=nlab; 
RUN; 
PROC MEANS data=pre7_1 noprint; 
   CLASS name order; 
   VAR stdlab; 
   OUTPUT out=table7_1(where=(_type_ = 3)) mean = means std = stds cv=cvs n=ns; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\Revision\SkinEthicLE_Table7_1b.doc' notoc_data; 
PROC REPORT data=table7_1 NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS order  means stds cvs; 
   DEFINE order / GROUP width = 5 'Chemical'; 
   DEFINE means/ANALYSIS mean format=8.1 CENTER 'mean SD'; 
   DEFINE stds/ANALYSIS mean format=8.1 CENTER 'std SD'; 
   DEFINE cvs/ANALYSIS mean format=8.1 CENTER 'cv SD'; 
RUN; QUIT; 
ODS RTF close; 
 
/* 7.2 concordance final classifications */ 
PROC SORT data=table7_1b out=pre7_2; BY name order; RUN; 
PROC FREQ data=pre7_2 noprint;  
   TABLES finalINI/out=pre7_2b; 
   BY name order; 
RUN; 
DATA pre7_2c; 
   SET pre7_2b; 
   IF percent NE 100 THEN BLV_concordant = 'NO '; 
   ELSE BLV_concordant = 'YES'; 
RUN; 
PROC SORT data=pre7_2c out=pre7_2d nodupkey; 
   BY name order;  
RUN; 
DATA pre7_2e; 
   MERGE pre7_2d pre7_2; 
   BY name order; 
RUN; 
PROC SORT data=BLV; BY laboratory name order; RUN; 
PROC SORT data=pre7_2e; BY laboratory name order; RUN; 
DATA pre7_2f; 
   MERGE BLV(where=(test=1)) pre7_2e(keep = laboratory name order BLV_concordant meanlab); 
   BY laboratory name order; 
RUN; 
DATA pre7_2g; 
   SET pre7_2f(where=(BLV_concordant = 'NO ')); 
   KEEP laboratory order name LS coloring MTT predGHS meanlab; 
RUN; 
PROC SORT data=pre7_2g; BY order name order name LS coloring mTT predGHS; RUN; 
PROC TRANSPOSE data=pre7_2g out=pre7_2t(drop=_name_); 
   BY order name LS coloring mTT predGHS; 
   VAR meanlab; 
   ID laboratory; 
RUN; 
DATA table7_2; 
   RETAIN order name LS coloring mtt predGHS CEETOX CARDAM L_OREAL; 
   SET pre7_2t; 
RUN; 
 
/* 7.3 descriptive statistics non-concordant results */ 
* see 7.2 ; 
 
/* 7.4 statement regarding BLV */ 
PROC FREQ data=pre7_2d; 
   TABLES BLV_concordant/out=tmp; 
RUN; 
DATA table7_4 ; 
   SET tmp; 
   WHERE BLV_concordant = 'YES'; 
   BLV_criteria = 'not fulfilled'; 
   IF percent >= 80 THEN BLV_criteria = 'fulfilled'; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\Revision\SkinEthicLE_Table7_4.doc' notoc_data; 
PROC REPORT data=table7_4 NOWINDOWS HEADLINE HEADSKIP ; 
   COLUMNS percent BLV_criteria; 
   DEFINE BLV_criteria / DISPLAY width=15 'Statement: criteria is '; 
   DEFINE percent / DISPLAY format=8.1 'Fraction(%)' width = 12; 
RUN; 
ODS RTF close;  
 
/* 7.5&7.6  Two-way ANOVA with laboratory and chemicals as factor */ 
DATA pre7_5; 
   SET pre7_1 (keep = laboratory name order meanlab); 
   IF meanlab NE 0 THEN meanlog = log(meanlab);  
RUN; 
ODS trace off; 
ODS listing close; 
PROC MIXED data=pre7_5; 
   CLASS laboratory name; 
   MODEL meanlog = laboratory name /outp=tmp1; 
   LSMEANS laboratory/pdiff cl adjust=tukey; 
   ODS OUTPUT tests3 = table7_5; 
   ODS OUTPUT lsmeans = table7_5partial; 
   ODS OUTPUT diffs = table7_6; 
   ODS OUTPUT covparms = covparms; 
RUN; 
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ODS listing; 
PROC GPLOT data=tmp1; 
   PLOT resid * pred; 
RUN;QUIT; 
DATA pre7_5_nooutlier (drop=tmp0) table7_5_outliers(drop=tmp0); 
   MERGE tmp1 covparms; 
   RETAIN tmp0; 
   IF estimate NE . THEN tmp0 = estimate; ELSE estimate = tmp0; 
   IF abs(resid) <= 3*sqrt(estimate) THEN OUTPUT pre7_5_nooutlier;  
   ELSE OUTPUT table7_5_outliers; 
RUN; 
 
proc print data=table7_5_outliers; run; 
ODS listing close; 
PROC MIXED data=pre7_5_nooutlier; 
   CLASS laboratory name; 
   MODEL meanlab = laboratory name /outp=tmp1 ; 
   LSMEANS laboratory/pdiff cl adjust=tukey alpha = 0.01; 
   ODS OUTPUT tests3 = table7_5; 
   ODS OUTPUT lsmeans = table7_5partial; 
   ODS OUTPUT diffs = table7_6; 
   ODS OUTPUT covparms = covparms; 
RUN; 
ODS listing; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\Revision\SkinEthicLE_Table7_5residualplot.doc' notoc_data; 
PROC GPLOT data=tmp1; 
   PLOT resid * pred; 
RUN;QUIT; 
ODS RTF close; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\Revision\SkinEthicLE_Table7_5.doc' notoc_data; 
PROC PRINT data=table7_5 NOOBS; RUN; 
ODS RTF close; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\Revision\SkinEthicLE_Table7_6.doc' notoc_data; 
PROC REPORT data=table7_6 NOWINDOWS HEADLINE HEADSKIP ; 
   COLUMNS laboratory _laboratory estimate stderr DF adjP; 
   DEFINE laboratory / DISPLAY; 
   DEFINE _laboratory /DISPLAY 'vs'; 
   DEFINE estimate/DISPLAY; 
   DEFINE stderr/DISPLAY; 
   DEFINE DF/DISPLAY; 
   DEFINE adjP/DISPLAY 'Tukey-corrected p-value' width=15; 
RUN; 
ODS RTF close; 
 
/* 7.7 Pearson correlations */ 
/* check labnames enzo hier beneden;*/ 
PROC SORT data=pre7_1; BY name; RUN; 
PROC TRANSPOSE data=pre7_1 out=pre7_7; 
   BY name; 
   ID laboratory; 
   VAR meanlab; 
RUN; 
PROC CORR data=pre7_7 noprint outp=pearson outs=spearman; 
VAR CEETOX CARDAM L_OREAL; 
RUN; 
/*PROC GPLOT data=pre7_7; */ 
/*   PLOT Beiersdorf * Harlan Beiersdorf * IIVS Harlan * IIVS;*/ 
/*RUN; QUIT;*/ 
DATA set1p (keep= _name_ CARDAM where=(_name_ NE 'CARDAM'))  
     set2p (keep= _name_ CEETOX where=(_name_ NE 'CEETOX'))  ; 
   SET pearson; 
   WHERE _TYPE_ = 'CORR'; 
RUN; 
DATA pre_pearson7_7(keep = laboratories pearson); 
   SET set1p(in=s1 rename=(CARDAM = pearson)) set2p(in=s2 rename=(CEETOX = pearson)); 
   IF s1 THEN with = 'CARDAM'; 
   IF s2 THEN with = 'CEETOX'; 
   IF _name_ = 'CARDAM' THEN DELETE; 
   Laboratories = TRIM(LEFT(with))||'-'||TRIM(LEFT(_name_)); 
RUN; 
DATA set1s (keep= _name_ CARDAM where=(_name_ NE 'CARDAM'))  
     set2s (keep= _name_ CEETOX where=(_name_ NE 'CEETOX'))  ; 
   SET spearman; 
   WHERE _TYPE_ = 'CORR'; 
RUN; 
DATA pre_spearman7_7(keep = laboratories spearman); 
   SET set1s(in=s1 rename=(CARDAM = spearman)) set2s(in=s2 rename=(CEETOX = spearman)); 
   IF s1 THEN with = 'CARDAM'; 
   IF s2 THEN with = 'CEETOX'; 
   IF _name_ = 'CARDAM' THEN DELETE; 
   Laboratories = TRIM(LEFT(with))||'-'||TRIM(LEFT(_name_)); 
RUN; 
DATA table7_7; 
   RETAIN laboratories pearson spearman; 
   MERGE pre_pearson7_7 pre_spearman7_7; 
   BY laboratories; 
   FORMAT pearson spearman 8.3; 
RUN; 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\Revision\SkinEthicLE_Table7_7.doc' notoc_data; 
PROC REPORT data=table7_7 NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS laboratories pearson spearman; 
   DEFINE laboratories / DISPLAY; 
   DEFINE pearson/ DISPLAY  format=8.3 width = 15 CENTER; 
   DEFINE spearman/ DISPLAY format=8.3 width = 15 CENTER; 
RUN; QUIT; 
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ODS RTF close; 
 
/* ------------------------------------- */ 
/* Section 8 of SAP: Predictive capacity */ 
/* ------------------------------------- */ 
 
PROC SORT data= pre_all_LE; BY laboratory name; RUN; 
DATA PCA; 
   SET pre_all_LE (drop=test); 
   BY laboratory name; 
   WHERE conclusion = 0; 
   RETAIN test 0; 
   test = test+1; 
   IF first.name THEN test=1; 
   IF test>3 THEN DELETE; 
   IF mean_viability > 50 THEN predINI = 'NI'; 
   ELSE predINI = 'I'; 
RUN; 
/* 8.1 sens, spec, acc */ 
%MACRO predmodel(lab=, output=); 
DATA pre8_1; 
   SET PCA; 
   %IF &lab NE %THEN %DO; 
      WHERE laboratory = &lab; 
   %END; 
   IF trueINI = 'I' THEN DO; 
      IF predINI = 'I' THEN result = 'TP'; 
   ELSE IF predINI = 'NI' THEN result = 'FN'; 
   END; 
   ELSE IF trueINI = 'NI' THEN DO; 
      IF predINI = 'NI' THEN result = 'TN'; 
   ELSE IF predINI = 'I' THEN result = 'FP'; 
   END; 
RUN; 
PROC SORT data=pre8_1; 
   BY trueINI predINI; 
RUN; 
DATA pre8_1b (drop=result); 
   SET pre8_1; 
   BY trueINI; 
   retain tp tn fp fn; 
   if (first.trueINI) then do; 
      tp=0; tn=0; fp=0; fn=0; 
   end; 
   if (result in ("TP")) then tp=tp+1; 
   if (result in ("TN")) then tn=tn+1; 
   if (result in ("FN")) then fn=fn+1; 
   if (result in ("FP")) then fp=fp+1; 
   else ; 
   if (last.trueINI) then output; 
run; 
DATA pre8_1C; 
   SET pre8_1B; 
   tntp=tn+tp; 
   fnfp=fn+fp; 
RUN; 
PROC SQL; 
   CREATE TABLE pre8_1D as 
   select sum(tp) as tp, sum(tn) as tn, sum(fp)as fp, sum(fn) as fn, sum(tntp) as 
          tntp, sum(fnfp) as fnfp 
   from pre8_1C; 
QUIT; 
PROC SQL; 
   CREATE TABLE pre8_1E as 
   select tp/(tp+fn) as sensitivity, tn/(tn+fp) as specificity, 
         (tn+tp)/(tn+tp+fn+fp) as accuracy 
    from pre8_1D; 
QUIT; 
PROC TRANSPOSE data=pre8_1D out=pre8_1F; 
   VAR tp tn fn fp tntp fnfp; 
RUN; 
DATA pre8_1G (drop=_name_ col1); 
   LENGTH group $20; 
   SET pre8_1F; 
   count=col1; 
   if _name_="tp" then do; 
      group="Sensitivity"; 
      response=0; 
      output; 
   end; 
   else if _name_="fn" then do; 
      group="Sensitivity"; 
      response=1; 
      output; 
   end; 
   else if _name_="tn" then do; 
      group="Specificity"; 
      response=0; 
      output; 
   end; 
   else if _name_="fp" then do; 
      group="Specificity"; 
      response=1; 
      output; 
   end; 
   else if _name_="tntp" then do; 
      group="Accuracy"; 
      response=0; 
      output; 
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   end; 
   else if _name_="fnfp" then do; 
      group="Accuracy"; 
      response=1; 
      output; 
   end; 
RUN; 
PROC SORT data=pre8_1G; BY group; RUN; 
ODS trace off; 
ODS listing close; 
PROC FREQ data= pre8_1G; 
   WEIGHT count; 
   BY group; 
   TABLES response/alpha=0.05 binomial(p=0.5); 
   exact binomial; 




   SET pre8_1CI; 
   WHERE name1 IN ('_BIN_' 'XL_BIN' 'XU_BIN'); 
RUN; 
PROC TRANSPOSE data=pre8_1TOTAL out=pre8_1TOTALt; 
   VAR nvalue1; 
   ID name1; 
   BY group; 
RUN; 
PROC TRANSPOSE data=pre8_1G out=pre8_1H; 
   VAR count; 
   ID response; 
   BY group; 
RUN; 
DATA &output; 
   MERGE pre8_1TOTALt pre8_1H; 








DATA table8_1 (keep = group laboratory _BIN_ XL_BIN XU_BIN abs abs2); 
   SET table8_1ceetox (in=set1) table8_1cardam (in=set2) 
       table8_1loreal (in=set3) table8_1TOTAL (in=set4); 
   IF set1 THEN laboratory = 'CEETOX'; 
   IF set2 THEN laboratory = 'CARDAM'; 
   IF set3 THEN laboratory = "L'Oreal"; 
   IF set4 THEN laboratory = 'Total'; 
   z = PUT(_0,$3.); 
   x = PUT(_1,$3.); 
   y = PUT(_0+_1,$3.); 
   abs = x||'/'||y; 
   abs2 = z||'/'||y; 
RUN; 
* report @8.2; 
 
/* 8.2 statement regarding predictive capacity */ 
DATA table8_2; 
   SET table8_1; 
   LENGTH PC_criteria $25; 
   IF group = 'Sensitivity' THEN DO; 
      PC_criteria = 'further evaluation'; 
      IF _BIN_ >= 0.90 THEN PC_criteria = 'definitely acceptable'; 
      IF _BIN_ <= 0.80 THEN PC_criteria = 'definitely unacceptable'; 
   END; 
   IF group = 'Specificity' THEN DO; 
      PC_criteria = 'further evaluation'; 
      IF _BIN_ >= 0.60 THEN PC_criteria = 'definitely acceptable'; 
      IF _BIN_ <= 0.50 THEN PC_criteria = 'definitely unacceptable'; 
   END; 
   IF group = 'Accuracy' THEN DO; 
      PC_criteria = 'further evaluation'; 
      IF _BIN_ >= 0.75 THEN PC_criteria = 'definitely acceptable'; 
      IF _BIN_ <= 0.65 THEN PC_criteria = 'definitely unacceptable'; 
   END; 
RUN; 
 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\Revision\SkinEthicLE_Table8_1.doc' notoc_data; 
PROC REPORT data=table8_2 NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS laboratory group abs2 _BIN_ XL_BIN XU_BIN PC_criteria; 
   DEFINE laboratory/GROUP; 
   DEFINE group/DISPLAY 'Characteristic' width = 15;  
   DEFINE abs2/DISPLAY 'No.'; 
   DEFINE _BIN_/DISPLAY 'Value' format=8.3 CENTER; 
   DEFINE XL_BIN/DISPLAY '95% lower limit'  format=8.3 width=15 CENTER; 
   DEFINE XU_BIN/DISPLAY '95% upper limit' format=8.3 width=15 CENTER; 
   DEFINE PC_criteria/DISPLAY 'Statement' width = 25; 
   BREAK after laboratory/SKIP; 
RUN; QUIT; 
ODS RTF close; 
 
 * falsepos/falseneg; 
PROC SORT data=PCA; BY order predGHS; RUN; 
DATA PCA2; 
   SET PCA; 
   IF predINI = 'NI' THEN value = 0; 
   ELSE value = 1; 
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   IF trueINI = 'NI' THEN true = 0; 
   ELSE true = 1; 
   mis=0; 
   IF value = 1 AND true = 0 THEN mis = 1; 
   IF value = 0 AND true = 1 THEN mis = 1; 
RUN; 
PROC TRANSPOSE data=PCA2(where=(laboratory = 'CARDAM')) out=extra1a prefix=B; 
   VAR value; 
   BY order name predGHS LS; 
   ID test; 
RUN; 
PROC TRANSPOSE data=PCA2(where=(laboratory = 'CEETOX')) out=extra1b prefix=H; 
   VAR value; 
   BY order name predGHS LS; 
   ID test; 
RUN; 
PROC TRANSPOSE data=PCA2(where=(laboratory = "L'OREAL")) out=extra1c prefix=V; 
   VAR value; 
   BY order name predGHS LS; 
   ID test; 
RUN; 
PROC TRANSPOSE data=PCA2(where=(laboratory = 'CARDAM')) out=extra1d prefix=misB; 
   VAR mis; 
   BY order name predGHS LS; 
   ID test; 
RUN; 
PROC TRANSPOSE data=PCA2(where=(laboratory = 'CEETOX')) out=extra1e prefix=misH; 
   VAR mis; 
   BY order name predGHS LS; 
   ID test; 
RUN; 
PROC TRANSPOSE data=PCA2(where=(laboratory = "L'OREAL")) out=extra1f prefix=misV; 
   VAR mis; 
   BY order name predGHS LS; 
   ID test; 
RUN; 
PROC SORT data=PCA2 out=PCA2b nodupkey; BY order; RUN; 
PROC TRANSPOSE data=PCA2b out=extra1g; 
   VAR true; 
   BY order name; 
RUN; 
DATA extra1; 
   MERGE extra1a extra1b extra1c extra1d extra1e extra1f extra1g; 
   BY order name; 
   med = MEDIAN(B1,B2,B3,H1,H2,H3,V1,V2,V3); 
   summis = SUM(misB1,misB2,misB3,misH1,misH2,misH3,misV1,misV2,misV3); 
   mis = '*'||TRIM(LEFT(PUT(summis,best12.)))||'/9'; 
   FORMAT B1--V3 med fmtini.; 
   label mis = 'Mispredicted tests/Total' 
    med = 'Final classification based on median'; 
RUN; 
PROC SORT data=extra1; 




/* ------------------------------------- */ 
/* Section 8 of SAP: Predictive capacity */ 
/* Based on test strategy      */ 
/* ------------------------------------- */ 
 
PROC SORT data= pre_all_LE; BY laboratory name; RUN; 
PROC SORT data= pre_all_SE; BY laboratory name; RUN; 
DATA pre_all_test; 
   SET pre_all_LE pre_all_SE; 
   IF keuze = '' THEN DELETE; 
RUN; 
 
PROC SORT data=pre_all_test nodupkey out=sele(keep = order keuze trueINI); BY order; RUN; 
PROC FREQ data=sele(where=(order NOT IN (106 107))); 
tables trueINI*keuze; 
run; 
PROC SORT data=pre_all_test; BY laboratory name; RUN; 
DATA PCA(where=(order NOT IN (106 107))); 
   SET pre_all_test (drop=test); 
   BY laboratory name; 
   WHERE conclusion = 0; 
   RETAIN test 0; 
   test = test+1; 
   IF first.name THEN test=1; 
   IF test>3 THEN DELETE; 
   IF mean_viability > 50 THEN predINI = 'NI'; 
   ELSE predINI = 'I'; 
RUN; 
/* 8.1 sens, spec, acc */ 
%MACRO predmodel(lab=, output=); 
DATA pre8_1; 
   SET PCA; 
   %IF &lab NE %THEN %DO; 
      WHERE laboratory = &lab; 
   %END; 
   IF trueINI = 'I' THEN DO; 
      IF predINI = 'I' THEN result = 'TP'; 
   ELSE IF predINI = 'NI' THEN result = 'FN'; 
   END; 
   ELSE IF trueINI = 'NI' THEN DO; 
      IF predINI = 'NI' THEN result = 'TN'; 
   ELSE IF predINI = 'I' THEN result = 'FP'; 
   END; 
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RUN; 
PROC SORT data=pre8_1; 
   BY trueINI predINI; 
RUN; 
DATA pre8_1b (drop=result); 
   SET pre8_1; 
   BY trueINI; 
   retain tp tn fp fn; 
   if (first.trueINI) then do; 
      tp=0; tn=0; fp=0; fn=0; 
   end; 
   if (result in ("TP")) then tp=tp+1; 
   if (result in ("TN")) then tn=tn+1; 
   if (result in ("FN")) then fn=fn+1; 
   if (result in ("FP")) then fp=fp+1; 
   else ; 
   if (last.trueINI) then output; 
run; 
DATA pre8_1C; 
   SET pre8_1B; 
   tntp=tn+tp; 
   fnfp=fn+fp; 
RUN; 
PROC SQL; 
   CREATE TABLE pre8_1D as 
   select sum(tp) as tp, sum(tn) as tn, sum(fp)as fp, sum(fn) as fn, sum(tntp) as 
          tntp, sum(fnfp) as fnfp 
   from pre8_1C; 
QUIT; 
PROC SQL; 
   CREATE TABLE pre8_1E as 
   select tp/(tp+fn) as sensitivity, tn/(tn+fp) as specificity, 
         (tn+tp)/(tn+tp+fn+fp) as accuracy 
    from pre8_1D; 
QUIT; 
PROC TRANSPOSE data=pre8_1D out=pre8_1F; 
   VAR tp tn fn fp tntp fnfp; 
RUN; 
DATA pre8_1G (drop=_name_ col1); 
   LENGTH group $20; 
   SET pre8_1F; 
   count=col1; 
   if _name_="tp" then do; 
      group="Sensitivity"; 
      response=0; 
      output; 
   end; 
   else if _name_="fn" then do; 
      group="Sensitivity"; 
      response=1; 
      output; 
   end; 
   else if _name_="tn" then do; 
      group="Specificity"; 
      response=0; 
      output; 
   end; 
   else if _name_="fp" then do; 
      group="Specificity"; 
      response=1; 
      output; 
   end; 
   else if _name_="tntp" then do; 
      group="Accuracy"; 
      response=0; 
      output; 
   end; 
   else if _name_="fnfp" then do; 
      group="Accuracy"; 
      response=1; 
      output; 
   end; 
RUN; 
PROC SORT data=pre8_1G; BY group; RUN; 
ODS trace off; 
ODS listing close; 
PROC FREQ data= pre8_1G; 
   WEIGHT count; 
   BY group; 
   TABLES response/alpha=0.05 binomial(p=0.5); 
   exact binomial; 




   SET pre8_1CI; 
   WHERE name1 IN ('_BIN_' 'XL_BIN' 'XU_BIN'); 
RUN; 
PROC TRANSPOSE data=pre8_1TOTAL out=pre8_1TOTALt; 
   VAR nvalue1; 
   ID name1; 
   BY group; 
RUN; 
PROC TRANSPOSE data=pre8_1G out=pre8_1H; 
   VAR count; 
   ID response; 
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   MERGE pre8_1TOTALt pre8_1H; 








DATA table8_1 (keep = group laboratory _BIN_ XL_BIN XU_BIN abs abs2); 
   SET table8_1ceetox (in=set1) table8_1cardam (in=set2) 
       table8_1loreal (in=set3) table8_1TOTAL (in=set4); 
   IF set1 THEN laboratory = 'CEETOX'; 
   IF set2 THEN laboratory = 'CARDAM'; 
   IF set3 THEN laboratory = "L'Oreal"; 
   IF set4 THEN laboratory = 'Total'; 
   x = PUT(_1,$3.); 
   z = PUT(_0,$3.); 
   y = PUT(_0+_1,$3.); 
   abs = x||'/'||y; 
   abs2 = z||'/'||y; 
RUN; 
* report @8.2; 
 
/* 8.2 statement regarding predictive capacity */ 
DATA table8_2; 
   SET table8_1; 
   LENGTH PC_criteria $25; 
   IF group = 'Sensitivity' THEN DO; 
      PC_criteria = 'further evaluation'; 
      IF _BIN_ >= 0.90 THEN PC_criteria = 'definitely acceptable'; 
      IF _BIN_ <= 0.80 THEN PC_criteria = 'definitely unacceptable'; 
   END; 
   IF group = 'Specificity' THEN DO; 
      PC_criteria = 'further evaluation'; 
      IF _BIN_ >= 0.60 THEN PC_criteria = 'definitely acceptable'; 
      IF _BIN_ <= 0.50 THEN PC_criteria = 'definitely unacceptable'; 
   END; 
   IF group = 'Accuracy' THEN DO; 
      PC_criteria = 'further evaluation'; 
      IF _BIN_ >= 0.75 THEN PC_criteria = 'definitely acceptable'; 
      IF _BIN_ <= 0.65 THEN PC_criteria = 'definitely unacceptable'; 
   END; 
RUN; 
 
ODS RTF body='\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data 
analysis\Reports\Revision\SkinEthicTEST_Table8_1.doc' notoc_data; 
PROC REPORT data=table8_2 NOWINDOWS HEADLINE HEADSKIP; 
   COLUMNS laboratory group abs2 _BIN_ XL_BIN XU_BIN PC_criteria; 
   DEFINE laboratory/GROUP; 
   DEFINE group/DISPLAY 'Characteristic' width = 15;  
   DEFINE abs2/DISPLAY 'No.'; 
   DEFINE _BIN_/DISPLAY 'Value' format=8.3 CENTER; 
   DEFINE XL_BIN/DISPLAY '95% lower limit'  format=8.3 width=15 CENTER; 
   DEFINE XU_BIN/DISPLAY '95% upper limit' format=8.3 width=15 CENTER; 
   DEFINE PC_criteria/DISPLAY 'Statement' width = 25; 
   BREAK after laboratory/SKIP; 
RUN; QUIT; 
ODS RTF close; 
 
 * falsepos/falseneg; 
PROC SORT data=PCA; BY order predGHS; RUN; 
DATA PCA2; 
   SET PCA; 
   IF predINI = 'NI' THEN value = 0; 
   ELSE value = 1; 
   IF trueINI = 'NI' THEN true = 0; 
   ELSE true = 1; 
   mis=0; 
   IF value = 1 AND true = 0 THEN mis = 1; 
   IF value = 0 AND true = 1 THEN mis = 1; 
RUN; 
PROC TRANSPOSE data=PCA2(where=(laboratory = 'CARDAM')) out=extra1a prefix=B; 
   VAR value; 
   BY order name predGHS LS; 
   ID test; 
RUN; 
PROC TRANSPOSE data=PCA2(where=(laboratory = 'CEETOX')) out=extra1b prefix=H; 
   VAR value; 
   BY order name predGHS LS; 
   ID test; 
RUN; 
PROC TRANSPOSE data=PCA2(where=(laboratory = "L'OREAL")) out=extra1c prefix=V; 
   VAR value; 
   BY order name predGHS LS; 
   ID test; 
RUN; 
PROC TRANSPOSE data=PCA2(where=(laboratory = 'CARDAM')) out=extra1d prefix=misB; 
   VAR mis; 
   BY order name predGHS LS; 
   ID test; 
RUN; 
PROC TRANSPOSE data=PCA2(where=(laboratory = 'CEETOX')) out=extra1e prefix=misH; 
   VAR mis; 
   BY order name predGHS LS; 
   ID test; 
RUN; 
PROC TRANSPOSE data=PCA2(where=(laboratory = "L'OREAL")) out=extra1f prefix=misV; 
   VAR mis; 
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   BY order name predGHS LS; 
   ID test; 
RUN; 
PROC SORT data=PCA2 out=PCA2b nodupkey; BY order; RUN; 
PROC TRANSPOSE data=PCA2b out=extra1g; 
   VAR true; 
   BY order name; 
RUN; 
DATA extra1; 
   MERGE extra1a extra1b extra1c extra1d extra1e extra1f extra1g; 
   BY order name; 
   med = MEDIAN(B1,B2,B3,H1,H2,H3,V1,V2,V3); 
   summis = SUM(misB1,misB2,misB3,misH1,misH2,misH3,misV1,misV2,misV3); 
   mis = '*'||TRIM(LEFT(PUT(summis,best12.)))||'/9'; 
   IF order = 20 THEN DO; 
         med = MEDIAN(H1,H2,V1,V2,V3); 
         summis = SUM(misV1,misV2,misV3); 
         mis = '*'||TRIM(LEFT(PUT(summis,best12.)))||'/3'; 
   END; 
   FORMAT B1--V3 med fmtini.; 
   label mis = 'Mispredicted tests/Total' 
    med = 'Final classification based on median'; 
RUN; 
PROC SORT data=extra1; 
   BY order; 
RUN; 
 
* overview of protocol selection; 
PROC SORT data=pre_all_test out=test (keep = order name keuze) nodupkey; 






*** NOG DOEN (combi met LE) ***; 
*******************************; 
/* 5.9 Summarise results for  NC and PC */ 
 
/*DEZE FILE PRE5_9 MOET JE NAAR EXCEL DOEN EN DAN INLEZEN IN R EN PLOTS MAKEN*/ 
 
PROC SORT data=RhT.SE2 out=ODnc(keep = laboratory run tissue chemical_code meanODnc) nodupkey; 
   BY laboratory run chemical_code; 
   where chemical_code NE 'PC'; 
RUN; 
PROC SORT data=pre_all_SE out=all_SE(keep = laboratory StdNC meanPC sdPC std_TA chemical_code run 
filename conclusion); 
   BY laboratory run chemical_code; 
RUN; 
DATA all_SE2; 
   MERGE all_SE(in=ok) ODnc; 
   BY laboratory run chemical_code; 
   IF ok; 
RUN; 
PROC SORT data=all_SE2 out=pre5_9(keep = laboratory meanODnc StdNC meanPC sdPC std_TA chemical_code run 
conclusion) nodupkey; 
BY laboratory filename;  
RUN; 
DATA pre5_9b; 
   SET pre5_9 pre5_9(in=set2); 
   IF set2 THEN laboratory = 'Total'; 
RUN; 
DATA pre5_9c; 
   RETAIN labstate StdNC meanPC sdPC;  
   SET pre5_9b; 
   labstate = TRIM(LEFT(laboratory)) || TRIM(LEFT('(SE)')); 
RUN; 
PROC SORT data=RhT.LE2 out=ODnc(keep = laboratory run tissue chemical_code meanODnc) nodupkey; 
   BY laboratory run chemical_code; 
   where chemical_code NE 'PC'; 
RUN; 
PROC SORT data=pre_all_LE out=all_LE(keep = laboratory StdNC meanPC sdPC std_TA chemical_code run 
filename conclusion); 
   BY laboratory run chemical_code; 
RUN; 
DATA all_LE2; 
   MERGE all_LE(in=ok) ODnc; 
   BY laboratory run chemical_code; 
   IF ok; 
RUN; 
PROC SORT data=all_LE2 out=pre5_9(keep = laboratory meanODnc StdNC meanPC sdPC std_TA chemical_code run 
conclusion) nodupkey; 
BY laboratory filename;  
RUN; 
DATA pre5_9b; 
   SET pre5_9 pre5_9(in=set2); 
   IF set2 THEN laboratory = 'Total'; 
RUN; 
DATA pre5_9e; 
   RETAIN labstate StdNC meanPC sdPC std_TA;  
   SET pre5_9b; 
   labstate = TRIM(LEFT(laboratory)) || TRIM(LEFT('(LE)')); 
RUN; 
DATA pre5_9f; 
   SET pre5_9c (in=se) pre5_9e (in=le); 
   IF se THEN protocol = 'SE'; 
   IF le THEN protocol = 'LE'; 
RUN; 
PROC SORT data=pre5_9f out=pre5_9g; BY labstate; RUN; 
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DATA _NULL_; 
   SET pre5_9f;  
   FILE '\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data analysis\Plots in 
R\skinethic.txt'; 
   PUT labstate meanODnc StdNC meanPC sdPC laboratory  protocol; 
RUN; 
* voor std van uncorr viab; 
PROC SORT data=RhT.SE2 out=ODnc(keep = laboratory run tissue chemical_code meanODnc) nodupkey; 
   BY laboratory run chemical_code; 
   where chemical_code NE 'PC'; 
RUN; 
PROC SORT data=pre_all_SE out=all_SE(keep = laboratory StdNC meanPC sdPC std_TA chemical_code run 
filename conclusion); 
   BY laboratory run chemical_code; 
RUN; 
DATA all_SE2; 
   MERGE all_SE(in=ok) ODnc; 
   BY laboratory run chemical_code; 
   IF ok; 
RUN; 
PROC SORT data=all_SE2 out=pre5_9(keep = laboratory meanODnc StdNC meanPC sdPC std_TA chemical_code run 
conclusion); 
BY laboratory filename;  
RUN; 
DATA pre5_9b; 
   SET pre5_9 pre5_9(in=set2); 
   IF set2 THEN laboratory = 'Total'; 
RUN; 
DATA pre5_9c; 
   RETAIN labstate StdNC meanPC sdPC;  
   SET pre5_9b; 
   labstate = TRIM(LEFT(laboratory)) || TRIM(LEFT('(SE)')); 
RUN; 
PROC SORT data=RhT.LE2 out=ODnc(keep = laboratory run tissue chemical_code meanODnc) nodupkey; 
   BY laboratory run chemical_code; 
   where chemical_code NE 'PC'; 
RUN; 
PROC SORT data=pre_all_LE out=all_LE(keep = laboratory StdNC meanPC sdPC std_TA chemical_code run 
filename conclusion); 
   BY laboratory run chemical_code; 
RUN; 
DATA all_LE2; 
   MERGE all_LE(in=ok) ODnc; 
   BY laboratory run chemical_code; 
   IF ok; 
RUN; 
PROC SORT data=all_LE2 out=pre5_9(keep = laboratory meanODnc StdNC meanPC sdPC std_TA chemical_code run 
conclusion); 
BY laboratory filename;  
RUN; 
DATA pre5_9b; 
   SET pre5_9 pre5_9(in=set2); 
   IF set2 THEN laboratory = 'Total'; 
RUN; 
DATA pre5_9e; 
   RETAIN labstate StdNC meanPC sdPC std_TA;  
   SET pre5_9b; 
   labstate = TRIM(LEFT(laboratory)) || TRIM(LEFT('(LE)')); 
RUN; 
DATA pre5_9f; 
   SET pre5_9c (in=se) pre5_9e (in=le); 
   IF se THEN protocol = 'SE'; 
   IF le THEN protocol = 'LE'; 
RUN; 
PROC SORT data=pre5_9f out=pre5_9g; BY labstate; RUN; 
DATA _NULL_; 
   SET pre5_9f (where=(conclusion IN (0 1) AND std_TA NE .));  
   FILE '\\tsn.tno.nl\Data\Projects\031\1\14497\Kluis\Biostatistiek\Data analysis\Plots in 
R\skinethic_TA.txt'; 
   PUT labstate std_TA laboratory  protocol; 
RUN; 
data select; 
   set pre5_9f (where=(conclusion IN (0 1) AND std_TA NE .));  
run; 
* Plots and statistics in R; 
 
/* ---------- */ 
/* appendix I */ 
/* ---------- */ 
PROC sort data=pre_all_SE out=appendix1 (keep = order name mtt coloring   
                                                                             where=(UPCASE(MTT) NE 'NO' 
OR UPCASE(coloring) NE 'NO')) nodupkey ;  
   BY order name;  
RUN; 
/* ----------- */ 
/* Appendix IV */ 
/* ----------- */ 
PROC SORT data=rht.se_remarks out=remarks_se (keep = filename laboratory remark); 
by filename; 
RUN; 
PROC SORT data=rht.le_remarks out=remarks_le (keep = filename laboratory remark); 
by filename; 
RUN; 
/* ---------------- */ 
/* Appendix VI */ 
/* ----------------*/ 
DATA appVI_SE/*(keep=order laboratory predGHS MTT coloring test meanODnc stdNC NCqual meanPC sdPC
 PCqual mean_TA std_TA qual_sd mean_NSC mean_MTT mean_viability conclusion pred50)*/; 
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   RETAIN order laboratory predGHS MTT coloring test meanODnc stdNC NCqual meanPC sdPC PCqual
 mean_TA std_TA qual_sd mean_NSC mean_MTT mean_viability conclusion pred50; 
   SET pre_all_SE; 
   IF mean_viability > 50 THEN pred50 = 'NI'; 
   ELSE pred50 = 'I'; 
RUN;  
PROC SORT data=appVI_SE; BY laboratory order test; RUN; 
* add std en call tav nsc en mtt; 
proc sort data=RhT.SE_extra out=sort nodupkey; 
   BY laboratory chemical_code run; 
RUN; 
DATA sort2; 
   SET sort; 
   KEEP chemical_code MTT coloring run laboratory NSMTTcall NSMTT_pct stdNSMTT_pct NSC_pct stdNSC_pct 
NSCcall; 
   IF chemical_code = 'PC' THEN DELETE; 
   IF SUBSTR(run,1,14) NE 'Chemical : Run' THEN DELETE; 
RUN; 
DATA sort3; 
   SET sort2; 
   runs = INPUT(SUBSTR(run,16,1),best12.); 
   DROP run; 
RUN; 
PROC SORT data=appVI_SE; BY laboratory chemical_code run; RUN; 
PROC SORT data=sort3(rename=(runs=run)); BY laboratory chemical_code run; RUN; 
DATA mergen /*(keep=SMTTcall NSMTT_pct stdNSMTT_pct NSC_pct stdNSC_pct NSCcall chemical_name run order
 laboratory predGHS MTT coloring test meanODnc stdNC NCqual meanPC sdPC PCqual mean_TA std_TA
 qual_sd mean_NSC mean_MTT mean_viability conclusion pred50)*/; 
   MERGE appVI_SE sort3; 
   BY laboratory chemical_code run; 
   IF mean_MTT EQ . AND mean_NSC EQ . THEN DELETE; 
RUN; 
PROC SORT data=mergen; BY laboratory order test; RUN; 
DATA mergen (keep=flag SMTTcall NSMTT_pct stdNSMTT_pct NSC_pct stdNSC_pct NSCcall chemical_name run 
order laboratory predGHS MTT coloring test meanODnc stdNC NCqual meanPC sdPC PCqual mean_TA
 std_TA qual_sd mean_NSC mean_MTT mean_viability conclusion pred50); 
   MERGE appVI_SE(in=set1) sort3; 
   BY laboratory chemical_code run; 
   IF set1 then flag = 1; 
RUN; 
PROC SORT data=mergen; BY laboratory order test; RUN; 
* 106 en 107; 
DATA chem106107;  
   SET RhT.SE_extra; 
   IF chemical_code IN ('L6' 'C52' 'X95' 'L100' 'C56' 'X32') THEN OUTPUT; 
RUN; 
proc sort data=chem106107 out=sortb nodupkey; 
   BY laboratory chemical_code run; 
RUN; 
 
DATA appVI_LE /*(keep=order laboratory predGHS MTT coloring test meanODnc stdNC NCqual meanPC sdPC
 PCqual mean_TA std_TA qual_sd mean_NSC mean_MTT mean_viability conclusion pred50)*/; 
   RETAIN order laboratory predGHS MTT coloring test meanODnc stdNC NCqual meanPC sdPC PCqual
 mean_TA std_TA qual_sd mean_NSC mean_MTT mean_viability conclusion pred50; 
   SET pre_all_LE; 
   IF mean_viability > 50 THEN pred50 = 'NI'; 
   ELSE pred50 = 'I'; 
RUN;  
PROC SORT data=appVI_LE; BY laboratory order test; RUN; 
* add std en call tav nsc en mtt; 
proc sort data=RhT.LE_extra out=sortc nodupkey; 
   BY laboratory chemical_code run; 
RUN; 
DATA sortc2; 
   SET sortc; 
   KEEP chemical_code MTT coloring run laboratory NSMTTcall NSMTT_pct stdNSMTT_pct NSC_pct stdNSC_pct 
NSCcall; 
   IF chemical_code = 'PC' THEN DELETE; 
   IF SUBSTR(run,1,14) NE 'Chemical : Run' THEN DELETE; 
RUN; 
DATA sortc3; 
   SET sortc2; 
   runs = INPUT(SUBSTR(run,16,1),best12.); 
   DROP run; 
RUN; 
PROC SORT data=appVI_LE; BY laboratory chemical_code run; RUN; 
PROC SORT data=sortc3(rename=(runs=run)); BY laboratory chemical_code run; RUN; 
DATA mergenC /*(keep=SMTTcall NSMTT_pct stdNSMTT_pct NSC_pct stdNSC_pct NSCcall chemical_name run order
 laboratory predGHS MTT coloring test meanODnc stdNC NCqual meanPC sdPC PCqual mean_TA std_TA
 qual_sd mean_NSC mean_MTT mean_viability conclusion pred50)*/; 
   MERGE appVI_LE sortc3; 
   BY laboratory chemical_code run; 
   IF mean_MTT EQ . AND mean_NSC EQ . THEN DELETE; 
RUN; 
PROC SORT data=mergenC; BY laboratory order test; RUN; 
DATA mergenC (keep=flag SMTTcall NSMTT_pct stdNSMTT_pct NSC_pct stdNSC_pct NSCcall chemical_name run 
order laboratory predGHS MTT coloring test meanODnc stdNC NCqual meanPC sdPC PCqual mean_TA
 std_TA qual_sd mean_NSC mean_MTT mean_viability conclusion pred50); 
   MERGE appVI_LE(in=set1) sortc3; 
   BY laboratory chemical_code run; 
   IF set1 then flag = 1; 
RUN; 
PROC SORT data=mergenC; BY laboratory order test; RUN; 
 
* 106 107; 
data od_LE (keep = chemical_code run meanODnc stdNC); 
   set rht.LE2; 
   WHERE chemical_code IN ('L6' 'C52' 'X95' 'L100'  'C56' 'X32'); 
RUN; 
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proc sort data=od_LE nodupkey; BY chemical_code run; RUN; 
data od_SE (keep = chemical_code run meanODnc stdNC); 
   set rht.SE2; 
   WHERE chemical_code IN ('L6' 'C52' 'X95' 'L100'  'C56' 'X32'); 
RUN; 
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Appendix III Receipt of data 
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Se 
No Remark Used Filename saved as LAB v 
date of 
receipt 
1 YES EIVS_CARDAM_SE_10HCE029_35.xls CARDAM_SE 1 Jan-11 C1(1) C2(1) C17(1) C19(1) C26(1) C30(1) C33(1) C34(1) C35(1) 
2 YES EIVS_CARDAM_SE_10HCE031_37.xls CARDAM_SE 1 Jan-11 C1(2) C2(2) C17(2) C19(2) C26(2) C30(2) C33(2) C34(2) C35(2) 
3 YES EIVS_CARDAM_SE_10HCE032_38.xls CARDAM_SE 1 Jan-11 C1(3) C2(3) C17(3) C19(3) C26(3) C30(3) C77(1) C34(3) C35(3) 
4 YES EIVS_CARDAM_SE_10HCE033_39(C77).xls CARDAM_SE 1 Jan-11 C77(2) 
5 YES EIVS_CARDAM_SE_10HCE033_39.xls CARDAM_SE 1 Jan-11 C33(3) C35(4) C36(1) C37(1) C49(1) C51(1) C54(1) C60(1) C63(1) C65(1) C66(1) 
6 YES EIVS_CARDAM_SE_10HCE034_40(C79).xls CARDAM_SE 1 Jan-11 C79(1) 
7 YES EIVS_CARDAM_SE_10HCE034_40.xls CARDAM_SE 1 Jan-11 C36(2) C37(2) C49(2) C51(2) C54(2) C60(2) C63(2) C65(2) C66(2) C75(2) C76(2) 
8 NO EIVS_CARDAM_SE_10HCE033Kt_40.xlsx CARDAM_SE 1 Jan-11 C6(Kt) C30(Kt) C34(Kt) C54(Kt) C75(Kt) C87(Kt) C90(Kt) C104(Kt) 
9 NO EIVS_CARDAM_SE_10HCE044_50.xlsx CARDAM_SE 1 Jan-11 C45(4) C53(4) C98(3) C101(3) C119(3) C123(3) C127(3) C132(3) C83(4) C6(3) 
10 YES EIVS_CARDAM_SE1_10HCE035_41.xls CARDAM_SE 1 Jan-11 C36(3) C37(3) C49(3) C51(3) C54(3) C60(3) C63(3) C65(3) C66(3) C75(3) C76(3) 
11 NO EIVS_CARDAM_SE1_10HCE036_42.xls CARDAM_SE 1 Jan-11 C104(1) C78(3) C79(3) C82(2) C85(2) C87(2) C88(2) C90(2) C91(2) C94(2) C96(2) 
12 NO EIVS_CARDAM_SE1_10HCE037_43.xls CARDAM_SE 1 Jan-11 C82(3) C85(3) C87(3) C88(3) C90(3) C91(3) C94(3) C96(3) C99(2) C104(2) C3(2) 
13 NO EIVS_CARDAM_SE1_10HCE040_46.xls CARDAM_SE 1 Jan-11 C99(3) C104(3) C3(3) C11(3) C12(3) C13(3) C15(3) C16(3) C21(3) C25(3) C27(3) 
14 YES EIVS_CARDAM_SE2_10HCE035_41.xls CARDAM_SE 1 Jan-11 C82(1) C85(1) C87(1) C88(1) C90(1) C91(1) C94(1) C96(1) 
15 NO EIVS_CARDAM_SE2_10HCE041_47.xls CARDAM_SE 1 Jan-11 C123(1) C127(1) C132(1) C134(1) C6(1) 
16 NO EIVS_CARDAM_SE2_10HCE042_48.xls CARDAM_SE 1 Jan-11 C127(2) C132(2) C134(2) C135(1) C136(1) C138(1) C6(2) 
17 
replaced by 
123 NO EIVS_CEETOX_SE_10HCE023_25_v1.0.xls CEETOX_SE 1 09/02/2011 x1(1) x2(1) x5(1) x6(1) x7(1) x16(1) x22(1) x28(1) x36(1) x38(1) 
18 
replaced by 
124 NO EIVS_CEETOX_SE_10HCE024_26_v1.0.xls CEETOX_SE 1 09/02/2011 x1(2) x2(2) x5(2) x6(2) x7(2) x16(2) x22(2) x28(2) x36(2) x38(2) 
19 
replaced by 
125 NO EIVS_CEETOX_SE_10HCE025_27_FUSION.XLS EIVS_CEETOX_SE_10HCE025_27_v1.0.XLS CEETOX_SE 1 09/02/2011 x1(3) x2(3) x5(3) x6(3) x7(3) x16(3) x22(3) x28(3) x36(3) x38(3) 
20 
replaced by 
126 NO EIVS_CEETOX_SE_10HCE027_29_v1.0.xls CEETOX_SE 1 09/02/2011 x63(1) x72(1) x73(1) x83(1) x86(1) x89(1) x93(1) x98(1) x99(1) x103(1) 
21 
replaced by 
127 NO EIVS_CEETOX_SE_10HCE028_30_v1.0.xls CEETOX_SE 1 09/02/2011 x63(2) x72(2) x73(2) x83(2) x86(2) x89(2) x93(2) x98(2) x99(2) x103(2) 
22 
replaced by 
128 NO EIVS_CEETOX_SE_10HCE042_48_v1.0.xls CEETOX_SE 1 09/02/2011 x63(3) x72(3) x73(3) x83(3) x86(3) x89(3) x93(3) x98(3) x99(3) x103(3) 
23 
replaced by 
129 NO EIVS_CEETOX_SE_10HCE043_49_v1.0.xls CEETOX_SE 1 09/02/2011 x45(1) x47(1) x49(1) x51(1) x52(1) x59(1) x68(1) 
24 
replaced by 





JOEY.XLS CEETOX_SE 1 09/02/2011 x45(3) x47(3) x49(3) x51(3) x52(3) x59(3) x68(3) 
26 
replaced by 
132 NO EIVS_CEETOX_SE_11HCE004_4_v1.0.xls CEETOX_SE 1 09/02/2011 x41(1) x17(1) x31(1) x91(1) x121(1) x3(1) x25(1) x30(1) x33(1) 
27 NO EIVS_LOREAL_SE_10HCE023_25.xls LOREAL_SE 1 02/03/2011 L5(1) L9(1) L11(1) L12(1) L17(1) L18(1) L20(1) L23(1) L24(1) L27(1) L28(1) 
28 NO EIVS_LOREAL_SE_10HCE024_26.xls LOREAL_SE 1 02/03/2011 L5(2) L9(2) L11(2) L12(2) L17(2) L18(2) L20(2) L23(2) L24(2) L27(2) L28(2) 
29 NO EIVS_LOREAL_SE_10HCE025_27.xls LOREAL_SE 1 02/03/2011 L30(1) L39(1) L43(1) L45(1) L48(1) L51(1) L55(1) L59(1) L60(1) L66(1) L68(1) 
30 NO EIVS_LOREAL_SE_10HCE026_28.xls LOREAL_SE 1 02/03/2011 L9(3) L12(3) L17(3) L20(3) L27(3) L43(2) 
31 NO EIVS_LOREAL_SE_10HCE027_29.xls LOREAL_SE 1 02/03/2011 L30(1) L39(1) L43(1) L45(1) L48(1) L51(1) L55(1) L59(1) L60(1) L66(1) L68(1) 
32 NO EIVS_LOREAL_SE_10HCE028_30.xls LOREAL_SE 1 02/03/2011 L5(2) L11(2) L23(2) L24(2) L30(2) L39(2) L48(2) L51(2) L55(2) L60(2) L68(2) 
33 NO EIVS_LOREAL_SE_10HCE029_35.xls LOREAL_SE 1 02/03/2011 L74(1) L75(1) L78(1) L81(1) L82(1) L85(1) L91(1) L94(1) L97(1) L98(1) L102(1) 
34 NO EIVS_LOREAL_SE_10HCE031_37.xls LOREAL_SE 1 02/03/2011 L45(3) L59(3) L66(3) L74(2) L82(2) L94(1) 
35 NO EIVS_LOREAL_SE_10HCE032_38.xls LOREAL_SE 1 02/03/2011 L74(3) L75(2) L78(2) L81(2) L82(3) L85(2) L91(2) L94(3) L97(2) L98(2) L102(2) 
36 NO EIVS_LOREAL_SE_10HCE033_39.xls LOREAL_SE 1 02/03/2011 L11(5) L18(3) L28(3) L73(2) L75(3) L78(3) L81(3) L85(3) L91(3) L97(3) 
37 NO EIVS_LOREAL_SE_10HCE034_40.xls LOREAL_SE 1 02/03/2011 L73(3) L98(3) L4(1) L7(1) L8(1) 
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38 NO EIVS_LOREAL_SE_10HCE035_41.xls LOREAL_SE 1 02/03/2011 L4(2) L7(2) L8(2) L29(1) L42(1) L56(1) L57(1) L61(1) L63(1) L64(1) 
39 NO EIVS_LOREAL_SE_10HCE036_42.xls LOREAL_SE 1 02/03/2011 L102(3) L7(3) L29(2) L57(2) 
40 NO EIVS_LOREAL_SE_10HCE037_43.xls LOREAL_SE 1 02/03/2011 L4(3) L8(3) L29(3) L42(2) L56(2) L61(2) L57(3) L63(2) L64(2) L67(1) L70(1) 
41 NO EIVS_LOREAL_SE_10HCE040_46.xls LOREAL_SE 1 02/03/2011 L30(4) L42(3) L56(3) L61(3) L63(3) L64(3) L67(2) L70(2) L72(1) L79(1) L83(1) 
42 NO EIVS_LOREAL_SE_10HCE041_47.xls LOREAL_SE 1 02/03/2011 L67(3) L72(2) L79(2) L83(2) L87(2) L90(1) L92(2) L96(1) L101(1) L99(1) 
43 NO EIVS_LOREAL_SE_10HCE042_48.xls LOREAL_SE 1 02/03/2011 L87(3) L90(2) L92(2) L99(2) L104(1) L119(1) L120(1) L130(1) L131(1) L132(1) 
44 NO EIVS_LOREAL_SE_10HCE043_49.xls LOREAL_SE 1 02/03/2011 L83(3) L96(2) L101(2) L104(2) L106(1) L107(1) L108(1) L109(1) L112(1) L113(1) 
45 NO EIVS_LOREAL_SE_10HCE044_50.xls LOREAL_SE 1 02/03/2011 L79(3) L96(3) L101(3) L106(2) L107(2) L108(2) L109(2) L112(2) L113(2) L114(1) L115(1) 
46 NO EIVS_LOREAL_SE_11HCE005_5.xls LOREAL_SE 1 02/03/2011 Kt-L70 Kt-L72 Kt-L90 Kt-L99 Kt-L104 Kt-L107 Kt-L119 Kt-L120 Kt-L132 Kt-L133 
47 
replacement 
of 27 YES EIVS_LOREAL_SE_10HCE023_25.xls LOREAL_SE 1 16/03/2011 L5(1) L9(1) L11(1) L12(1) L17(1) L18(1) L20(1) L23(1) L24(1) L27(1) L28(1) 
48 
replacement 
of 28 YES EIVS_LOREAL_SE_10HCE024_26.xls LOREAL_SE 1 16/03/2011 L5(2) L9(2) L11(2) L12(2) L17(2) L18(2) L20(2) L23(2) L24(2) L27(2) L28(2) 
49 
replacement 
of 29 YES EIVS_LOREAL_SE_10HCE025_27.xls LOREAL_SE 1 16/03/2011 L30(1) L39(1) L43(1) L45(1) L48(1) L51(1) L55(1) L59(1) L60(1) L66(1) L68(1) 
50 
replacement 
of 30 YES EIVS_LOREAL_SE_10HCE026_28.xls LOREAL_SE 1 16/03/2011 L9(3) L12(3) L17(3) L20(3) L27(3) L43(2) 
51 
replacement 
of 31 YES EIVS_LOREAL_SE_10HCE027_29.xls LOREAL_SE 1 16/03/2011 L30(2) L39(2) L43(3) L45(2) L48(2) L51(2) L55(2) L59(2) L60(2) L66(2) L68(2) 
52 
replacement 
of 32 YES EIVS_LOREAL_SE_10HCE028_30.xls LOREAL_SE 1 16/03/2011 L5(3) L11(4) L23(3) L24(3) L30(3) L39(3) L48(3) L51(3) L55(3) L60(3) 
53 
replacement 
of 33 YES EIVS_LOREAL_SE_10HCE029_35.xls LOREAL_SE 1 16/03/2011 L74(1) L75(1) L78(1) L81(1) L82(1) L85(1) L91(1) L94(1) L97(1) L98(1) L102(1) 
54 
replacement 
of 34 YES EIVS_LOREAL_SE_10HCE031_37.xls LOREAL_SE 1 16/03/2011 L45(3) L59(3) L66(3) L74(2) L82(2) L94(2) 
55 
replacement 
of 35 YES EIVS_LOREAL_SE_10HCE032_38.xls LOREAL_SE 1 16/03/2011 L74(3) L75(2) L78(2) L81(2) L82(3) L85(2) L91(2) L94(3) L97(2) L98(2) L102(2) 
56 
replacement 
of 36 YES EIVS_LOREAL_SE_10HCE033_39.xls LOREAL_SE 1 16/03/2011 L11(5) L18(3) L28(3) L73(2) L75(3) L78(3) L81(3) L85(3) L91(3) L97(3) 
57 
replacement 
of 37 YES EIVS_LOREAL_SE_10HCE034_40.xls LOREAL_SE 1 16/03/2011 L73(3) L98(3) L4(1) L7(1) L8(1) 
58 
replacement 
of 38 YES EIVS_LOREAL_SE_10HCE035_41.xls LOREAL_SE 1 16/03/2011 L4(2) L7(2) L8(2) L29(1) L42(1) L56(1) L57(1) L61(1) L63(1) L64(1) 
59 
replacement 
of 39 YES EIVS_LOREAL_SE_10HCE036_42.xls LOREAL_SE 1 16/03/2011 L102(3) L7(3) L29(2) L57(2) 
60 
replacement 
of 40 YES EIVS_LOREAL_SE_10HCE037_43.xls LOREAL_SE 1 16/03/2011 L4(3) L8(3) L29(3) L42(2) L56(2) L61(2) L57(3) L63(2) L64(2) L67(1) L70(1) 
61 
replacement 
of 41 YES EIVS_LOREAL_SE_10HCE040_46.xls LOREAL_SE 1 16/03/2011 L30(4) L42(3) L56(3) L61(3) L63(3) L64(3) L67(2) L70(2) L72(1) L79(1) L83(1) 
62 
replacement 
of 42 YES EIVS_LOREAL_SE_10HCE041_47.xls LOREAL_SE 1 16/03/2011 L67(3) L72(2) L79(2) L83(2) L87(2) L90(1) L92(1) L96(1) L101(1) L99(1) 
63 
replacement 
of 43 YES EIVS_LOREAL_SE_10HCE042_48.xls LOREAL_SE 1 16/03/2011 L87(3) L90(2) L92(2) L99(2) L104(1) L119(1) L120(1) L130(1) L131(1) L132(1) 
64 
replacement 
of 44 YES EIVS_LOREAL_SE_10HCE043_49.xls LOREAL_SE 1 16/03/2011 L83(3) L96(2) L101(2) L104(1) L106(1) L107(1) L108(1) L109(1) L112(1) L113(1) 
65 
replacement 
of 45 YES EIVS_LOREAL_SE_10HCE044_50.xls LOREAL_SE 1 16/03/2011 L79(3) L96(3) L101(3) L106(2) L107(2) L108(2) L109(2) L112(2) L113(2) L114(1) L115(1) 
66 
replacement 
of 46 YES EIVS_LOREAL_SE_11HCE005_5.xls LOREAL_SE 1 16/03/2011 Kt-L70 Kt-L72 Kt-L90 Kt-L99 Kt-L104 Kt-L107 Kt-L119 Kt-L120 Kt-L132 Kt-L133 
67 
replaced by 
133 NO EIVS_CEETOX_SE_11HCE006_6_v1.0.xls CEETOX_SE 1 04/05/2011 x41(2) x17(2) x31(2) x91(2) x121(2) x3(2) x25(2) x30(2) x33(2) 
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68 
replaced by 
134 NO EIVS_CEETOX_SE_11HCE007_7_v1.0.xls CEETOX_SE 1 04/05/2011 x41(3) x17(3) x31(3) x91(3) x121(3) x3(3) x25(3) x30(3) x33(3) 
69 
replacement 
of 11 YES EIVS_CARDAM_SE1_10HCE036_42.xls CARDAM_SE 1 12/05/2011 C78(3) C79(3) C82(2) C85(2) C87(2) C88(2) C90(2) C91(2) C94(2) C96(2) C99(1) 
70 
replacement 
of 12 YES EIVS_CARDAM_SE1_10HCE037_43.xls CARDAM_SE 1 12/05/2011 C82(3) C85(3) C87(3) C88(3) C90(3) C91(3) C94(3) C96(3) C99(2) C104(2) C3(2) 
71 
replacement 
of 13 YES EIVS_CARDAM_SE1_10HCE040_46.xls CARDAM_SE 1 12/05/2011 C99(3) C104(3) C3(3) C11(3) C12(3) C13(3) C15(3) C16(3) C21(3) C25(3) C27(3) 
72 YES EIVS_CARDAM_SE1_10HCE041_47.xls CARDAM_SE 1 12/05/2011 C38(3) C45(2) C46(2) C47(2) C50(2) C53(2) C62(2) C70(2) C83(2) C84(2) C98(1) 
73 YES EIVS_CARDAM_SE1_10HCE042_48.xls CARDAM_SE 1 12/05/2011 C45(3) C46(3) C47(3) C50(3) C53(3) C62(3) C70(3) C83(3) C84(3) C98(2) C101(2) 
74 YES EIVS_CARDAM_SE2_10HCE036_42.xls CARDAM_SE 1 12/05/2011 C11(1) C12(1) C13(1) C15(1) C16(1) C21(1) C25(1) C27(1) 
75 YES EIVS_CARDAM_SE2_10HCE037_43.xls CARDAM_SE 1 12/05/2011 C13(2) C15(2) C16(2) C21(2) C25(2) C27(2) C38(1) 
76 YES EIVS_CARDAM_SE2_10HCE040_46.xls CARDAM_SE 1 12/05/2011 C46(1) C47(1) C50(1) C53(1) C62(1) C70(1) C83(1) C84(1) 
77 
replacement 
of 15 YES EIVS_CARDAM_SE2_10HCE041_47.xls CARDAM_SE 1 12/05/2011 C123(1) C127(1) C132(1) C134(1) C6(1) 
78 
replacement 
of 16 YES EIVS_CARDAM_SE2_10HCE042_48.xls CARDAM_SE 1 12/05/2011 C127(2) C132(2) C134(2) C135(1) C136(1) C138(1) C6(2) 
79 
replacement 
of 8 YES EIVS_CARDAM_SE_10HCE033Kt_40.xlsx CARDAM_SE 1 12/05/2011 C6(Kt) C30(Kt) C34(Kt) C54(Kt) C75(Kt) C87(Kt) C90(Kt) C104(Kt) 
80 YES EIVS_CARDAM_SE_10HCE033kt_45.xls CARDAM_SE 1 12/05/2011 C3(Kt) 
81 
replacement 
of 9 YES EIVS_CARDAM_SE_10HCE044_50.xls CARDAM_SE 1 12/05/2011 C45(4) C53(4) C98(3) C101(3) C119(3) C123(3) C127(3) C132(3) C83(4) C6(3) 
82 YES EIVS_CARDAM_SE_11HCE001_Kt_2.xls CARDAM_SE 1 12/05/2011 C45(Kt) C53(Kt) C101(Kt) C113(Kt) C135(Kt) C128(Kt) 
83 YES EIVS_CARDAM_SE_11HCE003_3.xls CARDAM_SE 1 12/05/2011 C105(1) C106(1) C107(1) C108(1) C139(1) C110(1) C112(1) C134(3) C135(2) C136(2) C138(2) 
84 YES EIVS_CARDAM_SE_11HCE005_5.xls CARDAM_SE 1 12/05/2011 C105(2) C106(2) C107(2) C108(2) C139(2) C110(2) C112(2) C113(1) C135(3) C136(3) C138(3) 
85 YES EIVS_CARDAM_SE_11HCE006_6.xls CARDAM_SE 1 12/05/2011 C105(3) C106(3) C107(3) C108(3) C139(3) C110(3) C112(3) C113(2) C116(1) C120(1) C124(1) 
86 YES EIVS_CARDAM_SE_11HCE007_7.xls CARDAM_SE 1 12/05/2011 C113(3) C109(1) C116(2) C120(2) C125(1) C129(1) C131(1) 
87 YES EIVS_CARDAM_SE_11HCE008_8.xls CARDAM_SE 1 12/05/2011 C124(2) C109(2) C125(2) C129(2) C131(2) 
88 YES EIVS_CARDAM_SE_11HCE009_9.xls CARDAM_SE 1 12/05/2011 C124(3) C109(3) C125(3) C129(3) C131(3) C116(3) C120(3) 
89 
replaced by 
135 NO EIVS_CEETOX_SE_11HCE008_8_v1.0 JOEY.xls CEETOX_SE 1 16/06/2011 x13(1) x39(1) x8(1) x128(1) 
90 
replaced by 




EIVS_CEETOX_SE_11HCE010 FK_16_v1.0 Set 
1.xls CEETOX_SE 1 16/06/2011 X39(1) X8(1) X27(1) X46(1) X87(1) X109(1) X110(1) X119(1) X133(1) X136(1) 
92 YES 
EIVS_CEETOX_SE_11HCE010 FK_16_v1.0 Set 










2.xls CEETOX_SE 1 16/06/2011 x65(3) x81(3) x82(3) x117(3) x112(1) x126(1) x21(1) 
95 YES EIVS_CARDAM_SE_11HCE020 Killed_22.xls CARDAM_SE 1 19/07/2011 C48(Kt) C58(Kt) C141(Kt) C170(Kt) C195(Kt) 
96 YES EIVS_CARDAM_SE_11HCE020_18.xls CARDAM_SE 1 19/07/2011 C4(1) C9(1) C20(1) C39(1) C28(1) C48(1) C52(1) C55(1) C58(1) 
97 YES EIVS_CARDAM_SE_11HCE022_19.xls CARDAM_SE 1 19/07/2011 C4(2) C9(2) C14(1) C20(2) C28(2) C29(1) C39(2) C48(2) C52(2) 
98 YES EIVS_CARDAM_SE_11HCE024_20.xls CARDAM_SE 1 19/07/2011 C4(3) C9(3) C14(2) C28(3) C29(2) C52(3) C56(1) C58(2) 
99 YES EIVS_CARDAM_SE_11HCE026_21.xls CARDAM_SE 1 19/07/2011 C14(3) C20(3) C29(3) C52(4) C56(2) C64(1) C67(1) C71(1) C97(1) C114(1) 
100 YES EIVS_CARDAM_SE_11HCE029_23.xls CARDAM_SE 1 19/07/2011 C39(3) C48(3) C55(2) C52(5) C56(3) C58(3) C103(1) C137(1) C140(1) C141(1) 
101 YES EIVS_CARDAM_SE_11HCE032_25.xls CARDAM_SE 1 19/07/2011 C55(3) C64(2) C67(2) C163(1) C164(1) C166(1) C170(1) C185(1) C193(1) C195(1) C196(1) 
102 YES EIVS_CARDAM_SE_11HCE034_26.xls CARDAM_SE 1 19/07/2011 C97(2) C103(2) C114(2) C137(2) C140(2) C141(2) C163(2) C164(2) C166(2) C170(2) C185(2) 
103 YES EIVS_CARDAM_SE_11HCE036_27.xls CARDAM_SE 1 19/07/2011 C64(3) C67(3) C71(3) C97(3) C103(3) C114(3) C137(3) C140(3) C141(3) C163(3) C195(2) 
104 YES EIVS_CARDAM_SE_11HCE038_28.xls CARDAM_SE 1 19/07/2011 C164(3) C166(3) C170(3) C185(3) C193(3) C195(3) C196(3) 
  
TNO report | TNO 2013 R11617 | Final report  105 / 305
105 
replaced by 
139 NO EIVS_CEETOX_SE_11HCE022_19_v1.0.xls CEETOX_SE 1 08/08/2011 X21(3) X112(3) X126(3) X14(1) X46(1) X27(1) 
106 
MTT data 
needed NO EIVS_CEETOX_SE_11HCE029_30_v1.0.xls CEETOX_SE 1 11/08/2011 X24(1) X32(1) X42(1) X95(1) X143(1) X165(1) X173(1) 
107 YES EIVS_LOREAL_SE_11HCE020_18.xls LOREAL_SE 1 12/08/2011 L1(1) L6(1) L13(1) L15(1) L16(1) L32(1) L33(1) L36(1) L37(1) 
108 NO EIVS_LOREAL_SE_11HCE022_19.xls LOREAL_SE 1 12/08/2011 L50(1) L53(1) L58(1) L62(1) L65(1) L76(1) L80(1) L100(1) L111(1) L125(1) L127(1) 
109 YES EIVS_LOREAL_SE_11HCE024_20.xls LOREAL_SE 1 12/08/2011 L144(1) L148(1) L156(1) L161(1) L164(1) L169(1) L174(1) L185(1) L200(1) L15(2) L6(2) 
110 YES EIVS_LOREAL_SE_11HCE026_21.xls LOREAL_SE 1 12/08/2011 L1(2) L13(2) L16(2) L32(2) L33(2) L36(2) L37(2) L50(2) L53(2) 
111 NO EIVS_LOREAL_SE_11HCE029_23.xls LOREAL_SE 1 12/08/2011 L33(3) L58(2) L62(2) L65(2) L76(2) L80(2) L100(2) L111(2) L161(2) L169(2) L174(2) 
112 NO EIVS_LOREAL_SE_11HCE032_25(1).xls LOREAL_SE 1 12/08/2011 L125(2) L127(2) L144(2) L148(2) L156(2) L164(2) L185(2) L200(2) L1(3) L6(3) L13(3) 
113 YES EIVS_LOREAL_SE_11HCE032_25(2).xls LOREAL_SE 1 12/08/2011 L100(3) 
114 NO EIVS_LOREAL_SE_11HCE034_26(1).xls LOREAL_SE 1 12/08/2011 L6(4) L15(3) L32(3) L36(3) L37(3) L50(3) L53(3) L58(4) L62(3) L65(3) L76(3) 
115 YES EIVS_LOREAL_SE_11HCE034_26(2).xls LOREAL_SE 1 12/08/2011 L111(3) L125(3) L127(3) L144(3) L148(3) L156(3) L161(3) 
116 NO EIVS_LOREAL_SE_11HCE036_27.xls LOREAL_SE 1 12/08/2011 L6(5) L58(5) L164(3) L100(5) L169(3) L174(3) L185(3) L200(3) 
117 YES EIVS_LOREAL_SE_11HCE002_2.xls LOREAL_SE 1 18/08/2011 L122(1) L123(1) L126(1) L129(1) L133(1) L134(1) L136(1) L137(1) L139(1) L140(1) L114(2) 
118 YES EIVS_LOREAL_SE_11HCE006_6.xls LOREAL_SE 1 18/08/2011 L70(3) L72(3) L90(3) L99(3) L104(2) L106(3) L107(3) L108(3) 
119 YES EIVS_LOREAL_SE_11HCE007_7.xls LOREAL_SE 1 18/08/2011 L109(3) L112(3) L113(3) L114(3) L115(3) L118(2) L119(2) L120(2) L122(2) L123(2) 
120 YES EIVS_LOREAL_SE_11HCE008_8.xls LOREAL_SE 1 18/08/2011 L118(3) L119(3) L120(3) L122(3) L123(3) L126(2) L129(2) L130(2) L131(2) L132(2) L133(2) 
121 YES EIVS_LOREAL_SE_11HCE009_9.xls LOREAL_SE 1 18/08/2011 L126(3) L129(3) L130(3) L131(3) L132(3) L133(3) L134(3) L136(2) L137(2) L139(2) L140(2) 
122 YES EIVS_LOREAL_SE_11HCE014_14.xls LOREAL_SE 1 18/08/2011 L136(3) L137(3) L139(3) L140(3) 
123 
replacement 
of 17 YES EIVS_CEETOX_SE_10HCE023_25_v1.0.xls CEETOX_SE 2 31/10/2011 x1(1) x2(1) x5(1) x6(1) x7(1) x16(1) x22(1) x28(1) x36(1) x38(1) 
124 
replacement 
of 18 YES EIVS_CEETOX_SE_10HCE024_26_v1.0.xls CEETOX_SE 2 31/10/2011 x1(2) x2(2) x5(2) x6(2) x7(2) x16(2) x22(2) x28(2) x36(2) x38(2) 
125 
replacement 
of 19 YES EIVS_CEETOX_SE_10HCE025_27_v1.0.XLS CEETOX_SE 2 31/10/2011 x1(3) x2(3) x5(3) x6(3) x7(3) x16(3) x22(3) x28(3) x36(3) x38(3) 
126 
replacement 
of 20 YES EIVS_CEETOX_SE_10HCE027_29_v1.0.xls CEETOX_SE 2 31/10/2011 x63(1) x72(1) x73(1) x83(1) x86(1) x89(1) x93(1) x98(1) x99(1) x103(1) 
127 
replacement 
of 21 YES EIVS_CEETOX_SE_10HCE028_30_v1.0.xls CEETOX_SE 2 31/10/2011 x63(2) x72(2) x73(2) x83(2) x86(2) x89(2) x93(2) x98(2) x99(2) x103(2) 
128 
replacement 
of 22 YES EIVS_CEETOX_SE_10HCE042_48_v1.0.xls CEETOX_SE 2 31/10/2011 x63(3) x72(3) x73(3) x83(3) x86(3) x89(3) x93(3) x98(3) x99(3) x103(3) 
129 
replacement 
of 23 YES EIVS_CEETOX_SE_10HCE043_49_v1.0.xls CEETOX_SE 2 31/10/2011 x45(1) x47(1) x49(1) x51(1) x52(1) x59(1) x68(1) 
130 
replacement 
of 24 YES EIVS_CEETOX_SE_10HCE044_50_v1.0.xls CEETOX_SE 2 31/10/2011 x45(2) x47(2) x49(2) x51(2) x52(2) x59(2) x68(2) 
131 
replacement 
of 25 YES 
EIVS_CEETOX_SE_11HCE004_4_v1.0 
JOEY.XLS CEETOX_SE 2 31/10/2011 x45(3) x47(3) x49(3) x51(3) x52(3) x59(3) x68(3) 
132 
replacement 
of 26 YES EIVS_CEETOX_SE_11HCE004_4_v1.0.xls CEETOX_SE 2 31/10/2011 x41(1) x17(1) x31(1) x91(1) x121(1) x3(1) x25(1) x30(1) x33(1) 
133 
replacement 
of 67 YES EIVS_CEETOX_SE_11HCE006_6_v1.0.xls CEETOX_SE 2 31/10/2011 x41(2) x17(2) x31(2) x91(2) x121(2) x3(2) x25(2) x30(2) x33(2) 
134 
replacement 
of 68 YES EIVS_CEETOX_SE_11HCE007_7_v1.0.xls CEETOX_SE 2 31/10/2011 x41(3) x17(3) x31(3) x91(3) x121(3) x3(3) x25(3) x30(3) x33(3) 
135 
replacement 
of 89 YES EIVS_CEETOX_SE_11HCE008_8_v1.0 JOEY.xls CEETOX_SE 2 31/10/2011 x13(1) x39(1) x8(1) x128(1) 
136 
replacement 
of 90 YES EIVS_CEETOX_SE_11HCE008_8_v1.0 LISA.xls CEETOX_SE 2 31/10/2011 x62(1) x64(1) x65(1) x81(1) x82(1) x117(1) x43(1) x44(1) 
137 
replacement 
of 93 YES 
EIVS_CEETOX_SE_11HCE013_13_v1.0 Set 
1.xls CEETOX_SE 2 31/10/2011 x13(3) x39(3) x8(3) x128(3) x43(3) x62(3) x64(3) 
138 replacement YES EIVS_CEETOX_SE_11HCE013_13_v1.0 Set CEETOX_SE 2 31/10/2011 x65(3) x81(3) x82(3) x117(3) x112(1) x126(1) x21(1) 
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of 94 2.xls 
139 
replacement 
of 105 YES EIVS_CEETOX_SE_11HCE022_19_v1.0.xls CEETOX_SE 2 11/11/2011 X21(3) X112(3) X126(3) X14(1) X46(1) X27(1) 
140 YES EIVS_CEETOX_SE_11HCE009_9_v1.0 LISA.xls CEETOX_SE 1 31/10/2011 x62(2) x65(2) x81(2) x82(2) x117(2) #REF! #REF! 
141 YES EIVS_CEETOX_SE_11HCE009_9_v1.0.xls CEETOX_SE 1 31/10/2011 x13(1) x39(2) x8(2) x128(2) x64(2) x43(2) x44(2) 









UPDATED.xls CEETOX_SE 1 31/01/2012 X27(2) X46(2) X50(1) X53(1) X70(1) X84(1) X87(1) X102(1) X107(1) X108(1) X109(1) 
144 YES EIVS_CEETOX_SE_11HCE049_38_v1.0.xls CEETOX_SE 1 11/11/2011 X14(3) X27(3) X46(3) X50(2) X53(2) X70(2) X84(2) X87(2) X102(2) X107(2) X108(2) 
145 YES 
EIVS_CEETOX_SE_11HCE051_39_v1.0 SET 
1.xls CEETOX_SE 1 11/11/2011 X50(3) X53(3) X70(3) X84(3) X87(3) X102(3) X107(3) 
146 YES 
EIVS_CEETOX_SE_11HCE051_39_v1.0 SET 
2.xls CEETOX_SE 1 11/11/2011 X108(3) X109(3) X110(1) X111(1) X114(1) X115(1) X116(1) 
147 YES 
EIVS_CEETOX_SE_11HCE053_40_v1.0 SET 
1.xls CEETOX_SE 1 11/11/2011 X110(2) X111(2) X114(2) X115(2) X116(2) X118(1) X119(1) 
148 YES 
EIVS_CEETOX_SE_11HCE053_40_v1.0 SET 
2.xls CEETOX_SE 1 11/11/2011 X123(1) X125(1) X129(1) X131(1) X133(1) X134(1) X136(1) 
149 YES 
EIVS_CEETOX_SE_11HCE055_41_v1.0 SET 
1.xls CEETOX_SE 1 11/11/2011 X37(1) X143(1) X190(1) X131(2) X119(2) X173(1) X169(1) 
150 YES 
EIVS_CEETOX_SE_11HCE055_41_v1.0 SET 
2.xls CEETOX_SE 1 11/11/2011 X133(2) X127(1) X139(1) X40(1) X111(3) X138(1) 
151 YES 
EIVS_CEETOX_SE_11HCE057_42_v1.0 SET 
1.xls CEETOX_SE 1 11/11/2011 X37(2) X143(2) X190(2) X131(3) X119(3) X173(2) X169(2) 
152 YES 
EIVS_CEETOX_SE_11HCE057_42_v1.0 SET 
2.xls CEETOX_SE 1 11/11/2011 X133(3) X127(2) X139(2) X40(2) X138(2) 
153 YES 
EIVS_CEETOX_SE_11HCE059_43_v1.0 SET 
1.xls CEETOX_SE 1 16/12/2011 X37(3) X143(3) X190(3) X173(3) X169(3) X127(3) X139(3) 
154 YES 
EIVS_CEETOX_SE_11HCE059_43_v1.0 SET 
2.xls CEETOX_SE 1 16/12/2011 X40(3) X138(3) X118(2) X125(2) X123(2) X134(2) X129(2) 
155 YES 
EIVS_CEETOX_SE_11HCE061_44_v1.0 SET 
1.xls CEETOX_SE 1 16/12/2011 X118(3) X125(3) X123(3) X134(3) X129(3) X196(1) X110(3) 
156 YES 
EIVS_CEETOX_SE_11HCE061_44_v1.0 SET 
2.xls CEETOX_SE 1 16/12/2011 X114(3) X115(3) X116(3) X136(2) X11(1) X19(1) X29(1) 
157 YES EIVS_CEETOX_SE_11HCE063_45_v1.0.xls CEETOX_SE 1 16/12/2011 X11(2) X19(2) X29(2) X196(2) X136(3) X24(1) X32(1) X42(1) X55(1) X56(1) 
158 YES EIVS_CEETOX_SE_11HCE065_46_v1.0.xls CEETOX_SE 1 04/01/2012 X19(3) X196(3) X24(2) X32(2) X42(2) X55(2) X56(2) X61(1) X66(1) X75(1) X77(1) 
159 YES EIVS_CEETOX_SE_11HCE068_48_v1.0.xls CEETOX_SE 1 04/01/2012 X61(2) X66(2) X75(2) X77(2) X80(2) X94(1) X95(1) X113(1) X120(1) X157(1) X158(1) 
160 YES EIVS_CEETOX_SE_11HCE070_49_v1.0.xls CEETOX_SE 1 04/01/2012 X11(3) X19(4) X24(3) X29(3) X94(2) X95(2) X113(2) X120(2) X157(2) X158(2) X160(2) 
161 YES EIVS_CEETOX_SE_12HCE002_2_v1.0.xls CEETOX_SE 1 24/01/2012 X32(3) X42(3) X55(3) X56(3) 
162 YES EIVS_CEETOX_SE_12HCE004_3_v1.0.xls CEETOX_SE 1 24/01/2012 X61(3) X66(3) X75(3) X77(3) X80(3) X94(3) X95(3) X113(3) X120(3) X157(3) X158(3) 
163 
replacement 
of 108 YES 
EIVS_LOREAL_SE_11HCE022_19 (L58 retested 
on killed tissues oct2012).xlsx EIVS_LOREAL_SE_11HCE022_19 LOREAL_SE 2 16/11/2012 L50(1) L53(1) L58(1) L62(1) L65(1) L76(1) L80(1) L100(1) L111(1) L125(1) L127(1) 
164 
replacement 
of 111 YES 
EIVS_LOREAL_SE_11HCE029_23 (L58 retested 
on killed tissues Oct2012).xlsx EIVS_LOREAL_SE_11HCE029_23 LOREAL_SE 2 16/11/2012 L33(3) L58(2) L62(2) L65(2) L76(2) L80(2) L100(2) L111(2) L161(2) L169(2) L174(2) 
165 
replacement 
of 112 YES 
EIVS_LOREAL_SE_11HCE032_25(1) (L58 
retested on killed tissues Oct2012).xlsx EIVS_LOREAL_SE_11HCE032_25(1) LOREAL_SE 2 16/11/2012 L125(2) L127(2) L144(2) L148(2) L156(2) L164(2) L185(2) L200(2) L1(3) L6(3) L13(3) 
166 
replacement 
of 114 YES 
EIVS_LOREAL_SE_11HCE034_26(1) (L58 
retested on killed tissues Oct2012).xlsx EIVS_LOREAL_SE_11HCE034_26(1) LOREAL_SE 2 16/11/2012 L6(4) L15(3) L32(3) L36(3) L37(3) L50(3) L53(3) L58(4) L62(3) L65(3) L76(3) 
167 
replacement 
of 116 YES 
EIVS_LOREAL_SE_11HCE036_27 (L58 retested 
on killed tissues Oct2012).xlsx EIVS_LOREAL_SE_11HCE036_27 LOREAL_SE 2 16/11/2012 L6(5) L58(5) L164(3) L100(5) L169(3) L174(3) L185(3) L200(3) 
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LE 
No Remark Used Filename Saved as LAB v 
date of 
receipt content 
            1 YES EIVS_CARDAM_LE_10HCE029_35.xls CARDAM_LE 1 01/01/2011 C1(1) C2(1) C17(1) C19(1) C26(1) C30(1) C33(1) C34(1) C35(1) 
2 YES EIVS_CARDAM_LE_10HCE031_37.xls CARDAM_LE 1 01/01/2011 C1(2) C2(2) C17(2) C19(2) C26(2) C30(2) C33(2) C34(2) C35(2) 
3 YES EIVS_CARDAM_LE_10HCE032_38.xls CARDAM_LE 1 01/01/2011 C1(3) C2(3) C17(3) C19(3) C26(3) C30(3) C77(1) C34(3) C35(3) 
4 Opening file failed NO EIVS_CARDAM_LE_10HCE033_W39.xls CARDAM_LE 1 01/01/2011 
5 YES EIVS_CARDAM_LE_10HCE033_W39_(C77).xls CARDAM_LE 1 01/01/2011 C77(2) 
6 NO EIVS_CARDAM_LE_10HCE033Kt_40.xlsx CARDAM_LE 1 01/01/2011 C6(Kt) C30(Kt) C34(Kt) C54(Kt) C75(Kt) C87(Kt) C90(Kt) C104(Kt) 
7 NO EIVS_CARDAM_LE_10HCE033kt_45.xlsx CARDAM_LE 1 01/01/2011 C3(Kt) C87(Kt) 
8 Wrong file name NO EIVS_LABNAME_LE_10HCE034_40.xls LABNAME_LE 1 01/01/2011 C36(1) C37(1) C49(1) C51(1) C54(1) C60(1) C63(1) C65(1) C66(1) C75(1) C76(1) C77(1) C78(1) 
9 NO EIVS_CARDAM_LE_10HCE044_50.xlsx CARDAM_LE 1 01/01/2011 C45(4) C84(2) C98(2) C101(2) C119(3) C123(2) C127(2) C132(2) C135(2) C6(3) 
10 
incorrect run 
numbers NO EIVS_CARDAM_LE1_10HCE035_41.xls CARDAM_LE 1 01/01/2011 
C36(3) C37(3) C49(3) C51(3) C54(3) C60(3) C63(3) C65(3) C66(3) C75(3) C76(3) C77(2) C78(2) 
11 YES EIVS_CARDAM_LE1_10HCE036_42.xls CARDAM_LE 1 01/01/2011 C36(3) C37(3) C49(3) C51(3) C54(3) C60(3) C63(3) C65(3) C66(3) C75(3) C76(3) C78(2) C79(2) 
12 NO EIVS_CARDAM_LE1_10HCE037_43.xlsx CARDAM_LE 1 01/01/2011 C78(3) C79(3) C82(3) C85(3) C87(3) C88(3) C90(3) C91(3) C94(2) C96(3) C99(1) C104(1) C3(1) 
13 NO EIVS_CARDAM_LE1_10HCE040_46.xls CARDAM_LE 1 01/01/2011 C94(3) C99(2) C104(2) C3(2) C11(2) C12(2) C13(2) C15(2) C16(2) C21(2) C25(2) C27(2) C38(1) 
14 NO EIVS_CARDAM_LE1_10HCE041_47.xls CARDAM_LE 1 01/01/2011 C99(3) C104(3) C3(3) C11(3) C12(3) C13(3) C15(3) C16(3) C21(3) C25(3) C27(3) C38(2) C45(2) 
15 
wrong run number 
C79 NO EIVS_CARDAM_LE2_10HCE035_41.xlsx CARDAM_LE 1 01/01/2011 C79(2) C82(1) C85(1) C87(1) C88(1) C90(1) C91(1) C96(1) 
16 NO EIVS_CARDAM_LE2_10HCE041_47.xls CARDAM_LE 1 01/01/2011 C46(2) C47(2) C50(2) C53(2) C62(2) C70(2) C83(2) C119(1) C6(1) 
17 NO EIVS_CARDAM_LE2_10HCE042_48.xls CARDAM_LE 1 01/01/2011 C123(1) C127(1) C132(1) C134(1) C135(1) C6(2) 
18 Wrong file name NO EIVS_LABNAME_LE_10HCE034_40(C79).xls LABNAME_LE 1 01/01/2011 C79(1) 
19 YES EIVS_CARDAM_LE2_10HCE036_42.xls CARDAM_LE 1 01/01/2011 C82(2) C85(2) C87(2) C88(2) C90(2) C91(2) C94(1) C96(2) 
20 NO EIVS_CEETOX_LE_10HCE023_25_v1.0.xls CEETOX_LE 1 09/02/2011 x1(1) x2(1) x5(1) x6(1) x7(1) x16(1) x22(1) x28(1) x36(1) x38(1) 
21 NO EIVS_CEETOX_LE_10HCE024_26_v1.0.xls CEETOX_LE 1 09/02/2011 x1(2) x2(2) x5(2) x6(2) x7(2) x16(2) x22(2) x28(2) x36(2) x38(2) 
22 NO EIVS_CEETOX_LE_10HCE042_48_v1.0.xls CEETOX_LE 1 09/02/2011 x1(3) x2(3) x5(3) x6(3) x7(3) x16(3) x22(3) x28(3) x36(3) x38(3) 
23 NO EIVS_CEETOX_LE_10HCE043_49_v1.0.xls CEETOX_LE 1 09/02/2011 x1(4) x2(4) x5(4) x6(4) x7(4) x16(4) x22(4) x28(4) x36(4) x38(4) 
24 NO EIVS_CEETOX_LE_10HCE044_50_v1.0.xls CEETOX_LE 1 09/02/2011 x1(5) x2(5) x5(5) x6(5) x7(5) x16(5) x22(5) x28(5) x36(5) x38(5) 
25 NO EIVS_CEETOX_LE_11HCE003_3_v1.0 .xls CEETOX_LE 1 09/02/2011 x63(1) x72(1) x73(1) x83(1) x86(1) x89(1) x93(1) x98(1) x99(1) x103(1) 
26 equal to 25 NO EIVS_CEETOX_LE_11HCE003_3_v1.0 SET 1.xls CEETOX_LE 1 26/01/2011 x63(1) x72(1) x73(1) x83(1) x86(1) x89(1) x93(1) x98(1) x99(1) x103(1) 
27 NO EIVS_CEETOX_LE_11HCE004_4_v1.0 JOEY.XLS CEETOX_LE 1 09/02/2011 x45(2) x47(2) x49(1) x51(2) x52(2) x59(2) x68(2) 
28 NO EIVS_CEETOX_LE_11HCE004_4_v1.0.xls CEETOX_LE 1 09/02/2011 x41(1) x17(1) x31(1) x91(1) x121(1) x3(1) x25(1) x30(1) x33(1) 
29 replacement of 4 YES EIVS_CARDAM_LE_10HCE033_W39.xls CARDAM_LE 2 25/02/2011 C33(3) C35(4) C36(1) C37(1) C49(1) C51(1) C54(1) C60(1) C63(1) C65(1) C66(1) C75(1) C76(1) 
30 
replacement of 8; 
non-qual NC/PC YES EIVS_CARDAM_LE_10HCE034_40.xls CARDAM_LE 2 25/02/2011 C36(1) C37(1) C49(1) C51(1) C54(1) C60(1) C63(1) C65(1) C66(1) C75(1) C76(1) C77(1) C78(1) 
31 
replacement of 18; 
non-qual NC/PC YES EIVS_CARDAM_LE_10HCE034_40(C79).xls CARDAM_LE 1 25/02/2011 C79(1) 
32 replacement of 10 YES Corrected of EIVS_CARDAM_LE1_10HCE035_41.xls EIVS_CARDAM_LE1_10HCE035_41.xls CARDAM_LE 2 25/02/2011 C36(2) C37(2) C49(2) C51(2) C54(2) C60(2) C63(2) C65(2) C66(2) C75(2) C76(2) C77(3) C78(1) 
33 NO EIVS_LOREAL_LE_10HCE023_25.xls LOREAL_LE 1 02/03/2011 L5(1) L9(1) L11(1) L12(1) L17(1) L18(1) L20(1) L23(1) L24(1) L27(1) L28(1)  
34 NO EIVS_LOREAL_LE_10HCE024_26.xls LOREAL_LE 1 02/03/2011 L5(2) L9(2) L11(2) L12(2) L17(2) L18(2) L20(2) L23(2) L24(2) L27(2) L28(2)   
35 NO EIVS_LOREAL_LE_10HCE025_27.xls LOREAL_LE 1 02/03/2011 L30(1) L39(1) L43(1) L45(1) L48(1) L51(1) L55(1) L59(1) L60(1) L66(1) L68(1) L11(3)  
36 NO EIVS_LOREAL_LE_10HCE026_28.xls LOREAL_LE 1 02/03/2011 L9(3) L12(3) L17(3) L20(3) L27(3) L43(2)        
37 NO EIVS_LOREAL_LE_10HCE027_29.xls LOREAL_LE 1 02/03/2011 L30(1) L39(1) L43(1) L45(1) L48(1) L51(1) L55(1) L59(1) L60(1) L66(1) L68(1) L73(3)  
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38 NO EIVS_LOREAL_LE_10HCE028_30.xls LOREAL_LE 1 02/03/2011 L5(2) L11(2) L23(2) L24(2) L30(2) L39(2) L48(2) L51(2) L55(2) L60(2) L68(2)  
39 NO EIVS_LOREAL_LE_10HCE029_35.xls LOREAL_LE 1 02/03/2011 L74(1) L75(1) L78(1) L81(1) L82(1) L85(1) L91(1) L94(1) L97(1) L98(1) L102(1)   
40 NO EIVS_LOREAL_LE_10HCE031_37.xls LOREAL_LE 1 02/03/2011 L45(3) L59(3) L66(3) L74(2) L82(2) L94(2)        
41 NO EIVS_LOREAL_LE_10HCE032_38.xls LOREAL_LE 1 02/03/2011 L74(3) L75(2) L78(2) L81(2) L82(3) L85(2) L91(2) L94(3) L97(2) L98(2) L102(2)   
42 NO EIVS_LOREAL_LE_10HCE033_39.xls LOREAL_LE 1 02/03/2011 L18(3) L28(3) L39(3) L73(2) L75(3) L78(3) L81(3) L85(3) L91(3) L97(3)    
43 NO EIVS_LOREAL_LE_10HCE034_40(1).xls LOREAL_LE 1 02/03/2011 L73(3) L74(4) L75(4) L78(4) L81(4) L82(4) L91(4) L94(4) L97(4) L98(3) L102(3)   
44 NO EIVS_LOREAL_LE_10HCE034_40(2).xls LOREAL_LE 1 02/03/2011 L4(1) L7(1) L8(1)           
45 NO EIVS_LOREAL_LE_10HCE035_41.xls LOREAL_LE 1 02/03/2011 L85(4) L98(4) L4(2) L7(2) L8(2) L29(1) L42(1) L56(1) L57(1) L61(1) L63(1) L64(1) 
46 NO EIVS_LOREAL_LE_10HCE036_42.xls LOREAL_LE 1 02/03/2011 L102(4) L7(3) L29(2) L57(2)         
47 NO EIVS_LOREAL_LE_10HCE037_43.xls LOREAL_LE 1 02/03/2011 L4(3) L8(3) L29(3) L42(2) L56(2) L61(2) L57(2) L63(2) L64(2) L67(1) L70(1)  
48 NO EIVS_LOREAL_LE_10HCE040_46.xls LOREAL_LE 1 02/03/2011 L42(3) L56(3) L61(3) L63(3) L64(3) L67(2) L70(2) L72(1) L79(1) L83(1) L87(1) L92(1)  
49 NO EIVS_LOREAL_LE_10HCE041_47.xls LOREAL_LE 1 02/03/2011 L67(3) L72(2) L79(2) L83(2) L87(2) L90(1) L92(2) L96(1) L99(1) L101(1)   
50 NO EIVS_LOREAL_LE_10HCE042_48.xls LOREAL_LE 1 02/03/2011 L87(3) L90(2) L92(3) L99(2) L104(1) L119(1) L120(1) L130(1) L131(1) L132(1)    
51 NO EIVS_LOREAL_LE_10HCE043_49.xls LOREAL_LE 1 02/03/2011 L83(3) L96(2) L101(2) L104(2) L106(1) L107(1) L108(1) L109(1) L112(1) L113(1)    
52 NO EIVS_LOREAL_LE_10HCE044_50.xls LOREAL_LE 1 02/03/2011 L79(3) L96(3) L101(3) L106(2) L107(2) L108(2) L109(2) L112(2) L113(2) L114(1) L115(1) L118(1)  
53 NO EIVS_LOREAL_LE_11HCE005_5.xls LOREAL_LE 1 02/03/2011 Kt-L70 Kt-L72 Kt-L90 Kt-L99 Kt-L104 Kt-L107 Kt-L119 Kt-L120 Kt-L132 Kt-L133    
54 replacement of 33 YES EIVS_LOREAL_LE_10HCE023_25.xls LOREAL_LE 2 16/03/2011 L5(1) L9(1) L11(1) L12(1) L17(1) L18(1) L20(1) L23(1) L24(1) L27(1) L28(1)  
55 replacement of 34 YES EIVS_LOREAL_LE_10HCE024_26.xls LOREAL_LE 2 16/03/2011 L5(2) L9(2) L11(2) L12(2) L17(2) L18(2) L20(2) L23(2) L24(2) L27(2) L28(2)  
56 replacement of 35 YES EIVS_LOREAL_LE_10HCE025_27.xls LOREAL_LE 2 16/03/2011 L30(1) L39(1) L43(1) L45(1) L48(1) L51(1) L55(1) L59(1) L60(1) L66(1) L68(1) L11(3) 
57 replacement of 36 YES EIVS_LOREAL_LE_10HCE026_28.xls LOREAL_LE 2 16/03/2011 L9(3) L12(3) L17(3) L20(3) L27(3) L43(2)       
58 replacement of 37 YES EIVS_LOREAL_LE_10HCE027_29.xls LOREAL_LE 2 16/03/2011 L30(2) L39(1) L43(3) L45(2) L48(2) L51(2) L55(2) L59(2) L60(2) L66(2) L68(2) L73(1) 
59 replacement of 38 YES EIVS_LOREAL_LE_10HCE028_30.xls LOREAL_LE 2 16/03/2011 L5(3) L11(4) L23(3)  L24(3) L30(3) L39(2) L48(3) L51(3) L55(3) L60(3) L68(3) 
60 
replacement of 39; 
non-qual NC/PC NO EIVS_LOREAL_LE_10HCE029_35.xls LOREAL_LE 2 16/03/2011 
L74(1) L75(1) L78(1) L81(1) L82(1) L85(1) L91(1) L94(1) L97(1) L98(1) L102(1)  
61 replacement of 40 YES EIVS_LOREAL_LE_10HCE031_37.xls LOREAL_LE 2 16/03/2011 L45(3) L59(3) L66(3) L74(1) L82(1) L94(1)       
62 replacement of 41 YES EIVS_LOREAL_LE_10HCE032_38.xls LOREAL_LE 2 16/03/2011 L74(2) L75(1) L78(1) L81(1) L82(2) L85(1) L91(1) L94(2) L97(1) L98(1) L102(1)  
63 replacement of 42 YES EIVS_LOREAL_LE_10HCE033_39.xls LOREAL_LE 2 16/03/2011 L18(3) L28(3) L39(3) L73(2) L75(2) L78(2) L81(2) L85(2) L91(2) L97(2)   
64 replacement of 43 YES EIVS_LOREAL_LE_10HCE034_40(1).xls LOREAL_LE 2 16/03/2011 L73(3) L74(3) L75(3) L78(3) L81(3) L82(3) L91(3) L94(3) L97(3) L98(2) L102(2)  
65 replacement of 44 YES EIVS_LOREAL_LE_10HCE034_40(2).xls LOREAL_LE 2 16/03/2011 L4(1) L7(1) L8(1)          
66 replacement of 45 YES EIVS_LOREAL_LE_10HCE035_41.xls LOREAL_LE 2 16/03/2011 L85(3) L98(3) L4(2) L7(2) L8(2) L29(1) L42(1) L56(1) L57(1) L61(1) L63(1) L64(1) 
67 replacement of 46 YES EIVS_LOREAL_LE_10HCE036_42.xls LOREAL_LE 2 16/03/2011 L102(3) L7(3) L29(2) L57(2)         
68 replacement of 47 YES EIVS_LOREAL_LE_10HCE037_43.xls LOREAL_LE 2 16/03/2011 L4(3) L8(3) L29(3) L42(2) L56(2) L61(2) L57(3) L63(2) L64(2) L67(1) L70(1) 
69 replacement of 48 YES EIVS_LOREAL_LE_10HCE040_46.xls LOREAL_LE 2 16/03/2011 L42(3) L56(3) L61(3) L63(3) L64(3) L67(2) L70(2) L72(1) L79(1) L83(1) L87(1) L92(1) 
70 replacement of 49 YES EIVS_LOREAL_LE_10HCE041_47.xls LOREAL_LE 2 16/03/2011 L67(3) L72(2) L79(2) L83(2) L87(2) L90(1) L92(2) L96(1) L99(1) L101(1)  
71 replacement of 50 YES EIVS_LOREAL_LE_10HCE042_48.xls LOREAL_LE 2 16/03/2011 L87(3) L90(2) L92(3) L99(2) L104(1) L119(1) L120(1) L130(1) L131(1) L132(1)   
72 replacement of 51 YES EIVS_LOREAL_LE_10HCE043_49.xls LOREAL_LE 2 16/03/2011 L83(3) L96(2) L101(2) L104(2) L106(1) L107(1) L108(1) L109(1) L112(1) L113(1)   
73 replacement of 52 YES EIVS_LOREAL_LE_10HCE044_50.xls LOREAL_LE 2 16/03/2011 L79(3) L96(3) L101(3) L106(2) L107(2) L108(2) L109(2) L112(2) L113(2) L114(1) L115(1) L118(1) 
74 replacement of 53 YES EIVS_LOREAL_LE_11HCE005_5.xls LOREAL_LE 2 16/03/2011 Kt-L70 Kt-L72 Kt-L90 Kt-L99 Kt-L104 Kt-L107 Kt-L119 Kt-L120 Kt-L132 Kt-L133   
75 replacement of 15 YES EIVS_CARDAM_LE2_10HCE035_41-Corr C79.xls EIVS_CARDAM_LE2_10HCE035_41.xls CARDAM_LE 1 14/03/2011 C79(1) C82(1) C85(1) C87(1) C88(1) C90(1) C91(1) C96(1) 
76 replacement of 27 NO EIVS_CEETOX_LE_11HCE004_4_v1.0 JOEY Updated.xls CEETOX_LE 1 04/05/2011 x45(1) x47(1) x49(1) x51(1) x52(1) x59(1) x68(1) 
77 NO EIVS_CEETOX_LE_11HCE009_9_v1.0 Joey FAILED RUN.XLS CEETOX_LE 1 04/05/2011 x13(2) x39(2) x8(2) x128(2) x64(2) x43(2) x44(2) x103(3) x63(3) 
78 NO EIVS_CEETOX_LE_11HCE009_9_v1.0 LISA FAILED RUN.XLS CEETOX_LE 1 04/05/2011 x62(2) x65(2) x81(2) x82(2) x117(2) 
79 NO EIVS_CEETOX_LE_11HCE006_6_v1.0 SET 1 JOEY.XLS CEETOX_LE 1 04/05/2011 x72(2) x73(2) x83(2) x86(2) x89(2) x93(2) x98(2) x99(2) 
80 NO EIVS_CEETOX_LE_11HCE006_6_v1.0 SET 2 JOEY.XLS CEETOX_LE 1 04/05/2011 x45(2) x47(2) x49(2) x51(2) x52(2) x59(2) x68(2) 
81 NO EIVS_CEETOX_LE_11HCE006_6_v1.0.xls CEETOX_LE 1 04/05/2011 x41(2) x17(2) x31(2) x91(2) x121(2) x3(2) x25(2) x30(2) x33(2) 
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82 NO EIVS_CEETOX_LE_11HCE007_7_v1.0 SET 1.xls CEETOX_LE 1 04/05/2011 x63(2) x72(3) x73(3) x83(3) x86(3) x89(3) x93(3) x98(3) x99(3) 
83 NO EIVS_CEETOX_LE_11HCE007_7_v1.0 SET 2 Joey.xls CEETOX_LE 1 04/05/2011 x45(3) x47(3) x49(3) x51(3) x52(3) 
84 NO EIVS_CEETOX_LE_11HCE007_7_v1.0.xls CEETOX_LE 1 04/05/2011 x41(3) x17(3) x31(3) x91(3) x121(3) x3(3) x25(3) x30(3) x33(3) 
85 NO EIVS_CEETOX_LE_11HCE008_8_v1.0 LISA.XLS CEETOX_LE 1 04/05/2011 x62(1) x64(1) x65(1) x81(1) x82(1) x117(1) x43(1) x44(1) 
86 replacement of 12 YES EIVS_CARDAM_LE1_10HCE037_43.xlsx CARDAM_LE 1 12/05/2011 C78(3) C79(3) C82(3) C85(3) C87(3) C88(3) C90(3) C91(3) C94(2) C96(3) C99(1) C104(1) C3(1) 
87 replacement of 13 YES EIVS_CARDAM_LE1_10HCE040_46.xls CARDAM_LE 1 12/05/2011 C94(3) C99(2) C104(2) C3(2) C11(2) C12(2) C13(2) C15(2) C16(2) C21(2) C25(2) C27(2) C38(1) 
88 replacement of 14 YES EIVS_CARDAM_LE1_10HCE041_47.xls CARDAM_LE 1 12/05/2011 C99(3) C104(3) C3(3) C11(3) C12(3) C13(3) C15(3) C16(3) C21(3) C25(3) C27(3) C38(2) C45(2) 
89 YES EIVS_CARDAM_LE1_10HCE042_48.xls CARDAM_LE 1 12/05/2011 C38(3) C45(3) C46(3) C47(3) C50(3) C53(3) C62(3) C70(3) C83(3) C84(1) C98(1) C101(1) C119(2)
90 YES EIVS_CARDAM_LE2_10HCE037_43.xlsx CARDAM_LE 1 12/05/2011 C11(1) C12(1) C13(1) C15(1) C16(1) C21(1) C25(1) C27(1) 
91 YES EIVS_CARDAM_LE2_10HCE040_46.xls CARDAM_LE 1 12/05/2011 C45(1) C46(1) C47(1) C50(1) C53(1) C62(1) C70(1) C83(1) 
92 replacement of 16 YES EIVS_CARDAM_LE2_10HCE041_47.xls CARDAM_LE 1 12/05/2011 C46(2) C47(2) C50(2) C53(2) C62(2) C70(2) C83(2) C119(1) C6(1) 
93 replacement of 17 YES EIVS_CARDAM_LE2_10HCE042_48.xls CARDAM_LE 1 12/05/2011 C123(1) C127(1) C132(1) C134(1) C135(1) C6(2) 
94 replacement of 6 YES EIVS_CARDAM_LE_10HCE033Kt_40.xlsx CARDAM_LE 1 12/05/2011 C6(Kt) C30(Kt) C34(Kt) C54(Kt) C75(Kt) C87(Kt) C90(Kt) C104(Kt) 
95 replacement of 7 YES EIVS_CARDAM_LE_10HCE033kt_45.xlsx CARDAM_LE 1 12/05/2011 C3(Kt) C87(Kt) 
96 replacement of 9 YES EIVS_CARDAM_LE_10HCE044_50.xls CARDAM_LE 1 12/05/2011 C45(4) C84(2) C98(2) C101(2) C119(3) C123(2) C127(2) C132(2) C135(2) C6(3) 
97 YES EIVS_CARDAM_LE_11HCE001_Kt_2.xls CARDAM_LE 1 12/05/2011 C45(Kt) C53(Kt) C101(Kt) C113(Kt) C135(Kt) C128(Kt) 
98 YES EIVS_CARDAM_LE_11HCE003_3.xls CARDAM_LE 1 12/05/2011 C84(3) C98(3) C101(3) C123(3) C127(3) C132(3) C134(2) C135(3) C106(1) C107(1) C128(1) 
99 YES EIVS_CARDAM_LE_11HCE005_5.xls CARDAM_LE 1 12/05/2011 C105(1) C106(2) C107(2) C108(1) C110(1) C112(1) C134(3) C135(4) C136(1) C138(1) C139(1) C128(2) 
100 YES EIVS_CARDAM_LE_11HCE006_6.xls CARDAM_LE 1 12/05/2011 C105(2) C106(3) C107(3) C108(2) C110(2) C112(2) C113(1) C116(1) C136(2) C138(2) C139(2) C128(3) 
101 YES EIVS_CARDAM_LE_11HCE007_7.xls CARDAM_LE 1 12/05/2011 C105(3) C109(1) C120(1) C108(3) C125(1) C129(1) C113(2) C116(2) C131(1) 
102 YES EIVS_CARDAM_LE_11HCE008_8.xls CARDAM_LE 1 12/05/2011 C110(3) C109(2) C120(2) C124(1) C125(2) C129(2) C131(2) 
103 YES EIVS_CARDAM_LE_11HCE009_9.xls CARDAM_LE 1 12/05/2011 C136(3) C109(3) C120(3) C124(2) C138(3) C112(3) C113(3) C116(3) C139(3) 
104 MTT needed NO EIVS_CARDAM_LE_11HCE020_18.0.xls CARDAM_LE 1 12/05/2011 C124(3) C125(3) C129(3) C131(3) C4(1) C9(1) C20(1) C28(1) C48(1) C58(1) 
105 NO EIVS_CEETOX_LE_11HCE008_8_v1.0 JOEY.xls CEETOX_LE 1 16/06/2011 x13(1) x39(1) x8(1) x128(1) x103(2) x49(4) 
106 same as 85 NO EIVS_CEETOX_LE_11HCE008_8_v1.0 LISA.xls CEETOX_LE 1 16/06/2011 x62(1) x64(1) x65(1) x81(1) x82(1) x117(1) x43(1) x44(1) 
107 YES EIVS_CEETOX_LE_11HCE012 FK_16_v1.0 Set 1.xls CEETOX_LE 1 16/06/2011 X39(Kt) X8(Kt) X27(Kt) X46(Kt) X87(Kt) X108(Kt) X109(Kt) X110(Kt) X119(Kt) X133(Kt) X136(Kt) 
108 YES EIVS_CEETOX_LE_11HCE012 FK_16_v1.0 Set 2.xls CEETOX_LE 1 16/06/2011 x138(Kt) x139(Kt) 
109 NO EIVS_CEETOX_LE_11HCE013_13_v1.0 Set 1.xls CEETOX_LE 1 16/06/2011 x13(2) x39(1) x8(2) x128(2) x43(2) x62(2) x64(2) 
110 NO EIVS_CEETOX_LE_11HCE013_13_v1.0 Set 2.xls CEETOX_LE 1 16/06/2011 x65(2) x81(2) x82(2) x117(2) x112(1) x126(1) x21(1) x103(3) x63(3) x47(4) x17(4) 
111 YES EIVS_CARDAM_LE_11HCE020 Killed_22.xls CARDAM_LE 1 19/07/2011 C48(Kt) C58(Kt) C141(Kt) C170(Kt) C195(Kt) 
112 replacement of 104 YES EIVS_CARDAM_LE_11HCE020_18.xls CARDAM_LE 1 19/07/2011 C124(3) C125(3) C129(3) C131(3) C4(1) C9(1) C20(1) C28(1) C48(1) C58(1) 
113 YES EIVS_CARDAM_LE_11HCE022_19.xls CARDAM_LE 1 19/07/2011 C4(2) C9(2) C14(1) C20(2) C28(2) C29(1) C39(1) C48(2) C52(1) 
114 YES EIVS_CARDAM_LE_11HCE024_20.xls CARDAM_LE 1 19/07/2011 C4(3) C9(3) C14(2) C28(3) C29(2) C52(2) C56(1) C58(2) 
115 YES EIVS_CARDAM_LE_11HCE026_21.xls CARDAM_LE 1 19/07/2011 C14(3) C20(3) C29(3) C52(3) C56(2) C64(1) C67(1) C71(1) C97(1) C114(1) 
116 YES EIVS_CARDAM_LE_11HCE029_23.xls CARDAM_LE 1 19/07/2011 C39(2) C48(3) C55(1) C52(4) C56(3) C58(3) C103(1) C137(1) C140(1) C141(1) 
117 YES EIVS_CARDAM_LE_11HCE032_25.xls CARDAM_LE 1 19/07/2011 C39(3) C55(2) C64(2) C67(2) C163(1) C164(1) C166(1) C185(1) C170(1) C193(1) C195(1) C196(1) 
118 YES EIVS_CARDAM_LE_11HCE034_26.xls CARDAM_LE 1 19/07/2011 C55(3) C71(2) C97(2) C103(2) C114(2) C137(2) C140(2) C141(2) C163(2) C164(2) C166(2) C170(2) 
119 YES EIVS_CARDAM_LE_11HCE036_27.xls CARDAM_LE 1 19/07/2011 C64(3) C67(3) C71(3) C97(3) C103(3) C114(3) C137(3) C166(3) C185(2) C193(2) C195(2) C196(2) 
120 YES EIVS_CARDAM_LE_11HCE038_28.xls CARDAM_LE 1 19/07/2011 C140(3) C141(3) C163(3) C164(3) C166(4) C170(3) C185(3) C193(3) C195(3) C196(3) 
121 NO EIVS_CEETOX_LE_11HCE022_19_v1.0 SET 1.xls CEETOX_LE 1 08/08/2011 X21(2) X112(2) X126(2) X14(1) X46(1) X27(1) X50(1) X53(1) X70(1) X84(1) X87(1) X102(1) X107(1)
122 NO EIVS_CEETOX_LE_11HCE022_19_v1.0 SET 2.xls CEETOX_LE 1 08/08/2011 X108(1) X109(1) X110(1) X118(1) X136(1) X138(1) X139(1) X13(3) X43(3) X47(5) X59(3) X68(3) X8(3) 
123 NO EIVS_CEETOX_LE_11HCE022_19_v1.0 SET 3.xls CEETOX_LE 1 08/08/2011 X62(3) X64(3) X65(3) X81(3) X82(3) X117(3) X128(3) X39(3) PC2(1) PC3(1) 
124 MTT needed NO EIVS_CEETOX_LE_11HCE029_30_v1.0.xls CEETOX_LE 1 11/08/2011 X24(1) X32(1) X42(1) X95(1) X143(1) X165(1) X173(1) 
125 NO EIVS_CEETOX_LE_11HCE034_26_v1.0 Set 1.xls CEETOX_LE 1 11/08/2011 X14(2) X46(2) X27(2) X50(2) X53(2) X70(2) X84(2) X87(2) X102(2) X107(2) 
126 NO EIVS_CEETOX_LE_11HCE034_26_v1.0 Set 2.xls CEETOX_LE 1 11/08/2011 X108(2) X109(2) X110(2) X118(2) X136(2) X138(2) X139(2) X39(4) X21(3) X112(3) X126(3) 
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127 NO EIVS_CEETOX_LE_11HCE034_26_v1.0 Set 3.xls CEETOX_LE 1 11/08/2011 X111(1) X114(1) X115(1) X116(1) X119(1) X123(1) X125(1) X129(1) X131(1) X133(1) X134(1) 
128 NO EIVS_CEETOX_LE_11HCE040_29_v1.0 SET 1.xls CEETOX_LE 1 11/08/2011 X14(3) X46(3) X27(3) X50(3) X53(3) X70(3) X84(3) X87(3) X102(3) X107(3) 
129 NO EIVS_CEETOX_LE_11HCE040_29_v1.0 SET 2.xls CEETOX_LE 1 11/08/2011 X108(3) X109(3) X110(3) X118(3) X136(3) X138(3) X139(3) X111(2) X114(2) X115(2) X116(2) 
130 YES EIVS_LOREAL_LE_11HCE020_18.xls LOREAL_LE 1 12/08/2011 L1(1) L6(1) L13(1) L15(1) L16(1) L32(1) L33(1) L36(1) L37(1) 
131 YES EIVS_LOREAL_LE_11HCE022_19.xls LOREAL_LE 1 12/08/2011 L50(1) L53(1) L58(1) L62(1) L65(1) L76(1) L80(1) L100(1) L111(1) L125(1) L127(1) 
132 YES EIVS_LOREAL_LE_11HCE024_20.xls LOREAL_LE 1 12/08/2011 L144(1) L148(1) L156(1) L161(1) L164(1) L169(1) L174(1) L185(1) L200(1) L137(4) L6(2) 
133 YES EIVS_LOREAL_LE_11HCE026_21.xls LOREAL_LE 1 12/08/2011 L1(2) L13(2) L15(2) L16(2) L32(2) L33(2) L36(2) L37(2) L50(2) L53(2) L148(1) 
134 YES EIVS_LOREAL_LE_11HCE029_23.xls LOREAL_LE 1 12/08/2011 L33(3) L58(2) L62(2) L65(2) L76(2) L80(2) L100(2) L161(2) L169(2) L174(2) L111(2) L6 
135 YES EIVS_LOREAL_LE_11HCE032_25(1).xls LOREAL_LE 1 12/08/2011 L125(2) L127(2) L144(2) L148(2) L156(2) L164(2) L185(2) L200(2) L1(3) L6(3) L13(3) L16(3) L58(3) 
136 YES EIVS_LOREAL_LE_11HCE032_25(2).xls LOREAL_LE 1 12/08/2011 L100(3) 
137 YES EIVS_LOREAL_LE_11HCE034_26.xls LOREAL_LE 1 12/08/2011 L6(4) L15(3) L32(3) L36(3) L37(3) L50(3) L53(3) L62(3) L65(3) L76(3) L80(3) L111(3) L125(3) 
138 YES EIVS_LOREAL_LE_11HCE036_27.xls LOREAL_LE 1 12/08/2011 L6(5) L127(3) L144(3) L148(3) L156(3) L161(3) L164(3) L169(3) L174(3) L185(3) L200(3) 
139 YES EIVS_LOREAL_LE_11HCE002_2.xls LOREAL_LE 1 18/08/2011 L122(1) L123(1) L126(1) L129(1) L133(1) L134(1) L136(1) L137(1) L139(1) L140(1) L114(2) L115(2) 
140 YES EIVS_LOREAL_LE_11HCE006_6.xls LOREAL_LE 1 18/08/2011 L70(3) L72(3) L90(3) L99(3) L104(3) L106(3) L107(3) L108(3) 
141 YES EIVS_LOREAL_LE_11HCE007_7.xls LOREAL_LE 1 18/08/2011 L109(3) L112(3) L113(3) L114(3) L115(3) L118(2) L119(2) L120(2) L122(2) L123(2) 
142 YES EIVS_LOREAL_LE_11HCE008_8.xls LOREAL_LE 1 18/08/2011 L118(3) L119(3) L120(3) L122(3) L123(3) L126(2) L129(2) L130(2) L131(2) L132(2) L133(2) L134(2) 
143 YES EIVS_LOREAL_LE_11HCE009_9.xls LOREAL_LE 1 18/08/2011 L126(3) L129(3) L130(3) L131(3) L132(3) L133(3) L134(3) L136(2) L137(2) L139(2) L140(2) 
144 YES EIVS_LOREAL_LE_11HCE014_14.xls LOREAL_LE 1 18/08/2011 L136(3) L137(3) L139(3) L140(3) 
145 replacement of 20 YES EIVS_CEETOX_LE_10HCE023_25_v1.0 UPDATED.xls CEETOX_LE 2 31/10/2011 x1(1) x2(1) x5(1) x6(1) x7(1) x16(1) x22(1) x28(1) x36(1) x38(1) 
146 replacement of 21 YES EIVS_CEETOX_LE_10HCE024_26_v1.0.xls CEETOX_LE 2 31/10/2011 x1(2) x2(2) x5(2) x6(2) x7(2) x16(2) x22(2) x28(2) x36(2) x38(2) 
147 replacement of 22 YES EIVS_CEETOX_LE_10HCE042_48_v1.0 UPDATED.xls CEETOX_LE 2 31/10/2011 x1(3) x2(3) x5(3) x6(3) x7(3) x16(3) x22(3) x28(3) x36(3) x38(3) 
148 replacement of 23 YES EIVS_CEETOX_LE_10HCE043_49_v1.0 UPDATED.xls CEETOX_LE 2 31/10/2011 x1(4) x2(4) x5(4) x6(4) x7(4) x16(4) x22(4) x28(4) x36(4) x38(4) 
149 replacement of 24 YES EIVS_CEETOX_LE_10HCE044_50_v1.0 UPDATED.xls CEETOX_LE 2 31/10/2011 x1(5) x2(5) x5(5) x6(5) x7(5) x16(5) x22(5) x28(5) x36(5) x38(5) 
150 replacement of 25 YES EIVS_CEETOX_LE_11HCE003_3_v1.0 .xls CEETOX_LE 2 31/10/2011 x63(1) x72(1) x73(1) x83(1) x86(1) x89(1) x93(1) x98(1) x99(1) x103(1) 
151 replacement of 28 YES EIVS_CEETOX_LE_11HCE004_4_v1.0.xls CEETOX_LE 2 31/10/2011 x41(1) x17(1) x31(1) x91(1) x121(1) x3(1) x25(1) x30(1) x33(1) 
152 replacement of 76 YES EIVS_CEETOX_LE_11HCE004_4_v1.0 JOEY Updated.xls CEETOX_LE 2 31/10/2011 x45(1) x47(1) x49(1) x51(1) x52(1) x59(1) x68(1) 
153 replacement of 77 YES 
EIVS_CEETOX_LE_11HCE009_9_v1.0 Joey FAILED RUN 
UPDATED.XLS CEETOX_LE 2 31/10/2011 x13(2) x39(2) x8(2) x128(2) x64(2) x43(2) x44(2) x103(3) x63(3) 
154 replacement of 78 YES 
EIVS_CEETOX_LE_11HCE009_9_v1.0 LISA FAILED RUN 
UPDATED.XLS CEETOX_LE 2 31/10/2011 x62(2) x65(2) x81(2) x82(2) x117(2) 
155 replacement of 79 YES EIVS_CEETOX_LE_11HCE006_6_v1.0 SET 1 JOEY.XLS CEETOX_LE 2 31/10/2011 x72(2) x73(2) x83(2) x86(2) x89(2) x93(2) x98(2) x99(2) 
156 replacement of 80 YES EIVS_CEETOX_LE_11HCE006_6_v1.0 SET 2 JOEY.XLS CEETOX_LE 2 31/10/2011 x45(2) x47(2) x49(2) x51(2) x52(2) x59(2) x68(2) 
157 replacement of 81 YES EIVS_CEETOX_LE_11HCE006_6_v1.0.xls CEETOX_LE 2 31/10/2011 x41(2) x17(2) x31(2) x91(2) x121(2) x3(2) x25(2) x30(2) x33(2) 
158 replacement of 82 YES EIVS_CEETOX_LE_11HCE007_7_v1.0 SET 1.xls CEETOX_LE 2 31/10/2011 x63(2) x72(3) x73(3) x83(3) x86(3) x89(3) x93(3) x98(3) x99(3) 
159 replacement of 83 YES EIVS_CEETOX_LE_11HCE007_7_v1.0 SET 2 Joey.xls CEETOX_LE 2 31/10/2011 x45(3) x47(3) x49(3) x51(3) x52(3) 
160 replacement of 84 YES EIVS_CEETOX_LE_11HCE007_7_v1.0.xls CEETOX_LE 2 31/10/2011 x41(3) x17(3) x31(3) x91(3) x121(3) x3(3) x25(3) x30(3) x33(3) 
161 replacement of 85 YES EIVS_CEETOX_LE_11HCE008_8_v1.0 LISA.XLS CEETOX_LE 2 31/10/2011 x62(1) x64(1) x65(1) x81(1) x82(1) x117(1) x43(1) x44(1) 
162 replacement of 105 YES EIVS_CEETOX_LE_11HCE008_8_v1.0 JOEY.xls CEETOX_LE 2 31/10/2011 x13(1) x39(1) x8(1) x128(1) x103(2) x49(4) 
163 replacement of 109 YES EIVS_CEETOX_LE_11HCE013_13_v1.0 Set 1.xls CEETOX_LE 2 31/10/2011 x13(2) x39(1) x8(2) x128(2) x43(2) x62(2) x64(2) 
164 replacement of 110 YES EIVS_CEETOX_LE_11HCE013_13_v1.0 Set 2.xls CEETOX_LE 2 31/10/2011 x65(2) x81(2) x82(2) x117(2) x112(1) x126(1) x21(1) x103(3) x63(3) x47(4) x17(4) 
165 replacement of 121 YES EIVS_CEETOX_LE_11HCE022_19_v1.0 SET 1.xls CEETOX_LE 2 11/11/2011 X21(2) X112(2) X126(2) X14(1) X46(1) X27(1) X50(1) X53(1) X70(1) X84(1) X87(1) X102(1) 
166 replacement of 122 NO EIVS_CEETOX_LE_11HCE022_19_v1.0 SET 2.xls CEETOX_LE 2 11/11/2011 X108(1) X109(1) X110(1) X118(1) X136(1) X138(1) X139(1) X13(3) X43(3) X47(5) X59(3) X68(3) 
167 replacement of 123 YES EIVS_CEETOX_LE_11HCE022_19_v1.0 SET 3.xls CEETOX_LE 2 11/11/2011 X62(3) X64(3) X65(3) X81(3) X82(3) X117(3) X128(3) X39(3) PC2(1) PC3(1) X107(1)
168 replacement of 125 YES EIVS_CEETOX_LE_11HCE034_26_v1.0 Set 1.xls CEETOX_LE 2 11/11/2011 X14(2) X46(2) X27(2) X50(2) X53(2) X70(2) X84(2) X87(2) X102(2) X107(2) X8(3) 
169 replacement of 126 NO EIVS_CEETOX_LE_11HCE034_26_v1.0 Set 2.xls CEETOX_LE 2 11/11/2011 X108(2) X109(2) X110(2) X118(2) X136(2) X138(2) X139(2) X39(4) X21(3) X112(3) X126(3) 
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170 replacement of 127 YES EIVS_CEETOX_LE_11HCE034_26_v1.0 Set 3.xls CEETOX_LE 2 11/11/2011 X111(1) X114(1) X115(1) X116(1) X119(1) X123(1) X125(1) X129(1) X131(1) X133(1) X134(1) 
171 replacement of 128 YES EIVS_CEETOX_LE_11HCE040_29_v1.0 SET 1.xls CEETOX_LE 2 11/11/2011 X14(3) X46(3) X27(3) X50(3) X53(3) X70(3) X84(3) X87(3) X102(3) X107(3) 
172 replacement of 129 YES EIVS_CEETOX_LE_11HCE040_29_v1.0 SET 2.xls CEETOX_LE 2 11/11/2011 X108(3) X109(3) X110(3) X118(3) X136(3) X138(3) X139(3) X111(2) X114(2) X115(2) X116(2) 
173 EIVS_CEETOX_LE_11HCE020_18_v1.0 SET 1.xls CEETOX_LE 1 11/11/2011 #REF! #REF! #REF! #REF! #REF! #REF! #REF! #REF! 
174 EIVS_CEETOX_LE_11HCE020_18_v1.0 SET 2.xls CEETOX_LE 1 11/11/2011 X62(5) X64(5) X65(5) X81(5) X82(5) X117(5) X128(5) X39(5) 
X118 
FK(1) X68(5) 
175 EIVS_CEETOX_LE_11HCE047_37_v1.0.xls CEETOX_LE 1 11/11/2011 X111(6) X114(6) X115(6) X116(6) X50(6) X119(6) X123(6) X125(6) X129(6) X131(6) 
176 EIVS_CEETOX_LE_11HCE049_38_v1.0.xls CEETOX_LE 1 11/11/2011 X111(4) X114(4) X115(4) X116(4) X50(5) X119(3) X123(3) X125(3) X129(3) X131(3) 
177 EIVS_CEETOX_LE_11HCE051_39_v1.0.xls CEETOX_LE 1 11/11/2011 X133(2) X134(2) X119(4) X123(4) X125(4) X129(4) X131(4) X11(1) X19(1) X29(1) 
178 EIVS_CEETOX_LE_11HCE053_40_v1.0.xls CEETOX_LE 1 11/11/2011 X133(1) X134(1) X11(1) X19(1) X29(1) X24(1) X32(1) X37(1) 
179 EIVS_CEETOX_LE_11HCE055_41_v1.0.xls CEETOX_LE 1 11/11/2011 X37(2) X143(1) X190(1) X173(1) X169(1) X133(4) X127(1) 
180 EIVS_CEETOX_LE_11HCE057_42_v1.0.xls CEETOX_LE 1 11/11/2011 X37(1) X143(2) X190(2) X173(2) X169(2) X127(2) X40(1) 
181 EIVS_CEETOX_LE_11HCE059_43_v1.0.xls CEETOX_LE 1 16/12/2011 X37(2) X143(3) X190(3) X173(1) X169(3) X127(3) X40(2) X134(4) X196(1) X11(3) X19(3) 
182 EIVS_CEETOX_LE_11HCE061_44_v1.0.xls CEETOX_LE 1 16/12/2011 X37(5) X173(4) X40(3) X196(2) X11(4) X19(4) X24(2) X32(2) 
183 EIVS_CEETOX_LE_11HCE063_45_v1.0.xls CEETOX_LE 1 16/12/2011 X173(5) X24(3) X29(3) X196(3) X42(1) X55(1) X56(1) X61(1) X66(1) X75(1) 
184 EIVS_CEETOX_LE_11HCE065_46_v1.0.xls CEETOX_LE 1 04/01/2012 X24(2) X42(2) X55(2) X95(2) X113(2) X120(2) X157(2) X158(2) X160(2) X165(2) 
185 EIVS_CEETOX_LE_11HCE068_48_v1.0.xls CEETOX_LE 1 04/01/2012 X29(4) X77(2) X80(2) X94(2) X95(1) X113(1) X120(1) X157(1) X158(1) X160(1) X165(1) 
186 EIVS_CEETOX_LE_11HCE070_49_v1.0.xls CEETOX_LE 1 04/01/2012 X24(2) X42(2) X55(2) X95(2) X113(2) X120(2) X157(2) X158(2) X160(2) X165(2) 
187 EIVS_CEETOX_LE_12HCE002_2_v1.0 - Set 1.xls CEETOX_LE 1 24/01/2012 X24(5) X32(4) X42(4) X55(4) X56(3) X165(3) X66(3) 
188 EIVS_CEETOX_LE_12HCE002_2_v1.0 - Set 2.xls CEETOX_LE 1 24/01/2012 X75(3) X77(3) X80(3) X94(3) X95(1) X113(3) X120(3) X157(3) X158(3) X160(3) X61(1) 
189 EIVS_CEETOX_LE_12HCE004_3_v1.0.xls CEETOX_LE 1 24/01/2012 X95(4) X113(4) X120(4) X157(4) X158(4) X160(4) X165(4) X61(4) 
190 EIVS_CEETOX_LE_12HCE009_7_v1.0.xls CEETOX_LE 1 06/03/2012 x95(2) 
191 replacement of 151 
EIVS_CEETOX_LE_11HCE004_4_v1.0 UPDATE 
X17FK.XLS CEETOX_LE 2 21/12/2013 x17(1) 
192 replacement of 157 
EIVS_CEETOX_LE_11HCE006_6_v1.0 UPDATED 
X17FK.XLS CEETOX_LE 2 21/12/2013 x17(2) 
193 replacement of 160 
EIVS_CEETOX_LE_11HCE007_7_v1.0 UPDATE 
X17FK.XLS CEETOX_LE 2 21/12/2013 x17(3) 
194 replacement of 164 
EIVS_CEETOX_LE_11HCE013_13_v1.0 Set 2 
UPDATE X17FK.XLS CEETOX_LE 2 21/12/2013 x17(4) 
195 EIVS_CEETOX_LE_12HCE0 FK_48_v1.0 run 1.xls CEETOX_LE 2 21/12/2013 




2.xls CEETOX_LE 2 19/09/2012 X108(2) X109(2) X110(2) X118(2) X136(2) X138(2) X139(2) X39(6) X21(3) X112(3) X126(3) 
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Appendix IV Remarks and special observations by the study personal 
CARDAM in an email to TNO:  
I understand that the VMG still wants the freedom to decide what to do with the data were %NSC or %NSMTT > 50 %; but I would be very carefully 
using these mean viability and std viability, so I wrote that in my comment column. Maybe an idea is to make a separate table with this kind of data, 
or maybe already when >30 % ... 
 
SE 
laboratory remark filename 
CARDAM In the first and second tissue of C78, the test item was 
pulling towards the edges 
EIVS_CARDAM_SE1_10HCE035_41.xls 
CARDAM C76 has created a hole in the tissues EIVS_CARDAM_SE1_10HCE035_41.xls 
CARDAM Test item C78 was pulling towards the edges EIVS_CARDAM_SE1_10HCE036_42.xls 
CARDAM C96 this time the test item was not washed with a 
cotton bud ( as in 10HCE035), 
EIVS_CARDAM_SE1_10HCE036_42.xls 
CARDAM however minimal damage in the middle of the tissue 
was observed, so must be test item specific 
EIVS_CARDAM_SE1_10HCE036_42.xls 
CARDAM C104 tissue are broken EIVS_CARDAM_SE1_10HCE037_43.xls 
CARDAM C11 and C12: tissues are partially or completely 
damaged by the test item after wash step 
EIVS_CARDAM_SE1_10HCE037_43.xls 
CARDAM C90 tissue eaten away EIVS_CARDAM_SE1_10HCE037_43.xls 
CARDAM C45 tissue 2 test item still a little present on plastic cup 
after washing 
EIVS_CARDAM_SE1_10HCE040_46.xls 
CARDAM C45 tissues are still colored after washing step EIVS_CARDAM_SE1_10HCE041_47.xls 
CARDAM C62 test item melts after application on tissues EIVS_CARDAM_SE1_10HCE041_47.xls 
CARDAM C53: %NSMTT is unqualified because >50%; condition 2! 
(see e-mail from Nathalie 5th Nov 2010!) 
EIVS_CARDAM_SE1_10HCE041_47.xls 
CARDAM SD >18% for killed tissue C53 but this is not the case in 
run SE from week 48. Not repeat killed tissue because 
test 
EIVS_CARDAM_SE1_10HCE041_47.xls 
CARDAM item is not compatible for HCE test EIVS_CARDAM_SE1_10HCE041_47.xls 
CARDAM C45 tissues are still colored after washing step EIVS_CARDAM_SE1_10HCE042_48.xls 
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laboratory remark filename 
CARDAM C62 test item melts after application on tissues EIVS_CARDAM_SE1_10HCE042_48.xls 
CARDAM C6: no picture taken after 3h MTT because can not leave 
Biohazard in lab L0210 because of strong smell 
EIVS_CARDAM_SE1_10HCE042_48.xls 
CARDAM C53: %NSMTT is unqualified because >50%; condition 2! 
(see e-mail from Nathalie 5th Nov 2010!) 
EIVS_CARDAM_SE1_10HCE042_48.xls 
CARDAM C96 tissue has small black dot= pigment EIVS_CARDAM_SE2_10HCE035_41.xls 
CARDAM C96 very sticky so for washing needed to use cotton 
swab and after MTT incubation saw that all 3 tissues 
damaged 
EIVS_CARDAM_SE2_10HCE035_41.xls 
CARDAM C11 tissue 3 has come loose during washing step, but 
was not washed away 
EIVS_CARDAM_SE2_10HCE036_42.xls 
CARDAM / EIVS_CARDAM_SE2_10HCE037_43.xls 
CARDAM C62 test item melts after application on tissues EIVS_CARDAM_SE2_10HCE040_46.xls 
CARDAM C123 test item is ,not completely dissolved, suspension EIVS_CARDAM_SE2_10HCE041_47.xls 
CARDAM C134 test item reacts with the plastic cup, cup became 
white 
EIVS_CARDAM_SE2_10HCE041_47.xls 
CARDAM C6, no pictures, test item can not leave lab L0210, 
terrible smell. 
EIVS_CARDAM_SE2_10HCE041_47.xls 
CARDAM C138: Tissue 3 has a small hole after washing EIVS_CARDAM_SE2_10HCE042_48.xls 
CARDAM C134 test item reacts with the plastic cup EIVS_CARDAM_SE2_10HCE042_48.xls 
CARDAM C6, no pictures, test item can not leave lab L0210, 
terrible smell. 
EIVS_CARDAM_SE2_10HCE042_48.xls 
CARDAM No pictures from C30 en C33, short exposure. 
Observation done without pictures 
EIVS_CARDAM_SE_10HCE029_35.xls 
CARDAM Test item C17 sticks to tissue, wash off with cotton bud. EIVS_CARDAM_SE_10HCE029_35.xls 
CARDAM Test item C17and test item C30, MTT solution beneath 
tissue is purple after 3H incubation and not just tissue 
EIVS_CARDAM_SE_10HCE029_35.xls 
CARDAM PBS without Ca and Mg is used from set 4 short 
exposure untill positive controle long exposure 
EIVS_CARDAM_SE_10HCE029_35.xls 
CARDAM for C26, after 3 h MTT: 2 tissues white and 1 light purple 
(AVR) 
EIVS_CARDAM_SE_10HCE029_35.xls 
CARDAM First tissue of c17 was not fully covered + because the 
test item was hard to remove there can be 
EIVS_CARDAM_SE_10HCE031_37.xls 
CARDAM a possible damage of the tissues after washing EIVS_CARDAM_SE_10HCE031_37.xls 
CARDAM first tissue of c19 was damaged in the middle, after EIVS_CARDAM_SE_10HCE031_37.xls 
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laboratory remark filename 
10min all tissue were damaged 
CARDAM second tissue of c35 was not fully covered, a part of the 
tissue from tissue 1 and 2 was gone after washing 
EIVS_CARDAM_SE_10HCE031_37.xls 
CARDAM c35 was spread with a regular pipette EIVS_CARDAM_SE_10HCE031_37.xls 
CARDAM Test item C17 sticks to tissue, wash off with cotton bud. EIVS_CARDAM_SE_10HCE031_37.xls 
CARDAM Test item C17and testitem C30, MTT solution beneath 
tissue is purple after 3H incubation and not just tissue 
EIVS_CARDAM_SE_10HCE031_37.xls 
CARDAM C1, C2, C17, C19, C26 and C77 were applied with normal 
pipette 
EIVS_CARDAM_SE_10HCE032_38.xls 
CARDAM MTT stock solution was not completely dissolved EIVS_CARDAM_SE_10HCE032_38.xls 
CARDAM Test item C17 sticks to tissue, wash off with cotton bud. EIVS_CARDAM_SE_10HCE032_38.xls 
CARDAM Test item C17and test item C30, MTT solution beneath 
tissue is purple after 3H incubation and not just tissue 
EIVS_CARDAM_SE_10HCE032_38.xls 
CARDAM / EIVS_CARDAM_SE_10HCE033_39(C77).xls 
CARDAM C76 difficult to spread, liquid sticks together EIVS_CARDAM_SE_10HCE033_39.xls 
CARDAM / EIVS_CARDAM_SE_10HCE034_40(C79).xls 
CARDAM C78 tissue 1, air bubble was present during MTT 
incubation 
EIVS_CARDAM_SE_10HCE034_40.xls 
CARDAM C65 tissue 1, air bubble was present during MTT 
incubation 
EIVS_CARDAM_SE_10HCE034_40.xls 
CARDAM C76 has created a hole in the tissues EIVS_CARDAM_SE_10HCE034_40.xls 
CARDAM C45 and C101 tissues are still colored after washing step EIVS_CARDAM_SE_10HCE044_50.xls 
CARDAM C6 no picture taken because needs to stay in Biohazard 
because of smell 
EIVS_CARDAM_SE_10HCE044_50.xls 
CARDAM C53: %NSMTT is unqualified because >50%; condition 2! 
(see e-mail from Nathalie 5th Nov 2010!) 
EIVS_CARDAM_SE_10HCE044_50.xls 
CARDAM SD >18% for killed tissue C53 but this is not the case in 
run SE from week 48. Not repeat killed tissue because 
test 
EIVS_CARDAM_SE_10HCE044_50.xls 
CARDAM item is not compatible for HCE test EIVS_CARDAM_SE_10HCE044_50.xls 
CARDAM C134 and C138: It looks like a white precipitate is formed 
on the tissues. Reaction of test item with the tissue??? 
EIVS_CARDAM_SE_11HCE003_3.xls 
CARDAM Tissues might have had extra stress, Since the delivery 
by courier went first wrongly to UK and then to CARDAM 
EIVS_CARDAM_SE_11HCE003_3.xls 
CARDAM C138: It looks like a white precipitate is formed on the EIVS_CARDAM_SE_11HCE005_5.xls 
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laboratory remark filename 
tissues. Reaction of test item with the tissue??? 
CARDAM C113, solid that sticks together, difficult to spread. EIVS_CARDAM_SE_11HCE005_5.xls 
CARDAM C113, solid that sticks together, spreading was OK this 
time 
EIVS_CARDAM_SE_11HCE006_6.xls 
CARDAM C124 is a solid resin. You have to weigh 1 piece of +- 
30mg. It can not be spread on the tissue. On tissue 1 I 
tried to 
EIVS_CARDAM_SE_11HCE006_6.xls 
CARDAM use a mesh but it doesn't help. EIVS_CARDAM_SE_11HCE006_6.xls 
CARDAM C116, looks like glass pieces. EIVS_CARDAM_SE_11HCE006_6.xls 
CARDAM C109, sticky but with positive placement pipette it is OK EIVS_CARDAM_SE_11HCE007_7.xls 
CARDAM Wash with cotton tip EIVS_CARDAM_SE_11HCE007_7.xls 
CARDAM C109, sticky but with positive placement pipette it is OK EIVS_CARDAM_SE_11HCE008_8.xls 
CARDAM Wash with cotton tip EIVS_CARDAM_SE_11HCE008_8.xls 
CARDAM C124, resin, difficult to cover whole tissue. EIVS_CARDAM_SE_11HCE008_8.xls 
CARDAM C109, sticky but with positive placement pipette it is OK EIVS_CARDAM_SE_11HCE009_9.xls 
CARDAM Wash with cotton tip EIVS_CARDAM_SE_11HCE009_9.xls 
CARDAM C124, resin, difficult to cover whole tissue. EIVS_CARDAM_SE_11HCE009_9.xls 
CARDAM C28, first tissue damaged by cotton tip EIVS_CARDAM_SE_11HCE020_18.xls 
CARDAM C28 and C52, washed once more after MTT incubation, 
before isopropanol incubation 
EIVS_CARDAM_SE_11HCE020_18.xls 
CARDAM C28 and C52, washed once more after MTT incubation, 
before isopropanol incubation 
EIVS_CARDAM_SE_11HCE022_19.xls 
CARDAM C28 and C52, washed once more after MTT incubation, 
before isopropanol incubation 
EIVS_CARDAM_SE_11HCE024_20.xls 
CARDAM C52, washed once more after MTT incubation, before 
isopropanol incubation 
EIVS_CARDAM_SE_11HCE026_21.xls 
CARDAM C52, washed once more after MTT incubation, before 
isopropanol incubation 
EIVS_CARDAM_SE_11HCE029_23.xls 
CARDAM C55, wash with cotton tip, forms a mucus layer EIVS_CARDAM_SE_11HCE029_23.xls 
CARDAM C55, wash with cotton tip, forms a mucus layer EIVS_CARDAM_SE_11HCE032_25.xls 
CARDAM C163, viscous, difficult to spread EIVS_CARDAM_SE_11HCE032_25.xls 
CARDAM C163, viscous, difficult to spread EIVS_CARDAM_SE_11HCE034_26.xls 
CARDAM C163, viscous, difficult to spread EIVS_CARDAM_SE_11HCE036_27.xls 
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laboratory remark filename 
CEETOX C1c -- it felt like I scratched the tissue, there may be a 
small mark. 
EIVS_CEETOX_SE_10HCE023_25_v1.0.xls 
CEETOX C2a -- 10 seconds late rinsing. EIVS_CEETOX_SE_10HCE023_25_v1.0.xls 
CEETOX C2 -- plastic of the insert looks etched around the top. EIVS_CEETOX_SE_10HCE023_25_v1.0.xls 
CEETOX C3a -- touched the tip to the tissue during the 
application. 
EIVS_CEETOX_SE_10HCE023_25_v1.0.xls 
CEETOX C3 -- compound is very thin and difficult to spread. EIVS_CEETOX_SE_10HCE023_25_v1.0.xls 
CEETOX C4 -- tissue looks rippled. EIVS_CEETOX_SE_10HCE023_25_v1.0.xls 
CEETOX C5 -- compound spread at first, but then pulled to the 
sides and became harder to spread 
EIVS_CEETOX_SE_10HCE023_25_v1.0.xls 
CEETOX C6a -- chunks of the compounds, most of the tissue is 
covered 
EIVS_CEETOX_SE_10HCE023_25_v1.0.xls 
CEETOX C6b -- compound is still chunky, however there is better 
coverage; some compound was left in the glass weigh 
boat. 
EIVS_CEETOX_SE_10HCE023_25_v1.0.xls 
CEETOX There was not enough time to tap it out. EIVS_CEETOX_SE_10HCE023_25_v1.0.xls 
CEETOX C6c -- same as above, some compound left in plastic 
weigh boat as well. 
EIVS_CEETOX_SE_10HCE023_25_v1.0.xls 
CEETOX C7 -- like C5 very difficult to spread. C7b looked better, 
but pulled to sides again later 
EIVS_CEETOX_SE_10HCE023_25_v1.0.xls 
CEETOX C9a -- some compound fell out into the plastic weigh 
boat during application, and seemed to stick to the sides 
of the insert. 
EIVS_CEETOX_SE_10HCE023_25_v1.0.xls 
CEETOX C9c -- lost some compound in the plastic weigh boat. EIVS_CEETOX_SE_10HCE023_25_v1.0.xls 
CEETOX C9 -- during rinsing of a the compound looked like some 
had dissolved. 
EIVS_CEETOX_SE_10HCE023_25_v1.0.xls 
CEETOX in b there was a bubbled on the tissue. EIVS_CEETOX_SE_10HCE023_25_v1.0.xls 
CEETOX PCb - dropped in funnel during rinsing. Tissue looks fine. EIVS_CEETOX_SE_10HCE024_26_v1.0.xls 
CEETOX C1 - a little compound left in each glass weigh boat EIVS_CEETOX_SE_10HCE024_26_v1.0.xls 
CEETOX C3 - liquid is thin, a little difficulty spreading, but it looks 
like good coverage 
EIVS_CEETOX_SE_10HCE024_26_v1.0.xls 
CEETOX C4 - same as C3 EIVS_CEETOX_SE_10HCE024_26_v1.0.xls 
CEETOX C3 - plastic looks degraded during rinsing EIVS_CEETOX_SE_10HCE024_26_v1.0.xls 
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laboratory remark filename 
CEETOX C4b - tissue looks wrinkled EIVS_CEETOX_SE_10HCE024_26_v1.0.xls 
CEETOX C5 - compound pulled to sides, or looked like it 
evaporated 
EIVS_CEETOX_SE_10HCE024_26_v1.0.xls 
CEETOX C5 rinsing - plastic degraded EIVS_CEETOX_SE_10HCE024_26_v1.0.xls 
CEETOX C6 - clumpy, a little left in glass weigh boat in each EIVS_CEETOX_SE_10HCE024_26_v1.0.xls 
CEETOX C7 - a little difficulty spreading; tissue is mostly covered EIVS_CEETOX_SE_10HCE024_26_v1.0.xls 
CEETOX rinsing - plastic degraded EIVS_CEETOX_SE_10HCE024_26_v1.0.xls 
CEETOX C9 - some compound left in glass weigh boat EIVS_CEETOX_SE_10HCE024_26_v1.0.xls 
CEETOX C10 - a little difficulty spreading EIVS_CEETOX_SE_10HCE024_26_v1.0.xls 
CEETOX C9 rinsing - middle of tissue looks like compound melted EIVS_CEETOX_SE_10HCE024_26_v1.0.xls 
CEETOX NC c -- may have scratched the tissue, does not look 
scratched 
EIVS_CEETOX_SE_10HCE025_27_v1.0.xls 
CEETOX PC a -- bubbles around the rim of the tissue EIVS_CEETOX_SE_10HCE025_27_v1.0.xls 
CEETOX C1 -- some clumps, good coverage, a little compound 
stuck on the sides 
EIVS_CEETOX_SE_10HCE025_27_v1.0.xls 
CEETOX C3 -- compound not staying spread on earlier tissues (a 
and b). 
EIVS_CEETOX_SE_10HCE025_27_v1.0.xls 
CEETOX C4 -- a looks like it has good coverage, but b is not 
spreading well, c had good coverage 
EIVS_CEETOX_SE_10HCE025_27_v1.0.xls 
CEETOX C6 -- large clumps of compound in the middle, but tissue 
is mostly covered 
EIVS_CEETOX_SE_10HCE025_27_v1.0.xls 
CEETOX C7 -- Rinsing - plastic degraded EIVS_CEETOX_SE_10HCE025_27_v1.0.xls 
CEETOX b -- rinsed 10 seconds late EIVS_CEETOX_SE_10HCE025_27_v1.0.xls 
CEETOX C9 -- a some up on sides of insert; a little left in the glass 
weigh boat for all three 
EIVS_CEETOX_SE_10HCE025_27_v1.0.xls 
CEETOX C1 -- a would not spread, worked better after I went 
back to it 
EIVS_CEETOX_SE_10HCE027_29_v1.0.xls 
CEETOX C2 -- lots stuck in wht weigh boats; it was caked on and 
would not tap out. 
EIVS_CEETOX_SE_10HCE027_29_v1.0.xls 
CEETOX clumpy compound; broke up gently using the pipette EIVS_CEETOX_SE_10HCE027_29_v1.0.xls 
CEETOX Rinsing -- a dropped in funnel EIVS_CEETOX_SE_10HCE027_29_v1.0.xls 
CEETOX C3 -- clumpy compound; spread out with tip EIVS_CEETOX_SE_10HCE027_29_v1.0.xls 
CEETOX b -- lost some from the glass weigh boat while tapping EIVS_CEETOX_SE_10HCE027_29_v1.0.xls 
CEETOX C4 -- tissues looked slightly ripped during rinsing EIVS_CEETOX_SE_10HCE027_29_v1.0.xls 
CEETOX C5 -- residual compound left in the glass weigh boats EIVS_CEETOX_SE_10HCE027_29_v1.0.xls 
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laboratory remark filename 
CEETOX C6 -- compound was very difficult to spread because it 
was so thin 
EIVS_CEETOX_SE_10HCE027_29_v1.0.xls 
CEETOX C7 -- thin compound, some difficulty spreading EIVS_CEETOX_SE_10HCE027_29_v1.0.xls 
CEETOX Rinsing -- a ripped, c had small tear EIVS_CEETOX_SE_10HCE027_29_v1.0.xls 
CEETOX C9 -- some compound stuck to glass weigh boat EIVS_CEETOX_SE_10HCE027_29_v1.0.xls 
CEETOX clumpy compound; spread with pipette tip EIVS_CEETOX_SE_10HCE027_29_v1.0.xls 
CEETOX C10 -- compound appears to spread well, but after 10 
seconds it seems to pull away to the sides 
EIVS_CEETOX_SE_10HCE027_29_v1.0.xls 
CEETOX C1 -- difficult to spread; thin compound; c spread better 
than a and b 
EIVS_CEETOX_SE_10HCE028_30_v1.0.xls 
CEETOX C2 -- a coated on the glass weigh boat; some compound 
fell out of the weigh boat as well 
EIVS_CEETOX_SE_10HCE028_30_v1.0.xls 
CEETOX b same as a, some compound left on the outside of the 
glass weigh boat 
EIVS_CEETOX_SE_10HCE028_30_v1.0.xls 
CEETOX c less compound stuck in the glass weigh boat, spread 
better 
EIVS_CEETOX_SE_10HCE028_30_v1.0.xls 
CEETOX Rinsing -- plastic degraded EIVS_CEETOX_SE_10HCE028_30_v1.0.xls 
CEETOX C3 -- a stuck to glass weigh boat, difficult to tap out EIVS_CEETOX_SE_10HCE028_30_v1.0.xls 
CEETOX b came out better, but still some compound stuck EIVS_CEETOX_SE_10HCE028_30_v1.0.xls 
CEETOX c tapped some out of weigh boat, not all added to tissue 
(only a very small amount) 
EIVS_CEETOX_SE_10HCE028_30_v1.0.xls 
CEETOX Used pipette on all of these to move the compound 
around. Powder still on the tissue at rinsing, but 
clumped up 
EIVS_CEETOX_SE_10HCE028_30_v1.0.xls 
CEETOX C6 -- difficult to spread; rippled tissue at rinsing EIVS_CEETOX_SE_10HCE028_30_v1.0.xls 
CEETOX C7 -- slightly thin, but compound seemed to spread well EIVS_CEETOX_SE_10HCE028_30_v1.0.xls 
CEETOX c compound splashed a little out of insert EIVS_CEETOX_SE_10HCE028_30_v1.0.xls 
CEETOX Rinsing -- a had a small rip; c tissue folded up some EIVS_CEETOX_SE_10HCE028_30_v1.0.xls 
CEETOX C9 -- compound clumpy, some stuck on the glass weigh 
boat; good coverage 
EIVS_CEETOX_SE_10HCE028_30_v1.0.xls 
CEETOX C10 -- b spread better than a EIVS_CEETOX_SE_10HCE028_30_v1.0.xls 
CEETOX C1 -- thin liquid, pulled to sides, hard to spread EIVS_CEETOX_SE_10HCE042_48_v1.0.xls 
CEETOX C2 -- some compound stuck in weigh boat EIVS_CEETOX_SE_10HCE042_48_v1.0.xls 
CEETOX C3b -- a little clumpy, but seemed to spread ok EIVS_CEETOX_SE_10HCE042_48_v1.0.xls 
CEETOX C5 -- compound left in weigh boat; tissues stained EIVS_CEETOX_SE_10HCE042_48_v1.0.xls 
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CEETOX C6 -- a little difficulty spreading; tissues are rippled after 
rinsing 
EIVS_CEETOX_SE_10HCE042_48_v1.0.xls 
CEETOX C7c -- tissue doesn't look good, ripped on the bottom 
during rinsing 
EIVS_CEETOX_SE_10HCE042_48_v1.0.xls 
CEETOX C9b -- large clump, but the tissue is still covered EIVS_CEETOX_SE_10HCE042_48_v1.0.xls 
CEETOX C1 -- difficult to spread; tissues looked like they were 
peeling after they were rinsed 
EIVS_CEETOX_SE_10HCE043_49_v1.0.xls 
CEETOX C1 a -- tissue torn a little EIVS_CEETOX_SE_10HCE043_49_v1.0.xls 
CEETOX C2 a -- compound in weigh boat, some compound left in 
glass weigh boat 
EIVS_CEETOX_SE_10HCE043_49_v1.0.xls 
CEETOX C2 b and c -- some compound left in glass weigh boat EIVS_CEETOX_SE_10HCE043_49_v1.0.xls 
CEETOX C3 a -- could not spread well, used tip EIVS_CEETOX_SE_10HCE043_49_v1.0.xls 
CEETOX C3 b -- spread better, dosed 30 seconds late EIVS_CEETOX_SE_10HCE043_49_v1.0.xls 
CEETOX C4 a -- tissue came off (it appears) EIVS_CEETOX_SE_10HCE043_49_v1.0.xls 
CEETOX C4 b -- tissue degraded EIVS_CEETOX_SE_10HCE043_49_v1.0.xls 
CEETOX C6 -- hard to spread well and did not stay spread over 
the tissues 
EIVS_CEETOX_SE_10HCE043_49_v1.0.xls 
CEETOX C7 b -- dosed 30 seconds late EIVS_CEETOX_SE_10HCE043_49_v1.0.xls 
CEETOX C1 a -- tissue looked very smooth after rinsing; cannot 
tell if tissue was lost 
EIVS_CEETOX_SE_10HCE044_50_v1.0.xls 
CEETOX C2 -- compound left in all three glass weigh boats EIVS_CEETOX_SE_10HCE044_50_v1.0.xls 
CEETOX C3 -- compound left in all three glass weigh boats, not 
too much 
EIVS_CEETOX_SE_10HCE044_50_v1.0.xls 
CEETOX C4 -- tissue may have dissolved; cannot tell EIVS_CEETOX_SE_10HCE044_50_v1.0.xls 
CEETOX C7 FK a -- tissue cracked after rinsing EIVS_CEETOX_SE_10HCE044_50_v1.0.xls 
CEETOX C7 FK b -- dosed 30 seconds late EIVS_CEETOX_SE_10HCE044_50_v1.0.xls 
CEETOX NC c -- dropped in funnel EIVS_CEETOX_SE_11HCE004_4_v1.0 JOEY.xls 
CEETOX PC c -- dropped in funnel EIVS_CEETOX_SE_11HCE004_4_v1.0 JOEY.xls 
CEETOX C2 -- used tip to spread compound; some compound left 
in all weigh boats 
EIVS_CEETOX_SE_11HCE004_4_v1.0 JOEY.xls 
CEETOX C1 -- tissue looks like it has bubbles underneath it after 
rinsing 
EIVS_CEETOX_SE_11HCE004_4_v1.0 JOEY.xls 
CEETOX C3 -- dropped tissue a after compound dosed; had 
better coverage on tissues b and c 
EIVS_CEETOX_SE_11HCE004_4_v1.0 JOEY.xls 
CEETOX C4 -- tissues disintegrated during rinsing EIVS_CEETOX_SE_11HCE004_4_v1.0 JOEY.xls 
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CEETOX C6 -- compound is thin and difficult to spread EIVS_CEETOX_SE_11HCE004_4_v1.0 JOEY.xls 
CEETOX C7 - thin; difficult to spread EIVS_CEETOX_SE_11HCE004_4_v1.0 JOEY.xls 
CEETOX C1- precipitate in compound bottle EIVS_CEETOX_SE_11HCE004_4_v1.0.xls 
CEETOX C1a- 15 seconds late on rinse EIVS_CEETOX_SE_11HCE004_4_v1.0.xls 
CEETOX C2b- dropped rinsed tissue EIVS_CEETOX_SE_11HCE004_4_v1.0.xls 
CEETOX C3a- 15 seconds late on rinse EIVS_CEETOX_SE_11HCE004_4_v1.0.xls 
CEETOX C4- not all compound removed from tissue with extra 
rinse 
EIVS_CEETOX_SE_11HCE004_4_v1.0.xls 
CEETOX C4a- compound remaining in weigh boat EIVS_CEETOX_SE_11HCE004_4_v1.0.xls 
CEETOX C4b- clump of compound on tissue EIVS_CEETOX_SE_11HCE004_4_v1.0.xls 
CEETOX C4c- compound remaining in weigh boat EIVS_CEETOX_SE_11HCE004_4_v1.0.xls 
CEETOX C5b - late rinse EIVS_CEETOX_SE_11HCE004_4_v1.0.xls 
CEETOX C5c- dropped tissue in flask while rinsing EIVS_CEETOX_SE_11HCE004_4_v1.0.xls 
CEETOX C6a- dropped tissue in flask while rinsing EIVS_CEETOX_SE_11HCE004_4_v1.0.xls 
CEETOX C7b- nicked tissue EIVS_CEETOX_SE_11HCE004_4_v1.0.xls 
CEETOX C4 - After incubation the compound stained the media 
and tissue a dark color see pictures in 11HCE007 Lisa 
EIVS_CEETOX_SE_11HCE004_4_v1.0.xls 
CEETOX PC - extra rinse EIVS_CEETOX_SE_11HCE006_6_v1.0.xls 
CEETOX C2 - spread with tip EIVS_CEETOX_SE_11HCE006_6_v1.0.xls 
CEETOX C4 - not all compound removed after extra rinse EIVS_CEETOX_SE_11HCE006_6_v1.0.xls 
CEETOX C7a - 30 sec late rinsing EIVS_CEETOX_SE_11HCE006_6_v1.0.xls 
CEETOX C7c - extra rinse EIVS_CEETOX_SE_11HCE006_6_v1.0.xls 
CEETOX C8 - spread with tip EIVS_CEETOX_SE_11HCE006_6_v1.0.xls 
CEETOX C4 - After incubation the compound stained the media 
and tissue a dark color see pictures in 11HCE007 Lisa 
EIVS_CEETOX_SE_11HCE006_6_v1.0.xls 
CEETOX C1 - extra rinse EIVS_CEETOX_SE_11HCE007_7_v1.0.xls 
CEETOX C4b and c - compound left in weigh boat EIVS_CEETOX_SE_11HCE007_7_v1.0.xls 
CEETOX C4b - spread compound with tip EIVS_CEETOX_SE_11HCE007_7_v1.0.xls 
CEETOX C4 - not all compound removed after extra rinse EIVS_CEETOX_SE_11HCE007_7_v1.0.xls 
CEETOX C7 - extra rinse EIVS_CEETOX_SE_11HCE007_7_v1.0.xls 
CEETOX C4 - After incubation the compound stained the media 
and tissue a dark color see pictures in 11HCE007 Lisa 
EIVS_CEETOX_SE_11HCE007_7_v1.0.xls 
CEETOX x13 C1 -- used tip, some compound left in glass weigh 
boat 
EIVS_CEETOX_SE_11HCE008_8_v1.0 JOEY.xls 
CEETOX x39 C2 -- some compound left in glass weigh boat EIVS_CEETOX_SE_11HCE008_8_v1.0 JOEY.xls 
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CEETOX X8 C3 -- used tip; some compound left in both glass and 
plastic weigh boats (compound very fluttery) 
EIVS_CEETOX_SE_11HCE008_8_v1.0 JOEY.xls 
CEETOX x128 c C4c -- tissue looks ripped EIVS_CEETOX_SE_11HCE008_8_v1.0 JOEY.xls 
CEETOX C2 - spread with tip EIVS_CEETOX_SE_11HCE008_8_v1.0 LISA.xls 
CEETOX C2 - extra rinse EIVS_CEETOX_SE_11HCE008_8_v1.0 LISA.xls 
CEETOX C8 - not all compound removed after extra rinsing EIVS_CEETOX_SE_11HCE008_8_v1.0 LISA.xls 
CEETOX PC a - dropped tissue in flask EIVS_CEETOX_SE_11HCE009_9_v1.0 LISA.xls 
CEETOX C4 - spread with tip EIVS_CEETOX_SE_11HCE009_9_v1.0 LISA.xls 
CEETOX C4 FK a - dropped tissue in flask EIVS_CEETOX_SE_11HCE009_9_v1.0 LISA.xls 
CEETOX C1 x13 -- used tip; compound left in glass weigh boat EIVS_CEETOX_SE_11HCE009_9_v1.0.xls 
CEETOX C1b x13b -- very wet compounds EIVS_CEETOX_SE_11HCE009_9_v1.0.xls 
CEETOX C3 x8 -- used tip; color came off in post rinsing EIVS_CEETOX_SE_11HCE009_9_v1.0.xls 
CEETOX C3-MTT x8-MTT -- used tip EIVS_CEETOX_SE_11HCE009_9_v1.0.xls 
CEETOX C8 x44 b -- used tip to spread EIVS_CEETOX_SE_11HCE009_9_v1.0.xls 
CEETOX C7 x43 -- used tip EIVS_CEETOX_SE_11HCE009_9_v1.0.xls 
CEETOX C4 x128 -- tissues cracked after rinsing EIVS_CEETOX_SE_11HCE009_9_v1.0.xls 
CEETOX C1 X13 -- used tip to spread EIVS_CEETOX_SE_11HCE013_13_v1.0 set 1.xls 
CEETOX C3 X8 -- compound is staticy; used tip EIVS_CEETOX_SE_11HCE013_13_v1.0 set 1.xls 
CEETOX C5 X43 -- compound is staticy; all over the glass weigh 
boat; used tip to spread 
EIVS_CEETOX_SE_11HCE013_13_v1.0 set 1.xls 
CEETOX C4 X128 -- extra rinse, tissues cracked EIVS_CEETOX_SE_11HCE013_13_v1.0 set 1.xls 
CEETOX C7 X64 -- not a solution; settled out on the bottom; all 
tissues received extra rinse 
EIVS_CEETOX_SE_11HCE013_13_v1.0 set 1.xls 
CEETOX C6 c X62c -- dropped tissue in funnel EIVS_CEETOX_SE_11HCE013_13_v1.0 set 1.xls 
CEETOX C9 X81 -- precipitate in vial; cracked tissues EIVS_CEETOX_SE_11HCE013_13_v1.0 set 2.xls 
CEETOX C8b X65b -- dropped in funnel EIVS_CEETOX_SE_11HCE013_13_v1.0 set 2.xls 
CEETOX C13 X126 -- very small amount, difficult to cover the 
tissues 
EIVS_CEETOX_SE_11HCE013_13_v1.0 set 2.xls 
CEETOX C14 b and c X21 b and c -- tissues dropped in funnel EIVS_CEETOX_SE_11HCE013_13_v1.0 set 2.xls 
CEETOX NC b -- dosed 10 seconds late; dropped in funnel EIVS_CEETOX_SE_11HCE020_18_v1.0.xls 
CEETOX C1 X13 -- used tip to spread compound EIVS_CEETOX_SE_11HCE020_18_v1.0.xls 
CEETOX PC c -- dropped in funnel EIVS_CEETOX_SE_11HCE020_18_v1.0.xls 
CEETOX C4 X126 -- did not spread well on tissue; used tip, but 
clumps were too large 
EIVS_CEETOX_SE_11HCE020_18_v1.0.xls 
CEETOX Solid compounds left in all weigh boats. EIVS_CEETOX_SE_11HCE020_18_v1.0.xls 
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CEETOX NC b -- bubble on apical surface EIVS_CEETOX_SE_11HCE022_19_v1.0.xls 
CEETOX C2 X112 c -- compound remaining in weigh boat EIVS_CEETOX_SE_11HCE022_19_v1.0.xls 
CEETOX C4 X14 -- Spread with tip EIVS_CEETOX_SE_11HCE022_19_v1.0.xls 
CEETOX C4-MTT X14-MTT -- spread with tip EIVS_CEETOX_SE_11HCE022_19_v1.0.xls 
CEETOX C6-MTT X27-MTT b -- nicked tissue EIVS_CEETOX_SE_11HCE022_19_v1.0.xls 
CEETOX C6 X27 -- extra rinse and swab EIVS_CEETOX_SE_11HCE022_19_v1.0.xls 
CEETOX C6-MTT X27-MTT -- extra rinse and swab EIVS_CEETOX_SE_11HCE022_19_v1.0.xls 
CEETOX C1 X14 -- used tip to spread compound; compound left 
in glass weigh boat; compound did not fully cover the 
tissue 
EIVS_CEETOX_SE_11HCE047_37_v1.0.xls 
CEETOX C1-MTT X14-MTT -- used tip to spread compound; 
compound left in glass weigh boat; compound did not 
fully cover the tissue 
EIVS_CEETOX_SE_11HCE047_37_v1.0.xls 
CEETOX C2 X27 -- compound left in glass weigh boat and plastic 
weigh boats, the compound was very staticy 
EIVS_CEETOX_SE_11HCE047_37_v1.0.xls 
CEETOX C2-MTT X27-MTT -- compound left in glass weigh boat 
and plastic weigh boats, the compound was very staticy 
EIVS_CEETOX_SE_11HCE047_37_v1.0.xls 
CEETOX C3 X46 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE047_37_v1.0.xls 
CEETOX C4 X50 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE047_37_v1.0.xls 
CEETOX C6 X70 -- compound left in glass weigh boat; compound 
would not spread when wet 
EIVS_CEETOX_SE_11HCE047_37_v1.0.xls 
CEETOX C7 X84 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE047_37_v1.0.xls 
CEETOX C8 X87 -- compound left in glass weigh boat; used tip to 
spread; compound dissolved on tissue 
EIVS_CEETOX_SE_11HCE047_37_v1.0.xls 
CEETOX C9 X102 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE047_37_v1.0.xls 
CEETOX C10 X107 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE047_37_v1.0.xls 
CEETOX C11 X108 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE047_37_v1.0.xls 
CEETOX C12 X109 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE047_37_v1.0.xls 
CEETOX NC a -- dropped in funnel EIVS_CEETOX_SE_11HCE049_38_v1.0.xls 
CEETOX C1 X14 -- used tip to spread compound: compound did 
not cover the tissues well; compound left in glass weigh 
boat 
EIVS_CEETOX_SE_11HCE049_38_v1.0.xls 
CEETOX C1-MTT X14-MTT -- used tip to spread compound; 
compound did not cover the tissues well; 
EIVS_CEETOX_SE_11HCE049_38_v1.0.xls 
CEETOX C2 X27 -- compound left in glass weigh boat; extra swab EIVS_CEETOX_SE_11HCE049_38_v1.0.xls 
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on tissues 
CEETOX C2-MTT X27-MTT -- compound left in glass weigh boat; 
extra swab on tissues 
EIVS_CEETOX_SE_11HCE049_38_v1.0.xls 
CEETOX C3 X46 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE049_38_v1.0.xls 
CEETOX C4 X50 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE049_38_v1.0.xls 
CEETOX C6 X70 -- compound left in glass weigh boat; had to 
scrape off of the tissues because it stuck to them after 
dosing 
EIVS_CEETOX_SE_11HCE049_38_v1.0.xls 
CEETOX C7 X84 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE049_38_v1.0.xls 
CEETOX C8 X71 -- compound left in glass weigh boat; used tip to 
spread compound 
EIVS_CEETOX_SE_11HCE049_38_v1.0.xls 
CEETOX C9 X102 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE049_38_v1.0.xls 
CEETOX C11 X108 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE049_38_v1.0.xls 
CEETOX C10 X107 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE049_38_v1.0.xls 
CEETOX C12 X109 -- compound left in glass weigh boat; had to 
scrape the compound out of the weigh boat 
EIVS_CEETOX_SE_11HCE049_38_v1.0.xls 
CEETOX C1 X50 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE051_39_v1.0 set 1.xls 
CEETOX C3 X70 -- compound left in glass weigh boat; compound 
stuck to all tissues during rinsings 
EIVS_CEETOX_SE_11HCE051_39_v1.0 set 1.xls 
CEETOX C4 X84 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE051_39_v1.0 set 1.xls 
CEETOX C5 X87 -- compound left in glass weigh boat; not 
covering tissue totally; used tip to spread 
EIVS_CEETOX_SE_11HCE051_39_v1.0 set 1.xls 
CEETOX C6 X102 -- compound left in weigh boat EIVS_CEETOX_SE_11HCE051_39_v1.0 set 1.xls 
CEETOX C7 X107 -- compound left in weigh boat EIVS_CEETOX_SE_11HCE051_39_v1.0 set 1.xls 
CEETOX C8 X108 -- compound left in glass weigh boat; 
compound did not cover well 
EIVS_CEETOX_SE_11HCE051_39_v1.0 set 2.xls 
CEETOX C9 X109 -- compound left in glass weigh boat; 
compound stuck in glass weigh boat 
EIVS_CEETOX_SE_11HCE051_39_v1.0 set 2.xls 
CEETOX C10 X110 -- needed extra swabs to rinse the tissue EIVS_CEETOX_SE_11HCE051_39_v1.0 set 2.xls 
CEETOX C11 X111 -- compound left in glass weigh boat; used tip 
to spread 
EIVS_CEETOX_SE_11HCE051_39_v1.0 set 2.xls 
CEETOX C12 X114 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE051_39_v1.0 set 2.xls 
CEETOX C13 X115 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE051_39_v1.0 set 2.xls 
CEETOX C14 X116 -- compound left in glass weigh boat; used tip 
to spread 
EIVS_CEETOX_SE_11HCE051_39_v1.0 set 2.xls 
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CEETOX C2 X111 -- used tip to spread compound; compound left 
in glass weigh boat 
EIVS_CEETOX_SE_11HCE053_40_v1.0 set 1.xls 
CEETOX C1 X110 -- used 2 extra swabs while rinsing EIVS_CEETOX_SE_11HCE053_40_v1.0 set 1.xls 
CEETOX C3 X114 -- used tip to spread compound; compound left 
in glass weigh boat 
EIVS_CEETOX_SE_11HCE053_40_v1.0 set 1.xls 
CEETOX C4 X115 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE053_40_v1.0 set 1.xls 
CEETOX C5 X116 -- compound left in glass weigh boat; used tip to 
spread compound 
EIVS_CEETOX_SE_11HCE053_40_v1.0 set 1.xls 
CEETOX C6 X118 -- tissue c cracked EIVS_CEETOX_SE_11HCE053_40_v1.0 set 1.xls 
CEETOX C7 X119 -- compound left in glass weigh boat; 
compound dissolved on tissue 
EIVS_CEETOX_SE_11HCE053_40_v1.0 set 1.xls 
CEETOX C8 X123 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE053_40_v1.0 set 2.xls 
CEETOX C9 X125 -- compound left in glass weigh boat; used tip to 
spread compound 
EIVS_CEETOX_SE_11HCE053_40_v1.0 set 2.xls 
CEETOX C10 X129 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE053_40_v1.0 set 2.xls 
CEETOX C11 X131 -- compound left in glass weigh boat; used tip 
to spread compound; compound dissolved on tissue 
EIVS_CEETOX_SE_11HCE053_40_v1.0 set 2.xls 
CEETOX C13 X134 -- compound disappeared from weigh boat; it 
seems a much smaller amount than what I weighed out 
EIVS_CEETOX_SE_11HCE053_40_v1.0 set 2.xls 
CEETOX C3 X190 -- tissues were wet prior to dosing; needed to 
be swabbed 
EIVS_CEETOX_SE_11HCE055_41_v1.0 set 1.xls 
CEETOX C4 X131 -- used tip to spread compound; compound left 
in glass weigh boat 
EIVS_CEETOX_SE_11HCE055_41_v1.0 set 1.xls 
CEETOX C5 X119 -- compound dissolved on tissues; compound 
left in glass weigh boat 
EIVS_CEETOX_SE_11HCE055_41_v1.0 set 1.xls 
CEETOX C6 X173 -- used tip to spread compound; compound left 
in glass weigh boat 
EIVS_CEETOX_SE_11HCE055_41_v1.0 set 1.xls 
CEETOX C7 X169 -- used tip to spread compound; compound left 
in glass weigh boat 
EIVS_CEETOX_SE_11HCE055_41_v1.0 set 1.xls 
CEETOX C11 X40 -- compound left in glass weigh boat; extra 
swab; difficult to remove from the tissue 
EIVS_CEETOX_SE_11HCE055_41_v1.0 set 2.xls 
CEETOX C12 X108 -- compound left in glass weigh boat; used tip 
to spread compound 
EIVS_CEETOX_SE_11HCE055_41_v1.0 set 2.xls 
CEETOX C13 X111 -- compound left in glass weigh boat; used tip 
to spread compound 
EIVS_CEETOX_SE_11HCE055_41_v1.0 set 2.xls 
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CEETOX C4 X131 -- compound left in glass weigh boat; used tip to 
spread compound 
EIVS_CEETOX_SE_11HCE057_42_v1.0 set 1.xls 
CEETOX C6 X173 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE057_42_v1.0 set 1.xls 
CEETOX C5 X119 -- compound dissolved on tissue EIVS_CEETOX_SE_11HCE057_42_v1.0 set 1.xls 
CEETOX C7 X169 -- compound left in glass weigh boat; used tip to 
spread compound 
EIVS_CEETOX_SE_11HCE057_42_v1.0 set 1.xls 
CEETOX C11 X40 -- compound left in glass weigh boat; used extra 
swabs; compound was difficult to get off tissue 
EIVS_CEETOX_SE_11HCE057_42_v1.0 set 2.xls 
CEETOX C12 X108 -- compound left in glass weigh boat; used tip 
to spread compound on tissue a - this removed some of 
the compound 
EIVS_CEETOX_SE_11HCE057_42_v1.0 set 2.xls 
CEETOX C13 X111 -- compound left in glass weigh boat; a little 
compound spilled from tissue a - but there was good 
coverage 
EIVS_CEETOX_SE_11HCE057_42_v1.0 set 2.xls 
CEETOX C4 X173 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE059_43_v1.0 set 1.xls 
CEETOX C5 X169 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE059_43_v1.0 set 1.xls 
CEETOX C8 X40 -- compound left in glass weigh boat; hard to 
scrape off 
EIVS_CEETOX_SE_11HCE059_43_v1.0 set 2.xls 
CEETOX C9 X138 -- b cracked; c as well EIVS_CEETOX_SE_11HCE059_43_v1.0 set 2.xls 
CEETOX C10 X118 -- tissues a, b, and c cracked EIVS_CEETOX_SE_11HCE059_43_v1.0 set 2.xls 
CEETOX C11 X125 -- compound left in glass weigh boat; used tip 
to spread the compound 
EIVS_CEETOX_SE_11HCE059_43_v1.0 set 2.xls 
CEETOX C12 X123 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE059_43_v1.0 set 2.xls 
CEETOX C13 X134 -- compound disappeared over time; small 
rock on the tissue; used tip to spread; sticky 
EIVS_CEETOX_SE_11HCE059_43_v1.0 set 2.xls 
CEETOX C14 X129 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE059_43_v1.0 set 2.xls 
CEETOX C1 X118 -- thin, poor coverage; tissues cracked EIVS_CEETOX_SE_11HCE061_44_v1.0 set 1.xls 
CEETOX C2 X125 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE061_44_v1.0 set 1.xls 
CEETOX C3 X123 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE061_44_v1.0 set 1.xls 
CEETOX C4 X134 -- compound left in glass weigh boat; smaller 
than when weighed out; sticky; rock in middle of the 
tissue 
EIVS_CEETOX_SE_11HCE061_44_v1.0 set 1.xls 
CEETOX C5 X129 -- compound left in glass weigh boat; 
compound wet around edges at rinse 
EIVS_CEETOX_SE_11HCE061_44_v1.0 set 1.xls 
CEETOX C6 X196 -- compound left in glass weigh boat; needed EIVS_CEETOX_SE_11HCE061_44_v1.0 set 1.xls 
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extra swab 
CEETOX C7 X110 -- required extra swab EIVS_CEETOX_SE_11HCE061_44_v1.0 set 1.xls 
CEETOX C8 X114 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE061_44_v1.0 set 2.xls 
CEETOX C9 X115 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE061_44_v1.0 set 2.xls 
CEETOX C10 X116 -- compound left in glass weigh boat; very thin, 
covering on tissue 
EIVS_CEETOX_SE_11HCE061_44_v1.0 set 2.xls 
CEETOX C12 X11 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE061_44_v1.0 set 2.xls 
CEETOX C1 X11 -- compound left in glass weigh boat; compound 
staticy 
EIVS_CEETOX_SE_11HCE063_45_v1.0.xls 
CEETOX C4 X196 -- compound left in glass weigh boat; used extra 
swab 
EIVS_CEETOX_SE_11HCE063_45_v1.0.xls 
CEETOX C6 X24 -- compound left in glass weigh boat; extra swab EIVS_CEETOX_SE_11HCE063_45_v1.0.xls 
CEETOX C6-MTT X24-MTT -- compound left in glass weigh boat; 
used extra swab 
EIVS_CEETOX_SE_11HCE063_45_v1.0.xls 
CEETOX C7 X32 -- compound left in glass and plastic weigh boats; 
staticy 
EIVS_CEETOX_SE_11HCE063_45_v1.0.xls 
CEETOX C7-MTT X32-MTT -- compound left in glass and plastic 
weigh boats; staticy 
EIVS_CEETOX_SE_11HCE063_45_v1.0.xls 
CEETOX C7 FK X32 FK -- compound left in glass weigh boat; 
staticy; tissues stained more than the live tissues 
EIVS_CEETOX_SE_11HCE063_45_v1.0.xls 
CEETOX C8 X42 -- lost tissues, dissolved EIVS_CEETOX_SE_11HCE063_45_v1.0.xls 
CEETOX C9 X55 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE063_45_v1.0.xls 
CEETOX C10 X56 -- looks as though the tissue dissolved EIVS_CEETOX_SE_11HCE063_45_v1.0.xls 
CEETOX C2 X196 -- compound left in glass weigh boat; used extra 
swab 
EIVS_CEETOX_SE_11HCE065_46_v1.0.xls 
CEETOX C1 X19 -- used extra swab EIVS_CEETOX_SE_11HCE065_46_v1.0.xls 
CEETOX C3 X24 -- compound left in glass weigh boat; used extra 
swab 
EIVS_CEETOX_SE_11HCE065_46_v1.0.xls 
CEETOX C3-MTT X24-MTT -- compound left in glass weigh boat; 
used extra swab 
EIVS_CEETOX_SE_11HCE065_46_v1.0.xls 
CEETOX C4 X32 -- compound left in glass weigh boat; staticy; 
compound left in plastic weigh boat; extra swab 
EIVS_CEETOX_SE_11HCE065_46_v1.0.xls 
CEETOX C4-MTT X32-MTT -- compound left in glass weigh boat; 
staticy; compound left in plastic weigh boat; extra swab 
EIVS_CEETOX_SE_11HCE065_46_v1.0.xls 
CEETOX C6 X55 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE065_46_v1.0.xls 
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CEETOX C5 X42 -- only half of tissue left on tissue a EIVS_CEETOX_SE_11HCE065_46_v1.0.xls 
CEETOX C7 X56 -- lost tissues EIVS_CEETOX_SE_11HCE065_46_v1.0.xls 
CEETOX C8 X61 -- extra rinse and swab EIVS_CEETOX_SE_11HCE065_46_v1.0.xls 
CEETOX C10 X75 -- compound left in glass and plastic weigh 
boats; staticy 
EIVS_CEETOX_SE_11HCE065_46_v1.0.xls 
CEETOX C12 X80 -- compound left in glass weigh boat; extra 
swab; compound clumped; used tip to spread 
EIVS_CEETOX_SE_11HCE065_46_v1.0.xls 
CEETOX C11 X77 -- used extra swab EIVS_CEETOX_SE_11HCE065_46_v1.0.xls 
CEETOX NC -- tissue c dropped in funnel EIVS_CEETOX_SE_11HCE068_48_v1.0.xls 
CEETOX C1 X61 -- compound was very thick, could not spread; 
tissue C had very little compound dosed, tissue C 
dropped in funnel 
EIVS_CEETOX_SE_11HCE068_48_v1.0.xls 
CEETOX C3 X75 -- compound left in glass weigh boat; compound 
staticy; extra swab used 
EIVS_CEETOX_SE_11HCE068_48_v1.0.xls 
CEETOX C4 X77 -- extra swab used EIVS_CEETOX_SE_11HCE068_48_v1.0.xls 
CEETOX C5 X80 -- compound left in glass weigh boat; used tip to 
spread 
EIVS_CEETOX_SE_11HCE068_48_v1.0.xls 
CEETOX C7 X95 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE068_48_v1.0.xls 
CEETOX C7-MTT X95-MTT -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE068_48_v1.0.xls 
CEETOX C9 X120 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE068_48_v1.0.xls 
CEETOX C10 X157 -- compound left in glass weigh boat; used tip 
to spread 
EIVS_CEETOX_SE_11HCE068_48_v1.0.xls 
CEETOX C11 X158 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE068_48_v1.0.xls 
CEETOX C12 X160 -- compound left in glass weigh boat; used tip 
to spread 
EIVS_CEETOX_SE_11HCE068_48_v1.0.xls 
CEETOX C1 X11 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE070_49_v1.0.xls 
CEETOX C2 X19 -- compound hard to spread, extra swab used EIVS_CEETOX_SE_11HCE070_49_v1.0.xls 
CEETOX C3 X24 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE070_49_v1.0.xls 
CEETOX C3-MTT X24-MTT -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE070_49_v1.0.xls 
CEETOX C6 X95 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE070_49_v1.0.xls 
CEETOX C6-MTT X95-MTT -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE070_49_v1.0.xls 
CEETOX C8 X120 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE070_49_v1.0.xls 
CEETOX C9 X157 -- compound left in glass weigh boat, used tip to 
spread 
EIVS_CEETOX_SE_11HCE070_49_v1.0.xls 
CEETOX C10 X158 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE070_49_v1.0.xls 
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CEETOX C11 X160 -- compound left in glass weigh boat EIVS_CEETOX_SE_11HCE070_49_v1.0.xls 
CEETOX C1 X32 -- compound left in glass weigh boat EIVS_CEETOX_SE_12HCE002_2_v1.0.xls 
CEETOX C1-MTT X32-MTT -- compound left in glass weigh boat EIVS_CEETOX_SE_12HCE002_2_v1.0.xls 
CEETOX C1 FK X32 FK -- compound left in glass weigh boat; 
compound did not wash off as well as the live tissues did 
EIVS_CEETOX_SE_12HCE002_2_v1.0.xls 
CEETOX C2 X42 -- lost tissues EIVS_CEETOX_SE_12HCE002_2_v1.0.xls 
CEETOX C3 X55 -- compound left in glass weigh boat EIVS_CEETOX_SE_12HCE002_2_v1.0.xls 
CEETOX C4 X56 -- lost tissues EIVS_CEETOX_SE_12HCE002_2_v1.0.xls 
CEETOX C1 X61 -- very sticky; could not consistently pipette or 
dose; very difficult to manipulate 
EIVS_CEETOX_SE_12HCE004_3_v1.0.xls 
CEETOX C3 X75 -- compound left in glass weigh boat; very 
staticy; tissue b dropped in funnel 
EIVS_CEETOX_SE_12HCE004_3_v1.0.xls 
CEETOX C4 X77 -- used extra swab EIVS_CEETOX_SE_12HCE004_3_v1.0.xls 
CEETOX C5 X80 -- compound left in glass weigh boat; used tip to 
spread 
EIVS_CEETOX_SE_12HCE004_3_v1.0.xls 
CEETOX C7 X95 -- compound left in glass weigh boat EIVS_CEETOX_SE_12HCE004_3_v1.0.xls 
CEETOX C7-MTT X95-MTT -- compound left in glass weigh boat EIVS_CEETOX_SE_12HCE004_3_v1.0.xls 
CEETOX C9 X120 -- compound left in glass weigh boat EIVS_CEETOX_SE_12HCE004_3_v1.0.xls 
CEETOX C8 X113 -- tissue a dropped in funnel EIVS_CEETOX_SE_12HCE004_3_v1.0.xls 
CEETOX C10 X157 -- used tip to spread compound EIVS_CEETOX_SE_12HCE004_3_v1.0.xls 
CEETOX C11 X158 -- compound left in glass weigh boat EIVS_CEETOX_SE_12HCE004_3_v1.0.xls 
CEETOX C12 X160 -- compound left in glass weigh boat EIVS_CEETOX_SE_12HCE004_3_v1.0.xls 
L’OREAL TEST SUBSTANCE L11: EIVS_LOREAL_SE_10HCE023_25.xls 
L’OREAL Discrepancy observed between the three tissues : 
UNQUALIFIED run 
EIVS_LOREAL_SE_10HCE023_25.xls 
L’OREAL Substances L9 and L20: The substances stuck on the 
plastic which is not anymore transparent. 
EIVS_LOREAL_SE_10HCE023_25.xls 
L’OREAL The rinsing procedure was very difficult. The test 
substances might be not completely removed from the 
tissues. 
EIVS_LOREAL_SE_10HCE023_25.xls 
L’OREAL TEST SUBSTANCES L9 and L20: EIVS_LOREAL_SE_10HCE024_26.xls 
L’OREAL The substances stuck on the plastic which is not 
anymore transparent. 
EIVS_LOREAL_SE_10HCE024_26.xls 
L’OREAL The rinsing procedure was very difficult. Substances 
might be not completely removed from the tissues. 
EIVS_LOREAL_SE_10HCE024_26.xls 
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L’OREAL TEST SUBSTANCE L11: EIVS_LOREAL_SE_10HCE024_26.xls 
L’OREAL Discrepancy observed between the three tissues : 
UNQUALIFIED run 
EIVS_LOREAL_SE_10HCE024_26.xls 
L’OREAL TEST SUBSTANCE L66 EIVS_LOREAL_SE_10HCE025_27.xls 
L’OREAL The membrane was melted. EIVS_LOREAL_SE_10HCE025_27.xls 
L’OREAL TEST SUBSTANCE L30 EIVS_LOREAL_SE_10HCE025_27.xls 
L’OREAL In contact with the pre-wetted HCE tissue, the powder 
pebbled and stuck to the surface. 
EIVS_LOREAL_SE_10HCE025_27.xls 
L’OREAL During the rinsing step procedure, the substance (dense 
solid) were scratched to facilitate its removal. 
EIVS_LOREAL_SE_10HCE025_27.xls 
L’OREAL SD > 18% UNQUALIFIED TEST EIVS_LOREAL_SE_10HCE025_27.xls 
L’OREAL TEST SUBSTANCE L11: EIVS_LOREAL_SE_10HCE025_27.xls 
L’OREAL In the SOP, 30 ?L PBS are applied onto the tissue in 
order to improve the contact between the powder and 
the epithelium. 
EIVS_LOREAL_SE_10HCE025_27.xls 
L’OREAL To improve such contact, the PBS was not aspirate 
before applying the powder L11. 
EIVS_LOREAL_SE_10HCE025_27.xls 
L’OREAL The tissue should be well pre-wetting EIVS_LOREAL_SE_10HCE025_27.xls 
L’OREAL This technical aspect might explain that the 2 first runs 
were invalids. 
EIVS_LOREAL_SE_10HCE025_27.xls 
L’OREAL A SD > 18% and contradictorily classification were 
observed for the 3 tissues (high intra-run variability). 
EIVS_LOREAL_SE_10HCE025_27.xls 
L’OREAL TEST SUBSTANCE L43: EIVS_LOREAL_SE_10HCE025_27.xls 
L’OREAL The substances stuck on the plastic which is not 
anymore transparent. 
EIVS_LOREAL_SE_10HCE025_27.xls 
L’OREAL The rinsing procedure was very difficult. Substances 
might be not completely removed from the tissues. 
EIVS_LOREAL_SE_10HCE025_27.xls 
L’OREAL TEST SUBSTANCES L9 and L43: EIVS_LOREAL_SE_10HCE026_28.xls 
L’OREAL The substances stuck on the plastic which is not 
anymore transparent. 
EIVS_LOREAL_SE_10HCE026_28.xls 
L’OREAL The rinsing procedure was very difficult. Substances 
might be not completely removed from the tissues. 
EIVS_LOREAL_SE_10HCE026_28.xls 
L’OREAL TEST SUBSTANCE L17: EIVS_LOREAL_SE_10HCE026_28.xls 
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L’OREAL TEST SUBSTANCE L30: EIVS_LOREAL_SE_10HCE027_29.xls 
L’OREAL In contact with the pre-wetted HCE tissue, the powder 
pebbled and stuck to the surface. 
EIVS_LOREAL_SE_10HCE027_29.xls 
L’OREAL During the rinsing step procedure, the substance (dense 
solid) was scratched to facilitate its removal. 
EIVS_LOREAL_SE_10HCE027_29.xls 
L’OREAL TEST SUBSTANCE L66: EIVS_LOREAL_SE_10HCE027_29.xls 
L’OREAL The membrane was melted. EIVS_LOREAL_SE_10HCE027_29.xls 
L’OREAL TEST SUBSTANCE L43: EIVS_LOREAL_SE_10HCE027_29.xls 
L’OREAL The substances stuck on the plastic which is not 
anymore transparent. 
EIVS_LOREAL_SE_10HCE027_29.xls 
L’OREAL The rinsing procedure was very difficult. Substances 
might be not completely removed from the tissues 
EIVS_LOREAL_SE_10HCE027_29.xls 
L’OREAL TEST SUBSTANCE L55: EIVS_LOREAL_SE_10HCE028_30.xls 
L’OREAL The substances stuck on the plastic which is not 
anymore transparent. 
EIVS_LOREAL_SE_10HCE028_30.xls 
L’OREAL The rinsing procedure was very difficult. Substances 
might be not completely removed from the tissues. 
EIVS_LOREAL_SE_10HCE028_30.xls 
L’OREAL TEST SUBSTANCE L30: EIVS_LOREAL_SE_10HCE028_30.xls 
L’OREAL MTT interaction was observed during the run (and not 
during the checking step of potential direct MTT 
reduction of test chemical). 
EIVS_LOREAL_SE_10HCE028_30.xls 
L’OREAL So adapted killed tissues controls were added 
afterwards 
EIVS_LOREAL_SE_10HCE028_30.xls 
L’OREAL TEST SUBSTANCE L11: (SOLID) EIVS_LOREAL_SE_10HCE028_30.xls 
L’OREAL In the SOP, 30 ?L PBS are applied onto the tissue in 
order to improve the contact between the powder and 
the epithelium. 
EIVS_LOREAL_SE_10HCE028_30.xls 
L’OREAL To improve such contact, the PBS was not aspirate 
before applying the powder L11. 
EIVS_LOREAL_SE_10HCE028_30.xls 
L’OREAL The tissue should be well pre-wetting EIVS_LOREAL_SE_10HCE028_30.xls 
L’OREAL This technical aspect might explain that the 2 first runs 
were invalids. 
EIVS_LOREAL_SE_10HCE028_30.xls 
L’OREAL A SD > 18% and contradictorily classification were 
observed for the 3 tissues (high intra-run variability). 
EIVS_LOREAL_SE_10HCE028_30.xls 
L’OREAL TEST SUBSTANCE L81: EIVS_LOREAL_SE_10HCE029_35.xls 
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L’OREAL The test substance L81 dissolved the membrane of 
tissue constructs, 
EIVS_LOREAL_SE_10HCE029_35.xls 
L’OREAL but the integrity of the HCE tissue was not affected EIVS_LOREAL_SE_10HCE029_35.xls 
L’OREAL TEST SUBSTANCE L94: EIVS_LOREAL_SE_10HCE029_35.xls 
L’OREAL The substances stuck on the plastic which is not 
anymore transparent. 
EIVS_LOREAL_SE_10HCE029_35.xls 
L’OREAL The rinsing procedure was very difficult. Substances 
might be not completely removed from the tissues. 
EIVS_LOREAL_SE_10HCE029_35.xls 
L’OREAL TEST SUBSTANCE L74: EIVS_LOREAL_SE_10HCE029_35.xls 
L’OREAL L74 is a strong MTT-reducer given a NSMTT > 50% in the 
controls 
EIVS_LOREAL_SE_10HCE029_35.xls 
L’OREAL L74 was not retest since the SD was < 18% (qualified 
test). 
EIVS_LOREAL_SE_10HCE029_35.xls 
L’OREAL We still acquired three qualified tests for this chemical 
following the rules set out in the Performance 
EIVS_LOREAL_SE_10HCE029_35.xls 
L’OREAL Criteria document, independently of the control tissues 
(NSMTT>50%) 
EIVS_LOREAL_SE_10HCE029_35.xls 
L’OREAL The values are imported in the design import 
spreadsheet 
EIVS_LOREAL_SE_10HCE029_35.xls 
L’OREAL ADAPTED CONTROLS: EIVS_LOREAL_SE_10HCE031_37.xls 
L’OREAL The direct MTT reduction of test substances was 
evaluated using killed HCE tissues controls (one single 
run, 3 tissues / substance). 
EIVS_LOREAL_SE_10HCE031_37.xls 
L’OREAL The killed tissues used for the evaluation were provided 
from HCE tissues batch Nø10HCE029 (produced on 
March3 2010: less than a year) 
EIVS_LOREAL_SE_10HCE031_37.xls 
L’OREAL TEST SUBSTANCE L94: EIVS_LOREAL_SE_10HCE031_37.xls 
L’OREAL The substances stuck on the plastic which is not 
anymore transparent. 
EIVS_LOREAL_SE_10HCE031_37.xls 
L’OREAL The rinsing procedure was very difficult. Substances 
might be not completely removed from the tissues. 
EIVS_LOREAL_SE_10HCE031_37.xls 
L’OREAL TEST SUBSTANCE L74: EIVS_LOREAL_SE_10HCE031_37.xls 
L’OREAL L74 is a strong MTT-reducer given a NSMTT > 50% in the 
controls 
EIVS_LOREAL_SE_10HCE031_37.xls 
L’OREAL L74 was not retest since the SD was < 18% (qualified EIVS_LOREAL_SE_10HCE031_37.xls 
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test). 
L’OREAL We still acquired three qualified tests for this chemical 
following the rules set out in the Performance 
EIVS_LOREAL_SE_10HCE031_37.xls 
L’OREAL Criteria document, independently of the control tissues 
(NSMTT>50%) 
EIVS_LOREAL_SE_10HCE031_37.xls 
L’OREAL The values are imported in the design import 
spreadsheet 
EIVS_LOREAL_SE_10HCE031_37.xls 
L’OREAL TEST SUBSTANCE L81: EIVS_LOREAL_SE_10HCE032_38.xls 
L’OREAL The test substance L81 dissolved the membrane of 
tissue constructs, 
EIVS_LOREAL_SE_10HCE032_38.xls 
L’OREAL but the integrity of the HCE tissue was not affected EIVS_LOREAL_SE_10HCE032_38.xls 
L’OREAL The tissue is intact, but the membrane below is melted EIVS_LOREAL_SE_10HCE032_38.xls 
L’OREAL TEST SUBSTANCE L94: EIVS_LOREAL_SE_10HCE032_38.xls 
L’OREAL The substances stuck on the plastic which is not 
anymore transparent. 
EIVS_LOREAL_SE_10HCE032_38.xls 
L’OREAL The rinsing procedure was very difficult. Substances 
might be not completely removed from the tissues. 
EIVS_LOREAL_SE_10HCE032_38.xls 
L’OREAL TEST SUBSTANCE L74: EIVS_LOREAL_SE_10HCE032_38.xls 
L’OREAL L74 is a strong MTT-reducer given a NSMTT > 50% in the 
controls 
EIVS_LOREAL_SE_10HCE032_38.xls 
L’OREAL L7 was not retest since the SD was < 18% (qualified test). EIVS_LOREAL_SE_10HCE032_38.xls 
L’OREAL We still acquired three qualified tests for this chemical 
following the rules set out in the Performance 
EIVS_LOREAL_SE_10HCE032_38.xls 
L’OREAL Criteria document, independently of the control tissues 
(NSMTT>50%) 
EIVS_LOREAL_SE_10HCE032_38.xls 
L’OREAL The values are imported in the design import 
spreadsheet 
EIVS_LOREAL_SE_10HCE032_38.xls 
L’OREAL TEST SUBSTANCE L81: EIVS_LOREAL_SE_10HCE033_39.xls 
L’OREAL The test substance L81 dissolved the membrane of 
tissue constructs, 
EIVS_LOREAL_SE_10HCE033_39.xls 
L’OREAL but the integrity of the HCE tissue was not affected EIVS_LOREAL_SE_10HCE033_39.xls 
L’OREAL The tissue is intact, but the membrane below is melted EIVS_LOREAL_SE_10HCE033_39.xls 
L’OREAL TEST SUBSTANCE L11: EIVS_LOREAL_SE_10HCE033_39.xls 
L’OREAL In the SOP, 30 ?L PBS are applied onto the tissue in 
order to improve the contact between the powder and 
EIVS_LOREAL_SE_10HCE033_39.xls 
  
TNO report | TNO 2013 R11617 | Final report  133 / 305
laboratory remark filename 
the epithelium. 
L’OREAL To improve such contact, the PBS was not aspirate 
before applying the powder L11. 
EIVS_LOREAL_SE_10HCE033_39.xls 
L’OREAL The tissue should be well pre-wetting EIVS_LOREAL_SE_10HCE033_39.xls 
L’OREAL This technical aspect might explain that the 2 first runs 
were invalids 
EIVS_LOREAL_SE_10HCE033_39.xls 
L’OREAL A SD>18% and contradictorily classification were 
observed for the 3 tissues (high intra-run variability). 
EIVS_LOREAL_SE_10HCE033_39.xls 
L’OREAL ADAPTED CONTROLS: EIVS_LOREAL_SE_10HCE034_40.xls 
L’OREAL The direct MTT reduction of test substances was 
evaluated using killed HCE tissues controls (one single 
run, 3 tissues / substance). 
EIVS_LOREAL_SE_10HCE034_40.xls 
L’OREAL The killed tissues used for the evaluation were provided 
from HCE tissues batch Nø10HCE033 
EIVS_LOREAL_SE_10HCE034_40.xls 
L’OREAL (produced on September,27 2010: less than a year) EIVS_LOREAL_SE_10HCE034_40.xls 
L’OREAL TEST SUBSTANCE L7: EIVS_LOREAL_SE_10HCE034_40.xls 
L’OREAL L7 is a strong MTT-reducer given a NSMTT > 97% in the 
controls 
EIVS_LOREAL_SE_10HCE034_40.xls 
L’OREAL L7 was not retest since the SD was < 18% (qualified test) EIVS_LOREAL_SE_10HCE034_40.xls 
L’OREAL The values are imported in the design import 
spreadsheet 
EIVS_LOREAL_SE_10HCE034_40.xls 
L’OREAL TEST SUBSTANCE L7: EIVS_LOREAL_SE_10HCE035_41.xls 
L’OREAL L7 is a strong MTT-reducer given a NSMTT > 50% in the 
controls 
EIVS_LOREAL_SE_10HCE035_41.xls 
L’OREAL L7 was not retest since the SD was < 18% (qualified test). EIVS_LOREAL_SE_10HCE035_41.xls 
L’OREAL We still acquired three qualified tests for this chemical 
following the rules set out in the Performance Criteria 
document, independently of the control tissues 
(NSMTT>50%) 
EIVS_LOREAL_SE_10HCE035_41.xls 
L’OREAL The values are imported in the design import 
spreadsheet 
EIVS_LOREAL_SE_10HCE035_41.xls 
L’OREAL TEST SUBSTANCE L63: EIVS_LOREAL_SE_10HCE035_41.xls 
L’OREAL L63 should be withdrawn from the chemicals selection 
because of inconsistent chemical states 
EIVS_LOREAL_SE_10HCE035_41.xls 
L’OREAL The test substance evaluated in the run was a liquid EIVS_LOREAL_SE_10HCE035_41.xls 
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L’OREAL TEST SUBSTANCE L7: EIVS_LOREAL_SE_10HCE036_42.xls 
L’OREAL L7 is a strong MTT-reducer given a NSMTT > 50% in the 
controls 
EIVS_LOREAL_SE_10HCE036_42.xls 
L’OREAL L7 was not retest since the SD was < 18% (qualified test). EIVS_LOREAL_SE_10HCE036_42.xls 
L’OREAL We still acquired three qualified tests for this chemical 
following the rules set out in the Performance Criteria 
document 
EIVS_LOREAL_SE_10HCE036_42.xls 
L’OREAL independently of the control tissues (NSMTT>50%) EIVS_LOREAL_SE_10HCE036_42.xls 
L’OREAL The values are imported in the design import 
spreadsheet 
EIVS_LOREAL_SE_10HCE036_42.xls 
L’OREAL TEST SUBSTANCE L63: EIVS_LOREAL_SE_10HCE037_43.xls 
L’OREAL L63 should be withdrawn from the chemicals selection 
because of inconsistent chemical states 
EIVS_LOREAL_SE_10HCE037_43.xls 
L’OREAL The test substance evaluated within the run was a liquid EIVS_LOREAL_SE_10HCE037_43.xls 
L’OREAL TEST SUBSTANCE L63: EIVS_LOREAL_SE_10HCE040_46.xls 
L’OREAL L63 should be withdrawn from the chemicals selection 
because of inconsistent chemical states 
EIVS_LOREAL_SE_10HCE040_46.xls 
L’OREAL The test substance evaluated was a liquid EIVS_LOREAL_SE_10HCE040_46.xls 
L’OREAL TEST SUBSTANCE L30: EIVS_LOREAL_SE_10HCE040_46.xls 
L’OREAL MTT interaction was observed during the run (and not 
during the checking step of potential direct MTT 
reduction of test chemical). 
EIVS_LOREAL_SE_10HCE040_46.xls 
L’OREAL So adapted killed tissues controls were added 
afterwards 
EIVS_LOREAL_SE_10HCE040_46.xls 
L’OREAL NONE EIVS_LOREAL_SE_10HCE041_47.xls 
L’OREAL TEST SUBSTANCE L119: EIVS_LOREAL_SE_10HCE042_48.xls 
L’OREAL The membrane of the insert was damaged during the 
rinsing step procedure. 
EIVS_LOREAL_SE_10HCE042_48.xls 
L’OREAL TEST SUBSTANCE L104: EIVS_LOREAL_SE_10HCE043_49.xls 
L’OREAL Post treatment, it has been noticed that the test 
substance applied onto the three epithelial tissues was 
not the chemical L104. 
EIVS_LOREAL_SE_10HCE043_49.xls 
L’OREAL The raw data could not therefore be taken into account EIVS_LOREAL_SE_10HCE043_49.xls 
L’OREAL NONE EIVS_LOREAL_SE_10HCE044_50.xls 
L’OREAL Substances L133 and L140: The membrane of the insert EIVS_LOREAL_SE_11HCE002_2.xls 
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was damaged during the rinsing step procedure 
L’OREAL Test substance L137 EIVS_LOREAL_SE_11HCE002_2.xls 
L’OREAL This solid hardens and retracts in the presence of 
atmosphere. 
EIVS_LOREAL_SE_11HCE002_2.xls 
L’OREAL It is important to apply it onto the tissues as soon as it 
was weighed. 
EIVS_LOREAL_SE_11HCE002_2.xls 
L’OREAL It was notice that its volume was considerably reduced if 
the weighing occurred 1 hour before topical application. 
EIVS_LOREAL_SE_11HCE002_2.xls 
L’OREAL Very difficult application: contact with the surface was 
not homogeneous even by using a mesh - > partial 
contact which can explain inter-tissues variability. 
EIVS_LOREAL_SE_11HCE002_2.xls 
L’OREAL TEST SUBSTANCE L119: EIVS_LOREAL_SE_11HCE007_7.xls 
L’OREAL The membrane of the insert was damaged during the 
rinsing step procedure. 
EIVS_LOREAL_SE_11HCE007_7.xls 
L’OREAL TEST SUBSTANCE L119: EIVS_LOREAL_SE_11HCE008_8.xls 
L’OREAL The membrane of the insert was damaged during the 
rinsing step procedure. 
EIVS_LOREAL_SE_11HCE008_8.xls 
L’OREAL TEST SUBSTANCE L131: EIVS_LOREAL_SE_11HCE009_9.xls 
L’OREAL The membrane of the insert was damaged during the 
rinsing step procedure. 
EIVS_LOREAL_SE_11HCE009_9.xls 
L’OREAL TEST SUBSTANCE L137: EIVS_LOREAL_SE_11HCE009_9.xls 
L’OREAL This solid hardens and retracts in the presence of 
atmosphere. 
EIVS_LOREAL_SE_11HCE009_9.xls 
L’OREAL It is important to apply it onto the tissues as soon as it 
was weighed. 
EIVS_LOREAL_SE_11HCE009_9.xls 
L’OREAL It was notice that its volume was considerably reduced if 
the weighing occurred 1 hour before topical application. 
EIVS_LOREAL_SE_11HCE009_9.xls 
L’OREAL Very difficult application: contact with the surface was 
not homogeneous even by using a mesh - > partial 
contact which can explain inter-tissues variability. 
EIVS_LOREAL_SE_11HCE009_9.xls 
L’OREAL TEST SUBSTANCE L137: EIVS_LOREAL_SE_11HCE014_14.xls 
L’OREAL This solid hardens and retracts in the presence of 
atmosphere. 
EIVS_LOREAL_SE_11HCE014_14.xls 
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L’OREAL It was notice that its volume was considerably reduced if 
the weighing occurred 1 hour before topical application. 
EIVS_LOREAL_SE_11HCE014_14.xls 
L’OREAL Very difficult application: contact with the surface was 
not homogeneous even by using a mesh - > partial 
contact which can explain inter-tissues variability. 
EIVS_LOREAL_SE_11HCE014_14.xls 
L’OREAL Substance L6: EIVS_LOREAL_SE_11HCE020_18.xls 
L’OREAL very strong coloring chemical (red) EIVS_LOREAL_SE_11HCE020_18.xls 
L’OREAL High variability due to the staining coloring properties of 
the chemical (critical washing step) 
EIVS_LOREAL_SE_11HCE020_18.xls 
L’OREAL TEST SUBSTANCES L15 EIVS_LOREAL_SE_11HCE020_18.xls 
L’OREAL In contact with the pre-wetted HCE tissue, the powder 
pebbled and stuck to the surface. 
EIVS_LOREAL_SE_11HCE020_18.xls 
L’OREAL During the rinsing step procedure, the substance (dense 
solid) was scratched to facilitate its removal 
EIVS_LOREAL_SE_11HCE020_18.xls 
L’OREAL Initial remarks: 06/10/2011 EIVS_LOREAL_SE_11HCE022_19.xls 
L’OREAL TEST SUBSTANCE L58: EIVS_LOREAL_SE_11HCE022_19.xls 
L’OREAL strong MTT reducer - no issue during the washing step EIVS_LOREAL_SE_11HCE022_19.xls 
L’OREAL TEST SUBSTANCE L100: EIVS_LOREAL_SE_11HCE022_19.xls 
L’OREAL MTT and coloring test substance EIVS_LOREAL_SE_11HCE022_19.xls 
L’OREAL Visual observation: the tissues are not dead but only 
stained due to the color (red) 
EIVS_LOREAL_SE_11HCE022_19.xls 
L’OREAL --> not cytotoxicity observed EIVS_LOREAL_SE_11HCE022_19.xls 
L’OREAL 12/10/2012: EIVS_LOREAL_SE_11HCE022_19.xls 
L’OREAL Evaluation of L58 using killed tissues, as requested by 
the EIVS core group 
EIVS_LOREAL_SE_11HCE022_19.xls 
L’OREAL TEST SUBSTANCES L15 EIVS_LOREAL_SE_11HCE024_20.xls 
L’OREAL In contact with the pre-wetted HCE tissue, the powder 
pebbled and stuck to the surface. 
EIVS_LOREAL_SE_11HCE024_20.xls 
L’OREAL During the rinsing step procedure, the substance (dense 
solid) was scratched to facilitate its removal 
EIVS_LOREAL_SE_11HCE024_20.xls 
L’OREAL TEST SUBSTANCE L6: EIVS_LOREAL_SE_11HCE024_20.xls 
L’OREAL strong coloring chemical (powder): critical washing step EIVS_LOREAL_SE_11HCE024_20.xls 
L’OREAL high variability due to the chemical which was very 
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L’OREAL TEST SUBSTANCE L185: EIVS_LOREAL_SE_11HCE024_20.xls 
L’OREAL Sticky chemical : mesh was used to uniformly spread the 
chemical on the tissues 
EIVS_LOREAL_SE_11HCE024_20.xls 
L’OREAL INITIAL REMARKS ON 06/10/2011 EIVS_LOREAL_SE_11HCE029_23.xls 
L’OREAL TEST SUBSTANCES L174 EIVS_LOREAL_SE_11HCE029_23.xls 
L’OREAL The vial overturned: There is no more than 7 mL left in 
the vial 
EIVS_LOREAL_SE_11HCE029_23.xls 
L’OREAL TEST SUBSTANCE L6: EIVS_LOREAL_SE_11HCE029_23.xls 
L’OREAL The experiment was performed ONLY with KILLED 
tissues to determine the individual NSMTT values 
EIVS_LOREAL_SE_11HCE029_23.xls 
L’OREAL Cell viability determination: The data obtained with the 
living tissues are defined on files Nø 11HCE020_18; 
EIVS_LOREAL_SE_11HCE029_23.xls 
L’OREAL 11HCE024_20, 11HCE032_25, 11HCE034_26 and 
11HCE036_27 
EIVS_LOREAL_SE_11HCE029_23.xls 
L’OREAL MTT REDUCERS: TEST SUBSTANCES L6, L33, L58, L100, 
L161, L169 and L174 
EIVS_LOREAL_SE_11HCE029_23.xls 
L’OREAL To determine the NSMTT% of the MTT reducers, the 
experiment was performed using killed HCE tissues 
(batch Nø 11HCE028). 
EIVS_LOREAL_SE_11HCE029_23.xls 
L’OREAL The individual Ku and Kt-Cx values (6) obtained in this 
run was then reported to the respective Excel 
spreadsheets of each test substance 
EIVS_LOREAL_SE_11HCE029_23.xls 
L’OREAL 12/10/2012: EIVS_LOREAL_SE_11HCE029_23.xls 
L’OREAL Evaluation of L58 using killed tissues, as requested by 
the EIVS core group 
EIVS_LOREAL_SE_11HCE029_23.xls 
L’OREAL Initial remarks: 24/06/2011 EIVS_LOREAL_SE_11HCE032_25(1).xls 
L’OREAL TEST SUBSTANCE L185: EIVS_LOREAL_SE_11HCE032_25(1).xls 
L’OREAL Sticky chemical: A mesh was used to uniformly spread 
the chemical on the three tissues 
EIVS_LOREAL_SE_11HCE032_25(1).xls 
L’OREAL TEST SUBSTANCE L6: EIVS_LOREAL_SE_11HCE032_25(1).xls 
L’OREAL Difficult to rinse this MTT and coloring test substance : 
high variation observed 
EIVS_LOREAL_SE_11HCE032_25(1).xls 
L’OREAL TEST SUBSTANCE L158: EIVS_LOREAL_SE_11HCE032_25(1).xls 
L’OREAL Difficult to rinse this MTT reducer EIVS_LOREAL_SE_11HCE032_25(1).xls 
L’OREAL 12/10/2012: EIVS_LOREAL_SE_11HCE032_25(1).xls 
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L’OREAL Evaluation of L58 using killed tissues, as requested by 
the EIVS core group 
EIVS_LOREAL_SE_11HCE032_25(1).xls 
L’OREAL INITIAL REMARKS ON 07/01/2011 EIVS_LOREAL_SE_11HCE034_26(1).xls 
L’OREAL TEST SUBSTANCE L58: EIVS_LOREAL_SE_11HCE034_26(1).xls 
L’OREAL MTT reducer diffucilt to rinse: high variability observed EIVS_LOREAL_SE_11HCE034_26(1).xls 
L’OREAL TEST SUBSTANCE L15: EIVS_LOREAL_SE_11HCE034_26(1).xls 
L’OREAL In contact with the pre-wetted HCE tissue, the powder 
pebbled and stuck to the surface 
EIVS_LOREAL_SE_11HCE034_26(1).xls 
L’OREAL During the rinsing step procedure, the substance (dense 
solid) was scratched to facilitate its removal 
EIVS_LOREAL_SE_11HCE034_26(1).xls 
L’OREAL 12/10/2012: EIVS_LOREAL_SE_11HCE034_26(1).xls 
L’OREAL Evaluation of L58 using killed tissues, as requested by 
the EIVS core group 
EIVS_LOREAL_SE_11HCE034_26(1).xls 
L’OREAL INITIAL REMARKS ON 07/08/2011 EIVS_LOREAL_SE_11HCE036_27.xls 
L’OREAL TEST SUBSTANCE L6: EIVS_LOREAL_SE_11HCE036_27.xls 
L’OREAL difficult to rinse: more intense staining observed in one 
tissue 
EIVS_LOREAL_SE_11HCE036_27.xls 
L’OREAL 12/10/2012: EIVS_LOREAL_SE_11HCE036_27.xls 
L’OREAL Evaluation of L58 using killed tissues, as requested by 
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CARDAM C66 tissues are damaged by the test item EIVS_CARDAM_LE1_10HCE035_41.xls 
CARDAM C66 tissues are damaged by the test item EIVS_CARDAM_LE1_10HCE036_42.xls 
CARDAM C90 tissues eaten away EIVS_CARDAM_LE1_10HCE037_43.xls 
CARDAM C82, hole in tissues caused by test item EIVS_CARDAM_LE1_10HCE037_43.xls 
CARDAM C11 and C13 tissue came loose during washing step EIVS_CARDAM_LE1_10HCE040_46.xls 
CARDAM C11 and C13 tissue came loose during washing step EIVS_CARDAM_LE1_10HCE041_47.xls 
CARDAM C45 tissues are still colored after washing step EIVS_CARDAM_LE1_10HCE041_47.xls 
CARDAM C50: Half the tissue was gone in cup 1, in cup 3 was the 
tissue completely gone 
EIVS_CARDAM_LE1_10HCE042_48.xls 
CARDAM C45 tissues are still colored after washing step EIVS_CARDAM_LE1_10HCE042_48.xls 
CARDAM C53: %NSMTT is unqualified because >50%; condition 2! EIVS_CARDAM_LE1_10HCE042_48.xls 
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(see e-mail from Nathalie 5th Nov 2010!) 
CARDAM SD >18% for killed tissue C53 but this is not the case in 
run LE from week 47. Not repeat killed tissue because 
test 
EIVS_CARDAM_LE1_10HCE042_48.xls 
CARDAM item is not compatible for HCE test EIVS_CARDAM_LE1_10HCE042_48.xls 
CARDAM C96 washing was preformed using a cotton bud EIVS_CARDAM_LE2_10HCE035_41.xls 
CARDAM C82 tissues are damaged by the test item EIVS_CARDAM_LE2_10HCE035_41.xls 
CARDAM New data killed tissue C87 (from week 45). SD>18% in 
runs 10HCE036 and 10HCE037 with data killed 
EIVS_CARDAM_LE2_10HCE035_41.xls 
CARDAM tissue from week 40. EIVS_CARDAM_LE2_10HCE035_41.xls 
CARDAM With this new data from killed tissue, C87 changes from 
a non-irritant call to a irritant call 
EIVS_CARDAM_LE2_10HCE035_41.xls 
CARDAM Test item C82 has created a hole in the tissues EIVS_CARDAM_LE2_10HCE036_42.xls 
CARDAM Test item C94 has created a hole in tissue 2 EIVS_CARDAM_LE2_10HCE036_42.xls 
CARDAM C11, C12, tissue eaten away partially to complete EIVS_CARDAM_LE2_10HCE037_43.xls 
CARDAM C45 tissues are still colored after washing step EIVS_CARDAM_LE2_10HCE040_46.xls 
CARDAM C53: %NSMTT is unqualified because >50%; condition 2! 
(see e-mail from Nathalie 5th Nov 2010!) 
EIVS_CARDAM_LE2_10HCE040_46.xls 
CARDAM SD >18% for killed tissue C53 but this is not the case in 
run LE from week 47. Not repeat killed tissue because 
test 
EIVS_CARDAM_LE2_10HCE040_46.xls 
CARDAM item is not compatible for HCE test EIVS_CARDAM_LE2_10HCE040_46.xls 
CARDAM C6, no pictures, test item can not leave L0210, terrible 
smell 
EIVS_CARDAM_LE2_10HCE041_47.xls 
CARDAM C53: %NSMTT is unqualified because >50%; condition 2! 
(see e-mail from Nathalie 5th Nov 2010!) 
EIVS_CARDAM_LE2_10HCE041_47.xls 
CARDAM SD >18% for killed tissue C53 but this is not the case in 
run LE from week 47. Not repeat killed tissue because 
test 
EIVS_CARDAM_LE2_10HCE041_47.xls 
CARDAM item is not compatible for HCE test EIVS_CARDAM_LE2_10HCE041_47.xls 
CARDAM C134 test item reacts with the plastic cup, leaves a white 
precipitate on tissue; 
EIVS_CARDAM_LE2_10HCE042_48.xls 
CARDAM C6, no pictures, test item can not leave L0210, terrible 
smell 
EIVS_CARDAM_LE2_10HCE042_48.xls 
CARDAM No pictures from C30 en C33, short exposure. EIVS_CARDAM_LE_10HCE029_35.xls 
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Observation done without pictures 
CARDAM Test item C17 sticks to tissue, wash off with cotton bud. EIVS_CARDAM_LE_10HCE029_35.xls 
CARDAM Test item C17and testitem C30, MTT solution beneath 
tissue is purple after 3H incubation and not just tissue 
EIVS_CARDAM_LE_10HCE029_35.xls 
CARDAM PBS without Ca and Mg is used from set 4 short 
exposure untill positive controle long exposure 
EIVS_CARDAM_LE_10HCE029_35.xls 
CARDAM c17 was hard to spread across the surface of the tissue EIVS_CARDAM_LE_10HCE031_37.xls 
CARDAM The first tissue of c19 was damaged in the middle EIVS_CARDAM_LE_10HCE031_37.xls 
CARDAM Test item C17 sticks to tissue, wash off with cotton bud. EIVS_CARDAM_LE_10HCE031_37.xls 
CARDAM Test item C17and testitem C30, MTT solution beneath 
tissue is purple after 3H incubation and not just tissue 
EIVS_CARDAM_LE_10HCE031_37.xls 
CARDAM Tissue 2 and 3 of C26 came loose during washing step EIVS_CARDAM_LE_10HCE032_38.xls 
CARDAM C34, C34-MTT and C77 applied with normal pipette 
(AVR) 
EIVS_CARDAM_LE_10HCE032_38.xls 
CARDAM C77 tissues are eaten away by the test item EIVS_CARDAM_LE_10HCE033_39(C77).xls 
CARDAM C66 tissues are eaten away by the test item EIVS_CARDAM_LE_10HCE033_39.xls 
CARDAM NC tissue 1 air bubble present EIVS_CARDAM_LE_10HCE033_39.xls 
CARDAM C51-C54-C65: After 3 h MTT-incubation: living tissues on 
edge (purple) while white in the middle (AVR) 
EIVS_CARDAM_LE_10HCE033_39.xls 
CARDAM C35 by mistake 4 valid runs (AVR 04/01/2011) EIVS_CARDAM_LE_10HCE033_39.xls 
CARDAM C45 and C101 tissues are still colored after washing step EIVS_CARDAM_LE_10HCE044_50.xls 
CARDAM C127 andC132, hole in all tissues due to the test item EIVS_CARDAM_LE_10HCE044_50.xls 
CARDAM C6 no picture taken after 3h MTT because needs to stay 
in Biohazard because of smell 
EIVS_CARDAM_LE_10HCE044_50.xls 
CARDAM C6: %NSMTT is unqualified because >50%; condition 2! 
(see e-mail from Nathalie 5th Nov 2010!) 
EIVS_CARDAM_LE_10HCE044_50.xls 
CARDAM C134: It looks like a white precipitate is formed on the 
tissues. Reaction of test item with the tissue??? 
EIVS_CARDAM_LE_11HCE003_3.xls 
CARDAM C127, C132, hole in tissue caused by test item EIVS_CARDAM_LE_11HCE003_3.xls 
CARDAM C106 forms a mucus on tissue, remove with cotton tip EIVS_CARDAM_LE_11HCE003_3.xls 
CARDAM Tissues might have had extra stress, Since the delivery 
by courier went first wrongly to UK and then to CARDAM 
EIVS_CARDAM_LE_11HCE003_3.xls 
CARDAM C134, C138: It looks like a white precipitate is formed on 
the tissues. Reaction of test item with the tissue??? 
EIVS_CARDAM_LE_11HCE005_5.xls 
CARDAM C106 forms a mucus on tissue, remove with cotton tip EIVS_CARDAM_LE_11HCE005_5.xls 
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CARDAM C138: It looks like a white precipitate is formed on the 
tissues. Reaction of test item with the tissue??? 
EIVS_CARDAM_LE_11HCE006_6.xls 
CARDAM C106 forms a mucus on tissue, remove with cotton tip EIVS_CARDAM_LE_11HCE006_6.xls 
CARDAM C109, sticky but with positive displacement pipette is 
OK. 
EIVS_CARDAM_LE_11HCE007_7.xls 
CARDAM wash with cotton tip EIVS_CARDAM_LE_11HCE007_7.xls 
CARDAM C109, sticky but with positive displacement pipette is 
OK. 
EIVS_CARDAM_LE_11HCE008_8.xls 
CARDAM wash with cotton tip EIVS_CARDAM_LE_11HCE008_8.xls 
CARDAM C124, resin, difficult to cover whole tissue EIVS_CARDAM_LE_11HCE008_8.xls 
CARDAM C109, sticky but with positive displacement pipette is 
OK. 
EIVS_CARDAM_LE_11HCE009_9.xls 
CARDAM wash with cotton tip EIVS_CARDAM_LE_11HCE009_9.xls 
CARDAM C124, resin, difficult to cover whole tissue EIVS_CARDAM_LE_11HCE009_9.xls 
CARDAM C28 washed once more after MTT incubation, before 
isopropanol incubation 
EIVS_CARDAM_LE_11HCE020_18.xls 
CARDAM C124, resin, difficult to spread EIVS_CARDAM_LE_11HCE020_18.xls 
CARDAM C28 and C52, washed once more after 16 h incubation, 
before MTT incubation 
EIVS_CARDAM_LE_11HCE022_19.xls 
CARDAM C28 and C52, washed once more after post incubation, 
before MTT incubation 
EIVS_CARDAM_LE_11HCE024_20.xls 
CARDAM C52, washed once more after post incubation, before 
MTT incubation 
EIVS_CARDAM_LE_11HCE026_21.xls 
CARDAM C52, washed once more after post incubation, before 
MTT incubation 
EIVS_CARDAM_LE_11HCE029_23.xls 
CARDAM C55, wash with cotton tip, forms mucus layer EIVS_CARDAM_LE_11HCE029_23.xls 
CARDAM C55, wash with cotton tip, forms mucus layer EIVS_CARDAM_LE_11HCE032_25.xls 
CARDAM C163, viscous, difficult to spread EIVS_CARDAM_LE_11HCE032_25.xls 
CARDAM C55, wash with cotton tip, mucus layer EIVS_CARDAM_LE_11HCE034_26.xls 
CARDAM C163, viscous, difficult to spread EIVS_CARDAM_LE_11HCE034_26.xls 
CARDAM C163, difficult to spread, viscous EIVS_CARDAM_LE_11HCE038_28.xls 
CEETOX PC -- some compound on sides of each insert EIVS_CEETOX_LE_10HCE023_25_v1.0 UPDATED.xls 
CEETOX C1 -- some clumps, mostly spread EIVS_CEETOX_LE_10HCE023_25_v1.0 UPDATED.xls 
CEETOX C2b -- dosed 10 seconds late EIVS_CEETOX_LE_10HCE023_25_v1.0 UPDATED.xls 
CEETOX C3 -- difficult to spread, pulled to sides of insert EIVS_CEETOX_LE_10HCE023_25_v1.0 UPDATED.xls 
  
TNO report | TNO 2013 R11617 | Final report  142 / 305
laboratory remark filename 
CEETOX C4 -- difficult to spread, but mostly staying spread EIVS_CEETOX_LE_10HCE023_25_v1.0 UPDATED.xls 
CEETOX C5 -- very difficult to spread, pulled to sides, not 
covering the tissue 
EIVS_CEETOX_LE_10HCE023_25_v1.0 UPDATED.xls 
CEETOX C6 -- a little clumpy, some sticking to glass weigh boat EIVS_CEETOX_LE_10HCE023_25_v1.0 UPDATED.xls 
CEETOX C7 -- will not spread, pulls to the sides EIVS_CEETOX_LE_10HCE023_25_v1.0 UPDATED.xls 
CEETOX C9c -- a lot on the side of the insert, not as uniform 
spreading 
EIVS_CEETOX_LE_10HCE023_25_v1.0 UPDATED.xls 
CEETOX PC -- transferred late EIVS_CEETOX_LE_10HCE023_25_v1.0 UPDATED.xls 
CEETOX C3 -- plastic degrading, tissue pulled away EIVS_CEETOX_LE_10HCE023_25_v1.0 UPDATED.xls 
CEETOX C4 -- tissue is see through in places, very rippled; c -- 
tore the tissue 
EIVS_CEETOX_LE_10HCE023_25_v1.0 UPDATED.xls 
CEETOX C6 -- compound looks melted on to the tissue some EIVS_CEETOX_LE_10HCE023_25_v1.0 UPDATED.xls 
CEETOX a -- looks rippled and torn EIVS_CEETOX_LE_10HCE023_25_v1.0 UPDATED.xls 
CEETOX C7 -- plastic degrading EIVS_CEETOX_LE_10HCE023_25_v1.0 UPDATED.xls 
CEETOX a -- tissue may be cracked EIVS_CEETOX_LE_10HCE023_25_v1.0 UPDATED.xls 
CEETOX C8 -- tissue washed off (c slightly less than a and b) EIVS_CEETOX_LE_10HCE023_25_v1.0 UPDATED.xls 
CEETOX C9 -- compound came off in a clump from a; but b and c 
had liquid 
EIVS_CEETOX_LE_10HCE023_25_v1.0 UPDATED.xls 
CEETOX PCb - clumped to the side, tried to tap and spread EIVS_CEETOX_LE_10HCE024_26_v1.0.xls 
CEETOX C3 - difficulty spreading, pulled to sides EIVS_CEETOX_LE_10HCE024_26_v1.0.xls 
CEETOX C4 - same as C3, very thin EIVS_CEETOX_LE_10HCE024_26_v1.0.xls 
CEETOX C5 - difficult to spread, may have been evaporating EIVS_CEETOX_LE_10HCE024_26_v1.0.xls 
CEETOX C6 - a -- looks clumped, but good coverage EIVS_CEETOX_LE_10HCE024_26_v1.0.xls 
CEETOX b -- some compound fell out of insert EIVS_CEETOX_LE_10HCE024_26_v1.0.xls 
CEETOX C7b - better coverage than a; some difficulty spreading 
compound 
EIVS_CEETOX_LE_10HCE024_26_v1.0.xls 
CEETOX C9a - a little clumped on side, but good coverage EIVS_CEETOX_LE_10HCE024_26_v1.0.xls 
CEETOX Rinsing EIVS_CEETOX_LE_10HCE024_26_v1.0.xls 
CEETOX C3 - tissue wrinkled, plastic degraded EIVS_CEETOX_LE_10HCE024_26_v1.0.xls 
CEETOX C4 - wrinkled tissues EIVS_CEETOX_LE_10HCE024_26_v1.0.xls 
CEETOX a -- tissue ripped and fell off EIVS_CEETOX_LE_10HCE024_26_v1.0.xls 
CEETOX b -- tissue rolled up EIVS_CEETOX_LE_10HCE024_26_v1.0.xls 
CEETOX c -- tissue fell off EIVS_CEETOX_LE_10HCE024_26_v1.0.xls 
CEETOX C5 - plastic degraded; not full coverage EIVS_CEETOX_LE_10HCE024_26_v1.0.xls 
CEETOX C6 - melted compound, a and b have bubbles under the EIVS_CEETOX_LE_10HCE024_26_v1.0.xls 
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tissue 
CEETOX C7 - not covered, plastic degraded a little around the 
edge 
EIVS_CEETOX_LE_10HCE024_26_v1.0.xls 
CEETOX C8 - tissue looks broken EIVS_CEETOX_LE_10HCE024_26_v1.0.xls 
CEETOX C9 - compound turned to liquid on the tissue EIVS_CEETOX_LE_10HCE024_26_v1.0.xls 
CEETOX PC1a -- compound was very wet on top of tissue EIVS_CEETOX_LE_10HCE042_48_v1.0 UPDATED.xls 
CEETOX C3 or C13 -- compound difficult to spread EIVS_CEETOX_LE_10HCE042_48_v1.0 UPDATED.xls 
CEETOX C5 or C15 -- compound difficult to spread EIVS_CEETOX_LE_10HCE042_48_v1.0 UPDATED.xls 
CEETOX C7 or C17 -- compound difficult to spread EIVS_CEETOX_LE_10HCE042_48_v1.0 UPDATED.xls 
CEETOX C9 or C19 -- compound difficult to spread EIVS_CEETOX_LE_10HCE042_48_v1.0 UPDATED.xls 
CEETOX C8 or C18 -- tissue lost during rinsing or dissolved EIVS_CEETOX_LE_10HCE042_48_v1.0 UPDATED.xls 
CEETOX C1 b or C11 b -- clumps, not great coverage over the 
tissue 
EIVS_CEETOX_LE_10HCE043_49_v1.0 UPDATED.xls 
CEETOX C3 or C13 -- some difficulty spreading the compound EIVS_CEETOX_LE_10HCE043_49_v1.0 UPDATED.xls 
CEETOX C4 b or C14 b -- dosed 10 seconds late EIVS_CEETOX_LE_10HCE043_49_v1.0 UPDATED.xls 
CEETOX C5 or C15 -- very hard to spread; had better coverage 
not spreading 
EIVS_CEETOX_LE_10HCE043_49_v1.0 UPDATED.xls 
CEETOX C6 a or C16 a -- lost some compound in weigh boat EIVS_CEETOX_LE_10HCE043_49_v1.0 UPDATED.xls 
CEETOX C6 b or C16 b -- some compound left in glass weigh boat EIVS_CEETOX_LE_10HCE043_49_v1.0 UPDATED.xls 
CEETOX C7 or C17 -- very difficult to spread the compound EIVS_CEETOX_LE_10HCE043_49_v1.0 UPDATED.xls 
CEETOX C9 or C19 b and c -- clumps/rocks; had ok coverage over 
tissue 
EIVS_CEETOX_LE_10HCE043_49_v1.0 UPDATED.xls 
CEETOX C8 or C18 -- tissue dissolved EIVS_CEETOX_LE_10HCE043_49_v1.0 UPDATED.xls 
CEETOX C9 or C19 -- compound dissolved into a liquid EIVS_CEETOX_LE_10HCE043_49_v1.0 UPDATED.xls 
CEETOX C4/C14 -- hard to spread EIVS_CEETOX_LE_10HCE044_50_v1.0 UPDATED.xls 
CEETOX C5/C15 -- very difficult to spread EIVS_CEETOX_LE_10HCE044_50_v1.0 UPDATED.xls 
CEETOX C6/C16 b -- some clumps, but good coverage EIVS_CEETOX_LE_10HCE044_50_v1.0 UPDATED.xls 
CEETOX C6/C16 c -- tissue spilled; 1/4 of compound left in weigh 
boat (estimate) 
EIVS_CEETOX_LE_10HCE044_50_v1.0 UPDATED.xls 
CEETOX C7/C17 -- thin, somewhat hard to spread EIVS_CEETOX_LE_10HCE044_50_v1.0 UPDATED.xls 
CEETOX C9/C19 -- clumpy, but ok coverage EIVS_CEETOX_LE_10HCE044_50_v1.0 UPDATED.xls 
CEETOX C9/C19 a -- clumps, dosed 20 seconds late EIVS_CEETOX_LE_10HCE044_50_v1.0 UPDATED.xls 
CEETOX Rinsing EIVS_CEETOX_LE_10HCE044_50_v1.0 UPDATED.xls 
CEETOX C3/C13 -- plastic degraded EIVS_CEETOX_LE_10HCE044_50_v1.0 UPDATED.xls 
CEETOX C4/C14 -- tissue degraded, holes in it EIVS_CEETOX_LE_10HCE044_50_v1.0 UPDATED.xls 
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CEETOX C5/C15 -- plastic degraded EIVS_CEETOX_LE_10HCE044_50_v1.0 UPDATED.xls 
CEETOX C8/C18 -- no tissue EIVS_CEETOX_LE_10HCE044_50_v1.0 UPDATED.xls 
CEETOX C10/C20 -- did not cover tissue EIVS_CEETOX_LE_10HCE044_50_v1.0 UPDATED.xls 
CEETOX PC b -- some compound left in glass weigh boat EIVS_CEETOX_LE_11HCE003_3_v1.0.xls 
CEETOX C1 -- difficult to spread the compound EIVS_CEETOX_LE_11HCE003_3_v1.0.xls 
CEETOX C2 -- clumpy compound, but managed to get good 
coverage 
EIVS_CEETOX_LE_11HCE003_3_v1.0.xls 
CEETOX b -- lots of compound stuck in glass weigh boat EIVS_CEETOX_LE_11HCE003_3_v1.0.xls 
CEETOX c -- lots of compound in glass weigh boat and secondary 
weigh boat 
EIVS_CEETOX_LE_11HCE003_3_v1.0.xls 
CEETOX C3 -- clumps or rocks, but spread over tissue EIVS_CEETOX_LE_11HCE003_3_v1.0.xls 
CEETOX b -- some in weigh boat EIVS_CEETOX_LE_11HCE003_3_v1.0.xls 
CEETOX c -- used tip to spread, some compound in weigh boat EIVS_CEETOX_LE_11HCE003_3_v1.0.xls 
CEETOX C5 -- compound left in glass weigh boats EIVS_CEETOX_LE_11HCE003_3_v1.0.xls 
CEETOX C5 c -- tissue dropped, compound still covered the insert EIVS_CEETOX_LE_11HCE003_3_v1.0.xls 
CEETOX C6 -- compound thin, and difficult to spread EIVS_CEETOX_LE_11HCE003_3_v1.0.xls 
CEETOX C9 -- some compound left in glass weigh boats, and used 
tip to spread for all three tissues 
EIVS_CEETOX_LE_11HCE003_3_v1.0.xls 
CEETOX Rinsing EIVS_CEETOX_LE_11HCE003_3_v1.0.xls 
CEETOX C6 -- tissues wrinkled EIVS_CEETOX_LE_11HCE003_3_v1.0.xls 
CEETOX C3 -- tissue dropped, but recovered EIVS_CEETOX_LE_11HCE003_3_v1.0.xls 
CEETOX C7 -- tissues rippled and wrinkled EIVS_CEETOX_LE_11HCE003_3_v1.0.xls 
CEETOX PC -- used tip to spread EIVS_CEETOX_LE_11HCE004_4_v1.0 JOEY UPDATED.xls 
CEETOX C2 -- some compound in glass weigh boat; used tip EIVS_CEETOX_LE_11HCE004_4_v1.0 JOEY UPDATED.xls 
CEETOX C3 a -- used tip to spread EIVS_CEETOX_LE_11HCE004_4_v1.0 JOEY UPDATED.xls 
CEETOX C6 -- thin; difficult to spread EIVS_CEETOX_LE_11HCE004_4_v1.0 JOEY UPDATED.xls 
CEETOX Rinsing EIVS_CEETOX_LE_11HCE004_4_v1.0 JOEY UPDATED.xls 
CEETOX C1 -- tissue looks smooth EIVS_CEETOX_LE_11HCE004_4_v1.0 JOEY UPDATED.xls 
CEETOX C4 -- looks like the tissue was lost (applies to all three 
tissues) 
EIVS_CEETOX_LE_11HCE004_4_v1.0 JOEY UPDATED.xls 
CeeTox PCb- 15 seconds late on dosing EIVS_CEETOX_LE_11HCE004_4_v1.0.xls 
CeeTox C1b- bubbles in compound on tissue EIVS_CEETOX_LE_11HCE004_4_v1.0.xls 
CeeTox C4- not all compound removed from tissue with extra 
rinse 
EIVS_CEETOX_LE_11HCE004_4_v1.0.xls 
CeeTox C4a- some compund left in weigh boat EIVS_CEETOX_LE_11HCE004_4_v1.0.xls 
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CeeTox C6a- 1 min late on dosing EIVS_CEETOX_LE_11HCE004_4_v1.0.xls 
CeeTox C7- soapy, extra rinse EIVS_CEETOX_LE_11HCE004_4_v1.0.xls 
CeeTox C8c- dropped in flask EIVS_CEETOX_LE_11HCE004_4_v1.0.xls 
CeeTox C4 - After incubation the compound stained the media 
and tissue a dark color see pictures in 11HCE007 Lisa 
EIVS_CEETOX_LE_11HCE004_4_v1.0.xls 
CEETOX PC b -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE006_6_v1.0 SET 1 JOEY.xls 
CEETOX PC -- used tip on all tissues EIVS_CEETOX_LE_11HCE006_6_v1.0 SET 1 JOEY.xls 
CEETOX C12 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE006_6_v1.0 SET 1 JOEY.xls 
CEETOX C13 -- compound is staticky; some compound left in 
glass weigh boat 
EIVS_CEETOX_LE_11HCE006_6_v1.0 SET 1 JOEY.xls 
CEETOX C15 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE006_6_v1.0 SET 1 JOEY.xls 
CEETOX Rinsing EIVS_CEETOX_LE_11HCE006_6_v1.0 SET 1 JOEY.xls 
CEETOX C11 -- plastic degraded EIVS_CEETOX_LE_11HCE006_6_v1.0 SET 1 JOEY.xls 
CEETOX C16 -- tissues rippled EIVS_CEETOX_LE_11HCE006_6_v1.0 SET 1 JOEY.xls 
CEETOX C17 -- tissues rippled EIVS_CEETOX_LE_11HCE006_6_v1.0 SET 1 JOEY.xls 
CEETOX PC -- compound in glass weigh boat; used tip to spread EIVS_CEETOX_LE_11HCE006_6_v1.0 SET 2 JOEY.xls 
CEETOX C2 -- used tip to spread EIVS_CEETOX_LE_11HCE006_6_v1.0 SET 2 JOEY.xls 
CEETOX C3 -- used tip to spread; difficult to spread EIVS_CEETOX_LE_11HCE006_6_v1.0 SET 2 JOEY.xls 
CEETOX C6 FK -- harder to spread on FK tissues EIVS_CEETOX_LE_11HCE006_6_v1.0 SET 2 JOEY.xls 
CEETOX Rinsing EIVS_CEETOX_LE_11HCE006_6_v1.0 SET 2 JOEY.xls 
CEETOX C1 -- bumps on tissues EIVS_CEETOX_LE_11HCE006_6_v1.0 SET 2 JOEY.xls 
CEETOX C4 -- lost tissues in bucket; no chance in saving EIVS_CEETOX_LE_11HCE006_6_v1.0 SET 2 JOEY.xls 
CEETOX C4 FK a and c -- tissue cracked EIVS_CEETOX_LE_11HCE006_6_v1.0 SET 2 JOEY.xls 
CEETOX C6 -- not spread well on the tissues EIVS_CEETOX_LE_11HCE006_6_v1.0 SET 2 JOEY.xls 
CEETOX C7 -- tissues cracked EIVS_CEETOX_LE_11HCE006_6_v1.0 SET 2 JOEY.xls 
CEETOX PC - Spread with tip EIVS_CEETOX_LE_11HCE006_6_v1.0.xls 
CEETOX C2b - 30 seconds early rinse EIVS_CEETOX_LE_11HCE006_6_v1.0.xls 
CEETOX C4 - not all compound removed with extra rinse EIVS_CEETOX_LE_11HCE006_6_v1.0.xls 
CEETOX C4a - clumps of compound EIVS_CEETOX_LE_11HCE006_6_v1.0.xls 
CEETOX C5 - extra rinse, 30 seconds late on rinsing EIVS_CEETOX_LE_11HCE006_6_v1.0.xls 
CEETOX C6a - nicked tissue EIVS_CEETOX_LE_11HCE006_6_v1.0.xls 
CEETOX C7c - nicked tissue EIVS_CEETOX_LE_11HCE006_6_v1.0.xls 
CEETOX C4 - After incubation the compound stained the media 
and tissue a dark color see pictures in 11HCE007 Lisa 
EIVS_CEETOX_LE_11HCE006_6_v1.0.xls 
CEETOX PC a -- compound spilled; however, recovered EIVS_CEETOX_LE_11HCE007_7_v1.0 SET 2 JOEY.xls 
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CEETOX PC -- used tip EIVS_CEETOX_LE_11HCE007_7_v1.0 SET 2 JOEY.xls 
CEETOX C2 -- used tip to spread EIVS_CEETOX_LE_11HCE007_7_v1.0 SET 2 JOEY.xls 
CEETOX C3 -- used tip to spread EIVS_CEETOX_LE_11HCE007_7_v1.0 SET 2 JOEY.xls 
CEETOX Rinsing EIVS_CEETOX_LE_11HCE007_7_v1.0 SET 2 JOEY.xls 
CEETOX C4 -- tissue looks like it washed off the insert EIVS_CEETOX_LE_11HCE007_7_v1.0 SET 2 JOEY.xls 
CEETOX PC -- used tip to spread EIVS_CEETOX_LE_11HCE007_7_v1.0 set 1.xls 
CEETOX C11 -- hard to spread compound, tended to pull to the 
sides of the insert 
EIVS_CEETOX_LE_11HCE007_7_v1.0 set 1.xls 
CEETOX C12 -- used tip to spread EIVS_CEETOX_LE_11HCE007_7_v1.0 set 1.xls 
CEETOX C13 -- used tip to spread EIVS_CEETOX_LE_11HCE007_7_v1.0 set 1.xls 
CEETOX C19 -- used tip to spread EIVS_CEETOX_LE_11HCE007_7_v1.0 set 1.xls 
CEETOX Compound left in all glass weigh boats EIVS_CEETOX_LE_11HCE007_7_v1.0 set 1.xls 
CEETOX Rinisng EIVS_CEETOX_LE_11HCE007_7_v1.0 set 1.xls 
CEETOX C13 -- compound seemed to dissolve on the tissue EIVS_CEETOX_LE_11HCE007_7_v1.0 set 1.xls 
CEETOX C14 -- tissue appears to be gone EIVS_CEETOX_LE_11HCE007_7_v1.0 set 1.xls 
CEETOX PC - spread with tip EIVS_CEETOX_LE_11HCE007_7_v1.0.xls 
CEETOX C1 - extra rinse EIVS_CEETOX_LE_11HCE007_7_v1.0.xls 
CEETOX C1 - all tissue appears detatched from membrane EIVS_CEETOX_LE_11HCE007_7_v1.0.xls 
CEETOX C4b - compound remaining in weigh boat EIVS_CEETOX_LE_11HCE007_7_v1.0.xls 
CEETOX C4 - not all compound removed after extra rinse EIVS_CEETOX_LE_11HCE007_7_v1.0.xls 
CEETOX C4 - After incubation the compound stained the media 
and tissue a dark color see pictures in 11HCE007 Lisa 
EIVS_CEETOX_LE_11HCE007_7_v1.0.xls 
CEETOX PC -- used tip to spread, some compound left in glass 
weigh boat 
EIVS_CEETOX_LE_11HCE008_8_v1.0 JOEY.xls 
CEETOX PCb -- dosed 30 seconds late EIVS_CEETOX_LE_11HCE008_8_v1.0 JOEY.xls 
CEETOX x13 C1 -- used tip to spread EIVS_CEETOX_LE_11HCE008_8_v1.0 JOEY.xls 
CEETOX x39 C2 -- some compound left in glass weigh boat EIVS_CEETOX_LE_11HCE008_8_v1.0 JOEY.xls 
CEETOX x8 C2 -- used tip to spread; compound in glass weigh 
boat and outer weigh boat 
EIVS_CEETOX_LE_11HCE008_8_v1.0 JOEY.xls 
CEETOX X49 C7 -- used tip to spread EIVS_CEETOX_LE_11HCE008_8_v1.0 JOEY.xls 
CEETOX x128 C4 -- tissues cracked after rinsing EIVS_CEETOX_LE_11HCE008_8_v1.0 JOEY.xls 
CEETOX PC - spread with tip EIVS_CEETOX_LE_11HCE008_8_v1.0 LISA.xls 
CEETOX C1 - spread with tip EIVS_CEETOX_LE_11HCE008_8_v1.0 LISA.xls 
CEETOX C2 - spread with tip EIVS_CEETOX_LE_11HCE008_8_v1.0 LISA.xls 
CEETOX C2 - two extra rinses EIVS_CEETOX_LE_11HCE008_8_v1.0 LISA.xls 
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CEETOX C3 - extra rinse EIVS_CEETOX_LE_11HCE008_8_v1.0 LISA.xls 
CEETOX C4 - spread with tip EIVS_CEETOX_LE_11HCE008_8_v1.0 LISA.xls 
CEETOX C8a - spread with tip EIVS_CEETOX_LE_11HCE008_8_v1.0 LISA.xls 
CEETOX C8 - minute late rinsing, compound cemented to tissue 
used a swab to remove 
EIVS_CEETOX_LE_11HCE008_8_v1.0 LISA.xls 
CEETOX C8c - after recovery compound remained on tissue, re-
rinsed with swab 
EIVS_CEETOX_LE_11HCE008_8_v1.0 LISA.xls 
CEETOX PC -- used tip EIVS_CEETOX_LE_11HCE009_9_v1.0 JOEY FAILED RUN 
UPDATED.xls 
CEETOX C1 x13 -- used tip; compound left in glass weigh boat EIVS_CEETOX_LE_11HCE009_9_v1.0 JOEY FAILED RUN 
UPDATED.xls 
CEETOX C3 x8 -- used tip EIVS_CEETOX_LE_11HCE009_9_v1.0 JOEY FAILED RUN 
UPDATED.xls 
CEETOX C3-MTT x8-MTT -- used tip EIVS_CEETOX_LE_11HCE009_9_v1.0 JOEY FAILED RUN 
UPDATED.xls 
CEETOX C7 x43 -- used tip EIVS_CEETOX_LE_11HCE009_9_v1.0 JOEY FAILED RUN 
UPDATED.xls 
CEETOX Rinsing EIVS_CEETOX_LE_11HCE009_9_v1.0 JOEY FAILED RUN 
UPDATED.xls 
CEETOX C3 x8 and C3-MTT x8-MTT -- behind on rinsing; color 
would not come off 
EIVS_CEETOX_LE_11HCE009_9_v1.0 JOEY FAILED RUN 
UPDATED.xls 
CEETOX C8 x44 -- very difficult to rinse off; cemented to the 
tissue; had to use swab to break away 
EIVS_CEETOX_LE_11HCE009_9_v1.0 JOEY FAILED RUN 
UPDATED.xls 
CEETOX C3 x8 -- rinsed after post incubation to remove residual 
color 4 Mar 11 
EIVS_CEETOX_LE_11HCE009_9_v1.0 JOEY FAILED RUN 
UPDATED.xls 
CEETOX PC invalid, no comments EIVS_CEETOX_LE_11HCE009_9_v1.0 LISA FAILED RUN 
UPDATED.xls 
CEETOX PC -- used tip to spread EIVS_CEETOX_LE_11HCE013_13_v1.0 set 1.xls 
CEETOX C1 X13 -- used tip to spread EIVS_CEETOX_LE_11HCE013_13_v1.0 set 1.xls 
CEETOX C3 X8 -- staticy, all over glass weigh boat, used tip to 
spread 
EIVS_CEETOX_LE_11HCE013_13_v1.0 set 1.xls 
CEETOX C3-MTT X8-MTT -- same as above EIVS_CEETOX_LE_11HCE013_13_v1.0 set 1.xls 
CEETOX C4 X128 -- 1 minute late rinsing, extra rinse, ripped 
tissues 
EIVS_CEETOX_LE_11HCE013_13_v1.0 set 1.xls 
CEETOX C15 X103 -- hard to spread compound EIVS_CEETOX_LE_11HCE013_13_v1.0 set 2.xls 
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CEETOX C16 X63 -- compound would not stay spread EIVS_CEETOX_LE_11HCE013_13_v1.0 set 2.xls 
CEETOX C17 X47 -- stuck to glass weigh boat, used tip to apply 
and spread 
EIVS_CEETOX_LE_11HCE013_13_v1.0 set 2.xls 
CEETOX C18 X17 -- hard to spread compound EIVS_CEETOX_LE_11HCE013_13_v1.0 set 2.xls 
CEETOX C13 X126 -- compound dissolved on the tissues EIVS_CEETOX_LE_11HCE013_13_v1.0 set 2.xls 
CEETOX PC -- used tip to spread EIVS_CEETOX_LE_11HCE020_18_v1.0 set 1.xls 
CEETOX C1 X13 -- used tip to spread compound EIVS_CEETOX_LE_11HCE020_18_v1.0 set 1.xls 
CEETOX C4 X126 -- did not spread well over the tissues EIVS_CEETOX_LE_11HCE020_18_v1.0 set 1.xls 
CEETOX C6 X47 -- used tip to spread EIVS_CEETOX_LE_11HCE020_18_v1.0 set 1.xls 
CEETOX C8 X8 -- used tip to spread; all tissues received extra 
swab; one minute behind 
EIVS_CEETOX_LE_11HCE020_18_v1.0 set 1.xls 
CEETOX C8-MTT X8-MTT -- used tip to spread; all tissues received 
extra swab 
EIVS_CEETOX_LE_11HCE020_18_v1.0 set 1.xls 
CEETOX C5 X43 -- tissues a and c slightly ripped during rinsing EIVS_CEETOX_LE_11HCE020_18_v1.0 set 1.xls 
CEETOX After Post-Incubation swabbed X13, X8 and X8-MTT with 
PBS and cotton tip to remove excess color before placing 
in MTT 
EIVS_CEETOX_LE_11HCE020_18_v1.0 set 1.xls 
CEETOX C17 X128 -- thin, difficult to spread EIVS_CEETOX_LE_11HCE020_18_v1.0 set 2.xls 
CEETOX C18 X39 -- used tip to spread EIVS_CEETOX_LE_11HCE020_18_v1.0 set 2.xls 
CEETOX PC2 -- used tip to spread EIVS_CEETOX_LE_11HCE020_18_v1.0 set 2.xls 
CEETOX PC LE -- used tip to spread; compound left in weigh boat EIVS_CEETOX_LE_11HCE022_19_v1.0 set 1.xls 
CEETOX C1 X21 -- used tip to spread EIVS_CEETOX_LE_11HCE022_19_v1.0 set 1.xls 
CEETOX C3 X126 -- compound did not cover the tissue well; 
compound left in weigh boat 
EIVS_CEETOX_LE_11HCE022_19_v1.0 set 1.xls 
CEETOX C4 X14 -- compound did not cover well; used tip to 
spread; compound left in weigh boat 
EIVS_CEETOX_LE_11HCE022_19_v1.0 set 1.xls 
CEETOX C5 X46 -- compound left in weigh boat; c dropped in 
funnel; all tissues had compound left after rinsing 
EIVS_CEETOX_LE_11HCE022_19_v1.0 set 1.xls 
CEETOX C6 X27 -- compound left in weigh boat; all tissues 
received extra rinses 
EIVS_CEETOX_LE_11HCE022_19_v1.0 set 1.xls 
CEETOX C7 X50 -- compound left in weigh boat; used tip to 
spread 
EIVS_CEETOX_LE_11HCE022_19_v1.0 set 1.xls 
CEETOX C8 X53 -- tissues received extra rinse EIVS_CEETOX_LE_11HCE022_19_v1.0 set 1.xls 
CEETOX C10 X84 -- compound left in weigh boat; b dropped in 
funnel 
EIVS_CEETOX_LE_11HCE022_19_v1.0 set 1.xls 
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CEETOX C11 X87 -- compound left in weigh boat; used tip to 
spread compound 
EIVS_CEETOX_LE_11HCE022_19_v1.0 set 1.xls 
CEETOX C12 X102 -- compound left in weigh boat EIVS_CEETOX_LE_11HCE022_19_v1.0 set 1.xls 
CEETOX C13 X107 -- used tip to spread; compound left in weigh 
boat 
EIVS_CEETOX_LE_11HCE022_19_v1.0 set 1.xls 
CEETOX C14 X108 -- compound left in weigh boat; used tip; did 
not get good coverage with the compound 
EIVS_CEETOX_LE_11HCE022_19_v1.0 set 2.xls 
CEETOX C15 X109 -- compound left in weight boat; used tip to 
spread; compound solidified as a clump in weigh boat 
EIVS_CEETOX_LE_11HCE022_19_v1.0 set 2.xls 
CEETOX C16 X110 -- dosed as a liquid; a dosed 20 seconds late; 
extra rinse for all tissues 
EIVS_CEETOX_LE_11HCE022_19_v1.0 set 2.xls 
CEETOX C17 X118 b -- dosed 30 seconds late; tissue torn at 
rinsing 
EIVS_CEETOX_LE_11HCE022_19_v1.0 set 2.xls 
CEETOX C18 X138 -- compound left on tissue at rinsing EIVS_CEETOX_LE_11HCE022_19_v1.0 set 2.xls 
CEETOX C19 X139 -- tissues tearing at rinsing EIVS_CEETOX_LE_11HCE022_19_v1.0 set 2.xls 
CEETOX C21 X13 -- used tip to spread; compound left in weigh 
boats 
EIVS_CEETOX_LE_11HCE022_19_v1.0 set 2.xls 
CEETOX C22 X43 -- compound left in weigh boats; tissues ripped 
in the middle 
EIVS_CEETOX_LE_11HCE022_19_v1.0 set 2.xls 
CEETOX C23 X47 -- used tip to spread; compound left in weigh 
boats 
EIVS_CEETOX_LE_11HCE022_19_v1.0 set 2.xls 
CEETOX PC2 -- compound left in weigh boat; used tip to spread EIVS_CEETOX_LE_11HCE022_19_v1.0 set 2.xls 
CEETOX C25 X68 -- precipitate in liquid EIVS_CEETOX_LE_11HCE022_19_v1.0 set 2.xls 
CEETOX C26 X8 -- compound left in weigh boat; extra rinse and 
swab; extra rinse and swab before transfer to MTT 
EIVS_CEETOX_LE_11HCE022_19_v1.0 set 2.xls 
CEETOX C26-MTT X8-MTT -- compound left in weigh boat; extra 
rinse and swab; extra rinse and swab before transfer to 
MTT 
EIVS_CEETOX_LE_11HCE022_19_v1.0 set 2.xls 
CEETOX CdJ EIVS_CEETOX_LE_11HCE022_19_v1.0 set 2.xls 
CEETOX X47 is recorded as run 5 but is infact run 6. This is 
changed in the import program. 
EIVS_CEETOX_LE_11HCE022_19_v1.0 set 2.xls 
CEETOX C30 X81 -- extra swab; globs left on the tissue EIVS_CEETOX_LE_11HCE022_19_v1.0 set 3.xls 
CEETOX C31 X82 -- 10 seconds late rinsing tissue a EIVS_CEETOX_LE_11HCE022_19_v1.0 set 3.xls 
CEETOX C34 X39 -- compound left in weigh boat EIVS_CEETOX_LE_11HCE022_19_v1.0 set 3.xls 
CEETOX PC3 -- used tip to spread; compound left in weigh boat EIVS_CEETOX_LE_11HCE022_19_v1.0 set 3.xls 
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CEETOX PC -- used tip to spread; compound left in glass weigh 
boat 
EIVS_CEETOX_LE_11HCE034_26_v1.0 set 1.xls 
CEETOX C1 X14 -- used tip; rocks on the tissues, did not cover 
well; compound left in glass weigh boat 
EIVS_CEETOX_LE_11HCE034_26_v1.0 set 1.xls 
CEETOX C2 X46 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE034_26_v1.0 set 1.xls 
CEETOX C8 X87 -- compound left in glass weigh boat; used tip to 
spread; not good coverage 
EIVS_CEETOX_LE_11HCE034_26_v1.0 set 1.xls 
CEETOX Rinsing EIVS_CEETOX_LE_11HCE034_26_v1.0 set 1.xls 
CEETOX C1 X14 -- compound dissolved on tissue EIVS_CEETOX_LE_11HCE034_26_v1.0 set 1.xls 
CEETOX C3 X27 and C3-MTT X27-MTT -- hole in the color; color 
coming off only a little; extra rinse and swab 
EIVS_CEETOX_LE_11HCE034_26_v1.0 set 1.xls 
CEETOX C6 X70 -- extra swab EIVS_CEETOX_LE_11HCE034_26_v1.0 set 1.xls 
CEETOX C1 X14 and C1-MTT X14-MTT -- received two extra 
swabs before MTT 
EIVS_CEETOX_LE_11HCE034_26_v1.0 set 1.xls 
CEETOX PC -- used tip; compound left in glass weigh boat EIVS_CEETOX_LE_11HCE034_26_v1.0 set 2.xls 
CEETOX C11 X108 -- not good coverage; used tip to spread; 
compound left in glass weigh boat 
EIVS_CEETOX_LE_11HCE034_26_v1.0 set 2.xls 
CEETOX C12 X109 -- compound left in glass weigh boat; used tip 
to spread; compound gummed up on the tissue 
EIVS_CEETOX_LE_11HCE034_26_v1.0 set 2.xls 
CEETOX C14 X118 -- compound thin and difficult to spread EIVS_CEETOX_LE_11HCE034_26_v1.0 set 2.xls 
CEETOX C16 X138 -- compound thin and difficult to spread EIVS_CEETOX_LE_11HCE034_26_v1.0 set 2.xls 
CEETOX C17 X139 -- compound thin EIVS_CEETOX_LE_11HCE034_26_v1.0 set 2.xls 
CEETOX C19 X21 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE034_26_v1.0 set 2.xls 
CEETOX C20 X112 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE034_26_v1.0 set 2.xls 
CEETOX C21 X126 -- compound left in glass weigh boat; used tip 
to spread; would not come off of glass weigh boat 
EIVS_CEETOX_LE_11HCE034_26_v1.0 set 2.xls 
CEETOX Rinsing EIVS_CEETOX_LE_11HCE034_26_v1.0 set 2.xls 
CEETOX C11 X108 -- dissolved on tissue EIVS_CEETOX_LE_11HCE034_26_v1.0 set 2.xls 
CEETOX C12 X109 -- stuck on tissue, had to be wiped off with wet 
swab 
EIVS_CEETOX_LE_11HCE034_26_v1.0 set 2.xls 
CEETOX C12 a X109 a -- gel on top of tissue EIVS_CEETOX_LE_11HCE034_26_v1.0 set 2.xls 
CEETOX C14 X118 -- tissue degraded EIVS_CEETOX_LE_11HCE034_26_v1.0 set 2.xls 
CEETOX C15 X136 -- may have washed off the tissue EIVS_CEETOX_LE_11HCE034_26_v1.0 set 2.xls 
CEETOX C16 X138 -- tissue cracked EIVS_CEETOX_LE_11HCE034_26_v1.0 set 2.xls 
CEETOX CdJ EIVS_CEETOX_LE_11HCE034_26_v1.0 set 2.xls 
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CEETOX X39 is recorded as run 5 but is infact run 6. This is 
changed in the import program 
EIVS_CEETOX_LE_11HCE034_26_v1.0 set 2.xls 
CEETOX PC -- used tip to spread EIVS_CEETOX_LE_11HCE034_26_v1.0 set 3.xls 
CEETOX C22 X111 -- used tip to spread; compound left in glass 
weight boat 
EIVS_CEETOX_LE_11HCE034_26_v1.0 set 3.xls 
CEETOX C22c X111c -- compound spilled into plastic weigh boat EIVS_CEETOX_LE_11HCE034_26_v1.0 set 3.xls 
CEETOX C23 X114 -- compound left in glass weigh boat; used tip 
to spread 
EIVS_CEETOX_LE_11HCE034_26_v1.0 set 3.xls 
CEETOX C25 X116 -- used tip to spread EIVS_CEETOX_LE_11HCE034_26_v1.0 set 3.xls 
CEETOX C28 X125 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE034_26_v1.0 set 3.xls 
CEETOX C30 X131 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE034_26_v1.0 set 3.xls 
CEETOX C31 X133 -- compound thin EIVS_CEETOX_LE_11HCE034_26_v1.0 set 3.xls 
CEETOX C32 X134 -- compound would not spread; sat in the 
middle of the tissues 
EIVS_CEETOX_LE_11HCE034_26_v1.0 set 3.xls 
CEETOX PC -- used tip to spread; compound left in glass weigh 
boat 
EIVS_CEETOX_LE_11HCE040_29_v1.0 set 1.xls 
CEETOX C1 X14 -- used tip to spread; compound left in glass 
weigh boat; in a and b some compound came out of the 
glass weigh boat 
EIVS_CEETOX_LE_11HCE040_29_v1.0 set 1.xls 
CEETOX C1-MTT X14-MTT --used tip to spread; compound left in 
glass weigh boat 
EIVS_CEETOX_LE_11HCE040_29_v1.0 set 1.xls 
CEETOX C2 X46 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE040_29_v1.0 set 1.xls 
CEETOX C3 X27 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE040_29_v1.0 set 1.xls 
CEETOX C3-MTT c X27-MTT c -- tissue flipped; used tip to better 
spread remaining compound 
EIVS_CEETOX_LE_11HCE040_29_v1.0 set 1.xls 
CEETOX C4 X50 -- compound left in glass weigh boat; used tip to 
spread 
EIVS_CEETOX_LE_11HCE040_29_v1.0 set 1.xls 
CEETOX C4 a X50 a -- some compound came out of glass weigh 
boat 
EIVS_CEETOX_LE_11HCE040_29_v1.0 set 1.xls 
CEETOX C6 X70 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE040_29_v1.0 set 1.xls 
CEETOX C6 a X70 a -- compound hardened and could not spread; 
had better coverage with b and c 
EIVS_CEETOX_LE_11HCE040_29_v1.0 set 1.xls 
CEETOX C8 X87 -- compound left in glass weigh boat; used tip to 
spread; dissolved on tissues 
EIVS_CEETOX_LE_11HCE040_29_v1.0 set 1.xls 
CEETOX C9 X102 -- compound left in glass weigh boat; used tip to EIVS_CEETOX_LE_11HCE040_29_v1.0 set 1.xls 
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CEETOX C10 X07 -- compound left in glass weigh boat; used tip to 
spread 
EIVS_CEETOX_LE_11HCE040_29_v1.0 set 1.xls 
CEETOX Rinsing EIVS_CEETOX_LE_11HCE040_29_v1.0 set 1.xls 
CEETOX C2 X46 -- extra swab EIVS_CEETOX_LE_11HCE040_29_v1.0 set 1.xls 
CEETOX C3 X27 and C3-MTT and X27-MTT -- extra rinse and swab EIVS_CEETOX_LE_11HCE040_29_v1.0 set 1.xls 
CEETOX C3b and X27b -- ripped tissue EIVS_CEETOX_LE_11HCE040_29_v1.0 set 1.xls 
CEETOX C5 X53 -- extra swab EIVS_CEETOX_LE_11HCE040_29_v1.0 set 1.xls 
CEETOX C6 X70 -- extra swab, had to push the compound off EIVS_CEETOX_LE_11HCE040_29_v1.0 set 1.xls 
CEETOX PC -- used tip to spread; compound left in glass weigh 
boat 
EIVS_CEETOX_LE_11HCE040_29_v1.0 set 2.xls 
CEETOX C11 X108 -- poor coverage; used tip to spread; melted 
on the tissue 
EIVS_CEETOX_LE_11HCE040_29_v1.0 set 2.xls 
CEETOX C12 X109 -- had to scrape out of the weigh boat; used 
tip to spread; compound left in glass weigh boat 
EIVS_CEETOX_LE_11HCE040_29_v1.0 set 2.xls 
CEETOX C18 X111 -- used tip to spread; compound left in glass 
weigh boat 
EIVS_CEETOX_LE_11HCE040_29_v1.0 set 2.xls 
CEETOX C19 X114 a -- lost some compound in glass weigh boat EIVS_CEETOX_LE_11HCE040_29_v1.0 set 2.xls 
CEETOX compound left in all glass weigh boats EIVS_CEETOX_LE_11HCE040_29_v1.0 set 2.xls 
CEETOX C20 X115 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE040_29_v1.0 set 2.xls 
CEETOX C21 X116 -- used tip to spread; compound left in glass 
weigh boat 
EIVS_CEETOX_LE_11HCE040_29_v1.0 set 2.xls 
CEETOX Rinsing EIVS_CEETOX_LE_11HCE040_29_v1.0 set 2.xls 
CEETOX C11 X108 -- completely dissolved EIVS_CEETOX_LE_11HCE040_29_v1.0 set 2.xls 
CEETOX C13 X110 -- rinsed 30 seconds late; had to do extra swab EIVS_CEETOX_LE_11HCE040_29_v1.0 set 2.xls 
CEETOX C14 X118 -- tissues cracked EIVS_CEETOX_LE_11HCE040_29_v1.0 set 2.xls 
CEETOX C16 X138 -- tissues cracked EIVS_CEETOX_LE_11HCE040_29_v1.0 set 2.xls 
CEETOX C17 X139 -- tissues ripped EIVS_CEETOX_LE_11HCE040_29_v1.0 set 2.xls 
CEETOX PC -- used tip to spread compound, compound left in 
glass weigh boat 
EIVS_CEETOX_LE_11HCE047_37_v1.0.xls 
CEETOX C13 X111 -- used tip to spread compound, compound 
left in glass weigh boat 
EIVS_CEETOX_LE_11HCE047_37_v1.0.xls 
CEETOX C14 X114 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE047_37_v1.0.xls 
CEETOX C15 X115 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE047_37_v1.0.xls 
CEETOX C16 X116 -- compound left in glass weigh boat; can't tell EIVS_CEETOX_LE_11HCE047_37_v1.0.xls 
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if the compound completely covered the tissue visually 
CEETOX C17 X50 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE047_37_v1.0.xls 
CEETOX C18 X119 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE047_37_v1.0.xls 
CEETOX C19 X123 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE047_37_v1.0.xls 
CEETOX C20 X125 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE047_37_v1.0.xls 
CEETOX C21 X129 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE047_37_v1.0.xls 
CEETOX C22 X131 -- compound left in glass weigh boat; used tip 
to spread compound 
EIVS_CEETOX_LE_11HCE047_37_v1.0.xls 
CEETOX PC -- used tip to spread compound; compound left in 
glass weigh boat; tissue a looked very wet 
EIVS_CEETOX_LE_11HCE049_38_v1.0.xls 
CEETOX C1 X111 -- used tip to spread compound; compound left 
in glass weigh boat 
EIVS_CEETOX_LE_11HCE049_38_v1.0.xls 
CEETOX C2 X114 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE049_38_v1.0.xls 
CEETOX C3 X115 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE049_38_v1.0.xls 
CEETOX C4 X116 -- compound left in glass weigh boat; could not 
see compound well on tissue; used tip to spread 
compound 
EIVS_CEETOX_LE_11HCE049_38_v1.0.xls 
CEETOX C5 X50 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE049_38_v1.0.xls 
CEETOX C6 X119 -- compound left in glass weigh boat; used tip to 
spread compound 
EIVS_CEETOX_LE_11HCE049_38_v1.0.xls 
CEETOX C7 X123 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE049_38_v1.0.xls 
CEETOX C8 X125 -- compound left in glass weigh boat; used tip to 
spread compound 
EIVS_CEETOX_LE_11HCE049_38_v1.0.xls 
CEETOX C9 X129 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE049_38_v1.0.xls 
CEETOX C10 X131 -- compound left in glass weigh boat; used tip 
to spread; tissue a looked wet 
EIVS_CEETOX_LE_11HCE049_38_v1.0.xls 
CEETOX PC -- compound left in glass weigh boat; used tip to 
spread 
EIVS_CEETOX_LE_11HCE051_39_v1.0.xls 
CEETOX C14 X134 -- compound sat in the middle of the tissue; 
one rock, but not spread well; lost tissue a during rinsing 
EIVS_CEETOX_LE_11HCE051_39_v1.0.xls 
CEETOX C15 X119 -- compound left in glass weigh boat; used tip 
to spread compound; staticy; compound dissolved 
EIVS_CEETOX_LE_11HCE051_39_v1.0.xls 
CEETOX C16 X123 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE051_39_v1.0.xls 
CEETOX C17 X125 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE051_39_v1.0.xls 
CEETOX C18 X129 -- compound left in glass weigh boat; EIVS_CEETOX_LE_11HCE051_39_v1.0.xls 
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CEETOX C19 X131 -- compound left in glass weigh boat; used tip 
to spread; compound dissolved 
EIVS_CEETOX_LE_11HCE051_39_v1.0.xls 
CEETOX C22 X29 -- no tissue after rinsing EIVS_CEETOX_LE_11HCE051_39_v1.0.xls 
CEETOX Dosing EIVS_CEETOX_LE_11HCE053_40_v1.0.xls 
CEETOX PC -- compound left in glass weigh boat; used tip to 
spread compound 
EIVS_CEETOX_LE_11HCE053_40_v1.0.xls 
CEETOX C16 X134 -- compound left in glass weigh boat; 
compound did not cover the tissue 
EIVS_CEETOX_LE_11HCE053_40_v1.0.xls 
CEETOX C17 X11 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE053_40_v1.0.xls 
CEETOX C20 X24 -- compound left in glass weigh boat; tissue 
turned blue 
EIVS_CEETOX_LE_11HCE053_40_v1.0.xls 
CEETOX C20-MTT X24-MTT -- compound left in glass weigh boat; 
tissue turned blue 
EIVS_CEETOX_LE_11HCE053_40_v1.0.xls 
CEETOX C21 X32 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE053_40_v1.0.xls 
CEETOX C21-MTT X32-MTT -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE053_40_v1.0.xls 
CEETOX Rinsing EIVS_CEETOX_LE_11HCE053_40_v1.0.xls 
CEETOX C15 X133 -- tissues pulled away EIVS_CEETOX_LE_11HCE053_40_v1.0.xls 
CEETOX C19 X29 -- lost tissues a and b and half of c EIVS_CEETOX_LE_11HCE053_40_v1.0.xls 
CEETOX C20 X24 and C20-MTT X24-MTT -- very difficult to rinse 
off; approximately 30 seconds behind on later tissues 
EIVS_CEETOX_LE_11HCE053_40_v1.0.xls 
CEETOX C21 X32 and C21-MTT X32-MTT -- very difficult to rinse 
off; approximately 30 seconds behind on later tissues 
EIVS_CEETOX_LE_11HCE053_40_v1.0.xls 
CEETOX PC -- compound left in glass weigh boat; used tip to 
spread 
EIVS_CEETOX_LE_11HCE055_41_v1.0.xls 
CEETOX PC FK -- compound left in glass weigh boat; used tip to 
spread; tissues b and c had better coverage 
EIVS_CEETOX_LE_11HCE055_41_v1.0.xls 
CEETOX C18 X131 -- compound left in glass weigh boat; used tip 
to spread 
EIVS_CEETOX_LE_11HCE055_41_v1.0.xls 
CEETOX C19 X119 -- compound left in glass weigh boat; 
compound dissolved on the tissues 
EIVS_CEETOX_LE_11HCE055_41_v1.0.xls 
CEETOX C20 X173 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE055_41_v1.0.xls 
CEETOX C21 X169 -- compound left in glass weigh boat; used tip 
to spread 
EIVS_CEETOX_LE_11HCE055_41_v1.0.xls 
CEETOX PC -- compound left in glass weigh boat; used tip to EIVS_CEETOX_LE_11HCE057_42_v1.0.xls 
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CEETOX C18 X131 -- compound left in glass weigh boat; 
compound staticy and dissolved on the tissue 
EIVS_CEETOX_LE_11HCE057_42_v1.0.xls 
CEETOX C19 X119 -- compound left in glass weigh boat; 
compound dissolved on the tissue 
EIVS_CEETOX_LE_11HCE057_42_v1.0.xls 
CEETOX C20 X173 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE057_42_v1.0.xls 
CEETOX C24 X40 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE057_42_v1.0.xls 
CEETOX C25 X111 -- compound left in glass weigh boat; used tip 
to spread 
EIVS_CEETOX_LE_11HCE057_42_v1.0.xls 
CEETOX PC -- compound left in weigh boat; used tip to spread 
compound; tissues a and b were a little wet 
EIVS_CEETOX_LE_11HCE059_43_v1.0.xls 
CEETOX C18 X173 -- compound left in weigh boat EIVS_CEETOX_LE_11HCE059_43_v1.0.xls 
CEETOX C19 X169 -- compound left in weigh boat EIVS_CEETOX_LE_11HCE059_43_v1.0.xls 
CEETOX C21 X40 -- compound left in weigh boat; staticy, good 
coverage, needed extra swab 
EIVS_CEETOX_LE_11HCE059_43_v1.0.xls 
CEETOX C22 X134 -- compound left in weigh boat; sticky; less 
than when I weighed it out, used tip to spread 
EIVS_CEETOX_LE_11HCE059_43_v1.0.xls 
CEETOX C23 X196 -- compound left in weigh boat; used tip to 
spread compound 
EIVS_CEETOX_LE_11HCE059_43_v1.0.xls 
CEETOX C24 X11 -- compound left in weigh boat EIVS_CEETOX_LE_11HCE059_43_v1.0.xls 
CEETOX PC -- compound left in glass weigh boat; used tip to 
spread 
EIVS_CEETOX_LE_11HCE061_44_v1.0.xls 
CEETOX C16 X173 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE061_44_v1.0.xls 
CEETOX C17 X40 -- compound left in glass weigh boat; staticy EIVS_CEETOX_LE_11HCE061_44_v1.0.xls 
CEETOX C18 X196 -- compound left in glass weigh boat; used tip 
to spread 
EIVS_CEETOX_LE_11HCE061_44_v1.0.xls 
CEETOX C19 X11 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE061_44_v1.0.xls 
CEETOX C20 X24 -- compound left in glass weigh boat; extra 
swab 
EIVS_CEETOX_LE_11HCE061_44_v1.0.xls 
CEETOX C20-MTT X24-MTT -- compound left in glass weigh boat; 
extra swab 
EIVS_CEETOX_LE_11HCE061_44_v1.0.xls 
CEETOX C21 X32 -- compound left in glass weigh boat; extra 
swab 
EIVS_CEETOX_LE_11HCE061_44_v1.0.xls 
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CEETOX C21 FK X32 FK -- compound left in glass weigh boat; 
extra swab; tissue is more colored, stained tissue and 
the media 
EIVS_CEETOX_LE_11HCE061_44_v1.0.xls 
CEETOX PC -- compound left in glass weigh boat; used tip EIVS_CEETOX_LE_11HCE063_45_v1.0.xls 
CEETOX C11 X173 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE063_45_v1.0.xls 
CEETOX C12 X24 -- compound left in glass weigh boat; extra 
swab 
EIVS_CEETOX_LE_11HCE063_45_v1.0.xls 
CEETOX C12-MTT X24-MTT -- compound left in glass weigh boat; 
extra swab 
EIVS_CEETOX_LE_11HCE063_45_v1.0.xls 
CEETOX C13 X196 -- compound left in glass weigh boat; extra 
swab 
EIVS_CEETOX_LE_11HCE063_45_v1.0.xls 
CEETOX C16 X55 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE063_45_v1.0.xls 
CEETOX C18 X61 -- not good coverage; clumped on tissue; extra 
swab 
EIVS_CEETOX_LE_11HCE063_45_v1.0.xls 
CEETOX C20 X75 -- very staticy; compound left in glass and 
plastic weigh boats; used extra swab 
EIVS_CEETOX_LE_11HCE063_45_v1.0.xls 
CEETOX Dosing EIVS_CEETOX_LE_11HCE065_46_v1.0.xls 
CEETOX PC -- compound left in glass weigh boat; used tip to 
spread 
EIVS_CEETOX_LE_11HCE065_46_v1.0.xls 
CEETOX C13 X32 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE065_46_v1.0.xls 
CEETOX C13-MTT X32-MTT -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE065_46_v1.0.xls 
CEETOX C15 X55 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE065_46_v1.0.xls 
CEETOX C19 X75 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE065_46_v1.0.xls 
CEETOX C21 X80 -- compound left in glass weigh boat; used tip to 
spread 
EIVS_CEETOX_LE_11HCE065_46_v1.0.xls 
CEETOX C22 X94 -- compound would not stay spread over the 
tissues 
EIVS_CEETOX_LE_11HCE065_46_v1.0.xls 
CEETOX Rinsing EIVS_CEETOX_LE_11HCE065_46_v1.0.xls 
CEETOX C16 X56 -- lost some of the tissues EIVS_CEETOX_LE_11HCE065_46_v1.0.xls 
CEETOX C17 X61 -- extra rinse and swab required EIVS_CEETOX_LE_11HCE065_46_v1.0.xls 
CEETOX C18 X66 -- lost tissues EIVS_CEETOX_LE_11HCE065_46_v1.0.xls 
CEETOX C20 X77 -- extra swab EIVS_CEETOX_LE_11HCE065_46_v1.0.xls 
CEETOX PC -- compound left in glass weigh boat; used tip to 
spread compound 
EIVS_CEETOX_LE_11HCE068_48_v1.0.xls 
CEETOX C14 X29 -- tissues started to come off EIVS_CEETOX_LE_11HCE068_48_v1.0.xls 
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CEETOX C15 X77 -- extra swab used EIVS_CEETOX_LE_11HCE068_48_v1.0.xls 
CEETOX C16 X80 -- compound left in glass weigh boat; used tip to 
spread compound 
EIVS_CEETOX_LE_11HCE068_48_v1.0.xls 
CEETOX C17 X94 -- poor coverage on tissue EIVS_CEETOX_LE_11HCE068_48_v1.0.xls 
CEETOX C18 X95 -- compound left in glass weigh boat; extra 
swab used 
EIVS_CEETOX_LE_11HCE068_48_v1.0.xls 
CEETOX C18-MTT X95-MTT -- compound left in glass weigh boat; 
extra swab used 
EIVS_CEETOX_LE_11HCE068_48_v1.0.xls 
CEETOX C20 X120 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE068_48_v1.0.xls 
CEETOX C21 X157 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE068_48_v1.0.xls 
CEETOX C22 X158 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE068_48_v1.0.xls 
CEETOX C23 X160 -- compound left in glass weigh boat; used tip 
to spread compound 
EIVS_CEETOX_LE_11HCE068_48_v1.0.xls 
CEETOX PC -- compound left in glass weigh boat; used tip to 
spread 
EIVS_CEETOX_LE_11HCE070_49_v1.0.xls 
CEETOX C13 X24 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE070_49_v1.0.xls 
CEETOX C13-MTT X24-MTT -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE070_49_v1.0.xls 
CEETOX C15 X55 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE070_49_v1.0.xls 
CEETOX C16 X95 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE070_49_v1.0.xls 
CEETOX C16-MTT X95-MTT -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE070_49_v1.0.xls 
CEETOX C18 X120 -- tissue b dropped in funnel; compound left in 
glass weigh boat 
EIVS_CEETOX_LE_11HCE070_49_v1.0.xls 
CEETOX C19 X157 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE070_49_v1.0.xls 
CEETOX C20 X158 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE070_49_v1.0.xls 
CEETOX C21 X160 -- compound left in glass weigh boat EIVS_CEETOX_LE_11HCE070_49_v1.0.xls 
CEETOX PC -- compound left in glass weigh boat; used tip to 
spread 
EIVS_CEETOX_LE_12HCE002_2_v1.0 set 1.xls 
CEETOX C5 X24 -- compound left in glass weigh boat; tissue b 
damaged during rinsing 
EIVS_CEETOX_LE_12HCE002_2_v1.0 set 1.xls 
CEETOX C5-MTT X24-MTT -- compound left in glass weigh boat EIVS_CEETOX_LE_12HCE002_2_v1.0 set 1.xls 
CEETOX C6 X32 -- compound left in glass weigh boat; tissue c 
nicked 
EIVS_CEETOX_LE_12HCE002_2_v1.0 set 1.xls 
CEETOX C6-MTT X32-MTT -- compound left in glass weigh boat EIVS_CEETOX_LE_12HCE002_2_v1.0 set 1.xls 
CEETOX C6 FK X32 FK -- compound left in glass weigh boat EIVS_CEETOX_LE_12HCE002_2_v1.0 set 1.xls 
CEETOX C7 X42 -- extra rinse and swab required; tissue a nicked EIVS_CEETOX_LE_12HCE002_2_v1.0 set 1.xls 
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CEETOX C8 X55 -- compound left in glass weigh boat EIVS_CEETOX_LE_12HCE002_2_v1.0 set 1.xls 
CEETOX C9 X56 -- lost all tissues during rinsing EIVS_CEETOX_LE_12HCE002_2_v1.0 set 1.xls 
CEETOX C10 X165 -- extra rinse required EIVS_CEETOX_LE_12HCE002_2_v1.0 set 1.xls 
CEETOX C11 X66 -- extra rinse; lost half of tissues a and b; lost 
tissue c 
EIVS_CEETOX_LE_12HCE002_2_v1.0 set 1.xls 
CEETOX C12 X75 -- compound left in glass weigh boat; staticy EIVS_CEETOX_LE_12HCE002_2_v1.0 set 2.xls 
CEETOX C13 X77 -- extra swab EIVS_CEETOX_LE_12HCE002_2_v1.0 set 2.xls 
CEETOX C14 X80 -- compound left in glass weigh boat; used tip to 
spread 
EIVS_CEETOX_LE_12HCE002_2_v1.0 set 2.xls 
CEETOX C16 X95 -- compound left in glass weigh boat; extra 
swab used 
EIVS_CEETOX_LE_12HCE002_2_v1.0 set 2.xls 
CEETOX C16-MTT X95-MTT -- compound left in glass weigh boat; 
extra swab used; 30 seconds late on all tissues 
EIVS_CEETOX_LE_12HCE002_2_v1.0 set 2.xls 
CEETOX C18 X120 -- compound left in glass weigh boat EIVS_CEETOX_LE_12HCE002_2_v1.0 set 2.xls 
CEETOX C19 X157 -- compound left in glass weigh boat; used tip 
to spread 
EIVS_CEETOX_LE_12HCE002_2_v1.0 set 2.xls 
CEETOX C20 X158 -- compound left in glass weigh boat EIVS_CEETOX_LE_12HCE002_2_v1.0 set 2.xls 
CEETOX C21 X160 -- compound left in glass weigh boat EIVS_CEETOX_LE_12HCE002_2_v1.0 set 2.xls 
CEETOX C22 X61 -- compound changed; could not pipette as 
easily as previous runs; all tissues dosed late 
EIVS_CEETOX_LE_12HCE002_2_v1.0 set 2.xls 
CEETOX PC LE -- compound left in glass weigh boat; used tip to 
spread 
EIVS_CEETOX_LE_12HCE004_3_v1.0.xls 
CEETOX C14 X95 -- compound left in glass weigh boat; rinsed 20-
30 seconds late; used extra swab 
EIVS_CEETOX_LE_12HCE004_3_v1.0.xls 
CEETOX C14-MTT X95-MTT -- compound left in glass weigh boat; 
rinsed 20-30 seconds late; used extra swab 
EIVS_CEETOX_LE_12HCE004_3_v1.0.xls 
CEETOX C16 X120 -- compound left in glass weigh weigh boat EIVS_CEETOX_LE_12HCE004_3_v1.0.xls 
CEETOX C17 X157 -- compound left in glass weigh boat; used tip 
to spread 
EIVS_CEETOX_LE_12HCE004_3_v1.0.xls 
CEETOX C18 X158 -- compound left in glass weigh boat EIVS_CEETOX_LE_12HCE004_3_v1.0.xls 
CEETOX C19 X160 -- compound left in glass weigh boat EIVS_CEETOX_LE_12HCE004_3_v1.0.xls 
CEETOX C21 X61 -- very sticky; could not get a consistent dose; 
used extra swab during rinsing 
EIVS_CEETOX_LE_12HCE004_3_v1.0.xls 
CEETOX PC - used tip to spread EIVS_CEETOX_LE_12HCE009_7_v1.0.xls 
CEETOX X95 - used tip to sread EIVS_CEETOX_LE_12HCE009_7_v1.0.xls 
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CEETOX X95-MTT - used tip to spread EIVS_CEETOX_LE_12HCE009_7_v1.0.xls 
CEETOX PC2- used tip to spread EIVS_CEETOX_LE_12HCE009_7_v1.0.xls 
CEETOX PC- nicks on tissues EIVS_CEETOX_LE_12HCE009_7_v1.0.xls 
CEETOX X95- extra rinse and swab EIVS_CEETOX_LE_12HCE009_7_v1.0.xls 
CEETOX X95a- nick on tissue EIVS_CEETOX_LE_12HCE009_7_v1.0.xls 
CEETOX X95-MTT - extra rinse and swab EIVS_CEETOX_LE_12HCE009_7_v1.0.xls 
L’OREAL TEST SUBSTANCES L9 and L20: EIVS_LOREAL_LE_10HCE023_25.xls 
L’OREAL The substances stuck on the plastic which is not 
anymore transparent. 
EIVS_LOREAL_LE_10HCE023_25.xls 
L’OREAL The rinsing procedure was very difficult. Substances 
might be not completely removed from the tissues. 
EIVS_LOREAL_LE_10HCE023_25.xls 
L’OREAL TEST SUBSTANCE L12: EIVS_LOREAL_LE_10HCE023_25.xls 
L’OREAL The membrane of the insert was damaged during the 
rinsing step procedure. 
EIVS_LOREAL_LE_10HCE023_25.xls 
L’OREAL TEST SUBSTANCES L9 AND L20 EIVS_LOREAL_LE_10HCE024_26.xls 
L’OREAL The substances stuck on the plastic which is not 
anymore transparent. 
EIVS_LOREAL_LE_10HCE024_26.xls 
L’OREAL The rinsing procedure was very difficult. Substances 
might be not completely removed from the tissues. 
EIVS_LOREAL_LE_10HCE024_26.xls 
L’OREAL TEST SUBSTANCE L12 EIVS_LOREAL_LE_10HCE024_26.xls 
L’OREAL The membrane of the insert was damaged during the 
rinsing step procedure. 
EIVS_LOREAL_LE_10HCE024_26.xls 
L’OREAL TEST SUBSTANCE L11: EIVS_LOREAL_LE_10HCE024_26.xls 
L’OREAL Discrepancy observed between the three tissues : 
UNQUALIFIED run 
EIVS_LOREAL_LE_10HCE024_26.xls 
L’OREAL TEST SUBSTANCE L30 EIVS_LOREAL_LE_10HCE025_27.xls 
L’OREAL The test substance stuck onto the HCE tissues. The 
rinsing step was very difficult 
EIVS_LOREAL_LE_10HCE025_27.xls 
L’OREAL In contact with the pre-wetted HCE tissue, the powder 
pebbled and stuck to the surface. 
EIVS_LOREAL_LE_10HCE025_27.xls 
L’OREAL During the rinsing step procedure, the substance (dense 
solid) was scratched to facilitate its removal. 
EIVS_LOREAL_LE_10HCE025_27.xls 
L’OREAL Visually, the tissues are dead at both exposure times. EIVS_LOREAL_LE_10HCE025_27.xls 
L’OREAL The cell viability measured (above 50% suggesting non 
irritancy potential of the test substance) should not be 
EIVS_LOREAL_LE_10HCE025_27.xls 
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considered as relevant. 
L’OREAL The L30 should be classified as irritant. EIVS_LOREAL_LE_10HCE025_27.xls 
L’OREAL TEST SUBSTANCE L66: EIVS_LOREAL_LE_10HCE025_27.xls 
L’OREAL The membrane was melted. EIVS_LOREAL_LE_10HCE025_27.xls 
L’OREAL TEST SUBSTANCE L51: EIVS_LOREAL_LE_10HCE025_27.xls 
L’OREAL The membrane of the insert was damaged during the 
rinsing step procedure. 
EIVS_LOREAL_LE_10HCE025_27.xls 
L’OREAL TEST SUBSTANCE L11: EIVS_LOREAL_LE_10HCE025_27.xls 
L’OREAL In the SOP, 30 ?L PBS are applied onto the tissue in 
order to improve the contact between the powder and 
the epithelium 
EIVS_LOREAL_LE_10HCE025_27.xls 
L’OREAL To improve such contact, the PBS was not aspirate 
before applying the powder L11. 
EIVS_LOREAL_LE_10HCE025_27.xls 
L’OREAL The tissue should be well pre-wetting EIVS_LOREAL_LE_10HCE025_27.xls 
L’OREAL This technical aspect might explain that the 2 first runs 
were invalids. 
EIVS_LOREAL_LE_10HCE025_27.xls 
L’OREAL A SD > 18% and contradictorily classification were 
observed for the 3 tissues (high intra-run variability). 
EIVS_LOREAL_LE_10HCE025_27.xls 
L’OREAL TEST SUBSTANCE L43: EIVS_LOREAL_LE_10HCE025_27.xls 
L’OREAL The membrane of the insert was damaged during the 
rinsing step procedure 
EIVS_LOREAL_LE_10HCE025_27.xls 
L’OREAL TEST SUBSTANCES L12, L43: EIVS_LOREAL_LE_10HCE026_28.xls 
L’OREAL The membrane of the insert was damaged during the 
rinsing step procedure. 
EIVS_LOREAL_LE_10HCE026_28.xls 
L’OREAL TEST SUBSTANCES L9 L20 and L43: EIVS_LOREAL_LE_10HCE026_28.xls 
L’OREAL The substances stuck on the plastic which is not 
anymore transparent. 
EIVS_LOREAL_LE_10HCE026_28.xls 
L’OREAL The rinsing procedure was very difficult. Substances 
might be not completely removed from the tissues. 
EIVS_LOREAL_LE_10HCE026_28.xls 
L’OREAL TEST SUBSTANCE L30: EIVS_LOREAL_LE_10HCE027_29.xls 
L’OREAL In contact with the pre-wetted HCE tissue, the powder 
pebbled and stuck to the surface. 
EIVS_LOREAL_LE_10HCE027_29.xls 
L’OREAL During the rinsing step procedure, the substance (dense 
solid) was scratched to facilitate its removal. 
EIVS_LOREAL_LE_10HCE027_29.xls 
L’OREAL Visually, the tissues are dead at both exposure times. EIVS_LOREAL_LE_10HCE027_29.xls 
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L’OREAL The cell viability measured (above 50% suggesting non 
irritancy potential of the test substance) should not be 
considered as relevant. 
EIVS_LOREAL_LE_10HCE027_29.xls 
L’OREAL The test substance L30 should be classified as an irritant. EIVS_LOREAL_LE_10HCE027_29.xls 
L’OREAL TEST SUBSTANCE L66: EIVS_LOREAL_LE_10HCE027_29.xls 
L’OREAL The membrane was melted. EIVS_LOREAL_LE_10HCE027_29.xls 
L’OREAL TEST SUBSTANCE L51: EIVS_LOREAL_LE_10HCE027_29.xls 
L’OREAL The membrane of the insert was damaged during the 
rinsing step procedure. 
EIVS_LOREAL_LE_10HCE027_29.xls 
L’OREAL TEST SUBSTANCE L39: EIVS_LOREAL_LE_10HCE027_29.xls 
L’OREAL During the rinsing step procedure, the cell seeding on a 
tissue removed from the membrane 
EIVS_LOREAL_LE_10HCE027_29.xls 
L’OREAL (issue observed only with 1 out of 3 tissues) EIVS_LOREAL_LE_10HCE027_29.xls 
L’OREAL TEST SUBSTANCE L43: EIVS_LOREAL_LE_10HCE027_29.xls 
L’OREAL The membrane of the insert was damaged during the 
rinsing step procedure 
EIVS_LOREAL_LE_10HCE027_29.xls 
L’OREAL TEST SUBSTANCE L51 EIVS_LOREAL_LE_10HCE028_30.xls 
L’OREAL The membrane of the insert was damaged during the 
rinsing step procedure 
EIVS_LOREAL_LE_10HCE028_30.xls 
L’OREAL TEST SUBSTANCE L55: EIVS_LOREAL_LE_10HCE028_30.xls 
L’OREAL The substances stuck on the plastic which is not 
anymore transparent. 
EIVS_LOREAL_LE_10HCE028_30.xls 
L’OREAL The rinsing procedure was very difficult. Substances 
might be not completely removed from the tissues. 
EIVS_LOREAL_LE_10HCE028_30.xls 
L’OREAL TEST SUBSTANCE L30: EIVS_LOREAL_LE_10HCE028_30.xls 
L’OREAL In contact with the pre-wetted HCE tissue, the powder 
pebbled and stuck to the surface. 
EIVS_LOREAL_LE_10HCE028_30.xls 
L’OREAL During the rinsing step procedure, the substance (dense 
solid) was scratched to facilitate its removal. 
EIVS_LOREAL_LE_10HCE028_30.xls 
L’OREAL Visually, the tissues are dead at both exposure times. EIVS_LOREAL_LE_10HCE028_30.xls 
L’OREAL The cell viability measured (above 50% suggesting non 
irritancy potential of the test substance) should not be 
considered as relevant 
EIVS_LOREAL_LE_10HCE028_30.xls 
L’OREAL The test substance L30 should be classified as an irritant. EIVS_LOREAL_LE_10HCE028_30.xls 
L’OREAL INVALID RUN / POSITIVE CONTROL (PC) DID NOT MEET EIVS_LOREAL_LE_10HCE029_35.xls 
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THE ACCEPTANCE CRITERIA / MEAN VIABILITY VALUE 
ABOVE 50% 
L’OREAL TEST SUBSTANCE L80 EIVS_LOREAL_LE_10HCE029_35.xls 
L’OREAL The test substance L81 dissolved the membrane of 
tissue constructs, 
EIVS_LOREAL_LE_10HCE029_35.xls 
L’OREAL The membrane is melted EIVS_LOREAL_LE_10HCE029_35.xls 
L’OREAL TEST SUBSTANCES L94 and L98: EIVS_LOREAL_LE_10HCE029_35.xls 
L’OREAL The substances stuck on the plastic which is not 
anymore transparent 
EIVS_LOREAL_LE_10HCE029_35.xls 
L’OREAL The rinsing procedure was very difficult. Substances 
might be not completely removed from the tissues. 
EIVS_LOREAL_LE_10HCE029_35.xls 
L’OREAL TEST SUBSTANCE L85: EIVS_LOREAL_LE_10HCE029_35.xls 
L’OREAL L85 is a MTT-reducer given a NSMTT < 50% in the 
controls 
EIVS_LOREAL_LE_10HCE029_35.xls 
L’OREAL L85 was not retest since the SD was < 18% (qualified 
test). 
EIVS_LOREAL_LE_10HCE029_35.xls 
L’OREAL Visually, the tissues are dead at both exposure times. EIVS_LOREAL_LE_10HCE029_35.xls 
L’OREAL At the long exposure time, on the living tissues the 
crystals are permanent and could not be removed. 
EIVS_LOREAL_LE_10HCE029_35.xls 
L’OREAL The cell viability measured (above 50% suggesting non 
irritancy potential of the test substance) should not be 
considered as relevant. 
EIVS_LOREAL_LE_10HCE029_35.xls 
L’OREAL Visually, the cells are dead and we will classified L85 is 
an irritant. 
EIVS_LOREAL_LE_10HCE029_35.xls 
L’OREAL TEST SUBSTANCE L66: EIVS_LOREAL_LE_10HCE031_37.xls 
L’OREAL The membrane Is melted. EIVS_LOREAL_LE_10HCE031_37.xls 
L’OREAL TEST SUBSTANCE L94: EIVS_LOREAL_LE_10HCE031_37.xls 
L’OREAL The substances stuck on the plastic which is not 
anymore transparent. 
EIVS_LOREAL_LE_10HCE031_37.xls 
L’OREAL The rinsing procedure was very difficult. Substances 
might be not completely removed from the tissues 
EIVS_LOREAL_LE_10HCE031_37.xls 
L’OREAL ADAPTED CONTROLS: EIVS_LOREAL_LE_10HCE031_37.xls 
L’OREAL The direct MTT reduction of test substances was 
evaluated using killed HCE tissues controls (one single 
run, 3 tissues/substance). 
EIVS_LOREAL_LE_10HCE031_37.xls 
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L’OREAL The killed tissues used for the evaluation were provided 
from HCE tissues batch Nø10HCE029 (produced on 
March3 2010: less than a year) 
EIVS_LOREAL_LE_10HCE031_37.xls 
L’OREAL TEST SUBSTANCE L81: EIVS_LOREAL_LE_10HCE032_38.xls 
L’OREAL The test substance L81 dissolved the membrane of 
tissue constructs, 
EIVS_LOREAL_LE_10HCE032_38.xls 
L’OREAL The membrane is melted EIVS_LOREAL_LE_10HCE032_38.xls 
L’OREAL TEST SUBSTANCES L94 and L98: EIVS_LOREAL_LE_10HCE032_38.xls 
L’OREAL The substances stuck on the plastic which is not 
anymore transparent. 
EIVS_LOREAL_LE_10HCE032_38.xls 
L’OREAL The rinsing procedure was very difficult. Substances 
might be not completely removed from the tissues 
EIVS_LOREAL_LE_10HCE032_38.xls 
L’OREAL TEST SUBSTANCE L85: EIVS_LOREAL_LE_10HCE032_38.xls 
L’OREAL L85 is a MTT-reducer given a NSMTT < 50% in the 
controls 
EIVS_LOREAL_LE_10HCE032_38.xls 
L’OREAL L85 was not retest since the SD was < 18% (qualified 
test). 
EIVS_LOREAL_LE_10HCE032_38.xls 
L’OREAL Visually, the tissues are dead at both exposure times. EIVS_LOREAL_LE_10HCE032_38.xls 
L’OREAL At the long exposure time, on the living tissues the 
crystals are permanent and could not be removed. 
EIVS_LOREAL_LE_10HCE032_38.xls 
L’OREAL The cell viability measured (above 50% suggesting non 
irritancy potential of the test substance) should not be 
considered as relevant. 
EIVS_LOREAL_LE_10HCE032_38.xls 
L’OREAL Visually, the cells are dead and we will classify L85 is an 
irritant. 
EIVS_LOREAL_LE_10HCE032_38.xls 
L’OREAL TEST SUBSTANCE L81: EIVS_LOREAL_LE_10HCE033_39.xls 
L’OREAL The membrane is melted EIVS_LOREAL_LE_10HCE033_39.xls 
L’OREAL TEST SUBSTANCE L85: EIVS_LOREAL_LE_10HCE033_39.xls 
L’OREAL L85 is a MTT-reducer given a NSMTT < 50% in the 
controls 
EIVS_LOREAL_LE_10HCE033_39.xls 
L’OREAL L85 was not retest since the SD was < 18% (qualified 
test). 
EIVS_LOREAL_LE_10HCE033_39.xls 
L’OREAL Visually, the tissues are dead at both exposure times. EIVS_LOREAL_LE_10HCE033_39.xls 
L’OREAL At the long exposure time, on the living tissues the 
crystals are permanent and could not be removed. 
EIVS_LOREAL_LE_10HCE033_39.xls 
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L’OREAL The cell viability measured (above 50% suggesting non 
irritancy potential of the test substance) should not be 
considered as relevant. 
EIVS_LOREAL_LE_10HCE033_39.xls 
L’OREAL Visually, the cells are dead and we will classified L85 is 
an irritant. 
EIVS_LOREAL_LE_10HCE033_39.xls 
L’OREAL TEST SUBSTANCE L81: EIVS_LOREAL_LE_10HCE034_40(1).xls 
L’OREAL The test substance L81 dissolved the membrane of 
tissue constructs, 
EIVS_LOREAL_LE_10HCE034_40(1).xls 
L’OREAL The membrane is melted EIVS_LOREAL_LE_10HCE034_40(1).xls 
L’OREAL TEST SUBSTANCES L94 andL98: EIVS_LOREAL_LE_10HCE034_40(1).xls 
L’OREAL The substances stuck on the plastic which is not 
anymore transparent. 
EIVS_LOREAL_LE_10HCE034_40(1).xls 
L’OREAL The rinsing procedure was very difficult. Substances 
might be not completely removed from the tissues. 
EIVS_LOREAL_LE_10HCE034_40(1).xls 
L’OREAL ADAPTED CONTROLS: EIVS_LOREAL_LE_10HCE034_40(2).xls 
L’OREAL The direct MTT reduction of test substances was 
evaluated using killed HCE tissues controls 
EIVS_LOREAL_LE_10HCE034_40(2).xls 
L’OREAL (one single run, 3 tissues / substance) EIVS_LOREAL_LE_10HCE034_40(2).xls 
L’OREAL The killed tissues used for the evaluation were provided 
from HCE tissues batch Nø10HCE033 
EIVS_LOREAL_LE_10HCE034_40(2).xls 
L’OREAL (produced on September 27, 2010: less than a year) EIVS_LOREAL_LE_10HCE034_40(2).xls 
L’OREAL TEST SUBSTANCE L7: EIVS_LOREAL_LE_10HCE034_40(2).xls 
L’OREAL L7 is a strong MTT-reducer given a NSMTT > 50% in the 
controls 
EIVS_LOREAL_LE_10HCE034_40(2).xls 
L’OREAL L7 was not retest since the SD was < 18% (qualified test) EIVS_LOREAL_LE_10HCE034_40(2).xls 
L’OREAL We still acquired three qualified tests for this chemical 
following the rules set out in the Performance Criteria 
document, 
EIVS_LOREAL_LE_10HCE034_40(2).xls 
L’OREAL , independently of the control tissues (NSMTT>50%) EIVS_LOREAL_LE_10HCE034_40(2).xls 
L’OREAL The values are imported in the design import 
spreadsheet 
EIVS_LOREAL_LE_10HCE034_40(2).xls 
L’OREAL TEST SUBSTANCE L98: EIVS_LOREAL_LE_10HCE035_41.xls 
L’OREAL The substances stuck on the plastic which is not 
anymore transparent. 
EIVS_LOREAL_LE_10HCE035_41.xls 
L’OREAL The rinsing procedure was very difficult. Substances EIVS_LOREAL_LE_10HCE035_41.xls 
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might be not completely removed from the tissues. 
L’OREAL TEST SUBSTANCE L7: EIVS_LOREAL_LE_10HCE035_41.xls 
L’OREAL Nota bene: L7 is a strong MTT-reducer given a NSMTT > 
28% in the controls 
EIVS_LOREAL_LE_10HCE035_41.xls 
L’OREAL L7 was not retest since the SD was < 18% (qualified test). EIVS_LOREAL_LE_10HCE035_41.xls 
L’OREAL The values are imported in the design import 
spreadsheet 
EIVS_LOREAL_LE_10HCE035_41.xls 
L’OREAL TEST SUBSTANCE L85: EIVS_LOREAL_LE_10HCE035_41.xls 
L’OREAL L85 is a MTT-reducer given a NSMTT < 50% in the 
controls 
EIVS_LOREAL_LE_10HCE035_41.xls 
L’OREAL L85 was not retest since the SD was < 18% (qualified 
test). 
EIVS_LOREAL_LE_10HCE035_41.xls 
L’OREAL Visually, the tissues are dead at both exposure times. EIVS_LOREAL_LE_10HCE035_41.xls 
L’OREAL At the long exposure time, on the living tissues the 
crystals are permanent and could not be removed. 
EIVS_LOREAL_LE_10HCE035_41.xls 
L’OREAL The cell viability measured (above 50% suggesting non 
irritancy potential of the test substance) should not be 
considered as relevant 
EIVS_LOREAL_LE_10HCE035_41.xls 
L’OREAL Visually, the cells are dead and the test substance L85 
should be classified as an irritant. 
EIVS_LOREAL_LE_10HCE035_41.xls 
L’OREAL TEST SUBSTANCE L63: EIVS_LOREAL_LE_10HCE035_41.xls 
L’OREAL L63 should be withdrawn from the chemicals selection 
because of inconsistent chemical states 
EIVS_LOREAL_LE_10HCE035_41.xls 
L’OREAL The test substance evaluated in the run was a liquid EIVS_LOREAL_LE_10HCE035_41.xls 
L’OREAL TEST SUBSTANCE L7: EIVS_LOREAL_LE_10HCE036_42.xls 
L’OREAL L7 is a strong MTT-reducer given a NSMTT >26 % in the 
controls 
EIVS_LOREAL_LE_10HCE036_42.xls 
L’OREAL TEST SUBSTANCE L63: EIVS_LOREAL_LE_10HCE037_43.xls 
L’OREAL L63 should be withdrawn from the chemicals selection 
because of inconsistent chemical states 
EIVS_LOREAL_LE_10HCE037_43.xls 
L’OREAL The test substance evaluated was a liquid EIVS_LOREAL_LE_10HCE037_43.xls 
L’OREAL TEST SUBSTANCE L63: EIVS_LOREAL_LE_10HCE040_46.xls 
L’OREAL L63 should be withdrawn from the chemicals selection 
because of inconsistent chemical states 
EIVS_LOREAL_LE_10HCE040_46.xls 
L’OREAL The test substance evaluated was a liquid EIVS_LOREAL_LE_10HCE040_46.xls 
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L’OREAL NONE EIVS_LOREAL_LE_10HCE041_47.xls 
L’OREAL TEST SUBSTANCES L119 and L131: EIVS_LOREAL_LE_10HCE042_48.xls 
L’OREAL The membrane of the inserts was damaged during the 
rinsing step procedure. 
EIVS_LOREAL_LE_10HCE042_48.xls 
L’OREAL TEST SUBSTANCE L113 EIVS_LOREAL_LE_10HCE043_49.xls 
L’OREAL The membrane of the insert was damaged during the 
rinsing step procedure. 
EIVS_LOREAL_LE_10HCE043_49.xls 
L’OREAL TEST SUBSTANCE L113: EIVS_LOREAL_LE_10HCE044_50.xls 
L’OREAL The membrane of the insert was damaged during the 
rinsing step procedure. 
EIVS_LOREAL_LE_10HCE044_50.xls 
L’OREAL Substances L133 and L140: The membrane of the insert 
was damaged during the rinsing step procedure 
EIVS_LOREAL_LE_11HCE002_2.xls 
L’OREAL Test substance L137 EIVS_LOREAL_LE_11HCE002_2.xls 
L’OREAL This solid hardens and retracts in the presence of 
atmosphere. 
EIVS_LOREAL_LE_11HCE002_2.xls 
L’OREAL It is important to apply it onto the tissues as soon as it 
was weighed. 
EIVS_LOREAL_LE_11HCE002_2.xls 
L’OREAL It was notice that its volume was considerably reduced if 
the weighing occurred 1 hour before topical application. 
EIVS_LOREAL_LE_11HCE002_2.xls 
L’OREAL Very difficult application: contact with the surface was 
not homogeneous even by using a mesh - > partial 
contact which can explain inter-tissues variability. 
EIVS_LOREAL_LE_11HCE002_2.xls 
L’OREAL At the long exposure time (1 hour+16hrs), the substance 
is irritating but the results very are dependent 
EIVS_LOREAL_LE_11HCE002_2.xls 
L’OREAL of the topical application (contact of the substance with 
the surface of the tissues) 
EIVS_LOREAL_LE_11HCE002_2.xls 
L’OREAL TEST SUBSTANCE L119: EIVS_LOREAL_LE_11HCE007_7.xls 
L’OREAL The membrane of the insert was damaged during the 
rinsing step procedure. 
EIVS_LOREAL_LE_11HCE007_7.xls 
L’OREAL TEST SUBSTANCES L119 and L131: EIVS_LOREAL_LE_11HCE008_8.xls 
L’OREAL The membrane of the insert was damaged during the 
rinsing step procedure. 
EIVS_LOREAL_LE_11HCE008_8.xls 
L’OREAL TEST SUBSTANCES L131 and L133: EIVS_LOREAL_LE_11HCE009_9.xls 
L’OREAL The membrane of the insert was damaged during the 
rinsing step procedure. 
EIVS_LOREAL_LE_11HCE009_9.xls 
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L’OREAL TEST SUBSTANCE L137: EIVS_LOREAL_LE_11HCE009_9.xls 
L’OREAL This solid hardens and retracts in the presence of 
atmosphere. 
EIVS_LOREAL_LE_11HCE009_9.xls 
L’OREAL It is important to apply it onto the tissues as soon as it 
was weighed. 
EIVS_LOREAL_LE_11HCE009_9.xls 
L’OREAL It was notice that its volume was considerably reduced if 
the weighing occurred 1 hour before topical application. 
EIVS_LOREAL_LE_11HCE009_9.xls 
L’OREAL Very difficult application: contact with the surface was 
not homogeneous even by using a mesh - > partial 
contact which can explain inter-tissues variability. 
EIVS_LOREAL_LE_11HCE009_9.xls 
L’OREAL At the long exposure time (1 hour+16hrs), the substance 
is irritating but the results very are dependent 
EIVS_LOREAL_LE_11HCE009_9.xls 
L’OREAL of the topical application (contact of the substance with 
the surface of the tissues) 
EIVS_LOREAL_LE_11HCE009_9.xls 
L’OREAL TEST SUBSTANCE L137: EIVS_LOREAL_LE_11HCE014_14.xls 
L’OREAL This solid hardens and retracts in the presence of 
atmosphere. 
EIVS_LOREAL_LE_11HCE014_14.xls 
L’OREAL It is important to apply it onto the tissues as soon as it 
was weighed. 
EIVS_LOREAL_LE_11HCE014_14.xls 
L’OREAL It was notice that its volume was considerably reduced if 
the weighing occurred 1 hour before topical application. 
EIVS_LOREAL_LE_11HCE014_14.xls 
L’OREAL Very difficult application: contact with the surface was 
not homogeneous even by using a mesh - > partial 
contact which can explain inter-tissues variability. 
EIVS_LOREAL_LE_11HCE014_14.xls 
L’OREAL At the long exposure time (1 hour+16hrs), the substance 
is irritating but the results very are dependent 
EIVS_LOREAL_LE_11HCE014_14.xls 
L’OREAL of the topical application (contact of the substance with 
the surface of the tissues) 
EIVS_LOREAL_LE_11HCE014_14.xls 
L’OREAL Substance L6: EIVS_LOREAL_LE_11HCE020_18.xls 
L’OREAL Very strong coloring chemical (red) EIVS_LOREAL_LE_11HCE020_18.xls 
L’OREAL High variability due to its coloring properties EIVS_LOREAL_LE_11HCE020_18.xls 
L’OREAL TEST SUBSTANCE L125 EIVS_LOREAL_LE_11HCE022_19.xls 
L’OREAL The membrane of the insert was damaged during the 
rinsing step procedure. 
EIVS_LOREAL_LE_11HCE022_19.xls 
L’OREAL TEST SUBSTANCE L58 EIVS_LOREAL_LE_11HCE022_19.xls 
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L’OREAL Strong MTT reducer EIVS_LOREAL_LE_11HCE022_19.xls 
L’OREAL Not issue during the rinsing procedure EIVS_LOREAL_LE_11HCE022_19.xls 
L’OREAL TEST SUBSTANCE L6: EIVS_LOREAL_LE_11HCE024_20.xls 
L’OREAL very strong coloring chemical EIVS_LOREAL_LE_11HCE024_20.xls 
L’OREAL Visual observation: the tissues are not dead but only 
stained due to the color (red) 
EIVS_LOREAL_LE_11HCE024_20.xls 
L’OREAL TEST SUBSTANCE L148: EIVS_LOREAL_LE_11HCE024_20.xls 
L’OREAL Technical issue: the plate dropped during the MTT 
incubation step : no data acquisition 
EIVS_LOREAL_LE_11HCE024_20.xls 
L’OREAL TEST SUBSTANCE L185: EIVS_LOREAL_LE_11HCE024_20.xls 
L’OREAL Sticky chemical: A mesh was used to uniformly spread 
the chemical on the 3 tissues 
EIVS_LOREAL_LE_11HCE024_20.xls 
L’OREAL TEST SUBSTANCE L15: EIVS_LOREAL_LE_11HCE026_21.xls 
L’OREAL In contact with the pre-wetted HCE tissue, the powder 
pebbled and stuck to the surface 
EIVS_LOREAL_LE_11HCE026_21.xls 
L’OREAL During the rinsing step procedure, the substance (dense 
solid) was scratched to facilitate its removal 
EIVS_LOREAL_LE_11HCE026_21.xls 
L’OREAL TEST SUBSTANCE L174: EIVS_LOREAL_LE_11HCE029_23.xls 
L’OREAL The vial overturned: There is no more than 6 mL left in 
the vial 
EIVS_LOREAL_LE_11HCE029_23.xls 
L’OREAL TEST SUBSTANCE L58: EIVS_LOREAL_LE_11HCE029_23.xls 
L’OREAL strong MTT reducer EIVS_LOREAL_LE_11HCE029_23.xls 
L’OREAL visual observation: cytotoxicity observed for the three 
treated tissues 
EIVS_LOREAL_LE_11HCE029_23.xls 
L’OREAL TEST SUBSTANCE L6: EIVS_LOREAL_LE_11HCE029_23.xls 
L’OREAL The experiment was performed ONLY with KILLED 
tissues to determine the individual NSMTT values 
EIVS_LOREAL_LE_11HCE029_23.xls 
L’OREAL Cell viability determination: The data obtained with the 
living tissues are defined on files Nø 11HCE020_18; 
EIVS_LOREAL_LE_11HCE029_23.xls 
L’OREAL 11HCE024_20, 11HCE032_25, 11HCE034_26 and 
11HCE036_27 
EIVS_LOREAL_LE_11HCE029_23.xls 
L’OREAL MTT REDUCERS / killed tissues: TEST SUBSTANCES L6, 
L33, L58, L100, L161, L169 and L174 
EIVS_LOREAL_LE_11HCE029_23.xls 
L’OREAL To determine the NSMTT% of the MTT reducers, the 
experiment was performed using killed HCE tissues 
EIVS_LOREAL_LE_11HCE029_23.xls 
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(batch Nø 11HCE028). 
L’OREAL The individual Ku and Kt-Cx values (6) obtained in this 
run was then reported to the respective Excel 
spreadsheets of each test substance 
EIVS_LOREAL_LE_11HCE029_23.xls 
L’OREAL TEST SUBSTANCE L125: EIVS_LOREAL_LE_11HCE032_25(1).xls 
L’OREAL The membrane of the insert was damaged during the 
rinsing step procedure. 
EIVS_LOREAL_LE_11HCE032_25(1).xls 
L’OREAL TEST SUBSTANCE L185 EIVS_LOREAL_LE_11HCE032_25(1).xls 
L’OREAL Sticky chemical: A mesh was used to uniformly spread 
the chemical on the three tissues 
EIVS_LOREAL_LE_11HCE032_25(1).xls 
L’OREAL TEST SUBSTANCE L6: EIVS_LOREAL_LE_11HCE032_25(1).xls 
L’OREAL very strong coloring chemical EIVS_LOREAL_LE_11HCE032_25(1).xls 
L’OREAL very difficult to remove the staining chemical during the 
rinsing step procedure 
EIVS_LOREAL_LE_11HCE032_25(1).xls 
L’OREAL TEST SUBSTANCE L58: EIVS_LOREAL_LE_11HCE032_25(1).xls 
L’OREAL visual observation: cytotoxicity observed in the 3 treated 
tissues (Irritant) 
EIVS_LOREAL_LE_11HCE032_25(1).xls 
L’OREAL TEST SUBSTANCE L125 EIVS_LOREAL_LE_11HCE034_26.xls 
L’OREAL The membrane of the insert was damaged during the 
rinsing step procedure. 
EIVS_LOREAL_LE_11HCE034_26.xls 
L’OREAL TEST SUBSTANCE L6: EIVS_LOREAL_LE_11HCE034_26.xls 
L’OREAL MTT and coloring substance difficult to rinse: high 
variability observed 
EIVS_LOREAL_LE_11HCE034_26.xls 
L’OREAL TEST SUBSTANCE L15: EIVS_LOREAL_LE_11HCE034_26.xls 
L’OREAL In contact with the pre-wetted HCE tissue, the powder 
pebbled and stuck to the surface. 
EIVS_LOREAL_LE_11HCE034_26.xls 
L’OREAL During the rinsing step procedure, the substance (dense 
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Appendix V Reasoning for non-qualified test results 
NCqual = Negative control did not pass the criteria 
PCqual = Positive control did not pass the criteria 














conclusion laboratory Chemical run NCqual PCqual qual_sd 
Non-Qualified CARDAM 4 1 Qualified Qualified Non-qualified 
  34 1 Qualified Qualified Non-qualified 
  17 1 Qualified Qualified Non-qualified 
  75 2 Qualified Qualified Non-qualified 
 CEETOX 18 2 Qualified Qualified Non-qualified 
 L'OREAL 75 1 Qualified Qualified Non-qualified 
  75 2 Qualified Qualified Non-qualified 
conclusion laboratory Chemical run NCqual PCqual qual_sd 
Non-Qualified CARDAM 52 1 Qualified Qualified Non-qualified 
  34 3 Qualified Qualified Non-qualified 
 CEETOX 28 1 Qualified Non-qualified Qualified 
  28 2 Qualified Non-qualified Qualified 
  16 3 Qualified Non-qualified Qualified 
  38 1 Qualified Non-qualified Qualified 
  44 5 Qualified Non-qualified Qualified 
  19 2 Qualified Non-qualified Qualified 
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  55 4 Qualified Non-qualified Qualified 
  55 5 Qualified Non-qualified Qualified 
  29 2 Qualified Non-qualified Qualified 
  79 5 Qualified Non-qualified Qualified 
  24 3 Qualified Non-qualified Qualified 
  24 5 Qualified Non-qualified Qualified 
  35 3 Qualified Non-qualified Qualified 
  35 5 Qualified Non-qualified Qualified 
  58 1 Qualified Non-qualified Qualified 
  65 1 Qualified Non-qualified Qualified 
  53 2 Qualified Non-qualified Qualified 
  50 2 Qualified Non-qualified Qualified 
  93 1 Qualified Non-qualified Qualified 
  93 2 Qualified Non-qualified Qualified 
  52 2 Qualified Non-qualified Qualified 
  92 2 Qualified Non-qualified Qualified 
  49 4 Qualified Qualified Non-qualified 
  18 1 Qualified Non-qualified Qualified 
  9 1 Qualified Non-qualified Qualified 
  9 2 Qualified Non-qualified Qualified 
  99 5 Qualified Non-qualified Qualified 
  2 1 Qualified Non-qualified Qualified 
  2 2 Qualified Non-qualified Qualified 
  98 1 Qualified Non-qualified Qualified 
  98 2 Qualified Non-qualified Qualified 
  85 1 Qualified Non-qualified Qualified 
  85 2 Qualified Non-qualified Qualified 
  84 1 Qualified Non-qualified Qualified 
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  75 2 Qualified Non-qualified Qualified 
  20 1 Qualified Non-qualified Qualified 
  11 1 Qualified Non-qualified Qualified 
  11 2 Qualified Non-qualified Qualified 
  74 3 Qualified Non-qualified Qualified 
  74 5 Qualified Non-qualified Qualified 
  88 2 Qualified Non-qualified Qualified 
  94 3 Qualified Non-qualified Qualified 
  94 5 Qualified Non-qualified Qualified 
  73 1 Qualified Qualified Non-qualified 
  73 2 Qualified Qualified Non-qualified 
  73 5 Qualified Non-qualified Qualified 
  1 1 Qualified Non-qualified Qualified 
  1 2 Qualified Non-qualified Qualified 
  64 2 Qualified Qualified Non-qualified 
  39 2 Qualified Non-qualified Qualified 
  14 5 Qualified Non-qualified Qualified 
  54 1 Qualified Non-qualified Qualified 
  54 2 Qualified Non-qualified Qualified 
  4 4 Qualified Non-qualified Qualified 
  4 5 Qualified Non-qualified Qualified 
  8 3 Qualified Non-qualified Qualified 
  90 3 Qualified Non-qualified Qualified 
  90 5 Qualified Non-qualified Qualified 
  71 4 Qualified Non-qualified Qualified 
  71 5 Qualified Non-qualified Qualified 
  5 5 Qualified Non-qualified Qualified 
  6 1 Qualified Non-qualified Qualified 
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  6 2 Qualified Non-qualified Qualified 
  33 3 Qualified Non-qualified Qualified 
  33 5 Qualified Non-qualified Qualified 
  91 4 Qualified Non-qualified Qualified 
  91 5 Qualified Non-qualified Qualified 
  21 4 Qualified Non-qualified Qualified 
  21 5 Qualified Non-qualified Qualified 
 L'OREAL 74 1 Qualified Non-qualified Qualified 
  75 2 Qualified Qualified Non-qualified 
  65 3 Qualified Qualified Non-qualified 
  14 1 Qualified Non-qualified Qualified 
  81 1 Qualified Non-qualified Qualified 
  54 1 Qualified Non-qualified Qualified 
  83 1 Qualified Non-qualified Qualified 
  35 1 Qualified Non-qualified Qualified 
  93 1 Qualified Non-qualified Qualified 
  1 1 Qualified Non-qualified Qualified 
  94 1 Qualified Non-qualified Qualified 
  8 1 Qualified Non-qualified Qualified 
  
TNO report | TNO 2013 R11617 | Final report  174 / 305
Appendix VI Summary of all test results 
Mean   = mean of viability (corrected for %NSC or %NSMTT) 
Std    = standard deviation  
NQ    = Non-qualified 
 
Note to chemical 4 (Cardam, CeeTox and L'Oréal), chemical 20 (Cardam only), chemical 23 (CeeTox only) and chemical 91 (CeeTox only) for the SE 
protocol, and to chemical 4 (Cardam and CeeTox) and chemical 80 (CeeTox only) for the LE protocol: 
 
On May 10th 2012, after an evaluation of the first draft of the statistics report, the core VMG overrode the rule identifying 50% NSMTT as a cut-off to 
consider a chemical compatible with the test system as described in Chapter 2.5.1. of this report. In all these cases, rule 3 in Chapter 2.5.1. is fulfilled 
since the mean %NSC of all qualified tests is greater than (>) 50% and the classification of these qualified tests changes upon correction (from non-
irritant to irritant). However, the viability values obtained in the qualified tests are definitely within the linear range of the OD measurements (within the 
100% scale) and therefore, even though there is a strong MTT reduction occurring this is not interfering with the analytical capacity to measure 
formazan production. Moreover, the variability obtained between the different tests and controls is low. As such, these chemicals were considered 
compatible with the test method and their data were therefore included in all of the statistical analyses.  
 
SE 
    GHS        NC PC Uncorrected viability NSC MTT Final Final Classification 
Chemical laboratory classification MTT coloring test OD std Qual Mean% Std Qual Mean% Std Qual Mean% Std Qual Mean% Std Qual viability call 50% cutoff 
1 CARDAM no cat     1 0.9726 6.2232   14.6177 1.7458   92.275 5.4172   . .   . 0   92.275   NI 
1 CARDAM no cat     2 0.9459 5.8678   10.1547 0.3097   83.357 1.7607   . .   . 0   83.357   NI 
1 CARDAM no cat     3 1.0342 6.596   17.2116 4.0284   84.324 3.4535   . .   . 0   84.324   NI 
2 CARDAM no cat     1 0.9244 7.503   8.8632 1.6731   103.757 3.5331   . .   . 0   103.757   NI 
2 CARDAM no cat     2 1.017 4.957   7.2385 0.8518   76.972 5.3119   . .   . 0   76.972   NI 
2 CARDAM no cat     3 0.718 0.5669   11.8486 1.8037   76.029 0.3932   . .   . 0   76.029   NI 
3 CARDAM no cat     1 0.9726 6.2232   14.6177 1.7458   76.452 5.92   . .   . 0   76.452   NI 
3 CARDAM no cat     2 0.9459 5.8678   10.1547 0.3097   136.02 4.8978   . .   . 0   136.02   NI 
3 CARDAM no cat     3 1.0342 6.596   17.2116 4.0284   67.773 0.2797   . .   . 0   67.773   NI 
4 CARDAM no cat Yes   1 0.718 0.5669   11.8486 1.8037   89.215 20.054  NQ . .   103.231 28.525 NQ 0.669 NQ I 
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    GHS        NC PC Uncorrected viability NSC MTT Final Final Classification 
Chemical laboratory classification MTT coloring test OD std Qual Mean% Std Qual Mean% Std Qual Mean% Std Qual Mean% Std Qual viability call 50% cutoff 
4 CARDAM no cat Yes   2 1.0409 3.7109   11.1134 0.688   105.338 10.585   . .   71.201 19.674 NQ 34.138   I 
4 CARDAM no cat Yes   3 1.3506 1.4834   15.3147 2.0773   91.774 8.5707   . .   54.878 15.164   36.896   I 
4 CARDAM no cat Yes   4 0.7983 6.6925   8.8647 1.3042   114.767 13.627   . .   92.841 25.654 NQ 21.926   I 
5 CARDAM no cat Yes   1 0.9244 7.503   8.8632 1.6731   101.5 6.2602   . .   0 0   101.5   NI 
5 CARDAM no cat Yes   2 1.017 4.957   7.2385 0.8518   86 7.1475   . .   0 0   86   NI 
5 CARDAM no cat Yes   3 0.718 0.5669   11.8486 1.8037   76.034 3.6143   . .   0 0   76.034   NI 
6 CARDAM no cat     1 0.9459 5.8678   10.1547 0.3097   117.848 4.721   . .   . 0   117.848   NI 
6 CARDAM no cat     2 1.0342 6.596   17.2116 4.0284   105.91 6.3091   . .   . 0   105.91   NI 
6 CARDAM no cat     3 0.9244 7.503   8.8632 1.6731   108.019 5.5762   . .   . 0   108.019   NI 
7 CARDAM no cat     1 1.0351 6.5903   17.2836 4.0249   88.226 8.0545   . .   . 0   88.226   NI 
7 CARDAM no cat     2 0.9244 7.503   8.8632 1.6731   82.557 3.3443   . .   . 0   82.557   NI 
7 CARDAM no cat     3 1.017 4.957   7.2385 0.8518   65.282 4.8168   . .   . 0   65.282   NI 
8 CARDAM no cat     1 0.9726 6.2232   14.6177 1.7458   101.086 0.5218   . .   . 0   101.086   NI 
8 CARDAM no cat     2 0.9459 5.8678   10.1547 0.3097   124.276 7.8789   . .   . 0   124.276   NI 
8 CARDAM no cat     3 1.0342 6.596   17.2116 4.0284   102.184 4.4809   . .   . 0   102.184   NI 
9 CARDAM no cat Yes   1 0.9726 6.2232   14.6177 1.7458   98.987 5.4953   . .   0 0   98.987   NI 
9 CARDAM no cat Yes   2 0.9459 5.8678   10.1547 0.3097   112.225 10.558   . .   0 0   112.225   NI 
9 CARDAM no cat Yes   3 1.0342 6.596   17.2116 4.0284   96.55 7.2268   . .   0 0   96.55   NI 
10 CARDAM no cat     1 0.9247 7.5008   8.8895 1.6726   48.516 6.9841   . .   . 0   48.516   I 
10 CARDAM no cat     2 1.017 4.957   7.2385 0.8518   29.652 6.0345   . .   . 0   29.652   I 
10 CARDAM no cat     3 0.718 0.5669   11.8486 1.8037   33.651 2.4865   . .   . 0   33.651   I 
11 CARDAM no cat     1 0.9726 6.2232   14.6177 1.7458   68.347 8.2132   . .   . 0   68.347   NI 
11 CARDAM no cat     2 0.9459 5.8678   10.1547 0.3097   81.335 4.1797   . .   . 0   81.335   NI 
11 CARDAM no cat     3 1.0342 6.596   17.2116 4.0284   70.212 13.507   . .   . 0   70.212   NI 
12 CARDAM no cat     1 0.9764 3.0137   9.7414 1.6474   102.612 8.3303   . .   . 0   102.612   NI 
12 CARDAM no cat     2 1.068 12.107   9.0451 0.5407   107.319 7.4457   . .   . 0   107.319   NI 
12 CARDAM no cat     3 1.1217 5.8363   9.2331 2.1018   104.484 1.3521   . .   . 0   104.484   NI 
13 CARDAM no cat     1 0.9764 3.0137   9.7414 1.6474   100.415 4.6175   . .   . 0   100.415   NI 
13 CARDAM no cat     2 1.068 12.107   9.0451 0.5407   103.24 3.3193   . .   . 0   103.24   NI 
13 CARDAM no cat     3 1.169 5.4702   13.7342 2.2905   95.885 5.131   . .   . 0   95.885   NI 
14 CARDAM no cat     1 0.9455 5.8699   10.123 0.3098   109.45 6.6504   . .   . 0   109.45   NI 
14 CARDAM no cat     2 1.0342 6.596   17.2116 4.0284   94.292 6.708   . .   . 0   94.292   NI 
14 CARDAM no cat     3 0.9244 7.503   8.8632 1.6731   101.365 2.16   . .   . 0   101.365   NI 
15 CARDAM no cat     1 1.169 5.4702   13.7342 2.2905   92.258 4.1258   . .   . 0   92.258   NI 
15 CARDAM no cat     2 1.0074 8.5376   11.5659 1.2203   94.484 2.675   . .   . 0   94.484   NI 
15 CARDAM no cat     3 1.0398 3.5464   8.5117 0.9677   101.431 6.3823   . .   . 0   101.431   NI 
16 CARDAM no cat     1 0.9726 6.2232   14.6177 1.7458   95.889 6.7644   . .   . 0   95.889   NI 
16 CARDAM no cat     2 0.9459 5.8678   10.1547 0.3097   104.824 13.922   . .   . 0   104.824   NI 
16 CARDAM no cat     3 1.0342 6.596   17.2116 4.0284   94.298 3.1332   . .   . 0   94.298   NI 
17 CARDAM no cat     1 0.718 0.5669   11.8486 1.8037   82.311 19.427 NQ . .   . 0   82.311 NQ NI 
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17 CARDAM no cat     2 1.0409 3.7109   11.1134 0.688   108.099 4.7171   . .   . 0   108.099   NI 
17 CARDAM no cat     3 1.3506 1.4834   15.3147 2.0773   80.918 6.8003   . .   . 0   80.918   NI 
17 CARDAM no cat     4 0.7983 6.6925   8.8647 1.3042   102.702 7.1078   . .   . 0   102.702   NI 
18 CARDAM no cat     1 1.169 5.4702   13.7342 2.2905   94.048 10.641   . .   . 0   94.048   NI 
18 CARDAM no cat     2 1.0074 8.5376   11.5659 1.2203   84.439 7.7825   . .   . 0   84.439   NI 
18 CARDAM no cat     3 1.0398 3.5464   8.5117 0.9677   98.956 4.841   . .   . 0   98.956   NI 
19 CARDAM no cat     1 1.169 5.4702   13.7342 2.2905   95.161 6.7015   . .   . 0   95.161   NI 
19 CARDAM no cat     2 1.1543 3.3335   11.3124 1.9334   101.948 7.2522   . .   . 0   101.948   NI 
19 CARDAM no cat     3 1.0398 3.5464   8.5117 0.9677   104.822 8.5237   . .   . 0   104.822   NI 
20 CARDAM no cat Yes   1 0.9764 3.0137   9.7414 1.6474   98.102 2.9969   . .   51.803 8.5228   46.299   I 
20 CARDAM no cat Yes   2 1.1217 5.8363   9.2331 2.1018   90.395 8.6378   . .   45.457 7.419   44.938   I 
20 CARDAM no cat Yes   3 0.9438 9.67   16.1907 2.7495   119.378 12.966   . .   53.837 8.8178   65.542   NI 
21 CARDAM no cat     1 0.718 0.5669   11.8486 1.8037   64.928 9.9996   . .   . 0   64.928   NI 
21 CARDAM no cat     2 1.0409 3.7109   11.1134 0.688   99.492 5.9378   . .   . 0   99.492   NI 
21 CARDAM no cat     3 1.3506 1.4834   15.3147 2.0773   76.674 3.6515   . .   . 0   76.674   NI 
22 CARDAM no cat     1 0.718 0.5669   11.8486 1.8037   60.51 2.9225   . .   . 0   60.51   NI 
22 CARDAM no cat     2 1.0409 3.7109   11.1134 0.688   93.528 5.3215   . .   . 0   93.528   NI 
22 CARDAM no cat     3 1.3506 1.4834   15.3147 2.0773   94.325 5.8117   . .   . 0   94.325   NI 
23 CARDAM no cat Yes   1 1.0797 7.8357   6.7566 1.011   27.601 1.5061   . .   29.509 1.3447   0   I 
23 CARDAM no cat Yes   2 0.9533 3.5881   8.6662 1.4874   31.198 0.9651   . .   33.569 1.5229   0   I 
23 CARDAM no cat Yes   3 1.1437 1.1112   17.6846 0.1487   25.784 2.2355   . .   27.95 1.2694   0   I 
24 CARDAM no cat     1 1.0797 7.8357   6.7566 1.011   77.392 8.0488   . .   . 0   77.392   NI 
24 CARDAM no cat     2 0.9533 3.5881   8.6662 1.4874   72.514 0.297   . .   . 0   72.514   NI 
24 CARDAM no cat     3 1.1437 1.1112   17.6846 0.1487   61.339 0.7428   . .   . 0   61.339   NI 
25 CARDAM no cat Yes   1 0.9438 9.67   16.1907 2.7495   123.325 1.3277   . .   0.215 0.1312   123.11   NI 
25 CARDAM no cat Yes   2 1.1543 3.3335   11.3124 1.9334   103.496 1.2803   . .   0.205 0.1072   103.29   NI 
25 CARDAM no cat Yes   3 1.0398 3.5464   8.5117 0.9677   92.303 9.367   . .   0.168 0.1191   92.134   NI 
26 CARDAM no cat     1 1.0074 8.5376   11.5659 1.2203   99.628 5.8942   . .   . 0   99.628   NI 
26 CARDAM no cat     2 1.1543 3.3335   11.3124 1.9334   107.131 8.9299   . .   . 0   107.131   NI 
26 CARDAM no cat     3 1.0398 3.5464   8.5117 0.9677   102.528 8.7221   . .   . 0   102.528   NI 
28 CARDAM no cat     1 1.0351 6.5903   17.2836 4.0249   88.407 6.3071   . .   . 0   88.407   NI 
28 CARDAM no cat     2 0.9244 7.503   8.8632 1.6731   107.255 2.0699   . .   . 0   107.255   NI 
28 CARDAM no cat     3 1.017 4.957   7.2385 0.8518   76.859 4.3915   . .   . 0   76.859   NI 
29 CARDAM no cat     1 0.9438 9.67   16.1907 2.7495   109.72 13.364   . .   . 0   109.72   NI 
29 CARDAM no cat     2 1.1543 3.3335   11.3124 1.9334   100.941 13.87   . .   . 0   100.941   NI 
29 CARDAM no cat     3 1.0398 3.5464   8.5117 0.9677   104.08 6.6817   . .   . 0   104.08   NI 
30 CARDAM no cat     1 1.1585 5.6912   5.4455 2.2462   87.801 3.9968   . .   . 0   87.801   NI 
30 CARDAM no cat     2 1.0661 4.9967   19.5735 6.345   105.709 10.484   . .   . 0   105.709   NI 
30 CARDAM no cat     3 1.0748 9.2837   11.954 3.093   86.309 3.5904   . .   . 0   86.309   NI 
31 CARDAM no cat     1 1.1585 5.6912   5.4455 2.2462   93.012 6.0722   . .   . 0   93.012   NI 
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31 CARDAM no cat     2 1.0661 4.9967   19.5735 6.345   112.06 9.2893   . .   . 0   112.06   NI 
31 CARDAM no cat     3 1.0748 9.2837   11.954 3.093   97.516 5.0105   . .   . 0   97.516   NI 
32 CARDAM no cat   Yes 1 1.0166 4.9593   7.1959 0.8522   53.483 6.9763   1.3001 0.465   . 0   52.183   NI 
32 CARDAM no cat   Yes 2 0.718 0.5669   11.8486 1.8037   64.624 4.9133   0.6895 0.661   . 0   63.934   NI 
32 CARDAM no cat   Yes 3 1.0409 3.7109   11.1134 0.688   68.847 1.116   1.2905 0.475   . 0   67.556   NI 
33 CARDAM no cat Yes Yes 1 1.0409 3.7109   11.1134 0.688   98.713 3.3601   1.3978 1.639   1.084 1.3688   96.231   NI 
33 CARDAM no cat Yes Yes 2 1.3506 1.4834   15.3147 2.0773   79.4 6.3094   1.8523 1.316   0.755 1.055   76.792   NI 
33 CARDAM no cat Yes Yes 3 0.7983 6.6925   8.8647 1.3042   96.478 4.4473   1.7663 0.848   1.315 1.7848   93.396   NI 
34 CARDAM no cat Yes Yes 1 0.718 0.5669   11.8486 1.8037   136.405 21.505 NQ 5.5041 2.417   8.062 1.4602   122.838 NQ NI 
34 CARDAM no cat Yes Yes 2 1.0409 3.7109   11.1134 0.688   124.653 16.352   3.3768 0.129   4.85 1.0072   116.426   NI 
34 CARDAM no cat Yes Yes 3 1.3506 1.4834   15.3147 2.0773   97.199 7.5249   1.8721 0.131   3.738 0.7763   91.589   NI 
34 CARDAM no cat Yes Yes 4 0.7983 6.6925   8.8647 1.3042   123.162 0.5154   4.0753 0.295   6.324 1.3133   112.763   NI 
35 CARDAM no cat Yes   1 0.9699 2.5093   30.0959 3.9456   47.675 3.7452   . .   25.855 3.2968   21.82   I 
35 CARDAM no cat Yes   2 0.9148 3.1781   12.341 1.4603   95.617 10.612   . .   27.411 3.4952   68.206   NI 
35 CARDAM no cat Yes   3 0.7795 7.0435   21.6844 6.85   46.146 15.984   . .   32.17 4.1019   13.977   I 
36 CARDAM no cat     1 0.9699 2.5093   30.0959 3.9456   99.852 4.947   . .   . 0   99.852   NI 
36 CARDAM no cat     2 0.9148 3.1781   12.341 1.4603   113.055 13.812   . .   . 0   113.055   NI 
36 CARDAM no cat     3 0.7795 7.0435   21.6844 6.85   102.598 2.3385   . .   . 0   102.598   NI 
37 CARDAM no cat     1 1.1585 5.6912   5.4455 2.2462   93.422 0.8073   . .   . 0   93.422   NI 
37 CARDAM no cat     2 1.0661 4.9967   19.5735 6.345   107.126 10.007   . .   . 0   107.126   NI 
37 CARDAM no cat     3 1.0748 9.2837   11.954 3.093   79.587 12.585   . .   . 0   79.587   NI 
38 CARDAM no cat     1 0.9764 3.0137   9.7414 1.6474   106.52 1.8409   . .   . 0   106.52   NI 
38 CARDAM no cat     2 1.068 12.107   9.0451 0.5407   105.829 12.991   . .   . 0   105.829   NI 
38 CARDAM no cat     3 0.9438 9.67   16.1907 2.7495   87.475 12.289   . .   . 0   87.475   NI 
39 CARDAM no cat     1 1.068 12.107   9.0451 0.5407   105.125 5.171   . .   . 0   105.125   NI 
39 CARDAM no cat     2 1.1217 5.8363   9.2331 2.1018   95.771 2.4882   . .   . 0   95.771   NI 
39 CARDAM no cat     3 1.169 5.4702   13.7342 2.2905   98.159 3.9652   . .   . 0   98.159   NI 
40 CARDAM no cat     1 0.9764 3.0137   9.7414 1.6474   96.509 8.0542   . .   . 0   96.509   NI 
40 CARDAM no cat     2 0.9438 9.67   16.1907 2.7495   99.936 3.1692   . .   . 0   99.936   NI 
40 CARDAM no cat     3 1.0074 8.5376   11.5659 1.2203   93.281 9.598   . .   . 0   93.281   NI 
41 CARDAM no cat     1 1.0797 7.8357   6.7566 1.011   107.241 3.6838   . .   . 0   107.241   NI 
41 CARDAM no cat     2 0.9533 3.5881   8.6662 1.4874   95.187 1.132   . .   . 0   95.187   NI 
41 CARDAM no cat     3 1.1437 1.1112   17.6846 0.1487   98.544 3.0184   . .   . 0   98.544   NI 
42 CARDAM no cat Yes   1 0.9533 3.5881   8.6662 1.4874   90.657 2.3402   . .   1.482 1.9881   89.225   NI 
42 CARDAM no cat Yes   2 1.1437 1.1112   17.6846 0.1487   89.963 7.4368   . .   1.232 1.6556   88.774   NI 
42 CARDAM no cat Yes   3 1.1585 5.6912   5.4455 2.2462   93.766 8.0832   . .   1.22 1.6361   92.588   NI 
43 CARDAM no cat     1 1.0797 7.8357   6.7566 1.011   99.518 4.5152   . .   . 0   99.518   NI 
43 CARDAM no cat     2 0.9533 3.5881   8.6662 1.4874   94.493 7.4649   . .   . 0   94.493   NI 
43 CARDAM no cat     3 1.1437 1.1112   17.6846 0.1487   92.957 1.4856   . .   . 0   92.957   NI 
44 CARDAM no cat     1 1.0797 7.8357   6.7566 1.011   104.572 5.5815   . .   . 0   104.572   NI 
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44 CARDAM no cat     2 0.9533 3.5881   8.6662 1.4874   96.147 7.2442   . .   . 0   96.147   NI 
44 CARDAM no cat     3 1.1437 1.1112   17.6846 0.1487   93.732 7.2587   . .   . 0   93.732   NI 
45 CARDAM no cat     1 1.0797 7.8357   6.7566 1.011   104.348 2.6337   . .   . 0   104.348   NI 
45 CARDAM no cat     2 0.9533 3.5881   8.6662 1.4874   98.565 4.7463   . .   . 0   98.565   NI 
45 CARDAM no cat     3 1.1437 1.1112   17.6846 0.1487   91.599 5.3653   . .   . 0   91.599   NI 
46 CARDAM no cat     1 1.0797 7.8357   6.7566 1.011   92.703 8.392   . .   . 0   92.703   NI 
46 CARDAM no cat     2 0.9533 3.5881   8.6662 1.4874   85.911 2.7426   . .   . 0   85.911   NI 
46 CARDAM no cat     3 1.1437 1.1112   17.6846 0.1487   89.977 2.8635   . .   . 0   89.977   NI 
47 CARDAM no cat     1 1.0797 7.8357   6.7566 1.011   95.673 9.7519   . .   . 0   95.673   NI 
47 CARDAM no cat     2 0.9533 3.5881   8.6662 1.4874   101.694 7.7071   . .   . 0   101.694   NI 
47 CARDAM no cat     3 1.1437 1.1112   17.6846 0.1487   89.557 6.3812   . .   . 0   89.557   NI 
48 CARDAM no cat Yes   1 1.3506 1.4834   15.3147 2.0773   39.332 7.2528   . .   0 0   39.332   I 
48 CARDAM no cat Yes   2 1.0797 7.8357   6.7566 1.011   44.016 2.9106   . .   0.391 0.0722   43.625   I 
48 CARDAM no cat Yes   3 0.9533 3.5881   8.6662 1.4874   54.218 8.0634   . .   0.558 0.0818   53.66   NI 
49 CARDAM no cat Yes   1 1.0074 8.5376   11.5659 1.2203   105.731 5.4549   . .   0.083 0.0732   105.731   NI 
49 CARDAM no cat Yes   2 1.0398 3.5464   8.5117 0.9677   101.019 5.2457   . .   0 0   101.019   NI 
49 CARDAM no cat Yes   3 1.0153 3.8417   9.8825 1.2486   109.157 2.0682   . .   0.009 0.0147   109.157   NI 
50 CARDAM no cat     1 1.0074 8.5376   11.5659 1.2203   96.92 7.9794   . .   . 0   96.92   NI 
50 CARDAM no cat     2 1.1543 3.3335   11.3124 1.9334   83.084 9.7338   . .   . 0   83.084   NI 
50 CARDAM no cat     3 1.0153 3.8417   9.8825 1.2486   98.199 1.4852   . .   . 0   98.199   NI 
51 CARDAM no cat     1 1.0074 8.5376   11.5659 1.2203   93.144 6.7264   . .   . 0   93.144   NI 
51 CARDAM no cat     2 1.1543 3.3335   11.3124 1.9334   91.194 7.9805   . .   . 0   91.194   NI 
51 CARDAM no cat     3 1.0153 3.8417   9.8825 1.2486   98.247 6.306   . .   . 0   98.247   NI 
52 CARDAM no cat     1 1.0074 8.5376   11.5659 1.2203   101.924 4.1812   . .   . 0   101.924   NI 
52 CARDAM no cat     2 1.1543 3.3335   11.3124 1.9334   99.435 1.805   . .   . 0   99.435   NI 
52 CARDAM no cat     3 1.0153 3.8417   9.8825 1.2486   95.505 14.394   . .   . 0   95.505   NI 
53 CARDAM no cat     1 1.0074 8.5376   11.5659 1.2203   81.845 8.6247   . .   . 0   81.845   NI 
53 CARDAM no cat     2 1.0398 3.5464   8.5117 0.9677   94.292 8.3623   . .   . 0   94.292   NI 
53 CARDAM no cat     3 1.0153 3.8417   9.8825 1.2486   96.457 4.8582   . .   . 0   96.457   NI 
54 CARDAM cat 2B     1 0.9699 2.5093   30.0959 3.9456   81.737 4.9264   . .   . 0   81.737   NI 
54 CARDAM cat 2B     2 0.9148 3.1781   12.341 1.4603   68.543 8.6383   . .   . 0   68.543   NI 
54 CARDAM cat 2B     3 0.7795 7.0435   21.6844 6.85   65.893 10.711   . .   . 0   65.893   NI 
55 CARDAM cat 2B     1 1.0417 3.7082   11.1788 0.6875   2.71 0.385   . .   . 0   2.71   I 
55 CARDAM cat 2B     2 1.3506 1.4834   15.3147 2.0773   1.958 0.3357   . .   . 0   1.958   I 
55 CARDAM cat 2B     3 1.0797 7.8357   6.7566 1.011   3.691 1.7996   . .   . 0   3.691   I 
56 CARDAM cat 2B     1 1.0417 3.7082   11.1788 0.6875   89.207 15.167   . .   . 0   89.207   NI 
56 CARDAM cat 2B     2 1.3506 1.4834   15.3147 2.0773   66.585 8.282   . .   . 0   66.585   NI 
56 CARDAM cat 2B     3 0.7983 6.6925   8.8647 1.3042   88.728 5.683   . .   . 0   88.728   NI 
57 CARDAM cat 2B     1 0.718 0.5669   11.8486 1.8037   25.995 4.4113   . .   . 0   25.995   I 
57 CARDAM cat 2B     2 1.0409 3.7109   11.1134 0.688   41.469 1.898   . .   . 0   41.469   I 
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57 CARDAM cat 2B     3 1.3506 1.4834   15.3147 2.0773   34.219 5.507   . .   . 0   34.219   I 
58 CARDAM cat 2B     1 1.0409 3.7109   11.1134 0.688   42.893 2.9612   . .   . 0   42.893   I 
58 CARDAM cat 2B     2 1.3506 1.4834   15.3147 2.0773   26.087 3.8693   . .   . 0   26.087   I 
58 CARDAM cat 2B     3 0.7983 6.6925   8.8647 1.3042   34.145 11.685   . .   . 0   34.145   I 
59 CARDAM cat 2B     1 1.0417 3.7082   11.1788 0.6875   87.943 4.9369   . .   . 0   87.943   NI 
59 CARDAM cat 2B     2 1.3506 1.4834   15.3147 2.0773   70.27 10.403   . .   . 0   70.27   NI 
59 CARDAM cat 2B     3 0.7983 6.6925   8.8647 1.3042   84.807 4.2651   . .   . 0   84.807   NI 
60 CARDAM cat 2B     1 0.9438 9.67   16.1907 2.7495   36.569 1.3007   . .   . 0   36.569   I 
60 CARDAM cat 2B     2 1.1543 3.3335   11.3124 1.9334   29.781 4.6129   . .   . 0   29.781   I 
60 CARDAM cat 2B     3 1.0398 3.5464   8.5117 0.9677   33.864 8.0422   . .   . 0   33.864   I 
61 CARDAM cat 2B   Yes 1 1.0351 6.5903   17.2836 4.0249   74.108 2.5023   0.0923 0.16   . 0   74.016   NI 
61 CARDAM cat 2B   Yes 2 0.9244 7.503   8.8632 1.6731   96.675 12.875   0.0343 0.003   . 0   96.641   NI 
61 CARDAM cat 2B   Yes 3 1.017 4.957   7.2385 0.8518   91.988 2.6932   0.0503 0.053   . 0   91.938   NI 
62 CARDAM cat 2B     1 1.1437 1.1112   17.6846 0.1487   95.694 7.5369   . .   . 0   95.694   NI 
62 CARDAM cat 2B     2 1.1585 5.6912   5.4455 2.2462   97.927 6.0566   . .   . 0   97.927   NI 
62 CARDAM cat 2B     3 1.0748 9.2837   11.954 3.093   92.158 9.3776   . .   . 0   92.158   NI 
63 CARDAM cat 2B     1 1.1437 1.1112   17.6846 0.1487   92.492 8.9927   . .   . 0   92.492   NI 
63 CARDAM cat 2B     2 1.1585 5.6912   5.4455 2.2462   92.809 6.5504   . .   . 0   92.809   NI 
63 CARDAM cat 2B     3 1.0748 9.2837   11.954 3.093   97.079 8.074   . .   . 0   97.079   NI 
64 CARDAM cat 2B     1 0.718 0.5669   11.8486 1.8037   99.666 9.123   . .   . 0   99.666   NI 
64 CARDAM cat 2B     2 1.0409 3.7109   11.1134 0.688   96.663 9.0489   . .   . 0   96.663   NI 
64 CARDAM cat 2B     3 1.3506 1.4834   15.3147 2.0773   84.183 6.9135   . .   . 0   84.183   NI 
65 CARDAM cat 2B     1 1.1437 1.1112   17.6846 0.1487   88.923 6.3514   . .   . 0   88.923   NI 
65 CARDAM cat 2B     2 1.0661 4.9967   19.5735 6.345   117.382 5.6354   . .   . 0   117.382   NI 
65 CARDAM cat 2B     3 1.0748 9.2837   11.954 3.093   100.513 2.3703   . .   . 0   100.513   NI 
66 CARDAM cat 2B     1 1.1585 5.6912   5.4455 2.2462   65.224 5.4812   . .   . 0   65.224   NI 
66 CARDAM cat 2B     2 1.0661 4.9967   19.5735 6.345   105.119 2.4342   . .   . 0   105.119   NI 
66 CARDAM cat 2B     3 1.0748 9.2837   11.954 3.093   88.662 9.2228   . .   . 0   88.662   NI 
67 CARDAM cat 2A     1 1.0351 6.5903   17.2836 4.0249   3.426 1.1561   . .   . 0   3.426   I 
67 CARDAM cat 2A     2 0.9244 7.503   8.8632 1.6731   6.783 6.1918   . .   . 0   6.783   I 
67 CARDAM cat 2A     3 1.017 4.957   7.2385 0.8518   3.228 2.5722   . .   . 0   3.228   I 
68 CARDAM cat 2A*     1 0.9699 2.5093   30.0959 3.9456   2.959 2.1141   . .   . 0   2.959   I 
68 CARDAM cat 2A*     2 0.9148 3.1781   12.341 1.4603   4.509 0.7577   . .   . 0   4.509   I 
68 CARDAM cat 2A*     3 0.7795 7.0435   21.6844 6.85   0.306 0.057   . .   . 0   0.306   I 
69 CARDAM cat 2A*     1 0.9699 2.5093   30.0959 3.9456   81.825 6.1383   . .   . 0   81.825   NI 
69 CARDAM cat 2A*     2 0.9148 3.1781   12.341 1.4603   34.715 0.496   . .   . 0   34.715   I 
69 CARDAM cat 2A*     3 0.7795 7.0435   21.6844 6.85   68.611 13.418   . .   . 0   68.611   NI 
70 CARDAM cat 2A     1 1.0417 3.7082   11.1788 0.6875   10.22 2.1655   . .   . 0   10.22   I 
70 CARDAM cat 2A     2 1.3506 1.4834   15.3147 2.0773   12.23 1.5189   . .   . 0   12.23   I 
70 CARDAM cat 2A     3 0.7983 6.6925   8.8647 1.3042   7.829 1.1619   . .   . 0   7.829   I 
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71 CARDAM cat 2A*     1 0.9247 7.5008   8.8895 1.6726   4.544 1.0999   . .   . 0   4.544   I 
71 CARDAM cat 2A*     2 1.017 4.957   7.2385 0.8518   2.789 4.5093   . .   . 0   2.789   I 
71 CARDAM cat 2A*     3 0.718 0.5669   11.8486 1.8037   12.603 5.6128   . .   . 0   12.603   I 
72 CARDAM cat 2A*     1 1.3506 1.4834   15.3147 2.0773   4.665 0.2324   . .   . 0   4.665   I 
72 CARDAM cat 2A*     2 1.0797 7.8357   6.7566 1.011   3.425 0.1528   . .   . 0   3.425   I 
72 CARDAM cat 2A*     3 0.9533 3.5881   8.6662 1.4874   3.582 0.1649   . .   . 0   3.582   I 
73 CARDAM cat 2A*     1 0.9726 6.2232   14.6177 1.7458   94.405 6.0759   . .   . 0   94.405   NI 
73 CARDAM cat 2A*     2 0.9459 5.8678   10.1547 0.3097   99.419 15.949   . .   . 0   99.419   NI 
73 CARDAM cat 2A*     3 1.0342 6.596   17.2116 4.0284   87.589 7.7248   . .   . 0   87.589   NI 
74 CARDAM cat 2A Yes Yes 1 0.9699 2.5093   30.0959 3.9456   93.632 10.828   0.2801 0.142   0.794 0.999   92.723   NI 
74 CARDAM cat 2A Yes Yes 2 0.9148 3.1781   12.341 1.4603   104.835 4.8754   0.4992 0.247   0.952 1.1264   103.505   NI 
74 CARDAM cat 2A Yes Yes 3 0.7795 7.0435   21.6844 6.85   85.884 8.0964   0 0   0.812 1.143   85.367   NI 
75 CARDAM cat 2A     1 0.9699 2.5093   30.0959 3.9456   61.585 12.217   . .   . 0   61.585   NI 
75 CARDAM cat 2A     2 0.9148 3.1781   12.341 1.4603   30.63 21.58 NQ . .   . 0   30.63 NQ I 
75 CARDAM cat 2A     3 0.7795 7.0435   21.6844 6.85   19.942 5.2349   . .   . 0   19.942   I 
75 CARDAM cat 2A     4 0.9726 6.2232   14.6177 1.7458   10.124 3.3472   . .   . 0   10.124   I 
76 CARDAM cat 2A     1 0.718 0.5669   11.8486 1.8037   87.481 2.4592   . .   . 0   87.481   NI 
76 CARDAM cat 2A     2 1.0409 3.7109   11.1134 0.688   83.878 6.7189   . .   . 0   83.878   NI 
76 CARDAM cat 2A     3 1.3506 1.4834   15.3147 2.0773   70.896 1.938   . .   . 0   70.896   NI 
77 CARDAM cat 2A     1 0.9247 7.5008   8.8895 1.6726   113.567 7.5771   . .   . 0   113.567   NI 
77 CARDAM cat 2A     2 1.0166 4.9593   7.1959 0.8522   84.767 0.4835   . .   . 0   84.767   NI 
77 CARDAM cat 2A     3 0.718 0.5669   11.8486 1.8037   90.478 8.5524   . .   . 0   90.478   NI 
78 CARDAM cat 2A     1 0.9247 7.5008   8.8895 1.6726   103.042 12.363   . .   . 0   103.042   NI 
78 CARDAM cat 2A     2 1.0166 4.9593   7.1959 0.8522   82.037 3.984   . .   . 0   82.037   NI 
78 CARDAM cat 2A     3 0.718 0.5669   11.8486 1.8037   88.226 10.393   . .   . 0   88.226   NI 
79 CARDAM cat 2A*     1 1.3506 1.4834   15.3147 2.0773   71.794 9.6879   . .   . 0   71.794   NI 
79 CARDAM cat 2A*     2 1.0797 7.8357   6.7566 1.011   73.894 4.8026   . .   . 0   73.894   NI 
79 CARDAM cat 2A*     3 0.9533 3.5881   8.6662 1.4874   74.685 7.1851   . .   . 0   74.685   NI 
80 CARDAM cat 1 Yes   1 1.0417 3.7082   11.1788 0.6875   30.074 7.897   . .   24.041 1.8953   6.352   I 
80 CARDAM cat 1 Yes   2 1.3506 1.4834   15.3147 2.0773   21.219 1.9561   . .   18.51 1.4619   2.709   I 
80 CARDAM cat 1 Yes   3 0.7983 6.6925   8.8647 1.3042   23.304 1.9433   . .   34.022 2.4732   0   I 
81 CARDAM cat 1 Yes   1 1.0351 6.5903   17.2836 4.0249   0.383 0.1334   . .   0 0   0.383   I 
81 CARDAM cat 1 Yes   2 0.9244 7.503   8.8632 1.6731   0.447 0.1912   . .   0 0   0.447   I 
81 CARDAM cat 1 Yes   3 1.017 4.957   7.2385 0.8518   0.518 0.0252   . .   0 0   0.518   I 
82 CARDAM cat 1     1 1.169 5.4702   13.7342 2.2905   2.743 0.9543   . .   . 0   2.743   I 
82 CARDAM cat 1     2 1.0074 8.5376   11.5659 1.2203   4.698 0.2423   . .   . 0   4.698   I 
82 CARDAM cat 1     3 1.0398 3.5464   8.5117 0.9677   2.714 1.067   . .   . 0   2.714   I 
83 CARDAM cat 1     1 0.9699 2.5093   30.0959 3.9456   6.43 1.376   . .   . 0   6.43   I 
83 CARDAM cat 1     2 0.9148 3.1781   12.341 1.4603   1.794 0.574   . .   . 0   1.794   I 
83 CARDAM cat 1     3 0.9726 6.2232   14.6177 1.7458   2.644 0.0564   . .   . 0   2.644   I 
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84 CARDAM cat 1     1 1.169 5.4702   13.7342 2.2905   35.127 1.6084   . .   . 0   35.127   I 
84 CARDAM cat 1     2 1.1543 3.3335   11.3124 1.9334   16.848 1.7839   . .   . 0   16.848   I 
84 CARDAM cat 1     3 1.0398 3.5464   8.5117 0.9677   16.9 3.0001   . .   . 0   16.9   I 
85 CARDAM cat 1     1 0.9726 6.2232   14.6177 1.7458   66.681 1.0694   . .   . 0   66.681   NI 
85 CARDAM cat 1     2 0.9459 5.8678   10.1547 0.3097   74.581 16.28   . .   . 0   74.581   NI 
85 CARDAM cat 1     3 1.0342 6.596   17.2116 4.0284   73.485 8.5837   . .   . 0   73.485   NI 
86 CARDAM cat 1     1 1.068 12.107   9.0451 0.5407   107.101 6.1067   . .   . 0   107.101   NI 
86 CARDAM cat 1     2 1.1217 5.8363   9.2331 2.1018   99.868 5.2194   . .   . 0   99.868   NI 
86 CARDAM cat 1     3 1.169 5.4702   13.7342 2.2905   79.511 7.8438   . .   . 0   79.511   NI 
87 CARDAM cat 1     1 0.7795 7.0435   21.6844 6.85   101.8 9.226   . .   . 0   101.8   NI 
87 CARDAM cat 1     2 0.9727 6.2224   14.6279 1.7456   86.969 4.9984   . .   . 0   86.969   NI 
87 CARDAM cat 1     3 0.9459 5.8678   10.1547 0.3097   91.447 7.6121   . .   . 0   91.447   NI 
88 CARDAM cat 1 Yes   1 0.9764 3.0137   9.7414 1.6474   3.924 0.6689   . .   0.647 0.3668   3.277   I 
88 CARDAM cat 1 Yes   2 1.068 12.107   9.0451 0.5407   10.827 5.0381   . .   0.63 0.3354   10.197   I 
88 CARDAM cat 1 Yes   3 0.9438 9.67   16.1907 2.7495   7.654 1.3621   . .   0.669 0.3795   6.985   I 
89 CARDAM cat 1     1 0.9247 7.5008   8.8895 1.6726   71.785 7.0267   . .   . 0   71.785   NI 
89 CARDAM cat 1     2 1.0166 4.9593   7.1959 0.8522   72.118 12.97   . .   . 0   72.118   NI 
89 CARDAM cat 1     3 0.718 0.5669   11.8486 1.8037   83.982 11.36   . .   . 0   83.982   NI 
90 CARDAM cat 1     1 0.9247 7.5008   8.8895 1.6726   92.832 3.3154   . .   . 0   92.832   NI 
90 CARDAM cat 1     2 1.0166 4.9593   7.1959 0.8522   50.848 9.8944   . .   . 0   50.848   NI 
90 CARDAM cat 1     3 0.718 0.5669   11.8486 1.8037   88.836 12.08   . .   . 0   88.836   NI 
91 CARDAM cat 1 Yes   1 0.9244 7.503   8.8632 1.6731   59.041 1.1191   . .   1.716 2.9718   58.08   NI 
91 CARDAM cat 1 Yes   2 1.017 4.957   7.2385 0.8518   42.331 4.3717   . .   1.536 2.6596   41.53   I 
91 CARDAM cat 1 Yes   3 0.718 0.5669   11.8486 1.8037   60.914 2.0661   . .   5.184 4.7038   55.73   NI 
92 CARDAM cat 1 Yes   1 1.0074 8.5376   11.5659 1.2203   85.314 8.8093   . .   0.039 0.0669   85.314   NI 
92 CARDAM cat 1 Yes   2 1.1543 3.3335   11.3124 1.9334   78.705 8.8592   . .   0.054 0.0934   78.705   NI 
92 CARDAM cat 1 Yes   3 1.0153 3.8417   9.8825 1.2486   82.758 4.6571   . .   0.038 0.0663   82.758   NI 
93 CARDAM cat 1     1 0.9726 6.2232   14.6177 1.7458   71.054 0.5019   . .   . 0   71.054   NI 
93 CARDAM cat 1     2 0.9459 5.8678   10.1547 0.3097   87.403 0.6975   . .   . 0   87.403   NI 
93 CARDAM cat 1     3 1.0342 6.596   17.2116 4.0284   82.998 1.1613   . .   . 0   82.998   NI 
94 CARDAM cat 1     1 1.0351 6.5903   17.2836 4.0249   75.506 2.8963   . .   . 0   75.506   NI 
94 CARDAM cat 1     2 0.9244 7.503   8.8632 1.6731   78.067 2.9615   . .   . 0   78.067   NI 
94 CARDAM cat 1     3 1.017 4.957   7.2385 0.8518   81.782 7.3965   . .   . 0   81.782   NI 
95 CARDAM cat 1 Yes   1 0.9726 6.2232   14.6177 1.7458   1.292 0.4721   . .   0 0   1.292   I 
95 CARDAM cat 1 Yes   2 0.9459 5.8678   10.1547 0.3097   1.574 0.9569   . .   0 0   1.574   I 
95 CARDAM cat 1 Yes   3 1.0342 6.596   17.2116 4.0284   2.546 0.7959   . .   0 0   2.546   I 
96 CARDAM cat 1     1 1.0351 6.5903   17.2836 4.0249   82.077 10.057   . .   . 0   82.077   NI 
96 CARDAM cat 1     2 0.9244 7.503   8.8632 1.6731   91.422 4.1949   . .   . 0   91.422   NI 
96 CARDAM cat 1     3 1.017 4.957   7.2385 0.8518   98.738 13.049   . .   . 0   98.738   NI 
97 CARDAM cat 1     1 0.9726 6.2232   14.6177 1.7458   94.352 1.5769   . .   . 0   94.352   NI 
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97 CARDAM cat 1     2 0.9459 5.8678   10.1547 0.3097   98.659 4.954   . .   . 0   98.659   NI 
97 CARDAM cat 1     3 1.0342 6.596   17.2116 4.0284   94.351 1.795   . .   . 0   94.351   NI 
98 CARDAM cat 1   Yes 1 0.9764 3.0137   9.7414 1.6474   105.916 6.4749   5.9503 2.468   . 0   99.966   NI 
98 CARDAM cat 1   Yes 2 1.068 12.107   9.0451 0.5407   106.829 5.294   5.5291 3.555   . 0   101.3   NI 
98 CARDAM cat 1   Yes 3 1.1217 5.8363   9.2331 2.1018   105.514 10.694   28.4231 8.107   . 0   77.091   NI 
99 CARDAM cat 1     1 0.9247 7.5008   8.8895 1.6726   25.616 6.4178   . .   . 0   25.616   I 
99 CARDAM cat 1     2 1.0166 4.9593   7.1959 0.8522   16.795 1.7866   . .   . 0   16.795   I 
99 CARDAM cat 1     3 0.718 0.5669   11.8486 1.8037   23.581 1.9576   . .   . 0   23.581   I 
100 CARDAM cat 1     1 1.0074 8.5376   11.5659 1.2203   28.052 9.7589   . .   . 0   28.052   I 
100 CARDAM cat 1     2 1.1543 3.3335   11.3124 1.9334   55.149 0.8796   . .   . 0   55.149   NI 
100 CARDAM cat 1     3 1.0153 3.8417   9.8825 1.2486   27.078 1.1857   . .   . 0   27.078   I 
101 CARDAM cat 1   Yes 1 0.9764 3.0137   9.7414 1.6474   87.149 2.305   0.1092 0.088   . 0   87.039   NI 
101 CARDAM cat 1   Yes 2 1.068 12.107   9.0451 0.5407   101.361 5.1278   0 0   . 0   101.361   NI 
101 CARDAM cat 1   Yes 3 1.1217 5.8363   9.2331 2.1018   86.822 7.3901   0 0   . 0   86.822   NI 
102 CARDAM cat 1     1 0.9438 9.67   16.1907 2.7495   115.424 5.6026   . .   . 0   115.424   NI 
102 CARDAM cat 1     2 1.1543 3.3335   11.3124 1.9334   107.739 8.9385   . .   . 0   107.739   NI 
102 CARDAM cat 1     3 1.0398 3.5464   8.5117 0.9677   111.7 2.8527   . .   . 0   111.7   NI 
103 CARDAM cat 1     1 0.718 0.5669   11.8486 1.8037   9.095 1.8573   . .   . 0   9.095   I 
103 CARDAM cat 1     2 1.0409 3.7109   11.1134 0.688   4.994 0.1312   . .   . 0   4.994   I 
103 CARDAM cat 1     3 1.3506 1.4834   15.3147 2.0773   8.596 2.6823   . .   . 0   8.596   I 
104 CARDAM cat 1     1 0.9247 7.5008   8.8895 1.6726   111.647 6.9033   . .   . 0   111.647   NI 
104 CARDAM cat 1     2 1.0166 4.9593   7.1959 0.8522   87.276 1.4991   . .   . 0   87.276   NI 
104 CARDAM cat 1     3 0.718 0.5669   11.8486 1.8037   90.327 7.4102   . .   . 0   90.327   NI 
105 CARDAM cat 1     1 1.0409 3.7109   11.1134 0.688   9.048 2.5785   . .   . 0   9.048   I 
105 CARDAM cat 1     2 1.3506 1.4834   15.3147 2.0773   10.814 1.5779   . .   . 0   10.814   I 
105 CARDAM cat 1     3 0.7983 6.6925   8.8647 1.3042   7.685 0.3038   . .   . 0   7.685   I 
1 CEETOX no cat     1 0.962 4.611   22.9903 4.4348   88.999 8.1062   . .   . 0   88.999   NI 
1 CEETOX no cat     2 0.929 3.9191   29.0097 6.2734   83.872 1.4925   . .   . 0   83.872   NI 
1 CEETOX no cat     3 0.9467 4.8488   29.1021 9.2982   83.275 8.2948   . .   . 0   83.275   NI 
2 CEETOX no cat     1 0.962 4.611   22.9903 4.4348   104.262 7.3549   . .   . 0   104.262   NI 
2 CEETOX no cat     2 0.929 3.9191   29.0097 6.2734   86.796 2.5441   . .   . 0   86.796   NI 
2 CEETOX no cat     3 0.9467 4.8488   29.1021 9.2982   84.965 6.5128   . .   . 0   84.965   NI 
3 CEETOX no cat     1 0.987 5.3233   31.5772 5.9588   81.476 4.9045   . .   . 0   81.476   NI 
3 CEETOX no cat     2 0.8937 5.0139   18.0716 3.251   70.533 1.1873   . .   . 0   70.533   NI 
3 CEETOX no cat     3 1.0388 7.2757   17.1346 4.4428   87.309 3.1201   . .   . 0   87.309   NI 
4 CEETOX no cat Yes   1 1.0737 1.4905   13.7069 3.6941   95.359 6.5897   . .   91.4 4.176   0   I 
4 CEETOX no cat Yes   2 1.1075 6.7453   13.9804 2.5428   101.084 4.9123   . .   88.608 4.0485   0   I 
4 CEETOX no cat Yes   3 1.0803 4.2089   5.7853 1.2081   105.137 16.336   . .   90.836 4.1503   0   I 
5 CEETOX no cat Yes   1 1.0298 1.4609   13.5297 3.9804   108.189 5.0904   . .   0.599 0.3032   107.59   NI 
5 CEETOX no cat Yes   2 1.0467 1.2874   6.1306 0.4308   96.146 9.3872   . .   0.621 0.2983   95.525   NI 
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5 CEETOX no cat Yes   3 1.0643 12.666   3.2884 0.6509   102.834 2.2476   . .   0.579 0.2934   102.255   NI 
6 CEETOX no cat     1 0.962 4.611   22.9903 4.4348   123.164 10.087   . .   . 0   123.164   NI 
6 CEETOX no cat     2 0.929 3.9191   29.0097 6.2734   102.96 11.851   . .   . 0   102.96   NI 
6 CEETOX no cat     3 0.9467 4.8488   29.1021 9.2982   105.704 7.8612   . .   . 0   105.704   NI 
7 CEETOX no cat     1 0.987 5.3233   31.5772 5.9588   84.228 3.9401   . .   . 0   84.228   NI 
7 CEETOX no cat     2 0.8937 5.0139   18.0716 3.251   89.183 6.434   . .   . 0   89.183   NI 
7 CEETOX no cat     3 1.0388 7.2757   17.1346 4.4428   87.085 3.0809   . .   . 0   87.085   NI 
8 CEETOX no cat     1 0.987 5.3233   31.5772 5.9588   97.45 10.719   . .   . 0   97.45   NI 
8 CEETOX no cat     2 0.8937 5.0139   18.0716 3.251   106.621 15.611   . .   . 0   106.621   NI 
8 CEETOX no cat     3 1.0388 7.2757   17.1346 4.4428   114.519 5.4271   . .   . 0   114.519   NI 
9 CEETOX no cat     1 0.962 4.611   22.9903 4.4348   95.911 6.2223   . .   . 0   95.911   NI 
9 CEETOX no cat     2 0.929 3.9191   29.0097 6.2734   98.762 2.3585   . .   . 0   98.762   NI 
9 CEETOX no cat     3 0.9467 4.8488   29.1021 9.2982   89.736 2.0729   . .   . 0   89.736   NI 
10 CEETOX no cat     1 1.0373 6.1774   21.4332 3.0371   45.067 6.4625   . .   . 0   45.067   I 
10 CEETOX no cat     2 1.1943 4.4215   6.2238 1.3201   41.027 2.2565   . .   . 0   41.027   I 
10 CEETOX no cat     3 1.0052 11.181   4.6427 0.4745   36.229 2.5968   . .   . 0   36.229   I 
11 CEETOX no cat     1 0.962 4.611   22.9903 4.4348   81.41 4.9396   . .   . 0   81.41   NI 
11 CEETOX no cat     2 0.929 3.9191   29.0097 6.2734   84.284 2.9333   . .   . 0   84.284   NI 
11 CEETOX no cat     3 0.9467 4.8488   29.1021 9.2982   79.261 2.1657   . .   . 0   79.261   NI 
12 CEETOX no cat     1 0.961 2.7115   6.0527 0.4834   91.103 7.1983   . .   . 0   91.103   NI 
12 CEETOX no cat     2 0.933 6.0005   9.6642 0.8844   101.268 5.7898   . .   . 0   101.268   NI 
12 CEETOX no cat     3 0.9652 5.0074   4.4552 0.9126   95.959 2.8294   . .   . 0   95.959   NI 
13 CEETOX no cat     1 0.961 2.7115   6.0527 0.4834   100.919 11.279   . .   . 0   100.919   NI 
13 CEETOX no cat     2 0.933 6.0005   9.6642 0.8844   96.927 3.3228   . .   . 0   96.927   NI 
13 CEETOX no cat     3 0.9652 5.0074   4.4552 0.9126   97.289 5.0307   . .   . 0   97.289   NI 
14 CEETOX no cat Yes   1 1.0298 1.4609   13.5297 3.9804   101.376 3.3641   . .   0.022 0.0374   101.376   NI 
14 CEETOX no cat Yes   2 1.0467 1.2874   6.1306 0.4308   103.471 14.014   . .   0.032 0.0552   103.471   NI 
14 CEETOX no cat Yes   3 1.0643 12.666   3.2884 0.6509   93 9.1391   . .   0.021 0.0362   93   NI 
15 CEETOX no cat     1 0.933 6.0005   9.6642 0.8844   102.608 5.76   . .   . 0   102.608   NI 
15 CEETOX no cat     2 0.9425 4.0652   4.916 0.9039   92.927 4.1179   . .   . 0   92.927   NI 
15 CEETOX no cat     3 0.9652 5.0074   4.4552 0.9126   101.105 2.6427   . .   . 0   101.105   NI 
16 CEETOX no cat     1 0.987 5.3233   31.5772 5.9588   89.97 5.7747   . .   . 0   89.97   NI 
16 CEETOX no cat     2 0.8937 5.0139   18.0716 3.251   92.335 6.2466   . .   . 0   92.335   NI 
16 CEETOX no cat     3 1.0388 7.2757   17.1346 4.4428   99.358 5.0657   . .   . 0   99.358   NI 
17 CEETOX no cat     1 1.062 4.7143   10.1224 1.3169   95.182 4.5071   . .   . 0   95.182   NI 
17 CEETOX no cat     2 1.022 4.0686   4.2727 1.2027   100.277 4.1103   . .   . 0   100.277   NI 
17 CEETOX no cat     3 1.01 6.3364   15.7591 5.7839   104.736 5.2909   . .   . 0   104.736   NI 
18 CEETOX no cat     1 0.962 2.955   9.806 1.8214   103.222 2.7839   . .   . 0   103.222   NI 
18 CEETOX no cat     2 0.9745 7.154   6.4135 1.4749   64.666 36.156 NQ . .   . 0   0 NQ I 
18 CEETOX no cat     3 0.961 2.7115   6.0527 0.4834   95.421 2.716   . .   . 0   95.421   NI 
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18 CEETOX no cat     4 0.9425 4.0652   4.916 0.9039   78.373 2.4463   . .   . 0   78.373   NI 
19 CEETOX no cat     1 0.933 6.0005   9.6642 0.8844   103.573 2.7243   . .   . 0   103.573   NI 
19 CEETOX no cat     2 0.9425 4.0652   4.916 0.9039   91.972 4.7335   . .   . 0   91.972   NI 
19 CEETOX no cat     3 0.9652 5.0074   4.4552 0.9126   105.837 0.8326   . .   . 0   105.837   NI 
20 CEETOX no cat     1 1.0203 4.686   14.8808 2.8659   103.316 9.4194   . .   . 0   103.316   NI 
20 CEETOX no cat     2 0.9472 2.2448   15.344 2.6984   122.787 7.1064   . .   . 0   122.787   NI 
20 CEETOX no cat     3 0.9055 5.6584   4.1598 0.7497   107.362 10.663   . .   . 0   107.362   NI 
21 CEETOX no cat     1 1.0737 1.4905   13.7069 3.6941   85.998 5.7337   . .   . 0   85.998   NI 
21 CEETOX no cat     2 1.1075 6.7453   13.9804 2.5428   86.697 2.7047   . .   . 0   86.697   NI 
21 CEETOX no cat     3 1.0803 4.2089   5.7853 1.2081   86.1 5.3932   . .   . 0   86.1   NI 
22 CEETOX no cat     1 1.0373 6.1774   21.4332 3.0371   82.712 6.3753   . .   . 0   82.712   NI 
22 CEETOX no cat     2 1.1943 4.4215   6.2238 1.3201   48.284 10.198   . .   . 0   48.284   I 
22 CEETOX no cat     3 1.0052 11.181   4.6427 0.4745   40.507 17.077   . .   . 0   40.507   I 
23 CEETOX no cat Yes   1 1.0203 4.686   14.8808 2.8659   30.154 2.3838   . .   52.123 5.6635   0   I 
23 CEETOX no cat Yes   2 0.9472 2.2448   15.344 2.6984   30.565 1.1886   . .   56.308 6.101   0   I 
23 CEETOX no cat Yes   3 0.9055 5.6584   4.1598 0.7497   38.671 5.5412   . .   64.2 6.3817   0   I 
24 CEETOX no cat     1 1.0945 5.8222   5.7865 0.6135   72.651 1.9894   . .   . 0   72.651   NI 
24 CEETOX no cat     2 1.0692 5.1104   13.2502 3.2509   70.709 4.005   . .   . 0   70.709   NI 
24 CEETOX no cat     3 1.0803 4.2089   5.7853 1.2081   60.969 2.0847   . .   . 0   60.969   NI 
25 CEETOX no cat Yes   1 1.0203 4.686   14.8808 2.8659   94.169 5.1214   . .   0.011 0.0189   94.169   NI 
25 CEETOX no cat Yes   2 0.9472 2.2448   15.344 2.6984   98.803 2.8861   . .   0.012 0.0203   98.803   NI 
25 CEETOX no cat Yes   3 0.9055 5.6584   4.1598 0.7497   95.03 3.2494   . .   0.012 0.0213   95.03   NI 
26 CEETOX no cat     1 1.0203 4.686   14.8808 2.8659   98.269 1.6697   . .   . 0   98.269   NI 
26 CEETOX no cat     2 0.9472 2.2448   15.344 2.6984   99.367 7.4379   . .   . 0   99.367   NI 
26 CEETOX no cat     3 0.9055 5.6584   4.1598 0.7497   96.024 2.2025   . .   . 0   96.024   NI 
28 CEETOX no cat     1 0.962 4.611   22.9903 4.4348   95.495 8.4962   . .   . 0   95.495   NI 
28 CEETOX no cat     2 0.929 3.9191   29.0097 6.2734   92.483 4.4081   . .   . 0   92.483   NI 
28 CEETOX no cat     3 0.9467 4.8488   29.1021 9.2982   87.148 6.2354   . .   . 0   87.148   NI 
29 CEETOX no cat     1 0.933 6.0005   9.6642 0.8844   102.805 1.4568   . .   . 0   102.805   NI 
29 CEETOX no cat     2 0.9425 4.0652   4.916 0.9039   94.783 0.6675   . .   . 0   94.783   NI 
29 CEETOX no cat     3 0.9652 5.0074   4.4552 0.9126   99.948 2.4933   . .   . 0   99.948   NI 
30 CEETOX no cat     1 0.9935 6.2229   13.0683 3.082   82.922 3.1007   . .   . 0   82.922   NI 
30 CEETOX no cat     2 1.0203 4.686   14.8808 2.8659   76.609 5.1048   . .   . 0   76.609   NI 
30 CEETOX no cat     3 0.9472 2.2448   15.344 2.6984   80.943 2.4604   . .   . 0   80.943   NI 
31 CEETOX no cat     1 1.01 6.3364   15.7591 5.7839   99.257 5.0622   . .   . 0   99.257   NI 
31 CEETOX no cat     2 0.9935 6.2229   13.0683 3.082   98.49 5.1602   . .   . 0   98.49   NI 
31 CEETOX no cat     3 0.962 2.955   9.806 1.8214   99.082 1.6972   . .   . 0   99.082   NI 
32 CEETOX no cat     1 1.0373 6.1774   21.4332 3.0371   47.976 8.3111   . .   . 0   47.976   I 
32 CEETOX no cat     2 1.1943 4.4215   6.2238 1.3201   38.752 2.7597   . .   . 0   38.752   I 
32 CEETOX no cat     3 1.0052 11.181   4.6427 0.4745   47.322 5.1095   . .   . 0   47.322   I 
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33 CEETOX no cat Yes Yes 1 1.0945 5.8222   5.7865 0.6135   89.95 12.639   0.8223 0.121   0.005 0.0088   89.127   NI 
33 CEETOX no cat Yes Yes 2 1.0692 5.1104   13.2502 3.2509   99.002 2.5367   1.0133 0.619   0.005 0.009   97.989   NI 
33 CEETOX no cat Yes Yes 3 1.0803 4.2089   5.7853 1.2081   89.972 7.1893   0.5091 0.255   2.083 1.6982   87.38   NI 
34 CEETOX no cat Yes Yes 1 0.9827 1.3599   9.7015 1.7119   134.447 7.6462   5.6479 0.404   3.223 1.7525   125.577   NI 
34 CEETOX no cat Yes Yes 2 1.062 4.7143   10.1224 1.3169   99.733 10.574   3.4369 0.483   7.957 1.6216   88.34   NI 
34 CEETOX no cat Yes Yes 3 1.022 4.0686   4.2727 1.2027   117.123 6.1789   3.7997 1.045   3.033 1.6851   110.29   NI 
35 CEETOX no cat Yes   1 1.0945 5.8222   5.7865 0.6135   25.187 1.263   . .   15.304 2.0211   9.883   I 
35 CEETOX no cat Yes   2 1.0803 4.2089   5.7853 1.2081   85.653 4.865   . .   19.161 2.0476   66.492   NI 
35 CEETOX no cat Yes   3 0.9783 10.415   7.4957 0.5606   25.792 1.3428   . .   21.363 2.2611   4.429   I 
36 CEETOX no cat     1 0.987 5.3233   31.5772 5.9588   93.026 3.3828   . .   . 0   93.026   NI 
36 CEETOX no cat     2 0.8937 5.0139   18.0716 3.251   93.659 3.8639   . .   . 0   93.659   NI 
36 CEETOX no cat     3 1.0388 7.2757   17.1346 4.4428   102.743 6.5144   . .   . 0   102.743   NI 
37 CEETOX no cat Yes   1 1.01 6.3364   15.7591 5.7839   85.198 2.3148   . .   0 0   85.198   NI 
37 CEETOX no cat Yes   2 0.9935 6.2229   13.0683 3.082   83.426 5.9951   . .   0 0   83.426   NI 
37 CEETOX no cat Yes   3 0.962 2.955   9.806 1.8214   91.216 1.2903   . .   0.04 0.07   91.216   NI 
38 CEETOX no cat     1 0.962 2.955   9.806 1.8214   104.66 2.4912   . .   . 0   104.66   NI 
38 CEETOX no cat     2 0.9745 7.154   6.4135 1.4749   91.397 1.1346   . .   . 0   91.397   NI 
38 CEETOX no cat     3 0.9425 4.0652   4.916 0.9039   86.844 2.49   . .   . 0   86.844   NI 
39 CEETOX no cat     1 0.9745 7.154   6.4135 1.4749   103.506 5.492   . .   . 0   103.506   NI 
39 CEETOX no cat     2 0.961 2.7115   6.0527 0.4834   94.78 3.038   . .   . 0   94.78   NI 
39 CEETOX no cat     3 0.9597 3.8851   5.1059 1.2355   96.058 3.5692   . .   . 0   96.058   NI 
40 CEETOX no cat     1 1.0203 4.686   14.8808 2.8659   84.874 3.8958   . .   . 0   84.874   NI 
40 CEETOX no cat     2 0.9472 2.2448   15.344 2.6984   83.706 6.9922   . .   . 0   83.706   NI 
40 CEETOX no cat     3 0.9055 5.6584   4.1598 0.7497   86.159 5.8756   . .   . 0   86.159   NI 
41 CEETOX no cat     1 1.01 6.3364   15.7591 5.7839   105.578 2.9381   . .   . 0   105.578   NI 
41 CEETOX no cat     2 0.9935 6.2229   13.0683 3.082   95.269 2.3406   . .   . 0   95.269   NI 
41 CEETOX no cat     3 0.962 2.955   9.806 1.8214   96.362 2.484   . .   . 0   96.362   NI 
42 CEETOX no cat Yes   1 1.062 4.7143   10.1224 1.3169   92.075 5.0713   . .   12.963 9.1546   79.112   NI 
42 CEETOX no cat Yes   2 1.022 4.0686   4.2727 1.2027   103.164 9.6486   . .   9.301 8.8012   94.309   NI 
42 CEETOX no cat Yes   3 1.01 6.3364   15.7591 5.7839   87.921 2.0692   . .   9.268 8.7926   79.175   NI 
43 CEETOX no cat     1 1.062 4.7143   10.1224 1.3169   97.473 1.9746   . .   . 0   97.473   NI 
43 CEETOX no cat     2 1.022 4.0686   4.2727 1.2027   102.984 4.8927   . .   . 0   102.984   NI 
43 CEETOX no cat     3 1.01 6.3364   15.7591 5.7839   102.822 3.8741   . .   . 0   102.822   NI 
44 CEETOX no cat     1 1.0803 4.2089   5.7853 1.2081   101.728 14.237   . .   . 0   101.728   NI 
44 CEETOX no cat     2 0.9783 10.415   7.4957 0.5606   101.329 2.7661   . .   . 0   101.329   NI 
44 CEETOX no cat     3 0.9827 1.3599   9.7015 1.7119   98.287 4.9426   . .   . 0   98.287   NI 
45 CEETOX no cat     1 1.01 6.3364   15.7591 5.7839   96.881 4.1138   . .   . 0   96.881   NI 
45 CEETOX no cat     2 0.9935 6.2229   13.0683 3.082   90.102 3.0365   . .   . 0   90.102   NI 
45 CEETOX no cat     3 0.962 2.955   9.806 1.8214   98.233 5.6561   . .   . 0   98.233   NI 
46 CEETOX no cat Yes   1 1.062 4.7143   10.1224 1.3169   82.69 2.2867   . .   0.549 0.1438   82.141   NI 
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46 CEETOX no cat Yes   2 1.022 4.0686   4.2727 1.2027   102.038 4.1933   . .   0 0   102.038   NI 
46 CEETOX no cat Yes   3 1.01 6.3364   15.7591 5.7839   92.31 3.3846   . .   0 0   92.31   NI 
47 CEETOX no cat     1 1.01 6.3364   15.7591 5.7839   100.066 1.3861   . .   . 0   100.066   NI 
47 CEETOX no cat     2 0.9935 6.2229   13.0683 3.082   88.794 4.0964   . .   . 0   88.794   NI 
47 CEETOX no cat     3 1.0203 4.686   14.8808 2.8659   101.323 4.2981   . .   . 0   101.323   NI 
48 CEETOX no cat Yes   1 0.9935 6.2229   13.0683 3.082   37.292 8.707   . .   0 0   37.292   I 
48 CEETOX no cat Yes   2 1.0203 4.686   14.8808 2.8659   18.817 1.4573   . .   2.336 0.637   16.482   I 
48 CEETOX no cat Yes   3 0.9472 2.2448   15.344 2.6984   33.943 9.1642   . .   2.516 0.6863   31.427   I 
49 CEETOX no cat Yes   1 1.0203 4.686   14.8808 2.8659   102.172 6.4932   . .   0.011 0.0189   102.172   NI 
49 CEETOX no cat Yes   2 0.9472 2.2448   15.344 2.6984   114.288 6.8928   . .   0.012 0.0203   114.288   NI 
49 CEETOX no cat Yes   3 0.9055 5.6584   4.1598 0.7497   100.626 5.9619   . .   0.012 0.0213   100.626   NI 
50 CEETOX no cat     1 0.933 6.0005   9.6642 0.8844   95.105 3.5322   . .   . 0   95.105   NI 
50 CEETOX no cat     2 0.9425 4.0652   4.916 0.9039   88.912 3.4201   . .   . 0   88.912   NI 
50 CEETOX no cat     3 0.9652 5.0074   4.4552 0.9126   86.22 1.9205   . .   . 0   86.22   NI 
51 CEETOX no cat     1 1.0203 4.686   14.8808 2.8659   93.548 2.7237   . .   . 0   93.548   NI 
51 CEETOX no cat     2 0.9472 2.2448   15.344 2.6984   101.936 4.844   . .   . 0   101.936   NI 
51 CEETOX no cat     3 0.9055 5.6584   4.1598 0.7497   101.896 1.5621   . .   . 0   101.896   NI 
52 CEETOX no cat     1 0.933 6.0005   9.6642 0.8844   113.362 3.2346   . .   . 0   113.362   NI 
52 CEETOX no cat     2 0.9425 4.0652   4.916 0.9039   103.148 7.7354   . .   . 0   103.148   NI 
52 CEETOX no cat     3 0.9652 5.0074   4.4552 0.9126   105.06 4.0535   . .   . 0   105.06   NI 
53 CEETOX no cat     1 0.933 6.0005   9.6642 0.8844   102.036 7.9822   . .   . 0   102.036   NI 
53 CEETOX no cat     2 0.9425 4.0652   4.916 0.9039   94.147 5.5948   . .   . 0   94.147   NI 
53 CEETOX no cat     3 0.9652 5.0074   4.4552 0.9126   98.895 3.6268   . .   . 0   98.895   NI 
54 CEETOX cat 2B     1 0.962 4.611   22.9903 4.4348   86.902 6.9151   . .   . 0   86.902   NI 
54 CEETOX cat 2B     2 0.929 3.9191   29.0097 6.2734   82.921 4.1573   . .   . 0   82.921   NI 
54 CEETOX cat 2B     3 0.9467 4.8488   29.1021 9.2982   72.993 3.1714   . .   . 0   72.993   NI 
55 CEETOX cat 2B Yes   1 1.0737 1.4905   13.7069 3.6941   4.579 0.7068   . .   0 0   4.579   I 
55 CEETOX cat 2B Yes   2 1.1075 6.7453   13.9804 2.5428   4.424 0.2486   . .   0 0   4.424   I 
55 CEETOX cat 2B Yes   3 1.0803 4.2089   5.7853 1.2081   3.163 0.9564   . .   0 0   3.163   I 
56 CEETOX cat 2B Yes   1 1.0203 4.686   14.8808 2.8659   91.751 6.4633   . .   0.86 1.4901   91.751   NI 
56 CEETOX cat 2B Yes   2 0.9472 2.2448   15.344 2.6984   92.786 8.3754   . .   0.98 1.6966   92.786   NI 
56 CEETOX cat 2B Yes   3 0.9055 5.6584   4.1598 0.7497   85.514 8.5609   . .   0.81 1.4027   85.514   NI 
57 CEETOX cat 2B     1 1.0373 6.1774   21.4332 3.0371   39.589 4.1517   . .   . 0   39.589   I 
57 CEETOX cat 2B     2 1.1943 4.4215   6.2238 1.3201   33.352 1.7953   . .   . 0   33.352   I 
57 CEETOX cat 2B     3 1.0052 11.181   4.6427 0.4745   29.1 5.8378   . .   . 0   29.1   I 
58 CEETOX cat 2B Yes   1 0.9935 6.2229   13.0683 3.082   30.817 4.868   . .   0 0   30.817   I 
58 CEETOX cat 2B Yes   2 1.0203 4.686   14.8808 2.8659   31.999 1.3619   . .   0 0   31.999   I 
58 CEETOX cat 2B Yes   3 0.9472 2.2448   15.344 2.6984   34.594 5.6601   . .   0 0   34.594   I 
59 CEETOX cat 2B Yes   1 0.9935 6.2229   13.0683 3.082   89.096 3.7206   . .   0 0   89.096   NI 
59 CEETOX cat 2B Yes   2 0.9055 5.6584   4.1598 0.7497   86.49 2.6507   . .   0 0   86.49   NI 
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59 CEETOX cat 2B Yes   3 0.962 2.955   9.806 1.8214   91.632 4.3861   . .   0.133 0.2152   91.545   NI 
60 CEETOX cat 2B     1 1.0203 4.686   14.8808 2.8659   25.041 4.7602   . .   . 0   25.041   I 
60 CEETOX cat 2B     2 0.9472 2.2448   15.344 2.6984   36.6 3.7269   . .   . 0   36.6   I 
60 CEETOX cat 2B     3 0.9055 5.6584   4.1598 0.7497   39.849 6.216   . .   . 0   39.849   I 
61 CEETOX cat 2B     1 0.987 5.3233   31.5772 5.9588   90.003 6.2584   . .   . 0   90.003   NI 
61 CEETOX cat 2B     2 0.8937 5.0139   18.0716 3.251   84.502 0.5337   . .   . 0   84.502   NI 
61 CEETOX cat 2B     3 1.0388 7.2757   17.1346 4.4428   96.358 10.1   . .   . 0   96.358   NI 
62 CEETOX cat 2B     1 0.9935 6.2229   13.0683 3.082   91.662 7.0008   . .   . 0   91.662   NI 
62 CEETOX cat 2B     2 0.9055 5.6584   4.1598 0.7497   100.626 8.194   . .   . 0   100.626   NI 
62 CEETOX cat 2B     3 0.962 2.955   9.806 1.8214   98.77 3.1117   . .   . 0   98.77   NI 
63 CEETOX cat 2B     1 0.9935 6.2229   13.0683 3.082   89.23 2.4298   . .   . 0   89.23   NI 
63 CEETOX cat 2B     2 0.9055 5.6584   4.1598 0.7497   84.392 17.053   . .   . 0   84.392   NI 
63 CEETOX cat 2B     3 0.962 2.955   9.806 1.8214   100.641 9.0449   . .   . 0   100.641   NI 
64 CEETOX cat 2B     1 1.062 4.7143   10.1224 1.3169   84.338 0.7299   . .   . 0   84.338   NI 
64 CEETOX cat 2B     2 1.022 4.0686   4.2727 1.2027   94.08 4.6801   . .   . 0   94.08   NI 
64 CEETOX cat 2B     3 1.01 6.3364   15.7591 5.7839   94.043 6.417   . .   . 0   94.043   NI 
65 CEETOX cat 2B     1 0.9935 6.2229   13.0683 3.082   99.262 9.8788   . .   . 0   99.262   NI 
65 CEETOX cat 2B     2 0.9055 5.6584   4.1598 0.7497   106.35 5.4272   . .   . 0   106.35   NI 
65 CEETOX cat 2B     3 0.962 2.955   9.806 1.8214   103.361 2.2887   . .   . 0   103.361   NI 
66 CEETOX cat 2B     1 0.9935 6.2229   13.0683 3.082   80.674 2.4253   . .   . 0   80.674   NI 
66 CEETOX cat 2B     2 0.9055 5.6584   4.1598 0.7497   82.938 13.165   . .   . 0   82.938   NI 
66 CEETOX cat 2B     3 0.962 2.955   9.806 1.8214   84.685 2.6914   . .   . 0   84.685   NI 
67 CEETOX cat 2A     1 1.0298 1.4609   13.5297 3.9804   16.459 4.0131   . .   . 0   16.459   I 
67 CEETOX cat 2A     2 1.0467 1.2874   6.1306 0.4308   20.844 2.6813   . .   . 0   20.844   I 
67 CEETOX cat 2A     3 1.0643 12.666   3.2884 0.6509   33.683 5.035   . .   . 0   33.683   I 
68 CEETOX cat 2A*     1 1.0298 1.4609   13.5297 3.9804   4.58 0.4511   . .   . 0   4.58   I 
68 CEETOX cat 2A*     2 1.0467 1.2874   6.1306 0.4308   5.43 1.9229   . .   . 0   5.43   I 
68 CEETOX cat 2A*     3 1.0643 12.666   3.2884 0.6509   4.557 0.8801   . .   . 0   4.557   I 
69 CEETOX cat 2A*     1 0.987 5.3233   31.5772 5.9588   72.915 2.3595   . .   . 0   72.915   NI 
69 CEETOX cat 2A*     2 0.8937 5.0139   18.0716 3.251   58.187 7.3608   . .   . 0   58.187   NI 
69 CEETOX cat 2A*     3 1.0388 7.2757   17.1346 4.4428   63.838 7.6709   . .   . 0   63.838   NI 
70 CEETOX cat 2A     1 1.0373 6.1774   21.4332 3.0371   12.404 1.1211   . .   . 0   12.404   I 
70 CEETOX cat 2A     2 1.1943 4.4215   6.2238 1.3201   8.554 0.6298   . .   . 0   8.554   I 
70 CEETOX cat 2A     3 1.0052 11.181   4.6427 0.4745   5.72 0.8209   . .   . 0   5.72   I 
71 CEETOX cat 2A* Yes   1 1.0737 1.4905   13.7069 3.6941   4.735 1.1717   . .   0 0   4.735   I 
71 CEETOX cat 2A* Yes   2 1.1075 6.7453   13.9804 2.5428   5.388 1.3095   . .   0 0   5.388   I 
71 CEETOX cat 2A* Yes   3 1.0803 4.2089   5.7853 1.2081   4.243 0.9306   . .   0 0   4.243   I 
72 CEETOX cat 2A* Yes   1 0.9935 6.2229   13.0683 3.082   4.026 0.5544   . .   0 0   4.026   I 
72 CEETOX cat 2A* Yes   2 0.962 2.955   9.806 1.8214   3.915 0.2101   . .   0 0   3.915   I 
72 CEETOX cat 2A* Yes   3 0.9745 7.154   6.4135 1.4749   3.079 0.2236   . .   5.883 0.2136   0   I 
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73 CEETOX cat 2A*     1 1.0298 1.4609   13.5297 3.9804   65.464 4.6913   . .   . 0   65.464   NI 
73 CEETOX cat 2A*     2 1.0467 1.2874   6.1306 0.4308   47.596 4.9355   . .   . 0   47.596   I 
73 CEETOX cat 2A*     3 1.0643 12.666   3.2884 0.6509   35.656 5.5386   . .   . 0   35.656   I 
74 CEETOX cat 2A Yes   1 1.0945 5.8222   5.7865 0.6135   88.001 4.071   . .   0.117 0.1525   88.001   NI 
74 CEETOX cat 2A Yes   2 1.0692 5.1104   13.2502 3.2509   86.08 8.0847   . .   0.12 0.1561   86.08   NI 
74 CEETOX cat 2A Yes   3 1.0803 4.2089   5.7853 1.2081   25.208 4.4499   . .   3.548 0.5077   21.66   I 
75 CEETOX cat 2A     1 0.962 4.611   22.9903 4.4348   60.412 5.258   . .   . 0   60.412   NI 
75 CEETOX cat 2A     2 0.929 3.9191   29.0097 6.2734   64.442 9.0425   . .   . 0   64.442   NI 
75 CEETOX cat 2A     3 0.9467 4.8488   29.1021 9.2982   59.296 2.0017   . .   . 0   59.296   NI 
76 CEETOX cat 2A     1 1.062 4.7143   10.1224 1.3169   44.397 15.556   . .   . 0   44.397   I 
76 CEETOX cat 2A     2 1.022 4.0686   4.2727 1.2027   58.806 10.25   . .   . 0   58.806   NI 
76 CEETOX cat 2A     3 1.01 6.3364   15.7591 5.7839   75.627 5.2326   . .   . 0   75.627   NI 
77 CEETOX cat 2A     1 1.062 4.7143   10.1224 1.3169   49.749 4.6346   . .   . 0   49.749   I 
77 CEETOX cat 2A     2 1.022 4.0686   4.2727 1.2027   102.332 5.4269   . .   . 0   102.332   NI 
77 CEETOX cat 2A     3 1.01 6.3364   15.7591 5.7839   101.634 4.4001   . .   . 0   101.634   NI 
78 CEETOX cat 2A     1 1.062 4.7143   10.1224 1.3169   93.158 6.9012   . .   . 0   93.158   NI 
78 CEETOX cat 2A     2 1.022 4.0686   4.2727 1.2027   97.603 2.7109   . .   . 0   97.603   NI 
78 CEETOX cat 2A     3 1.01 6.3364   15.7591 5.7839   106.205 7.4845   . .   . 0   106.205   NI 
79 CEETOX cat 2A*     1 1.0803 4.2089   5.7853 1.2081   75.332 2.7213   . .   . 0   75.332   NI 
79 CEETOX cat 2A*     2 0.9783 10.415   7.4957 0.5606   81.38 3.0819   . .   . 0   81.38   NI 
79 CEETOX cat 2A*     3 0.9827 1.3599   9.7015 1.7119   88.382 7.4347   . .   . 0   88.382   NI 
80 CEETOX cat 1 Yes   1 1.0373 6.1774   21.4332 3.0371   29.9 1.5058   . .   34.769 2.4445   0   I 
80 CEETOX cat 1 Yes   2 1.1943 4.4215   6.2238 1.3201   26.263 3.3251   . .   30.198 2.1231   0.05   I 
80 CEETOX cat 1 Yes   3 1.0052 11.181   4.6427 0.4745   33.228 4.0675   . .   35.881 2.5227   0.68   I 
81 CEETOX cat 1 Yes   1 1.0298 1.4609   13.5297 3.9804   3.771 2.5014   . .   0.534 0.4665   3.237   I 
81 CEETOX cat 1 Yes   2 1.0467 1.2874   6.1306 0.4308   1.704 0.3344   . .   0.525 0.459   1.178   I 
81 CEETOX cat 1 Yes   3 1.0643 12.666   3.2884 0.6509   1.832 0.047   . .   0.517 0.4514   1.315   I 
82 CEETOX cat 1     1 0.9745 7.154   6.4135 1.4749   1.642 0.543   . .   . 0   1.642   I 
82 CEETOX cat 1     2 0.961 2.7115   6.0527 0.4834   0.902 0.2103   . .   . 0   0.902   I 
82 CEETOX cat 1     3 0.9597 3.8851   5.1059 1.2355   1.494 0.2388   . .   . 0   1.494   I 
83 CEETOX cat 1     1 0.987 5.3233   31.5772 5.9588   10.233 1.8753   . .   . 0   10.233   I 
83 CEETOX cat 1     2 0.8937 5.0139   18.0716 3.251   3.786 1.203   . .   . 0   3.786   I 
83 CEETOX cat 1     3 1.0388 7.2757   17.1346 4.4428   2.005 0.2206   . .   . 0   2.005   I 
84 CEETOX cat 1     1 0.962 2.955   9.806 1.8214   13.704 2.471   . .   . 0   13.704   I 
84 CEETOX cat 1     2 0.9745 7.154   6.4135 1.4749   10.091 0.6013   . .   . 0   10.091   I 
84 CEETOX cat 1     3 0.9425 4.0652   4.916 0.9039   2.034 0.3611   . .   . 0   2.034   I 
85 CEETOX cat 1     1 0.962 4.611   22.9903 4.4348   77.685 6.0936   . .   . 0   77.685   NI 
85 CEETOX cat 1     2 0.929 3.9191   29.0097 6.2734   90.133 1.7764   . .   . 0   90.133   NI 
85 CEETOX cat 1     3 0.9467 4.8488   29.1021 9.2982   79.736 2.6975   . .   . 0   79.736   NI 
86 CEETOX cat 1     1 0.961 2.7115   6.0527 0.4834   79.032 8.1917   . .   . 0   79.032   NI 
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86 CEETOX cat 1     2 0.933 6.0005   9.6642 0.8844   86.031 2.9163   . .   . 0   86.031   NI 
86 CEETOX cat 1     3 0.9652 5.0074   4.4552 0.9126   75.496 2.8619   . .   . 0   75.496   NI 
87 CEETOX cat 1     1 1.0373 6.1774   21.4332 3.0371   81.973 5.1766   . .   . 0   81.973   NI 
87 CEETOX cat 1     2 1.1943 4.4215   6.2238 1.3201   87.036 6.4852   . .   . 0   87.036   NI 
87 CEETOX cat 1     3 1.0052 11.181   4.6427 0.4745   31.902 2.8872   . .   . 0   31.902   I 
88 CEETOX cat 1 Yes   1 0.9745 7.154   6.4135 1.4749   5.952 2.774   . .   2.446 0.1649   3.506   I 
88 CEETOX cat 1 Yes   2 0.961 2.7115   6.0527 0.4834   8.29 2.7714   . .   0.486 0.1673   7.804   I 
88 CEETOX cat 1 Yes   3 0.9597 3.8851   5.1059 1.2355   4.672 0.8385   . .   1.667 0.1675   3.005   I 
89 CEETOX cat 1     1 1.0373 6.1774   21.4332 3.0371   66.308 1.467   . .   . 0   66.308   NI 
89 CEETOX cat 1     2 1.1943 4.4215   6.2238 1.3201   56.433 4.5137   . .   . 0   56.433   NI 
89 CEETOX cat 1     3 1.0052 11.181   4.6427 0.4745   16.697 1.693   . .   . 0   16.697   I 
90 CEETOX cat 1     1 1.0737 1.4905   13.7069 3.6941   79.292 7.9398   . .   . 0   79.292   NI 
90 CEETOX cat 1     2 1.0692 5.1104   13.2502 3.2509   82.541 6.4582   . .   . 0   82.541   NI 
90 CEETOX cat 1     3 1.0803 4.2089   5.7853 1.2081   64.579 5.417   . .   . 0   64.579   NI 
91 CEETOX cat 1 Yes   1 1.0737 1.4905   13.7069 3.6941   73.549 5.8708   . .   87.644 9.3139   0   I 
91 CEETOX cat 1 Yes   2 1.1075 6.7453   13.9804 2.5428   72.009 4.1564   . .   84.966 9.0294   0   I 
91 CEETOX cat 1 Yes   3 1.0803 4.2089   5.7853 1.2081   64.039 1.82   . .   87.103 9.2564   0   I 
92 CEETOX cat 1 Yes   1 0.933 6.0005   9.6642 0.8844   87.049 6.4445   . .   0.857 0.1072   86.191   NI 
92 CEETOX cat 1 Yes   2 0.9425 4.0652   4.916 0.9039   82.935 5.8363   . .   0.849 0.1061   82.087   NI 
92 CEETOX cat 1 Yes   3 0.9652 5.0074   4.4552 0.9126   77.327 5.6474   . .   0.622 0.1036   76.705   NI 
93 CEETOX cat 1     1 0.962 4.611   22.9903 4.4348   99.099 12.165   . .   . 0   99.099   NI 
93 CEETOX cat 1     2 0.929 3.9191   29.0097 6.2734   86.311 3.36   . .   . 0   86.311   NI 
93 CEETOX cat 1     3 0.9467 4.8488   29.1021 9.2982   90.282 5.4575   . .   . 0   90.282   NI 
94 CEETOX cat 1     1 1.0737 1.4905   13.7069 3.6941   52.546 1.2057   . .   . 0   52.546   NI 
94 CEETOX cat 1     2 1.0692 5.1104   13.2502 3.2509   74.606 6.6967   . .   . 0   74.606   NI 
94 CEETOX cat 1     3 1.0803 4.2089   5.7853 1.2081   54.613 8.2217   . .   . 0   54.613   NI 
95 CEETOX cat 1     1 0.987 5.3233   31.5772 5.9588   9.591 0.5066   . .   . 0   9.591   I 
95 CEETOX cat 1     2 0.8937 5.0139   18.0716 3.251   4.42 0.6996   . .   . 0   4.42   I 
95 CEETOX cat 1     3 1.0388 7.2757   17.1346 4.4428   16.958 4.3729   . .   . 0   16.958   I 
96 CEETOX cat 1     1 0.987 5.3233   31.5772 5.9588   101.013 13.472   . .   . 0   101.013   NI 
96 CEETOX cat 1     2 0.8937 5.0139   18.0716 3.251   98.844 8.903   . .   . 0   98.844   NI 
96 CEETOX cat 1     3 1.0388 7.2757   17.1346 4.4428   97.176 8.3087   . .   . 0   97.176   NI 
97 CEETOX cat 1     1 1.0298 1.4609   13.5297 3.9804   100.858 8.3212   . .   . 0   100.858   NI 
97 CEETOX cat 1     2 1.0467 1.2874   6.1306 0.4308   85.287 4.845   . .   . 0   85.287   NI 
97 CEETOX cat 1     3 1.0643 12.666   3.2884 0.6509   73.567 5.563   . .   . 0   73.567   NI 
98 CEETOX cat 1 Yes Yes 1 0.9745 7.154   6.4135 1.4749   99.555 4.1917   2.2405 0.427   20.079 14.127   77.236   NI 
98 CEETOX cat 1 Yes Yes 2 0.961 2.7115   6.0527 0.4834   100.364 5.8154   1.8557 0.433   18.262 14.326   80.246   NI 
98 CEETOX cat 1 Yes Yes 3 0.9425 4.0652   4.916 0.9039   88.665 2.8786   2.0159 0.652   18.621 14.607   68.028   NI 
99 CEETOX cat 1     1 1.0803 4.2089   5.7853 1.2081   7.93 3.7807   . .   . 0   7.93   I 
99 CEETOX cat 1     2 0.9783 10.415   7.4957 0.5606   2.606 0.3992   . .   . 0   2.606   I 
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99 CEETOX cat 1     3 0.9827 1.3599   9.7015 1.7119   13.67 2.5729   . .   . 0   13.67   I 
100 CEETOX cat 1     1 0.962 2.955   9.806 1.8214   44.404 11.157   . .   . 0   44.404   I 
100 CEETOX cat 1     2 0.9745 7.154   6.4135 1.4749   23.978 7.9548   . .   . 0   23.978   I 
100 CEETOX cat 1     3 0.961 2.7115   6.0527 0.4834   23.344 0.534   . .   . 0   23.344   I 
101 CEETOX cat 1     1 0.961 2.7115   6.0527 0.4834   84.929 7.9872   . .   . 0   84.929   NI 
101 CEETOX cat 1     2 0.933 6.0005   9.6642 0.8844   97.535 8.6294   . .   . 0   97.535   NI 
101 CEETOX cat 1     3 0.9652 5.0074   4.4552 0.9126   90.641 4.8994   . .   . 0   90.641   NI 
102 CEETOX cat 1     1 0.961 2.7115   6.0527 0.4834   98.144 11.429   . .   . 0   98.144   NI 
102 CEETOX cat 1     2 0.933 6.0005   9.6642 0.8844   102.733 5.0127   . .   . 0   102.733   NI 
102 CEETOX cat 1     3 0.9652 5.0074   4.4552 0.9126   97.772 4.8564   . .   . 0   97.772   NI 
103 CEETOX cat 1 Yes   1 1.062 4.7143   10.1224 1.3169   2.401 0.3063   . .   0.659 0.0815   1.742   I 
103 CEETOX cat 1 Yes   2 1.022 4.0686   4.2727 1.2027   5.235 0.3954   . .   0 0   5.235   I 
103 CEETOX cat 1 Yes   3 1.01 6.3364   15.7591 5.7839   5.594 0.2756   . .   0 0   5.594   I 
104 CEETOX cat 1 Yes   1 0.9827 1.3599   9.7015 1.7119   94.607 6.9748   . .   0 0   94.607   NI 
104 CEETOX cat 1 Yes   2 1.062 4.7143   10.1224 1.3169   82.847 3.1681   . .   0.989 0.5165   81.858   NI 
104 CEETOX cat 1 Yes   3 1.022 4.0686   4.2727 1.2027   90.46 7.2585   . .   0 0   90.46   NI 
105 CEETOX cat 1   Yes 1 0.9827 1.3599   9.7015 1.7119   6.954 0.4347   0.5597 0.206   . 0   6.394   I 
105 CEETOX cat 1   Yes 2 1.062 4.7143   10.1224 1.3169   6.026 1.1234   0.4551 0.082   . 0   5.571   I 
105 CEETOX cat 1   Yes 3 1.022 4.0686   4.2727 1.2027   5.887 0.3954   0.2283 0.185   . 0   5.659   I 
1 L'OREAL no cat Yes   1 1.0984 6.2426   10.0373 3.1479   83.884 3.9556   . .   0 0   83.884   NI 
1 L'OREAL no cat Yes   2 0.9895 8.2623   12.4962 0.7382   78.733 4.1519   . .   0 0   78.733   NI 
1 L'OREAL no cat Yes   3 1.1226 6.9506   7.1143 0.5129   82.899 2.5844   . .   0 0   82.899   NI 
2 L'OREAL no cat Yes   1 1.0714 5.8627   13.4695 6.1612   89.309 0.3494   . .   0 0   89.309   NI 
2 L'OREAL no cat Yes   2 1.0381 6.4191   29.1556 3.9327   94.087 5.4835   . .   0 0   94.087   NI 
2 L'OREAL no cat Yes   3 1.0069 11.957   16.5246 1.7463   96.363 3.3758   . .   0 0   96.363   NI 
3 L'OREAL no cat     1 1.0714 5.8627   13.4695 6.1612   80.867 4.995   . .   . 0   80.867   NI 
3 L'OREAL no cat     2 1.0069 11.957   16.5246 1.7463   87.188 8.0931   . .   . 0   87.188   NI 
3 L'OREAL no cat     3 1.062 3.9289   23.3122 2.3466   80.733 2.9814   . .   . 0   80.733   NI 
4 L'OREAL no cat Yes   1 0.9378 6.6852   10.5136 1.0684   109.936 6.1005   . .   97.771 4.6386   12.165   I 
4 L'OREAL no cat Yes   2 1.0796 2.8004   22.9833 3.7713   95.131 6.7051   . .   84.937 4.0297   10.194   I 
4 L'OREAL no cat Yes   3 0.9759 7.716   5.137 2.0706   91.36 15.53   . .   94.257 4.4575   4.046   I 
5 L'OREAL no cat Yes   1 1.0312 7.8231   19.1107 2.864   89.536 6.2483   . .   0.664 0.8588   88.958   NI 
5 L'OREAL no cat Yes   2 1.0434 3.8172   15.872 3.6247   89.713 10.446   . .   0.641 0.8396   89.165   NI 
5 L'OREAL no cat Yes   3 1.0381 6.4191   29.1556 3.9327   86.99 4.0985   . .   0.575 0.8059   86.542   NI 
6 L'OREAL no cat     1 1.0714 5.8627   13.4695 6.1612   107.535 6.6454   . .   . 0   107.535   NI 
6 L'OREAL no cat     2 1.0069 11.957   16.5246 1.7463   118.996 6.8327   . .   . 0   118.996   NI 
6 L'OREAL no cat     3 1.062 3.9289   23.3122 2.3466   111.776 3.2603   . .   . 0   111.776   NI 
7 L'OREAL no cat Yes   1 1.0714 5.8627   13.4695 6.1612   94.35 6.4871   . .   0 0   94.35   NI 
7 L'OREAL no cat Yes   2 1.0069 11.957   16.5246 1.7463   93.728 7.9472   . .   0 0   93.728   NI 
7 L'OREAL no cat Yes   3 0.9895 8.2623   12.4962 0.7382   87.014 10.102   . .   0 0   87.014   NI 
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8 L'OREAL no cat     1 1.0984 6.2426   10.0373 3.1479   102.575 6.0462   . .   . 0   102.575   NI 
8 L'OREAL no cat     2 1.1226 6.9506   7.1143 0.5129   104.311 5.1186   . .   . 0   104.311   NI 
8 L'OREAL no cat     3 0.9378 6.6852   10.5136 1.0684   105.555 6.1904   . .   . 0   105.555   NI 
9 L'OREAL no cat Yes   1 1.0312 7.8231   19.1107 2.864   95.442 6.0667   . .   0.2 0.1116   95.242   NI 
9 L'OREAL no cat Yes   2 1.0434 3.8172   15.872 3.6247   88.272 5.5605   . .   0.174 0.1103   88.098   NI 
9 L'OREAL no cat Yes   3 1.0381 6.4191   29.1556 3.9327   99.225 3.0594   . .   0.086 0.0911   99.152   NI 
10 L'OREAL no cat     1 1.054 3.814   16.0283 1.7483   33.831 8.0064   . .   . 0   33.831   I 
10 L'OREAL no cat     2 1.0116 6.9056   18.2308 1.401   26.668 10.422   . .   . 0   26.668   I 
10 L'OREAL no cat     3 1.1381 4.2836   22.3701 1.5167   31.592 10.389   . .   . 0   31.592   I 
11 L'OREAL no cat Yes   1 1.0312 7.8231   19.1107 2.864   76.499 2.4345   . .   0 0   76.499   NI 
11 L'OREAL no cat Yes   2 1.0434 3.8172   15.872 3.6247   76.687 4.4172   . .   0 0   76.687   NI 
11 L'OREAL no cat Yes   3 1.0381 6.4191   29.1556 3.9327   86.69 1.59   . .   0 0   86.69   NI 
12 L'OREAL no cat     1 1.1657 2.2252   14.1003 4.5157   84.012 2.2886   . .   . 0   84.012   NI 
12 L'OREAL no cat     2 1.0699 1.3117   7.9993 2.1576   91.829 5.6058   . .   . 0   91.829   NI 
12 L'OREAL no cat     3 1.0886 2.3885   13.0998 3.6209   93.686 7.3358   . .   . 0   93.686   NI 
13 L'OREAL no cat     1 1.1507 5.8417   10.5126 2.2159   97.985 7.3522   . .   . 0   97.985   NI 
13 L'OREAL no cat     2 1.0839 3.4473   11.3807 1.6156   93.98 4.1011   . .   . 0   93.98   NI 
13 L'OREAL no cat     3 1.0886 2.3885   13.0998 3.6209   94.041 4.6537   . .   . 0   94.041   NI 
14 L'OREAL no cat     1 1.0984 6.2426   10.0373 3.1479   88.863 2.9379   . .   . 0   88.863   NI 
14 L'OREAL no cat     2 1.1226 6.9506   7.1143 0.5129   89.318 4.9467   . .   . 0   89.318   NI 
14 L'OREAL no cat     3 1.1342 6.6464   7.7929 0.3475   84.668 5.8571   . .   . 0   84.668   NI 
15 L'OREAL no cat     1 1.1657 2.2252   14.1003 4.5157   83.947 3.681   . .   . 0   83.947   NI 
15 L'OREAL no cat     2 1.0839 3.4473   11.3807 1.6156   99.986 7.1608   . .   . 0   99.986   NI 
15 L'OREAL no cat     3 1.0886 2.3885   13.0998 3.6209   96.984 2.237   . .   . 0   96.984   NI 
16 L'OREAL no cat Yes   1 1.0312 7.8231   19.1107 2.864   99.053 4.6327   . .   0 0   99.053   NI 
16 L'OREAL no cat Yes   2 1.0434 3.8172   15.872 3.6247   107.495 10.205   . .   0 0   107.495   NI 
16 L'OREAL no cat Yes   3 1.0381 6.4191   29.1556 3.9327   109.614 2.3275   . .   0 0   109.614   NI 
17 L'OREAL no cat     1 1.0796 2.8004   22.9833 3.7713   101.477 3.4135   . .   . 0   101.477   NI 
17 L'OREAL no cat     2 1.0711 4.8318   18.988 2.0633   99.788 3.2822   . .   . 0   99.788   NI 
17 L'OREAL no cat     3 1.054 3.814   16.0283 1.7483   91.719 5.7436   . .   . 0   91.719   NI 
18 L'OREAL no cat     1 1.1657 2.2252   14.1003 4.5157   94.779 4.4616   . .   . 0   94.779   NI 
18 L'OREAL no cat     2 1.0839 3.4473   11.3807 1.6156   103.584 3.278   . .   . 0   103.584   NI 
18 L'OREAL no cat     3 1.0886 2.3885   13.0998 3.6209   102.575 2.4754   . .   . 0   102.575   NI 
19 L'OREAL no cat     1 1.1657 2.2252   14.1003 4.5157   94.942 2.9532   . .   . 0   94.942   NI 
19 L'OREAL no cat     2 1.0699 1.3117   7.9993 2.1576   102.123 4.2152   . .   . 0   102.123   NI 
19 L'OREAL no cat     3 1.0886 2.3885   13.0998 3.6209   101.162 7.4486   . .   . 0   101.162   NI 
20 L'OREAL no cat Yes   1 1.1657 2.2252   14.1003 4.5157   90.072 13.35   . .   33.864 5.9876   56.208   NI 
20 L'OREAL no cat Yes   2 1.0699 1.3117   7.9993 2.1576   91.691 23.903 NQ . .   37.021 6.5239   54.67 NQ NI 
20 L'OREAL no cat Yes   3 1.0151 10.577   10.1356 2.2709   84.5 16.983   . .   38.896 6.8762   45.605   I 
20 L'OREAL no cat Yes   4 1.0886 2.3885   13.0998 3.6209   67.246 22.275 NQ . .   36.187 6.4119   31.059 NQ I 
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20 L'OREAL no cat Yes   5 1.0775 4.8828   7.542 1.545   77.926 14.643   . .   36.635 6.4777   41.291   I 
21 L'OREAL no cat Yes   1 1.054 3.814   16.0283 1.7483   83.815 13.003   . .   0.191 0.0457   83.624   NI 
21 L'OREAL no cat Yes   2 1.0116 6.9056   18.2308 1.401   86.836 2.9332   . .   0.209 0.0477   86.626   NI 
21 L'OREAL no cat Yes   3 1.0525 12.287   12.4424 1.9531   87.333 2.877   . .   0.217 0.0458   87.116   NI 
22 L'OREAL no cat     1 1.0116 6.9056   18.2308 1.401   87.63 6.1188   . .   . 0   87.63   NI 
22 L'OREAL no cat     2 1.0572 3.0636   22.3841 2.3749   56.048 1.7457   . .   . 0   56.048   NI 
22 L'OREAL no cat     3 1.1011 8.6438   10.2576 1.8071   62.478 11.7   . .   . 0   62.478   NI 
23 L'OREAL no cat Yes   1 0.9104 3.4928   11.7281 1.7263   35.025 2.669   . .   35.926 2.2777   0.651   I 
23 L'OREAL no cat Yes   2 1.2025 4.9661   15.5048 2.8848   26.146 4.5367   . .   27.165 1.7243   1.259   I 
23 L'OREAL no cat Yes   3 1.1119 11.947   12.3524 3.4802   29.988 1.4163   . .   28.338 1.8648   1.65   I 
24 L'OREAL no cat Yes   1 1.1381 4.2836   22.3701 1.5167   71.888 6.9645   . .   0.07 0.1218   71.888   NI 
24 L'OREAL no cat Yes   2 1.1842 4.5251   10.6102 2.3635   66.601 3.7353   . .   0.092 0.1601   66.549   NI 
24 L'OREAL no cat Yes   3 1.1528 5.5368   18.3909 5.9045   66.558 3.2551   . .   0.085 0.1469   66.535   NI 
25 L'OREAL no cat Yes   1 1.13 3.7783   3.5811 2.501   86.555 2.8489   . .   0 0   86.555   NI 
25 L'OREAL no cat Yes   2 1.0699 1.3117   7.9993 2.1576   98.977 5.2493   . .   0 0   98.977   NI 
25 L'OREAL no cat Yes   3 1.0886 2.3885   13.0998 3.6209   95.404 4.3855   . .   0 0   95.404   NI 
26 L'OREAL no cat     1 1.13 3.7783   3.5811 2.501   87.513 3.861   . .   . 0   87.513   NI 
26 L'OREAL no cat     2 1.0151 10.577   10.1356 2.2709   93.94 11.702   . .   . 0   93.94   NI 
26 L'OREAL no cat     3 1.0775 4.8828   7.542 1.545   101.579 4.5672   . .   . 0   101.579   NI 
28 L'OREAL no cat     1 1.0714 5.8627   13.4695 6.1612   97.961 6.7204   . .   . 0   97.961   NI 
28 L'OREAL no cat     2 1.0069 11.957   16.5246 1.7463   100.909 6.1952   . .   . 0   100.909   NI 
28 L'OREAL no cat     3 1.062 3.9289   23.3122 2.3466   95.516 0.4666   . .   . 0   95.516   NI 
29 L'OREAL no cat     1 1.1657 2.2252   14.1003 4.5157   90.795 5.7409   . .   . 0   90.795   NI 
29 L'OREAL no cat     2 1.0151 10.577   10.1356 2.2709   90.487 4.5973   . .   . 0   90.487   NI 
29 L'OREAL no cat     3 1.0886 2.3885   13.0998 3.6209   91.097 3.5566   . .   . 0   91.097   NI 
30 L'OREAL no cat     1 0.9104 3.4928   11.7281 1.7263   96.305 5.4845   . .   . 0   96.305   NI 
30 L'OREAL no cat     2 1.1528 5.5368   18.3909 5.9045   85.122 7.1817   . .   . 0   85.122   NI 
30 L'OREAL no cat     3 1.2025 4.9661   15.5048 2.8848   85.949 3.617   . .   . 0   85.949   NI 
31 L'OREAL no cat     1 0.9104 3.4928   11.7281 1.7263   95.873 6.0786   . .   . 0   95.873   NI 
31 L'OREAL no cat     2 1.1842 4.5251   10.6102 2.3635   96.608 5.2356   . .   . 0   96.608   NI 
31 L'OREAL no cat     3 1.1528 5.5368   18.3909 5.9045   88.655 2.7941   . .   . 0   88.655   NI 
32 L'OREAL no cat Yes Yes 1 1.0796 2.8004   22.9833 3.7713   64.791 0.609   0.704 0.195   32.407 9.0174   31.68   I 
32 L'OREAL no cat Yes Yes 2 0.9759 7.716   5.137 2.0706   58.163 10.819   1.9247 0.612   36.21 9.9748   20.029   I 
32 L'OREAL no cat Yes Yes 3 1.0711 4.8318   18.988 2.0633   53.682 3.7176   1.4595 0.077   32.647 9.0767   19.576   I 
33 L'OREAL no cat Yes Yes 1 1.0116 6.9056   18.2308 1.401   92.757 6.609   1.1121 0.315   0.503 0.0897   91.142   NI 
33 L'OREAL no cat Yes Yes 2 1.1381 4.2836   22.3701 1.5167   85.68 2.6537   0.8875 0.169   0.523 0.0797   84.27   NI 
33 L'OREAL no cat Yes Yes 3 1.0525 12.287   12.4424 1.9531   100.169 5.7993   1.0452 0.237   0.565 0.0862   98.559   NI 
34 L'OREAL no cat Yes Yes 1 1.0116 6.9056   18.2308 1.401   128.461 7.4773   3.5901 0.405   4.697 0.1338   120.173   NI 
34 L'OREAL no cat Yes Yes 2 1.1381 4.2836   22.3701 1.5167   110.206 7.0392   2.7855 0.075   4.186 0.1189   103.235   NI 
34 L'OREAL no cat Yes Yes 3 1.0525 12.287   12.4424 1.9531   109.902 2.1476   2.7301 0.463   4.526 0.1286   102.646   NI 
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35 L'OREAL no cat Yes   1 1.0984 6.2426   10.0373 3.1479   40.476 14.543   . .   11.699 7.7253   28.777   I 
35 L'OREAL no cat Yes   2 1.1226 6.9506   7.1143 0.5129   27.801 1.0372   . .   11.69 7.5586   16.111   I 
35 L'OREAL no cat Yes   3 1.1342 6.6464   7.7929 0.3475   44.22 12.207   . .   11.514 7.4818   32.706   I 
36 L'OREAL no cat     1 1.0312 7.8231   19.1107 2.864   96.533 0.934   . .   . 0   96.533   NI 
36 L'OREAL no cat     2 1.0434 3.8172   15.872 3.6247   92.502 5.1353   . .   . 0   92.502   NI 
36 L'OREAL no cat     3 1.1342 6.6464   7.7929 0.3475   92.566 2.983   . .   . 0   92.566   NI 
37 L'OREAL no cat     1 1.0572 3.0636   22.3841 2.3749   86 5.4976   . .   . 0   86   NI 
37 L'OREAL no cat     2 1.1011 8.6438   10.2576 1.8071   85.012 9.1275   . .   . 0   85.012   NI 
37 L'OREAL no cat     3 1.1842 4.5251   10.6102 2.3635   86.419 4.4792   . .   . 0   86.419   NI 
38 L'OREAL no cat     1 1.1657 2.2252   14.1003 4.5157   89.168 7.214   . .   . 0   89.168   NI 
38 L'OREAL no cat     2 1.0699 1.3117   7.9993 2.1576   99.752 4.5226   . .   . 0   99.752   NI 
38 L'OREAL no cat     3 1.0886 2.3885   13.0998 3.6209   93.919 7.3003   . .   . 0   93.919   NI 
39 L'OREAL no cat     1 1.1657 2.2252   14.1003 4.5157   94.404 3.6505   . .   . 0   94.404   NI 
39 L'OREAL no cat     2 1.0699 1.3117   7.9993 2.1576   93.241 6.2094   . .   . 0   93.241   NI 
39 L'OREAL no cat     3 1.0886 2.3885   13.0998 3.6209   104.481 4.4225   . .   . 0   104.481   NI 
40 L'OREAL no cat     1 1.1507 5.8417   10.5126 2.2159   78.801 12.385   . .   . 0   78.801   NI 
40 L'OREAL no cat     2 1.13 3.7783   3.5811 2.501   77.304 8.3865   . .   . 0   77.304   NI 
40 L'OREAL no cat     3 1.0886 2.3885   13.0998 3.6209   99.969 6.4781   . .   . 0   99.969   NI 
41 L'OREAL no cat     1 1.0572 3.0636   22.3841 2.3749   91.124 9.1357   . .   . 0   91.124   NI 
41 L'OREAL no cat     2 1.1011 8.6438   10.2576 1.8071   101.028 5.2708   . .   . 0   101.028   NI 
41 L'OREAL no cat     3 1.0525 12.287   12.4424 1.9531   96.139 11.391   . .   . 0   96.139   NI 
42 L'OREAL no cat Yes   1 1.0572 3.0636   22.3841 2.3749   78.587 1.9679   . .   0.018 0.0162   78.587   NI 
42 L'OREAL no cat Yes   2 1.1011 8.6438   10.2576 1.8071   100.18 3.066   . .   0.091 0.0788   100.101   NI 
42 L'OREAL no cat Yes   3 1.0525 12.287   12.4424 1.9531   96.491 9.788   . .   0.059 0.0514   96.462   NI 
43 L'OREAL no cat     1 1.1011 8.6438   10.2576 1.8071   98.897 5.2429   . .   . 0   98.897   NI 
43 L'OREAL no cat     2 0.9104 3.4928   11.7281 1.7263   102.353 1.4535   . .   . 0   102.353   NI 
43 L'OREAL no cat     3 1.1842 4.5251   10.6102 2.3635   94.002 4.4696   . .   . 0   94.002   NI 
44 L'OREAL no cat     1 1.0572 3.0636   22.3841 2.3749   97.421 9.8347   . .   . 0   97.421   NI 
44 L'OREAL no cat     2 1.1011 8.6438   10.2576 1.8071   100.224 4.8996   . .   . 0   100.224   NI 
44 L'OREAL no cat     3 1.1842 4.5251   10.6102 2.3635   93.435 6.972   . .   . 0   93.435   NI 
45 L'OREAL no cat     1 1.0572 3.0636   22.3841 2.3749   83.055 17.169   . .   . 0   83.055   NI 
45 L'OREAL no cat     2 1.1011 8.6438   10.2576 1.8071   93.065 5.3908   . .   . 0   93.065   NI 
45 L'OREAL no cat     3 1.0525 12.287   12.4424 1.9531   96.481 4.2385   . .   . 0   96.481   NI 
46 L'OREAL no cat     1 1.1011 8.6438   10.2576 1.8071   84.188 4.1097   . .   . 0   84.188   NI 
46 L'OREAL no cat     2 0.9104 3.4928   11.7281 1.7263   93.178 11.114   . .   . 0   93.178   NI 
46 L'OREAL no cat     3 1.1842 4.5251   10.6102 2.3635   82.178 10.68   . .   . 0   82.178   NI 
47 L'OREAL no cat     1 1.0572 3.0636   22.3841 2.3749   92.994 8.2059   . .   . 0   92.994   NI 
47 L'OREAL no cat     2 1.1011 8.6438   10.2576 1.8071   85.395 7.5384   . .   . 0   85.395   NI 
47 L'OREAL no cat     3 1.1842 4.5251   10.6102 2.3635   95.92 2.1998   . .   . 0   95.92   NI 
48 L'OREAL no cat     1 0.9104 3.4928   11.7281 1.7263   37.672 1.3768   . .   . 0   37.672   I 
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48 L'OREAL no cat     2 1.1528 5.5368   18.3909 5.9045   34.986 9.8848   . .   . 0   34.986   I 
48 L'OREAL no cat     3 1.2025 4.9661   15.5048 2.8848   45.487 6.6064   . .   . 0   45.487   I 
49 L'OREAL no cat Yes   1 1.13 3.7783   3.5811 2.501   95.54 4.7689   . .   0 0   95.54   NI 
49 L'OREAL no cat Yes   2 1.0699 1.3117   7.9993 2.1576   99.966 2.8576   . .   0 0   99.966   NI 
49 L'OREAL no cat Yes   3 1.0775 4.8828   7.542 1.545   104.942 6.7551   . .   0 0   104.942   NI 
50 L'OREAL no cat     1 1.13 3.7783   3.5811 2.501   85.763 1.7401   . .   . 0   85.763   NI 
50 L'OREAL no cat     2 1.0151 10.577   10.1356 2.2709   91.006 7.1958   . .   . 0   91.006   NI 
50 L'OREAL no cat     3 1.0886 2.3885   13.0998 3.6209   96.659 4.2045   . .   . 0   96.659   NI 
51 L'OREAL no cat     1 1.13 3.7783   3.5811 2.501   85.82 2.1741   . .   . 0   85.82   NI 
51 L'OREAL no cat     2 1.0151 10.577   10.1356 2.2709   94.291 4.8561   . .   . 0   94.291   NI 
51 L'OREAL no cat     3 1.0886 2.3885   13.0998 3.6209   103.479 4.2837   . .   . 0   103.479   NI 
52 L'OREAL no cat     1 1.13 3.7783   3.5811 2.501   97.931 8.0403   . .   . 0   97.931   NI 
52 L'OREAL no cat     2 1.0151 10.577   10.1356 2.2709   104.011 5.393   . .   . 0   104.011   NI 
52 L'OREAL no cat     3 1.0886 2.3885   13.0998 3.6209   87.771 7.7624   . .   . 0   87.771   NI 
53 L'OREAL no cat     1 1.13 3.7783   3.5811 2.501   97.499 3.3428   . .   . 0   97.499   NI 
53 L'OREAL no cat     2 1.0151 10.577   10.1356 2.2709   92.009 1.055   . .   . 0   92.009   NI 
53 L'OREAL no cat     3 1.0775 4.8828   7.542 1.545   96.546 4.645   . .   . 0   96.546   NI 
54 L'OREAL cat 2B     1 1.0984 6.2426   10.0373 3.1479   76.698 2.154   . .   . 0   76.698   NI 
54 L'OREAL cat 2B     2 1.1226 6.9506   7.1143 0.5129   71.114 10.373   . .   . 0   71.114   NI 
54 L'OREAL cat 2B     3 1.1342 6.6464   7.7929 0.3475   43.178 9.6577   . .   . 0   43.178   I 
55 L'OREAL cat 2B Yes   1 1.1381 4.2836   22.3701 1.5167   2.242 0.2234   . .   0.017 0.0287   2.242   I 
55 L'OREAL cat 2B Yes   2 1.1528 5.5368   18.3909 5.9045   1.258 0.2918   . .   0 0   1.258   I 
55 L'OREAL cat 2B Yes   3 1.2025 4.9661   15.5048 2.8848   1.408 0.353   . .   0.025 0.0432   1.408   I 
56 L'OREAL cat 2B     1 1.1381 4.2836   22.3701 1.5167   71.561 13.63   . .   . 0   71.561   NI 
56 L'OREAL cat 2B     2 1.1528 5.5368   18.3909 5.9045   73.694 7.1339   . .   . 0   73.694   NI 
56 L'OREAL cat 2B     3 1.2025 4.9661   15.5048 2.8848   68.033 6.7306   . .   . 0   68.033   NI 
57 L'OREAL cat 2B     1 1.0116 6.9056   18.2308 1.401   32.761 2.0249   . .   . 0   32.761   I 
57 L'OREAL cat 2B     2 1.1381 4.2836   22.3701 1.5167   36.866 9.0975   . .   . 0   36.866   I 
57 L'OREAL cat 2B     3 1.2025 4.9661   15.5048 2.8848   10.841 0.4724   . .   . 0   10.841   I 
58 L'OREAL cat 2B Yes   1 1.1381 4.2836   22.3701 1.5167   12.283 10.054   . .   0 0   12.283   I 
58 L'OREAL cat 2B Yes   2 1.1842 4.5251   10.6102 2.3635   22.044 9.3965   . .   0 0   22.044   I 
58 L'OREAL cat 2B Yes   3 1.1528 5.5368   18.3909 5.9045   13.577 3.3783   . .   0 0   13.577   I 
59 L'OREAL cat 2B Yes   1 0.9104 3.4928   11.7281 1.7263   66.956 10.188   . .   0 0   66.956   NI 
59 L'OREAL cat 2B Yes   2 1.1528 5.5368   18.3909 5.9045   77.813 4.1308   . .   0 0   77.813   NI 
59 L'OREAL cat 2B Yes   3 1.2025 4.9661   15.5048 2.8848   66.406 5.1893   . .   0 0   66.406   NI 
60 L'OREAL cat 2B     1 1.1657 2.2252   14.1003 4.5157   17.698 5.1189   . .   . 0   17.698   I 
60 L'OREAL cat 2B     2 1.0151 10.577   10.1356 2.2709   25.514 2.9665   . .   . 0   25.514   I 
60 L'OREAL cat 2B     3 1.0886 2.3885   13.0998 3.6209   20.356 5.2293   . .   . 0   20.356   I 
61 L'OREAL cat 2B   Yes 1 1.0312 7.8231   19.1107 2.864   83.223 4.7391   0.2974 0.151   . 0   82.926   NI 
61 L'OREAL cat 2B   Yes 2 1.0434 3.8172   15.872 3.6247   90.197 7.1552   0.0527 0.091   . 0   90.144   NI 
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61 L'OREAL cat 2B   Yes 3 1.062 3.9289   23.3122 2.3466   87.526 1.1488   0.3719 0.122   . 0   87.154   NI 
62 L'OREAL cat 2B     1 1.1011 8.6438   10.2576 1.8071   94.846 6.6608   . .   . 0   94.846   NI 
62 L'OREAL cat 2B     2 1.1842 4.5251   10.6102 2.3635   84.686 1.2626   . .   . 0   84.686   NI 
62 L'OREAL cat 2B     3 1.1528 5.5368   18.3909 5.9045   95.739 3.5673   . .   . 0   95.739   NI 
63 L'OREAL cat 2B     1 0.9104 3.4928   11.7281 1.7263   98.704 2.393   . .   . 0   98.704   NI 
63 L'OREAL cat 2B     2 1.1528 5.5368   18.3909 5.9045   84.754 1.2674   . .   . 0   84.754   NI 
63 L'OREAL cat 2B     3 1.2025 4.9661   15.5048 2.8848   106.136 5.0759   . .   . 0   106.136   NI 
64 L'OREAL cat 2B     1 1.054 3.814   16.0283 1.7483   86.556 2.774   . .   . 0   86.556   NI 
64 L'OREAL cat 2B     2 1.0116 6.9056   18.2308 1.401   97.435 1.2197   . .   . 0   97.435   NI 
64 L'OREAL cat 2B     3 1.1011 8.6438   10.2576 1.8071   101.645 8.2815   . .   . 0   101.645   NI 
65 L'OREAL cat 2B     1 0.9104 3.4928   11.7281 1.7263   95.293 4.1005   . .   . 0   95.293   NI 
65 L'OREAL cat 2B     2 1.2025 4.9661   15.5048 2.8848   93.189 3.339   . .   . 0   93.189   NI 
65 L'OREAL cat 2B     3 1.1119 11.947   12.3524 3.4802   95.267 4.1656   . .   . 0   95.267   NI 
66 L'OREAL cat 2B     1 0.9104 3.4928   11.7281 1.7263   80.894 0.8714   . .   . 0   80.894   NI 
66 L'OREAL cat 2B     2 1.1842 4.5251   10.6102 2.3635   84.41 5.8328   . .   . 0   84.41   NI 
66 L'OREAL cat 2B     3 1.1528 5.5368   18.3909 5.9045   79.478 2.8162   . .   . 0   79.478   NI 
67 L'OREAL cat 2A Yes   1 1.0714 5.8627   13.4695 6.1612   15.711 2.6862   . .   0 0   15.711   I 
67 L'OREAL cat 2A Yes   2 1.0069 11.957   16.5246 1.7463   2.509 0.8883   . .   0 0   2.509   I 
67 L'OREAL cat 2A Yes   3 0.9895 8.2623   12.4962 0.7382   8.098 1.0784   . .   0.018 0.0311   8.098   I 
68 L'OREAL cat 2A*     1 1.0714 5.8627   13.4695 6.1612   5.241 0.1331   . .   . 0   5.241   I 
68 L'OREAL cat 2A*     2 1.0069 11.957   16.5246 1.7463   0.7 0.1294   . .   . 0   0.7   I 
68 L'OREAL cat 2A*     3 1.062 3.9289   23.3122 2.3466   6.166 0.3488   . .   . 0   6.166   I 
69 L'OREAL cat 2A*     1 1.0312 7.8231   19.1107 2.864   64.953 6.0409   . .   . 0   64.953   NI 
69 L'OREAL cat 2A*     2 1.0434 3.8172   15.872 3.6247   76.012 2.818   . .   . 0   76.012   NI 
69 L'OREAL cat 2A*     3 1.062 3.9289   23.3122 2.3466   58.066 5.4003   . .   . 0   58.066   NI 
70 L'OREAL cat 2A     1 1.1381 4.2836   22.3701 1.5167   17.852 3.4889   . .   . 0   17.852   I 
70 L'OREAL cat 2A     2 1.1528 5.5368   18.3909 5.9045   15.784 1.0041   . .   . 0   15.784   I 
70 L'OREAL cat 2A     3 1.2025 4.9661   15.5048 2.8848   9.919 1.3042   . .   . 0   9.919   I 
71 L'OREAL cat 2A* Yes   1 1.0711 4.8318   18.988 2.0633   4.984 3.7342   . .   0 0   4.984   I 
71 L'OREAL cat 2A* Yes   2 1.054 3.814   16.0283 1.7483   7.434 2.2329   . .   0.102 0.1136   7.375   I 
71 L'OREAL cat 2A* Yes   3 1.0525 12.287   12.4424 1.9531   5.258 1.5095   . .   0.119 0.1255   5.174   I 
72 L'OREAL cat 2A* Yes   1 0.9104 3.4928   11.7281 1.7263   5.22 0.7859   . .   3.07 2.9811   2.149   I 
72 L'OREAL cat 2A* Yes   2 1.2025 4.9661   15.5048 2.8848   4.791 0.3088   . .   2.294 2.2568   2.498   I 
72 L'OREAL cat 2A* Yes   3 1.1119 11.947   12.3524 3.4802   6.579 2.4369   . .   1.498 2.3831   5.14   I 
73 L'OREAL cat 2A*     1 1.0069 11.957   16.5246 1.7463   105.519 7.1159   . .   . 0   105.519   NI 
73 L'OREAL cat 2A*     2 1.1342 6.6464   7.7929 0.3475   78.839 2.5109   . .   . 0   78.839   NI 
73 L'OREAL cat 2A*     3 0.9378 6.6852   10.5136 1.0684   88.916 8.3904   . .   . 0   88.916   NI 
74 L'OREAL cat 2A Yes Yes 1 1.0984 6.2426   10.0373 3.1479   88.938 4.0111   1.1668 1.355   1.22 0.1917   86.552   NI 
74 L'OREAL cat 2A Yes Yes 2 1.1226 6.9506   7.1143 0.5129   89.817 4.4035   0.533 0.125   1.461 0.1876   87.823   NI 
74 L'OREAL cat 2A Yes Yes 3 0.9759 7.716   5.137 2.0706   92.404 3.1866   0.2271 0.111   1.988 0.2158   90.189   NI 
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75 L'OREAL cat 2A     1 1.0312 7.8231   19.1107 2.864   32.679 27.365 NQ . .   . 0   32.679 NQ I 
75 L'OREAL cat 2A     2 1.0434 3.8172   15.872 3.6247   24.707 39.171 NQ . .   . 0   24.707 NQ I 
75 L'OREAL cat 2A     3 1.0714 5.8627   13.4695 6.1612   13.477 9.6748   . .   . 0   13.477   I 
75 L'OREAL cat 2A     4 1.062 3.9289   23.3122 2.3466   14.162 3.9196   . .   . 0   14.162   I 
75 L'OREAL cat 2A     5 1.1342 6.6464   7.7929 0.3475   12.354 2.7362   . .   . 0   12.354   I 
76 L'OREAL cat 2A     1 0.9378 6.6852   10.5136 1.0684   65.68 11.069   . .   . 0   65.68   NI 
76 L'OREAL cat 2A     2 1.0796 2.8004   22.9833 3.7713   53.811 3.444   . .   . 0   53.811   NI 
76 L'OREAL cat 2A     3 1.0711 4.8318   18.988 2.0633   60.588 7.5801   . .   . 0   60.588   NI 
77 L'OREAL cat 2A     1 1.0711 4.8318   18.988 2.0633   98.805 4.4425   . .   . 0   98.805   NI 
77 L'OREAL cat 2A     2 1.054 3.814   16.0283 1.7483   95.696 4.0743   . .   . 0   95.696   NI 
77 L'OREAL cat 2A     3 1.0116 6.9056   18.2308 1.401   97.929 3.7123   . .   . 0   97.929   NI 
78 L'OREAL cat 2A     1 1.0796 2.8004   22.9833 3.7713   93.38 3.5729   . .   . 0   93.38   NI 
78 L'OREAL cat 2A     2 1.0711 4.8318   18.988 2.0633   91.097 3.7193   . .   . 0   91.097   NI 
78 L'OREAL cat 2A     3 1.054 3.814   16.0283 1.7483   89.321 1.3172   . .   . 0   89.321   NI 
79 L'OREAL cat 2A*     1 0.9104 3.4928   11.7281 1.7263   87.21 7.9302   . .   . 0   87.21   NI 
79 L'OREAL cat 2A*     2 1.2025 4.9661   15.5048 2.8848   75.65 5.3726   . .   . 0   75.65   NI 
79 L'OREAL cat 2A*     3 1.1119 11.947   12.3524 3.4802   88.361 4.7695   . .   . 0   88.361   NI 
80 L'OREAL cat 1 Yes   1 1.0312 7.8231   19.1107 2.864   25.876 4.7809   . .   35.681 4.024   0   I 
80 L'OREAL cat 1 Yes   2 1.0434 3.8172   15.872 3.6247   30.442 3.9044   . .   35.265 3.977   0   I 
80 L'OREAL cat 1 Yes   3 1.0381 6.4191   29.1556 3.9327   29.323 0.591   . .   35.445 3.9973   0   I 
81 L'OREAL cat 1     1 1.0984 6.2426   10.0373 3.1479   0.587 0.1202   . .   . 0   0.587   I 
81 L'OREAL cat 1     2 1.1226 6.9506   7.1143 0.5129   0.966 0.2649   . .   . 0   0.966   I 
81 L'OREAL cat 1     3 1.1342 6.6464   7.7929 0.3475   0.654 0.0511   . .   . 0   0.654   I 
82 L'OREAL cat 1     1 1.1657 2.2252   14.1003 4.5157   6.318 1.1729   . .   . 0   6.318   I 
82 L'OREAL cat 1     2 1.0699 1.3117   7.9993 2.1576   4.412 0.5134   . .   . 0   4.412   I 
82 L'OREAL cat 1     3 1.0886 2.3885   13.0998 3.6209   3.724 1.2376   . .   . 0   3.724   I 
83 L'OREAL cat 1 Yes   1 1.0984 6.2426   10.0373 3.1479   2.968 1.4839   . .   0 0   2.968   I 
83 L'OREAL cat 1 Yes   2 0.9895 8.2623   12.4962 0.7382   2.946 0.091   . .   0 0   2.946   I 
83 L'OREAL cat 1 Yes   3 1.1226 6.9506   7.1143 0.5129   1.777 0.0379   . .   0.019 0.0326   1.777   I 
84 L'OREAL cat 1     1 1.1507 5.8417   10.5126 2.2159   17.469 5.7766   . .   . 0   17.469   I 
84 L'OREAL cat 1     2 1.0839 3.4473   11.3807 1.6156   26.008 6.0469   . .   . 0   26.008   I 
84 L'OREAL cat 1     3 1.0886 2.3885   13.0998 3.6209   17.443 3.4609   . .   . 0   17.443   I 
85 L'OREAL cat 1     1 1.0312 7.8231   19.1107 2.864   65.553 17.15   . .   . 0   65.553   NI 
85 L'OREAL cat 1     2 1.0434 3.8172   15.872 3.6247   64.576 7.4549   . .   . 0   64.576   NI 
85 L'OREAL cat 1     3 1.062 3.9289   23.3122 2.3466   80.66 5.9342   . .   . 0   80.66   NI 
86 L'OREAL cat 1     1 1.1507 5.8417   10.5126 2.2159   89.358 8.1023   . .   . 0   89.358   NI 
86 L'OREAL cat 1     2 1.0839 3.4473   11.3807 1.6156   84.85 7.839   . .   . 0   84.85   NI 
86 L'OREAL cat 1     3 1.0151 10.577   10.1356 2.2709   87.973 5.6462   . .   . 0   87.973   NI 
87 L'OREAL cat 1 Yes   1 1.0714 5.8627   13.4695 6.1612   83.601 6.97   . .   0.273 0.4724   83.601   NI 
87 L'OREAL cat 1 Yes   2 1.0069 11.957   16.5246 1.7463   98.135 7.1749   . .   0.188 0.3259   98.135   NI 
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87 L'OREAL cat 1 Yes   3 0.9895 8.2623   12.4962 0.7382   88.024 4.4284   . .   0.405 0.6338   87.849   NI 
88 L'OREAL cat 1 Yes   1 1.1507 5.8417   10.5126 2.2159   3.313 0.4661   . .   0 0   3.313   I 
88 L'OREAL cat 1 Yes   2 1.0839 3.4473   11.3807 1.6156   3.952 1.2749   . .   0 0   3.952   I 
88 L'OREAL cat 1 Yes   3 1.0699 1.3117   7.9993 2.1576   4.34 0.3353   . .   0 0   4.34   I 
89 L'OREAL cat 1     1 1.0796 2.8004   22.9833 3.7713   73.923 5.6655   . .   . 0   73.923   NI 
89 L'OREAL cat 1     2 1.0711 4.8318   18.988 2.0633   58.025 5.3204   . .   . 0   58.025   NI 
89 L'OREAL cat 1     3 1.054 3.814   16.0283 1.7483   72.412 4.1878   . .   . 0   72.412   NI 
90 L'OREAL cat 1 Yes   1 1.1381 4.2836   22.3701 1.5167   51.581 12.975   . .   0.089 0.0811   51.516   NI 
90 L'OREAL cat 1 Yes   2 1.0525 12.287   12.4424 1.9531   23.331 9.1629   . .   0.158 0.1329   23.173   I 
90 L'OREAL cat 1 Yes   3 1.2025 4.9661   15.5048 2.8848   32.779 5.2349   . .   0.089 0.0805   32.711   I 
91 L'OREAL cat 1 Yes   1 1.0796 2.8004   22.9833 3.7713   52.168 9.4291   . .   3.466 0.8625   48.702   I 
91 L'OREAL cat 1 Yes   2 0.9759 7.716   5.137 2.0706   36.705 12.081   . .   4.136 0.9541   32.569   I 
91 L'OREAL cat 1 Yes   3 1.0711 4.8318   18.988 2.0633   22.349 4.2611   . .   3.464 0.8886   18.885   I 
92 L'OREAL cat 1 Yes   1 1.13 3.7783   3.5811 2.501   77.68 2.3545   . .   0 0   77.68   NI 
92 L'OREAL cat 1 Yes   2 1.0699 1.3117   7.9993 2.1576   82.503 3.6032   . .   0 0   82.503   NI 
92 L'OREAL cat 1 Yes   3 1.0775 4.8828   7.542 1.545   79.261 1.4825   . .   0 0   79.261   NI 
93 L'OREAL cat 1     1 1.0984 6.2426   10.0373 3.1479   86.307 10.015   . .   . 0   86.307   NI 
93 L'OREAL cat 1     2 1.1226 6.9506   7.1143 0.5129   66.461 10.029   . .   . 0   66.461   NI 
93 L'OREAL cat 1     3 1.1342 6.6464   7.7929 0.3475   68.626 10.599   . .   . 0   68.626   NI 
94 L'OREAL cat 1     1 1.0984 6.2426   10.0373 3.1479   77.957 4.6101   . .   . 0   77.957   NI 
94 L'OREAL cat 1     2 1.1226 6.9506   7.1143 0.5129   75.07 5.4602   . .   . 0   75.07   NI 
94 L'OREAL cat 1     3 1.1342 6.6464   7.7929 0.3475   77.647 2.5004   . .   . 0   77.647   NI 
95 L'OREAL cat 1     1 1.0714 5.8627   13.4695 6.1612   1.422 0.2358   . .   . 0   1.422   I 
95 L'OREAL cat 1     2 1.0069 11.957   16.5246 1.7463   1.324 0.1125   . .   . 0   1.324   I 
95 L'OREAL cat 1     3 1.062 3.9289   23.3122 2.3466   1.35 0.1964   . .   . 0   1.35   I 
96 L'OREAL cat 1     1 1.0312 7.8231   19.1107 2.864   92.161 2.6444   . .   . 0   92.161   NI 
96 L'OREAL cat 1     2 1.0434 3.8172   15.872 3.6247   108.885 2.7002   . .   . 0   108.885   NI 
96 L'OREAL cat 1     3 1.1342 6.6464   7.7929 0.3475   74.15 8.8212   . .   . 0   74.15   NI 
97 L'OREAL cat 1     1 1.0714 5.8627   13.4695 6.1612   94.949 0.1641   . .   . 0   94.949   NI 
97 L'OREAL cat 1     2 1.0069 11.957   16.5246 1.7463   88.122 2.0609   . .   . 0   88.122   NI 
97 L'OREAL cat 1     3 1.062 3.9289   23.3122 2.3466   89.454 5.6991   . .   . 0   89.454   NI 
98 L'OREAL cat 1   Yes 1 1.1507 5.8417   10.5126 2.2159   89.315 6.7229   1.4238 0.205   . 0   87.891   NI 
98 L'OREAL cat 1   Yes 2 1.0839 3.4473   11.3807 1.6156   80.588 3.2231   2.4096 0.46   . 0   78.178   NI 
98 L'OREAL cat 1   Yes 3 1.0151 10.577   10.1356 2.2709   86.595 0.3864   4.2247 1.544   . 0   82.371   NI 
99 L'OREAL cat 1     1 1.054 3.814   16.0283 1.7483   17.403 2.6717   . .   . 0   17.403   I 
99 L'OREAL cat 1     2 1.0116 6.9056   18.2308 1.401   26.113 1.7162   . .   . 0   26.113   I 
99 L'OREAL cat 1     3 1.0572 3.0636   22.3841 2.3749   26.262 2.4977   . .   . 0   26.262   I 
100 L'OREAL cat 1     1 1.13 3.7783   3.5811 2.501   27.798 11.068   . .   . 0   27.798   I 
100 L'OREAL cat 1     2 1.0151 10.577   10.1356 2.2709   69.408 1.7058   . .   . 0   69.408   NI 
100 L'OREAL cat 1     3 1.0775 4.8828   7.542 1.545   56.67 3.7312   . .   . 0   56.67   NI 
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101 L'OREAL cat 1   Yes 1 1.1507 5.8417   10.5126 2.2159   80.51 5.1756   0.4374 0.136   . 0   80.073   NI 
101 L'OREAL cat 1   Yes 2 1.0839 3.4473   11.3807 1.6156   77.429 4.4023   0.0846 0.063   . 0   77.345   NI 
101 L'OREAL cat 1   Yes 3 1.0151 10.577   10.1356 2.2709   80.292 6.6746   0.1806 0.055   . 0   80.111   NI 
102 L'OREAL cat 1     1 1.1507 5.8417   10.5126 2.2159   94.247 14.794   . .   . 0   94.247   NI 
102 L'OREAL cat 1     2 1.0839 3.4473   11.3807 1.6156   86.167 3.0025   . .   . 0   86.167   NI 
102 L'OREAL cat 1     3 1.0886 2.3885   13.0998 3.6209   95.534 0.9852   . .   . 0   95.534   NI 
103 L'OREAL cat 1     1 1.0796 2.8004   22.9833 3.7713   5.033 0.8176   . .   . 0   5.033   I 
103 L'OREAL cat 1     2 1.0711 4.8318   18.988 2.0633   5.528 0.2059   . .   . 0   5.528   I 
103 L'OREAL cat 1     3 1.054 3.814   16.0283 1.7483   4.75 0.1362   . .   . 0   4.75   I 
104 L'OREAL cat 1     1 1.0116 6.9056   18.2308 1.401   94.181 4.9305   . .   . 0   94.181   NI 
104 L'OREAL cat 1     2 1.0572 3.0636   22.3841 2.3749   83.325 3.8567   . .   . 0   83.325   NI 
104 L'OREAL cat 1     3 1.1011 8.6438   10.2576 1.8071   94.951 1.8167   . .   . 0   94.951   NI 
105 L'OREAL cat 1     1 0.9378 6.6852   10.5136 1.0684   8.783 0.7349   . .   . 0   8.783   I 
105 L'OREAL cat 1     2 1.0796 2.8004   22.9833 3.7713   7.39 0.0809   . .   . 0   7.39   I 




Chemical 106 and 107 are considered incompatible with the test method because of strong colour interference and so SkinEthicTM HCE shows a limitation for colours that strongly 
interfere with MTT using the current system of photometry. These two chemicals are excluded for the statistical analysis. 
    
GHS  
      
NC PC Uncorrected viability NSC MTT Final 
Chemical laboratory classification MTT coloring test OD std Qual Mean% Std Qual Mean% Std Qual Mean% Std Qual Mean% Std Qual viability 
106 CARDAM cat 1 No Yes 1 0.976 3.0137   9.7414 1.6474   302.354 143.08 NQ 113.225 68.9216 NQ .     189.129 
106 CARDAM cat 1 No Yes 2 1.068 12.107   9.0451 0.5407   127.641 6.526   38.008 6.1534   .     89.633 
106 CARDAM cat 1 No Yes 3 1.122 5.8363   9.2331 2.1018   157.851 11.792   53.201 13.7369   .     104.649 
106 CARDAM cat 1 No Yes 4 1.169 5.4702   13.7342 2.2905   141.654 42.681 NQ 40.789 7.4833   .     100.865 
106 CARDAM cat 1 No Yes 5 0.944 9.67   16.1907 2.7495   181.669 9.382   46.755 11.4809   .     134.914 
107 CARDAM cat 1 No Yes 1 1.122 5.8363   9.2331 2.1018   94.926 7.962   9.594 1.4075   .     85.332 
107 CARDAM cat 1 No Yes 2 1.169 5.4702   13.7342 2.2905   115.09 10.187   14.118 3.1246   .     100.972 
107 CARDAM cat 1 No Yes 3 0.944 9.67   16.1907 2.7495   120.772 14.917   26.57 7.7849   .     94.202 
106 CEETOX cat 1 Yes Yes 1 0.933 6.0005   9.6642 0.8844   116.827 11.997   21.15 10.1158   369.453 9.1978   0 
106 CEETOX cat 1 Yes Yes 2 0.943 4.0652   4.916 0.9039   95.367 15.265   17.224 3.6529   365.853 9.1051   0 
106 CEETOX cat 1 Yes Yes 3 0.965 5.0074   4.4552 0.9126   102.383 10.761   10.309 6.8809   357.14 8.8913   0 
107 CEETOX cat 1 Yes Yes 1 0.975 7.154   6.4135 1.4749   95.69 10.332   10.501 12.2832   45.972 20.3287 NQ 0 
107 CEETOX cat 1 Yes Yes 2 0.961 2.7115   6.0527 0.4834   100.85 1.033   8.012 2.692   87.496 76.6765 NQ 0 
107 CEETOX cat 1 Yes Yes 3 0.96 3.8851   5.1059 1.2355   90.57 1.928   8.927 2.7099   171.778 45.0243 NQ 0 
106 L'OREAL cat 1 Yes Yes 1 1.151 5.8417   10.5126 2.2158   129.626 29.204 NQ 44.458 32.2886 NQ 38.515 26.5231 NQ 46.653 
106 L'OREAL cat 1 Yes Yes 2 1.13 3.7783   3.5811 2.501   151.154 23.624 NQ 40.603 17.0624   39.185 27.0057 NQ 71.366 
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106 L'OREAL cat 1 Yes Yes 3 1.015 10.577   10.1356 2.2709   122.012 8.34   17.142 2.3774   43.309 30.0667 NQ 61.561 
106 L'OREAL cat 1 Yes Yes 4 1.089 2.3885   13.0998 3.6209   100.194 12.88   28.386 11.1773   40.382 28.0366 NQ 31.427 
106 L'OREAL cat 1 Yes Yes 5 1.078 4.8828   7.542 1.545   108.042 28.288 NQ 25.794 8.8653   40.796 28.3241 NQ 41.452 
107 L'OREAL cat 1 Yes Yes 1 1.166 2.2252   14.1003 4.5157   97.605 6.456   18.475 20.4689 NQ 35.767 19.5041 NQ 43.363 
107 L'OREAL cat 1 Yes Yes 2 1.07 1.3117   7.9993 2.1576   100.28 12.892   11.632 7.3035   39.077 21.2509 NQ 49.571 
107 L'OREAL cat 1 Yes Yes 3 1.015 10.577   10.1356 2.2709   104.737 5.261   17.687 3.3834   42.073 22.3985 NQ 44.977 
107 L'OREAL cat 1 Yes Yes 4 1.089 2.3885   13.0998 3.6209   91.598 3.139   6.042 1.3004   38.344 20.8711 NQ 47.212 





    GHS        NC PC Uncorrected viability NSC MTT Final Final Classification 
Chemical Laboratory classification MTT coloring test OD std Qual Mean% Std Qual Mean% Std Qual Mean% Std Qual Mean% Std Qual viability call 50% cutoff 
1 CARDAM no cat No No 1 0.995 8.509   37.816 5.18   22.312 4.817   . .   .     22.312   I 
1 CARDAM no cat No No 2 1.239 7.199   48.279 4.314   5.335 3.399   . .   .     5.335   I 
1 CARDAM no cat No No 3 0.868 2.37   16.136 6.351   9.402 4.759   . .   .     9.402   I 
2 CARDAM no cat No No 1 0.973 6.201   17.996 5.229   9.655 2.66   . .   .     9.655   I 
2 CARDAM no cat No No 2 0.81 1.341   32.239 2.548   2.647 0.564   . .   .     2.647   I 
2 CARDAM no cat No No 3 1.206 7.734   17.834 6.314   2.076 0.206   . .   .     2.076   I 
3 CARDAM no cat No No 1 0.995 8.509   37.816 5.18   1.278 0.654   . .   .     1.278   I 
3 CARDAM no cat No No 2 1.239 7.199   48.279 4.314   3.518 2.872   . .   .     3.518   I 
3 CARDAM no cat No No 3 0.868 2.37   16.136 6.351   2.403 1.461   . .   .     2.403   I 
4 CARDAM no cat Yes No 1 0.811 1.341   32.262 2.547   59.204 12.23   . .   84.184 27.4 NQ 0   I 
4 CARDAM no cat Yes No 2 1.206 7.734   17.834 6.314   51.154 9.87   . .   56.781 18.423 NQ 0.706   I 
4 CARDAM no cat Yes No 3 1.18 12.54   25.225 3.808   62.867 8.699   . .   57.757 18.822 NQ 6.576   I 
5 CARDAM no cat Yes No 1 0.973 6.201   17.996 5.229   5.834 3.187   . .   0.93 0   4.9   I 
5 CARDAM no cat Yes No 2 0.81 1.341   32.239 2.548   13.931 2.76   . .   1.1229 0.8371   12.808   I 
5 CARDAM no cat Yes No 3 1.206 7.734   17.834 6.314   3.879 1.722   . .   0.7547 0.5626   3.124   I 
6 CARDAM no cat No No 1 1.239 7.199   48.279 4.314   12.402 8.108   . .   .     12.402   I 
6 CARDAM no cat No No 2 0.868 2.37   16.136 6.351   20.19 0.807   . .   .     20.19   I 
6 CARDAM no cat No No 3 0.973 6.201   17.996 5.229   19.609 8.038   . .   .     19.609   I 
7 CARDAM no cat No No 1 1.239 7.199   48.281 4.314   5.541 5.757   . .   .     5.541   I 
7 CARDAM no cat No No 2 0.869 2.369   16.153 6.349   5.285 1.145   . .   .     5.285   I 
7 CARDAM no cat No No 3 0.973 6.201   17.996 5.229   6.501 2.141   . .   .     6.501   I 
8 CARDAM no cat No No 1 0.995 8.509   37.816 5.18   43.931 6.75   . .   .     43.931   I 
8 CARDAM no cat No No 2 1.239 7.199   48.279 4.314   21.448 2.351   . .   .     21.448   I 
8 CARDAM no cat No No 3 0.868 2.37   16.136 6.351   37.506 2.856   . .   .     37.506   I 
9 CARDAM no cat Yes No 1 0.995 8.509   37.816 5.18   56.286 3.471   . .   0.2178 0.2944   56.085   NI 
9 CARDAM no cat Yes No 2 1.239 7.199   48.279 4.314   31.341 12.95   . .   0.1748 0.2364   31.179   I 
9 CARDAM no cat Yes No 3 0.868 2.37   16.136 6.351   58.77 9.122   . .   0.2636 0.3454   58.519   NI 
10 CARDAM no cat No No 1 0.973 6.201   17.996 5.229   0.406 0.301   . .   .     0.406   I 
10 CARDAM no cat No No 2 0.81 1.341   32.239 2.548   1.954 0.524   . .   .     1.954   I 
10 CARDAM no cat No No 3 1.206 7.734   17.834 6.314   1.085 0.315   . .   .     1.085   I 
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11 CARDAM no cat No No 1 0.995 8.509   37.816 5.18   32.285 15.84   . .   .     32.285   I 
11 CARDAM no cat No No 2 1.239 7.199   48.279 4.314   26.327 0.646   . .   .     26.327   I 
11 CARDAM no cat No No 3 0.868 2.37   16.136 6.351   24.933 6.934   . .   .     24.933   I 
12 CARDAM no cat No No 1 1.22 3.711   36.294 7.468   99.068 8.198   . .   .     99.068   NI 
12 CARDAM no cat No No 2 1.051 9.065   10.033 2.886   98.767 13.27   . .   .     98.767   NI 
12 CARDAM no cat No No 3 1.083 4.893   10.142 3.1   92.19 3.924   . .   .     92.19   NI 
13 CARDAM no cat No No 1 1.22 3.711   36.294 7.468   103.01 7.253   . .   .     103.012   NI 
13 CARDAM no cat No No 2 1.051 9.065   10.033 2.886   114.66 11.3   . .   .     114.661   NI 
13 CARDAM no cat No No 3 0.887 9.248   23.751 10   100.53 8.418   . .   .     100.532   NI 
14 CARDAM no cat No No 1 1.239 7.199   48.281 4.314   70.273 7.2   . .   .     70.273   NI 
14 CARDAM no cat No No 2 0.868 2.37   16.136 6.351   110.11 3.526   . .   .     110.11   NI 
14 CARDAM no cat No No 3 0.973 6.201   17.996 5.229   105.45 4.39   . .   .     105.447   NI 
15 CARDAM no cat No No 1 0.887 9.248   23.751 10   100.83 9.644   . .   .     100.83   NI 
15 CARDAM no cat No No 2 0.9 3.814   14.278 3.816   100.48 15.56   . .   .     100.476   NI 
15 CARDAM no cat No No 3 0.99 8.386   37.684 6.95   93.329 6.11   . .   .     93.329   NI 
16 CARDAM no cat No No 1 0.995 8.509   37.816 5.18   99.586 9.613   . .   .     99.586   NI 
16 CARDAM no cat No No 2 1.239 7.199   48.279 4.314   73.629 9.717   . .   .     73.629   NI 
16 CARDAM no cat No No 3 0.868 2.37   16.136 6.351   109.86 8.408   . .   .     109.855   NI 
17 CARDAM no cat No No 1 0.811 1.341   32.262 2.547   88.816 6.554   . .   .     88.816   NI 
17 CARDAM no cat No No 2 1.206 7.734   17.834 6.314   74.963 7.226   . .   .     74.963   NI 
17 CARDAM no cat No No 3 1.18 12.54   25.225 3.808   95.166 3.711   . .   .     95.166   NI 
18 CARDAM no cat No No 1 0.887 9.248   23.751 10   94.652 7.192   . .   .     94.652   NI 
18 CARDAM no cat No No 2 0.943 4.444   25.036 15.37   104.76 2.061   . .   .     104.758   NI 
18 CARDAM no cat No No 3 0.99 8.386   37.684 6.95   104.92 5.04   . .   .     104.919   NI 
19 CARDAM no cat No No 1 0.887 9.248   23.751 10   97.537 9.182   . .   .     97.537   NI 
19 CARDAM no cat No No 2 0.943 4.444   25.036 15.37   108.46 10.64   . .   .     108.459   NI 
19 CARDAM no cat No No 3 0.99 8.386   37.684 6.95   97.17 15   . .   .     97.17   NI 
20 CARDAM no cat Yes No 1 1.22 3.711   36.294 7.468   62.958 17.64   . .   40.874 10.611   22.084   I 
20 CARDAM no cat Yes No 2 1.083 4.893   10.142 3.1   63.854 12.15   . .   46.089 11.958   17.765   I 
20 CARDAM no cat Yes No 3 0.992 2.274   10.261 2.629   57.127 6.099   . .   50.26 13.046   6.867   I 
21 CARDAM no cat No No 1 0.811 1.341   32.262 2.547   63.786 2.671   . .   .     63.786   NI 
21 CARDAM no cat No No 2 1.206 7.734   17.834 6.314   55.806 2.202   . .   .     55.806   NI 
21 CARDAM no cat No No 3 1.18 12.54   25.225 3.808   60.57 2.536   . .   .     60.57   NI 
22 CARDAM no cat No No 1 0.811 1.341   32.262 2.547   1.231 0.205   . .   .     1.231   I 
22 CARDAM no cat No No 2 1.206 7.734   17.834 6.314   0.918 0.167   . .   .     0.918   I 
22 CARDAM no cat No No 3 1.18 12.54   25.225 3.808   1.076 0.167   . .   .     1.076   I 
23 CARDAM no cat Yes No 1 1.169 3.808   3.2487 0.788   53.793 0.812   . .   38.178 4.2769   15.614   I 
23 CARDAM no cat Yes No 2 1.005 2.625   25.131 3.811   61.723 3.259   . .   44.612 4.9753   17.111   I 
23 CARDAM no cat Yes No 3 1.062 9.186   13.713 4.398   60.934 7.034   . .   42.043 4.7065   18.89   I 
24 CARDAM no cat No No 1 1.005 2.625   25.131 3.811   1.04 0.162   . .   .     1.04   I 
24 CARDAM no cat No No 2 1.062 9.186   13.713 4.398   1.486 1.313   . .   .     1.486   I 
24 CARDAM no cat No No 3 1.253 4.783   49.521 4.149   1.254 0.062   . .   .     1.254   I 
25 CARDAM no cat Yes No 1 0.992 2.274   10.261 2.629   100.13 4.771   . .   0.2877 0.25   99.887   NI 
25 CARDAM no cat Yes No 2 0.943 4.444   25.036 15.37   100.02 13.44   . .   0.3523 0.3059   99.696   NI 
25 CARDAM no cat Yes No 3 0.982 7.089   28.69 3.421   95.643 8.221   . .   0.2908 0.2527   95.4   NI 
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26 CARDAM no cat No No 1 0.9 3.814   14.278 3.816   3.457 0.523   . .   .     3.457   I 
26 CARDAM no cat No No 2 0.943 4.444   25.036 15.37   4.055 0.531   . .   .     4.055   I 
26 CARDAM no cat No No 3 0.982 7.089   28.69 3.421   3.327 0.515   . .   .     3.327   I 
28 CARDAM no cat No No 1 1.239 7.199   48.281 4.314   76.263 6.953   . .   .     76.263   NI 
28 CARDAM no cat No No 2 0.869 2.369   16.153 6.349   108.8 6.285   . .   .     108.801   NI 
28 CARDAM no cat No No 3 0.973 6.201   17.996 5.229   107.48 1.542   . .   .     107.476   NI 
29 CARDAM no cat No No 1 0.992 2.274   10.261 2.629   107.06 2.243   . .   .     107.059   NI 
29 CARDAM no cat No No 2 0.943 4.444   25.036 15.37   93.867 4.295   . .   .     93.867   NI 
29 CARDAM no cat No No 3 0.982 7.089   28.69 3.421   101.11 9.111   . .   .     101.114   NI 
30 CARDAM no cat No No 1 1.12 9.591   48.297 3.425   74.85 6.843   . .   .     74.85   NI 
30 CARDAM no cat No No 2 1.018 9.297   44.999 2.039   93.499 0.616   . .   .     93.499   NI 
30 CARDAM no cat No No 3 1.22 3.711   36.294 7.468   75.832 4.094   . .   .     75.832   NI 
31 CARDAM no cat No No 1 1.12 9.591   48.297 3.425   99.9 4.298   . .   .     99.9   NI 
31 CARDAM no cat No No 2 1.018 9.297   44.999 2.039   114.34 7.73   . .   .     114.336   NI 
31 CARDAM no cat No No 3 1.22 3.711   36.294 7.468   99.743 9.781   . .   .     99.743   NI 
32 CARDAM no cat No Yes 1 0.81 1.341   32.239 2.548   8.911 1.715   0.327 0.08   .     8.584   I 
32 CARDAM no cat No Yes 2 1.206 7.734   17.834 6.314   6.721 0.156   0.4727 0.11   .     6.248   I 
32 CARDAM no cat No Yes 3 1.18 12.54   25.225 3.808   10.274 0.563   0.5988 0.31   .     9.675   I 
33 CARDAM no cat Yes Yes 1 1.18 12.54   25.225 3.808   110.8 4.261   1.4814 1.63   0.9109 0.68   108.405   NI 
33 CARDAM no cat Yes Yes 2 0.72 9.549   13.318 7.805   112.61 2.66   4.7196 3.28   1.6118 1.1151   106.283   NI 
33 CARDAM no cat Yes Yes 3 1.169 3.808   3.2487 0.788   108.8 5.514   2.1121 1.35   0.9926 0.6867   105.697   NI 
34 CARDAM no cat Yes Yes 1 0.811 1.341   32.262 2.547   70.721 11.82   8.0733 2.47   12.781 1.379   49.866   I 
34 CARDAM no cat Yes Yes 2 1.206 7.734   17.834 6.314   57.885 8.321   5.5083 0.97   8.823 0.9272   43.554   I 
34 CARDAM no cat Yes Yes 3 1.18 12.54   25.225 3.808   57.861 42.38 NQ 5.7717 0.78   8.7797 0.9473   45.181 NQ I 
34 CARDAM no cat Yes Yes 4 0.72 9.549   13.318 7.805   80.325 9.077   9.4299 1.53   14.397 1.5534   56.498   NI 
35 CARDAM no cat Yes No 1 1.11 3.386   33.855 6.392   82.25 6.144   . .   4.9572 6.6349   77.293   NI 
35 CARDAM no cat Yes No 2 0.896 13.12   16.769 5.392   104.56 8.027   . .   6.1417 8.2203   98.42   NI 
35 CARDAM no cat Yes No 3 0.907 10.72   44.643 5.2   106.21 13.05   . .   6.0624 8.1141   100.151   NI 
36 CARDAM no cat No No 1 1.11 3.386   33.855 6.392   99.449 7.484   . .   .     99.449   NI 
36 CARDAM no cat No No 2 0.896 13.12   16.769 5.392   103.7 5.461   . .   .     103.698   NI 
36 CARDAM no cat No No 3 0.907 10.72   44.643 5.2   110.54 3.823   . .   .     110.541   NI 
37 CARDAM no cat No No 1 1.12 9.591   48.297 3.425   106.93 17.32   . .   .     106.933   NI 
37 CARDAM no cat No No 2 1.018 9.297   44.999 2.039   100.01 5.358   . .   .     100.005   NI 
37 CARDAM no cat No No 3 1.253 4.783   49.521 4.149   90.2 16.12   . .   .     90.2   NI 
38 CARDAM no cat No No 1 1.051 9.065   10.033 2.886   108.1 7.177   . .   .     108.104   NI 
38 CARDAM no cat No No 2 0.992 2.274   10.261 2.629   91.689 1.357   . .   .     91.689   NI 
38 CARDAM no cat No No 3 0.9 3.814   14.278 3.816   115.41 10.83   . .   .     115.413   NI 
39 CARDAM no cat No No 1 1.051 9.065   10.033 2.886   114.96 3.986   . .   .     114.959   NI 
39 CARDAM no cat No No 2 1.083 4.893   10.142 3.1   96.432 4.691   . .   .     96.432   NI 
39 CARDAM no cat No No 3 0.887 9.248   23.751 10   92.495 3.849   . .   .     92.495   NI 
40 CARDAM no cat No No 1 0.992 2.274   10.261 2.629   77.558 1.751   . .   .     77.558   NI 
40 CARDAM no cat No No 2 0.9 3.814   14.278 3.816   87.26 2.807   . .   .     87.26   NI 
40 CARDAM no cat No No 3 0.943 4.444   25.036 15.37   98.529 5.082   . .   .     98.529   NI 
41 CARDAM no cat No No 1 1.005 2.625   25.131 3.811   96.488 5.97   . .   .     96.488   NI 
41 CARDAM no cat No No 2 1.062 9.186   13.713 4.398   98.938 5.177   . .   .     98.938   NI 
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41 CARDAM no cat No No 3 1.12 9.591   48.297 3.425   99.025 5.407   . .   .     99.025   NI 
42 CARDAM no cat Yes No 1 1.062 9.186   13.713 4.398   83.843 3.249   . .   0.1507 0.1155   83.693   NI 
42 CARDAM no cat Yes No 2 1.12 9.591   48.297 3.425   94.847 11.69   . .   0.1429 0.1096   94.704   NI 
42 CARDAM no cat Yes No 3 1.253 4.783   49.521 4.149   75.451 3.937   . .   0.1277 0.0979   75.324   NI 
43 CARDAM no cat No No 1 1.005 2.625   25.131 3.811   107.74 2.867   . .   .     107.736   NI 
43 CARDAM no cat No No 2 1.062 9.186   13.713 4.398   104.11 6.317   . .   .     104.107   NI 
43 CARDAM no cat No No 3 1.12 9.591   48.297 3.425   107.14 8.894   . .   .     107.143   NI 
44 CARDAM no cat No No 1 1.169 3.808   3.2487 0.788   95.817 7.899   . .   .     95.817   NI 
44 CARDAM no cat No No 2 1.005 2.625   25.131 3.811   100.72 9.625   . .   .     100.715   NI 
44 CARDAM no cat No No 3 1.062 9.186   13.713 4.398   94.253 9.322   . .   .     94.253   NI 
45 CARDAM no cat No No 1 1.005 2.625   25.131 3.811   101.25 9.078   . .   .     101.253   NI 
45 CARDAM no cat No No 2 1.062 9.186   13.713 4.398   99.964 2.401   . .   .     99.964   NI 
45 CARDAM no cat No No 3 1.018 9.297   44.999 2.039   114.67 6.06   . .   .     114.667   NI 
46 CARDAM no cat No No 1 1.169 3.808   3.2487 0.788   74.948 16.6   . .   .     74.948   NI 
46 CARDAM no cat No No 2 1.005 2.625   25.131 3.811   95.383 6.715   . .   .     95.383   NI 
46 CARDAM no cat No No 3 1.062 9.186   13.713 4.398   92.867 5.376   . .   .     92.867   NI 
47 CARDAM no cat No No 1 1.005 2.625   25.131 3.811   85.746 11.25   . .   .     85.746   NI 
47 CARDAM no cat No No 2 1.062 9.186   13.713 4.398   74.644 4.353   . .   .     74.644   NI 
47 CARDAM no cat No No 3 1.253 4.783   49.521 4.149   82.926 8.546   . .   .     82.926   NI 
48 CARDAM no cat Yes No 1 1.18 12.54   25.225 3.808   3.684 0.115   . .   2.1889 0.6913   1.496   I 
48 CARDAM no cat Yes No 2 0.72 9.549   13.318 7.805   5.217 0.344   . .   3.476 1.1336   1.741   I 
48 CARDAM no cat Yes No 3 1.169 3.808   3.2487 0.788   3.514 2.422   . .   2.1135 0.6981   1.815   I 
48 CARDAM no cat Yes No 4 1.005 2.625   25.131 3.811   3.15 0.318   . .   2.6577 0.8121   0.51   I 
49 CARDAM no cat Yes No 1 0.9 3.814   14.278 3.816   77.871 7.246   . .   0.5113 0.8192   77.395   NI 
49 CARDAM no cat Yes No 2 0.99 8.386   37.684 6.95   69.814 8.698   . .   0.3401 0.589   69.685   NI 
49 CARDAM no cat Yes No 3 0.982 7.089   28.69 3.421   51.767 13.35   . .   0.4708 0.7517   51.327   NI 
50 CARDAM no cat No No 1 0.9 3.814   14.278 3.816   106.07 1.877   . .   .     106.067   NI 
50 CARDAM no cat No No 2 0.99 8.386   37.684 6.95   97.354 8.425   . .   .     97.354   NI 
50 CARDAM no cat No No 3 0.982 7.089   28.69 3.421   101.44 3.22   . .   .     101.441   NI 
51 CARDAM no cat No No 1 0.9 3.814   14.278 3.816   108.97 9.861   . .   .     108.968   NI 
51 CARDAM no cat No No 2 0.943 4.444   25.036 15.37   100.66 5.001   . .   .     100.656   NI 
51 CARDAM no cat No No 3 0.982 7.089   28.69 3.421   103.91 13.66   . .   .     103.911   NI 
52 CARDAM no cat No No 1 0.9 3.814   14.278 3.816   74.507 55.16 NQ . .   .     74.507 NQ NI 
52 CARDAM no cat No No 2 0.943 4.444   25.036 15.37   105.92 3.977   . .   .     105.921   NI 
52 CARDAM no cat No No 3 0.99 8.386   37.684 6.95   85.6 12.75   . .   .     85.6   NI 
52 CARDAM no cat No No 4 0.982 7.089   28.69 3.421   96.77 7.122   . .   .     96.77   NI 
53 CARDAM no cat No No 1 0.9 3.814   14.278 3.816   125.65 3.404   . .   .     125.653   NI 
53 CARDAM no cat No No 2 0.99 8.386   37.684 6.95   110.36 7.849   . .   .     110.355   NI 
53 CARDAM no cat No No 3 0.982 7.089   28.69 3.421   106.08 5.216   . .   .     106.084   NI 
54 CARDAM cat 2B No No 1 1.11 3.386   33.855 6.392   2.512 0.539   . .   .     2.512   I 
54 CARDAM cat 2B No No 2 0.896 13.12   16.769 5.392   1.937 1.223   . .   .     1.937   I 
54 CARDAM cat 2B No No 3 0.907 10.72   44.643 5.2   0.68 0.225   . .   .     0.68   I 
55 CARDAM cat 2B No No 1 1.18 12.54   25.225 3.808   0.712 0.062   . .   .     0.712   I 
55 CARDAM cat 2B No No 2 1.169 3.808   3.2487 0.788   0.955 0.092   . .   .     0.955   I 
55 CARDAM cat 2B No No 3 1.005 2.625   25.131 3.811   0.737 0.08   . .   .     0.737   I 
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56 CARDAM cat 2B No No 1 1.18 12.54   25.225 3.808   10.087 2.767   . .   .     10.087   I 
56 CARDAM cat 2B No No 2 0.72 9.549   13.318 7.805   9.733 3.148   . .   .     9.733   I 
56 CARDAM cat 2B No No 3 1.169 3.808   3.2487 0.788   4.86 2.646   . .   .     4.86   I 
57 CARDAM cat 2B No No 1 0.811 1.341   32.262 2.547   0.454 0.272   . .   .     0.454   I 
57 CARDAM cat 2B No No 2 1.206 7.734   17.834 6.314   0.957 0.512   . .   .     0.957   I 
57 CARDAM cat 2B No No 3 1.18 12.54   25.225 3.808   0.965 0.591   . .   .     0.965   I 
58 CARDAM cat 2B No No 1 1.206 7.734   17.834 6.314   1.284 0.964   . .   .     1.284   I 
58 CARDAM cat 2B No No 2 1.18 12.54   25.225 3.808   0.726 0.363   . .   .     0.726   I 
58 CARDAM cat 2B No No 3 0.72 9.549   13.318 7.805   0.44 0.121   . .   .     0.44   I 
59 CARDAM cat 2B No No 1 1.18 12.54   25.225 3.808   33.087 1.029   . .   .     33.087   I 
59 CARDAM cat 2B No No 2 0.72 9.549   13.318 7.805   39.88 8.414   . .   .     39.88   I 
59 CARDAM cat 2B No No 3 1.169 3.808   3.2487 0.788   21.355 5.464   . .   .     21.355   I 
60 CARDAM cat 2B No No 1 0.992 2.274   10.261 2.629   0.991 0.467   . .   .     0.991   I 
60 CARDAM cat 2B No No 2 0.943 4.444   25.036 15.37   0.785 0.352   . .   .     0.785   I 
60 CARDAM cat 2B No No 3 0.99 8.386   37.684 6.95   0.643 0.146   . .   .     0.643   I 
61 CARDAM cat 2B No Yes 1 1.239 7.199   48.281 4.314   59.817 3.134   0.0865 0.08   .     59.731   NI 
61 CARDAM cat 2B No Yes 2 0.869 2.369   16.153 6.349   90.072 3.802   0 0   .     90.072   NI 
61 CARDAM cat 2B No Yes 3 0.973 6.201   17.996 5.229   89.007 3.647   0.4263 0.16   .     88.581   NI 
62 CARDAM cat 2B No No 1 1.062 9.186   13.713 4.398   98.47 7.422   . .   .     98.47   NI 
62 CARDAM cat 2B No No 2 1.12 9.591   48.297 3.425   101.6 7.958   . .   .     101.597   NI 
62 CARDAM cat 2B No No 3 1.253 4.783   49.521 4.149   78.449 9.032   . .   .     78.449   NI 
63 CARDAM cat 2B No No 1 1.12 9.591   48.297 3.425   83.959 6.982   . .   .     83.959   NI 
63 CARDAM cat 2B No No 2 1.018 9.297   44.999 2.039   95.894 2.384   . .   .     95.894   NI 
63 CARDAM cat 2B No No 3 1.253 4.783   49.521 4.149   73.414 4.24   . .   .     73.414   NI 
64 CARDAM cat 2B No No 1 0.811 1.341   32.262 2.547   74.312 6.765   . .   .     74.312   NI 
64 CARDAM cat 2B No No 2 1.206 7.734   17.834 6.314   61.939 7.556   . .   .     61.939   NI 
64 CARDAM cat 2B No No 3 1.18 12.54   25.225 3.808   75.775 4.704   . .   .     75.775   NI 
65 CARDAM cat 2B No No 1 1.018 9.297   44.999 2.039   74.621 10.12   . .   .     74.621   NI 
65 CARDAM cat 2B No No 2 1.253 4.783   49.521 4.149   40.455 1.5   . .   .     40.455   I 
65 CARDAM cat 2B No No 3 1.22 3.711   36.294 7.468   41.957 8.924   . .   .     41.957   I 
66 CARDAM cat 2B No No 1 1.12 9.591   48.297 3.425   1.203 0.386   . .   .     1.203   I 
66 CARDAM cat 2B No No 2 1.018 9.297   44.999 2.039   1.39 0.264   . .   .     1.39   I 
66 CARDAM cat 2B No No 3 1.22 3.711   36.294 7.468   8.415 2.637   . .   .     8.415   I 
67 CARDAM cat 2A No No 1 1.239 7.199   48.281 4.314   0.795 0.305   . .   .     0.795   I 
67 CARDAM cat 2A No No 2 0.869 2.369   16.153 6.349   0.85 0.423   . .   .     0.85   I 
















No No 1 1.11 3.386   33.855 6.392   0.847 0.893   . .   .     0.847   I 
69 CARDAM cat 2A No No 2 0.896 13.12   16.769 5.392   0.283 0.034   . .   .     0.283   I 
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No No 3 0.907 10.72   44.643 5.2   0.119 0.102   . .   .     0.119   I 
70 CARDAM cat 2A No No 1 1.18 12.54   25.225 3.808   1.302 0.433   . .   .     1.302   I 
70 CARDAM cat 2A No No 2 0.72 9.549   13.318 7.805   1.292 0.739   . .   .     1.292   I 




































No No 3 0.868 2.37   16.136 6.351   97.236 2.04   . .   .     97.236   NI 
74 CARDAM cat 2A Yes Yes 1 1.11 3.386   33.855 6.392   91.954 3.991   0.2118 0.04   1.7455 0.385   89.997   NI 
74 CARDAM cat 2A Yes Yes 2 0.896 13.12   16.769 5.392   211.33 6.195   0.1092 0.12   2.2464 0.477   208.979   NI 
74 CARDAM cat 2A Yes Yes 3 0.907 10.72   44.643 5.2   105.13 4.029   0 0   2.0667 0.4709   103.061   NI 
75 CARDAM cat 2A No No 1 1.11 3.386   33.855 6.392   0.994 0.084   . .   .     0.994   I 
75 CARDAM cat 2A No No 2 0.896 13.12   16.769 5.392   0.765 0.048   . .   .     0.765   I 
75 CARDAM cat 2A No No 3 0.907 10.72   44.643 5.2   0.867 0.108   . .   .     0.867   I 
75 CARDAM cat 2A No No 4 0.995 8.509   37.816 5.18   0.69 0.138   . .   .     0.69   I 
76 CARDAM cat 2A No No 1 1.18 12.54   25.225 3.808   85.477 3.58   . .   .     85.477   NI 
76 CARDAM cat 2A No No 2 0.72 9.549   13.318 7.805   98.356 1.491   . .   .     98.356   NI 
76 CARDAM cat 2A No No 3 1.169 3.808   3.2487 0.788   74.255 9.515   . .   .     74.255   NI 
77 CARDAM cat 2A No No 1 0.973 6.201   17.996 5.229   101.18 6.643   . .   .     101.178   NI 
77 CARDAM cat 2A No No 2 0.81 1.341   32.239 2.548   80.837 4.582   . .   .     80.837   NI 
77 CARDAM cat 2A No No 3 1.206 7.734   17.834 6.314   100.18 4.666   . .   .     100.177   NI 
78 CARDAM cat 2A No No 1 0.973 6.201   17.996 5.229   101.1 1.148   . .   .     101.101   NI 
78 CARDAM cat 2A No No 2 0.81 1.341   32.239 2.548   75.821 10.23   . .   .     75.821   NI 












No No 3 1.253 4.783   49.521 4.149   64.159 7.333   . .   .     64.159   NI 
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80 CARDAM cat 1 Yes No 1 1.206 7.734   17.834 6.314   33.506 5.1   . .   35.62 7.7812   1.028   I 
80 CARDAM cat 1 Yes No 2 1.18 12.54   25.225 3.808   38.559 5.519   . .   36.28 7.9498   3.18   I 
80 CARDAM cat 1 Yes No 3 0.72 9.549   13.318 7.805   39.748 1.637   . .   59.379 13.036   0   I 
81 CARDAM cat 1 Yes No 1 1.239 7.199   48.281 4.314   0.418 0.399   . .   0.0238 0.0412   0.418   I 
81 CARDAM cat 1 Yes No 2 0.869 2.369   16.153 6.349   0.397 0.061   . .   0.0371 0.0643   0.397   I 
81 CARDAM cat 1 Yes No 3 0.973 6.201   17.996 5.229   0.514 0.229   . .   0.036 0.0623   0.514   I 
82 CARDAM cat 1 No No 1 0.887 9.248   23.751 10   1.091 0.899   . .   .     1.091   I 
82 CARDAM cat 1 No No 2 0.9 3.814   14.278 3.816   0.676 0.064   . .   .     0.676   I 
82 CARDAM cat 1 No No 3 0.99 8.386   37.684 6.95   0.401 0.184   . .   .     0.401   I 
83 CARDAM cat 1 No No 1 1.11 3.386   33.855 6.392   0.245 0.062   . .   .     0.245   I 
83 CARDAM cat 1 No No 2 0.896 13.12   16.769 5.392   0.374 0.048   . .   .     0.374   I 
83 CARDAM cat 1 No No 3 0.995 8.509   37.816 5.18   0.134 0.003   . .   .     0.134   I 
84 CARDAM cat 1 No No 1 0.887 9.248   23.751 10   0.68 0.497   . .   .     0.68   I 
84 CARDAM cat 1 No No 2 0.943 4.444   25.036 15.37   0.362 0.072   . .   .     0.362   I 
84 CARDAM cat 1 No No 3 0.99 8.386   37.684 6.95   0.535 0.142   . .   .     0.535   I 
85 CARDAM cat 1 No No 1 0.995 8.509   37.816 5.18   0.824 0.305   . .   .     0.824   I 
85 CARDAM cat 1 No No 2 1.239 7.199   48.279 4.314   0.256 0.026   . .   .     0.256   I 
85 CARDAM cat 1 No No 3 0.868 2.37   16.136 6.351   0.622 0.084   . .   .     0.622   I 
86 CARDAM cat 1 No No 1 1.051 9.065   10.033 2.886   5.675 3.8   . .   .     5.675   I 
86 CARDAM cat 1 No No 2 1.083 4.893   10.142 3.1   15.114 4.678   . .   .     15.114   I 
86 CARDAM cat 1 No No 3 0.887 9.248   23.751 10   3.823 0.775   . .   .     3.823   I 
87 CARDAM cat 1 No No 1 0.907 10.72   44.643 5.2   0.522 0.067   . .   .     0.522   I 
87 CARDAM cat 1 No No 2 0.997 8.495   37.918 5.171   0.311 0.08   . .   .     0.311   I 
87 CARDAM cat 1 No No 3 1.239 7.199   48.279 4.314   0.451 0.157   . .   .     0.451   I 
88 CARDAM cat 1 Yes No 1 1.22 3.711   36.294 7.468   0.47 0.027   . .   0.056 0.0537   0.414   I 
88 CARDAM cat 1 Yes No 2 1.051 9.065   10.033 2.886   0.976 0.299   . .   0.1126 0.0624   0.863   I 
88 CARDAM cat 1 Yes No 3 0.992 2.274   10.261 2.629   0.972 0.395   . .   0.0739 0.0661   0.898   I 
89 CARDAM cat 1 No No 1 0.973 6.201   17.996 5.229   1.419 0.121   . .   .     1.419   I 
89 CARDAM cat 1 No No 2 0.81 1.341   32.239 2.548   1.211 0.18   . .   .     1.211   I 
89 CARDAM cat 1 No No 3 1.206 7.734   17.834 6.314   1.208 0.18   . .   .     1.208   I 
90 CARDAM cat 1 No No 1 0.973 6.201   17.996 5.229   5.918 3.882   . .   .     5.918   I 
90 CARDAM cat 1 No No 2 0.81 1.341   32.239 2.548   13.625 16.84   . .   .     13.625   I 
90 CARDAM cat 1 No No 3 1.206 7.734   17.834 6.314   9.211 7.196   . .   .     9.211   I 
91 CARDAM cat 1 Yes No 1 0.973 6.201   17.996 5.229   9.285 7.417   . .   0.0936 0.0825   9.203   I 
91 CARDAM cat 1 Yes No 2 0.81 1.341   32.239 2.548   1.516 0.326   . .   0.1138 0.1003   1.415   I 
91 CARDAM cat 1 Yes No 3 1.206 7.734   17.834 6.314   1.661 0.631   . .   0.0765 0.0674   1.594   I 
92 CARDAM cat 1 Yes No 1 0.9 3.814   14.278 3.816   7.529 1.753   . .   0.4687 0.3505   7.06   I 
92 CARDAM cat 1 Yes No 2 0.943 4.444   25.036 15.37   7.031 0.531   . .   0.5037 0.3344   6.527   I 
92 CARDAM cat 1 Yes No 3 0.982 7.089   28.69 3.421   5.427 0.391   . .   0.4125 0.3212   5.014   I 
93 CARDAM cat 1 No No 1 0.995 8.509   37.816 5.18   34.64 2.09   . .   .     34.64   I 
93 CARDAM cat 1 No No 2 1.239 7.199   48.279 4.314   25.605 4.628   . .   .     25.605   I 
93 CARDAM cat 1 No No 3 0.868 2.37   16.136 6.351   25.069 7.207   . .   .     25.069   I 
94 CARDAM cat 1 No No 1 0.869 2.369   16.153 6.349   17.47 2.054   . .   .     17.47   I 
94 CARDAM cat 1 No No 2 0.973 6.201   17.996 5.229   14.357 6.445   . .   .     14.357   I 
94 CARDAM cat 1 No No 3 0.81 1.341   32.239 2.548   23.821 14.95   . .   .     23.821   I 
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95 CARDAM cat 1 Yes No 1 0.995 8.509   37.816 5.18   0.33 0.051   . .   0.0045 0.0077   0.33   I 
95 CARDAM cat 1 Yes No 2 1.239 7.199   48.279 4.314   0.212 0.061   . .   0 0   0.212   I 
95 CARDAM cat 1 Yes No 3 0.868 2.37   16.136 6.351   0.756 0.106   . .   0 0   0.756   I 
96 CARDAM cat 1 No No 1 1.239 7.199   48.281 4.314   42.678 7.727   . .   .     42.678   I 
96 CARDAM cat 1 No No 2 0.869 2.369   16.153 6.349   68.453 4.497   . .   .     68.453   NI 
96 CARDAM cat 1 No No 3 0.973 6.201   17.996 5.229   77.196 5.952   . .   .     77.196   NI 
97 CARDAM cat 1 No No 1 0.995 8.509   37.816 5.18   65.492 2.707   . .   .     65.492   NI 
97 CARDAM cat 1 No No 2 1.239 7.199   48.279 4.314   49.507 3.455   . .   .     49.507   I 
97 CARDAM cat 1 No No 3 0.868 2.37   16.136 6.351   73.543 4.676   . .   .     73.543   NI 
98 CARDAM cat 1 No Yes 1 1.22 3.711   36.294 7.468   79.215 10.79   10.202 5.95   .     69.013   NI 
98 CARDAM cat 1 No Yes 2 1.051 9.065   10.033 2.886   79.587 9.083   10.856 9.77   .     68.731   NI 
98 CARDAM cat 1 No Yes 3 1.083 4.893   10.142 3.1   88.405 12.45   3.9575 0.51   .     84.447   NI 
99 CARDAM cat 1 No No 1 0.973 6.201   17.996 5.229   1.601 0.31   . .   .     1.601   I 
99 CARDAM cat 1 No No 2 0.81 1.341   32.239 2.548   2.312 0.58   . .   .     2.312   I 
99 CARDAM cat 1 No No 3 1.206 7.734   17.834 6.314   1.88 0.143   . .   .     1.88   I 
100 CARDAM cat 1 No No 1 0.9 3.814   14.278 3.816   1.891 0.258   . .   .     1.891   I 
100 CARDAM cat 1 No No 2 0.99 8.386   37.684 6.95   1.473 0.682   . .   .     1.473   I 
100 CARDAM cat 1 No No 3 0.982 7.089   28.69 3.421   1.585 0.499   . .   .     1.585   I 
101 CARDAM cat 1 No Yes 1 1.22 3.711   36.294 7.468   64.654 3.649   0.5532 0.46   .     64.101   NI 
101 CARDAM cat 1 No Yes 2 1.051 9.065   10.033 2.886   77.647 8.13   0.119 0.1   .     77.528   NI 
101 CARDAM cat 1 No Yes 3 1.083 4.893   10.142 3.1   59.991 3.287   0.5511 0.34   .     59.44   NI 
102 CARDAM cat 1 No No 1 0.992 2.274   10.261 2.629   90.011 9.478   . .   .     90.011   NI 
102 CARDAM cat 1 No No 2 0.943 4.444   25.036 15.37   95.049 5.04   . .   .     95.049   NI 
102 CARDAM cat 1 No No 3 0.99 8.386   37.684 6.95   100.03 5.422   . .   .     100.027   NI 
103 CARDAM cat 1 No No 1 0.811 1.341   32.262 2.547   1.174 0.072   . .   .     1.174   I 
103 CARDAM cat 1 No No 2 1.206 7.734   17.834 6.314   1.508 0.141   . .   .     1.508   I 
103 CARDAM cat 1 No No 3 1.18 12.54   25.225 3.808   1.157 0.381   . .   .     1.157   I 
104 CARDAM cat 1 No No 1 0.973 6.201   17.996 5.229   96.175 7.28   . .   .     96.175   NI 
104 CARDAM cat 1 No No 2 0.81 1.341   32.239 2.548   70.493 4.594   . .   .     70.493   NI 
104 CARDAM cat 1 No No 3 1.206 7.734   17.834 6.314   85.336 1.747   . .   .     85.336   NI 
105 CARDAM cat 1 No No 1 1.18 12.54   25.225 3.808   2.347 1.984   . .   .     2.347   I 
105 CARDAM cat 1 No No 2 0.72 9.549   13.318 7.805   1.695 1.029   . .   .     1.695   I 
105 CARDAM cat 1 No No 3 1.169 3.808   3.2487 0.788   1.01 0.194   . .   .     1.01   I 
1 CEETOX no cat No No 1 1.061 5.816   83.276 0.966 NQ . .   . .   .     0 NQ I 
1 CEETOX no cat No No 2 0.931 4.593   85.407 7.847 NQ . .   . .   .     0 NQ I 
1 CEETOX no cat No No 3 1.061 3.431   18.843 5.17   8.125 2.448   . .   .     8.125   I 
1 CEETOX no cat No No 4 1.099 1.557   26.79 5.02   2.442 0.835   . .   .     2.442   I 
1 CEETOX no cat No No 5 1.097 2.786   36.449 2.106   7.539 1.634   . .   .     7.539   I 
2 CEETOX no cat No No 1 1.061 5.816   83.276 0.966 NQ . .   . .   .     0 NQ I 
2 CEETOX no cat No No 2 0.931 4.593   85.407 7.847 NQ . .   . .   .     0 NQ I 
2 CEETOX no cat No No 3 1.061 3.431   18.843 5.17   2.687 0.288   . .   .     2.687   I 
2 CEETOX no cat No No 4 1.099 1.557   26.79 5.02   1.942 0.115   . .   .     1.942   I 
2 CEETOX no cat No No 5 1.097 2.786   36.449 2.106   2.645 0.184   . .   .     2.645   I 
3 CEETOX no cat No No 1 1.109 7.989   44.805 3.75   1.879 0.104   . .   .     1.879   I 
3 CEETOX no cat No No 2 1.219 9.931   24.606 3.854   1.34 0.024   . .   .     1.34   I 
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3 CEETOX no cat No No 3 0.814 4.296   4.0131 1.662   2.928 0.303   . .   .     2.928   I 
4 CEETOX no cat Yes No 1 0.984 11.67   4.1935 4.007   66.272 3.026   . .   64.629 17.96   0   I 
4 CEETOX no cat Yes No 2 1.074 3.69   13.347 3.511   60.627 5.247   . .   59.183 16.468   0   I 
4 CEETOX no cat No No 3 1.117 7.674   70.816 2.256 NQ . .   . .   . .   0  NQ I 
4 CEETOX no cat No No 4 1.11 5.842   53.747 6.399 NQ . .   . .   . 17.225   0  NQ I 
4 CEETOX no cat Yes No 5 1.11 5.842   53.747 6.399   67.343 6.169   . .   62.975 17.225   0   I 
5 CEETOX no cat Yes No 1 1.126 12.55   38.801 3.402   0 0   . .   2.3242 0.2003   0   I 
5 CEETOX no cat Yes No 2 1.168 7.79   34.309 1.912   5.666 3.084   . .   2.1122 0.1931   3.554   I 
5 CEETOX no cat Yes No 3 1.026 4.323   2.3871 0.22   6.772 5.383   . .   2.5171 0.2197   4.255   I 
5 CEETOX no cat No No 4 1.11 5.842   53.747 6.399 NQ . .   . .   . .   0 NQ I 
6 CEETOX no cat No No 1 1.061 5.816   83.276 0.966 NQ . .   . .   . .   0 NQ I 
6 CEETOX no cat No No 2 0.931 4.593   85.407 7.847 NQ . .   . .   . .   0 NQ I 
6 CEETOX no cat No No 3 1.061 3.431   18.843 5.17   8.974 6.199   . .   .     8.974   I 
6 CEETOX no cat No No 4 1.099 1.557   26.79 5.02   2.685 0.315   . .   .     2.685   I 
6 CEETOX no cat No No 5 1.097 2.786   36.449 2.106   6.384 1.492   . .   .     6.384   I 
7 CEETOX no cat No No 1 1.109 7.989   44.805 3.75   4.315 0.702   . .   .     4.315   I 
7 CEETOX no cat No No 2 1.219 9.931   24.606 3.854   6.016 2.157   . .   .     6.016   I 
7 CEETOX no cat No No 3 0.814 4.296   4.0131 1.662   9.869 1.304   . .   .     9.869   I 
8 CEETOX no cat No No 1 1.109 7.989   44.805 3.75   36.19 11.37   . .   .     36.19   I 
8 CEETOX no cat No No 2 0.814 4.296   4.0131 1.662   28.01 3.747   . .   .     28.01   I 
8 CEETOX no cat No No 3 1.038 3.122   66.148 3.566 NQ . .   . .   .     0 NQ I 
8 CEETOX no cat No No 4 1.074 3.69   13.347 3.511   22.015 5.525   . .   .     22.015   I 
9 CEETOX no cat No No 1 1.061 5.816   83.276 0.966 NQ . .   . .   .     0 NQ I 
9 CEETOX no cat No No 2 0.931 4.593   85.407 7.847 NQ . .   . .   .     0 NQ I 
9 CEETOX no cat No No 3 1.061 3.431   18.843 5.17   42.496 4.526   . .   .     42.496   I 
9 CEETOX no cat No No 4 1.099 1.557   26.79 5.02   34.451 3.367   . .   .     34.451   I 
9 CEETOX no cat No No 5 1.097 2.786   36.449 2.106   48.67 3.803   . .   .     48.67   I 
10 CEETOX no cat No No 1 1.022 1.825   49.764 7.681   2.104 1.152   . .   .     2.104   I 
10 CEETOX no cat No No 2 1.011 6.903   31.312 5.994   3.708 0.804   . .   .     3.708   I 
10 CEETOX no cat No No 3 0.808 6.022   3.1753 0.179   1.897 0.588   . .   .     1.897   I 
11 CEETOX no cat No No 1 1.061 5.816   83.276 0.966 NQ . .   . .   .     0 NQ I 
11 CEETOX no cat No No 2 0.931 4.593   85.407 7.847 NQ . .   . .   .     0 NQ I 
11 CEETOX no cat No No 3 1.061 3.431   18.843 5.17   82.257 8.263   . .   .     82.257   NI 
11 CEETOX no cat No No 4 1.099 1.557   26.79 5.02   57.646 6.937   . .   .     57.646   NI 
11 CEETOX no cat No No 5 1.097 2.786   36.449 2.106   60.283 2.673   . .   .     60.283   NI 
12 CEETOX no cat No No 1 0.955 1.687   23.277 7.239   114.17 4.642   . .   .     114.169   NI 
12 CEETOX no cat No No 2 1.117 6.85   19.866 5.959   94.463 3.444   . .   .     94.463   NI 
12 CEETOX no cat No No 3 0.997 8.889   9.1441 3.404   95.67 7.566   . .   .     95.67   NI 
13 CEETOX no cat No No 1 1.117 6.85   19.866 5.959   97.119 2.853   . .   .     97.119   NI 
13 CEETOX no cat No No 2 0.986 9.055   41.765 3.931   104.28 2.336   . .   .     104.278   NI 
13 CEETOX no cat No No 3 1.108 15.91   36.132 3.321   120.51 11.64   . .   .     120.512   NI 
14 CEETOX no cat Yes No 1 1.126 12.55   38.801 3.402   94.33 6.774   . .   0.0395 0.0684   94.33   NI 
14 CEETOX no cat Yes No 2 1.168 7.79   34.309 1.912   92.793 7.007   . .   0 0   92.793   NI 
14 CEETOX no cat Yes No 3 1.026 4.323   2.3871 0.22   111.4 5.398   . .   0.0325 0.0563   111.4   NI 
14 CEETOX no cat No No 4 1.11 5.842   53.747 6.399 NQ . .   . .   . .   0 NQ I 
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15 CEETOX no cat No No 1 1.117 6.85   19.866 5.959   97.642 5.08   . .   .     97.642   NI 
15 CEETOX no cat No No 2 0.986 9.055   41.765 3.931   102.4 6.79   . .   .     102.401   NI 
15 CEETOX no cat No No 3 1.108 15.91   36.132 3.321   88.247 3.977   . .   .     88.247   NI 
16 CEETOX no cat No No 1 1.109 7.989   44.805 3.75   100.12 1.569   . .   .     100.12   NI 
16 CEETOX no cat No No 2 1.066 7.842   3.9856 2.185   99.078 2.767   . .   .     99.078   NI 
16 CEETOX no cat No No 3 1.038 3.122   66.148 3.566 NQ . .   . .   .     0 NQ I 
16 CEETOX no cat No No 4 1.074 3.69   13.347 3.511   95.979 2.94   . .   .     95.979   NI 
17 CEETOX no cat No No 1 1.026 4.323   2.3871 0.22   99.659 5.782   . .   .     99.659   NI 
17 CEETOX no cat No No 2 1.354 3.187   31.068 12.67   93.88 4.209   . .   .     93.88   NI 
17 CEETOX no cat No No 3 1.017 7.024   26.217 4.983   98.935 5.031   . .   .     98.935   NI 
18 CEETOX no cat No No 1 1.114 3.349   38.602 7.556   93.429 2.181   . .   .     93.429   NI 
18 CEETOX no cat No No 2 1.114 3.349   38.602 7.556 NQ . .   . .   .     0 NQ I 
18 CEETOX no cat No No 3 0.936 3.064   30.876 8.046   104.02 8.227   . .   .     104.024   NI 
18 CEETOX no cat No No 4 0.99 7.261   33.12 5.324   103.92 2.648   . .   .     103.921   NI 
19 CEETOX no cat No No 1 0.986 9.055   41.765 3.931   115.81 3.313   . .   .     115.81   NI 
19 CEETOX no cat No No 2 0.872 8.034   61.365 6.357 NQ . .   . .   .     0 NQ I 
19 CEETOX no cat No No 3 1.108 15.91   36.132 3.321   90.91 7.137   . .   .     90.91   NI 
19 CEETOX no cat No No 4 0.997 8.889   9.1441 3.404   97.125 3.651   . .   .     97.125   NI 
20 CEETOX no cat No No 1 1.102 4.826   52.117 3.403 NQ . .   . .   .     0 NQ I 
20 CEETOX no cat No No 2 1.066 10.35   39.425 8.798   37.111 11.04   . .   .     37.111   I 
20 CEETOX no cat No No 3 0.99 7.261   33.12 5.324   24.217 14.44   . .   .     24.217   I 
21 CEETOX no cat No No 1 0.984 11.67   4.1935 4.007   86.116 1.363   . .   .     86.116   NI 
21 CEETOX no cat No No 2 1.074 3.69   13.347 3.511   57.134 3.677   . .   .     57.134   NI 
21 CEETOX no cat No No 3 1.117 7.674   70.816 2.256 NQ . .   . .   .     0 NQ I 
21 CEETOX no cat No No 4 1.11 5.842   53.747 6.399 NQ . .   . .   .     0 NQ I 
21 CEETOX no cat No No 5 1.11 5.842   53.747 6.399   76.259 2.579   . .   .     76.259   NI 
22 CEETOX no cat No No 1 1.022 1.825   49.764 7.681   1.925 0.396   . .   .     1.925   I 
22 CEETOX no cat No No 2 1.011 6.903   31.312 5.994   3.214 0.329   . .   .     3.214   I 
22 CEETOX no cat No No 3 0.808 6.022   3.1753 0.179   3.897 0.373   . .   .     3.897   I 
23 CEETOX no cat Yes No 1 1.026 4.323   2.3871 0.22   54.791 1.961   . .   49.091 0.659   5.7   I 
23 CEETOX no cat Yes No 2 1.281 2.862   35.038 5.007   59.927 1.721   . .   39.24 0.528   20.687   I 
23 CEETOX no cat Yes No 3 1.006 1.79   41.106 8.615   55.83 4.349   . .   49.95 0.6721   5.879   I 
24 CEETOX no cat No No 1 1.066 7.842   3.9856 2.185   1.876 0.355   . .   .     1.876   I 
24 CEETOX no cat No No 2 1.038 3.122   66.148 3.566 NQ . .   . .   .     0 NQ I 
24 CEETOX no cat No No 3 1.038 3.122   66.148 3.566   1.382 0.142   . .   .     1.382   I 
24 CEETOX no cat No No 4 1.11 5.842   53.747 6.399 NQ . .   . .   .     0 NQ I 
24 CEETOX no cat No No 5 1.11 5.842   53.747 6.399   1.738 0.123   . .   .     1.738   I 
25 CEETOX no cat Yes No 1 1.066 10.35   39.425 8.798   80.319 3.111   . .   0 0   80.319   NI 
25 CEETOX no cat Yes No 2 0.953 8.886   46.459 4.808   102.31 8.918   . .   0 0   102.308   NI 
25 CEETOX no cat Yes No 3 0.936 3.064   30.876 8.046   84.437 7.975   . .   0 0   84.437   NI 
26 CEETOX no cat No No 1 1.066 10.35   39.425 8.798   3.658 0.891   . .   .     3.658   I 
26 CEETOX no cat No No 2 0.953 8.886   46.459 4.808   2.535 0.517   . .   .     2.535   I 
26 CEETOX no cat No No 3 0.936 3.064   30.876 8.046   2.991 0.608   . .   .     2.991   I 
28 CEETOX no cat No No 1 1.061 5.816   83.276 0.966 NQ . .   . .   .     0 NQ I 
28 CEETOX no cat No No 2 0.931 4.593   85.407 7.847 NQ . .   . .   .     0 NQ I 
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28 CEETOX no cat No No 3 1.061 3.431   18.843 5.17   99.717 2.292   . .   .     99.717   NI 
28 CEETOX no cat No No 4 1.099 1.557   26.79 5.02   97.633 3.167   . .   .     97.633   NI 
28 CEETOX no cat No No 5 1.097 2.786   36.449 2.106   97.644 4.025   . .   .     97.644   NI 
29 CEETOX no cat No No 1 0.986 9.055   41.765 3.931   106.66 3.482   . .   .     106.662   NI 
29 CEETOX no cat No No 2 0.872 8.034   61.365 6.357 NQ . .   . .   .     0 NQ I 
29 CEETOX no cat No No 3 1.108 15.91   36.132 3.321   89.857 6.604   . .   .     89.857   NI 
29 CEETOX no cat No No 4 0.997 8.889   9.1441 3.404   101.92 6.066   . .   .     101.922   NI 
30 CEETOX no cat No No 2 1.336 6.791   37.862 2.415   75.25 1.397   . .   .     75.25   NI 
30 CEETOX no cat No No 3 0.971 8.015   29.607 1.188   79.495 12.62   . .   .     79.495   NI 
30 CEETOX no cat No No 4 1.114 3.349   38.602 7.556   81.185 1.448   . .   .     81.185   NI 
31 CEETOX no cat No No 2 1.336 6.791   37.862 2.415   97.904 4.043   . .   .     97.904   NI 
31 CEETOX no cat No No 3 1.006 1.79   41.106 8.615   103.25 0.459   . .   .     103.246   NI 
31 CEETOX no cat No No 4 0.971 8.015   29.607 1.188   99.966 3.789   . .   .     99.966   NI 
32 CEETOX no cat No No 1 1.022 1.825   49.764 7.681   12.2 1.314   . .   .     12.2   I 
32 CEETOX no cat No No 2 1.011 6.903   31.312 5.994   31.625 9.075   . .   .     31.625   I 
32 CEETOX no cat No No 3 0.808 6.022   3.1753 0.179   21.052 0.842   . .   .     21.052   I 
33 CEETOX no cat Yes Yes 1 1.066 7.842   3.9856 2.185   104.22 1.498   1.4067 0.38   0.7346 0.3392   102.079   NI 
33 CEETOX no cat No No 2 1.038 3.122   66.148 3.566 NQ . .   . 0.75   . 0.3101   0 NQ I 
33 CEETOX no cat Yes Yes 3 1.038 3.122   66.148 3.566   90.126 3.363   2.2823 0.75   0.3571 0.3101   87.502   NI 
33 CEETOX no cat No No 4 1.11 5.842   53.747 6.399 NQ . .   . 0.28   . 0.3524   0 NQ I 
33 CEETOX no cat Yes Yes 5 1.11 5.842   53.747 6.399   115.05 5.045   1.0231 0.28   0.6983 0.3524   113.332   NI 
34 CEETOX no cat Yes Yes 1 1.026 4.323   2.3871 0.22   108.54 3.289   10.052 1.62   7.2426 0.3042   91.247   NI 
34 CEETOX no cat Yes Yes 2 1.354 3.187   31.068 12.67   68.575 5.127   5.7013 0.47   5.4057 0.2307   57.468   NI 
34 CEETOX no cat Yes Yes 3 1.017 7.024   26.217 4.983   80.206 13.57   1.005 1.74   12.633 0   66.568   NI 
35 CEETOX no cat Yes No 1 1.066 7.842   3.9856 2.185   86.199 16.47   . .   0.9378 0.1952   85.261   NI 
35 CEETOX no cat No No 2 1.038 3.122   66.148 3.566 NQ . .   . .   . 0.1939   0 NQ I 
35 CEETOX no cat Yes No 3 1.038 3.122   66.148 3.566   79.77 3.964   . .   0.5434 0.1939   79.227   NI 
35 CEETOX no cat No No 4 1.11 5.842   53.747 6.399 NQ . .   . .   . 0.2028   0 NQ I 
35 CEETOX no cat Yes No 5 1.11 5.842   53.747 6.399   107.36 3.143   . .   0.9094 0.2028   106.447   NI 
36 CEETOX no cat No No 1 1.109 7.989   44.805 3.75   99.504 4.259   . .   .     99.504   NI 
36 CEETOX no cat No No 2 1.219 9.931   24.606 3.854   100.97 2.893   . .   .     100.971   NI 
36 CEETOX no cat No No 3 0.814 4.296   4.0131 1.662   108.48 1.339   . .   .     108.477   NI 
37 CEETOX no cat Yes No 1 1.026 4.323   2.3871 0.22   96.119 4.265   . .   0.5684 0.0487   95.551   NI 
37 CEETOX no cat Yes No 2 1.281 2.862   35.038 5.007   90.749 6.111   . .   0.3643 0.039   90.385   NI 
37 CEETOX no cat Yes No 3 1.006 1.79   41.106 8.615   103.78 4.473   . .   0.4637 0.0497   103.312   NI 
38 CEETOX no cat No No 1 1.114 3.349   38.602 7.556   89.732 6.101   . .   .     89.732   NI 
38 CEETOX no cat No No 2 1.114 3.349   38.602 7.556 NQ . .   . .   .     0 NQ I 
38 CEETOX no cat No No 3 0.936 3.064   30.876 8.046   103.47 5.83   . .   .     103.472   NI 
38 CEETOX no cat No No 4 0.99 7.261   33.12 5.324   109.29 5.938   . .   .     109.29   NI 
39 CEETOX no cat No No 1 0.955 1.687   23.277 7.239   112.88 7.391   . .   .     112.877   NI 
39 CEETOX no cat No No 2 1.117 6.85   19.866 5.959   97.045 7.459   . .   .     97.045   NI 
39 CEETOX no cat No No 3 1.117 6.85   19.866 5.959 NQ . .   . .   .     0 NQ I 
39 CEETOX no cat No No 4 1.108 15.91   36.132 3.321   88.322 4.675   . .   .     88.322   NI 
40 CEETOX no cat No No 1 0.953 8.886   46.459 4.808   82.637 2.689   . .   .     82.637   NI 
40 CEETOX no cat No No 2 0.936 3.064   30.876 8.046   84.972 11   . .   .     84.972   NI 
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40 CEETOX no cat No No 3 0.99 7.261   33.12 5.324   80.007 10.1   . .   .     80.007   NI 
41 CEETOX no cat No No 2 1.336 6.791   37.862 2.415   95.609 6.104   . .   .     95.609   NI 
41 CEETOX no cat No No 3 1.006 1.79   41.106 8.615   106.26 4.339   . .   .     106.26   NI 
41 CEETOX no cat No No 4 0.971 8.015   29.607 1.188   91.31 2.873   . .   .     91.31   NI 
42 CEETOX no cat Yes No 1 1.026 4.323   2.3871 0.22   81.195 5.517   . .   0.341 0.1226   80.854   NI 
42 CEETOX no cat Yes No 2 1.281 2.862   35.038 5.007   73.588 4.495   . .   0.2732 0.0982   73.315   NI 
42 CEETOX no cat Yes No 3 1.006 1.79   41.106 8.615   80.242 8.3   . .   0.3478 0.125   79.894   NI 
43 CEETOX no cat No No 1 1.026 4.323   2.3871 0.22   107.18 4.826   . .   .     107.178   NI 
43 CEETOX no cat No No 2 1.354 3.187   31.068 12.67   91.996 0.544   . .   .     91.996   NI 
43 CEETOX no cat No No 3 1.017 7.024   26.217 4.983   97.722 5.728   . .   .     97.722   NI 
44 CEETOX no cat No No 1 1.074 3.69   13.347 3.511   96.848 6.924   . .   .     96.848   NI 
44 CEETOX no cat No No 2 1.026 4.323   2.3871 0.22   96.119 1.05   . .   .     96.119   NI 
44 CEETOX no cat No No 3 1.281 2.862   35.038 5.007   104.32 4.311   . .   .     104.32   NI 
44 CEETOX no cat No No 4 1.11 5.842   53.747 6.399 NQ . .   . .   .     0 NQ I 
45 CEETOX no cat No No 2 1.336 6.791   37.862 2.415   88.772 9.699   . .   .     88.772   NI 
45 CEETOX no cat No No 3 1.006 1.79   41.106 8.615   104.03 7.731   . .   .     104.025   NI 
45 CEETOX no cat No No 4 0.971 8.015   29.607 1.188   87.223 3.854   . .   .     87.223   NI 
46 CEETOX no cat Yes No 1 1.026 4.323   2.3871 0.22   73.595 6.09   . .   8.1195 1.1813   65.476   NI 
46 CEETOX no cat Yes No 2 1.281 2.862   35.038 5.007   83.984 7.081   . .   6.4143 0.9465   77.57   NI 
46 CEETOX no cat Yes No 3 1.006 1.79   41.106 8.615   92.647 6.073   . .   8.165 1.2048   84.482   NI 
47 CEETOX no cat No No 2 1.336 6.791   37.862 2.415   40.706 2.147   . .   .     40.706   I 
47 CEETOX no cat No No 3 1.006 1.79   41.106 8.615   48.741 9.853   . .   .     48.741   I 
47 CEETOX no cat No No 4 0.971 8.015   29.607 1.188   57.17 6.438   . .   .     57.17   NI 
48 CEETOX no cat Yes No 2 1.336 6.791   37.862 2.415   3.456 0.369   . .   1.9461 0.2547   1.509   I 
48 CEETOX no cat Yes No 3 0.971 8.015   29.607 1.188   5.41 0.568   . .   2.679 0.3507   2.731   I 
48 CEETOX no cat Yes No 4 1.114 3.349   38.602 7.556   3.682 0.36   . .   2.335 0.3057   1.347   I 
49 CEETOX no cat Yes No 1 1.066 10.35   39.425 8.798   82.648 3.517   . .   0.3074 0.4794   82.429   NI 
49 CEETOX no cat Yes No 2 0.953 8.886   46.459 4.808   85.487 7.43   . .   0.3789 0.5536   85.19   NI 
49 CEETOX no cat Yes No 3 0.99 7.261   33.12 5.324   77.095 29.23 NQ . .   0.791 0.6231   0 NQ I 
49 CEETOX no cat Yes No 4 0.955 1.687   23.277 7.239   95.865 0.366   . .   0.9073 0.6461   94.957   NI 
50 CEETOX no cat No No 1 0.986 9.055   41.765 3.931   103.59 4.937   . .   .     103.585   NI 
50 CEETOX no cat No No 2 0.872 8.034   61.365 6.357 NQ . .   . .   .     0 NQ I 
50 CEETOX no cat No No 3 1.108 15.91   36.132 3.321   80.557 5.827   . .   .     80.557   NI 
50 CEETOX no cat No No 4 0.997 8.889   9.1441 3.404   95.921 4.929   . .   .     95.921   NI 
51 CEETOX no cat No No 1 1.066 10.35   39.425 8.798   90.105 6.198   . .   .     90.105   NI 
51 CEETOX no cat No No 2 0.953 8.886   46.459 4.808   94.999 12.22   . .   .     94.999   NI 
51 CEETOX no cat No No 3 0.936 3.064   30.876 8.046   113.43 2.593   . .   .     113.426   NI 
52 CEETOX no cat No No 1 0.986 9.055   41.765 3.931   111.19 3.216   . .   .     111.194   NI 
52 CEETOX no cat No No 2 0.872 8.034   61.365 6.357 NQ . .   . .   .     0 NQ I 
52 CEETOX no cat No No 3 1.108 15.91   36.132 3.321   93.619 13.69   . .   .     93.619   NI 
52 CEETOX no cat No No 4 0.997 8.889   9.1441 3.404   97.192 8.061   . .   .     97.192   NI 
53 CEETOX no cat No No 1 0.986 9.055   41.765 3.931   104.48 4.017   . .   .     104.481   NI 
53 CEETOX no cat No No 2 0.872 8.034   61.365 6.357 NQ . .   . .   .     0 NQ I 
53 CEETOX no cat No No 3 1.108 15.91   36.132 3.321   81.58 8.688   . .   .     81.58   NI 
53 CEETOX no cat No No 4 0.997 8.889   9.1441 3.404   91.909 2.692   . .   .     91.909   NI 
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54 CEETOX cat 2B No No 1 1.061 5.816   83.276 0.966 NQ . .   . .   .     0 NQ I 
54 CEETOX cat 2B No No 2 0.931 4.593   85.407 7.847 NQ . .   . .   .     0 NQ I 
54 CEETOX cat 2B No No 3 1.061 3.431   18.843 5.17   2.766 1.19   . .   .     2.766   I 
54 CEETOX cat 2B No No 4 1.099 1.557   26.79 5.02   1.547 0.298   . .   .     1.547   I 
54 CEETOX cat 2B No No 5 1.097 2.786   36.449 2.106   4.606 1.914   . .   .     4.606   I 
55 CEETOX cat 2B Yes No 1 0.984 11.67   4.1935 4.007   2.845 0.31   . .   0 0   2.845   I 
55 CEETOX cat 2B Yes No 2 1.074 3.69   13.347 3.511   1.227 0.257   . .   0 0   1.227   I 
55 CEETOX cat 2B No No 3 1.117 7.674   70.816 2.256 NQ . .   . .   . .   0 NQ I 
55 CEETOX cat 2B No No 4 1.11 5.842   53.747 6.399 NQ . .   . .   .     0 NQ I 
55 CEETOX cat 2B Yes No 5 1.11 5.842   53.747 6.399   1.77 0.649   . .   0.3789 0.4087   1.462   I 
56 CEETOX cat 2B Yes No 1 1.026 4.323   2.3871 0.22   8.818 5.993   . .   0.341 0.1711   8.477   I 
56 CEETOX cat 2B Yes No 2 1.281 2.862   35.038 5.007   8.639 6.421   . .   0.1821 0.1371   8.457   I 
56 CEETOX cat 2B Yes No 3 1.006 1.79   41.106 8.615   7.751 4.657   . .   0.2319 0.1745   7.519   I 
57 CEETOX cat 2B No No 1 1.022 1.825   49.764 7.681   0.913 0.361   . .   .     0.913   I 
57 CEETOX cat 2B No No 2 1.011 6.903   31.312 5.994   1.45 0.151   . .   .     1.45   I 
57 CEETOX cat 2B No No 3 0.808 6.022   3.1753 0.179   2.536 0.446   . .   .     2.536   I 
58 CEETOX cat 2B Yes No 1 1.336 6.791   37.862 2.415   1.085 0.404   . .   0.3368 0.3198   0.761   I 
58 CEETOX cat 2B No No 2 1.336 6.791   37.862 2.415 NQ . .   . .   . 0.3198   0 NQ I 
58 CEETOX cat 2B Yes No 3 1.114 3.349   38.602 7.556   2.994 0.604   . .   0.3243 0.3218   2.724   I 
58 CEETOX cat 2B Yes No 4 1.066 10.35   39.425 8.798   1.938 0.098   . .   0.0677 0.1173   1.938   I 
59 CEETOX cat 2B Yes No 1 1.026 4.323   2.3871 0.22   26.437 3.041   . .   0.0379 0.0409   26.437   I 
59 CEETOX cat 2B Yes No 2 1.281 2.862   35.038 5.007   22.17 5.285   . .   0 0   22.17   I 
59 CEETOX cat 2B Yes No 3 1.006 1.79   41.106 8.615   26.681 6.426   . .   0 0   26.681   I 
60 CEETOX cat 2B No No 1 1.066 10.35   39.425 8.798   2.22 0.151   . .   .     2.22   I 
60 CEETOX cat 2B No No 2 0.953 8.886   46.459 4.808   1.853 0.429   . .   .     1.853   I 
60 CEETOX cat 2B No No 3 0.936 3.064   30.876 8.046   1.959 0.269   . .   .     1.959   I 
61 CEETOX cat 2B No No 1 1.109 7.989   44.805 3.75   10.149 0.636   . .   .     10.149   I 
61 CEETOX cat 2B No No 2 1.219 9.931   24.606 3.854   7.752 3.093   . .   .     7.752   I 
61 CEETOX cat 2B No No 3 0.814 4.296   4.0131 1.662   8.661 0.307   . .   .     8.661   I 
62 CEETOX cat 2B No No 2 1.336 6.791   37.862 2.415   93.875 3.449   . .   .     93.875   NI 
62 CEETOX cat 2B No No 3 0.971 8.015   29.607 1.188   98.472 10.74   . .   .     98.472   NI 
62 CEETOX cat 2B No No 4 1.114 3.349   38.602 7.556   97.86 11.12   . .   .     97.86   NI 
63 CEETOX cat 2B No No 2 1.336 6.791   37.862 2.415   77.682 8.06   . .   .     77.682   NI 
63 CEETOX cat 2B No No 3 0.971 8.015   29.607 1.188   78.276 5.153   . .   .     78.276   NI 
63 CEETOX cat 2B No No 4 1.114 3.349   38.602 7.556   94.477 3.552   . .   .     94.477   NI 
64 CEETOX cat 2B No No 2 1.026 4.323   2.3871 0.22   69.763 17.98   . .   .     69.763   NI 
64 CEETOX cat 2B No No 3 1.354 3.187   31.068 12.67   48.898 33.97 NQ . .   .     0 NQ I 
64 CEETOX cat 2B No No 4 1.017 7.024   26.217 4.983   76.307 5.501   . .   .     76.307   NI 
64 CEETOX cat 2B No No 5 0.971 8.015   29.607 1.188   86.656 4.464   . .   .     86.656   NI 
65 CEETOX cat 2B No No 1 1.336 6.791   37.862 2.415   62.113 16.81   . .   .     62.113   NI 
65 CEETOX cat 2B No No 2 1.336 6.791   37.862 2.415 NQ . .   . .   .     0 NQ I 
65 CEETOX cat 2B No No 3 1.114 3.349   38.602 7.556   86.499 12.22   . .   .     86.499   NI 
65 CEETOX cat 2B No No 4 0.936 3.064   30.876 8.046   79.558 11.58   . .   .     79.558   NI 
66 CEETOX cat 2B No No 2 1.336 6.791   37.862 2.415   4.516 2.293   . .   .     4.516   I 
66 CEETOX cat 2B No No 3 0.971 8.015   29.607 1.188   2.851 0.665   . .   .     2.851   I 
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66 CEETOX cat 2B No No 4 1.114 3.349   38.602 7.556   46.535 10.61   . .   .     46.535   I 
67 CEETOX cat 2A No No 1 1.126 12.55   38.801 3.402   9.164 0.683   . .   .     9.164   I 
67 CEETOX cat 2A No No 2 1.168 7.79   34.309 1.912   22.092 6.167   . .   .     22.092   I 
























No No 3 0.814 4.296   4.0131 1.662   1.188 0.094   . .   .     1.188   I 
70 CEETOX cat 2A No No 1 1.022 1.825   49.764 7.681   1.354 0.246   . .   .     1.354   I 
70 CEETOX cat 2A No No 2 1.011 6.903   31.312 5.994   1.796 0.318   . .   .     1.796   I 




















































No No 5 1.11 5.842   53.747 6.399 NQ . .   . .   .     0 NQ I 
73 CEETOX cat 2A No No 6 1.11 5.842   53.747 6.399   100.67 5.11   . .   .     100.666   NI 
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74 CEETOX cat 2A Yes No 1 1.066 7.842   3.9856 2.185   85.777 4.406   . .   2.4539 0.3722   83.323   NI 
74 CEETOX cat 2A No No 2 1.038 3.122   66.148 3.566 NQ . .   . .   . .   0 NQ I 
74 CEETOX cat 2A No No 3 1.11 5.842   53.747 6.399 NQ . .   . .   . 0.3867   0 NQ I 
74 CEETOX cat 2A Yes No 4 1.11 5.842   53.747 6.399   95.372 6.375   . .   3.1504 0.3867   92.222   NI 
74 CEETOX cat 2A Yes No 5 1.11 5.842   53.747 6.399   78.506 6.095   . .   2.0947 0.3867   76.412   NI 
75 CEETOX cat 2A No No 1 0.931 4.593   85.407 7.847 NQ . .   . .   .     0 NQ I 
75 CEETOX cat 2A No No 2 0.931 4.593   85.407 7.847   1.273 0.125   . .   .     1.273   I 
75 CEETOX cat 2A No No 3 1.099 1.557   26.79 5.02   1.305 0.026   . .   .     1.305   I 
75 CEETOX cat 2A No No 4 1.097 2.786   36.449 2.106   1.201 0.173   . .   .     1.201   I 
76 CEETOX cat 2A No No 1 1.026 4.323   2.3871 0.22   53.394 5.53   . .   .     53.394   NI 
76 CEETOX cat 2A No No 2 1.354 3.187   31.068 12.67   77.86 4.815   . .   .     77.86   NI 
76 CEETOX cat 2A No No 3 1.017 7.024   26.217 4.983   66.262 7.789   . .   .     66.262   NI 
77 CEETOX cat 2A No No 1 1.026 4.323   2.3871 0.22   85.596 9.926   . .   .     85.596   NI 
77 CEETOX cat 2A No No 2 1.354 3.187   31.068 12.67   79.313 15.68   . .   .     79.313   NI 
77 CEETOX cat 2A No No 3 1.017 7.024   26.217 4.983   95.838 0.768   . .   .     95.838   NI 
78 CEETOX cat 2A No No 1 1.026 4.323   2.3871 0.22   86.457 6.712   . .   .     86.457   NI 
78 CEETOX cat 2A No No 2 1.354 3.187   31.068 12.67   85.31 6.583   . .   .     85.31   NI 
















No No 4 1.11 5.842   53.747 6.399 NQ . .   . .   . .   0 NQ I 
80 CEETOX cat 1 Yes No 1 1.022 1.825   49.764 7.681   44.055 2.365   . .   55.701 1.1774   0   I 
80 CEETOX cat 1 Yes No 2 1.011 6.903   31.312 5.994   57.663 6.246   . .   56.279 1.1896   0   I 
80 CEETOX cat 1 Yes No 3 0.808 6.022   3.1753 0.179   50.825 2.677   . .   70.412 1.4884   0   I 
81 CEETOX cat 1 Yes No 1 1.126 12.55   38.801 3.402   0.947 0.093   . .   0.4885 0.2279   0.459   I 
81 CEETOX cat 1 Yes No 2 1.168 7.79   34.309 1.912   0.97 0.108   . .   0.3282 0.2197   0.642   I 
81 CEETOX cat 1 Yes No 3 1.033 4.978   17.027 15.53   0.823 0.256   . .   0.3712 0.2485   0.457   I 
82 CEETOX cat 1 No No 1 0.955 1.687   23.277 7.239   1.169 0.151   . .   .     1.169   I 
82 CEETOX cat 1 No No 2 1.117 6.85   19.866 5.959   1.015 0.362   . .   .     1.015   I 
82 CEETOX cat 1 No No 3 1.108 15.91   36.132 3.321   0.482 0.209   . .   .     0.482   I 
83 CEETOX cat 1 No No 1 1.109 7.989   44.805 3.75   0.857 0.119   . .   .     0.857   I 
83 CEETOX cat 1 No No 2 1.219 9.931   24.606 3.854   0.725 0.247   . .   .     0.725   I 
83 CEETOX cat 1 No No 3 0.814 4.296   4.0131 1.662   1.126 0.256   . .   .     1.126   I 
84 CEETOX cat 1 No No 1 1.114 3.349   38.602 7.556   1.272 0.144   . .   .     1.272   I 
84 CEETOX cat 1 No No 2 1.114 3.349   38.602 7.556 NQ . .   . .   .     0 NQ I 
84 CEETOX cat 1 No No 3 0.955 1.687   23.277 7.239   2.129 0.673   . .   .     2.129   I 
84 CEETOX cat 1 No No 4 0.986 9.055   41.765 3.931   1.167 0.128   . .   .     1.167   I 
85 CEETOX cat 1 No No 1 1.061 5.816   83.276 0.966 NQ . .   . .   .     0 NQ I 
85 CEETOX cat 1 No No 2 0.931 4.593   85.407 7.847 NQ . .   . .   .     0 NQ I 
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85 CEETOX cat 1 No No 3 1.061 3.431   18.843 5.17   0.597 0.314   . .   .     0.597   I 
85 CEETOX cat 1 No No 4 1.099 1.557   26.79 5.02   0.85 0.205   . .   .     0.85   I 
85 CEETOX cat 1 No No 5 1.097 2.786   36.449 2.106   0.623 0.121   . .   .     0.623   I 
86 CEETOX cat 1 No No 1 0.955 1.687   23.277 7.239   2.862 3.128   . .   .     2.862   I 
86 CEETOX cat 1 No No 2 1.117 6.85   19.866 5.959   1.403 0.416   . .   .     1.403   I 
86 CEETOX cat 1 No No 3 1.108 15.91   36.132 3.321   3.928 3.049   . .   .     3.928   I 
87 CEETOX cat 1 No No 1 1.022 1.825   49.764 7.681   1.272 0.482   . .   .     1.272   I 
87 CEETOX cat 1 No No 2 1.011 6.903   31.312 5.994   1.154 0.446   . .   .     1.154   I 
87 CEETOX cat 1 No No 3 0.808 6.022   3.1753 0.179   2.124 1.553   . .   .     2.124   I 
88 CEETOX cat 1 Yes No 1 0.955 1.687   23.277 7.239   2.111 0.332   . .   0.157 0.1982   1.954   I 
88 CEETOX cat 1 Yes No 2 1.117 6.85   19.866 5.959   1.866 0.052   . .   0.3134 0.1695   1.552   I 
88 CEETOX cat 1 No No 3 1.117 6.85   19.866 5.959 NQ . .   . .   . 0.1695   0 NQ I 
88 CEETOX cat 1 Yes No 4 1.108 15.91   36.132 3.321   1.67 0.326   . .   2.0767 0.1709   0   I 
89 CEETOX cat 1 No No 1 1.022 1.825   49.764 7.681   1.99 0.057   . .   .     1.99   I 
89 CEETOX cat 1 No No 2 1.011 6.903   31.312 5.994   1.813 0.198   . .   .     1.813   I 
89 CEETOX cat 1 No No 3 0.808 6.022   3.1753 0.179   2.474 0.373   . .   .     2.474   I 
90 CEETOX cat 1 No No 1 0.984 11.67   4.1935 4.007   2.387 0.414   . .   .     2.387   I 
90 CEETOX cat 1 No No 2 1.038 3.122   66.148 3.566 NQ . .   . .   .     0 NQ I 
90 CEETOX cat 1 No No 3 1.038 3.122   66.148 3.566   2.111 0.44   . .   .     2.111   I 
90 CEETOX cat 1 No No 4 1.11 5.842   53.747 6.399 NQ . .   . .   .     0 NQ I 
90 CEETOX cat 1 No No 5 1.11 5.842   53.747 6.399   3.914 1.001   . .   .     3.914   I 
91 CEETOX cat 1 Yes No 1 0.984 11.67   4.1935 4.007   14.477 2.874   . .   0 0   14.477   I 
91 CEETOX cat 1 Yes No 2 1.074 3.69   13.347 3.511   4.642 4.533   . .   0 0   4.642   I 
91 CEETOX cat 1 No No 3 1.117 7.674   70.816 2.256 NQ . .   . .   . .   0 NQ I 
91 CEETOX cat 1 No No 4 1.11 5.842   53.747 6.399 NQ . .   . .   . 0.3431   0 NQ I 
91 CEETOX cat 1 Yes No 5 1.11 5.842   53.747 6.399   16.06 6.581   . .   0.3951 0.3431   15.719   I 
92 CEETOX cat 1 Yes No 1 0.986 9.055   41.765 3.931   11.684 2.476   . .   0.6087 0.4314   11.075   I 
92 CEETOX cat 1 No No 2 0.872 8.034   61.365 6.357 NQ . .   . .   . .   0 NQ I 
92 CEETOX cat 1 Yes No 3 1.108 15.91   36.132 3.321   9.27 0.847   . .   2.468 0.384   6.802   I 
92 CEETOX cat 1 Yes No 4 0.997 8.889   9.1441 3.404   5.567 2.101   . .   0.5015 0.4265   5.065   I 
93 CEETOX cat 1 No No 1 1.061 5.816   83.276 0.966 NQ . .   . .   . .   0 NQ I 
93 CEETOX cat 1 No No 2 0.931 4.593   85.407 7.847 NQ . .   . .   . .   0 NQ I 
93 CEETOX cat 1 No No 3 1.061 3.431   18.843 5.17   38.111 13.42   . .   .     38.111   I 
93 CEETOX cat 1 No No 4 1.099 1.557   26.79 5.02   65.473 5.144   . .   .     65.473   NI 
93 CEETOX cat 1 No No 5 1.097 2.786   36.449 2.106   55.221 13.45   . .   .     55.221   NI 
94 CEETOX cat 1 No No 1 0.984 11.67   4.1935 4.007   2.337 0.346   . .   .     2.337   I 
94 CEETOX cat 1 No No 2 1.038 3.122   66.148 3.566 NQ . .   . .   .     0 NQ I 
94 CEETOX cat 1 No No 3 1.038 3.122   66.148 3.566   8.865 2.352   . .   .     8.865   I 
94 CEETOX cat 1 No No 4 1.11 5.842   53.747 6.399 NQ . .   . .   .     0 NQ I 
94 CEETOX cat 1 No No 5 1.11 5.842   53.747 6.399   26.811 6.292   . .   .     26.811   I 
95 CEETOX cat 1 No No 1 1.109 7.989   44.805 3.75   1.068 0.452   . .   .     1.068   I 
95 CEETOX cat 1 No No 2 1.219 9.931   24.606 3.854   1.189 0.226   . .   .     1.189   I 
95 CEETOX cat 1 No No 3 0.814 4.296   4.0131 1.662   1.454 0.912   . .   .     1.454   I 
96 CEETOX cat 1 No No 1 1.109 7.989   44.805 3.75   41.708 7.646   . .   .     41.708   I 
96 CEETOX cat 1 No No 2 1.219 9.931   24.606 3.854   45.584 9.022   . .   .     45.584   I 
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96 CEETOX cat 1 No No 3 0.814 4.296   4.0131 1.662   50.491 6.507   . .   .     50.491   NI 
97 CEETOX cat 1 No No 1 1.168 7.79   34.309 1.912   61.781 1.522   . .   .     61.781   NI 
97 CEETOX cat 1 No No 2 1.033 4.978   17.027 15.53   59.555 4.387   . .   .     59.555   NI 
97 CEETOX cat 1 No No 3 1.066 7.842   3.9856 2.185   65.192 1.71   . .   .     65.192   NI 
98 CEETOX cat 1 No No 1 1.102 4.826   52.117 3.403 NQ . .   . .   . .   0 NQ I 
98 CEETOX cat 1 Yes Yes 2 0.99 7.261   33.12 5.324   92.124 3.229   6.2773 1.49   10.821 2.2536   75.025   NI 
98 CEETOX cat 1 No No 3 0.99 7.261   33.12 5.324 NQ . .   . 1.49   . 2.2536   0 NQ I 
98 CEETOX cat 1 Yes Yes 4 0.955 1.687   23.277 7.239   91.729 8.983   5.6535 1.3   11.639 2.3365   74.437   NI 
98 CEETOX cat 1 Yes Yes 5 1.108 15.91   36.132 3.321   74.432 7.182   21.866 7.28   11.603 2.0151   40.963   I 
99 CEETOX cat 1 No No 1 1.074 3.69   13.347 3.511   1.133 0.117   . .   .     1.133   I 
99 CEETOX cat 1 No No 2 1.026 4.323   2.3871 0.22   1.543 0.296   . .   .     1.543   I 
99 CEETOX cat 1 No No 3 1.281 2.862   35.038 5.007   1.665 0.158   . .   .     1.665   I 
99 CEETOX cat 1 No No 4 1.11 5.842   53.747 6.399 NQ . .   . .   .     0 NQ I 
100 CEETOX cat 1 No No 1 0.936 3.064   30.876 8.046   2.422 0.51   . .   .     2.422   I 
100 CEETOX cat 1 No No 2 0.99 7.261   33.12 5.324   1.75 0.127   . .   .     1.75   I 
100 CEETOX cat 1 No No 3 0.955 1.687   23.277 7.239   2.094 0.659   . .   .     2.094   I 
101 CEETOX cat 1 No No 1 1.117 6.85   19.866 5.959   71.881 7.426   . .   .     71.881   NI 
101 CEETOX cat 1 No No 2 0.986 9.055   41.765 3.931   83.006 2.132   . .   .     83.006   NI 
101 CEETOX cat 1 No No 3 1.108 15.91   36.132 3.321   63.552 3.025   . .   .     63.552   NI 
102 CEETOX cat 1 No No 1 0.955 1.687   23.277 7.239   104.14 14.14   . .   .     104.135   NI 
102 CEETOX cat 1 No No 2 1.117 6.85   19.866 5.959   86.657 7.298   . .   .     86.657   NI 
102 CEETOX cat 1 No No 3 1.108 15.91   36.132 3.321   64.244 14.38   . .   .     64.244   NI 
103 CEETOX cat 1 Yes No 1 1.026 4.323   2.3871 0.22   1.332 0.149   . .   0.2328 0.3353   1.25   I 
103 CEETOX cat 1 Yes No 2 1.354 3.187   31.068 12.67   0.493 0.497   . .   0 0   0.493   I 
103 CEETOX cat 1 Yes No 3 1.017 7.024   26.217 4.983   0.95 0   . .   13.387 0.5407   0   I 
104 CEETOX cat 1 Yes No 1 1.026 4.323   2.3871 0.22   80.741 2.631   . .   0.2815 0.2625   80.464   NI 
104 CEETOX cat 1 Yes No 2 1.354 3.187   31.068 12.67   85.716 5.336   . .   0.156 0.154   85.593   NI 
104 CEETOX cat 1 Yes No 3 1.017 7.024   26.217 4.983   77.208 6.907   . .   12.633 0   64.575   NI 
105 CEETOX cat 1 No Yes 1 1.026 4.323   2.3871 0.22   1.185 0.442   0.6496 0.1   .     0.606   I 
105 CEETOX cat 1 No Yes 2 1.354 3.187   31.068 12.67   1.121 0.238   0.4064 0.07   .     0.714   I 
105 CEETOX cat 1 No Yes 3 1.017 7.024   26.217 4.983   0 0   0 0   .     0   I 
1 L’OREAL no cat No No 1 1.215 6.134   65.417 5.374 NQ . .   . .   . 0.1764   0 NQ I 
1 L’OREAL no cat Yes No 2 1.215 6.134   65.417 5.374   1.475 0.214   . .   0.1775 0.1764   1.315   I 
1 L’OREAL no cat Yes No 3 1.207 1.747   16.571 4.591   19.737 8.397   . .   0.109 0.119   19.662   I 
1 L’OREAL no cat Yes No 4 0.954 5.639   25.157 6.823   8.134 4.728   . .   0.0809 0.1154   8.125   I 
2 L’OREAL no cat Yes No 1 1.167 5.4   28.91 0.885   1.935 0.041   . .   0 0   1.935   I 
2 L’OREAL no cat Yes No 2 1.171 5.113   44.435 13.63   2.021 0.247   . .   0 0   2.021   I 
2 L’OREAL no cat Yes No 3 1.141 5.08   15.556 0.808   3.442 2.589   . .   0 0   3.442   I 
3 L’OREAL no cat No No 1 1.167 5.4   28.91 0.885   1.164 0.112   . .   .     1.164   I 
3 L’OREAL no cat No No 2 1.141 5.08   15.556 0.808   0.811 0.244   . .   .     0.811   I 
3 L’OREAL no cat No No 3 1.158 6.507   37.465 0.834   0.831 0.094   . .   .     0.831   I 
4 L’OREAL no cat Yes No 1 0.954 5.639   25.157 6.823   66.379 10.18   . .   30.612 6.7693   35.767   I 
4 L’OREAL no cat Yes No 2 1.041 2.734   5.2453 0.719   64.189 7.059   . .   28.101 6.2066   36.088   I 
4 L’OREAL no cat Yes No 3 1.112 4.848   7.1871 3.378   64.562 0.261   . .   26.274 5.8127   38.288   I 
5 L’OREAL no cat Yes No 1 1.084 8.313   30.98 5.154   8.158 4.449   . .   3.5418 2.571   4.705   I 
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5 L’OREAL no cat Yes No 2 1.045 4.151   33.69 6.079   3.057 0.486   . .   3.8017 2.6682   0   I 
5 L’OREAL no cat Yes No 3 1.171 5.113   44.435 13.63   7.728 3.467   . .   3.4443 2.3804   4.284   I 
6 L’OREAL no cat No No 1 1.167 5.4   28.91 0.885   3.385 1.111   . .   .     3.385   I 
6 L’OREAL no cat No No 2 1.141 5.08   15.556 0.808   14.357 2.922   . .   .     14.357   I 
6 L’OREAL no cat No No 3 1.158 6.507   37.465 0.834   11.238 3.749   . .   .     11.238   I 
7 L’OREAL no cat Yes No 1 1.167 5.4   28.91 0.885   4.71 3.057   . .   0 0   4.71   I 
7 L’OREAL no cat Yes No 2 1.141 5.08   15.556 0.808   7.709 4.709   . .   0 0   7.709   I 
7 L’OREAL no cat Yes No 3 1.011 5.403   48.7 2.057   0.852 0.052   . .   0.366 0.2047   0.486   I 
8 L’OREAL no cat No No 1 1.215 6.134   65.417 5.374 NQ . .   . .   .     0 NQ I 
8 L’OREAL no cat No No 2 1.215 6.134   65.417 5.374   23.297 3.211   . .   .     23.297   I 
8 L’OREAL no cat No No 3 0.954 5.639   25.157 6.823   29.309 4.875   . .   .     29.309   I 
8 L’OREAL no cat No No 4 1.041 2.734   5.2453 0.719   15.629 2.902   . .   .     15.629   I 
9 L’OREAL no cat Yes No 1 1.084 8.313   30.98 5.154   30.968 4.386   . .   0.0738 0.1278   30.946   I 
9 L’OREAL no cat Yes No 2 1.045 4.151   33.69 6.079   29.381 4.01   . .   0.1484 0.1812   29.233   I 
9 L’OREAL no cat Yes No 3 1.171 5.113   44.435 13.63   19.755 4.426   . .   0.185 0.1617   19.57   I 
10 L’OREAL no cat No No 1 1.158 1.866   26.395 0.521   1.164 0.299   . .   .     1.164   I 
10 L’OREAL no cat No No 2 1.189 2.082   10.92 1.838   0.892 0.462   . .   .     0.892   I 
10 L’OREAL no cat No No 3 1.118 0.919   31.095 4.839   1.364 0.857   . .   .     1.364   I 
11 L’OREAL no cat Yes No 1 1.084 8.313   30.98 5.154   74.86 4.774   . .   0.0277 0.0479   74.86   NI 
11 L’OREAL no cat Yes No 2 1.045 4.151   33.69 6.079   69.28 9.957   . .   0.0707 0.1225   69.28   NI 
11 L’OREAL no cat Yes No 3 1.171 5.113   44.435 13.63   49.103 3.64   . .   0.0807 0.1397   49.103   I 
12 L’OREAL no cat No No 1 1.166 6.115   0.8351 0.175   83.587 2.695   . .   .     83.587   NI 
12 L’OREAL no cat No No 2 1.403 1.696   30.786 9.616   96.308 7.132   . .   .     96.308   NI 
12 L’OREAL no cat No No 3 1.161 3.337   40.266 4.053   93.549 7.368   . .   .     93.549   NI 
13 L’OREAL no cat No No 1 1.144 6.145   1.6528 0.635   97.021 6.737   . .   .     97.021   NI 
13 L’OREAL no cat No No 2 1.071 2.796   33.29 7.118   96.48 7.74   . .   .     96.48   NI 
13 L’OREAL no cat No No 3 1.161 3.337   40.266 4.053   85.999 3.523   . .   .     85.999   NI 
14 L’OREAL no cat No No 1 1.215 6.134   65.417 5.374 NQ . .   . .   .     0 NQ I 
14 L’OREAL no cat No No 2 1.215 6.134   65.417 5.374   87.512 1.371   . .   .     87.512   NI 
14 L’OREAL no cat No No 3 1.22 1.963   28.513 4.792   89.487 2.908   . .   .     89.487   NI 
14 L’OREAL no cat No No 4 0.954 5.639   25.157 6.823   99.569 5.871   . .   .     99.569   NI 
15 L’OREAL no cat No No 1 1.166 6.115   0.8351 0.175   94.101 5.025   . .   .     94.101   NI 
15 L’OREAL no cat No No 2 1.071 2.796   33.29 7.118   96.315 8.799   . .   .     96.315   NI 
15 L’OREAL no cat No No 3 1.161 3.337   40.266 4.053   89.673 1.305   . .   .     89.673   NI 
16 L’OREAL no cat Yes No 1 1.084 8.313   30.98 5.154   95.291 0.3   . .   0.0343 0.0595   95.291   NI 
16 L’OREAL no cat Yes No 2 1.045 4.151   33.69 6.079   103.48 3.869   . .   0.0729 0.1262   103.479   NI 
16 L’OREAL no cat Yes No 3 1.171 5.113   44.435 13.63   97.837 5.769   . .   0.0949 0.1643   97.822   NI 
17 L’OREAL no cat No No 1 1.041 2.734   5.2453 0.719   86.429 5.045   . .   .     86.429   NI 
17 L’OREAL no cat No No 2 1.118 0.451   21.723 7.774   90.337 8.516   . .   .     90.337   NI 
17 L’OREAL no cat No No 3 1.158 1.866   26.395 0.521   79.685 2.503   . .   .     79.685   NI 
18 L’OREAL no cat No No 1 1.166 6.115   0.8351 0.175   92.052 4.652   . .   .     92.052   NI 
18 L’OREAL no cat No No 2 1.071 2.796   33.29 7.118   103.48 1.503   . .   .     103.483   NI 
18 L’OREAL no cat No No 3 1.161 3.337   40.266 4.053   93.9 4.43   . .   .     93.9   NI 
19 L’OREAL no cat No No 1 1.166 6.115   0.8351 0.175   98.734 6.043   . .   .     98.734   NI 
19 L’OREAL no cat No No 2 1.403 1.696   30.786 9.616   107.25 3.553   . .   .     107.249   NI 
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19 L’OREAL no cat No No 3 1.161 3.337   40.266 4.053   94.252 5.002   . .   .     94.252   NI 
20 L’OREAL no cat Yes No 1 1.166 6.115   0.8351 0.175   42.034 17.14   . .   62.469 9.0062   0   I 
20 L’OREAL no cat Yes No 2 1.403 1.696   30.786 9.616   39.73 7.303   . .   51.865 7.4832   0   I 
20 L’OREAL no cat Yes No 3 1.117 3.017   25.194 7.837   36.964 8.234   . .   64.616 9.3985   0   I 
21 L’OREAL no cat Yes No 1 1.158 1.866   26.395 0.521   66.573 5.018   . .   0 0   66.573   NI 
21 L’OREAL no cat Yes No 2 1.189 2.082   10.92 1.838   63.627 1.167   . .   0 0   63.627   NI 
21 L’OREAL no cat Yes No 3 1.119 2.182   18.851 9.32   68.993 2.341   . .   0 0   68.993   NI 
22 L’OREAL no cat No No 1 1.189 2.082   10.92 1.838   1.122 0.795   . .   .     1.122   I 
22 L’OREAL no cat No No 2 1.169 2.795   24.645 3.859   1.078 0.041   . .   .     1.078   I 
22 L’OREAL no cat No No 3 1.151 3.882   20.444 5.887   1.053 0.093   . .   .     1.053   I 
23 L’OREAL no cat Yes No 1 1.184 2.242   14.222 1.597   31.458 0.801   . .   1.544 1.481   29.914   I 
23 L’OREAL no cat Yes No 2 1.162 3.08   44.054 2.436   30.198 4.072   . .   1.5456 1.5087   28.653   I 
23 L’OREAL no cat Yes No 3 1.137 0.244   13.707 2.66   2.305 0.295   . .   1.8358 1.5429   0.471   I 
24 L’OREAL no cat Yes No 1 1.118 0.919   31.095 4.839   0.834 0.503   . .   0 0   0.834   I 
24 L’OREAL no cat Yes No 2 1.214 2.527   46.43 0.591   0.376 0.029   . .   0 0   0.376   I 
24 L’OREAL no cat Yes No 3 1.362 3.038   40.51 0.668   0.549 0.122   . .   0 0   0.549   I 
25 L’OREAL no cat Yes No 1 1.143 5.763   29.636 4.03   99.551 3.464   . .   0 0   99.551   NI 
25 L’OREAL no cat Yes No 2 1.403 1.696   30.786 9.616   94.438 5.306   . .   0 0   94.438   NI 
25 L’OREAL no cat Yes No 3 1.122 1.609   27.629 3.813   68.744 3.113   . .   0 0   68.744   NI 
26 L’OREAL no cat No No 1 1.143 5.763   29.636 4.03   2.301 0.232   . .   .     2.301   I 
26 L’OREAL no cat No No 2 1.117 3.017   25.194 7.837   3.034 0.721   . .   .     3.034   I 
26 L’OREAL no cat No No 3 1.122 1.609   27.629 3.813   2.465 0.25   . .   .     2.465   I 
28 L’OREAL no cat No No 1 1.167 5.4   28.91 0.885   94.743 7.359   . .   .     94.743   NI 
28 L’OREAL no cat No No 2 1.141 5.08   15.556 0.808   90.959 4.122   . .   .     90.959   NI 
28 L’OREAL no cat No No 3 1.158 6.507   37.465 0.834   88.244 1   . .   .     88.244   NI 
29 L’OREAL no cat No No 1 1.166 6.115   0.8351 0.175   95.089 3.501   . .   .     95.089   NI 
29 L’OREAL no cat No No 2 1.117 3.017   25.194 7.837   87.727 6.059   . .   .     87.727   NI 
29 L’OREAL no cat No No 3 1.122 1.609   27.629 3.813   90.097 6.403   . .   .     90.097   NI 
30 L’OREAL no cat No No 1 1.184 2.242   14.222 1.597   66.935 6.926   . .   .     66.935   NI 
30 L’OREAL no cat No No 2 1.362 3.038   40.51 0.668   79.054 2.62   . .   .     79.054   NI 
30 L’OREAL no cat No No 3 1.162 3.08   44.054 2.436   79.691 2.811   . .   .     79.691   NI 
31 L’OREAL no cat No No 1 1.184 2.242   14.222 1.597   97.316 1.203   . .   .     97.316   NI 
31 L’OREAL no cat No No 2 1.214 2.527   46.43 0.591   92.574 5.721   . .   .     92.574   NI 
31 L’OREAL no cat No No 3 1.362 3.038   40.51 0.668   84.829 3.375   . .   .     84.829   NI 
32 L’OREAL no cat Yes Yes 1 1.041 2.734   5.2453 0.719   5.727 0.418   1.1592 0.29   1.5371 0.8863   3.031   I 
32 L’OREAL no cat Yes Yes 2 1.112 4.848   7.1871 3.378   4.092 0.839   0.5473 0.18   1.375 0.83   2.17   I 
32 L’OREAL no cat Yes Yes 3 1.118 0.451   21.723 7.774   4.088 1.179   0.4412 0.07   1.4309 0.8322   2.216   I 
33 L’OREAL no cat Yes Yes 1 1.189 2.082   10.92 1.838   89.051 4.561   0.5427 0.18   0.0388 0.0672   88.508   NI 
33 L’OREAL no cat Yes Yes 2 1.118 0.919   31.095 4.839   92.322 4.602   0.255 0.15   0.0383 0.0663   92.067   NI 
33 L’OREAL no cat Yes Yes 3 1.119 2.182   18.851 9.32   104.93 8.24   0.554 0.06   0.0357 0.0619   104.371   NI 
34 L’OREAL no cat Yes Yes 1 1.189 2.082   10.92 1.838   66.769 5.409   3.4945 0.25   6.2317 0.3237   57.043   NI 
34 L’OREAL no cat Yes Yes 2 1.118 0.919   31.095 4.839   65.19 4.432   3.7771 0.7   6.6178 0.3442   54.796   NI 
34 L’OREAL no cat Yes Yes 3 1.119 2.182   18.851 9.32   77.936 15.22   5.8184 0.96   6.5973 0.3383   65.52   NI 
35 L’OREAL no cat No No 1 1.215 6.134   65.417 5.374 NQ . .   . .   . 1.5527   0 NQ I 
35 L’OREAL no cat Yes No 2 1.215 6.134   65.417 5.374   85.967 5.533   . .   1.3707 1.5527   84.596   NI 
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35 L’OREAL no cat Yes No 3 1.22 1.963   28.513 4.792   90.61 6.236   . .   1.3488 1.5372   89.262   NI 
35 L’OREAL no cat Yes No 4 1.041 2.734   5.2453 0.719   97.907 2.867   . .   1.6331 1.801   96.274   NI 
36 L’OREAL no cat No No 1 1.084 8.313   30.98 5.154   102.43 3.705   . .   .     102.433   NI 
36 L’OREAL no cat No No 2 1.045 4.151   33.69 6.079   110.47 6.695   . .   .     110.467   NI 
36 L’OREAL no cat No No 3 1.22 1.963   28.513 4.792   101.13 4.186   . .   .     101.127   NI 
37 L’OREAL no cat No No 1 1.169 2.795   24.645 3.859   85.737 4.406   . .   .     85.737   NI 
37 L’OREAL no cat No No 2 1.151 3.882   20.444 5.887   83.006 3.173   . .   .     83.006   NI 
37 L’OREAL no cat No No 3 1.214 2.527   46.43 0.591   90.159 2.26   . .   .     90.159   NI 
38 L’OREAL no cat No No 1 1.166 6.115   0.8351 0.175   96.268 3.966   . .   .     96.268   NI 
38 L’OREAL no cat No No 2 1.403 1.696   30.786 9.616   100.86 2.793   . .   .     100.858   NI 
38 L’OREAL no cat No No 3 1.161 3.337   40.266 4.053   97.064 10.56   . .   .     97.064   NI 
39 L’OREAL no cat No No 1 1.166 6.115   0.8351 0.175   97.729 3.933   . .   .     97.729   NI 
39 L’OREAL no cat No No 2 1.403 1.696   30.786 9.616   94.618 8.101   . .   .     94.618   NI 
39 L’OREAL no cat No No 3 1.161 3.337   40.266 4.053   94.391 0.442   . .   .     94.391   NI 
40 L’OREAL no cat No No 1 1.144 6.145   1.6528 0.635   94.782 3.001   . .   .     94.782   NI 
40 L’OREAL no cat No No 2 1.071 2.796   33.29 7.118   74.376 7.79   . .   .     74.376   NI 
40 L’OREAL no cat No No 3 1.161 3.337   40.266 4.053   94.18 14.4   . .   .     94.18   NI 
41 L’OREAL no cat No No 1 1.169 2.795   24.645 3.859   92.756 3.146   . .   .     92.756   NI 
41 L’OREAL no cat No No 2 1.151 3.882   20.444 5.887   95.925 5.298   . .   .     95.925   NI 
41 L’OREAL no cat No No 3 1.119 2.182   18.851 9.32   96.776 2.828   . .   .     96.776   NI 
42 L’OREAL no cat Yes No 1 1.169 2.795   24.645 3.859   74.057 3.067   . .   0 0   74.057   NI 
42 L’OREAL no cat Yes No 2 1.151 3.882   20.444 5.887   79.115 1.958   . .   0.0043 0.0075   79.115   NI 
42 L’OREAL no cat Yes No 3 1.119 2.182   18.851 9.32   76.238 1.867   . .   0.0581 0.0604   76.233   NI 
43 L’OREAL no cat No No 1 1.151 3.882   20.444 5.887   94.581 4.906   . .   .     94.581   NI 
43 L’OREAL no cat No No 2 1.184 2.242   14.222 1.597   95.517 0.247   . .   .     95.517   NI 
43 L’OREAL no cat No No 3 1.214 2.527   46.43 0.591   93.62 2.342   . .   .     93.62   NI 
44 L’OREAL no cat No No 1 1.169 2.795   24.645 3.859   94.234 4.922   . .   .     94.234   NI 
44 L’OREAL no cat No No 2 1.151 3.882   20.444 5.887   87.078 0.931   . .   .     87.078   NI 
44 L’OREAL no cat No No 3 1.214 2.527   46.43 0.591   89.017 0.72   . .   .     89.017   NI 
45 L’OREAL no cat No No 1 1.169 2.795   24.645 3.859   89.716 2.714   . .   .     89.716   NI 
45 L’OREAL no cat No No 2 1.151 3.882   20.444 5.887   91.837 4.49   . .   .     91.837   NI 
45 L’OREAL no cat No No 3 1.119 2.182   18.851 9.32   98.091 3.935   . .   .     98.091   NI 
46 L’OREAL no cat No No 1 1.151 3.882   20.444 5.887   54.131 8.582   . .   .     54.131   NI 
46 L’OREAL no cat No No 2 1.184 2.242   14.222 1.597   93.096 6.064   . .   .     93.096   NI 
46 L’OREAL no cat No No 3 1.214 2.527   46.43 0.591   84.614 3.815   . .   .     84.614   NI 
47 L’OREAL no cat No No 1 1.169 2.795   24.645 3.859   49.016 11.12   . .   .     49.016   I 
47 L’OREAL no cat No No 2 1.151 3.882   20.444 5.887   43.114 7.459   . .   .     43.114   I 
47 L’OREAL no cat No No 3 1.214 2.527   46.43 0.591   30.902 4.799   . .   .     30.902   I 
48 L’OREAL no cat No No 1 1.184 2.242   14.222 1.597   5.735 0.542   . .   .     5.735   I 
48 L’OREAL no cat No No 2 1.362 3.038   40.51 0.668   3.445 0.145   . .   .     3.445   I 
48 L’OREAL no cat No No 3 1.162 3.08   44.054 2.436   3.726 0.179   . .   .     3.726   I 
49 L’OREAL no cat Yes No 1 1.143 5.763   29.636 4.03   88.067 1.818   . .   0 0   88.067   NI 
49 L’OREAL no cat Yes No 2 1.403 1.696   30.786 9.616   88.544 3.95   . .   0 0   88.544   NI 
49 L’OREAL no cat Yes No 3 1.122 1.609   27.629 3.813   79.082 1.477   . .   0 0   79.082   NI 
50 L’OREAL no cat No No 1 1.071 2.796   33.29 7.118   100.5 2.787   . .   .     100.5   NI 
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50 L’OREAL no cat No No 2 1.117 3.017   25.194 7.837   88.364 6.963   . .   .     88.364   NI 
50 L’OREAL no cat No No 3 1.122 1.609   27.629 3.813   91.708 4.236   . .   .     91.708   NI 
51 L’OREAL no cat No No 1 1.143 5.763   29.636 4.03   102.08 5.554   . .   .     102.081   NI 
51 L’OREAL no cat No No 2 1.117 3.017   25.194 7.837   96.865 6.475   . .   .     96.865   NI 
51 L’OREAL no cat No No 3 1.122 1.609   27.629 3.813   66.853 8.417   . .   .     66.853   NI 
52 L’OREAL no cat No No 1 1.143 5.763   29.636 4.03   101.97 3.353   . .   .     101.972   NI 
52 L’OREAL no cat No No 2 1.117 3.017   25.194 7.837   98.199 5.073   . .   .     98.199   NI 
52 L’OREAL no cat No No 3 1.122 1.609   27.629 3.813   98.939 5.337   . .   .     98.939   NI 
53 L’OREAL no cat No No 1 1.143 5.763   29.636 4.03   104.08 3.779   . .   .     104.078   NI 
53 L’OREAL no cat No No 2 1.117 3.017   25.194 7.837   87.664 2.052   . .   .     87.664   NI 
53 L’OREAL no cat No No 3 1.122 1.609   27.629 3.813   108.42 5.453   . .   .     108.423   NI 
54 L’OREAL cat 2B No No 1 1.215 6.134   65.417 5.374 NQ . .   . .   .     0 NQ I 
54 L’OREAL cat 2B No No 2 1.215 6.134   65.417 5.374   0.555 0.015   . .   .     0.555   I 
54 L’OREAL cat 2B No No 3 1.22 1.963   28.513 4.792   0.413 0.028   . .   .     0.413   I 
54 L’OREAL cat 2B No No 4 0.954 5.639   25.157 6.823   0.468 0.034   . .   .     0.468   I 
55 L’OREAL cat 2B Yes No 1 1.118 0.919   31.095 4.839   0.92 0.048   . .   0 0   0.92   I 
55 L’OREAL cat 2B Yes No 2 1.362 3.038   40.51 0.668   0.962 0.094   . .   0 0   0.962   I 
55 L’OREAL cat 2B Yes No 3 1.162 3.08   44.054 2.436   0.984 0.056   . .   0.0487 0.0844   0.982   I 
56 L’OREAL cat 2B No No 1 1.118 0.919   31.095 4.839   0.664 0.132   . .   .     0.664   I 
56 L’OREAL cat 2B No No 2 1.362 3.038   40.51 0.668   0.645 0.093   . .   .     0.645   I 
56 L’OREAL cat 2B No No 3 1.162 3.08   44.054 2.436   0.727 0.329   . .   .     0.727   I 
57 L’OREAL cat 2B No No 1 1.158 1.866   26.395 0.521   0.692 0.127   . .   .     0.692   I 
57 L’OREAL cat 2B No No 2 1.189 2.082   10.92 1.838   1.101 0.163   . .   .     1.101   I 
57 L’OREAL cat 2B No No 3 1.118 0.919   31.095 4.839   0.286 0.027   . .   .     0.286   I 
58 L’OREAL cat 2B Yes No 1 1.118 0.919   31.095 4.839   0.388 0.116   . .   0 0   0.388   I 
58 L’OREAL cat 2B Yes No 2 1.214 2.527   46.43 0.591   0.239 0.01   . .   0 0   0.239   I 
58 L’OREAL cat 2B Yes No 3 1.362 3.038   40.51 0.668   0.41 0.028   . .   0 0   0.41   I 
59 L’OREAL cat 2B Yes No 1 1.184 2.242   14.222 1.597   21.196 4.499   . .   0 0   21.196   I 
59 L’OREAL cat 2B Yes No 2 1.362 3.038   40.51 0.668   0.575 0.069   . .   0 0   0.575   I 
59 L’OREAL cat 2B Yes No 3 1.162 3.08   44.054 2.436   20.027 9.052   . .   0 0   20.027   I 
60 L’OREAL cat 2B No No 1 1.166 6.115   0.8351 0.175   0.429 0.07   . .   .     0.429   I 
60 L’OREAL cat 2B No No 2 1.117 3.017   25.194 7.837   0.566 0.047   . .   .     0.566   I 
60 L’OREAL cat 2B No No 3 1.161 3.337   40.266 4.053   0.775 0.212   . .   .     0.775   I 
61 L’OREAL cat 2B No Yes 1 1.084 8.313   30.98 5.154   70.04 1.064   0.2767 0.04   .     69.764   NI 
61 L’OREAL cat 2B No Yes 2 1.045 4.151   33.69 6.079   86.21 1.466   0.4642 0.14   .     85.746   NI 
61 L’OREAL cat 2B No Yes 3 1.158 6.507   37.465 0.834   71.661 8.38   0.3542 0.04   .     71.307   NI 
62 L’OREAL cat 2B No No 1 1.151 3.882   20.444 5.887   93.212 5.778   . .   .     93.212   NI 
62 L’OREAL cat 2B No No 2 1.214 2.527   46.43 0.591   88.27 6.142   . .   .     88.27   NI 
62 L’OREAL cat 2B No No 3 1.362 3.038   40.51 0.668   86.195 3.253   . .   .     86.195   NI 
63 L’OREAL cat 2B No No 1 1.184 2.242   14.222 1.597   88.452 0.533   . .   .     88.452   NI 
63 L’OREAL cat 2B No No 2 1.362 3.038   40.51 0.668   86.32 5.561   . .   .     86.32   NI 
63 L’OREAL cat 2B No No 3 1.162 3.08   44.054 2.436   88.642 2.966   . .   .     88.642   NI 
64 L’OREAL cat 2B No No 1 1.158 1.866   26.395 0.521   73.271 0.159   . .   .     73.271   NI 
64 L’OREAL cat 2B No No 2 1.189 2.082   10.92 1.838   68.532 1.769   . .   .     68.532   NI 
64 L’OREAL cat 2B No No 3 1.151 3.882   20.444 5.887   78.342 0.9   . .   .     78.342   NI 
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65 L’OREAL cat 2B No No 1 1.184 2.242   14.222 1.597   13.391 7.957   . .   .     13.391   I 
65 L’OREAL cat 2B No No 2 1.162 3.08   44.054 2.436   68.057 1.931   . .   .     68.057   NI 
65 L’OREAL cat 2B No No 3 1.137 0.244   13.707 2.66   44.987 24.05 NQ . .   .     44.987 NQ I 
65 L’OREAL cat 2B No No 4 1.143 5.763   29.636 4.03   92.491 10.74   . .   .     92.491   NI 
66 L’OREAL cat 2B No No 1 1.184 2.242   14.222 1.597   62.22 10.37   . .   .     62.22   NI 
66 L’OREAL cat 2B No No 2 1.214 2.527   46.43 0.591   18.556 4.2   . .   .     18.556   I 
66 L’OREAL cat 2B No No 3 1.362 3.038   40.51 0.668   3.315 1.986   . .   .     3.315   I 
67 L’OREAL cat 2A Yes No 1 1.167 5.4   28.91 0.885   1.387 1.045   . .   0 0   1.387   I 
67 L’OREAL cat 2A Yes No 2 1.141 5.08   15.556 0.808   0.958 0.852   . .   0 0   0.958   I 
























No No 3 1.158 6.507   37.465 0.834   1.867 1.989   . .   .     1.867   I 
70 L’OREAL cat 2A No No 1 1.118 0.919   31.095 4.839   0.796 0.029   . .   .     0.796   I 
70 L’OREAL cat 2A No No 2 1.362 3.038   40.51 0.668   1.007 0.054   . .   .     1.007   I 




































No No 3 0.954 5.639   25.157 6.823   97.272 4.536   . .   .     97.272   NI 
74 L’OREAL cat 2A No No 1 1.215 6.134   65.417 5.374 NQ . .   . 0.02   . 0.1713   0 NQ I 
74 L’OREAL cat 2A Yes Yes 2 1.215 6.134   65.417 5.374   89.152 1.886   0.8903 0.02   0.6957 0.1713   87.566   NI 
74 L’OREAL cat 2A Yes Yes 3 0.954 5.639   25.157 6.823   108.16 3.756   1.3621 0.02   0.9343 0.2167   105.86   NI 
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    GHS        NC PC Uncorrected viability NSC MTT Final Final Classification 
Chemical Laboratory classification MTT coloring test OD std Qual Mean% Std Qual Mean% Std Qual Mean% Std Qual Mean% Std Qual viability call 50% cutoff 
74 L’OREAL cat 2A Yes Yes 4 1.112 4.848   7.1871 3.378   81.22 6.072   0.4154 0.04   0.8007 0.186   80.004   NI 
75 L’OREAL cat 2A No No 1 1.084 8.313   30.98 5.154   1.133 0.546   . .   .     1.133   I 
75 L’OREAL cat 2A No No 2 1.045 4.151   33.69 6.079   30.458 49.34 NQ . .   .     30.458 NQ I 
75 L’OREAL cat 2A No No 3 1.167 5.4   28.91 0.885   1.274 0.088   . .   .     1.274   I 
75 L’OREAL cat 2A No No 4 1.158 6.507   37.465 0.834   0.796 0.389   . .   .     0.796   I 
76 L’OREAL cat 2A No No 1 0.954 5.639   25.157 6.823   80.058 5.567   . .   .     80.058   NI 
76 L’OREAL cat 2A No No 2 1.041 2.734   5.2453 0.719   60.811 7.86   . .   .     60.811   NI 
76 L’OREAL cat 2A No No 3 1.118 0.451   21.723 7.774   72.566 5.978   . .   .     72.566   NI 
77 L’OREAL cat 2A No No 1 1.118 0.451   21.723 7.774   91.228 6.137   . .   .     91.228   NI 
77 L’OREAL cat 2A No No 2 1.158 1.866   26.395 0.521   87.171 5.285   . .   .     87.171   NI 
77 L’OREAL cat 2A No No 3 1.189 2.082   10.92 1.838   91.157 2.664   . .   .     91.157   NI 
78 L’OREAL cat 2A No No 1 1.041 2.734   5.2453 0.719   87.471 4.774   . .   .     87.471   NI 
78 L’OREAL cat 2A No No 2 1.118 0.451   21.723 7.774   84.321 5.653   . .   .     84.321   NI 












No No 3 1.137 0.244   13.707 2.66   47.748 14.38   . .   .     47.748   I 
80 L’OREAL cat 1 Yes No 1 1.084 8.313   30.98 5.154   23.428 0.447   . .   37.755 3.6437   0   I 
80 L’OREAL cat 1 Yes No 2 1.045 4.151   33.69 6.079   32.527 1.65   . .   39.181 3.7813   0   I 
80 L’OREAL cat 1 Yes No 3 1.171 5.113   44.435 13.63   34.372 3.732   . .   34.956 3.3735   1.234   I 
81 L’OREAL cat 1 No No 1 1.215 6.134   65.417 5.374 NQ . .   . .   .     0 NQ I 
81 L’OREAL cat 1 No No 2 1.215 6.134   65.417 5.374   0.97 0.177   . .   .     0.97   I 
81 L’OREAL cat 1 No No 3 1.22 1.963   28.513 4.792   0.488 0.06   . .   .     0.488   I 
81 L’OREAL cat 1 No No 4 0.954 5.639   25.157 6.823   0.611 0.218   . .   .     0.611   I 
82 L’OREAL cat 1 No No 1 1.166 6.115   0.8351 0.175   0.4 0.07   . .   .     0.4   I 
82 L’OREAL cat 1 No No 2 1.403 1.696   30.786 9.616   0.245 0.068   . .   .     0.245   I 
82 L’OREAL cat 1 No No 3 1.161 3.337   40.266 4.053   0.402 0.05   . .   .     0.402   I 
83 L’OREAL cat 1 No No 1 1.215 6.134   65.417 5.374 NQ . .   . .   .     0 NQ I 
83 L’OREAL cat 1 Yes No 2 1.215 6.134   65.417 5.374   0.948 0.623   . .   0 0   0.948   I 
83 L’OREAL cat 1 Yes No 3 1.207 1.747   16.571 4.591   0.605 0.104   . .   0 0   0.605   I 
83 L’OREAL cat 1 Yes No 4 0.954 5.639   25.157 6.823   0.285 0.055   . .   0 0   0.285   I 
84 L’OREAL cat 1 No No 1 1.144 6.145   1.6528 0.635   0.619 0.204   . .   .     0.619   I 
84 L’OREAL cat 1 No No 2 1.071 2.796   33.29 7.118   0.364 0.047   . .   .     0.364   I 
84 L’OREAL cat 1 No No 3 1.161 3.337   40.266 4.053   0.474 0.057   . .   .     0.474   I 
85 L’OREAL cat 1 No No 1 1.084 8.313   30.98 5.154   0.466 0.1   . .   .     0.466   I 
85 L’OREAL cat 1 No No 2 1.045 4.151   33.69 6.079   0.574 0.16   . .   .     0.574   I 
85 L’OREAL cat 1 No No 3 1.158 6.507   37.465 0.834   0.289 0.059   . .   .     0.289   I 
86 L’OREAL cat 1 No No 1 1.144 6.145   1.6528 0.635   11.368 3.74   . .   .     11.368   I 
86 L’OREAL cat 1 No No 2 1.071 2.796   33.29 7.118   4.311 2.6   . .   .     4.311   I 
86 L’OREAL cat 1 No No 3 1.117 3.017   25.194 7.837   7.567 1.57   . .   .     7.567   I 
87 L’OREAL cat 1 Yes No 1 1.167 5.4   28.91 0.885   1.51 0.416   . .   0 0   1.51   I 
87 L’OREAL cat 1 Yes No 2 1.141 5.08   15.556 0.808   2.171 0.805   . .   0 0   2.171   I 
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    GHS        NC PC Uncorrected viability NSC MTT Final Final Classification 
Chemical Laboratory classification MTT coloring test OD std Qual Mean% Std Qual Mean% Std Qual Mean% Std Qual Mean% Std Qual viability call 50% cutoff 
87 L’OREAL cat 1 Yes No 3 1.011 5.403   48.7 2.057   1.09 0.772   . .   0 0   1.09   I 
88 L’OREAL cat 1 Yes No 1 1.144 6.145   1.6528 0.635   0.99 0.167   . .   0 0   0.99   I 
88 L’OREAL cat 1 Yes No 2 1.071 2.796   33.29 7.118   0.643 0.023   . .   0 0   0.643   I 
88 L’OREAL cat 1 Yes No 3 1.403 1.696   30.786 9.616   0.815 0.075   . .   0 0   0.815   I 
89 L’OREAL cat 1 No No 1 1.041 2.734   5.2453 0.719   1.561 0.099   . .   .     1.561   I 
89 L’OREAL cat 1 No No 2 1.118 0.451   21.723 7.774   1.167 0.092   . .   .     1.167   I 
89 L’OREAL cat 1 No No 3 1.158 1.866   26.395 0.521   1.518 0.218   . .   .     1.518   I 
90 L’OREAL cat 1 Yes No 1 1.118 0.919   31.095 4.839   4.283 3.194   . .   0.5885 0.6127   3.771   I 
90 L’OREAL cat 1 Yes No 2 1.169 2.795   24.645 3.859   25.713 16.81   . .   0.5903 0.6058   25.183   I 
90 L’OREAL cat 1 Yes No 3 1.119 2.182   18.851 9.32   4.368 2.397   . .   0.6433 0.6525   3.774   I 
91 L’OREAL cat 1 Yes No 1 1.041 2.734   5.2453 0.719   7.681 2.889   . .   3.3063 2.8439   4.374   I 
91 L’OREAL cat 1 Yes No 2 1.112 4.848   7.1871 3.378   11.323 12.35   . .   3.0815 2.6633   8.384   I 
91 L’OREAL cat 1 Yes No 3 1.118 0.451   21.723 7.774   15.202 3.507   . .   3.0734 2.6474   12.128   I 
92 L’OREAL cat 1 Yes No 1 1.143 5.763   29.636 4.03   0.62 0.083   . .   0.0676 0.0595   0.56   I 
92 L’OREAL cat 1 Yes No 2 1.403 1.696   30.786 9.616   7.056 3.478   . .   0.0471 0.0418   7.02   I 
92 L’OREAL cat 1 Yes No 3 1.122 1.609   27.629 3.813   4.02 0.927   . .   0.0094 0.0138   4.02   I 
93 L’OREAL cat 1 No No 1 1.215 6.134   65.417 5.374 NQ . .   . .   .     0 NQ I 
93 L’OREAL cat 1 No No 2 1.215 6.134   65.417 5.374   17.034 4.873   . .   .     17.034   I 
93 L’OREAL cat 1 No No 3 1.22 1.963   28.513 4.792   36.583 10.1   . .   .     36.583   I 
93 L’OREAL cat 1 No No 4 0.954 5.639   25.157 6.823   20.012 9.12   . .   .     20.012   I 
94 L’OREAL cat 1 No No 1 1.215 6.134   65.417 5.374 NQ . .   . .   .     0 NQ I 
94 L’OREAL cat 1 No No 2 1.215 6.134   65.417 5.374   11.518 1.58   . .   .     11.518   I 
94 L’OREAL cat 1 No No 3 1.22 1.963   28.513 4.792   16.217 4.688   . .   .     16.217   I 
94 L’OREAL cat 1 No No 4 0.954 5.639   25.157 6.823   16.61 4.525   . .   .     16.61   I 
95 L’OREAL cat 1 No No 1 1.167 5.4   28.91 0.885   0.618 0.054   . .   .     0.618   I 
95 L’OREAL cat 1 No No 2 1.141 5.08   15.556 0.808   1.082 1.124   . .   .     1.082   I 
95 L’OREAL cat 1 No No 3 1.158 6.507   37.465 0.834   0.425 0.131   . .   .     0.425   I 
96 L’OREAL cat 1 No No 1 1.084 8.313   30.98 5.154   49.663 9.665   . .   .     49.663   I 
96 L’OREAL cat 1 No No 2 1.045 4.151   33.69 6.079   38.227 1.07   . .   .     38.227   I 
96 L’OREAL cat 1 No No 3 1.22 1.963   28.513 4.792   35.157 10.65   . .   .     35.157   I 
97 L’OREAL cat 1 No No 1 1.167 5.4   28.91 0.885   67.488 1.938   . .   .     67.488   NI 
97 L’OREAL cat 1 No No 2 1.158 6.507   37.465 0.834   63.442 4.753   . .   .     63.442   NI 
97 L’OREAL cat 1 No No 3 1.22 1.963   28.513 4.792   60.011 2.542   . .   .     60.011   NI 
98 L’OREAL cat 1 No Yes 1 1.144 6.145   1.6528 0.635   26.048 4.527   2.7313 1.01   .     23.317   I 
98 L’OREAL cat 1 No Yes 2 1.071 2.796   33.29 7.118   50.143 11.9   3.6837 0.91   .     46.459   I 
98 L’OREAL cat 1 No Yes 3 1.117 3.017   25.194 7.837   31.103 5.456   3.8408 3.92   .     27.262   I 
99 L’OREAL cat 1 No No 1 1.158 1.866   26.395 0.521   1.235 0.19   . .   .     1.235   I 
99 L’OREAL cat 1 No No 2 1.189 2.082   10.92 1.838   1.237 0.097   . .   .     1.237   I 
99 L’OREAL cat 1 No No 3 1.169 2.795   24.645 3.859   1.332 0.18   . .   .     1.332   I 
100 L’OREAL cat 1 No No 1 1.143 5.763   29.636 4.03   1.31 0.331   . .   .     1.31   I 
100 L’OREAL cat 1 No No 2 1.117 3.017   25.194 7.837   0.762 0.094   . .   .     0.762   I 
100 L’OREAL cat 1 No No 3 1.122 1.609   27.629 3.813   1.297 0.27   . .   .     1.297   I 
101 L’OREAL cat 1 No Yes 1 1.144 6.145   1.6528 0.635   71.722 3.625   0.9022 1.03   .     70.82   NI 
101 L’OREAL cat 1 No Yes 2 1.071 2.796   33.29 7.118   75.215 2.562   0.235 0.07   .     74.98   NI 
101 L’OREAL cat 1 No Yes 3 1.117 3.017   25.194 7.837   45.83 6.411   0.9595 1.16   .     44.871   I 
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Chemical Laboratory classification MTT coloring test OD std Qual Mean% Std Qual Mean% Std Qual Mean% Std Qual Mean% Std Qual viability call 50% cutoff 
102 L’OREAL cat 1 No No 1 1.144 6.145   1.6528 0.635   84.685 10.06   . .   .     84.685   NI 
102 L’OREAL cat 1 No No 2 1.071 2.796   33.29 7.118   86.882 4.908   . .   .     86.882   NI 
102 L’OREAL cat 1 No No 3 1.161 3.337   40.266 4.053   77.44 2.903   . .   .     77.44   NI 
103 L’OREAL cat 1 No No 1 1.041 2.734   5.2453 0.719   1.052 0.137   . .   .     1.052   I 
103 L’OREAL cat 1 No No 2 1.118 0.451   21.723 7.774   0.715 0.03   . .   .     0.715   I 
103 L’OREAL cat 1 No No 3 1.158 1.866   26.395 0.521   0.981 0.093   . .   .     0.981   I 
104 L’OREAL cat 1 No No 1 1.189 2.082   10.92 1.838   80.426 4.441   . .   .     80.426   NI 
104 L’OREAL cat 1 No No 2 1.169 2.795   24.645 3.859   97.452 1.021   . .   .     97.452   NI 
104 L’OREAL cat 1 No No 3 1.151 3.882   20.444 5.887   84.223 2.44   . .   .     84.223   NI 
105 L’OREAL cat 1 No No 1 0.954 5.639   25.157 6.823   2.122 0.311   . .   .     2.122   I 
105 L’OREAL cat 1 No No 2 1.041 2.734   5.2453 0.719   1.427 0.05   . .   .     1.427   I 
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Chemical 106 and 107 are considered incompatible with the test method because of strong colour interference and so SkinEthicTM HCE shows a limitation for colours that strongly 
interfere with MTT using the current system of photometry. These two chemicals are excluded for the statistical analysis. 
  
GHS  
   
NC PC Uncorrected viability NSC MTT Final 
Chemical laboratory classification MTT coloring test OD std Qual Mean% Std Qual Mean% Std Qual Mean% Mean% viability 
106 CARDAM cat 1 No Yes 1 1.051 9.0646 Qualified 10.0328 2.8859 Qualified 200.444 54.382 Non-qualified 327.467 . 0 
106 CARDAM cat 1 No Yes 2 1.083 4.8929 Qualified 10.1424 3.1003 Qualified 154.682 17.55 Qualified 27.746 . 126.936 
106 CARDAM cat 1 No Yes 3 0.887 9.2479 Qualified 23.7508 10 Qualified 113.977 6.54 Qualified 72.133 . 41.843 
106 CARDAM cat 1 No Yes 4 0.992 2.2742 Qualified 10.2611 2.6287 Qualified 112.74 13.573 Qualified 60.074 . 52.666 
107 CARDAM cat 1 No Yes 1 1.083 4.8929 Qualified 10.1424 3.1003 Qualified 64.612 5.791 Qualified 17.377 . 47.235 
107 CARDAM cat 1 No Yes 2 0.887 9.2479 Qualified 23.7508 10 Qualified 78.085 6.733 Qualified 34.252 . 43.833 
107 CARDAM cat 1 No Yes 3 0.992 2.2742 Qualified 10.2611 2.6287 Qualified 66.187 14.918 Qualified 14.221 . 51.966 
106 CEETOX cat 1 Yes Yes 1 0.986 9.0546 Qualified 41.7653 3.9306 Qualified 99.256 15.703 Qualified 29.202 349.239 0 
106 CEETOX cat 1 No No 2 0.872 8.0336 Qualified 61.3649 6.3574 Non-qualified . . Qualified . . 0 
106 CEETOX cat 1 Yes Yes 3 0.997 8.8887 Qualified 9.1441 3.4044 Qualified 64.878 5.08 Qualified 24.841 345.353 0 
107 CEETOX cat 1 No No 1 1.102 4.8262 Qualified 52.1174 3.4029 Non-qualified . . Qualified . . 0 
107 CEETOX cat 1 Yes Yes 2 0.99 7.2609 Qualified 33.1202 5.3244 Qualified 79.418 4.38 Qualified 14.137 76.809 0 
107 CEETOX cat 1 Yes Yes 3 1.117 6.8498 Qualified 19.8657 5.9588 Qualified 74.672 3.45 Qualified 10.582 52.94 0 
107 CEETOX cat 1 Yes Yes 4 1.108 15.906 Qualified 36.1324 3.3205 Qualified 80.873 13.806 Qualified 19.293 273.529 0 
106 L'OREAL cat 1 Yes Yes 1 1.144 6.1445 Qualified 1.6528 0.6346 Qualified 66.395 13.785 Qualified 39.766 131.889 0 
106 L'OREAL cat 1 Yes Yes 2 1.143 5.763 Qualified 29.6358 4.0301 Qualified 98.699 8.198 Qualified 119.582 132.049 0 
106 L'OREAL cat 1 Yes Yes 3 1.117 3.0174 Qualified 25.1936 7.8366 Qualified 77.497 25.978 Qualified 43.393 135.025 0 
106 L'OREAL cat 1 Yes Yes 4 1.161 3.3371 Qualified 40.2656 4.053 Qualified 111.753 23.189 Qualified 36.871 129.859 0 
106 L'OREAL cat 1 Yes Yes 5 1.122 1.6091 Qualified 27.629 3.8131 Qualified 63.933 2.988 Qualified 13.115 134.401 0 
107 L'OREAL cat 1 Yes Yes 1 1.166 6.1154 Qualified 0.8351 0.1747 Qualified 61.132 6.824 Qualified 11.175 29.452 20.504 
107 L'OREAL cat 1 Yes Yes 2 1.403 1.6958 Qualified 30.7863 9.6157 Qualified 56.792 5.412 Qualified 8.189 24.55 24.053 
107 L'OREAL cat 1 Yes Yes 3 1.117 3.0174 Qualified 25.1936 7.8366 Qualified 80.784 2.301 Qualified 11.687 30.789 38.308 
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GUIDANCE ON EYE IRRITATION VALIDATION STUDY (EIVS) 1 
CONDUCT FOR THE RECONSTRUCTED HUMAN TISSUE (RhT) 2 
ASSAYS AND PERFORMANCE CRITERIA TO ASSESS THE 3 
SCIENTIFIC VALIDITY OF SkinEthic
TM
 HCE AND EpiOcular
TM
 EIT 4 
Disclaimer: The Validation Management Group (VMG) of the Eye Irritation Validation Study 5 
(EIVS) proposes in this document a guidance on the conduct of certain aspects of EIVS, as well as 6 
“test method performance criteria” that describe the performance deemed by the VMG as 7 
necessary for a test method to be scientifically valid and considered for regulatory acceptance. 8 
Nevertheless, the EIVS VMG recognises that regulatory authorities ultimately make the 9 
determination of what is considered adequate performance for their relevant regulatory decisions. 10 
 11 
1. DEFINITIONS 12 
EpiOcular
TM
 model/construct: A reconstructed human tissue (RhT) construct produced by 13 
MatTek Corporation, consisting of a non-keratinized multilayered epithelium prepared from non-14 
transformed, human-derived epidermal keratinocytes. 15 
SkinEthic
TM
 Human Corneal Epithelium (HCE) model/construct: A RhT construct produced 16 
by SkinEthic
TM
 Laboratories, consisting of a a multilayered epithelium prepared from 17 
immortalized human corneal epithelial cells. 18 
EpiOcular
TM
 Eye Irritation Test (EIT): A test method to predict eye irritation, employing the 19 
EpiOcular
TM
 RhT construct as test system and a protocol defining different exposure and post-20 
exposure incubations for liquids and solids (i.e., liquids: 30 min exposure followed by 120 min 21 




 HCE Short-time Exposure (SE): A test method to predict eye irritation, employing 24 
the SkinEthic
TM
 HCE RhT construct as test system and a short-time exposure of test chemicals 25 
(i.e., 10 min exposure without post-treatment incubation). 26 
SkinEthic
TM
 HCE Long-time Exposure (LE): A test method to predict eye irritation, employing 27 
the SkinEthic
TM
 HCE RhT construct as test system and a long-time exposure of test chemicals 28 
(i.e., 1 h exposure followed by 16 h post-treatment incubation). 29 
Eye irritation Peptide Reactivity Assay (EPRA): A test method to predict chemical reactivity, 30 




 HCE test strategy/method: A test strategy to predict eye irritation, consisting of 33 
three separate assays (i.e., EPRA, SkinEthic
TM
 HCE SE, and SkinEthic
TM
 HCE LE). In the 34 
SkinEthic
TM
 HCE test strategy, chemical reactivity, as determined by the EPRA, is used to decide 35 
if a chemical is tested with SkinEthic
TM
 HCE SE (reactive chemicals) or SkinEthic
TM
 HCE LE 36 
(non-reactive or inclusive chemicals). 37 
Negative control (NC): A reference test chemical that does not induce a cytotoxic effect in the 38 
treated tissues (i.e., does not reduce their viability). It is used to verify if the viability of the tissues 39 
used for testing, as quantified by the MTT assay, is within a defined acceptance range of optical 40 
density (OD) (i.e., SkinEthic
TM
 HCE SE/LE: 0.7 ≤ ODNC < 1.5; EpiOcular
TM
 EIT: ODNC > 1.0). 41 
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Positive control (PC): A reference test chemical known to induce a cytotoxic effect in the treated 42 
tissues (i.e., SkinEthic
TM
 HCE SE/LE: < 50% viability; EpiOcular
TM
 EIT: < 50% viability), as 43 
quantified by using the MTT assay. It is used to verify if the tissue batch used for testing is 44 
responding to the reference chemical within a defined acceptance range of % viability (relative to 45 
NC). It should be noted that the positive control does not need to be an in vivo irritant chemical 46 
(based on the Draize eye irritation test). 47 
Test chemical: Any chemical (substance or mixture) being tested as a single entity. 48 
Test: A single test chemical concurrently tested in a minimum of two/three tissue replicates as 49 
defined in the corresponding SOP. A “test” for a test chemical is defined when the cytotoxic effect 50 
by using MTT is quantitatively measured. A reported technical issue before the viability 51 
measurement is not considered as a “test” for the test chemical (see section 2.2.3). 52 
Run: A run consists of multiple tests with different test chemicals (one test per test chemical) 53 
conducted concurrently with a test with NC and a test with PC, tested by one operator, as defined 54 
in the corresponding SOP. 55 
Qualified run: A run is qualified if it meets the test acceptance criteria for the NC and PC, as 56 
defined in the corresponding SOP. Otherwise, the run will be considered as non-qualified. 57 
Qualified test: A test is qualified if it meets the criteria for an acceptable test, as defined in the 58 
corresponding SOP, and is within a qualified run. Otherwise, the test will be considered as non-59 
qualified. 60 
Test sequence: The total number of tests performed for a single test chemical in a single 61 
laboratory, which includes any re-testing. A test sequence may include both qualified and non-62 
qualified tests. The first two tests having technical issues for each test chemical, tests included in 63 
the first two runs presenting technical issues, and tests included in the first six non-qualified runs 64 
are not considered as part of a test sequence. 65 
Complete test sequence: A test sequence is considered complete if it contains three qualified 66 
tests. Otherwise, the test sequence will be considered as incomplete. 67 
 68 
2. TESTING PROCEDURES 69 
2.1 Testing Chemicals for the Eye Irritation Validation Study (EIVS) 70 
In order to establish the reliability and relevance of the SkinEthic
TM
 HCE SE, LE and test strategy 71 
and of the EpiOcular
TM
 EIT during EIVS, all test chemicals selected for the validation study (at 72 
least 104) should be tested with SkinEthic
TM
 HCE SE, SkinEthic
TM
 HCE LE and 73 
EpiOcular
TM
 EIT in three laboratories. SkinEthic
TM
 HCE SE and SkinEthic
TM
 HCE LE will be 74 
run in parallel in the same three laboratories, while three other laboratories will be responsible for 75 
running the EpiOcular
TM
 EIT. In each laboratory, all test chemicals should be tested in three 76 
independent qualified runs per test method performed with different production tissue 77 
batches and at sufficiently spaced time points (at least one week apart), with the final objective 78 
of obtaining three qualified tests per test chemical. In each run, each test chemical, as well as the 79 
negative control (NC) and the positive control (PC) should be concurrently tested in a minimum of 80 
three tissue replicates for SkinEthic
TM
 HCE SE/LE and two tissue replicates for 81 
EpiOcular
TM
 EIT (see note below), respectively. Even if more than one test chemical is tested in 82 
the same run, one replicate set for each NC and PC is sufficient. 83 
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Any tissues pre-selection (before the testing, untreated tissues), procedural change or technical 84 
issue (during the testing, tissue treated) that may impact on test method reproducibility assessment, 85 
will be documented (see data reporting templates in the annexes to the SOPs) and reported to the 86 
core VMG. 87 
Note on the number of replicates for the EpiOcular
TM
 EIT: 88 
The EpiOcular
TM
 EIT has been developed using two concurrently tested tissue replicates on the 89 
basis of practical considerations in the technical procedures for conduct of this assay. The 90 
variability between two concurrently treated tissue replicates was found to be low in the 296 pairs 91 
of replicates produced by seven laboratories for a wide set of test chemicals during the pre-92 
validation study of the EpiOcular
TM
 EIT. Briefly, 99%, 95%, 90% and 74% of the 296 pairs of 93 
concurrently treated tissue replicates showed a difference of viability below 20%, 15%, 10% and 94 
5%, repectively. Two independent biostatisticians evaluated the data and their conclusions led the 95 
VMG to consider the use of two tissue replicates for EpiOcular
TM
 EIT in EIVS as sufficiently 96 
statistically and scientifically justified. 97 
 98 
2.2 Re-conducting Tests/Runs ("Re-testing"/"Re-running") 99 
It is possible that one or several tests pertaining to one or more test chemicals does/do not meet the 100 
test acceptance criteria as given in the corresponding SOP or is/are not acceptable for other 101 
reasons. It is also possible that acceptance criteria for the NC and/or PC, as defined in the 102 
corresponding SOP, are not met for one or more runs. In these cases, re-testing/re-running is 103 
allowed to complete missing data as described below. Importantly, each laboratory should not 104 
produce more than three qualified tests per test chemical, per test method, and re-testing/re-105 
running is allowed only to try to accomplish the objective of producing three qualified tests per 106 
test chemical, per test method. Excess production of data and subsequent data selection are 107 
regarded as not appropriate. All tested tissues must be reported. The extent of unacceptable 108 
tests/runs will be documented and the basis for the likely cause of each will be provided.  109 
2.2.1 Re-testing of test chemicals: If one or more test chemicals within a qualified run 110 
does/do not meet the test acceptance criteria (non-qualified test(s)), a maximum number of 111 
two additional tests per test chemical, per test method
1
, per laboratory is/are admissible ("re-112 
testing") to complement missing data. More precisely, since in case of re-testing also PC and 113 
NC have to be concurrently tested, a maximum number of two additional qualified runs may 114 
be conducted for each test chemical. Non-qualified tests have to be documented and reported. 115 
2.2.2 Re-running runs: If a run does not meet the acceptance criteria for the NC and/or PC, 116 
as defined in the corresponding SOP (non-qualified run), the full run must be repeated for 117 
all test chemicals included in the non-qualified run. A maximum number of six
2
 additional 118 
runs are admissible per laboratory, per test method
1
 ("re-running") to complement missing 119 
data due to failure of NC or PC acceptance criteria. Non-qualified runs have to be documented 120 
and reported. None of the tests within the first six non-qualified runs obtained by a laboratory 121 
for each test method
1
 should be considered for applying section 2.2.1, or for any calculations. 122 




 HCE SE and SkinEthic
TM
 HCE LE are considered as two separate and independent test 
methods when considering re-testing and re-running. 
2
 This limit was defined by calculating the critical (smallest) number of repetitions that will result in a 
probability less then 5% assuming a binomial distribution with a failing rate of 10% and 30 runs in total. 
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After producing six non-qualified runs with one test method
1
, a laboratory should stop testing 123 
and immediately inform the core VMG through the Coordinator Jan Lammers 124 
(jan.lammers@tno.nl), with the VMG Chair Stuart Freeman (stuart.j.freeman@talktalk.net) in 125 
copy (to take action in the absence of the Coordinator). The core VMG will then analyse in 126 
detail all the non-qualified runs obtained by the laboratory with that test method
1
 to that point, 127 
looking at e.g., the consistency/inconsistency of the reason(s) leading to non-qualification and 128 
the time span between the non-qualified runs, in order to decide if the tests within further non-129 
qualified runs should be considered as non-qualified tests. In such a case, further repetition of 130 
runs will be considered as re-testing for all test chemicals included in those runs. 131 
Moreover, after producing three consecutive non-qualified runs with one test method
1
, a 132 
laboratory should stop testing and immediately inform the core VMG through the Coordinator 133 
Jan Lammers (jan.lammers@tno.nl), with the VMG Chair Stuart Freeman 134 
(stuart.j.freeman@talktalk.net) in copy (to take action in the absence of the Coordinator). The 135 
core VMG will then investigate if the laboratory is having systematic technical problems, by 136 
looking at e.g., the consistency/inconsistency of the reason(s) leading to non-qualification. 137 
If the core VMG identifies a systematic technical problem as the cause for non-qualified runs, 138 
the lead laboratory may be informed and involved in troubleshooting. 139 
2.2.3 Re-testing/re-running for technical reasons: If a test/run fails because of technical 140 
reasons (technical issue) and the test/run was not finished (no viability measurement) re-141 
testing is allowed twice for each test chemical in each laboratory, for each test method
1
, and 142 
re-running is also allowed twice in each laboratory, for each test method
1
, independently of 143 
the provisions described in sections 2.2.1 and 2.2.2. The reasons will be documented and 144 
reported to the core VMG. 145 
Examples of technical issues include e.g. tissues that are mechanically damaged during the test 146 
or tissues for which some amount of test chemical is accidentally applied to the culture 147 
medium. If a technical issue occurs, all replicates of the corresponding test chemical should be 148 
withdrawn from any further step of the test procedure. It should be avoided that OD 149 
measurements of tissues with known unacceptable technical quality will be performed 150 
(including the remaining replicates of the test chemical). 151 
Moreover, if systematic technical issues occur in one laboratory, leading to loss of data for 152 
more than one test chemical, testing should be stopped and the core VMG informed 153 
immediately through the Coordinator Jan Lammers (jan.lammers@tno.nl), with the VMG 154 
Chair Stuart Freeman (stuart.j.freeman@talktalk.net) in copy (to take action in the absence of 155 
the Coordinator), so that appropriate measures can be taken (e.g. the lead laboratory informed 156 
and involved in trying to solve a potential technical problem). 157 
Tissues which feature obvious, visible damage (e.g. contamination or cuts in the epithelium) 158 
should be discarded and not used at all in order to avoid a posterior technical issue. 159 
 160 
3. TEST ACCEPTANCE CRITERIA 161 
The test acceptance criteria for test chemicals, NC, PC, Non Specific Color controls and Non 162 
Specific MTT reduction controls are described in the corresponding SOPs and have been approved 163 
by the VMG. For example regarding variability, these acceptance criteria were defined as follows: 164 
SkinEthic
TM
 HCE SE/LE: SD > 18%; EpiOcular
TM
 EIT: Range > 20%. Importantly, if during or 165 
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after completion of EIVS the predefined test acceptance criteria are found not to be appropriate 166 
due to failure of a high number of tests (non-qualified tests) and/or runs (non-qualified runs), the 167 
VMG may revise these criteria on the basis of the evaluation of the acquired data. All 168 
modifications have to be scientifically/statistically justified. 169 
 170 
4. CALCULATION OF RELIABILITY (REPRODUCIBILITY) AND 171 
PREDICTIVE CAPACITY (ACCURACY) 172 
The independent biostatistician assigned to the validation study will be responsible for calculating 173 
the reliability and predictive capacity values in EIVS, in accordance with the rules described 174 
below. The ECVAM biostatistician will perform an independent review and quality assurance 175 
on the calculations performed by the independent biostatistician. 176 
While the reproducibility and predictive capacity of EpiOcular
TM
 EIT will be evaluated in a single 177 
assessment (as described in sections 4.1-4.3) because each chemical will be tested in a single 178 
protocol (as a solid or a liquid), for SkinEthic
TM
 HCE three independent assessments will be 179 
performed. Since all the selected test chemicals will be tested in both SkinEthic
TM
 HCE SE and 180 
SkinEthic
TM
 HCE LE, these two assays can be evaluated not only as part of a testing strategy with 181 
EPRA but also as independent test methods. Thus, the SkinEthic
TM
 HCE testing strategy, the 182 
SkinEthic
TM
 HCE SE and the SkinEthic
TM
 HCE LE will all be independently evaluated for their 183 
reproducibility and predictive capacity as described in sections 4.1-4.3. Finally, the EPRA will be 184 
evaluated for its reproducibility according to sections 4.1 and 4.2 (see also Project Plan). 185 
 186 
4.1 Within Laboratory Reproducibility (WLR) 187 
For each laboratory, concordance of classifications and overall Standard Deviation will be 188 
calculated based only on qualified tests from test chemicals for which at least two qualified tests 189 
are available. The final report should state how many and which test chemicals per laboratory have 190 
none or only one qualified test (omitted from WLR calculations), as well as how many and which 191 
test chemicals per laboratory have two or three qualified tests (used for WLR calculations). In 192 
addition, the overall Standard Deviation associated with each laboratory will be calculated using 193 
all available test sequences, i.e. including both qualified and non-qualified tests. 194 
 195 
4.2 Between Laboratory Reproducibility (BLR) 196 
For the calculation of BLR the final classification for each test chemical in each participating 197 
laboratory should be obtained by using the arithmetic mean value of viability over the different 198 
qualified tests performed. Concordance of classifications between laboratories and overall 199 
Standard Deviation of the study will be calculated based only on qualified tests from test 200 
chemicals for which at least one qualified test per laboratory is available. The final report 201 
should state how many and which test chemicals do not have at least one qualified test per 202 
laboratory (omitted from BLR calculation), as well as how many and which test chemicals have 3, 203 
4, 5, 6, 7, 8 or 9 qualified tests that can be used to calculate BLR (with at least one qualified test 204 
per laboratory). In addition, the overall Standard Deviation of the study will be calculated using all 205 
available test sequences, i.e. including both qualified and non-qualified tests. 206 
 207 
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4.3 Predictive Capacity (Accuracy) 208 
All qualified tests for each test chemical will be used to calculate the predictive capacity values. 209 
The calculations will be based on the individual predictions of each qualified test in each 210 
laboratory and not on the arithmetic mean values of viability over the different qualified tests 211 
performed. 212 
By using all qualified tests to calculate the predictive capacity values, the probability of obtaining 213 
0% underprediction of Category 1 chemicals (0 out of about 200 tests), as requested in section 6.4 214 
(see below), is extremely low due to the accepted fact that reproducibility of SkinEthic
TM
 HCE 215 
SE/LE and EpiOcular
TM
 EIT both within and between laboratories is not 100% (see section 6.3). 216 
Therefore, the rate of underprediction of Category 1 chemicals as No Category (Cat 1 → No Cat), 217 
will be calculated using the mode of the in vitro predictions of all qualified tests obtained in the 218 
three participating laboratories for each test chemical classified as UN GHS/EU CLP Category 1 219 
based on in vivo Draize eye irritation data. This approach more closely reflects the real testing 220 
situation (post-validation). Thus, in a post-validation testing situation, a single qualified test 221 
obtained in one laboratory is usually sufficient to classify a test chemical, but if a borderline result, 222 
such as non-concordant replicate measurements and/or mean percent viability equal to 50±5%, is 223 
obtained, a second test may be considered, as well as a third one, in case of discordant results 224 
between the first two tests, in which case the mode of the three classifications is taken as the final 225 
decision. 226 
 227 
5. STUDY QUALITY CRITERION 228 
To limit the bias introduced in the calculations of reliability and predictive capacity due to the 229 
exclusion of the most variable tests (non-qualified tests) from some of the calculations (see section 230 
4), and also to avoid further bias introduced by a reduction of the data used in some of the 231 
calculations (at least 104 test chemicals are needed to reach the statistical power defined for the 232 
study), the VMG decided to define a target value for the number of complete test sequences that 233 
should be available after re-testing as an objective to secure the quality of the study, i.e. to limit the 234 
amount of missing data due to the predefined test acceptance criteria (see section 3). 235 
 236 
5.1 Target Number of Complete Test Sequences After Re-testing  237 
In each participating laboratory, at least 85% of the test sequences (see definition in section 1) 238 
should contain three qualified tests (89 out of 104 test sequences, for 104 test chemicals). 239 
If this criterion is not met, and before deciding that the required statistical power and study quality 240 
are not reached, the VMG may (i) investigate for potential reasons of misclassification, (ii) if 241 
deemed appropriate, revise the test acceptance criteria on the basis of the evaluation of the 242 
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6. PERFORMANCE CRITERIA TO ASSESS THE SCIENTIFIC 248 
VALIDITY OF THE TEST METHODS 249 
Prior to the initiation of the validation study, the VMG defined test method performance criteria, 250 
which it considered appropriate for judging the performance of the SkinEthic
TM
 HCE SE, LE and 251 
test strategy and of the EpiOcular
TM
 EIT with the test chemicals selected for EIVS. The test 252 
method performance criteria described below provide some guidance on the target values which 253 
the VMG would ideally like to attain in EIVS in terms of test method performance (reliability and 254 
predictive capacity) for the SkinEthic
TM
 HCE SE, LE and/or test strategy and for the EpiOcular
TM
 255 
EIT. One recommendation of a previous ESAC Peer Review Panel on cell-based assays was to 256 
receive guidance from the VMG to evaluate the performance of these cell-based assays. Therefore, 257 
within the framework of EIVS, the VMG also suggests the use of these test method performance 258 
criteria as a basis for the evaluation of the performance of the SkinEthic
TM
 HCE LE, SE and test 259 
strategy and of the EpiOcular
TM
 EIT by the ESAC Peer Review Panel after the completion of 260 
EIVS. 261 
The test method performance criteria developed by the VMG for EIVS and described below took 262 
into account: (a) the background and specific objectives of the validation study (see EIVS Project 263 
Plan); (b) the requirements of regulatory authorities and industry when testing and classifying 264 
chemicals for eye irritation; (c) the within test variability in the in vivo Draize eye irritation data 265 
and the manner in which those data are currently used for classifying eye irritants according to UN 266 
GHS / EU CLP (UN, 2007; EC, 2008); (d) the standards of performance which are expected from 267 
the in vitro tests evaluated; (e) the way in which the in vitro tests are to be used (as a test within a 268 
tiered test strategy); and (f) the power of the design of the validation study. 269 
It should be noted that the performance criteria on predictive capacity listed in section 6.4 should 270 
only be used to evaluate the validity of the SkinEthic
TM
 HCE SE, LE and test test strategy and of 271 
the EpiOcular
TM
 EIT as stand-alone test methods for the identification of chemicals not classified 272 
as eye irritants, in the framework of the Bottom-up/Top-down test strategy (please see the 273 
objective and goals of EIVS set out in the Project Plan). Therefore, even if the accuracy values 274 
obtained in EIVS for any of these RhT test methods are considered “definitely unacceptable” by 275 
the VMG as described in section 6.4, the test method(s) may still be useful for other purposes, e.g. 276 
the identification of chemicals not classified as eye irritants in combination with other 277 
appropriately validated test methods (i.e., use of more than one test method to identify the majority 278 
of non-classified chemicals). The EIVS VMG will consider these situations when evaluating the 279 
results of the validation study. 280 
 281 
6.1 Flexibility Clause 282 
Although the EIVS VMG is of the opinion that the definition of target values for test method 283 
performance prior to initiation of the experimental phase of a validation study is beneficial, 284 
bearing in mind the post-validation acceptance process, it also acknowledges that in a prospective 285 
validation study not all circumstances and possible outcomes can be considered beforehand. Thus, 286 
the following predefined and agreed target values are to be considered in the context of the 287 
practical study outcome. In case amendments are considered necessary, these will have to be 288 
scientifically justified. 289 
 290 
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6.2 Limitations of the Test Methods 291 
The VMG also considers that it will be important to define the limitations of the test methods, and 292 
try to rationalize any apparent reasons for misclassifications before making a final 293 
recommendation about the scientific validity of the RhT test methods under evaluation. If potential 294 
reasons for misclassification strictly related to the test methods are identified, these should be 295 
considered for defining the limitations of the test method. If the estimated reliability and/or 296 
accuracy values of a test method can be improved by excluding identified limitations, these values 297 
should also be compared to the predefined test method performance criteria (sections 6.3-6.4). 298 
 299 
6.3 Target Values for Reproducibility 300 
Analysis of reproducibility will not be limited to the parameters described below. Other statistical 301 
tools, e.g. the overall Standard Deviation and Coefficient of Variation of the study calculated from 302 
all qualified tests as from all available tests (qualified and non-qualified), will also be considered 303 
before making a final decision on the reproducibility of the test methods. 304 
6.3.1 Within one laboratory (and over time): The concordance of classifications (not 305 
classified / classified) for the set of chemicals tested during validation obtained in different, 306 
independent runs within a single laboratory should ideally be equal or higher () than 85% 307 
for all participating laboratories
3
. 308 
6.3.2 Between laboratories: The concordance of final classifications (not classified / 309 
classified) for the set of chemicals tested during validation obtained by the different 310 
participating laboratories should ideally be equal or higher () than 80%4. 311 
 312 
6.4 Target Values for Predictive Capacity (Accuracy) 313 
The SkinEthic
TM
 HCE SE, LE and test strategy and the EpiOcular
TM
 EIT are being validated for 314 
their usefulness as stand-alone (independent) test methods to identify chemicals not classified as 315 
eye irritant (UN GHS/EU CLP No Category; “non-irritants”) and their reliable discrimination from 316 
all classes of eye irritant chemicals as e.g. the initial step in a Bottom-Up approach (in the 317 
framework of a Bottom-Up/Top-Down test strategy, Scott L. et al., 2010). The SkinEthic™ HCE 318 
test strategy and the EpiOcular™ EIT were developed for maximum sensitivity (ability to detect 319 
positives, with low rate of false negatives) rather than for optimal accuracy with balanced 320 
sensitivity and specificity (ability to detect negatives, with low rate of false positives). However, it 321 
was also sought to achieve a sufficiently high specificity in order to allow the identification of the 322 
highest number of chemicals not classified as irritant to the eye. By achievement of satisfactory 323 
                                                 
3
 The within laboratory reproducibility values obtained in the pre-validation of the SkinEthic
TM
 
HCE were of 90 to 100% concordance of classifications, and for EpiOcular
TM
 EIT of 95 to 100% 
concordance of classifications (considering the classification cut-off of 60% viability) or of 90 to 
100% concordance of classifications (considering the classification cut-off of 50% viability). 
4
 The between laboratory reproducibility values obtained in the pre-validation of the SkinEthic
TM
 
HCE were of 95 to 100% concordance of classifications, and for EpiOcular
TM
 EIT 100% 
concordance of classifications (considering the classification cut-off of 60% viability) or 96% 
concordance of classifications (considering the classification cut-off of 50% viability). 
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specificity, the SkinEthic™ HCE test strategy and the EpiOcular™ EIT would present stand-alone 324 
(independent) test methods for identification of “non-irritants”. 325 
Based on these premises, the EIVS VMG defined “definitely acceptable” and “definitely 326 
unacceptable” rates of overprediction and underprediction for determining the predictive 327 
performance of the SkinEthic
TM
 HCE SE, LE and test strategy and of the EpiOcular
TM
 EIT, which 328 
are outlined in Table 1. In particular, the following points were felt to be important to recommend 329 
the test methods as being sufficiently predictive to be considered as scientifically valid: 330 
(a) About 10% false negatives should be “definitely acceptable” (sensitivity ≥ 90%), while 331 
more than 20% would be “definitely unacceptable”5. In previous validation studies for eye 332 
irritation led by ECVAM (Cytotoxicity and Cell-based assays) or ICCVAM (Organotypic 333 
assays) the Peer-Review Panels responsible for evaluating the validated test methods 334 
considered 0% false negatives as a test method performance criterion for acceptance of test 335 
methods to be used as an initial step in a Bottom-Up test strategy (identification of 336 
chemicals not classified as eye irritant). However, the Draize rabbit eye test shows the 337 
potential for up to 10% over classification of chemicals as UN GHS Cat. 2 (instead of UN 338 
GHS No Cat.) due solely to its within test variability (Zuang V. et al., 2010). The actual rate 339 
of overprediction of the Draize test may be even higher when considering other factors like 340 
between laboratory variability and predictivity. Thus, the EIVS VMG is of the opinion that a 341 
False Negative rate up to 10% should be “definitely acceptable” for the UN GHS and EU 342 
CLP classification and labelling systems (UN, 2007; EC, 2008) for a test method to be 343 
considered useful for the identification of chemicals not classified as eye irritants as a stand-344 
alone test (inititial step in a Bottom-up approach). Nevertheless, the nature, severity, 345 
duration, and frequency of in vivo eye injuries (based on the Draize eye irritation test) for 346 
chemicals that produce false negative results from in vitro tests will be fully discussed and 347 
considered by the VMG in assessing the usefulness and limitations of the in vitro test 348 
methods for regulatory hazard classification and labelling purposes. 349 
(b) Ideally, no ocular corrosives/severe eye irritants (Category 1) should be underpredicted as 350 
No Category, but more than 10% Cat 1 chemicals being underclassified as No Category 351 
would be “definitely unacceptable”. 352 
(c) About 40% false positives should be “definitely acceptable” (specificity ≥ 60%), while more 353 
than 50% would be “definitely unacceptable”6. Since the purpose of the test methods will be 354 
the identification of chemicals not classified as eye irritant (UN GHS/EU CLP No Category) 355 
as an initial step of a Bottom-Up test strategy (Scott L. et al. 2010), the VMG considered 356 
that it is acceptable to have a lower specificity than sensitivity (higher false positives than 357 
false negatives). Nevertheless, specificity should not be too low in order to allow for the 358 
correct identification of the majority of the chemicals not classified as irritant to the eye. 359 
 360 
                                                 
5
 During pre-validation, the EpiOcular
TM
 EIT showed a sensitivity of 99% (considering the 
classification cut-off of 60% viability) or of 96% (considering the classification cut-off of 50% 
viability), while the SkinEthic
TM
 HCE test strategy showed a sensitivity of 87%. 
6
 During pre-validation, the EpiOcular
TM
 EIT showed a specificity of 65% (considering the 
classification cut-off of 60% viability) or of 72% (considering the classification cut-off of 50% 
viability), while the SkinEthic
TM
 HCE test strategy showed a specificity of 69%. 
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(d) About 25% of overall misclassifications would be “definitely acceptable” (overall accuracy 361 
≥ 75%), while more than 35% would be “definitely unacceptable”. Potential reasons for 362 
misclassification will be analysed in detail, including individual tissue score lesions of 363 
misclassified chemicals, which may be considered in future regulatory acceptance of the 364 
evaluated assays. 365 
(e) Misclassification of borderline chemicals, identified from in vivo Draize eye irritation data 366 
and/or structure-activity relationship considerations, would be easier to justify compared to 367 
non-borderline chemicals. 368 
If the “definitely acceptable” rates of overprediction and underprediction defined in Table 1 are 369 
not attained in the validation study, but the rates obtained are not considered “definitely 370 
unacceptable” (Table 1), the VMG will not decide on the recommendation about the scientific 371 
validity of the test method before all the validation data have been evaluated and discussed as 372 





 HCE SE, SkinEthic
TM
 HCE LE and SkinEthic
TM
 HCE test 374 
strategy) as obtained in EIVS are considered “definitely unacceptable” by the VMG for a stand-375 
alone test method, even taking into account any possible limitations of the test methods, these may 376 
still be useful for other purposes, e.g. the identification of chemicals not classified as eye irritants 377 
in combination with other methods. The EIVS VMG will consider these situations when 378 
evaluating the results of the validation study.  379 
 380 
Table 1. VMG accepted rates of overprediction and underprediction for the SkinEthic
TM
 HCE SE, LE and 381 


















rates  ≤ 10 0 ≤ 40 ≤ 25 
Further evaluations 
necessary before any 
recommendation is made 
10 < FN ≤ 20 0 < Cat 1 FN ≤ 10 40 < FP ≤ 50 25 < OM ≤ 35 
“Definitely unacceptable” 
rates > 20 > 10 > 50 > 35 
a
 equal to (1-Sensitivity) 383 
b
 based on the mode of all qualified tests (see section 4.3) 384 
c
 equal to (1-Specificity) 385 
d
 equal to (1-Overall accuracy) 386 
387 
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Instructions for the Testing of 




1. Controls for direct MTT-reducers and coloured test chemicals 
Controls for direct MTT-reducers (freeze killed tissues with MTT) and/or coloured test 
chemicals (living tissues without MTT) must always be performed irrespectively of the results 
of the viability tests. Therefore, even though Non-Specific MTT-reduction (NSMTT) and/or 
Non-Specific Colour (NSC) corrections will have no effect for MTT reducers and/or coloured 
test chemicals that are already identified as irritant in the viability tests, NSMTT and NSC 
controls must still be acquired for these chemicals. 
 
2. Test chemicals showing %NSMTT or %NSC > 50% in any of the control tests performed 
A test cannot be considered as non-qualified based only on the %NSMTT or %NSC values. 
According to the current EpiOcularTM EIT and SkinEthicTM HCE protocols, a %NSMTT or 
%NSC > 50% may suggest that the chemical is incompatible with the test method, but does 
not per se disqualify the test where it was obtained. A test can only be considered as non-
qualified based on the variability of the two (EpiOcularTM EIT) or three (SkinEthicTM HCE) 
tissue replicates used in the %viability measurements or controls, or if it is included in a non-
qualified run, where either the positive control or the negative control did not meet the test 
acceptance criteria. Moreover, the %NSMTT and %NSC cut-offs for deciding whether a 
direct-MTT reducer or coloured test chemical is compatible with the test method (currently 
defined as 50%) may be revised post-hoc by the Validation Management Group (VMG) once 
the testing phase of the ECVAM/COLIPA Eye Irritation Validation Study (EIVS) is 
completed and relevant statistical analysis have been performed.  
Therefore, the laboratories participating in EIVS should always try to obtain three qualified 
viability tests and controls for direct MTT-reducers and/or coloured test chemicals even if 
%NSC or %NSMTT are > 50%. It will be up to the VMG to decide whether the test chemical 
should be considered incompatible with the test method when analysing the data acquired by 
all participating laboratories. 
 2
3. Re-testing due to failure to meet test acceptance criteria 
Re-testing due to failure to meet test acceptance criteria should always be performed up to the 
maximum number of re-tests allowed and as long as three qualified tests (a complete test 
sequence) have not been obtained. Importantly, re-testing should continue up to the 
maximum number of re-tests allowed even when it becomes clear that a complete test 
sequence (three qualified tests) can no longer be obtained (see below: cases 5, 9, 13 and 18). 
This rule applies to all test chemicals (including coloured, non-coloured, MTT-reducer and 
non-MTT-reducer chemicals) and is important because according to sections 4.1, 4.2 and 4.3 
of the Guidance on EIVS Conduct and Performance Criteria, the Within Laboratory 
Reproducibility will be calculated for "test chemicals for which at least two qualified tests are 
available", the Between Laboratory Reproducibility will be calculated for "test chemicals for 
which at least one qualified test per laboratory is available", and the Predictive Capacity will 
be calculated using all qualified tests obtained for each test chemical. Therefore, the order of 
qualified/non-qualified results should not dictate whether to proceed with testing since this 
would artificially bias the evaluation of the robustness of the protocol. 
Finally, no further testing of a chemical by a laboratory should be performed once three 
qualified tests have been obtained for a test method (see below: cases 1, 2, 3, 6, 7, 10, 11, 15 
and 16). Excess production of data and subsequent data selection are regarded as not 
appropriate. All tested tissues must be reported. 
 
3.1. Extra re-testing of NSMTT control tissues due to failure to meet the test acceptance 
criterion 
NSMTT controls are tested independently from viability tests (and NSC controls) since they 
use freeze killed tissues, which can only be used after all tissues from the same batch have 
already been used in a previous week. Moreover, NSMTT controls for one test method1 only 
need to be performed once in each laboratory, for each direct MTT-reducer test chemical. If a 
NSMTT control within a qualified run does not meet the test acceptance criterion 
(SkinEthicTM HCE SE/LE: SD%NSMTT > 18%; EpiOcularTM EIT: Range%NSMTT > 20%) (non-
qualified NSMTT control test), a maximum number of two additional NSMTT control tests 
per direct MTT-reducer chemical, per test method1, per laboratory are admissible ("re-
testing") to try obtaining one qualified NSMTT control for that chemical. Each additional 
NSMTT control test must be acquired concurrently with the negative control. All non-
qualified NSMTT control tests have to be documented and reported. 
It is important to note that although only one qualified NSMTT control test needs to be 
performed in each laboratory for each test method1 for each direct MTT-reducer test 
chemical, a different %NSMTT value must be calculated from the single NSMTT control OD 
to correct each qualified viability test obtained. The %NSMTT value used to correct a 
qualified viability test must be calculated relative to the negative control that was run 
concurrently to that specific viability test. Depending on the negative control OD value that is 
used to calculate %NSMTT, it is possible that the same NSMTT control may meet the test 
acceptance criterion for one (or two) viability test(s), but not for the other. Thus, a NSMTT 
control only qualifies if it meets the test acceptance criterion for all the qualified 
viability tests it needs to correct. 
If more than one qualified NSMTT control test is obtained in one laboratory for the same test 
chemical with the same test method1, the mean of the different corrected OD values obtained 
                                                 
1 SkinEthicTM HCE SE and SkinEthicTM HCE LE are considered as two separate and independent test methods 
when considering re-testing and re-running. 
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for those NSMTT control tests (EpiOcularTM EIT: ODKC; SkinEthicTM HCE SE/LE: ODKT-
ODKU) should be used to calculate one single %NSMTT value per qualified viability test. 
 
3.2. Extra re-testing of coloured test chemicals due to failure to meet the test acceptance 
criterion in NSC control tissues 
For coloured chemicals, NSC controls must be run concurrently with every viability test since 
the same tissue batch must be used for a viability test and its NSC control. Therefore, a 
viability test that meets the test acceptance criterion (SkinEthicTM HCE SE/LE: SD%Viability ≤ 
18%; EpiOcularTM EIT: Range%Viability ≤ 20%) may still not qualify if the concurrent NSC 
control does not meet its test acceptance criterion (SkinEthicTM HCE SE/LE: SD%NSC > 18%; 
EpiOcularTM EIT: Range%NSC > 20%) (see below: for example, cases 6, 7, 8 and 9). In order 
to compensate for the higher probability of obtaining a non-qualified test with a coloured 
chemical (where two separate test acceptance criteria must be met) as compared to a non-
coloured chemical (where only one test acceptance criterion must be met), a maximum 
number of four additional tests per coloured chemical, per test method1, per laboratory are 
admissible to try obtaining a complete test sequence. Thus, a total of seven tests may be 
performed with coloured test chemicals in order to try obtaining three qualified tests (where 
both the viability test and the NSC control qualify). This corresponds to two extra re-tests in 
addition to the two already permitted in the Guidance on EIVS Conduct and Performance 
Criteria. However, the sixth and seventh tests for coloured test chemicals can only be 
performed if in the first five tests there are no more than two tests with SD%Viability > 18% 
(SkinEthicTM HCE SE/LE) or with Range%Viability > 20% (EpiOcularTM EIT), and no more 
than two tests with SD%NSC > 18% (SkinEthicTM HCE SE/LE) or with Range%NSC > 20% 
(EpiOcularTM EIT) (see below: cases 4, 5, 8, 9, 12, 13 and 14 where a 6th and 7th test cannot 
be performed; and cases 15, 16, 17 and 18 where up to 7 tests must be performed to generate a 
complete test sequence). Each additional viability test and NSC control test must be acquired 
concurrently with the positive control and the negative control. All non-qualified tests 
(including viability tests and concurrent NSC controls) have to be documented and reported. 
 
4. Re-running due to failure to meet test acceptance criteria for the positive or the negative 
control 
 
4.1. Extra re-running in each laboratory due to failure to meet test acceptance criteria for the 
positive or the negative control 
If a run does not meet the acceptance criteria for the negative control and/or positive control, 
as defined in the SkinEthicTM HCE and EpiOcularTM EIT protocols (non-qualified run), the 
full run must be repeated for all test chemicals included in the non-qualified run. A maximum 
number of eight2 additional runs are admissible per laboratory, per test method1 ("re-running") 
to complement missing data due to failure to meet the negative control or positive control 
acceptance criteria. Thus, in addition to the six re-runs already foreseen in the Guidance on 
EIVS Conduct and Performance Criteria, two extra re-runs are now permitted. This 
amendment is proposed because the total number of runs required to generate three tests per 
test chemical in one laboratory is higher than the 30 initially predicted, which did not consider 
the need to run NSMTT and NSC controls. Assuming that 1/3 of the chemicals (about 35) will 
                                                 
2 This limit was defined by calculating the critical (smallest) number of repetitions that will result in a 
probability less then 5% assuming a binomial distribution with a failing rate of 10% and 40 runs in total. 
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require controls in three runs, an extra 10 runs will be required to generate three tests per test 
chemical plus controls in one laboratory. These extra 10 runs justify the two extra re-runs now 
permitted. Non-qualified runs have to be documented and reported. None of the tests within 
the first eight non-qualified runs obtained by a laboratory for each test method1 should be 
considered non-qualified, nor should they be used for any calculations. 
 
5. Re-testing due to technical issues 
 
5.1. Extra re-testing of NSMTT control tissues due to technical issues 
A NSMTT control test for a direct MTT-reducer test chemical may be repeated twice (re-
tested) to replace NSMTT control tests that failed due to technical reasons (technical issue) 
and that were not finished (OD measurement not performed). These two re-tests are allowed 
in each laboratory and for each test method1, independently of the re-testing allowed due to 
failure to meet the test acceptance criterion (see section 3.1 above). A NSMTT control that 
fails due to technical reasons does not disqualify viability tests or NSC controls since, as 
explained above, NSMTT controls are independent from viability tests and NSC controls (see 
section 3.1). All technical issues must be documented and reported to the core VMG. 
 
 
5.2. Extra re-testing of coloured test chemicals due to technical issues in NSC control tissues 
A coloured test chemical may be re-tested twice (including viability test and NSC control) to 
replace tests that failed due to a technical issue in NSC controls and that were not finished 
(OD measurement not performed for either the viability tissues or the NSC control tissues). 
Thus, four re-tests (including viability test and NSC control) due to 2 technical issues in 
viability tissues and 2 technical issues in NSC control tissues are allowed per coloured test 
chemical in each laboratory, for each test method1, independently of the re-testing allowed 
due to failure to meet test acceptance criteria (see section 3.2 above). Each time a coloured 
test chemical is re-tested due to technical reasons, both the viability test and the NSC control 
must be re-tested concurrently since, as explained above, the same tissue batch must be used 
for the viability test and its NSC control (see section 3.1). All technical issues must be 
documented and reported to the core VMG. 
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  Test 1 Test 2 Test 3 Test 4 Test 5 Test 6 Test 7 
SD/range 
%Viab. < cut-off < cut-off < cut-off     
SD/range 





Test YES YES YES     
A 4th and 5th test is not required since all 3 first tests qualified. 
 
SD/range 
%Viab. < cut-off > cut-off < cut-off < cut-off    
SD/range 





Test YES No YES YES    
A 5th, 6th and 7th test is not required since 3 qualified tests were obtained in 4 tests. 
 
SD/range 
%Viab. > cut-off < cut-off > cut-off < cut-off < cut-off   
SD/range 





Test No YES No YES YES   
A 6th and 7th test is not required since 3 qualified tests were obtained in 5 tests. 
 
SD/range 
%Viab. > cut-off < cut-off > cut-off < cut-off > cut-off   
SD/range 





Test No YES No YES No   
A 6th and 7th test cannot be performed under the revised rules for re-testing since within the 
first 5 tests there are 3 tests with SD or range of %Viability above the cut-off. 
 
SD/range 
%Viab. > cut-off > cut-off < cut-off > cut-off *   
SD/range 





Test No No YES No *   
A 6th and 7th tests cannot be performed under the revised rules for re-testing since within the 
first 5 tests there are 3 tests with SD or range of %Viability above the cut-off. 
* A 5th test must be performed even though a complete test sequence (one containing 3 
qualified tests) can no longer be obtained in 5 tests. 
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  Test 1 Test 2 Test 3 Test 4 Test 5 Test 6 Test 7 
SD/range 
%Viab. < cut-off < cut-off < cut-off < cut-off    
SD/range 





Test YES YES No YES    
A 5th, 6th and 7th test is not required since 3 qualified tests were obtained in 4 tests. 
 
SD/range 
%Viab. < cut-off < cut-off < cut-off < cut-off < cut-off   
SD/range 





Test YES No YES No YES   
A 6th and 7th test is not required since 3 qualified tests were obtained in 5 tests. 
 
SD/range 
%Viab. < cut-off < cut-off < cut-off < cut-off < cut-off   
SD/range 





Test No No YES YES No   
A 6th and 7th test cannot be performed under the revised rules for re-testing since within the 
first 5 tests there are 3 tests with SD or range of %NSC above the cut-off. 
 
SD/range 
%Viab. < cut-off < cut-off < cut-off * *   
SD/range 





Test No No No * *   
A 6th and 7th test cannot be performed under the revised rules for re-testing since there are 
already 3 tests with SD or range of %NSC above the cut-off in the first 3 tests. 
* A 4th and 5th test must be performed even though a complete test sequence (one containing 3 
qualified tests) can no longer be obtained in 5 tests. 
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  Test 1 Test 2 Test 3 Test 4 Test 5 Test 6 Test 7 
SD/range 
%Viab. > cut-off < cut-off < cut-off < cut-off < cut-off   
SD/range 





Test No No YES YES YES   
A 6th and 7th test is not required since 3 qualified tests were obtained in 5 tests. 
 
SD/range 
%Viab. > cut-off > cut-off < cut-off < cut-off < cut-off   
SD/range 





Test No No YES YES YES   
A 6th and 7th test is not required since 3 qualified tests were obtained in 5 tests. 
 
SD/range 
%Viab. > cut-off > cut-off < cut-off < cut-off > cut-off   
SD/range 





Test No No YES YES No   
A 6th and 7th test cannot be performed under the revised rules for re-testing since within the 
first 5 tests there are 3 tests with SD or range of %Viability above the cut-off. 
 
SD/range 
%Viab. > cut-off > cut-off > cut-off * *   
SD/range 





Test No No No * *   
A 6th and 7th test cannot be performed under the revised rules for re-testing since there are 
already 3 tests with SD or range of %Viability above the cut-off in the first 3 tests. 
* A 4th and 5th test must be performed even though a complete test sequence (one containing 3 
qualified tests) can no longer be obtained in 5 tests. 
 
SD/range 
%Viab. > cut-off < cut-off > cut-off < cut-off > cut-off   
SD/range 





Test No YES No YES No   
A 6th and 7th test cannot be performed under the revised rules for re-testing since within the 




  Test 1 Test 2 Test 3 Test 4 Test 5 Test 6 Test 7 
SD/range 
%Viab. > cut-off < cut-off > cut-off < cut-off < cut-off < cut-off  
SD/range 





Test No YES No YES No YES  
A 6th test must be acquired under the revised rules for re-testing to try obtaining 3 qualified 
tests, since within the first 5 tests there are only 2 tests with SD or range of %Viability above 
the cut-off and only 2 tests with SD or range of %NSC above the cut-off. 
A 7th test is not required since 3 qualified tests were obtained in 6 tests. 
 
SD/range 
%Viab. > cut-off > cut-off < cut-off < cut-off < cut-off < cut-off < cut-off 
SD/range 





Test No No No No YES YES YES 
A 6th and 7th test must be acquired under the revised rules for re-testing to try obtaining 3 
qualified tests, since within the first 5 tests there are only 2 tests with SD or range of 
%Viability above the cut-off and only 2 tests with SD or range of %NSC above the cut-off. 
 
SD/range 
%Viab. > cut-off < cut-off < cut-off < cut-off < cut-off > cut-off < cut-off 
SD/range 





Test No YES No No YES No No 
A 6th and 7th test must be acquired under the revised rules for re-testing to try obtaining 3 
qualified tests, since within the first 5 tests there is only 1 test with SD or range of %Viability 
above the cut-off and only 2 tests with SD or range of %NSC above the cut-off. 
 
SD/range 
%Viab. > cut-off < cut-off < cut-off < cut-off > cut-off > cut-off * 
SD/range 





Test No YES No No No No * 
A 6th and 7th test must be acquired under the revised rules for re-testing to try obtaining 3 
qualified tests, since within the first 5 tests there are only 2 tests with SD or range of 
%Viability above the cut-off and only 2 tests with SD or range of %NSC above the cut-off. 
* A 7th test must be performed even though a complete test sequence (one containing 3 
qualified tests) can no longer be obtained in 7 tests. 
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 1 
EYE IRRITATION VALIDATION STUDY (EIVS) 2 
PROJECT PLAN 3 
Validation of the SkinEthic™ HCE SE, LE and Test Strategy and of the 4 
EpiOcular™ EIT for the Prediction of Acute Eye Irritation  5 
 6 
 7 
1. Definitions 8 
EpiOcular
TM
 model/construct: A reconstructed human tissue (RhT) construct produced by 9 
MatTek Corporation, consisting of a non-keratinized multilayered epithelium prepared from non-10 
transformed, human-derived epidermal keratinocytes. 11 
SkinEthic
TM
 Human Corneal Epithelium (HCE) model/construct: A RhT construct produced 12 
by SkinEthic
TM
 Laboratories, consisting of a a multilayered epithelium prepared from 13 
immortalized human corneal epithelial cells. 14 
EpiOcular
TM
 Eye Irritation Test (EIT): A test method to predict eye irritation, employing the 15 
EpiOcular
TM
 RhT construct as test system and a protocol defining different exposure and post-16 
exposure incubations for liquids and solids (i.e., liquids: 30 min exposure followed by 120 min 17 




 HCE Short-time Exposure (SE): A test method to predict eye irritation, employing 20 
the SkinEthic
TM
 HCE RhT construct as test system and a short-time exposure of test chemicals 21 
(i.e., 10 min exposure without post-treatment incubation). 22 
SkinEthic
TM
 HCE Long-time Exposure (LE): A test method to predict eye irritation, employing 23 
the SkinEthic
TM
 HCE RhT construct as test system and a long-time exposure of test chemicals 24 
(i.e., 1 h exposure followed by 16 h post-treatment incubation). 25 
Eye irritation Peptide Reactivity Assay (EPRA): A test method to predict chemical reactivity, 26 




 HCE test strategy/method: A test strategy to predict eye irritation, consisting of 29 
three separate assays (i.e., EPRA, SkinEthic
TM
 HCE SE, and SkinEthic
TM
 HCE LE). In the 30 
SkinEthic
TM
 HCE test strategy, chemical reactivity, as determined by the EPRA, is used to decide 31 
if a chemical is tested with SkinEthic
TM
 HCE SE (reactive chemicals) or SkinEthic
TM
 HCE LE 32 
(non-reactive or inconclusive chemicals). 33 
34 
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2. Study Objective 35 
The objective of this study is to formally validate the SkinEthic
TM
 HCE SE, LE and test strategy 36 
and the EpiOcular
TM
 EIT by inter-laboratory ring trial study, to facilitate international acceptance 37 
in regulatory schemes for hazard assessment of chemicals. In particular, these test 38 
methods/strategy shall be incorporated into a tiered test strategy (so-called Bottom-Up/Top-Down 39 
test strategy, as defined in an ECVAM workshop held in 2005, Scott L. et al., 2010) as e.g. the 40 
initial step in a Bottom-Up approach or the second step in a Top-Down Approach. The ultimate 41 
purpose of a tiered test strategy will be to replace the traditional in vivo Draize eye irritation test 42 
[Method B.5 of EC Regulation 440/2008 (EC, 2008a) or OECD TG 405 (OECD, 2002)]. 43 
3. Study Goals 44 
The goal of the Eye Irritation Validation Study (EIVS) is to assess the relevance (predictive 45 
capacity) and reliability (reproducibility within and between laboratories) of the SkinEthic
TM
 HCE 46 
SE, LE and test strategy and of the EpiOcular
TM
 EIT, by testing a statistically significant number 47 
of coded test chemicals (substances and mixtures), supported by complete and quality assured in 48 
vivo Draize eye irritation data for comparative evaluation of results. 49 
Specifically, EIVS will assess the validity of the SkinEthic
TM
 HCE SE, LE and test strategy and of 50 
the EpiOcular
TM
 EIT as stand-alone (independent) test methods to reliably discriminate chemicals 51 
not classified as eye irritant (“non-irritants”) from all classes of eye irritant chemicals (in the 52 
framework of a Bottom-Up/Top-Down test strategy, Scott L. et al., 2010), defined according to the 53 
United Nations Globally Harmonized System (GHS) of Classification and Labelling of Chemicals 54 
(UN GHS: No Category versus Category 1/Category 2A/Category 2B; UN, 2007) and as 55 
implemented in the European Commission Regulation (EC) No 1272/2008 on classification, 56 
labelling and packaging of substances and mixtures, amending and repealing Directives 57 
67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 (EU CLP: No 58 
Category versus Category 1/Category 2). 59 
The SkinEthic™ HCE test strategy and the EpiOcular™ EIT were developed for maximum 60 
sensitivity (ability to detect positives, with low rate of false negatives) rather than for optimal 61 
overall accuracy with balanced sensitivity and specificity (ability to detect negatives, with low rate 62 
of false positives). Sensitivity had therefore a bigger weight than specificity and overall accuracy 63 
in their development. However, it was also sought to achieve a sufficiently high specificity and 64 
overall accuracy, in order to allow identification of the highest number of chemicals not classified 65 
as irritant to the eye. By achieving satisfactory specificity, the SkinEthic™ HCE test strategy and 66 
the EpiOcular™ EIT would represent stand-alone (independent) test methods for the identification 67 
of “non-irritants”. Importantly, the test methods are not intended to differentiate between UN 68 
GHS/EU CLP Category 1 (irreversible effects) and UN GHS/EU CLP Category 2 (reversible 69 
effects). As proposed by the ECVAM workshop of February 2005, this differentiation would be 70 
left to another tier of the Bottom-Up/Top-Down test strategy (Scott L. et al., 2010). 71 
The EIVS will be undertaken in accordance with the principles and criteria documented in the 72 
OECD Guidance Document on the Validation and International Acceptance of New or Updated 73 
Test Methods for Hazard Assessment (No. 34, OECD, 2005) and according to the Modular 74 
Approach to validation (Hartung T. et al., 2004). 75 
4. Test Methods 76 
The SkinEthic
TM
 HCE SE, LE and test strategy and the EpiOcular
TM
 EIT have progressed through 77 
protocol optimisation and multi-laboratory assessment and will be evaluated in EIVS. The 78 
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SkinEthic
TM
 HCE SE/LE and the EpiOcular
TM
 EIT use as test systems reconstructed human tissue 79 
(RhT) constructs, and consist of a topical exposure of the neat test chemical to the epithelial surface 80 
of the tissue construct. 81 
The EpiOcular™ tissue construct is a non-keratinized multilayered epithelium prepared from non-82 
transformed, human-derived epidermal keratinocytes. It is intended to model the cornea epithelium 83 
with progressively stratified but not cornified cells. These cells are not transformed or transfected 84 
with genes to induce an extended life span in culture. The “tissue” is prepared in inserts with a 85 
porous membrane (MTI-003) through which the nutrients pass to the cells. A cell suspension is 86 
seeded into the MTI-003 membrane in specialized medium. After a period of initial cell 87 
proliferation, the medium is removed from the top of the tissue so that the epithelial surface is in 88 
direct contact with the air. This allows the test chemical to be directly applied to the epithelial 89 
surface in a fashion similar to how the corneal epithelium would be exposed in vivo. The ability to 90 
expose the tissue topically is essential to model the same kind of progressive injury expected in 91 
vivo. It also allows both solid and liquid test chemicals to be applied directly to the tissue. In the 92 
EpiOcular
TM
 EIT, liquids and solids are treated with different exposure and post-exposure incubations 93 
(i.e., liquids: 30 min exposure followed by 120 min post-treatment incubation, and solids: 90 min 94 
exposure followed by 18 hours post-treatment incubation). 95 
To construct SkinEthic™ HCE tissues, immortalized human corneal epithelial cells are cultured in 96 
a chemically defined medium and seeded on a polycarbonate membrane at the air–liquid interface. 97 
The tissue construct obtained is a multilayered epithelium resembling the in vivo corneal 98 
epithelium. As in vivo, columnar basal cells are present, including Wing cells. The model is 99 
characterized by the presence of specific ultra structural figures like intermediate filaments, mature 100 
hemi-desmosomes and desmosomes. Specific cytokeratins 64kD (K.3) have also been described 101 
(Nguyen D.H. et al., 2003). 102 
The SkinEthic
TM
 HCE test strategy uses three separate assays, i.e. EPRA, SkinEthic
TM
 HCE SE, 103 
and SkinEthic
TM
 HCE LE. In this strategy, test chemicals are tested in a short-time exposure 104 
(SkinEthic
TM
 HCE SE: 10 min exposure without post-treatment incubation) or a long-time 105 
exposure (SkinEthic
TM
 HCE LE: 1 h exposure followed by 16 h post-treatment incubation) 106 
depending on their chemical reactivity (defined as the electrophilic potential to react with cysteine 107 
or lysine containing peptides), as measured by the Eye irritation Peptide Reactivity Assay (EPRA). 108 





HCE SE or SkinEthic
TM
 HCE LE), the relative tissue viability is determined against the negative 110 
control-treated constructs by the reduction of the vital dye MTT (3-[4,5-dimethylthiazol-2-yl]-2,5-111 
diphenyltetrazolium bromide). Tissues treated with eye irritants (UN GHS/EU CLP Category 2 and 112 
Category 1) are expected to show a decrease in viability below a certain threshold in respect to the 113 
negative control. 114 
115 
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5. Validation Management Group 116 
The management structure of EIVS and the responsibilities of the different members are shown in 117 
Figure 1. The Validation Management Group (VMG), with supervisory role, comprises: 118 
 119 
Core VMG 120 
- Chair (Stuart Freeman) 121 
- Co-chair (Valérie Zuang) 122 
- COLIPA sponsor representative (Pauline McNamee; alternate: Penny Jones) 123 
- ECVAM sponsor representative (João Barroso) 124 
- TNO coordinator representative (Jan Lammers; alternate: Ruud Woutersen) 125 
- TNO biostatistician (Carina de Jong-Rubingh) 126 
- ECVAM biostatistician (André Kleensang until 30.09.2010)
1
 127 
- Independent scientist (Chantra Eskes) 128 
- Chemicals Selection Group (CSG) coordinator (Thomas Cole) 129 
 130 
 131 
Representatives of the lead laboratories 132 
- SkinEthic
TM
 HCE test strategy lead laboratory: L’Oréal (Nathalie Alépée) 133 
- EpiOcular
TM
 EIT lead laboratory: Beiersdorf (Uwe Pfannenbecker) 134 
 135 
In addition, in the framework of the International Cooperation on Alternative Test Methods 136 
(ICATM), Liaisons from the USA, Japan and Canada are represented on the VMG namely: 137 
- NICEATM (William Stokes; alternates: Warren Casey, David Allen, Elizabeth Lipscomb) 138 
- ICCVAM (Jill Merrill) 139 
- JaCVAM (Hajime Kojima) 140 
- Health Canada (Alison McLaughlin) 141 
 142 
Operational decisions will be taken by the core VMG only. Representation of the lead laboratories 143 
allows consultation on technical issues relating to the test systems and monitoring progress of 144 
experimental work, but will not be involved in discussions regarding the chemicals selection. The 145 
ICATM liaisons are invited to advise the VMG. 146 
 147 
148 
                                               
1
 From 30 September 2010, there will be no official representation from an ECVAM biostatistician 
in the VMG. Nevertheless, ECVAM will continue providing the planned biostatistical support to 
EIVS after this date. 
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6. Study Coordination and Sponsorship  169 
6.1. Overall study coordination  170 
The overall study coordination will be conducted by ECVAM. This will include the organisation 171 
of all necessary VMG meetings and teleconferences, and the maintenance of a website where all 172 
EIVS documents not related to chemical selection are made available to VMG members and 173 
ICATM liaisons. ECVAM will also be responsible for organising the Quality Control audits on 174 
data collection, handling and analysis, as well as on the biostatistical reports produced by the TNO 175 
biostatistician. 176 
6.2. Logistical coordination and communication 177 
The TNO (Quality of Life) representative will coordinate the communication flow between all 178 
parties, draft minutes of VMG meetings and telephone conferences, organize meetings between 179 
laboratories, and organise the study conduct. TNO has also responsibility for logistics of test 180 
chemical acquisition, coding and distribution. Finally, the TNO representative will arrange quality 181 
control audits on the RhT production sites. 182 
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6.3. Study sponsorship  183 
ECVAM and COLIPA will co-sponsor EIVS, with the main financial support being provided by 184 
COLIPA. 185 
 186 
COLIPA will finance:  187 
- conduct of the chemical reactivity assays 188 
- lead and participating laboratories for the two test methods  189 
- statistical support provided by TNO 190 
- financial support of the independent chair of the VMG 191 
- independent CRO responsible for the test chemicals purchase, coding and distribution to the 192 
laboratories 193 
- overall logistical coordination of the study 194 
- part of the independent QC audit on the RhT models production sites  195 
- purchase cost of existing chemicals 196 
- purchase of a proportion of the RhT tissues 197 
 198 
ECVAM will finance: 199 
- management and coordination of the study, including the organisation of all VMG meetings 200 
- statistical support provided by ECVAM 201 
- part of the independent QC audit on the RhT models production sites  202 
- independent QC audit on data collection, handling and analysis 203 
- independent QC audit of the biostatistical report(s) 204 
- purchase of a proportion of the RhT tissues 205 
- publication of the study 206 
7. Chemicals Selection  207 
7.1. Chemicals Selection Group (CSG)  208 
The CSG is composed of the following members: 209 
Tom Cole (ECVAM; coordinator) 210 
João Barroso (ECVAM) 211 
Chantra Eskes (independent scientist) 212 
William Stokes (NICEATM) 213 
Amanda Cockshott (HSE; UK Competent Authority) 214 
Betty Hakkert (RIVM; NL Competent Authority) 215 
 216 
The roles and responsibilities of the CSG are shown in Figure 1. 217 
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The members of Competent Authorities (Amanda Cockshott and Betty Hakkert) will give support 218 
in reviewing in vivo Draize eye irritation reports on CosIng ingredients provided by DG SANCO. 219 
In the framework of the International Cooperation on Alternative Test Methods (ICATM), liaisons 220 
from NICEATM, ICCVAM, JaCVAM and Health Canada are invited to propose eligible test 221 
chemicals for selection, supported by quality assured in vivo Draize eye irritation data. 222 
7.2. Chemicals selection 223 
A principal criterion for selection of test chemicals is availability of supporting complete and 224 
quality assured in vivo Draize eye irritation data, for comparative evaluation of in vitro method 225 
predictive capacity. Complete in vivo Draize eye irritation data sets comprise severity and duration 226 
of ocular toxicity effects, registered over a 21 day observation period as irritation scores for 227 
corneal opacity, iritis and conjunctival chemosis/redness. Eligibility of test chemicals will be 228 
confirmed by compilation of in vivo Draize eye irritation data into a customised Excel template 229 
where algorithms generate systematic assignment of eye irritation EU DSD, UN GHS / EU CLP 230 
and US EPA classifications. 231 
Intending to challenge performance of the in vitro tissue models, diverse chemicals will be sought 232 
that have not been previously tested during protocol R&D, optimisation and pre-validation. 233 
Therefore, in shortlisting chemicals from recognised sources (e.g., ECETOC, TSCA, ZEBET, 234 
NIHS Japan, EPA, etc.) those chemicals reported in the original test submissions will be avoided. 235 
One potential source for screening eligible chemicals which will be considered by the CSG is the 236 
official European Commission inventory of cosmetic ingredients (CosIng). CosIng is supported by 237 
consolidated documentation (opinions) issued by the Scientific Committee on Consumer Safety 238 
(SCCS) with references to confidential in vivo Draize eye irritation studies archived by DG-239 
SANCO. In collaboration with SCCS and DG-SANCO, in vivo Draize eye irritation data on 240 
CosIng chemicals will be reviewed, and sample material availability determined. For eligible 241 
chemicals, in vivo Draize eye irritation study sponsors will be requested to authorise use and 242 
eventual publication of eye irritation data and, in cases of proprietary production, to supply sample 243 
material for in vitro assay. 244 
Proprietary new substances notified under Directive 67/548/EEC present another unique potential 245 
source, qualified by in vivo Draize eye irritation studies compliant with official guidelines and 246 
reviewed by Competent Authorities. Notification files (with summary in vivo Draize eye irritation 247 
data) archived in a confidential new chemicals database (NCD) accessible to authorised European 248 
Commission and Competent Authority personnel in the CSG, allow shortlisting of eligible 249 
candidates according to the notifier/producer. Under the auspices of the European Partnership for 250 
Alterative Approaches to Animal Testing (EPAA) affiliated companies will be invited to 251 
collaborate in determining availability of sample material, with release of supporting in vivo 252 
Draize eye irritation study reports. Initiative within cooperative companies to propose additional 253 
and/or alternative chemicals would also be welcomed. 254 
A sample size calculation by the ECVAM biostatistician and the TNO biostatistician has shown 255 
that 104 test chemicals will be required for this validation study. 256 
Ideally, chemical selection should achieve a balanced set of (i) irritancy (UN GHS/EU CLP 257 
categories 1 and 2 versus no category); (ii) physical state (liquids versus solids); and (iii) EPRA 258 
reactivity (reactive versus non-reactive). Acknowledging practicality of achieving a perfectly 259 
balanced set covering all three conditions, the VMG agreed the following limits: (i) an overall 260 
50±5% split of UN GHS/EU CLP categories 1 and 2 versus no category, with a 50/50 split 261 
between category 1 and category 2, including adequate representation of UN GHS sub-categories 262 
2A and 2B; (ii) an overall 50±10% split of solids versus liquids; and (iii) an overall 50±15% split 263 
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of reactive versus non-reactive chemicals (based on EPRA analyses). Similarly, the selection 264 
would aim for an even distribution of physical state (50±10% split of liquids versus solids) and 265 
EPRA reactivity (50±15% split of reactive versus non-reactive) among each irritancy sub-group 266 
(no category, category 2B, category 2A and category 1).  267 
Significantly, since EPRA reactivity is not known in advance, the parameter cannot be applied as 268 
an eligibility criterion a priori. Thus, the VMG agreed to a wider limit of acceptance (50±15%) for 269 
the proportion of reactive versus non-reactive chemicals. In event of EPRA results demonstrating 270 
significant bias in reactivity distribution, this limit would have to be reconsidered. 271 
The chemical selection would also aim for representation of a range of ocular toxicity effects, 272 
evident from distributions and persistence of irritation scores. 273 
Final approval of the test chemicals proposed by the CSG is the responsibility of the core VMG. 274 
Respecting non-disclosure of chemical identities to the test facilities, the VMG lead laboratory 275 
representatives will not participate in the selection process. 276 
The VMG recognises that commercial availability of selected test chemicals would facilitate future 277 
identification of performance standard reference chemicals, relevant to similar method catch-up 278 
studies (Performance Standards-based validation). Therefore, the CSG will limit the selection of 279 
proprietary chemicals and will aim at having at least ⅔ of commercially available chemicals (~70 280 
chemicals) in their final chemical selection (at least 104 test chemicals), which present a balanced 281 
distribution of irritancy, physical state and reactivity similar to the overall set of selected test 282 
chemicals (see above). As such, ample scope for establishing a robust set of reference chemicals 283 
upon completion of EIVS shall be ensured. 284 
8. Chemical Acquisition, Coding and Distribution 285 
Independent coding and distribution of test chemicals will be contracted out by the sponsor 286 
COLIPA to TNO. TNO is certified according to ISO 9001 and GLP, and has proven experience of 287 
reliable services. TNO will purchase, code and supply existing chemicals, including cosmetic 288 
ingredients from the CosIng inventory. The CSG coordinator will ask companies producing new 289 
chemicals to send samples directly to TNO for coding and distribution. All test chemicals will be 290 
randomly coded. Each test chemical will have a code that is unique for each laboratory. The same 291 
code will be used for the SkinEthic
TM
 HCE SE and for the SkinEthic
TM
 HCE LE assays but 292 
otherwise distinct codes will also be used for each test method/assay (i.e., EpiOcular
TM
 EIT, 293 
SkinEthic
TM
 HCE SE/LE and EPRA) that is run in the same laboratory. The codes will be 294 
generated and provided by the TNO biostatistician. Expiry dates will be provided for all test 295 
chemicals. Furthermore, when available, a single Molecular Weight and a single purity for each 296 
coded test chemical will be provided to the laboratories performing the EPRA to allow preparation 297 
of Molar solutions, as required by the EPRA Protocol. This includes pure substances and mixtures. 298 
For mixtures, the single purity will be determined by the sum of the proportion of its components 299 
(excluding water), while the single Molecular Weight will be determined by considering the 300 
individual Molecular Weights of each component in the mixture (excluding water) and their 301 
individual proportions. In exceptional cases (e.g., complex mixtures or polymers) Molecular 302 
Weights and exact proportions of components may not be available. 303 
Personnel responsible for chemical acquisition, coding and distribution shall be independent from 304 
those conducting the EPRA for EIVS. 305 
306 
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9. Receipt and Handling of Chemicals 307 
Coded test chemicals as well as a health and safety information package will be dispatched to the 308 
Safety Officer of each participating laboratory (see sections 10.1-10.3 and 11.4) in appropriate 309 
packaging, compliant with relevant regulatory requirements. The participating laboratories shall be 310 
notified by TNO when the test chemicals are shipped, shall make proper provision for their 311 
receipt, and promptly acknowledge that they have been received. Upon receipt at the laboratory, 312 
the test chemicals shall be stored in appropriate storage conditions as indicated in the unsealed 313 
accompanying documentation and must be stored for at least six months following submission of 314 
the final biostatistical report to the VMG. 315 
The health and safety information package will include a sealed envelope for each test chemical 316 
identified by chemical code. Each envelope will contain a MSDS and a certificate of analysis for 317 
the respective test chemical. A sealed envelope shall be opened at the laboratory only in an 318 
emergency/need-to-know situation. At the end of EIVS, the Safety Officer shall return the health 319 
and safety information package with all unopened envelopes to the VMG (Logistics Coordinator). 320 
If a sealed envelope from the health and safety information package is opened by the laboratory, 321 
the Safety Officer shall immediately notify the VMG designated contact, i.e. the Logistics 322 
Coordinator (Jan Lammers, TNO). 323 
The Study Director of each laboratory (see sections 10.1-10.3 and 11.1) shall receive essential 324 
information about the test chemicals (e.g. storage instructions). Upon receipt, each laboratory must 325 
complete and return the Test Chemical Receipt Report (Annex I). 326 
Appropriate routine safety procedures shall be followed in handling the test chemicals unless 327 
otherwise specified in the unsealed documentation supplied at the time of chemical distribution. 328 
Laboratory personnel shall be instructed to treat all coded test chemicals as very hazardous and to 329 
dispose of laboratory waste as toxic waste. 330 
10. Participating Laboratories 331 
The laboratories participating in the study are defined as shown in Figure 1. The specific 332 
obligations and responsibilities of the participating laboratories will be specified in contracts 333 
between the sponsor COLIPA and the laboratories. These include, but are not limited to, the 334 
adherence to this project plan throughout the study, the adherence to the test method protocol, the 335 
adherence to the work program, assuring compliance with GLP-like principles, specifying and 336 
applying proper Quality Assurance procedures, and meeting the data submission deadlines. The 337 
participating laboratories shall have competence in performing the test method(s) and shall provide 338 
competent personnel, adequate facilities, equipment, supplies, and proper health and safety 339 





 HCE SE/LE and EPRA, and for providing training to the technical 341 
staff of the other testing facilities. The contracts between COLIPA and the laboratories should also 342 
clarify the ownership of results and the publication procedures. 343 
The participating laboratories are allowed to freely communicate and meet during the training and 344 
transfer phases of EIVS. Such meetings will be organized by the lead laboratories and can occur 345 
without a formal approval by the VMG. However, during the testing phase, the participating 346 
laboratories and the personnel responsible for providing training on the test methods, will no 347 
longer contact each other regarding this validation study without the previous knowledge and 348 
approval by the VMG. All VMG approved meetings or other forms of communication between the 349 
participating laboratories during the testing phase will be organized by the Logistics Coordinator 350 
in collaboration with the lead laboratories. 351 
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10.1. Cys/Lys EPRA 352 
Three laboratories will participate in EIVS for testing with the EPRA. These are: 353 
 Lead laboratory – L’Oréal 354 
o Study Director: Nathalie Alépée 355 
o Safety Officer: Joan Eilstein 356 
 Laboratory 1 – TNO 357 
o Study Director: Brigitte Buscher 358 
o Safety Officer: Hans Ram 359 
 Laboratory 2 – CARDAM 360 
o Study Director: Griet Jacobs 361 
o Safety Officer: Frank Vander Plaetse / Katrien Smits 362 
10.2. EpiOcular
TM
 EIT 363 
Three laboratories will participate in EIVS for testing with the EpiOcular
TM
 EIT. These are: 364 
 Lead laboratory – Beiersdorf 365 
o Study Director: Uwe Pfannenbecker 366 
o Safety Officer: Peter Klaws 367 
 Laboratory 2 – Harlan Laboratories Ltd. (UK) 368 
o Study Director: Andrew Whittingham 369 
o Safety Officer: Christine Cauldwell 370 
 Laboratory 3 – IIVS 371 
o Study Director: Hans Raabe 372 
o Safety Officer: Nathan Wilt 373 
A reserve laboratory is also identified as Pierre-Fabre (Contact Person: Sandrine Bessou-Touya) 374 
10.3. SkinEthic
TM
 HCE SE/LE 375 
Three laboratories will participate in EIVS for for testing with the SkinEthic
TM
 HCE SE/LE. These 376 
are: 377 
 Lead laboratory – L’Oréal 378 
o Study Director: Nathalie Alépée 379 
o Safety Officer: Samuel Blond 380 
 Laboratory 2 – CARDAM 381 
o Study Director: An van Rompay 382 
o Safety Officer: Frank Vander Plaetse / An Jacobs 383 
 Laboratory 3 – CeeTox Inc. 384 
o Study Director: Colleen Toole 385 
o Safety Officer: Karen Rutherford 386 
A reserve laboratory is to be identified. 387 
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11. Laboratory Personnel 388 
11.1. Study Directors 389 
Each participating laboratory shall appoint a Study Director (see sections 10.1-10.3), a scientist of 390 
appropriate education, training, and experience in the field. The Study Director represents the 391 
single point of study control with ultimate responsibility for the overall technical conduct of the 392 
study, the documentation and reporting of the results, as well as GLP adherence or adherence to 393 
the minimum quality requirements (see section 14). 394 
The Study Director is responsible for collecting the data of his/her laboratory and to send them to 395 
the Logistics Coordinator of the study (to be forwarded to the TNO biostatistician) according to 396 
the timelines established in the Project Plan (see section 17). 397 
The Study Directors are also responsible for sending timely Study Reports to the contact person of 398 
the VMG, i.e. the Logistics Coordinator, who will monitor the progress of the study. Such reports 399 
should include all relevant experimental data as well as all deviations from the Project Plan and 400 
Test Method protocols. 401 
The study directors will be the primary contact point for the communications between the VMG 402 
and the testing facilities unless otherwise requested. 403 
11.2. Quality Assurance (QA) Officers 404 
For participating laboratories that are GLP compliant the Quality Assurance Officer shall assure 405 
conformity with GLP requirements for all aspects of the study (facilities, equipment, personnel, 406 
methods, practices, records, controls, SOPs, Test Method protocol, final reports (for data 407 
integrity), and archives). The Quality Assurance Officer is entirely separate from and independent 408 
of the personnel engaged in the direction and conduct of the study. 409 
Participating laboratories that are not GLP compliant, shall appoint an individual to assure that all 410 
records, documents, raw data and reports are available to the VMG if an inspection is requested, 411 
and ensure that the quality assurance provisions detailed in the section 14 (see below) have been 412 
implemented. 413 
11.3. Experimental team 414 




 HCE SE/LE and EPRA requires personnel 415 
trained and competent in the specific techniques and general laboratory procedures. Each 416 
individual engaged in the conduct of, or responsible for, the supervision of a validation study shall 417 
have education, training, and experience, or combination thereof, to enable that individual to 418 
perform the assigned duties. 419 
11.4. Safety Officers 420 
A designated Safety Officer (not otherwise involved in the actual conduct of the validation study) 421 
at each participating laboratory (see sections 10.1-10.3) will receive the blinded (coded) test 422 
chemicals and shall transfer the test chemicals to the responsible person of the laboratory. Sealed 423 
Material Safety Data Sheets (MSDSs) will accompany the test chemicals and the Safety Officer 424 
shall retain the package until the completion of EIVS. Additional sealed MSDSs can be sent to the 425 
testing facilities upon request of the Safety Officer if this information needs to be kept in more 426 
than one location. At the end of the validation study, the Safety Officer shall return the unopened 427 
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packages to the Logistics Coordinator of the study. If any laboratory personnel should open the 428 
packages at any time during the validation study, the Safety Officer shall promptly notify the 429 
VMG through the Logistics Coordinator (Jan Lammers, TNO). 430 
12. Study Design 431 
12.1. Eye irritation Peptide Reactivity Assay (“chemical reactivity”) 432 
Chemical reactivity is defined in this validation study as the electrophilic potential to react with 433 
cysteine or lysine containing peptides. 434 
The lead laboratory for the Cysteine/Lysine Eye Irritation Peptide Reactivity Assay (EPRA) is 435 
L’Oréal. Training of the other participating laboratories (TNO and CARDAM) in conducting the 436 
EPRA shall be provided by the test method developer (Procter & Gamble). The lead laboratory in 437 
collaboration with the test method developer will be responsible for issuing a final test method 438 
protocol. Upon completion of the training phase, participating laboratories shall test 5-10 test 439 
chemicals to demonstrate transferability of the assay and to confirm test method protocol 440 
adequacy. Importantly, training of TNO and CARDAM in conducting the EPRA and their 441 
respective transferability studies will not occur at the same time during EIVS because TNO will be 442 
involved in testing for chemical selection and for reliability assessment while CARDAM will only 443 
do testing for reliability assessment (see below). The trained participating laboratories will be 444 
responsible for issuing training and transfer reports upon completion of the transferability study. 445 
The results of the training phase and of the transferability study of a laboratory will be reviewed 446 
and approved by the VMG before that laboratory progresses with testing for EIVS (testing phase). 447 
If the transferability data do not meet test acceptance criteria, the VMG will work with the 448 
participating laboratory and the lead laboratory to identify the problems and make corrections 449 
where needed.  450 
In a first stage of the EIVS testing phase, all eligible chemicals identified by the CSG will have 451 
their chemical reactivity determined based on the EPRA, in a blind study in a single laboratory 452 
(TNO), with a single test consisting of three replicate measurements. Since chemicals found 453 
eligible by the CSG will not all become available for EPRA testing at TNO at the same time (due 454 
to differences in the time required to gain access to in vivo Draize eye irritation study reports for 455 
different chemicals, and to differences in the time required to obtain commercially available and 456 
proprietary chemical samples), the selection of a final test chemical set will be phased, with 457 
subsets of 30-50 test chemicals being selected by the CSG in different stages, as the data from the 458 
EPRA analysis becomes available, and until the final amount of at least 104 test chemicals is 459 
reached. These chemical subsets shall be as balanced as possible considering the criteria described 460 
in section 7.2 (with some flexibility allowed) and, upon approval by the core VMG, they will be 461 
distributed to the participating laboratories for viability assessment. Importantly, the total chemical 462 
set of at least 104 test chemicals (considering all selected subsets) shall be well balanced and meet 463 
all the criteria defined in section 7.2. 464 
Upon completion of the viability assessment study, a preliminary evaluation of the usefulness of 465 
the SkinEthic
TM
 HCE test strategy composed of the EPRA, the SkinEthic
TM
 HCE SE and the 466 
SkinEthic
TM
 HCE LE assays will be performed using the reactivity data obtained by TNO for all 467 
the selected test chemicals (at least 104) and the viability data obtained with SkinEthic
TM
 HCE SE 468 
and SkinEthic
TM
 HCE LE for the same test chemicals. If by combining the three assays in a test 469 
strategy a better predictive capacity is obtained as compared to the SkinEthic
TM
 HCE SE or the 470 
SkinEthic
TM
 HCE LE assays alone, chemical reactivity data will be obtained for a subset of the full 471 
validation set, in three laboratories (L’Oréal, TNO and CARDAM), in a second step to assess the 472 
reliability of the EPRA. Each of these three laboratories will test each test chemical in this subset 473 
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in three independent tests (performed in separate runs) consisting of three replicate measurements 474 
each, in order to strictly determine reproducibility (WLR and BLR) of the EPRA. TNO, as one of 475 
the three laboratories, will be testing these chemicals in three new independent tests (performed in 476 
separate runs). 477 
The definitive number and characteristics of the chemicals to be tested for reliability assessment of 478 
the EPRA will be decided on later by the VMG with the help of statistical power analysis 479 
performed by the biostatisticians, but at least 20 chemicals and up to the maximum number of 480 
chemicals that can be tested in two separate runs for one peptide will be tested. When selecting the 481 
subset of test chemicals to assess the reliability of the EPRA, preference will be given to test 482 
chemicals that classify differently in SkinEthic™ HCE SE and SkinEthic™ HCE LE, since this 483 
would allow the use of these data for calculating the predictive capacity of the SkinEthic
TM
 HCE 484 
test strategy. However, if all of these cannot be included in the selection, the data of a single test 485 
acquired by TNO for the selected test chemicals (at least 104) will be used to determine the 486 
predictive capacity of the proposed SkinEthic
TM
 HCE test strategy, and other chemicals may be 487 
chosen for reliability assessment. 488 
12.2. Biological assays 489 
The lead laboratories for the EpiOcular
TM
 EIT and the SkinEthic
TM
 HCE SE/LE are Beiersdorf and 490 
L’Oréal, respectively. Training of the participating laboratories in conducting the EpiOcularTM EIT 491 
or the SkinEthic
TM
 HCE SE/LE assays shall be provided by the respective test method developer 492 
(MatTek Corporation for EpiOcular
TM
 EIT and L’Oréal for SkinEthicTM HCE SE/LE). The lead 493 
laboratories in collaboration with the test method developers will be responsible for issuing final 494 
test method protocols. Upon completion of the training phase, participating laboratories shall test 495 
5-10 chemicals to demonstrate transferability of the assay and to confirm test method protocol 496 
adequacy. The test method developers in collaboration with the participating laboratories will be 497 
responsible for issuing training and transfer reports upon completion of the transferability studies. 498 
The results of the training phase and of the transferability studies for a particular test method will 499 
be reviewed and approved by the VMG before progression of the study for that test method. If the 500 
transferability data do not meet test acceptance criteria, the VMG will work with the participating 501 
laboratory and the lead laboratory to identify the problems and make corrections where needed. 502 
In the testing phase of EIVS, each of the test chemicals in the final chemical selection set (at least 503 




 HCE SE and 504 
SkinEthic
TM
 HCE LE) in at least three independent tests (using different tissue batches and 505 
performed in separate runs) by each of three independent laboratories (see Document “Guidance 506 
on Study Conduct and Test Method Performance Criteria for EIVS”). Thus, each chemical will be 507 
tested with the two different exposure/post-treatment periods of the SkinEthic
TM
 HCE SE/LE 508 
protocol (10 min and 1 h + 16 h post-treatment), and with one of the two EpiOcular
TM
 EIT 509 
exposure procedures depending on the test chemical being solid or liquid (30 min + 120 min post-510 
treatment, or 90 min + 18 h post-treatment). Importantly, the three laboratories participating in the 511 
validation of EpiOcular
TM
 EIT will not be instructed on the physical state of the test chemicals. 512 
Therefore, each laboratory participating in the validation of the EpiOcular
TM
 EIT shall decide on 513 
the physical state of each test chemical and the appropriate exposure procedure to use. Finally, 514 
each control and test chemical included in one run will be tested in two (EpiOcular
TM
 EIT) or three 515 
(SkinEthic
TM
 HCE SE/LE) replicate tissues. 516 
The EIVS RhT testing phase will be conducted in two or more consecutive phases to allow for 517 
periodic opportunities to evaluate the frequency of technical errors and any other problems that 518 
might occur during testing. At least at the end of each RhT testing phase the Study Directors will 519 
forward the data acquired by their laboratories to the Logistics Coordinator after internal quality 520 
check (see Table 2 in section 17) who will provide it to the TNO biostatistician for immediate 521 
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preliminary analyses of Within Laboratory Reproducibility (WLR) and compliance with Study 522 
Quality criteria (number of complete/incomplete test sequences as described in the Performance 523 
Criteria). Once completed, these phased statistical analyses and their conclusions will be provided 524 
to the core VMG who will review them and determine if modifications to the protocol and/or study 525 
plan are warranted/appropriate in order to avoid future occurrences of identified issues. All 526 
participating laboratories should adhere to these testing phases and ideally complete testing of all 527 
chemicals in one phase (by obtaining three qualified tests per chemical) before testing chemicals 528 
of following phases. However, for practical reasons and in order to minimise the cost of the study, 529 
the participating laboratories may delay the testing of MTT reducers and/or colorants in order to 530 
test them all together in a later testing phase, provided delayed chemicals will not expire. 531 
Moreover, chemicals with short expiry dates included in later testing phases of the study may be 532 
moved to an earlier phase to avoid testing after the expiration date. 533 
13. Data Collection, Handling, and Analysis 534 
The Logistics Coordinator will collect the data from each participating laboratory via the Study 535 
Directors (see section 11.1) at least at the end of each RhT testing phase (see section 12.2 and 536 
Table 2 in section 17) and will forward it to the TNO biostatistician. The TNO biostatistician will 537 
organise the data in specific data collection software (MS EXCEL spreadsheets). The collected 538 
data shall be circulated to every participating laboratory for a quality check. At the end of each 539 
RhT testing phase a preliminary analysis of WLR and compliance with Study Quality criteria (see 540 
above) will be performed without decoding the test chemicals (to avoid breaking the code before 541 
completion of the study). Upon completion of the RhT testing phases by all participating 542 
laboratories and preliminary “blind” determination of WLR and Study Quality criteria for each 543 
laboratory, test chemicals will be decoded and the TNO biostatistician will do a complete 544 
statistical analysis of the data and provide a final biostatistical report to the VMG. The ECVAM 545 
biostatistician will do a quality control of the processes of data collection, handling and analysis, 546 
as well as of the final biostatistical report. The data management procedures and statistical tools 547 
that will be used for data analysis and included in the final biostatistical report will be described in 548 
a Statistical Analyses and Reporting Plan. This Plan shall be developed by the ECVAM and TNO 549 
biostatisticians before the end of the experimental phase of the study and shall be approved by the 550 
VMG before the biostatistical analyses begin. 551 
Based on final data analysis, the VMG reserves the possibility to identify the most suitable test 552 
strategies for the identification of non classified chemicals from classified ones. 553 
The VMG has the responsibility of producing the final report and publication of the study. These 554 
will include the results of the EIVS and the VMG conclusions/recommendations on the outcome 555 
of the study. VMG conclusions/recommendations will be supported by the Performance Criteria 556 
defined by the VMG prior to initiation of the testing phase of EIVS. The draft statistical report and 557 
the draft validation study report shall be circulated to every participating laboratory for review and 558 
comments prior to finalisation. The VMG should review all comments received and make 559 
revisions if deemed appropriate. 560 
14. Quality Assurance, Good Laboratory Practice 561 
14.1. Laboratories 562 
Participating laboratories that are compliant with Good Laboratory Practices (GLP) will perform 563 
the studies in accordance with GLP standards (OECD, 1999). Non GLP-compliant laboratories 564 
shall use the OECD principles of GLP as guidelines for conducting the validation study. Any 565 
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deviations from these principles should be documented along with a discussion of their 566 
impact on the study results. 567 
It is considered that the following requirements (Balls M. et al., 1995) are essential for the mutual 568 
acceptance of information produced in the validation process: 569 
 Qualified personnel, and appropriate facilities, equipment and materials shall be available 570 
for the timely and proper conduct of the study 571 
 Records of the qualifications, training and experience, and a job description for each 572 
professional and technical individual involved in the study, shall be maintained. 573 
 For each study, an individual with appropriate qualifications, training and experience shall 574 
be appointed to be responsible for its overall conduct and for any report issued (Study 575 
Director, see section 11.1).  576 
 Instruments used for the generation of experimental data shall be inspected regularly, 577 
cleaned, maintained and calibrated according to established SOPs, if available, or to 578 
manufacturers' instructions. Records of these processes shall be kept, and made available 579 
for inspection on request. 580 
 Reagents shall be labelled, as appropriate, to indicate their source, identity, concentration 581 
and stability.  The labelling shall include the preparation and expiry dates, and specific 582 
storage conditions. 583 
 All data generated during a study shall be recorded directly, promptly and legibly by the 584 
individual(s) responsible.  These entries shall be attributable and dated. 585 
 All changes to data shall be identified with the date and the identity of the individual 586 
responsible, and a reason for the change shall be documented at the time. 587 
14.2. Tissue model suppliers 588 
According to OECD GLP Consensus Document No.5 “Compliance of Laboratory Suppliers with 589 
GLP Principles” the responsibility for the quality and fitness for use of equipment and materials 590 
rests entirely with the management of the test facility (OECD, 1999). 591 
The acceptability of equipment and materials in laboratories complying to GLP principles should 592 
therefore be guaranteed to any regulatory authority to whom studies are submitted. In some 593 
countries where GLP has been implemented, suppliers belong to national regulatory or voluntary 594 
accreditation schemes (for example, for laboratory animals) which can provide users with 595 
additional documentary evidence that they are using a test system of a defined quality. 596 
The audits on the RhT tissue production sites (MatTek Corporation and EpiSkin Laboratories) will 597 
be carried out by TNO and ECVAM, and will focus on the procedures established to guarantee a 598 
defined quality of the tissue models, as defined in the audit protocol previously approved by the 599 
VMG. 600 
15. Health and Safety 601 
Each laboratory shall conform to all applicable statutes in effect at the time of this validation 602 
study. The designated Safety Officer (see sections 10.1-10.3 and 11.4) shall be the point of contact 603 
for health and safety issues. 604 
16. Records and Archives 605 
At the end of EIVS, the original raw (if applicable; not possible for GLP compliant laboratories) 606 
and processed data or copies thereof shall be submitted to ECVAM and COLIPA for storing and 607 
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archiving. In addition, other records relevant to EIVS (instrument logs, calibration records, facility 608 
logs, etc.) should be made available for inspection upon request by the VMG. 609 
Raw and processed data or copies thereof (depending if the laboratory is or not GLP compliant) 610 
shall be stored and archived at the participating laboratory for at least five years after completion 611 
of EIVS. The data which are stored electronically shall be periodically copied, and backup files 612 
shall be produced and maintained. 613 
17. Timelines 614 
The following tables summarise the critical activities of the study and the estimated completion 615 
timelines. Timelines might need to be reviewed during the study. 616 
 617 
Table 1. Study timelines 618 
Critical activities Timing (*finalisation) 
Chemical eligibility / availability from suppliers 





o 29 October 2010 
o VMG III 3-4 June 2009* 
o 29 October 2010 
o 29 October 2010 
Project Plan 
o Finalisation 
o Approval by VMG  
 
o VMG VII 28-29 September 2010 
o 1 December 2010 
Guidance on Study Conduct and Test Method 
Performance Criteria for EIVS 
o Finalisation 
o Approval by VMG 
 
 
o VMG VII 28-29 September 2010 
o 1 December 2010 
Study design approval by VMG o 30 July 2009* 
EPRA 
o Cut-off for EPRA  
o EPRA updated/final Protocol approval 
 
 
o EPRA study plan 
o # and identity of chemicals tested for 
reproducibility assessment of EPRA 
EPRA testing at TNO for chemicals selection 
o Training  
o Transferability study  
o Beginning of testing 
EPRA reliability assessment 
o Training  
o Transferability study 
o Beginning of testing 
 
o VMG III 3-4 June 2009* 
o 18 December 2009* (slightly 
revised and approved on VMG VII 
28-29 September 2010) 
o VMG V 24-25 November 2009* 
o T.b.d. by July 2011 
 
 
o 3-4 June 2009* 
o 13 July-16 October 2009* 
o March 2010 
 
o T.b.d. by March 2011 
o T.b.d. by March 2011 
o T.b.d. by July 2011 
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SkinEthic
TM
 HCE SE/LE 
o Performance under UN GHS classification  
(TST data) 
o QA audit on RhT production site 
o Training 
o Transferability study 
o SkinEthicTM HCE SE/LE final Protocol 
approval 
o Beginning of testing (see Table 2) 
 
o VMG III 3-4 June 2009* 
 
o 19 March 2010* 
o 19-29 January 2010* 
o 8 February-9 April 2010* 
o 17 June 2010* 
 




o QA audit on RhT production site 
o Insert to be used 
o Cut-off to be used 
o Training 
o Transferability study 
o Final Protocol approval 
o Beginning of testing (see Table 2) 
 
o 26 May 2010* 
o 9 September 2010* 
o 9 September 2010* 
o October-November 2010 
o November 2010  
o December 2010 
o January 2011 
CSG final chemical selection and Core VMG 
approval 
o 1st set (34 test chemicals) 
o 2nd set (46 test chemicals) 
o 3rd and final set (24-27 test chemicals) 
 
 
o 10 June 2010* 
o 8 September 2010* 
o 10 December 2010 
Chemical coding and distribution June 2010-January 2011 
Participating laboratory contracts December 2009-January 2011 
Contract with SkinEthic Laboratories for the supply 
of SkinEthic
TM
 HCE tissues 
February 2010 





Delivery of final statistical report (biostatistician) 
Within 2 months after completion of testing 
phase 
Delivery of final study report (VMG) 
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34 test chemicals 
(selected on 10/06/2010) 
Starting date: 21 June 2010 
Finishing date: February 2011 
Data collection by Study Directors and 
dispatch to Logistics Coordinator: 
by February 2011 
~40 test chemicals 
(½ liquids, ½ solids) 
Starting date: December 2010 
Finishing date: March 2011 
Data collection by Study Directors and 
dispatch to Logistics Coordinator: 




46 test chemicals 
(selected on 08/09/2010) 
Starting date: October 2010 
Finishing date: May 2011 
Data collection by Study Directors and 
dispatch to Logistics Coordinator: 
by May 2011 
~40 test chemicals 
Starting date: March 2011 
Finishing date: May 2011 
Data collection by Study Directors and 
dispatch to Logistics Coordinator: 




24-27 test chemicals 
Starting date: March 2011 
Finishing date: July 2011 
Data collection by Study Directors and 
dispatch to Logistics Coordinator: 
by July 2011 
24-27 test chemicals 
Starting date: May 2011 
Finishing date: July 2011 
Data collection by Study Directors and 
dispatch to Logistics Coordinator: 
by July 2011 
 622 
18. Documents and Data 623 
1. ECVAM and/or the Logistics Coordinator, after consultation with the VMG, supplies EIVS 624 
documentation 'in confidence' to participating laboratories. Unless and until ECVAM places these 625 
documents in the public domain, they may not be published or communicated/distributed to other 626 
third parties without the knowledge and consent of ECVAM after consultation with the VMG. 627 
2. All study data generated by the contracted laboratories are the property of the European 628 
Commission/ECVAM and COLIPA. These data may not be published, communicated or 629 
circulated/distributed to third parties without the knowledge and consent of the European 630 
Commission/ECVAM and COLIPA, and the knowledge of the VMG. 631 
4. ECVAM and COLIPA reserve the right to be the first to promptly publish and communicate the 632 
outcomes of the validation process. 633 
634 
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Annex I - Test Chemicals Receipt Report Template 677 
 678 
Testing Facility: 679 
 680 
Test Chemicals Received by: 681 
 682 
Test Chemicals Receipt Date: 683 
 684 
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description of the 
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      YES  / NO   
      YES  / NO   
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Appendix IX Post-validation analyses: 2 vs 3 tissues 
Results reported by Joe Haseman (7-13-12) from NICEATM 
 
Analysis of Short Time Exposure Data 
 
 
This report addresses the following issue:  The current testing paradigm for the short time exposure data 
is three runs, each with three samples.  Within a run, the three samples are averaged, and if the average 
viability is greater than 50%, the run is considered “positive”; otherwise it is considered “negative”.   
 
The question of interest:  What would be the impact of reducing the number of samples in a given run 
from three to two?  More specifically, how often would averaging the viability of two samples and 
comparing it to 50% change the classification for that run relative to the classification based on averaging 
the viability of three samples? 
 
To address this question, I considered all the runs for which I was given data and considered the 
consequence of using only two of the three observed samples as the basis for classification for that run.  
There are three possible pairs of samples (first and second; first and third; second and third).  I then 
compared the classification for that run based on each pair with the classification based on the full three 
samples. 
 
Obviously, if all three samples were <50% or all were >50%, then there would be no change in 
classification.  Reducing the sample size could possibly change the classification only if there were some 
samples in the run that exceeded 50% and others that were less than 50%. 
 
The rest of this report presents the results of this statistical analysis, but the bottom line is this:  Reducing 
the number of samples from 3 to 2 for the short time exposure data will have almost no impact on the 
classification decision for a given run.  The probability is less than 1% that such a reduction would 
change the classification for a given run.  A companion report deals with the long time exposure data and 
reaches a similar conclusion.  
 
General comments on the data and analysis: 
 
(1) Approximately 90% of the chemicals had complete agreement among all the samples/runs 
evaluated with regard to classification (i.e., for a given chemical, all samples were either >50% 
or were <50% approximately 90% of the time, regardless of lab).  This is outstanding 
consistency. 
 
(2) Moreover, approximately 97% of the individual runs had complete agreement among the three 
samples with regard to classification.  Again, the overall consistency of response was 
outstanding.  Of the hundreds of runs evaluated, there were only a handful (detailed below) 
that produced any classification disagreement at all among the samples within the run, so it is 
only this few number of runs that could produce a possible classification inconsistency by 
reducing the sample size from 3 to 2. 
 
(3) The 50% cutoff point is very reasonable. 
 
(4) All chemicals had three runs. 
 
(5) Unlike the case for the long time exposure chemicals (which had approximately a 50-50 mix of 
“positives’ and “negatives”), the short time exposure data had far more “positives” than 
“negatives” (approximately 77% “positive” and 23% “negatives”). 
 
(6) The variability among runs was somewhat greater than the variability within a run among 
samples.  There were a few cases at certain labs in which one run for a given chemical 
produced 3 samples with viability <50%, while a second run produced 3 samples with viability 
>50%.  Thus, maintaining multiple runs is more important than maintaining multiple samples, 
but overall, even the reproducibility among runs was quite good. 
 
(7) No single lab stood out as being clearly superior to the others with regard to reproducibility, 
although overall Cardam and L’Oreal did a slightly better job in this regard than did Ceetox. 
 
(8) I received two sets of raw data, the first from Elizabeth Lipscomb and then later another 
dataset from ECVAM.  The data appeared to be identical, although a handful of runs in the 
ECVAM data included a “correction” for something that was subtracted from the original 
viability value.  For the analyses summarized in this report, I used the viability values that 
Elizabeth Lipscomb sent me.  The ECVAM data also noted that certain chemicals were 
“excluded”, and certain runs within a chemical were “non-qualified” because of excessive 
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variability among samples within the run.  I noted all of these occurrences in this report, but I 
deleted them from my calculations. Among the more than 900 runs, there were very few (8 by 




At some point, it would be a good idea to “decode” the chemicals to see if there was a consistency in 
classification of specific chemicals across labs.  However, that was not the objective of this evaluation, 











              Summary of Results for SE Protocol:  Cardam 
 
Number of usable chemicals: 104 
Number of excluded chemicals:  2 (C53, and C58) 
Non-qualified runs:  C35, Run 2 
                                  C45, Run 1 
                                  C52, Runs 1 and 4 
                                  C83, Run 1 
All chemicals had 3 runs 
Total number of useable runs: 312 
Total number of pairwise comparisons = 936 
Bracketed data were excluded 
 
Chemical       Run results        Range of      Impact of reducing samples per 
   Code               (>50%)            scores              per run from 3 to 2 
 
C1                  3/3  0/3  3/3     34.14 to 88.12           None 
C101              3/3  3/3  3/3     74.19 to 102.58         None 
C103              3/3  3/3  3/3     97.97 to 121.54         None 
C104              3/3  3/3  3/3     72.51 to 106.79         None 
C105              3/3  3/3  3/3     94.23 to 110.54         None 
C106              3/3  3/3  3/3     83.11 to 98.71           None 
C107              3/3  3/3  3/3     87.79 to 105.59         None 
C108              3/3  3/3  3/3     86.59 to 102.52         None 
C109              3/3  3/3  3/3     70.54 to 117.83         None 
C11                0/3  0/3  0/3     0.12 to 19.01             None 
C110              3/3  3/3  3/3     87.76 to 106.44         None 
C112              3/3  3/3  3/3     83.57 to 109.81         None 
C113              3/3  3/3  3/3     82.93 to 100.48         None 
C114              3/3  3/3  3/3     87.94 to 114.66         None 
C116              3/3  3/3  3/3     84.30 to 104.35         None 
C119              0/3  0/3  0/3    20.75 to 45.78            None 
C12                1/3  0/3  0/3     24.05 to 56.37 [---]      1/9 
C120              3/3  3/3  3/3     85.54 to 105.20         None 
C123              0/3  0/3  0/3     6.66 to 13.34             None 
C124              3/3  3/3  3/3     82.12 to 123.05         None 
C125              3/3  3/3  3/3     59.38 to 107.49         None 
C127              3/3  3/3  3/3     58.16 to 102.30         None 
C128              0/3  0/3  0/3     23.21 to 32.16           None 
C129              3/3  3/3  3/3     87.02 to 121.48         None 
C13                3/3  1/3  3/3     41.91 to 110.32 [+++]  1/9 
C131              3/3  3/3  3/3     84.26 to 115.87         None 
C132              3/3  3/3  3/3     59.00 to 90.81           None 
C134              0/3  0/3  0/3     1.76 to 5.58               None 
C135              0/3  0/3  2/3     32.52 to 63.37 [--+]   1/9        
C136              3/3  3/3  3/3     61.01 to 79.77           None 
C137              0/3  0/3  0/3     26.80 to 43.05           None               
C138              0/3  0/3  0/3     3.27 to 4.93               None 
C139              3/3  3/3  3/3     60.75 to 85.07           None 
C14                3/3  3/3  3/3     93.06 to 110.29         None 
C140              3/3  3/3  3/3     84.95 to 118.80         None 
C141              3/3  3/3  3/3     84.55 to 124.83         None 
C15                3/3  3/3  3/3     78.39 to 116.41         None 
C16                3/3  3/3  3/3     84.16 to 120.66         None 
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C163              3/3  3/3  3/3     94.15 to 114.78         None 
C164              3/3  3/3  3/3     83.36 to 105.49         None 
C166              3/3  3/3  3/3     78.96 to 106.44         None 
C170              3/3  3/3  3/3     70.86 to 95.07           None 
C185              3/3  3/3  3/3     72.47 to 106.13         None 
C19                3/3  3/3  3/3     53.53 to 84.86           None 
C193              0/3  3/3  0/3     17.26 to 56.08           None 
C195              3/3  3/3  3/3     97.47 to 110.93         None 
C196              3/3  3/3  3/3     71.97 to 103.93         None 
C2                  3/3  3/3  3/3     96.82 to 129.00         None 
C20                3/3  3/3  3/3     90.00 to 105.69         None 
C21                0/3  0/3  0/3     14.77 to 30.35           None 
C25                3/3  3/3  3/3     57.32 to 95.42           None 
C26                0/3  0/3  0/3     0.26 to 5.22               None 
C27                3/3  3/3  3/3     81.91 to 118.02         None 
C28                3/3  3/3  3/3     95.05 to 116.42         None 
C29                3/3  3/3  3/3     70.99 to 113.50         None 
C3                  3/3  0/3  3/3     37.49 to 63.02           None 
C30                1/3  3/3  1/3     34.16 to 107.82 [-+-]   1/9 
C33                0/3  0/3  0/3     1.22 to 7.88               None 
C34                3/3  3/3  3/3     79.71 to 107.78         None 
C35      3/3  [1/3]  0/3  0/3     6.31 to 75.29             None      
C36                3/3  3/3  3/3     92.41 to 104.15         None 
C37                3/3  3/3  3/3     88.08 to 118.30         None 
C38                2/3  3/3  3/3     45.97 to 70.04 [+++] None 
C39                3/3  3/3  3/3     73.32 to 120.81         None 
C4                  3/3  3/3  3/3     93.21 to 115.11         None 
C45      [3/3]  3/3  3/3  3/3     88.51 to 143.36         None 
C46                3/3  3/3  3/3     57.91 to 105.31         None 
C47                3/3  3/3  3/3     57.17 to 100.79         None 
C48                0/3  0/3  0/3     3.17 to 16.52             None 
C49                3/3  3/3  3/3     78.69 to 116.34         None 
C50                0/3  0/3  0/3     22.95 to 42.83           None 
C51                3/3  3/3  3/3    81.00 to 97.88            None 
C52  [3/3]  3/3  3/3  [3/3]  3/3  120.20 to 188.94    None 
[C53        3/3  3/3  3/3  3/3     66.72 to 117.40]             - 
C54                3/3  3/3  3/3     88.22 to 123.44         None 
C55                3/3  3/3  3/3     83.32 to 105.68         None 
C56                3/3  3/3  3/3     87.26 to 137.29         None 
[C58               3/3  3/3  3/3     82.79 to 132.92]            - 
C6                  0/3  0/3  0/3     18.99 to 38.64           None 
C60                3/3  3/3  3/3     97.11 to 131.11         None 
C62                0/3  0/3  0/3     4.89 to 11.27             None 
C63                3/3  3/3  3/3     70.71 to 88.00           None 
C64                0/3  0/3  0/3     2.00 to 4.97               None 
C65                3/3  3/3  3/3     55.89 to 86.10           None 
C66                3/3  3/3  3/3     56.43 to 87.90           None 
C67                3/3  3/3  3/3     88.69 to 101.90         None 
C70                3/3  3/3  3/3     78.05 to 107.99         None 
C71                3/3  3/3  3/3     78.50 to 105.63         None 
C75                0/3  0/3  0/3     0.91 to 3.27               None 
C76                3/3  3/3  3/3     67.47 to 141.67         None 
C77                3/3  3/3  3/3     81.71 to 108.82         None 
C78                3/3  3/3  3/3     100.91 to 122.20       None 
C79                3/3  3/3  3/3     86.86 to 114.39         None 
C82                3/3  3/3  3/3     60.10 to 97.25           None 
C83      [3/3]  3/3  3/3  3/3     74.80 to 113.41         None 
C84                3/3  3/3  3/3     69.70 to 90.36           None 
C85                3/3  3/3  3/3     71.85 to 109.15         None 
C88                3/3  3/3  3/3     70.69 to 111.87         None 
C9                  3/3  3/3  3/3     78.89 to 107.07         None 
C90                0/3  0/3  0/3     0.26 to 0.66               None 
C91                0/3  0/3  0/3     0.58 to 13.73             None 
C94                3/3  3/3  3/3     73.82 to 87.55           None 
C96                3/3  3/3  3/3     71.36 to 111.21         None 
C97                0/3  0/3  0/3     14.00 to 36.16           None 
C98                0/3  0/3  0/3     7.32 to 12.52             None 
C99                3/3  3/3  3/3     71.57 to 107.78         None 
 
 
The likelihood that a reduction in sample size from 3 to 2 would change the classification for a run for 
Cardam  is only 4/936 or 0.4%. 
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                Revised Summary of Results for SE Protocol:  L’Oreal 
 
Number of usable chemicals: 102 
Number of excluded chemicals:  4 (L6, L7, L58 and L100) 
Non-qualified runs:  L11, Runs 1 and  2 
All chemicals had 3 runs  
Total number of useable runs: 306 
Total number of pairwise comparisons = 918  
Bracketed data excluded 
 
 
Chemical       Run results        Range of      Impact of reducing samples per 
   Code               (>50%)            scores              per run from 3 to 2 
 
L1                  3/3  3/3  3/3     77.63 to 97.02           None 
[L100  3/3  3/3  3/3  3/3  3/3   88.10 to 114.95]           - 
L101              3/3  3/3  3/3     51.88 to 92.89           None 
L102              3/3  3/3  3/3     84.75 to 95.31           None 
L104              1/3  0/3  0/3     15.70 to 66.00 [+--]     1/9         
L106              3/3  3/3  3/3     81.41 to 109.20         None 
L107              3/3  3/3  3/3     76.85 to 103.71         None 
L108              3/3  3/3  3/3     65.82 to 101.20         None 
L109              3/3  3/3  3/3     75.35 to 93.49           None 
L11   [1/3]  [1/3]  0/3  0/3  0/3   2.49 to 20.74         None       
L111              3/3  3/3  3/3     91.74 to 109.61         None 
L112              3/3  3/3  3/3     86.06 to 104.46         None 
L113              3/3  3/3  3/3     79.25 to 99.97           None    
L114              3/3  3/3  3/3     70.01 to 101.79         None 
L115              3/3  3/3  3/3     89.57 to 103.82         None 
L118              3/3  3/3  3/3     83.32 to 101.86         None 
L119              3/3  3/3  3/3     62.84 to 79.78           None 
L12                3/3  3/3  3/3     79.10 to 99.99           None 
L120              0/3  0/3  0/3     1.22 to 32.21             None 
L122              3/3  3/3  3/3     86.60 to 101.87         None 
L123              3/3  3/3  3/3     76.27 to 91.03           None  
L125              0/3  0/3  0/3     11.91 to 28.32           None 
L126              3/3  3/3  3/3     83.86 to 103.95         None 
L127              3/3  3/3  3/3     84.45 to 95.62           None 
L129              0/3  0/3  1/3     27.41 to 53.10 [---]    None 
L13                3/3  3/3  3/3     72.37 to 86.69           None 
L130              0/3  0/3  0/3     8.64 to 20.51             None 
L131              3/3  3/3  3/3     60.28 to 86.71           None 
L132              0/3  0/3  0/3     0.93 to 2.44               None 
L133              3/3  3/3  3/3     55.61 to 82.01           None 
L134              3/3  3/3  3/3     79.20 to 102.64         None 
L136              3/3  3/3  3/3     70.75 to 96.30           None    
L137              3/3  3/3  3/3     89.34 to 99.06           None 
L139              0/3  0/3  0/3     4.44 to 9.39               None 
L140              0/3  0/3  0/3     21.92 to 37.88           None 
L144              3/3  3/3  3/3     82.84 to 109.65         None 
L148              3/3  3/3  3/3     83.76 to 101.22         None 
L15                3/3  3/3  3/3     64.98 to 106.13         None 
L156              3/3  3/3  3/3     83.90 to 108.29         None 
L16                3/3  3/3  3/3     78.52 to 97.18           None 
L161              3/3  3/3  3/3     83.28 to 104.69         None 
L164              0/3  3/3  3/3     18.88 to 71.25           None 
L169              3/3  3/3  3/3     91.96 to 109.72         None 
L17                3/3  3/3  3/3     72.21 to 88.47           None      
L174              3/3  3/3  3/3     75.63 to 83.60           None 
L18                3/3  3/3  3/3     89.41 to 98.43           None 
L185              3/3  3/3  3/3     80.76 to 105.78         None 
L20                3/3  3/3  3/3     84.56 to 102.45         None 
L200              3/3  3/3  3/3     91.27 to 101.52         None 
L23                2/3  3/3  3/3     45.75 to 84.83 [+++] None 
L24                3/3  3/3  3/3     53.01 to 77.98           None 
L27                3/3  3/3  3/3     93.91 to 116.11         None 
L28                3/3  3/3  3/3     67.13 to 111.24         None  
L29                1/3  0/3  0/3     17.65 to 62.82 [+--]     1/9    
L32                3/3  3/3  3/3     79.28 to 108.86         None 
L33                0/3  0/3  0/3     3.00 to 5.42               None 
L36                3/3  3/3  3/3     888.90 to 103.78       None 
L37                0/3  0/3  0/3     11.08 to 32.83           None 
L39                3/3  3/3  3/3     82.92 to 95.13           None 
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L4                  3/3  2/3  3/3     49.96 to 78.37 [+++] None 
L42                3/3  3/3  3/3     52.07 to 79.95           None 
L43                3/3  3/3  3/3     87.79 to 99.59           None 
L45                0/3  0/3  0/3     1.95 to 17.41             None 
L48                0/3  0/3  0/3     0.57 to 6.52               None 
L5                  3/3  3/3  3/3     79.22 to 97.95           None 
L50                3/3  3/3  3/3     90.66 to 105.43         None 
L51                3/3  3/3  3/3     77.40 to 95.84           None 
L53                3/3  3/3  3/3     80.46 to 108.24         None 
L55                3/3  3/3  3/3     102.65 to 123.46       None 
L56                0/3  0/3  0/3     4.42 to 5.96               None 
L57                3/3  2/3  3/3     46.95 to 68.54 [+++] None 
[L58  3/3  3/3  3/3  3/3  3/3    51.45 to 112.72]          - 
L59                3/3  3/3  3/3     78.56 to 105.22         None 
[L6      3/3  3/3  3/3  3/3  3/3   89.35 to 178.31]         - 
L60                3/3  3/3  3/3     92.14 to 108.05         None 
L61                3/3  3/3  3/3     87.83 to 95.37           None 
L62                3/3  3/3  3/3     81.01 to 103.65         None 
L64                3/3  3/3  3/3     85.09 to 105.38         None 
L65                3/3  3/3  3/3     88.78 to 108.17         None 
L66                3/3  3/3  3/3     77.01 to 102.83         None 
L67                3/3  3/3  3/3     92.11 to 101.91         None 
L68                0/3  0/3  0/3     1.14 to 1.69               None 
[L7                  3/3  3/3  3/3     73.43 to 115.91]         - 
L70                0/3  0/3  0/3     0.68 to 10.00             None 
L72                3/3  3/3  3/3     68.90 to 92.80           None 
L73                3/3  3/3  3/3     76.03 to 111.97         None 
L75                3/3  3/3  3/3     79.39 to 92.25           None 
L76                3/3  3/3  3/3     82.38 to 102.14         None 
L78                0/3  0/3  0/3     0.48 to 1.27               None 
L79                3/3  3/3  3/3     84.12 to 109.33         None 
L8                  0/3  0/3  0/3     6.98 to 9.63               None 
L80                0/3  0/3  0/3     2.69 to 7.67               None 
L81                3/3  3/3  0/3     32.04 to 79.86           None 
L82                0/3  0/3  0/3     1.75 to 4.68               None 
L83                0/3  0/3  0/3     15.19 to 29.13           None 
L85                1/3  0/3  1/3     26.68 to 58.01 [---]    None 
L87                0/3  0/3  0/3     18.52 to 43.08           None 
L9                  0/3  0/3  0/3     21.66 to 34.22           None 
L90                3/3  3/3  3/3     83.92 to 106.16         None 
L91                3/3  3/3  3/3     54.96 to 97.66           None 
L92                0/3  0/3  0/3     10.41 to 42.98           None 
L94                3/3  3/3  3/3     75.79 to 87.39           None 
L96                3/3  3/3  3/3     79.65 to 99.72           None 
L97                3/3  3/3  3/3     69.00 to 83.24           None 
L98                3/3  3/3  3/3     98.39 to 110.25         None 





The likelihood that a reduction in sample size from 3 to 2 would change the classification for a run for 
L’Oreal  is only 2/918 or 0.2%. 
 
 
                Revised Summary of Results for SE Protocol:  Ceetox 
 
Number of usable chemicals: 102 
Number of excluded chemicals:  4 (X32, X62, X81, X95) 
Non-qualified runs:  X19, Run 2 
All chemicals had 3 useable runs  
Total number of useable runs: 306 
Total number of pairwise comparisons = 918  
Bracketed data excluded 
 
 
Chemical       Run results        Range of      Impact of reducing samples per 
   Code                (>50%)             scores              per run from 3 to 2 
X1                  3/3  3/3  3/3     85.69 to 100.66         None 
X102              3/3  3/3  3/3     85.51 to 114.55         None 
X103              3/3  3/3  3/3     84.68 to 105.20         None 
X107              3/3  3/3  3/3     95.35 to 108.63         None 
X108              3/3  3/3  3/3     85.59 to 114.25         None 
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X109              3/3  3/3  3/3     80.95 to 106.67         None 
X11                3/3  3/3  3/3     85.20 to 107.54         None 
X110              3/3  3/3  3/3     78.46 to 92.65           None 
X111              3/3  3/3  3/3     85.20 to 107.54         None 
X112              3/3  3/3  3/3     92.53 to 118.13         None 
X113              3/3  3/3  3/3     87.44 to 106.66         None 
X114              3/3  3/3  3/3     88.32 to 103.62         None 
X115              3/3  3/3  3/3     92.60 to 107.49         None 
X116              3/3  3/3  3/3     93.41 to 105.02         None 
X117              0/3  0/3  0/3     2.14 to 5.34               None 
X118              3/3  3/3  3/3     83.86 to 96.24           None 
X119              0/3  0/3  0/3     17.27 to 47.26           None 
X120              3/3  3/3  3/3     94.08 to 104.41         None 
X121              0/3  0/3  0/3     4.89 to 13.61             None 
X123              3/3  3/3  3/3     64.75 to 109.60         None 
X125              3/3  3/3  3/3     83.93 to 109.59         None 
X126              3/3  3/3  3/3     72.31 to 93.86           None 
X127              0/3  0/3  0/3     19.63 to 44.28           None 
X128              3/3  3/3  3/3     58.56 to 74.69           None 
X129              3/3  3/3  3/3     72.65 to 97.77           None 
X13                0/3  3/3  0/3     24.30 to 91.05           None 
X131              3/3  3/3  3/3     72.00 to 85.24           None 
X133              0/3  0/3  0/3     26.15 to 39.20           None 
X134              3/3  3/3  3/3     88.46 to 111.52         None 
X136              0/3  0/3  0/3     2.92 to 4.66               None 
X138              3/3  3/3  3/3     76.85 to 98.66           None 
X139              0/3  0/3  0/3     27.67 to 44.95           None 
X14                0/3  0/3  0/3     5.12 to 7.36               None 
X143              3/3  3/3  3/3     88.37 to 101.81         None 
X157              3/3  3/3  3/3     87.71 to 111.22         None 
X158              3/3  3/3  3/3     84.84 to 98.14           None 
X16                3/3  3/3  3/3     82.47 to 111.99         None 
X160              3/3  3/3  3/3     94.45 to 115.67         None 
X165              3/3  3/3  3/3     71.63 to 92.89           None 
X169              3/3  3/3  3/3     90.48 to 106.14         None 
X173              3/3  3/3  3/3     94.26 to 121.71         None 
X19      3/3  [2/3]  3/3  3/3     75.60 to 105.46         None 
X190              3/3  3/3  3/3     91.10 to 105.51         None 
X196              2/3  0/3  0/3     14.79 to 51.28 [---]     1/9 
X2                  3/3  3/3  3/3     87.43 to 101.47         None 
X21                0/3  0/3  0/3     2.35 to 16.32             None 
X22                3/3  3/3  3/3     79.82 to 108.71         None 
X24                3/3  3/3  3/3     85.36 to 105.93         None 
X25                3/3  3/3  0/3     14.79 to 67.98           None 
X27                3/3  3/3  3/3     89.34 to 139.21         None 
X28                3/3  3/3  3/3     70.69 to 91.89           None 
X29                0/3  0/3  0/3     1.75 to 16.11             None 
X3                  3/3  1/3  1/3     21.06 to 90.05 [+--}    3/9       
X30                1/3  0/3  0/3     33.78 to 51.16 [---}   None 
X31                0/3  0/3  0/3     24.24 to 37.92           None           - 
[X32               3/3  3/3  3/3     85.02 to 105.64]            - 
X33                0/3  0/3  0/3     24.67 to 43.11           None 
X36                3/3  3/3  3/3     54.99 to 73.43           None 
X37                3/3  3/3  3/3     92.83 to 130.79         None 
X38                3/3  3/3  3/3     76.04 to 87.21           None 
X39                3/3  3/3  0/3     21.40 to 92.69           None 
X40                3/3  3/3  3/3     76.28 to 90.67           None 
X41                3/3  3/3  0/3     30.16 to 93.23           None 
X42                0/3  0/3  0/3     3.73 to 10.09             None 
X43                3/3  3/3  2/3     45.60 to 82.31 [+++] None 
X45                0/3  0/3  0/3     11.99 to 37.58           None 
X46                3/3  3/3  3/3     83.51 to 99.37           None 
X47                3/3  1/3  0/3     30.96 to 69.82 [+--]  None 
X49                3/3  3/3  3/3     68.45 to 106.28         None 
X5                  3/3  3/3  3/3     76.18 to 94.94           None 
X50                3/3  3/3  3/3     83.51 to 101.24         None 
X51                0/3  0/3  0/3     1.31 to 6.31               None 
X52                0/3  0/3  0/3     3.57 to 7.61               None 
X53                3/3  3/3  3/3     90.51 to 109.75         None 
X55                3/3  3/3  3/3     92.87 to 109.08         None 
X56                0/3  0/3  0/3     0.68 to 2.26               None 
X59                3/3  3/3  3/3     85.03 to 119.30         None 
X6                  3/3  3/3  3/3     69.89 to 94.73           None 
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X61                3/3  3/3  3/3     92.70 to 106.97         None 
[X62               3/3  3/3  3/3     87.72 to 120..12]          - 
X63                3/3  3/3  3/3     87.71 to 121.20         None 
X64                3/3  3/3  3/3     58.89 to 87.77           None 
X65                0/3  0/3  0/3     3.21 to 6.68               None 
X66                3/3  3/3  3/3     71.90 to 89.39           None 
X68                3/3  3/3  3/3     90.30 to 113.61         None 
X7                  3/3  3/3  3/3     94.15 to 131.17         None 
X70                2/3  2/3  3/3     26.48 to 80.35 [-++]   1/9 
X72                3/3  3/3  3/3     89.37 to 109.96         None 
X73                0/3  0/3  0/3     3.94 to 21.98             None 
X75                3/3  3/3  3/3     84.96 to 107.66         None 
X77                3/3  3/3  3/3     91.81 to 113.68         None 
X8                  3/3  3/3  3/3     80.45 to 104.29         None 
X80                3/3  3/3  3/3     76.07 to 103.97         None 
[X81               3/3  3/3  3/3     61.99 to 80.22]            - 
X82                3/3  3/3  3/3     80.22 to 92.19           None 
X83                0/3  0/3  0/3     1.76 to 12.07             None 
X84                1/3  3/3  3/3     47.05 to 106.58 [-++]   2/9     
X86                3/3  3/3  3/3     83.94 to 107.60         None 
X87                0/3  0/3  0/3     2.09 to 5.89               None 
X89                3/3  3/3  3/3     79.70 to 95.24           None 
X91                1/3  0/3  1/3     36.30 to 57.57 [---]    2/9         
X93                3/3  3/3  3/3     69.56 to 90.86           None 
X94                3/3  3/3  3/3     89.14 to 107.34         None 
[X95               3/3  3/3  3/3     78.16 to 130.65]           - 
X98                3/3  3/3  3/3     51.57 to 75.62           None 
X99                3/3  3/3  3/3     88.69 to 116.50         None 
 
 
The likelihood that a reduction in sample size from 3 to 2 would change the classification for a run for 
Ceetox  is only 9/918 or 0.98% 
 
 
Samples with less than complete agreement.   
 
These are the only runs whose classifications could be altered by reducing the number of samples from 
3 to 2 
 
Lab    Chemical     Run            Sample 
                                            1      2      3       Mean 
Cardam    C12          1     43.0  46.2  56.4     48.5 
Cardam    C13          2     49.2  61.5  41.9     50.9 
Cardam    C135        3     63.4  48.2  51.1     54.2 
Cardam    C30          1     52.0  45.8  45.2     47.7 
Cardam    C30          3     64.3  34.2  40.0     46.2 
Cardam    C38          1     59.8  46.0  54.7     53.5 
 
L’Oreal    L104        1     40.8  47.9  66.0     51.6      
L’Oreal    L129        3     53.1  41.3  42.0     45.5 
L’Oreal    L23          1     45.8  69.1  68.6     61.2 
L’Oreal    L29          1     48.8  44.9  62.8     52.2 
L’Oreal    L4            2   49.96  56.6  54.9     53.8 
L’Oreal    L57          2     68.5  59.0  47.0     58.2      
L’Oreal    L85          1     30.1  57.1  34.3     40.5    
L’Oreal    L85          3     34.8  58.0  39.8     44.2 
 
Ceetox      X196       1     31.5  50.4  51.3     44.4 
Ceetox      X3           2     59.9  40.6  44.4     48.3 
Ceetox      X3           3     21.1  47.4  53.0     40.5 
Ceetox      X30         1     51.2  45.8  38.3     45.1 
Ceetox      X43         3     61.7  56.5  45.6     54.6 
Ceetox      X47         2     46.3  43.5  53.1     47.6 
Ceetox      X70         1     54.4  52.3  26.5     44.4 
Ceetox      X70         2     63.3  66.1  47.1     58.8 
Ceetox      X84         1     47.1  47.0  55.1     49.7 
Ceetox      X91         1     42.9  43.4  57.6     48.0 
















                               SUMMARY PERFORMANCE BY LAB 
 
                                                                                 Cardam        L’Oreal        Ceetox 
No. chemicals with adequate studies                         104               102                102 
No. chemicals with 100% sample agreement          95 (91%)    93 (91%)     90 (88%)    
     Positives                                                                   75              71                  69 
     Negatives                                                                  20              22                 21 
 
No. adequate runs                                                     312                306                 306 
No. runs with 100% agreement                                306 (98%)     298 (97%)      295 (96%) 
 
No. of possible pairs of  
samples among all runs                                              936                918                918 
 
No. of pairs of that would give a 




Analysis of Long Time Exposure Data 
 
This report addresses the following issue:  The current testing paradigm for the long time exposure data 
is three runs, each with three samples.  Within a run, the three samples are averaged, and if the average 
viability is greater than 50%, the run is considered “positive”; otherwise it is considered “negative”.   
 
The question of interest:  What would be the impact of reducing the number of samples in a given run 
from three to two?  More specifically, how often would averaging the viability of two samples and 
comparing it to 50% change the classification for that run relative to the classification based on averaging 
the viability of three samples? 
 
To address this question, I considered all the runs for which I was given data and considered the 
consequence of using only two of the three observed samples as the basis for classification for that run.  
There are three possible pairs of samples (first and second; first and third; second and third).  I then 
compared the classification for that run based on each pair with the classification based on the full three 
samples. 
 
Obviously, if all three samples were <50% or all were >50%, then there would be no change in 
classification.  Reducing the sample size could possibly change the classification only if there were some 
samples in the run that exceeded 50% and others that were less than 50%. 
 
The rest of this report presents the results of this statistical analysis, but the bottom line is this:  Reducing 
the number of samples from 3 to 2 for the long time exposure data will have almost no impact on the 
classification decision for a given run.  The probability is less than 1% that such a reduction would 
change the classification for a given run.  A companion report deals with the short time exposure data 
and reaches a similar conclusion.  
 
General comments on the data and analysis: 
 
(1) More than 90% of the chemicals had complete agreement among all the samples/runs 
evaluated with regard to classification (i.e., for a given chemical, all samples were either >50% 
or were <50% more than 90% of the time, regardless of lab).  This is outstanding consistency. 
 
(2) Moreover, 97% of the individual runs had complete agreement among the three samples with 
regard to classification.  Again, the overall consistency of response was outstanding.  Of the 
hundreds of runs evaluated, there were only a handful (detailed below) that produced any 
classification disagreement at all among the samples within the run, so it is only this few 
number of runs that could produce a possible classification inconsistency by reducing the 
sample size from 3 to 2. 
 
(3) The 50% cutoff point is very reasonable. 
 
(4) Most (but not all) chemicals had 3 runs.  Two chemicals (at Cardam) had 4 runs; three (at 
Ceetox) had 2 runs; one (at Ceetox) had a single run.  All runs had three samples. 
 
(5) There was approximately a 50-50 mix of “positives” and “negatives”, which was good. 
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(6) The variability among runs was somewhat greater than the variability within a run among 
samples.  There were a few cases at certain labs in which one run for a given chemical 
produced 3 samples with viability <50%, while a second run produced 3 samples with viability 
>50%.  Thus, maintaining multiple runs is more important than maintaining multiple samples, 
but overall, even the reproducibility among runs was quite good. 
 
(7) No single lab stood out as being clearly superior to the others with regard to reproducibility, 
although overall Cardam did a slightly better job in this regard than did the other two labs. 
 
(8) I received two sets of raw data, the first from Elizabeth Lipscomb and then later another 
dataset from ECVAM.  The data appeared to be identical, although a handful of runs in the 
ECVAM data included a “correction” for something that was subtracted from the original 
viability value.  In one instance (noted in my report), I used these corrected values in my 
calculations, as it made a difference in the classification.  In all other cases, I used the viability 
values that Elizabeth Lipscomb sent me.  The ECVAM data also noted that certain chemicals 
were “excluded”, and certain runs within a chemical were “non-qualified” because of excessive 
variability among samples within the run.  I noted all of these occurrences in this report, but I 
deleted them from my calculations. Among the more than 900 runs, there were very few (8 by 




At some point, it would be a good idea to “decode” the chemicals to see if there was a consistency in 
classification of specific chemicals across labs.  However, that was not the objective of this evaluation, 











                Revised Summary of Results for LE Protocol:  Cardam 
 
Number of usable chemicals: 103 
Number of excluded chemicals:  3 (C52, C53, and C58) 
Non-qualified runs:  C66, Run 1 
                                  C45, Run 3 
All chemicals had 3 runs except C35 and C135 (4 runs) 
Total number of useable runs: 311 
Total number of pairwise comparisons = 933    (101 x 9) + (2 x 12) 
Bracketed data were excluded 
 
Chemical       Run results        Range of      Impact of reducing samples per 
   Code               (>50%)             scores              per run from 3 to 2 
 
C1                  0/3  0/3  0/3     0.04 to 1.87               None 
C101              3/3  3/3  3/3     104.19 to 115.47       None 
C103              3/3  3/3  3/3     83.83 to 104.44         None 
C104              0/3  0/3  0/3     2.06 to 16.18             None 
C105              3/3  3/3  3/3     89.82 to 104.85         None 
C106              3/3  3/3  3/3     55.82 to 101.75         None 
C107              3/3  3/3  3/3     86.02 to 106.30         None 
C108              3/3  3/3  3/3     97.23 to 117.17         None 
C109              3/3  3/3  3/3     73.96 to 126.20         None 
C11                0/3  0/3  0/3     0.30 to 1.12               None 
C110              3/3  3/3  3/3     90.77 to 120.39         None 
C112              3/3  3/3  3/3     70.29 to 94.12           None 
C113              3/3  3/3  3/3     72.00 to 108.34         None 
C114              3/3  3/3  3/3     81.38 to 120.45         None 
C116              3/3  3/3  3/3     69.36 to 107.87         None 
C119              0/3  0/3  0/3     0.31 to 2.29               None 
C12                0/3  0/3  0/3     0.21 to 2.36               None 
C120              3/3  3/3  3/3     69.88 to 98.64           None 
C123              0/3  0/3  0/3     0.62 to 1.80               None 
C124              2/3  0/3  1/3     32.64 to 85.13 [+--]   None 
C125              0/3  0/3  0/3     0.89 to 11.25             None 
C127              0/3  0/3  0/3     3.28 to 12.72             None 
C128              3/3  3/3  3/3     52.95 to 68.83           None 
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C129              3/3  3/3  3/3     93.14 to 118.97         None 
C13                0/3  0/3  0/3     3.47 to 33.07             None 
C131              3/3  3/3  3/3     70.04 to 94.01           None 
C132              0/3  0/3  0/3     15.55 to 47.86           None 
C134              0/3  0/3  0/3     0.66 to 1.06               None 
C135       0/3  0/3  0/3  0/3     0.87 to 5.62               None 
C136              3/3  3/3  3/3     55.67 to 72.98           None 
C137              0/3  0/3  0/3     0.41 to 1.40               None               
C138              0/3  0/3  0/3     0.58 to 1.09               None 
C139              0/3  0/3  0/3     0.52 to 2.98               None 
C14                3/3  3/3  3/3     88.09 to 119.20         None 
C140              3/3  3/3  3/3     91.11 to 111.49         None 
C141              3/3  3/3  3/3     87.98 to 114.53         None 
C15                3/3  3/3  3/3     73.02 to 102.29         None 
C16                3/3  3/3  3/3     77.45 to 108.15         None 
C163              0/3  0/3  0/3     2.91 to 4.67               None 
C164              3/3  3/3  3/3     88.39 to 119.58         None 
C166   [ 2/3]  3/3  3/3  3/3     71.10 to 106.92         None 
C170              0/3  0/3  0/3     5.19 to 9.52               None 
C185              3/3  3/3  3/3     88.32 to 107.41         None 
C19                0/3  0/3  0/3     0.47 to 2.94               None 
C193              0/3  0/3  0/3     0.96 to 2.25               None 
C195              3/3  3/3  2/3    37.32 to 86.20 [+++]     1/9 
C196              3/3  3/3  3/3    102.89 to 128.94        None 
C2                  3/3  3/3  3/3    92.42 to 114.92          None 
C20                3/3  3/3  3/3    91.02 to 123.19          None 
C21                0/3  0/3  0/3     1.31 to 2.82               None 
C25                0/3  0/3  0/3     1.03 to 1.51               None 
C26                0/3  0/3  0/3     0.23 to 2.15               None 
C27                3/3  3/3  3/3     71.13 to 103.15         None 
C28                3/3  3/3  3/3     66.75 to 102.48         None 
C29                0/3  0/3  0/3     2.93 to 19.06             None 
C3                  0/3  0/3  0/3     1.07 to 17.15             None 
C30                3/3  3/3  3/3     76.78 to 115.22         None 
C33                0/3  0/3  0/3     0.13 to 0.40               None 
C34                3/3  3/3  3/3     87.40 to 217.81         None 
C35         0/3  0/3  0/3  0/3     0.57 to 1.08               None      
C36                3/3  1/3  3/3     46.32 to 78.88 [+-+]  1/9 
C37                3/3  3/3  3/3     67.09 to 119.50         None 
C38                0/3  0/3  0/3     6.57 to 10.65             None 
C39                3/3  3/3  3/3     90.39 to 127.92         None 
C4                  3/3  3/3  3/3     83.45 to 107.84         None 
C45         3/3  2/3  [2/3]  3/3  48.35 to 88.00 {+++]  None 
C46                3/3  3/3  3/3     54.02 to 66.82           None 
C47                0/3  0/3  0/3     0.74 to 1.46               None 
C48                0/3  0/3  0/3     0.44 to 1.40               None 
C49                3/3  3/3  3/3     59.10 to 104.02         None 
C50                0/3  0/3  0/3     0.25 to 1.58               None 
C51                0/3  0/3  0/3     1.42 to 27.25             None 
[C52        3/3  3/3  3/3  3/3  101.68 to 236.55]           - 
[C53               3/3  3/3  3/3     40.04 to 73.31]             - 
C54                3/3  0/3  3/3     16.67 to 68.68           None 
C55                3/3  3/3  3/3     75.59 to 102.00         None 
C56                3/3  3/3  2/3     49.08 to 83.56 [+++]  None 
[C58               3/3  3/3  3/3     44.43 to 79.54]            - 
C6                  0/3  0/3  0/3     28.51 to 44.49            None 
C60                1/3  0/3  0/3     18.81 to 51.48 [---]    None 
C62                0/3  0/3  0/3     0.84 to 1.60               None 
C63                0/3  0/3  0/3     18.07 to 36.25           None 
C64                0/3  0/3  0/3     0.22 to 2.12               None 
C65                0/3  0/3  0/3     17.03 to 49.40           None 
C66                0/3  0/3  0/3     0.24 to 1.10               None 
C67                3/3  3/3  3/3     86.42 to 118.44         None 
C70                3/3  3/3  3/3     53.38 to 81.18           None 
C71                3/3  3/3  3/3     86.93 to 110.71         None 
C75                0/3  0/3  0/3     0.15 to 0.84               None 
C76                0/3  0/3  0/3     0.48 to 6.19               None 
C77                0/3  0/3  0/3     0.24 to 0.62               None 
C78                0/3  0/3  0/3     5.53 to 28.86             None 
C79                3/3  3/3  3/3     65.96 to 114.18         None 
C82                0/3  0/3  0/3     1.46 to 12.13             None 
C83                3/3  3/3  3/3     67.77 to 98.02           None 
C84                3/3  3/3  3/3     65.68 to 100.07         None 
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C85                3/3  3/3  3/3     71.99 to 108.77         None 
C88                1/3  3/3  3/3     37.80 to 82.74 [-++]  None 
C9                  3/3  3/3  3/3     56.46 to 87.02           None 
C90                0/3  0/3  0/3     0.16 to 0.88               None 
C91                0/3  0/3  0/3     0.49 to 1.63               None 
C94                0/3  0/3  0/3     9.56 to 39.37             None 
C96                3/3  3/3  3/3     56.32 to 94.43           None 
C97                0/3  0/3  0/3     0.30 to 1.25               None 
C98                0/3  0/3  0/3     0.86 to 4.63               None 
C99                0/3  0/3  0/3     1.89 to 12.43             None 
 
 
The likelihood that a reduction in sample size from 3 to 2 would change the classification for a run for 
Cardam  is only 2/933 or 0.2% 
 
                Revised Summary of Results for LE Protocol:  L’Oreal 
 
Number of usable chemicals: 105 
Number of excluded chemicals:  1 (L6) 
Non-qualified runs:  L11, Run 2 
                                 L137, Run 3 
All chemicals had 3 runs  
Total number of useable runs: 315 
Total number of pairwise comparisons = 945    (105 x 9)  
Bracketed data excluded 
 
 
Chemical       Run results        Range of      Impact of reducing samples per 
   Code               (>50%)             scores              per run from 3 to 2 
 
L1                  0/3  1/3  0/3     22.97 to 63.28 [---]     1/9 
L100              3/3  3/3  3/3     51.06 to 82.79           None 
L101              0/3  0/3  0/3     0.39 to 1.97               None 
L102              3/3  3/3  3/3     75.54 to 114.39         None 
L104              0/3  0/3  0/3     0.69 to 41.52             None 
L106              3/3  3/3  3/3     89.14 to 101.98         None 
L107              3/3  3/3  3/3     70.98 to 80.78           None 
L108              3/3  3/3  3/3     87.61 to 102.59         None 
L109              3/3  3/3  3/3     80.57 to 91.71           None 
L11         0/3  [1/3]  0/3  0/3  0.35 to 21.54             None       
L111              3/3  3/3  3/3     90.59 to 109.80         None 
L112              3/3  3/3  3/3     86.01 to 99.77           None 
L113              2/3  1/3  0/3     25.36 to 56.45 [---]     1/9    
L114              2/3  3/3  3/3     48.25 to 93.01 [+++]  1/9 
L115              3/3  3/3  3/3     90.14 to 99.84           None 
L118              3/3  3/3  3/3     82.55 to 96.92           None 
L119              0/3  0/3  0/3     0.33 to 1.33               None 
L12                0/3  0/3  0/3     2.77 to 11.98             None 
L120              0/3  0/3  0/3     0.23 to 0.52               None 
L122              3/3  3/3  3/3     81.17 to 98.52           None 
L123              3/3  0/3  0/3     1.75 to 73.97             None  
L125              0/3  0/3  0/3     0.35 to 1.02               None 
L126              3/3  3/3  3/3     80.51 to 91.60           None 
L127              3/3  3/3  3/3     82.71 to 98.51           None 
L129              0/3  0/3  0/3     3.30 to 6.36               None 
L13                3/3  3/3  0/3     38.43 to 77.70           None 
L130              0/3  0/3  0/3     0.77 to 1.05               None 
L131              0/3  0/3  0/3     0.53 to 1.11               None 
L132              0/3  0/3  0/3     0.87 to 1.05               None 
L133              0/3  0/3  0/3     0.50 to 29.19             None 
L134              3/3  3/3  3/3     59.25 to 81.90           None 
L136              0/3  3/3  2/3     11.71 to 56.74 [-+-]    1/9    
L137      0/3   3/3  [1/3]  3/3  7.86 to 100.90           None 
L139              0/3  0/3  0/3     0.83 to 4.90               None 
L140              0/3  0/3  0/3     2.07 to 34.00             None 
L144              3/3  3/3  3/3     92.94 to 105.16         None 
L148              3/3  3/3  3/3     83.64 to 102.26         None 
L15                3/3  3/3  3/3     65.40 to 109.18         None 
L156              3/3  3/3  3/3     61.21 to 105.75         None 
L16                0/3  0/3  0/3     1.85 to 13.97             None 
L161              3/3  3/3  3/3     66.11 to 100.53         None 
L164              0/3  0/3  0/3     0.70 to 1.67               None 
L169              3/3  3/3  3/3     77.48 to 91.57           None 
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L17                3/3  3/3  2/3     44.92 to 80.28 [++-]    1/9 
L174              0/3  0/3  0/3     0.54 to 9.85               None 
L18                3/3  3/3  3/3     97.64 to 107.96         None 
L185              0/3  0/3  0/3     2.09 to 3.66               None 
L20                0/3  0/3  0/3     16.57 to 33.67           None 
L200              3/3  3/3  3/3     85.91 to 112.89         None 
L23                0/3  0/3  0/3     0.24 to 0.72               None 
L24                0/3  0/3  0/3     0.37 to 4.16               None 
L27                3/3  3/3  3/3     92.91 to 107.80         None 
L28                1/3  0/3  0/3     37.36 to 60.81 [---]     2/9   
L29                0/3  0/3  0/3     2.65 to 25.46             None 
L32                3/3  3/3  3/3     75.42 to 96.07           None 
L33                0/3  0/3  0/3     0.62 to 1.18               None 
L36                3/3  3/3  3/3     82.67 to 103.15         None 
L37                0/3  0/3  0/3     0.31 to 0.85               None 
L39                3/3  3/3  3/3     57.08 to 69.71           None 
L4                  3/3  3/3  3/3     52.22 to 85.82           None 
L42                0/3  0/3  0/3     1.07 to 1.74               None 
L43                0/3  0/3  0/3     1.65 to 6.41               None 
L45                0/3  0/3  0/3     0.41 to 3.32               None 
L48                0/3  0/3  0/3     0.28 to 1.31               None 
L5                  3/3  3/3  3/3     62.00 to 87.30           None 
L50                3/3  3/3  3/3     87.25 to 104.73         None 
L51                0/3  0/3  0/3     0.65 to 1.29               None 
L53                3/3  3/3  3/3     86.19 to 102.09         None 
L55                0/3  0/3  0/3     2.23 to 16.94             None 
L56                0/3  0/3  0/3     0.69 to 1.20               None 
L57                0/3  0/3  0/3     3.08 to 6.19               None 
L58                2/3  0/3  0/3     22.28 to 52.96 [---]     1/9 
L59                0/3  0/3  0/3     0.51 to 2.70               None 
[L6      3/3  3/3  3/3  3/3  3/3   55.898 to 125.70]       - 
L60                3/3  3/3  3/3     86.37 to 100.20         None 
L61                3/3  3/3  3/3     78.00 to 90.51           None 
L62                3/3  3/3  3/3     84.97 to 104.47         None 
L64                3/3  3/3  3/3     77.59 to 97.11           None 
L65                3/3  3/3  3/3     86.93 to 103.08         None 
L66                0/3  0/3  0/3     0.80 to 12.49             None 
L67                3/3  3/3  3/3     81.08 to 98.31           None 
L68                0/3  0/3  0/3     0.27 to 2.37               None 
L7                  3/3  3/3  3/3     55.94 to 76.28           None 
L70                0/3  0/3  0/3     0.46 to 1.47               None 
L72                3/3  3/3  3/3     62.50 to 72.35           None 
L73                3/3  3/3  3/3     83.66 to 101.89         None 
L75                3/3  3/3  3/3     85.98 to 104.99         None 
L76                3/3  3/3  3/3     80.61 to 102.54         None 
L78                0/3  0/3  0/3     0.42 to 1.12               None 
L79                3/3  3/3  3/3     66.53 to 79.26           None 
L8                  0/3  0/3  0/3     1.19 to 2.39               None 
L80                0/3  0/3  0/3     0.20 to 0.48               None 
L81                0/3  0/3  0/3     0.38 to 0.57               None 
L82                0/3  0/3  0/3     0.22 to 1.67               None 
L83                0/3  0/3  0/3     1.02 to 1.53               None 
L85                3/3  3/3  3/3     80.21 to 100.91         None 
L87                0/3  0/3  0/3     0.42 to 2.08               None 
L9                  0/3  0/3  0/3     22.92 to 38.66           None 
L90                3/3  3/3  3/3     85.06 to 110.95         None 
L91                0/3  0/3  0/3     11.86 to 44.42           None 
L92                0/3  0/3  0/3     0.27 to 1.22               None 
L94                0/3  0/3  0/3     1.33 to 26.40             None 
L96                3/3  3/3  3/3     77.34 to 98.09           None 
L97                0/3  0/3  0/3     10.19 to 21.83           None 
L98                0/3  0/3  0/3     12.43 to 32.19           None 





The likelihood that a reduction in sample size from 3 to 2 would change the classification for a run for 















                Revised Summary of Results for LE Protocol:  Ceetox 
 
Number of usable chemicals: 103 
Number of excluded chemicals:  5 (X17, X31, X32, X62, X95) 
Non-qualified runs:  X47, Runs 1 and 2 
                                 X50, Run 2 
                                 X173, Run 3 
All chemicals had 3 useable runs, except X37, X39, & X47 (2 runs) and X44 (1 run)  
Total number of useable runs: 304 
Total number of pairwise comparisons = 912    (99 x 9) + (3 x 6) + (1 x 3) 
Bracketed data excluded 
 
 
Chemical       Run results        Range of      Impact of reducing samples per 
   Code                (>50%)            scores              per run from 3 to 2 
X1                  3/3  3/3  3/3     94.02 to 102.29         None 
X102              3/3  3/3  3/3     68.54 to 93.63           None 
X103              3/3  3/3  3/3    92.94 to 101.91         None 
X107              3/3  3/3  3/3     91.94 to 112.73         None 
X108              3/3  3/3  3/3     72.06 to 88.66           None 
X109              3/3  3/3  3/3     67.47 to 98.49           None 
X11                3/3  3/3  3/3     84.85 to 112.44         None 
X110              3/3  3/3  3/3     84.74 to 103.91         None 
X111              0/3  2/3  3/3     37.63 to 64.33 [--+]    1/9 
X112              3/3  3/3  3/3     89.18 to 108.01         None 
X113              3/3  3/3  3/3     82.69 to 118.92         None 
X114              3/3  3/3  3/3     79.27 to 110.81         None 
X115              3/3  3/3  3/3     88.75 to 111.26         None 
X116              3/3  3/3  3/3     94.39 to 103.51         None 
X117              0/3  0/3  0/3     0.96 to 3.18               None 
X118              0/3  0/3  0/3     16.08 to 31.72           None 
X119              0/3  0/3  0/3     3.03 to 5.96               None 
X120              3/3  3/3  3/3     82.38 to 109.38         None 
X121              0/3  0/3  0/3     1.13 to 2.45               None 
X123              3/3  3/3  3/3     68.49 to 98.37           None 
X125              3/3  3/3  3/3     85.57 to 109.20         None 
X126              0/3  0/3  1/3     18.48 to 59.77 [---]      1/9 
X127              0/3  0/3  0/3     1.38 to 2.39               None 
X128              0/3  0/3  0/3     1.23 to 2.13               None 
X129              0/3  0/3  1/3     2.30 to 58.49 [---]       1/9 
X13                3/3  3/3  3/3     71.80 to 110.46         None 
X131              3/3  3/3  3/3     69.59 to 93.70           None 
X133              0/3  0/3  0/3     0.62 to 3.67               None 
X134              3/3  3/3  3/3     51.07 to 100.61         None 
X136              0/3  0/3  0/3     0.88 to 1.75               None 
X138              0/3  0/3  0/3     2.26 to 15.49             None 
X139              3/3  3/3  3/3     50.84 to 61.79           None 
X14                0/3  0/3  0/3     0.0 to 1.59                 None 
X143              3/3  3/3  3/3     75.93 to 108.45         None 
X157              3/3  3/3  3/3     75.97 to 109.05         None 
X158              3/3  3/3  3/3     74.03 to 107.32         None 
X16                0/3  3/3  1/3     22.62 to 70.76 [-++]   1/9 
X160              3/3  3/3  3/3     79.71 to 114.68         None 
X165              0/3  0/3  0/3     4.28 to 13.98             None 
X169              3/3  3/3  3/3     85.59 to 115.56         None 
[X17       3/3   3/3  3/3  3/3     59.97 to 100.99]          - 
X173       3/3  3/3  [3/3]  3/3   79.12 to 96.28          None 
X19                3/3  3/3  3/3     91.18 to 112.30         None 
X190              0/3  0/3  0/3     1.96 to 4.41               None 
X196              0/3  0/3  0/3     1.48 to 2.79               None 
X2                  0/3  0/3  2/3     30.58 to 51.28 [---]     1/9 
X21                0/3  0/3  0/3     1.01 to 1.85               None 
X22                0/3  0/3  0/3     1.82 to 3.00               None 
X24                3/3  3/3  3/3     75.14 to 102.04         None 
X25                0/3  0/3  0/3     1.62 to 2.82               None 
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X27                3/3  3/3  3/3     63.10 to 111.81         None 
X28                0/3  0/3  0/3     0.33 to 1.06               None 
X29                0/3  0/3  0/3     1.03 to 2.90               None 
X3                  0/3  0/3  0/3     1.57 to 4.25               None 
X30                0/3  0/3  0/3     0.99 to 4.58               None 
[X31                3/3  3/3  3/3     41.98 to 64.57]            - 
[X32                3/3  3/3  3/3     70.61 to 96.57]            - 
X33                0/3  0/3  0/3     0.51 to 3.03               None 
X36                0/3  0/3  0/3     1.08 to 1.40               None 
X37                0/3  0/3            15.01 to 49.66           None 
X38                3/3  3/3  3/3     51.62 to 91.32           None 
X39                3/3  3/3            82.82 to 101.28         None 
X40                3/3  3/3  3/3     71.71 to 97.67           None 
X41                0/3  0/3  0/3     0.66 to 3.75               None 
X42                0/3  0/3  0/3     1.31 to 2.50               None 
X43                0/3  0/3  0/3     2.22 to 30.71             None 
X44                3/3                   66.41 to 87.18           None 
X45                0/3  0/3  0/3     8.38 to 28.86             None 
X46                3/3  3/3  3/3     70.31 to 91.69           None 
X47    [2/3]  [3/3]  3/3  3/3     80.13 to 98.52           None 
X49                3/3  3/3  3/3     55.49 to 66.72           None 
X5                  0/3  0/3  0/3     1.50 to 10.73             None 
X50       3/3  [2/3] 3/3  3/3     50.28 to 90.97           None 
X51                0/3  0/3  0/3     0.53 to 1.07               None 
X52                0/3  0/3  0/3     0.96 to 1.64               None 
X53                3/3  3/3  3/3     89.04 to 105.76         None 
X55                3/3  3/3  3/3     83.25 to 118.34         None 
X56                0/3  0/3  0/3     0.36 to 1.34               None 
X59                3/3  3/3  3/3     86.74 to 117.13         None 
X6                  0/3  0/3  0/3     1.23 to 6.10               None 
X61                3/3  3/3  3/3     88.88 to 118.44         None 
[X62               3/3  3/3  3/3     54.62 to 72.86]            - 
X63                0/3  0/3  0/3     15.94 to 46.50           None 
X64                0/3  0/3  0/3     1.61 to 5.07               None 
X65                0/3  0/3  0/3     0.85 to 1.71               None 
X66                0/3  0/3  0/3     0.54 to 6.47               None 
X68                0/3  0/3  0/3     0.0 to 12.93               None 
X7                  0/3  0/3  0/3     2.01 to 13.89             None 
X70                2/3  3/3  3/3     47.84 to 81.69 [+++] None 
X72                3/3  3/3  3/3     94.63 to 109.40         None 
X73                0/3  0/3  0/3     0.63 to 2.46               None 
X75                3/3  3/3  2/3     47.64 to 113.89 [+++] None 
X77                3/3  3/3  3/3     95.04 to 132.51         None 
X8                  3/3  3/3  3/3     86.32 to 120.01         None 
X80                3/3  3/3  3/3     60.50 to 85.39           None 
X81                0/3  0/3  0/3     1.66 to 21.44             None 
X82                3/3  3/3  3/3     54.81 to 87.66           None 
X83                0/3  0/3  0/3     0.46 to 1.41               None 
X84                3/3  3/3  3/3     67.98 to 97.20           None 
X86                0/3  0/3  0/3     5.39 to 11.25             None 
X87                0/3  0/3  0/3     0.09 to 1.46               None 
X89                0/3  0/3  0/3     3.65 to 10.93             None 
X91                0/3  0/3  0/3     11.25 to 37.33           None 
X93                0/3  0/3  0/3     1.33 to 13.13             None 
X94                3/3  3/3  3/3     85.33 to 109.59         None 
[X95               3/3  3/3            61.07 to 116.44]           - 
X98                0/3  0/3  0/3     0.38 to 1.29               None 
X99                0/3  1/3  1/3     33.12 to 57.31 [--+]     2/9 
 
 
The likelihood that a reduction in sample size from 3 to 2 would change the classification for a run for 
Ceetox  is only 7/912 or 0.8% 
 
Samples with less than complete agreement.   
 
These are the only runs whose classifications could be altered by reducing the number of samples from 
3 to 2 
 
Lab    Chemical     Run            Sample 
                                            1      2      3       Mean 
Cardam    C124        1     64.9  73.8  41.9     60.2   
Cardam    C124        3     42.8  50.4  32.6     41.9 
Cardam    C195        3     37.3  54.3  63.6     51.7 
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Cardam    C36          2     53.2  46.3  49.0     49.5 
Cardam    C45          2     58.8  61.6  48.3     56.2   
Cardam    C56          3     73.0  76.5  49.1     66.2 
Cardam    C60          1     51.5  41.8  38.5     43.9     
Cardam    C88          1     38.6  37.8  51.6     42.7 
 
L-Oreal    L1            2*   59.6  43.4  36.4     46.5      
L-Oreal    L113        1     36.2  56.5  54.4     49.0 
L-Oreal    L113        2     38.3  39.3  51.7     43.1 
L-Oreal    L114        1     64.0  48.2  50.2     54.1 
L-Oreal    L136        3     53.5  58.3  31.4     47.7 
L-Oreal    L17          3     44.9  51.5  50.9     49.1 
L-Oreal    L28          1     43.7  60.8  44.5     49.7 
L-Oreal    L58          1     53.0  22.3  50.9     42.1 
 
Ceetox      X111       2     37.6  56.4  52.2     48.7 
Ceetox      X126       3     48.0  38.3  59.8     48.7 
Ceetox      X129       3     38.2  42.9  58.5     46.5 
Ceetox      X16         3     47.4  47.5  70.8     55.2 
Ceetox      X2           3     50.4  44.3  51.3     48.7 
Ceetox      X70         1     58.9  47.8  53.4     53.4 
Ceetox      X75         3     72.4  72.7  47.6     64.2 
Ceetox      X99         2     35.7  47.6  53.5     45.6 
Ceetox      X99         3     44.3  49.8  57.3     50.5 
 





                               SUMMARY PERFORMANCE BY LAB 
 
                                                                                 Cardam        L’Oreal        Ceetox 
No. chemicals with adequate studies                         103               105                103 
No. chemicals with 100% sample agreement          95 (92%) )   95 (90%)  95 (92%)    
     Positives                                                                   47              46                  48 
     Negatives                                                                  48              49                  47 
 
No. adequate runs                                                     311                315                 304 
No. runs with 100% agreement                                303 (97%)     307 (97%)      295 (97%) 
 
No. of possible pairs of  
samples among all runs                                              933                945                912 
 
No. of pairs of that would give a 
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Appendix X EPRA Results 
Legend : 
Chemical EPRA code name 
1 41 1-bromohexane 
2 42 1-methylpropyl benzene 
3 43 2-ethoxyethyl methacrylate 
4 44 iso-octylthioglycolate INCI name: ISOOCTYL THIOGLYCOLATE 
5 45 4-(methylthio)-benzaldehyde 
6 47 dipropyl disulphide 
7 48 1-bromo-4-chlorobutane 
8 51 1-bromo-octane 
9 53 1,9-decadiene 
10 54 2,2-dimethyl-3-pentanol  
11 50 2-(2-ethoxyethoxy) ethanol INCI name: ETHOXYDIGLYCOL 
12 61 bisphenol A, epichlorohydrin polymer, ethoxylated, propoxylated (53-57% aqueousemulsion) 
13 62 
bisphenol A, diethylene triamine, epichlorohydrin 
polymer, ethoxylated, propoxylated (56% aqueous 
emulsion) 
14 63 dioctyl ether INCI name: DICAPRYLYL ETHER 
15 64 dioctyl carbonate INCI name: DICAPRYLYL CARBONATE 
16 65 2-propylheptyl octanoate INCI name: PROPYLHEPTYL CAPRYLATE 
17 101 polyglyceryl-3 diisooctadecanoate INCI name: POLYGLYCERYL-3 DIISOSTEARATE 
18 60 
steareth-10 allyl ether/acrylates copolymer (30% 
aqueous) INCI name: STEARETH-10 ALLYL 
ETHER/ACRYLATES COPOLYMER 
19 113 dimethyl siloxane, mono dimethylvinylsiloxy- and  mono trimethoxysiloxy-terminated  (95%) 
20 99 ricinoleic acid tin salt 
21 100 1-ethyl-3-methylimidazolium ethylsulphate 
22 103 3-phenoxybenzyl alcohol  
23 123 ethyl thioglycolate INCI name: ETHYL THIOGLYCOLATE 
24 134 glycidyl methacrylate  
25 143 piperonyl butoxide INCI name: PIPERONYL BUTOXIDE 
26 144 propiconazole 
27 49 2-ethylhexylthioglycolate 
28 67 4,4'-methylene bis-(2,6-di-tert-butylphenol) 
29 136 tetradecyl tetradecanoate INCI name: MYRISTYL MYRISTATE 
30 137 1,1-dimethylguanidine sulphate 
31 138 potassium tetrafluoroborate 
32 69 2,6-dihydroxy-3,4-dimethylpyridine INCI name: 2,6-DIHYDROXY-3,4-DIMETHYLPYRIDINE 
33 70 
2,2'-[[4-[(2-methoxyethyl)amino]-3-
nitrophenyl]imino]bis-ethanol INCI name: HC BLUE 
NO. 11 
34 71 2,2'-[[3-methyl-4-[(4-nitrophenyl)azo]phenyl]imino]bis-
ethanol INCI name: DISPERSE RED 17 
35 72 2,5,6-triamino-4-pyrimidinol sulphate INCI name: 2,5,6-TRIAMINO-4-PYRIMIDINOL SULFATE 
36 73 1-(4-chlorophenyl)-3-(3,4-dichlorophenyl) urea INCI 
name: TRICLOCARBAN 
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Chemical EPRA code name 
37 114 polyethylene glycol (PEG-40) hydrogenated castor oil INCI name: PEG-40 HYDROGENATED CASTOR OIL 
38 74 
2,2'-methylene-bis-(6-(2H-benzotriazol-2-yl)-4-(1,1,3,3-





[(2-ethylhexyl)oxy]-phenol]  INCI name: BIS-
ETHYLHEXYLOXYPHENOL METHOXYPHENYL 
TRIAZINE 












benzoate INCI name: DIETHYLAMINO 
HYDROXYBENZOYL HEXYL BENZOATE 





(trimethylammonium)propoxy)ethyl ether chloride (91%) 
INCI name: POLYQUATERNIUM-10 
47 115 3,4-dimethoxy benzaldehyde INCI name: VERATRALDEHYDE 
48 126 sodium hydrogensulphite  INCI name: SODIUM BISULFITE 
49 153 propyl-4-hydroxybenzoate INCI name: PROPYLPARABEN 
50 146 iodosulfuron-methyl-sodium  
51 147 1,5-di(2,4-dimethylphenyl)-3-methyl-1,3,5-triazapenta-1,4-diene common name: Amitraz 




common name: Thiamethoxam 
54 7 3-chloropropionitrile 
55 117 2-methylpropanal INCI name: 2-METHYLPROPANAL 
56 118 isopropyl acetoacetate 
57 87 2-methyl-1-pentanol 
58 128 1-(1-methyl-2-propoxyethoxy)propan-2-ol INCI name: PPG-2 PROPYL ETHER 
59 129 ethyl-2-methyl acetoacetate 
60 139 diethyl toluamide INCI name: DIETHYL TOLUAMIDE  
common name: DEET 
61 39 2-hydroxy-1,4-naphthoquinone INCI name: LAWSONE 
62 121 1,4-dibutoxy benzene 
63 122 4-nitrobenzoic acid 
64 98 ethyl 2,6-dichloro-5-fluoro-beta-oxo-3-pyridine propionate 
65 132 2,2-dimethyl-3-methylenebicyclo [2.2.1] heptane INCI 
name: CAMPHENE 
66 133 sodium chloroacetate 
67 3 gamma-butyrolactone INCI name: BUTYROLACTONE 
68 5 cyclopentanol 
69 15 alkyl (C10-16) glucoside sodium carboxylate (~ 30% 
aqueous) INCI name: SODIUM CARBOXYMETHYL 
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Chemical EPRA code name 




sulphate (30% aqueous) INCI name: CAMPHOR 
BENZALKONIUM METHOSULFATE 
71 89 1-propoxy-2-propanol INCI name: PROPYLENE GLYCOL PROPYL ETHER 
72 116 
2,4,11,13-tetraazatetradecanediimidamide, N,N''-bis(4-
chlorophenyl)-3,12-diimino-, di-D-gluconate (20% 
aqueous) INCI name: CHLORHEXIDINE 
DIGLUCONATE 
73 32 3,3'-dithiopropionic acid 
74 34 2-amino-3-hydroxy pyridine INCI name: 2-AMINO-3-HYDROXYPYRIDINE 
75 36 sodium benzoate INCI name: SODIUM BENZOATE 
76 94 6,7-dihydro-2,3-dimethyl-imidazo[1,2-a]pyridin-8(5H)-
one 




79 119 ammonium nitrate INCI name: AMMONIUM NITRATE 
80 1 methylthioglycolate INCI name: METHYL THIOGLYCOLATE 
81 2 3-diethylaminopropionitrile 
82 8 coco alkyl dimethyl betaine (~ 30% aqueous) INCI 
name: COCO-BETAINE 
83 9 coco amidopropyl betaine (~ 30% aqueous) INCI name: COCAMIDOPROPYL BETAINE 
84 10 sodium coco amphoacetate (~ 30% aqueous) 
85 11 triethanol ammonium alkyl sulphate (~ 40% aqueous) INCI name: TEA-C12-14 ALKYL SULFATE 
86 12 di-sodium alkyl ether sulfosuccinate (~ 30% aqueous) INCI name: DISODIUM LAURETH SULFOSUCCINATE 
87 13 sodium alkyl ether sulphate (~ 30% aqueous) INCI 
name: SODIUM LAURETH SULFATE 
88 14 
bisphenol A, diethylene triamine, epichlorohydrin, 
polypropylene glycol diglycidyl ether, polymer (~ 60% 
aqueous) 
89 81 ethoxylated (5 EO) alkyl (C10-14) alcohol 
90 82 alkyl (C10-16) glucoside (~ 50% aqueous) INCI name: LAURYL GLUCOSIDE 
91 80 (ethylenediaminepropyl)trimethoxysilane 
92 152 tetraethylene glycol diacrylate 
93 16 2,5-dimethyl-2,5-hexanediol 
94 17 dodecanoic acid  INCI name: LAURIC ACID 
95 18 1,2,4-triazole sodium salt 
96 19 1-naphthalene acetic acid 
97 20 sodium oxalate INCI name: SODIUM OXALATE 
98 21 
4,4'-(4,5,6,7-tetrabromo-3H-2,1-benzoxathiol-3-
ylidene)bis[2,6-dibromophenol] S,S-dioxide INCI name: 
TETRABROMOPHENOL BLUE 
99 25 1,2-benzisothiazol-3(2H)-one  INCI name: BENZISOTHIAZOLINONE 
100 141 ethyl lauroyl arginate HCl INCI name: ETHYL LAUROYL ARGINATE HCL 
101 30 2-[(4-aminophenyl)azo]-1,3-dimethyl-1H-imidazolium 
chloride INCI name: BASIC ORANGE 31 
102 31 
disodium 2,2'-([1,1'-biphenyl]-4,4'-
diyldivinylene)bis(benzenesulphonate) INCI name: 
DISODIUM DISTYRYLBIPHENYL DISULFONATE 
103 91 3,4-dimethyl-1H-pyrazole 
104 93 N-(2-amino-4,6-dichloropyrimidin-5-yl) formamide 
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Chemical EPRA code name 




hydrochloride INCI name: BASIC VIOLET 2 
107 90 xanthylium, 3,6-bis(diethylamino)-9-[2-(methoxycarbonyl)phenyl]-tetrafluoroborate 
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Results_EPRA_EIVS_first 
batch 030510 decoded 
(JBA).xls 






  Lysine-peptide Remarks Cysteine-peptide Remarks 
Reactivity 








depletion SD   
1 IRR liquid 1 22.18       0.00         
Cat 1     2 23.19       0.00         
      3 27.12 24.16 2.6   4.14 1.38 2.4   R 
                        
  
2 IRR liquid 1 24.36       83.48         
Cat 1     2 30.15       92.83         
      3 34.78 29.76 5.2   96.90 91.07 6.9   R 
                        
  
3 IRR liquid 1 1.79       0.00         
Cat 2A     2 2.10       1.55         
      3 2.76 2.22 0.5   4.98 2.17 2.5   NR 
                        
  
4 IRR liquid 1 0       9.46         
Cat 2A     2 0       13.51         
      3 0 0 0.0   18.62 13.86 4.6   R 
                        
  
5 IRR liquid 1 0.00       0         
Cat 2A/B     2 0.00       3.45         
      3 0.00 0.00 0.0   12.02 5.16 6.2   NR 
                        
  
6 IRR liquid 1 0.37       0.00         
Cat 2B     2 0.47       2.68         
    3 0.87 0.57 0.3   9.75 4.14 5.0   NR 
                        
  
7 IRR liquid 1 81.72       90.89         
Cat 2B     2 86.47       96.91         
      3 89.79 85.99 4.1   99.15 95.65 4.3   R 
                        
  
8 IRR liquid 1 1.83       0         
Cat 1     2 1.80       0         
    3 2.49 2.04 0.4   2.99 1.00 1.7   NR 
                        
  
9 IRR liquid 1 2.27       0         
Cat 1     2 2.25       0         
    3 2.31 2.28 0.0   0       NR 
                        
  
10 IRR liquid 1 0.54       -17.03         
Cat 1     2 0.95       -15.77         
    3 0.74 0.74 0.2   -16.11 -16.30 0.7 no interference 
repeat 
analysis cys 
                        
  
11 IRR liquid 1 94.39       1.15         
Cat 1     2 94.25       1.16         
    3 94.58 94.41 0.2   9.68 4.00 4.9   R 
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12 IRR liquid 1 84.12     interference 2.01         
Cat 1     2 85.46     interference 4.42         
    3 86.46 85.35 1.2 interference 7.89 4.77 3.0   N/A 
                        
  
13 IRR liquid 1 89.51     interference -38.0     interference   
Cat 1     2 89.41     interference -37.6     interference   
    3 89.72 89.55 0.2 interference -37.7 -37.8 0.2 interference N/A 
                        
  
15 IRR liquid 1 <-10     interference 4.39     interference   
Cat 2A     2 <-10     interference 9.42     interference   
    3 <-10     interference 11.57 8.46 3.7 interference N/A 
                        
  
16 IRR solid 1 0.98       1.17         
Cat 1     2 1.24       0.00         
      3 1.01 1.08 0.1   6.03 2.40 3.2   NR 
                        
  
17 IRR solid 1 0.58       1.85         
Cat 1     2 0.08       4.20         
      3 0.42 0.36 0.3   6.66 4.24 2.4   NR 
                        
  
18 IRR solid 1 2.50       0.38         
Cat 1     2 2.33       5.06         
      3 2.79 2.54 0.2   9.39 4.94 4.5   NR 
                        
  
19 IRR  solid 1 1.15       5.02         
Cat 1     2 1.09       5.21         
      3 1.70 1.31 0.3   8.33 6.19 1.9   R or N/A? 
                        
  
20 IRR solid 1 0.30       0.00         
Cat 1     2 0.39       8.09         
      3 0.16 0.28 0.1 10 mM 9.01 5.70 5.0 10 mM NR or N/A?? 
                        
  
22 IRR solid 1 0.00       -661.9     interference   
Cat 1     2 0.00       -665.1     interference   
    3 0.00 0.00 0.0   -651.8 -659.6 7.0 interference N/A 
                        
  
24 IRR solid 1 13.13       93.47         
Cat 1     2 20.58       96.31         
      3 20.95 18.22 4.4   96.89 95.56 1.8   R 
                        
  
26 IRR solid 1 11.29       11.57         
Cat 1     2 13.40       18.68         
      3 14.46 13.05 1.6   20.72 16.99 4.8   R 
                        
  
27 IRR solid 1 32.23       1.30         
Cat 1     2 30.28       6.72         
      3 34.03 32.18 1.9   7.33 5.12 3.3   R 
                        
  
32 IRR solid 1 11.62     interference 96.93         
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Cat 2A/B     2 12.58     interference 97.58         
      3 13.44 12.55 0.9 interference 97.84 97.45 0.5   R 
                        
  
34 IRR solid 1 19.11       99.59         
Cat 2A     2 22.98       99.58         
      3 22.56 21.55 2.1   99.60 99.59 0.0   R 
                        
  
35 IRR solid 1 33.43       100.00         
    2 41.12       100.00         
      3 48.04 40.86 7.3   100.00 100.00 0.0   R 
                        
  
36 IRR solid 1 -104.00     interference -747.1     interference   
Cat 2A     2 -106.71     interference -732.3     interference   
    3 -108.24 -106.32 2.2 interference -694.5 -724.6 27.2 interference N/A 
                        
  
37 IRR solid 1 21.17       100.00         
Cat 2A     2 23.27       100.00         
      3 30.19 24.87 4.7   100.00 100.00 0.0   R 
                        
  
39 IRR solid 1 <-10     interference 18.94         
Cat 2B     2 <-10     interference 25.52         
      3 <-10     interference 26.92 23.79 4.3   R 
                        
  
40 NIRR liquid 1 1.02       41.82         
No Cat     2 1.35       51.83         
      3 2.03 1.47 0.5   57.93 50.53 8.1   R 
                        
  
41 NIRR liquid 1 0.46       16.31         
No Cat     2 0.66       19.52         
      3 0.51 0.54 0.1   27.22 21.02 5.6   R 
                        
  
42 NIRR liquid 1 0       0.00         
No Cat     2 0.33       0.80         
      3 0.07 0.13 0.2   7.65 2.82 4.2   NR 
                        
  
43 NIRR liquid 1 7.78       43.12         
No Cat     2 9.10       51.10         
      3 8.99 8.63 0.7   59.58 51.27 8.2   R 
                        
  
45 NIRR liquid 1 23.38     interference 0         
No Cat     2 23.52     interference 0         
      3 23.61 23.51 0.1 interference 0 0 0   N/A 
                        
  
46 NIRR liquid 1 2.70       20.24         
No Cat     2 0.63       25.81         
      3 0.00 1.11 1.4   33.94 26.66 6.9   R 
                        
  
47 NIRR liquid 1 0       86.74         
No Cat     2 0.28       87.62         
      3 0.01 0.09 0.2   88.34 87.57 0.8   R 
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48 NIRR liquid 1 1.48       30.85         
No Cat     2 2.13       42.79         
      3 2.41 2.01 0.5   51.47 41.70 10.4   R 
                        
  
49 NIRR liquid 1 11.58       <-10         
No Cat     2 14.79       <-10         
      3 17.05 14.47 2.7   <-10 <-10   
No co-elution 
observed R 
                        
  
50 NIRR liquid 1 0.22       0.00         
No Cat     2 0.69       0.00         
    3 0.30 0.40 0.3   0.00 0.00 0.0   NR 
                        
  
51 NIRR liquid 1 0       0.37         
No Cat     2 0       0.53         
      3 0 0.00 0.0   3.43 1.45 1.7   NR 
                        
  
52 NIRR liquid 1 0       3.15         
No Cat     2 0       2.09         
      3 0 0 0.0   5.41 3.55 1.7   NR 
                        
  
53 NIRR liquid 1 0.43       0.00         
No Cat     2 0.14       2.92         
      3 0.30 0.29 0.1   7.36 3.43 3.7   NR 
                        
  
55 NIRR liquid 1 0.25       0.00         
No Cat     2 1.19       2.58         
      3 0.20 0.54 0.6   7.50 3.36 3.8   NR 
                        
  
56 NIRR liquid 1 0.64       0.00         
No Cat     2 0.91       3.00         
      3 0.74 0.76 0.1   5.79 2.93 2.9   NR 
                        
  
57 NIRR liquid 1 0.37       0.28         
No Cat     2 0.44       2.42         
      3 0.73 0.51 0.2   7.25 3.32 3.6   NR 
                        
  
58 NIRR liquid 1 0.05       0         
No Cat     2 0.16       0         
    3 0.56 0.26 0.3   5.93 1.98 3.4   NR 
                        
  
59 NIRR liquid 1 0       7.01         
No Cat     2 0.47       15.03         
      3 0.00 0.16 0.3   11.39 11.14 4.0   R 
                        
  
63 NIRR liquid 1 0.00       0.70         
No Cat     2 0.00       4.38         
    3 0.00 0.00 0.0   5.16 3.41 2.4   NR 
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64 NIRR liquid 1 0       0.47         
No Cat     2 0       3.64         
    3 0 0.00 0.0   4.32 2.81 2.1   NR 
                        
  
65 NIRR liquid 1 0       0.00         
No Cat     2 0       0.00         
    3 0 0 0.0   0.00 0.00 0.0   NR 
                        
  
67 NIRR solid 1 0.00       1.69         
No Cat     2 0.00       3.48         
      3 0.00 0.00 0.0   8.09 4.42 3.3   NR 
                        
  
68 NIRR solid 1 1.70       98.11         
No Cat     2 1.59       97.57         
      3 1.54 1.61 0.1 insoluble 98.44 98.04 0.4 insoluble R 
                        
  
72 NIRR solid 1 13.60       99.82         
No Cat     2 13.34       100.00         
      3 12.98 13.30 0.3 insoluble 100.00 99.94 0.1 insoluble R 
                        
  
73 NIRR solid 1 1.25       0.00         
No Cat     2 1.52       2.79         
    3 2.10 1.62 0.4   7.67 3.49 3.9   NR 
                        
  
77 NIRR solid 1 2.38                 
No Cat     2 1.80                 
    3 1.53 1.90 0.4 insoluble       insoluble 
repeat 
analysis cys 
                        
  
                        
  
Results_EPRA_EIVS_second 
batch 310810 decoded 
(JBA).xls 
                      
  
21 IRR solid 1 100.00       42.16     
dissolved in 50 % 
DMSO/acetonitrile   
      2 88.03       50.21     
peptide 
concentration In 
ref control was 
<0.45 mM (0.31 
mM)   
      3 88.19 92.07 6.9 
interference 
(1.4 % rel. 
to Ref 
Control) 57.18 49.85 7.5   R 
                        
  
23 IRR solid 1 42.59       100.00         
      2 40.96       100.00         
      3 38.85 40.80 1.9   100.00 100.00 0.0   R 
                        
  
25 IRR solid 1       interference 100.00         
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      2       interference 100.00         
      3       interference 100.00 100.00 0.0   R 
                        
  
44 NIRR liquid 1 9.90       -15.97         
      2 12.19       -15.12         
      3 14.04 12.05 2.1 
interference 
(5 % relative 
to REF 
control) -18.45 -16.52 1.7 
no interference in 
Co-elution control R 
                        
  
54 NIRR liquid 1 1.22       0.00         
      2 1.81       1.01         
      3 1.62 1.55 0.3   5.58 2.20 3.0   NR 
                        
  
69 NIRR solid 1 5.72       100.00         
      2 0.12       100.00         
      3 6.09 3.97 3.3   100.00 100.00 0.0 interference N/A 
                        
  
70 NIRR solid 1 91.04     interference 70.66         
      2 89.65     interference 84.22         
      3 88.84 89.84 1.1 interference 93.22 82.70 11.4   R 
                        
  
71 NIRR solid 1 36.86       62.28         
      2 26.07       70.27         
      3 22.49 28.47 7.5   80.58 71.04 9.2   R 
                        
  
78 IRR liquid 1 3.79       0.00         
      2 3.98       0.00         
      3 3.80 3.86 0.1 
interference 
(1.2 %) 3.97 1.32 2.3   NR 
                        
  
80 IRR liquid 1 0.00       0.37         
      2 0.00       1.00         
      3 0.00 0.00 0.0   1.97 1.12 0.8   NR 
                        
  
81 IRR liquid 1 0.97       0.00         
      2 1.63       1.47         
      3 1.57 1.39 0.4   5.34 2.27 2.8   NR 
                        
  
82 IRR liquid 1 0.00       0.00         
      2 0.00       0.57         
      3 0.00 0.00 0.0 10 mM 3.40 1.32 1.8 10 mM N/A 
                        
  
87 IRR liquid 1 1.41       1.22         
      2 1.69       2.97         
      3 2.18 1.76 0.4   4.56 2.92 1.7   NR 
                        
  
89 IRR liquid 1 1.54       0.00         
      2 1.89       1.51         
      3 1.76 1.73 0.2   7.27 2.92 3.8   NR 
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90 IRR solid 1 2.74       91.31         
      2 2.54       99.50         
      3 2.43 2.57 0.2   99.86 96.89 4.8   R 
                        
  
91 IRR solid 1 0.00       1.92         
      2 0.00       4.41         
      3 0.18 0.06 0.1 
interference 
(3 % rel. to 
Ref Control 
C) 5.10 3.81 1.7   NR 
                        
  
92 IRR solid 1       interference 0.00         
      2       interference 0.00         
      3       interference 0.00 0.00     N/A 
                        
  
93 IRR solid 1 12.37       81.16     
dissolved in 50 % 
DMSO/acetonitrile   
      2 22.36       80.30     
peptide 
concentration In 
ref control was 
0.31 mM   
      3 24.04 19.59 6.3   79.57 80.34 0.8 
interference (2.4 
%) R 
                        
  
94 IRR solid 1 2.26       0.00         
      2 1.93       1.74         
      3 1.87 2.02 0.2   2.55 1.43 1.3   NR 
                        
  
95 IRR solid 1 18.85       53.89         
      2 24.39       62.42         
      3 28.47 23.90 4.8   70.54 62.28 8.3   R 
                        
  
96 IRR solid 1 30.82       98.96         
      2 28.65       99.08         
      3 29.47 29.65 1.1   99.18 99.07 0.1   R 
                        
  
97 IRR solid 1 41.27       37.02         
      2 38.94       47.31         
      3 37.63 39.28 1.8   55.62 46.65 9.3   R 
                        
  
98 IRR solid 1 0.72       84.93         
      2 0.49       91.05         
      3 0.32 0.51 0.2   94.45 90.14 4.8   R 
                        
  
100 NIRR liquid 1 0.01       2.71         
      2 0.95       4.06         
      3 0.23 0.40 0.5   10.42 5.73 4.1   NR 
                        
  
101 NIRR liquid 1 0       0.00         
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      2 0       0.00         
      3 0 0 0   3.54 1.18 2.0   NR 
                        
  
102 NIRR  liquid 1 6.27       0.00         
      2 6.26       3.23         
      3 7.23 6.59 0.6 
interference 
(2 % rel. to 
Ref Control 
C) 7.61 3.61 3.8   R 
                        
  
103 NIRR liquid 1 1.51       0.00         
      2 1.32       1.98         
      3 1.67 1.50 0.2   3.38 1.78 1.7   NR 
                        
  
105 NIRR solid 1 0.17       5.45         
      2 0.00       5.87         
      3 0.00 0.06 0.1   2.52 4.61 1.8   NR 
                        
  
106 NIRR solid 1 0.96       100?     injection error?   
      2 0.99       8.28         
      3 0.36 0.77 0.4   11.34 9.81 2.2 
mean depletion 
without replicate 1 R 
                        
  
107 NIRR solid 1 0.00       1.41         
      2 0.00       5.77         
      3 0.00 0.00 0.0   12.34 6.51 5.5   R 
                        
  
108 NIRR solid 1 1.50       0.22         
      2 1.45       4.35         
      3 1.62 1.53 0.1 10 mM 9.60 4.72 4.7 10 mM NR at 10 mM 
                        
  
110 NIRR solid 1 0.01       4.57         
      2 0.00       2.33         
      3 0.00 0.00 0.0   2.08 2.99 1.4   NR 
                        
  
111 NIRR solid 1 2.87       0.00         
      2 2.75       0.00         
      3 2.32 2.64 0.3 10 mM 0.00 0.00 0.0 10 mM N/A 
                        
  
113 NIRR liquid 1 -10.85       0.00         
      2 -10.74       0.00         
      3 -11.33 -11.0 0.3 
no 
interference 
observed 0.00 0.00 0   N/A 
                        
  
114 NIRR solid 1 0.74       5.28         
      2 0.27       8.10         
      3 0.46 0.49 0.2   13.01 8.80 3.9   R 
                        
  
115 NIRR solid 1 29.08       -2033.76     interference at 9   
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min 
      2 28.43       3.38     
interference at 9.7 
min   
      3 27.42 28.31 0.8   95.58 -644.93 1203.6 
interference at 9.7 
min R 
                        
  
116 IRR liquid 1 0.00       6.10         
      2 0.00       10.96         
      3 0.00 0.00 0.0 
interference 
(4 %) 10.87 9.31 2.8   R 
                        
  
117 IRR liquid 1 7.03       14.57         
      2 6.68       17.97         
      3 6.83 6.84 0.2   21.03 17.86 3.2   R 
                        
  
118 IRR liquid 1 2.29       4.82         
      2 0.00       10.34         
      3 0.00 0.76 1.3   8.54 7.90 2.8   R 
                        
  
119 IRR solid 1 1.59       0.00         
      2 0.42       0.83         
      3 0.00 0.67 0.8   4.55 1.80 2.4   NR 
                        
  
121 IRR solid 1 0.00       4.58         
      2 0.00       8.99         
      3 0.00 0.00 0.0   10.28 7.95 3.0   R 
                        
  
122 IRR solid 1 4.48       2.10         
      2 5.74       7.45         
      3 4.81 5.01 0.7   10.02 6.52 4.0   R 
                        
  
123 NIRR liquid 1 -17.02       2.37         
      2 -12.55       3.20         
      3 -3.41 -10.99 6.9 interference! 7.73 4.43 2.9   N/A 
                        
  
126 NIRR solid 1 2.46       0.00         
      2 2.04       0.00         
      3 2.92 2.47 0.4   17.86 5.95 10.3   NR 
                        
  
128 IRR liquid 1 0.29       11.19         
      2 0.12       5.08         
      3 0.08 0.16 0.1   10.35 8.88 3.3   R 
                        
  
129 IRR liquid 1 1.57       0.27         
      2 1.51       0.00         
      3 1.83 1.64 0.2   5.78 2.02 3.3   NR 
                        
  
130 IRR liquid 1 11.13       6.99         
      2 10.59       4.73         
      3 9.79 10.50 0.7   8.61 6.78 1.9   R 
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131 IRR liquid 1 0.23       4.14         
      2 0.00       9.44         
      3 0.09 0.11 0.1   13.72 9.10 4.8   R 
                        
  
132 IRR solid 1 0.00       1.35         
      2 0.00       8.17         
      3 0.00 0.00 0.0   8.40 5.97 4.0   R 
                        
  
133 IRR solid 1 0.19       28.18         
      2 0.20       39.60         
      3 0.66 0.35 0.3   41.61 36.46 7.2   R 
                        
  
134 NIRR liquid 1 23.32     interference       interference   
      2 23.43     interference       interference   
      3 21.59 22.78 1.0 interference       interference N/A 
                        
  
137 NIRR solid 1 0.00       0.00         
      2 0.00       0.00         
      3 0.04 0.01 0.0   0.04 0.01 0.0   NR 
                        
  
138 NIRR solid 1 0.12     10 mM 17.43         
      2 0.05       5.68         
      3 0.00 0.06 0.1   7.45 10.19 6.3   R 
                        
  
10 IRR liquid 1 0.54     
result 
obtained in 
April 2010 -17.03     
same result as in 
April 2010   
*     2 0.95     
result 
obtained in 
April 2010 -16.67     
no interference 
observed   
*     3 0.74 0.74 0.20 
result 
obtained in 
April 2010 -16.08 -16.59 0.48 before the run N/A 
                        
  
14 IRR liquid 1 4.10       0         
*     2 2.07       0         
*     3 2.23 2.80 1.13   0 0 0   NR 
                        
  
30 IRR solid 1 1.17       0.0         
*     2 0.32       1.2         
*     3 0.34 0.61 0.48   3.2 1.4 1.6   NR 
                        
  




run 0.0     10 mM   
*     2 0.18     
10 mM; 
interference 
during the 5.6     10 mM   
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run 




run 5.8 3.8 3.3 10 mM N/A 
                        
  
33 IRR solid 1 -334.8     interference 98.09         
*     2 -413.1     interference 98.14         
*     3 -422.9 -390.3 48.3 interference 98.05 98.09 0.05   R 
                        
  
60 NIRR liquid 1 3.07       52.78         
*     2 1.45       54.83         
*     3 3.64 2.72 1.14   65.87 57.83 7.04   R 
                        
  
61 NIRR liquid 1 0.43       12.82         
*     2 1.89       17.23         
*     3 1.29 1.20 0.74   20.94 17.00 4.06   R 
                        
  
62 NIRR liquid 1 0.00       4.2     10 mM   
*     2 0.00       11.2     
Ref control (50 % 
DMSO) not 
accepted   
*     3 0.00 0.00 0.00 10 mM 15.3 10.2 5.6 
also not after 
repeat analysis 
(mean conc< 0.45 
mM)  N/A 
                      
(Same as for test 
chemical 
Tetrabromophenol 
Blue)   
74 NIRR solid 1 0.0     insoluble 0.0     insoluble   
*     2 0.8     insoluble 0.4     insoluble   
*     3 1.0 0.6 0.5 insoluble 6.9 2.4 3.9 insoluble N/A 
                        
  
75 NIRR solid 1 0.92       0.00         
*     2 0.00       0.00         
*     3 0.54 0.49 0.46   2.47 0.82 1.43   NR 
                        
  
76 NIRR solid 1 0.20     10 mM 0     10 mM   
*     2 2.51     10 mM 0     10 mM   
*     3 2.06 1.59 1.23 10 mM 0 0 0 10 mM N/A 
                        
  
83 NIRR liquid 1 0.91       0         
*     2 0.80       0         
*     3 1.46 1.06 0.35   0 0 0   NR 
                        
  
99 NIRR liquid 1 1.69       0.00         
*     2 1.88       0.00         
*     3 2.71 2.10 0.54   3.09 1.03 1.79   NR 
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113 NIRR liquid 1 27.86     
see also 
result in run 
13 0.00     
result obtained in 
August 2010   
*     2 -11.64     
no 
interference 
observed 0.00     
result obtained in 
August 2010   
*     3 -11.41 1.60 22.74 
before the 
run 0.00 0.00 0 
result obtained in 
August 2010 N/A 
                        
  
136 NIRR solid 1 0.0     insoluble 0.0     insoluble   
*     2 1.4     insoluble 5.2     insoluble   
*     3 0.0 0.5 0.8 insoluble 12.2 5.8 6.1 insoluble N/A 
                        
  
139 IRR liquid 1 5.01       0.0         
*     2 5.19       0.2         
*     3 6.06 5.42 0.56   5.1 1.8 2.9   NR 
                        
  
141 IRR solid 1 0.00       0.00         
*     2 0.00       4.29         
*     3 0.52 0.17 0.30   4.04 2.78 2.41   NR 
                        
  
142 IRR solid 1 0.34       1.5         
*     2 0.00       5.6         
*     3 0.32 0.22 0.19   11.6 6.2 5.0   R 
                        
  
143 NIRR liquid 1 0.42       0.62         
*     2 0.00       0.71         
*     3 0.71 0.38 0.36   1.12 0.82 0.27   NR 
                        
  
144 NIRR liquid 1 0.14       0.0         
*     2 0.18       2.5         
*     3 0.70 0.34 0.32   6.3 2.9 3.2   NR 
                        
  
145 NIRR solid 1 2.01       8.60         
*     2 1.36       1.78         
*     3 0.78 1.38 0.62   2.27 4.22 3.81   NR 
                        
  
146 NIRR solid 1 4.60       99.08         
*     2 6.40       99.13         
*     3 4.78 5.26 0.99   99.35 99.19 0.14   R 
                        
  
147 NIRR solid 1 6.68       4.3         
*     2 5.16       5.6         
*     3 6.99 6.27 0.98   10.1 6.6 3.1   R 
                        
  
148 NIRR solid 1 1.76       0     
mean depletion -5 
%   
*     2 1.21       0     
interference 7 % 
relative to Ref 
Control   
  
TNO report | TNO 2013 R11617 | Final report  303 / 305
*     3 1.72 1.56 0.31   0 0 0   NR 
                        
  
149 NIRR solid 1 0.83       0.0         
*     2 0.00       3.5         
*     3 0.33 0.39 0.42   6.5 3.3 3.2   NR 
                        
  
150 NIRR solid 1 73.22     interference 5.41         
*     2 71.82     interference 8.26         
*     3 73.12 72.72 0.78 interference 10.86 8.18 2.73   R 
                        
  
151 IRR liquid 1 0.71       0.0         
new     2 0.54       0.0         
*     3 0.74 0.66 0.11   0.0 0.0 0.0   NR 
                        
  
152 IRR liquid 1       interference 99.2         
new     2       interference 99.2         
*     3       interference 99.1 99.2 0.1   R 
                        
  
153 NIRR solid 1 1.17       3.2         
new     2 0.48       1.8         
*     3 0.59 0.75 0.37   5.3 3.4 1.8   NR 




                      
  
                        
  
10 IRR liquid 1 0.54       -17.03         
Cat 1     2 0.95       -15.77         
    3 0.74 0.74 0.2   -16.11 -16.30 0.7 no interference 
repeat 
analysis cys 
                        
  
21 IRR solid 1 100.00       42.16     
dissolved in 50 % 
DMSO/acetonitrile   
      2 88.03       50.21     
peptide 
concentration In 
ref control was 
<0.45 mM (0.31 
mM)   
      3 88.19 92.07 6.9 
interference 
(1.4 % rel. 
to Ref 
Control) 57.18 49.85 7.5   R 
                          
113 NIRR liquid 1 -10.85       0.00         
      2 -10.74       0.00         
      3 -11.33 -11.0 0.3 
no 
interference 
observed 0.00 0.00 0   N/A 
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10     1 -       -14.7     dissolved in water   
      2 -       -16.0         
      3 -       -14.0 -14.9 1.0 
no signal in co-
elution control 
during the run   
                        
  
14     1 99.5     
pure 
chemical; 
not diluted -730.7     
pure chemical; not 
diluted   




acetonitrile -766.3     
depletion related 
to peptide in 
acetonitrile R 





with time -764.5 -753.8 20.055631 




                        
  
99     1 38.7     
pure 
chemical; 
not diluted 30.9     
pure chemical; not 
diluted   
      2 52.3     
not 
completely 
dissolved 20.9     
not completely 
dissolved R 




acetonitrile 29.5 27.1 5.4 
depletion related 










run       
no signal in co-
elution control 
during the run   
113     1 -10.7     
dissolved in 
IPA -         
      2 -6.0       -         
      3 -6.7 -7.8 2.5 
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